﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Delaveris, CS
   Chiu, SH
   Riley, NM
   Bertozzi, CR
AF Delaveris, Corleone S.
   Chiu, Shannon H.
   Riley, Nicholas M.
   Bertozzi, Carolyn R.
TI Modulation of immune cell reactivity with cis-binding Siglec agonists
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE glycocalyx; glycopolymer; Siglec; immunotherapy; inflammation
ID SIALIC-ACID; COMPUTATIONAL PLATFORM; CD33-RELATED SIGLECS; NEGATIVE
   REGULATION; AGE; ACTIVATION; RECEPTOR; TARGET; CD22; IMMUNOTHERAPY
AB Inflammatory pathologies caused by phagocytes lead to numerous debilitating conditions, including chronic pain and blindness due to age-related macular degeneration. Many members of the sialic acid-binding immunoglobulin-like lectin (Siglec) family are immunoinhibitory receptors whose agonism is an attractive approach for antiinflammatory therapy. Here, we show that synthetic lipid-conjugated glycopolypeptides can insert into cell membranes and engage Siglec receptors in cis, leading to inhibitory signaling. Specifically, we construct a cis-binding agonist of Siglec-9 and show that it modulates mitogen-activated protein kinase (MAPK) signaling in reporter cell lines, immortalized macrophage and microglial cell lines, and primary human macrophages. Thus, these cis-binding agonists of Siglecs present a method for therapeutic suppression of immune cell reactivity.
C1 [Delaveris, Corleone S.; Chiu, Shannon H.; Riley, Nicholas M.; Bertozzi, Carolyn R.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
   [Delaveris, Corleone S.; Chiu, Shannon H.; Bertozzi, Carolyn R.] Stanford Univ, Stanford ChEM H, Stanford, CA 94305 USA.
   [Bertozzi, Carolyn R.] Stanford Univ, HHMI, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Howard Hughes Medical
   Institute; Stanford University
RP Bertozzi, CR (通讯作者)，Stanford Univ, Dept Chem, Stanford, CA 94305 USA.; Bertozzi, CR (通讯作者)，Stanford Univ, Stanford ChEM H, Stanford, CA 94305 USA.; Bertozzi, CR (通讯作者)，Stanford Univ, HHMI, Stanford, CA 94305 USA.
EM bertozzi@stanford.edu
OI Delaveris, Corleone/0000-0002-7291-2338; Riley,
   Nicholas/0000-0002-1536-2966; Chiu, Shannon/0000-0003-4659-9875
FU National Cancer Institute [R01CA227942]; NSF Graduate Research
   Fellowship [DGE-114747]; Stanford Interdisciplinary Graduate Fellowship;
   ChEM-H; NIH [K00 CA21245403]; Stanford Bio-X Undergraduate Research
   Program Fellowship
FX We thank Simon Wisnovsky and Melissa A. Gray for their advice related to
   molecular biology analysis of Siglecs; Elizabeth R. Webster and
   Christopher J. Cambier for their advice on FRET microscopy; Payton
   Weidenbacher for assistance with Octet protein binding; and Stephen
   Lynch for his advice in acquiring and processing polymer NMR spectra.
   Plasmids containing Pd26ST and NmCSS were kind gifts from Xi Chen. The
   plasmid containing lentiCRISPRv2 was a gift from Feng Zhang (Addgene
   plasmid 52961; http://www.addgene.org/52961/; RRID:Addgene_52961). This
   work was supported by National Cancer Institute Grant R01CA227942.
   C.S.D. was supported by an NSF Graduate Research Fellowship (DGE-114747)
   and a Stanford Interdisciplinary Graduate Fellowship affiliated with
   ChEM-H. S.H.C. was supported by a Stanford Bio-X Undergraduate Research
   Program Fellowship. N.M.R. was funded through an NIH Predoctoral to
   Postdoctoral Transition Award (Grant K00 CA21245403). Figure
   illustrations were created using BioRender.com.
CR Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200
   Angata T, 2015, TRENDS PHARMACOL SCI, V36, P645, DOI 10.1016/j.tips.2015.06.008
   Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841
   Barnes Peter J, 2004, COPD, V1, P59, DOI 10.1081/COPD-120028701
   Beatson R, 2016, NAT IMMUNOL, V17, P1273, DOI 10.1038/ni.3552
   Berges C, 2005, BIOCHEM BIOPH RES CO, V333, P896, DOI 10.1016/j.bbrc.2005.05.171
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031
   Bull C, 2017, IMMUNOL CELL BIOL, V95, P408, DOI 10.1038/icb.2016.105
   Bull C, 2016, TRENDS BIOCHEM SCI, V41, P519, DOI 10.1016/j.tibs.2016.03.007
   Bull C, 2015, ACS CHEM BIOL, V10, P2353, DOI 10.1021/acschembio.5b00501
   Cesano A, 2003, SEMIN ONCOL, V30, P253, DOI 10.1053/sonc.2003.50057
   Cooper PR, 2013, BRAIN RES, V1534, P13, DOI 10.1016/j.brainres.2013.08.035
   Courtney AH, 2009, P NATL ACAD SCI USA, V106, P2500, DOI 10.1073/pnas.0807207106
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056
   Curtin SA, 1999, J AM CHEM SOC, V121, P7427, DOI 10.1021/ja990905g
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   Dam TK, 2010, GLYCOBIOLOGY, V20, P270, DOI 10.1093/glycob/cwp186
   Davies John Q, 2005, Methods Mol Biol, V290, P105
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Delaveris CS, 2020, P NATL ACAD SCI USA, V117, P12643, DOI 10.1073/pnas.1921962117
   DELAVERIS CS, PXD018774 PROTEOMEXC
   Deming TJ, 2000, J AM CHEM SOC, V122, P5710, DOI 10.1021/ja994281q
   DiDonato J, 1996, MOL CELL BIOL, V16, P1295
   Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942
   Duan ST, 2020, ANNU REV IMMUNOL, V38, P365, DOI 10.1146/annurev-immunol-102419-035900
   Forrester MA, 2018, CELL IMMUNOL, V332, P58, DOI 10.1016/j.cellimm.2018.07.008
   Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988
   HaileMariam M, 2018, J PROTEOME RES, V17, P2917, DOI 10.1021/acs.jproteome.8b00505
   Haney MS, 2018, NAT GENET, V50, P1716, DOI 10.1038/s41588-018-0254-1
   Hong S.J., 2020, BIORXIV
   Hudak JE, 2014, NAT CHEM BIOL, V10, P69, DOI [10.1038/NCHEMBIO.1388, 10.1038/nchembio.1388]
   Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200
   Ishida A, 2014, J BIOL CHEM, V289, P25341, DOI 10.1074/jbc.M113.523480
   Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783
   Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005
   Kortmann J, 2015, J IMMUNOL, V195, P815, DOI 10.4049/jimmunol.1403100
   Laubli H, 2014, P NATL ACAD SCI USA, V111, P14211, DOI 10.1073/pnas.1409580111
   Lizcano A, 2017, BLOOD, V129, P3100, DOI 10.1182/blood-2016-11-751636
   Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007
   Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737
   Malaker SA, 2019, P NATL ACAD SCI USA, V116, P7278, DOI 10.1073/pnas.1813020116
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Morrissey M. A., 2019, BIORXIV
   Nycholat CM, 2019, J AM CHEM SOC, V141, P14032, DOI 10.1021/jacs.9b05769
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Pan H, 2019, ACS SYNTH BIOL, V8, P2315, DOI 10.1021/acssynbio.9b00127
   Perdicchio M, 2016, P NATL ACAD SCI USA, V113, P3329, DOI 10.1073/pnas.1507706113
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pluvinage JV, 2019, NATURE, V568, P187, DOI 10.1038/s41586-019-1088-4
   Prescher H, 2015, BIOORGAN MED CHEM, V23, P5915, DOI 10.1016/j.bmc.2015.06.069
   Pronobis MI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160509
   Riley NM, 2016, ANAL CHEM, V88, P74, DOI 10.1021/acs.analchem.5b04123
   Rillahan CD, 2013, ACS CHEM BIOL, V8, P1417, DOI 10.1021/cb400125w
   Rillahan CD, 2012, ANGEW CHEM INT EDIT, V51, P11014, DOI 10.1002/anie.201205831
   Schwarz F, 2015, ELIFE, V4, DOI 10.7554/eLife.06184
   Shahraz A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16800
   Shurer CR, 2018, ACS BIOMATER SCI ENG, V4, P388, DOI 10.1021/acsbiomaterials.7b00037
   Spence S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3459
   Stanczak MA, 2018, J CLIN INVEST, V128, P4912, DOI 10.1172/JCI120612
   Tian RR, 2020, CELL MOL IMMUNOL, V17, P887, DOI 10.1038/s41423-020-0452-5
   Toubai T, 2014, BLOOD, V123, P3512, DOI 10.1182/blood-2013-12-545335
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112
   Woods EC, 2015, ANGEW CHEM INT EDIT, V54, P15782, DOI 10.1002/anie.201508783
   Xiao H, 2016, P NATL ACAD SCI USA, V113, P10304, DOI 10.1073/pnas.1608069113
   Youngblood BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126219
   Yu H, 2006, ANGEW CHEM INT EDIT, V45, P3938, DOI 10.1002/anie.200600572
   Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200
   Zhou JY, 2018, TRENDS IMMUNOL, V39, P523, DOI 10.1016/j.it.2018.04.004
NR 76
TC 20
Z9 22
U1 12
U2 43
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 19
PY 2021
VL 118
IS 3
AR e2012408118
DI 10.1073/pnas.2012408118
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PU9QX
UT WOS:000609633900021
PM 33431669
OA Green Published
DA 2022-11-30
ER

PT J
AU Eells, JT
AF Eells, Janis T.
TI Mitochondrial Dysfunction in the Aging Retina
SO BIOLOGY-BASEL
LA English
DT Review
DE aging; mitochondria; retina; optic nerve; diabetic retinopathy;
   age-related macular degeneration; glaucoma
ID OXIDATIVE STRESS; DIABETIC-RETINOPATHY; METABOLIC MEMORY; GLAUCOMA;
   FISSION; DAMAGE; ABNORMALITIES; VULNERABILITY; DEGENERATION;
   PATHOGENESIS
AB Mitochondria are central in retinal cell function and survival and they perform functions that are critical to cell function. Retinal neurons have high energy requirements, since large amounts of ATP are needed to generate membrane potentials and power membrane pumps. Mitochondria over the course of aging undergo a number of changes. Aged mitochondria exhibit decreased rates of oxidative phosphorylation, increased reactive oxygen species (ROS) generation and increased numbers of mtDNA mutations. Mitochondria in the neural retina and the retinal pigment epithelium are particularly susceptible to oxidative damage with aging. Many age-related retinal diseases, including glaucoma and age-related macular degeneration, have been associated with mitochondrial dysfunction. Therefore, mitochondria are a promising therapeutic target for the treatment of retinal disease.
C1 [Eells, Janis T.] Univ Wisconsin, Dept Biomed Sci, Milwaukee, WI 53211 USA.
C3 University of Wisconsin System; University of Wisconsin Milwaukee
RP Eells, JT (通讯作者)，Univ Wisconsin, Dept Biomed Sci, Milwaukee, WI 53211 USA.
EM jeells@uwm.edu
OI Eells, Janis/0000-0002-4857-4746
FU National Institutes of Health [NIH/NEI] [R43-EY025892, P30-EY01931];
   NATIONAL EYE INSTITUTE [R43EY025892, P30EY001931] Funding Source: NIH
   RePORTER
FX This work was supported in part by the National Institutes of Health
   [NIH/NEI R43-EY025892 and NIH/NEI P30-EY01931].
CR Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P2533, DOI 10.1167/iovs.05-1639
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Ameur A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002028
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Baltan S, 2010, J NEUROSCI, V30, P5644, DOI 10.1523/JNEUROSCI.5956-09.2010
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Coughlin L, 2015, INVEST OPHTH VIS SCI, V56, P1437, DOI 10.1167/iovs.14-16126
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Harun-Or-Rashid M, 2018, J NEUROSCI, V38, P5122, DOI 10.1523/JNEUROSCI.3652-17.2018
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Ju WK, 2008, INVEST OPHTH VIS SCI, V49, P4903, DOI 10.1167/iovs.07-1661
   Ju WK, 2007, INVEST OPHTH VIS SCI, V48, P2145, DOI 10.1167/iovs.06-0573
   Ju WK, 2015, GLIA, V63, P736, DOI 10.1002/glia.22781
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kleesattel D, 2015, INVEST OPHTH VIS SCI, V56, P8215, DOI 10.1167/iovs.15-17885
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Kowluru RA, 2017, VISION RES, V139, P30, DOI 10.1016/j.visres.2017.02.011
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   Kowluru RA, 2013, CURR MED CHEM, V20, P3226, DOI 10.2174/09298673113209990029
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Lee WH, 2016, ELIFE, V5, DOI 10.7554/eLife.19264
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   MEDRANO CJ, 1995, EXP EYE RES, V61, P273, DOI 10.1016/S0014-4835(05)80122-8
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Quinlan CL, 2014, J BIOL CHEM, V289, P8312, DOI 10.1074/jbc.M113.545301
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 51
TC 47
Z9 47
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD JUN
PY 2019
VL 8
IS 2
DI 10.3390/biology8020031
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA II6FD
UT WOS:000475287600012
PM 31083549
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Meadway, A
   Wang, XL
   Curcio, CA
   Zhang, YH
AF Meadway, Alexander
   Wang, Xiaolin
   Curcio, Christine A.
   Zhang, Yuhua
TI Microstructure of subretinal drusenoid deposits revealed by adaptive
   optics imaging
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPY; COHERENCE TOMOGRAPHY; RETICULAR
   PSEUDODRUSEN; MACULAR DEGENERATION; CONE PHOTORECEPTORS; GEOGRAPHIC
   ATROPHY; HIGH-RESOLUTION; 3 DIMENSIONS; HUMAN RETINA; NEOVASCULARIZATION
AB Subretinal drusenoid deposits (SDD), a recently recognized lesion associated with progression of age-related macular degeneration, were imaged with adaptive optics scanning laser ophthalmoscopy (AO-SLO) and optical coherence tomography (AO-OCT). AO-SLO revealed a distinct en face structure of stage 3 SDD, showing a hyporeflective annulus surrounded reflective core packed with hyperreflective dots bearing a superficial similarity to the photoreceptors in the unaffected retina. However, AO-OCT suggested that the speckled appearance over the SDD rendered by AO-SLO was the lesion material itself, rather than photoreceptors. AO-OCT assists proper interpretation and understanding of the SDD structure and the lesions' impact on surrounding photoreceptors produced by AO-SLO and vice versa. (C) 2014 Optical society of America
C1 [Meadway, Alexander; Wang, Xiaolin; Curcio, Christine A.; Zhang, Yuhua] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Zhang, Yuhua] Univ Alabama Birmingham, Dept Vis Sci, Birmingham, AL 35294 USA.
   [Zhang, Yuhua] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Meadway, A (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 1670 Univ Blvd, Birmingham, AL 35294 USA.
EM zhanghua@uab.edu
OI Meadway, Alexander/0000-0001-9815-7783
FU EyeSight Foundation of Alabama; International Retina Research Foundation
   [5R21EY021903]; Songs for Sight, Buck Trust of Alabama [R01EY06109];
   Research to Prevent Blindness; Buck Trust of Alabama; NIH [P30 EY003039]
FX This project is funded by EyeSight Foundation of Alabama (YZ),
   International Retina Research Foundation (YZ), 5R21EY021903 (YZ), Songs
   for Sight, Buck Trust of Alabama, R01EY06109 (CC), and institutional
   support from Research to Prevent Blindness, EyeSight Foundation of
   Alabama, Buck Trust of Alabama, and NIH P30 EY003039. The authors
   gratefully thank the Clinical Research Unit of UAB Department of
   Ophthalmology led by Dr. Cynthia Owsley for assistance of study patients
   recruitment and standard ophthalmoscopy. The authors also thank Qiang
   Yang, PhD, Montana State University, for helping develop the AO-SLO
   image process software. AO-OCT images were registered using the StackReg
   plugin provided by http://bigwww.epfl.ch/thevenaz/stackreg/#LegalBlurb.
CR Burns SA, 2007, J OPT SOC AM A, V24, P1313, DOI 10.1364/JOSAA.24.001313
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cooper RF, 2011, BIOMED OPT EXPRESS, V2, P2577, DOI 10.1364/BOE.2.002577
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Hammer DX, 2012, J OPT SOC AM A, V29, P2598, DOI 10.1364/JOSAA.29.002598
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Kocaoglu OP, 2011, BIOMED OPT EXPRESS, V2, P748, DOI 10.1364/BOE.2.000748
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Pallikaris A, 2003, INVEST OPHTH VIS SCI, V44, P4580, DOI 10.1167/iovs.03-0094
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   Roorda A, 2010, OPTOMETRY VISION SCI, V87, P260, DOI 10.1097/OPX.0b013e3181d39479
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schmitz-Valckenberg S., INVEST OPHTHALMOL VI, V52, P5009
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
   Zawadzki RJ, 2008, OPT EXPRESS, V16, P8126, DOI 10.1364/OE.16.008126
   Zawadzki RJ, 2007, J OPT SOC AM A, V24, P1373, DOI 10.1364/JOSAA.24.001373
   Zawadzki RJ, 2011, BIOMED OPT EXPRESS, V2, P1674, DOI 10.1364/BOE.2.001674
   Zhang Y, 2005, OPT EXPRESS, V13, P4792, DOI 10.1364/OPEX.13.004792
   Zhang Y., AM J OPHTHALMOL
   Zhang Y., 2006, P SPIE, V6306
   ZHANG Y, 2006, P SPIE, V6138
   Zhang Y, 2006, OPT EXPRESS, V14, P4380, DOI 10.1364/OE.14.004380
   Zhang YH, 2006, OPT LETT, V31, P1268, DOI 10.1364/OL.31.001268
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 50
TC 34
Z9 35
U1 0
U2 11
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2014
VL 5
IS 3
BP 713
EP 727
DI 10.1364/BOE.5.000713
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA AC6YF
UT WOS:000332671800006
PM 24688808
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fawzi, AA
   Lee, NG
   Eliott, D
   Song, J
   Stewart, JM
AF Fawzi, A. A.
   Lee, N. G.
   Eliott, D.
   Song, J.
   Stewart, J. M.
TI Retinal findings in patients with Alport Syndrome: expanding the
   clinical spectrum
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COL4A5 COLLAGEN GENE; IV COLLAGEN; OCULAR MANIFESTATIONS; MACULAR
   DEGENERATION; BASEMENT-MEMBRANES; MUTATIONS; IDENTIFICATION; NEPHRITIS;
   HOLE
AB Aims: To describe previously unreported retinal findings in patients with Alport Syndrome (AS), as well as review the range of ophthalmic manifestations.
   Methods: Retrospective review of clinical records of patients with AS.
   Results: Nine patients with AS were identified, of whom three had no eye findings, four showed classic features of AS, and two had new findings, bull's eye and vitelliform maculopathy. The genetic mutation responsible for the disease in the patient with vitelliform subretinal deposits was identified.
   Conclusions: Patients with AS can present with a variety of ophthalmic manifestations. Bull's eye maculopathy and vitelliform deposits can be features of AS. The mechanism of these new macular findings remains unknown. Possible pathophysiological overlap with other maculopathies including age-related macular degeneration is discussed.
C1 [Stewart, J. M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Fawzi, A. A.; Lee, N. G.; Eliott, D.] Univ So Calif, Keck Sch Med, Doheny Retina Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Song, J.] Childrens Hosp Los Angeles, Dept Ophthalmol, Los Angeles, CA 90027 USA.
C3 University of California System; University of California San Francisco;
   University of Southern California; Children's Hospital Los Angeles
RP Stewart, JM (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA.
EM stewartj@vision.ucsf.edu
RI Lee, Nahyoung/O-1004-2018; fawzi, amani/AAA-9199-2021
OI Lee, Nahyoung/0000-0001-7892-2871; fawzi, amani/0000-0002-9568-3558
FU Man May See and Research
FX Funding: That Man May See and Research to Prevent Blindness.
CR BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Colville DJ, 1997, OPHTHALMIC GENET, V18, P161, DOI 10.3109/13816819709041431
   Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981
   GOVAN JAA, 1983, BRIT J OPHTHALMOL, V67, P493, DOI 10.1136/bjo.67.8.493
   Gupta V, 2002, RETINA-J RET VIT DIS, V22, P499, DOI 10.1097/00006982-200208000-00018
   Heiskari N, 1996, J AM SOC NEPHROL, V7, P702
   JAMPOL LM, 1975, AM J OPHTHALMOL, V79, P452, DOI 10.1016/0002-9394(75)90622-4
   KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658
   Kashtan CE, 2006, PEDIATR TRANSPLANT, V10, P651, DOI 10.1111/j.1399-3046.2006.00528.x
   Knebelmann B, 1996, AM J HUM GENET, V59, P1221
   Lemmink HH, 1997, HUM MUTAT, V9, P477
   LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MCCOY RC, 1982, KIDNEY INT, V21, P642, DOI 10.1038/ki.1982.72
   Meleg-Smith S, 2001, ULTRASTRUCT PATHOL, V25, P193
   Mete UO, 1996, ACTA OPHTHALMOL SCAN, V74, P77
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Pelit A, 2004, J PEDIAT OPHTH STRAB, V41, P59, DOI 10.3928/0191-3913-20040101-14
   Shaikh S, 2003, RETINA-J RET VIT DIS, V23, P119, DOI 10.1097/00006982-200302000-00025
   Shaw EA, 2007, NEPHROL DIAL TRANSPL, V22, P104, DOI 10.1093/ndt/gfl607
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Usui T, 2004, RETINA-J RET VIT DIS, V24, P977, DOI 10.1097/00006982-200412000-00026
   Zhang KW, 2008, PEDIATR NEPHROL, V23, P1245, DOI 10.1007/s00467-008-0759-4
NR 24
TC 28
Z9 30
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2009
VL 93
IS 12
BP 1606
EP 1611
DI 10.1136/bjo.2009.158089
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 525BE
UT WOS:000272187300014
PM 19635720
DA 2022-11-30
ER

PT J
AU Zhang, LL
   Xu, JS
   Sanders, VM
   Letson, AD
   Roberts, CJ
   Xu, RX
AF Zhang, Leilei
   Xu, Jeff S.
   Sanders, Virginia M.
   Letson, Alan D.
   Roberts, Cynthia J.
   Xu, Ronald X.
TI Multifunctional microbubbles for image-guided antivascular endothelial
   growth factor therapy
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE microbubble; age-related macular degeneration; fluorescence; ultrasound;
   multimodal imaging; Avastin; bevacizumab; drug delivery
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; PREVALENCE; EYE
AB We synthesize multifunctional microbubbles (MBs) for targeted delivery of antivascular endothelial growth factor (antiVEGF) therapy with multimodal imaging guidance. Poly-lactic-co-glycolic acid (PLGA) MBs encapsulating Texas Red dye are fabricated by a modified double-emulsion process. Simultaneous ultrasound and fluorescence imaging are achieved using Texas Red encapsulated MBs. The MBs are conjugated with Avastin, an antiVEGF antibody for treating neovascular age-related macular degeneration (AMD). The conjugation efficiency is characterized by enzyme-linked immunosorbent assay (ELISA). The efficiency for targeted binding of Avastin-conjugated MBs is characterized by microscopic imaging. Our work demonstrates the technical potential of using multifunctional MBs for targeted delivery of antiVEGF therapy in the treatment of exudative AMD. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3457669]
C1 [Zhang, Leilei; Xu, Jeff S.; Roberts, Cynthia J.; Xu, Ronald X.] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.
   [Sanders, Virginia M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Letson, Alan D.; Roberts, Cynthia J.; Xu, Ronald X.] Ohio State Univ, Dept Ophthalmol, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University
RP Xu, RX (通讯作者)，Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.
EM xu.202@osu.edu
RI Roberts, Cynthia/E-3961-2011; Pepose, Jay/M-5140-2019; Zhang,
   Lei/GYQ-7446-2022
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barth TFE, 2002, CELL COMMUN ADHES, V9, P1, DOI 10.1080/15419060212184
   Huang JW, 2010, BIOMATERIALS, V31, P1278, DOI 10.1016/j.biomaterials.2009.11.008
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P167
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Kim C, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302808
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Xu JS, 2010, BIOMATERIALS, V31, P1716, DOI 10.1016/j.biomaterials.2009.11.052
   Xu RX, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3147424
NR 14
TC 14
Z9 14
U1 0
U2 10
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY-JUN
PY 2010
VL 15
IS 3
AR 030515
DI 10.1117/1.3457669
PG 3
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 635GF
UT WOS:000280642900011
PM 20614998
OA Bronze
DA 2022-11-30
ER

PT J
AU Wang, SK
   Cepko, CL
AF Wang, Sean K.
   Cepko, Constance L.
TI Targeting Microglia to Treat Degenerative Eye Diseases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE microglia; retina; neurodegeneration; neuroinflammation;
   neuroprotection; immunomodulation; therapies
ID INDUCED CHOROIDAL NEOVASCULARIZATION; FRACTALKINE RECEPTOR CX(3)CR1;
   MOUSE MODEL; RETINAL DEGENERATION; ACTIVATED MICROGLIA; RODENT MODEL;
   TNF-ALPHA; INTERLEUKIN-1-BETA INHIBITION; RETINITIS-PIGMENTOSA; VISUAL
   FUNCTION
AB Microglia have been implicated in many degenerative eye disorders, including retinitis pigmentosa, age-related macular degeneration, glaucoma, diabetic retinopathy, uveitis, and retinal detachment. While the exact roles of microglia in these conditions are still being discovered, evidence from animal models suggests that they can modulate the course of disease. In this review, we highlight current strategies to target microglia in the eye and their potential as treatments for both rare and common ocular disorders. These approaches include depleting microglia with chemicals or radiation, reprogramming microglia using homeostatic signals or other small molecules, and inhibiting the downstream effects of microglia such as by blocking cytokine activity or phagocytosis. Finally, we describe areas of future research needed to fully exploit the therapeutic value of microglia in eye diseases.
C1 [Wang, Sean K.] Stanford Univ, Sch Med, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Cepko, Constance L.] Harvard Med Sch, Blavatnik Inst, Dept Genet, Boston, MA 02115 USA.
   [Cepko, Constance L.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Cepko, Constance L.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
C3 Stanford University; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Howard Hughes Medical Institute
RP Cepko, CL (通讯作者)，Harvard Med Sch, Blavatnik Inst, Dept Genet, Boston, MA 02115 USA.; Cepko, CL (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.; Cepko, CL (通讯作者)，Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM cepko@genetics.med.harvard.edu
OI Wang, Sean K/0000-0003-1557-8510
CR Alt C, 2014, INVEST OPHTH VIS SCI, V55, P5314, DOI 10.1167/iovs.14-14254
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Anderson MG, 2005, P NATL ACAD SCI USA, V102, P4566, DOI 10.1073/pnas.0407357102
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Arroba AI, 2011, INVEST OPHTH VIS SCI, V52, P9124, DOI 10.1167/iovs.11-7736
   AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D
   Bae KR, 2014, J NEUROIMMUNE PHARM, V9, P424, DOI 10.1007/s11481-014-9540-6
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Beli E, 2016, J MOL MED, V94, P1255, DOI 10.1007/s00109-016-1433-0
   Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007
   Bodea LG, 2014, J NEUROSCI, V34, P8546, DOI 10.1523/JNEUROSCI.5002-13.2014
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chan YK, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd3438
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Charles-Messance H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1655-5
   Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528
   Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2007, AM J PATHOL, V171, P580, DOI 10.2353/ajpath.2007.070272
   Cukras CA, 2012, INVEST OPHTH VIS SCI, V53, P3865, DOI 10.1167/iovs.11-9413
   Dagkalis A, 2009, IMMUNOLOGY, V128, P25, DOI 10.1111/j.1365-2567.2009.03046.x
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Denieffe S, 2013, BRAIN BEHAV IMMUN, V34, P86, DOI 10.1016/j.bbi.2013.07.174
   Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961
   Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544
   Drucker DJ, 2017, J CLIN INVEST, V127, P4217, DOI 10.1172/JCI97233
   Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998
   During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Elia AE, 2016, EUR J NEUROL, V23, P45, DOI 10.1111/ene.12664
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496
   Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9
   Fu JM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081154
   Galloway DA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00790
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069
   HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8
   He C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023290118
   Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177
   Hernandez C, 2016, DIABETES, V65, P172, DOI 10.2337/db15-0443
   Hilla AM, 2017, J NEUROSCI, V37, P6113, DOI 10.1523/JNEUROSCI.0584-17.2017
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031
   Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768
   Huang R, 2018, J MOL NEUROSCI, V64, P200, DOI 10.1007/s12031-017-1020-z
   Humphries MM, 2012, EUR J HUM GENET, V20, P64, DOI 10.1038/ejhg.2011.151
   Hutter E, 2010, ACS NANO, V4, P2595, DOI 10.1021/nn901869f
   Hutter G, 2019, P NATL ACAD SCI USA, V116, P997, DOI 10.1073/pnas.1721434116
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Jaffe GJ, 2016, NEW ENGL J MED, V375, P932, DOI 10.1056/NEJMoa1509852
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kaeslin MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165314
   Kalm M, 2009, J NEUROIMMUNOL, V206, P70, DOI 10.1016/j.jneuroim.2008.11.002
   Kataoka K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.73
   Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2
   Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000
   Kim HA, 2020, OPHTHALMOLOGY, V127, P555, DOI 10.1016/j.ophtha.2019.10.038
   Kitamura Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36473-2
   Klee K, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107816
   Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Kuno R, 2005, J NEUROIMMUNOL, V162, P89, DOI 10.1016/j.jneuroim.2005.01.015
   Labandeira-Garcia JL, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00365
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lehrman EK, 2018, NEURON, V100, P120, DOI 10.1016/j.neuron.2018.09.017
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Liu XY, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00008
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Maes ME, 2019, NEUROSCI LETT, V707, DOI 10.1016/j.neulet.2019.134310
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   de la Camara CMF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11764
   Masuda T, 2020, CELL REP, V30, P1271, DOI 10.1016/j.celrep.2020.01.010
   Maurer M, 2021, J ALLER CL IMM-PRACT, V9, P1067, DOI 10.1016/j.jaip.2020.11.043
   Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Menzel F, 2018, GLIA, V66, P15, DOI 10.1002/glia.23239
   Mirzaei M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12858-7
   Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509
   Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018
   Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600
   Noailles A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0186-3
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Obata H, 1999, ACTA OPHTHALMOL SCAN, V77, P151, DOI 10.1034/j.1600-0420.1999.770207.x
   Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781
   Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004
   Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Olivares-Gonzalez L, 2020, FASEB J, V34, P13839, DOI 10.1096/fj.202000044RR
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Otani A, 2012, AM J PATHOL, V180, P328, DOI 10.1016/j.ajpath.2011.09.025
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Nguyen QD, 2016, LANCET, V388, P1183, DOI 10.1016/S0140-6736(16)31339-3
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Rodrigues GA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2519-x
   Rodriguez-de la Rosa L, 2012, NEUROBIOL DIS, V46, P476, DOI 10.1016/j.nbd.2012.02.013
   Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rosario AM, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.26
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schwarzer P, 2020, AM J PATHOL, V190, P412, DOI 10.1016/j.ajpath.2019.10.011
   Sfikakis PP, 2010, DIABETES CARE, V33, P1523, DOI 10.2337/dc09-2372
   Shahulhameed S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00154
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shin TH, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00420-3
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Stahel M, 2016, RETINA-J RET VIT DIS, V36, P385, DOI 10.1097/IAE.0000000000000701
   Sterling JK, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108271
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Subhramanyam CS, 2019, SEMIN CELL DEV BIOL, V94, P112, DOI 10.1016/j.semcdb.2019.05.004
   SUZUMURA A, 1993, J IMMUNOL, V151, P2150
   Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200
   Tan ZZ, 2021, INVEST OPHTH VIS SCI, V62
   Tap WD, 2019, LANCET, V394, P478, DOI 10.1016/S0140-6736(19)30764-0
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Thielens NM, 2017, MOL IMMUNOL, V89, P73, DOI 10.1016/j.molimm.2017.05.025
   Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x
   Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24
   Trittibach P, 2008, GENE THER, V15, P1478, DOI 10.1038/gt.2008.109
   van Hagen PM, 2014, ACTA OPHTHALMOL, V92, pe691, DOI 10.1111/aos.12471
   Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015
   Villacampa P, 2013, J BIOL CHEM, V288, P17631, DOI 10.1074/jbc.M113.468819
   Wan CK, 2016, J IMMUNOL, V196, P543, DOI 10.4049/jimmunol.1502080
   Wang K, 2014, GLIA, V62, P1943, DOI 10.1002/glia.22715
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang SK, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150796
   Wang SK, 2020, MOL THER-METH CLIN D, V19, P376, DOI 10.1016/j.omtm.2020.10.003
   Wang SK, 2020, J CLIN INVEST, V130, P4360, DOI 10.1172/JCI136160
   Wang SK, 2019, P NATL ACAD SCI USA, V116, P10140, DOI 10.1073/pnas.1901787116
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang X, 2017, J NEUROSCI, V37, P3294, DOI 10.1523/JNEUROSCI.2717-16.2017
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wei X, 2018, INVEST OPHTH VIS SCI, V59
   Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109
   Wolf A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16400-8
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Yang L, 2009, ARCH OPHTHALMOL-CHIC, V127, P1475, DOI 10.1001/archophthalmol.2009.288
   Yao RM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00986
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Yuan ZH, 2019, MOL VIS, V25, P359
   Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zangerolamo L, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119252
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang LJ, 2016, IMMUNOBIOLOGY, V221, P1133, DOI 10.1016/j.imbio.2016.06.021
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a
NR 171
TC 4
Z9 4
U1 5
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 17
PY 2022
VL 13
AR 843558
DI 10.3389/fimmu.2022.843558
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA ZM7HL
UT WOS:000764523500001
PM 35251042
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, ZC
   Zhou, Y
   Tan, G
   Li, J
AF Zhao, Zhi-Chun
   Zhou, Ying
   Tan, Gang
   Li, Juan
TI Research progress about the effect and prevention of blue light on eyes
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE blue light; ocular injury; prevention
ID CORNEAL EPITHELIAL-CELLS; RETINAL DEGENERATION; VISUAL IMPAIRMENT;
   OXIDATIVE STRESS; MYOPIA; SLEEP; INVOLVEMENT; EXPOSURE; DAMAGE
AB In recent years, people have become increasingly attentive to light pollution influences on their eyes. In the visible spectrum, short-wave blue light with wavelength between 415 nm and 455 nm is closely related to eye light damage. This high energy blue light passes through the cornea and lens to the retina causing diseases such as dry eye, cataract, age-related macular degeneration, even stimulating the brain, inhibiting melatonin secretion, and enhancing adrenocortical hormone production, which will destroy the hormonal balance and directly affect sleep quality. Therefore, the effect of Blu-rays on ocular is becoming an important concern for the future. We describe blue light's effects on eye tissues, summarize the research on eye injury and its physical prevention and medical treatment.
C1 [Zhao, Zhi-Chun; Li, Juan] Xian 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi, Peoples R China.
   [Zhao, Zhi-Chun; Zhou, Ying; Tan, Gang] Univ South China, Dept Ophthalmol, Affiliated Hosp 1, Hengyang 421001, Hunan, Peoples R China.
C3 University of South China
RP Li, J (通讯作者)，Xian 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi, Peoples R China.
EM cornea@163.com
FU National Natural Science Foundation of China [81400424]; Science and
   Technology Research and Development Project of Shaanxi Province
   [2014K11-03-07-04]; Innovative Talents Promotion Project of Shaanxi
   Province [2017KJXX-87]; Hunan Province Education Department Outstanding
   Youth Science Foundation [15B210]
FX Supported by National Natural Science Foundation of China (No.
   81400424); Science and Technology Research and Development Project of
   Shaanxi Province (No. 2014K11-03-07-04); Innovative Talents Promotion
   Project of Shaanxi Province (No. 2017KJXX-87); Hunan Province Education
   Department Outstanding Youth Science Foundation (No. 15B210).
CR Ayaki M, 2013, REJUV RES, V16, P35, DOI 10.1089/rej.2012.1369
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Bai J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1910450
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bi W.M., 2014, RECENT ADV OPHTHALMO, V34, P289
   Choi W, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4727415
   Czepita Damian, 2010, Klin Oczna, V112, P293
   del Olmo-Aguado S, 2016, NEUROCHEM RES, V41, P2324, DOI 10.1007/s11064-016-1946-5
   Foulds WS, 2013, INVEST OPHTH VIS SCI, V54, P8004, DOI 10.1167/iovs.13-12476
   Gabel V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07060-8
   Gao SS, 2011, MOL VIS, V17, P3180
   Geiger P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.333
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Ishii M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.71
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Kim GH, 2016, GRAEF ARCH CLIN EXP, V254, P705, DOI 10.1007/s00417-015-3258-x
   King A, 2010, PHOTOCHEM PHOTOBIOL, V79, P470
   Lee HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167671
   Lee JB, 2014, INVEST OPHTH VIS SCI, V55, P4119, DOI 10.1167/iovs.13-13441
   Li Haihui, 2014, Zhonghua Yan Ke Za Zhi, V50, P814
   Liu R, 2011, EXP EYE RES, V92, P447, DOI 10.1016/j.exer.2011.03.003
   [刘学政 Liu Xuezheng], 2003, [眼视光学杂志, Chinese Journal of Optometry & Ophthalmology], V5, P29
   Lu B, 2017, OPHTHALMIC RES, V57, P252, DOI 10.1159/000452282
   Makdoumi K, 2017, ACTA OPHTHALMOL, V95, P498, DOI 10.1111/aos.13409
   Munch M, 2016, NEUROPSYCHOBIOLOGY, V74, P207, DOI 10.1159/000477093
   Nakamura M, 2017, BIOL PHARM BULL, V40, P1219, DOI 10.1248/bpb.b16-01008
   Niwano Y, 2014, BRIT J OPHTHALMOL, V98, P990, DOI 10.1136/bjophthalmol-2014-305205
   Osborne NN, 2014, EXP EYE RES, V128, P8, DOI 10.1016/j.exer.2014.08.012
   [钱一峰 Qian Yifeng], 2012, [中国实验动物学报, Acta Laboratorium Animalis Scientia Sinica], V20, P5
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rocha EM, 2013, CURR OPIN OPHTHALMOL, V24, P348, DOI 10.1097/ICU.0b013e32836227bf
   Rose KA, 2008, ARCH OPHTHALMOL-CHIC, V126, P527, DOI 10.1001/archopht.126.4.527
   Rose KA, 2008, OPHTHALMOLOGY, V115, P1279, DOI 10.1016/j.ophtha.2007.12.019
   Rucker F, 2015, INVEST OPHTH VIS SCI, V56, P6121, DOI 10.1167/iovs.15-17238
   Scheuermaier K, 2018, BEHAV BRAIN RES, V348, P267, DOI 10.1016/j.bbr.2018.04.021
   Song XJ, 2014, INVEST OPHTH VIS SCI, V55, P745, DOI 10.1167/iovs.12-10457
   Wei SF, 2017, CURR EYE RES, V42, P1401, DOI 10.1080/02713683.2017.1332767
   Xie C, 2014, PHOTOCHEM PHOTOBIOL, V90, P853, DOI 10.1111/php.12250
   Zhao HL, 2017, INT J OPHTHALMOL-CHI, V10, P1261, DOI 10.18240/ijo.2017.08.13
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
   Zheng QX, 2015, EXP EYE RES, V134, P133, DOI 10.1016/j.exer.2015.02.013
   Zizi F, 2002, J GERONTOL A-BIOL, V57, pM691, DOI 10.1093/gerona/57.10.M691
   Zou LL, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/9197631
NR 43
TC 40
Z9 41
U1 12
U2 86
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2018
VL 11
IS 12
BP 1999
EP 2003
DI 10.18240/ijo.2018.12.20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD8SU
UT WOS:000452830000020
PM 30588436
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Markabi, S
AF Markabi, Sabri
TI COMBINATION THERAPY FROM THE REGULATORY PERSPECTIVE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; combination
   therapy
AB For a combination regimen to receive regulatory approval, it must provide some incremental advantage over a previous standard. Although this advantage is typically a greater likelihood of achieving a clinically relevant endpoint, there are others. For example, the additive effects of two agents may allow each to be employed in relatively low doses, improving tolerability. In age-related macular degeneration, one challenge to the combination of pharmaceutical agents is the delivery of adequate quantities of two or more pharmaceutical agents to the back of the eye. The confined space limits accommodation of substantial single dose volumes, whereas repeated invasive delivery through intravitreal injection may be impractical. Innovative delivery strategies may be crucial to future progress. RETINA 29:S9-S11, 2009
C1 Alcon Res LTD, Res & Dev, Ft Worth, TX 76134 USA.
C3 Novartis; Alcon
RP Markabi, S (通讯作者)，Alcon Res LTD, Res & Dev, Ft Worth, TX 76134 USA.
CR Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   *NEI FDA, 2006, NEI FDA OPHTH CLIN D
NR 2
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S9
EP S11
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700004
DA 2022-11-30
ER

PT J
AU Wolf, G
AF Wolf, G
TI Lipofuscin and macular degeneration
SO NUTRITION REVIEWS
LA English
DT Review
DE age-related macular degeneration; Stargardt disease; lipofuscin; retina;
   all-trans-retinal
ID ABCR; DAMAGE; FLUOROPHORE; A2E; PHOTORECEPTORS; ACCUMULATION;
   INVOLVEMENT; INSIGHTS; CELLS
AB The accumulation of the autofluorescent pigment lipofuscin in the retina that occurs with aging has been explained as a side effect of the visual cycle. It occurs when two molecules of all-trans-retinal condense with one molecule of phosphatidylethanolamine in the discs of the rod outer segments, and is followed by uptake into retinal pigment epithelium (RPE) and conversion to the stable A2E, a pyridinium bisretinoid that is toxic to RPE cells. The accumulation of A2E, the major component of lipofuscin causes RPE cell apoptosis, thereby explaining age-related macular degeneration and macular degeneration characteristic of Stargardt disease. The drug isotretinoin (13-cis-retinoic acid) prevents accumulation of A2E in mice by slowing down the visual cycle and might therefore be used to prevent macular degeneration.
C1 Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley
RP Wolf, G (通讯作者)，Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
CR Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BRIZZEE KR, 1981, AGE PIGMENTS, P102
   Ellis CN, 2001, J AM ACAD DERMATOL, V45, pS150, DOI 10.1067/mjd.2001.113717
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, P NATL ACAD SCI USA, V100, P4353, DOI 10.1073/pnas.1031478100
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPARROW JR, 2003, IN PRESS J BIOL CHEM
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wysowski DK, 2001, J AM ACAD DERMATOL, V45, P515, DOI 10.1067/mjd.2001.117730
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
NR 21
TC 51
Z9 60
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD OCT
PY 2003
VL 61
IS 10
BP 342
EP 346
DI 10.1301/nr.2003.oct.342-346
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 738PJ
UT WOS:000186296800002
PM 14604266
DA 2022-11-30
ER

PT J
AU Chan, TCW
   Berka, JLW
   Deliyanti, D
   Hunter, D
   Fung, A
   Liew, G
   White, A
AF Chan, Thomas CW.
   Berka, Jennifer L. Wilkinson
   Deliyanti, Devy
   Hunter, Damien
   Fung, Adrian
   Liew, Gerald
   White, Andrew
TI The role of reactive oxygen species in the pathogenesis and treatment of
   retinal diseases
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Reactive oxygen species; Oxidative stress; Retinal disease;
   Pathogenesis; Treatment
ID ENDOTHELIAL GROWTH-FACTOR; CONE CELL-DEATH; MITOCHONDRIAL OXIDATIVE
   STRESS; GLYCATION END-PRODUCTS; LIGHT-INDUCED DAMAGE;
   DIABETIC-RETINOPATHY; NADPH OXIDASE; MACULAR DEGENERATION;
   ANGIOTENSIN-II; POLYMORPHONUCLEAR LEUKOCYTES
AB Reactive oxygen species (ROS) normally play an important physiological role in health regulating cellular processes and signal transduction. The amount of ROS is usually kept in fine balance with the generation of ROS largely being offset by the body's antioxidants. A tipping of this balance has increasingly been recognised as a contributor to human disease. The retina, as a result of its cellular anatomy and physical location, is a potent generator of ROS that has been linked to several major retinal diseases. This review will provide a summary of the role of oxidative stress in the pathogenesis of diabetic retinopathy, age-related macular degeneration, myopia, retinal vein occlusion, retinitis pigmentosa and retinopathy of prematurity. Therapies aimed at controlling oxidative stress in these diseases are also examined.
C1 [Chan, Thomas CW.; Hunter, Damien; Liew, Gerald; White, Andrew] Univ Sydney, Fac Med & Hlth, Discipline Ophthalmol & Eye Hlth, Sydney, NSW, Australia.
   [Berka, Jennifer L. Wilkinson; Deliyanti, Devy] Univ Melbourne, Sch Biomed Sci, Dept Anat & Neurosci, Med Bldg 181,Grattan St, Parkville, Vic 3010, Australia.
   [Berka, Jennifer L. Wilkinson; Deliyanti, Devy] Monash Univ, Dept Diabet, Cent Clin Sch, Melbourne, Vic 3004, Australia.
   [Hunter, Damien; Liew, Gerald; White, Andrew] Westmead Inst Med Res, Ctr Vis Res, Westmead, NSW, Australia.
   [Fung, Adrian] Univ Sydney, Westmead Clin Sch, Fac Med & Hlth, Sydney, NSW, Australia.
   [Fung, Adrian] Univ Sydney, Cent Clin Sch, Fac Med & Hlth, Sydney, NSW, Australia.
   [Fung, Adrian] Macquarie Univ, Fac Med Hlth & Human Sci, N Ryde, NSW, Australia.
   [Fung, Adrian; White, Andrew] Save Sight Inst, 8 Macquarie St, Sydney, NSW, Australia.
   [White, Andrew] Personal Eyes, Level 6,34 Charles St, Parramatta 2150, Australia.
C3 University of Sydney; University of Melbourne; Monash University;
   University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney; Macquarie University;
   University of Sydney
RP White, A (通讯作者)，176 Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM andrew.white@sydney.edu.au
RI White, Andrew JR/E-8462-2013; Liew, Gerald/AAB-6870-2022;
   Wilkinson-Berka, Jennifer/D-4232-2011
OI Wilkinson-Berka, Jennifer/0000-0003-3512-4030
CR Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007
   Agardh E, 2000, CURR EYE RES, V21, P543, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT543
   Age Related Eye Disease Study Research Group, 2011, ARCH OPHTHALMOL-CHIC, V119, P1417
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Allingham MJ, 2018, INVEST OPHTH VIS SCI, V59, P3355, DOI 10.1167/iovs.17-23073
   Alrashdi SF, 2018, AM J PATHOL, V188, P805, DOI 10.1016/j.ajpath.2017.11.009
   Altenhofer S., 2012, CELL MOL LIFE SCI, P1
   Angayarkanni N, 2008, EYE, V22, P969, DOI 10.1038/sj.eye.6703062
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976
   Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Barrera-Chimal J, 2019, KIDNEY INT, V96, P302, DOI 10.1016/j.kint.2019.02.030
   Bayir H, 2005, CRIT CARE MED, V33, pS498, DOI 10.1097/01.CCM.0000186787.64500.12
   Becatti M, 2016, J THROMB HAEMOST, V14, P2287, DOI 10.1111/jth.13482
   Beharry KD, 2013, INVEST OPHTH VIS SCI, V54, P7644, DOI 10.1167/iovs.13-13040
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bernabe-Garcia M., 2019, J PARENTER ENTERAL N, V43
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306
   Berson EL, 2012, ARCH OPHTHALMOL-CHIC, V130, P707, DOI 10.1001/archophthalmol.2011.2580
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cannavo A, 2019, VITAM HORM, V109, P387, DOI 10.1016/bs.vh.2018.09.005
   Canonica J, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107747
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0
   Cota F, 2022, J MATERN-FETAL NEO M, V35, P175, DOI 10.1080/14767058.2020.1712700
   Davies S., 1998, P 13 INT C EYE RES P, V102
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Dehne N, 2009, EXP CELL RES, V315, P1791, DOI 10.1016/j.yexcr.2009.03.019
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Deliyanti D, 2020, HYPERTENSION, V75, P1091, DOI 10.1161/HYPERTENSIONAHA.119.14100
   Deliyanti D, 2018, INVEST OPHTH VIS SCI, V59, P815, DOI 10.1167/iovs.17-22920
   Deliyanti D, 2016, CLIN SCI, V130, P1375, DOI 10.1042/CS20160068
   Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z
   Di Marco E, 2015, CLIN SCI, V129, P199, DOI 10.1042/CS20150093
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403
   Erol MK, 2016, RETINA-J RET VIT DIS, V36, P1191, DOI 10.1097/IAE.0000000000000866
   Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1
   Fedor M, 2017, BIOL TRACE ELEM RES, V176, P1, DOI 10.1007/s12011-016-0805-1
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   FREEDMAN SF, 1992, EXP EYE RES, V55, P767, DOI 10.1016/0014-4835(92)90181-Q
   Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906
   FRYCZKOWSKI AW, 1989, INT OPHTHALMOL, V13, P269, DOI 10.1007/BF02280087
   Fuortes, 1972, PHYSL PHOTORECEPTOR, VVolume 7/2, P667
   Gate L, 1999, BIOMED PHARMACOTHER, V53, P169, DOI 10.1016/S0753-3322(99)80086-9
   Genuth S, 2005, DIABETES, V54, P3103, DOI 10.2337/diabetes.54.11.3103
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Good WV, 2006, BRIT J OPHTHALMOL, V90, P1378, DOI 10.1136/bjo.2006.098582
   Gordillo GM, 2003, AM J SURG, V186, P259, DOI 10.1016/S0002-9610(03)00211-3
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Haque R, 2017, J RECEPT SIG TRANSD, V37, P560, DOI 10.1080/10799893.2017.1369120
   Harindhanavudhi T, 2011, DIABETES CARE, V34, P1838, DOI 10.2337/dc11-0476
   Hartnett ME, 2010, DOC OPHTHALMOL, V120, P25, DOI 10.1007/s10633-009-9181-x
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Jamieson E, 2012, INVEST OPHTH VIS SCI, V53, P6728, DOI 10.1167/iovs.12-10492
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jo DH, 2019, GLIA, V67, P321, DOI 10.1002/glia.23542
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   KELLY LW, 1993, EXP EYE RES, V56, P341, DOI 10.1006/exer.1993.1044
   Tran-Viet KN, 2012, MOL VIS, V18, P937
   Kim Eun Bi, 2016, Korean J Ophthalmol, V30, P172, DOI 10.3341/kjo.2016.30.3.172
   Kim YK, 2002, DIABETES, V51, P522, DOI 10.2337/diabetes.51.2.522
   Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kortuem K, 2000, INVEST OPHTH VIS SCI, V41, P3176
   Kotwal R.S., 2009, J SPEC OPER MED, V9, P59
   KOWLURU R, 1994, CURR EYE RES, V13, P891, DOI 10.3109/02713689409015092
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Li JM, 2010, DIABETES, V59, P1528, DOI 10.2337/db09-1057
   Li XB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029350, 10.1371/journal.pone.0051199]
   Liew G., 2020, INVEST OPHTHALMOL VI
   Liu QP, 2018, MOL CELL BIOCHEM, V445, P105, DOI 10.1007/s11010-017-3256-x
   Liu R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/902842
   Lutty GA, 1997, AM J PATHOL, V151, P707
   Lutty GA, 2017, VISION RES, V139, P161, DOI 10.1016/j.visres.2017.04.011
   Maeno T, 2009, BRIT J OPHTHALMOL, V93, P1479, DOI 10.1136/bjo.2008.154930
   Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa
   de la Camara CMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074223
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   MCCORD J M, 1986, Journal of Free Radicals in Biology and Medicine, V2, P307
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCNEIL JD, 1985, ANN RHEUM DIS, V44, P780, DOI 10.1136/ard.44.11.780
   Meng WH, 2018, ACTA OPHTHALMOL, V96, pE811, DOI 10.1111/aos.13769
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B
   Mima A, 2012, INVEST OPHTH VIS SCI, V53, P8424, DOI 10.1167/iovs.12-10207
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, P7256, DOI 10.1167/iovs.14-15193
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Montezano AC, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0431-2
   Narayanan SP, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.23
   Narayanan SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022460
   Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nitta K, 2019, MOL VIS, V25, P859
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   Ozawa Yoko, 2011, Exp Diabetes Res, V2011, P108328, DOI 10.1155/2011/108328
   Palenski TL, 2013, MICROVASC RES, V89, P57, DOI 10.1016/j.mvr.2013.06.007
   Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Portillo JAC, 2014, DIABETOLOGIA, V57, P2222, DOI 10.1007/s00125-014-3321-x
   Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S
   Rana I, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107902
   Ranchon I, 1999, INVEST OPHTH VIS SCI, V40, P1191
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Santos JM, 2011, FREE RADICAL BIO MED, V51, P1849, DOI 10.1016/j.freeradbiomed.2011.08.017
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sedeek M, 2012, J CARDIOVASC TRANSL, V5, P509, DOI 10.1007/s12265-012-9387-2
   Seki M, 2004, DIABETES, V53, P2412, DOI 10.2337/diabetes.53.9.2412
   Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4
   Sen CK, 2002, ANN NY ACAD SCI, V957, P239, DOI 10.1111/j.1749-6632.2002.tb02920.x
   Sheibani N, 1999, HISTOL HISTOPATHOL, V14, P285, DOI 10.14670/HH-14.285
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   SHIH YF, 1991, J OCUL PHARMACOL, V7, P83, DOI 10.1089/jop.1991.7.83
   Silva KC, 2009, DIABETES, V58, P1382, DOI 10.2337/db09-0166
   Silverstone B Z, 1986, Metab Pediatr Syst Ophthalmol (1985), V9, P581
   Simoncini S, 2005, INT IMMUNOL, V17, P489, DOI 10.1093/intimm/dxh229
   SIMONELLI F, 1989, EXP EYE RES, V49, P181, DOI 10.1016/0014-4835(89)90088-2
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Son SM, 2012, DIABETES METAB J, V36, P190, DOI 10.4093/dmj.2012.36.3.190
   Song Y, 2008, ACTA PHARMACOL SIN, V29, P823, DOI 10.1111/j.1745-7254.2008.00822.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Takeuchi M, 2000, J NEUROPATH EXP NEUR, V59, P1094, DOI 10.1093/jnen/59.12.1094
   Tan SM, 2015, EXP EYE RES, V136, P1, DOI 10.1016/j.exer.2015.04.015
   Tan SM, 2013, INVEST OPHTH VIS SCI, V54, P555, DOI 10.1167/iovs.12-10685
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tenconi PE, 2019, EXP EYE RES, V184, P243, DOI 10.1016/j.exer.2019.04.028
   Tewari S, 2012, ANTIOXID REDOX SIGN, V17, P492, DOI 10.1089/ars.2011.4333
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Wei YH, 2016, FREE RADICAL BIO MED, V99, P234, DOI 10.1016/j.freeradbiomed.2016.08.013
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wilkinson-Berka JL, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107766
   Wilkinson-Berka JL, 2014, ANTIOXID REDOX SIGN, V20, P2726, DOI 10.1089/ars.2013.5357
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Winkler BS, 1999, MOL VIS, V5
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Xu HB, 2001, BIOL TRACE ELEM RES, V79, P39, DOI 10.1385/BTER:79:1:39
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yamagishi SI, 2008, OPHTHAL RES, V40, P10, DOI 10.1159/000111152
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yokota H, 2011, INVEST OPHTH VIS SCI, V52, P8123, DOI 10.1167/iovs.11-8318
   Yu FJ, 2020, J PROTEOMICS, V221, DOI 10.1016/j.jprot.2020.103684
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
NR 173
TC 16
Z9 17
U1 3
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2020
VL 201
AR 108255
DI 10.1016/j.exer.2020.108255
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PI4FR
UT WOS:000601048900003
PM 32971094
DA 2022-11-30
ER

PT J
AU Kameyama, O
   Usui, Y
   Kimura, K
   Nakamura, A
   Sota, T
   Goto, H
AF Kameyama, Ori
   Usui, Yoshihiko
   Kimura, Keisuke
   Nakamura, Atsushi
   Sota, Takayuki
   Goto, Hiroshi
TI Noninvasive diagnostics supporting system for choroidal melanoma: a
   pilot study
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Near-Infrared hyperspectral imager; Choroidal melanoma
ID EMISSION COMPUTED-TOMOGRAPHY; UVEAL MALIGNANT-MELANOMA; MELANOCYTIC
   SKIN-LESIONS; ABCD RULE; DERMATOSCOPY; MICROSCOPY; FEATURES; GROWTH
AB To examine the usefulness of a near-infrared hyperspectral imager (NIR-HSI) system in discriminating uveal melanoma from other intraocular tumors.
   The NIR-HSI, which had been developed as a screening system for age-related macular degeneration, was used to measure near-infrared hyperspectral data (NIR-HSD) of a lesion located at the ocular fundus of 17 Japanese patients, including 5 with choroidal melanoma and 12 with other intraocular tumors. The index was derived from each NIR-HSD. Non-parametric statistical analysis was performed.
   Diagnostic accuracy of 94.1 % was achieved when the threshold value of the index was set to minimize the average value of false-positive and -negative fractions.
   The NIR-HSI system is useful as a noninvasive diagnostic supporting system for choroidal melanoma.
C1 [Kameyama, Ori; Sota, Takayuki] Waseda Univ, Dept Elect Engn & Biosci, Shinjuku Ku, Tokyo 1698555, Japan.
   [Usui, Yoshihiko; Kimura, Keisuke; Goto, Hiroshi] Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, Tokyo 1600023, Japan.
   [Nakamura, Atsushi; Sota, Takayuki] Waseda Univ, Res Inst Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan.
C3 Waseda University; Tokyo Medical University; Waseda University
RP Usui, Y (通讯作者)，Tokyo Med Univ Hosp, Dept Ophthalmol, Shinjuku Ku, Tokyo 1600023, Japan.
EM usuyoshi@gmail.com
RI /AAD-1824-2020
CR Argenziano G, 1998, ARCH DERMATOL, V134, P1563, DOI 10.1001/archderm.134.12.1563
   Collaborative Ocular Melanoma Grp, 2006, ARCH OPHTHALMOL-CHIC, V124, P1684
   Goto H, 2001, AM J OPHTHALMOL, V132, P937, DOI 10.1016/S0002-9394(01)01142-4
   Goto Hiroshi, 2004, Int J Clin Oncol, V9, P74, DOI 10.1007/s10147-003-0380-2
   Hawkins BS, 2004, AM J OPHTHALMOL, V138, P936, DOI 10.1016/j.ajo.2004.07.006
   HOLMAN BL, 1984, J NUCL MED, V25, P25
   HOLMAN BL, 1983, J NUCL MED, V24, P922
   Kaneko A., 1979, RIUSHO GANKA, V33, P941
   Khoobehi B, 2004, INVEST OPHTH VIS SCI, V45, P1464, DOI 10.1167/iovs.03-1069
   KRUSE FA, 1993, REMOTE SENS ENVIRON, V44, P145, DOI 10.1016/0034-4257(93)90013-N
   Menzies SW, 1996, ARCH DERMATOL, V132, P1178, DOI 10.1001/archderm.132.10.1178
   Menzies SW, 1996, MELANOMA RES, V6, P55, DOI 10.1097/00008390-199602000-00008
   MORIMOTO K, 2007, J TOKYO MED U, V65, P137
   NACHBAR F, 1994, J AM ACAD DERMATOL, V30, P551, DOI 10.1016/S0190-9622(94)70061-3
   Nagaoka T, 2013, SKIN RES TECHNOL, V19, pE290, DOI 10.1111/j.1600-0846.2012.00642.x
   Nagaoka T, 2012, SKIN RES TECHNOL, V18, P301, DOI 10.1111/j.1600-0846.2011.00571.x
   SCHEIDLER J, 1992, BRIT J OPHTHALMOL, V76, P457, DOI 10.1136/bjo.76.8.457
   Shields CL, 2009, ARCH OPHTHALMOL-CHIC, V127, P981, DOI 10.1001/archophthalmol.2009.151
   Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P360, DOI 10.1001/archopht.118.3.360
   SHIELDS CL, 1995, OPHTHALMOLOGY, V102, P1351, DOI 10.1016/S0161-6420(95)30864-0
   Shields JA, 2005, RETINA-J RET VIT DIS, V25, P767, DOI 10.1097/00006982-200509000-00013
   Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2
   Sou R, 2004, JPN J OPHTHALMOL, V48, P54, DOI 10.1007/s10384-003-0016-0
   STOLZ W, 1994, EUR J DERMATOL, V4, P521
   Vo-Dinh T, 2004, IEEE ENG MED BIOL, V23, P40
   World Medical Association, DECL HELS ETH PRINC
   Yamauchi Y, 2012, JPN J OPHTHALMOL, V56, P577, DOI 10.1007/s10384-012-0184-x
   Yoshimura M, 2011, JPN J OPHTHALMOL, V55, P148, DOI 10.1007/s10384-010-0915-9
NR 28
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2015
VL 59
IS 1
BP 48
EP 54
DI 10.1007/s10384-014-0351-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5TM
UT WOS:000348282600008
PM 25287149
DA 2022-11-30
ER

PT J
AU Voleti, VB
   Hubschman, JP
AF Voleti, Vinod B.
   Hubschman, Jean-Pierre
TI Age-related eye disease
SO MATURITAS
LA English
DT Review
DE Aging; Vision; Ocular; Ophthalmology; Ophthalmic; Low-vision; Vision
   loss; Blindness; Sight; Cataract; Glaucoma; Diabetic retinopathy;
   Proliferative diabetic retinopathy; Diabetic macular edema; Retinal vein
   occlusion; Central retinal vein occlusion; Brach retinal vein occlusion;
   Age-related macular degeneration; Macular degeneration; Anti-VEGF
ID RETINAL-VEIN-OCCLUSION; DIABETIC MACULAR EDEMA; RISK-FACTORS; VITREOUS
   LEVELS; RANIBIZUMAB; GLAUCOMA; DEGENERATION; PREVALENCE; VITRECTOMY;
   FEATURES
AB As with many organs, compromised function of the eye is accompanied with age and has become increasingly prevalent with the aging population. When decreased visual loss becomes significant, patients' ability to perform activities of daily living becomes compromised. This decrease in function is met with morbidity and mortality, as well as a large socioeconomic burdon throughout the world. This review summarizes the most common age-related eye diseases, including cataract, glaucoma, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. Although our understanding of the genetic and biochemical pathways of these diseases is sill at its primitive stages, we have become able to help our patients improve the quality of life as they age. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
RP Hubschman, JP (通讯作者)，100 Stein Plaza, Los Angeles, CA 90095 USA.
EM hubschman@jsei.ucla.edu
OI Hubschman, Jean-Pierre/0000-0002-8631-3467
FU Price Foundation Retina Research Fund
FX This research was supported by the Price Foundation Retina Research Fund
   (VV and J-PH).
CR [Anonymous], 2001, ARCH OPHTHALMOL-CHIC, V119, P1416
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Borrillo JL, 2001, CURR OPIN OPHTHALMOL, V12, P207, DOI 10.1097/00055735-200106000-00011
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P4297, DOI 10.1167/iovs.08-1826
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Dally LG, 2002, AM J OPHTHALMOL, V134, P481
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Ehlers JP, 2011, SURV OPHTHALMOL, V56, P281, DOI 10.1016/j.survophthal.2010.11.006
   Friedman DS, 2007, INVEST OPHTH VIS SCI, V48, P5052, DOI 10.1167/iovs.07-0290
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gedde SJ, 2010, CURR OPIN OPHTHALMOL, V21, P123, DOI 10.1097/ICU.0b013e3283360b68
   Hartley KL, 2008, RETINA-J RET VIT DIS, V28, P410, DOI 10.1097/IAE.0b013e31816102f2
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Keltner JL, 2006, OPHTHALMOLOGY, V113, P1603, DOI 10.1016/j.ophtha.2006.05.061
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein BEK, 2004, INVEST OPHTH VIS SCI, V45, P59, DOI 10.1167/iovs.03-0516
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Knudtson MD, 2009, ARCH GERONTOL GERIAT, V49, P22, DOI 10.1016/j.archger.2008.04.006
   Lichtinger A, 2012, CURRENT OPINION OPHT, V23, P33
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Michael R, 2011, PHILOS T R SOC B, V366, P1278, DOI 10.1098/rstb.2010.0300
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2009, OPHTHALMOLOGY, V116, P87, DOI 10.1016/j.ophtha.2008.09.034
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   Rao GN, 2011, CURR OPIN OPHTHALMOL, V22, P4, DOI 10.1097/ICU.0b013e3283414fc8
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rolim de Moura C, 2007, COCHRANE DB SYST REV
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sharma P, 2008, SURV OPHTHALMOL, V53, pS17, DOI 10.1016/j.survophthal.2008.08.003
   The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Uy HS, 2012, CURRENT OPINION OPHT, V23, P40
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yochim BP, 2012, J GLAUCOMA, V21, P250, DOI 10.1097/IJG.0b013e3182071b7e
   Yorston D, 2008, BRIT J OPHTHALMOL, V92, P365, DOI 10.1136/bjo.2007.124495
NR 51
TC 25
Z9 28
U1 1
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD MAY
PY 2013
VL 75
IS 1
BP 29
EP 33
DI 10.1016/j.maturitas.2013.01.018
PG 5
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA 136VW
UT WOS:000318392500005
PM 23474322
DA 2022-11-30
ER

PT J
AU Pinto, RVB
   Smiddy, WE
   Culbertson, W
AF Pinto, RVB
   Smiddy, WE
   Culbertson, W
TI Choroidal neovascularization following laser in situ keratomileusis
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID MACULAR HEMORRHAGE
AB Two cases of choroidal neovascularization occurring after laser in situ keratomileusis (LASIK) are presented from two separate centers. In the first case, an extrafoveal choroidal neovascular membrane, apparently associated with age-related macular degeneration, occurred 3 months after a LASIK procedure was performed on a 64-year-old man with hyperopia. Argon laser treatment and subsequent photodynamic therapy were performed and resulted in stabilization of vision. The second case involved neovascularization 3 weeks following a LASIK procedure for myopia, apparently associated with the myopia. No treatment was recommended and the vision stabilized at 20/50. Although the cause is not clear, careful preoperative macular evaluation and attention to symptoms that might herald the presence of choroidal neovascularization are recommended for patients undergoing LASIK.
C1 Univ Miami, Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   Inst Mineiro Olhos Belo Horizonte, Belo Horizonte, MG, Brazil.
C3 Bascom Palmer Eye Institute; University of Miami
RP Smiddy, WE (通讯作者)，Univ Miami, Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
CR Arevalo JF, 2000, OPHTHALMOLOGY, V107, P258, DOI 10.1016/S0161-6420(99)00078-0
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Chen YC, 2001, RETINA-J RET VIT DIS, V21, P174, DOI 10.1097/00006982-200104000-00013
   Ellies P, 2000, J CATARACT REFR SURG, V26, P922, DOI 10.1016/S0886-3350(00)00313-8
   Luna JD, 1999, GRAEF ARCH CLIN EXP, V237, P611, DOI 10.1007/s004170050286
   Ruiz-Moreno JM, 2001, RETINA-J RET VIT DIS, V21, P115, DOI 10.1097/00006982-200104000-00003
NR 6
TC 3
Z9 3
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2004
VL 35
IS 1
BP 63
EP 66
DI 10.3928/1542-8877-20040101-14
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 808EQ
UT WOS:000220552800012
PM 14750767
DA 2022-11-30
ER

PT J
AU Wu, HJ
   Sekiryu, T
   Sugano, Y
   Itagaki, K
   Kasai, A
   Shintake, H
AF Wu, Huajui
   Sekiryu, Tetsuju
   Sugano, Yukinori
   Itagaki, Kanako
   Kasai, Akihito
   Shintake, Hiroaki
TI A modified measuring method to investigate the choriocapillaris flow
   void of polypoidal choroidal vasculopathy with swept source optical
   coherence tomography angiography
SO QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
LA English
DT Article
DE Choriocapillaris (CC); flow void; polypoidal choroidal vasculopathy
   (PCV); optical coherence tomography angiography (OCTA)
ID ENDOTHELIAL GROWTH-FACTOR
AB Background: To propose a modified method to investigate the flow void of polypoidal choroidal vasculopathy (PCV) choriocapillaris.
   Methods: This paper involves a retrospective study. Included 30 PCV affect eyes, 30 old control eyes, 20 young control eyes, 15 affect eyes with anti-VEGF intravitreal injection treatment, and 8 fellow eyes of anti-VEGF intravitreal injection treatment group. After the choriocapillaris slab [10 mu m thick starting 30 mu m beneath to the retinal pigment epithelium (RPE)-fit reference] was extracted from macular optical coherence tomography angiography 6x6-mm scans, the flow void was segmented by the Phansalkar method. We analyzed the flow void sizes-frequency histogram in order to investigate the differences of flow void proportion between groups. Then we verified the differences between groups after anti-VEGF intravitreal injection treatment.
   Results: On the difference curve between the PCV group and Old control group, there was a peak appeared at the flow void sizes range from 900 to 1,125 mu m(2). The average number of flow void sizes from 900 to 1,125 mu m(2) was significantly higher in the Old control group than that in the Young control group (P<0.05) and there was no difference between the affect eyes group and the Old control group. The proportion of flow void sizes from 900 to 1,125 mu m(2) were remarkably higher in the affect eyes group compared to the Old control group (P<0.05), showing no difference between the Young control group and the Old control group. The average number of flow void sizes from 900 to 1,125 mu m(2) and the proportion of flow void sizes range from 900 to 1,125 mu m(2) were significantly higher in the treatment group after the treatment (P<0.05) and there was no difference in the fellow eyes of treatment group. The choroidal thickness was significantly reduced after the treatment of the treatment group (P<0.001), while the fellow eyes of the treatment group had no difference.
   Conclusions: Our method was specific for the pathological changes in choriocapillaris structures of PCV affect eyes, fellow eyes, and the affect eyes after anti-VEGF treatment.
C1 [Wu, Huajui; Sekiryu, Tetsuju; Sugano, Yukinori; Itagaki, Kanako; Kasai, Akihito; Shintake, Hiroaki] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Fukushima, Japan.
C3 Fukushima Medical University
RP Wu, HJ (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Fukushima, Fukushima, Japan.
EM hz210321@gmail.com
OI Wu, Huajui/0000-0003-3764-2472
CR Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kim K, 2020, AM J OPHTHALMOL, V217, P240, DOI 10.1016/j.ajo.2020.05.017
   Kim K, 2020, OPHTHALMOLOGICA, V243, P172, DOI 10.1159/000501212
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lang T, 2004, CROAT MED J, V45, P361
   Moussa Kareem, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS128, DOI 10.1097/ICB.0000000000000464
   MURRAY GD, 1988, BRIT J SURG, V75, P664, DOI 10.1002/bjs.1800750714
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SOILLE P, 1990, P SOC PHOTO-OPT INS, V1360, P240, DOI 10.1117/12.24211
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Ng WY, 2016, INVEST OPHTH VIS SCI, V57, P4933, DOI 10.1167/iovs.16-20191
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 36
TC 4
Z9 4
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2223-4292
EI 2223-4306
J9 QUANT IMAG MED SURG
JI Quant. Imaging Med. Surg.
PD JUL
PY 2021
VL 11
IS 7
BP 3146
EP 3156
DI 10.21037/qims-20-1027
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA SD8SF
UT WOS:000651645600021
PM 34249641
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Gau, D
   Vignaud, L
   Francoeur, P
   Koes, D
   Guillonneau, X
   Roy, P
AF Gau, David
   Vignaud, Lucile
   Francoeur, Paul
   Koes, David
   Guillonneau, Xavier
   Roy, Partha
TI Inhibition of ocular neovascularization by novel anti-angiogenic
   compound
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Angiogenesis; AMD; Profilin; Actin; Small molecule compound
ID MACULAR DEGENERATION; VEGF-A; MIGRATION
AB Aberrant angiogenesis lies at the heart of a wide range of ocular pathologies such as proliferative diabetic retinopathy, wet age-related macular degeneration and retinopathy of prematurity. This study explores the antiangiogenic activity of a novel small molecule investigative compound capable of inhibiting profilin1-actin interaction recently identified by our group. We demonstrate that our compound is capable of inhibiting migration, proliferation and angiogenic activity of microvascular endothelial cells in vitro as well as choroidal neovascularization (CNV) ex vivo. In mouse model of laser-injury induced CNV, intravitreal administration of this compound diminishes sub-retinal neovascularization. Finally, our preliminary structure-activity relationship study (SAR) demonstrates that this small molecule compound is amenable to improvement in biological activity through structural modifications.
C1 [Gau, David; Roy, Partha] Univ Pittsburgh, Bioengn, Pittsburgh, PA 15219 USA.
   [Vignaud, Lucile; Guillonneau, Xavier] Sorbonne Univ, Inst Vis, INSERM, Paris, France.
   [Francoeur, Paul; Koes, David] Univ Pittsburgh, Computat Biol, Pittsburgh, PA 15219 USA.
   [Roy, Partha] Univ Pittsburgh, Pathol, Pittsburgh, PA 15219 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Roy, P (通讯作者)，Univ Pittsburgh, 306 CNBIO,300 Technol Dr, Pittsburgh, PA 15219 USA.
EM par19@pitt.edu
RI Koes, David Ryan/M-4523-2018; guillonneau, xavier/AAF-9495-2021;
   Guillonneau, xavier/E-3995-2017
OI Koes, David Ryan/0000-0002-6892-6614; guillonneau,
   xavier/0000-0001-7379-3935; Guillonneau, xavier/0000-0001-7379-3935;
   Roy, Partha/0000-0002-4946-8531; Francoeur, Paul/0000-0002-1440-567X
FU National Cancer Center fellowship [T32-HL129964]; Imaging Sciences in
   Translational Cardiovascular Training Program fellowship [T32-HL129964];
   DOD [W81XWH-19-1-0768]; NIH [CA248873, GM108340-04]
FX This work was supported by National Cancer Center fellowship and Imaging
   Sciences in Translational Cardiovascular Training Program fellowship
   (T32-HL129964) (to Gau), DOD Grant #W81XWH-19-1-0768 (Roy) and NIH
   grants CA248873 (Roy) and GM108340-04 (Koes).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Allen A, 2020, J BIOL CHEM, V295, P15636, DOI 10.1074/jbc.RA120.013963
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Ding ZJ, 2006, J CELL SCI, V119, P4127, DOI 10.1242/jcs.03178
   Ding ZJ, 2009, EXP CELL RES, V315, P2963, DOI 10.1016/j.yexcr.2009.07.004
   Gau D, 2020, J BIOL CHEM, V295, P9618, DOI 10.1074/jbc.RA120.012613
   Gau D, 2017, ANGIOGENESIS, V20, P663, DOI 10.1007/s10456-017-9560-y
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Nirmal J, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108187
   Olvera-Montano O, 2019, DRUG DES DEV THER, V13, P3813, DOI 10.2147/DDDT.S219350
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
NR 16
TC 0
Z9 0
U1 2
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2021
VL 213
AR 108861
DI 10.1016/j.exer.2021.108861
EA NOV 2021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XE9QF
UT WOS:000723715600001
PM 34822853
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kuse, Y
   Takahashi, K
   Inoue, Y
   Izawa, H
   Nakamura, S
   Shimazawa, M
   Hara, H
AF Kuse, Yoshiki
   Takahashi, Kei
   Inoue, Yuki
   Izawa, Hiroshi
   Nakamura, Shinsuke
   Shimazawa, Masamitsu
   Hara, Hideaki
TI Intravitreal aflibercept protects photoreceptors of mice against
   excessive light exposure
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Retina; Placental growth factor; Age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; VEGF-A; DAMAGE; PLGF
AB Our previous studies found that an anti-placental growth factor (PlGF) antibody protected the retina in light-induced retinal damage model, a model of non-exudative age-related macular degeneration (AMD). Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF) and PlGF. In present study, we revealed that the intravitreal injection of aflibercept lessens light-induced retinal damage, while anti-VEGF antibody has no effect on the light-exposed retina. Moreover, PlGF disrupted the tight junctions between the human retinal pigment epithelial cells in vitro, and aflibercept blocked the disruption. These data suggest that the aflibercept may be an effective treatment of non-exudative AMD. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Kuse, Yoshiki; Takahashi, Kei; Inoue, Yuki; Izawa, Hiroshi; Nakamura, Shinsuke; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Kuse, Yoshiki/AAB-7445-2021
OI Hara, Hideaki/0000-0003-2046-9001; Takahashi, Kei/0000-0002-7455-0465
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Ciombor KK, 2013, CLIN CANCER RES, V19, P1920, DOI 10.1158/1078-0432.CCR-12-2911
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Otsuka T, 2013, J PHARMACOL SCI, V123, P209, DOI 10.1254/jphs.13066FP
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
NR 13
TC 2
Z9 2
U1 0
U2 0
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD AUG
PY 2018
VL 137
IS 4
BP 407
EP 411
DI 10.1016/j.jphs.2018.07.010
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GU1LI
UT WOS:000445022600013
PM 30150144
OA gold
DA 2022-11-30
ER

PT J
AU Bo, QY
   Ma, S
   Han, Q
   Wang, FE
   Li, XR
   Zhang, Y
AF Bo, Qiyu
   Ma, Shan
   Han, Qian
   Wang, Fei E.
   Li, Xiaorong
   Zhang, Yan
TI Role of Autophagy in Photoreceptor Cell Survival and Death
SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
LA English
DT Article
DE autophagy; photoreceptor cell; retinal detachment; age-related macular
   degeneration; retinitis pigmentosa; Leber's congenital amaurosis
ID MACULAR DEGENERATION; RETINAL-DETACHMENT; BECLIN 1; APOPTOSIS;
   MECHANISMS; ACTIVATION; PATHWAY; DISEASE; PHOSPHORYLATION; MACHINERY
AB Autophagy, a highly conserved self-degradation process that occurs under both physiological and pathological conditions, provides the raw material and energy for cell regeneration under normal circumstances. Dysregulated autophagy under diseased conditions may cause protein accumulation, organelle dysfunction, and even cell death. Recent studies have shown that autophagy regulates the structural integrity and physiological functions of retinal photoreceptor cells and contributes to the pathogenesis of retinopathies such as retinal detachment, age-related macular degeneration, retinitis pigmentosa, and Leber's congenital amaurosis. In this review, we discuss the role of autophagy in photoreceptor cell survival and death in retinal physiology and diseases, and suggest the possibility that autophagy-targeting therapy may be a new strategy for retinal diseases marked by photoreceptor cell death.
C1 [Bo, Qiyu; Ma, Shan; Han, Qian; Wang, Fei E.; Li, Xiaorong; Zhang, Yan] Tianjin Med Univ, Coll Optometry & Ophthalmol, Tianjin Med Univ Eye Hosp, Tianjin Med Univ Eye Inst, Tianjin 300384, Peoples R China.
C3 Tianjin Medical University
RP Wang, FE (通讯作者)，Tianjin Med Univ, Coll Optometry & Ophthalmol, Tianjin Med Univ Eye Hosp, Tianjin Med Univ Eye Inst, Fukang Rd 251, Tianjin 300384, Peoples R China.
EM wangfei1@gmail.com; xiaorli@163.com; yanzhang9927@163.com
FU Ph.D. Programs Foundation of the Ministry of Education of China
   [20111202110008, 20121202120005]; 45th Scientific Research Foundation
   for the Returned Overseas Chinese Scholars, State Education Ministry;
   third phase construction of Tianjin Medical University "211" project
   [2010GSI19]; start-up fund for introduction of talents to Tianjin
   Medical University Eye Hospital [TJEC20101110]
FX This work was supported by the Ph.D. Programs Foundation of the Ministry
   of Education of China (20111202110008 to X.L.; 20121202120005 to Y.Z.);
   the 45th Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, State Education Ministry, to Y.Z.; the start-up fund
   for introduction of talents to Tianjin Medical University Eye Hospital
   (TJEC20101110 to Y.Z.); and the graduate student innovation fund from
   the third phase construction of Tianjin Medical University "211" project
   (2010GSI19 to S.M.).
CR Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Balmer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074162
   Besirli CG, 2011, INVEST OPHTH VIS SCI, V52, P4193, DOI 10.1167/iovs.10-7090
   Cai X, 2009, OPHTHALMIC GENET, V30, P57, DOI 10.1080/13816810802626399
   Chinskey ND, 2014, INVEST OPHTH VIS SCI, V55, P688, DOI 10.1167/iovs.13-12951
   Cho KS, 2012, INVEST OPHTH VIS SCI, V53, P5344, DOI 10.1167/iovs.12-9827
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hufnagel RB, 2012, GRAEF ARCH CLIN EXP, V250, P1117, DOI 10.1007/s00417-012-2028-2
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P65, DOI 10.4161/auto.3431
   Kunchithapautham K, 2011, INVEST OPHTH VIS SCI, V52, P2967, DOI 10.1167/iovs.10-6278
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   MADREPERLA SA, 1990, ARCH OPHTHALMOL-CHIC, V108, P358, DOI 10.1001/archopht.1990.01070050056030
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Metrailler S, 2012, EXP EYE RES, V96, P70, DOI 10.1016/j.exer.2011.12.019
   Midorikawa R, 2010, J NEUROSCI, V30, P10703, DOI 10.1523/JNEUROSCI.2061-10.2010
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Raemy E, 2014, CHEM PHYS LIPIDS, V179, P70, DOI 10.1016/j.chemphyslip.2013.12.002
   Rahimi A, 2013, APOPTOSIS, V18, P1492, DOI 10.1007/s10495-013-0895-6
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398
   REME CE, 1977, INVEST OPHTH VIS SCI, V16, P815
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Ross W H, 2000, Curr Opin Ophthalmol, V11, P191, DOI 10.1097/00055735-200006000-00007
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zacks DN, 2007, ARCH OPHTHALMOL-CHIC, V125, P1389, DOI 10.1001/archopht.125.10.1389
   Zacks DN, 2006, INVEST OPHTH VIS SCI, V47, P1691, DOI 10.1167/iovs.05-1209
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
NR 54
TC 16
Z9 16
U1 1
U2 13
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1045-4403
EI 2162-6502
J9 CRIT REV EUKAR GENE
JI Crit. Rev. Eukaryot. Gene Expr.
PY 2015
VL 25
IS 1
BP 23
EP 32
DI 10.1615/CritRevEukaryotGeneExpr.2015012376
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CF7FN
UT WOS:000352721700003
PM 25955815
DA 2022-11-30
ER

PT J
AU Kaluzny, JJ
   Szkulmowska, A
   Bajraszewski, T
   Szkulmowski, M
   Kaluzny, BJ
   Gorczynska, I
   Targowski, P
   Wojtkowski, M
AF Kaluzny, J. J.
   Szkulmowska, A.
   Bajraszewski, T.
   Szkulmowski, M.
   Kaluzny, B. J.
   Gorczynska, I.
   Targowski, P.
   Wojtkowski, M.
TI Retinal imaging by spectral optical coherence tomography
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE spectral optical coherence tomography; retinal imaging; retinal layers;
   central serous chorioretinopathy; choroidal neovascularization
ID ULTRAHIGH-RESOLUTION; HIGH-SPEED; IN-VIVO
AB PURPOSE. To demonstrate applicability of high speed spectral optical coherence tomography (SOCT) method for imaging retinal pathologies in clinical conditions.
   METHODS. SOCT was performed in 67 eyes with different macular diseases. Examinations were carried out with the prototype SOCT instrument constructed in the Institute of Physics, Nicolaus Copernicus University, Toruri, Poland. A broadband superluminescent diode was used as a light source.
   RESULTS. The disturbances of retinal layer structure concerning mainly outer segments of photoreceptors were observed in case of central serous chorioretinopathy and choroidal neovascularization in age-related macular degeneration. Large drusen were often related to significant changes of outer nuclear layer thickness and reflectivity.
   CONCLUSIONS. SOCT detects small disturbances of the retinal structure and helps to precisely determine layers involved in different pathologies.
C1 Nicholas Copernicus Univ, Coll Med, Dept Ophthalmol, PL-85094 Bydgoszcz, Poland.
   Nicholas Copernicus Univ, Inst Phys, PL-87100 Torun, Poland.
C3 Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum;
   Nicolaus Copernicus University
RP Kaluzny, JJ (通讯作者)，Nicholas Copernicus Univ, Coll Med, Dept Ophthalmol, Ul M Curie Sklodowskiej 9, PL-85094 Bydgoszcz, Poland.
EM kubeye@poczta.onet.pl
RI Gorczynska, Iwona M./P-9367-2015; Targowski, Piotr/I-8563-2012; Maciej,
   Szkulmowski/B-7923-2009; Wojtkowski, Maciej/D-6822-2014; Kaluzny,
   Bartlomiej J/F-1183-2014; Szkulmowski, Maciej/D-6244-2014; Targowski,
   Piotr/N-3258-2019
OI Gorczynska, Iwona M./0000-0002-6120-8791; Targowski,
   Piotr/0000-0002-7405-7662; Kaluzny, Bartlomiej J/0000-0002-1332-3592;
   Szkulmowski, Maciej/0000-0002-2006-0524; Targowski,
   Piotr/0000-0002-7405-7662; Szkulmowska, Anna/0000-0002-2939-0829;
   Wojtkowski, Maciej/0000-0003-0599-0878; Kaluzny,
   Jakub/0000-0003-1908-2141
CR Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Costa RA, 2006, PROG RETIN EYE RES, V25, P325, DOI 10.1016/j.preteyeres.2006.03.001
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   FERCHER AF, 1988, OPT LETT, V13, P186, DOI 10.1364/OL.13.000186
   FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang SH, 2004, INT J IMMUNOPATH PH, V17, P1
   IZATT JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P1584, DOI 10.1001/archopht.1994.01090240090031
   Kaluzny BJ, 2006, CORNEA, V25, P960, DOI 10.1097/01.ico.0000224644.81719.59
   Kaluzny BJ, 2006, OPHTHAL PHYSL OPT, V26, P127, DOI 10.1111/j.1475-1313.2006.00371.x
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   SCUMAN JS, 2004, OPTICAL COHERENCE TO, P57
   SWANSON EA, 1992, OPT LETT, V17, P151, DOI 10.1364/OL.17.000151
   Szkulmowski M, 2005, OPT COMMUN, V246, P569, DOI 10.1016/j.optcom.2004.11.024
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2003, OPT LETT, V28, P1745, DOI 10.1364/OL.28.001745
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 34
TC 6
Z9 6
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2007
VL 17
IS 2
BP 238
EP 245
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177UZ
UT WOS:000247179300014
PM 17415698
DA 2022-11-30
ER

PT J
AU Singh, M
   Chee, CKL
AF Singh, Mandeep
   Chee, Caroline K. L.
TI Spectral domain optical coherence tomography imaging of retinal diseases
   in Singapore
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID ULTRAHIGH-RESOLUTION; PATHOLOGY
AB In this retrospective case series, the authors reviewed cases of patients with macular disorders whose eyes had been imaged using spectral domain optical coherence tomography (SD-OCT) (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA). SD-OCT images were obtained from patients with a variety of ocular conditions attending a tertiary retinal clinic in Singapore from August 2007 to December 2007, according to standardized protocols. Images of 428 eyes from 301 patients were reviewed. Ocular diagnoses included diabetic macular edema, exudative age-related macular degeneration, central serous chorioretinopathy, cystoid macular edema, retinal vent and artery occlusions, infective chorioretinitis, and others. The authors present four cases of particular interest to illustrate how SD-OCT was useful in complementing the clinician's assessment of macular disease.
C1 [Singh, Mandeep; Chee, Caroline K. L.] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore 119074, Singapore.
   [Chee, Caroline K. L.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore
RP Chee, CKL (通讯作者)，Natl Univ Singapore Hosp, Dept Ophthalmol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
OI Singh, Mandeep/0000-0003-1749-0088
CR Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
NR 11
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2008
VL 39
IS 4
SU S
BP S120
EP S125
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 335IC
UT WOS:000258283000023
DA 2022-11-30
ER

PT J
AU Tudor, C
   Pintea, A
AF Tudor, Cristina
   Pintea, Adela
TI A Brief Overview of Dietary Zeaxanthin Occurrence and Bioaccessibility
SO MOLECULES
LA English
DT Review
DE zeaxanthin; bioaccessibility; INFOGEST; antioxidants; ocular health
ID IN-VITRO BIOACCESSIBILITY; PIGMENT OPTICAL-DENSITY; CAROTENOID ESTERS;
   ANTIOXIDANT ACTIVITY; BETA-CAROTENE; EGG-YOLK; COGNITIVE FUNCTION;
   MESO-ZEAXANTHIN; VITAMIN-A; LUTEIN
AB As it exhibits no provitamin A activity, the dietary intake of zeaxanthin is not considered essential. However, its contribution to ocular health has long been acknowledged. Numerous publications emphasize the importance of zeaxanthin alongside lutein in ocular diseases such as cataracts and age-related macular degeneration which constitute an important health concern, especially among the elderly. Considering that the average dietary ratio of lutein to zeaxanthin favors the first, more bioaccessible food sources of zeaxanthin that can hinder the development and progression of the above-mentioned disorders are of great interest. In this paper, a brief overview of the more recent state of knowledge as regards dietary sources together with their respective zeaxanthin bioaccessibility assessed through a standardized in vitro digestion method was provided.
C1 [Tudor, Cristina; Pintea, Adela] Univ Agr Sci & Vet Med, Dept Chem & Biochem, Manastur St 3-5, Cluj Napoca 400372, Romania.
C3 University of Agricultural Sciences & Veterinary Medicine Cluj Napoca
RP Pintea, A (通讯作者)，Univ Agr Sci & Vet Med, Dept Chem & Biochem, Manastur St 3-5, Cluj Napoca 400372, Romania.
EM cristina.tudor@usamvcluj.ro; apintea@usamvcluj.ro
RI Pintea, Adela/C-4521-2011
OI Pintea, Adela/0000-0002-9914-2070; Tudor, Cristina/0000-0002-2578-4505
FU Romanian Ministry of Research and Innovation, PCCDI-UEFISCDI within
   PNCDI III [PN-III-P1-1.2-PCCDI-2017-0046/, 1/2018]
FX This research was funded by a grant of the Romanian Ministry of Research
   and Innovation, PCCDI-UEFISCDI, project
   PN-III-P1-1.2-PCCDI-2017-0046/No. 1/2018, within PNCDI III.
CR Abdel-Aal ESM, 2007, J AGR FOOD CHEM, V55, P787, DOI 10.1021/jf062764p
   Al-Delaimy WK, 2004, PUBLIC HEALTH NUTR, V7, P713, DOI 10.1079/PHN2004598
   Asensio-Grau A, 2018, J FUNCT FOODS, V46, P579, DOI 10.1016/j.jff.2018.05.025
   Garzon GA, 2012, J AGR FOOD CHEM, V60, P4709, DOI 10.1021/jf205347f
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bernaerts TMM, 2020, J FUNCT FOODS, V65, DOI 10.1016/j.jff.2019.103770
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Burgos G, 2013, PLANT FOOD HUM NUTR, V68, P385, DOI 10.1007/s11130-013-0381-x
   Canene-Adams K, 2009, CAROTENOIDS SER, V5, P115, DOI 10.1007/978-3-7643-7501-0_7
   Carvalho E, 2013, FOOD CHEM, V139, P744, DOI 10.1016/j.foodchem.2012.12.047
   Cha KH, 2012, J AGR FOOD CHEM, V60, P9437, DOI 10.1021/jf303207x
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Christensen K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051101
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Cilla A, 2012, J AGR FOOD CHEM, V60, P7282, DOI 10.1021/jf301165r
   Cordero BF, 2011, APPL MICROBIOL BIOT, V91, P341, DOI 10.1007/s00253-011-3262-y
   Costa G.A., 2017, J FOOD COMPOS ANAL, V68, P53, DOI [10.1016/j.jfca.2017.02.012, DOI 10.1016/J.JFCA.2017.02.012]
   de Campo C, 2019, FOOD CHEM, V301, DOI 10.1016/j.foodchem.2019.125230
   de la Parra C, 2007, J AGR FOOD CHEM, V55, P4177, DOI 10.1021/jf063487p
   de Oliveira GPR, 2007, J FOOD SCI, V72, pS79, DOI 10.1111/j.1750-3841.2006.00235.x
   Delgado-Pelayo R, 2016, FOOD CHEM, V199, P165, DOI 10.1016/j.foodchem.2015.11.135
   Delgado-Pelayo R, 2014, FOOD RES INT, V65, P272, DOI 10.1016/j.foodres.2014.03.025
   Delgado-Pelayo R, 2012, J AGR FOOD CHEM, V60, P8225, DOI 10.1021/jf302719g
   Dragovic-Uzelac V, 2007, FOOD CHEM, V102, P966, DOI 10.1016/j.foodchem.2006.04.001
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Dwyer JH, 2004, ARTERIOSCL THROM VAS, V24, P313, DOI 10.1161/01.ATV.0000109955.80818.8a
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Failla ML, 2019, FOOD CHEM FUNCT ANAL, V13, P390
   Fernandez-Garcia E, 2012, FOOD RES INT, V46, P438, DOI 10.1016/j.foodres.2011.06.007
   Fernandez-Garcia E, 2009, NUTR RES, V29, P751, DOI 10.1016/j.nutres.2009.09.016
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gille A, 2019, FOOD RES INT, V118, P40, DOI 10.1016/j.foodres.2017.12.040
   Giordano E, 2018, ARCH BIOCHEM BIOPHYS, V647, P33, DOI 10.1016/j.abb.2018.04.008
   Gomez-Maqueo A, 2020, FOOD CHEM, V316, DOI 10.1016/j.foodchem.2020.126369
   Granado-Lorencio F, 2009, FOOD CHEM, V114, P747, DOI 10.1016/j.foodchem.2008.10.058
   Granado-Lorencio F, 2007, J AGR FOOD CHEM, V55, P6387, DOI 10.1021/jf070301t
   Grashorn M, 2016, WOODHEAD PUBL FOOD S, V295, P283, DOI 10.1016/B978-0-08-100371-8.00014-2
   Guil-Guerrero JL, 2006, EUR FOOD RES TECHNOL, V224, P1, DOI 10.1007/s00217-006-0281-5
   Hammond BR, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00254
   Hempel J, 2017, FOOD CHEM, V218, P525, DOI 10.1016/j.foodchem.2016.09.065
   Henriksen BS, 2013, INVEST OPHTH VIS SCI, V54, P5568, DOI 10.1167/iovs.13-12331
   Hu CC, 2008, FOOD CHEM, V109, P439, DOI 10.1016/j.foodchem.2007.12.043
   Huang WP, 2018, J AGR FOOD CHEM, V66, P891, DOI 10.1021/acs.jafc.7b05400
   Hulshof PJM, 2006, J FOOD COMPOS ANAL, V19, P67, DOI 10.1016/j.jfca.2005.04.005
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Inbaraj BS, 2008, J PHARMACEUT BIOMED, V47, P812, DOI 10.1016/j.jpba.2008.04.001
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson EJ, 2012, AM J CLIN NUTR, V96, p1161S, DOI 10.3945/ajcn.112.034611
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Kishimoto Y, 2017, FOOD RES INT, V99, P944, DOI 10.1016/j.foodres.2017.03.003
   Knockaert G, 2012, FOOD CHEM, V133, P60, DOI 10.1016/j.foodchem.2011.12.066
   Kopec RE, 2018, J FOOD COMPOS ANAL, V68, P16, DOI 10.1016/j.jfca.2017.06.008
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Lemmens L, 2014, TRENDS FOOD SCI TECH, V38, P125, DOI 10.1016/j.tifs.2014.05.005
   Leth T, 2000, EUR J LIPID SCI TECH, V102, P128, DOI 10.1002/(SICI)1438-9312(200002)102:2<128::AID-EJLT128>3.3.CO;2-8
   Lu QY, 2005, J NUTR BIOCHEM, V16, P23, DOI 10.1016/j.jnutbio.2004.08.003
   Mageney V, 2016, J AGR FOOD CHEM, V64, P3251, DOI 10.1021/acs.jafc.6b00268
   Marhuenda-Munoz M, 2019, EUR J CLIN NUTR, V72, P18, DOI 10.1038/s41430-018-0305-9
   Mariutti LRB, 2018, ARCH BIOCHEM BIOPHYS, V648, P36, DOI 10.1016/j.abb.2018.04.005
   McClements DJ, 2020, CURR OPIN FOOD SCI, V31, P57, DOI 10.1016/j.cofs.2019.11.005
   Mercadante AZ, 2017, FOOD RES INT, V99, P830, DOI 10.1016/j.foodres.2016.12.018
   Minekus M, 2014, FOOD FUNCT, V5, P1113, DOI 10.1039/c3fo60702j
   Murillo AG, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090390
   Murillo E, 2010, FOOD CHEM, V122, P167, DOI 10.1016/j.foodchem.2010.02.034
   Niesor EJ, 2014, LIPIDS, V49, P1233, DOI 10.1007/s11745-014-3958-8
   Nimalaratne C, 2012, J AGR FOOD CHEM, V60, P12547, DOI 10.1021/jf303828n
   Nolan JM, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2015.35
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   O'Sullivan AM, 2011, P NUTR SOC, V70, pE62, DOI 10.1017/S0029665111001029
   Xavier AAO, 2019, CURR OPIN FOOD SCI, V26, P1, DOI 10.1016/j.cofs.2019.02.015
   Olmedilla-Alonso B, 2019, HANDBOOK OF NUTRITION, DIET, AND THE EYE, 2ND EDITION, P529, DOI 10.1016/B978-0-12-815245-4.00032-6
   Palafox-Carlos H, 2011, J FOOD SCI, V76, pR6, DOI 10.1111/j.1750-3841.2010.01957.x
   Palombo P, 2007, SKIN PHARMACOL PHYS, V20, P199, DOI 10.1159/000101807
   Parada J, 2007, J FOOD SCI, V72, pR21, DOI 10.1111/j.1750-3841.2007.00274.x
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Cano MP, 2019, FOOD RES INT, V123, P538, DOI 10.1016/j.foodres.2019.05.017
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Pop RM, 2014, FOOD CHEM, V147, P1, DOI 10.1016/j.foodchem.2013.09.083
   Pugliese A, 2014, EUR J NUTR, V53, P501, DOI 10.1007/s00394-013-0555-1
   Reboul E, 2013, NUTRIENTS, V5, P3563, DOI 10.3390/nu5093563
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Roberts RL, 2013, AM J LIFESTYLE MED, V7, P182, DOI 10.1177/1559827613477827
   Rodrigo MJ, 2015, FOOD FUNCT, V6, P1950, DOI [10.1039/c5fo00258c, 10.1039/C5FO00258C]
   Rodrigues DB, 2017, J AGR FOOD CHEM, V65, P11220, DOI 10.1021/acs.jafc.7b04854
   Rodrigues DB, 2016, FOOD FUNCT, V7, P4992, DOI [10.1039/C6FO01293K, 10.1039/c6fo01293k]
   Rodriguez-Amaya DB, 2016, IFT PRESS SER, P225
   Rostamabadi H, 2019, J CONTROL RELEASE, V298, P38, DOI 10.1016/j.jconrel.2019.02.005
   Sachindra NM, 2005, LWT-FOOD SCI TECHNOL, V38, P221, DOI 10.1016/j.lwt.2004.06.003
   Sadda S, 2013, OPHTHALMOLOGICA, V230, P10
   Schweiggert RM, 2017, CRIT REV FOOD SCI, V57, P1807, DOI 10.1080/10408398.2015.1012756
   Schweiggert RM, 2016, FOOD CHEM, V200, P274, DOI 10.1016/j.foodchem.2016.01.038
   Schweiggert U, 2007, EUR FOOD RES TECHNOL, V225, P261, DOI 10.1007/s00217-006-0413-y
   Sentandreu E, 2020, J CLEAN PROD, V262, DOI 10.1016/j.jclepro.2020.121325
   Shin HS, 2016, POULTRY SCI, V95, P2366, DOI 10.3382/ps/pew127
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Shyam R, 2017, ARCH BIOCHEM BIOPHYS, V634, P21, DOI 10.1016/j.abb.2017.09.013
   Stinco CM, 2020, FOOD CHEM, V331, DOI 10.1016/j.foodchem.2020.127259
   Stinco CM, 2019, J FOOD COMPOS ANAL, V78, P24, DOI 10.1016/j.jfca.2019.01.019
   Torregrosa F, 2005, J AGR FOOD CHEM, V53, P9519, DOI 10.1021/jf051171w
   Tudor C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010076
   Victoria-Campos CI, 2013, J AGR FOOD CHEM, V61, P9938, DOI 10.1021/jf4032124
   Victoria-Campos CI, 2013, J AGR FOOD CHEM, V61, P3642, DOI 10.1021/jf3054559
   Vishwanathan R, 2013, LUTEIN ZEAXANTHIN EY, P215, DOI [10.1007/978-1-62703-203-2_13, DOI 10.1007/978-1-62703-203-2_13]
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   von Lintig J, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2019.158580
   Walk AM, 2017, INT J PSYCHOPHYSIOL, V118, P1, DOI 10.1016/j.ijpsycho.2017.05.005
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weller P, 2003, J AGR FOOD CHEM, V51, P7044, DOI 10.1021/jf034803s
   Wen X, 2017, J AGR FOOD CHEM, V65, P6140, DOI 10.1021/acs.jafc.7b02514
   Yabuzaki J, 2017, DATABASE-OXFORD, DOI 10.1093/database/bax004
   Zhang SH, 2020, FOOD FUNCT, V11, P944, DOI [10.1039/C9FO02622C, 10.1039/c9fo02622c]
   Zhong LJ, 2016, FOOD CHEM, V210, P541, DOI 10.1016/j.foodchem.2016.05.002
   Zou ZY, 2011, ATHEROSCLEROSIS, V219, P789, DOI 10.1016/j.atherosclerosis.2011.08.006
NR 119
TC 5
Z9 7
U1 10
U2 28
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2020
VL 25
IS 18
AR 4067
DI 10.3390/molecules25184067
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OG6LR
UT WOS:000581993400001
PM 32899907
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gellermann, W
   Bernstein, PS
AF Gellermann, W
   Bernstein, PS
TI Noninvasive detection of macular pigments in the human eye
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; Raman spectroscopy
ID LUTEIN SUPPLEMENTATION; SPECTRAL REFLECTANCE; CAROTENOID-PIGMENTS; RAMAN
   MEASUREMENT; OPTICAL-DENSITY; ZEAXANTHIN; CONE; DEGENERATION;
   LIPOFUSCIN; PATHOGENESIS
AB There is currently strong interest in developing noninvasive technologies for the detection of macular carotenoid pigments in the human eye. These pigments, consisting of lutein and zeaxanthin, are taken up from the diet and are thought to play an important role in the prevention of age-related macular degeneration, the leading cause of blindness in the elderly in the Western world. It may be possible to prevent or delay the onset of this debilitating disease with suitable dietary intervention strategies. We review the most commonly used detection techniques based on heterochromatic flicker photometry, fundus reflectometry, and autofluorescense techniques and put them in perspective with recently developed more molecule-specific Raman detection methods. (C) 2004 Society of Photo-Optical Instrumentation Engineers.
C1 Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   Dixon Laser Inst, Salt Lake City, UT 84112 USA.
   Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Gellermann, W (通讯作者)，Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
FU NATIONAL EYE INSTITUTE [R29EY011600, R42EY012324, R41EY012324] Funding
   Source: NIH RePORTER; NEI NIH HHS [1R41 EY 12324-01, 2R42 EY 12324-02,
   R29 EY 11600] Funding Source: Medline
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2002, PURE APPL CHEM, V74, P1419, DOI 10.1351/pac200274081419
   Bernstein PS, 1999, AGE RELATED MACULAR, P1
   BERNSTEIN PS, 2000, ENV STRESSORS EFFECT, P423
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1971, VISION RES, V11, P1057, DOI 10.1016/0042-6989(71)90112-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   BURROWS JL, UNPUB OPHTHALMOLOGY
   DELORI FC, 1977, ARCH OPHTHALMOL-CHIC, V95, P861, DOI 10.1001/archopht.1977.04450050139018
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1989, APPL OPTICS, V28, P1061, DOI 10.1364/AO.28.001061
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Gellermann W, 2002, OPT LETT, V27, P833, DOI 10.1364/OL.27.000833
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   Koyama Y., 1995, CAROTENOIDS B, P135
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Otake S, 2000, J OPT SOC AM A, V17, P615, DOI 10.1364/JOSAA.17.000615
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   SCHALCH W, 1999, CRC MOD NUT, P215
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P270, DOI 10.1007/s003470100533
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   SOMMERBERG OG, 1999, CURR EYE RES, V19, P502
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   WERNER JS, 1979, J OPT SOC AM, V69, P422, DOI 10.1364/JOSA.69.000422
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   WINTCH SW, EVALUATION 2 MACULAR
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 60
TC 26
Z9 26
U1 0
U2 5
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JAN-FEB
PY 2004
VL 9
IS 1
BP 75
EP 85
DI 10.1117/1.1628240
PG 11
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 765BR
UT WOS:000188247700006
PM 14715058
DA 2022-11-30
ER

PT J
AU Kjeldsen, EW
   Nordestgaard, LT
   Frikke-Schmidt, R
AF Kjeldsen, Emilie W.
   Nordestgaard, Liv T.
   Frikke-Schmidt, Ruth
TI HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE Alzheimer&#8217; s disease; blindness; diabetes; drusen; epidemiology;
   genetics; high-density lipoprotein; infection; mortality
ID HIGH-DENSITY-LIPOPROTEIN; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; ALZHEIMERS-DISEASE; MACULAR DEGENERATION; MENDELIAN
   RANDOMIZATION; HIGH-RISK; CIRCULATING METABOLITES; INSULIN-SECRETION;
   DIABETES-MELLITUS
AB High density lipoprotein (HDL) cholesterol has traditionally been considered the "good cholesterol", and most of the research regarding HDL cholesterol has for decades revolved around the possible role of HDL in atherosclerosis and its therapeutic potential within atherosclerotic cardiovascular disease. Randomized trials aiming at increasing HDL cholesterol have, however, failed and left questions to what role HDL cholesterol plays in human health and disease. Recent observational studies involving non-cardiovascular diseases have shown that high levels of HDL cholesterol are not necessarily associated with beneficial outcomes as observed for age-related macular degeneration, type II diabetes, dementia, infection, and mortality. In this narrative review, we discuss these interesting associations between HDL cholesterol and non-cardiovascular diseases, covering observational studies, human genetics, and plausible mechanisms.
C1 [Kjeldsen, Emilie W.; Nordestgaard, Liv T.; Frikke-Schmidt, Ruth] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.
   [Kjeldsen, Emilie W.; Nordestgaard, Liv T.; Frikke-Schmidt, Ruth] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, DK-2200 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen
RP Frikke-Schmidt, R (通讯作者)，Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.; Frikke-Schmidt, R (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, DK-2200 Copenhagen, Denmark.
EM emilie.westerlin.kjeldsen@regionh.dk;
   liv.tybjaerg.nordestgaard@regionh.dk; ruth.frikke-schmidt@regionh.dk
OI Frikke-Schmidt, Ruth/0000-0003-4084-5027; Tybjaerg Nordestgaard,
   Liv/0000-0002-5490-0034; Westerlin Kjeldsen, Emilie/0000-0001-7112-9387
FU Lundbeck Foundation [R278-2018-804]; Danish Heart Foundation
FX Ruth Frikke-Schmidt is funded by the Lundbeck Foundation (grant no.
   R278-2018-804) and the Danish Heart Foundation.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   An Y, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0353-1
   Anstey KJ, 2017, J ALZHEIMERS DIS, V56, P215, DOI 10.3233/JAD-160826
   Autran D, 2000, ATHEROSCLEROSIS, V153, P453, DOI 10.1016/S0021-9150(00)00428-7
   Balazs Z, 2004, J NEUROCHEM, V89, P939, DOI 10.1111/j.1471-4159.2004.02373.x
   Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
   Barter PJ, 2011, CIRCULATION, V124, P555, DOI 10.1161/CIRCULATIONAHA.111.018259
   Bellenguez C., 2020, MEDRXIV, P1, DOI [10.1101/2020.10.01.20200659, DOI 10.1101/2020.10.01.20200659]
   Boren J, 2020, EUR HEART J, V41, P2313, DOI 10.1093/eurheartj/ehz962
   Bowe B, 2016, CLIN J AM SOC NEPHRO, V11, P1784, DOI 10.2215/CJN.00730116
   Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905
   Brunham LR, 2007, NAT MED, V13, P340, DOI 10.1038/nm1546
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cardner M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131491
   Catapano AL, 2014, CARDIOVASC RES, V103, P372, DOI 10.1093/cvr/cvu150
   CHEN CH, 1982, BIOCHEM BIOPH RES CO, V107, P1091, DOI 10.1016/0006-291X(82)90633-7
   Chen ES, 2009, CLIN EXP MED, V9, P319, DOI 10.1007/s10238-009-0051-3
   Chen JA, 2015, JAMA NEUROL, V72, P414, DOI 10.1001/jamaneurol.2014.4040
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cochran BJ, 2014, ARTERIOSCL THROM VAS, V34, P2261, DOI 10.1161/ATVBAHA.114.304131
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Cosentino F., 2019, EUR HEART J, V41, P255, DOI [DOI 10.1093/EURHEARTJ/EHZ486, 10.1093/eurheartj/ehz486, DOI 10.1093/eurheartj/ehz486]
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663
   den Hollander AI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017202
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Do R, 2013, NAT GENET, V45, P1345, DOI 10.1038/ng.2795
   Drew BG, 2012, NAT REV ENDOCRINOL, V8, P237, DOI 10.1038/nrendo.2011.235
   Drew BG, 2009, CIRCULATION, V119, P2103, DOI 10.1161/CIRCULATIONAHA.108.843219
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Edmunds SJ, 2019, DIABETOLOGIA, V62, P1257, DOI 10.1007/s00125-019-4877-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fall T, 2015, DIABETES, V64, P2676, DOI 10.2337/db14-1710
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fazio S, 2013, CIRC RES, V113, P94, DOI 10.1161/CIRCRESAHA.113.301832
   Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
   Frikke-Schmidt R, 2008, JAMA-J AM MED ASSOC, V299, P2524, DOI 10.1001/jama.299.21.2524
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gatti A, 2009, DIABETES CARE, V32, P1550, DOI 10.2337/dc09-0256
   Gaugler J, 2019, ALZHEIMERS DEMENT, V15, P321, DOI 10.1016/j.jalz.2019.01.010
   GLOMSET JA, 1962, BIOCHIM BIOPHYS ACTA, V65, P128, DOI 10.1016/0006-3002(62)90156-7
   GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8
   Gregg EW, 2016, LANCET DIABETES ENDO, V4, P537, DOI 10.1016/S2213-8587(16)30010-9
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Haase CL, 2015, DIABETES, V64, P3328, DOI 10.2337/db14-1603
   Haase CL, 2012, J CLIN ENDOCR METAB, V97, pE248, DOI 10.1210/jc.2011-1846
   Haase CL, 2010, J CLIN ENDOCR METAB, V95, pE500, DOI 10.1210/jc.2010-0450
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Han R, 2007, DIABETOLOGIA, V50, P1960, DOI 10.1007/s00125-007-0752-7
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Holmes MV, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2017.78
   Hottman DA, 2014, NEUROBIOL DIS, V72, P22, DOI 10.1016/j.nbd.2014.07.015
   Hou LM, 2019, FASEB J, V33, P8479, DOI 10.1096/fj.201802512RR
   HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
   Jansen IE, 2019, NAT GENET, V51, P404, DOI 10.1038/s41588-018-0311-9
   Johannsen TH, 2012, J AM COLL CARDIOL, V60, P2041, DOI 10.1016/j.jacc.2012.07.045
   Rasmussen IJ, 2021, CURR OPIN LIPIDOL, V32, P55, DOI 10.1097/MOL.0000000000000723
   Keene D, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4379
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ko DT, 2016, J AM COLL CARDIOL, V68, P2073, DOI 10.1016/j.jacc.2016.08.038
   Kontush A, 2008, CURR DIABETES REP, V8, P51, DOI 10.1007/s11892-008-0010-5
   Kunkle BW, 2019, NAT GENET, V51, P414, DOI 10.1038/s41588-019-0358-2
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955
   Lehti M, 2013, CIRCULATION, V128, P2364, DOI 10.1161/CIRCULATIONAHA.113.001551
   Li NS, 2014, ATHEROSCLEROSIS, V233, P130, DOI 10.1016/j.atherosclerosis.2013.12.013
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581
   Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6
   Madsen CM, 2021, ARTERIOSCL THROM VAS, V41, P128, DOI 10.1161/ATVBAHA.120.314050
   Madsen CM, 2018, EUR HEART J, V39, P1181, DOI 10.1093/eurheartj/ehx665
   Madsen CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/eurheartj/ehx163
   Mancuso E, 2020, ARTERIOSCL THROM VAS, V40, P2941, DOI 10.1161/ATVBAHA.120.314640
   Meilhac O, 2015, HANDB EXP PHARMACOL, V224, P509, DOI 10.1007/978-3-319-09665-0_16
   Menon V, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2019-000943
   Moreno-Grau S, 2019, ALZHEIMERS DEMENT, V15, P1333, DOI 10.1016/j.jalz.2019.06.4950
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nicholls SJ, 2018, JAMA CARDIOL, V3, P806, DOI 10.1001/jamacardio.2018.2112
   Nilsson O, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165613
   Nordestgaard LT, 2021, J CLIN ENDOCR METAB, V106, pE2749, DOI 10.1210/clinem/dgab095
   Nordestgaard LT, 2015, ALZHEIMERS DEMENT, V11, P1430, DOI 10.1016/j.jalz.2015.04.006
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Organization WH, 2017, GLOB ACT PLAN PUBL H
   Ostergaard SD, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001841
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Proitsi P, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001713
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rasmussen KL, 2019, EUR HEART J, V40, P2813, DOI 10.1093/eurheartj/ehz402
   Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P1491, DOI 10.1001/archneurol.2010.297
   RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601
   Richardson TG, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003062
   Rosenson RS, 2012, CIRCULATION, V125, P1905, DOI 10.1161/CIRCULATIONAHA.111.066589
   Sasso FC, 2019, DIABETES RES CLIN PR, V150, P236, DOI 10.1016/j.diabres.2019.03.028
   Schmidt MI, 2005, DIABETES CARE, V28, P2013, DOI 10.2337/diacare.28.8.2013
   Schou J, 2012, DIABETES CARE, V35, P2600, DOI 10.2337/dc12-0082
   Schwartz GG, 2020, DIABETES CARE, V43, P1077, DOI 10.2337/dc19-2204
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Siebel AL, 2013, CIRC RES, V113, P167, DOI 10.1161/CIRCRESAHA.113.300689
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Speer T, 2018, EUR HEART J, V39, P1191, DOI 10.1093/eurheartj/ehx734
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sturek JM, 2010, J CLIN INVEST, V120, P2575, DOI 10.1172/JCI41280
   Svensson T, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-018-0336-y
   Trinder M, 2021, CIRCULATION, V143, P921, DOI 10.1161/CIRCULATIONAHA.120.048568
   Trinder M, 2020, ARTERIOSCL THROM VAS, V40, P267, DOI 10.1161/ATVBAHA.119.313381
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tynkkynen J, 2018, ALZHEIMERS DEMENT, V14, P723, DOI 10.1016/j.jalz.2018.01.003
   Tynkkynen J, 2016, AGE, V38, P465, DOI 10.1007/s11357-016-9950-x
   van der Lee SJ, 2018, ALZHEIMERS DEMENT, V14, P707, DOI 10.1016/j.jalz.2017.11.012
   Van Lenten BJ, 2009, CURR ATHEROSCLER REP, V11, P52, DOI 10.1007/s11883-009-0008-8
   Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Vollenweider P, 2015, HANDB EXP PHARMACOL, V224, P405, DOI 10.1007/978-3-319-09665-0_12
   von Eckardstein A, 2016, CURR OPIN LIPIDOL, V27, P264, DOI 10.1097/MOL.0000000000000294
   von Eckardstein A, 2014, CARDIOVASC RES, V103, P384, DOI 10.1093/cvr/cvu143
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   White J, 2016, JAMA CARDIOL, V1, P692, DOI 10.1001/jamacardio.2016.1884
   Wilson PWF, 2007, ARCH INTERN MED, V167, P1068, DOI 10.1001/archinte.167.10.1068
   World Health Organization, 2016, GLOBAL REPORT DIABET
   Xiang AS, 2019, LANCET DIABETES ENDO, V7, P575, DOI 10.1016/S2213-8587(19)30003-8
   Yalcinkaya M, 2020, J LIPID RES, V61, P492, DOI 10.1194/jlr.RA119000509
   Zanoni P, 2016, SCIENCE, V351, P1166, DOI 10.1126/science.aad3517
   Zhang PH, 2017, MOL MED REP, V16, P9279, DOI 10.3892/mmr.2017.7831
NR 130
TC 7
Z9 7
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2021
VL 22
IS 9
AR 4547
DI 10.3390/ijms22094547
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SC0SF
UT WOS:000650391900001
PM 33925284
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Eandi, CM
   Alovisi, C
   De Sanctis, U
   Grignolo, FM
AF Eandi, Chiara M.
   Alovisi, Camilla
   De Sanctis, Ugo
   Grignolo, Federico M.
TI Treatment for neovascularage related macular degeneration: The state of
   the art
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Retina; Choroid; Macula; Degeneration; Angiogenesis; Anti-VEGF
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT INJECTION; 2.0 MG
   RANIBIZUMAB; PLASMA-LEVELS; CHOROIDAL NEOVASCULARIZATION;
   CLINICAL-TRIALS; DOSING REGIMEN; FACTOR VEGF; BEVACIZUMAB; SAFETY
AB With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Eandi, Chiara M.; Alovisi, Camilla; De Sanctis, Ugo; Grignolo, Federico M.] Univ Turin, Dept Surg Sci, Eye Clin, Via Juvarra 19, I-10122 Turin, Italy.
C3 University of Turin
RP Eandi, CM (通讯作者)，Univ Turin, Dept Surg Sci, Eye Clin, Via Juvarra 19, I-10122 Turin, Italy.
EM chiara.eandi@unito.it
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Avery R. L, 2014, BR J OPHTHALMOL, V98
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Berg K., 2015, OPHTHALMOLOGY
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Despreaux R., 2015, GRAEFES ARCH CLIN EX, V2015
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkes N, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3275
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jansen RM, 2013, MED LAW, V32, P65
   Johnson D, 2013, CURR OPIN OPHTHALMOL, V24, P205, DOI 10.1097/ICU.0b013e32835f8ec0
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Mantel I., 2015, RETINA
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Wykoff C. C., 2015, OPHTHALMOLOGY, V18
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 75
TC 19
Z9 19
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2016
VL 787
SI SI
BP 78
EP 83
DI 10.1016/j.ejphar.2016.03.002
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DW0EX
UT WOS:000383314800010
PM 26948315
DA 2022-11-30
ER

PT J
AU Sant'Anna, R
   Navarro, S
   Ventura, S
   Paraoan, L
   Foguel, D
AF Sant'Anna, Ricardo
   Navarro, Susanna
   Ventura, Salvador
   Paraoan, Luminita
   Foguel, Debora
TI Amyloid properties of the leader peptide of variant B cystatin C:
   implications for Alzheimer and macular degeneration
SO FEBS LETTERS
LA English
DT Article
DE Alzheimers' disease and exudative age-related macular degeneration;
   human cystatin C; protein aggregation
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO; NATURAL POLYPHENOLS; SECONDARY
   STRUCTURE; CRYSTAL-STRUCTURE; GAMMA-TRACE; HOT-SPOTS; BETA; AGGREGATION;
   SEQUENCE
AB Variant B (VB) of cystatin C has a mutation in its signal peptide (A25T), which interferes with its processing leading to reduced secretion and partial retention in the vicinity of the mitochondria. There are genetic evidences of the association of VB with Alzheimer's disease (AD) and age-related macular degeneration (AMD). Here, we investigated aggregation and amyloid propensities of unprocessed VB combining computational and in vitro studies. Aggregation predictors revealed the presence of four aggregation-prone regions, with a strong one at the level of the signal peptide, which indeed formed toxic aggregates and mature amyloid fibrils in solution. In light of these results, we propose for the first time the role of the signal peptide in pathogenesis of AD and AMD.
C1 [Sant'Anna, Ricardo; Navarro, Susanna; Ventura, Salvador] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Spain.
   [Sant'Anna, Ricardo; Navarro, Susanna; Ventura, Salvador] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain.
   [Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Foguel, Debora] Univ Fed Rio de Janeiro, Programa Biol Estrutural, Inst Bioquim Med Leopoldo Meis, BR-21941901 Rio De Janeiro, Brazil.
C3 Autonomous University of Barcelona; Autonomous University of Barcelona;
   University of Liverpool; Universidade Federal do Rio de Janeiro
RP Ventura, S (通讯作者)，Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra 08193, Spain.; Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.; Foguel, D (通讯作者)，Univ Fed Rio de Janeiro, Programa Biol Estrutural, Inst Bioquim Med Leopoldo Meis, BR-21941901 Rio De Janeiro, Brazil.
EM salvador.ventura@uab.es; lparaoan@liverpool.ac.uk;
   foguel@bioqmed.ufrj.br
RI Paraoan, Luminita/K-1066-2016; Ventura, Salvador/C-7021-2008; Ventura,
   Salvador/AAY-3170-2021
OI Paraoan, Luminita/0000-0001-7568-7116; Ventura,
   Salvador/0000-0002-9652-6351; Ventura, Salvador/0000-0002-9652-6351;
   Navarro, Susanna/0000-0001-8160-9536; Foguel, Debora/0000-0001-7312-7115
FU Brazilian program Science without Borders - CAPES; Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Ministerio de Economia y Competividad, Spain [BFU2013-44763-P]
FX RS was a recipient of a fellowship from the Brazilian program Science
   without Borders - CAPES. We also thank the funding agencies Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) and Ministerio de Economia y Competividad, Spain
   [BFU2013-44763-P].
CR Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815
   Belli M, 2011, EMBO REP, V12, P657, DOI 10.1038/embor.2011.116
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699
   BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101
   BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   Conchillo-Sole O, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-65
   de Groot NS, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-18
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659
   Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012
   Ferreira N, 2012, AMYLOID, V19, P39, DOI 10.3109/13506129.2012.668502
   Ferreira N, 2011, FEBS LETT, V585, P2424, DOI 10.1016/j.febslet.2011.06.030
   Finckh U, 2000, ARCH NEUROL-CHICAGO, V57, P1579, DOI 10.1001/archneur.57.11.1579
   Gauthier Sebastien, 2011, Front Biosci (Schol Ed), V3, P541, DOI 10.2741/s170
   GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024
   Grubb AO, 2001, ADV CLIN CHEM, V35, P63, DOI 10.1016/S0065-2423(01)35015-1
   Hasegawa A, 2007, J NEUROCHEM, V100, P12, DOI 10.1111/j.1471-4159.2006.04169.x
   Hua Y, 2012, INT J NEUROSCI, V122, P431, DOI 10.3109/00207454.2012.672502
   Ida H, 2004, MOL VIS, V10, P439
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Iwata K, 2006, P NATL ACAD SCI USA, V103, P18119, DOI 10.1073/pnas.0607180103
   JACKSON M, 1991, CAN J CHEM, V69, P1639, DOI 10.1139/v91-240
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kolodziejczyk R, 2010, FEBS J, V277, P1726, DOI 10.1111/j.1742-4658.2010.07596.x
   LERNER UH, 1992, J BONE MINER RES, V7, P433
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malmo C, 2006, FASEB J, V20, P346, DOI 10.1096/fj.05-4652fje
   MERZ PA, 1983, ACTA NEUROPATHOL, V60, P113, DOI 10.1007/BF00685355
   Mi W, 2007, NAT GENET, V39, P1440, DOI 10.1038/ng.2007.29
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nagai A, 1998, MOL CHEM NEUROPATHOL, V33, P63, DOI 10.1007/BF02815860
   Oliveberg M, 2010, NAT METHODS, V7, P187, DOI 10.1038/nmeth0310-187
   Palsdottir A, 2006, BRAIN PATHOL, V16, P55
   Palsdottir A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000099
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Reumers J, 2009, HUM MUTAT, V30, P431, DOI 10.1002/humu.20905
   Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099
   Sant'Anna R, 2014, J BIOL CHEM, V289, P28324, DOI 10.1074/jbc.M114.563981
   Sastre M, 2004, NEUROBIOL AGING, V25, P1033, DOI 10.1016/j.neurobiolaging.2003.11.006
   TAVERA C, 1992, BIOCHEM BIOPH RES CO, V182, P1082, DOI 10.1016/0006-291X(92)91842-E
   Tsiolaki PL, 2015, J STRUCT BIOL, V191, P272, DOI 10.1016/j.jsb.2015.07.013
   Tsiolaki PL, 2015, FEBS LETT, V589, P159, DOI 10.1016/j.febslet.2014.11.041
   Tsolis AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054175
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991
   WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912
   Wistow G, 2002, MOL VIS, V8, P205
   Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 62
TC 9
Z9 9
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD MAR
PY 2016
VL 590
IS 5
BP 644
EP 654
DI 10.1002/1873-3468.12093
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DF5OY
UT WOS:000371402700006
PM 26865059
OA Bronze
DA 2022-11-30
ER

PT J
AU Fowler, BJ
   Gelfand, BD
   Kim, Y
   Kerur, N
   Tarallo, V
   Hirano, Y
   Amarnath, S
   Fowler, DH
   Radwan, M
   Young, MT
   Pittman, K
   Kubes, P
   Agarwal, HK
   Parang, K
   Hinton, DR
   Bastos-Carvalho, A
   Li, SJ
   Yasuma, T
   Mizutani, T
   Yasuma, R
   Wright, C
   Ambati, J
AF Fowler, Benjamin J.
   Gelfand, Bradley D.
   Kim, Younghee
   Kerur, Nagaraj
   Tarallo, Valeria
   Hirano, Yoshio
   Amarnath, Shoba
   Fowler, Daniel H.
   Radwan, Marta
   Young, Mark T.
   Pittman, Keir
   Kubes, Paul
   Agarwal, Hitesh K.
   Parang, Keykavous
   Hinton, David R.
   Bastos-Carvalho, Ana
   Li, Shengjian
   Yasuma, Tetsuhiro
   Mizutani, Takeshi
   Yasuma, Reo
   Wright, Charles
   Ambati, Jayakrishna
TI Nucleoside reverse transcriptase inhibitors possess intrinsic
   anti-inflammatory activity
SO SCIENCE
LA English
DT Article
ID VERSUS-HOST-DISEASE; P2X(7) RECEPTOR; MACULAR DEGENERATION; INFLAMMASOME
   ACTIVATION; CASPASE-1 ACTIVATION; NLRP3 INFLAMMASOME; P2X7 RECEPTOR; ATP
   RELEASE; INTERLEUKIN-18; PATHOGENESIS
AB Nucleoside reverse transcriptase inhibitors (NRTIs) are mainstay therapeutics for HIV that block retrovirus replication. Alu (an endogenous retroelement that also requires reverse transcriptase for its life cycle)-derived RNAs activate P2X7 and the NLRP3 inflammasome to cause cell death of the retinal pigment epithelium in geographic atrophy, a type of age-related macular degeneration. We found that NRTIs inhibit P2X7-mediated NLRP3 inflammasome activation independent of reverse transcriptase inhibition. Multiple approved and clinically relevant NRTIs prevented caspase-1 activation, the effector of the NLRP3 inflammasome, induced by Alu RNA. NRTIs were efficacious in mouse models of geographic atrophy, choroidal neovascularization, graft-versus-host disease, and sterile liver inflammation. Our findings suggest that NRTIs are ripe for drug repurposing in P2X7-driven diseases.
C1 [Fowler, Benjamin J.; Gelfand, Bradley D.; Kim, Younghee; Kerur, Nagaraj; Tarallo, Valeria; Hirano, Yoshio; Bastos-Carvalho, Ana; Li, Shengjian; Yasuma, Tetsuhiro; Mizutani, Takeshi; Yasuma, Reo; Wright, Charles; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [Fowler, Benjamin J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Microbiol Immunol & Human Genet, Lexington, KY 40536 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Biomed Engn, Lexington, KY 40536 USA.
   [Tarallo, Valeria] CNR, Inst Genet & Biophys, Angiogenesis Lab, I-80125 Naples, Italy.
   [Amarnath, Shoba; Fowler, Daniel H.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
   [Radwan, Marta; Young, Mark T.] Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.
   [Pittman, Keir; Kubes, Paul] Univ Calgary, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
   [Agarwal, Hitesh K.; Parang, Keykavous] Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR);
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Cardiff University; University of Calgary; Chapman University
   System; Chapman University; University of Southern California;
   University of Southern California
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
EM jamba2@email.uky.edu
RI Parang, Keykavous/ABC-1584-2021; Gelfand, Brad/L-3926-2019; amarnath,
   shoba/AAP-4391-2020; Young, Mark T/E-8928-2010
OI Parang, Keykavous/0000-0001-8600-0893; Young, Mark
   T/0000-0002-9615-9002; Hirano, Yoshio/0000-0002-9173-0839; Tarallo,
   Valeria/0000-0002-6920-4402
FU NIH [DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238,
   R01EY024068, T32HL091812, UL1RR033173, K99EY024336]; Doris Duke
   Distinguished Clinical Scientist Award; Burroughs Wellcome Fund Clinical
   Scientist Award in Translational Research; Ellison Medical Foundation
   Senior Scholar in Aging Award; Foundation Fighting Blindness Individual
   Investigator Research Award; Harrington Discovery Institute
   Scholar-Innovator Award; Dr. E. Vernon Smith and Eloise C. Smith Macular
   Degeneration Endowed Chair; Research to Prevent Blindness departmental
   unrestricted grant; Programme for Advanced Medical Education - Fundacao
   Calouste Gulbenkian; Programme for Advanced Medical Education - Fundacao
   Champalimaud; Programme for Advanced Medical Education - Ministerio da
   Saude; Programme for Advanced Medical Education - Fundacao para a
   Ciencia e Tecnologia, Portugal; Bayer Global Ophthalmology Research
   Award; Alcon Japan Research award; Beckman Initiative for Macular
   Research; American Heart Association; International Retinal Research
   Foundation (IRRF); Fight for Sight postdoctoral award; Loris and David
   Rich Postdoctoral Scholar Award (IRRF); Center for Cancer Research,
   National Cancer Institute; Biotechnology and Biological Sciences
   Research Council (BBSRC) grant [BB/J017345/1]; NIH grants [P30EY003040,
   R01EY001545]; Arnold and Mabel Beckman Foundation; Alberta Innovates
   Health Solutions Graduate Studentship; BBSRC; BBSRC [BB/J017345/1]
   Funding Source: UKRI; Biotechnology and Biological Sciences Research
   Council [BB/J017345/1] Funding Source: researchfish; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117, TL1TR000115] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES
   [UL1RR033173, TL1RR033172] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [K99EY024336, R01EY020672, R01EY018350, R01EY024068,
   R01EY018836, P30EY003040, R01EY022238, R01EY001545] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091812]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [DP1GM114862] Funding Source: NIH RePORTER
FX We thank B. K. Ambati, K. Ambati, A. M. Adams, A. M. Rao, and G. S. Rao
   for discussions; L. Toll, G. R. Pattison R. King, L. Xu, M. McConnell,
   C. Payne, D. Robertson, G. Botzet, and J. May for technical assistance;
   G. Dubyak for discussions and providing the HEK293-P2X7 cell line; and
   the University of Kentucky Viral Core (COBRE) for providing
   lentivirus-GFP. The data presented in this manuscript are tabulated in
   the main paper and in the supplementary materials. J.A. and B.J.F. are
   listed as inventors on a patent application for the therapeutic use of
   NRTIs and chemical derivatives filed by their employer, the University
   of Kentucky. J.A. is a cofounder of iVeena, Inc., which has licensed the
   technology described in this work. J.A. was supported by NIH grants
   (DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238, and
   R01EY024068), Doris Duke Distinguished Clinical Scientist Award,
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, Ellison Medical Foundation Senior Scholar in Aging Award,
   Foundation Fighting Blindness Individual Investigator Research Award,
   Harrington Discovery Institute Scholar-Innovator Award, Dr. E. Vernon
   Smith and Eloise C. Smith Macular Degeneration Endowed Chair, and
   Research to Prevent Blindness departmental unrestricted grant; B. J. F.
   by NIH T32HL091812 and UL1RR033173; A. B. C. by the Programme for
   Advanced Medical Education (sponsored by Fundacao Calouste Gulbenkian,
   Fundacao Champalimaud, Ministerio da Saude and Fundacao para a Ciencia e
   Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award;
   Y.H. by Alcon Japan Research award; N.K. by Beckman Initiative for
   Macular Research and NIH K99EY024336; B. D. G. by American Heart
   Association and International Retinal Research Foundation (IRRF); T.Y.
   by Fight for Sight postdoctoral award; and C. W. by The Loris and David
   Rich Postdoctoral Scholar Award (IRRF). D. H. F and S. A. are supported
   by the Center for Cancer Research, National Cancer Institute. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH. M. T.Y. and M. R.
   are supported by Biotechnology and Biological Sciences Research Council
   (BBSRC) grant BB/J017345/1. D. R. H. is supported by NIH grants
   P30EY003040 and R01EY001545 and by the Arnold and Mabel Beckman
   Foundation. K.P. is supported by an Alberta Innovates Health Solutions
   Graduate Studentship, and M.R. by the BBSRC. me-d4T is available from
   the University of Kentucky via a Materials Transfer Agreement.
CR Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947
   Agarwal HK, 2011, BIOORG MED CHEM LETT, V21, P1917, DOI 10.1016/j.bmcl.2011.02.070
   Ahmad R, 2002, J VIROL, V76, P12448, DOI 10.1128/JVI.76.24.12448-12456.2002
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2014, GUID US ANT AG HIV 1
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Baroja-Mazo A, 2013, BBA-BIOMEMBRANES, V1828, P79, DOI 10.1016/j.bbamem.2012.01.002
   Center for Drug Evaluation and Research Center for Biologics Evaluation and Research, 2002, EST SAF START DOS CL
   Chattergoon MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004082
   Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200
   Gourine AV, 2005, BRIT J PHARMACOL, V146, P139, DOI 10.1038/sj.bjp.0706287
   Hu HZ, 1999, IMMUNOLOGY, V98, P379, DOI 10.1046/j.1365-2567.1999.00881.x
   Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861
   Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   McDonald B, 2010, SCIENCE, V330, P362, DOI 10.1126/science.1195491
   Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5
   Pelegrin P, 2008, J IMMUNOL, V180, P7147, DOI 10.4049/jimmunol.180.11.7147
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Qu Y, 2011, J IMMUNOL, V186, P6553, DOI 10.4049/jimmunol.1100478
   Riteau N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.144
   Salas E, 2013, J PHARMACOL EXP THER, V347, P802, DOI 10.1124/jpet.113.209452
   Schmaltz C, 2003, BLOOD, V101, P2440, DOI 10.1182/blood-2002-07-2109
   Solini A, 1999, J CELL SCI, V112, P297
   Stylianou E, 2003, CLIN EXP IMMUNOL, V132, P462, DOI 10.1046/j.1365-2249.2003.02179.x
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X
   Wang JJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1112, DOI 10.1152/ajpcell.00097.2007
   Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242
   Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273
NR 40
TC 145
Z9 154
U1 1
U2 42
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 21
PY 2014
VL 346
IS 6212
BP 1000
EP 1003
DI 10.1126/science.1261754
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AU6EL
UT WOS:000345696000045
PM 25414314
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Hahn, SM
   Maity, A
AF Hahn, Stephen M.
   Maity, Amit
TI GENERAL PRINCIPLES OF RADIATION AND CHEMORADIATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE radiation; chemotherapy; macular degeneration
AB High-resolution, three-dimensional functional imaging has improved delivery of radiotherapy to tumors while minimizing damage to adjacent, healthy tissue. A growing array of energy sources and delivery systems, including external delivery of protons and brachy-therapy, are also credited with improvement in the therapeutic index of treating diseases with radiation. In many malignancies, the therapeutic effects of radiotherapy can be significantly augmented by coordinated delivery of adjunctive therapies, particularly chemotherapy. In age-related macular degeneration (AMD) and other diseases of the eye, radiotherapy combined with pharmaceutical agents, including antiangiogenesis therapies, have the potential to an additive or synergistic effect. In AMD, the most significant challenge for radiotherapy may be precise delivery to the target and avoidance of damage to surrounding tissues. RETINA 29:S30-S31, 2009
C1 [Hahn, Stephen M.; Maity, Amit] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Hahn, SM (通讯作者)，Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
EM hahn@xrt.upenn.edu
OI Maity, Amit/0000-0001-7151-2845
NR 0
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S30
EP S31
DI 10.1097/IAE.0b013e3181ad2692
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700011
PM 19553795
DA 2022-11-30
ER

PT J
AU Beatty, S
   Nolan, J
   Kavanagh, H
   O'Donovan, O
AF Beatty, S
   Nolan, J
   Kavanagh, H
   O'Donovan, O
TI Macular pigment optical density and its relationship with serum and
   dietary levels of lutein and zeaxanthin
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE age-related maculopathy; carotenoids; lutein; zeaxanthin
ID BETA-CAROTENE; OXIDATIVE STRESS; TISSUE CONCENTRATIONS;
   ALPHA-TOCOPHEROL; PLASMA; AGE; SUPPLEMENTATION; ABSORPTION;
   IDENTIFICATION; XANTHOPHYLLS
AB Observational evidence is accumulating that the onset of age-related maculopathy, the leading cause of legal blindness in the Western World, could be delayed, or even averted, with antioxidant supplements. Lutein (L) and zeaxanthin (Z) are two hydroxycarotenoids with antioxidant activity which accumulate at the macula, where they are collectively known as macular pigment (MP). It has been shown that MP is entirely of dietary origin, and that L and Z levels in serum, diet, and retina correlate. However, the nature of the relationships between L and Z in foodstuffs, blood, and macula is confounded by many variables including processes which influence digestion, absorption, and transport of the compounds in question, and accumulation and stabilization of the carotenoids in the tissues. If macular pigment is protective for age-related maculopathy, a clear understanding of the mechanisms whereby L and Z arrive at the target tissue (retina) from their source (foodstuff) is essential. In this paper, we review the literature germane to this growing area of interest. (C) 2004 Elsevier Inc. All rights reserved.
C1 Waterford Inst Technol, Macular Pigment Lab, Waterford, Ireland.
C3 South East Technological University (SETU)
RP Beatty, S (通讯作者)，Waterford Inst Technol, Macular Pigment Lab, Cork Rd, Waterford, Ireland.
EM dualta@iol.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; O' Donovan, Orla/0000-0003-3980-8835
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Carroll YL, 1999, EUR J CLIN NUTR, V53, P644, DOI 10.1038/sj.ejcn.1600827
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Erdman Jr. J.W., 1988, CLIN NUTR, V7, P101
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   Goldbohm RA, 1998, INT J VITAM NUTR RES, V68, P378
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   HAMMOND BR, 1988, J OPT SOC AM, V14, P1187
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mayne ST, 1998, AM J CLIN NUTR, V68, P642, DOI 10.1093/ajcn/68.3.642
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   OLMEDILLA B, 1994, AM J CLIN NUTR, V60, P106, DOI 10.1093/ajcn/60.1.106
   Paolisso G, 1998, J AM GERIATR SOC, V46, P833, DOI 10.1111/j.1532-5415.1998.tb02716.x
   Park JS, 1998, J NUTR, V128, P1802, DOI 10.1093/jn/128.10.1802
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   Rondanelli M, 1997, AGING-CLIN EXP RES, V9, P221, DOI 10.1007/BF03340153
   ROSENBERG IH, 1989, AM J CLIN NUTR, V50, P1231, DOI 10.1093/ajcn/50.5.1231
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   *USDA, 1998, AGR RES SERV
   VandenLangenberg GM, 1996, J AM DIET ASSOC, V96, P1271, DOI 10.1016/S0002-8223(96)00332-X
NR 61
TC 89
Z9 102
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD OCT 1
PY 2004
VL 430
IS 1
BP 70
EP 76
DI 10.1016/j.abb.2004.03.015
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 851CQ
UT WOS:000223663400010
PM 15325913
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Apatoff, MB
   Sengillo, JD
   White, EC
   Bakhoum, MF
   Bassuk, AG
   Mahajan, VB
   Tsang, SH
AF Apatoff, Mary Ben L.
   Sengillo, Jesse D.
   White, Eugenia C.
   Bakhoum, Mathieu F.
   Bassuk, Alexander G.
   Mahajan, Vinit B.
   Tsang, Stephen H.
TI Autologous stem cell therapy for inherited and acquired retinal disease
SO REGENERATIVE MEDICINE
LA English
DT Review
DE autologous; induced pluripotent stem cells; retinal degeneration; stem
   cell
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; PRECLINICAL MODEL;
   PROGENITOR CELLS; GANGLION-CELLS; TRANSPLANTATION; MOUSE; GENERATION;
   DIFFERENTIATION; INTEGRATION
AB The mammalian retina, derived from neural ectoderm, has little regenerative potential. For conditions where irreversible retinal pigment epithelium or photoreceptor cell loss occurs, advanced techniques are required to restore vision. Inherited retinal dystrophies and some acquired conditions, such as age-related macular degeneration, have a similar end result of photoreceptor cell death leading to debilitating vision loss. These diseases stand to benefit from future regenerative medicine as dietary recommendations and current pharmacologic therapy only seek to prevent further disease progression. Cell-based strategies, such as autologously derived induced pluripotent stem cells, have come a long way in overcoming previous technical and ethical concerns. Clinical trials for such techniques are already underway. These trials and the preceding preclinical studies will be discussed in the context of retinal disease.
C1 [Apatoff, Mary Ben L.; Sengillo, Jesse D.; Tsang, Stephen H.] Columbia Univ, Jonas Childrens Vis Care & Bernard & Shirlee Brow, New York, NY 10032 USA.
   [Apatoff, Mary Ben L.; Sengillo, Jesse D.; White, Eugenia C.; Bakhoum, Mathieu F.; Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Sengillo, Jesse D.] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Mahajan, Vinit B.] Stanford Univ, Byers Eye Inst, Om Lab, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Mahajan, Vinit B.] Palo Alto Vet Adm, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Tsang, Stephen H.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Tsang, Stephen H.] Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA.
C3 Columbia University; Columbia University; State University of New York
   (SUNY) System; State University of New York (SUNY) Downstate Medical
   Center; University of Iowa; Stanford University; Columbia University;
   Columbia University
RP Tsang, SH (通讯作者)，Columbia Univ, Jonas Childrens Vis Care & Bernard & Shirlee Brow, New York, NY 10032 USA.; Tsang, SH (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.; Tsang, SH (通讯作者)，Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.; Tsang, SH (通讯作者)，Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA.
EM sht2@cumc.columbia.edu
OI Mahajan, Vinit/0000-0003-1886-1741; Bakhoum,
   Mathieu/0000-0001-8989-8205; Bassuk, Alexander/0000-0002-4067-2157
FU National Institute of Health [5P30EY019007, R01EY018213, R01EY024698,
   R01EY026682, R21AG050437]; National Cancer Institute Core
   [5P30CA013696]; Research to Prevent Blindness (RPB) Physician-Scientist
   Award; RPB, New York, NY, USA; RPB Medical Student Eye Research
   Fellowship; Tistou and Charlotte Kerstan Foundation; Schneeweiss Stem
   Cell Fund, New York State [C029572]; Foundation Fighting Blindness New
   York Regional Research Center Grant [C-NY05-0705-0312]; Crowley Family
   Fund; Gebroe Family Foundation; NATIONAL CANCER INSTITUTE [P30CA013696]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY026682,
   R01EY024698, R01EY018213, P30EY019007] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R21AG050437] Funding Source: NIH RePORTER
FX Jonas Children's Vision Care and Bernard & Shirlee Brown Glaucoma
   Laboratory are supported by the National Institute of Health
   (5P30EY019007, R01EY018213, R01EY024698, R01EY026682 and R21AG050437),
   National Cancer Institute Core (5P30CA013696), the Research to Prevent
   Blindness (RPB) Physician-Scientist Award, unrestricted funds from RPB,
   New York, NY, USA. JD Sengillo is supported by the RPB Medical Student
   Eye Research Fellowship. SH Tsang is a member of the RD-CURE Consortium
   and is supported by the Tistou and Charlotte Kerstan Foundation, the
   Schneeweiss Stem Cell Fund, New York State (C029572), the Foundation
   Fighting Blindness New York Regional Research Center Grant
   (C-NY05-0705-0312), the Crowley Family Fund and the Gebroe Family
   Foundation. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Palomo ABA, 2015, FIBROGENESIS TISSUE, V8, DOI 10.1186/s13069-015-0026-9
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Boudreault K, 2016, JAMA OPHTHALMOL, V134, P711, DOI 10.1001/jamaophthalmol.2016.0803
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Casaroli-Marano RP, 2014, DEV OPHTHALMOL, V53, pXI, DOI 10.1159/000359982
   Chen X, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0451-8
   Edel MJ, 2010, GENE DEV, V24, P561, DOI 10.1101/gad.1876710
   Eiraku M, 2012, NAT PROTOC, V7, P69, DOI 10.1038/nprot.2011.429
   Fu XM, 2014, CELL MOL IMMUNOL, V11, P14, DOI 10.1038/cmi.2013.60
   Garg A, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6010004
   Giacalone JC, 2016, STEM CELL TRANSL MED, V5, P132, DOI 10.5966/sctm.2015-0206
   Gill KP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.2
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Jorkasky JF, 2014, ATTITUDINAL SURVEY M
   Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   McLenachan S, 2012, STEM CELLS DEV, V21, P2891, DOI 10.1089/scd.2012.0190
   Nadri S, 2013, MOL BIOL REP, V40, P3883, DOI 10.1007/s11033-012-2360-y
   Okano H, 2013, CIRC RES, V112, P523, DOI 10.1161/CIRCRESAHA.111.256149
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Sengillo JD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020053
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Sommer CA, 2010, STEM CELLS, V28, P64, DOI 10.1002/stem.255
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanaka T, 2016, INVEST OPHTH VIS SCI, V57, P3348, DOI 10.1167/iovs.16-19166
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Wiley L. A., 2014, COLD SPRING HARB PER, V5
   Wiley LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30742
   Yao J, 2011, BIOMATERIALS, V32, P1041, DOI 10.1016/j.biomaterials.2010.09.063
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
NR 62
TC 8
Z9 8
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0751
EI 1746-076X
J9 REGEN MED
JI Regen. Med.
PD JAN
PY 2018
VL 13
IS 1
BP 89
EP 96
DI 10.2217/rme-2017-0089
PG 8
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA FW4GH
UT WOS:000425270600009
PM 29360008
OA Green Published
DA 2022-11-30
ER

PT J
AU Moreno, AM
   Fernandez, MC
   Bohorquez, VM
   Soto, GR
AF Monzon Moreno, Antonio
   Camean Fernandez, Manuel
   Merino Bohorquez, Vicente
   Ramirez Soto, Gabriel
TI INTRAVITREAL BEVACIZUMAB SYRINGES: WORKING PROTOCOL
SO ATENCION FARMACEUTICA
LA English
DT Review
AB The monoclonal antibody bevacizumab has been widely used using intravitreal syringes to treat age-related macular degeneration, even though it has not been officially approved for this indication (off-label use). On the other hand, ranibizumab has been officially approved for this indication. Bevacizumab could have other off-label uses (retinal vein occlusion, diabetic retinopathy, neovascular glaucoma, diabetic macular edema, etc). The objective of this paper is to review the off-label uses of bevacizumab and to present a proposal of the procedure for preparing intravitreal syringes of bevacizumab.
   Conclusions: some bibliographic documentation exists to support some of the off-label uses of bevacizumab, and we present a proposal of a procedure for preparing intravitreal syringes of bevacizumab with the best quality guarantees.
C1 [Monzon Moreno, Antonio] Hosp Univ Virgen Macarena, Seville, Spain.
   [Camean Fernandez, Manuel; Merino Bohorquez, Vicente] Hosp Univ Virgen Macarena, Serv Pharm, Seville, Spain.
   [Ramirez Soto, Gabriel] Hosp Univ Virgen Macarena, Pharm Management Clin Serv Unit, Seville, Spain.
C3 Hospital Universitario Virgen Macarena; Hospital Universitario Virgen
   Macarena; Hospital Universitario Virgen Macarena
RP Moreno, AM (通讯作者)，Hosp Univ Virgen Macarena, Seville, Spain.
OI Ramirez Soto, Gabriel/0000-0003-0234-9567
NR 0
TC 0
Z9 0
U1 0
U2 0
PU RASGO EDITORIAL
PI BARCELONA
PA LLANCA 16, DPCHO. 2., BARCELONA, SPAIN
SN 1139-7357
J9 ATEN FARM
JI Aten. Farm.
PD SEP-OCT
PY 2013
VL 15
IS 5
BP 351
EP 357
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V38WN
UT WOS:000209373600008
DA 2022-11-30
ER

PT J
AU Kuppermann, BD
AF Kuppermann, Baruch D.
TI DRUG DELIVERY STRATEGIES FOR COMBINATION OPHTHALMIC TREATMENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE combination therapy; drug delivery; retinal pharmacotherapeutics
AB The most significant obstacle to the combination of drug therapies in age-related macular degeneration (AMD) may be drug delivery. Although the posterior of the eye can be reached by intravitreal injections and implants, AMD is a chronic disease process that is likely to require prolonged or indefinite exposure to anti proliferative agents. In addition to the difficulty of repeat dosing in the vitreal space, ocular anatomy prohibits substantial drug volumes, a limitation further compounded when combining two or more agents. With low penetration to target areas of AMD, pathophysiology, and risk of significant systemic toxicity through systemic drug delivery, innovative strategies for introducing agents to their site of action may be the critical component of improved outcomes. RETINA 29:S24-S26, 2009
C1 Univ Calif Irvine, Retina Serv, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Kuppermann, BD (通讯作者)，Univ Calif Irvine, Retina Serv, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
EM bdkupper@uci.edu
CR Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
NR 1
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S24
EP S26
DI 10.1097/IAE.0b013e3181ad2463
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700009
PM 19553793
DA 2022-11-30
ER

PT J
AU Mallick, SB
   Bhagwandin, S
   Ivanisevic, A
AF Mallick, Shrestha Basu
   Bhagwandin, Sandhya
   Ivanisevic, Albena
TI Characterization of collagen fibers in Bruch's membrane using chemical
   force microscopy
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE AFM (atomic force microscopy); bioanalytical methods; interface/surface
   analysis
ID HUMAN CORNEA; HUMAN MACULA; ADHESION; FIBRILS; SCLERA; PROTEOGLYCANS;
   ASSEMBLIES; AGE
AB Bruch's membrane is a layer composed of collagen fibers located just beneath the retina. This study validates a strategy used to map the morphological and adhesion characteristics of collagen fibers in Bruch's membrane. Atomic force microscopy tips were functionalized with different chemical groups and used to map the hydrophilic and hydrophobic regions on the surface of the eye tissue. The largest adhesion forces were observed when tips functionalized with NH2 groups were used. The trend in the adhesion forces was rationalized based on the distribution of different functional groups in the triple-helical structure of the collagen fibers. The results of this study can be used to design more effective strategies to treat eye diseases such as age-related macular degeneration.
C1 Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
   Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
   Purdue Univ, Dept Phys, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University West
   Lafayette Campus; Purdue University System; Purdue University; Purdue
   University West Lafayette Campus; University of Miami; Purdue University
   System; Purdue University; Purdue University West Lafayette Campus
RP Ivanisevic, A (通讯作者)，Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
EM albena@purdue.edu
CR Butt HJ, 2005, SURF SCI REP, V59, P1, DOI 10.1016/j.surfrep.2005.08.003
   Eaton P, 2002, LANGMUIR, V18, P3387, DOI 10.1021/la015633l
   FRIESBIE CD, 1994, SCIENCE, V265, P2071
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   HULMES DJ, 1981, NATURE, V293, P234
   Kadler KE, 1996, BIOCHEM J, V316, P1
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Lydataki S, 2002, SINGLE MOL, V3, P141, DOI 10.1002/1438-5171(200206)3:2/3<141::AID-SIMO141>3.0.CO;2-#
   Mallick SB, 2005, J PHYS CHEM B, V109, P19052, DOI 10.1021/jp053605w
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Meller D, 1997, CELL TISSUE RES, V288, P111, DOI 10.1007/s004410050798
   Miyagawa A, 2001, CORNEA, V20, P651, DOI 10.1097/00003226-200108000-00019
   Miyagawa A, 2000, JPN J OPHTHALMOL, V44, P591, DOI 10.1016/S0021-5155(00)00272-0
   NOY A, 1995, J AM CHEM SOC, V117, P7943, DOI 10.1021/ja00135a012
   Plassard C, 2005, LANGMUIR, V21, P7263, DOI 10.1021/la050440+
   Poggi MA, 2005, CHEM MATER, V17, P4289, DOI 10.1021/cm048346m
   Poggi MA, 2004, NANO LETT, V4, P61, DOI 10.1021/nl0348701
   Robert L, 2001, PATHOL BIOL, V49, P353, DOI 10.1016/S0369-8114(01)00144-4
   Sherratt MJ, 2005, BIOMATERIALS, V26, P7192, DOI 10.1016/j.biomaterials.2005.05.010
   Simon A, 2006, MICRON, V37, P1, DOI 10.1016/j.micron.2005.06.006
   Tambe NS, 2005, NANOTECHNOLOGY, V16, P1549, DOI 10.1088/0957-4484/16/9/024
   Tiribilli B, 2005, ULTRAMICROSCOPY, V102, P227, DOI 10.1016/j.ultramic.2004.10.003
   Vezenov DV, 1997, J AM CHEM SOC, V119, P2006, DOI 10.1021/ja963375m
   Yamamoto S, 1997, ARCH HISTOL CYTOL, V60, P371, DOI 10.1679/aohc.60.371
   Yamamoto S, 2002, JPN J OPHTHALMOL, V46, P496, DOI 10.1016/S0021-5155(02)00558-0
   Zhang J, 2005, BIOMATERIALS, V26, P3353, DOI 10.1016/j.biomaterials.2004.08.019
NR 28
TC 9
Z9 10
U1 3
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD OCT
PY 2006
VL 386
IS 3
BP 652
EP 657
DI 10.1007/s00216-006-0538-7
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 087AB
UT WOS:000240713500029
PM 16850296
DA 2022-11-30
ER

PT J
AU Shivaji, S
AF Shivaji, Sisinthy
TI A systematic review of gut microbiome and ocular inflammatory diseases:
   Are they associated?
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular de-generation; dysbiosis; gut microbiome; keratitis;
   ocular disease; uveitis
AB The primary focus of this review was to establish the possible association of dysbiotic changes in the gut bacterial microbiomes with both intestinal and extra-intestinal diseases with emphasis on ocular diseases such as bacterial keratitis, fungal keratitis, uveitis, age-related macular degeneration, and ocular mucosal diseases. For this particular purpose, a systematic search was conducted using PubMed and Google Scholar for publications related to gut microbiome and human health (using the keywords: gut microbiome, ocular disease, dysbiosis, keratitis, uveitis, and AMD). The predictions are that microbiome studies would help to unravel dysbiotic changes in the gut bacterial microbiome at the taxonomic and functional level and thus form the basis to mitigate inflammatory diseases of the eye by using nutritional supplements or fecal microbiota transplantation.
C1 [Shivaji, Sisinthy] LV Prasad Eye Inst, Prof Brien Holden Eye Res Ctr, Jhaveri Microbiol Ctr, LV Prasad Marg,Banjara Hills, Hyderabad 500034, Telangana, India.
C3 L. V. Prasad Eye Institute
RP Shivaji, S (通讯作者)，LV Prasad Eye Inst, Prof Brien Holden Eye Res Ctr, Jhaveri Microbiol Ctr, LV Prasad Marg,Banjara Hills, Hyderabad 500034, Telangana, India.
EM shivas@lvpei.org
FU Department of Biotechnology, Government of India
   [BT/PR12057/MED/12/676/2014, BT/PR32404/MED/30/2136/2019]
FX This work was supported by the Prof. Brien Holden Eye Research Centre, L
   V Prasad Eye Institute, Hyderabad, India. We would also like to thank
   Department of Biotechnology, Government of India for the following
   grants: BT/PR12057/MED/12/676/2014 and BT/PR32404/MED/30/2136/2019.
CR Acharya C, 2017, GASTROENTEROL CLIN N, V46, P155, DOI 10.1016/j.gtc.2016.09.013
   Anand S, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01945
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chakravarthy SK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199640
   Damman CJ, 2012, AM J GASTROENTEROL, V107, P1452, DOI 10.1038/ajg.2012.93
   de Paiva CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23561
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Dicksved J, 2009, J MED MICROBIOL, V58, P509, DOI 10.1099/jmm.0.007302-0
   Doan T, 2016, INVEST OPHTH VIS SCI, V57, P5116, DOI 10.1167/iovs.16-19803
   Dong QF, 2011, INVEST OPHTH VIS SCI, V52, P5408, DOI 10.1167/iovs.10-6939
   Drago L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111837
   Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110
   Fisher K, 2009, MICROBIOL-SGM, V155, P1749, DOI 10.1099/mic.0.026385-0
   Flemer B, 2017, GUT, V66, P633, DOI 10.1136/gutjnl-2015-309595
   Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053
   Hatziioanou D, 2017, MICROBIOL-SGM, V163, P1292, DOI 10.1099/mic.0.000515
   Heissigerova J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5065703
   Horai R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00232
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Ignacio A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.031
   Iovieno A, 2008, GRAEF ARCH CLIN EXP, V246, P435, DOI 10.1007/s00417-007-0682-6
   Jayasudha R, 2018, J BIOSCIENCES, V43, P835, DOI 10.1007/s12038-018-9798-6
   Kho ZY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01835
   Kiang L, 2017, INVEST OPHTH VIS SCI, V58
   Kim S, 2017, NATURE, V549, P528, DOI 10.1038/nature23910
   Levine Jonathan S, 2011, Gastroenterol Hepatol (N Y), V7, P235
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Liu P, 2019, BRAIN BEHAV IMMUN, V80, P633, DOI 10.1016/j.bbi.2019.05.008
   Livingston M, 2010, IMMUNOL CELL BIOL, V88, P99, DOI 10.1038/icb.2009.71
   Lukiw WJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01544
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Murri M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-46
   Nakamura YK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12163-3
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Nayyar A, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00257-5
   Ozkan J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10494-9
   Pelzel HR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-62
   Pineda MD, 2011, MED SCI MONITOR, V17, pCR347
   Prakash S, 2011, BIOL-TARGETS THER, V5, P71, DOI 10.2147/BTT.S19099
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Qiu DX, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02627
   Qiu YG, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/9129163
   Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214
   Rinninella E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7010014
   Prashanthi GS, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7090309
   Sandhya P, 2016, INT J RHEUM DIS, V19, P8, DOI 10.1111/1756-185X.12728
   Scher JU, 2015, ARTHRITIS RHEUMATOL, V67, P128, DOI 10.1002/art.38892
   Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533
   Shin H, 2016, MBIO, V7, DOI 10.1128/mBio.00198-16
   Shivaji S, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9931-1
   Shivaji S, 2017, GUT PATHOG, V9, DOI 10.1186/s13099-017-0163-3
   Shivaji S, 2019, INVEST OPHTH VIS SCI, V60, P451, DOI 10.1167/iovs.18-26076
   Sokol H, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-0792-5
   Tang WHW, 2017, CIRC RES, V120, P1183, DOI 10.1161/CIRCRESAHA.117.309715
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Vavricka SR, 2015, INFLAMM BOWEL DIS, V21, P1982, DOI 10.1097/MIB.0000000000000392
   Verhagen FH, 2018, INVEST OPHTH VIS SCI, V59, P878, DOI 10.1167/iovs.17-23643
   Wieers G, 2020, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00454
   Wu WQ, 2020, ENGINEERING-PRC, V6, P415, DOI 10.1016/j.eng.2019.07.026
   Zarate-Blades CR, 2017, GUT MICROBES, V8, P59, DOI 10.1080/19490976.2016.1273996
   Zheng P, 2016, MOL PSYCHIATR, V21, P786, DOI 10.1038/mp.2016.44
   Zhou Y, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0099-x
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 69
TC 3
Z9 3
U1 0
U2 7
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAR
PY 2021
VL 69
IS 3
BP 535
EP 542
DI 10.4103/ijo.IJO_1362_20
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ3ZW
UT WOS:000624463600012
PM 33595467
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bacherini, D
   Mastropasqua, R
   Borrelli, E
   Capuano, V
   Iovino, C
   Dragotto, F
   Caporossi, T
   Rizzo, S
   Giansanti, F
AF Bacherini, Daniela
   Mastropasqua, Rodolfo
   Borrelli, Enrico
   Capuano, Vittorio
   Iovino, Claudio
   Dragotto, Francesco
   Caporossi, Tomaso
   Rizzo, Stanislao
   Giansanti, Fahrizio
TI OCT-A in the Management of Vitreoretinal Diseases and Surgery
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE epiretinal macular membrane; macular hole; OCT angiography; retinal
   detachment; vitreoretinal interface disorders
ID OPTICAL COHERENCE TOMOGRAPHY; RHEGMATOGENOUS RETINAL-DETACHMENT;
   THICKNESS MACULAR HOLE; EPIRETINAL MEMBRANES; CAPILLARY PLEXUSES;
   ANGIOGRAPHY; VITRECTOMY; PREVALENCE; FEATURES
AB Optical coherence tomography angiography is a relatively new noninvasive technique that is changing our approach in the management of several retinal diseases such as neovascular age-related macular degeneration, occlusive retinal diseases, or diabetic retinopathy, but it could also be useful in nonprimary vascular retinal pathologies such as vitreoretinal interface surgical disorders.
   In idiopathic vitreoretinal interface disorders and surgical retinal diseases, the study of vascular involvement, not commonly assessed by invasive methods, could be useful to reveal specific vascular abnormalities. Such information may be useful for a more detailed phenotyping of each clinical picture before and after surgical treatment, providing potential new prognostic biomarkers.
   The review discusses the current and potential utility of optical coherence tomography angiography to study vitreoretinal pathologies of surgical interest.
C1 [Bacherini, Daniela; Dragotto, Francesco; Caporossi, Tomaso; Giansanti, Fahrizio] Univ Florence, AOU Careggi, Dept Neurosci, Psychol Drug Res & Child Hlth Eye Clin, I-50139 Florence, Italy.
   [Bacherini, Daniela; Mastropasqua, Rodolfo; Borrelli, Enrico; Capuano, Vittorio; Iovino, Claudio] Univ Modena & Reggio Emilia, Young Ophthalmologists Retinal Imaging Soc, Modena, Italy.
   [Mastropasqua, Rodolfo] Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy.
   [Borrelli, Enrico] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Capuano, Vittorio] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Iovino, Claudio] Univ Campania Luigi Vanvitelli, Eye Clin, Multidisciplinary Dept Med Surg & Dent Sci, Naples, Italy.
   [Rizzo, Stanislao] Fdn Policlin Univ A Gemelli IRCCS, UOC Oculist, Rome, Italy.
   [Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Rizzo, Stanislao] CNR, Ist Neurosci, Pisa, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi;
   Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universita della Campania Vanvitelli; Catholic University of the Sacred
   Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred
   Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Neuroscienze (IN-CNR)
RP Bacherini, D (通讯作者)，Univ Florence, AOU Careggi, Dept Neurosci, Psychol Drug Res & Child Hlth Eye Clin, I-50139 Florence, Italy.
EM daniela.bacherini@gmail.com
RI Mastropasqua, Rodolfo/AAC-6453-2022; Iovino, Claudio/O-7680-2019
OI Iovino, Claudio/0000-0003-1984-0555; Dragotto,
   Francesco/0000-0003-1753-1097
CR Agarwal A, 2019, RETINA-J RET VIT DIS, V39, P2167, DOI 10.1097/IAE.0000000000002276
   Ahn J, 2018, GRAEF ARCH CLIN EXP, V256, P11, DOI 10.1007/s00417-017-3814-7
   Baba T, 2020, RETINA-J RET VIT DIS, V40, P1585, DOI 10.1097/IAE.0000000000002637
   Baba T, 2018, SPEKTRUM AUGENHEILKD, V32, P31, DOI 10.1007/s00717-017-0375-4
   Bacherini D, 2017, OPHTHALMIC SURG LASE, V48, P62
   Bacherini D, 2018, MINERVA OFTALMOL, V60, DOI [10.23736/s0026-4903.18.01807-x, DOI 10.23736/S0026-4903.18.01807-X]
   Begaj T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239138
   Bonfiglio V, 2020, ACTA OPHTHALMOL, V98, pE563, DOI 10.1111/aos.14315
   Caporossi T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75292-2
   Carpineto P, 2019, RETINA-J RET VIT DIS, V39, P1061, DOI 10.1097/IAE.0000000000002546
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gaucher D, 2007, VISION RES, V47, P612, DOI 10.1016/j.visres.2006.11.017
   Guber J, 2019, OPHTHALMOL THER, V8, P297, DOI 10.1007/s40123-019-0185-7
   Hashimoto Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119376
   Heimann H, 2001, GRAEF ARCH CLIN EXP, V239, P567, DOI 10.1007/s004170100319
   HOCHHEIMER BF, 1971, ARCH OPHTHALMOL-CHIC, V86, P564
   Hong EH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.35
   Inoue M, 2014, DEV OPHTHALMOL, V54, P159, DOI 10.1159/000360462
   Jackson TL, 2014, OPHTHALMOLOGY, V121, P643, DOI 10.1016/j.ophtha.2013.07.015
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kim YJ, 2018, BRIT J OPHTHALMOL, V102, P1086, DOI 10.1136/bjophthalmol-2017-311188
   Kim YJ, 2018, BRIT J OPHTHALMOL, V102, P966, DOI 10.1136/bjophthalmol-2017-311132
   Kobashi H, 2014, CURR EYE RES, V39, P204, DOI 10.3109/02713683.2013.838270
   Kusuhara S, 2014, OPHTHALMOLOGICA, V231, P125, DOI 10.1159/000355492
   Lecleire-Collet A, 2006, AM J OPHTHALMOL, V142, P176, DOI 10.1016/j.ajo.2006.01.080
   Lee JY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59504-3
   Mastropasqua L, 2018, INT OPHTHALMOL, V38, P1465, DOI 10.1007/s10792-017-0608-1
   Mastropasqua R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122067
   McCarty DJ, 2005, AM J OPHTHALMOL, V140, P288, DOI 10.1016/j.ajo.2005.03.032
   Meuer SM, 2015, OPHTHALMOLOGY, V122, P787, DOI 10.1016/j.ophtha.2014.10.014
   Michalewska Z, 2018, RETINA-J RET VIT DIS, V38, pS154, DOI 10.1097/IAE.0000000000002199
   Michalewska Z, 2018, OSLI RETINA, V49, P111, DOI 10.3928/23258160-20180129-05
   Miyazaki M, 2003, GRAEF ARCH CLIN EXP, V241, P642, DOI 10.1007/s00417-003-0723-8
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   PICCOLINO FC, 1983, OPHTHALMOLOGICA, V186, P17
   Pierro L, 2017, OSLI RETINA, V48, P648, DOI 10.3928/23258160-20170802-07
   Rizzo S, 2020, OPHTHALMOL RETINA, V4, P996, DOI 10.1016/j.oret.2020.04.017
   Rizzo S, 2017, OSLI RETINA, V48, P62, DOI 10.3928/23258160-20161219-09
   Ruiz-Moreno JM, 2008, BRIT J OPHTHALMOL, V92, P640, DOI 10.1136/bjo.2007.136176
   Sato T, 2017, GRAEF ARCH CLIN EXP, V255, P2071, DOI 10.1007/s00417-017-3743-5
   SATOH Y, 1989, Nippon Ganka Gakkai Zasshi, V93, P1002
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   Smith AJ, 2008, OPHTHALMOLOGY, V115, P1923, DOI 10.1016/j.ophtha.2008.05.025
   Stec LA, 2004, RETINA-J RET VIT DIS, V24, P341, DOI 10.1097/00006982-200406000-00001
   Stevenson W, 2016, CLIN OPHTHALMOL, V10, P527, DOI 10.2147/OPTH.S97722
   Sun ZC, 2012, GRAEF ARCH CLIN EXP, V250, P1587, DOI 10.1007/s00417-012-1997-5
   Tsen CL, 2019, GRAEF ARCH CLIN EXP, V257, P1847, DOI 10.1007/s00417-019-04381-4
   Tsuboi K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.20
   Ullrich S, 2002, BRIT J OPHTHALMOL, V86, P390, DOI 10.1136/bjo.86.4.390
   Veckeneer M, 2017, EYE, V31, P1274, DOI 10.1038/eye.2017.137
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Wilczynski T, 2019, CLIN INTERV AGING, V14, P505, DOI 10.2147/CIA.S189417
   Woo JM, 2018, CURR EYE RES, V43, P674, DOI 10.1080/02713683.2018.1437922
   Yeo JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70254-0
   Yui N, 2019, GRAEF ARCH CLIN EXP, V257, P245, DOI 10.1007/s00417-018-4133-3
NR 57
TC 3
Z9 3
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD JAN-FEB
PY 2021
VL 10
IS 1
BP 12
EP 19
DI 10.1097/APO.0000000000000373
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RI6UD
UT WOS:000637043300004
PM 33512825
OA gold
DA 2022-11-30
ER

PT J
AU Stanga, PE
   Lim, JI
   Hamilton, P
AF Stanga, PE
   Lim, JI
   Hamilton, P
TI Indocyanine green angiography in choriorefinal diseases: Indications and
   interpretation - An evidence-based update
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   SCANNING LASER OPHTHALMOSCOPE; PLACOID PIGMENT EPITHELIOPATHY; ANGIOID
   STREAKS; FLUORESCEIN ANGIOGRAPHY; NEOVASCULAR MEMBRANES; MACULAR
   DEGENERATION; PATHOLOGICAL MYOPIA; FUNDUS CAMERA
AB Topic/Purpose: To assess the clinical usefulness and relevance of indocyanine green angiography (ICG) in the investigation of chorioretinal disorders and assess specifically in what conditions it may add useful information to that obtained using standard fluorescein angiography.
   Clinical Relevance: Many publications on ICG have appeared in recent years touting its use in ophthalmology. These publications have led to increasing use of this technique and to its application in numerous retinal diseases in which the fluorescein angiographic findings have been thoroughly described.
   Methods/Literature Reviewed: During this systematic literature review, we identified and reviewed a total of 376 articles, from among which we selected 92 that we considered most relevant to our purpose of evaluating published evidence as to the efficacy of ICG. We excluded many articles with weak study designs and those that simply duplicated previously published information. Our literature search used PubMed and was confined to articles in English or that included an English abstract.
   Results: Our systematic review suggests that ICG has relatively few specific indications for use as justified by previously published peer-reviewed studies. In keeping with the requirements for this Journal's evidence-based articles, we have divided our clinical recommendations for the use of ICG into three categories: (A) strongly recommended and supported by strong evidence; (B) recommended with moderately strong supporting evidence; (C) not recommended at present because supported only by anecdotal or group consensus evidence.
   A. We highly recommended ICG for (1) identification of polypoidal choroidal vasculopathy, (2) occult choroidal neovascularization, (3) neovascularization associated with pigment epithelial detachments, and (4) recurrent choroidal neovascular membranes. These are all conditions in which ICG contributes to the identification of lesions that may be treatable.
   B. We recommend ICG with some enthusiasm for identifying feeder vessels in age-related macular degeneration, choroidal neovascular membranes, chronic central serous retinopathy, multiple evanescent white dot syndrome, vasculitis, acute multifocal placoid pigment epitheliopathy, Vogt-Koyanagi-Harada syndrome, macular lesions associated with angioid streaks, and birdshot retinopathy. In all these conditions, ICG may help establish a diagnosis and provide some useful guidance for therapy.
   C. At present, we do not recommend ICG for scleritis and posterior scleritis, drusen differentiation, Behcet's disease, or sarcoidosis, because it has not been demonstrated to add useful clinical information.
   Conclusions: ICG, although now a well established technique, has clear advantage over fluorescein angiography in relatively few chorioretinal disorders. It has, however, contributed to the understanding of pathologic processes in many ocular diseases. As yet, no published randomized controlled clinical trials show any benefit to the use of ICG in the management of any specific ocular disease.
C1 Moorfields Eye Hosp, London EC1V 2PD, England.
   Univ Liverpool, Royal Liverpool Hosp, St Pauls Eye Unit, Liverpool L69 3BX, Merseyside, England.
   Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA 90089 USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Royal Liverpool & Broadgreen University Hospitals
   NHS Trust; Royal Liverpool University Hospital; University of Liverpool;
   University of Southern California
RP Hamilton, P (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
CR AHUJA R, UNPUB POLYPOIDAL VAS
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akman A, 1998, EYE, V12, P646, DOI 10.1038/eye.1998.162
   Amoaku WMK, 1995, EYE, V9, P738, DOI 10.1038/eye.1995.187
   Arend O, 1995, Ger J Ophthalmol, V4, P257
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Auer C, 1998, AM J OPHTHALMOL, V126, P471, DOI 10.1016/S0002-9394(98)00119-6
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   BISCHOFF PM, 1995, RETINA-J RET VIT DIS, V15, P91, DOI 10.1097/00006982-199515020-00002
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Bonte CA, 1998, RETINA-J RET VIT DIS, V18, P476, DOI 10.1097/00006982-199805000-00018
   Brancato R, 1996, Eur J Ophthalmol, V6, P39
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Cohen SM, 1997, OPHTHALMIC SURG LAS, V28, P65
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   FLOWER RW, 1972, AM J OPHTHALMOL, V73, P458, DOI 10.1016/0002-9394(72)90079-7
   FLOWER RW, 1976, JOHNS HOPKINS MED J, V138, P33
   Gelisken F, 1998, RETINA-J RET VIT DIS, V18, P37
   Gelisken F, 1998, JPN J OPHTHALMOL, V42, P300, DOI 10.1016/S0021-5155(98)00010-0
   Giovannini A, 1996, Eur J Ophthalmol, V6, P299
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Howe L, 1998, EYE, V12, P761, DOI 10.1038/eye.1998.199
   HOWE LJ, 1995, OPHTHALMOLOGY, V102, P790, DOI 10.1016/S0161-6420(95)30955-4
   Howe LJ, 1997, EYE, V11, P554, DOI 10.1038/eye.1997.142
   HYVARINEN L, 1980, ACTA OPHTHALMOL, V58, P528
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kadayifcilar S, 1999, EUR J OPHTHALMOL, V9, P68, DOI 10.1177/112067219900900112
   Kadrmas EF, 1997, INT OPHTHALMOL CLIN, V37, P171, DOI 10.1097/00004397-199703740-00015
   KLEIN GJ, 1990, INVEST OPHTH VIS SCI, V31, P629
   Kohno T, 1998, AM J OPHTHALMOL, V126, P248, DOI 10.1016/S0002-9394(98)00153-6
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P346, DOI 10.1007/s004170050089
   Lafaut BA, 1997, GRAEF ARCH CLIN EXP, V235, P330, DOI 10.1007/BF01739644
   LE D, 1994, AM J OPHTHALMOL, V117, P7
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   LIM JI, 1995, AM J OPHTHALMOL, V120, P75, DOI 10.1016/S0002-9394(14)73761-4
   Maberley DAL, 1999, RETINA-J RET VIT DIS, V19, P37, DOI 10.1097/00006982-199901000-00006
   MARUYAMA Y, 1995, SURV OPHTHALMOL, V39, pS40, DOI 10.1016/S0039-6257(05)80072-4
   MASUDA T, 1916, ACTA SOC OPHTH JAPON, V20, P1518
   MASUDA T, 1917, ACTA SOC OPHTHALMOL, V20, P158
   MASUDA T, 1915, CHUO GANKA IHO, V7, P123
   MASUDA T, 1917, ACTA SOC OPHTHALMOL, V20, P1381
   MASUDA T, 1917, ACTA SOC OPHTHALMOL, V20, P1518
   MASUDA T, 1917, ACTA SOC OPHTHALMOL, V20, P478
   MASUDA T, 1917, ACTA SOC OPHTHALMOL, V20, P1049
   Matsuo T, 1999, OPHTHALMOLOGY, V106, P295, DOI 10.1016/S0161-6420(99)90069-6
   Midena E, 1996, OPHTHALMOLOGY, V103, P1651, DOI 10.1016/S0161-6420(96)30450-8
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Muci-Mendoza R, 1999, OPHTHALMOLOGY, V106, P311, DOI 10.1016/S0161-6420(99)90055-6
   Mueller AJ, 1998, ARCH OPHTHALMOL-CHIC, V116, P31, DOI 10.1001/archopht.116.1.31
   Obana A, 1996, RETINA-J RET VIT DIS, V16, P97, DOI 10.1097/00006982-199616020-00002
   Ohno-Matsui K, 1998, JPN J OPHTHALMOL, V42, P293, DOI 10.1016/S0021-5155(98)00008-2
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Olsen TW, 1996, ARCH OPHTHALMOL-CHIC, V114, P97, DOI 10.1001/archopht.1996.01100130093018
   Oshima Y, 1996, AM J OPHTHALMOL, V122, P58, DOI 10.1016/S0002-9394(14)71964-6
   Parodi MB, 1998, INT OPHTHALMOL, V22, P1, DOI 10.1023/A:1006054221016
   Parodi MB, 1996, BRIT J OPHTHALMOL, V80, P416, DOI 10.1136/bjo.80.5.416
   Pece A, 1998, AM J OPHTHALMOL, V126, P604, DOI 10.1016/S0002-9394(98)00123-8
   Pece A, 1997, ACTA OPHTHALMOL SCAN, V75, P261
   Piccolino FC, 1996, RETINA-J RET VIT DIS, V16, P19, DOI 10.1097/00006982-199616010-00005
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Piccolino FC, 1996, OPHTHALMOLOGY, V103, P1837
   QUARANTA M, 1995, AM J OPHTHALMOL, V119, P136, DOI 10.1016/S0002-9394(14)73865-6
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Salati C, 1997, Bull Soc Belge Ophtalmol, V265, P29
   SCHEIDER A, 1989, AM J OPHTHALMOL, V108, P458, DOI 10.1016/S0002-9394(14)73325-2
   Schneider U, 1995, KLIN MONATSBL AUGENH, V207, P372, DOI 10.1055/s-2008-1035392
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   Shiraga F, 2000, OPHTHALMOLOGY, V107, P600, DOI 10.1016/S0161-6420(99)00126-8
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Shiraki K, 1997, INT OPHTHALMOL, V21, P43, DOI 10.1023/A:1005898714237
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Slakter JS, 1997, OPHTHALMOLOGY, V104, P1813, DOI 10.1016/S0161-6420(97)30022-0
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1998, RETINA-J RET VIT DIS, V18, P44
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
   Takahashi K, 1998, AM J OPHTHALMOL, V126, P91, DOI 10.1016/S0002-9394(98)00069-5
   Takahashi Kyoichi, 1999, Nippon Ganka Gakkai Zasshi, V103, P404
   Uyama M, 1999, RETINA-J RET VIT DIS, V19, P12, DOI 10.1097/00006982-199901000-00003
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wolfensberger TJ, 1999, OPHTHALMOLOGY, V106, P285, DOI 10.1016/S0161-6420(99)90067-2
   Wolfensberger TJ, 1999, AM J OPHTHALMOL, V127, P350, DOI 10.1016/S0002-9394(98)00325-0
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 1994, Eur J Ophthalmol, V4, P191
   YUZAWA M, 1994, ACTA OPHTHALMOL, V72, P128
NR 96
TC 203
Z9 223
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2003
VL 110
IS 1
BP 15
EP 21
AR PII S0161-6420(02)01563-4
DI 10.1016/S0161-6420(02)01563-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 633PT
UT WOS:000180292200015
PM 12511340
DA 2022-11-30
ER

PT J
AU Dansingani, KK
   Tan, ACS
   Gilani, F
   Phasukkijwatana, N
   Novais, E
   Querques, L
   Waheed, NK
   Duker, JS
   Querques, G
   Yannuzzi, LA
   Sarraf, D
   Freund, KB
AF Dansingani, Kunal K.
   Tan, Anna C. S.
   Gilani, Fatimah
   Phasukkijwatana, Nopasak
   Novais, Eduardo
   Querques, Lea
   Waheed, Nadia K.
   Duker, Jay S.
   Querques, Giuseppe
   Yannuzzi, Lawrence A.
   Sarraf, David
   Freund, K. Bailey
TI Subretinal Hyperreflective Material Imaged With Optical Coherence
   Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; OCT ANGIOGRAPHY;
   RANIBIZUMAB
AB PURPOSE: The range of subretinal hyperreflective material (SHRM) seen in macular disease includes type 2 macular neovascularization, fibrosis, exudation, vitelliform material, and hemorrhage. The prognostic significance of SHRM has been evaluated retrospectively in clinical trials, but discriminating SHRM subtypes traditionally requires multiple imaging modalities. The purpose of this study is to describe optical coherence tomography angiography (OCTA) flow characteristics and artifacts that might help to distinguish SHRM subtypes.
   DESIGN: Validity analysis.
   METHODS: Patients with age-related macular degeneration (AMD), myopia, pachychoroid disease, and macular dystrophy, manifesting SHRM on optical coherence tomography (OCT), were recruited. Clinical chart review and multimodal imaging established the SHRM subtype. All patients underwent OCTA. OCT and OCTA images were examined together for (1) intrinsic flow, (2) retinal projection onto the anterior SHRM surface (strong, weak, absent), (3) retinal projection through SHRM onto retinal pigment epithelium (RPE), and (4) masking of choriocapillaris flow.
   RESULTS: Thirty-three eyes of 25 patients were included (type 2 neovascularization x3; fibrosis x4; exudation x10; hemorrhage x5; vitelliform x17). Mean age per eye was 76 years (standard deviation: 12). Intrinsic flow was strongest in type 2 neovascularization. Subretinal fibrosis showed limited flow in residual large-caliber vessels and branches. Flow was not detected within foci of exudation, hemorrhage, or vitelliform lesions. Retina-SHRM surface projection was strongest onto smooth-surfaced SHRM and weaker onto exudation. Retinal projection was weakest on the surface of vitelliform lesions. Retina-RPE projection was masked by dense hemorrhage and vitelliform material. In compound SHRM, OCTA distinguished between vascular and avascular components.
   CONCLUSION: Optical coherence tomography angiography can distinguish vascular from avascular SHRM components. OCTA artifacts may distinguish certain avascular SHRM components. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Dansingani, Kunal K.; Tan, Anna C. S.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Dansingani, Kunal K.; Tan, Anna C. S.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dansingani, Kunal K.] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [Tan, Anna C. S.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA.
   [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand.
   [Novais, Eduardo; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
   [Novais, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Querques, Lea; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Milan, Italy.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of Nebraska System; University of Nebraska
   Medical Center; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; National University of
   Singapore; Singapore National Eye Center; University of California
   System; University of California Los Angeles; Mahidol University; Tufts
   University; Universidade de Sao Paulo; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; New York University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Greater Los Angeles Healthcare System
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Phasukkijwatana, Nopasak/T-8630-2019; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Querques,
   Giuseppe/0000-0002-3292-9581; Novais, Eduardo/0000-0001-6790-4627
FU LUESTHER T. MERTZ RETINAL RESEARCH CENTER; Macula Foundation, Inc, New
   York, New York
FX FUNDING/SUPPORT: FUNDING SUPPORT WAS RECEIVED FROM THE LUESTHER T. MERTZ
   RETINAL RESEARCH CENTER AND THE Macula Foundation, Inc, New York, New
   York. The funding bodies supported this research but had no role in the
   design, conduct, or decision to publish.
CR Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
NR 17
TC 51
Z9 54
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2016
VL 169
BP 235
EP 248
DI 10.1016/j.ajo.2016.06.031
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4UA
UT WOS:000383637300025
PM 27349411
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Battista, M
   Gelormini, F
   Sacconi, R
   Querques, L
   Vella, G
   Vigano, C
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Battista, Marco
   Gelormini, Francesco
   Sacconi, Riccardo
   Querques, Lea
   Vella, Giovanna
   Vigano, Chiara
   Bandello, Francesco
   Querques, Giuseppe
TI Rate of misdiagnosis and clinical usefulness of the correct diagnosis in
   exudative neovascular maculopathy secondary to AMD versus pachychoroid
   disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR
AB The aim of this study was to explore the relative prevalence and clinical differences between age-related macular degeneration (AMD) and pachychoroid disease in patients older than 50 years with newly diagnosed exudative neovascular maculopathy, and also assess the rate of misdiagnosis between these two disorders. In this retrospective observational study, we reviewed data from patients 50 years of age and older with newly diagnosed treatment-naive exudative macular neovascularization (MNV) secondary to AMD or pachychoroid disease. Of the 139 patients (139 eyes) who fulfilled the inclusion criteria, 35 patients were graded as being affected by pachychoroid disease complicated by exudative MNV and 104 subjects had neovascular AMD. Therefore, prevalence of pachychoroid disease complicated by exudative MNV was 25.2% (confidence interval-CI 18.2-33.2%). Mean +/- SD age was 67.0 +/- 8.8 years in the pachychoroid disease group and 80.6 +/- 6.6 years in the neovascular AMD group (P<0.0001). At baseline, BCVA was better in patients with pachychoroid disease complicated by exudative MNV (0.4 +/- 0.3 LogMAR vs. 0.7 +/- 0.5 LogMAR, P=0.003). At the 1-year follow-up visit, BCVA was still better in patients with pachychoroid-associated MNV (0.34 +/- 0.32 LogMAR vs. 0.59 +/- 0.52 LogMAR; P=0.005). In our study cohort, 19 patients were graded to be affected by pachychoroid disease complicated by exudative MNV even though a diagnosis of neovascular AMD was erroneously reported in their medical records at baseline. In conclusion, pachychoroid disease is a frequent cause of exudative MNV in aged patients with a high rate of misdiagnosis. A correct diagnosis may be important as these two disorders differ in terms of clinical characteristics and prognosis.
C1 [Borrelli, Enrico; Battista, Marco; Gelormini, Francesco; Sacconi, Riccardo; Querques, Lea; Vigano, Chiara; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
   [Borrelli, Enrico; Battista, Marco; Gelormini, Francesco; Sacconi, Riccardo; Querques, Lea; Vella, Giovanna; Vigano, Chiara; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Milan, Italy.
   [Vella, Giovanna] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Ophthalmol, Pisa, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; University of Pisa
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Milan, Italy.
EM giuseppe.querques@unisr.it
RI Battista, Marco/AAO-3106-2021
OI Battista, Marco/0000-0001-5940-6177; bandello,
   francesco/0000-0003-3238-9682; Querques, Giuseppe/0000-0002-3292-9581;
   Sacconi, Riccardo/0000-0003-2891-2012
CR Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Huang YJ, 2012, INVEST OPHTH VIS SCI, V53, P2133, DOI 10.1167/iovs.11-8755
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Sartini F, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090221
   Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
NR 28
TC 6
Z9 6
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 23
PY 2020
VL 10
IS 1
AR 20344
DI 10.1038/s41598-020-77566-1
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PA7YB
UT WOS:000595844900002
PM 33230253
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lim, TH
   Lai, TYY
   Takahashi, K
   Wong, TY
   Chen, LJ
   Ruamviboonsuk, P
   Tan, CS
   Lee, WK
   Cheung, CMG
   Ngah, NF
   Patalauskaite, R
   Margaron, P
   Koh, A
AF Lim, Tock H.
   Lai, Timothy Y. Y.
   Takahashi, Kanji
   Wong, Tien Y.
   Chen, Lee-Jen
   Ruamviboonsuk, Paisan
   Tan, Colin S.
   Lee, Won Ki
   Cheung, Chui Ming Gemmy
   Ngah, Nor Fariza
   Patalauskaite, Ramune
   Margaron, Philippe
   Koh, Adrian
CA EVEREST II Study Grp
TI Comparison of Ranibizumab With or Without Verteporfin Photodynamic
   Therapy for Polypoidal Choroidal Vasculopathy The EVEREST II Randomized
   Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; COMBINATION; DIAGNOSIS; NEOVASCULARIZATION;
   EFFICACY; SAFETY
AB Importance The 2-year efficacy and safety of combination therapy of ranibizumab administered together with verteporfin photodynamic therapy (vPDT) compared with ranibizumab monotherapy in participants with polypoidal choroidal vasculopathy (PCV) are unclear.
   Objective To compare treatment outcomes of ranibizumab, 0.5 mg, plus prompt vPDT combination therapy with ranibizumab, 0.5 mg, monotherapy in participants with PCV for 24 months.
   Design, Setting, and Participants This 24-month, phase IV, double-masked, multicenter, randomized clinical trial (EVEREST II) was conducted among Asian participants from August 7, 2013, to March 2, 2017, with symptomatic macular PCV confirmed using indocyanine green angiography.
   Interventions Participants (N = 322) were randomized 1:1 to ranibizumab, 0.5 mg, plus vPDT (combination therapy group; n = 168) or ranibizumab, 0.5 mg, plus sham PDT (monotherapy group; n = 154). All participants received 3 consecutive monthly ranibizumab injections, followed by a pro re nata regimen. Participants also received vPDT (combination group) or sham PDT (monotherapy group) on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions.
   Main Outcomes and Measures Evaluation of combination therapy vs monotherapy at 24 months in key clinical outcomes, treatment exposure, and safety. Polypoidal lesion regression was defined as the absence of indocyanine green hyperfluorescence of polypoidal lesions. Results Among 322 participants (mean [SD] age, 68.1 [8.8] years; 225 [69.9%] male), the adjusted mean best-corrected visual acuity (BCVA) gains at month 24 were 9.6 letters in the combination therapy group and 5.5 letters in the monotherapy group (mean difference, 4.1 letters; 95% CI, 1.0-7.2 letters; P = .005), demonstrating that combination therapy was superior to monotherapy by the BCVA change from baseline to month 24. Combination therapy was superior to monotherapy in terms of complete polypoidal lesion regression at month 24 (81 of 143 [56.6%] vs 23 of 86 [26.7%] participants; P < .001). Participants in the combination group received fewer ranibizumab injections (median, 6.0 [interquartile range (IQR), 4.0-11.0]) than the monotherapy group (median, 12.0 [IQR, 7.0-17.0]) up to month 24. The combination group required a median of 2.0 (IQR, 1.0-3.0) vPDT treatments for 24 months, with 75 of 168 participants (44.6%) requiring only 1 vPDT treatment.
   Conclusions and Relevance The 24-month data findings confirm that ranibizumab therapy, given as monotherapy or in combination with vPDT, is efficacious and safe for treatment of PCV. Combination therapy with vPDT added to ranibizumab achieved superior BCVA gain, increased odds of complete polypoidal lesion regression, and fewer treatment episodes compared with ranibizumab monotherapy.
C1 [Lim, Tock H.; Tan, Colin S.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore, Singapore.
   [Lim, Tock H.; Tan, Colin S.] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Osaka, Japan.
   [Wong, Tien Y.; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Ngah, Nor Fariza] Hosp Shah Alam, Dept Ophthalmol, Shah Alam, Malaysia.
   [Patalauskaite, Ramune] Novartis Ireland Ltd, Dublin, Ireland.
   [Margaron, Philippe] Novartis Pharma AG, Basel, Switzerland.
   [Koh, Adrian] Camden Med Ctr, Eye & Retina Surg, Singapore, Singapore.
C3 Tan Tock Seng Hospital; Chinese University of Hong Kong; Kansai Medical
   University; National University of Singapore; Singapore National Eye
   Center; Mackay Memorial Hospital; Rajavithi Hospital; Catholic
   University of Korea; Seoul St. Mary's Hospital; Novartis; Novartis
RP Lim, TH (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore, Singapore.
EM tock_han_lim@nhg.com.sg
RI Tan, Colin S/K-8972-2012; Wong, Tien Yin/AAC-9724-2020; Lai, Timothy Y
   Y/AAC-2120-2020
OI Tan, Colin S/0000-0003-3088-5690; Wong, Tien Yin/0000-0002-8448-1264;
   Lai, Timothy Y Y/0000-0002-7832-6428
FU Novartis Pharma AG
FX This trial was supported by Novartis Pharma AG.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   ZHANG X, 2018, BIOMED RES INT, V2018, DOI DOI 10.1155/2018/9640131
NR 28
TC 52
Z9 54
U1 4
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2020
VL 138
IS 9
BP 935
EP 942
DI 10.1001/jamaophthalmol.2020.2443
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NS2LN
UT WOS:000572098900001
PM 32672800
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Falavarjani, KG
   Al-Sheikh, M
   Akil, H
   Sadda, SR
AF Falavarjani, Khalil Ghasemi
   Al-Sheikh, Mayss
   Akil, Handan
   Sadda, Srinivas R.
TI Image artefacts in swept-source optical coherence tomography angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID THICKNESS MEASUREMENTS; MACULAR THICKNESS; ERRORS
AB Purpose To describe optical coherence tomography angiography (OCTA) image artefacts in eyes with and without ocular pathologies.
   Methods The OCTA images of healthy subjects and patients with age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions were retrospectively reviewed. All OCTA images were obtained using a swept-source OCTA instrument (Triton, Topcon). The frequency of various image artefacts including segmentation, banding, motion, projection, masking, unmasking, doubling of the retinal vessels, blink, stretching, out-of-window and crisscross artefacts was assessed. The impact of the artefact on the grading of the images for the foveal avascular zone in deep and superficial retinal layers, capillary non-perfusion and choroidal neovascularisation (CNV) was evaluated.
   Results OCTA images of 57 eyes of 48 subjects including 23 eyes (40.3%) with CNV, 13 eyes (22.8%) with dry age-related macular degeneration, 9 eyes (15.7%) with cystoid macular oedema due to diabetic retinopathy or retinal vein occlusion and 12 normal eyes (21.1%) were available for evaluation. At least one type of artefact was present in the images from 51 eyes (89.4%). Banding artefact, segmentation, motion, unmasking, blink, vessel doubling, masking and out-of-window artefacts were found in 51 (89.4%), 35 (61.4%), 28 (49.1%), 9 (15.8%), 5 (8.8%), 1 (1.7%), 1 eye (1.7%) and 1 eye (1.7%), respectively. Projection artefact, stretch artefact or crisscross artefact was not observed. Banding, motion and segmentation artefacts were statistically significantly more frequent in eyes with ocular pathology compared with control eyes (all p<0.001). Eyes with choroidal diseases had significantly higher rate of segmentation error in the choriocapillaris slab compared with eyes with only retinal disease (p=0.02). In nine eyes (17.6%), the artefacts were deemed severe enough by the graders to preclude accurate grading of the image.
   Conclusions Image artefacts occur frequently in OCTA images. The artefacts are more frequent in eyes with pathology.
C1 [Falavarjani, Khalil Ghasemi; Al-Sheikh, Mayss; Akil, Handan; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Tehran, Iran.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Iran University of
   Medical Sciences
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Falavarjani, Khalil Ghasemi/I-4029-2019
OI Ghasemi Falavarjani, Khalil/0000-0001-5221-1844
FU Optos; Genentech; Allergan; Carl Zeiss Meditec
FX SRS is a consultant for Optos, Genentech and Allergan, and receives
   research support from Optos, Genentech, Allergan and Carl Zeiss Meditec.
CR Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Coscas G, 2016, DEV OPHTHALMOL, V56, P30, DOI 10.1159/000442774
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   Falavarjani KG, 2015, EUR J OPHTHALMOL, V25, P218, DOI 10.5301/ejo.5000539
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Morales MU, 2013, CAN J OPHTHALMOL, V48, P368, DOI 10.1016/j.jcjo.2013.05.022
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Song Y, 2012, RETINA-J RET VIT DIS, V32, P569, DOI 10.1097/IAE.0b013e31821f5d69
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
NR 10
TC 112
Z9 112
U1 2
U2 32
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2017
VL 101
IS 5
BP 564
EP 568
DI 10.1136/bjophthalmol-2016-309104
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2MQ
UT WOS:000402331100005
PM 27439739
DA 2022-11-30
ER

PT J
AU Iyengar, SK
AF Iyengar, Sudha K.
TI The quest for genes causing complex traits in ocular medicine -
   Successes, interpretations, and challenges
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; MACULAR DEGENERATION;
   GENOMEWIDE-SCAN; SUSCEPTIBILITY LOCI; QUANTITATIVE TRAIT; LINKAGE
   ANALYSIS; FACTOR-H; MOLECULAR-GENETICS; CLINICAL-FEATURES
AB Gene mapping and positional cloning have gained acceptance as state-of-the-art methods to identify molecules that cause common complex diseases. However, the use of specialized technology, varying study designs, and misconceptions about the role of novel findings in genetics has led to confusion among basic scientists and health care professionals alike regarding the importance of these findings in molecular diagnostics and individualized medicine. To alleviate this confusion, the successes achieved in the past few years in mapping of genes for complex traits such as age-related macular degeneration and glaucoma are interpreted in the context of the appropriate population biology framework. The current article veers away from propagating the overly simplistic belief of a linear relationship between a specific gene and age-related macular degeneration, particularly one that equates possession of a specific risk allele as the only precursor to end-stage disease. Ascribing predictive properties to a single gene without consideration of its network partners, timing of action, or environmental correlates argues for a static view of gene action. Modern viewpoints of the mechanisms of action of a gene are contextual and encompass more cohesive frameworks, ranging from the developmental timing of action, to the genomic and environmental milieu. In this regard, gene mapping studies that have been so immensely successful in the gene detection phase of a study provide biased perspectives on the importance of these genes and the corresponding risk alleles in the general population because of their limited sample size and constrained design. To move the field of gene-based diagnosis forward, it will be necessary to conduct additional cohort and longitudinal studies using the original gene finding studies as a knowledge base to develop predictive models. In summary, while we have achieved great successes in finding genes for complex traits, the application of these findings to clinical medicine is not straightforward. The key question of who will develop disease in the future remains.
C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg 1315,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM ski@case.edu
RI /S-1190-2019
OI /0000-0001-7488-250X
FU NEI NIH HHS [EY015814, EY016482] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY016482] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091
   Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503
   AMOS CI, 1994, AM J HUM GENET, V54, P535
   BAILER AJ, 1990, BIOMETRICS, V46, P1201, DOI 10.2307/2532462
   Baird PN, 2003, HUM GENET, V112, P110, DOI 10.1007/s00439-002-0865-5
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BROWN DL, 1994, AM J HUM GENET, V54, P544
   Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610
   Chung Mina, 2002, Ophthalmol Clin North Am, V15, P459, DOI 10.1016/S0896-1549(02)00045-7
   Colomb E, 2001, CLIN GENET, V60, P220, DOI 10.1034/j.1399-0004.2001.600308.x
   Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Doris PA, 2002, HYPERTENSION, V39, P323, DOI 10.1161/hy0202.104087
   Duggirala R, 1997, GENET EPIDEMIOL, V14, P987, DOI 10.1002/(SICI)1098-2272(1997)14:6<987::AID-GEPI71>3.0.CO;2-G
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELSTON RC, 1995, AM J HUM GENET, V56, P15
   ELSTON RC, 1995, CLIN EXP ALLERGY, V25, P103, DOI 10.1111/j.1365-2222.1995.tb00434.x
   ELSTON RC, 1978, ANNU REV BIOPHYS BIO, V7, P253, DOI 10.1146/annurev.bb.07.060178.001345
   Evans DM, 2006, TRENDS GENET, V22, P350, DOI 10.1016/j.tig.2006.05.001
   EWENS WJ, 1995, AM J HUM GENET, V57, P455
   Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69
   Fan JB, 2004, GENOME RES, V14, P878, DOI 10.1101/gr.2167504
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351
   Francis PJ, 2006, J ROY SOC MED, V99, P189, DOI 10.1258/jrsm.99.4.189
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Goddard KAB, 2001, AM J HUM GENET, V68, P1197, DOI 10.1086/320103
   GOLDGAR DE, 1990, AM J HUM GENET, V47, P957
   Gunderson KL, 2006, METHOD ENZYMOL, V410, P359, DOI 10.1016/S0076-6879(06)10017-8
   Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804
   Guo SW, 1998, AM J HUM GENET, V63, P252, DOI 10.1086/301928
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731
   HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204
   Hauser ER, 2004, GENET EPIDEMIOL, V27, P53, DOI 10.1002/gepi.20000
   Hewitt AW, 2006, CLIN EXP OPHTHALMOL, V34, P472, DOI 10.1111/j.1442-9071.2006.01268.x
   HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   JAMES JW, 1971, ANN HUM GENET, V35, P47, DOI 10.1111/j.1469-1809.1956.tb01377.x
   Kelly J, 1999, INT OPHTHALMOL CLIN, V39, P83, DOI 10.1097/00004397-199903940-00008
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Kruglyak L, 1996, AM J HUM GENET, V58, P1347
   Kuehn BM, 2006, JAMA-J AM MED ASSOC, V295, P1633, DOI 10.1001/jama.295.14.1633
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728
   Lawrence RW, 2005, PHILOS T R SOC B, V360, P1589, DOI 10.1098/rstb.2005.1689
   Libby RT, 2005, ANNU REV GENOM HUM G, V6, P15, DOI 10.1146/annurev.genom.6.080604.162209
   Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457
   Lin S, 2004, GENOME RES, V14, P1624, DOI 10.1101/gr.2204604
   Lin S, 2002, AM J HUM GENET, V71, P1129, DOI 10.1086/344347
   LIPSHUTZ RJ, 1994, GENOMICS, V19, P417, DOI 10.1006/geno.1994.1089
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675
   MACDONALD IM, 1994, CLIN INVEST MED, V17, P474
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2006, NAT REV GENET, V7, P812, DOI 10.1038/nrg1919
   MORTON NE, 1959, AM J HUM GENET, V11, P1
   OLIPHANT A, 2002, BIOTECHNIQUES S, V5658, P60
   Olson JM, 1999, AM J HUM GENET, V65, P1760, DOI 10.1086/302662
   PADHUKASAHASRAM B, 2006, GENETICS        0915
   Palmer LJ, 2005, LANCET, V366, P1223, DOI 10.1016/S0140-6736(05)67485-5
   Peacock E, 2005, PHARMACOGENOMICS, V6, P439, DOI 10.1517/14622416.6.4.439
   Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449
   Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272
   Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   RISCH N, 1990, AM J HUM GENET, V46, P222
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rotimi CN, 2006, INVEST OPHTH VIS SCI, V47, P3262, DOI 10.1167/iovs.05-1537
   Schaid DJ, 2003, HUM HERED, V55, P86, DOI 10.1159/000072313
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   SHASTRY BS, 1993, CLIN GENET, V44, P275
   SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331
   Shen R, 2005, MUTAT RES-FUND MOL M, V573, P70, DOI 10.1016/j.mrfmmm.2004.07.022
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   STRACHAN T, 2003, HUMAN MOL GENETICS, V3
   STRACHAN T, 1999, HUMAN MOL GENETICS, V2
   Tang S, 2003, HUM GENET, V113, P276, DOI 10.1007/s00439-003-0964-y
   Thomas DC, 2004, STAT METHODS GENETIC
   Tsuchiya T, 2006, MOL GENET METAB, V89, P174, DOI 10.1016/j.ymgme.2006.05.013
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wiggs Janey L, 2005, Ophthalmol Clin North Am, V18, P335, DOI 10.1016/j.ohc.2005.05.003
   Wiggs JL, 1998, AM J HUM GENET, V63, P1549, DOI 10.1086/302098
   Wilson SH, 2004, MOL INTERV, V4, P147
   Wright AF, 2001, GENOME BIOL, V2
   Young Terri L, 2003, Curr Opin Ophthalmol, V14, P296, DOI 10.1097/00055735-200310000-00011
   Zeggini E, 2005, NAT GENET, V37, P1320, DOI 10.1038/ng1670
   Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270
   1982, BIRTH DEFECTS ORIG A, V18, P1
NR 100
TC 11
Z9 11
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 11
EP 18
DI 10.1001/archopht.125.1.11
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800002
PM 17210847
DA 2022-11-30
ER

PT J
AU Butler, JM
   Hall, N
   Narendran, N
   Yang, YC
   Paraoan, L
AF Butler, Joe M.
   Hall, Neil
   Narendran, Niro
   Yang, Yit C.
   Paraoan, Luminita
TI Identification of candidate protective variants for common diseases and
   evaluation of their protective potential
SO BMC GENOMICS
LA English
DT Article
DE Candidate gene; Protective variants; Common variants; Missense mutation;
   Gene selection; Age-related macular degeneration; Non-synonymous SNP;
   Gain of function; Ancestral allele; Type 2 diabetes; Inflammatory bowel
   disease; Multiple sclerosis and rheumatoid arthritis
ID GENOME-WIDE ASSOCIATION; OF-FUNCTION MUTATIONS; SUSCEPTIBILITY LOCI;
   MACULAR DEGENERATION; METAANALYSIS; SELECTION; RISK; POLYMORPHISMS;
   PSORIASIS; INFERENCE
AB Background: Human polymorphisms with derived alleles that are protective against disease may provide powerful translational opportunities. Here we report a method to identify such candidate polymorphisms and apply it to common non-synonymous SNPs (nsSNPs) associated with common diseases. Our study also sought to establish which of the identified protective nsSNPs show evidence of positive selection, taking this as indirect evidence that the protective variant has a beneficial effect on phenotype. Further, we performed an analysis to quantify the predicted effect of each protective variant on protein function/structure.
   Results: An initial analysis of eight SNPs previously identified as associated with age-related macular degeneration (AMD), revealed that two of them have a derived allele that is protective against developing the disease. One is in the complement component 2 gene (C2; E318D) and the other is in the complement factor B gene (CFB; R32Q). Then, combining genomewide ancestral allele information with known common disease-associated nsSNPs from the GWAS catalog, we found 32 additional SNPs which have a derived allele that is disease protective. Out of the total 34 identified candidate protective variants (CPVs), we found that 30 show stronger evidence of positive selection than the protective variant in lipoprotein lipase (LPL; S447X), which has already been translated into gene therapy. Furthermore, 11 of these CPVs have a higher probability of affecting protein structure than the lipoprotein lipase protective variant (LPL; S447X).
   Conclusions: We identify 34 CPVs from the human genome. Diseases they confer protection against include, but are not limited to, type 2 diabetes, inflammatory bowel disease, age-related macular degeneration, multiple sclerosis and rheumatoid arthritis. We propose that those 30 CPVs with evidence of stronger positive selection than the LPL protective variant, may be considered as priority candidates for therapeutic approaches. The next step towards translation will require testing the hypotheses generated by our analyses, specifically whether the CPV arose from a gain-of-function or a loss-of-function mutation.
C1 [Butler, Joe M.; Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, 6 West Derby St, Liverpool L7 8TX, Merseyside, England.
   [Hall, Neil] Norwich Res Pk, Earlham Inst, Norwich NR4 7UH, Norfolk, England.
   [Narendran, Niro; Yang, Yit C.] Royal Wolverhampton NHS Trust, New Cross Hosp, Dept Ophthalmol, Wolverhampton WV10 0QP, W Midlands, England.
C3 University of Liverpool; UK Research & Innovation (UKRI); Biotechnology
   and Biological Sciences Research Council (BBSRC); Earlham Institute; New
   Cross Hospital
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, 6 West Derby St, Liverpool L7 8TX, Merseyside, England.
EM lparaoan@liverpool.ac.uk
RI Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Hall, Neil/0000-0003-2808-0009
FU R & D Royal Wolverhampton NHS Trust, Wolverhampton, UK
FX The authors gratefully acknowledge the support from R & D Royal
   Wolverhampton NHS Trust, Wolverhampton, UK.
CR Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764
   Bahlo M, 2000, THEOR POPUL BIOL, V57, P79, DOI 10.1006/tpbi.1999.1447
   Berndt SI, 2013, NAT GENET, V45, P501, DOI 10.1038/ng.2606
   Bolton KL, 2010, NAT GENET, V42, P880, DOI 10.1038/ng.666
   Bouatia-Naji N, 2009, NAT GENET, V41, P89, DOI 10.1038/ng.277
   De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Field Y, 2016, SCIENCE, V354, P760, DOI 10.1126/science.aag0776
   Fingerlin TE, 2013, NAT GENET, V45, P613, DOI 10.1038/ng.2609
   Flannick J, 2014, NAT GENET, V46, P357, DOI 10.1038/ng.2915
   Freilinger T, 2012, NAT GENET, V44, P777, DOI 10.1038/ng.2307
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gaudet D, 2013, GENE THER, V20, P361, DOI 10.1038/gt.2012.43
   Gautier M, 2012, BIOINFORMATICS, V28, P1176, DOI 10.1093/bioinformatics/bts115
   Grossman SR, 2013, CELL, V152, P703, DOI 10.1016/j.cell.2013.01.035
   Jonathan C, 2005, NAT GENET, V37, P161, DOI 10.1038/ng1509
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Kirino Y, 2013, NAT GENET, V45, P202, DOI 10.1038/ng.2520
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kozyrev SV, 2008, NAT GENET, V40, P211, DOI 10.1038/ng.79
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Li H, 2011, NATURE, V475, P493, DOI 10.1038/nature10231
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Myouzen K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002949
   Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311
   Niu WQ, 2011, J HUM HYPERTENS, V25, P383, DOI 10.1038/jhh.2010.68
   Okada Y, 2012, NAT GENET, V44, P511, DOI 10.1038/ng.2231
   Paten B, 2008, GENOME RES, V18, P1814, DOI 10.1101/gr.076554.108
   Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051
   Rader DJ, 2005, ARTERIOSCL THROM VAS, V25, P2018, DOI 10.1161/01.ATV.0000183606.81315.85
   Ross CJD, 2005, ARTERIOSCL THROM VAS, V25, P2143, DOI 10.1161/01.ATV.0000176971.27302.b0
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Siddiq A, 2012, HUM MOL GENET, V21, P5373, DOI 10.1093/hmg/dds381
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Steinthorsdottir V, 2014, NAT GENET
   Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694
   Sullivan D, 2012, JAMA-J AM MED ASSOC, V308, P2497, DOI 10.1001/jama.2012.25790
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Tong Y, 2010, MOL VIS, V16, P1958
   Trevino LR, 2009, NAT GENET, V41, P1001, DOI 10.1038/ng.432
   Vithana EN, 2012, NAT GENET, V44, P1142, DOI 10.1038/ng.2390
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609
   Voight BF, 2006, PLOS BIOL, V4, P659, DOI 10.1371/journal.pbio.0040072
   Wallace C, 2010, NAT GENET, V42, P68, DOI 10.1038/ng.493
   Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849
   Yang WL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000841
   Yu XQ, 2012, NAT GENET, V44, P178, DOI 10.1038/ng.1047
   Yuan DQ, 2013, MOL VIS, V19, P374
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
   Zhang RJ, 2011, MOL BIOL REP, V38, P5079, DOI 10.1007/s11033-010-0654-5
NR 63
TC 13
Z9 13
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 3
PY 2017
VL 18
AR 575
DI 10.1186/s12864-017-3964-3
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA FC7UD
UT WOS:000407046900002
PM 28774272
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lam, N
   Leat, SJ
   Leung, A
AF Lam, Norris
   Leat, Susan J.
   Leung, Alison
TI Low-vision Service Provision by Optometrists: A Canadian Nationwide
   Survey
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision; low-vision services; visual impairment; rehabilitation;
   service provision; barriers
ID BEAVER DAM EYE; OLDER-ADULTS; VISUAL IMPAIRMENT; REHABILITATION;
   EXPERIENCE; DISABILITY; BARRIERS; PROJECT; ACCESS
AB Purpose. To document the degree to which Canadian optometrists are involved in the provision of low-vision (LV) care and their referral patterns. To investigate the barriers to providing optometric low-vision services (LVS).
   Methods. Practicing optometrists across Canada were randomly sampled and invited to participate in a questionnaire that included questions on personal profile, primary practice profile, levels of LV care offered, patterns of referral, and barriers to provision of LV care. Questions included a combination of multiple choice and open-ended formats, and included hypothetical cases.
   Results. A total of 459 optometrists responded (response rate, 24.8%). Optometrists estimated that 1% (range, 0 to 100%) of their patients were LV patients yet also estimated that 10% of their patients had acuity equal to or worse than 20/40. Thirty-five percent of respondents indicated that their primary practice offered LV care, 75.6% would manage a patient with minimum disability and simple goals themselves, whereas 10.7% would manage a patient with more than minimal visual disability who needed more specialized LV devices (e.g., telescopes, electronic aids, and custom-designed microscopes); 84.3% of optometrists would assess for basic magnification and lighting in a hypothetical patient with early age-related macular degeneration, whereas 15% would undertake full LV rehabilitation in advanced age-related macular degeneration. Optometrists commonly referred to CNIB (formerly the Canadian National Institute for the Blind), yet only 10.7% of respondents almost always received a written report after referral. Those who would not undertake LV assessment stated that they lacked the knowledge, equipment, or experience; that LV assessment is too time consuming; and that the cost is too prohibitive.
   Conclusions. This is the first comprehensive study of LVS provision by optometrists in Canada. In order for optometrists to become more involved in LVS, there is a need for more LV education, provincial health coverage of optometric LVS, and better collaboration communication between LV providers.
C1 [Lam, Norris; Leat, Susan J.; Leung, Alison] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON N2L 3G1, Canada.
C3 University of Waterloo
RP Lam, N (通讯作者)，100-200 Univ Ave E, Toronto, ON M5H 3C6, Canada.
EM nhylam@uwaterloo.ca
OI Leat, Susan/0000-0002-7082-035X
FU Canadian Optometric Education Trust Fund
FX This work was funded by the Canadian Optometric Education Trust Fund.
   The authors are grateful for the involvement of optometrists who
   responded to our survey. The authors acknowledge the provincial colleges
   and associations of optometrists for providing the contact information
   of the practicing optometrists. The contents of this article were
   presented as a poster at the American Academy of Optometry meeting in
   Boston, MA, in October 12, 2011.
CR Alberta Health Website, OPT PRIC LIST 01 OCT
   Bentley SA, 2014, CLIN EXP OPTOM, V97, P214, DOI 10.1111/cxo.12139
   British Columbia Ministry of Health, 2008, OPT PAYM SCHED
   Canadian National Institute for the Blind (CNIB), SPEC TECHN EQ PROGR
   Canadian National Institute for the Blind (CNIB), OUR RANG SERV
   Canadian National Institute for the Blind (CNIB), WER HER EV STEP WAY
   Cruess AF, 2011, CAN J OPHTHALMOL, V46, P315, DOI 10.1016/j.jcjo.2011.06.006
   Edlow RC, 2009, OPTOMETRY, V80, P267, DOI 10.1016/j.optm.2009.03.003
   Gilmour GR, 2006, CAN J OPHTHALMOL, V41, P370, DOI 10.1139/I06-024
   Gold D., 2005, INT C SER, V1282, P139
   Gresset E, 2005, INT C SERIES, V1282, P283, DOI [10.1016/j.ics.2005.05.105, DOI 10.1016/J.ICS.2005.05.105]
   Health Canada, CAN HLTH ACT ANN REP
   Kammer R, 2009, OPTOMETRY, V80, P185, DOI 10.1016/j.optm.2008.10.015
   Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P207, DOI 10.1111/j.1442-9071.1996.tb01582.x
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P8, DOI 10.1111/j.1475-1313.1990.tb01098.x
   Leat SJ, 1999, OPTOMETRY VISION SCI, V76, P198, DOI 10.1097/00006324-199904000-00023
   Lim HY, 2008, CLIN EXP OPTOM, V91, P177, DOI 10.1111/j.1444-0938.2007.00214.x
   Lovie-Kitchin JE, 2010, OPTOMETRY VISION SCI, V87, P948, DOI 10.1097/OPX.0b013e3181ff99be
   Lovie-Kitchin JE., 1996, CLIN EXP OPTOM, V79, P227
   Millar WJ., VISION PROBLEMS SENI
   Ministry of Health and Long-term Care, ASS DEV PROGR VIS AI
   National Coalition for Vision Health, FDN CAN VIS HLTH STR
   O'Connor PM, 2008, CLIN EXP OPHTHALMOL, V36, P547, DOI 10.1111/j.1442-9071.2008.01830.x
   Pollard TL, 2003, OPHTHAL PHYSL OPT, V23, P321, DOI 10.1046/j.1475-1313.2003.00123.x
   Robillard N, 2006, CAN J OPHTHALMOL, V41, P362, DOI 10.1139/I06-022
   Robinson B, 2013, OPHTHAL EPIDEMIOL, V20, P123, DOI 10.3109/09286586.2013.789915
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Ryan B, 2014, CLIN EXP OPTOM, V97, P209, DOI 10.1111/cxo.12157
   Southall K, 2012, J VISUAL IMPAIR BLIN, V106, P261, DOI 10.1177/0145482X1210600502
   Spafford MM, 2010, J APPL GERONTOL, V29, P579, DOI 10.1177/0733464809345494
   Statistics Canada, FACTS SEEING LIM
   Statistics Canada, POP BROAD AG GROUPS
   Steinman BA, 2012, J AGING HEALTH, V24, P307, DOI 10.1177/0898264311422600
   Strong JG., PRINCIPLES PRACTICES
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
NR 37
TC 11
Z9 11
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2015
VL 92
IS 3
BP 365
EP 374
DI 10.1097/OPX.0000000000000512
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA CC4HO
UT WOS:000350314000021
PM 25599339
DA 2022-11-30
ER

PT J
AU Sigler, EJ
   Mascarenhas, KG
   Tsai, JC
   Loewen, NA
AF Sigler, Eric J.
   Mascarenhas, Kristy G.
   Tsai, James C.
   Loewen, Nils A.
TI Clinicopathologic Correlation of Disc and Peripapillary Region Using
   SD-OCT
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE Fourier domain OCT; spectral domain OCT; SD-OCT; low-pressure glaucoma;
   optic disc size; prelaminar canal depth; peripapillary choroidal
   thickness
ID OPTIC-NERVE HEAD; NORMAL-TENSION GLAUCOMA; CENTRAL CORNEAL THICKNESS;
   PRIMARY OPEN-ANGLE; INTRAOCULAR-PRESSURE REDUCTION; COHERENCE
   TOMOGRAPHY; LAMINA-CRIBROSA; CHOROIDAL THICKNESS; 3-D HISTOMORPHOMETRY;
   UNTREATED PATIENTS
AB Purpose. To describe a technique for evaluating peripapillary and optic nerve head (ONH) anatomy using spectral domain optical coherence tomography (SD-OCT) raster scanning in humans and compare quantifiable parameters between diagnosis categories.
   Methods. Ninety-five eyes of 51 consecutive patients were evaluated in this retrospective cross-sectional pilot study. Cirrus 5-line raster SD-OCTs with a resolution of 5 to 15 mu m obtained through the ONH were included. A single observer manually measured neural canal opening (NCO), prelaminar canal depth (PLCD), peripapillary choroidal thickness (PPCT), and canal nerve fiber layer (CNFL) in normals, ocular hypertension, primary open-angle glaucoma (POAG), low-pressure glaucoma (LPG), secondary glaucoma, and early atrophic age-related macular degeneration. Clinical information, including central corneal thickness (CCT), was obtained via medical record review. Mean anatomical values within diagnosis categories were compared using one-way analysis of variance andmultivariate analysis. Bivariate analysiswas used to investigate relationships between continuous variables, and significant (p < 0.05) relationships were incorporated into the final statistical model.
   Results. Horizontal NCO was significantly greater in eyes with LPG than that in normals (p = 0.021). The PPCT was thinner in age-related macular degeneration (p = 0.001) and glaucoma (p = 0.004) compared with that in controls (normals). Mean CNFL was thinner in POAG (p < 0.001) and LPG (p = 0.053) compared with that in normals. Vertical NCO was inversely correlated to CCT (p = 0.013). Multivariate analysis indicated a positive correlation between PLCD and PPCT (p = 0.008) and an inverse correlation between CNFL and PLCD(p < 0.001). Controlling for PPCT, PLCD and CCT were inversely correlated (p < 0.001).
   Conclusions. The SD-OCT raster scanning may be used to quantify ONH anatomy in humans. The NCO differences between POAG and LPG may indicate a distinct structural vulnerability in LPG. In addition, CNFL, PPCT, and PLCD may be important parameters to consider in glaucoma. The PLCD correlates with PPCT and should be considered in new models of glaucoma pathogenesis. (Optom Vis Sci 2013;90:84-93)
C1 [Loewen, Nils A.] Univ Pittsburgh, Inst Eye & Ear, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15213 USA.
   [Sigler, Eric J.] Charles Retina Inst, Div Vitreoretinal Surg, Memphis, TN USA.
   [Mascarenhas, Kristy G.; Tsai, James C.] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Yale University
RP Loewen, NA (通讯作者)，Univ Pittsburgh, Inst Eye & Ear, Dept Ophthalmol, Sch Med, 203 Lothrop St,Suite 819, Pittsburgh, PA 15213 USA.
EM loewenna@upmc.edu
RI Loewen, Nils/E-9946-2014
OI Loewen, Nils/0000-0001-7167-1213
FU Research to Prevent Blindness, Inc., New York, NY; NATIONAL EYE
   INSTITUTE [K08EY022737] Funding Source: NIH RePORTER
FX Supported in part by a departmental Challenge Grant from Research to
   Prevent Blindness, Inc., New York, NY.
CR Agoumi Y, 2011, OPHTHALMOLOGY, V118, P52, DOI 10.1016/j.ophtha.2010.05.016
   Alward WL, 1998, AM J OPHTHALMOL, V126, P498
   Anderson DR, 2003, AM J OPHTHALMOL, V136, P820, DOI 10.1016/S0002-9394(03)00478-1
   Bellezza AJ, 2003, INVEST OPHTH VIS SCI, V44, P623, DOI 10.1167/iovs.01-1282
   Bellezza AJ, 2003, BRIT J OPHTHALMOL, V87, P1284, DOI 10.1136/bjo.87.10.1284
   Brandt James D, 2004, Curr Opin Ophthalmol, V15, P85, DOI 10.1097/00055735-200404000-00004
   Budenz DL, 2005, OPHTHALMOLOGY, V112, P3, DOI 10.1016/j.ophtha.2004.06.039
   Budenz DL, 2008, OPHTHALMOLOGY, V115, P661, DOI 10.1016/j.ophtha.2007.05.035
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Burgoyne CF, 2004, INVEST OPHTH VIS SCI, V45, P4388, DOI 10.1167/iovs.04-0022
   Burgoyne CF, 2001, J GLAUCOMA, V10, pS16, DOI 10.1097/00061198-200110001-00007
   BURK ROW, 1992, GRAEF ARCH CLIN EXP, V230, P552, DOI 10.1007/BF00181778
   CRISTINI G, 1991, OPHTHALMOLOGICA, V202, P81, DOI 10.1159/000310179
   Danias J, 1999, AM J OPHTHALMOL, V127, P623
   Doughty MJ, 2000, SURV OPHTHALMOL, V44, P367, DOI 10.1016/S0039-6257(00)00110-7
   Downs JC, 2007, INVEST OPHTH VIS SCI, V48, P3195, DOI 10.1167/iovs.07-0021
   Drance SM, 1999, AM J OPHTHALMOL, V127, P120
   Ehrlich JR, 2011, EXP EYE RES, V92, P189, DOI 10.1016/j.exer.2011.01.002
   Fatehee N, 2011, INVEST OPHTH VIS SCI, V52, P6192, DOI 10.1167/iovs.10-7137
   Fortune B, 2011, INVEST OPHTH VIS SCI, V52, P6651, DOI 10.1167/iovs.11-7578
   FRANCOIS J, 1964, ARCH OPHTHALMOL-CHIC, V71, P219
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Herndon LW, 2004, ARCH OPHTHALMOL-CHIC, V122, P17, DOI 10.1001/archopht.122.1.17
   Hoffmann EM, 2007, SURV OPHTHALMOL, V52, P32, DOI 10.1016/j.survophthal.2006.10.002
   Kohlhaas M, 2006, ARCH OPHTHALMOL-CHIC, V124, P471, DOI 10.1001/archopht.124.4.471
   KUBOTA T, 1993, BRIT J OPHTHALMOL, V77, P430, DOI 10.1136/bjo.77.7.430
   Lee EJ, 2012, INVEST OPHTH VIS SCI, V53, P198, DOI 10.1167/iovs.11-7848
   Leung CKS, 2011, OPHTHALMOLOGY, V118, P1558, DOI 10.1016/j.ophtha.2011.01.026
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   Medeiros FA, 2003, AM J OPHTHALMOL, V136, P805, DOI 10.1016/S0002-9394(03)00484-7
   Mwanza JC, 2011, OPHTHALMOLOGY, V118, P241, DOI 10.1016/j.ophtha.2010.06.036
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Pakravan M, 2007, BRIT J OPHTHALMOL, V91, P26, DOI 10.1136/bjo.2006.106039
   Park HYL, 2012, OPHTHALMOLOGY, V119, P10, DOI 10.1016/j.ophtha.2011.07.033
   Park SC, 2012, OPHTHALMOLOGY, V119, P3, DOI 10.1016/j.ophtha.2011.07.012
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Pena JDO, 2001, INVEST OPHTH VIS SCI, V42, P2303
   Peng PH, 2011, J GLAUCOMA, V20, P355, DOI 10.1097/IJG.0b013e3181efb07d
   QUIGLEY HA, 1995, AUST NZ J OPHTHALMOL, V23, P85, DOI 10.1111/j.1442-9071.1995.tb00135.x
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Schuman Joel S, 2008, Trans Am Ophthalmol Soc, V106, P426
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   Sharma A, 2011, OPHTHALMOLOGY, V118, P1348, DOI 10.1016/j.ophtha.2010.12.008
   Sigal IA, 2011, INVEST OPHTH VIS SCI, V52, P1896, DOI 10.1167/iovs.10-5500
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Strouthidis NG, 2011, INVEST OPHTH VIS SCI, V52, P1206, DOI 10.1167/iovs.10-5599
   Strouthidis NG, 2009, INVEST OPHTH VIS SCI, V50, P214, DOI 10.1167/iovs.08-2302
   Tomita G, 2000, Curr Opin Ophthalmol, V11, P116, DOI 10.1097/00055735-200004000-00009
   TUULONEN A, 1992, ARCH OPHTHALMOL-CHIC, V110, P211, DOI 10.1001/archopht.1992.01080140067029
   Yang HL, 2007, INVEST OPHTH VIS SCI, V48, P5068, DOI 10.1167/iovs.07-0790
   Yang HL, 2007, INVEST OPHTH VIS SCI, V48, P4597, DOI 10.1167/iovs.07-0349
   Yang HL, 2011, INVEST OPHTH VIS SCI, V52, P7109, DOI 10.1167/iovs.11-7448
   Yang HL, 2011, INVEST OPHTH VIS SCI, V52, P345, DOI 10.1167/iovs.09-5122
   Yin ZQ, 1997, J GLAUCOMA, V6, P23
NR 57
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JAN
PY 2013
VL 90
IS 1
BP 84
EP 93
DI 10.1097/OPX.0b013e318278fc15
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063QP
UT WOS:000313015200020
PM 23232801
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Campagna, G
   Chamberlain, P
   Orengo-Nania, S
   Biggerstaff, K
   Khandelwal, S
AF Campagna, Giovanni
   Chamberlain, Paul
   Orengo-Nania, Silvia
   Biggerstaff, Kristin
   Khandelwal, Sumitra
TI Ophthalmic Conditions Associated with Inpatient Falls among Veterans
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID FIELD LOSS INCREASES; VISUAL RISK-FACTORS; OLDER-PEOPLE; INJURIOUS
   FALLS; VISION LOSS; PREVENTING FALLS; IMPAIRMENT; ADULTS; INDIVIDUALS;
   PREVALENCE
AB SIGNIFICANCE Efforts to describe the relationship between pathological visual impairment and fall risk are typically confined to community dwellers. Among admitted patients, however, the associations are less understood. Fall risk assessment tools are used in some clinical settings, but most do not capture the suspected importance of ophthalmic pathologies in predicting the likelihood of an inpatient fall. PURPOSE The purpose of this study was to determine the association between ophthalmic conditions and inpatient falls at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), where vision and ophthalmic conditions are not considered when assessing fall risk. METHODS This is a population-based, retrospective case-control study of 805 patients admitted to the MEDVAMC in January 2014 who had also visited the MEDVAMC Eye Clinic within 1 year of admission. The patients' eye examinations, ophthalmic diagnoses, and other indicators of constitutive health were compared between 60 patients who experienced an inpatient fall ("cases") and 749 patients who did not ("controls"). Significant differences between the cases and the controls were determined using logistic regression models. RESULTS Baseline demographics were similar among the two groups. Ophthalmic conditions associated with an increased incidence of inpatient falls included age-related macular degeneration (odds ratio, 3.9; 95% confidence interval, 1.5 to 9.9; P = .008) and a presenting visual acuity of worse than 20/40 in the better-seeing eye (odds ratio, 2.0; 95% confidence interval, 1.0 to 4.1; P = .04). Those without falls demonstrated a better mean presenting visual acuity in the better-seeing eye compared with those who fell (logMAR, 0.12 +/- 0.23 vs. 0.28 +/- 0.49, P < .001). CONCLUSIONS In this population, age-related macular degeneration and poor presenting visual acuity in the better-seeing eye are associated with increased incidence of inpatient falls. An assessment of visual function and ophthalmic diagnoses may be warranted upon admission to the hospital for increased prevention of inpatient falls.
C1 [Campagna, Giovanni; Chamberlain, Paul] Baylor Coll Med, Sch Med, Houston, TX 77030 USA.
   [Chamberlain, Paul; Orengo-Nania, Silvia; Biggerstaff, Kristin; Khandelwal, Sumitra] Baylor Coll Med, Cullen Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA.
   [Orengo-Nania, Silvia; Biggerstaff, Kristin; Khandelwal, Sumitra] Michael E DeBakey VA Med Ctr, Eye Care Line, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine
RP Khandelwal, S (通讯作者)，Baylor Coll Med, Cullen Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA.; Khandelwal, S (通讯作者)，Michael E DeBakey VA Med Ctr, Eye Care Line, Houston, TX 77030 USA.
EM Sumitra.Khandelwal@bcm.edu
OI Khandelwal, Sumitra/0000-0003-1216-1947; Campagna,
   Giovanni/0000-0003-4005-6888
CR Agency for Healthcare Research and Quality, 2013, PREV FALLS HOSP
   Bhangu J, 2016, HEART, V102, P681, DOI 10.1136/heartjnl-2015-308706
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   Bouldin ELD, 2013, J PATIENT SAF, V9, P13, DOI 10.1097/PTS.0b013e3182699b64
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Coleman AL, 2007, J AM GERIATR SOC, V55, P357, DOI 10.1111/j.1532-5415.2007.01094.x
   Crews JE, 2016, MMWR-MORBID MORTAL W, V65, P433, DOI 10.15585/mmwr.mm6517a2
   Cumming RG, 2007, J AM GERIATR SOC, V55, P175, DOI 10.1111/j.1532-5415.2007.01046.x
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   Hallemans A, 2010, GAIT POSTURE, V32, P547, DOI 10.1016/j.gaitpost.2010.07.018
   Helbostad JL, 2009, GAIT POSTURE, V30, P233, DOI 10.1016/j.gaitpost.2009.05.004
   Johns Hopkins Medicine, 2015, HEALTHC SOL FALLS CO
   To KG, 2014, OPHTHAL EPIDEMIOL, V21, P79, DOI 10.3109/09286586.2014.885058
   Kim EAN, 2007, J ADV NURS, V60, P427, DOI 10.1111/j.1365-2648.2007.04419.x
   Koski K, 1998, GERONTOLOGY, V44, P232, DOI 10.1159/000022017
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux E, 2010, GRAEF ARCH CLIN EXP, V248, P527, DOI 10.1007/s00417-009-1260-x
   Leat SJ, 2018, OPHTHAL PHYSL OPT, V38, P106, DOI 10.1111/opo.12428
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   Lord SR, 2006, AGE AGEING, V35, P42, DOI 10.1093/ageing/afl085
   Lord SR, 2010, CLIN GERIATR MED, V26, P569, DOI 10.1016/j.cger.2010.06.002
   Mehravaran S, 2012, AGING HLTH, V8, P549
   Morrison S, 2010, DIABETES CARE, V33, P748, DOI 10.2337/dc09-1699
   Nagamatsu LS, 2009, NEUROPSYCHOLOGIA, V47, P2749, DOI 10.1016/j.neuropsychologia.2009.05.022
   NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164
   Otto CM, 2016, HEART, V102, P651, DOI 10.1136/heartjnl-2016-309648
   Patino CM, 2010, OPHTHALMOLOGY, V117, P199, DOI 10.1016/j.ophtha.2009.06.063
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Ray CT, 2008, J REHABIL RES DEV, V45, P1117, DOI 10.1682/JRRD.2008.01.0016
   Reed-Jones RJ, 2013, MATURITAS, V75, P22, DOI 10.1016/j.maturitas.2013.01.019
   Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x
   Sakata K, 2006, OPHTHALMOLOGY, V113, P1385, DOI 10.1016/j.ophtha.2006.04.023
   Steinman B. A., 2011, INSIGHT, V4, P83
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719
   Ustun Ihsan, 2006, Anadolu Kardiyol Derg, V6, P394
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Yau RK, 2013, DIABETES CARE, V36, P3985, DOI 10.2337/dc13-0429
NR 38
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD DEC
PY 2018
VL 95
IS 12
BP 1114
EP 1119
DI 10.1097/OPX.0000000000001312
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA HC5TS
UT WOS:000451865900005
PM 30451809
DA 2022-11-30
ER

PT J
AU Werginz, P
   Wang, BY
   Chen, ZC
   Palanker, D
AF Werginz, Paul
   Wang, Bing-Yi
   Chen, Zhijie Charles
   Palanker, Daniel
TI On optimal coupling of the 'electronic photoreceptors' into the
   degenerate retina
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE bipolar cell; ribbon synapse; neural stimulation; retinal prosthesis;
   electro-neural interface
ID GANGLION-CELLS; BIPOLAR CELLS; ELECTRICAL-STIMULATION; COMPUTATIONAL
   MODEL; RIBBON SYNAPSES; VISUAL-ACUITY; CONTRAST; MECHANISMS; DEPRESSION;
   CHANNELS
AB Objective To restore sight in atrophic age-related macular degeneration, the lost photoreceptors can be replaced with electronic implants, which replicate their two major functions: (1) converting light into an electric signal, and (2) transferring visual information to the secondary neurons in the retinal neural network-the bipolar cells (BC). We study the selectivity of BC activation by subretinal implants and dynamics of their response to pulsatile waveforms in order to optimize the electrical stimulation scheme such that retinal signal processing with 'electronic photoreceptors' remains as close to natural as possible. Approach A multicompartmental model of a BC was implemented to simulate responses of the voltage-gated calcium channels and subsequent synaptic vesicle release under continuous and pulsatile stimuli. We compared the predicted response under various frequencies, pulse durations, and alternating gratings to the corresponding experimental measurements. In addition, electric field was computed for various electrode configurations in a 3-d finite element model to assess the stimulation selectivity via spatial confinement of the field. Main results The modeled BC-mediated retinal responses were, in general, in good agreement with previously published experimental results. Kinetics of the calcium pumps and of the neurotransmitter release in ribbon synapses, which underpin the BC's temporal filtering and rectifying functions, allow mimicking the natural BC response with high frequency pulsatile stimulation, thereby preserving features of the retinal signal processing, such as flicker fusion, adaptation to static stimuli and non-linear summation of subunits in receptive field. Selectivity of the BC stimulation while avoiding direct activation of the downstream neurons (amacrine and ganglion cells-RGCs) is improved with local return electrodes. Significance If the retinal neural network is preserved to a large extent in age-related macular degeneration, selective stimulation of BCs with proper spatial and temporal modulation of the extracellular electric field may retain many features of the natural retinal signal processing and hence allow highly functional restoration of sight.
C1 [Werginz, Paul] Vienna Univ Technol, Inst Anal & Sci Comp, Vienna, Austria.
   [Wang, Bing-Yi] Stanford Univ, Dept Phys, Stanford, CA 94305 USA.
   [Wang, Bing-Yi; Chen, Zhijie Charles; Palanker, Daniel] Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
   [Chen, Zhijie Charles] Stanford Univ, Elect Engn, Stanford, CA 94305 USA.
   [Palanker, Daniel] Stanford Univ, Ophthalmol, Stanford, CA 94305 USA.
C3 Technische Universitat Wien; Stanford University; Stanford University;
   Stanford University; Stanford University
RP Werginz, P (通讯作者)，Vienna Univ Technol, Inst Anal & Sci Comp, Vienna, Austria.
EM paul.werginz@tuwien.ac.at
RI Werginz, Paul/AAZ-4360-2020
OI Werginz, Paul/0000-0002-3441-3167; Palanker, Daniel/0000-0002-0480-3025;
   Wang, Bing-Yi/0000-0001-8336-3285; Chen, Zhijie/0000-0003-2705-065X
FU Austrian Science Fund [FWF J3947]; NIH [EY027786]; DoD
   [W81XWH-19-1-0738]; AFOSR [FA9550-19-1-0402]; Research to Prevent
   Blindness; Wu Tsai Neurosciences Institute at Stanford
FX We would like to thank Professor Frank Rattay for helpful discussions
   during preparation of the manuscript. PW was supported by the Austrian
   Science Fund (FWF J3947). BW, ZC and DP were supported by the NIH grant
   EY027786, DoD grant W81XWH-19-1-0738, AFOSR grant FA9550-19-1-0402, Wu
   Tsai Neurosciences Institute at Stanford, and Research to Prevent
   Blindness. DP has financial interest in the PRIMA implant due to his
   patents licensed to Pixium Vision by Stanford University and his role as
   a consultant to the company.
CR [Anonymous], 1901, ARCH ITAL BIOL
   Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468
   Balasubramanian Revathi, 2014, Curr Ophthalmol Rep, V2, P100
   Boinagrov D, 2016, IEEE T BIOMED CIRC S, V10, P85, DOI 10.1109/TBCAS.2014.2376528
   Boinagrov D, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026008
   Burrone J, 2002, NEURON, V33, P101, DOI 10.1016/S0896-6273(01)00565-7
   Chen ZJ, 2020, PHYS REV APPL, V13, DOI 10.1103/PhysRevApplied.13.014004
   Demb JB, 2001, J NEUROSCI, V21, P7447, DOI 10.1523/JNEUROSCI.21-19-07447.2001
   Dittman JS, 1998, J NEUROSCI, V18, P6147
   DOBSON V, 1978, VISION RES, V18, P1469, DOI 10.1016/0042-6989(78)90001-9
   ENCKE J, 2013, BIOMED ENG BIOMED S1, V58, DOI DOI http://doi.org/10.1515/bmt-2013-4035
   EULER T, 1995, J COMP NEUROL, V361, P461, DOI 10.1002/cne.903610310
   Flores T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47082-y
   Fohlmeister JF, 2010, J NEUROPHYSIOL, V103, P1357, DOI 10.1152/jn.00123.2009
   Ghosh KK, 2004, J COMP NEUROL, V469, P70, DOI 10.1002/cne.10985
   Greenberg RJ, 1999, IEEE T BIO-MED ENG, V46, P505, DOI 10.1109/10.759051
   HARNOIS C, 1984, EXP BRAIN RES, V57, P1
   Ho E, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/ab34b3
   Ho E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21447-1
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   KARWOSKI CJ, 1985, J NEUROPHYSIOL, V54, P1607, DOI 10.1152/jn.1985.54.6.1607
   Kasi H, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-44
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Lagnado L, 2015, ANNU REV VIS SCI, V1, P235, DOI 10.1146/annurev-vision-082114-035709
   Lorach H, 2015, VISION RES, V111, P142, DOI 10.1016/j.visres.2014.09.007
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Margalit E, 2006, INVEST OPHTH VIS SCI, V47, P2606, DOI 10.1167/iovs.05-1093
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Oesch NW, 2011, NAT NEUROSCI, V14, P1555, DOI 10.1038/nn.2945
   OKSALA ARVO, 1959, ACTA OPHTHALMOL, V37, P388
   Palanker D, 2020, OPHTHALMOLOGY, DOI [10.1016/j.ophth.2020.20.024, DOI 10.1016/J.OPHTH.2020.20.024]
   Pan ZH, 2001, NEURON, V32, P89, DOI 10.1016/S0896-6273(01)00454-8
   Pandarinath C, 2010, FRONT COMPUT NEUROSC, V4, DOI 10.3389/fncom.2010.00002
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Raghuram V, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00436
   Rall W., 1964, NEURAL THEORY MODELI, P73
   Rattay F, 1999, NEUROSCIENCE, V89, P335, DOI 10.1016/S0306-4522(98)00330-3
   Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010
   Sikora MA, 2005, J NEUROSCI METH, V145, P47, DOI 10.1016/j.jneumeth.2004.11.023
   Singer JH, 2006, J NEUROPHYSIOL, V95, P3191, DOI 10.1152/jn.01309.2005
   Singer JH, 2003, J NEUROSCI, V23, P10923
   SOKOL S, 1978, VISION RES, V18, P33, DOI 10.1016/0042-6989(78)90074-3
   Stringer C, 2019, CURR OPIN NEUROBIOL, V55, P22, DOI 10.1016/j.conb.2018.11.005
   Suh B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001973
   Walston ST, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aab4ed
   Wan QF, 2011, VISUAL NEUROSCI, V28, P109, DOI 10.1017/S0952523810000453
   Werginz P, 2015, VISION RES, V111, P170, DOI 10.1016/j.visres.2014.12.002
   Werginz P, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/4/046013
NR 48
TC 7
Z9 7
U1 0
U2 2
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD AUG
PY 2020
VL 17
IS 4
AR 045008
DI 10.1088/1741-2552/aba0d2
PG 15
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA MU3RJ
UT WOS:000555589200001
PM 32613948
OA hybrid
DA 2022-11-30
ER

PT J
AU Ryoo, NK
   Ahn, SJ
   Park, KH
   Ahn, J
   Seo, J
   Han, JW
   Kim, KW
   Woo, SJ
AF Ryoo, Na-Kyung
   Ahn, Seong Joon
   Park, Kyu Hyung
   Ahn, Jeeyun
   Seo, Jiyeong
   Han, Ji Won
   Kim, Ki Woong
   Woo, Se Joon
TI Thickness of retina and choroid in the elderly population and its
   association with Complement Factor H polymorphism: KLoSHA Eye study
SO PLOS ONE
LA English
DT Article
ID NERVE-FIBER LAYER; OPTICAL COHERENCE TOMOGRAPHY; MACULAR-DEGENERATION;
   VASCULAR HYPERPERMEABILITY; AGE; CHORIOCAPILLARIS; PREVALENCE;
   ETHNICITY; MEMBRANE; OCT
AB Purpose
   To analyze the associations of retinal and choroidal thickness on enhanced-depth imaging optical coherence tomography (EDI-OCT) with clinical, ophthalmic and genetic factors in the normal elderly population (aged 65 years or older).
   Methods
   In this prospective, population-based cohort study, people aged 65 years or older were enrolled in the baseline study of the Korean Longitudinal Study on Health and Aging (KLoSHA) Eye Study. All participants underwent spectral domain-OCT scan using the EDI technique. A topographic map of the retina was obtained and subfoveal choroidal thickness (SFCT) was measured manually. Blood samples from all subjects were genotyped for major age-related macular degeneration (AMD)-associated single nucleotide polymorphisms (SNPs) the major AMD-associated SNPs; CFH Y402H rs1061170, CFH I62V rs800292, ARMS2 A69S rs10490924. A statistical analysis was conducted to compare the retinal thickness, choroidal thickness, and AMD risk genotypes.
   Results
   Among the three hundred eighty people enrolled, the mean age was 76.6 years (range 6599 years). Factors that showed correlation with either tomographic retinal parameters, retinal nerve fiber layer, or SFCT, were age and gender. Significant age-related decrease in thickness was observed in the RNFL, mean central thickness (MCT) and SFCT. Gender differences existed in central foveolar thickness (CFT) and MCT, where it was thicker in men. While chorioretinal parameters were not related with other genotypes, CFH rs1061170 risk genotype was significantly associated with thin SFCT. The group containing the AMD-risk allele (CT) had a 14.7% reduction in the SFCT compared to the non-risk TT group.
   Conclusions
   In addition to the well-known association with AMD, CFH rs1061170 is a significant genetic risk factor associated with choroidal thinning in normal eyes of the elderly population. Such findings may provide further insight into the pathogenesis of age-related macular degeneration as well as normal aging. In addition, our study provides the first normative data on retinal and choroidal thickness in population-based aged groups with a mean age over seventy-five.
C1 [Ryoo, Na-Kyung; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnam, South Korea.
   [Ryoo, Na-Kyung] Vet Hlth Serv Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Seong Joon] Hanyang Univ, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Dept Ophthalmol, Seoul Metropolitan Govt, Seoul, South Korea.
   [Seo, Jiyeong] Gyeongsang Natl Univ Hosp, Changwon Hosp, Dept Psychiat, Chang Won, South Korea.
   [Han, Ji Won; Kim, Ki Woong] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Seongnam, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Med, Dept Neuropsychiat, Seoul, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul, South Korea.
C3 Seoul National University (SNU); Veterans Health Service Medical Center;
   Hanyang University; Seoul National University (SNU); Seoul National
   University Hospital; Gyeongsang National University; Gyeongsang National
   University Hospital; Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU)
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnam, South Korea.
EM sejoon1@snu.ac.kr
RI Woo, Se Joon/I-7357-2013
OI Woo, Se Joon/0000-0003-3692-7169; Ahn, Jeeyun/0000-0001-9017-1652
FU Seoul National University Bundang Hospital Research Funds [11-2008-002,
   03-2009-008, 11-2009-037, 11-2010-037, 18-2018-024]; National Research
   Foundation of Korea (NRF) - Ministry of Education, Science, and
   Technology [2009-0072603]; NRF [2016R1D1A1B03934724]; NRF Bio & Medical
   Technology Development Program - Korean government (MSIP)
   [2018M3A9B5021319]; NRF Bio & Medical Technology Development Program -
   Korean government (MSIT) [2018M3A9B5021319]; Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea [HI09C1379
   [A092077], A111161]
FX This study was supported by Seoul National University Bundang Hospital
   Research Funds (grant nos. 11-2008-002, 03-2009-008, 11-2009-037,
   11-2010-037, 18-2018-024 [PMC]), a National Research Foundation of Korea
   (NRF) grant funded by the Ministry of Education, Science, and Technology
   (2009-0072603), NRF grant 2016R1D1A1B03934724 and the NRF Bio & Medical
   Technology Development Program (grant no. 2018M3A9B5021319) funded by
   the Korean government (MSIP and MSIT), and grants from the Korea Health
   Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
   (grant nos. HI09C1379 [A092077] and A111161). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adhi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037638
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Demirkaya N, 2013, INVEST OPHTH VIS SCI, V54, P4934, DOI 10.1167/iovs.13-11913
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kanamori A, 2003, OPHTHALMOLOGICA, V217, P273, DOI 10.1159/000070634
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kelty PJ, 2008, INVEST OPHTH VIS SCI, V49, P2668, DOI 10.1167/iovs.07-1000
   Kim Jeehyoung, 2016, Dent Hypotheses, V7, P73
   Kim NR, 2011, INVEST OPHTH VIS SCI, V52, P3413, DOI 10.1167/iovs.10-6648
   Lattanzio R, 2002, EUR J OPHTHALMOL, V12, P482, DOI 10.1177/112067210201200606
   Lee BR, 2009, RETINA-J RET VIT DIS, V29, P1328, DOI 10.1097/IAE.0b013e3181ac7d30
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Oshitari T, 2007, CLIN OPHTHALMOL, V1, P133
   Park JH, 2007, PSYCHIAT INVEST, V4, P80
   Poinoosawmy D, 1997, BRIT J OPHTHALMOL, V81, P350, DOI 10.1136/bjo.81.5.350
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Roh Young-Rae, 2013, Korean J Ophthalmol, V27, P268, DOI 10.3341/kjo.2013.27.4.268
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shin JW, 2012, OPHTHALMOLOGY, V119, P1017, DOI 10.1016/j.ophtha.2011.10.029
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Toprak AB, 2000, BRIT J OPHTHALMOL, V84, P473, DOI 10.1136/bjo.84.5.473
   Wakitani Y, 2003, RETINA-J RET VIT DIS, V23, P177, DOI 10.1097/00006982-200304000-00007
   Wexler A, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-13
   Wong ACM, 2005, EYE, V19, P292, DOI 10.1038/sj.eye.6701466
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 40
TC 19
Z9 20
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2018
VL 13
IS 12
AR e0209276
DI 10.1371/journal.pone.0209276
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HG0IO
UT WOS:000454627200039
PM 30596689
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Calabrese, A
   Aguilar, C
   Faure, G
   Matonti, F
   Hoffart, L
   Castet, E
AF Calabrese, Aurelie
   Aguilar, Carlos
   Faure, Geraldine
   Matonti, Frederic
   Hoffart, Louis
   Castet, Eric
TI A Vision Enhancement System to Improve Face Recognition with Central
   Vision Loss
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; SPATIAL-FREQUENCIES; IMAGE-ENHANCEMENT;
   EYE-MOVEMENTS; PERCEPTION; REHABILITATION; CONTRAST; POPULATION;
   DISABILITY; FEATURES
AB SIGNIFICANCE: The overall goal of this work is to validate a low vision aid system that uses gaze as a pointing tool and provides smart magnification. We conclude that smart visual enhancement techniques as well as gaze contingency should improve the efficiency of assistive technology for the visually impaired.
   PURPOSE: A low vision aid, using gaze-contingent visual enhancement and primarily intended to help reading with central vision loss, was recently designed and tested with simulated scotoma. Here, we present a validation of this system for face recognition in age-related macular degeneration patients.
   METHODS: Twelve individuals with binocular central vision loss were recruited and tested on a face identification-matching task. Gaze position was measured in real time, thanks to an eye tracker. In the visual enhancement condition, at any time during the screen exploration, the fixated face was segregated from background and considered as a region of interest that could be magnified into a region of augmented vision by the participant, if desired. In the natural exploration condition, participants also performed the matching task but without the visual aid. Response time and accuracy were analyzed with mixed-effects models to (1) compare the performance with and without visual aid and (2) estimate the usability of the system.
   RESULTS: On average, the percentage of correct response for the natural exploration condition was 41%. This value was significantly increased to 63% with visual enhancement (95% confidence interval, 45 to 78%). For the large majority of our participants (83%), this improvement was accompanied by moderate increase in response time, suggesting a real functional benefit for these individuals.
   CONCLUSIONS: Without visual enhancement, participants with age-related macular degeneration performed poorly, confirming their struggle for face recognition and the need to use efficient visual aids. Our system significantly improved face identification accuracy by 55%, proving to be helpful under laboratory conditions. Copyright (C) 2018 American Academy of Optometry
C1 [Calabrese, Aurelie; Castet, Eric] Aix Marseille Univ, Lab Psychol Cognit, Marseille, France.
   [Aguilar, Carlos] Nice Sophia Antipolis Univ, Lab Bases, Corpus, Langage, Nice, France.
   [Faure, Geraldine] Univ Hosp La Timone, Low Vis Clin, Marseille, France.
   [Matonti, Frederic; Hoffart, Louis] Aix Marseille Univ, Univ Hosp La Timone, Dept Ophthalmol, Marseille, France.
C3 UDICE-French Research Universities; Aix-Marseille Universite;
   UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French
   Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; UDICE-French Research Universities;
   Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille
RP Calabrese, A (通讯作者)，Aix Marseille Univ, Lab Psychol Cognit, Marseille, France.
EM aurelie.calabrese@univ-amu.fr
OI Calabrese, Aurelie/0000-0002-7078-3595
FU Essilor International; Fondation de France (Berthe Fouassier
   post-doctoral grant)
FX Essilor International (PhD grant; to CA) and Fondation de France (Berthe
   Fouassier post-doctoral grant; to AC).
CR Aguilar C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174910
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Bernard JB, 2016, OPTOMETRY VISION SCI, V93, P510, DOI 10.1097/OPX.0000000000000819
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Calabrese A, 2014, INVEST OPHTH VIS SCI, V55, P3638, DOI 10.1167/iovs.13-13408
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Castet E, 2012, SEEING PERCEIVING, V25, P449, DOI 10.1163/187847611X620955
   Crossland M., 2007, VISUAL IMPAIRMENT RE, V9, P59, DOI DOI 10.1080/13882350701643582
   Crossland MD, 2014, OPHTHAL PHYSL OPT, V34, P552, DOI 10.1111/opo.12136
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Duchowski AT, 2009, EUROGRAPHICS SHORT P, P9
   FIORENTINI A, 1983, PERCEPTION, V12, P195, DOI 10.1068/p120195
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fok D, 2011, WORK, V39, P37, DOI 10.3233/WOR-2011-1149
   Fujita Kyoko, 2004, Nippon Ganka Gakkai Zasshi, V108, P202
   Goldstein JE, 2015, JAMA OPHTHALMOL, V133, P762, DOI 10.1001/jamaophthalmol.2015.0693
   Gosselin F, 2001, VISION RES, V41, P2261, DOI 10.1016/S0042-6989(01)00097-9
   Henderson JM, 2005, MEM COGNITION, V33, P98, DOI 10.3758/BF03195300
   Johnson AP, 2017, INVEST OPHTH VIS SCI, V58, P2520, DOI 10.1167/iovs.16-21349
   Leelasawassuk T., 2017, P 8 AUGM HUM INT C, P1
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   McCulloch DL, 2011, OPHTHAL PHYSL OPT, V31, P240, DOI 10.1111/j.1475-1313.2011.00828.x
   Melmoth DR, 2000, INVEST OPHTH VIS SCI, V41, P2811
   Melmoth DR, 2003, VISION RES, V43, P769, DOI 10.1016/S0042-6989(02)00685-5
   Meyniel C, 2017, FRONT SYST NEUROSCI, V11, DOI 10.3389/fnsys.2017.00082
   Moshtael H, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.6
   Ohman A., 1998, KAROLINSKA DIRECTED
   OrCam MyEye, PORT WEAR VIS SYST B
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Peyrin C, 2017, VISION RES, V130, P36, DOI 10.1016/j.visres.2016.11.004
   R Core Team, 2018, R LANG ENV STAT COMP
   Samsung Electronics, REL VIS AID APPL VIS
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Virgili G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub3
   Watson GR, 2001, J AM GERIATR SOC, V49, P317, DOI 10.1046/j.1532-5415.2001.4930317.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 7
Z9 7
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD SEP
PY 2018
VL 95
IS 9
BP 738
EP 746
DI 10.1097/OPX.0000000000001263
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GS3SK
UT WOS:000443540400008
PM 30169352
DA 2022-11-30
ER

PT J
AU Giganti, M
   Beer, PM
   Lemanski, N
   Hartman, C
   Schartman, J
   Falk, N
AF Giganti, Monica
   Beer, Paul M.
   Lemanski, Nicole
   Hartman, Coby
   Schartman, Jerome
   Falk, Naomi
TI ADVERSE EVENTS AFTER INTRAVITREAL INFLIXIMAB (REMICADE)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; diabetic macular edema; intravitreal
   infliximab; monoclonal antibody
ID ENDOTHELIAL GROWTH-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1;
   MONOCLONAL-ANTIBODY INFLIXIMAB; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; TNF; ALPHA; CELLS; HOMEOSTASIS; EXPRESSION
AB Purpose: To determine the tolerability of intravitreal infliximab (Remicade) in patients with refractory diabetic macular edema or choroidal neovascularization secondary to age-related macular degeneration.
   Methods: This is a prospective, interventional, noncomparative, open-label, 12-week pilot study of intravitreal infliximab in four patients who failed conventional therapies. Two had diabetic macular edema and two had choroidal neovascularization secondary to age-related macular degeneration. All patients received 0.5 mg/0.05 mL intravitreal infliximab and were eligible for a second injection at 6 weeks if reinjection criteria were met. Outcome measures were best-corrected visual acuity using standard Early Treatment Diabetic Retinopathy Study refraction, central retinal thickness on optical coherence tomography, fluorescein angiography, standard electroretinography, and microperimetry. Patients were evaluated at Days 0 and 1 and Weeks 2, 6, and 12. Six months after study completion, all patients were tested for human antimouse and human antichimeric antibodies.
   Results: At Week 12, visual acuity scores had declined in three patients. All patients had persistence of cystoid macular edema on optical coherence tomography, although two had a decrease in central retinal thickness. Three patients had an overall worsened appearance on angiography. On the final electroretinography, all patients had a decrease in maximal combined responses, from 7% to 24% from baseline, which may have been within expected variability of electroretinography data. To photopic flicker stimulus, three patients had slower latency of response, and all had decreased amplitudes. All patients declined on microperimetry. The first patient entered in the study met the criteria for a second injection because of improved standard electroretinography and microperimetry at Week 6. However, 2 weeks after the second injection, he developed panuveitis. Two other patients, after one injection only, had evidence of inflammation (vitritis or panuveitis) on examination at Week 6. Three patients developed systemic antibodies against infliximab (human antichimeric antibodies).
   Conclusion: Low-dose intravitreal infliximab was not well tolerated in this small group of patients and was both immunogenic and probably retinotoxic. RETINA 30:71-80,2010
C1 [Giganti, Monica; Beer, Paul M.; Hartman, Coby; Schartman, Jerome; Falk, Naomi] Retina Consultants PLLC, Slingerlands, NY 12159 USA.
   [Giganti, Monica; Beer, Paul M.; Hartman, Coby; Schartman, Jerome; Falk, Naomi] Albany Med Coll, Dept Ophthalmol, Albany, NY 12208 USA.
C3 Albany Medical College
RP Giganti, M (通讯作者)，Retina Consultants PLLC, 1220 New Scotland Rd,Suite 201, Slingerlands, NY 12159 USA.
EM drgiganti@retinaconsultant.org
FU Retina Research Foundation
FX Supported by a grant from the Retina Research Foundation.
CR Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Hui DY, 2007, ARTERIOSCL THROM VAS, V27, P1677, DOI 10.1161/ATVBAHA.107.146894
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Markomichelakis NN, 2004, AM J OPHTHALMOL, V138, P648, DOI 10.1016/j.ajo.2004.04.066
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   RYAN SJ, 2001, RETINA, P113
   Sfikakis PP, 2005, DIABETES CARE, V28, P445, DOI 10.2337/diacare.28.2.445
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727
   Yang P, 2004, INVEST OPHTH VIS SCI, V45, P2438, DOI 10.1167/iovs.03-0805
NR 20
TC 96
Z9 101
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2010
VL 30
IS 1
BP 71
EP 80
DI 10.1097/IAE.0b013e3181bcef3b
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZX
UT WOS:000278547300009
PM 19996827
DA 2022-11-30
ER

PT J
AU Keam, SJ
   Scott, LJ
   Curran, MP
AF Keam, SJ
   Scott, LJ
   Curran, MP
TI Verteporfin - A review of its use in the management of subfoveal
   choroidal neovascularisation
SO DRUGS
LA English
DT Review
DE Verteporfin; photodynamic therapy; choroidal neovascularisation;
   age-related macular degeneration; presumed ocular histoplasmosis
   syndrome; pathologic myopia; pharmacodynamics; pharmacokinetics;
   therapeutic use; tolerability
ID OCULAR HISTOPLASMOSIS SYNDROME; AGE-RELATED MACULOPATHY; PIGMENT
   EPITHELIAL TEAR; QUALITY-OF-LIFE; RING-A BPD; PHOTODYNAMIC THERAPY;
   MACULAR DEGENERATION; ECONOMIC-EVALUATION; ADVERSE REACTION; SECONDARY
AB Verteporfin (Visudyne(R)) therapy (photodynamic therapy with intravenous liposomal verteporfin) is the first treatment to effectively prevent the loss of visual acuity in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD), pathological myopia or presumed ocular histoplasmosis syndrome (POHS).
   In adult patients with classic subfoveal CNV or occult with no classic subfoveal CNV secondary to AMD, or subfoveal CNV secondary to pathological myopia or POHS, verteporfin therapy slows or prevents loss of visual acuity. In well designed clinical trials, verteporfin therapy was superior to placebo in patients with subfoveal classic-containing CNV and occult with no classic CNV secondary to AMD at 12 and/or 24 months (Treatment of Age-related macular degeneration with Photodynamic therapy [TAP] Investigation and Verteporfin In Photodynamic therapy [VIP-AMD] trial) and in patients with pathological myopia at 12 months (Verteporfin In Photodynamic therapy [VIP-PM] trial). Limited data suggest that verteporfin therapy also prevents loss of visual acuity in patients with subfoveal CNV secondary to POHS.
   Verteporfin therapy was generally well tolerated in clinical trials; most adverse events were mild to moderate in intensity and transient. The most frequently reported verteporfin therapy-related adverse events (incidence > 2%) were visual disturbance, injection-site reactions, photosensitivity reactions and infusion-related back pain. Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss.
   Conclusion: Photodynamic therapy with verteporfin, the first photosensitiser approved for the treatment of subfoveal CNV, is a well tolerated treatment that stabilises or slows visual acuity loss in adult patients with predominantly classic or occult with no classic subfoveal CNV secondary to AMD, and subfoveal CNV secondary to pathological myopia or POHS. Thus, verteporfin therapy provides a valuable option for the management of these patients for whom treatment options are few, and should be considered as a first-line therapy in these difficult-to-manage conditions.
C1 Adis Int Ltd, Auckland, New Zealand.
C3 Adis International
RP Keam, SJ (通讯作者)，Adis Int Ltd, Auckland, New Zealand.
EM demail@adis.co.nz
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   *AM AC OPTH, SUMM BENCHM PREF PRA
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atebara NH, 1998, OPHTHALMOLOGY, V105, P1598, DOI 10.1016/S0161-6420(98)99024-8
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   BASKIN MA, 1980, AM J OPHTHALMOL, V89, P77, DOI 10.1016/0002-9394(80)90233-0
   BEAUMONT P, 2002, RET 2002 C SEP 28 OC
   Berger AS, 1997, ARCH OPHTHALMOL-CHIC, V115, P991, DOI 10.1001/archopht.1997.01100160161004
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 2003, INVEST OPHTH VIS SCI, V44, pE1100
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busquets MA, 2003, RETINA-J RET VIT DIS, V23, P299, DOI 10.1097/00006982-200306000-00003
   Cahill MT, 2002, AM J OPHTHALMOL, V134, P281, DOI 10.1016/S0002-9394(02)01475-7
   CHEN JC, 2002, INVEST OPHTH VIS SCI, V43, pE586
   Ciulla TA, 2001, CURR OPIN OPHTHALMOL, V12, P442, DOI 10.1097/00055735-200112000-00009
   CUMMINGS HL, 1995, ARCH OPHTHALMOL-CHIC, V113, P465, DOI 10.1001/archopht.1995.01100040081031
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   *EUR AG EV MED PRO, SUMM PROD CHAR VIS
   EVANS J, 1995, CAUSES BLINDNESS PAR, V57, P1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Houle JM, 2002, RETINA-J RET VIT DIS, V22, P691, DOI 10.1097/00006982-200212000-00002
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   *JAP AG REL MAC DE, 2003, AM J OPTHALMOL
   KAISER PK, 2003, INVEST OPHTH VIS SCI, V44, pE1099
   KAISER PK, 2000, TODAYS THER TRENDS, V18, P313
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LAFAUT BA, 2000, B SOC BELGE OPHTALMO, V278, P49
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Lees M, 2003, VALUE HEALTH, V6, P239, DOI 10.1016/S1098-3015(10)63950-2
   Lees MJ, 2003, OPHTHALMOLOGY, V110, P626, DOI 10.1016/S0161-6420(02)01870-5
   LEWIS ML, 1980, OPHTHALMOLOGY, V87, P390, DOI 10.1016/S0161-6420(80)35226-3
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380
   McMillan TA, 1996, INT OPHTHALMOL CLIN, V36, P179, DOI 10.1097/00004397-199603630-00016
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Miller PD, 2001, OSTEOPOROSIS INT, V12, P3
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mittra RA, 2002, OPTOMETRY VISION SCI, V79, P218, DOI 10.1097/00006324-200204000-00008
   Montero JA, 2003, BRIT J OPHTHALMOL, V87, P173, DOI 10.1136/bjo.87.2.173
   *NAT I CLIN EXC, GUID US PHOT THER AG
   NELSON JS, 1988, J NATL CANCER I, V80, P1599, DOI 10.1093/jnci/80.20.1599
   Noffke AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P143
   *NOV PHARM AUSTR P, VIS VERT PRESCR INF
   *NOV PHARM CAN INC, VIS PRESC INF
   POOLER JP, 1981, MED PHYS, V8, P614, DOI 10.1118/1.595020
   POTTER MJ, 2003, INVEST OPHTH VIS SCI, V44, pE1772
   *QLT INC, COMM VIS APPR STAT
   *QLT INC, 2003, DAT FIL
   Ratkay LG, 2000, BIODRUGS, V14, P127, DOI 10.2165/00063030-200014020-00006
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1990, PHOTOCHEM PHOTOBIOL, V52, P495, DOI 10.1111/j.1751-1097.1990.tb01791.x
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   ROBERTS WG, 1992, CANCER RES, V52, P924
   Rousset N, 2000, RES EXP MED, V199, P341, DOI 10.1007/s004339900044
   *ROYAL COLL OPTH, GUID PHOT THER
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   SAPERSTEIN DA, 2002, INVEST OPHTH VIS SCI, V43, pE982
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt MG, 2002, POLIT VIERTELJAHR, V43, P3, DOI 10.1007/s11615-002-0002-z
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U, 2001, OPHTHALMOLOGE, V98, P216, DOI 10.1007/s003470170189
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   SCHMIDTERFURTH U, 2003, INVEST OPHTH VIS SCI, V44, pE1102
   SCHMIDTERFURTH U, RET 2002 C SEP 28 OC
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   SINGERMAN LJ, 2002, RET 2002 C SEP 28 OC
   SMITH DH, 2002, VALUE HEALTH, V5, P247
   SMITH DH, MODELLING LOG TERM B
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   Spaide RF, 2003, AM J OPHTHALMOL, V135, P549, DOI 10.1016/S0002-9394(02)01983-9
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   Stokkermans, 2000, Clin Eye Vis Care, V12, P15, DOI 10.1016/S0953-4431(99)00043-0
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   SUNER I, 2002, RET 2002 C SEP 28 OC
   SuttorpSchulten MSA, 1997, OCUL IMMUNOL INFLAMM, V5, P71, DOI 10.3109/09273949709085054
   Takashima T, 2001, JPN J OPHTHALMOL, V45, P84, DOI 10.1016/S0021-5155(00)00305-1
   Tano Y, 2002, AM J OPHTHALMOL, V134, P645, DOI 10.1016/S0002-9394(02)01883-4
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wilkinson CP, 1996, ARCH OPHTHALMOL-CHIC, V114, P677
   WORMALD R, 2003, COCHRANE DB SYST REV
   NOVARTIS PRECIBING I
   2000, PHARM J, V265, P213
   2001, PINK SHEET, V63, P18
   1999, PINK SHEET, V61, P5
   NOVARTIS OPTHALMICS
NR 124
TC 32
Z9 38
U1 2
U2 10
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PY 2003
VL 63
IS 22
BP 2521
EP 2554
DI 10.2165/00003495-200363220-00016
PG 34
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 743GA
UT WOS:000186563000016
PM 14609361
DA 2022-11-30
ER

PT J
AU Colak, E
   Majkic-Singh, N
   Zoric, L
   Radosavljevic, A
   Kosanovic-Jakovic, N
AF Colak, Emina
   Majkic-Singh, Nada
   Zoric, Lepsa
   Radosavljevic, Aleksandra
   Kosanovic-Jakovic, Natalija
TI The impact of inflammation to the antioxidant defense parameters in AMD
   patients
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; oxidative stress; antioxidants;
   inflammation
ID C-REACTIVE PROTEIN; MACULAR DEGENERATION; OXIDATIVE STRESS;
   INTERLEUKIN-6; PATHOGENESIS; ASSOCIATION; BIOMARKERS; DISEASES; RISK
AB Background and aims: Oxidative stress and inflammation are postulated to be involved in the pathogenesis of the age-related macular degeneration (AMD) although the mechanism linking the oxidation and inflammation is still unknown. The aim of this study was the analysis of the antioxidant capacity measured by levels of the antioxidant enzymes: superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and total antioxidant status (TAS) along with the inflammatory markers such as Creactive protein (CRP), interleukin-6 (IL-6) and fibrinogen in AMD patients in order to analyze the relationship of the inflammatory markers with the antioxidant parameters and their association with AMD. Methods: The cross-sectional study, carried out in the University clinical setting, included 84 patients with the age-related macular degeneration, aged 71.25 +/- 7.14 years and 84 aged-matched control subjects (CG). Results: Statistical analysis revealed significantly lower GR (p=0.007) and TAS (p<0.000) values in the group of AMD patients compared to the controls. Logistic regression analysis showed that higher values of inflammatory markers (CRP>3 mg/L, IL>4.9 pg/mL, fibrinogen>3.8 g/L) and lower values of antioxidative parameters (SOD< 900 U/gHb, GR<55 U/L and TAS<1.15 mmol/L) were significantly associated with AMD (ORCRP: 1.29, 95% CI 0.54-3.12, p<0.05; ORIL-6: 3.53, 95% CI 1.16-10.75, p=0.024; ORFIB: 3.06, 95% CI 1.78-7.92, p=0.019; ORSOD: 2.39, 95% CI 0.78-7.35, p<0.05; ORGR: 4.04, 95% CI 1.28-12.73, p= 0.013; ORTAS: 2.9, 95% CI 1.46.3, p=0.032). Conclusions: Based on the results obtained, it may be concluded that the antioxidant defense system was significantly reduced in patients with AMD and the probability to develop AMD was higher in older individuals with lower values of antioxidant parameters and higher values of inflammatory markers. (C) 2012, Editrice Kurtis
C1 [Colak, Emina; Majkic-Singh, Nada] Univ Belgrade, Sch Pharm, Clin Ctr Serbia, Inst Med Biochem, Belgrade 11001, Serbia.
   [Zoric, Lepsa; Radosavljevic, Aleksandra; Kosanovic-Jakovic, Natalija] Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Ophthalmol,Med Retina Dept, Belgrade 11001, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; Clinical Centre of
   Serbia; University of Belgrade
RP Colak, E (通讯作者)，Clin Ctr Serbia, Inst Med Biochem, Visegradska 26, Belgrade 11000, Serbia.
EM eminacolak@sbb.rs
RI Radosavljevic, Aleksandra/K-3730-2014; Radosavljevic,
   Aleksandra/AAK-2407-2020; Čolak, Emina/AAQ-1969-2021
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Radosavljevic,
   Aleksandra/0000-0002-8859-5103; Čolak, Emina/0000-0003-1901-3146
FU Ministry of Science, Technology and Development of the Republic of
   Serbia [175036]
FX This study was conducted as a part of the Project No. 175036 financially
   supported by the Ministry of Science, Technology and Development of the
   Republic of Serbia.
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   BURSTEIN SA, 1994, STEM CELLS, V12, P386, DOI 10.1002/stem.5530120405
   Colak E., 2008, J MED BIOCHEM, V27, P1, DOI DOI 10.2478/V10011-007-0049-X
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Jong PT, 2005, INVEST OPHTHALMOL VI, V46
   Goldberg DM., 1983, METHODS ENZYMATIC AN, V3, P258
   GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0
   Hubner-Wozniak E, 2011, J MED BIOCHEM, V30, P103, DOI 10.2478/v10011-011-0008-4
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klouche M, 2000, CIRCULATION, V101, P1799, DOI 10.1161/01.CIR.101.15.1799
   Lange CAK, 2012, OPHTHALMOLOGICA, V227, P115, DOI 10.1159/000331418
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Nagaoka T, 2008, INVEST OPHTH VIS SCI, V49, P2053, DOI 10.1167/iovs.07-1387
   Nikoli-Kokic A, 2010, J MED BIOCHEM, V29, P189, DOI 10.2478/v10011-010-0018-7
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Omoigui Sota, 2007, Immun Ageing, V4, P1, DOI 10.1186/1742-4933-4-1
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEINO Y, 1994, CYTOKINE, V6, P87, DOI 10.1016/1043-4666(94)90013-2
   Verma S, 2003, J THORAC CARDIOV SUR, V126, P1886, DOI 10.1016/j.jtcvs.2003.07.026
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wakamatsu TH, 2008, ARQ BRAS OFTALMOL, V71, P72, DOI 10.1590/S0004-27492008000700015
   WILLIAMS N, 1992, CIBA F SYMP, V167, P160
   Winkler B S, 1999, Mol Vis, V5, P32
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
NR 30
TC 16
Z9 16
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD DEC
PY 2012
VL 24
IS 6
BP 588
EP 594
DI 10.3275/8593
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 257MR
UT WOS:000327389100004
PM 22982945
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Worthington, KS
   Flamme-Wiese, MJ
   Riker, MJ
   Andrade, JD
   Ueberheide, BM
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Chirco, Kathleen R.
   Worthington, Kristan S.
   Flamme-Wiese, Miles J.
   Riker, Megan J.
   Andrade, Joshua D.
   Ueberheide, Beatrix M.
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Preparation and evaluation of human choroid extracellular matrix
   scaffolds for the study of cell replacement strategies
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Decellularization; Choroid; Choriocapillaris; Extracellular matrix;
   Age-related macular degeneration
ID ENDOTHELIAL PROGENITOR CELLS; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; ORTHOTOPIC TRANSPLANTATION; BRUCHS MEMBRANE; HUMAN EYES;
   CULTURE; REGENERATION; EXPRESSION; ATROPHY
AB Endothelial cells (ECs) of the choriocapillaris are one of the first cell types lost during age-related macular degeneration (AMD), and cell replacement therapy is currently a very promising option for patients with advanced AMD. We sought to develop a reliable method for the production of human choroidal extracellular matrix (ECM) scaffolds, which will allow for the study of choroidal EC (CEC) replacement strategies in an environment that closely resembles the native tissue. Human RPE/choroid tissue was treated sequentially with Triton X-100, SDS, and DNase to remove all native cells. While all cells were successfully removed from the tissue, collagen IV, elastin, and laminin remained, with preserved architecture of the acellular vascular tubes. The ECM scaffolds were then co-cultured with exogenous ECs to determine if the tissue can support cell growth and allow EC reintegration into the decellularized choroidal vasculature. Both monkey and human ECs took up residence in the choriocapillary tubes of the decellularized tissue. Together, these data suggest that our decellularization methods are sufficient to remove all cellular material yet gentle enough to preserve tissue structure and allow for the optimization of cell replacement strategies.
   Statement of Significance
   Age-related macular degeneration (AMD) is a devastating disease affecting more than 600 million people worldwide. Endothelial cells of the choriocapillaris (CECs) are among the first cell types lost in early AMD, and cell replacement therapy is currently the most promising option for restoring vision in patients with advanced AMD. In order to study CEC replacement strategies we have generated a 3D choroid scaffold using a novel decellularization method in human RPE/choroid tissue. To our knowledge, this is the first report describing decellularization of human RPE/choroid, as well as recellularization of a choroid scaffold with CECs. This work will aid in our development and optimization of cell replacement strategies using a tissue scaffold that is similar to the in vivo environment. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Chirco, Kathleen R.; Worthington, Kristan S.; Flamme-Wiese, Miles J.; Riker, Megan J.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA 52246 USA.
   [Chirco, Kathleen R.; Worthington, Kristan S.; Flamme-Wiese, Miles J.; Riker, Megan J.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52246 USA.
   [Andrade, Joshua D.; Ueberheide, Beatrix M.] NYU, Sch Med, Prote Lab, New York, NY 10016 USA.
   [Ueberheide, Beatrix M.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
C3 University of Iowa; University of Iowa; New York University; New York
   University
RP Mullins, RF (通讯作者)，Stephen A Wynn Inst Vis Res, 375 Newton Rd, Iowa City, IA 5224 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013; Worthington, Kristan/AAI-2212-2019
OI Mullins, Robert/0000-0002-5006-0891; Ueberheide,
   Beatrix/0000-0003-2512-0204; Worthington, Kristan/0000-0002-0693-0685;
   Stone, Edwin M./0000-0003-3343-4414; Tucker, Budd/0000-0003-2178-1742
FU NIH [EY024605]; Elmer and Sylvia Sramek Charitable Foundation; Research
   to Prevent Blindness; Carver Chair in Ocular Cell Biology; NATIONAL EYE
   INSTITUTE [P30EY025580, R01EY024605] Funding Source: NIH RePORTER
FX We would like to thank the Iowa Lions Eye Bank and the donors and their
   families for their invaluable contributions to this work. This work was
   supported by NIH grant EY024605, the Elmer and Sylvia Sramek Charitable
   Foundation, Research to Prevent Blindness, and the Carver Chair in
   Ocular Cell Biology.
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Caralt M, 2015, AM J TRANSPLANT, V15, P64, DOI 10.1111/ajt.12999
   Chirco K.R., 2016, EYE
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Cotto-Rios XM, 2012, CELL REP, V2, P1475, DOI 10.1016/j.celrep.2012.11.011
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De Waele J, 2015, BIOMATERIALS, V41, P122, DOI 10.1016/j.biomaterials.2014.11.025
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Kamprom W, 2016, EUR J CELL BIOL, V95, P153, DOI 10.1016/j.ejcb.2016.02.001
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kundu J, 2016, ACTA BIOMATER, V31, P61, DOI 10.1016/j.actbio.2015.11.028
   Lin H, 2016, TISSUE ENG PT A, V22, P65, DOI [10.1089/ten.TEA.2015.0286, 10.1089/ten.tea.2015.0286]
   Liu XP, 1997, EXP EYE RES, V65, P117, DOI 10.1006/exer.1997.0317
   Luo HL, 2013, BIOMATERIALS, V34, P6748, DOI 10.1016/j.biomaterials.2013.05.045
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684
   Ott HC, 2010, NAT MED, V16, P927, DOI 10.1038/nm.2193
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thum T, 2007, CIRC RES, V100, P434, DOI 10.1161/01.RES.0000257912.78915.af
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang J, 2016, BIOMATERIALS, V89, P114, DOI 10.1016/j.biomaterials.2016.02.040
   Zhang YY, 2009, BIOMATERIALS, V30, P4021, DOI 10.1016/j.biomaterials.2009.04.005
   Zhao HF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111846
NR 35
TC 15
Z9 16
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL 15
PY 2017
VL 57
BP 293
EP 303
DI 10.1016/j.actbio.2017.05.011
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA EZ9HY
UT WOS:000405041900024
PM 28483697
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, YX
   Zhang, JS
   You, QS
   Xu, L
   Jonas, JB
AF Wang, Ya Xing
   Zhang, Jing Shang
   You, Qi Sheng
   Xu, Liang
   Jonas, Jost B.
TI Ocular diseases and 10-year mortality: The Beijing Eye Study 2001/2011
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE Beijing Eye Study; cataract; diabetic retinopathy; glaucoma; mortality;
   retinal vein occlusion
ID BEAVER DAM EYE; CORONARY-HEART-DISEASE; OPEN-ANGLE GLAUCOMA; BLUE
   MOUNTAINS EYE; VISUAL IMPAIRMENT; CARDIOVASCULAR MORTALITY;
   ATHEROSCLEROSIS RISK; MACULAR DEGENERATION; ANTERIOR-CHAMBER; POPULATION
AB Purpose: To examine the relationship between major ocular diseases and mortality.
   Methods: The population-based longitudinal study Beijing Eye Study was performed in 2001 and repeated in 2011. The participants underwent a detailed ophthalmic examination at baseline in 2001.
   Results: Of 4439 subjects examined in 2001, 2695 (60.7%) subjects returned for the follow-up examination in 2011, while 379 (8.5%) subjects were dead and 1365 (30.8%) subjects were alive, however, did not agree to be re-examined. In multivariate regression analysis, mortality was significantly associated with the systemic parameters of older age (p < 0.001; Odds ratio (OR): 1.07; 95% confidence interval (CI): 1.05, 1.09), male gender (p < 0.001; OR: 0.56; 95% CI: 0.40, 0.78), lower level of education (p < 0.001; OR: 0.66; 95% CI: 0.59, 0.74) and smoking (p < 0.001; OR: 1.84; 95% CI: 1.36, 2.49) and with the ocular parameters of presence of diabetic retinopathy (p = 0.002; OR: 2.26; 95% CI: 1.34, 3.81), non-glaucomatous optic nerve damage (p = 0.001; OR: 4.90; 95% CI: 1.90, 12.7) and higher degree of nuclear cataract (p = 0.002; OR: 1.29; 95% CI: 1.10, 1.52). In that model, mortality was not significantly (all p > 0.05) associated with refractive error, cortical or subcapsular posterior cataract, intraocular pressure, best corrected visual acuity, visual field defects, prevalence of age-related macular degeneration, retinal vein occlusions, open-angle glaucoma and angle-closure glaucoma.
   Conclusions: After adjustment for age, gender, level of education and smoking, mortality was significantly higher in subjects with diabetic retinopathy, non-glaucomatous optic nerve damage and nuclear cataract. Other major ophthalmic parameters and disorders such as hyperopia, myopia, high myopia, pterygium, age-related macular degeneration, retinal vein occlusion, glaucoma and cortical or nuclear cataract were not significantly associated with mortality in the multivariate analysis.
C1 [Wang, Ya Xing; Zhang, Jing Shang; You, Qi Sheng; Xu, Liang; Jonas, Jost B.] Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Beijing Inst Ophthalmol, 17 Hougou Lane, Beijing 100005, Peoples R China.
EM xlbio1@163.com; jost.jonas@medma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016; You, Qisheng/AAG-7153-2020
OI wang, YA XING/0000-0003-2749-7793; You, Qisheng/0000-0003-0743-7320
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Cheung N, 2007, DIABETES CARE, V30, P1742, DOI 10.2337/dc07-0264
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Hirai FE, 2007, AM J EPIDEMIOL, V166, P724, DOI 10.1093/aje/kwm126
   Jonas JB, 2009, ACTA OPHTHALMOL, V87, P247, DOI 10.1111/j.1755-3768.2008.01385.x
   Juutilainen A, 2007, DIABETES CARE, V30, P292, DOI 10.2337/dc06-1747
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Lee AJ, 2006, OPHTHALMOLOGY, V113, P1069, DOI 10.1016/j.ophtha.2006.02.062
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 2005, NEUROLOGY, V65, P1005, DOI 10.1212/01.wnl.0000179177.15900.ca
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang YX, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2007.01143.x
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8
   Wu SY, 2008, ARCH OPHTHALMOL-CHIC, V126, P365, DOI 10.1001/archophthalmol.2007.77
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu L, 2007, AM J OPHTHALMOL, V144, P972, DOI 10.1016/j.ajo.2007.07.015
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
NR 28
TC 35
Z9 35
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2014
VL 92
IS 6
BP E424
EP E428
DI 10.1111/aos.12370
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4VD
UT WOS:000340585800002
PM 24612916
OA Bronze
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Kannan, R
   Kitamura, M
   Spee, C
   Barron, E
   Ryan, SJ
   Hinton, DR
AF Sreekumar, Parameswaran G.
   Kannan, Ram
   Kitamura, Mizuki
   Spee, Christine
   Barron, Ernesto
   Ryan, Stephen J.
   Hinton, David R.
TI alpha B Crystallin Is Apically Secreted within Exosomes by Polarized
   Human Retinal Pigment Epithelium and Provides Neuroprotection to
   Adjacent Cells
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR; PROTEINS; HSP70; DEGENERATION; PATHOGENESIS; EXPRESSION;
   LOCALIZATION; TRAFFICKING; RELEVANCE; PROTEOME
AB alpha B Crystallin is a chaperone protein with anti-apoptotic and anti-inflammatory functions and has been identified as a biomarker in age-related macular degeneration. The purpose of this study was to determine whether alpha B crystallin is secreted from retinal pigment epithelial (RPE) cells, the mechanism of this secretory pathway and to determine whether extracellular alpha B crystallin can be taken up by adjacent retinal cells and provide protection from oxidant stress. We used human RPE cells to establish that alpha B crystallin is secreted by a non-classical pathway that involves exosomes. Evidence for the release of exosomes by RPE and localization of alpha B crystallin within the exosomes was achieved by immunoblot, immunofluorescence, and electron microscopic analyses. Inhibition of lipid rafts or exosomes significantly reduced alpha B crystallin secretion, while inhibitors of classic secretory pathways had no effect. In highly polarized RPE monolayers, alpha B crystallin was selectively secreted towards the apical, photoreceptor-facing side. In support, confocal microscopy established that alpha B crystallin was localized predominantly in the apical compartment of RPE monolayers, where it colocalized in part with exosomal marker CD63. Severe oxidative stress resulted in barrier breakdown and release of alpha B crystallin to the basolateral side. In normal mouse retinal sections, alpha B crystallin was identified in the interphotoreceptor matrix. An increased uptake of exogenous alpha B crystallin and protection from apoptosis by inhibition of caspase 3 and PARP activation were observed in stressed RPE cultures. alpha B Crystallin was taken up by photoreceptors in mouse retinal explants exposed to oxidative stress. These results demonstrate an important role for alpha B crystallin in maintaining and facilitating a neuroprotective outer retinal environment and may also explain the accumulation of alpha B crystallin in extracellular sub-RPE deposits in the stressed microenvironment in age-related macular degeneration. Thus evidence from our studies supports a neuroprotective role for alpha B crystallin in ocular diseases.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram; Kitamura, Mizuki; Spee, Christine; Barron, Ernesto; Ryan, Stephen J.; Hinton, David R.] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Kannan, Ram; Ryan, Stephen J.; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Sreekumar, PG (通讯作者)，Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU Arnold and Mabel Beckman Foundation; National Institutes of Health
   [EY01545, EY03040]; Department of Ophthalmology by Research to Prevent
   Blindness, Inc.; NATIONAL EYE INSTITUTE [P30EY003040, R01EY001545]
   Funding Source: NIH RePORTER
FX The Arnold and Mabel Beckman Foundation, National Institutes of Health
   Grants (EY01545, EY03040), and a grant to the Department of
   Ophthalmology by Research to Prevent Blindness, Inc. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR ADLER AJ, 1989, EXP EYE RES, V49, P1067, DOI 10.1016/S0014-4835(89)80027-2
   Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2
   Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200
   Bryantsev AL, 2007, EXP CELL RES, V313, P195, DOI 10.1016/j.yexcr.2006.10.004
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Danysh BP, 2010, MATRIX BIOL, V29, P228, DOI 10.1016/j.matbio.2009.12.004
   de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0
   Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4
   Gupta S, 2007, AM J PHYSIOL-HEART C, V292, pH3052, DOI 10.1152/ajpheart.01355.2006
   Hauck SM, 2005, PROTEOMICS, V5, P3623, DOI 10.1002/pmic.200401223
   HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Jin JK, 2008, AM J PHYSIOL-HEART C, V294, pH337, DOI 10.1152/ajpheart.00881.2007
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Karakousis PC, 2001, MOL VIS, V7, P154
   Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Steiner-Champliaud MF, 2006, MOL VIS, V12, P892
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 145
Z9 151
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2010
VL 5
IS 10
AR e12578
DI 10.1371/journal.pone.0012578
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 660WH
UT WOS:000282676700001
PM 20949024
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jun, JJ
   Duker, JS
   Baumal, CR
   McCabe, F
   Reichel, E
   Rogers, AH
   Seddon, JM
   Tolentino, FI
AF Jun, Jason J.
   Duker, Jay S.
   Baumal, Caroline R.
   McCabe, Frank
   Reichel, Elias
   Rogers, Adam H.
   Seddon, Johanna M.
   Tolentino, Felipe I.
TI CYSTOID MACULAR EDEMA WITHOUT MACULAR THICKENING A Retrospective Optical
   Coherence Tomographic Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE optical coherence tomography; cystoid macular edema; age-related macular
   degeneration; diabetic retinopathy
ID THICKNESS MEASUREMENTS; FLUORESCEIN ANGIOGRAPHY; RETINAL THICKNESS;
   VISUAL-ACUITY; REPRODUCIBILITY; UVEITIS; REPEATABILITY; DEGENERATION;
   LATANOPROST; RISK
AB Background: This is a retrospective observational case series of 37 eyes of 32 patients meeting the inclusion criteria intended to describe the appearance, prevalence, and associated risk factors for cystoid macular edema in eyes with normal foveal thickness and contour as determined by optical coherence tomography (OCT).
   Methods: A retrospective review of all patients with macular disease who underwent OCT evaluation at the New England Eye Center from January to March 2007 and met the study inclusion criteria was performed. Optical coherence tomography scans were evaluated for the presence of intraretinal cystic fluid or cystoid macular edema but with normal retinal thickness and foveal contour. Retinal thickness and contour were evaluated using OCT mapping software. The main outcome measures were as follows: OCT-defined entity based on the presence of cystoid spaces within the fovea, "normal" foveal thickness (<252 mu m), normal foveal contour, and best-corrected visual acuity on the date of examination.
   Results: Thirty-seven eyes of 32 patients were determined to have cystoid macular edema with normal foveal thickness and contour on OCT. The overall prevalence within our patient population was 4.9%. Mean foveal thickness (standard deviation) for these patients was 201.4 mm (28.9) compared with normal mean foveal thickness (standard deviation) of 212 mm (20.0). Of the 32 patients, 17 (53.1%) had a primary diagnosis of age-related macular degeneration. The mean visual acuity (Snellen; logarithm of the minimum angle of resolution) was 20/80 (0.60).
   Conclusion: Cystoid macular edema in the setting of normal foveal thickness and contour as determined by OCT has not been extensively described. This entity is not pathognomonic of a single diagnosis and can occur in the setting of several disparate diagnoses as seen in our cohort. Chief among these were age-related macular degeneration and diabetic retinopathy. Acute postcataract cystoid macular edema was absent. RETINA 30: 917-923, 2010
C1 [Jun, Jason J.; Duker, Jay S.; Baumal, Caroline R.; McCabe, Frank; Reichel, Elias; Rogers, Adam H.; Seddon, Johanna M.; Tolentino, Felipe I.] Tufts Univ, Sch Med, Tufts Med Ctr, New England Eye Ctr, Boston, MA 02116 USA.
C3 Tufts Medical Center; Tufts University
RP Duker, JS (通讯作者)，Tufts Univ, Sch Med, Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,10th Floor, Boston, MA 02116 USA.
EM jduker@tuftsmedicalcenter.org
FU Carl Zeiss Meditech
FX Jay S. Duker has disclosed receiving research support from Carl Zeiss
   Meditech for work unrelated to this study.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Ayyala RS, 1998, AM J OPHTHALMOL, V126, P602, DOI 10.1016/S0002-9394(98)00127-5
   Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   Brown JC, 2004, ARCH OPHTHALMOL-CHIC, V122, P330, DOI 10.1001/archopht.122.3.330
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   Catier A, 2005, AM J OPHTHALMOL, V140, P200, DOI 10.1016/j.ajo.2005.02.053
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Cohen SM, 2007, RETINA-J RET VIT DIS, V27, P59, DOI 10.1097/01.iae.0000256663.94734.e1
   de Faria JML, 1999, ACTA OPHTHALMOL SCAN, V77, P170
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   FETKENHOUR CL, 1977, T AM ACAD OPHTHALMOL, V83, P515
   FISHMAN GA, 1977, ARCH OPHTHALMOL-CHIC, V95, P1993
   Fu A, 2004, OPHTHALMOLOGY
   Garcia-Arumi J, 2003, OPHTHALMOLOGY, V110, P1164, DOI 10.1016/S0161-6420(03)00259-8
   GASS JDM, 1966, ARCH OPHTHALMOL-CHIC, V76, P646, DOI 10.1001/archopht.1966.03850010648005
   Gaudric A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1410, DOI 10.1001/archopht.124.10.1410
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   IRVINE SR, 1953, AM J OPHTHALMOL, V36, P599, DOI 10.1016/0002-9394(53)90302-X
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   Markomichelakis NN, 2004, OPHTHALMOLOGY, V111, P946, DOI 10.1016/j.ophtha.2003.08.037
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   NEWSOME DA, 1986, AM J OPHTHALMOL, V101, P354, DOI 10.1016/0002-9394(86)90831-7
   Norregaard JC, 1999, OPHTHALMOLOGY, V106, P42, DOI 10.1016/S0161-6420(99)90004-0
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   ROSENBAUM JT, 1989, J RHEUMATOL, V16, P792
   Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P1187, DOI 10.1016/j.ophtha.2005.12.020
   SOUBRANE G, 1988, J FR OPHTALMOL, V11, P711
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P343, DOI 10.1097/00006982-200306000-00009
   THOMAS JV, 1978, ARCH OPHTHALMOL-CHIC, V96, P625
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Warwar RE, 1998, OPHTHALMOLOGY, V105, P263, DOI 10.1016/S0161-6420(98)92977-3
   Wegener M, 1998, J CATARACT REFR SURG, V24, P1152, DOI 10.1016/S0886-3350(98)80112-0
   WELEBER RG, 2001, RETINITIS PIGMENTOSA
   Zeimer R, 1996, INVEST OPHTH VIS SCI, V37, P1994
NR 44
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2010
VL 30
IS 6
BP 917
EP 923
DI 10.1097/IAE.0b013e3181cbd9e5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AG
UT WOS:000278549100011
PM 20168270
DA 2022-11-30
ER

PT J
AU Curriero, FC
   Pinchoff, J
   van Landingham, SW
   Ferrucci, L
   Friedman, DS
   Ramulu, PY
AF Curriero, Frank C.
   Pinchoff, Jessie
   van Landingham, Suzanne W.
   Ferrucci, Luigi
   Friedman, David S.
   Ramulu, Pradeep Y.
TI Alteration of Travel Patterns With Vision Loss From Glaucoma and Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; OLDER-ADULTS; PHYSICAL-ACTIVITY;
   MOBILITY; FALLS; RISK; ASSOCIATION; PERFORMANCE; PREVALENCE
AB IMPORTANCE The distance patients can travel outside the home influences how much of the world they can sample and to what extent they can live independently. Recent technological advances have allowed travel outside the home to be directly measured in patients' real-world routines.
   OBJECTIVE To determine whether decreased visual acuity (VA) from age-related macular degeneration (AMD) and visual field (VF) loss from glaucoma are associated with restricted travel patterns in older adults. DESIGN Cross-sectional study.
   SETTING Patients were recruited from an eye clinic, while travel patterns were recorded during their real-world routines using a cellular tracking device.
   PARTICIPANTS Sixty-one control subjects with normal vision, 84 subjects with glaucoma with bilateral VF loss, and 65 subjects with AMD with bilateral or severe unilateral loss of VA had their location tracked every 15 minutes between 7 AM and 11 PM for 7 days using a tracking device.
   MAIN OUTCOMES AND MEASURES Average daily excursion size (defined as maximum distance away from home) and average daily excursion span (defined as maximum span of travel) were defined for each individual. The effects of vision loss on travel patterns were evaluated after controlling for individual and geographic factors.
   RESULTS In multivariable models comparing subjects with AMD and control subjects, average excursion size and span decreased by approximately one-quarter mile for each line of better-eye VA loss (P < .03 for both). Similar but not statistically significant associations were observed between average daily excursion size and span for severity of better-eye VF loss in subjects with glaucoma and control subjects. Being married or living with someone and younger age were associated with more distant travel, while less-distant travel was noted for older individuals, African Americans, and those living in more densely populated regions.
   CONCLUSIONS AND RELEVANCE Age-related macular degeneration-related loss of VA, but not glaucoma-related loss of VF, is associated with restriction of travel to more nearby locations. This constriction of life space may impact quality of life and restrict access to services.
C1 [Curriero, Frank C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA.
   [Curriero, Frank C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
   [Pinchoff, Jessie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [van Landingham, Suzanne W.; Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, NIH, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School
   of Public Health; Johns Hopkins University; Johns Hopkins Medicine;
   National Institutes of Health (NIH) - USA; NIH National Institute on
   Aging (NIA)
RP Curriero, FC (通讯作者)，Dept Environm Hlth Sci, 615 N Wolfe St E6614, Baltimore, MD 21205 USA.
EM fcurrier@jhsph.edu
OI Friedman, David/0000-0002-2055-5797
FU Dennis W. Jahnigen Memorial Award, National Institutes of Health
   [EY018595]; Research to Prevent Blindness Robert and Helen Schaub
   Special Scholar Award; Intramural Research Program of the National
   Institutes of Health; NATIONAL EYE INSTITUTE [K23EY018595] Funding
   Source: NIH RePORTER
FX This work was supported by the Dennis W. Jahnigen Memorial Award,
   National Institutes of Health grant EY018595, the Research to Prevent
   Blindness Robert and Helen Schaub Special Scholar Award, and the
   Intramural Research Program of the National Institutes of Health
CR Alma MA, 2011, DISABIL REHABIL, V33, P63, DOI 10.3109/09638288.2010.488711
   [Anonymous], 2012, R LANG ENV STAT COMP
   Asaoka R, 2011, INVEST OPHTH VIS SCI, V52, P7007, DOI 10.1167/iovs.11-7643
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x
   Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   Black AA, 2011, OPTOMETRY VISION SCI, V88, P1275, DOI 10.1097/OPX.0b013e31822f4d6a
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Diggle P., 2002, J AM STAT ASSOC, V90, DOI DOI 10.2307/2983303
   Environmental Systems Research Institute, 2011, ARCGIS DESKT REL 10
   Freeman EE, 2006, INVEST OPHTH VIS SCI, V47, P514, DOI 10.1167/iovs.05-0934
   Freeman EE, 2008, OPHTHALMOLOGY, V115, P233, DOI 10.1016/j.ophtha.2007.04.050
   Freeman EE, 2006, AM J PUBLIC HEALTH, V96, P1254, DOI 10.2105/AJPH.2005.069146
   Friedman DS, 2007, OPHTHALMOLOGY, V114, P2232, DOI 10.1016/j.ophtha.2007.02.001
   Friedman DS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1625, DOI 10.1001/archopht.124.11.1625
   GOLLEDGE RG, 1993, T I BRIT GEOGR, V18, P63, DOI 10.2307/623069
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Lord SR, 2010, CLIN GERIATR MED, V26, P569, DOI 10.1016/j.cger.2010.06.002
   National Institutes of Health National Eye Institute, NAT EYE HLTH ED PROG
   Peel C, 2005, PHYS THER, V85, P1008, DOI 10.1093/ptj/85.10.1008
   Pelletier AL, 2009, AM FAM PHYSICIAN, V79, P963
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.037
   Ramulu PY, 2012, J PHYS ACT HEALTH, V9, P809, DOI 10.1123/jpah.9.6.809
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Richman J, 2010, ARCH OPHTHALMOL-CHIC, V128, P1576, DOI 10.1001/archophthalmol.2010.275
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Stalvey BT, 1999, J APPL GERONTOL, V18, P460, DOI 10.1177/073346489901800404
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
NR 37
TC 17
Z9 17
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2013
VL 131
IS 11
BP 1420
EP 1426
DI 10.1001/jamaophthalmol.2013.4471
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 291RZ
UT WOS:000329848300007
PM 24030033
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Krebs, I
   Smretschnig, E
   Moussa, S
   Brannath, W
   Womastek, I
   Binder, S
AF Krebs, Ilse
   Smretschnig, Eva
   Moussa, Sarah
   Brannath, Werner
   Womastek, Irene
   Binder, Susanne
TI Quality and Reproducibility of Retinal Thickness Measurements in Two
   Spectral-Domain Optical Coherence Tomography Machines
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; OCT
AB PURPOSE. To evaluate the accuracy and reproducibility of retinal thickness measurements in exudative age-related macular degeneration (AMD) by the Spectralis (Heidelberg Engineering, Heidelberg, Germany) and the Cirrus (Carl Zeiss Meditec, Dublin, CA) optical coherence tomography (OCT) systems.
   METHODS. Eyes with exudative age-related macular degeneration were randomly assigned to one of eight groups, each different in the sequence of examiner and OCT system. The 512 x 128 cube program of the Cirrus and the 30 degrees x 25 degrees volume scan containing 32 lines of the Spectralis were performed twice. The correlation between the examinations was expressed by the interclass correlation coefficient (ICC).
   RESULTS. Enrolled in the study were 112 patients and 112 eyes (mean age, 76.5 +/- 7.9 years; range 51-89), with 14 patients in each group. The mean error scores per line were 0.53 and 0.52 in the Cirrus, significantly (P < 0.001) lower than in the Spectralis (0.83 and 0.98). For automatic central retinal thickness (CRT), the ICC for Cirrus (all examinations calculated) was 0.61 for groups 1 to 4 (the same examiner) and 0.65 for groups 5 to 8 (two different examiners); for Spectralis (13.4% not calculated) the ICC was 0.93 for groups 1 to 4 and 0.86 for groups 5 to 8. After error correction, the Cirrus ICC improved to 1.0 and 0.99 and the Spectralis ICC to 1.0 in both groups.
   CONCLUSIONS. Considerable differences were found between the two systems, both of which incorporate the spectral-domain technology. Different positioning of segmentation lines, control of localization, density of included scan lines, and number of available maps explain the differences in segmentation quality and reproducibility. Manual correction of segmentation and centralization improves the reproducibility. (ClinicalTrials.gov number, NCT00927303.) (Invest Ophthalmol Vis Sci. 2011;52:6925-6933) DOI:10.1167/iovs.10-6612
C1 [Krebs, Ilse; Smretschnig, Eva; Moussa, Sarah; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, Ilse; Smretschnig, Eva; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Brannath, Werner; Womastek, Irene] Med Univ, Core Unit Med Stat & Informat, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
FU L. Boltzmann Institute
FX Supported by an unrestricted research grant from the L. Boltzmann
   Institute (SB).
CR Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hagen S, 2011, RETINA-J RET VIT DIS, V31, P41, DOI 10.1097/IAE.0b013e3181dde71e
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Ho J, 2010, INVEST OPHTH VIS SCI, V51, P3714, DOI 10.1167/iovs.09-4057
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   KREBS I, BR J OPHTHALMOL
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Pierro L, 2010, AM J OPHTHALMOL, V150, P199, DOI 10.1016/j.ajo.2010.03.015
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 22
TC 38
Z9 38
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 6925
EP 6933
DI 10.1167/iovs.10-6612
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300072
PM 21791591
DA 2022-11-30
ER

PT J
AU Booij, JC
   Baas, DC
   Beisekeeva, J
   Gorgels, TGMF
   Bergen, AAB
AF Booij, J. C.
   Baas, D. C.
   Beisekeeva, J.
   Gorgels, T. G. M. F.
   Bergen, A. A. B.
TI The dynamic nature of Bruch's membrane
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Bruch's membrane; Drusen; AMD; Aging; Molecular composition; Inner
   collagenous layer; Outer collagenous layer; Elastin layer; Basal
   membrane
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; AGE-RELATED-CHANGES;
   GLYCATION END-PRODUCTS; MACULAR DEGENERATION; EXTRACELLULAR-MATRIX;
   OXIDATIVE STRESS; MORPHOMETRIC-ANALYSIS; PSEUDOXANTHOMA ELASTICUM;
   INDUCED INFLAMMATION
AB Bruch's membrane (BM) is a unique pentalaminar structure, which is strategically located between the retinal pigment epithelium (RPE) and the fenestrated choroidal capillaries of the eye. BM is an elastin- and collagen-rich extracellular matrix that acts as a molecular sieve. BM partly regulates the reciprocal exchange of biomolecules, nutrients, oxygen, fluids and metabolic waste products between the retina and the general circulation. Accumulating evidence suggests that the molecular, structural and functional properties of BM are dependent on age, genetic constitution, environmental factors, retinal location and disease state. As a result, part of the properties of BM are unique to each human individual at a given age, and therefore uniquely affect the development of normal vision and ocular disease.
   The changes occurring in BM with age include increased calcification of elastic fibres, increased cross-linkage of collagen fibres and increased turnover of glycosaminoglycans. In addition, advanced glycation end products (AGES) and fat accumulate in BM.
   These age-related changes may not only influence the normal age-related health of photoreceptor cells, but also the onset and progression of diseases like retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Undoubtedly, BM is the site of drusen development. Confluent drusen and uncontrolled activation of the complement cascade are most likely the first signs of AMD. Furthermore, the nature of adhesive interactions between the RPE and BM are instrumental in the development of retinal detachments and proliferative retinal disease. Finally, BM is passively or actively involved in a range of other retinal disorders such as Pseudoxanthoma elasticum (PXE), Sorsby's Fundus Dystrophy and Malattia Leventinese.
   Here, we review the dynamic nature of Bruch's membrane, from molecule to man, during development, aging and disease. We propose a simple and straightforward nomenclature for BM deposits. Finally, we attempt to correlate recently published mRNA expression profiles of the RPE and choroid with molecular, structural and functional properties of BM. Our review may shed light on the complex involvement of BM in retinal pathology, notably age-related macular degeneration. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Booij, J. C.; Baas, D. C.; Beisekeeva, J.; Gorgels, T. G. M. F.; Bergen, A. A. B.] Inst Royal Netherlands Acad Arts & Sci KNAW, Dept Clin & Mol Ophthalmogenet, NIN, NL-1105 BA Amsterdam, Netherlands.
   [Bergen, A. A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [Bergen, A. A. B.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical
   Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam
RP Bergen, AAB (通讯作者)，Inst Royal Netherlands Acad Arts & Sci KNAW, Dept Mol Ophthalmogenet, NIN, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM a.bergen@nin.knaw.nl
RI Bergen, Arthur/J-3637-2013
OI Baas, Dominique C./0000-0003-0989-9828; Bergen,
   Arthur/0000-0002-6333-9576
FU 'Algemene Nederlandse Vereniging ter Voorkoming van Blind heid' (ANVVB);
   Macula Foundation of the Netherlands; 'Landelijke Stichting voor Blinden
   en Slechtzienden'; 'Rotterdamse Blinden Belangen'; 'Blindenpenning';
   'Gelderse Blinden Vereniging'; 'Stichting Uitzicht'
FX The authors thank the 'Algemene Nederlandse Vereniging ter Voorkoming
   van Blind heid' (ANVVB), the Macula Foundation of the Netherlands, the
   'Landelijke Stichting voor Blinden en Slechtzienden', the 'Rotterdamse
   Blinden Belangen', the 'Blindenpenning', the 'Gelderse Blinden
   Vereniging', and 'Stichting Uitzicht' for their financial contributions.
CR AESSOPOS A, 1989, AM J OPHTHALMOL, V108, P356, DOI 10.1016/S0002-9394(14)73300-8
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Albini TA, 2005, BRIT J OPHTHALMOL, V89, P901, DOI 10.1136/bjo.2004.060293
   Altunay H, 2007, ANAT HISTOL EMBRYOL, V36, P116, DOI 10.1111/j.1439-0264.2006.00736.x
   APPEL A, 1979, J BIOL CHEM, V254, P2199
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316
   Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BOK D, 1993, J CELL SCI, P189
   BOOIJ JC, NEW STRATEGY I UNPUB
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   BRAEKEVELT CR, 1983, ANAT EMBRYOL, V166, P415, DOI 10.1007/BF00305927
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Brewer GJ, 2007, EXP BIOL MED, V232, P323
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CALL TW, 1990, EXP EYE RES, V51, P451, DOI 10.1016/0014-4835(90)90158-Q
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Chen Changzheng, 2003, Yan Ke Xue Bao, V19, P15
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Danciger M, 2007, MOL VIS, V13, P79
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Gensler G, 2002, J NUTR, V132, P697
   GIACHELLI CM, 2009, KIDNEY INT
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   GLENNER GG, 1989, ANNU REV MED, V40, P45
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Gorgels TGMF, 2005, HUM MOL GENET, V14, P1763, DOI 10.1093/hmg/ddi183
   Gorgels TGMF, 2007, MOL CELL BIOL, V27, P1433, DOI 10.1128/MCB.01037-06
   Gugliucci A, 2007, CLIN CHIM ACTA, V377, P213, DOI 10.1016/j.cca.2006.09.028
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   GUYMER R, 1998, BRUCHS MEMBRANE DRUS, P693
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HEWITT AT, 1985, CURR EYE RES, V4, P169, DOI 10.3109/02713688509000846
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Hirabayashi Yoshifumi, 2003, Medical Electron Microscopy, V36, P139, DOI 10.1007/s00795-003-0218-z
   HOGAN M J, 1961, Trans Pac Coast Otoophthalmol Soc Annu Meet, V42, P61
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   IACOBINI C, 2009, J PATHOL
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KANG SJ, 2009, HISTOPATHOLOGY AGE R, P3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KELLY UL, 2009, ARV ANN M
   KEMPEN J, 2008, INVESTIGATION INTERA
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lamme EN, 1996, J HISTOCHEM CYTOCHEM, V44, P1311, DOI 10.1177/44.11.8918906
   LANDERS RA, 1994, J NEUROCHEM, V63, P737
   LARUSSO J, 2009, J INVEST DERMATOL
   Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   LENGYEL I, 2007, EXP EYE RES
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Maccioni RB, 2001, ARCH MED RES, V32, P367, DOI 10.1016/S0188-4409(01)00316-2
   Maeda K, 2006, MOL PHARMACEUT, V3, P70, DOI 10.1021/mp050063u
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Marmor MF, 2008, DOC OPHTHALMOL, V117, P257, DOI 10.1007/s10633-008-9132-y
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Mathieu JM, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-21
   MCKUSICK VA, 1972, J PEDIATR-US, V80, P530, DOI 10.1016/S0022-3476(72)80531-6
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   NARAYANAN AS, 1983, J BIOL CHEM, V258, P1694
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   OLSON MD, 1979, INVEST OPHTH VIS SCI, V18, P329
   Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350-9462(01)00023-4
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   Pietkiewicz J, 2008, POSTEP HIG MED DOSW, V62, P511
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   ROBERTS JM, 1990, EXP EYE RES, V50, P165, DOI 10.1016/0014-4835(90)90227-L
   ROHRER B, 2009, INVEST OPHTHALMOL VI
   Rops ALWMM, 2004, KIDNEY INT, V65, P768, DOI 10.1111/j.1523-1755.2004.00451.x
   SCHACHERN PA, 1984, ARCH OTOLARYNGOL, V110, P15
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SCHOENSIEGEL F, DYSTROPHIC CAR UNPUB
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smit AJ, 2004, CURR MED CHEM, V11, P2767, DOI 10.2174/0929867043364342
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Sourris KC, 2009, CURR DRUG TARGETS, V10, P42, DOI 10.2174/138945009787122905
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stone Edwin M., 1992, Human Molecular Genetics, V1, P685, DOI 10.1093/hmg/1.9.685
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   TAKEI Y, 1975, INVEST OPHTH VISUAL, V14, P903
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   van Soest SS, 2007, MOL VIS, V13, P1608
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WIMMERS S, 2007, PROG RETIN EYE RES
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2003, INVEST OPHTH VIS SCI, V44, P226, DOI 10.1167/iovs.01-1202
   Xu HP, 2004, J LEUKOCYTE BIOL, V75, P224, DOI 10.1189/jlb.1002479
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 165
TC 342
Z9 345
U1 0
U2 49
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2010
VL 29
IS 1
BP 1
EP 18
DI 10.1016/j.preteyeres.2009.08.003
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 561EU
UT WOS:000274959500001
PM 19747980
DA 2022-11-30
ER

PT J
AU Martinez, B
   Peplow, PV
AF Martinez, Bridget
   Peplow, Philip, V
TI MicroRNAs in laser-induced choroidal neovascularization in mice and
   rats: their expression and potential therapeutic targets
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE age-related macular degeneration; angiogenesis; animal model; blood
   plasma; choroid; laser; microRNAs; neovascularization; retina; retinal
   pigment epithelium; therapeutic targets; vascular endothelial growth
   factor
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SUBRETINAL
   NEOVASCULARIZATION; MOUSE MODEL; RETINAL NEOVASCULARIZATION; OCULAR
   ANGIOGENESIS; ANIMAL-MODELS; BIOMARKERS; VEGF; INHIBITION
AB Choroidal neovascularization characterizes wet age-related macular degeneration. Choroidal neovascularization formation involves a primarily angiogenic process that is combined with both inflammation and proteolysis. A primary cause of choroidal neovascularization pathogenesis is alterations in pro- and anti-angiogenic factors derived from the retinal pigment epithelium, with vascular endothelium growth factor being mainly responsible for both clinical and experimental choroidal neovascularization. MicroRNAs (miRNAs) which are short, non-coding, endogenous RNA molecules have a major role in regulating various pathological processes, including inflammation and angiogenesis. A review of recent studies with the mouse laser-induced choroidal neovascularization model has shown alterations in miRNA expression in choroidal neovascularization tissues and could be potential therapeutic targets for wet age-related macular degeneration. Upregulation of miR-505 (days 1 and 3 post-laser), miR-155 (day 14) occurred in retina; miR-342-5p (days 3 and 7), miR-126-3p (day 14) in choroid; miR-23a, miR-24, miR-27a (day 7) in retina/choroid; miR-505 (days 1 and 3) in retinal pigment epithelium/choroid; downregulation of miR-155 (days 1 and 3), miR-29a, miR-29b, miR-29c (day 5), miR-93 (day 14), miR-126 (day 14) occurred in retinal pigment epithelium/choroid. Therapies using miRNA mimics or inhibitors were found to decrease choroidal neovascularization lesions. Choroidal neovascularization development was reduced by overexpression of miR-155, miR-188-5p, miR-(5,B,7), miR-126-3p, miR-342-5p, miR-93, miR-126, miR-195a-3p, miR-24, miR-21, miR-31, miR-150, and miR-184, or suppression of miR-505, miR-126-3p, miR-155, and miR-23/27. Further studies are warranted to determine miRNA expression in mouse laser-induced choroidal neovascularization models in order to validate and extend the reported findings. Important experimental variables need to be standardized; these include the strain and age of animals, gender, number and position of laser burns to the eye, laser parameters to induce choroidal neovascularization lesions including wavelength, power, spot size, and duration.
C1 [Martinez, Bridget] Los Alamos Natl Lab, Phys Chem & Appl Spect, Chem Div, Los Alamos, NM USA.
   [Martinez, Bridget] St Georges Univ, Dept Med, Sch Med, True Blue, Grenada.
   [Peplow, Philip, V] Univ Otago, Dept Anat, Dunedin, New Zealand.
C3 United States Department of Energy (DOE); Los Alamos National
   Laboratory; University of Otago
RP Peplow, PV (通讯作者)，Univ Otago, Dept Anat, Dunedin, New Zealand.
EM phil.peplow@otago.ac.nz
CR Afzal A, 2007, MICROVASC RES, V74, P131, DOI 10.1016/j.mvr.2007.04.011
   Agrawal Saloni, 2014, World J Biol Chem, V5, P1, DOI 10.4331/wjbc.v5.i1.1
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Allatayfeh M, 2012, COLD SPRING HARB PER, V2
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Askou AL, 2017, HUM GENE THER METHOD, V28, P222, DOI 10.1089/hgtb.2017.079
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   BAUM JULES L., 1965, TRANS AMER OPHTHALMOL SOC, V63, P91
   Bhise NS, 2011, EXPERT OPIN DRUG DEL, V8, P485, DOI 10.1517/17425247.2011.558082
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Cai JJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-88
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Cao WJ, 2015, ARTERIOSCL THROM VAS, V35, P2401, DOI 10.1161/ATVBAHA.115.306506
   Carmeliet P, 1998, INT J BIOCHEM CELL B, V30, P661, DOI 10.1016/S1357-2725(97)00121-0
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   ELDIRINI AA, 1991, RETINA-J RET VIT DIS, V11, P244, DOI 10.1097/00006982-199111020-00010
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Gao F, 2016, MOL REPROD DEV, V83, P413, DOI 10.1002/mrd.22638
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hou HY, 2018, EXP EYE RES, V175, P115, DOI 10.1016/j.exer.2018.06.010
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Juzwik CA, 2019, PROG NEUROBIOL, V182, DOI 10.1016/j.pneurobio.2019.101664
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Landskroner-Eiger S, 2013, COLD SPRING HARB PER, V3
   Li YL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028269
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Martinez B, 2021, NEURAL REGEN RES, V16, P440, DOI 10.4103/1673-5374.293131
   Martinez B, 2020, NEURAL REGEN RES, V15, P606, DOI 10.4103/1673-5374.266905
   Martinez B, 2019, NEURAL REGEN RES, V14, P1858, DOI 10.4103/1673-5374.259602
   Martinez B, 2019, NEURAL REGEN RES, V14, P242, DOI 10.4103/1673-5374.244784
   Meister G, 2007, CELL, V131, P25, DOI 10.1016/j.cell.2007.09.021
   Mens MMJ, 2018, STEM CELL REV REP, V14, P309, DOI 10.1007/s12015-018-9808-y
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Peng QH, 2016, TOXICOL SCI, V152, P273, DOI 10.1093/toxsci/kfw085
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Ruan Q, 2011, MOL CANCER RES, V9, P1632, DOI 10.1158/1541-7786.MCR-11-0327
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Toma HS, 2010, MICROVASC RES, V80, P295, DOI 10.1016/j.mvr.2010.05.011
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yan XC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003042
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Zhang PF, 2018, INFLAMMATION, V41, P143, DOI 10.1007/s10753-017-0672-8
   Zhao S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12832
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094743
   Zhuang Z, 2015, MOL VIS, V21, P1173
NR 90
TC 4
Z9 4
U1 5
U2 33
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD APR
PY 2021
VL 16
IS 4
BP 621
EP 627
DI 10.4103/1673-5374.295271
PG 7
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA OM1ET
UT WOS:000585772900004
PM 33063711
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Balaiya, S
   Khetpal, V
   Chalam, KV
AF Balaiya, Sankarathi
   Khetpal, Vijay
   Chalam, Kakarla V.
TI Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor
   activation in choroidal endothelial cells through hypoxia inducible
   factor-2 alpha
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR 1-ALPHA; CANCER-CELLS; SIRTUIN 1; DEACETYLASE; EXPRESSION;
   INHIBITOR; SURVIVAL; PROTEIN; PROLIFERATION; METABOLISM
AB Purpose: Hypoxia is a critical pathological factor in a variety of retinal diseases, including age-related macular degeneration. It upregulates angiogenic growth factors and promotes neovascularization. Hypoxia changes the cellular redox state and activates class III histone deacetylase sirtuin1 (SIRT1). Activated SIRT1 signals hypoxia inducible factor (HIF)-2 alpha, which transactivates vascular endothelial growth factor (VEGF) and erythropoietin. In this study, we investigated the role of hypoxia induced SIRT1 in choroidal neovascularization in relation to age-related macular degeneration.
   Methods: Choroidal endothelial cells (RF/6A) were maintained in a semiconfluent state and hypoxia was induced by exposing the cells to cobalt chloride for 24 h. Induction of hypoxia was confirmed by flow cytometric analysis and the levels of SIRT1 were noted in a hypoxic condition as well in the cells after blocking SIRT1 activity using sirtinol. The role of SIRT1 in the activation of HIF-2 alpha and nuclear factor-kappa B (RelA/p65) during hypoxia in the presence or absence of SIRT1 was assessed using immunoblot analysis. VEGF levels were quantified using enzyme-linked immunosorbent assay.
   Results: Hypoxic induction was confirmed using flow cytometric analysis, which showed cell cycle arrest starting at a 200 mu M concentration of cobalt chloride. Hypoxic treatment (200 mu M concentration of cobalt chloride) increased SIRT1 levels to 7.8%, which reduced to control level after its activity was inhibited (p<0.05). Activated SIRT1 mediates HIF-2 alpha and nuclear factor-kappa B (RelA/p65) expression to 4.5 fold and fivefold, respectively, compared to control, and the levels were suppressed following sirtinol treatment (4.1% and 39.3% respectively; p=0.01). Hypoxic treatment increased VEGF levels by 94.9 +/- 19.6 pg/ml compared to control levels (25.58 +/- 3.58 pg/ml). These levels decreased to 10.29 +/- 0.2 pg/ml after blocking SIRT1 activity using sirtinol, compared to control (p<0.01).
   Conclusions: Our study results demonstrate that hypoxia mimetic cobalt chloride induces SIRT1 and augments HIF-2 alpha, which activates and releases VEGF.
C1 [Balaiya, Sankarathi; Khetpal, Vijay; Chalam, Kakarla V.] Univ Florida, Dept Ophthalmol, Coll Med, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Dept Ophthalmol, Coll Med, 580 W 8th St,Tower 2, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019
OI Chalam, K V/0000-0002-0004-9416; Chalam, kakarla/0000-0001-9325-8665
CR Ardyanto TD, 2006, INT J ONCOL, V29, P549
   Balaiya S, 2011, CUT OCULAR TOXICOL
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Guo B, 2010, MOL VIS, V16, P793
   Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617
   Hipkiss AR, 2008, BIOGERONTOLOGY, V9, P49, DOI 10.1007/s10522-007-9110-x
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200
   Koltai E, 2010, MECH AGEING DEV, V131, P21, DOI 10.1016/j.mad.2009.11.002
   Liang XJ, 2008, MOL CANCER RES, V6, P1499, DOI 10.1158/1541-7786.MCR-07-2130
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02
   Nasu Y, 2008, OSTEOARTHR CARTILAGE, V16, P723, DOI 10.1016/j.joca.2007.10.014
   Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049
   Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039
   Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC
   Saunders LR, 2009, SCIENCE, V323, P1021, DOI 10.1126/science.1170007
   Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845
   Vengellur A, 2004, TOXICOL SCI, V82, P638, DOI 10.1093/toxsci/kfh278
   Wenger RH, 2000, J EXP BIOL, V203, P1253
   Yang SJ, 2004, J BIOCHEM MOL BIOL, V37, P480
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zhang H, 2008, CHINESE GERMAN J CLI, V7, P230
NR 27
TC 28
Z9 33
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 17
PY 2012
VL 18
IS 12-14
BP 114
EP 120
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 904ZF
UT WOS:000301238700003
PM 22275802
DA 2022-11-30
ER

PT J
AU Peiretti, E
   Ferrara, DC
   Caminiti, G
   Mura, M
   Hughes, J
AF Peiretti, Enrico
   Ferrara, Daniela C.
   Caminiti, Giulia
   Mura, Marco
   Hughes, John
TI CHOROIDAL NEOVASCULARIZATION IN CAUCASIAN PATIENTS WITH LONGSTANDING
   CENTRAL SEROUS CHORIORETINOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chronic central serous chorioretinopathy; indocyanine-green angiography;
   polypoidal choroidal vasculopathy
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; TERM-FOLLOW-UP; PHOTODYNAMIC
   THERAPY; FUNDUS AUTOFLUORESCENCE; VASCULOPATHY; ANGIOGRAPHY; SECONDARY;
   AGE
AB Purpose:To report the frequency of choroidal neovascularization (CNV) in Caucasian patients with chronic central serous chorioretinopathy (CSC).Methods:Retrospective consecutive series of 272 eyes (136 patients) who were diagnosed as having chronic CSC based on clinical and multimodal fundus imaging findings and documented disease activity for at least 6 months. The CNVs were mainly determined by indocyanine-green angiography.Results:Patients were evaluated and followed for a maximum of 6 years, with an average follow-up of 14 12 months. Distinct CNV was identified in 41 eyes (34 patients). Based on fluorescein angiography, 37 eyes showed occult with no classic CNV, 3 eyes showed predominantly classic and 1 eye had a disciform CNV. Furthermore, indocyanine-green angiography revealed polypoidal choroidal vasculopathy lesions, in 27 of the 37 eyes, classified as occult CNV on fluorescein angiography. In total, 17.6% of our patients with chronic CSC were found to have CNV that upon indocyanine-green angiography were recognized as being polypoidal choroidal vasculopathy.Conclusion:In our series of Caucasian patients, we found a significant correlation between chronic CSC and CNV, in which the majority of patients with CNV were found to have polypoidal choroidal vasculopathy. Our findings suggest that indocyanine-green angiography is an indispensable tool in the investigation of chronic CSC.
C1 [Peiretti, Enrico; Caminiti, Giulia] Univ Cagliari, Eye Clin, Dept Surg Sci, I-09100 Cagliari, Italy.
   [Ferrara, Daniela C.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Mura, Marco; Hughes, John] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1012 WX Amsterdam, Netherlands.
C3 University of Cagliari; Tufts Medical Center; University of Amsterdam;
   Academic Medical Center Amsterdam
RP Peiretti, E (通讯作者)，Univ Cagliari, Eye Clin, Dept Surg Sci, Via Osped 48, I-09100 Cagliari, Italy.
EM enripei@hotmail.com
RI Mura, Marco/F-8780-2018
OI Mura, Marco/0000-0001-5283-5366; Peiretti, Enrico/0000-0003-1088-0163
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Bandello F, 2001, J FR OPHTALMOL, V24, P448
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Canakis C, 2004, OPHTHAL SURG LAS IM, V35, P168, DOI 10.3928/1542-8877-20040301-17
   Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Konstantinidis L, 2010, EUR J OPHTHALMOL, V20, P955, DOI 10.1177/112067211002000524
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Maia Hugo Soares, 2005, Arq. Bras. Oftalmol., V68, P561, DOI 10.1590/S0004-27492005000400027
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Peiretti Enrico, 2008, Retin Cases Brief Rep, V2, P31, DOI 10.1097/01.iae.0000243064.91851.78
   PICCOLINO FC, 1995, EYE, V9, P324, DOI 10.1038/eye.1995.63
   Piccolino FC, 2008, RETINA-J RET VIT DIS, V28, P1008, DOI 10.1097/IAE.0b013e31816b4b86
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043
   Uyama M, 1999, RETINA-J RET VIT DIS, V19, P12, DOI 10.1097/00006982-199901000-00003
   Yang CS, 2009, J CHIN MED ASSOC, V72, P501, DOI 10.1016/S1726-4901(09)70417-4
   YANNUZZI LA, 1987, RETINA-J RET VIT DIS, V7, P111, DOI 10.1097/00006982-198700720-00009
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 44
TC 42
Z9 45
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1360
EP 1367
DI 10.1097/IAE.0000000000000529
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600009
PM 26102435
DA 2022-11-30
ER

PT J
AU Schwartz, SD
   Hubschman, JP
   Heilwell, G
   Franco-Cardenas, V
   Pan, CK
   Ostrick, RM
   Mickunas, E
   Gay, R
   Klimanskaya, I
   Lanza, R
AF Schwartz, Steven D.
   Hubschman, Jean-Pierre
   Heilwell, Gad
   Franco-Cardenas, Valentina
   Pan, Carolyn K.
   Ostrick, Rosaleen M.
   Mickunas, Edmund
   Gay, Roger
   Klimanskaya, Irina
   Lanza, Robert
TI Embryonic stem cell trials for macular degeneration: a preliminary
   report
SO LANCET
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; TRANSPLANTATION; TRANSLOCATION; MORPHOLOGY;
   RPE
AB Background It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients.
   Methods We started two prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry age-related macular degeneration-the leading cause of blindness in the developed world. Preoperative and postoperative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing. These studies are registered with ClinicalTrials.gov, numbers NCT01345006 and NCT01344993.
   Findings Controlled hESC differentiation resulted in greater than 99% pure RPE. The cells displayed typical RPE behaviour and integrated into the host RPE layer forming mature quiescent monolayers after trans plantation in animals. The stage of differentiation substantially affected attachment and survival of the cells in vitro after clinical formulation. Lightly pigmented cells attached and spread in a substantially greater proportion (>90%) than more darkly pigmented cells after culture. After surgery, structural evidence confirmed cells had attached and continued to persist during our study. We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months. Although there is little agreement between investigators on visual endpoints in patients with low vision, it is encouraging that during the observation period neither patient lost vision. Best corrected visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual acuity chart) in the study eye of the patient with Stargardt's macular dystrophy, and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).
   Interpretation The hESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months. The future therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.
C1 [Schwartz, Steven D.; Hubschman, Jean-Pierre; Heilwell, Gad; Franco-Cardenas, Valentina; Pan, Carolyn K.; Ostrick, Rosaleen M.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.
   [Mickunas, Edmund; Gay, Roger; Klimanskaya, Irina; Lanza, Robert] Adv Cell Technol, Marlborough, MA 01752 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Schwartz, SD (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.
EM schwartz@jsei.ucla.edu; rlanza@advancedcell.com
OI Hubschman, Jean-Pierre/0000-0002-8631-3467; Pan,
   Carolyn/0000-0002-1031-7488; Lanza, Robert/0000-0002-3047-3074
FU Advanced Cell Technology
FX Advanced Cell Technology.
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188
   Fink DW, 2009, ESSENTIALS OF STEM CELL BIOLOGY, 2ND EDITION, P619, DOI 10.1016/B978-0-12-374729-7.00068-8
   Gamm DM, 2008, STEM CELLS, V26, P3182, DOI 10.1634/stemcells.2008-0300
   Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Klimanskaya I, 2005, LANCET, V365, P1636, DOI 10.1016/S0140-6736(05)66473-2
   Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142
   Lanza RP, 2002, NAT BIOTECHNOL, V20, P689, DOI 10.1038/nbt703
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu F, 2007, MOL VIS, V13, P2066
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Okamura RM, 2007, J NEUROIMMUNOL, V192, P134, DOI 10.1016/j.jneuroim.2007.09.030
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
NR 31
TC 988
Z9 1073
U1 12
U2 318
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 25
PY 2012
VL 379
IS 9817
BP 713
EP 720
DI 10.1016/S0140-6736(12)60028-2
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 899CU
UT WOS:000300792600027
PM 22281388
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Kwon, M
   Ramachandra, C
   Satgunam, P
   Mel, BW
   Peli, E
   Tjan, BS
AF Kwon, MiYoung
   Ramachandra, Chaithanya
   Satgunam, PremNandhini
   Mel, Bartlett W.
   Peli, Eli
   Tjan, Bosco S.
TI Contour Enhancement Benefits Older Adults with Simulated Central Field
   Loss
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision questionnaire; rehabilitation; functional ability; Veterans
   Affairs Low-Vision Visual Functioning Questionnaire; Impact of Vision
   Impairment Questionnaire
ID CONTRAST SENSITIVITY GRADIENT; VISUAL-ACUITY; PSYCHOPHYSICS; CATARACT;
   AGE; RECOGNITION; VISION; PEOPLE; SHAPE
AB Purpose. Age-related macular degeneration is the leading cause of vision loss among Americans aged >65 years. Currently, no effective treatment can reverse the central vision loss associated with most age-related macular degeneration. Digital image-processing techniques have been developed to improve image visibility for peripheral vision; however, both the selection and efficacy of such methods are limited. Progress has been difficult for two reasons: the exact nature of image enhancement that might benefit peripheral vision is not well understood, and efficient methods for testing such techniques have been elusive. The current study aims to develop both an effective image enhancement technique for peripheral vision and an efficient means for validating the technique.
   Methods. We used a novel contour-detection algorithm to locate shape-defining edges in images based on natural-image statistics. We then enhanced the scene by locally boosting the luminance contrast along such contours. Using a gaze-contingent display, we simulated central visual field loss in normally sighted young (aged 18-30 years) and older adults (aged 58-88 years). Visual search performance was measured as a function of contour enhancement strength ["Original" (unenhanced), "Medium," and "High"]. For preference task, a separate group of subjects judged which image in a pair "would lead to better search performance."
   Results. We found that although contour enhancement had no significant effect on search time and accuracy in young adults, Medium enhancement resulted in significantly shorter search time in older adults (about 13% reduction relative to Original). Both age-groups preferred images with Medium enhancement over Original (2-7 times). Furthermore, across age-groups, image content types, and enhancement strengths, there was a robust correlation between preference and performance.
   Conclusions. Our findings demonstrate a beneficial role of contour enhancement in peripheral vision for older adults. Our findings further suggest that task-specific preference judgments can be an efficient surrogate for performance testing. (Optom Vis Sci 2012; 89: 1374-1384)
C1 [Kwon, MiYoung; Tjan, Bosco S.] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
   [Mel, Bartlett W.; Tjan, Bosco S.] Univ So Calif, Neurosci Grad Program, Los Angeles, CA 90089 USA.
   [Ramachandra, Chaithanya; Mel, Bartlett W.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
   [Satgunam, PremNandhini; Peli, Eli] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; Harvard University; Harvard Medical
   School; Schepens Eye Research Institute
RP Tjan, BS (通讯作者)，Univ So Calif, Dept Psychol, 3620 S McClintock Ave,SGM 501, Los Angeles, CA 90089 USA.
EM btjan@usc.edu
OI Peli, Eli/0000-0002-1340-9257; Satgunam,
   PremNandhini/0000-0001-8631-733X
FU NIH [R01EY016093, R01EY17707]; NATIONAL EYE INSTITUTE [R01EY017707,
   R01EY016093, R01EY005957] Funding Source: NIH RePORTER
FX This work was supported by NIH grants R01EY016093 and R01EY17707. We
   thanks Jessica Leigh Gonzales and Eric Trinh for their help with subject
   recruitment and data collection.
CR Aguilar C, 2011, VISION RES, V51, P997, DOI 10.1016/j.visres.2011.02.010
   ANDERSON SJ, 1991, J PHYSIOL-LONDON, V442, P47, DOI 10.1113/jphysiol.1991.sp018781
   ARTAL P, 1995, VISION RES, V35, P939, DOI 10.1016/0042-6989(94)00180-T
   Bernard JB, 2007, VISION RES, V47, P3447, DOI 10.1016/j.visres.2007.10.005
   BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Chung STL, 2011, INVEST OPHTH VIS SCI, V52, P1164, DOI 10.1167/iovs.10-6034
   Cornsweet T., 1970, VISUAL PERCEPTION
   CRASSINI B, 1988, PERCEPTION, V17, P315, DOI 10.1068/p170315
   ELLIOTT DB, 1987, OPHTHAL PHYSL OPT, V7, P415, DOI 10.1111/j.1475-1313.1987.tb00771.x
   ELLIOTT DB, 1990, EYE, V4, P712, DOI 10.1038/eye.1990.100
   Fine EM, 1999, OPTOMETRY VISION SCI, V76, P468, DOI 10.1097/00006324-199907000-00022
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fullerton M, 2007, J OPT SOC AM A, V24, pB174, DOI 10.1364/JOSAA.24.00B174
   Fullerton M, 2008, J SOC INF DISPLAY, V16, P493, DOI 10.1889/1.2896328
   HUTTENLOCHER DP, 1990, INT J COMPUT VISION, V5, P195, DOI 10.1007/BF00054921
   KNILL DC, 1992, J OPT SOC AM A, V9, P1449, DOI 10.1364/JOSAA.9.001449
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Luo G, OPHTHALMIC IN PRESS
   Makela P, 2001, VISION RES, V41, P599, DOI 10.1016/S0042-6989(00)00259-5
   Oliva A, 2001, INT J COMPUT VISION, V42, P145, DOI 10.1023/A:1011139631724
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Peli E, 2009, INT J ARTIF INTELL T, V18, P415, DOI 10.1142/S0218213009000214
   Pelli DG, 2008, NAT NEUROSCI, V11, P1129, DOI 10.1038/nn.2187
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pidcoe PE, 2006, INVEST OPHTH VIS SCI, V47, P169, DOI 10.1167/iovs.04-0564
   POINTER JS, 1989, VISION RES, V29, P1133, DOI 10.1016/0042-6989(89)90061-8
   POINTER JS, 1990, VISION RES, V30, P497, DOI 10.1016/0042-6989(90)90090-8
   Ramachandra C, 2011, COMP SYST NEUR C SAL
   ROBSON JG, 1981, VISION RES, V21, P409, DOI 10.1016/0042-6989(81)90169-3
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Satgunam P, 2012, OPTOMETRY VISION SCI, V89, pE1364, DOI 10.1097/OPX.0b013e318266f92f
   Superstein R, 1999, J CATARACT REFR SURG, V25, P575, DOI 10.1016/S0886-3350(99)80059-5
   Thibos LN, 1996, VISION RES, V36, P249, DOI 10.1016/0042-6989(95)00109-D
   TULUNAYKEESEY U, 1988, J OPT SOC AM A, V5, P2191, DOI 10.1364/JOSAA.5.002191
NR 37
TC 24
Z9 25
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD SEP
PY 2012
VL 89
IS 9
BP 1374
EP 1384
DI 10.1097/OPX.0b013e3182678e52
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 001FH
UT WOS:000308445400018
PM 22885784
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Aung, KH
   Liu, H
   Ke, ZW
   Jiang, S
   Huang, JH
AF Aung, Kaung Htet
   Liu, Hua
   Ke, Zongwen
   Jiang, Shuang
   Huang, Jianhua
TI Glabridin Attenuates the Retinal Degeneration Induced by Sodium Iodate
   In Vitro and In Vivo
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; apoptosis; glabridin; oxidative
   stress; retinal pigment epithelial (RPE) cells; sodium iodate
ID MACULAR DEGENERATION; ELECTRORETINOGRAM; ERK1/2; CELLS
AB Background
   Age-related macular degeneration (AMD) is one of the major causes of blindness in the elderly over the age of 60. AMD is divided into dry AMD and wet AMD. Although there are certain treatment methods for wet age-related macular degeneration (AMD), there are no effective treatments for dry AMD yet, and finding new drugs or treatment methods for dry AMD has become a priority. For this purpose, this study explored Glabridin (Glab), an isoflavane found in the root extract of licorice, which has never been investigated in relation to eye diseases.
   Purpose
   To investigate the effect of Glab on the sodium iodate (NaIO3) induced retinal degeneration in vitro and in vivo.
   Methods
   In vitro, cell viability and cytotoxicity were tested with methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay among the groups of ARPE-19 cells. The cell apoptosis was tested with Hoechst 33342 staining and flow cytometry. The level of Reactive oxygen species (ROS) was measured to check the effect on oxidative stress. The protein expressions of phosphorylation of ERK1/2 and p38 were detected by Western blotting. In vivo, C57BL/6J mice were pretreated with Glab intraperitoneally for one week and continued for 4 weeks. NaIO3 was given to mice through tail vein intravenous injection after 1 week of Glab administration. The retinas of mice were monitored by Optical coherence tomography (OCT) and electroretinography (ERG) at 1w, 2w, 3w, and 4w, respectively, followed by H&E staining.
   Results
   In vitro, the Glab protected the retinal pigment epithelial (RPE) cells against oxidative stress and apoptosis by inhibiting phosphorylation of ERK1/2 and the p38 MAPK pathway. In vivo, Glab significantly prevented retinal damage by stopping the progression of retinal degeneration and reducing the formation of deposits on the RPE layer induced by NaIO3. According to the findings of electroretinogram (ERG), Glab helped to maintain the normal function of the retina.
   Conclusion
   Glabridin has a protective effect against retinal degeneration. It is suggested that Glab be further investigated for the treatment of retinal degeneration diseases.
C1 [Aung, Kaung Htet; Liu, Hua; Jiang, Shuang] Jinzhou Med Univ, Affiliated Hosp 3, Dept Ophthalmol, Jinzhou, Peoples R China.
   [Aung, Kaung Htet; Ke, Zongwen] Jinzhou Med Univ, Grad Sch, Jinzhou, Peoples R China.
   [Huang, Jianhua] Jinzhou Med Univ, Affiliated Hosp 1, Key Lab Surg Liaoning Prov, Jinzhou, Peoples R China.
C3 Jinzhou Medical University; Jinzhou Medical University; Jinzhou Medical
   University
RP Liu, H (通讯作者)，Jinzhou Med Univ, Affiliated Hosp 3, Dept Ophthalmol, Jinzhou, Peoples R China.; Huang, JH (通讯作者)，Jinzhou Med Univ, Affiliated Hosp 1, Key Lab Surg Liaoning Prov, Jinzhou, Peoples R China.
EM lh5095153@163.com; hjhuadr@163.com
FU Natural Science Foundation of Liaoning Province [201602287]; Liaoning
   Distinguished Professor Project [XLYC1802113, XLYC1802039]
FX This work was supported in part by grants from the Natural Science
   Foundation of Liaoning Province (201602287) and Liaoning Distinguished
   Professor Project to JH (XLYC1802113) and HL (XLYC1802039).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2018, QUANTITATIVE FINANCE
   ASI H, 1992, DOC OPHTHALMOL, V79, P125, DOI 10.1007/BF00156572
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Carmeli E, 2009, TOXICOL IND HEALTH, V25, P321, DOI 10.1177/0748233709103034
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   He HJ, 2019, J CELL MOL MED, V23, P3495, DOI 10.1111/jcmm.14246
   Huang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098943
   Huang KQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00107
   Jiang LP, 2018, MOL MED REP, V17, P1499, DOI 10.3892/mmr.2017.8021
   LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0
   Li S. H., 2018, INT J MOL SCI, V19
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Morrison Deborah K, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011254
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pyakurel A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00295-17
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Zeiss CJ, 2013, ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE, P97, DOI 10.1016/B978-0-12-415894-8.00005-1
   Zhang L, 2018, ONCOL LETT, V15, P7037, DOI 10.3892/ol.2018.8260
   Zhang LP, 2017, ONCOTARGET, V8, P18935, DOI 10.18632/oncotarget.14277
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zou JR, 2019, MOL MED REP, V19, P759, DOI 10.3892/mmr.2018.9712
NR 32
TC 6
Z9 6
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 15
PY 2020
VL 11
AR 566699
DI 10.3389/fphar.2020.566699
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OK8GB
UT WOS:000584881400001
PM 33178017
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Narjes, B
   Aline, D
   Laurent, L
   Benedicte, B
   Lucy, M
   Stephane, G
   Lionel, B
AF Narjes, Babchia
   Aline, DeAraujo
   Laurent, Leclere
   Benedicte, Buteau
   Lucy, Martine
   Stephane, Gregoire
   Lionel, Bretillon
TI Docosahexaenoic acid modulates oxidative stress-induced apoptosis via
   PI3K/Akt m-TOR/p70S6K pathways in human RPE cells
SO EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Docosahexaenoic acid; Lipids; Oxidative stress; Phosphatidylinositol
   3-kinase; Retinal degeneration
ID PIGMENT EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL
   3-KINASE; DOWN-REGULATION; GROWTH-FACTOR; AKT; SURVIVAL; INHIBITION;
   PHOSPHATIDYLSERINE; STIMULATION
AB Oxidative stress (OS) plays a critical role in the pathogenesis of age-related macular degeneration (AMD), especially by targeting the retinal pigment epithelium (RPE). Dietary habits with high consumption of long-chain omega-3 polyunsaturated fatty acids, including docosahexaenoic acid (DHA), have been reported to prevent the development and progression of AMD. Nevertheless, it is still unclear how DHA affects AMD, although the conversion of DHA into neuroprotective metabolites has been demonstrated to participate in this effect, at least experimentally. The present study aimed to investigate the involvement of the phosphatidylinositol 3-kinase (PI3K)/Akt and mammalian target of rapamycin complex (m-TOR)/p70S6K pathways in human RPE cells in response to OS, and then to assess the effect of DHA in the signaling pathways and protection against RPE cell death. For this purpose, we used ARPE-19 cells exposed to the prooxidant agent, tert-butyl hydroperoxide (t-BHP). We found that exposing cells to t-BHP inhibited the activation of Akt and p70S6K. However, in cells enriched with DHA and then exposed to t-BHP, we demonstrated that Akt and p70S6K remained phosphorylated for a longer time after stress. In addition, DHA reduced the percentage of apoptotic cells induced by OS. This study suggests that: (i) PI3K/Akt and m-TOR/P70S6K pathways are involved in the response of RPE to OS; and that (ii) DHA protected RPE cells from apoptosis triggered by OS by enhancing the phosphorylation of Akt and P70S6K.
   Practical applicationsOxidative stress plays a critical role in age-related macular degeneration. DHA has been reported to prevent the development and evolution of AMD. An understanding of the PI3K/Akt and m-TOR/P70S6K pathways involved in the response of RPE to OS may contribute to treatments involving the protection of RPE cells from apoptosis through enhancing the phosphorylation of Akt/P70S6K. Docosahexaenoic acid protected RPE cells from apoptosis triggered by oxidative stress by enhancing the phosphorylation of Akt and P70S6K.
C1 [Narjes, Babchia; Aline, DeAraujo; Laurent, Leclere; Benedicte, Buteau; Lucy, Martine; Stephane, Gregoire; Lionel, Bretillon] CNRS, Ctr Sci Gout & Alimentat, UMR 6265, Dijon, France.
   [Narjes, Babchia; Aline, DeAraujo; Laurent, Leclere; Benedicte, Buteau; Lucy, Martine; Stephane, Gregoire; Lionel, Bretillon] INRA, Ctr Sci Gout & Alimentat, UMR 1324, F-21034 Dijon, France.
   [Narjes, Babchia; Aline, DeAraujo; Laurent, Leclere; Benedicte, Buteau; Lucy, Martine; Stephane, Gregoire; Lionel, Bretillon] Univ Bourgogne, Ctr Sci Gout & Alimentat, Dijon, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Institut Agro; AgroSup Dijon; Universite
   de Bourgogne; INRAE; Institut Agro; AgroSup Dijon; Centre National de la
   Recherche Scientifique (CNRS); Universite de Bourgogne; Institut Agro;
   AgroSup Dijon; Centre National de la Recherche Scientifique (CNRS);
   Universite de Bourgogne
RP Narjes, B (通讯作者)，17 Rue Sully, F-21000 Dijon, France.
EM narjesbabchia@gmail.com
RI Babchia, Narjes/ABE-3509-2021
CR Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Babchia N, 2008, INVEST OPHTH VIS SCI, V49, P2348, DOI 10.1167/iovs.07-1305
   Babchia N, 2010, INVEST OPHTH VIS SCI, V51, P421, DOI 10.1167/iovs.09-3974
   Bazan NG, 2008, ADV EXP MED BIOL, V613, P39
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Carraway H, 2004, BREAST CANCER RES, V6, P219, DOI 10.1186/bcr927
   Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hecquet C, 2003, INVEST OPHTH VIS SCI, V44, P1320, DOI 10.1167/iovs.02-0519
   Huang BX, 2011, J CELL BIOL, V192, P979, DOI 10.1083/jcb.201005100
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217
   Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Kim HY, 2010, PROSTAG LEUKOTR ESS, V82, P165, DOI 10.1016/j.plefa.2010.02.025
   Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99
   Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3
   Mita MM, 2003, CANCER BIOL THER, V2, pS169
   NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Simon E, 2011, EXP EYE RES, V93, P628, DOI 10.1016/j.exer.2011.07.016
   Valamanesh F, 2009, MOL VIS, V15, P2634
   Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
NR 41
TC 0
Z9 0
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1438-7697
EI 1438-9312
J9 EUR J LIPID SCI TECH
JI Eur. J. Lipid Sci. Technol.
PD JUN
PY 2015
VL 117
IS 6
BP 786
EP 796
DI 10.1002/ejlt.201400155
PG 11
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA CJ8IW
UT WOS:000355744500008
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Reynolds, R
   Maller, J
   Fagerness, JA
   Daly, MJ
   Rosner, B
AF Seddon, Johanna M.
   Reynolds, Robyn
   Maller, Julian
   Fagerness, Jesen A.
   Daly, Mark J.
   Rosner, Bernard
TI Prediction Model for Prevalence and Incidence of Advanced Age-Related
   Macular Degeneration Based on Genetic, Demographic, and Environmental
   Variables
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BODY-MASS INDEX; FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING; RISK-FACTORS;
   VARIANT; SUSCEPTIBILITY; ASSOCIATION; CFH; MACULOPATHY; PROGRESSION
AB PURPOSE. The joint effects of genetic, ocular, and environmental variables were evaluated and predictive models for prevalence and incidence of AMD were assessed.
   METHODS. Participants in the multicenter Age-Related Eye Disease Study (AREDS) were included in a prospective evaluation of 1446 individuals, of which 279 progressed to advanced AMD (geographic atrophy or neovascular disease) and 1167 did not progress during 6.3 years of follow-up. For prevalent AMD, 509 advanced cases were compared with 222 controls. Covariates for the incidence analysis included age, sex, education, smoking, body mass index (BMI), baseline AMD grade, and the AREDS vitamin-mineral treatment assignment. DNA specimens were evaluated for six variants in five genes related to AMD. Unconditional logistic regression analyses were performed for prevalent and incident advanced AMD. An algorithm was developed and receiver operating characteristic curves and C statistics were calculated to assess the predictive ability of risk scores to discriminate progressors from nonprogressors.
   RESULTS. All genetic polymorphisms were independently related to prevalence of advanced AMD, controlling for genetic factors, smoking, BMI, and AREDS treatment. Multivariate odds ratios (ORs) were 3.5 (95% confidence interval [CI], 1.7-7.1) for CFH Y402H; 3.7 (95% CI, 1.6-8.4) for CFH rs1410996; 25.4 (95% CI, 8.6-75.1) for LOC387715 A69S (ARMS2); 0.3 (95% CI, 0.1-0.7) for C2 E318D; 0.3 (95% CI, 0.1-0.5) for CFB; and 3.6 (95% CI, 1.4-9.4) for C3 R102G, comparing the homozygous risk/protective genotypes to the referent genotypes. For incident AMD, all these variants except CFB were significantly related to progression to advanced AMD, after controlling for baseline AMD grade and other factors, with ORs from 1.8 to 4.0 for presence of two risk alleles and 0.4 for the protective allele. An interaction was seen between CFH402H and treatment, after controlling for all genotypes. Smoking was independently related to AMD, with a multiplicative joint effect with genotype on AMD risk. The C statistic for the full model with all variables was 0.831 for progression to advanced AMD.
   CONCLUSIONS. Factors reflective of nature and nurture are independently related to prevalence and incidence of advanced AMD, with excellent predictive power. (Invest Ophthalmol Vis Sci. 2009;50:2044-2053) DOI:10.1167/iovs.08-3064
C1 [Maller, Julian; Fagerness, Jesen A.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Maller, Julian; Fagerness, Jesen A.; Daly, Mark J.] Broad Inst Harvard, Program Med & Populat Genet, Boston, MA USA.
   [Maller, Julian; Fagerness, Jesen A.; Daly, Mark J.] MIT, Boston, MA USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
   [Seddon, Johanna M.] Tufts Univ, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr,Sch Med, Boston, MA 02111 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute;
   Massachusetts Institute of Technology (MIT); Harvard University; Harvard
   Medical School; Tufts Medical Center; Tufts University
RP Seddon, JM (通讯作者)，Tufts Univ, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr,Sch Med, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017; maller, julian B/A-9323-2009
OI Daly, Mark J/0000-0002-0949-8752; Maller, Julian/0000-0002-1565-9559
FU National Institutes of Health (NIH) National Eye Institute
   [R01-EY11309]; Foundation Fighting Blindness, Owing Mills, MD;
   Age-Related Macular Degeneration Research Fund; Ophthalmic Epidemiology
   and Genetics Service; Tufts Medical Center; Tufts University School of
   Medicine; Massachusetts Lions Eye Research Fund Inc., Northboro, MA;
   National Center for Research Resources to the Broad Institute Center for
   Genotyping and Analysis [U54 RR020278]; Research to Prevent Blindness
   Inc., New York, NY; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020278]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011309]
   Funding Source: NIH RePORTER
FX Supported by Grant R01-EY11309 from the National Institutes of Health
   (NIH) National Eye Institute; the Foundation Fighting Blindness, Owing
   Mills, MD; the Age-Related Macular Degeneration Research Fund,
   Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center,
   Tufts University School of Medicine; the Massachusetts Lions Eye
   Research Fund Inc., Northboro, MA; Grant U54 RR020278 from the National
   Center for Research Resources to the Broad Institute Center for
   Genotyping and Analysis; and unrestricted grants from Research to
   Prevent Blindness Inc., New York, NY.
CR D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Rosner B, 2009, BIOMETRICS, V65, P188, DOI 10.1111/j.1541-0420.2008.01062.x
   Rosner B., 2000, FUNDAMENTALS BIOSTAT
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   SEDDON J, 2007, PRINCIPLES PRACTICE
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 38
TC 216
Z9 234
U1 0
U2 22
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2009
VL 50
IS 5
BP 2044
EP 2053
DI 10.1167/iovs.08-3064
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 436YC
UT WOS:000265451000011
PM 19117936
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Taveau, N
   Cubizolle, A
   Guillou, L
   Pinquier, N
   Moine, E
   Cia, D
   Kalatzis, V
   Vercauteren, J
   Durand, T
   Crauste, C
   Brabet, P
AF Taveau, Nicolas
   Cubizolle, Aurelie
   Guillou, Laurent
   Pinquier, Nicolas
   Moine, Esperance
   Cia, David
   Kalatzis, Vasiliki
   Vercauteren, Joseph
   Durand, Thierry
   Crauste, Celine
   Brabet, Philippe
TI Preclinical pharmacology of a lipophenol in a mouse model of
   light-induced retinopathy
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; STARGARDT-DISEASE; VISUAL CYCLE; PHOTOCHEMICAL
   DAMAGE; PHOTORECEPTOR; DEGENERATION; PROTECTION; RETINA; A2E; INHIBITORS
AB Experimental & Molecular Medicine: Vision loss: Shedding light on how to prevent retinal damage Treating retinal damage in both aging and young patients might now be easier, thanks to treatment with a lipophenol, an omega-3 fatty acid linked to an antioxidant. The retina is the part of the eye that senses light, aided by light-sensitive pigments. However, these light-sensitive pigments can be converted by light to toxic byproducts, and in some individuals, these toxic byproducts can accumulate, damaging the retina and leading to vision loss. Philippe Brabet at the Montpellier Institute of Neuroscience in France and co-workers found that lipophenol treatment protected retinal cells from damage in a mouse model of retinal disease, and that a single dose has been effective in preserving vision. These results may help in finding new treatments for retinal diseases such as Stargardt disease and age-related macular degeneration.
   Environmental light has deleterious effects on the outer retina in human retinopathies, such asABCA4-related Stargardt's disease and dry age-related macular degeneration. These effects involve carbonyl and oxidative stress, which contribute to retinal cell death and vision loss. Here, we used an albinoAbca4(-/-)mouse model, the outer retina of which shows susceptibility to acute photodamage, to test the protective efficacy of a new polyunsaturated fatty acid lipophenol derivative. Anatomical and functional analyses demonstrated that a single intravenous injection of isopropyl-phloroglucinol-DHA, termed IP-DHA, dose-dependently decreased light-induced photoreceptor degeneration and preserved visual sensitivity. This protective effect persisted for 3 months. IP-DHA did not affect the kinetics of the visual cycle in vivo or the activity of the RPE65 isomerase in vitro. Moreover, IP-DHA administered by oral gavage showed significant protection of photoreceptors against acute light damage. In conclusion, short-term tests inAbca4-deficient mice, following single-dose administration and light exposure, identify IP-DHA as a therapeutic agent for the prevention of retinal degeneration.
C1 [Taveau, Nicolas; Cubizolle, Aurelie; Guillou, Laurent; Pinquier, Nicolas; Kalatzis, Vasiliki; Brabet, Philippe] INSERM, U1051, Institut Neurosci Montpellier, F-34091 Montpellier, France.
   [Taveau, Nicolas; Cubizolle, Aurelie; Guillou, Laurent; Kalatzis, Vasiliki; Brabet, Philippe] Univ Montpellier, F-34091 Montpellier, France.
   [Moine, Esperance; Vercauteren, Joseph; Durand, Thierry; Crauste, Celine] Univ Montpellier, IBMM, UMR 5247, CNRS,ENSCM, F-34095 Montpellier, France.
   [Cia, David] Fac Med & Pharm, Lab Biophys Neurosensorielle, UMR INSERM 1107, F-63001 Clermont Ferrand, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Universite de Montpellier; Centre National de
   la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC);
   Ecole nationale superieure de chimie de Montpellier; Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Franche-Comte
RP Brabet, P (通讯作者)，INSERM, U1051, Institut Neurosci Montpellier, F-34091 Montpellier, France.; Brabet, P (通讯作者)，Univ Montpellier, F-34091 Montpellier, France.
EM philippe.brabet@inserm.fr
RI Brabet, Philippe/AAO-8522-2020; Kalatzis, Vasiliki/F-6170-2019;
   Vercauteren, Joseph/AAF-7151-2019
OI Brabet, Philippe/0000-0003-2739-1622; Kalatzis,
   Vasiliki/0000-0002-9626-8807; Vercauteren, Joseph/0000-0002-0201-1235;
   Cia, David/0000-0002-1146-7904; Moine, Esperance/0000-0002-4579-1323
FU Fondation Stargardt under the Aegis of Fondation Valentin Hauy
   [2017-03]; Retina France; ANR [ANR-18-CE18-0017-03]; SATT AxLR
   [18/0093]; Inserm; CNRS; University of Montpellier; Fondation Stargardt;
   Agence National de la Recherche
FX We would like to thank A-L. Bonnefont and M. Cren for their expertize in
   the IV injection of mice; C. Diez for assistance with the
   hyperreflectivity study; J. Bonnet for his technical assistance; the
   RHEM platform for the histologic preparation of paraffin sections; the
   INM facility for the management and maintenance of mice; and Montpellier
   RIO Imaging for the use of imaging tools. Fondation Stargardt, (2017-03)
   under the Aegis of Fondation Valentin Hauy, Retina France, ANR
   (ANR-18-CE18-0017-03), and SATT AxLR (18/0093) funded this research. We
   thank Inserm, CNRS, and University of Montpellier for their support. We
   disclose grant support received from Fondation Stargardt and Agence
   National de la Recherche.
CR Adler L, 2017, EXP EYE RES, V155, P121, DOI 10.1016/j.exer.2017.02.007
   Aldini G, 2014, FREE RADICAL BIO MED, V69, P145, DOI 10.1016/j.freeradbiomed.2014.01.017
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bhullar KS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/891748
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Chekroud K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050231
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   Crauste C, 2014, EUR J ORG CHEM, V2014, P4548, DOI 10.1002/ejoc.201402282
   Cubizolle A, 2020, J CELL MOL MED, V24, P5057, DOI 10.1111/jcmm.15135
   Cubizolle A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180148
   Dornstauder B, 2012, INVEST OPHTH VIS SCI, V53, P2256, DOI 10.1167/iovs.11-8569
   Drouin G, 2019, J NUTR BIOCHEM, V63, P186, DOI 10.1016/j.jnutbio.2018.09.029
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Ferguson LR, 2012, BIOL PROCED ONLINE, V14, DOI 10.1186/1480-9222-14-9
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Hussain RM, 2018, EXPERT OPIN PHARMACO, V19, P471, DOI 10.1080/14656566.2018.1448060
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Khan KN, 2018, OPHTHALMOLOGY, V125, P735, DOI 10.1016/j.ophtha.2017.11.020
   Kielar ML, 2003, J AM SOC NEPHROL, V14, P389, DOI 10.1097/01.ASN.0000045047.44107.0B
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kiser PD, 2017, J PHARMACOL EXP THER, V362, P131, DOI 10.1124/jpet.117.240721
   Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538
   Liu YX, 2014, J PHOTOCH PHOTOBIO B, V140, P85, DOI 10.1016/j.jphotobiol.2014.07.016
   Lu LJ, 2017, GRAEF ARCH CLIN EXP, V255, P1057, DOI 10.1007/s00417-017-3619-8
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   Qi SN, 2017, MOL VIS, V23, P171
   Reinisalo M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/340520
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Ryu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071178
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shin Y, 2018, BBA-MOL BASIS DIS, V1864, P2420, DOI 10.1016/j.bbadis.2018.04.014
   Shindou H, 2017, J BIOL CHEM, V292, P12054, DOI [10.1074/jbc.M117.790568, 10.1074/jbc.m117.790568]
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   van Norren D, 2011, PHOTOCHEM PHOTOBIOL, V87, P747, DOI 10.1111/j.1751-1097.2011.00921.x
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005
   Wright CB, 2015, PROG MOL BIOL TRANSL, V134, P433, DOI 10.1016/bs.pmbts.2015.06.009
   Wu L, 2014, INVEST OPHTH VIS SCI, V55, P1910, DOI 10.1167/iovs.14-13867
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
NR 57
TC 6
Z9 6
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUL
PY 2020
VL 52
IS 7
BP 1090
EP 1101
DI 10.1038/s12276-020-0460-7
EA JUL 2020
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA NI2RP
UT WOS:000546510900001
PM 32641711
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hughes, AE
   Bridgett, S
   Meng, WH
   Li, MY
   Curcio, CA
   Stambolian, D
   Bradley, DT
AF Hughes, Anne E.
   Bridgett, Stephen
   Meng, Weihua
   Li, Mingyao
   Curcio, Christine A.
   Stambolian, Dwight
   Bradley, Declan T.
TI Sequence and Expression of Complement Factor H Gene Cluster Variants and
   Their Roles in Age-Related Macular Degeneration Risk
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE complement factor H; genetic variation; gene expression; genetic
   association; haplotype
ID HEMOLYTIC-UREMIC SYNDROME; RHEUMATIC-DISEASES; CFH; SUSCEPTIBILITY;
   AUTOANTIBODIES; POLYMORPHISM; ASSOCIATION; PROTEINS; RETINA;
   IDENTIFICATION
AB PURPOSE. To investigate how potentially functional genetic variants are coinherited on each of four common complement factor H (CFH) and CFH-related gene haplotypes and to measure expression of these genes in eye and liver tissues.
   METHODS. We sequenced the CFH region in four individuals (one homozygote for each of four common CFH region haplotypes) to identify all genetic variants. We studied associations between the haplotypes and AMD phenotypes in 2157 cases and 1150 controls. We examined RNA-seq profiles in macular and peripheral retina and retinal pigment epithelium/choroid/sclera (RCS) from eight eye donors and three liver samples.
   RESULTS. The haplotypic coinheritance of potentially functional variants (including missense variants, novel splice sites, and the CFHR3-CFHR1 deletion) was described for the four common haplotypes. Expression of the short and long CFH transcripts differed markedly between the retina and liver. We found no expression of any of the five CFH-related genes in the retina or RCS, in contrast to the liver, which is the main source of the circulating proteins.
   CONCLUSIONS. We identified all genetic variants on common CFH region haplotypes and described their coinheritance. Understanding their functional effects will be key to developing and stratifying AMD therapies. The small scale of our expression study prevented us from investigating the relationships between CFH region haplotypes and their expression, and it will take time and collaboration to develop epidemiologic-scale studies. However, the striking difference between systemic and ocular expression of complement regulators shown in this study suggests important implications for the development of intraocular and systemic treatments.
C1 [Hughes, Anne E.; Bridgett, Stephen; Meng, Weihua; Bradley, Declan T.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Li, Mingyao] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Queens University Belfast; University of Pennsylvania; University of
   Alabama System; University of Alabama Birmingham; University of
   Pennsylvania
RP Hughes, AE (通讯作者)，169 Ballylesson Rd, Belfast BT8 8JU, Antrim, North Ireland.
EM annehughes169@btinternet.com
RI Bradley, Declan/AFN-7904-2022; Bradley, Declan T/AFO-1353-2022
OI Bridgett, Stephen/0000-0001-9330-5820; Bradley,
   Declan/0000-0003-1468-1823
FU National Eye Institute; Guide Dogs for the Blind Association
   [OR2010-03c]; National Eye Institute [R01EY023164]; Arnold and Mabel
   Beckman Initiative for Macular Research; Public Health Agency
   [EAT/3976/08] Funding Source: researchfish; NATIONAL EYE INSTITUTE
   [P30EY001583, R01EY023164] Funding Source: NIH RePORTER
FX The AMD dataset used for the analyses described in this paper was
   obtained from the NEI-AMD database, through dbGaP accession no.
   phs000182.v1.p1. Funding support for NEI-AMD was provided by the
   National Eye Institute.; Supported by Guide Dogs for the Blind
   Association Grant OR2010-03c (AEH), National Eye Institute Grant
   R01EY023164, and the Arnold and Mabel Beckman Initiative for Macular
   Research (CAC and DS).
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   [Anonymous], 2012, TRUSEQ DNA SAMPLE PR
   [Anonymous], 2014, E MTAB 2386 RNA SEQ
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Bradley DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120757
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2010, KIDNEY INT, V78, P782, DOI 10.1038/ki.2010.275
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Luo C, 2011, MOL VIS, V17, P1588
   Luo XB, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4194
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Melis JPM, 2015, MOL IMMUNOL, V67, P117, DOI 10.1016/j.molimm.2015.01.028
   Purcell S., 2009, PLINK
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zadura AF, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4016
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 53
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2016
VL 57
IS 6
BP 2763
EP 2769
DI 10.1167/iovs.15-18744
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8OA
UT WOS:000378041700045
PM 27196323
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU de Castro, JPF
   Mullins, RF
   Manea, AM
   Hernandez, J
   Wallen, T
   Kuehn, MH
AF de Castro, J. P. Fernandez
   Mullins, R. F.
   Manea, A. M.
   Hernandez, J.
   Wallen, T.
   Kuehn, M. H.
TI Lipofuscin in human glaucomatous optic nerves
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE lipofuscin; glaucoma; AMD; aging; optic nerve
ID MEMBRANE; DISEASE; AGE; ACTIVATION; MECHANISMS; RETINA; OXYGEN; BRAIN
AB Lipofuscin accumulation has been observed in a number of neurodegenerative diseases. We recently found that autofluorescent particles also occur in the aged human optic nerve. In this study we sought to determine the nature of these particles and their correlation with aging, age-related macular degeneration (AMD) and primary open angle glaucoma (POAG). Groups of eight optic nerves from patients diagnosed with primary open angle glaucoma, age-related macular degeneration, age-matched controls and four optic nerves derived from controls younger than 42 years were used for the study. All samples were fixed in paraformaldehyde and frozen frontal sections were prepared. Sections were analyzed with fluorescence microscopy, bright field microscopy, Sudan black staining and spectrofluorometry using a confocal laser scanning microscope. Sections were photographed and analyzed to establish the distribution, quantity, and size of the autofluorescent particles. Additionally, transmission electron microscopy was used to determine the ultrastructural location of the granules. On unstained sections under light microscopy granules are detectable as pale brown inclusions and are easily stained with oil-soluble dyes, such as Sudan black. Granules fluoresce when excited at all tested wavelengths but lose their fluorescence after staining with Sudan black. These particles are distributed throughout the axonal columns, but not in the septa, and appear to be located within the glia ensheathing optic nerve axons. The histologic properties of the granules seen in the optic nerve sections correspond to lipofuscin aggregates, a result of incomplete degradation of oxidized proteins. Our morphometric analyses indicate that overall the optic nerves from control, glaucoma, and AMD donors contain similar amounts of lipofuscin. However, optic nerves derived from donors with glaucoma contain lipofuscin particles that are larger than those observed in the age-matched control and AMD groups. Furthermore optic nerves from glaucoma donors display a smaller diameter than those from age-matched controls resulting in a higher concentration of lipofuscin in glaucomatous optic nerves. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [de Castro, J. P. Fernandez] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [de Castro, J. P. Fernandez; Mullins, R. F.; Hernandez, J.; Wallen, T.; Kuehn, M. H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Manea, A. M.] Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS 66103 USA.
C3 University of Louisville; University of Iowa; University of Kansas;
   University of Kansas Medical Center
RP Kuehn, MH (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM markus-kuehn@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Kuehn, Markus/0000-0003-3940-198X
FU NIH [EY019485, EY022044, EY017451]; NATIONAL EYE INSTITUTE [R01EY022044,
   R01EY017451, R01EY019485] Funding Source: NIH RePORTER
FX These studies were supported by NIH grants EY019485, EY022044, (MHK) and
   EY017451 (RFM). The authors appreciate the help of Dr. Kai Wang
   (University of Iowa Department of Biostatistics) for his help with the
   analysis of the data.
CR Abramoff MD, 2004, J BIOPHOTONICS INT, V11, P36
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Coleman AL, 2008, SURV OPHTHALMOL, V53, pS3, DOI 10.1016/j.survophthal.2008.08.006
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DOLMAN CL, 1980, ARCH OPHTHALMOL-CHIC, V98, P2053
   Ferreira SM, 2010, INVEST OPHTH VIS SCI, V51, P4635, DOI 10.1167/iovs.09-5044
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   GOYAL VK, 1982, EXP GERONTOL, V17, P481, DOI 10.1016/S0531-5565(82)80010-7
   Idone V, 2008, J CELL BIOL, V180, P905, DOI 10.1083/jcb.200708010
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jolly RD, 2002, ARCH GERONTOL GERIAT, V34, P205, DOI 10.1016/S0167-4943(01)00219-9
   JONAS JB, 1995, GRAEF ARCH CLIN EXP, V233, P421, DOI 10.1007/BF00180945
   Ju WK, 2008, INVEST OPHTH VIS SCI, V49, P4903, DOI 10.1167/iovs.07-1661
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001
   Peters A., 2007, BRAIN AGING MODELS M, DOI [10.1201/9781420005523-5, DOI 10.1201/9781420005523-5]
   SCHNEEBE.EE, 1968, J CELL BIOL, V37, P781, DOI 10.1083/jcb.37.3.781
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sulzer D, 2008, J NEUROCHEM, V106, P24, DOI 10.1111/j.1471-4159.2008.05385.x
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P705, DOI 10.1167/iovs.06-0810
   Warburton S, 2007, MOL VIS, V13, P318
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
NR 27
TC 7
Z9 7
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2013
VL 111
BP 61
EP 66
DI 10.1016/j.exer.2013.03.019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 155ZF
UT WOS:000319788700007
PM 23567206
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Viola, F
   Massacesi, A
   Orzalesi, N
   Ratiglia, R
   Staurenghi, G
AF Viola, Francesco
   Massacesi, Amedeo
   Orzalesi, Nicola
   Ratiglia, Roberto
   Staurenghi, Giovanni
TI RETINAL ANGIOMATOUS PROLIFERATION Natural History and Progression of
   Visual Loss
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE fluorescein angiography; indocyanine green angiography; neovascular form
   of age-related macular degeneration; retinal angiomatous proliferation;
   scanning laser ophthalmoscope
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; TYPE-3 NEOVASCULARIZATION;
   RANIBIZUMAB; ANASTOMOSES; VERTEPORFIN
AB Purpose: To investigate the natural history and visual outcome in eyes with untreated retinal angiomatous proliferation, a neovascular form of age-related macular degeneration.
   Methods: Fourteen consecutive white patients (11 women, 78%, mean age, 74 years) with 16 eyes affected by retinal angiomatous proliferation were prospectively followed-up without treatment by means of complete ophthalmologic examinations at regular intervals, including best-corrected visual acuity and dynamic fluorescein and indocyanine green angiography using a scanning laser ophthalmoscope.
   Results: The patients were observed for a mean of 20 months (range, 6-44 months). Mean visual acuity in the eyes with retinal angiomatous proliferation was 0.48 at the initial examination, decreased to 0.23 after 6 months, and was 0.19 at the final examination, with a mean decrease of 6 lines from baseline. In 13 eyes (81%), visual acuity deteriorated by 2 Early Treatment Diabetic Retinopathy Study lines or worse by the time of the 6-month examination, and 31% of the patients had experienced severe loss of vision; the remaining 3 eyes (19%) showed a relatively stable clinical course and visual acuity. By the time of the final examination, visual acuity had decreased to 0.1 or worse in 11 eyes (69%), and 5 of the 14 patients (36%) were legally blind. At the final examination, 10 eyes (62%) showed a subretinal fibrosis and 9 (56%) showed a retinal choroidal anastomosis.
   Conclusion: Retinal angiomatous proliferation is a distinct form of neovascular age-related macular degeneration with high vasogenic potential, having its own clinical course and visual prognosis. The poor visual outcome is because of the exudative nature of the retinal angiomatous proliferation, and progression to poor vision is common and rapid (within 3 months in faster cases, and within 1 year in slower cases). The treatment options for this type of neovascular lesion should be planned bearing in mind its unfavorable natural history. RETINA 29:732-739, 2009
C1 [Viola, Francesco; Ratiglia, Roberto] Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Eye Clin, Milan, Italy.
   [Massacesi, Amedeo] San Giuseppe Hosp, Eye Clin, Milan, Italy.
   [Orzalesi, Nicola] Univ Milan, Eye Clin, San Paolo Hosp, Milan, Italy.
   [Staurenghi, Giovanni] Univ Milan, Eye Clin, Dept Clin Sci Luigi Sacco, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; San
   Paolo-Polo Universitaria Hospital; University of Milan; University of
   Milan; Luigi Sacco Hospital
RP Viola, F (通讯作者)，Univ Milan, Fdn IRCCS, Osped Maggiore Policlin, Eye Clin, Via M Fanti 6, Milan, Italy.
EM francesco.viola@unimi.it
RI viola, francesco/AAK-5583-2020; Staurenghi, Giovanni/K-4388-2017
OI viola, francesco/0000-0003-1208-913X; Staurenghi,
   Giovanni/0000-0002-2299-5251
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   BRESSLER SB, 2005, ANN M AM SOC RET SPE
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Massacesi AL, 2008, GRAEF ARCH CLIN EXP, V246, P89, DOI 10.1007/s00417-007-0638-x
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 21
TC 59
Z9 62
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP 732
EP 739
DI 10.1097/IAE.0b013e3181a395cb
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HS
UT WOS:000267496600002
PM 19516115
DA 2022-11-30
ER

PT J
AU Lee, WK
   Iida, T
   Ogura, Y
   Chen, SJ
   Wong, TY
   Mitchell, P
   Cheung, GCM
   Zhang, ZQ
   Leal, S
   Ishibashi, T
AF Lee, Won Ki
   Iida, Tomohiro
   Ogura, Yuichiro
   Chen, Shih-Jen
   Wong, Tien Yin
   Mitchell, Paul
   Cheung, Gemmy Chui Ming
   Zhang, Zhongqi
   Leal, Sergio
   Ishibashi, Tatsuro
CA PLANET Investigators
TI Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal
   Vasculopathy in the PLANET Study A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; SHORT-TERM EFFICACY; MACULAR
   DEGENERATION; RANIBIZUMAB; COMBINATION
AB IMPORTANCE Polypoidal choroidal vasculopathy (PCV) is common in Asian populations, but an optimal treatment approach remains to be confirmed.
   OBJECTIVE To evaluate intravitreal aflibercept injection (IAI) in participants with PCV and compare IAI monotherapy with IAI plus rescue photodynamic therapy (PDT).
   DESIGN, SETTING, AND PARTICIPANTS This 96-week, double-masked, sham-controlled phase 3b/4 randomized clinical trial was conducted at multiple centers in Australia, Germany, Hong Kong, Hungary, Japan, Singapore, South Korea, and Taiwan from May 2014 to August 2016, and included adults 50 years or older with symptomatic macular PCV and a best-corrected visual acuity of 73 to 24 Early Treatment Diabetic Retinopathy Study letters (20/40-20/320 Snellen equivalent).
   INTERVENTIONS Participants received 2mg of IAI at weeks 0, 4, and 8. At week 12, participants with a suboptimal response were randomized 1: 1 to receive IAI plus sham PDT (IAI monotherapy) or a "rescue" of IAI plus rescue PDT (IAI/PDT). Participants who did not qualify for rescue received IAI every 8 weeks; those qualifying for rescue received IAI every 4 weeks plus sham/active PDT. When the rescue criteria were no longer met, injection intervals were gradually extended to 8 weeks.
   MAIN OUTCOMES AND MEASURES Noninferiority of IAI monotherapy to IAI/PDT for mean change in best-corrected visual acuity from baseline to week 52 (95% CI of the difference entirely above -5 letters).
   RESULTS Of the 318 participants, the mean (SD) age was 70.6 (8.2) years, 96 (30.2%) were women, and 152 (47.8%) were Japanese. Monotherapy with IAI was noninferior to IAI/PDT for the primary end point (+10.7 vs + 10.8 letters, respectively; 95% CI, -2.9 to 1.6; P = .55), with few participants requiring rescue therapy (19 [12.1%] vs 23 [14.3%], respectively). Participants in both treatment groups had similar reductions in central subfield thickness from baseline to week 52 (-137.7 [IAI monotherapy] vs -143.5 mu m [IAI/PDT]). At week 52, 49 (38.9%) and 60 participants (44.8%) had no polypoidal lesions observed on indocyanine green angiography in the IAI monotherapy and IAI/PDT groups, respectively. Furthermore, 116 (81.7%) and 136 (88.9%), respectively, had no polypoidal lesions with leakage. The most frequent ocular adverse events were conjunctival hemorrhage (IAI monotherapy, 8 [5.1%]) and dry eye (IAI/PDT, 9 [5.6%]).
   CONCLUSIONS AND RELEVANCE Improvement in visual and/or functional outcomes was achieved in more than 85% of participants who were treated with IAI monotherapy, with no signs of leakage from polypoidal lesions in more than 80%. As fewer than 15% met the criteria of a suboptimal response to receive PDT, the potential benefit of adding PDT cannot be determined.
C1 [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Wong, Tien Yin; Cheung, Gemmy Chui Ming] Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin; Cheung, Gemmy Chui Ming] Natl Eye Ctr, Singapore, Singapore.
   [Wong, Tien Yin; Cheung, Gemmy Chui Ming] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Zhang, Zhongqi; Leal, Sergio] Bayer Pharmaceut, Berlin, Germany.
   [Ishibashi, Tatsuro] Kyushu Univ Hosp, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Tokyo Women's
   Medical University; Nagoya City University; National Yang Ming Chiao
   Tung University; Taipei Veterans General Hospital; National University
   of Singapore; Singapore National Eye Center; National University of
   Singapore; University of Sydney; Westmead Institute for Medical
   Research; Bayer AG; Bayer Healthcare Pharmaceuticals; Kyushu University
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Bayer
FX Funding was provided by Bayer for the overall study and medical writing
   and editorial assistance for this article.
CR Bayer, EYL PRESCR INF
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   CHAKRAVARTHY U, 2012, OPHTHALMOLOGY, V119
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Genentech, LUC PRESCR INF
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 130
Z9 134
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2018
VL 136
IS 7
BP 786
EP 793
DI 10.1001/jamaophthalmol.2018.1804
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM9GK
UT WOS:000438554300016
PM 29801063
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kansara, VS
   Muya, LW
   Ciulla, TA
AF Kansara, Viral S.
   Muya, Leroy W.
   Ciulla, Thomas A.
TI Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib
   Suspension Via Ocular and Systemic Disposition in Rabbits
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE suprachoroidal injection; receptor tyrosine kinase inhibitor; axitinib;
   VEGF; pharmacokinetics; AMD; intravitreal
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; DRUG-DELIVERY;
   CHOROIDAL NEOVASCULARIZATION; POSTERIOR SEGMENT; FACTOR THERAPY;
   IN-VITRO; RANIBIZUMAB; SPACE; INHIBITOR
AB Purpose: Axitinib, a tyrosine kinase inhibitor, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors -1, -2 and -3. Suprachoroidal (SC) delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti-VEGFA agents. This study evaluated the ocular pharmacokinetics and systemic disposition of axitinib after SC administration in rabbits.
   Methods: Rabbits received axitinib as either a single SC injection (0.03, 0.10, 1.00, or 4.00 mg/eye; n = 4/group) or a single intravitreal injection (1 mg/eye; n = 4/group) in three separate studies. Axitinib concentrations were measured in several ocular compartments and in plasma at predetermined timepoints for up to 91 days. The pharmacokinetics parameters were estimated by noncompartmental analysis.
   Results: A single SC injection of axitinib suspension (1 mg/eye) resulted in an 11-fold higher mean axitinib exposure in the posterior eye cup, comparedwith intravitreal injection. Sustained levels of axitinib in the retinal pigment epithelium-choroid-sclera (RCS) and retina were observed throughout the duration of studies after a single SC axitinib injection (0.1 and 4.0mg/eye), with lowexposure in the vitreous humor, aqueous humor, and plasma. Axitinib levels in the RCS were 3 to 5 log orders higher than the reported in vitro ( VEGF receptor-2 autophosphorylation inhibition) 50% inhibitory concentration value after 0.1 and 4.0 mg/eye dose levels throughout the 65-day and 91-day studies, respectively.
   Conclusions: This study demonstrates that SC axitinib suspension has a favorable pharmacokinetics profile with potential as a long-acting therapeutic candidate targeted to affected choroid and retinal pigment epithelium in neovascular age-related macular degeneration.
   Translational Relevance: Suprachoroidal axitinib suspension has potential to decrease the treatment burden in neovascular age-related macular degeneration, as a longacting therapeutic candidate, and could yield greater efficacy, as apotent tyrosine kinase pan-VEGF inhibitor, compared with current standard anti-VEGF-A therapies.
C1 [Kansara, Viral S.; Muya, Leroy W.; Ciulla, Thomas A.] Clearside Biomed Inc, 900 Northpoint Pkwy Suite 200, Alpharetta, GA 30005 USA.
RP Ciulla, TA (通讯作者)，Clearside Biomed Inc, 900 Northpoint Pkwy Suite 200, Alpharetta, GA 30005 USA.
EM thomas.ciulla@clearsidebio.com
CR Aamir Aziz, SUSTAINED RELEASE SU
   Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], GLOBENEWSWIRE
   Avery R., SAFETY EFFICACY OTX
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burke B, 2017, INVEST OPHTH VIS SCI, V58
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Chaney P., 2019, OPHTH INN SUMM OCT 1
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   ClinicalTrials.gov, 2008, OP LAB PIL STUD TG10
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dugel PU, 2019, RETIN TODAY, P21
   Edelhauser H, 2013, INVEST OPHTH VIS SCI, V54
   Einmahl S, 2002, INVEST OPHTH VIS SCI, V43, P1533
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Gilger BC, 2006, INVEST OPHTH VIS SCI, V47, P2596, DOI 10.1167/iovs.05-1540
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Jung JH, 2018, INVEST OPHTH VIS SCI, V59, P2069, DOI 10.1167/iovs.17-23758
   Kaiser PK, 2020, INVEST OPHTH VIS SCI, V61
   Kane FE, 2015, J OCUL PHARMACOL TH, V31, P11, DOI 10.1089/jop.2014.0100
   Kang S, 2013, CURR EYE RES, V38, P119, DOI 10.3109/02713683.2012.727520
   Kansara VS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.13.21
   Kernt M, 2012, GROWTH FACTORS, V30, P49, DOI 10.3109/08977194.2011.639300
   Kim HM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.7
   Kim SH, 2007, INVEST OPHTH VIS SCI, V48, P808, DOI 10.1167/iovs.06-0670
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Riquelme M, 2018, CLIN EXP OPHTHALMOL, V46, P1063, DOI 10.1111/ceo.13333
   MacCumberM, 2021, VIRT ANN MAC SOC M F
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Modern Retina, 2016, TOP TREATM NEOV AMD
   Nakano A, 2016, EXP EYE RES, V143, P120, DOI 10.1016/j.exer.2015.10.016
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Opthea Limited, OPT 302 PHAS 2B WET
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Pfizer Labs I, INL PACK INS
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shi S, 2019, INT J PHARMACEUT, V560, P19, DOI 10.1016/j.ijpharm.2019.01.051
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Thiele S, 2013, KLIN MONATSBL AUGENH, V230, P247, DOI 10.1055/s-0032-1328161
   Wan CR, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.27
   Wong WL, 2014, LANCET GLOB HLTH, V2
   Yeh S, 2020, OPHTHALMOLOGY, V127, P948, DOI 10.1016/j.ophtha.2020.01.006
   Yuan XY, 2015, ACS NANO, V9, P1749, DOI 10.1021/nn506599f
NR 59
TC 4
Z9 4
U1 3
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2021
VL 10
IS 7
AR 19
DI 10.1167/tvst.10.7.19
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TD3KJ
UT WOS:000669229500012
PM 34128964
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Meyer, RD
   Sacks, DB
   Rahimi, N
AF Meyer, Rosana D.
   Sacks, David B.
   Rahimi, Nader
TI IQGAP1-Dependent Signaling Pathway Regulates Endothelial Cell
   Proliferation and Angiogenesis
SO PLOS ONE
LA English
DT Article
AB Background: Vascular endothelial growth factor receptor-2 (VEGFR-2) signaling is an obligate requirement for normal development and pathological angiogenesis such as cancer and age-related macular degeneration. Although autophosphorylation of tyrosine 1173 (Y1173) of VEGFR-2 is considered a focal point for its angiogenic signal relay, however, the mechanism of phosphorylation of Y1173, signaling proteins that are recruited to this residue and their role in angiogenesis is not fully understood.
   Methodology/Principal Findings: In this study we demonstrate that c-Src kinase directly through its Src homology 2 (SH2) domain and indirectly via c-Cbl binds to phospho-Y1057 of VEGFR-2. Activation of c-Src kinase by a positive feedback mechanism phosphorylates VEGFR-2 at multi-docking site, Y1173. c-Src also catalyzes tyrosine phosphorylation of IQGAP1 and acts as an adaptor to bridge IQGAP1 to VEGFR-2. In turn, IQGAP1 activates b-Raf and mediates proliferation of endothelial cells. Silencing expression of IQGAP1 and b-Raf revealed that their activity is essential for VEGF to stimulate angiogenesis in an in vivo angiogenesis model of chicken chorioallantoic membrane (CAM).
   Conclusions/Significance: Angiogenesis contributes to the pathology of numerous human diseases ranging from cancer to age-related macular degeneration. Determining molecular mechanism of tyrosine phosphorylation of VEGFR-2 and identification of molecules that are relaying its angiogenic signaling may identify novel targets for therapeutic intervention against angiogenesis-associated diseases. Our study shows that recruitment and activation of c-Src by VEGFR-2 plays a pivotal role in relaying angiogenic signaling of VEGFR-2; it phosphorylates VEGFR-2 at Y1173, facilitates association and activation of IQGAP1 and other signaling proteins to VEGFR-2. IQGAP1-dependent signaling, in part, is critically required for endothelial cell proliferation, a key step in angiogenesis. Thus, Y1057 of VEGFR-2 serves to regulate VEGFR-2 function in a combinatorial manner by supporting both diversity of recruitment of angiogenic signaling proteins to VEGFR-2, and its ability to promote angiogenesis.
C1 [Meyer, Rosana D.; Rahimi, Nader] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA.
   [Sacks, David B.] Harvard Univ, Sch Med, Boston, MA USA.
   [Sacks, David B.] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA.
C3 Boston University; Harvard University; Harvard Medical School; Harvard
   University; Brigham & Women's Hospital
RP Meyer, RD (通讯作者)，Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA.
EM nrahimi@bu.edu
OI Sacks, David/0000-0003-3100-0735; Rahimi, Nader/0000-0002-6745-1725
FU National Institutes of Health; Massachusetts Lions Foundation
FX This study was supported in part by grants from the National Institutes
   of Health (NR and DBS) and Massachusetts Lions Foundation grant to the
   Department of Ophthalmology.
CR Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015
   Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100
   Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200
   Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442
   Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459
   MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0
   Meyer RD, 2004, ONCOGENE, V23, P5523, DOI 10.1038/sj.onc.1207712
   Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200
   Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200
   Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781
   Ren JG, 2007, P NATL ACAD SCI USA, V104, P10465, DOI 10.1073/pnas.0611308104
   Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200
   Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102
   Sanjay A, 2006, FEBS J, V273, P5442, DOI 10.1111/j.1742-4658.2006.05535.x
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Singh AJ, 2005, MOL BIOL CELL, V16, P2106, DOI 10.1091/mbc.E04-08-0749
   Singh AJ, 2007, P NATL ACAD SCI USA, V104, P5413, DOI 10.1073/pnas.0700809104
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
   Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200
NR 33
TC 72
Z9 77
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2008
VL 3
IS 12
AR e3848
DI 10.1371/journal.pone.0003848
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 436YN
UT WOS:000265452100007
PM 19050761
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Ishiko, S
   van de Velde, F
   Yoshida, A
AF Ishiko, Satoshi
   van de Velde, Frans
   Yoshida, Akitoshi
TI Paradoxical Improvement of Visual Acuity in Macular Disease
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Microperimetry; Scanning laser ophthalmoscope; Macular disease;
   Preferred retinal locus of fixation; Scotoma
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SCANNING LASER OPHTHALMOSCOPY;
   THERAPY; DEGENERATION
AB Purpose: Improvement in visual acuity is often considered the best indicator of the effectiveness of a treatment in age-related maculopathy. However, during the course of the disease, the location of the patients' preferred retinal locus of fixation may change. This can lead to an unexpected functional improvement, unrelated to treatment.
   Methods: From a running database of 1,369 retina patients, we identified 116 patients over 60 years of age when age-related maculopathy was diagnosed based on the following inclusion criteria: one study eye with an initial acuity of the logarithm of the minimum angle of resolution (logMAR) 0.7 or worse, a fellow eye with central fixation and a follow-up period of 3 years or more with precise documentation of the preferred retinal locus of fixation and scotoma distribution for both eyes using scanning laser ophthalmoscopy-based microperimetry.
   Results: We expected an improvement in the visual acuity in one eye (study eye) without the possibility of improvement due to previous or concurrent treatment in that eye. Twelve patients met the selection criteria. Over time, these patients had significant improvements in the visual acuity in the weaker study eye, characteristically accompanied by a concurrent decrease in visual acuity in the other eye, which initially had better visual acuity. Moreover, in all the study eyes, an unstable pseudo-central von Noorden fixation pattern evolved into a more stable eccentric preferred retinal locus.
   Conclusions: Visual acuity remains the gold standard for assessing visual functioning in age-related maculopathy when interpreted with caution. Improvements in visual acuity can occur solely due to the course of the disease in the other eye and as a result of its impact on binocular fixation characteristics. This finding has significant implications for low-vision rehabilitation and evaluation of various therapies in large long-term clinical studies.
C1 [Ishiko, Satoshi; Yoshida, Akitoshi] Asahikawa Med Coll, Dept Ophthalmol, Asahikawa, Hokkaido 0788510, Japan.
   [van de Velde, Frans] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
   [van de Velde, Frans] Univ Antwerp Hosp, Dept Ophthalmol, Antwerp, Belgium.
C3 Asahikawa Medical College; Harvard University; Harvard Medical School;
   Schepens Eye Research Institute; University of Antwerp
RP Ishiko, S (通讯作者)，Asahikawa Med Coll, Dept Ophthalmol, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.
EM ishiko@asahikawa-med.ac.jp
CR Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Ludvigh E, 1941, AM J OPHTHALMOL, V24, P303, DOI [10.1016/S0002-9394(41)90648-7, DOI 10.1016/S0002-9394(41)90648-7]
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAINSTER MA, 1982, OPHTHALMOLOGY, V89, P852, DOI 10.1016/s0161-6420(82)34714-4
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   PLESCH A, 1989, P SOC PHOTO-OPT INS, V1161, P390
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   TIMBERLAKE GT, 1989, LASERS LIGHT OPHTHAL, V2, P211
   VandeVelde FJ, 1996, PROC SPIE, V2930, P79, DOI 10.1117/12.260859
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Wertheim T., 1894, Z PSYCHOL, V7, P172
NR 23
TC 9
Z9 10
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL
PY 2010
VL 35
IS 7
BP 651
EP 656
DI 10.3109/02713681003707235
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 663OU
UT WOS:000282898000012
PM 20597651
DA 2022-11-30
ER

PT J
AU Choudhary, M
   Tayyari, F
   Handa, JT
   Malek, G
AF Choudhary, Mayur
   Tayyari, Faryan
   Handa, James T.
   Malek, Goldis
TI Characterization and identification of measurable endpoints in a mouse
   model featuring age-related retinal pathologies: a platform to test
   therapies
SO LABORATORY INVESTIGATION
LA English
DT Article
ID MACULAR DEGENERATION; APOLIPOPROTEIN-E; PIGMENT EPITHELIUM; CHOROIDAL
   NEOVASCULARIZATION; SODIUM IODATE; RD8 MUTATION; MICE; DRUSEN; CELLS;
   ACCUMULATION
AB Apolipoprotein B100 (apoB100) is the structural protein of cholesterol carriers including low-density lipoproteins. It is a constituent of sub-retinal pigment epithelial (sub-RPE) deposits and pro-atherogenic plaques, hallmarks of early dry age-related macular degeneration (AMD), an ocular neurodegenerative blinding disease, and cardiovascular disease, respectively. Herein, we characterized the retinal pathology of transgenic mice expressing mouse apoB100 in order to catalog their functional and morphological ocular phenotypes as a function of age and establish measurable endpoints for their use as a mouse model to test potential therapies. ApoB100 mice were found to exhibit an age-related decline in retinal function, as measured by electroretinogram (ERG) recordings of their scotopic a-wave, scotopic b-wave; and c-wave amplitudes. ApoB100 mice also displayed a buildup of the cholesterol carrier, apolipoprotein E (apoE) within and below the supporting extracellular matrix, Bruch's membrane (BrM), along with BrM thickening, and accumulation of thin diffuse electron-dense sub-RPE deposits, the severity of which increased with age. Moreover, the combination of apoB100 and advanced age were found to be associated with RPE morphological changes and the presence of sub-retinal immune cells as visualized in RPE-choroid flatmounts. Finally, aged apoB100 mice showed higher levels of circulating and ocular pro-inflammatory cytokines, supporting a link between age and increased local and systemic inflammation. Collectively, the data support the use of aged apoB100 mice as a platform to evaluate potential therapies for retinal degeneration, specifically drugs intended to target removal of lipids from Bruch's membrane and/or alleviate ocular inflammation.
   Apolipoprotein B100 (apoB100) is the structural protein of several of the lipoprotein cholesterol carriers and accumulates in extracellular deposits in the systemic disease atherosclerosis, and the neurodegenerative blinding disease, age-related macular degeneration. Herein, the authors characterized the retinal pathology of transgenic mice expressing mouse apoB100, in order to catalog their functional and morphological ocular phenotypes, as a function of age, and establish measurable endpoints for their use as a pre-clinical mouse model to test potential therapies.
C1 [Choudhary, Mayur; Tayyari, Faryan; Malek, Goldis] Duke Univ, Dept Ophthalmol, Sch Med, Durham, NC 27710 USA.
   [Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
C3 Duke University; Johns Hopkins University; Johns Hopkins Medicine; Duke
   University
RP Malek, G (通讯作者)，Duke Univ, Dept Ophthalmol, Sch Med, Durham, NC 27710 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
EM gmalek@duke.edu
FU National Eye Institute [EY027802, EY028160, EY032751, EY027691, P30
   EY005722]; Research to Prevent Blindness, Inc (RPB) Core grant (Duke Eye
   Center); RPB grant (Wilmer Eye Institute)
FX This research was supported by funding from the National Eye Institute:
   EY027802 (G. M.), EY028160 (G.M.), EY032751 (G.M.), EY027691 (J.T.H.),
   P30 EY005722 (Duke Eye Center), a Research to Prevent Blindness, Inc
   (RPB) Core grant (Duke Eye Center), and an unrestricted RPB grant
   (Wilmer Eye Institute).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552
   Cai SW, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165604
   Cao X, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144469
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Choudhary M, 2016, J BIOMOL SCREEN, V21, P1007, DOI 10.1177/1087057116659856
   Claybon A, 2011, JOVE-J VIS EXP, DOI 10.3791/2563
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Gomez JM, 2004, GROWTH HORM IGF RES, V14, P91, DOI 10.1016/j.ghir.2003.11.004
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huh HY, 1996, BLOOD, V87, P2020
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kaplan RC, 2007, J CLIN ENDOCR METAB, V92, P1319, DOI 10.1210/jc.2006-1631
   Kielczewski JL, 2011, AM J PATHOL, V178, P1517, DOI 10.1016/j.ajpath.2010.12.031
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853
   Kretschmer F, 2017, J NEUROPHYSIOL, V118, P300, DOI 10.1152/jn.00055.2017
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lu CK, 2005, AM J OPHTHALMOL, V139, P1142, DOI 10.1016/j.ajo.2004.12.021
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malek G., 2020, DRUG DELIVERY CHALLE, DOI [10.1007/7355_2020_93 83-123, DOI 10.1007/7355_2020_9383-123]
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   OYSTER CW, 1972, VISION RES, V12, P183, DOI 10.1016/0042-6989(72)90110-1
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Reis A, 2014, DIABETES, V63, P3926, DOI 10.2337/db13-1673
   Reisenhofer MH, 2017, CURR MOL MED, V17, P100, DOI 10.2174/1566524017666170331162048
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Sahu B, 2015, MOL VIS, V21, P273
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Yonehara K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001533
NR 71
TC 0
Z9 0
U1 2
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD OCT
PY 2022
VL 102
IS 10
BP 1132
EP 1142
DI 10.1038/s41374-022-00795-7
EA MAY 2022
PG 11
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 4W1XK
UT WOS:000797765400001
PM 35589984
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Spaide, RF
   Curcio, CA
   Malek, G
   Imamura, Y
AF Zweifel, Sandrine A.
   Spaide, Richard F.
   Curcio, Christine A.
   Malek, Goldis
   Imamura, Yutaka
TI Reticular Pseudodrusen Are Subretinal Drusenoid Deposits
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; DOCOSAHEXAENOIC ACID; MACULAR DEGENERATION;
   BASAL DEPOSITS; CELLS; EYES; AUTOFLUORESCENCE; CHOLESTEROL; METABOLISM;
   TURNOVER
AB Purpose: To characterize reticular pseudodrusen, a potential risk factor for late age-related macular degeneration.
   Design: Retrospective, observational case series.
   Participants: Fifty-eight eyes of 33 patients with pseudodrusen (20 female).
   Methods: Consecutive patients with reticular pseudodrusen, diagnosed by their typical appearance and distribution using ophthalmoscopy, the blue channel of color fundus photographs, and near infrared images. The patients were imaged by spectral domain optical coherence tomography (SD OCT), and correlations were made between the near infrared images and the SD OCT images. The SD OCT findings in patients with pseudodrusen were compared with previously reported histologic findings of subretinal drusenoid deposits. The histologic specimens were reevaluated with the additional knowledge of the clinical information.
   Main Outcome Measures: Spectral domain optical coherence tomography and histologic characteristics of pseudodrusen.
   Results: The mean age of the 33 patients was 81.7 years. The correlating SD OCT scans showed collections of granular hyperreflective material above the retinal pigment epithelium (RPE), in the subretinal space located primarily between the RPE and the boundary between the inner and outer segments of the photoreceptors (IS/OS boundary). In a more advanced stage, this material formed small mounds that broke through the IS/OS boundary. There were no correlates to the deposits seen under the RPE or in the choroid. These findings were similar in character to previously reported histologic characterization of subretinal drusenoid deposits, which had identified the presence of membranous debris, unesterified cholesterol, and complement within the deposits.
   Conclusions: Pseudodrusen seen by clinical examination may be subretinal drusenoid deposits seen by histologic examination. This unexpected location suggests that potential pathophysiologic mechanisms on both sides of the RPE need to be taken into account in theories related to the development of age-related macular degeneration.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 303-312 (C) 2010 by the American Academy of Ophthalmology.
C1 [Zweifel, Sandrine A.; Spaide, Richard F.; Imamura, Yutaka] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Zweifel, Sandrine A.; Imamura, Yutaka] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Callahan Eye Fdn Hosp, Sch Med, Birmingham, AL 35294 USA.
   [Malek, Goldis] Duke Univ, Dept Ophthalmol & Pathol, Durham, NC USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of Alabama System; University of Alabama
   Birmingham; Duke University
RP Spaide, RF (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@yahoo.com
RI Zweifel, Sandrine/AAX-5045-2020; Spaide, Richard/ABD-7368-2020
OI Malek, Goldis/0000-0003-0026-2388
FU Macula Foundation, Inc.; Koureisha Ganshikkan Kenkyu Zaidan; Mishima
   Saiichikinen Gankakenkyu Kokusaikouryu Kikin; Takeda Kagaku Shinkou
   Zaidan
FX Supported in part by The Macula Foundation, Inc. Dr. Imamura was funded
   by grants from Koureisha Ganshikkan Kenkyu Zaidan, Mishima Saiichikinen
   Gankakenkyu Kokusaikouryu Kikin, and Takeda Kagaku Shinkou Zaidan.
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   CHEN HM, 1993, EXP EYE RES, V57, P369, DOI 10.1006/exer.1993.1136
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   JACQUES SL, 1991, PHOTOCHEM PHOTOBIOL, V53, P769, DOI 10.1111/j.1751-1097.1991.tb09891.x
   Kezic J, 2008, J LEUKOCYTE BIOL, V84, P721, DOI 10.1189/jlb.0308166
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
NR 30
TC 309
Z9 318
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2010
VL 117
IS 2
BP 303
EP U139
DI 10.1016/j.ophtha.2009.07.014
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555RB
UT WOS:000274530300017
PM 19815280
DA 2022-11-30
ER

PT J
AU Keam, SJ
   Scott, LJ
   Curran, MP
AF Keam, SJ
   Scott, LJ
   Curran, MP
TI Spotlight on verteporfin in subfoveal choroidal neovascularisation
SO DRUGS & AGING
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; MOUSE-TUMOR MODEL; REPORT NO. 1; RING-A BPD;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; PATHOLOGICAL MYOPIA; HUMAN
   EYES; BENZOPORPHYRIN; TAP
AB Verteporfin (Visudyne(R)) therapy (photodynamic therapy with intravenous liposomal verteporfin) is the first treatment to effectively prevent the loss of visual acuity in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD), pathological myopia or presumed ocular histoplasmosis syndrome (POHS).
   In adult patients with classic subfoveal CNV or occult with no classic subfoveal CNV secondary to AMD, or subfoveal CNV secondary to pathological myopia or POHS, verteporfin therapy slows or prevents loss of visual acuity. In well designed clinical trials, verteporfin therapy was superior to placebo in patients with subfoveal classic-containing CNV and occult with no classic CNV secondary to AMD at 12 and/or 24 months (Treatment of Age-related macular degeneration with Photodynamic therapy [TAP] Investigation and Verteporfin In Photodynamic therapy [VIP-AMD] trial) and in patients with pathological myopia at 12 months (Verteporfin In Photodynamic therapy [VIP-PM] trial). Limited data suggest that verteporfin therapy also prevents loss of visual acuity in patients with subfoveal CNV secondary to POHS.
   Verteporfin therapy was generally well tolerated in clinical trials; most adverse events were mild to moderate in intensity and transient. The most frequently reported verteporfin therapy-related adverse events (incidence >2%) were visual disturbance, injection-site reactions, photosensitivity reactions and infusion-related back pain. Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss.
   Conclusion: Photodynamic therapy with verteporfin, the first photosensitiser approved for the treatment of subfoveal CNV, is a well tolerated treatment that stabilises or slows visual acuity loss in adult patients with predominantly classic or occult with no classic subfoveal CNV secondary to AMD, and subfoveal CNV secondary to pathological myopia or POHS. Thus, verteporfin therapy provides a valuable option for the management of these patients for whom treatment options are few, and should be considered as a first-line therapy in these difficult-to-manage conditions.
C1 Adis Int Ltd, Auckland 1311, New Zealand.
C3 Adis International
RP Keam, SJ (通讯作者)，Adis Int Ltd, 41 Centorian Dr,Private Bag 65901, Auckland 1311, New Zealand.
EM demail@adis.co.nz
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   BEAUMONT P, 2002, RET 2002 C SEP 28 OC
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHEN JC, 2002, INVEST OPHTH VIS SCI, V43, pE586
   *EMEA, SUMM PROD CHAR VIS O
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   KAISER PK, 2003, INVEST OPHTH VIS SCI, V44, pE1099
   Lees M, 2003, VALUE HEALTH, V6, P239, DOI 10.1016/S1098-3015(10)63950-2
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   POOLER JP, 1981, MED PHYS, V8, P614, DOI 10.1118/1.595020
   *QLT INC, COMM VIS APPR STAT
   *QLT INC, 2003, NEW CLIN DAT CONF RO
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1990, PHOTOCHEM PHOTOBIOL, V52, P495, DOI 10.1111/j.1751-1097.1990.tb01791.x
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   Rousset N, 2000, RES EXP MED, V199, P341, DOI 10.1007/s004339900044
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   SAPERSTEIN DA, 2002, INVEST OPHTH VIS SCI, V43, pE982
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   SINGERMAN LJ, 2002, RET 2002 C SEP 28 OC
   SMITH DH, 2002, VALUE HEALTH, V5, P247
   SMITH DH, MODELLING LONG TERM
   WORMALD R, 2003, COCHRANE LIB DATABAS
   2000, PHARM J, V265, P213
   2001, PINK SHEET, V63, P18
NR 46
TC 6
Z9 7
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2004
VL 21
IS 3
BP 203
EP 209
DI 10.2165/00002512-200421030-00005
PG 7
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 802YA
UT WOS:000220197600006
PM 14979737
DA 2022-11-30
ER

PT J
AU Liu, JH
   Yang, L
   Wang, XR
   Wang, SB
   Huang, ZQ
   Li, CY
   Liu, Y
   Cheng, YQ
   Liu, CX
   Wang, ZC
AF Liu, Jiahui
   Yang, Liu
   Wang, Xiaoran
   Wang, Shoubi
   Huang, Zheqian
   Li, Chaoyang
   Liu, Ying
   Cheng, Yaqi
   Liu, Chengxiu
   Wang, Zhichong
TI Embryonic stem cell microenvironment enhances proliferation of human
   retinal pigment epithelium cells by activating the PI3K signaling
   pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Embryonic stem cell microenvironment; Proliferation; PI3K pathway;
   Regenerative medicine
ID MACULAR DEGENERATION; RPE MONOLAYERS; AGE; DIFFERENTIATION; PREVALENCE;
   APOPTOSIS; CAPACITY; SURVIVAL; PERIOD
AB BackgroundRetinal pigment epithelium (RPE) replacement has been proposed as an efficacious treatment for age-related macular degeneration (AMD), which is the primary cause of vision loss in the elderly worldwide. The embryonic stem cell (ESC) microenvironment has been demonstrated to enable mature cells to gain a powerful proliferative ability and even enhance the stem/progenitor phenotype via activation of the phosphoinositide 3-kinase (PI3K) signaling pathway. As the PI3K signaling pathway plays a pivotal role in proliferation and homeostasis of RPE, we hypothesize that the stemness and proliferative capability of RPE can be enhanced by the ESC microenvironment via activation of the PI3K signaling pathway.MethodsTo investigate whether the ESC microenvironment improves the stem cell phenotype and proliferation properties of human RPE (hRPE) cells by regulating the PI3K signaling pathway, primary hRPE cells were cocultured with either ESCs or human corneal epithelial cells (CECs) for 72h, after which their proliferation, apoptosis, cell cycle progression, and colony formation were assayed to evaluate changes in their biological characteristics. Gene expression was detected by real-time PCR and protein levels were determined by western blotting or immunofluorescence. LY294002, an antagonist of the PI3K signaling pathway, was used to further confirm the mechanism involved.ResultsIn comparison to hRPE cells cultured alone, hRPE cells cocultured with ESCs had an increased proliferative capacity, reduced apoptotic rate, and higher colony-forming efficiency. The expression of the stem cell-associated marker KLF4 and the differentiation marker CRALBP increased and decreased, respectively, in hRPE cells isolated from the ESC coculture. Furthermore, PI3K pathway-related genes were significantly upregulated in hRPE cells after exposure to ESCs. LY294002 reversed the pro-proliferative effect of ESCs on hRPE cells. In contrast, CECs did not share the ability of ESCs to influence the biological behavior and gene expression of hRPE cells.ConclusionsOur findings indicate that the ESC microenvironment enhances stemness and proliferation of hRPE cells, partially via activation of the PI3K signaling pathway. This study may have a significant impact and clinical implication on cell therapy in regenerative medicine, specifically for age-related macular degeneration.
C1 [Liu, Jiahui] Southern Med Univ, Affiliated Dongguan Peoples Hosp, Dongguan, Peoples R China.
   [Yang, Liu; Wang, Xiaoran; Wang, Shoubi; Huang, Zheqian; Li, Chaoyang; Liu, Ying; Cheng, Yaqi; Wang, Zhichong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
   [Liu, Chengxiu] Qingdao Univ, Coll Med, Affiliated Hosp, Qingdao, Peoples R China.
C3 Southern Medical University - China; Sun Yat Sen University; Qingdao
   University
RP Wang, ZC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
EM wangzhichong@gzzoc.com
RI Li, Chao/GSM-8117-2022
OI Li, Chao/0000-0001-6110-6210
FU National Key R&D program of China [2018YFC1106000]; Guangdong Basic and
   Applied Basic Research Foundation [2019A1515110618]
FX This work was supported by The National Key R&D program of China
   (2018YFC1106000) and Guangdong Basic and Applied Basic Research
   Foundation (2019A1515110618).
CR Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262
   Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447
   Chou YF, 2008, CELL, V135, P449, DOI 10.1016/j.cell.2008.08.035
   Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660
   Conboy IM, 2011, AGING-US, V3, P555, DOI 10.18632/aging.100333
   Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Enomoto K, 2006, INVEST OPHTH VIS SCI, V47, P4330, DOI 10.1167/iovs.05-1581
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Guo Y, 2006, STEM CELLS, V24, P850, DOI 10.1634/stemcells.2005-0457
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Huang C, 2012, J CELL BIOCHEM, V113, P590, DOI 10.1002/jcb.23383
   Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601
   Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092
   Lea IA, 2007, CARCINOGENESIS, V28, P1851, DOI 10.1093/carcin/bgm176
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Liu JH, 2019, THERANOSTICS, V9, P4764, DOI 10.7150/thno.33139
   Liu JB, 2007, EXP EYE RES, V84, P599, DOI 10.1016/j.exer.2006.11.014
   Liu Y, 2010, TISSUE ENG PART C-ME, V16, P793, DOI [10.1089/ten.tec.2009.0380, 10.1089/ten.TEC.2009.0380]
   Liu ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053576
   Lu XY, 2010, MOL VIS, V16, P611
   Mariotti C, 2015, CELL TISSUE RES, V362, P21, DOI 10.1007/s00441-015-2185-9
   Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366
   Ozmert E, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1549-6
   Park H, 2007, TISSUE ENG, V13, P1867, DOI 10.1089/ten.2006.0198
   Parrales A, 2011, BBA-MOL CELL RES, V1813, P1758, DOI 10.1016/j.bbamcr.2011.06.009
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Qin M, 2005, STEM CELLS, V23, P712, DOI 10.1634/stemcells.2004-0195
   Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226
   Saini JS, 2016, ADV EXP MED BIOL, V854, P557, DOI 10.1007/978-3-319-17121-0_74
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sands RW, 2007, CURR OPIN BIOTECH, V18, P448, DOI 10.1016/j.copbio.2007.10.004
   Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241
   Singla DK, 2008, AM J PHYSIOL-HEART C, V295, pH907, DOI 10.1152/ajpheart.00279.2008
   Soni DV, 2008, CELL CYCLE, V7, P1285, DOI 10.4161/cc.7.9.5711
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Y, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-144
   Yousef H, 2014, AGING-US, V6, P602, DOI 10.18632/aging.100659
   Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2
   Zhou CJ, 2014, STEM CELLS DEV, V23, P1741, DOI 10.1089/scd.2013.0585
   Zhou J, 2011, INT J BIOCHEM CELL B, V43, P1168, DOI 10.1016/j.biocel.2011.04.010
NR 61
TC 2
Z9 2
U1 2
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 23
PY 2020
VL 11
IS 1
AR 411
DI 10.1186/s13287-020-01923-0
PG 12
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NV9RL
UT WOS:000574648900004
PM 32967731
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Li, YF
   Song, DL
   Song, Y
   Zhao, LL
   Wolkow, N
   Tobias, JW
   Song, WC
   Dunaief, JL
AF Li, Yafeng
   Song, Delu
   Song, Ying
   Zhao, Liangliang
   Wolkow, Natalie
   Tobias, John W.
   Song, Wenchao
   Dunaief, Joshua L.
TI Iron-induced Local Complement Component 3 (C3) Up-regulation via
   Non-canonical Transforming Growth Factor (TGF)- Signaling in the Retinal
   Pigment Epithelium
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE CCAAT; Enhancer-binding Protein (C; EBP); Extracellular Signal-regulated
   Kinase (ERK); Iron; Signaling; Transforming Growth Factor (TGF-); AMD;
   C3; RPE; SMAD3
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; OXIDATIVE STRESS; FACTOR-B;
   SMAD PROTEINS; KNOCKOUT MICE; ACTIVATION; CELLS; PHOSPHORYLATION; RISK
AB Background: Human age-related macular degeneration (AMD) retinas exhibit iron overload and localized C3 accumulation in the retinal pigment epithelium (RPE). Results: Iron induces C3 expression via ERK1/2, SMAD3, and CCAAT/enhancer-binding protein- (C/EBP-) in a non-canonical TGF- signaling pathway. Conclusion: An iron-mediated pathway leads to complement dysregulation, an etiologic feature of AMD. Significance: Regulating iron-induced C3 expression suggests a novel therapeutic approach for AMD.
   Dysregulation of iron homeostasis may be a pathogenic factor in age-related macular degeneration (AMD). Meanwhile, the formation of complement-containing deposits under the retinal pigment epithelial (RPE) cell layer is a pathognomonic feature of AMD. In this study, we investigated the molecular mechanisms by which complement component 3 (C3), a central protein in the complement cascade, is up-regulated by iron in RPE cells. Modulation of TGF- signaling, involving ERK1/2, SMAD3, and CCAAT/enhancer-binding protein-, is responsible for iron-induced C3 expression. The differential effects of spatially distinct SMAD3 phosphorylation sites at the linker region and at the C terminus determined the up-regulation of C3. Pharmacologic inhibition of either ERK1/2 or SMAD3 phosphorylation decreased iron-induced C3 expression levels. Knockdown of SMAD3 blocked the iron-induced up-regulation and nuclear accumulation of CCAAT/enhancer-binding protein-, a transcription factor that has been shown previously to bind the basic leucine zipper 1 domain in the C3 promoter. We show herein that mutation of this domain reduced iron-induced C3 promoter activity. In vivo studies support our in vitro finding of iron-induced C3 up-regulation. Mice with a mosaic pattern of RPE-specific iron overload demonstrated co-localization of iron-induced ferritin and C3d deposits. Humans with aceruloplasminemia causing RPE iron overload had increased RPE C3d deposition. The molecular events in the iron-C3 pathway represent therapeutic targets for AMD or other diseases exacerbated by iron-induced local complement dysregulation.
C1 [Li, Yafeng; Song, Delu; Song, Ying; Zhao, Liangliang; Wolkow, Natalie; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Tobias, John W.] Univ Penn, Penn Mol Profiling Facil, Philadelphia, PA 19104 USA.
   [Song, Wenchao] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, Scheie Eye Inst, Perelman Sch Med, Dept Ophthalmol,Stellar Chance Labs 305B, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
RI Regan, Clinton/E-6250-2012
OI Wolkow, Natalie/0000-0003-1524-115X
FU National Institutes of Health [R01EY015240, R01EY023709, T32EY007035];
   Research to Prevent Blindness; Beckman Institute for Macular Research;
   Paul and Evanina Bell Mackall Foundation Trust; F. M. Kirby Foundation;
   NATIONAL EYE INSTITUTE [T32EY007035, P30EY001583, R01EY023709,
   R01EY015240] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01EY015240 (to J. L. D.), R01EY023709 (to W. S.), and
   T32EY007035, a vision science training grant (to the University of
   Pennsylvania). This work was also supported by Research to Prevent
   Blindness, The Beckman Institute for Macular Research, the Paul and
   Evanina Bell Mackall Foundation Trust, and the F. M. Kirby Foundation.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bae E, 2012, BIOCHEM BIOPH RES CO, V427, P593, DOI 10.1016/j.bbrc.2012.09.103
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feinberg MW, 2004, J BIOL CHEM, V279, P16388, DOI 10.1074/jbc.M309664200
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   FLINT DH, 1993, J BIOL CHEM, V268, P22369
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.3.2
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hough C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042513
   Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084
   Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584
   Kamato D, 2014, J PHARM PHARMACOL, V66, P1722, DOI 10.1111/jphp.12298
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOLB WP, 1989, COMPLEMENT INFLAMMAT, V6, P175, DOI 10.1159/000463093
   Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669
   Maranto J, 2008, J NEUROIMMUNE PHARM, V3, P43, DOI 10.1007/s11481-007-9096-9
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g
   Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010
   Munoz P, 2011, J BIOL CHEM, V286, P13382, DOI 10.1074/jbc.M110.213785
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Salvador GA, 2011, NEUROTOXICOLOGY, V32, P75, DOI 10.1016/j.neuro.2010.11.006
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Tarasewicz E, 2012, CELL CYCLE, V11, P2443, DOI 10.4161/cc.20546
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wang G., 2008, THESIS STATE U NEW J
   Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200
   WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181
   Wolkow N, 2012, AM J PATHOL, V180, P1614, DOI 10.1016/j.ajpath.2011.12.041
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 61
TC 25
Z9 25
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 8
PY 2015
VL 290
IS 19
BP 11918
EP 11934
DI 10.1074/jbc.M115.645903
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CH9XA
UT WOS:000354388600010
PM 25802332
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Banerjee, I
   de Sisternes, L
   Hallak, JA
   Leng, T
   Osborne, A
   Rosenfeld, PJ
   Gregori, G
   Durbin, M
   Rubin, D
AF Banerjee, Imon
   de Sisternes, Luis
   Hallak, Joelle A.
   Leng, Theodore
   Osborne, Aaron
   Rosenfeld, Philip J.
   Gregori, Giovanni
   Durbin, Mary
   Rubin, Daniel
TI Prediction of age-related macular degeneration disease using a
   sequential deep learning approach on longitudinal SD-OCT imaging
   biomarkers
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PREVALENCE; EYE
AB We propose a hybrid sequential prediction model called "Deep Sequence", integrating radiomics-engineered imaging features, demographic, and visual factors, with a recursive neural network (RNN) model in the same platform to predict the risk of exudation within a future time-frame in non-exudative AMD eyes. The proposed model provides scores associated with risk of exudation in the short term (within 3 months) and long term (within 21 months), handling challenges related to variability of OCT scan characteristics and the size of the training cohort. We used a retrospective clinical trial dataset that includes 671 AMD fellow eyes with 13,954 observations before any signs of exudation for training and validation in a tenfold cross validation setting. Deep Sequence achieved high performance for the prediction of exudation within 3 months (0.96 +/- 0.02 AUCROC) and within 21 months (0.97 +/- 0.02 AUCROC) on cross-validation. Training the proposed model on this clinical trial dataset and testing it on an external real-world clinical dataset showed high performance for the prediction within 3-months (0.82 AUCROC) but a clear decrease in performance for the prediction within 21-months (0.68 AUCROC). While performance differences at longer time intervals may be derived from dataset differences, we believe that the high performance and generalizability achieved in short-term predictions may have a high clinical impact allowing for optimal patient follow-up, adding the possibility of more frequent, detailed screening and tailored treatments for those patients with imminent risk of exudation.
C1 [Banerjee, Imon] Emory Univ, Dept Biomed Informat, Atlanta, GA 30322 USA.
   [Banerjee, Imon] Emory Univ, Dept Radiol, Atlanta, GA 30322 USA.
   [Rubin, Daniel] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [de Sisternes, Luis; Durbin, Mary] Carl Zeiss Meditec Inc, Dublin, CA 94568 USA.
   [Hallak, Joelle A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94303 USA.
   [Osborne, Aaron] Genentech Inc, San Francisco, CA 94080 USA.
   [Rosenfeld, Philip J.; Gregori, Giovanni] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Emory University; Emory University; Stanford University; Carl Zeiss AG;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Stanford University; Roche
   Holding; Genentech; Bascom Palmer Eye Institute; University of Miami
RP Banerjee, I (通讯作者)，Emory Univ, Dept Biomed Informat, Atlanta, GA 30322 USA.; Banerjee, I (通讯作者)，Emory Univ, Dept Radiol, Atlanta, GA 30322 USA.
EM imon.banerjee@emory.edu
RI ; Rubin, Daniel/E-3740-2010
OI Leng, Theodore/0000-0002-8461-3562; Banerjee, Imon/0000-0002-3327-8004;
   Rubin, Daniel/0000-0001-5057-4369
FU Genentech Inc.; BrightFocus Foundation; Research to Prevent Blindness;
   NIH [P30-EY026877]
FX This project was supported by a grant from Genentech Inc. and partially
   supported by BrightFocus Foundation Grant (JH, LG, DL, TL), Research to
   Prevent Blindness and NIH grant P30-EY026877.
CR Aurell S, 2019, ACTA OPHTHALMOL, V97, P519, DOI 10.1111/aos.13989
   Banerjee I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27946-5
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   BREIMAN L, 2001, MACH LEARN, V0045
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Cox DavidRoxbee., 1984, ANAL SURVIVAL DATA, DOI [10.1201/9781315137438/analysis-survival-data-cox-oakes, DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES]
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169
   Graves A, 2012, STUD COMPUT INTELL, V385, P1, DOI 10.1007/978-3-642-24797-2
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Meinshausen N, 2006, J MACH LEARN RES, V7, P983
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   van Assen M, 2020, J THORAC IMAG, V35, pS3, DOI 10.1097/RTI.0000000000000485
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 23
TC 15
Z9 15
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 22
PY 2020
VL 10
IS 1
AR 15434
DI 10.1038/s41598-020-72359-y
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NZ6LX
UT WOS:000577218500006
PM 32963300
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, JX
   Zhang, XY
   Li, G
   Xu, F
   Li, S
   Teng, LS
   Li, YX
   Sun, FY
AF Liu, Jiaxin
   Zhang, Xueyan
   Li, Ge
   Xu, Fei
   Li, Shuang
   Teng, Lesheng
   Li, Youxin
   Sun, Fengying
TI Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded
   PLGA Nanoparticles For Potential Intravitreal Applications
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE nanoparticles; dexamethasone; bevacizumab; anti-angiogenesis; VEGF
ID POLYMER HYBRID NANOPARTICLES; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; DRUG-DELIVERY; RANIBIZUMAB; INHIBITION; THERAPY; VEGF
AB Purpose: Age-related macular degeneration is a multifactorial disease involving inflammation and choroidal neovascularization. Vascular endothelial growth factor (VEGF) has been regarded as a potential therapeutic target to treat choroidal neovascularization. Dexamethasone can interfere with the expression or action of VEGF while bevacizumab targets and combines with VEGF. We propose electrostatically-conjugated bevacizumab-bearing dexamethasone-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine nanoparticles (eBev-DPPNs) for angiogenic combination treatment of ocular diseases.
   Methods: We prepared a novel nanoparticle composed of poly (D, L-lactide-co-glycolide) and polyethylenimine and loaded the nanoparticles with dexamethasone. Bevacizumab was adsorbed onto the surfaces of the nanoparticles by electrostatic interactions. The eBev-DPPNs were evaluated according to their size, polydispersity index, zeta potential, morphology, drug loading, release behavior, and stability. The structural stability of bevacizumab on the surface of the nanoparticles was also analyzed. Subsequently, angiogenesis was investigated in the presence of the eBev-DPPNs using cell apoptosis, wound healing, Transwell invasion, and tube formation assays on the human umbilical vein endothelial cells (HUVECs) in vitro and chick embryo chorioallantoic membrane assay in vivo. The eBev-DPPNs intravitreal injection was applied in the laser-induced rabbit choroidal neovascularization (CNV) model to confirm the role for potential intravitreal applications.
   Results: The eBev-DPPNs was about 200 nm in diameter, with a narrow diameter distribution, and the surface charge was neutral (0.85 +/- 0.37mV), which made the eBev-DPPNs stable under physiological conditions. The apoptosis, migration, invasion, and tube formation assays showed that the eBev-DPPNs had a good anti-angiogenic effect on HUVECs. The eBev-DPPNs also provided a strong inhibitory effect on VEGF secretion from HUVECs. Moreover, in vivo chick embryo chorioallantoic membrane assay showed eBev-DPPNs greatly reduced the amount of blood vessels. The leakage area of CNV decreased in the eBev-DPPNs group on rabbit CNV model.
   Conclusion: The eBev-DPPNs are a promising novel anti-angiogenesis therapeutic for potential intravitreal applications such as age-related macular degeneration.
C1 [Liu, Jiaxin; Zhang, Xueyan; Li, Ge; Xu, Fei; Li, Shuang; Teng, Lesheng; Li, Youxin; Sun, Fengying] Jilin Univ, Sch Life Sci, 2699 Qianjin St, Changchun 130012, Jilin, Peoples R China.
C3 Jilin University
RP Li, YX; Sun, FY (通讯作者)，Jilin Univ, Sch Life Sci, 2699 Qianjin St, Changchun 130012, Jilin, Peoples R China.
EM liyouxin@jlu.edu.cn; sunfengying@jlu.edu.cn
OI Teng, Lesheng/0000-0003-1623-5384; Liu, Jiaxin/0000-0002-8770-2093; Li,
   Shuang/0000-0001-9853-5035
FU Jilin Province Science and Technology Development Program
   [20180101269JC]; State Key Laboratory of LongActing and Targeting Drug
   Delivery System; Shandong Luye Pharmaceutical Co., Ltd.
FX This research was supported by the Jilin Province Science and Technology
   Development Program (No. 20180101269JC), and the State Key Laboratory of
   LongActing and Targeting Drug Delivery System, and Shandong Luye
   Pharmaceutical Co., Ltd.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barcia E, 2009, EXP EYE RES, V89, P238, DOI 10.1016/j.exer.2009.03.012
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan Linda W, 2003, Expert Rev Anticancer Ther, V3, P357, DOI 10.1586/14737140.3.3.357
   Fornaguera C, 2015, J CONTROL RELEASE, V211, P134, DOI 10.1016/j.jconrel.2015.06.002
   Garg NK, 2015, RSC ADV, V5, P62989, DOI 10.1039/c5ra12459j
   Gomez-Graete C, 2007, INT J PHARMACEUT, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   Gong CY, 2013, BIOMATERIALS, V34, P1413, DOI 10.1016/j.biomaterials.2012.10.068
   Hoffart L, 2010, CLIN EXP OPHTHALMOL, V38, P346, DOI 10.1111/j.1442-9071.2010.02252.x
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Kassumeh SA, 2018, CURR EYE RES, V43, P702, DOI 10.1080/02713683.2018.1437455
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Li ML, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-79
   Liu JX, 2019, INT J PHARMACEUT, V563, P228, DOI 10.1016/j.ijpharm.2019.04.012
   Liu L, 2013, AM J PATHOL, V182, P1412, DOI 10.1016/j.ajpath.2012.12.020
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Nimesh S., 2013, GENE THER, P197
   Olbrich C, 2001, J CONTROL RELEASE, V77, P345, DOI 10.1016/S0168-3659(01)00506-5
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Qi XP, 2012, INVEST OPHTH VIS SCI, V53, P574, DOI 10.1167/iovs.11-8728
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Shen J, 2014, INVEST OPHTH VIS SCI, V55, P1056, DOI 10.1167/iovs.13-13650
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Terelak-Borys B, 2016, THER CLIN RISK MANAG, V12, P1467, DOI 10.2147/TCRM.S110556
   Voravud Narin, 1999, Journal of the Medical Association of Thailand, V82, P394
   Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831
   Xie J, 2016, BIOTECHNOL ADV, V34, P343, DOI 10.1016/j.biotechadv.2016.04.002
   Xu JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   Yu KT, 2016, INT J PHARMACEUT, V497, P78, DOI 10.1016/j.ijpharm.2015.11.033
   Zakarija A, 2005, CURR OPIN ONCOL, V17, P578, DOI 10.1097/01.cco.0000183672.15133.ab
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhao JL, 2018, EUR J PHARM BIOPHARM, V130, P39, DOI 10.1016/j.ejpb.2018.06.020
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
NR 36
TC 20
Z9 20
U1 1
U2 43
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2019
VL 14
BP 8819
EP 8834
DI 10.2147/IJN.S217038
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA JL4BQ
UT WOS:000495476400001
PM 31819410
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Weigert, G
   Kaya, S
   Pemp, B
   Sacu, S
   Lasta, M
   Werkmeister, RM
   Dragostinoff, N
   Simader, C
   Garhofer, G
   Schmidt-Erfurth, U
   Schmetterer, L
AF Weigert, Guenther
   Kaya, Semira
   Pemp, Berthold
   Sacu, Stefan
   Lasta, Michael
   Werkmeister, Rene Marcel
   Dragostinoff, Nikolaus
   Simader, Christian
   Garhofer, Gerhard
   Schmidt-Erfurth, Ursula
   Schmetterer, Leopold
TI Effects of Lutein Supplementation on Macular Pigment Optical Density and
   Visual Acuity in Patients with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EYE DISEASE; VITAMIN-C; MACULOPATHY; CAROTENOIDS; ZEAXANTHIN;
   EPIDEMIOLOGY; POPULATION; ANCILLARY; PROGRESS; TRIAL
AB PURPOSE. There is evidence from several large-scale clinical trials that reduced intake of lutein, a major component of the macular pigment, is a risk factor for the development of AMD. In the present study (LISA; Lutein Intervention Study Austria) it was hypothesized that lutein supplementation increases macular pigment optical density (MPOD). In addition, an investigation was conducted into whether lutein supplementation improves visual acuity (VA) and macular function (mean differential light threshold; MDLT), as assessed with microperimetry.
   METHODS. One hundred twenty-six patients with AMD (AREDS [Age-related Eye Disease Study] stages 2, 3, and 4) were included in this randomized (2: 1), placebo-controlled, double-masked parallel group study. Lutein or placebo was administered for 6 months. MPOD was measured with a custom-built reflectometer. VA was assessed with ETDRS (Early Treatment Diabetic Retinopathy Study) charts, and MDLT was assessed with a microperimeter.
   RESULTS. Lutein significantly increased MPOD by 27.9% +/- 2.9% (P = 0.001 versus placebo). No significant effect of lutein supplementation on MDLT or VA was seen, although a tendency toward an increase was seen for both parameters (MDLT, P = 0.096 versus placebo; VA, P = 0.070 versus placebo). A significant correlation was found, however, between the increase in MPOD after 6 months and the increase in MDLT after 6 months (r = 0.25, P = 0.027), as well as between the increase in MPOD after 6 months and the increase in VA after 6 months (r = 0.27, P = 0.013).
   CONCLUSIONS. The present study demonstrates that lutein supplementation increases MPOD, as assessed with an objective method. The correlation between the change in MPOD and the change in VA and MDLT indicates that patients who show a pronounced increase in MPOD also benefit in terms of visual function. (ClinicalTrials.gov number, NCT00879671.) (Invest Ophthalmol Vis Sci. 2011; 52: 8174-8178) DOI:10.1167/iovs.11-7522
C1 [Kaya, Semira; Pemp, Berthold; Lasta, Michael; Garhofer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Weigert, Guenther; Pemp, Berthold; Sacu, Stefan; Simader, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Werkmeister, Rene Marcel; Dragostinoff, Nikolaus; Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
OI Dragostinoff, Nikolaus/0000-0001-9372-9084; Schmetterer,
   Leopold/0000-0002-7189-1707; Pemp, Berthold/0000-0002-0569-0229;
   Simader, Christian/0000-0002-1784-2883; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Pharmaselect, Vienna, Austria
FX Supported by Pharmaselect, Vienna, Austria.
CR Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Gellermann W, 2004, J BIOMED OPT, V9, P75, DOI 10.1117/1.1628240
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Ma L, 2009, BRIT J NUTR, V102, P186, DOI 10.1017/S0007114508163000
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Tan AG, 2008, OPHTHALMOLOGY, V115, P1693, DOI 10.1016/j.ophtha.2008.04.005
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Zagers NPA, 2002, APPL OPTICS, V41, P4686, DOI 10.1364/AO.41.004686
   Zeitz O, 2009, KLIN MONATSBL AUGENH, V226, P27, DOI 10.1055/s-2008-1027600
NR 37
TC 100
Z9 103
U1 0
U2 25
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2011
VL 52
IS 11
BP 8174
EP 8178
DI 10.1167/iovs.11-7522
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 834MY
UT WOS:000295966600051
PM 21873668
DA 2022-11-30
ER

PT J
AU Yu, Y
   Wagner, EK
   Souied, EH
   Seitsonen, S
   Immonen, IJ
   Happola, P
   Raychaudhuri, S
   Daly, MJ
   Seddon, JM
AF Yu, Yi
   Wagner, Erin K.
   Souied, Eric H.
   Seitsonen, Sanna
   Immonen, Ilkka J.
   Happola, Paavo
   Raychaudhuri, Soumya
   Daly, Mark J.
   Seddon, Johanna M.
TI Protective coding variants in CFH and PELI3 and a variant near CTRB1 are
   associated with age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; CARDIOVASCULAR
   RISK-FACTORS; RARE VARIANTS; GENETIC-VARIANTS; FACTOR-I; SUSCEPTIBILITY;
   GENOTYPE; LINKAGE; POLYMORPHISM
AB Although numerous common age-relatedmacular degeneration (AMD) alleles have been discovered using genome-wide association studies, substantial disease heritability remains unexplained. We sought to identify additional common and rare variants associated with advanced AMD. A total of 4,332 cases and 25,268 controls of European ancestry from three different populations were genotyped using the Illumina Infinium HumanExome BeadChip. We performed meta-analyses to identify associations with common variants, and single variant and gene-based burden tests to identify rare variants. Two protective, low-frequency, non-synonymous variants were significantly associated with a decrease in AMD risk: A307V in PELI3 (odds ratio [OR] = 0.14, P = 4.3 x 10(-10)) and N1050Y in CFH (OR = 0.76, P = 6.2 x 10(-12)). The new variants have a large effect size, similar to some rare mutations we reported previously in a targeted sequencing study, which remain significant in this analysis: CFH R1210C (OR = 18.82, P = 3.5 x 10(-07)), C3 K155Q (OR = 3.27, P = 1.5 x 10(-10)) and C9 P167S (OR = 2.04, P = 2.8 x 10(-07)). We also identified a strong protective signal for a common variant (rs8056814) near CTRB1 associated with a decrease in AMD risk (logistic regression: OR = 0.71, P = 1.8 x 10(-07)). Suggestive protective loci were identified in the COL4A3 and APOH genes. Our results support the involvement of common and low-frequency protective variants in this vision-threatening condition. This study expands the roles of the innate immune pathway as well as the extracellular matrix and high-density lipoprotein pathways in the aetiology of AMD.
C1 [Yu, Yi; Wagner, Erin K.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Wagner, Erin K.; Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Souied, Eric H.] Creteil Univ Paris Est, Hop Intercommunal, Hop Henri Mondor, Paris, France.
   [Seitsonen, Sanna; Immonen, Ilkka J.] Univ Helsinki, Eye Clin, Helsinki, Finland.
   [Happola, Paavo] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland.
   [Raychaudhuri, Soumya; Daly, Mark J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Raychaudhuri, Soumya; Daly, Mark J.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University; Assistance Publique Hopitaux
   Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital
   Universitaire Henri-Mondor - APHP; University of Helsinki; University of
   Helsinki; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Partners Healthcare System; Harvard University;
   Brigham & Women's Hospital; Harvard University; Brigham & Women's
   Hospital; University of Manchester; Harvard University; Massachusetts
   General Hospital; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752; Raychaudhuri,
   Soumya/0000-0002-1901-8265
FU National Institutes of Health, Bethesda, MD [R01-EY011309, 1R01AR063759,
   U19 AI111224-01]; Massachusetts Lions Eye Research Fund, Inc.; Research
   to Prevent Blindness, Inc., New York, NY; Doris Duke Charitable
   Foundation Grant [2013097]; Macular Degeneration Research Fund of the
   Ophthalmic Epidemiology and Genetics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine, Boston, MA;
   NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI111224]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASES [R01AR063759] Funding Source: NIH
   RePORTER
FX Components of this project were supported by the National Institutes of
   Health [R01-EY011309, 1R01AR063759, U19 AI111224-01], Bethesda, MD;
   Massachusetts Lions Eye Research Fund, Inc.; Unrestricted grants from
   Research to Prevent Blindness, Inc., New York, NY; Doris Duke Charitable
   Foundation Grant [#2013097]; and genotyping was funded by the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine, Boston, MA.
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Borodulin K, 2015, EUR J PUBLIC HEALTH, V25, P539, DOI 10.1093/eurpub/cku174
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379
   Dastani Z, 2010, EUR J HUM GENET, V18, P342, DOI 10.1038/ejhg.2009.157
   Di Domizio J, 2013, EXPERT REV CLIN IMMU, V9, P201, DOI [10.1586/eci.12.106, 10.1586/ECI.12.106]
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feng S, 2014, BIOINFORMATICS, V30, P2828, DOI 10.1093/bioinformatics/btu367
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldstein JI, 2012, BIOINFORMATICS, V28, P2543, DOI 10.1093/bioinformatics/bts479
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonsen A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3539
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2011, CELL, V147, P57, DOI 10.1016/j.cell.2011.09.011
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Siednienko J, 2012, NAT IMMUNOL, V13, P1055, DOI 10.1038/ni.2429
   Sklar P, 2008, MOL PSYCHIATR, V13, P558, DOI 10.1038/sj.mp.4002151
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vartiainen E, 2010, INT J EPIDEMIOL, V39, P504, DOI 10.1093/ije/dyp330
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 66
TC 12
Z9 12
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2016
VL 25
IS 23
BP 5276
EP 5285
DI 10.1093/hmg/ddw336
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EP0FT
UT WOS:000397063300019
PM 28011711
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lores-Motta, L
   van Asten, F
   Muether, PS
   Smailhodzic, D
   Groenewoud, JM
   Omar, A
   Chen, J
   Koenekoop, RK
   Fauser, S
   Hoyng, CB
   den Hollander, AI
   de Jong, EK
AF Lores-Motta, Laura
   van Asten, Freekje
   Muether, Philipp S.
   Smailhodzic, Dzenita
   Groenewoud, Joannes M.
   Omar, Amer
   Chen, John
   Koenekoop, Robert K.
   Fauser, Sascha
   Hoyng, Carel B.
   den Hollander, Anneke I.
   de Jong, Eiko K.
TI A genetic variant in NRP1 is associated with worse response to
   ranibizumab treatment in neovascular age-related macular degeneration
SO PHARMACOGENETICS AND GENOMICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; INTRAVITREAL
   RANIBIZUMAB; ANTI-VEGF; GASTRIC-CANCER; FACTOR THERAPY; TUMOR-GROWTH;
   NEUROPILIN-1; POLYMORPHISMS; CELLS
C1 [Lores-Motta, Laura; van Asten, Freekje; Smailhodzic, Dzenita; Hoyng, Carel B.; den Hollander, Anneke I.; de Jong, Eiko K.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Groenewoud, Joannes M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Sci, NL-6525 EX Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 EX Nijmegen, Netherlands.
   [Muether, Philipp S.; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Omar, Amer] Montreal Retina Inst, Westmount, PQ, Canada.
   [Chen, John] McGill Univ, Dept Ophthalmol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada.
   [Koenekoop, Robert K.] McGill Univ, Dept Pediat Surg Human Genet & Ophthalmol, Ctr Hlth, Montreal, PQ, Canada.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Cologne; McGill University; McGill
   University
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Omar, Amer/M-5342-2019; Lorés-Motta, Laura/M-6054-2015; Hollander,
   Anneke den/N-4911-2014; Koenekoop, Robert/AAT-6676-2021; de Jong,
   Eiko/P-3407-2015; van Asten, Freekje/P-6028-2015; Groenewoud, Hans
   JMM/R-3588-2017
OI Omar, Amer/0000-0003-1520-392X; de Jong, Eiko/0000-0001-6520-0407; van
   Asten, Freekje/0000-0002-8141-4234; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Lores-Motta, Laura/0000-0002-2423-9126
FU European Union [317472]; Foundation Fighting Blindness Canada; Canadian
   Institutes for Health Research
FX This project has received funding from the European Union's Seventh
   Framework Programme for research, technological development and
   demonstration under grant agreement no. 317472 (EyeTN).; R.K. Koenekoop
   is supported by the Foundation Fighting Blindness Canada and the
   Canadian Institutes for Health Research.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811
   Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49
   Berge M, 2011, J HEPATOL, V55, P866, DOI 10.1016/j.jhep.2011.01.033
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Evans IM, 2011, MOL CELL BIOL, V31, P1174, DOI 10.1128/MCB.00903-10
   Fantin A, 2014, DEVELOPMENT, V141, P556, DOI 10.1242/dev.103028
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001
   Kawamura H, 2008, BLOOD, V112, P3638, DOI 10.1182/blood-2007-12-125856
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koch KR, 2012, GRAEF ARCH CLIN EXP, V250, P201, DOI 10.1007/s00417-011-1792-8
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8
   Raimondi C, 2014, J EXP MED, V211, P1167, DOI 10.1084/jem.20132330
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schuch G, 2002, BLOOD, V100, P4622, DOI 10.1182/blood.V100.13.4622
   Schultheis AM, 2008, CLIN CANCER RES, V14, P7554, DOI 10.1158/1078-0432.CCR-08-0351
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Stephenson JM, 2002, INT J CANCER, V101, P409, DOI 10.1002/ijc.10611
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P2119, DOI 10.1200/JCO.2011.39.9824
   Wang L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001161
   Wang VM, 2012, MOL VIS, V18, P2578
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099
   Xu Y, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-155
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zhu H, 2014, CLIN TRANSL ONCOL, V16, P732, DOI 10.1007/s12094-013-1141-y
NR 50
TC 10
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1744-6872
EI 1744-6880
J9 PHARMACOGENET GENOM
JI Pharmacogenet. Genomics
PD JAN
PY 2016
VL 26
IS 1
BP 20
EP 27
DI 10.1097/FPC.0000000000000180
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
GA CY8XD
UT WOS:000366691100003
PM 26426212
OA Green Published
DA 2022-11-30
ER

PT J
AU Singh, M
   Chee, CKL
AF Singh, Mandeep
   Chee, Caroline K. L.
TI Spectral Domain Optical Coherence Tomography Imaging of Retinal Diseases
   in Singapore
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID ULTRAHIGH-RESOLUTION
AB In this retrospective case series, the authors reviewed cases of patients with macular disorders whose eyes had been imaged using spectral domain optical coherence tomography (SD-OCT) (Cirrus HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA). SD-OCT images were obtained from patients with a variety of ocular conditions attending a tertiary retinal clinic in Singapore from August 2007 to December 2007, according to standardized protocols. Images of 428 eyes from 301 patients were reviewed. Ocular diagnoses included diabetic macular edema, exudative age-related macular degeneration, central serous chorioretinopathy, cystoid macular edema, retinal vein and artery occlusions, infective chorioretinitis, and others. The authors present four cases of particular interest to illustrate how SD-OCT was useful in complementing the clinician's assessment of macular disease. [Ophthalmic Surg Lasers Imaging 2009;40:336-341.]
C1 [Singh, Mandeep; Chee, Caroline K. L.] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore 119074, Singapore.
   [Chee, Caroline K. L.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore
RP Chee, CKL (通讯作者)，Natl Univ Singapore Hosp, Dept Ophthalmol, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
RI Singh, Mandeep/AAS-8842-2021
OI Singh, Mandeep/0000-0003-1749-0088
CR Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
NR 11
TC 6
Z9 6
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2009
VL 40
IS 3
BP 336
EP 341
DI 10.3928/15428877-20090430-23
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 446RY
UT WOS:000266140000023
PM 19485306
DA 2022-11-30
ER

PT J
AU Jaffe, DH
   Chan, W
   Bezlyak, V
   Skelly, A
AF Jaffe, Dena H.
   Chan, Wing
   Bezlyak, Vladimir
   Skelly, Adrian
TI The economic and humanistic burden of patients in receipt of current
   available therapies for neovascular age-related macular degeneration
SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
LA English
DT Article
DE age-related macular degeneration; NHWS; resource utilization; treatment
   burden
ID RANIBIZUMAB; PREVALENCE; ADULTS
AB Aim: To determine the economic and humanistic burden of neovascular age-relatedmacular degeneration (nAMD) in a cohort of patients treated with anti-VEGF in Europe and the US. Patients & methods: 79 respondents from the EU and 63 from the US with a self-reported diagnosis of nAMD and in current receipt of treatment, as reported in an international, general population survey, were compared with non-nAMD controls. Results: Anti-VEGF-treated nAMD patients in the EU had a greater utilization of healthcare resources, poorer quality of life and greater overall activity impairment versus non-nAMD controls. In the US cohort, treated nAMD patients had significantly greater resource utilization for ophthalmologist visits only. Conclusion: The burden of care associated with nAMD on EU and US healthcare systems, and on patients who are in receipt of nAMD therapy, is significant and likely to be unsustainable.
C1 [Jaffe, Dena H.] Kantar Hlth, Tel Aviv, Israel.
   [Chan, Wing] Novartis Pharmaceut, E Hanover, NJ 07936 USA.
   [Bezlyak, Vladimir; Skelly, Adrian] Novartis Pharma AG, Basel, Switzerland.
C3 Novartis; Novartis
RP Skelly, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM adrian.skelly@novartis.com
FU Novartis Pharma AG, Basel, Switzerland; Novartis Pharma AG
FX This study was supported by funding from Novartis Pharma AG, Basel,
   Switzerland. D H. Jaffe is an employee of Kantar Health, which has
   received funding from Novartis Pharma AG. W Chan, V Bezlyak and A Skelly
   are employees of Novartis. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chaudhry S, 2005, MED CARE, V43, P607, DOI 10.1097/01.mlr.0000163658.65008.ec
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Huo T, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0858-2
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang W, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3141
NR 19
TC 13
Z9 13
U1 1
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 2042-6305
EI 2042-6313
J9 J COMP EFFECT RES
JI J. Comp. Eff. Res.
PD NOV
PY 2018
VL 7
IS 11
BP 1125
EP 1132
DI 10.2217/cer-2018-0058
PG 8
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA HC9MH
UT WOS:000452129900008
PM 30238792
OA hybrid
DA 2022-11-30
ER

PT J
AU Doyle, E
   Khaninala, M
   Shah, SP
   Ong, DG
   Casswell, AG
AF Doyle, E.
   Khaninala, M.
   Shah, S. P.
   Ong, D. G.
   Casswell, A. G.
TI One-year results of photodynamic therapy for small predominantly classic
   choroidal neovascular membranes secondary to age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; outcome;
   choroidal neovascular membranes
ID VERTEPORFIN THERAPY; LESION SIZE; RANIBIZUMAB; TAP
AB PURPOSE. To determine the visual and angiographic outcomes of patients with small predominantly classic choroidal neovascular membranes (CNV) undergoing photodynamic therapy (PDT).
   METHODS. The subjects were a cohort of patients with age-related predominantly classic CNV with lesion size of greatest linear diameter of 2000 mu m or less treated with PDT Lesion size and visual acuity were recorded at baseline and at 3-month intervals. Visual treatment failure was defined as either loss of at least 15 letters or visual acuity less than 35 letters on a modified Early Treatment Diabetic Retinopathy Study chart. Lesion treatment failure was defined as increase in greatest linear diameter (GLD) of at least 500 mu m.
   RESULTS: Twenty-five eyes of 25 patients were included. Visual treatment failure occurred in 16 and mean visual acuity dropped from 58 letters to 34 letters (P < 0.0001). In 11 of these patients this occurred within the first 3 months. Lesion treatment failure occurred in 18 patients. Mean GLD increased from 1331 to 2935 mu m (p < 0.0001). Early growth of the lesion was associated with poor visual outcome with growth in GLD in the first 3 months of 310 mu m in patients without eventual visual treatment failure and 1131 mu m in patients with eventual visual failure (p=0.027).
   CONCLUSIONS. Small predominantly classic lesions commonly cause visual deterioration if treated with PDT alone. In the first year over 50% may lose at least 15 letters or drop below 35 letters, with most visual loss occurring in the first 3 months. Visual loss is associated with early /eSion growth.
C1 [Doyle, E.; Khaninala, M.; Shah, S. P.; Ong, D. G.; Casswell, A. G.] Sussex Eye Hosp, Brighton, E Sussex, England.
   [Doyle, E.; Khaninala, M.; Shah, S. P.; Ong, D. G.; Casswell, A. G.] Univ Sussex, Hosp NHS Trust, Brighton, E Sussex, England.
C3 University of Sussex
RP Doyle, E (通讯作者)，1 Shagbrook Cottages,Reigate Rd, Surrey RH2 9RE, England.
EM EdRachie@btinternet.com
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bhatnagar A, 2006, EYE, V20, P491, DOI 10.1038/sj.eye.6701907
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Michels S, 2005, OPHTHALMOLOGY, V112, P2070, DOI 10.1016/j.ophtha.2005.06.034
NR 10
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2007
VL 17
IS 5
BP 760
EP 767
DI 10.1177/112067210701700512
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 251GJ
UT WOS:000252360300012
PM 17932852
DA 2022-11-30
ER

PT J
AU Mao, K
   Shu, WT
   Qiu, QH
   Gu, Q
   Wu, XW
AF Mao, Ke
   Shu, Wanting
   Qiu, Qinghua
   Gu, Qing
   Wu, Xingwei
TI Salvianolic Acid A Protects Retinal Pigment Epithelium from
   OX-LDL-induced Inflammation in an Age-Related Macular Degeneration Model
SO DISCOVERY MEDICINE
LA English
DT Article
ID MITOCHONDRIAL-DNA DAMAGE; OXIDATIVE STRESS; NLRP3 INFLAMMASOME;
   HYDROGEN-PEROXIDE; ANTIOXIDANT RESPONSE; INDUCED APOPTOSIS; OXIDIZED
   LDL; RAT MODEL; CELLS; RPE
AB Backgrounds: Salvianolic acid A (Sal A), an active monomer of Salvia miltiorrhiza, is a phenolic carboxylic acid derivative. The present study was performed to investigate the underlying mechanism of the anti-inflammation effect of Sal A, especially focusing on mTOR-KEAP1-Nrf2 and P2X7R-PKRNLRP3 signaling pathways. Methods: SD mice were divided into four groups: PBS, oxidized-low density lipoprotein (ox-LDL, 3 mg/kg), and ox-LDL (3 mg/kg) + Sal A (5 mg/kg) and + Sal A (10 mg/ml) groups. In in vitro experiments, ARPE-19 cells were cultured with serum free medium (SFM) or ox-LDL (100 mg/L), with or without Sal A (5 mu M/50 mu M) for 24 hours. Results: Sal A attenuated ox-LDL-induced lipidosis and apoptosis in the retinal pigment epithelium (RPE) layer. Ox-LDL elevated ROS level and induced RPE inflammation, which were inhibited by Sal A pretreatment. Sal A activated PI3K/AKT/mTOR signaling pathway, which further promoted the disassociation of Keap1-Nrf2 complex and the phosphorylation of Nrf2. PI3K and mTOR chemical inhibitors abolished Sal A-induced Nrf2 activation while it had no influence on nlrp3 expression. Sal A also inhibited RPE inflammation by inactivating the P2x7r-Pkr-Nlrp3 signaling pathway. Conclusions: The above results indicate that Sal A protects RPE from lipid oxidative damage and chronic inflammation through up-regulating Nrf2 and inactivating the P2x7r-Pkr-Nlrp3 signaling pathway.
C1 [Mao, Ke; Shu, Wanting; Qiu, Qinghua; Gu, Qing; Wu, Xingwei] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wu, XW (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.
EM wxweye@sina.com
FU Shanghai Natural Science Foundation [14401972600]
FX This work was supported by a grant from Shanghai Natural Science
   Foundation (14401972600). The authors would like to thank Qing Gu for
   excellent technical support and Professor Liyi Yin for critically
   reviewing the manuscript.
CR Ahsan A, 2015, APOPTOSIS, V20, P1563, DOI 10.1007/s10495-015-1175-4
   Altaf A, 2015, CORONARY ARTERY DIS, V26, P409, DOI 10.1097/MCA.0000000000000255
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bensaoula T, 2000, OPHTHALMOLOGY, V107, P1746, DOI 10.1016/S0161-6420(00)00264-5
   Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Chen WM, 2016, FASEB J, V30, P2500, DOI 10.1096/fj.201500109R
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113
   Coll RC, 2010, J INNATE IMMUN, V2, P406, DOI 10.1159/000315469
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang K, 2016, SCI REP-UK, V6, DOI 10.1038/srep22632
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lee YJ, 2012, FOOD CHEM TOXICOL, V50, P116, DOI 10.1016/j.fct.2011.10.035
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lu MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26585
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Montserrat-de la Paz S, 2016, FOOD FUNCT, V7, P1345, DOI [10.1039/c6fo00136j, 10.1039/C6FO00136J]
   Oh KS, 2011, INT IMMUNOPHARMACOL, V11, P1901, DOI 10.1016/j.intimp.2011.07.022
   Peng K, 2015, INT J MOL MED, V35, P1179, DOI 10.3892/ijmm.2015.2129
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Qin RA, 2012, J TRADIT CHIN MED, V32, P63, DOI 10.1016/S0254-6272(12)60033-8
   Qiu YT, 2015, CURR EYE RES, V40, P415, DOI 10.3109/02713683.2014.927507
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sinha D, 2013, ARCH TOXICOL, V87, P383, DOI 10.1007/s00204-012-0920-5
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Velez G, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/106486
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P1671, DOI 10.1167/iovs.07-1099
   Wang X, 2013, DIABETES, V62, P444, DOI 10.2337/db12-0244
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang L, 2013, J NUTR BIOCHEM, V24, P903, DOI 10.1016/j.jnutbio.2012.06.008
   Zhang YL, 2010, BIOCHEM BIOPH RES CO, V394, P377, DOI 10.1016/j.bbrc.2010.03.026
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
NR 49
TC 15
Z9 17
U1 0
U2 19
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD FEB
PY 2017
VL 23
IS 125
BP 129
EP 148
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ES4JI
UT WOS:000399500100006
PM 28371616
DA 2022-11-30
ER

PT J
AU Zhang, BY
   Yin, X
   Li, JQ
   Ren, C
   Liu, WM
   Liu, GQ
   Lu, PR
AF Zhang, Bingyu
   Yin, Xue
   Li, Jianqing
   Ren, Chi
   Liu, Weiming
   Liu, Gaoqin
   Lu, Peirong
TI Essential contribution of macrophage Tie2 signal mediated autophagy in
   laser-induced choroidal neovascularization
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Autophagy; Age-related macular degeneration; Choroidal
   neovascularization; Tie2-expressing macrophage (TEMs)
ID CORNEAL NEOVASCULARIZATION; REGULATES AUTOPHAGY; ENDOTHELIAL-CELLS;
   ANGIOGENESIS; AMPK; PHOSPHORYLATION; DEGENERATION; EXPRESSION;
   PATHOGENESIS; ISCHEMIA
AB Autophagy plays critical roles in various ocular diseases, including age-related macular degeneration (AMD). Tie2-expressing macrophages (TEMs) play crucial roles in angiogenesis. To investigate the role of TEMs and autophagy in the development of AMD, we employed macrophage-specific Tie2 knockout mice and used a laser-induced choroidal neovascularization (CNV). The results showed that TEMs can promote CNV formation by up-regulating the level of autophagy. These results were further verified by in vitro cell experiments that peritoneal macrophages from Tie2 knockout mice can inhibit the expression of autophagy-related factors and inhibit the expression of angiogenic factor of VEGF by activating AMPK signaling pathway. Our results suggest that TEMs and macrophage Tie2 signal mediated-autophagy play critical role in experimental CNV, and they may be novel preventive targets for AMD treatment.
C1 [Zhang, Bingyu; Yin, Xue; Li, Jianqing; Ren, Chi; Liu, Weiming; Liu, Gaoqin; Lu, Peirong] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Shizi St 188, Suzhou 215006, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Shizi St 188, Suzhou 215006, Jiangsu, Peoples R China.
EM lupeirong@suda.edu.cn
RI Liu, Gaoqin/AAG-1684-2021
OI Liu, Weiming/0000-0002-0625-9297
FU National Natural Science Foundation of China [81671641, 30972712];
   Jiangsu Provincial Medical Innovation Team [CXTDA2017039]; Jiangsu
   Provincial Natural Science Foundation [BK20151208]; Soochow Scholar
   Project of Soochow University [R5122001]
FX Tie2<SUP>flox/+</SUP> mice and LyzCre<SUP>+</SUP> mice are kind gifts
   from Dr. Yulong He of Soochow University. This work was supported by the
   National Natural Science Foundation of China (grant nos. 81671641,
   30972712), Jiangsu Provincial Medical Innovation Team (grant no.
   CXTDA2017039), Jiangsu Provincial Natural Science Foundation (grant no.
   BK20151208) and the Soochow Scholar Project of Soochow University (grant
   no. R5122001).
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chen L, 2016, CANCER RES, V76, P6828, DOI 10.1158/0008-5472.CAN-16-1114
   Coffelt SB, 2011, J IMMUNOL, V186, P4183, DOI 10.4049/jimmunol.1002802
   De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Du JH, 2017, OPHTHALMOLOGICA, V237, P85, DOI 10.1159/000455270
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fu DX, 2016, DIABETOLOGIA, V59, P2251, DOI 10.1007/s00125-016-4058-5
   Germano Domenico, 2014, Hepatobiliary Surg Nutr, V3, P166, DOI 10.3978/j.issn.2304-3881.2014.06.04
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Li R, 2015, REC ADV OPHTHALMOL, V35, P1132, DOI DOI 10.13389/J.CNKI.RA0.2015.0310
   Li R, 2016, CURR EYE RES, V41, P1566, DOI 10.3109/02713683.2016.1145234
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu PR, 2008, J IMMUNOL, V180, P4283, DOI 10.4049/jimmunol.180.6.4283
   Lu PR, 2009, INVEST OPHTH VIS SCI, V50, P4761, DOI 10.1167/iovs.08-2732
   Mack HID, 2012, AUTOPHAGY, V8, P1197, DOI 10.4161/auto.20586
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moss A, 2013, CYTOKINE GROWTH F R, V24, P579, DOI 10.1016/j.cytogfr.2013.05.009
   Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200
   Ohashi K, 2010, J BIOL CHEM, V285, P22291, DOI 10.1074/jbc.M110.123794
   Ouchi N, 2005, CIRC RES, V96, P838, DOI 10.1161/01.RES.0000163633.10240.3b
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Patel AS, 2013, EMBO MOL MED, V5, P858, DOI 10.1002/emmm.201302752
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726
   Shen B, 2014, ARTERIOSCL THROM VAS, V34, P1221, DOI 10.1161/ATVBAHA.113.302923
   Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   Wang DW, 2017, AM J PHYSIOL-CELL PH, V313, pC674, DOI 10.1152/ajpcell.00257.2016
   Wang WJ, 2017, AUTOPHAGY, V13, P941, DOI 10.1080/15548627.2017.1293768
   Wang XJ, 2017, BRIT J CANCER, V117, P1371, DOI 10.1038/bjc.2017.297
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576
   Zhu HP, 2016, ARTERIOSCL THROM VAS, V36, P1868, DOI 10.1161/ATVBAHA.116.307743
   Zibrova D, 2017, BIOCHEM J, V474, P983, DOI 10.1042/BCJ20160980
NR 49
TC 6
Z9 6
U1 1
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2020
VL 193
DI 10.1016/j.exer.2020.107972
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KZ8MD
UT WOS:000523511400013
PM 32059975
DA 2022-11-30
ER

PT J
AU Hovatta, O
   Rodin, S
   Antonsson, L
   Tryggvason, K
AF Hovatta, Outi
   Rodin, Sergey
   Antonsson, Liselotte
   Tryggvason, Karl
TI Concise Review: Animal Substance-Free Human Embryonic Stem Cells Aiming
   at Clinical Applications
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Review
DE Clinical translation; Embryonic stem cells; Pluripotent stem cells;
   Serum-free; Stem cell culture
ID SERUM REPLACEMENT MEDIUM; TERM SELF-RENEWAL; REGENERATIVE MEDICINE;
   HUMAN BLASTOCYSTS; FEEDER CELLS; LINES; DIFFERENTIATION; GROWTH;
   FIBROBLASTS; DERIVATION
AB Human embryonic stem cells have been considered the gold standard as a cell source for regenerative medicine since they were first cultured in 1998. They are pluripotent and can form principally all the cells types in the body. They are obtained from supernumerary human in vitro fertilization embryos that cannot be used for infertility treatment. Following studies on factors regulating pluripotency and differentiation, we now have techniques to establish and effectively expand these cells in animal substance-free conditions, even from single cells biopsied from eight-cell stage embryos in chemically defined feeder-free cultures. The genetic stability and absence of tumorigenic mutations can be determined. There are satisfactory animal tests for functionality and safety. The first clinical trials are ongoing for two indications: age-related macular degeneration and spinal cord injury.
C1 [Hovatta, Outi; Antonsson, Liselotte] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Rodin, Sergey; Tryggvason, Karl] Karolinska Inst, Dept Biochem & Biophys, Stockholm, Sweden.
   [Hovatta, Outi; Antonsson, Liselotte] Karolinska Univ Hosp, Stockholm, Sweden.
   [Tryggvason, Karl] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders Program, Singapore, Singapore.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska University Hospital; National University of Singapore
RP Hovatta, O (通讯作者)，Karolinska Univ, Huddinge Hosp, K57, SE-14186 Stockholm, Sweden.
EM Outi.Hovatta@ki.se
OI Rodin, Sergey/0000-0002-6954-1986
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Akopian V, 2010, IN VITRO CELL DEV-AN, V46, P247, DOI 10.1007/s11626-010-9297-z
   Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015
   Bhattacharya B, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-22
   Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005
   Cai J, 2007, HEPATOLOGY, V45, P1229, DOI 10.1002/hep.21582
   Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193
   CERDAN C, 2007, CURR PROTOC STEM CEL, pCH1
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576
   Crook JM, 2007, CELL STEM CELL, V1, P490, DOI 10.1016/j.stem.2007.10.004
   Daughtry B, 2014, STEM CELL TRANSL MED, V3, P290, DOI 10.5966/sctm.2013-0127
   Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152
   Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200
   Domogatskaya A, 2012, ANNU REV CELL DEV BI, V28, P523, DOI 10.1146/annurev-cellbio-101011-155750
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   FISHEL SB, 1984, SCIENCE, V223, P816, DOI 10.1126/science.6546453
   Hovatta O, 2003, HUM REPROD, V18, P1404, DOI 10.1093/humrep/deg290
   Hovatta O, 2010, STEM CELLS, V28, P1005, DOI 10.1002/stem.436
   Hovatta O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010263
   Ilic D, 2009, STEM CELLS DEV, V18, P1343, DOI 10.1089/scd.2008.0416
   Inzunza J, 2005, STEM CELLS, V23, P544, DOI 10.1634/stemcells.2004-0201
   Jacobs K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5227
   Jacquet L, 2013, EMBO MOL MED, V5, P10, DOI 10.1002/emmm.201201973
   Klaffky E, 2001, DEV BIOL, V239, P161, DOI 10.1006/dbio.2001.0404
   Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004
   Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142
   Koivisto H, 2004, REPROD BIOMED ONLINE, V9, P330, DOI 10.1016/S1472-6483(10)62150-5
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177
   Ma H, 2014, NATURE, V511, P177, DOI 10.1038/nature13551
   Melkoumian Z, 2010, NAT BIOTECHNOL, V28, P606, DOI 10.1038/nbt.1629
   Murdoch A, 2012, STEM CELL REV REP, V8, P91, DOI 10.1007/s12015-011-9288-9
   Narva E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615
   Nat R, 2007, GLIA, V55, P385, DOI 10.1002/glia.20463
   Piltti KM, 2013, STEM CELL TRANSL MED, V2, P961, DOI 10.5966/sctm.2013-0064
   Qu CJ, 2013, INT J BIOCHEM CELL B, V45, P1802, DOI 10.1016/j.biocel.2013.05.029
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Rodin S, 2010, NAT BIOTECHNOL, V28, P611, DOI 10.1038/nbt.1620
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SEIGER A, 1989, Fetal Therapy, V4, P104
   Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006
   Strom S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015329
   Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947
   Tannenbaum SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035325
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Unger C, 2008, HUM MOL GENET, V17, pR48, DOI 10.1093/hmg/ddn079
   Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031
   Villa-Diaz LG, 2010, NAT BIOTECHNOL, V28, P581, DOI 10.1038/nbt.1631
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 53
TC 14
Z9 15
U1 1
U2 23
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD NOV
PY 2014
VL 3
IS 11
BP 1269
EP 1274
DI 10.5966/sctm.2014-0129
PG 6
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AT6OA
UT WOS:000345057500012
PM 25298372
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Talks, JS
   Lotery, AJ
   Ghanchi, F
   Sivaprasad, S
   Johnston, RL
   Patel, N
   McKibbin, M
   Bailey, C
   Mahmood, S
AF Talks, James S.
   Lotery, Andrew J.
   Ghanchi, Faruque
   Sivaprasad, Sobha
   Johnston, Robert L.
   Patel, Nishal
   McKibbin, Martin
   Bailey, Clare
   Mahmood, Sajjad
CA United Kingdom Aflibercept Users
TI First-Year Visual Acuity Outcomes of Providing Aflibercept According to
   the VIEW Study Protocol for Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB Purpose: Aflibercept has the potential advantage of reducing capacity problems by allowing 2 monthly visits for patients with neovascular macular degeneration (nAMD) compared with monthly pro re nata regimens that are the most commonly used in the United Kingdom. This study aimed to report the visual outcomes achieved in routine clinical practice using the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) protocol at 1 year and compare with trials data and other real-world reports.
   Design: Retrospective data analysis from an electronic medical record.
   Participants: Consecutive series of treatment-naive patients initiated on aflibercept for nAMD at least 1 year before data extraction.
   Methods: Data were anonymized and remotely extracted from 16 centers in the United Kingdom that use the same electronic medical record (EMR) system (Medisoft Ophthalmology; Medisoft Limited, Leeds, UK).
   Main Outcome Measures: The minimum data set defined before first data entry and mandated by the EMR included age, gender, visual acuity, injection episodes, and complications.
   Results: The mean age was 80.0 years (median, 81.0 years) and 63.7% were women. During the first year of treatment with aflibercept, 1840 treatment-naive eyes of 1682 patients received a median of 8 (mean, 7.0) injections at a median of 8 (mean, 7.3) visits. The mean baseline visual acuity was 53.7 letters, improving to 58.8 letters (+5.1-letter gain) at 1 year. In first-treated eyes, the respective figures were 52.7 letters at baseline and 58.2 letters at 1 year, a gain of +5.5 letters. The proportion achieving 70 letters or more increased from 16.4% at baseline to 33.7% at 1 year, and 92% avoided moderate visual loss at 1 year.
   Conclusions: The visual acuity outcomes are comparable to randomized trials and better than many previous real-world data collections, with a mean +5.1-letter gain at 1 year compared with +8.4 letters in the integrated analysis of the VIEW 1 and VIEW 2 studies. Early visual gains were maintained through the year. Collection of outcomes beyond clinical trials can have limitations but better reflect the full pool of patients actually treated and are important to determine whether a particular treatment is performing as expected. Such data also have the potential to improve services by setting up a mechanism to compare sites. (C) 2016 by the American Academy of Ophthalmology.
C1 [Talks, James S.] Newcastle Upon Tyne Hosp Fdn NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southamptom, England.
   [Ghanchi, Faruque] Bradford Teaching Hosp, Bradford, W Yorkshire, England.
   [Sivaprasad, Sobha] Kings Coll Hosp NHS Fdn Trust, London, England.
   [Johnston, Robert L.] Gloucestershire Hosp NHS Fdn Trust, Gloucester, England.
   [Patel, Nishal] East Kent Hosp Univ NHS Fdn Trust, Ashford, Kent, England.
   [McKibbin, Martin] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
   [Bailey, Clare] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Mahmood, Sajjad] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of
   Southampton; King's College Hospital NHS Foundation Trust;
   Gloucestershire Hospitals NHS Foundation Trust; University of Leeds;
   University of Bristol; Manchester Royal Eye Hospital; University of
   Manchester
RP Talks, JS (通讯作者)，Royal Victoria Infirm, Newcastle Eye Ctr, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM james.talks@nuth.nhs.uk
RI Sivaprasad, S./D-6876-2015; Mahmood, Sajjad/AAK-7645-2021
OI Sivaprasad, S./0000-0001-8952-0659; Lotery, Andrew/0000-0001-5541-4305;
   McKibbin, Martin/0000-0003-4388-243X; Talks, James/0000-0001-6126-6476
FU Bayer; Novartis; Allergan
FX The authors have received travel bursaries and attended advisory boards
   for Bayer, Novartis, and Allergan.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 12
TC 71
Z9 74
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 337
EP 343
DI 10.1016/j.ophtha.2015.09.039
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2TK
UT WOS:000368362200026
PM 26578446
DA 2022-11-30
ER

PT J
AU Litts, KM
   Ach, T
   Hammack, KM
   Sloan, KR
   Zhang, YH
   Freund, KB
   Curcio, CA
AF Litts, Katie M.
   Ach, Thomas
   Hammack, Kristen M.
   Sloan, Kenneth R.
   Zhang, Yuhua
   Freund, K. Bailey
   Curcio, Christine A.
TI Quantitative Analysis of Outer Retinal Tubulation in Age-Related Macular
   Degeneration From Spectral-Domain Optical Coherence Tomography and
   Histology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE spectral-domain optical coherence tomography; photoreceptors; cones;
   Muller cells; age-related macular degeneration; outer retinal
   tubulation; ellipsoid; histology
ID PIGMENT EPITHELIUM; LIGHT-SCATTERING; INNER SEGMENTS; INTACT-CELLS;
   DENSITY; PHOTORECEPTORS; TOPOGRAPHY; STRESS; BAND
AB PURPOSE. To assess outer retinal tubulation (ORT) morphology from spectral-domain optical coherence tomography (SD-OCT) volumes and donor eye histology, analyze ORT reflectivity, and estimate the number of cones surviving in ORT.
   METHODS. In SD-OCT volumes from nine patients with advanced AMD, ORT was analyzed en face and in B-scans. The hyperreflective ORT border in cross-section was delineated and surface area calculated. Reflectivity was compared between ORT types (Closed, Open, Forming, and Branching). A flatmount retina from a donor with neovascular AMD was labeled to visualize the external limiting membrane that delimits ORT and allow measurements of cross-sectional cone area, center-to-center cone spacing, and cone density. The number of cones surviving in ORT was estimated.
   RESULTS. By en face SD-OCT, ORT varies in complexity and shape. Outer retinal tubulation networks almost always contain Closed cross-sections. Spectral-domain OCT volumes containing almost exclusively Closed ORTs showed no significant direction-dependent differences in hyperreflective ORT border intensity. The surface areas of partial ORT assessed by SD-OCT volumes ranged from 0.16 to 1.76 mm(2). From the flatmount retina, the average cross-sectional area of cone inner segments was 49.1 +/- 7.9 mu m(2). The average cone spacing was 7.5 +/- 0.6 mu m. Outer retinal tubulation cone density was 20,351 cones/mm2. The estimated number of cones in ORT in a macula ranged from 26,399 to 186,833 cones, which is 6% to 44% of the cones present in a healthy macula.
   CONCLUSIONS. These first estimates for cone density and number of cones surviving in ORT suggest that ORT formation considerably distorts the photoreceptor mosaic. Results provide additional insight into the reflectivity characteristics and number of ORT cones observable in living patients by SD-OCT, as cones persist and disease progresses.
C1 [Litts, Katie M.; Ach, Thomas; Hammack, Kristen M.; Sloan, Kenneth R.; Zhang, Yuhua; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Litts, Katie M.] Univ Alabama Birmingham, Vis Sci Grad Program, Birmingham, AL 35294 USA.
   [Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Hammack, Kristen M.; Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Comp & Informat Sci, Birmingham, AL 35294 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Wurzburg; University of Alabama System; University of
   Alabama Birmingham; Vitreous Retina Macula Consultants of New York; New
   York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, EyeSight Fdn Alabama,Vis Res Labs, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Ach, Thomas/AAE-7870-2021; Litts, Katie M/AAK-1564-2021; Freund, K.
   Bailey/V-7488-2018
OI Ach, Thomas/0000-0001-6583-8283; Litts, Katie M/0000-0001-6707-8273;
   Freund, K. Bailey/0000-0002-7888-9773
FU Vision Science Graduate Program; National Institutes of Health (NIH)
   [EY06019]; DFG (German Research Foundation) [AC265/1-1, AC265/2-1]; NIH
   [EY024378]; Research to Prevent Blindness; EyeSight Foundation of
   Alabama; Macula Foundation, Inc.; International Retinal Research
   Foundation; National Eye Institute [P30 EY003039]; Arnold and Mabel
   Beckman Initiative for Macular Research; NATIONAL EYE INSTITUTE
   [P30EY003039, R01EY024378] Funding Source: NIH RePORTER
FX Supported by Vision Science Graduate Program (KML), National Institutes
   of Health (NIH) Grant EY06019 (CAC), DFG (German Research Foundation)
   AC265/1-1 and AC265/2-1 (TA), NIH EY024378 (YZ), unrestricted funds to
   the Department of Ophthalmology from Research to Prevent Blindness and
   EyeSight Foundation of Alabama (CAC, YZ); Macula Foundation, Inc.,
   (KBF); acquisition of donor eyes received additional support from
   International Retinal Research Foundation, National Eye Institute P30
   EY003039, and the Arnold and Mabel Beckman Initiative for Macular
   Research.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Syed R, 2013, INVEST OPHTH VIS SCI, V54, P950, DOI 10.1167/iovs.12-10707
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Wilk MA, 2014, INVEST OPHTH VIS SCI, V55, P4186, DOI 10.1167/iovs.13-13217
   WILLIAMS DS, 1990, J COMP NEUROL, V295, P155, DOI 10.1002/cne.902950113
   Wilson JD, 2005, OPT LETT, V30, P2442, DOI 10.1364/OL.30.002442
   Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 39
TC 20
Z9 23
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2016
VL 57
IS 6
BP 2647
EP 2656
DI 10.1167/iovs.16-19262
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8OA
UT WOS:000378041700034
PM 27177321
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Bora, NS
   Kaliappan, S
   Jha, P
   Xu, Q
   Sivasankar, B
   Harris, CL
   Morgan, BP
   Bora, PS
AF Bora, Nalini S.
   Kaliappan, Sankaranarayanan
   Jha, Purushottam
   Xu, Qin
   Sivasankar, Baalasubramanian
   Harris, Claire L.
   Morgan, B. Paul
   Bora, Puran S.
TI CD59, a complement regulatory protein, controls choroidal
   neovascularization in a mouse model of wet-type age-related macular
   degeneration
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID DECAY-ACCELERATING FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS;
   MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM; TARGETED EXPRESSION;
   DISEASE SEVERITY; DRUSEN FORMATION; FACTOR-B; DEFICIENCY; MICE
AB We have shown that membrane attack complex (MAC) formation via the activation of the alternative pathway plays a central role in the laser-induced choroidal neovascularization (CNV). This study was undertaken to understand the role of a complement regulatory protein, CD59, which controls MAC assembly and function, in this model. CNV was induced by laser photocoagulation in C5713L/6 and Cd59a(-/-) mice using an argon laser. Animals from each group were sacrificed on day 1, 3, 5, and 7 postlaser. Retinal pigment epithelium-choroid-scleral tissue was examined to determine the incidence and size of CNV complex, and semi-quantitative RT-PCR and Western blot analysis for CD59a was studied. Recombinant soluble mouse CD59a-IgG2a fusion (rsCD59a-Fc) protein was injected via i.p. or intravitreal routes 24 h before laser. Our results demonstrated that CD59a (both mRNA and protein) was down-regulated during laser-induced CNV. Cd59a(-/-) mice developed CNV complex early in the disease process. Increased MAC deposition was also observed in these Cd59a(-/-) mice. Administration of rsCD59a-Fc inhibited the development of CNV complex in the mouse model by blocking MAC formation and also inhibited expression of angiogenic growth factors. These data provide strong evidence that CD59a plays a crucial role in regulating complement activation and MAC formation essential for the release of growth factors that drive the development of laser-induced CNV in mice. Thus, our results suggest that the inhibition of complement by soluble CD59 may provide a novel therapeutic alternative to current treatment.
C1 Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, Little Rock, AR 72205 USA.
   Univ Cardiff Wales, Sch Med, Dept Med Biochem & Immunol, Cardiff, S Glam, Wales.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   Cardiff University
RP Bora, NS (通讯作者)，Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, 4301 W Markham,Slot 523, Little Rock, AR 72205 USA.
EM NBora@UAMS.edu; PBora@UAMS.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Morgan, Paul/0000-0003-4075-7676;
   Bora, Puran/0000-0003-4781-1217
FU NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016460, S10RR019395]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013335,
   R01EY014623] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10 RR19395,
   2P20 RR16460] Funding Source: Medline; NEI NIH HHS [R01 EY013335-05,
   EY13335, EY014623] Funding Source: Medline
CR Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684
   Bao LH, 2002, J IMMUNOL, V168, P3601, DOI 10.4049/jimmunol.168.7.3601
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   COUSER WG, 1995, J AM SOC NEPHROL, V5, P1888
   Cybulsky AV, 1999, AM J PATHOL, V155, P1701, DOI 10.1016/S0002-9440(10)65485-5
   Davoust N, 1999, J IMMUNOL, V163, P6551
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Harris CL, 2003, IMMUNOLOGY, V109, P117, DOI 10.1046/j.1365-2567.2003.01628.x
   HOLGUIN MH, 1992, CURR TOP MICROBIOL, V178, P61
   Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kyriakides C, 1999, J APPL PHYSIOL, V87, P2357, DOI 10.1152/jappl.1999.87.6.2357
   Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836
   Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015
   Mitchell DA, 2002, J IMMUNOL, V168, P2538, DOI 10.4049/jimmunol.168.5.2538
   Miwa T, 2002, AM J PATHOL, V161, P1077, DOI 10.1016/S0002-9440(10)64268-X
   Miwa T, 2001, INT IMMUNOPHARMACOL, V1, P445, DOI 10.1016/S1567-5769(00)00043-6
   Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1
   MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C
   MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477
   Qian YM, 2000, J IMMUNOL, V165, P2528, DOI 10.4049/jimmunol.165.5.2528
   Quigg RJ, 1998, J EXP MED, V188, P1321, DOI 10.1084/jem.188.7.1321
   Quigg RJ, 1998, J IMMUNOL, V160, P4553
   QUIGG RJ, 1995, IMMUNOGENETICS, V42, P362, DOI 10.1007/BF00179397
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Samano Eliana Sueco Tibana, 2004, Rev. Hosp. Clin., V59, P138, DOI 10.1590/S0041-87812004000300009
   Sogabe H, 2001, J IMMUNOL, V167, P2791, DOI 10.4049/jimmunol.167.5.2791
   Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P4195
   SPICER AP, 1995, J IMMUNOL, V155, P3079
   Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7
   Turnberg D, 2003, J AM SOC NEPHROL, V14, P2271, DOI 10.1097/01.ASN.0000083901.47783.2E
   Williams AS, 2004, ARTHRITIS RHEUM-US, V50, P3035, DOI 10.1002/art.20478
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
NR 55
TC 79
Z9 96
U1 0
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2007
VL 178
IS 3
BP 1783
EP 1790
DI 10.4049/jimmunol.178.3.1783
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 130TC
UT WOS:000243820900063
PM 17237428
OA Bronze
DA 2022-11-30
ER

PT J
AU Zheng, F
   Gregori, G
   Schaal, KB
   Legarreta, AD
   Miller, AR
   Roisman, L
   Feuer, WJ
   Rosenfeld, PJ
AF Zheng, Fang
   Gregori, Giovanni
   Schaal, Karen B.
   Legarreta, Andrew D.
   Miller, Andrew R.
   Roisman, Luiz
   Feuer, William J.
   Rosenfeld, Philip J.
TI Choroidal Thickness and Choroidal Vessel Density in Nonexudative
   Age-Related Macular Degeneration Using Swept-Source Optical Coherence
   Tomography Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal thickness; choroidal vessel density; swept-source OCT;
   nonexudative AMD
ID 1060 NM OCT; RETICULAR PSEUDODRUSEN; AXIAL LENGTH; HEALTHY;
   SEGMENTATION; EYES; VOLUME; VASCULATURE; ASSOCIATION; MAPS
AB PURPOSE. To analyze the relationship between choroidal thickness and the distribution of choroidal blood vessels in eyes with nonexudative AMD.
   METHODS. Eyes with a diagnosis of nonexudative AMD were imaged using a prototype 100-kHz swept-source (SS) optical coherence tomography (OCT) instrument (Carl Zeiss Meditec, Dublin, CA, USA) with a central wavelength of 1050 nm. We used an OCT cube scan pattern consisting of 512 x 512 A-scans over a 12 x 12 mm retinal area. The eyes were partitioned into two groups based on the presence or absence of reticular pseudodrusen (RPD). All scans were segmented using an automated algorithm. In addition, five eyes from each of the two groups were randomly chosen for manual segmentation. Binary choroidal vessels maps were generated from suitable OCT choroidal slabs, and the relationship between the density of large choroidal vessels and choroidal thickness was analyzed using an Early Treatment Diabetic Retinopathy Study-like target centered on the fovea.
   RESULTS. Twenty-five eyes were enrolled in each group. The automated algorithm produced accurate choroidal thickness maps with an average difference between the manual and automated segmentations of 13.7 mu m. There was a significant and stable correlation between choroidal thickness and choroidal vessel density across the two groups. Both average choroidal thickness and vessel density were significantly lower in eyes with RPD.
   CONCLUSIONS. Our fully automated choroidal segmentation algorithm was able to capture the different patterns of choroidal thickness over a wide area. Choroidal thickness has a clear relationship with the density of large choroid vessels in our sample, irrespective of the presence or absence of RPD.
C1 [Zheng, Fang; Gregori, Giovanni; Schaal, Karen B.; Legarreta, Andrew D.; Miller, Andrew R.; Roisman, Luiz; Feuer, William J.; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Zheng, Fang] Tianjin Med Univ, Dept Ophthalmol, Gen Hosp, Tianjin, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; Tianjin Medical
   University
RP Gregori, G (通讯作者)，Bascom Palmer Eye Inst, Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM ggregori@med.miami.edu
RI roisman, luiz/AAD-3822-2019; Legarreta, Andrew/GRY-0710-2022
FU Carl Zeiss Meditec, Inc.; Macula Vision Research Foundation; Emma Clyde
   Hodge Memorial Foundation; Feig Family Foundation; Research to Prevent
   Blindness, Inc.; National Eye Institute Center Core grant [P30EY014801];
   CAPES Foundation, Ministry of Education of Brazil, Brasilia-Brazil;
   German Research Foundation Grant [SCHA 1869/1-1]; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX Supported by grants from Carl Zeiss Meditec, Inc.; the Macula Vision
   Research Foundation; the Emma Clyde Hodge Memorial Foundation; the Feig
   Family Foundation; an unrestricted grant from Research to Prevent
   Blindness, Inc.; a National Eye Institute Center Core grant
   (P30EY014801) to the Department of Ophthalmology, University of Miami
   Miller School of Medicine; the CAPES Foundation, Ministry of Education
   of Brazil, Brasilia-Brazil (LR); and German Research Foundation Grant
   SCHA 1869/1-1 (KBS).
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P7775, DOI 10.1167/iovs.14-14915
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Aoyagi R, 2012, CLIN EXP OPTOM, V95, P212, DOI 10.1111/j.1444-0938.2011.00668.x
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Chinn SR, 1997, OPT LETT, V22, P340, DOI 10.1364/OL.22.000340
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Dansingani KK, 2015, RETINA, V36, P499
   Erkul SO, 2014, INT OPHTHALMOL, V34, P35, DOI 10.1007/s10792-013-9787-6
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Esmaeelpour M, 2012, INVEST OPHTH VIS SCI, V53, P6803, DOI 10.1167/iovs.12-10314
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Galgauskas S, 2016, EUR J OPHTHALMOL, V26, P163, DOI 10.5301/ejo.5000677
   Gerendas BS, 2016, AM J OPHTHALMOL, V162, P150, DOI 10.1016/j.ajo.2015.10.020
   Gerendas BS, 2014, AM J OPHTHALMOL, V158, P1039, DOI 10.1016/j.ajo.2014.08.001
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Ho J, 2011, OPHTHALMOLOGY, V118, P2001, DOI 10.1016/j.ophtha.2011.02.049
   Huang WB, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-23
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kase S, 2016, EUR J OPHTHALMOL, V26, P158, DOI 10.5301/ejo.5000676
   KUBOTA T, 1993, BRIT J OPHTHALMOL, V77, P430, DOI 10.1136/bjo.77.7.430
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Maruko I, 2015, RETINA, V36, P992
   Mohler KJ, 2015, INVEST OPHTH VIS SCI, V56, P6284, DOI 10.1167/iovs.15-16670
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nunes RP, 2015, OSLI RETINA, V46, P162, DOI 10.3928/23258160-20150213-17
   Ohsugi H, 2013, OPTOMETRY VISION SCI, V90, P599, DOI 10.1097/OPX.0b013e3182924017
   Philip AM, 2016, BR J OPHTHALMOL, V100, P1039
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rhodes LA, 2015, INVEST OPHTH VIS SCI, V56, P1872, DOI 10.1167/iovs.14-16179
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
   Tanabe H, 2012, RETINA-J RET VIT DIS, V32, P134, DOI 10.1097/IAE.0b013e318217ff87
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Vural AD, 2014, RETINA-J RET VIT DIS, V34, P1223, DOI 10.1097/IAE.0000000000000043
   Wang Fenghua, 2012, Ophthalmic Surg Lasers Imaging, V43, pS32, DOI 10.3928/15428877-20121001-06
   Wong IY, 2013, RETINA-J RET VIT DIS, V33, P423, DOI 10.1097/IAE.0b013e3182753b5a
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zengin MO, 2014, BRIT J OPHTHALMOL, V98, P233, DOI 10.1136/bjophthalmol-2013-304044
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 52
TC 48
Z9 48
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2016
VL 57
IS 14
BP 6256
EP 6264
DI 10.1167/iovs.16-20161
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI3HG
UT WOS:000392380000047
PM 27849311
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ho, AC
   Heier, JS
   Holekamp, NM
   Garfinkel, RA
   Ladd, B
   Awh, CC
   Singh, RP
   Sanborn, GE
   Jacobs, JH
   Elman, MJ
   Loewenstein, A
   Eichenbaum, DA
AF Ho, Allen C.
   Heier, Jeffrey S.
   Holekamp, Nancy M.
   Garfinkel, Richard A.
   Ladd, Byron
   Awh, Carl C.
   Singh, Rishi P.
   Sanborn, George E.
   Jacobs, Jennifer H.
   Elman, Michael J.
   Loewenstein, Anat
   Eichenbaum, David A.
TI Real-World Performance of a Self-Operated Home Monitoring System for
   Early Detection of Neovascular Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE ForeseeHome AMD Monitoring System(&#174); neovascular age-related
   macular degeneration; AREDS2-HOME study
ID VISUAL-ACUITY; CLINICAL CHARACTERISTICS; RANIBIZUMAB; OUTCOMES; VEGF;
   DISEASE; EYE; ASSOCIATION; BEVACIZUMAB; CONVERSION
AB The real-world performance of a home telemonitoring strategy (ForeseeHome AMD Monitoring System(R), Notal Vision, Inc.,Manassas VA, USA) was evaluated and compared to the device arm of the AREDS2-HOME study among patients with intermediate AMD (iAMD) who converted to neovascular AMD (nAMD). All patients with confirmed conversion to nAMD who used the home monitoring system from 10/2009 through 9/2018 were identified by Notal Vision Diagnostic Clinic's medical records. Selected outcome variables were evaluated, including visual acuity (VA) at baseline and at conversion, and change in visual acuity (VA) from baseline to time of conversion. In total, 8991 patients performed 3,200,999 tests at a frequency of 5.6 +/- 3.2 times/week. The 306 eyes that converted from iAMD to nAMD over the study period (a 2.7% annual rate) were included in the analyses. There was a median (interquartile range) change of -3.0 (0.0-(-10.0)) letters among converted eyes, 81% [95% confidence interval (72-88%)] maintained a VA >= 20/40 at the time of conversion, while 69% of the conversion detections were triggered by system alerts. The real-world performance of an at-home testing strategy was similar to that reported for the device arm of the AREDS2-HOME study. The home telemonitoring system can markedly increase early detection of conversion to nAMD.
C1 [Ho, Allen C.] Wills Eye Hosp & Res Inst, 840 Walnut St, Philadelphia, PA 19107 USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, 50 Staniford St,Ste 600, Boston, MA 02114 USA.
   [Holekamp, Nancy M.] Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63124 USA.
   [Garfinkel, Richard A.] Retina Grp Washington, 110 Irving St NW, Washington, DC 20010 USA.
   [Ladd, Byron] Virginia Eye Inst, 6946 Forest Ave Suite 100, Richmond, VA 23230 USA.
   [Awh, Carl C.] Tennessee Retina, 345 23rd Ave North,Suite 350, Nashville, TN 37203 USA.
   [Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, Ctr Ophthalm Bioinformat, 9500 Euclid Ave,I-32, Cleveland, OH 44106 USA.
   [Sanborn, George E.; Jacobs, Jennifer H.] Notal Vis, 7717 Coppermine Dr, Manassas, VA 20109 USA.
   [Elman, Michael J.] Elman Retina, 7671 Quarterfield Rd 100, Glen Burnie, MD 21061 USA.
   [Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-6209105 Tel Aviv, Israel.
   [Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.
   [Eichenbaum, David A.] Retina Vitreous Associates Florida, 4344 Cent Ave, St Petersburg, FL 33711 USA.
C3 Jefferson University; Ophthalmic Consultants of Boston; Cleveland Clinic
   Foundation; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv
   University; Sackler Faculty of Medicine
RP Loewenstein, A (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, IL-6209105 Tel Aviv, Israel.; Loewenstein, A (通讯作者)，Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.
EM achomd@gmail.com; jsheier@eyeboston.com; nholekamp@gmail.com;
   rgarfinkel@rgw.com; laddb@vaeye.com; carlawh@gmail.com; singhr@ccf.org;
   georges@notalvision.com; jjacobs@notalvision.com; elman@elmanretina.com;
   anatl@tivmc.gov.il; deichenbaum@rvaf.com
OI Garfinkel, Richard/0000-0001-6414-2743; Ladd, Byron/0000-0002-1450-2963;
   Ho, Allen/0000-0003-3921-608X; Eichenbaum, David/0000-0003-0654-0668;
   Elman, Michael/0000-0001-7726-9508; Heier, Jeffrey/0000-0003-4625-3145
FU Notal Vision, Inc.
FX Sponsorship for this study and Rapid Service Fee were funded by Notal
   Vision, Inc.
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Chamard C, 2019, J FR OPHTALMOL, V42, P1049, DOI 10.1016/j.jfo.2019.02.017
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Evans RN, 2020, OPHTHALMOLOGY, V127, P1191, DOI 10.1016/j.ophtha.2020.03.020
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Ho A.C., 2018, P 2018 ASCRS ASOA AN
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Hsiang SL, 2020, NATURE, V585, pE7, DOI [10.1038/s41586-020-2691-0, 10.1038/s41586-020-2404-8]
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kim J.E., 2019, P MAC SOC BON SPRING
   Kim J.E., 2014, P AM SOC RET SPEC 20
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McGuinness MB, 2020, OPHTHALMOL RETINA, V4, P881, DOI 10.1016/j.oret.2020.03.015
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu H.J., OPHTHALMOL RETINA, P2020
   Zapata MA, 2021, GRAEF ARCH CLIN EXP, V259, P1993, DOI 10.1007/s00417-021-05093-4
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 37
TC 6
Z9 6
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2021
VL 10
IS 7
AR 1355
DI 10.3390/jcm10071355
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RL0HL
UT WOS:000638665400001
PM 33806058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Oshima, Y
   Ishibashi, Y
   Umeda, N
   Nagata, T
   Yoshida, S
   Uchio, E
   Kondo, H
   Sonoda, KH
   Ishibashi, T
AF Oshima, Yuji
   Ishibashi, Yumi
   Umeda, Naoyasu
   Nagata, Tatsuo
   Yoshida, Shigeo
   Uchio, Eiichi
   Kondo, Hiroyuki
   Sonoda, Koh-hei
   Ishibashi, Tatsuro
TI Correlation between improvement in visual acuity and QOL after
   Ranibizumab treatment for age-related macular degeneration patients:
   QUATRO study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Patient satisfaction; Quality of
   vision; Ranibizumab
AB Background: To evaluate the correlation between visual acuity improvement and vision-related QOL after ranibizumab treatment in Japanese patients with AMD.
   Methods: In this one-year prospective, interventional, open-label, multicenter study involving four sites, patients with neovascular AMD were enrolled and observed for 12 months. Treatment-naive patients received 0.5 mg ranibizumab as needed after three initial monthly doses. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at every visit. Evaluations with the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and patient satisfaction questionnaire were performed at baseline and 3 and 12 months after initial treatment. The primary endpoint was change in BCVA and QOL 3 months after ranibizumab treatment. QOL outcomes were also assessed in the better and poor BVCA subgroups.
   Results: The study enrolled 100 patients. The mean logMAR BCVA after treatment improved significantly from 0.43 to 0.30 at 3 months (p< 0.0001), and 0.28 at 12 months (p< 0.0001). The mean NEI-VFQ-25 composite scores improved from 79.48 to 84.13 at 3 months (p< 0.0001), and 86.0 at 12 months (p< 0.0001). The 3 and 12-month changes in NEI-VFQ-25 score and BCVA showed significant correlation. In the poor baseline visual acuity group (decimal BCVA <= 0.5), there was a significant correlation between the changes in the NEI-VFQ-25 score and BCVA (p=0.02) but not in the better baseline visual acuity group (decimal BCVA > 0.6, p=0.1) at 3 months. There were no significant differences in the satisfaction questionnaire score from baseline to at 3 months (p=0.54) and 12 months (p=0.23). The average CMT improved significantly from 340 to 264 mu m at 3 months (p< 0.0001) and to 268 mu m at 12 months (p< 0.0001).
   Conclusions: Intravitreal ranibizumab treatment resulted in improvement in visual acuity, anatomical change, and visual function change in Japanese AMD patients. Significant improvement was seen in patient visual function, and this was correlated with changes in VA, except immediately after loading dose treatment in patients with higher baseline VA. The patients' satisfaction with the treatment remained unchanged during the study period.
C1 [Oshima, Yuji; Sonoda, Koh-hei; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Ishibashi, Yumi; Yoshida, Shigeo] Kurume Univ, Sch Med, Dept Ophthalmol, Fukuoka, Japan.
   [Umeda, Naoyasu; Uchio, Eiichi] Fukuoka Univ, Sch Med, Dept Ophthalmol, Fukuoka, Japan.
   [Nagata, Tatsuo; Kondo, Hiroyuki] Univ Occupat & Environm Hlth, Dept Ophthalmol, Fukuoka, Japan.
C3 Kyushu University; Kurume University; Fukuoka University; University of
   Occupational & Environmental Health - Japan
RP Oshima, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM yuji@eye.med.kyushu-u.ac.jp
OI Oshima, Yuji/0000-0001-6284-977X
FU Novartis Pharma Japan (Tokyo Japan); JSPS KAKENHI [Kiban C 17 K11454]
FX This work was supported by Novartis Pharma Japan (Tokyo Japan) and the
   JSPS KAKENHI Grant (#Kiban C 17 K11454 [to Y.O.]). We declare that
   Novartis Pharma provided charges for data collection and statistical
   analysis. The sponsor did not have any additional role in the study
   design, data analysis, decision to publish, or preparation of the
   manuscript.
CR Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gomi F, 2019, JPN J OPHTHALMOL, V63, P437, DOI 10.1007/s10384-019-00687-2
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Joko T, 2020, PATIENT PREFER ADHER, V14, P553, DOI 10.2147/PPA.S228890
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 32
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 23
PY 2021
VL 21
IS 1
AR 58
DI 10.1186/s12886-021-01816-7
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PW2UV
UT WOS:000610530500001
PM 33485320
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Supuran, CT
AF Supuran, Claudiu T.
TI Agents for the prevention and treatment of age-related macular
   degeneration and macular edema: a literature and patent review
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE Age-related macular degeneration; macular edema; VEGF; ranibizumab;
   bevacizumab; aflibercept; pegaptanib; carbonic anhydrase; sulfonamide
ID CARBONIC-ANHYDRASE INHIBITORS; TOPICAL DORZOLAMIDE; MANAGEMENT;
   EFFICACY; ACETAZOLAMIDE; RANIBIZUMAB; MACULOPATHY; PEGAPTANIB;
   THERAPIES; GLAUCOMA
AB Introduction: Macular degeneration (MD) and macular edema (ME) are ophthalmologic diseases affecting an increasing number of the aging population. Until recently, there were few therapeutic options for both conditions but the last two decades saw important advances. Areas covered: This review summarizes the agents used for the treatment of age-related MD (AMD), which include verteporfin, for photodynamic therapy, and anti-VEGF agents, the aptamer pegaptanib, the monoclonal antibodies (MAbs) ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) and the fusion protein aflibercept (Eylea (R)). All these drugs are effective only for the wet form of AMD, whereas for the dry form there is no treatment available. ME is, on the other hand, treated with nonsteroidal anti-inflammatory drugs and carbonic anhydrase (CA) inhibitors. Recently, MAbs such as ranibizumab and bevacizumab were also shown to be effective for the management of the cystoid and diabetic ME. Expert opinion: There are important advances made in the field in the last years but longer-acting anti-VEGF agents or drugs with less ocular side effects are needed. Many such agents are in clinical development.
C1 [Supuran, Claudiu T.] Univ Firenze, NEUROFARBA Dept, Sez Sci Farmaceut & Nutraceut, Via Ugo Schiff 6, I-50019 Florence, Italy.
C3 University of Florence
RP Supuran, CT (通讯作者)，Univ Firenze, NEUROFARBA Dept, Sez Sci Farmaceut & Nutraceut, Via Ugo Schiff 6, I-50019 Florence, Italy.
EM claudiu.supuran@unifi.it
OI Supuran, Claudiu/0000-0003-4262-0323
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Arechederra RL, 2013, BIOORGAN MED CHEM, V21, P1544, DOI 10.1016/j.bmc.2012.06.053
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Braithwaite T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub3
   Campbell M, 2019, BIOCHEM PHARMACOL, V164, P321, DOI 10.1016/j.bcp.2019.04.029
   Carta F, 2012, EXPERT OPIN THER PAT, V22, P79, DOI 10.1517/13543776.2012.649006
   Coney JM, 2019, INT MED CASE REP J, V12, P161, DOI 10.2147/IMCRJ.S192524
   COX SN, 1988, ARCH OPHTHALMOL-CHIC, V106, P1190
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Dans KC, 2019, GRAEF ARCH CLIN EXP, V257, P741, DOI 10.1007/s00417-018-04232-8
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2005, NAT REV DRUG DISCOV, V4, P187, DOI 10.1038/nrd1677
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Giusti Cristiano, 2001, International Ophthalmology, V24, P79, DOI 10.1023/A:1016354517304
   Grover S, 1997, RETINA-J RET VIT DIS, V17, P222, DOI 10.1097/00006982-199705000-00009
   Hageman GS, 2018, Patent No. [US2018335436, 2018335436]
   Hageman GS., 2018, Patent No. [US2018371547, 2018371547]
   Horani M, 2019, OPHTHALMOL THER, V8, P235, DOI 10.1007/s40123-019-0177-7
   Huang QZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186180
   Huckfeldt RM, 2017, SEMIN OPHTHALMOL, V32, P43, DOI 10.1080/08820538.2016.1228404
   Kim DG, 2018, CAN J OPHTHALMOL, V53, pE103, DOI 10.1016/j.jcjo.2017.10.022
   Kusuzaki K, 2017, J ENZYM INHIB MED CH, V32, P908, DOI 10.1080/14756366.2017.1335310
   Lee JH, 2018, Patent No. [KR20180053929, 20180053929]
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liew G, 2015, INVEST OPHTH VIS SCI, V56, P1531, DOI 10.1167/iovs.14-15995
   Makri OE, 2018, CURR DRUG SAF, V13, P208, DOI 10.2174/1574886313666180619163845
   Marchetti C, 2019, ONCOTARGETS THER, V12, P1095, DOI 10.2147/OTT.S155425
   Masini E, 2013, EXPERT OPIN THER PAT, V23, P705, DOI 10.1517/13543776.2013.794788
   McLaughlin J, 2019, Patent No. [WO2019079718, 2019079718]
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Meyer KM, 2012, GRAEF ARCH CLIN EXP, V250, P463, DOI 10.1007/s00417-011-1642-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray CD, 2014, EYE, V28, P1218, DOI 10.1038/eye.2014.180
   Narayanan R, 2006, NAT REV DRUG DISCOV, V5, P815, DOI 10.1038/nrd2157
   Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nishimiya D, 2018, Patent No. [TW201840589, 201840589]
   Nocentini A, 2018, EXPERT OPIN THER PAT, V28, P729, DOI 10.1080/13543776.2018.1508453
   O'Neil BH, 2003, EXPERT OPIN INV DRUG, V12, P1939, DOI 10.1517/eoid.12.12.1939.21995
   Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x
   Peters KG, 2017, Patent No. [GB2549865, 2549865]
   Pham B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022031
   Piozzi E, 2017, EUR J OPHTHALMOL, V27, pE179, DOI 10.5301/ejo.5001010
   Pries W., 2018, Patent No. [US2018353530, 2018353530]
   Rebello G, 2004, P NATL ACAD SCI USA, V101, P6617, DOI 10.1073/pnas.0401529101
   Remky A, 2005, ACTA OPHTHALMOL SCAN, V83, P154, DOI 10.1111/j.1600-0420.2005.00406.x
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Scaria A., 2019, Patent No. [AU2019203413, 2019203413]
   Schori C, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107690
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467
   Supuran CT, 2018, EXPERT OPIN INV DRUG, V27, P963, DOI 10.1080/13543784.2018.1548608
   Supuran CT, 2018, EXPERT OPIN THER PAT, V28, P709, DOI 10.1080/13543776.2018.1523897
   Supuran CT, 2018, EXPERT OPIN THER PAT, V28, P713, DOI 10.1080/13543776.2018.1519023
   Supuran CT, 2018, METABOLITES, V8, DOI 10.3390/metabo8020025
   Supuran CT, 2017, METABOLITES, V7, DOI 10.3390/metabo7030048
   Supuran CT, 2016, J ENZYM INHIB MED CH, V31, P1254, DOI 10.1080/14756366.2016.1201479
   Supuran CT, 2016, BIOCHEM J, V473, P2023, DOI 10.1042/BCJ20160115
   Supuran CT, 2016, EXPERT OPIN DRUG MET, V12, P423, DOI 10.1517/17425255.2016.1154534
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575
   Testa F, 2019, OPHTHALMIC GENET, V40, P207, DOI 10.1080/13816810.2019.1616303
   Thobani A, 2011, RETINA-J RET VIT DIS, V31, P312, DOI 10.1097/IAE.0b013e3181e587f9
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Washington I., 2018, Patent No. [USRE47045, 47045]
   Whitcup SM, 1996, OPHTHALMOLOGY, V103, P1054, DOI 10.1016/S0161-6420(96)30567-8
   Wolfensberger TJ, 2017, DEV OPHTHALMOL, V58, P74, DOI 10.1159/000455275
   Wolfensberger TJ, 1999, DOC OPHTHALMOL, V97, P387, DOI 10.1023/A:1002143802926
   Zhang S, 2018, Patent No. [CN107602699, 107602699]
NR 77
TC 30
Z9 30
U1 0
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD OCT 3
PY 2019
VL 29
IS 10
SI SI
BP 761
EP 767
DI 10.1080/13543776.2019.1671353
EA SEP 2019
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JF2SJ
UT WOS:000487660600001
PM 31540558
DA 2022-11-30
ER

PT J
AU Ting, DSJ
   Foo, VHX
   Yang, LWY
   Sia, JT
   Ang, M
   Lin, HT
   Chodosh, J
   Mehta, JS
   Ting, DSW
AF Ting, Darren Shu Jeng
   Foo, Valencia H. X.
   Yang, Lily Wei Yun
   Sia, Josh Tjunrong
   Ang, Marcus
   Lin, Haotian
   Chodosh, James
   Mehta, Jodhbir S.
   Ting, Daniel Shu Wei
TI Artificial intelligence for anterior segment diseases: Emerging
   applications in ophthalmology
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE cornea; conjunctiva; telemedicine; lens and zonules; glaucoma
ID OPTICAL COHERENCE TOMOGRAPHY; MACHINE LEARNING CLASSIFIERS;
   COMPUTER-AIDED DIAGNOSIS; KERATOCONUS DETECTION; DIABETIC-RETINOPATHY;
   GLOBAL PREVALENCE; GLAUCOMA; CLASSIFICATION; SYSTEM; CATARACT
AB With the advancement of computational power, refinement of learning algorithms and architectures, and availability of big data, artificial intelligence (AI) technology, particularly with machine learning and deep learning, is paving the way for 'intelligent' healthcare systems. AI-related research in ophthalmology previously focused on the screening and diagnosis of posterior segment diseases, particularly diabetic retinopathy, age-related macular degeneration and glaucoma. There is now emerging evidence demonstrating the application of AI to the diagnosis and management of a variety of anterior segment conditions. In this review, we provide an overview of AI applications to the anterior segment addressing keratoconus, infectious keratitis, refractive surgery, corneal transplant, adult and paediatric cataracts, angle-closure glaucoma and iris tumour, and highlight important clinical considerations for adoption of AI technologies, potential integration with telemedicine and future directions.
C1 [Ting, Darren Shu Jeng] Univ Nottingham, Acad Ophthalmol, Nottingham, England.
   [Ting, Darren Shu Jeng] Queens Med Ctr, Dept Ophthalmol, Nottingham, England.
   [Ting, Darren Shu Jeng; Ang, Marcus; Mehta, Jodhbir S.; Ting, Daniel Shu Wei] Singapore Eye Res Inst, Singapore, Singapore.
   [Foo, Valencia H. X.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Yang, Lily Wei Yun] NUS Yong Loo Lin Sch Med, Singapore, Singapore.
   [Sia, Josh Tjunrong] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Ang, Marcus; Mehta, Jodhbir S.] Singapore Natl Eye Ctr, Cornea & Ext Dis, Singapore, Singapore.
   [Lin, Haotian] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   [Chodosh, James] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Howe Lab, Ophthalmol, Boston, MA 02115 USA.
   [Ting, Daniel Shu Wei] Singapore Natl Eye Ctr, Vitreoretinal Dept, Singapore 168751, Singapore.
C3 University of Nottingham; University of Nottingham; National University
   of Singapore; Singapore National Eye Center; Singapore National Eye
   Center; National University of Singapore; National University of
   Singapore; Singapore National Eye Center; Singapore National Eye Center;
   Sun Yat Sen University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Singapore National Eye Center
RP Ting, DSW (通讯作者)，Singapore Natl Eye Ctr, Vitreoretinal Dept, Singapore 168751, Singapore.
EM daniel.ting.s.w@singhealth.com.sg
OI Bidwai, Pooja Vishal/0000-0002-3077-4395; Lin,
   Haotian/0000-0003-4672-9721; Ting, Daniel Shu Wei/0000-0003-2264-7174
FU MRC [MR/T001674/1] Funding Source: UKRI
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Accardo PA, 2002, J BIOMED INFORM, V35, P151, DOI 10.1016/S1532-0464(02)00513-0
   Acharya RU, 2010, J MED SYST, V34, P619, DOI 10.1007/s10916-009-9275-8
   Achiron A, 2017, J REFRACT SURG, V33, P592, DOI 10.3928/1081597X-20170616-03
   Al-Fahdawi S, 2018, COMPUT METH PROG BIO, V160, P11, DOI 10.1016/j.cmpb.2018.03.015
   Amil P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38136-8
   Andreanos KD, 2017, OPHTHALMOL THER, V6, P245, DOI 10.1007/s40123-017-0099-1
   Ang A., 2019, ELECT ENG SYSTEMS SC
   [Anonymous], REV OPHTHALMOLOGY
   Arbelaez MC, 2012, OPHTHALMOLOGY, V119, P2231, DOI 10.1016/j.ophtha.2012.06.005
   Baskaran M, 2015, OPHTHALMOLOGY, V122, P2380, DOI 10.1016/j.ophtha.2015.07.030
   Brookes NH, 2017, CELL TISSUE BANK, V18, P167, DOI 10.1007/s10561-017-9622-9
   Cardoso J, 2017, FETAL INFANT OPHTHAL
   Chastang PJ, 2000, J CATARACT REFR SURG, V26, P675, DOI 10.1016/S0886-3350(00)00303-5
   Chen X, 2017, IEEE T BIO-MED ENG, V64, P786, DOI 10.1109/TBME.2016.2573642
   Cheung CYL, 2011, INVEST OPHTH VIS SCI, V52, P1314, DOI 10.1167/iovs.10-5427
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Collier SA, 2014, MMWR-MORBID MORTAL W, V63, P1027
   Court JH, 2015, CLIN OPHTHALMOL, V9, P745, DOI 10.2147/OPTH.S75000
   Cui T, 2020, AM J OPHTHALMOL, V210, P71, DOI 10.1016/j.ajo.2019.10.015
   Dabasia PL, 2015, INVEST OPHTH VIS SCI, V56, P3929, DOI 10.1167/iovs.15-16727
   Dabbah MA, 2010, LECT NOTES COMPUT SC, V6361, P300
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dey D, 2019, J AM COLL CARDIOL, V73, P1317, DOI 10.1016/j.jacc.2018.12.054
   Dimililer K, 2016, PROCEDIA COMPUT SCI, V102, P325, DOI 10.1016/j.procs.2016.09.408
   Dirisamer M, 2012, ARCH OPHTHALMOL-CHIC, V130, P280, DOI 10.1001/archophthalmol.2011.343
   Dos Santos VA, 2019, BIOMED OPT EXPRESS, V10, P622, DOI 10.1364/BOE.10.000622
   DOUGHTY MJ, 1992, EXP EYE RES, V55, P145, DOI 10.1016/0014-4835(92)90102-X
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foot B, 2017, EYE, V31, P771, DOI 10.1038/eye.2017.1
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Fu HZ, 2019, AM J OPHTHALMOL, V203, P37, DOI 10.1016/j.ajo.2019.02.028
   Fu HZ, 2020, IEEE T CYBERNETICS, V50, P3358, DOI 10.1109/TCYB.2019.2897162
   Fu HZ, 2018, LECT NOTES COMPUT SC, V11071, P356, DOI 10.1007/978-3-030-00934-2_40
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gao XT, 2012, IEEE ENG MED BIO, P4434, DOI 10.1109/EMBC.2012.6346950
   Gatinel D., 2012, INT J KERATOCONUS EC, V1, P36
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Godefrooij DA, 2017, AM J OPHTHALMOL, V175, P169, DOI 10.1016/j.ajo.2016.12.015
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Gunn PJG, 2018, BMJ OPEN OPHTHALMOL, V3, DOI 10.1136/bmjophth-2017-000127
   Guo LY, 2015, COMPUT IND, V69, P72, DOI 10.1016/j.compind.2014.09.005
   Hayashi T, 2020, EYE CONTACT LENS, V46, P121, DOI 10.1097/ICL.0000000000000634
   Hidalgo IR, 2017, CORNEA, V36, P689, DOI 10.1097/ICO.0000000000001194
   Issarti I, 2019, COMPUT BIOL MED, V109, P33, DOI 10.1016/j.compbiomed.2019.04.024
   Jiang JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201142
   Kamiya K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031313
   Khokhar SK, 2017, INDIAN J OPHTHALMOL, V65, P1340, DOI 10.4103/ijo.IJO_1023_17
   Khor WB, 2018, AM J OPHTHALMOL, V195, P161, DOI 10.1016/j.ajo.2018.07.040
   Koh V, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0960-3
   Konstantopoulos A, 2011, INVEST OPHTH VIS SCI, V52, P1093, DOI 10.1167/iovs.10-6067
   Koprowski R, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0243-5
   Kortuem K, 2018, BRIT J OPHTHALMOL, V102, P1391, DOI 10.1136/bjophthalmol-2017-311494
   Kotecha A, 2017, EYE, V31, P899, DOI 10.1038/eye.2017.9
   Kovacs I, 2016, J CATARACT REFR SURG, V42, P275, DOI 10.1016/j.jcrs.2015.09.020
   Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041
   Lambert SR, 2015, J AAPOS, V19, P393, DOI [10.1016/j.jaapos.2015.05.008, 10.1016/j.jaapos.2015.01.013]
   Lavanya R, 2008, OPHTHALMOLOGY, V115, P1720, DOI 10.1016/j.ophtha.2008.03.015
   Lavric A, 2019, COMPUT INTEL NEUROSC, V2019, DOI 10.1155/2019/8162567
   LeCun Y., 2015, NATURE, V521, P436, DOI DOI 10.1038/NATURE14539
   Li QC, 2019, DIABETES RES CLIN PR, V151, P33, DOI 10.1016/j.diabres.2019.03.039
   Lin HT, 2019, ECLINICALMEDICINE, V9, P52, DOI 10.1016/j.eclinm.2019.03.001
   Liu XX, 2019, NAT MED, V25, P1467, DOI 10.1038/s41591-019-0603-3
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Liu Z, 2020, COMPUT METH PROG BIO, V187, DOI 10.1016/j.cmpb.2019.105019
   Long EP, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0024
   Lopes BT, 2018, AM J OPHTHALMOL, V195, P223, DOI 10.1016/j.ajo.2018.08.005
   Modjtahedi BS, 2018, CLIN OPHTHALMOL, V12, P2095, DOI 10.2147/OPTH.S171263
   Mohammadpour M, 2018, J CURR OPHTHALMOL, V30, P110, DOI 10.1016/j.joco.2017.11.002
   Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393
   Ngiam J, 2011, P 28 INT C INT C MAC, P689, DOI DOI 10.5555/3104482.3104569
   Niazi MKK, 2019, LANCET ONCOL, V20, pE253, DOI 10.1016/S1470-2045(19)30154-8
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P13, DOI 10.1016/j.cmpb.2016.03.011
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P65, DOI 10.1016/j.cmpb.2016.03.018
   Niwas SI, 2016, IEEE J BIOMED HEALTH, V20, P343, DOI 10.1109/JBHI.2014.2387207
   Nolan WP, 2007, OPHTHALMOLOGY, V114, P33, DOI 10.1016/j.ophtha.2006.05.073
   Nongpiur ME, 2013, OPHTHALMOLOGY, V120, P48, DOI 10.1016/j.ophtha.2012.07.005
   Nurzynska K, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10030060
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Panchapakesan J, 1997, Ophthalmic Epidemiol, V4, P119
   Patel TP, 2018, CORNEA, V37, P331, DOI 10.1097/ICO.0000000000001488
   Perez Lopez Yadini, 2019, VipIMAGE 2019. Proceedings of the VII ECCOMAS Thematic Conference on Computational Vision and Medical Image Processing. Lecture Notes in Computational Vision and Biomechanics (LNCVB 34), P391, DOI 10.1007/978-3-030-32040-9_40
   Phan S, 2019, JPN J OPHTHALMOL, V63, P276, DOI 10.1007/s10384-019-00659-6
   Porporato N, 2018, CLIN EXP OPHTHALMOL, V46, P147, DOI 10.1111/ceo.13120
   Quartilho A, 2020, EYE, V34, P657, DOI 10.1038/s41433-019-0554-4
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Razeghinejad MR, 2018, SURV OPHTHALMOL, V63, P754, DOI 10.1016/j.survophthal.2018.05.001
   Ruiz Hidalgo I, 2016, CORNEA, V35, P827, DOI 10.1097/ICO.0000000000000834
   Saad A, 2016, J REFRACT SURG, V32, P510, DOI 10.3928/1081597X-20160523-01
   Saba L, 2019, EUR J RADIOL, V114, P14, DOI 10.1016/j.ejrad.2019.02.038
   Saini JS, 2003, CURR EYE RES, V27, P111, DOI 10.1076/ceyr.27.2.111.15949
   Sakata LM, 2008, ARCH OPHTHALMOL-CHIC, V126, P181, DOI 10.1001/archophthalmol.2007.46
   Sharif MS, 2015, COMPUT METH PROG BIO, V122, P421, DOI 10.1016/j.cmpb.2015.09.003
   Sharif MS, 2015, APPL SOFT COMPUT, V36, P269, DOI 10.1016/j.asoc.2015.07.019
   Sheeladevi S, 2016, EYE, V30, P1160, DOI 10.1038/eye.2016.156
   Shetty R, 2008, CORNEA, V27, P1022, DOI 10.1097/ICO.0b013e318172fc54
   Shi GH, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.25
   Silverman RH, 2014, INVEST OPHTH VIS SCI, V55, P1580, DOI 10.1167/iovs.13-12578
   Smadja D, 2013, AM J OPHTHALMOL, V156, P237, DOI 10.1016/j.ajo.2013.03.034
   Smolek MK, 1997, INVEST OPHTH VIS SCI, V38, P2290
   Solebo AL, 2019, ECLINICALMEDICINE, V9, P7, DOI 10.1016/j.eclinm.2019.03.002
   Souza MB, 2010, CLINICS, V65, P1223, DOI 10.1590/S1807-59322010001200002
   Sramka M, 2019, PEERJ, V7, DOI 10.7717/peerj.7202
   Taylor S, 2019, JAMA OPHTHALMOL, V137, P1022, DOI 10.1001/jamaophthalmol.2019.2433
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSJ, 2019, BRIT J OPHTHALMOL, V103, P1537, DOI 10.1136/bjophthalmol-2019-315025
   Ting DSJ, 2019, EYE, V33, P812, DOI 10.1038/s41433-018-0323-9
   Ting DSJ, 2018, EYE, V32, P1416, DOI 10.1038/s41433-018-0085-4
   Treder M, 2019, CORNEA, V38, P157, DOI 10.1097/ICO.0000000000001776
   Twa MD, 2005, OPTOMETRY VISION SCI, V82, P1038, DOI 10.1097/01.opx.0000192350.01045.6f
   Ung L, 2019, SURV OPHTHALMOL, V64, P255, DOI 10.1016/j.survophthal.2018.12.003
   Valdes-Mas MA, 2014, COMPUT METH PROG BIO, V116, P39, DOI 10.1016/j.cmpb.2014.04.003
   Vega-Estrada A, 2015, J CATARACT REFR SURG, V41, P1145, DOI 10.1016/j.jcrs.2014.08.045
   Vega-Estrada A, 2013, AM J OPHTHALMOL, V155, P575, DOI 10.1016/j.ajo.2012.08.020
   Vigueras-Guillen Juan P, 2019, BMC Biomed Eng, V1, P4, DOI 10.1186/s42490-019-0003-2
   Vigueras-Guillen JP, 2018, IEEE T MED IMAGING, V37, P2278, DOI 10.1109/TMI.2018.2841910
   Wang W, 2016, INVEST OPHTH VIS SCI, V57, P5872, DOI 10.1167/iovs.16-19894
   Wu XH, 2019, BRIT J OPHTHALMOL, V103, P1553, DOI 10.1136/bjophthalmol-2019-314729
   Wu XL, 2018, IEEE ACCESS, V6, P13449, DOI 10.1109/ACCESS.2018.2808941
   Xiong L, 2017, J HEALTHC ENG, V2017, DOI 10.1155/2017/5645498
   Xu BY, 2019, AM J OPHTHALMOL, V208, P273, DOI 10.1016/j.ajo.2019.08.004
   Xu X, 2020, IEEE J BIOMED HEALTH, V24, P556, DOI 10.1109/JBHI.2019.2914690
   Xu YW, 2013, LECT NOTES COMPUT SC, V8150, P468, DOI 10.1007/978-3-642-40763-5_58
   Xu YW, 2012, IEEE ENG MED BIO, P3167, DOI 10.1109/EMBC.2012.6346637
   Yamazaki N, 2014, OPHTHALMOLOGY, V121, P2153, DOI 10.1016/j.ophtha.2014.04.043
   Yang JJ, 2016, COMPUT METH PROG BIO, V124, P45, DOI 10.1016/j.cmpb.2015.10.007
   Yoo TK, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0135-8
   Yousefi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205998
   Yu F, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1860
   Zaki WMDW, 2018, COMPUT METH PROG BIO, V154, P71, DOI 10.1016/j.cmpb.2017.10.026
   Zhang HY, 2019, COMPUT METH PROG BIO, V182, DOI 10.1016/j.cmpb.2019.07.006
   Zulkifley MA, 2019, MULTIMED TOOLS APPL, P1
NR 134
TC 42
Z9 44
U1 23
U2 112
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2021
VL 105
IS 2
BP 158
EP 168
DI 10.1136/bjophthalmol-2019-315651
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QB6HE
UT WOS:000614238600004
PM 32532762
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Sharma, A
   Kumar, N
   Parachuri, N
   Kuppermann, B
   Bandello, F
AF Sharma, Ashish
   Kumar, Nilesh
   Parachuri, Nikulaa
   Kuppermann, Baruch
   Bandello, Francesco
TI Supplemental nutrition for retinal health: Evidence based analysis of
   commercial preparations in India
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE AMD; AREDS-2; nutritional supplement
ID SELENIUM
AB Purpose: Antioxidants have been lately postulated as supportive and prophylactic supplements for various retinal disorders, especially age-related macular degeneration (AMD). Forty-eight brands of such supplements containing lutein and zeaxanthin are available in India. The aim of the study was to assess the market leaders in supplements for ophthalmology in view of AREDS recommendations. Methods: Descriptive review of top-selling supplements for eye health were compared to the contents of the AREDS-recommended levels. Results: None of the top 10 selling brands had exact or near similar composition as recommended in the AREDS-2 study, which is the most widely accepted level-1 evidence in AMD prevention. Conclusion: Physicians prescribing these antioxidants, especially for the prevention of advanced AMD, should be vigilant and aware of the contents of the prescribed brands.
C1 [Sharma, Ashish; Kumar, Nilesh; Parachuri, Nikulaa] Lotus Eye Hosp & Inst, Dept Vitreoretina, Avinashi Rd, Coimbatore, Tamil Nadu, India.
   [Kumar, Nilesh] Madhavi Netralaya, Vitreo Retina Div, Ara, Bihar, India.
   [Parachuri, Nikulaa] Sankara Eye Hosp, Dept Vitreoretina, Coimbatore, Tamil Nadu, India.
   [Kuppermann, Baruch] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Bandello, Francesco] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Sharma, Ashish] Lotus Eye Hosp & Inst, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.
C3 University of California System; University of California Irvine;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Sharma, A (通讯作者)，Lotus Eye Hosp & Inst, Avinashi Rd, Coimbatore 641014, Tamil Nadu, India.
EM drashish79@hotmail.com
FU Research to Prevent Blindness
FX Dr. Kuppermann acknowledges an unrestricted grant from Research to
   Prevent Blindness to the Gavin Herbert Eye Institute at the University
   of California, Irvine
CR [Anonymous], LAW NUTR SUPPLEMENTA
   [Anonymous], REAL WORLD DATA SETS
   [Anonymous], DIETARY SUPPLEMENT S
   [Anonymous], 2020, NUTR C FS QUESTIONS
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   [Anonymous], LUTEIN ZEAXANTHIN
   Bansal R, 2019, APPL CLIN RES CLIN T, V06, P46
   Boindala S, 2019, INDIAN J MED RES, V150, P248, DOI 10.4103/ijmr.IJMR_1719_18
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   FSSAI, 2020, REC DAIL ALL RDA
   Health Supplements: FSSAI, HLTH SUPPLEMENTS FSS
   Houghton LA, 2016, J NUTR, V146, P1670, DOI 10.3945/jn.116.235127
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Middha P, 2019, NICOTINE TOB RES, V21, P1045, DOI 10.1093/ntr/nty115
   nutraingredients-asia.com, INDIAS NEW FUNCTIONA
   Pastori D, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000364
   Reboul E, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040838
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2022
VL 70
IS 6
BP 2061
EP 2064
DI 10.4103/ijo.IJO_3101_21
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3H8KT
UT WOS:000832280100035
PM 35647982
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sene, A
   Chin-Yee, D
   Apte, RS
AF Sene, Abdoulaye
   Chin-Yee, David
   Apte, Rajendra S.
TI Seeing through VEGF: innate and adaptive immunity in pathological
   angiogenesis in the eye
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
DE angiogenesis; vascular endothelial growth factor (VEGF); immune
   regulation; neovascularization; age-related macular degeneration (AMD);
   diabetic retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR EDEMA SECONDARY; CHOROIDAL
   NEOVASCULARIZATION; MACROPHAGE ACTIVATION; TRAP-EYE; INTRAVITREAL
   AFLIBERCEPT; CHOLESTEROL EFFLUX; IL17RC PROMOTER; PALOMID 529;
   CELL-DEATH
AB The central role of vascular endothelial growth factor (VEGF) signaling in regulating normal vascular development and pathological angiogenesis has been documented in multiple studies. Ocular anti-VEGF therapy is highly effective for treating a subset of patients with blinding eye disorders such as diabetic retinopathy and neovascular age-related macular degeneration (AMD). However, chronic VEGF suppression can lead to adverse effects associated with poor visual outcomes due to the loss of prosurvival and neurotrophic capacities of VEGF. In this review, we discuss emerging evidence for immune-related mechanisms that regulate ocular angiogenesis in a VEGF-independent manner. These novel molecular and cellular pathways may provide potential therapeutic avenues for a multitarget strategy, preserving the neuroprotective functions of VEGF in those patients whose disease is unresponsive to VEGF neutralization.
C1 [Sene, Abdoulaye; Chin-Yee, David; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Neurosci Program, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Sene, A (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA.
EM senea@vision.wustl.edu; apte@vision.wustl.edu
RI Sene, Abdoulaye/D-3342-2015
OI Sene, Abdoulaye/0000-0001-9194-7264
FU National Institutes of Health (NIH) [R01EY019287]; NIH Vision Core grant
   [P30EY02687]; Carl Marshall Reeves and Mildred Almen Reeves Foundation
   Inc.; Research to Prevent Blindness Inc.; American Federation for Aging
   Research; Lacy Foundation Research Award; Thome Foundation; NATIONAL EYE
   INSTITUTE [P30EY002687, R01EY019287] Funding Source: NIH RePORTER
FX This work was supported by a National Institutes of Health (NIH) grant
   R01EY019287; NIH Vision Core grant P30EY02687; the Carl Marshall Reeves
   and Mildred Almen Reeves Foundation Inc. Award; the Research to Prevent
   Blindness Inc. Career Development Award and Physician Scientist Award to
   R.S.A.; the American Federation for Aging Research; the Lacy Foundation
   Research Award; and the Thome Foundation.
CR Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bock F, 2013, PROG RETIN EYE RES, V34, P89, DOI 10.1016/j.preteyeres.2013.01.001
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen Z, 2008, CYTOKINE, V41, P71, DOI 10.1016/j.cyto.2007.09.009
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chou J, 2014, ADV EXP MED BIOL, V801, P669, DOI 10.1007/978-1-4614-3209-8_84
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Cursiefen C, 2012, BRIT J OPHTHALMOL, V96, P3, DOI 10.1136/bjo.2011.204701
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Frantz S, 2005, CIRC RES, V96, P15, DOI 10.1161/01.RES.0000153188.68898.ac
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez F. O., 2014, F1000PRIME REPORTS, V6, P13
   Mechoulam Hadas, 2003, Am J Pharmacogenomics, V3, P261, DOI 10.2165/00129785-200303040-00004
   Midena E, 2014, EUR J OPHTHALMOL, V24, P459
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Newman AC, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-13
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   PALMER EA, 1988, ARCH OPHTHALMOL-CHIC, V106, P471
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pelletier J, 2014, MOL NEUROBIOL
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Raimondi C, 2014, J EXP MED, V211, P1167, DOI 10.1084/jem.20132330
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Safi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/801269
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Sapieha P, 2012, BLOOD, V120, P2182, DOI 10.1182/blood-2012-04-396846
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   SMITH AC, 2003, INVEST OPHTHALMOL VI, V44
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041
   Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012
   Terry T L, 1942, Trans Am Ophthalmol Soc, V40, P262
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
NR 99
TC 82
Z9 85
U1 0
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD JAN
PY 2015
VL 21
IS 1
BP 43
EP 51
DI 10.1016/j.molmed.2014.10.005
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA AY9IC
UT WOS:000347862800006
PM 25457617
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tochitsky, I
   Kienzler, MA
   Isacoff, E
   Kramer, RH
AF Tochitsky, Ivan
   Kienzler, Michael A.
   Isacoff, Ehud
   Kramer, Richard H.
TI Restoring Vision to the Blind with Chemical Photoswitches
SO CHEMICAL REVIEWS
LA English
DT Review
ID OPTICAL CONTROL; VISUAL FUNCTION; MACULAR DEGENERATION; GENE-THERAPY;
   RETINAL DEGENERATION; GLUTAMATE-RECEPTOR; ION CHANNELS; AZOBENZENE
   PHOTOSWITCHES; OPTOGENETIC PHARMACOLOGY; PHOTORECEPTORS RESTORES
AB Degenerative retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD) affect millions of people around the world and lead to irreversible vision loss if left untreated. A number of therapeutic strategies have been developed over the years to treat these diseases or restore vision to already blind patients. In this Review, we describe the development and translational application of light-sensitive chemical photoswitches to restore visual function to the blind retina and compare the translational potential of photoswitches with other vision-restoring therapies. This therapeutic strategy is enabled by an efficient fusion of chemical synthesis, chemical biology, and molecular biology and is broadly applicable to other biological systems. We hope this Review will be of interest to chemists as well as neuroscientists and clinicians.
C1 [Tochitsky, Ivan] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.
   [Tochitsky, Ivan] Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA.
   [Kienzler, Michael A.] Univ Maine, Dept Chem, Orono, ME 04469 USA.
   [Isacoff, Ehud; Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
   [Isacoff, Ehud; Kramer, Richard H.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
   [Isacoff, Ehud] Lawrence Berkeley Natl Lab, Biosci Div, Berkeley, CA 94720 USA.
C3 Harvard University; Boston Children's Hospital; Harvard University;
   Harvard Medical School; University of Maine System; University of Maine
   Orono; University of California System; University of California
   Berkeley; University of California System; University of California
   Berkeley; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory
RP Isacoff, E; Kramer, RH (通讯作者)，Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.; Isacoff, E; Kramer, RH (通讯作者)，Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.; Isacoff, E (通讯作者)，Lawrence Berkeley Natl Lab, Biosci Div, Berkeley, CA 94720 USA.
EM ehud@berkeley.edu; rhkramer@berkeley.edu
RI isacoff, ehud/AAP-1459-2020
OI Tochitsky, Ivan/0000-0003-0650-9193; Isacoff, Ehud
   Y./0000-0003-4775-9359
FU National Institutes of Health Nanomedicine Center for the Optical
   Control of Biological Function [2PN2EY018241]; National Science
   Foundation Major Research Instrumentation Award [1041078]; EAGER award
   [IOS-1451027]; National Eye Institute [EY018957, P30 EY003176]; Thome
   Foundation for Biomedical Research; Foundation Fighting Blindness;  [S10
   RR028971]; NATIONAL EYE INSTITUTE [R01EY024334, P30EY003176] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKE [R01NS100911] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   Nanomedicine Center for the Optical Control of Biological Function
   (2PN2EY018241) (E.I. and RH.K) and instrumentation award (S10 RR028971),
   the National Science Foundation Major Research Instrumentation Award
   (1041078) and EAGER award (IOS-1451027) (E.I.), as well as grants to
   R.H.K. from the National Eye Institute (EY018957, P30 EY003176), the
   Thome Foundation for Biomedical Research, and the Foundation Fighting
   Blindness. E.Y.I. and R.H.K. are members of the board of directors of
   Photoswitch Biosciences, Inc., and Photoswitch Therapeutics, Inc., which
   are developing commercial applications for chemical photo switches.
   E.Y.I. and R.H.K. are inventors on U.S. Patent no. 9334231 related to
   using chemical photoswitches to treat blindness.
CR ADAMUS G, 1992, CURR EYE RES, V11, P657, DOI 10.3109/02713689209000739
   Adelmann G., 1999, IONOTROPIC GLUTAMATE
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], 2018, MED LETT DRUGS THER, V60, P53
   Artigas JM, 2012, INVEST OPHTH VIS SCI, V53, P4076, DOI 10.1167/iovs.12-9471
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Banghart M, 2004, NAT NEUROSCI, V7, P1381, DOI 10.1038/nn1356
   Banghart MR, 2009, ANGEW CHEM INT EDIT, V48, P9097, DOI 10.1002/anie.200904504
   Barrett JM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00330
   Barrett JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep33565
   BARTELS E, 1971, P NATL ACAD SCI USA, V68, P1820, DOI 10.1073/pnas.68.8.1820
   Beharry AA, 2011, CHEM SOC REV, V40, P4422, DOI 10.1039/c1cs15023e
   Bennett J, 2017, MOL THER, V25, P1076, DOI 10.1016/j.ymthe.2017.03.008
   Berlin S, 2017, EMBO REP, V18, P677, DOI 10.15252/embr.201744010
   Berlin S, 2016, ELIFE, V5, DOI 10.7554/eLife.12040
   Berry MH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01990-7
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Bleger D, 2015, ANGEW CHEM INT EDIT, V54, P11338, DOI 10.1002/anie.201500628
   Bleger D, 2012, J AM CHEM SOC, V134, P20597, DOI 10.1021/ja310323y
   Broichhagen J, 2015, ACS CENTRAL SCI, V1, P383, DOI 10.1021/acscentsci.5b00260
   Browne LE, 2014, P NATL ACAD SCI USA, V111, P521, DOI 10.1073/pnas.1318582111
   Burnstock G, 2011, ADV PHARMACOL, V61, P333, DOI 10.1016/B978-0-12-385526-8.00011-4
   Bush RA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017368
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Calbo J, 2017, J AM CHEM SOC, V139, P1261, DOI 10.1021/jacs.6b11626
   Caporale N, 2011, MOL THER, V19, P1212, DOI 10.1038/mt.2011.103
   CHABALA LD, 1985, BIOPHYS J, V48, P241, DOI 10.1016/S0006-3495(85)83777-2
   Chambers JJ, 2006, J NEUROPHYSIOL, V96, P2792, DOI 10.1152/jn.00318.2006
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Cheng Christiana L, 2013, Mol Vis, V19, P955
   Chung MK, 2008, NAT NEUROSCI, V11, P555, DOI 10.1038/nn.2102
   Clark DA, 2016, CURR BIOL, V26, pR1062, DOI 10.1016/j.cub.2016.08.003
   Dagnelie G, 2017, CLIN EXP OPHTHALMOL, V45, P152, DOI 10.1111/ceo.12812
   Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214
   Diamond JS, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00027
   Dingledine R, 1999, PHARMACOL REV, V51, P7
   Dong M, 2015, CHEM COMMUN, V51, P12981, DOI 10.1039/c5cc02804c
   Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69
   Drivas TG, 2012, NEURON, V75, P185, DOI 10.1016/j.neuron.2012.06.010
   Duncan JL, 2017, CLIN EXP OPTOM, V100, P144, DOI 10.1111/cxo.12444
   Fehrentz T, 2011, ANGEW CHEM INT EDIT, V50, P12156, DOI 10.1002/anie.201103236
   Feldbauer K, 2009, P NATL ACAD SCI USA, V106, P12317, DOI 10.1073/pnas.0905852106
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fortin DL, 2008, NAT METHODS, V5, P331, DOI [10.1038/NMETH.1187, 10.1038/nmeth.1187]
   Franke H, 2005, NEUROCHEM INT, V47, P235, DOI 10.1016/j.neuint.2005.04.022
   Garcia-Amoros J, 2012, ANGEW CHEM INT EDIT, V51, P12820, DOI 10.1002/anie.201207602
   Garcia-Amoros J, 2010, ORG LETT, V12, P3514, DOI 10.1021/ol1013679
   Gaub BM, 2014, P NATL ACAD SCI USA, V111, pE5574, DOI 10.1073/pnas.1414162111
   Gautier A, 2008, CHEM BIOL, V15, P128, DOI 10.1016/j.chembiol.2008.01.007
   GINTANT GA, 1983, CIRC RES, V52, P735, DOI 10.1161/01.RES.52.6.735
   Gollisch T, 2010, NEURON, V65, P150, DOI 10.1016/j.neuron.2009.12.009
   Gorostiza P, 2007, P NATL ACAD SCI USA, V104, P10865, DOI 10.1073/pnas.0701274104
   Greenwald S., 2012, INVEST OPHTH VIS SCI, V53, P3639
   Gronemeyer T, 2006, PROTEIN ENG DES SEL, V19, P309, DOI 10.1093/protein/gzl014
   Groynom R, 2015, J DRUG TARGET, V23, P710, DOI 10.3109/1061186X.2015.1060978
   Habermacher C, 2016, ELIFE, V5, DOI 10.7554/eLife.11050
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819
   Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn
   Hinner MJ, 2010, CURR OPIN BIOTECH, V21, P766, DOI 10.1016/j.copbio.2010.09.011
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Izquierdo-Serra M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12221
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones B. W., 2018, WEBVISION ORG RETINA
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Kienzler MA, 2017, CURR OPIN NEUROBIOL, V45, P202, DOI 10.1016/j.conb.2017.05.021
   Kienzler MA, 2013, J AM CHEM SOC, V135, P17683, DOI 10.1021/ja408104w
   Kimbrel EA, 2015, NAT REV DRUG DISCOV, V14, P681, DOI 10.1038/nrd4738
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Klapper SD, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00074
   Klapper SD, 2016, NEURON, V92, P3, DOI 10.1016/j.neuron.2016.09.030
   Klippenstein V, 2014, J NEUROSCI, V34, P980, DOI 10.1523/JNEUROSCI.3725-13.2014
   Ko KW, 2016, NAT NEUROSCI, V19, P826, DOI 10.1038/nn.4293
   Kochendoerfer GG, 1999, TRENDS BIOCHEM SCI, V24, P300, DOI 10.1016/S0968-0004(99)01432-2
   Kramer RH, 2013, NAT NEUROSCI, V16, P816, DOI 10.1038/nn.3424
   Krispel CM, 2006, NEURON, V51, P409, DOI 10.1016/j.neuron.2006.07.010
   KROUSE ME, 1985, J GEN PHYSIOL, V86, P235, DOI 10.1085/jgp.86.2.235
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Laprell L, 2016, ACS CHEM NEUROSCI, V7, P15, DOI 10.1021/acschemneuro.5b00234
   Laprell L, 2017, J CLIN INVEST, V127, P2598, DOI 10.1172/JCI92156
   Laprell L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9076
   Leippe P, 2017, BIOCHEMISTRY-US, V56, P5214, DOI 10.1021/acs.biochem.7b00687
   Lerch MM, 2016, ANGEW CHEM INT EDIT, V55, P10978, DOI 10.1002/anie.201601931
   LESTER HA, 1980, J GEN PHYSIOL, V75, P207, DOI 10.1085/jgp.75.2.207
   Levitz J, 2017, P NATL ACAD SCI USA, V114, pE3546, DOI 10.1073/pnas.1619652114
   Levitz J, 2013, NAT NEUROSCI, V16, P507, DOI 10.1038/nn.3346
   Lin WC, 2015, NEURON, V88, P879, DOI 10.1016/j.neuron.2015.10.026
   Lin WC, 2014, ACS CHEM BIOL, V9, P1414, DOI 10.1021/cb500167u
   LoPachin RM, 2012, ENVIRON HEALTH PERSP, V120, P1650, DOI 10.1289/ehp.1205432
   Lorach H, 2015, INVEST OPHTH VIS SCI, V56, P4644, DOI 10.1167/iovs.14-16011
   Loukovaara S, 2015, ACTA OPHTHALMOL, V93, P67, DOI 10.1111/aos.12507
   Lowery AJ, 2015, IEEE ENG MED BIO, P1041, DOI 10.1109/EMBC.2015.7318543
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Marc R, 2014, ACS CHEM NEUROSCI, V5, P895, DOI 10.1021/cn5001233
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Merino E, 2011, CHEM SOC REV, V40, P3835, DOI 10.1039/c0cs00183j
   Miyashita T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00045
   Moore NA, 2018, EXPERT OPIN BIOL TH, V18, P37, DOI 10.1080/14712598.2018.1389886
   Mourot A, 2018, BRIT J PHARMACOL, V175, P2296, DOI 10.1111/bph.13923
   Mourot A, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00005
   Mourot A, 2012, NAT METHODS, V9, P396, DOI [10.1038/NMETH.1897, 10.1038/nmeth.1897]
   Mourot A, 2011, ACS CHEM NEUROSCI, V2, P536, DOI 10.1021/cn200037p
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nikonov S, 2016, INVEST OPHTH VIS SCI, V57
   Niswender CM, 2010, ANNU REV PHARMACOL, V50, P295, DOI 10.1146/annurev.pharmtox.011008.145533
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Parmeggiani F, 2011, CURR GENOMICS, V12, P236, DOI 10.2174/138920211795860080
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Rau H., 1990, PHOTOCHEM PHOTOPHYS, P119
   Reh TA, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17659
   Rieke F, 2009, NEURON, V64, P605, DOI 10.1016/j.neuron.2009.11.028
   Ruiz MD, 2015, J MED CHEM, V58, P7093, DOI 10.1021/jm501981g
   Rullo A, 2014, CHEM COMMUN, V50, P14613, DOI 10.1039/c4cc06612j
   Samanta S, 2013, ANGEW CHEM INT EDIT, V52, P14127, DOI 10.1002/anie.201306352
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Slijkerman RWN, 2015, PROG RETIN EYE RES, V48, P137, DOI 10.1016/j.preteyeres.2015.04.004
   Somia N, 2000, NAT REV GENET, V1, P91, DOI 10.1038/35038533
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010
   Stawski P, 2012, ANGEW CHEM INT EDIT, V51, P5748, DOI 10.1002/anie.201109265
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Szobota S, 2007, NEURON, V54, P535, DOI 10.1016/j.neuron.2007.05.010
   Szymanski W, 2013, CHEM REV, V113, P6114, DOI 10.1021/cr300179f
   Tang ZM, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1183-y
   Tewari M, 2015, AGEING RES REV, V24, P328, DOI 10.1016/j.arr.2015.10.001
   Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010
   Tochitsky I, 2017, SCI REP-UK, V7, DOI 10.1038/srep45487
   Tochitsky I, 2016, NEURON, V92, P100, DOI 10.1016/j.neuron.2016.08.038
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Tochitsky I, 2012, NAT CHEM, V4, P105, DOI [10.1038/NCHEM.1234, 10.1038/nchem.1234]
   Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013
   Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225
   Volgraf M, 2006, NAT CHEM BIOL, V2, P47, DOI 10.1038/nchembio756
   Volgraf M, 2007, J AM CHEM SOC, V129, P260, DOI 10.1021/ja067269o
   Wassmer S, 2016, MOL THER, V24, pS35, DOI 10.1016/S1525-0016(16)32889-1
   Weleber RG, 2016, OPHTHALMOLOGY, V123, P1606, DOI 10.1016/j.ophtha.2016.03.003
   Werblin FS, 2010, VISUAL NEUROSCI, V27, P1, DOI 10.1017/S0952523810000076
   Weston CE, 2014, J AM CHEM SOC, V136, P11878, DOI 10.1021/ja505444d
   Williams DS, 2017, GENE THER, V24, P68, DOI 10.1038/gt.2016.81
   Winter JO, 2007, J BIOMAT SCI-POLYM E, V18, P1031, DOI 10.1163/156856207781494403
   Yue L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2094
   Zele AJ, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01594
   Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744
NR 157
TC 79
Z9 80
U1 5
U2 58
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2665
EI 1520-6890
J9 CHEM REV
JI Chem. Rev.
PD NOV 14
PY 2018
VL 118
IS 21
SI SI
BP 10748
EP 10773
DI 10.1021/acs.chemrev.7b00723
PG 26
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA HB5LH
UT WOS:000451101800006
PM 29874052
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ehmann, D
   Shahlaee, A
   Ho, AC
AF Ehmann, David
   Shahlaee, Abtin
   Ho, Allen C.
TI Cell therapy for retinal disease
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE macular degeneration; neurotrophic; regenerative; retinal dystrophy;
   stem cell
ID PLURIPOTENT STEM-CELLS; DEGENERATIVE DISEASES; PIGMENTED EPITHELIUM;
   RETINITIS-PIGMENTOSA; CLINICAL-TRIAL; TRANSPLANTATION; REPAIR;
   DIFFERENTIATION; REGENERATION
AB Purpose of review
   The following review will provide an update on stem cell therapy with a focus on completed and ongoing human trials.
   Recent findings
   Significant progress has brought stem cell therapy from proof-of-concept animal models to human clinical trials. Although in its infancy, valuable safety and efficacy data are starting to emerge from trials looking at cell therapies for age-related macular degeneration, Stargardt's macular dystrophy, retinitis pigmentosa, and ischemic retinopathies.
   Summary
   Although clinical trials continue to enroll and evaluate stem cell therapy in patients with retinal diseases, preliminary results using both cellular replacement and trophic models have provided initial support for this exciting therapy. Results of these pivotal trials will form a key foundation for moving forward toward the ultimate goal of preventing blinding disease.
C1 [Ehmann, David; Shahlaee, Abtin; Ho, Allen C.] Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@midatlanticretina.com
OI Ho, Allen/0000-0003-3921-608X
CR Al-Shamekh S, 2014, TRANSL RES, V163, P377, DOI 10.1016/j.trsl.2013.11.002
   Alonso-Alonso ML, 2015, WORLD J STEM CELLS, V7, P641, DOI 10.4252/wjsc.v7.i3.641
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Atala A, 2015, LANCET, V385, P487, DOI 10.1016/S0140-6736(14)61820-1
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Croze RH, 2014, DEV OPHTHALMOL, V53, P81, DOI 10.1159/000357361
   Fox IJ, 2014, SCIENCE, V345, P889, DOI 10.1126/science.1247391
   Garcia JM, 2015, WORLD J STEM CELLS, V7, P160, DOI 10.4252/wjsc.v7.i1.160
   He YX, 2014, INT J MOL SCI, V15, P14456, DOI 10.3390/ijms150814456
   Jeon S, 2015, BMB REP, V48, P193, DOI 10.5483/BMBRep.2015.48.4.276
   Jian Q, 2015, EXP EYE RES, V132, P34, DOI 10.1016/j.exer.2015.01.008
   Kundu J, 2014, DEV OPHTHALMOL, V53, P143, DOI 10.1159/000357369
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   Megaw R, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0498-9
   Ng Tsz Kin, 2014, World J Stem Cells, V6, P111, DOI 10.4252/wjsc.v6.i2.111
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pearson RA, 2014, BIOTECHNOL ADV, V32, P485, DOI 10.1016/j.biotechadv.2014.01.001
   Ramsden CM, 2014, DEV OPHTHALMOL, V53, P97, DOI 10.1159/000357363
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2015, ACTA OPHTHALMOL, V93, pE174, DOI 10.1111/aos.12473
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stern J, 2014, DEV OPHTHALMOL, V53, P70, DOI 10.1159/000357328
   Tena A, 2014, DEV OPHTHALMOL, V53, P122, DOI 10.1159/000357360
   Tibbetts MD, 2012, CURR OPIN OPHTHALMOL, V23, P226, DOI 10.1097/ICU.0b013e328352407d
   Tucker BA, 2014, HUM MOL GENET, V23, pR9, DOI 10.1093/hmg/ddu124
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
NR 29
TC 4
Z9 4
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2016
VL 27
IS 3
BP 185
EP 190
DI 10.1097/ICU.0000000000000254
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK2TJ
UT WOS:000374767000002
PM 26859132
DA 2022-11-30
ER

PT J
AU Chong, V
AF Chong, Victor
TI Biological, Preclinical and Clinical Characteristics of Inhibitors of
   Vascular Endothelial Growth Factors
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Avastin; Diabetic macular edema;
   EYLEA; Lucentis; Macugen; Vascular endothelial growth factors
ID ANTI-VEGF ANTIBODY; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; IRIS
   NEOVASCULARIZATION; NONHUMAN PRIMATE; TYROSINE KINASE; SOLID TUMORS;
   FELLOW EYES; IN-VITRO; RANIBIZUMAB
AB Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized our treatment of these conditions. There are 4 anti-VEGF agents that are either approved or in common use in ophthalmology, namely pegaptanib (Macugen, Pfizer), ranibizumab (Lucentis, Novartis), aflibercept or VEGF Trap-Eye (EYLEA, Bayer) and bevacizumab (Avastin, Roche). There are differences between them. In this review, the differences are discussed in detail. Furthermore, an attempt is made to explain some of the clinical trial data based on their differences in ocular efficacy, duration of action, and local and systemic safety concerns. Copyright (C) 2012 S. Karger AG, Basel
C1 Oxford Univ Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
RP Chong, V (通讯作者)，Oxford Univ Hosp, Oxford Eye Hosp, Headley Way, Oxford OX3 9DU, England.
EM victor.chong@eye.ox.ac.uk
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2011, REG PHARM VEGF TRAP
   Baca M, 1997, J BIOL CHEM, V272, P10678
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2009, OPHTHALMOLOGY, V116, P168, DOI 10.1016/j.ophtha.2008.09.016
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gower EW, 2011, ADVERSE EVENT RATES
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kim H, 2009, MOL VIS, V15
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673
   Lohela M, 2003, THROMB HAEMOSTASIS, V90, P167, DOI 10.1160/TH03-04-0200
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Meyer CH, 2011, RETINA, V31, P1877
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Novartis, 2006, LUC PRESCR INF
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Presta LG, 1997, CANCER RES, V57, P4593
   Ribatti D, 2011, INT J DEV BIOL, V55, P383, DOI 10.1387/ijdb.103216dr
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2008, GRAEF ARCH CLIN EXP, V246, P1379, DOI 10.1007/s00417-008-0874-8
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
NR 52
TC 33
Z9 36
U1 0
U2 22
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 227
SU 1
BP 2
EP 10
DI 10.1159/000337152
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 935VG
UT WOS:000303549700002
PM 22517120
DA 2022-11-30
ER

PT J
AU Li, J
   Zhang, F
   Bian, W
   Chen, YY
   Liu, JY
   Liu, ZY
   Xiong, Y
   Wan, XH
AF Li, Jing
   Zhang, Feng
   Bian, Wei
   Chen, Yanyun
   Liu, Jianying
   Liu, Zhenyu
   Xiong, Ying
   Wan, Xiuhua
TI cGAS inhibition alleviates Alu RNA-induced immune responses and
   cytotoxicity in retinal pigmented epithelium
SO CELL AND BIOSCIENCE
LA English
DT Article
DE RPE; AMD; GA; cGAS; Alu RNA; EGCG; RSVL
ID NLRP3 INFLAMMASOME ACTIVATION; MACULAR DEGENERATION; CELL-DEATH; K+
   EFFLUX; DNA; STRESS; MECHANISM; DISEASE; RANIBIZUMAB; TRIGGERS
AB Background The degeneration of retinal pigmented epithelium (RPE) cells results in severe diseases, such as age-related macular degeneration (AMD) that causes blindness in millions of individuals. Results We report that targeting GMP-AMP (cGAMP) synthase (cGAS) alleviates Alu RNA-induced immune responses and cytotoxicity in RPE. We find that the deletion of cGAS in RPE inhibits the Alu RNA-stimulated interferon production. cGAS deficiency also protects RPE from cell death triggered by Alu RNA. Importantly, two natural chemicals, epigallocatechin gallate (EGCG) and resveratrol (RSVL), are effective in suppressing the immunogenic and cytotoxic effect of Alu RNA in RPE. Conclusions Our findings further demonstrate the crucial role of cGAS in the Alu RNA-induced RPE damage and present EGCG and RSVL as potential therapies for AMD and other RPE degeneration-related conditions.
C1 [Li, Jing; Chen, Yanyun; Liu, Jianying; Liu, Zhenyu; Xiong, Ying; Wan, Xiuhua] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing 100730, Peoples R China.
   [Zhang, Feng; Bian, Wei] Army Med Univ, Sergeant Sch, Affiliated Hosp, Dept Emergency Med, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Capital Medical University; Army Medical University
RP Li, J (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing 100730, Peoples R China.
EM crystal_lijing@ccmu.edu.cn; wanxh@ccmu.edu.cn
FU China National Natural Science Foundation [82171037]; Beijing Hospitals
   Authority Clinical Medicine Development of special funding support
   [XMLX202133]
FX This work was supported by grants from China National Natural Science
   Foundation (No. 82171037) and Beijing Hospitals Authority Clinical
   Medicine Development of special funding support (XMLX202133).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Bowie A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002919
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Cai H, 2021, J IMMUNOL, V206, P2453, DOI 10.4049/jimmunol.2001111
   Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558
   Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gross CJ, 2016, IMMUNITY, V45, P761, DOI 10.1016/j.immuni.2016.08.010
   Guillen-Boixet J, 2020, CELL, V181, P346, DOI 10.1016/j.cell.2020.03.049
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Hasler J, 2006, NUCLEIC ACIDS RES, V34, P5491, DOI 10.1093/nar/gkl706
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x
   Jayabalan AK, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021719118
   Jhang JJ, 2016, MOL NUTR FOOD RES, V60, P2297, DOI 10.1002/mnfr.201600106
   Jiang LZ, 2016, NAT PROTOC, V11, P655, DOI 10.1038/nprot.2016.028
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Keating SE, 2011, TRENDS IMMUNOL, V32, P574, DOI 10.1016/j.it.2011.08.004
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Lee HE, 2019, MOLECULES, V24, DOI 10.3390/molecules24112138
   Liu ZS, 2019, NAT IMMUNOL, V20, P18, DOI 10.1038/s41590-018-0262-4
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935
   Mortimer L, 2016, NAT IMMUNOL, V17, P1176, DOI 10.1038/ni.3538
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590-021-00886-5
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tsai PY, 2011, FREE RADICAL BIO MED, V51, P744, DOI 10.1016/j.freeradbiomed.2011.05.016
   Wahab A, 2017, MOLECULES, V22, DOI 10.3390/molecules22081329
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Wen HT, 2012, NAT IMMUNOL, V13, P352, DOI 10.1038/ni.2228
   Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Xian HX, 2021, IMMUNITY, V54, P1463, DOI 10.1016/j.immuni.2021.05.004
   Xu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06522-5
   Yang PG, 2020, CELL, V181, P325, DOI 10.1016/j.cell.2020.03.046
   Zhao M, 2022, EMBO REP, V23, DOI 10.15252/embr.202153166
   Zhong X, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801230
   Zierhut C, 2020, TRENDS CELL BIOL, V30, P594, DOI 10.1016/j.tcb.2020.05.006
NR 56
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD JUL 25
PY 2022
VL 12
IS 1
AR 116
DI 10.1186/s13578-022-00854-y
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 3E4FG
UT WOS:000829939100001
PM 35879806
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ahmad, I
   Teotia, P
   Erickson, H
   Xia, XH
AF Ahmad, Iqbal
   Teotia, Pooja
   Erickson, Helen
   Xia, Xiaohuan
TI Recapitulating developmental mechanisms for retinal regeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Retina; Development; Regeneration; Pluripotent stem cells; Disease
   modeling; Organoid
ID PLURIPOTENT STEM-CELLS; OPEN-ANGLE GLAUCOMA; ROD PHOTORECEPTOR
   DIFFERENTIATION; IN-VITRO DIFFERENTIATION; OPTIC-CUP MORPHOGENESIS;
   FIBER LAYER THICKNESS; MULLER GLIA; GANGLION-CELLS; PIGMENT-EPITHELIUM;
   TRANSCRIPTION FACTORS
AB Degeneration of specific retinal neurons in diseases like glaucoma, age-related macular degeneration, and retinitis pigmentosa is the leading cause of irreversible blindness. Currently, there is no therapy to modify the disease-associated degenerative changes. With the advancement in our knowledge about the mechanisms that regulate the development of the vertebrate retina, the approach to treat blinding diseases through regenerative medicine appears a near possibility. Recapitulation of developmental mechanisms is critical for reproducibly generating cells in either 2D or 3D culture of pluripotent stem cells for retinal repair and disease modeling. It is the key for unlocking the neurogenic potential of Muller glia in the adult retina for therapeutic regeneration. Here, we examine the current status and potential of the regenerative medicine approach for the retina in the backdrop of developmental mechanisms.
C1 [Ahmad, Iqbal; Teotia, Pooja; Erickson, Helen] Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Durham Res Ctr 1,Room 4034, Omaha, NE 68198 USA.
   [Xia, Xiaohuan] Tongji Univ, Sch Med, Shanghai Tenth Peoples Hosp, Ctr Translat Neurodegenerat & Regenerat Therapy, Shanghai 200072, Peoples R China.
C3 University of Nebraska System; University of Nebraska Medical Center;
   Tongji University
RP Ahmad, I (通讯作者)，Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Durham Res Ctr 1,Room 4034, Omaha, NE 68198 USA.
EM iahmad@unmc.edu
OI Xia, Xiaohuan/0000-0002-0287-6319
FU National Institutes of Health [2R01EY022051-05, R01EY029778-01]; Pearson
   Foundation; Lincy Foundation; Nebraska Department of Health and Human
   Services [LB606]
FX We are thankful to Nam Nguyen for artwork and Matt Van Hook and John
   Sorrentino for critiques and editorial help. Biorender.com was used for
   the artwork. This work was supported by National Institutes of Health
   (2R01EY022051-05, R01EY029778-01), Pearson Foundation, Lincy Foundation,
   and Nebraska Department of Health and Human Services (LB606).
CR Abmad I, 2001, INVEST OPHTH VIS SCI, V42, P2743
   Acharya HR, 1997, BIOCHEM BIOPH RES CO, V233, P459, DOI 10.1006/bbrc.1997.6483
   Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Adler R, 2007, DEV BIOL, V305, P1, DOI 10.1016/j.ydbio.2007.01.045
   Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0
   Ahmad I, 1997, DEV BIOL, V185, P92, DOI 10.1006/dbio.1997.8546
   Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P5758, DOI 10.1167/iovs.11-7308
   Akhtar T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101491
   Alfano G, 2011, DEVELOPMENT, V138, P261, DOI 10.1242/dev.051037
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   ALTSHULER D, 1993, DEVELOPMENT, V119, P1317
   ALTSHULER D, 1992, DEVELOPMENT, V114, P947
   Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582
   Anderson AM, 2012, DEVELOPMENT, V139, P991, DOI 10.1242/dev.077255
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763
   AUSTIN CP, 1995, DEVELOPMENT, V121, P3637
   Ayuso C, 2010, GENOME MED, V2, DOI 10.1186/gm155
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Berkers G, 2019, CELL REP, V26, P1701, DOI 10.1016/j.celrep.2019.01.068
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Bernier G, 2000, MECH DEVELOP, V93, P59, DOI 10.1016/S0925-4773(00)00271-9
   Bohrer LR, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040278
   Bolinches-Amoros A, 2018, STEM CELL RES, V28, P96, DOI 10.1016/j.scr.2018.01.004
   Bond LM, 2011, MOL BIOL CELL, V22, P54, DOI 10.1091/mbc.E10-06-0553
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Boucherie C, 2013, STEM CELLS, V31, P408, DOI 10.1002/stem.1268
   BRAISTED JE, 1994, DEVELOPMENT, V120, P2409
   Brooks MJ, 2019, STEM CELL REP, V13, P891, DOI 10.1016/j.stemcr.2019.09.009
   Brown NL, 2001, DEVELOPMENT, V128, P2497
   Brzezinski JA, 2012, DEV BIOL, V365, P395, DOI 10.1016/j.ydbio.2012.03.006
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Carl M, 2002, DEVELOPMENT, V129, P4057
   Carnes MU, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004372
   Casano AM, 2015, DEV CELL, V32, P469, DOI 10.1016/j.devcel.2015.01.018
   Cayouette M, 2003, DEVELOPMENT, V130, P2329, DOI 10.1242/dev.00446
   Cayouette M, 2006, TRENDS NEUROSCI, V29, P563, DOI 10.1016/j.tins.2006.08.003
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Chen GK, 2010, CELL STEM CELL, V7, P240, DOI 10.1016/j.stem.2010.06.017
   Chen J, 2017, INT J DEV NEUROSCI, V60, P94, DOI 10.1016/j.ijdevneu.2017.01.015
   Chen J, 2016, STEM CELL RES THER, V7, DOI [10.1186/s13287-015-0264-1, 10.1186/s40064-016-2963-1]
   Cheng CY, 2015, INVEST OPHTH VIS SCI, V56, P478, DOI 10.1167/iovs.14-15863
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   Chichagova Valeria, 2019, Curr Protoc Stem Cell Biol, V50, pe95, DOI 10.1002/cpsc.95
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   Chow RL, 1999, DEVELOPMENT, V126, P4213
   Chuang JC, 2002, BIOESSAYS, V24, P519, DOI 10.1002/bies.10097
   Cimadamore F, 2013, P NATL ACAD SCI USA, V110, pE3017, DOI 10.1073/pnas.1220176110
   COHEN A, 1994, J NEUROBIOL, V25, P953, DOI 10.1002/neu.480250805
   Collin J, 2019, STEM CELLS, V37, P609, DOI 10.1002/stem.2974
   Conner C, 2014, J NEUROSCI, V34, P14403, DOI 10.1523/JNEUROSCI.0498-14.2014
   Cora V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050391
   Cornish EE, 2004, VISION RES, V44, P2019, DOI 10.1016/j.visres.2004.03.030
   Costa-Mattioli M, 2013, NAT NEUROSCI, V16, P1537, DOI 10.1038/nn.3546
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Danno H, 2008, P NATL ACAD SCI USA, V105, P5408, DOI 10.1073/pnas.0710954105
   Das AV, 2006, DEV BIOL, V299, P283, DOI 10.1016/j.ydbio.2006.07.029
   Das AV, 2008, DEV NEUROSCI-BASEL, V30, P389, DOI 10.1159/000178017
   Davis AA, 2000, MOL CELL NEUROSCI, V15, P11, DOI 10.1006/mcne.1999.0806
   de Melo J, 2005, DEVELOPMENT, V132, P311, DOI 10.1242/dev.01560
   Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201
   Del Debbio CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152025
   Del Debbio CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012425
   Deng WL, 2018, STEM CELL REP, V10, P1267, DOI 10.1016/j.stemcr.2018.02.003
   Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176
   Dorgau B, 2019, BIOMATERIALS, V199, P63, DOI 10.1016/j.biomaterials.2019.01.028
   Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0
   DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4
   Eberle D, 2011, INVEST OPHTH VIS SCI, V52, P6462, DOI 10.1167/iovs.11-7399
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Elliott J, 2008, NEURON, V60, P26, DOI 10.1016/j.neuron.2008.08.008
   Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0
   Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7
   Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055
   Fausett BV, 2008, J NEUROSCI, V28, P1109, DOI 10.1523/JNEUROSCI.4853-07.2008
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Fingert JH, 2011, HUM MOL GENET, V20, P2482, DOI 10.1093/hmg/ddr123
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fischer AJ, 2002, J NEUROSCI, V22, P9387
   Fischer AJ, 2014, GLIA, V62, P1608, DOI 10.1002/glia.22703
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Fujimura N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00138
   Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Geng X, 2008, DEV CELL, V15, P236, DOI 10.1016/j.devcel.2008.07.003
   Ghosh AK, 2010, HUM MOL GENET, V19, P90, DOI 10.1093/hmg/ddp469
   GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gorsuch RA, 2014, EXP EYE RES, V123, P131, DOI 10.1016/j.exer.2013.07.012
   Graham DR, 2005, INVEST OPHTH VIS SCI, V46, P2601, DOI 10.1167/iovs.05-0129
   Guerin MB, 2006, INT J DEV BIOL, V50, P665, DOI 10.1387/ijdb.062159mg
   HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602
   Hallam D, 2018, STEM CELLS, V36, P1535, DOI 10.1002/stem.2883
   Hambright D, 2012, MOL VIS, V18, P920
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haston KM, 2016, ANNU REV PHARMACOL, V56, P489, DOI 10.1146/annurev-pharmtox-010715-103548
   Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Hendrickson A, 2008, EXP EYE RES, V87, P415, DOI 10.1016/j.exer.2008.07.016
   Hiler D, 2015, CELL STEM CELL, V17, P101, DOI 10.1016/j.stem.2015.05.015
   HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0
   HITCHCOCK PF, 1992, TRENDS NEUROSCI, V15, P103, DOI 10.1016/0166-2236(92)90020-9
   HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X
   Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Hyer J, 2003, DEV BIOL, V259, P351, DOI 10.1016/S0012-1606(03)00205-7
   Iglesias AI, 2014, HUM MOL GENET, V23, P1320, DOI 10.1093/hmg/ddt522
   Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029
   Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245
   James J, 2003, J NEUROSCI, V23, P8193
   James J, 2004, J NEUROBIOL, V61, P359, DOI 10.1002/neu.20064
   Janssen SF, 2013, PROG RETIN EYE RES, V37, P31, DOI 10.1016/j.preteyeres.2013.09.001
   Jeong Y, 2008, NAT GENET, V40, P1348, DOI 10.1038/ng.230
   Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   JOHNS PR, 1982, J NEUROSCI, V2, P178
   Jorstad NL, 2017, NATURE, V548, P103, DOI 10.1038/nature23283
   Julian D, 1998, J COMP NEUROL, V394, P271
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kay JN, 2001, NEURON, V30, P725, DOI 10.1016/S0896-6273(01)00312-9
   Kelley MW, 1999, NEUROREPORT, V10, P2389, DOI 10.1097/00001756-199908020-00031
   Khanna H, 2006, J BIOL CHEM, V281, P27327, DOI 10.1074/jbc.M605500200
   Kim J, 2005, SCIENCE, V308, P1927, DOI 10.1126/science.1110175
   Koso H, 2007, DEV BIOL, V301, P141, DOI 10.1016/j.ydbio.2006.09.027
   Koso H, 2009, INVEST OPHTH VIS SCI, V50, P5411, DOI 10.1167/iovs.08-3246
   Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600
   Kruczek K, 2017, STEM CELL REP, V8, P1659, DOI 10.1016/j.stemcr.2017.04.030
   Kugler M, 2015, HISTOCHEM CELL BIOL, V144, P443, DOI 10.1007/s00418-015-1354-y
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lagutin O, 2001, DEV DYNAM, V221, P342, DOI 10.1002/dvdy.1148
   Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lakowski J, 2018, STEM CELLS, V36, P709, DOI 10.1002/stem.2775
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lancaster MA, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039347
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Langer KB, 2018, STEM CELL REP, V10, P1282, DOI 10.1016/j.stemcr.2018.02.010
   Le TT, 2006, DEV BIOL, V295, P764, DOI 10.1016/j.ydbio.2006.03.055
   Lenkowski JR, 2014, PROG RETIN EYE RES, V40, P94, DOI 10.1016/j.preteyeres.2013.12.007
   Levine EM, 1997, J NEUROSCI, V17, P6277
   Levine EM, 2000, CELL MOL LIFE SCI, V57, P224, DOI 10.1007/PL00000686
   Li KJ, 2017, ACTA BIOMATER, V54, P117, DOI 10.1016/j.actbio.2017.02.032
   LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136
   Li X, 2002, SCIENCE, V297, P1180
   Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551
   Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284
   Liu B, 2013, INVEST OPHTH VIS SCI, V54, P444, DOI 10.1167/iovs.12-10774
   Liu C, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156166
   Liu W, 2010, J CLIN INVEST, V120, P3568, DOI 10.1172/JCI43219
   Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522
   Llonch S, 2018, DEV BIOL, V433, P132, DOI 10.1016/j.ydbio.2017.09.028
   Longobardi E, 2014, DEV DYNAM, V243, P59, DOI 10.1002/dvdy.24016
   Loosli F, 2003, EMBO REP, V4, P894, DOI 10.1038/sj.embor.embor919
   Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649
   Lowe A, 2016, STEM CELL REP, V6, P743, DOI 10.1016/j.stemcr.2016.03.011
   Lu AL, 2009, ENDOCRINOLOGY, V150, P1536, DOI 10.1210/en.2008-1092
   Ma WX, 2004, J NEUROSCI, V24, P7150, DOI 10.1523/JNEUROSCI.2266-04.2004
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marcos S, 2015, DEVELOPMENT, V142, P3009, DOI 10.1242/dev.122176
   Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2
   Martinez-Morales JR, 2005, DEV CELL, V8, P565, DOI 10.1016/j.devcel.2005.01.022
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475
   MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3
   McCabe KL, 1999, DEVELOPMENT, V126, P5713
   McFarlane S, 1998, DEVELOPMENT, V125, P3967
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Megaw R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00111-8
   Mellough CB, 2019, STEM CELL TRANSL MED, V8, P694, DOI 10.1002/sctm.18-0267
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Meyer K, 2014, P NATL ACAD SCI USA, V111, P829, DOI 10.1073/pnas.1314085111
   MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8
   Mic FA, 2004, DEV DYNAM, V231, P270, DOI 10.1002/dvdy.20128
   Miesfeld JB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28420-y
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Minegishi Y, 2013, HUM MOL GENET, V22, P3559, DOI 10.1093/hmg/ddt210
   Moore KB, 2004, DEV CELL, V6, P55, DOI 10.1016/S1534-5807(03)00395-2
   Morquette B, 2015, CELL DEATH DIFFER, V22, P612, DOI 10.1038/cdd.2014.149
   Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184
   Morrow EM, 1999, DEVELOPMENT, V126, P23
   Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786
   Murga-Zamalloa CA, 2010, HUM MOL GENET, V19, P3591, DOI 10.1093/hmg/ddq275
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Nelson BR, 2006, DEV NEUROSCI-BASEL, V28, P128, DOI 10.1159/000090759
   Neumann CJ, 2000, SCIENCE, V289, P2137, DOI 10.1126/science.289.5487.2137
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Nickerson PEB, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00017
   Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155
   Nishida Akihiro, 2005, Nippon Ganka Gakkai Zasshi, V109, P708
   Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017
   Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553
   Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028
   Oh YM, 2018, P NATL ACAD SCI USA, V115, pE12417, DOI 10.1073/pnas.1812518115
   Ohgushi M, 2010, CELL STEM CELL, V7, P225, DOI 10.1016/j.stem.2010.06.018
   Ohlemacher SK, 2016, STEM CELLS, V34, P1553, DOI 10.1002/stem.2356
   Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008
   Pan L, 2008, DEVELOPMENT, V135, P1981, DOI 10.1242/dev.010751
   Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707
   Parameswaran S, 2015, STEM CELLS, V33, P1743, DOI 10.1002/stem.1987
   Parameswaran S, 2014, DEVELOPMENT, V141, P4087, DOI 10.1242/dev.107326
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566
   Park SE, 2019, SCIENCE, V364, P960, DOI 10.1126/science.aaw7894
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pera EM, 2001, DEV CELL, V1, P655, DOI 10.1016/S1534-5807(01)00069-7
   Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Pittler SJ, 2004, J BIOL CHEM, V279, P19800, DOI 10.1074/jbc.M401864200
   Pollak J, 2013, DEVELOPMENT, V140, P2619, DOI 10.1242/dev.091355
   Porter FD, 1997, DEVELOPMENT, V124, P2935
   Quadrato G, 2017, NATURE, V545, P48, DOI 10.1038/nature22047
   Quinn PM, 2019, STEM CELL REP, V12, P906, DOI 10.1016/j.stemcr.2019.03.002
   QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031
   Qureshi IA, 2010, CELL CYCLE, V9, P4477, DOI 10.4161/cc.9.22.13973
   Ramachandran R, 2011, P NATL ACAD SCI USA, V108, P15858, DOI 10.1073/pnas.1107220108
   Ramachandran R, 2010, NAT CELL BIOL, V12, P1101, DOI 10.1038/ncb2115
   Ramachandran R, 2010, J COMP NEUROL, V518, P4196, DOI 10.1002/cne.22448
   Martinez-Morales JR, 2009, DEVELOPMENT, V136, P2165, DOI 10.1242/dev.033563
   Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   RAYMOND PA, 1988, J NEUROBIOL, V19, P431, DOI 10.1002/neu.480190504
   REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1
   Rehfeld F, 2015, CELL TISSUE RES, V359, P145, DOI 10.1007/s00441-014-1872-2
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Reinhardt P, 2013, CELL STEM CELL, V12, P354, DOI 10.1016/j.stem.2013.01.008
   Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134
   Reyes-Aguirre LI, 2013, NEUROSCIENCE, V254, P347, DOI 10.1016/j.neuroscience.2013.09.048
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Riesenberg AN, 2009, J NEUROSCI, V29, P12865, DOI 10.1523/JNEUROSCI.3382-09.2009
   Riesenberg AN, 2009, GENESIS, V47, P175, DOI 10.1002/dvg.20479
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Rong SS, 2019, EXP EYE RES, V180, P129, DOI 10.1016/j.exer.2018.12.014
   Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300
   Rowe RG, 2019, NAT REV GENET, V20, P377, DOI 10.1038/s41576-019-0100-z
   Roy A, 2013, J NEUROSCI, V33, P6877, DOI 10.1523/JNEUROSCI.4216-12.2013
   Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Sasai Y, 2013, NATURE, V493, P318, DOI 10.1038/nature11859
   Sasai Y, 2012, DEVELOPMENT, V139, P4111, DOI 10.1242/dev.079590
   Schwarz N, 2017, HUM MOL GENET, V26, P2480, DOI 10.1093/hmg/ddx143
   Sharma TP, 2017, STEM CELL RES, V21, P58, DOI 10.1016/j.scr.2017.03.005
   Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245
   Shimada H, 2017, CELL REP, V20, P384, DOI 10.1016/j.celrep.2017.06.045
   Shindou H, 2017, J BIOL CHEM, V292, P12054, DOI [10.1074/jbc.M117.790568, 10.1074/jbc.m117.790568]
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Sinn R, 2013, MECH DEVELOP, V130, P347, DOI 10.1016/j.mod.2013.05.001
   Sison SL, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0893-8
   Skowronska-Krawczyk D, 2015, MOL CELL, V59, P931, DOI 10.1016/j.molcel.2015.07.027
   Sluch VM, 2017, STEM CELL TRANSL MED, V6, P1972, DOI 10.1002/sctm.17-0059
   Sluch VM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16595
   Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021
   Smukler SR, 2006, J CELL BIOL, V172, P79, DOI 10.1083/jcb.200508085
   Spalding KL, 2004, J NEUROBIOL, V60, P319, DOI 10.1002/neu.20028
   Srinivas M, 2006, MOL ENDOCRINOL, V20, P1728, DOI 10.1210/me.2005-0505
   Stappert L, 2015, CELL TISSUE RES, V359, P47, DOI 10.1007/s00441-014-1981-y
   Stavridis MP, 2007, DEVELOPMENT, V134, P2889, DOI 10.1242/dev.02858
   Stern CD, 2005, DEVELOPMENT, V132, P2007, DOI 10.1242/dev.01794
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun Y, 2018, ANNU REV VIS SCI, V4, P101, DOI 10.1146/annurev-vision-091517-034018
   SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeda M, 2008, INVEST OPHTH VIS SCI, V49, P1142, DOI 10.1167/iovs.07-0434
   Teotia P, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.178012
   Teotia P, 2017, STEM CELLS, V35, P2239, DOI 10.1002/stem.2675
   Teotia P, 2017, STEM CELLS, V35, P572, DOI 10.1002/stem.2513
   Tetreault N, 2009, DEV BIOL, V327, P541, DOI 10.1016/j.ydbio.2008.12.022
   Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8
   Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   Ueki Y, 2015, P NATL ACAD SCI USA, V112, P13717, DOI 10.1073/pnas.1510595112
   VanderWall KB, 2019, STEM CELL REP, V12, P201, DOI 10.1016/j.stemcr.2018.12.010
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107
   Vitorino M, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-14
   Volkner M, 2016, STEM CELL REP, V6, P525, DOI 10.1016/j.stemcr.2016.03.001
   Voronina VA, 2004, HUM MOL GENET, V13, P315, DOI 10.1093/hmg/ddh025
   Walker A, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1074
   Wall DS, 2009, J CELL BIOL, V184, P101, DOI 10.1083/jcb.200805155
   Wan J, 2008, VISION RES, V48, P223, DOI 10.1016/j.visres.2007.11.002
   Wan J, 2007, BIOCHEM BIOPH RES CO, V363, P347, DOI 10.1016/j.bbrc.2007.08.178
   Wang J, 2014, PROG RETIN EYE RES, V38, P1, DOI 10.1016/j.preteyeres.2013.08.004
   Wang L, 2018, CELL REP, V22, P2601, DOI 10.1016/j.celrep.2018.01.075
   Wang SW, 2001, GENE DEV, V15, P24, DOI 10.1101/gad.855301
   Wang XW, 2018, CELL REP, V24, P2540, DOI 10.1016/j.celrep.2018.07.105
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   WATANABE T, 1992, DEVELOPMENT, V114, P899
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732
   Wiley LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30742
   Wilson HV, 1907, SCIENCE, V25, P912, DOI 10.1126/science.25.649.912
   Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9
   Wohl SG, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.179556
   Wohl SG, 2016, GLIA, V64, P743, DOI 10.1002/glia.22958
   Wong RCB, 2017, AGING-US, V9, P1341, DOI 10.18632/aging.101231
   Wu SQ, 2018, INVEST OPHTH VIS SCI, V59, P1571, DOI 10.1167/iovs.17-23648
   Xia XH, 2019, DEV BIOL, V450, P90, DOI 10.1016/j.ydbio.2019.03.013
   Xia XH, 2018, DEV BIOL, V440, P113, DOI 10.1016/j.ydbio.2018.05.007
   Xia XH, 2016, INT J STEM CELLS, V9, P169, DOI 10.15283/ijsc16020
   Xia XH, 2016, DEV BIOL, V410, P70, DOI 10.1016/j.ydbio.2015.12.010
   Xiang YF, 2019, CELL STEM CELL, V24, P487, DOI 10.1016/j.stem.2018.12.015
   Yang XH, 2004, SEMIN CELL DEV BIOL, V15, P91, DOI 10.1016/j.semcdb.2003.09.004
   Yang ZY, 2003, DEV BIOL, V264, P240, DOI 10.1016/j.ydbio.2003.08.005
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yao K, 2016, CELL REP, V17, P165, DOI 10.1016/j.celrep.2016.08.078
   Yaron O, 2006, DEVELOPMENT, V133, P1367, DOI 10.1242/dev.02311
   Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703
   Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780
   Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
   Yoshikawa M, 2017, INVEST OPHTH VIS SCI, V58, P2510, DOI 10.1167/iovs.16-20797
   YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215
   Young TL, 2004, NEURON, V41, P867, DOI 10.1016/S0896-6273(04)00141-2
   Yun S, 2009, DEVELOPMENT, V136, P3895, DOI 10.1242/dev.041202
   Zaghloul NA, 2005, BIOL CELL, V97, P321, DOI 10.1042/BC2004/0521
   Zagozewski JL, 2014, CLIN GENET, V86, P453, DOI 10.1111/cge.12493
   Zerti D, 2020, STEM CELLS, V38, P45, DOI 10.1002/stem.3082
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
   Zhang XM, 2001, DEVELOPMENT, V128, P943
   Zhang YL, 2019, NEURON, V103, P39, DOI 10.1016/j.neuron.2019.04.033
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zhao XF, 2014, CELL REP, V9, P272, DOI 10.1016/j.celrep.2014.08.047
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
   Zhu J, 2018, STEM CELL TRANSL MED, V7, P210, DOI 10.1002/sctm.17-0205
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
   Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7
   Zuchero JB, 2015, DEVELOPMENT, V142, P3805, DOI 10.1242/dev.129304
NR 363
TC 14
Z9 14
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2020
VL 76
AR 100824
DI 10.1016/j.preteyeres.2019.100824
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ3TM
UT WOS:000541151000006
PM 31843569
DA 2022-11-30
ER

PT J
AU Becerra, MO
   Contreras, LM
   Lo, MH
   Diaz, JM
   Herrera, GC
AF Ochoa Becerra, Mario
   Mojica Contreras, Luis
   Hsieh Lo, Ming
   Mateos Diaz, Juan
   Castillo Herrera, Gustavo
TI Lutein as a functional food ingredient: Stability and bioavailability
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Review
DE Bioaccessibility; Bioavailability; Lutein; Stability; Food matrix;
   Dietary source
ID IN-VITRO BIOACCESSIBILITY; FLESHED SWEET-POTATO; ALL-TRANS-LUTEIN;
   VITAMIN-A; CAROTENOID COMPOSITION; CHEMICAL-STABILITY; BETA-CAROTENE;
   ANTIOXIDANT CAPACITY; FROZEN STORAGE; MICROALGAE
AB Lutein is a carotenoid found in numerous organisms ranging from bacteria to algae, yeasts, and plants. The biological importance of this pigment emerged from various studies demonstrating its antioxidant potential, playing a significant role in the prevention of age-related macular degeneration and other diseases such as cancer. Lutein is also essential in the development of infants brain and must be consumed in sufficient amounts to obtain its health benefits. Lutein biologically effective dose is difficult to achieve due to its low lutein bioaccessibility and bioavailability in food sources. These factors are differentially affected by the properties of the food matrix, the processing, and the presence of other dietary components. The objective of this literature review was to explore lutein stability and bioavailability by modifications and variations associated with food technological procedures.
C1 [Ochoa Becerra, Mario; Mojica Contreras, Luis; Hsieh Lo, Ming; Castillo Herrera, Gustavo] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, CIATEJ, Tecnol Alimentaria, Unidad Zapopan, Camino Arenero 1227, Zapopan 45019, Jalisco, Mexico.
   [Mateos Diaz, Juan] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, CIATEJ, Biotecnol Ind, Unidad Zapopan, Camino Arenero 1227, Zapopan 45019, Jalisco, Mexico.
RP Herrera, GC (通讯作者)，Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, CIATEJ, Tecnol Alimentaria, Unidad Zapopan, Camino Arenero 1227, Zapopan 45019, Jalisco, Mexico.
EM gcastillo@ciatej.mx
OI Castillo Herrera, Gustavo A./0000-0002-0538-7318; Mateos-Diaz, Juan
   Carlos/0000-0002-6723-6654
FU Consejo Nacional de Ciencia y Tecnologia CONACyT-Mexico [836478]
FX Author Mario Ochoa was supported by a scholarship from the Consejo
   Nacional de Ciencia y Tecnologia CONACyT-Mexico, number 836478.
CR Abdel-Aal ESM, 2015, J AGR FOOD CHEM, V63, P9740, DOI 10.1021/acs.jafc.5b04430
   Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Abdel-Aal EM, 2010, J AGR FOOD CHEM, V58, P10109, DOI 10.1021/jf102400t
   Acien FG, 2012, BIOTECHNOL ADV, V30, P1344, DOI 10.1016/j.biotechadv.2012.02.005
   Agostini-Costa TD, 2012, REV BRAS FRUTIC, V34, P234, DOI 10.1590/S0100-29452012000100031
   Ahmad FT, 2013, J CEREAL SCI, V58, P408, DOI 10.1016/j.jcs.2013.08.004
   Gonzalez IA, 2011, INT J FOOD SCI TECH, V46, P840, DOI 10.1111/j.1365-2621.2011.02569.x
   Alfonsi K, 2008, GREEN CHEM, V10, P31, DOI 10.1039/b711717e
   Aman R, 2005, FOOD CHEM, V92, P753, DOI 10.1016/j.foodchem.2004.10.031
   Amorim-Carrilho KT, 2014, TRAC-TREND ANAL CHEM, V56, P49, DOI 10.1016/j.trac.2013.12.011
   Martinez-Delgado AA, 2017, FOOD CHEM, V225, P23, DOI 10.1016/j.foodchem.2016.11.092
   [Anonymous], [No title captured]
   [Anonymous], 2018, BCC RES
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Arunkumar R, 2013, FOOD CHEM, V141, P327, DOI 10.1016/j.foodchem.2013.02.108
   Garzon GA, 2012, J AGR FOOD CHEM, V60, P4709, DOI 10.1021/jf205347f
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beltran B, 2012, NUTR HOSP, V27, P1334, DOI 10.3305/nh.2012.27.4.5886
   Berner LA, 2001, J NUTR, V131, P2177, DOI 10.1093/jn/131.8.2177
   Bettler J, 2010, EUR J NUTR, V49, P45, DOI 10.1007/s00394-009-0047-5
   Bohm V, 2012, MOL NUTR FOOD RES, V56, P296, DOI [10.1002/mnfr.201100281, 10.1002/mnfr.769]
   Boon CS, 2010, CRIT REV FOOD SCI, V50, P515, DOI 10.1080/10408390802565889
   Bosma TL, 2003, CROP SCI, V43, P2118, DOI 10.2135/cropsci2003.2118
   Bouzari A, 2015, J AGR FOOD CHEM, V63, P957, DOI 10.1021/jf5058793
   Breithaupt DE, 2002, COMP BIOCHEM PHYS B, V132, P721, DOI 10.1016/S1096-4959(02)00096-9
   Burgos G, 2013, PLANT FOOD HUM NUTR, V68, P385, DOI 10.1007/s11130-013-0381-x
   Burgos G, 2012, FOOD CHEM, V133, P1131, DOI 10.1016/j.foodchem.2011.09.002
   CHEN BH, 1995, J AGR FOOD CHEM, V43, P1912, DOI 10.1021/jf00055a029
   Chen CY, 2016, BIORESOURCE TECHNOL, V200, P500, DOI 10.1016/j.biortech.2015.10.071
   Cheng CJ, 2019, FOOD HYDROCOLLOID, V87, P229, DOI 10.1016/j.foodhyd.2018.08.013
   Chiste RC, 2012, J AGR FOOD CHEM, V60, P5884, DOI 10.1021/jf301904f
   Chitchumroonchokchai C, 2004, J NUTR, V134, P2280, DOI 10.1093/jn/134.9.2280
   Choix FJ, 2018, J APPL PHYCOL, V30, P2247, DOI 10.1007/s10811-018-1433-2
   Clowutimon W, 2018, FOOD BIOPROD PROCESS, V110, P6, DOI 10.1016/j.fbp.2018.04.003
   de Azevedo-Meleiro CH, 2009, J SEP SCI, V32, P3652, DOI 10.1002/jssc.200900311
   de Faria AF, 2009, PLANT FOOD HUM NUTR, V64, P108, DOI 10.1007/s11130-009-0111-6
   de Quiros ARB, 2006, J FOOD COMPOS ANAL, V19, P97, DOI 10.1016/j.jfca.2005.04.004
   de Sa MC, 2003, FOOD CHEM, V83, P595, DOI 10.1016/S0308-8146(03)00227-9
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   Del Campo JA, 2007, APPL MICROBIOL BIOT, V74, P1163, DOI 10.1007/s00253-007-0844-9
   DelgadoVargas F, 1996, J SCI FOOD AGR, V72, P283, DOI [10.1002/(SICI)1097-0010(199611)72:3<283::AID-JSFA652>3.3.CO;2-M, 10.1002/(SICI)1097-0010(199611)72:3&lt;283::AID-JSFA652&gt;3.0.CO;2-V]
   Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002
   Donado-Pestana CM, 2012, PLANT FOOD HUM NUTR, V67, P262, DOI 10.1007/s11130-012-0298-9
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Fabryova T, 2019, ALGAL RES, V41, DOI 10.1016/j.algal.2019.101574
   Faulks RM, 2005, BBA-MOL BASIS DIS, V1740, P95, DOI 10.1016/j.bbadis.2004.11.012
   Fernandez-Orozco R, 2013, FOOD CHEM, V141, P2864, DOI 10.1016/j.foodchem.2013.05.016
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466
   Fish WW, 2003, J AGR FOOD CHEM, V51, P3582, DOI 10.1021/jf030022f
   Garcia-Herrera P, 2013, J SCI FOOD AGR, V93, P1692, DOI 10.1002/jsfa.5952
   Giordano E, 2018, ARCH BIOCHEM BIOPHYS, V647, P33, DOI 10.1016/j.abb.2018.04.008
   Gong MY, 2016, BIOTECHNOL ADV, V34, P1396, DOI 10.1016/j.biotechadv.2016.10.005
   Gouveia L., 2003, Innovative Food Science & Emerging Technologies, V4, P227, DOI 10.1016/S1466-8564(03)00002-X
   Granado F, 2006, EXP BIOL MED, V231, P1733, DOI 10.1177/153537020623101110
   Granado-Lorencio F, 2007, J AGR FOOD CHEM, V55, P6387, DOI 10.1021/jf070301t
   Granado-Lorencio F, 2010, J NUTR BIOCHEM, V21, P133, DOI 10.1016/j.jnutbio.2008.12.002
   Guedes AC, 2011, MAR DRUGS, V9, P625, DOI 10.3390/md9040625
   Gurmu F, 2014, INT J VITAM NUTR RES, V84, P65, DOI 10.1024/0300-9831/a000194
   Hadjal T, 2013, FOOD CHEM, V138, P2442, DOI 10.1016/j.foodchem.2012.12.022
   Hajare R., 2013, INT J PHARM SCI, V22, P152
   Hayes K, 2001, AM J CLIN NUTR, V74, P211
   Heber D, 2002, EXP BIOL MED, V227, P920, DOI 10.1177/153537020222701013
   Henriksen BS, 2014, J PEDIATR GASTR NUTR, V59, P552, DOI 10.1097/MPG.0000000000000471
   Hsieh-Lo M, 2019, ALGAL RES, V42, DOI 10.1016/j.algal.2019.101600
   Iwamoto T, 2000, J Atheroscler Thromb, V7, P216
   Jackson JG, 1998, J NUTR BIOCHEM, V9, P2, DOI 10.1016/S0955-2863(97)00132-0
   Kamil A, 2016, FOOD CHEM, V192, P915, DOI 10.1016/j.foodchem.2015.07.106
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khalil M, 2012, J FUNCT FOODS, V4, P602, DOI 10.1016/j.jff.2012.03.006
   Kline MA, 2011, J AGR FOOD CHEM, V59, P7203, DOI 10.1021/jf200740c
   Kopec RE, 2018, J FOOD COMPOS ANAL, V68, P16, DOI 10.1016/j.jfca.2017.06.008
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Kuhnen S, 2011, J SCI FOOD AGR, V91, P1548, DOI 10.1002/jsfa.4346
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lin JH, 2015, BIORESOURCE TECHNOL, V184, P421, DOI 10.1016/j.biortech.2014.09.099
   Liu CX, 2018, INT DAIRY J, V83, P28, DOI 10.1016/j.idairyj.2018.03.008
   Lopez A, 2014, J FOOD COMPOS ANAL, V33, P39, DOI 10.1016/j.jfca.2013.10.001
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mertz C, 2009, J FOOD COMPOS ANAL, V22, P381, DOI 10.1016/j.jfca.2008.06.008
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Molino A, 2019, ENERGIES, V12, DOI 10.3390/en12142806
   Mora-Gutierrez A, 2018, J DAIRY SCI, V101, P18, DOI 10.3168/jds.2017-13105
   Morais H, 2002, FOOD SCI TECHNOL INT, V8, P55, DOI [10.1106/1082013022914, 10.1177/1082013202008001914]
   Mortensen A, 2006, PURE APPL CHEM, V78, P1477, DOI 10.1351/pac200678081477
   Muller L, 2016, CRIT REV FOOD SCI, V56, P1868, DOI 10.1080/10408398.2013.801827
   Murillo E, 2010, FOOD CHEM, V122, P167, DOI 10.1016/j.foodchem.2010.02.034
   Natchigal A. M., 2012, Acta Horticulturae, P309
   Nwachukwu ID, 2016, TRENDS FOOD SCI TECH, V49, P74, DOI 10.1016/j.tifs.2015.12.005
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Xavier AAO, 2018, J FOOD COMPOS ANAL, V68, P60, DOI 10.1016/j.jfca.2017.01.015
   Olmedilla B, 2001, BRIT J NUTR, V85, P227, DOI 10.1079/BJN2000248
   Panova IG, 2017, EXP EYE RES, V160, P31, DOI 10.1016/j.exer.2017.04.008
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pintea Adela, 2003, Acta Biologica Szegediensis, V47, P37
   Priyadarshani AMB, 2014, CRIT REV FOOD SCI, V54, P561, DOI 10.1080/10408398.2011.595019
   Qiao YL, 2009, JNCI-J NATL CANCER I, V101, P507, DOI 10.1093/jnci/djp037
   Qv XY, 2011, FOOD HYDROCOLLOID, V25, P1596, DOI 10.1016/j.foodhyd.2011.01.006
   Read A, 2015, FOOD CHEM, V174, P263, DOI 10.1016/j.foodchem.2014.11.074
   Rigon RT, 2016, J FOOD SCI TECH MYS, V53, P1515, DOI 10.1007/s13197-015-2111-x
   Rodriguez-Amaya DB, 2016, CURR OPIN FOOD SCI, V7, P20, DOI 10.1016/j.cofs.2015.08.004
   Rubio-Diaz DE, 2010, J AGR FOOD CHEM, V58, P8692, DOI 10.1021/jf1012665
   Saini RK, 2018, FOOD CHEM, V240, P90, DOI 10.1016/j.foodchem.2017.07.099
   Sandmann G, 2015, ADV BIOCHEM ENG BIOT, V148, P449, DOI 10.1007/10_2014_277
   Brum AAS, 2017, COLLOID SURFACE A, V522, P477, DOI 10.1016/j.colsurfa.2017.03.041
   SCHAEFFER JL, 1988, POULTRY SCI, V67, P608, DOI 10.3382/ps.0670608
   Shanmugam S, 2011, INT J PHARMACEUT, V412, P99, DOI 10.1016/j.ijpharm.2011.04.015
   Soares AT, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01529
   Song JF, 2015, ULTRASON SONOCHEM, V27, P602, DOI 10.1016/j.ultsonch.2015.04.020
   Steiner BM, 2018, TRENDS FOOD SCI TECH, V82, P71, DOI 10.1016/j.tifs.2018.10.003
   Sun Z, 2016, ADV BIOCHEM ENG BIOT, V153, P37, DOI 10.1007/10_2015_331
   Tacken KJM, 2009, ARCH DIS CHILD-FETAL, V94, pF447, DOI 10.1136/adc.2008.153577
   Tanaka T, 2012, MOLECULES, V17, P3202, DOI 10.3390/molecules17033202
   van den Berg H, 2000, J SCI FOOD AGR, V80, P880, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;880::AID-JSFA646&gt;3.0.CO;2-1
   van Lent DM, 2016, CLIN NUTR ESPEN, V13, pE1, DOI 10.1016/j.clnesp.2016.02.096
   VANZOERENGROBBEN D, 1993, ACTA PAEDIATR, V82, P645, DOI 10.1111/j.1651-2227.1993.tb18032.x
   Alvarez-Henao MV, 2018, FOOD CHEM, V256, P181, DOI 10.1016/j.foodchem.2018.02.059
   Vishwanathan R., 2009, NANO BIOMED ENG, V1, P38, DOI [10.5101/nbe.v1i1.p38-49, DOI 10.5101/NBE.V1I1.P38-49]
   Walsh RP, 2015, J AGR FOOD CHEM, V63, P9677, DOI 10.1021/acs.jafc.5b03691
   Weber D, 2012, MOL NUTR FOOD RES, V56, P251, DOI 10.1002/mnfr.201100230
   Weigel F, 2018, FOOD CHEM, V242, P395, DOI 10.1016/j.foodchem.2017.09.060
   West CE, 1998, INT J VITAM NUTR RES, V68, P371
   World Health Organization, 2002, WORLD HLTH REP
   Xiao YB, 2018, MAR DRUGS, V16, DOI 10.3390/md16080283
   Yang C, 2018, FOOD CHEM, V249, P66, DOI 10.1016/j.foodchem.2017.12.055
   Yen HW, 2013, BIORESOURCE TECHNOL, V135, P166, DOI 10.1016/j.biortech.2012.10.099
   Yi J, 2016, FOOD CHEM, V200, P91, DOI 10.1016/j.foodchem.2016.01.035
   Yonekura L, 2007, MOL NUTR FOOD RES, V51, P107, DOI 10.1002/mnfr.200600145
   Yoshida H, 2010, ATHEROSCLEROSIS, V209, P520, DOI 10.1016/j.atherosclerosis.2009.10.012
NR 133
TC 68
Z9 68
U1 32
U2 106
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
EI 2214-9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD MAR
PY 2020
VL 66
AR 103771
DI 10.1016/j.jff.2019.103771
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA KT0NV
UT WOS:000518708200001
OA gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Donaldson, LF
   Beazley-Long, N
AF Donaldson, Lucy F.
   Beazley-Long, Nicholas
TI Alternative RNA splicing: contribution to pain and potential therapeutic
   strategy
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID EP3 RECEPTOR ISOFORMS; PROTEIN-KINASE-C; CALCIUM-CHANNELS; MICE LACKING;
   DRG NEURONS; FUNCTIONAL-CHARACTERIZATION; CAPSAICIN-RECEPTOR;
   NEUROPATHIC PAIN; RECENT PROGRESS; CA2+ CHANNELS
AB Since the sequencing of metazoan genomes began, it has become clear that the number of expressed proteins far exceeds the number of genes. It is now estimated that more than 98% of human genes give rise to multiple proteins through alternative pre-mRNA splicing. In this review, we highlight the known alternative splice variants of many channels, receptors, and growth factors that are important in nociception and pain. Recently, pharmacological control of alternative splicing has been proposed as potential therapy in cancer, wet age-related macular degeneration, retroviral infections, and pain. Thus, we also consider the effects that known splice variants of molecules key to nociception/pain have on nociceptive processing and/or analgesic action, and the potential for control of alternative pre-mRNA splicing as a novel analgesic strategy.
C1 [Donaldson, Lucy F.] Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
   Univ Nottingham, Arthrit Res UK Pain Ctr, Nottingham NG7 2UH, England.
C3 University of Nottingham; University of Nottingham
RP Donaldson, LF (通讯作者)，Univ Nottingham, Sch Life Sci, Nottingham NG7 2UH, England.
EM Lucy.Donaldson@nottingham.ac.uk
RI Beazley-long, Nicholas/I-7131-2019
OI Beazley-long, Nicholas/0000-0001-7342-2771; Donaldson,
   Lucy/0000-0002-4242-5790
FU Arthritis Research UK [20400]; University of Nottingham; Versus
   Arthritis [20400] Funding Source: researchfish
FX This work was supported by Arthritis Research UK (Ref 20400, support for
   NBL) and the University of Nottingham. We would like to thank David
   Bates for commenting on the final manuscript.
CR Abbadie C, 2001, NEUROREPORT, V12, P3069, DOI 10.1097/00001756-200110080-00017
   Akopian AN, 2011, CURR PHARM BIOTECHNO, V12, P89
   Altier C, 2007, J NEUROSCI, V27, P6363, DOI 10.1523/JNEUROSCI.0307-07.2007
   Alvarez FJ, 2000, J COMP NEUROL, V422, P464, DOI 10.1002/1096-9861(20000703)422:3<464::AID-CNE11>3.0.CO;2-#
   AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0
   Andrade A, 2010, NAT NEUROSCI, V13, P1249, DOI 10.1038/nn.2643
   Ataman ZA, 2007, STRUCTURE, V15, P1603, DOI 10.1016/j.str.2007.10.012
   Bagal SK, 2014, BIOORG MED CHEM LETT, V24, P3690, DOI 10.1016/j.bmcl.2014.06.038
   Bar KJ, 2004, J NEUROSCI, V24, P642, DOI 10.1523/JNEUROSCI.0882-03.2004
   BARKER PA, 1993, J BIOL CHEM, V268, P15150
   Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200
   BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x
   Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031
   Bennett DLH, 2014, LANCET NEUROL, V13, P587, DOI 10.1016/S1474-4422(14)70024-9
   Benoliel R, 2000, NEUROSCI LETT, V291, P61, DOI 10.1016/S0304-3940(00)01337-9
   Beqollari D, 2010, J NEUROPHYSIOL, V104, P439, DOI 10.1152/jn.00799.2009
   Bilson HA, 2004, FEBS LETT, V572, P271, DOI 10.1016/j.febslet.2004.06.089
   Blaustein M, 2007, INT J BIOCHEM CELL B, V39, P2031, DOI 10.1016/j.biocel.2007.04.004
   Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407
   Bockaert J, 2006, CELL TISSUE RES, V326, P553, DOI 10.1007/s00441-006-0286-1
   Bolan EA, 2004, SYNAPSE, V51, P11, DOI 10.1002/syn.10277
   Bonomi Serena, 2013, Int J Cell Biol, V2013, P962038, DOI 10.1155/2013/962038
   Bowersox SS, 1996, J PHARMACOL EXP THER, V279, P1243
   Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2
   Buraei Z, 2013, BBA-BIOMEMBRANES, V1828, P1530, DOI 10.1016/j.bbamem.2012.08.028
   Burnstock G, 2013, EUR J PHARMACOL, V716, P24, DOI 10.1016/j.ejphar.2013.01.078
   Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393
   Castiglioni AJ, 2006, J PHYSIOL-LONDON, V576, P119, DOI 10.1113/jphysiol.2006.115030
   Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906
   Chang A, 1998, EUR J PHARMACOL, V351, P189, DOI 10.1016/S0014-2999(98)00366-5
   Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240
   CHEN Y, 1994, J BIOL CHEM, V269, P7839
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Cizkova D, 2002, EXP BRAIN RES, V147, P456, DOI 10.1007/s00221-002-1217-3
   Connor M, 1999, BRIT J PHARMACOL, V126, P1553, DOI 10.1038/sj.bjp.0702457
   Davila HM, 1999, ANN NY ACAD SCI, V868, P102, DOI 10.1111/j.1749-6632.1999.tb11281.x
   de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199
   Deval E, 2015, NEUROPHARMACOLOGY, V94, P49, DOI 10.1016/j.neuropharm.2015.02.009
   Enna SJ, 2006, ADV PHARMACOL, V54, P1, DOI 10.1016/S1054-3589(06)54001-3
   Eswarappa SM, 2014, CELL, V157, P1605, DOI 10.1016/j.cell.2014.04.033
   Fang Z, 2007, J BIOL CHEM, V282, P4757, DOI 10.1074/jbc.M605248200
   Fang Z, 2010, KOREAN J PHYSIOL PHA, V14, P45, DOI 10.4196/kjpp.2010.14.1.45
   Fedorov O, 2011, CHEM BIOL, V18, P67, DOI 10.1016/j.chembiol.2010.11.009
   Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x
   Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103
   Gammons MVR, 2013, INVEST OPHTH VIS SCI, V54, P5797, DOI 10.1167/iovs.13-11634
   Gaunitz C, 2002, AMINO ACIDS, V23, P177, DOI 10.1007/s00726-001-0125-3
   Geib T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008204
   Ghosh G, 2011, FEBS J, V278, P587, DOI 10.1111/j.1742-4658.2010.07992.x
   Giunti P, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00036
   Graziewicz MA, 2008, MOL THER, V16, P1316, DOI 10.1038/mt.2008.85
   Hansen RR, 2011, PAIN, V152, P1766, DOI 10.1016/j.pain.2011.03.024
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x
   Hong DS, 2014, INVEST NEW DRUG, V32, P436, DOI 10.1007/s10637-013-0046-5
   Huh JW, 2010, GENES GENET SYST, V85, P65, DOI 10.1266/ggs.85.65
   Hulse RP, 2014, NEUROBIOL DIS, V71, P245, DOI 10.1016/j.nbd.2014.08.012
   Hulse R.P, 2013, NEUR M PLANN SOC NEU
   Hulse RP, 2015, CLIN SCI, V129, P741, DOI 10.1042/CS20150124
   Jarecki BW, 2009, CHANNELS, V3, P259
   Jiang YQ, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-67
   Just S, 2001, NEUROSCI LETT, V312, P133, DOI 10.1016/S0304-3940(01)02199-1
   Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7
   Kerr NCH, 2004, J BIOL CHEM, V279, P24826, DOI 10.1074/jbc.M401281200
   Kim SO, 2013, REPRODUCTION, V146, P625, DOI 10.1530/REP-13-0274
   Kole R, 2012, NAT REV DRUG DISCOV, V11, P125, DOI 10.1038/nrd3625
   Lana B, 2014, PAIN, V155, P522, DOI 10.1016/j.pain.2013.12.001
   Lee C, 2014, BIOL PSYCHIAT, V75, P765, DOI 10.1016/j.biopsych.2013.08.028
   Levine JD, 2007, BBA-MOL BASIS DIS, V1772, P989, DOI 10.1016/j.bbadis.2007.01.008
   Licatalosi DD, 2010, NAT REV GENET, V11, P75, DOI 10.1038/nrg2673
   Lin WH, 2015, BRAIN, V138, P891, DOI 10.1093/brain/awv012
   Lipscombe D, 2013, TRENDS NEUROSCI, V36, P598, DOI 10.1016/j.tins.2013.06.008
   Liu QR, 2009, GENES BRAIN BEHAV, V8, P519, DOI 10.1111/j.1601-183X.2009.00498.x
   Lu G, 2005, MOL PHARMACOL, V67, P1119, DOI 10.1124/mol.104.009852
   Lu ZG, 2015, J CLIN INVEST, V125, P2626, DOI 10.1172/JCI81070
   Lujan R, 2010, J CHEM NEUROANAT, V40, P1, DOI 10.1016/j.jchemneu.2010.03.003
   LUQUE JM, 1994, NEUROSCIENCE, V63, P629, DOI 10.1016/0306-4522(94)90510-X
   Markovic D, 2009, CELL MOL LIFE SCI, V66, P3337, DOI 10.1007/s00018-009-0093-4
   Matsuoka Y, 2007, BIOCHEM BIOPH RES CO, V362, P682, DOI 10.1016/j.bbrc.2007.08.022
   McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3
   Mich PM, 2008, MOL PHARMACOL, V74, P904, DOI 10.1124/mol.108.045153
   Mittendorf KF, 2012, BIOCHEMISTRY-US, V51, P5541, DOI 10.1021/bi3007065
   Mourich DV, 2009, CURR OPIN MOL THER, V11, P124
   Nakae A, 2008, NEUROSCI RES, V60, P228, DOI 10.1016/j.neures.2007.10.004
   Noel J, 2011, CHANNELS, V5, P400, DOI 10.4161/chan.5.5.16469
   Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396
   Pasternak GW, 2014, J CLIN ONCOL, V32, P1655, DOI 10.1200/JCO.2013.53.1079
   Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138
   Patel R, 2013, J NEUROSCI, V33, P16412, DOI 10.1523/JNEUROSCI.1026-13.2013
   Pohl M, 2013, BIOSYSTEMS, V114, P31, DOI 10.1016/j.biosystems.2013.07.003
   Raymond CK, 2004, J BIOL CHEM, V279, P46234, DOI 10.1074/jbc.M406387200
   Ryberg E, 2005, FEBS LETT, V579, P259, DOI 10.1016/j.febslet.2004.11.085
   Rycroft BK, 2007, J PHYSIOL-LONDON, V580, P883, DOI 10.1113/jphysiol.2006.125880
   Sagar DR, 2005, EUR J NEUROSCI, V22, P371, DOI 10.1111/j.1460-9568.2005.04206.x
   Sasabe T, 2010, INT J ENV RES PUB HE, V7, P1448, DOI 10.3390/ijerph7041448
   Sato M, 2007, BIOCHEM SOC T, V35, P1035, DOI 10.1042/BST0371035
   Schirmeyer J, 2010, J MOL NEUROSCI, V41, P310, DOI 10.1007/s12031-009-9315-3
   Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706
   Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756
   Schumacher MA, 2010, FRONT BIOSCI-LANDMRK, V15, P872, DOI 10.2741/3651
   Smith ESJ, 2007, NEUROSCI LETT, V426, P12, DOI 10.1016/j.neulet.2007.07.047
   Soret J, 2006, PROG MOLEC, V44, P65
   Sussman JD, 2008, ANN NY ACAD SCI, V1132, P283, DOI 10.1196/annals.1405.022
   Swayne LA, 2008, PFLUG ARCH EUR J PHY, V456, P459, DOI 10.1007/s00424-007-0390-4
   Tanowitz M, 2008, J BIOL CHEM, V283, P35614, DOI 10.1074/jbc.M806588200
   Terashima T, 2013, NEUROPHARMACOLOGY, V75, P1, DOI 10.1016/j.neuropharm.2013.06.018
   Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3
   Vazquez E, 2006, SEMIN CELL DEV BIOL, V17, P607, DOI 10.1016/j.semcdb.2006.11.004
   Veale EL, 2010, J BIOL CHEM, V285, P29295, DOI 10.1074/jbc.M110.108423
   Viguier F, 2013, EUR J PHARMACOL, V716, P8, DOI 10.1016/j.ejphar.2013.01.074
   Wang QD, 2000, J NEUROCHEM, V74, P1290
   Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649
   Westenbroek RE, 1998, J NEUROSCI, V18, P6319
   WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966
   Wotherspoon G, 2005, NEUROSCIENCE, V135, P235, DOI 10.1016/j.neuroscience.2005.06.009
   Xu J, 2015, P NATL ACAD SCI USA, V112, P279, DOI 10.1073/pnas.1419183112
   Xu J, 2014, J NEUROSCI, V34, P11048, DOI 10.1523/JNEUROSCI.3986-13.2014
   Yalcin I, 2010, EXP NEUROL, V221, P115, DOI 10.1016/j.expneurol.2009.10.008
   Yokoyama K, 2004, EUR J NEUROSCI, V20, P3516, DOI 10.1111/j.1460-9568.2004.03810.x
   Yu GH, 2002, MOL BRAIN RES, V105, P115, DOI 10.1016/S0169-328X(02)00399-6
   Zhang CS, 2008, J NEUROSCI, V28, P8604, DOI 10.1523/JNEUROSCI.0628-08.2008
   Zhang XY, 2013, AM J HUM GENET, V93, P957, DOI 10.1016/j.ajhg.2013.09.016
   Zheng Fei, 2012, Int J Physiol Pathophysiol Pharmacol, V4, P188
   Zhou YM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3399
NR 124
TC 23
Z9 23
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD NOV
PY 2016
VL 21
IS 11
BP 1787
EP 1798
DI 10.1016/j.drudis.2016.06.017
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ED2DP
UT WOS:000388654100007
PM 27329269
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Irani, Y
   Brereton, HM
   Tilton, RG
   Coster, DJ
   Williams, KA
AF Irani, Yazad
   Brereton, Helen M.
   Tilton, Ronald G.
   Coster, Douglas J.
   Williams, Keryn A.
TI Production of scFv Antibody Fragments from a Hybridoma with Functional
   Activity Against Human Vascular Endothelial Growth Factor
SO HYBRIDOMA
LA English
DT Article
AB Vascular endothelial growth factor (VEGF) plays a major role in the development of aberrant neovascularization in ocular diseases such as diabetic retinopathy and age-related macular degeneration (ARMD), and is an important therapeutic target for these diseases. Monoclonal antibodies specific for VEGF are in clinical use for some patients with ARMD, delivered by intraocular injection. We have shown previously that single chain antibody fragments (scFv) penetrate into the eye when applied topically to the ocular surface. Here we describe the production of a scFv from a monoclonal antibody specific for human VEGF and demonstrate its ability to decrease proliferation of human umbilical vein endothelial cells in culture. A suitably formulated anti-VEGF scFv may have potential as a less invasive topical treatment for potentially blinding neovascular diseases of the eye.
C1 [Irani, Yazad; Brereton, Helen M.; Coster, Douglas J.; Williams, Keryn A.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA, Australia.
   [Tilton, Ronald G.] Univ Texas Med Branch, Div Endocrinol, Galveston, TX USA.
   [Tilton, Ronald G.] Univ Texas Med Branch, Stark Diabet Ctr, Galveston, TX USA.
C3 Flinders University South Australia; University of Texas System;
   University of Texas Medical Branch Galveston; University of Texas
   System; University of Texas Medical Branch Galveston
RP Brereton, HM (通讯作者)，Flinders Univ S Australia, Dept Ophthalmol, Bedford Pk, SA 5042, Australia.
EM helen.brereton@flinders.edu.au
OI Irani, Yazad/0000-0002-2861-5774
FU National Health and Medical Research Council of Australia; Ophthalmic
   Research Institute of Australia; Flinders Medical Centre Foundation
FX This work was supported by the National Health and Medical Research
   Council of Australia, the Ophthalmic Research Institute of Australia,
   and the Flinders Medical Centre Foundation. The authors wish to thank
   Tina Lavranos for provision of advice and reagents for the endothelial
   cell proliferation assay, and Miriam Keane for advice on statistics.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALLANSMITH M, 1979, INVEST OPHTH VIS SCI, V18, P947
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Coia G, 2001, J IMMUNOL METHODS, V251, P187, DOI 10.1016/S0022-1759(01)00300-3
   De Vriese AS, 2001, J AM SOC NEPHROL, V12, P1734, DOI 10.1681/ASN.V1281734
   Irani Y, 2008, J IMMUNOL METHODS, V336, P246, DOI 10.1016/j.jim.2008.04.014
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6
   Lin ZH, 2008, APPL BIOCHEM BIOTECH, V144, P15, DOI 10.1007/s12010-007-8011-4
   Mavrangelos C, 2001, PROTEIN EXPRES PURIF, V23, P289, DOI 10.1006/prep.2001.1506
   OTTIGER M, 2008, INVEST OPHTHALM 0829
   Smith KA, 2003, INT J ONCOL, V22, P333
   Thiel MA, 2002, CLIN EXP IMMUNOL, V128, P67, DOI 10.1046/j.1365-2249.2002.01808.x
   Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392
   Turner ML, 2005, INT J PARASITOL, V35, P981, DOI 10.1016/j.ijpara.2005.03.015
   Vitaliti A, 2000, CANCER RES, V60, P4311
   Williams KA, 2005, EYE, V19, P910, DOI 10.1038/sj.eye.6701669
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 18
TC 1
Z9 1
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1554-0014
EI 1557-8348
J9 HYBRIDOMA
JI Hybridoma
PD JUN
PY 2009
VL 28
IS 3
BP 205
EP 209
DI 10.1089/hyb.2009.0001
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology
GA 457GE
UT WOS:000266915700008
PM 19445630
DA 2022-11-30
ER

PT J
AU Nayyar, A
   Gindina, S
   Barron, A
   Hu, Y
   Danias, J
AF Nayyar, Ashima
   Gindina, Sofya
   Barron, Arturo
   Hu, Yan
   Danias, John
TI Do epigenetic changes caused by commensal microbiota contribute to
   development of ocular disease? A review of evidence
SO HUMAN GENOMICS
LA English
DT Review
ID HELICOBACTER-PYLORI INFECTION; OPEN-ANGLE GLAUCOMA; MACULAR
   DEGENERATION; GUT MICROBIOTA; PERIODONTAL INFECTIONS; INTESTINAL
   MICROBIOTA; TRABECULAR MESHWORK; METABOLIC-DISORDERS; GLOBAL PREVALENCE;
   T-CELL
AB There is evidence that genetic polymorphisms and environmentally induced epigenetic changes play an important role in modifying disease risk. The commensal microbiota has the ability to affect the cellular environment throughout the body without requiring direct contact; for example, through the generation of a pro-inflammatory state. In this review, we discuss evidence that dysbiosis in intestinal, pharyngeal, oral, and ocular microbiome can lead to epigenetic reprogramming and inflammation making the host more susceptible to ocular disease such as autoimmune uveitis, age-related macular degeneration, and open angle glaucoma. Several mechanisms of action have been proposed to explain how changes to commensal microbiota contribute to these diseases. This is an evolving field that has potentially significant implications in the management of these conditions especially from a public health perspective.
C1 [Nayyar, Ashima; Gindina, Sofya; Barron, Arturo; Hu, Yan; Danias, John] Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA.
   [Danias, John] Suny Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY 11203 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Downstate Medical Center; State University of New York (SUNY)
   System; State University of New York (SUNY) Downstate Medical Center
RP Danias, J (通讯作者)，Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA.; Danias, J (通讯作者)，Suny Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY 11203 USA.
EM john.danias@downstate.edu
CR Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947-2714.159325
   Acott TS, 2008, EXP EYE RES, V86, P543, DOI 10.1016/j.exer.2008.01.013
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Albenberg LG, 2014, GASTROENTEROLOGY, V146, P1564, DOI 10.1053/j.gastro.2014.01.058
   Alipour S, 2017, BIOMED PHARMACOTHER, V91, P526, DOI 10.1016/j.biopha.2017.04.106
   Alvarez-Arellano Lourdes, 2014, World J Gastrointest Pathophysiol, V5, P400, DOI 10.4291/wjgp.v5.i4.400
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   [Anonymous], 2015, FACTS GLAUC
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   von-B FB, 2015, REV CHIL INFECTOL, V32, P150, DOI 10.4067/S0716-10182015000300003
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blum HE, 2017, ADV MED SCI-POLAND, V62, P414, DOI 10.1016/j.advms.2017.04.005
   Bravo JA, 2011, P NATL ACAD SCI USA, V108, P16050, DOI 10.1073/pnas.1102999108
   Bultman SJ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201500902
   Sete MRC, 2016, REV BRAS REUMATOL, V56, P165, DOI 10.1016/j.rbre.2015.09.001
   CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7
   Carding Simon, 2015, Microbial Ecology in Health and Disease, V26, P26191, DOI 10.3402/mehd.v26.26191
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   CASPI RR, 1988, J IMMUNOL, V140, P1490
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x
   Challa P, 2008, MOL VIS, V14, P146
   Challa Pratap, 2011, Int Ophthalmol Clin, V51, P37, DOI 10.1097/IIO.0b013e31821e52fe
   Chan CC, 2004, HISTOL HISTOPATHOL, V19, P1219, DOI 10.14670/HH-19.1219
   Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Chen J, 2015, CURR MOL MED, V15, P550, DOI 10.2174/1566524015666150731100318
   Croswell A, 2009, INFECT IMMUN, V77, P2741, DOI 10.1128/IAI.00006-09
   de Haas EN, 2018, NEUROSCI BIOBEHAV R, V95, P170, DOI 10.1016/j.neubiorev.2018.07.007
   DeGruttola AK, 2016, INFLAMM BOWEL DIS, V22, P1137, DOI 10.1097/MIB.0000000000000750
   Desmettre TJ, 2018, J FR OPHTALMOL
   Donohoe DR, 2014, CANCER DISCOV, V4, P1387, DOI 10.1158/2159-8290.CD-14-0501
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Evertts AG, 2013, J BIOL CHEM, V288, P12142, DOI 10.1074/jbc.M112.428318
   Fang DF, 2017, J EXP MED, V214, P1861, DOI 10.1084/jem.20170494
   Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019
   Fuchshofer R, 2006, INVEST OPHTH VIS SCI, V47, P794, DOI 10.1167/iovs.05-0292
   Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gonzalez MM, 2018, J OPHTHALMIC INFLAMM, V8, DOI 10.1186/s12348-018-0148-5
   Grossniklaus HE, 2015, PROG MOL BIOL TRANSL, V134, P383, DOI 10.1016/bs.pmbts.2015.06.001
   Hallak JA, 2015, INVEST OPHTH VIS SCI, V56, P5990, DOI 10.1167/iovs.15-17036
   He C, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00639
   Heissigerova J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5065703
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Holzapfel WH, 1998, INT J FOOD MICROBIOL, V41, P85, DOI 10.1016/S0168-1605(98)00044-0
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Horai R, 2017, EXPERT REV CLIN IMMU, V13, P291, DOI 10.1080/1744666X.2017.1288098
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Janowitz C, 2019, INVEST OPHTH VIS SCI, V60, P420, DOI 10.1167/iovs.18-24813
   Joachim SC, 2007, MOL VIS, V13, P1573
   Kaisar MMM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01429
   Kamer AR, 2008, J ALZHEIMERS DIS, V13, P437
   Kiel JW, 2010, INTEGRATED SYSTEMS P
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kountouras J, 2004, J CELL MOL MED, V8, P317, DOI 10.1111/j.1582-4934.2004.tb00321.x
   Kountouras J, 2001, OPHTHALMOLOGY, V108, P599, DOI 10.1016/S0161-6420(00)00598-4
   Kountouras J, 2015, INVEST OPHTH VIS SCI, V56, P8029, DOI 10.1167/iovs.15-17969
   Kozarov EV, 2005, ARTERIOSCL THROM VAS, V25, pE17, DOI 10.1161/01.ATV.0000155018.67835.1a
   Lazarevic V, 2011, NAT IMMUNOL, V12, P96, DOI 10.1038/ni.1969
   Lee D, 2015, GASTROENTEROLOGY, V148, P1087, DOI 10.1053/j.gastro.2015.01.007
   Leger MM, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700242
   Li HX, 2010, AMINO ACIDS, V39, P1107, DOI 10.1007/s00726-010-0582-7
   Li L, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-26
   Lin H, 2015, INVEST OPHTH VIS SCI, V56
   Lin L, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0187-3
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Liu MM, 2013, CURR GENOMICS, V14, P166, DOI 10.2174/1389202911314030002
   Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889
   Lu Louise J., 2016, Yale Journal of Biology and Medicine, V89, P325
   Lu YY, 2018, BRIT J NUTR, V120, P385, DOI 10.1017/S0007114518001526
   Luo AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00417
   Luo X, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/864871
   Lyte M, 2011, BIOESSAYS, V33, P574, DOI 10.1002/bies.201100024
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   McDermott AM, 2013, EXP EYE RES, V117, P53, DOI 10.1016/j.exer.2013.07.014
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Miller D, 2009, CURR OPIN ALLERGY CL, V9, P466, DOI 10.1097/ACI.0b013e3283303e1b
   Motulsky Arno G, 2006, J Zhejiang Univ Sci B, V7, P167, DOI 10.1631/jzus.2006.B0167
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pasquale LR, 2016, OPHTHALMOLOGY, V123, P2318, DOI 10.1016/j.ophtha.2016.07.014
   Pelzel HR, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-62
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Polla D, 2017, J GLAUCOMA, V26, P320, DOI 10.1097/IJG.0000000000000465
   Qin YF, 2018, J BIOCHEM, V163, P105, DOI 10.1093/jb/mvx080
   Qiu YG, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/9129163
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   ROHEN JW, 1972, A GRAEF ARCH KLIN EX, V183, P251, DOI 10.1007/BF00496153
   Rosenbaum JT, 2018, NAT REV RHEUMATOL, V14, P704, DOI 10.1038/s41584-018-0097-2
   Rosenbaum JT, 2016, JPN J OPHTHALMOL, V60, P1, DOI 10.1007/s10384-015-0416-y
   Rosenbaum JT, 2011, ARTHRITIS RHEUM-US, V63, P3195, DOI 10.1002/art.30558
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Saito T, 2007, PERIODONTOL 2000, V43, P254, DOI 10.1111/j.1600-0757.2006.00186.x
   Sankaridurg PR, 2000, J CLIN MICROBIOL, V38, P4420, DOI 10.1128/JCM.38.12.4420-4424.2000
   Scannapieco FA, 2016, PERIODONTOL 2000, V72, P153, DOI 10.1111/prd.12129
   Shaik MM, 2014, CNS NEUROL DISORD-DR, V13, P460, DOI 10.2174/18715273113126660152
   Sng CCA, 2015, PROG BRAIN RES, V221, P243, DOI 10.1016/bs.pbr.2015.06.008
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tadayoni Ramin, 2014, J Ophthalmic Vis Res, V9, P405, DOI 10.4103/2008-322X.150799
   Takahashi K, 2011, J BIOL CHEM, V286, P35755, DOI 10.1074/jbc.M111.271007
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Verhagen FH, 2018, INVEST OPHTH VIS SCI, V59, P878, DOI 10.1167/iovs.17-23643
   Wall R, 2014, ADV EXP MED BIOL, V817, P221, DOI 10.1007/978-1-4939-0897-4_10
   Wang BH, 2017, ENGINEERING, V3, P71, DOI 10.1016/J.ENG.2017.01.008
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P30, DOI 10.1001/archopht.125.1.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie LX, 2008, AM J OPHTHALMOL, V146, P260, DOI 10.1016/j.ajo.2008.04.019
   Xu L, 2007, AM J OPHTHALMOL, V144, P461, DOI 10.1016/j.ajo.2007.05.013
   Yucel YH, 2009, EXP EYE RES, V89, P810, DOI 10.1016/j.exer.2009.08.010
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zoellner H, 2011, SEMIN THROMB HEMOST, V37, P181, DOI 10.1055/s-0031-1273082
NR 121
TC 18
Z9 18
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD MAR 13
PY 2020
VL 14
IS 1
AR 11
DI 10.1186/s40246-020-00257-5
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KU8QN
UT WOS:000519976900001
PM 32169120
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wallsh, JO
   Gallemore, RP
AF Wallsh, Josh O.
   Gallemore, Ron P.
TI Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment
   Options
SO CELLS
LA English
DT Review
DE anti-VEGF; macular degeneration; diabetic retinopathy; resistant;
   retinal vein occlusion
ID DIABETIC MACULAR EDEMA; ENDOTHELIAL GROWTH-FACTOR; DEXAMETHASONE
   INTRAVITREAL IMPLANT; POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN
   PHOTODYNAMIC THERAPY; FLUOCINOLONE ACETONIDE IMPLANT; 2.0 MG
   RANIBIZUMAB; ONE-YEAR OUTCOMES; AFLIBERCEPT TREATMENT; MICROPULSE LASER
AB Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in the treatment of numerous retinal diseases, most notably exudative age-related macular degeneration (eAMD), diabetic retinopathy and retinal vein occlusions. While offering significant functional and anatomic benefits in most patients, there exists a subset of 15-40% of eyes that fail to respond or only partially respond. For these cases, various treatment options have been explored with a range of outcomes. These options include steroid injections, laser treatment (both thermal therapy for retinal vascular diseases and photodynamic therapy for eAMD), abbreviated anti-VEGF treatment intervals, switching anti-VEGF agents and topical medications. In this article, we review the effectiveness of these treatment options along with a discussion of the current research into future directions for anti-VEGF-resistant eyes.
C1 [Wallsh, Josh O.] Albany Med Coll, Dept Ophthalmol, Albany, NY 12208 USA.
   [Gallemore, Ron P.] Retina Macula Inst, Torrance, CA 90503 USA.
C3 Albany Medical College
RP Gallemore, RP (通讯作者)，Retina Macula Inst, Torrance, CA 90503 USA.
EM jwallsh@hotmail.com; rongallemoremd@gmail.com
CR Abouhussein MA, 2020, INT OPHTHALMOL, V40, P1147, DOI 10.1007/s10792-019-01280-9
   Akhlaghi M, 2019, J CURR OPHTHALMOL, V31, P157, DOI 10.1016/j.joco.2018.11.006
   Alkahest, 2019, ALK PRES POS RES PHA
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Asahi MG, 2015, INT MED CASE REP J, V8, P305, DOI 10.2147/IMCRJ.S92794
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Bakri SJ, 2005, AM J OPHTHALMOL, V139, P290, DOI 10.1016/j.ajo.2004.09.038
   Bansal P, 2016, INT OPHTHALMOL, V36, P207, DOI 10.1007/s10792-015-0103-5
   Barikian A, 2017, RETINA-J RET VIT DIS, V37, P1337, DOI 10.1097/IAE.0000000000001366
   Benner JD, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000293
   Blindbaek SL, 2020, ACTA OPHTHALMOL, V98, P347, DOI 10.1111/aos.14266
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 2018, AM J OPHTHALMOL, V195, P93, DOI 10.1016/j.ajo.2018.07.030
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Busch C, 2019, ACTA DIABETOL, V56, P1341, DOI 10.1007/s00592-019-01416-4
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Chen E, 2012, ARVO M, V53, P2032
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Choi Young Jae, 2006, Korean J Ophthalmol, V20, P205
   Chronopoulos A, 2022, EUR J OPHTHALMOL, V32, P443, DOI 10.1177/1120672121992982
   Clemens CR, 2020, GRAEF ARCH CLIN EXP, V258, P1411, DOI 10.1007/s00417-020-04675-y
   Cohen MN, 2016, CAN J OPHTHALMOL, V51, P342, DOI 10.1016/j.jcjo.2016.02.001
   Coney JM, 2019, INT MED CASE REP J, V12, P161, DOI 10.2147/IMCRJ.S192524
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Cunningham F, 2019, CURR EYE RES, V44, P813, DOI 10.1080/02713683.2019.1614197
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Medeiros MD, 2014, J OCUL PHARMACOL TH, V30, P709, DOI 10.1089/jop.2014.0010
   Eadie JA, 2014, RETINA-J RET VIT DIS, V34, P2439, DOI 10.1097/IAE.0000000000000238
   Entezari M, 2005, EUR J OPHTHALMOL, V15, P746, DOI 10.1177/112067210501500614
   Eris E, 2019, INT OPHTHALMOL, V39, P1575, DOI 10.1007/s10792-018-0977-0
   Faghihi Hooshang, 2017, Med Hypothesis Discov Innov Ophthalmol, V6, P67
   Falavarjani KG, 2016, GRAEF ARCH CLIN EXP, V254, P2159, DOI 10.1007/s00417-016-3374-2
   Finetti F, 2008, J BIOL CHEM, V283, P2139, DOI 10.1074/jbc.M703090200
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Galor A, 2010, BRIT J OPHTHALMOL, V94, P551, DOI 10.1136/bjo.2008.153197
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1146, DOI 10.1001/archophthalmol.2010.172
   Genentech, 2017, LUC PACK INS
   Georgalas I, 2019, CUTAN OCUL TOXICOL, V38, P330, DOI 10.1080/15569527.2019.1614020
   Ghanbari H, 2017, INT OPHTHALMOL, V37, P867, DOI 10.1007/s10792-016-0335-z
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Gross JG, 2018, JAMA OPHTHALMOL, V136, P1138, DOI 10.1001/jamaophthalmol.2018.3255
   Guler E, 2017, CUTAN OCUL TOXICOL, V36, P180, DOI 10.3109/15569527.2015.1127254
   Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221
   Han DY, 2013, ALLERGY ASTHMA IMMUN, V5, P224, DOI 10.4168/aair.2013.5.4.224
   Hatz K, 2018, OPHTHALMOLOGICA, V239, P205, DOI 10.1159/000485852
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsia Ning-Yi, 2015, Taiwan J Ophthalmol, V5, P128, DOI 10.1016/j.tjo.2015.05.001
   Huang QZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186180
   Husum YS, 2021, ACTA OPHTHALMOL, V99, pE1354, DOI 10.1111/aos.14825
   Iacono P, 2017, BRIT J OPHTHALMOL, V101, P791, DOI 10.1136/bjophthalmol-2016-308726
   Ip MS, 2019, JAMA OPHTHALMOL, V137, P281, DOI 10.1001/jamaophthalmol.2018.6111
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishibashi T, 2015, OPHTHALMOLOGY, V122, P1402, DOI 10.1016/j.ophtha.2015.02.006
   Itatani Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041232
   Jeon S, 2014, RETINA-J RET VIT DIS, V34, P1606, DOI 10.1097/IAE.0000000000000109
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Khan Z, 2017, OSLI RETINA, V48, P160, DOI 10.3928/23258160-20170130-10
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kim JH, 2015, ACTA OPHTHALMOL, V93, pE178, DOI 10.1111/aos.12504
   Kim K, 2019, RETINA-J RET VIT DIS, V39, P303, DOI 10.1097/IAE.0000000000001947
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Klein Kendra A, 2017, Int J Retina Vitreous, V3, P16, DOI 10.1186/s40942-017-0064-0
   Kocabora MS, 2008, CLIN OPHTHALMOL, V2, P167
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   La Mantia A, 2018, INT J OPHTHALMOL-CHI, V11, P1951, DOI 10.18240/ijo.2018.12.13
   Laiginhas R, 2018, GRAEF ARCH CLIN EXP, V256, P83, DOI 10.1007/s00417-017-3836-1
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lazic R, 2014, RETINA-J RET VIT DIS, V34, P719, DOI 10.1097/IAE.0b013e3182a48958
   Lee CS, 2018, RETINA-J RET VIT DIS, V38, P951, DOI 10.1097/IAE.0000000000001637
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P1953, DOI 10.1097/IAE.0000000000002293
   Lehmann-Clarke L, 2015, KLIN MONATSBL AUGENH, V232, P552, DOI 10.1055/s-0035-1545783
   Li SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184998
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Maleki A, 2020, J OPHTHAL VIS RES, V15, P453, DOI 10.18502/jovr.v15i4.7785
   Marquis LM, 2020, GRAEF ARCH CLIN EXP, V258, P1591, DOI 10.1007/s00417-020-04730-8
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Massin P, 2016, CLIN OPHTHALMOL, V10, P1257, DOI 10.2147/OPTH.S105385
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   McCluskey JD, 2019, INT MED CASE REP J, V12, P93, DOI 10.2147/IMCRJ.S191171
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mimouni M, 2018, JPN J OPHTHALMOL, V62, P652, DOI 10.1007/s10384-018-0619-0
   Mirshahi A, 2019, J CURR OPHTHALMOL, V31, P168, DOI 10.1016/j.joco.2019.01.008
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moisseiev E, 2018, EUR J OPHTHALMOL, V28, P68, DOI 10.5301/ejo.5001000
   Muftuoglu IK, 2017, GRAEF ARCH CLIN EXP, V255, P709, DOI 10.1007/s00417-016-3547-z
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Nalcaci S, 2019, TURK OFTALMOL DERG, V49, P73, DOI 10.4274/tjo.galenos.2018.84665
   Neubauer AS, 2013, CLIN OPHTHALMOL, V7, P121, DOI 10.2147/OPTH.S38559
   Nguyen D., 2008, ANTI VEGF TREATMENT
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Noma H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073427
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Obeid A, 2019, OPHTHALMOLOGY, V126, P407, DOI 10.1016/j.ophtha.2018.07.027
   Park UC, 2021, ACTA OPHTHALMOL, V99, pE899, DOI 10.1111/aos.14719
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pessoa B, 2018, OPHTHALMIC RES, V59, P68, DOI 10.1159/000484091
   Peyman G, 2011, EUR J OPHTHALMOL, V21, P162, DOI 10.5301/EJO.2010.3272
   Pinna A, 2017, EUR J OPHTHALMOL, V27, P326, DOI 10.5301/ejo.5000888
   Regeneron Pharmaceuticals, 2019, EYL PACK INS
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rishi Pukhraj, 2020, GMS Ophthalmol Cases, V10, pDoc21, DOI 10.3205/oc000148
   Rishi Pukhraj, 2012, Oman J Ophthalmol, V5, P79
   Romanek J, 2020, Cesk Slov Oftalmol, V76, P88, DOI 10.31348/2020/16
   Rouvas A, 2019, INT OPHTHALMOL, V39, P431, DOI 10.1007/s10792-018-0833-2
   Sadiq MA, 2015, SAUDI J OPHTHALMOL, V29, P287, DOI 10.1016/j.sjopt.2015.05.005
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Salimi A, 2021, INDIAN J OPHTHALMOL, V69, P360, DOI 10.4103/ijo.IJO_459_20
   Sanders S.M, 2009, INVESTIG OPHTHALMOL, V50, P1479
   Schmit-Eilenberger VK, 2015, CLIN OPHTHALMOL, V9, P801, DOI 10.2147/OPTH.S79785
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Shah Ankoor R, 2017, J Vitreoretin Dis, V1, P169, DOI 10.1177/2474126416682569
   Shah Ankoor R, 2016, J Ophthalmic Vis Res, V11, P183, DOI 10.4103/2008-322X.183928
   Shah Sanket U, 2012, Acta Ophthalmol, V90, pe569, DOI 10.1111/j.1755-3768.2011.02372.x
   Silva-Garcia R, 2014, CLIN OPHTHALMOL, V8, P2529, DOI 10.2147/OPTH.S68028
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Soheilian M, 2015, INT OPHTHALMOL, V35, P421, DOI 10.1007/s10792-014-9967-z
   Spooner K, 2019, ACTA OPHTHALMOL, V97, pE706, DOI 10.1111/aos.14046
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Srividya G, 2018, EYE, V32, P820, DOI 10.1038/eye.2017.285
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Terashima H, 1996, JPN J OPHTHALMOL, V40, P142
   Thomas BJ, 2016, CLIN OPHTHALMOL, V10, P1679, DOI 10.2147/OPTH.S110789
   Todorich Bozho, 2017, J Vitreoretin Dis, V1, P65, DOI 10.1177/2474126416683299
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Topal T, 2017, TURK OFTALMOL DERG, V47, P133, DOI 10.4274/tjo.34735
   Totan Y, 2016, CURR EYE RES, V41, P107, DOI 10.3109/02713683.2014.1002048
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Waibel S, 2018, KLIN MONATSBL AUGENH, V235, P616, DOI 10.1055/s-0043-106308
   Wallsh J, 2016, CLIN OPHTHALMOL, V10, P947, DOI 10.2147/OPTH.S105412
   Wang M, 2019, DIABETOLOGIA, V62, P335, DOI 10.1007/s00125-018-4755-3
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Witkin AJ, 2017, SEMIN OPHTHALMOL, V32, P309, DOI 10.3109/08820538.2015.1072222
   Wolfe JD, 2016, EUR J OPHTHALMOL, V26, P168, DOI 10.5301/ejo.5000686
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Xie TH, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108507
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yin MY, 2019, CORNEA, V38, P1239, DOI 10.1097/ICO.0000000000001995
   Yong M H, 2015, Med J Malaysia, V70, P358
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zheng L, 2016, ONCOTARGET, V7, P77902, DOI 10.18632/oncotarget.12843
   Zhu LP, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1113-z
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
   Zur D, 2015, OSLI RETINA, V46, P338, DOI 10.3928/23258160-20150323-07
NR 175
TC 24
Z9 25
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAY
PY 2021
VL 10
IS 5
AR 1049
DI 10.3390/cells10051049
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SI2NM
UT WOS:000654662900001
PM 33946803
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bond, WS
   Rex, TS
AF Bond, Wesley S.
   Rex, Tonia S.
TI Evidence that erythropoietin modulates neuroinflammation through
   differential action on neurons, astrocytes, and microglia
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE erythropoietin; neuroinflammation; microglia; astrocytes; signaling
   pathways
ID BLOOD-BRAIN-BARRIER; RETINAL GANGLION-CELLS; NRF2 SIGNALING PATHWAY;
   OXIDATIVE STRESS; RAT MODEL; BETA-CATENIN; IN-VITRO; COGNITIVE
   IMPAIRMENT; CYTOKINE PRODUCTION; INJURY
AB Neuroinflammation is a normal and healthy response to neuronal damage. However, excessive or chronic neuroinflammation exacerbates neurodegeneration after trauma and in progressive diseases such as Alzheimer's, Parkinson's, age-related macular degeneration, and glaucoma. Therefore, molecules that modulate neuroinflammation are candidates as neuroprotective agents. Erythropoietin (EPO) is a known neuroprotective agent that indirectly attenuates neuroinflammation, in part, by inhibiting neuronal apoptosis. In this review, we provide evidence that EPO also modulates neuroinflammation upstream of apoptosis by acting directly on glia. Further, the signaling induced by EPO may differ depending on cell type and context possibly as a result of activation of different receptors. While significant progress has been made in our understanding of EPO signaling, this review also identifies areas for future study in terms of the role of EPO in modulating neuroinflammation.
C1 [Bond, Wesley S.; Rex, Tonia S.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Bond, Wesley S.; Rex, Tonia S.] Vanderbilt Univ, Med Ctr, Vanderbilt Brain Inst, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University
RP Rex, TS (通讯作者)，Vanderbilt Univ, Dept Ophthalmol & Visual Sci, 11425 Langford MRB 4,2213 Garland Ave, Nashville, TN 37232 USA.
EM tonia.rex@vanderbilt.edu
OI Bond, Wesley/0000-0001-9715-0336
FU NEI NIH HHS [R01 EY022349, P30 EY008126] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY022349] Funding Source: NIH RePORTER
CR Al-Qahtani JM, 2014, NEUROCHEM RES, V39, P161, DOI 10.1007/s11064-013-1201-2
   Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575
   Bailey DM, 2014, ACTA PHYSIOL, V212, P175, DOI 10.1111/apha.12313
   Barichello T, 2014, TRANSL RES, V163, P503, DOI 10.1016/j.trsl.2013.12.008
   Blake TJ, 2002, J LEUKOCYTE BIOL, V72, P1246
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101
   Broxmeyer HE, 2013, J EXP MED, V210, P205, DOI 10.1084/jem.20122760
   Chen CM, 2004, BLOOD, V104, P73, DOI 10.1182/blood-2003-04-1340
   Chin H, 1998, BLOOD, V91, P3734
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Chu HL, 2014, LAB INVEST, V94, P1042, DOI 10.1038/labinvest.2014.84
   Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200
   Chung YH, 2006, BRAIN RES, V1085, P132, DOI 10.1016/j.brainres.2006.02.087
   Colella P, 2011, HUM MOL GENET, V20, P2251, DOI 10.1093/hmg/ddr115
   Comim CM, 2012, J NEURAL TRANSM, V119, P1267, DOI 10.1007/s00702-012-0774-2
   De Simone R, 2002, J NEUROPATH EXP NEUR, V61, P237, DOI 10.1093/jnen/61.3.237
   Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X
   Diaz Z, 2005, J NEUROCHEM, V93, P392, DOI 10.1111/j.1471-4159.2005.03038.x
   Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96
   Eilert-Olsen M, 2012, GLIA, V60, P432, DOI 10.1002/glia.22277
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47
   Fusco FR, 2004, NEUROSCI LETT, V365, P137, DOI 10.1016/j.neulet.2004.04.070
   Genc K, 2010, CELL BIOCHEM FUNCT, V28, P197, DOI 10.1002/cbf.1639
   Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037
   Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450
   Gonzalez FF, 2013, STROKE, V44, P753, DOI 10.1161/STROKEAHA.111.000104
   Goodnough LT, 2007, EXP HEMATOL, V35, P167, DOI 10.1016/j.exphem.2007.01.026
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Gui DM, 2011, INT J OPHTHALMOL-CHI, V4, P40, DOI 10.3980/j.issn.2222-3959.2011.01.09
   Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106
   Hagemeyer N, 2012, MOL MED, V18, P628, DOI 10.2119/molmed.2011.00457
   Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156
   Hines-Beard J, 2013, CURR GENE THER, V13, P275
   Ingley E, 2012, IUBMB LIFE, V64, P402, DOI 10.1002/iub.1024
   Jia Y, 2014, J MOL NEUROSCI, V53, P117, DOI 10.1007/s12031-013-0208-0
   Jin W, 2014, J TRAUMA ACUTE CARE, V76, P1228, DOI 10.1097/TA.0000000000000211
   Jin W, 2011, J TRAUMA, V71, P680, DOI 10.1097/TA.0b013e3181f6b984
   Jubinsky PT, 1997, BLOOD, V90, P1867, DOI 10.1182/blood.V90.5.1867
   Kakhana K, 2005, BIOCHEM BIOPH RES CO, V335, P424, DOI 10.1016/j.bbrc.2005.07.095
   Kilic U, 2004, FASEB J, V18, P249, DOI 10.1096/fj.04-2493fje
   Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009
   Kumral A, 2005, DEV BRAIN RES, V160, P146, DOI 10.1016/j.devbrainres.2005.08.006
   Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490
   Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313
   Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758
   Li G, 2008, NEUROSCI LETT, V442, P143, DOI 10.1016/j.neulet.2008.07.007
   Li Y, 2008, ACTA NEUROCHIR SUPPL, V105, P105
   Lifshitz L, 2010, HAEMATOL-HEMATOL J, V95, P1823, DOI 10.3324/haematol.2010.025015
   Liu J, 2006, GLIA, V53, P360, DOI 10.1002/glia.20289
   Liu YQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085282, 10.1371/journal.pone.0090942]
   Lu MJ, 2012, LIFE SCI, V90, P776, DOI 10.1016/j.lfs.2012.04.012
   Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23
   Maiese K, 2012, INT J MOL SCI, V13, P11102, DOI 10.3390/ijms130911102
   Meloni BP, 2006, J NEUROSCI RES, V83, P584, DOI 10.1002/jnr.20755
   Mengozzi M, 2012, P NATL ACAD SCI USA, V109, P9617, DOI 10.1073/pnas.1200554109
   Mennini T, 2006, MOL MED, V12, P153, DOI 10.2119/2006-00045.Mennini
   Mitsuma T, 2010, J MOL BIOL, V402, P669, DOI 10.1016/j.jmb.2010.07.060
   Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713
   Myklebust JH, 2002, EXP HEMATOL, V30, P990, DOI 10.1016/S0301-472X(02)00868-8
   Nadam J, 2007, NEUROBIOL DIS, V25, P412, DOI 10.1016/j.nbd.2006.10.009
   Nairz M, 2011, IMMUNITY, V34, P61, DOI 10.1016/j.immuni.2011.01.002
   Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001
   Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807
   Palis J, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00003
   Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2
   Rizzo MT, 2010, MOL NEUROBIOL, V42, P52, DOI 10.1007/s12035-010-8132-6
   Sattler MB, 2004, CELL DEATH DIFFER, V11, pS181, DOI 10.1038/sj.cdd.4401504
   Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430
   Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440
   Shang YC, 2011, CURR NEUROVASC RES, V8, P270
   Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14
   Sullivan T, 2011, NEUROCHEM RES, V36, P613, DOI 10.1007/s11064-010-0272-6
   Sullivan TA, 2012, EXP EYE RES, V96, P36, DOI 10.1016/j.exer.2012.01.006
   Sullivan TA, 2011, HUM GENE THER, V22, P1191, DOI 10.1089/hum.2011.052
   Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017
   Tong Q, 2008, J BIOL CHEM, V283, P10385, DOI 10.1074/jbc.M710231200
   Tsai JC, 2005, CURR EYE RES, V30, P1025, DOI 10.1080/02713680500320729
   Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067
   Vitellaro-Zuccarello L, 2008, NEUROSCIENCE, V151, P452, DOI 10.1016/j.neuroscience.2007.11.004
   Wang GB, 2014, MOL CELL BIOCHEM, V385, P125, DOI 10.1007/s11010-013-1821-5
   Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285
   Weinreb O, 2013, FREE RADICAL BIO MED, V62, P52, DOI 10.1016/j.freeradbiomed.2013.01.017
   Weishaupt JH, 2004, INVEST OPHTH VIS SCI, V45, P1514, DOI 10.1167/iovs.03-1039
   Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022
   Wenker SD, 2013, FEBS J, V280, P1630, DOI 10.1111/febs.12172
   Wilms H, 2009, J NEUROIMMUNOL, V212, P106, DOI 10.1016/j.jneuroim.2009.04.018
   Xie ZG, 2012, CURR EYE RES, V37, P138, DOI 10.3109/02713683.2011.647225
   Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001
   Xu F, 2013, J INFECT DIS, V208, P528, DOI 10.1093/infdis/jit177
   Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje
   Yazihan N, 2008, INJURY, V39, P1408, DOI 10.1016/j.injury.2008.03.010
   Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
   Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018
   Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757
   Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb
   Zhou TF, 2013, J SURG RES, V183, P304, DOI 10.1016/j.jss.2012.11.035
NR 107
TC 58
Z9 59
U1 0
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 22
PY 2014
VL 5
AR 523
DI 10.3389/fimmu.2014.00523
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CI1IM
UT WOS:000354497200001
PM 25374571
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Garcia-Arumi, J
   Figueroa, MS
   Barquet, LA
   Ruiz-Moreno, JM
   Monclus-Arbona, L
AF Garcia-Layana, A.
   Garcia-Arumi, J.
   Figueroa, M. S.
   Arias Barquet, L.
   Ruiz-Moreno, J. M.
   Monclus-Arbona, L.
CA Spanish AMD Multictr Grp
TI Management of Wet Age-Related Macular Degeneration in Spain: Challenges
   for Treat and Extend Implementation in Routine Clinical Practice
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; DELPHI METHOD; RECOMMENDATIONS; GUIDELINES;
   REGIMEN; RANIBIZUMAB; AFLIBERCEPT; LIFE
AB Purpose. To ascertain wet AMD (wAMD) management patterns in Spain. Methods. A two-round Delphi study conducted through a questionnaire-based survey designed from literature review and validated by an independent Steering Committee. Results. Forty-nine retina specialists experienced in wAMD participated by answering the two-round study questionnaire. Retina specialists are the main responsible for wAMD diagnosis and monitoring, including visits and associated procedures, with a median time per visit of 15 minutes. Standard treatment strategies are based on anti-VEGF administration, including standard loading dose administration followed by maintenance with aflibercept or ranibizumab (81% of patients). Although treat and extend (T&E) dosing strategy is considered as optimal for wAMD management (78% of the panelists), the main routine healthcare limitations (i.e., visits overload, reduced staff, short visit time, coordination issues, lack of facilities) conduct to self-defined "flexible" strategies, based on T&E and pro-re-nata (PRN) protocols. Conclusion. Proactive treatment patterns (T&E) are the preferred ones by the retina specialists in Spain. However, their proper implementation is difficult due to healthcare resource limitations, as well as organisation and logistic issues. The use of anti-VEGF agents with longer duration of action could facilitate the use of strict T&E approaches according to routine clinical practices.
C1 [Garcia-Layana, A.] Clin Univ Navarra, Ave Pio XII 36, Pamplona 31008, Spain.
   [Garcia-Arumi, J.] Hosp Valle De Hebron, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.
   [Figueroa, M. S.] Vissum Madrid, Santa Hortensia 58, Madrid 28002, Spain.
   [Arias Barquet, L.] Hosp Bellvitge Princeps Espanya, C Feixa Llarga S-N, Barcelona 08907, Spain.
   [Ruiz-Moreno, J. M.] Hosp Univ Puerta de Hierro Majadahonda, Joaquin Rodrigo 2, Madrid 28222, Spain.
   [Monclus-Arbona, L.] Bayer Hispania SL, Ave Baix Llobregat 3-5, Barcelona 08970, Spain.
   [Spanish AMD Multictr Grp] IQVIA Informat, Barcelona, Spain.
C3 University of Navarra; Hospital Universitari Vall d'Hebron; Hospital
   Puerta de Hierro-Majadahonda; Bayer AG
RP Garcia-Layana, A (通讯作者)，Clin Univ Navarra, Ave Pio XII 36, Pamplona 31008, Spain.
EM aglayana@unav.es; jgarcia.arumi@gmail.com; figueroa@servicom2000.com;
   luisariasbarquet@gmail.com; josemaria.ruiz@uclm.es;
   jordi.mondejar@bayer.com
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788; Garcia-Arumi,
   Jose/0000-0001-8827-1160; ARIAS, LUIS/0000-0001-7041-5576
FU Bayer Hispania S.L. Logistics
FX The authors want to acknowledge the participation of the 49 panelists
   that filled the two rounds of the Delphi questionnaire (S Abengoechea, M
   Abraldes, MS Alforja, JJ Araiz, F Armada, J Ascaso, JJ Barbon, E
   Basauri, F Cabrera, J Campos, J Canal, C Cava, E Cervera, LM Cordoves, J
   Crespi, A Exposito, C Fernandez, M Fernandez, G Fernandez, G
   Fernandez-Baca, A Fernandez-Vega, P Gili, B Goldaracena, E Gutierrez, M
   Lafuente, J Lavid, MI Lopez, JA Lopez, L Lopez, N Martinez, JJ Martinez,
   J Montero, R Navarro, A Navea, AI Oca, V Poposki, E Rodriguez, E
   Rodriguez, M Ruiz, O Ruiz, L Sararols, R Torres, P Udaondo, MA Zapata,
   and J Zarranz). The study has been sponsored by Bayer Hispania S.L.
   Logistics. Coordination and medical writing have been conducted by
   IQVIA.
CR Amoaku W, 2018, CLIN OPHTHALMOL, V12, P1731, DOI 10.2147/OPTH.S174560
   Androudi S, 2016, ADV THER, V33, P715, DOI 10.1007/s12325-016-0332-7
   [Anonymous], 2014, GUIAS PRACT CLIN SER
   Casaroli-Marano R, 2013, Arch Soc Esp Oftalmol, V88, P307, DOI 10.1016/j.oftal.2012.10.009
   Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   EMA, 2017, EUR PUBL ASS REP EPA
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/595132
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Okoli C, 2004, INFORM MANAGE-AMSTER, V42, P15, DOI 10.1016/j.im.2003.11.002
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Skulmoski GJ, 2007, J INF TECHNOL EDUC-R, V6, P1
   Suleman J, 2015, INVEST OPHTH VIS SCI, V56
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 31
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD SEP 30
PY 2019
VL 2019
AR 9821509
DI 10.1155/2019/9821509
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JG7YO
UT WOS:000492292900001
PM 31662900
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Olson, LM
   Schnetz-Boutaud, N
   Gallins, P
   Wang, GF
   Scott, WK
   Agarwal, A
   Jakobsdottir, J
   Conley, Y
   Weeks, DE
   Gorin, MB
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Olson, Lana M.
   Schnetz-Boutaud, Nathalie
   Gallins, Paul
   Wang, Gaofeng
   Scott, William K.
   Agarwal, Anita
   Jakobsdottir, Johanna
   Conley, Yvette
   Weeks, Daniel E.
   Gorin, Michael B.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Dissection of Chromosome 16p12 Linkage Peak Suggests a Possible Role for
   CACNG3 Variants in Age-Related Macular Degeneration Susceptibility
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENERAL PEDIGREES; FACTOR-B; RISK; ASSOCIATION;
   MACULOPATHY; POLYMORPHISM; SCAN; LOC387715; INCREASES
AB PURPOSE. Age-related macular degenerati.on (AMD) is a complex disorder of the retina., characterized by drusen, geographic atrophy, and choroidal neovascularization. Cigarette smoking and the genetic variants CFH Y402H, ARMS2 A69S, (TB R32Q, and C3 R102G have been strongly and consistently associated with AMD. Multiple linkage studies have found evidence suggestive of another AMD locus on chromosome 16p12 but the gene responsible has yet to be identified.
   METHODS. In the initial phase of the study, single-nucleotide polymorphisms (SNPs) across chromosome 16 were examined for linkage and/or association in 575 Caucasian individuals from 118 multiplex and 77 singleton families Additional variants were tested in an independent dataset of unrelated cases and controls. According to these results, in combination with gene expression data and biological knowledge, five genes were selected for further study: CACNG3, HS3ST4, IL4R, Q7Z6F8, and ITGAM.
   RESULTS. After genotyping additional tagging SNPs across each gene, the strongest evidence for linkage and association was found within CACNG3 (rs757200 nonparametric LOD* = 3.3, API. (association in the presence of linkage) P = 0.06, and rs2238498 MQLS (modified quasi-likelihood score) P = 0.006 in the families; rs2283550 P = 1.3 X 10(-6), and rs4787924 P 0.002 in the case-control dataset). After adjusting for known AMD risk factors, rs2283550 remained strongly associated (I) = 2.4 X 10(-4)). Furthermore, the association signal at rs4787924 was replicated in an independent damsel (P = 0.035) and in a joint analysis of all the data (p = 0.001).
   CONCLUSIONS. These results suggest that CACNG3 is the best candidate for an AMD risk gene within the 16p12 linkage peak. More studies are needed to confirm this association and clarify the role of the gene in AMD pathogenesis. (Invest Ophthalmol Sci. 2011;52:1748-1754) DOI:10.1167/iovs.09-5112
C1 [Spencer, Kylee L.; Olson, Lana M.; Schnetz-Boutaud, Nathalie; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
   [Gallins, Paul; Wang, Gaofeng; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA.
   [Jakobsdottir, Johanna] Univ Chicago, Dept Stat, Chicago, IL 60637 USA.
   [Conley, Yvette; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, Los Angeles Med Ctr, Los Angeles, CA USA.
C3 Vanderbilt University; University of Miami; Vanderbilt University;
   University of Chicago; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center
RP Spencer, KL (通讯作者)，525 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.
EM kylee.spencer@vanderbilt.edu
RI Haines, Jonathan/C-3374-2012; Weeks, Daniel E/B-2995-2012
OI Haines, Jonathan/0000-0002-4351-4728; Weeks, Daniel
   E/0000-0001-9410-7228; Scott, William/0000-0001-9336-6404; Jakobsdottir,
   Johanna/0000-0002-8019-9683; Conley, Yvette/0000-0002-1784-6067
FU American Health Assistance Foundation; Research to Prevent Blindness,
   New York; Harold and Pauline Price Foundation; National Institutes of
   Health [EY09859, EY12118]; NATIONAL EYE INSTITUTE [R01EY009859,
   U10EY012118, R01EY012118] Funding Source: NIH RePORTER
FX Supported by grants from the American Health Assistance Foundation,
   Research to Prevent Blindness, New York, the Harold and Pauline Price
   Foundation, and Grants EY09859 and EY12118 from the National Institutes
   of Health.
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   BOWES RC, 2006, INVEST OPHTH VIS SCI, V47, P2305
   Boyles AL, 2005, HUM HERED, V59, P220, DOI 10.1159/000087122
   COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gudbjartsson DF, 2005, NAT GENET, V37, P1015, DOI 10.1038/ng1005-1015
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hancock DB, 2007, GENET EPIDEMIOL, V31, P883, DOI 10.1002/gepi.20249
   Hauser ER, 2004, GENET EPIDEMIOL, V27, P53, DOI 10.1002/gepi.20000
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin ER, 2003, AM J HUM GENET, V73, P1016, DOI 10.1086/378779
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   Martin ER, 2003, GENET EPIDEMIOL, V25, P203, DOI 10.1002/gepi.10258
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenthal R, 2005, FASEB J, V19, P178, DOI 10.1096/fj.05-4495fje
   SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2000, MOL VIS, V6, P287
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wong KK, 2007, AM J HUM GENET, V80, P91, DOI 10.1086/510560
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 44
TC 6
Z9 6
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1748
EP 1754
DI 10.1167/iovs.09-5112
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742SR
UT WOS:000288965300066
PM 21169531
OA Green Published
DA 2022-11-30
ER

PT J
AU Wygledowska-Promienska, D
   Piotrowska-Gwozdz, A
   Piotrowska-Seweryn, A
   Mazur-Piotrowska, G
AF Wygledowska-Promienska, Dorota
   Piotrowska-Gwozdz, Anna
   Piotrowska-Seweryn, Agnieszka
   Mazur-Piotrowska, Grazyna
TI Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular
   Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Intravitreal Injections; Macular Degeneration; Tomography, Optical
   Coherence
ID ENDOTHELIAL GROWTH-FACTOR; SHORT-TERM OUTCOMES; VEGF TRAP; INTRAVITREAL
   AFLIBERCEPT; ANATOMICAL OUTCOMES; TOPICAL BROMFENAC; NEOVASCULAR AMD;
   EXUDATIVE AMD; RANIBIZUMAB; EYES
AB Background: Among many protocols for treatment of exudative AMD, combined therapy of anti-VEGF agents and non-steroidal anti-inflammatory drugs (NSAIDs) seems to be an ideal alternative to monotherapy based on ranibizumab or bevacizumab. The aim of this study was to evaluate the effectiveness of aflibercept and bromfenac in the treatment of exudative AMD.
   Material/Methods: The study was conducted on a group of 27 patients with exudative AMD who were administered intravitreal aflibercept and topical bromfenac (study group) once a month. Additional injections were administered up to 3 months after the third administration, depending on response to treatment. The control group consisted of subjects treated with aflibercept only. Visual acuity and anatomical outcomes in optical coherence tomography (OCT) were assessed at baseline visit, 4 months after the first dose, and 6 months after the start of the treatment.
   Results: Visual acuity improved over time in the study group and the differences between the groups were statistically significant. No statistically significant differences were found in OCT parameters.
   Conclusions: Combined therapy of aflibercept and bromfenac in the treatment of wet AMD is more effective than single aflibercept therapy.
C1 [Wygledowska-Promienska, Dorota; Piotrowska-Gwozdz, Anna; Mazur-Piotrowska, Grazyna] Med Univ Silesia, Dept Clin Ophthalmol, Sch Med Katowice, Katowice, Poland.
   [Piotrowska-Seweryn, Agnieszka] Med Univ Silesia, Clin Dept Laryngol, Sch Med Katowice, Katowice, Poland.
C3 Medical University Silesia; Medical University Silesia
RP Piotrowska-Gwozdz, A (通讯作者)，Med Univ Silesia, Dept Clin Ophthalmol, Sch Med Katowice, Katowice, Poland.
EM aniapio.fm@interia.pl
OI Piotrowska-Seweryn, Agnieszka/0000-0003-1733-1167
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gerding H, 2015, KLIN MONATSBL AUGENH, V232, P560, DOI 10.1055/s-0035-1545775
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jones J, 2009, EXPERT OPIN PHARMACO, V10, P2379, DOI 10.1517/14656560903188425
   Jorstad OK, 2015, ACTA OPHTHALMOL, V93, pE510, DOI 10.1111/aos.12681
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Nowak Jerzy Z, 2007, Postepy Hig Med Dosw (Online), V61, P83
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Schalnus R, 2003, OPHTHALMOLOGICA, V217, P89, DOI 10.1159/000068563
   Stankiewicz A, 2010, PRZEWODNIK LEKARZA, V2, P153
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Thorel J, 2015, J CLIN PHARM THER, V40, P477, DOI 10.1111/jcpt.12278
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Van Meter MEM, 2010, CURR OPIN ONCOL, V22, P586, DOI 10.1097/CCO.0b013e32833edc0c
   Wygledowska-Promienska D, 2014, MED SCI MONITOR, V20, P1168, DOI 10.12659/MSM.890671
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 30
TC 10
Z9 12
U1 0
U2 7
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD DEC 15
PY 2015
VL 21
BP 3906
EP 3912
DI 10.12659/MSM.895977
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CZ8NF
UT WOS:000367355700001
PM 26667262
OA Green Published
DA 2022-11-30
ER

PT J
AU Cai, H
   Shin, MC
   Tezel, TH
   Kaplan, HJ
   Del Priore, LV
AF Cai, Hui
   Shin, Min C.
   Tezel, Tongalp H.
   Kaplan, Henry J.
   Del Priore, Lucian V.
TI Use of iris pigment epithelium to replace retinal pigment epithelium in
   age-related macular degeneration - A gene expression analysis
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Review
ID HUMAN BRUCHS MEMBRANE; CHOROIDAL NEOVASCULAR MEMBRANES; PHOTORECEPTOR
   CELL RESCUE; RCS DYSTROPHIC RATS; IN-VITRO; SUBRETINAL SPACE; RPE
   TRANSPLANTATION; ROYAL-COLLEGE; MESSENGER-RNA; SURVIVAL
AB Objective: To determine the gene expression profiles of primary retinal pigment epithelium ( RPE) and iris pigment epithelium ( IPE) using microarrays.
   Methods: Primary RPE and IPE from 6 human donor eyes were collected, and total RNA was isolated. Differences in gene expression were determined using a human genechip ( human U95Av2 [ 12 600 probes]; Affymetrix Inc, Santa Clara, Calif).
   Results: Hierarchical cluster analysis differentiated the gene expression profiles of RPE and IPE clusters into 2 distinct groups. A mean +/- SD of 5308 +/- 416 gene probes were expressed in RPE vs 6130 +/- 205 in IPE. Sixty-eight genes were expressed only in RPE; 154 genes were expressed only in IPE. Twenty- two additional genes had greater than 3-fold increased expression in RPE vs IPE, and 147 genes had greater than 3-fold decreased expression in RPE vs IPE.
   Conclusion: There are major differences in the gene expression profiles of primary RPE vs IPE.
   Clinical Relevance: The different gene expression profiles of primary RPE vs IPE harvested from the same donor eyes infer that it may be difficult for IPE to replace all aspects of damaged RPE function in transplantation studies.
C1 Columbia Univ, Dept Ophthalmol, Harkness Eye Inst, New York, NY 10032 USA.
   Univ Louisville, Kentucky Lions Eye Ctr, Louisville, KY 40292 USA.
C3 Columbia University; University of Louisville
RP Del Priore, LV (通讯作者)，Columbia Univ, Dept Ophthalmol, Harkness Eye Inst, 635 W 165th St, New York, NY 10032 USA.
EM ld394@columbia.edu
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2000, CURR EYE RES, V20, P268
   Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Abe T, 1999, TOHOKU J EXP MED, V189, P179, DOI 10.1620/tjem.189.179
   Abe Toshiaki, 2002, Nippon Ganka Gakkai Zasshi, V106, P778
   *AFF CORP, 2004, AFF GEN EXPR AN MAN
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Arnhold S, 2004, EXP NEUROL, V187, P410, DOI 10.1016/j.expneurol.2004.02.015
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bindewald A, 2004, OPHTHALMOLOGE, V101, P886, DOI 10.1007/s00347-004-1077-2
   Boulton ME, 2004, OPHTHALMOLOGE, V101, P877
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   Chowers I, 2003, INVEST OPHTH VIS SCI, V44, P3732, DOI 10.1167/iovs.02-1080
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Crafoord S, 2001, ACTA OPHTHALMOL SCAN, V79, P509, DOI 10.1034/j.1600-0420.2001.790517.x
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DELPRIORE LV, 1995, OPHTHALMOLOGY, V102, P1125, DOI 10.1016/S0161-6420(95)30903-7
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   DELPRIORE LV, 1997, SEMIN OPHTHALMOL, V12, P45
   DESAI VN, 1995, ARCH OPHTHALMOL-CHIC, V113, P409, DOI 10.1001/archopht.1995.01100040023014
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Enzmann V, 1999, TRANSPL IMMUNOL, V7, P9, DOI 10.1016/S0966-3274(99)80013-6
   Enzmann V, 2001, CURR EYE RES, V23, P98, DOI 10.1076/ceyr.23.2.98.5474
   Enzmann V, 2001, GRAEF ARCH CLIN EXP, V239, P445, DOI 10.1007/s004170100297
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   GAUR V, 1992, EXP EYE RES, V54, P91, DOI 10.1016/0014-4835(92)90073-2
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Gouras P, 1989, Prog Clin Biol Res, V314, P659
   GOURAS P, 1991, INVEST OPHTH VIS SCI, V32, P1704
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hojo M, 2004, INVEST OPHTH VIS SCI, V45, P3721, DOI 10.1167/iovs.04-0059
   Hollborn M, 2005, MOL VIS, V11, P397
   HU DN, 1992, INVEST OPHTH VIS SCI, V33, P2443
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Itaya H, 2004, INVEST OPHTH VIS SCI, V45, P4520, DOI 10.1167/iovs.04-0684
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   JIANG LQ, 1994, INVEST OPHTH VIS SCI, V35, P4300
   Jordan JF, 2002, GRAEF ARCH CLIN EXP, V240, P403, DOI 10.1007/s00417-002-0436-4
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Klassen H, 2001, EXP NEUROL, V169, P114, DOI 10.1006/exnr.2000.7617
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   Krajewski Pawel, 2002, Journal of Applied Genetics, V43, P269
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   LI LX, 1990, PROG BRAIN RES, V82, P179
   LI LX, 1991, CURR EYE RES, V10, P947, DOI 10.3109/02713689109020331
   Li Yibin, 2002, Zhonghua Yan Ke Za Zhi, V38, P372
   Lin N, 1996, CURR EYE RES, V15, P1069, DOI 10.3109/02713689609017657
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Raychaudhuri S, 2001, TRENDS BIOTECHNOL, V19, P189, DOI 10.1016/S0167-7799(01)01599-2
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Sauve Y, 1998, EXP NEUROL, V152, P243, DOI 10.1006/exnr.1998.6849
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   Schraermeyer U, 2000, GRAEF ARCH CLIN EXP, V238, P979, DOI 10.1007/s004170000194
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   SHEEDLO HJ, 1991, TRENDS NEUROSCI, V14, P347, DOI 10.1016/0166-2236(91)90160-V
   SHEEDLO HJ, 1989, EXP EYE RES, V48, P841, DOI 10.1016/0014-4835(89)90067-5
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Steinhorst UH, 2001, KLIN MONATSBL AUGENH, V218, P192, DOI 10.1055/s-2001-13080
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 2004, OPHTHALMOLOGE, V101, P882, DOI 10.1007/s00347-004-1084-3
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   Thumann G, 1999, GRAEF ARCH CLIN EXP, V237, P1046, DOI 10.1007/s004170050343
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wistow G, 2002, MOL VIS, V8, P196
   YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zamiri P, 2004, INVEST OPHTH VIS SCI, V45, P177, DOI 10.1167/iovs.03-0211
   Zhang Chun, 2003, Yan Ke Xue Bao, V19, P49
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhu Ying, 2003, Zhonghua Yan Ke Za Zhi, V39, P660
NR 102
TC 23
Z9 26
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2006
VL 124
IS 9
BP 1276
EP 1285
DI 10.1001/archopht.124.9.1276
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 083DD
UT WOS:000240435200008
PM 16966623
OA Bronze
DA 2022-11-30
ER

PT J
AU Klettner, A
   Puls, S
   Treumer, F
   Roider, J
   Hillenkamp, J
AF Klettner, Alexa
   Puls, Svenja
   Treumer, Felix
   Roider, Johann
   Hillenkamp, Jost
TI Compatibility of Recombinant Tissue Plasminogen Activator and
   Bevacizumab Co-Applied for Neovascular Age-Related Macular Degeneration
   With Submacular Hemorrhage
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL HEMORRHAGE; INTRAVITREAL INJECTION; PNEUMATIC DISPLACEMENT;
   EXPANSILE GAS; GROWTH-FACTOR; MANAGEMENT; RABBITS
AB Objective: To investigate the compatibility of recombinant tissue plasminogen activator (rtPA) and bevacizumab in vitro because during surgery, rtPA or rtPA-induced plasmin may cleave and inactivate bevacizumab.
   Methods: To simulate the intraoperative range of mixing ratios of rtPA, bevacizumab, and subretinal blood, we calculated the volumes of 12 submacular hemorrhages (SHs) with a spherical cap formula using measurements derived from fundus photographs and spectral-domain optical coherence tomographic images. Bevacizumab was incubated with rtPA or plasmin before gel electrophoresis with Coomassie blue and silver staining. The anti-angiogenetic activity of bevacizumab in the presence of rtPA with or without clotted human blood or of plasmin was quantified by vascular endothelial growth factor-enzyme-linked immunosorbent assay after incubation with the supernatant of porcine retinal pigment epithelium cell cultures.
   Results: The mean (SD) volume of SH was 28.6 (24.7) mm(3) (range, 6.2-94.6 mm(3)). In sodium dodecyl sulfate-polyacrylamid electrophoresis with Coomassie blue or silver staining, bevacizumab displayed characteristic patterns of protein bands. No additional fragments were detected in co-application of bevacizumab with either rtPA or plasmin. The anti-angiogenetic activity of bevacizumab remained unchanged in co-application with rtPA with or without blood or plasmin.
   Conclusions: We demonstrated the absence of cleavage or functional inactivation of bevacizumab by rtPA in an in-vitro model of their intraoperative co-application as a treatment of SH.
C1 [Klettner, Alexa; Puls, Svenja; Treumer, Felix; Roider, Johann; Hillenkamp, Jost] Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Hillenkamp, J (通讯作者)，Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM hillenka@hotmail.com
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Faure C, 2011, BRIT J OPHTHALMOL, V95, P743, DOI 10.1136/bjo.2010.190462
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   MARS WM, 1993, AM J PATHOL, V143, P949
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   TREUMER F, BR J OPHTHALMOL
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   Verheu HMW, 2007, CLIN CANCER RES, V13, P5341, DOI 10.1158/1078-0432.CCR-07-0847
NR 28
TC 12
Z9 14
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2012
VL 130
IS 7
BP 875
EP 881
DI 10.1001/archophthalmol.2012.120
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 974FR
UT WOS:000306416900009
PM 22410628
OA hybrid
DA 2022-11-30
ER

PT J
AU Wilkinson-Berka, JL
   Suphapimol, V
   Jerome, JR
   Deliyanti, D
   Allingham, MJ
AF Wilkinson-Berka, Jennifer L.
   Suphapimol, Varaporn
   Jerome, Jack R.
   Deliyanti, Devy
   Allingham, Michael J.
TI Angiotensin II and aldosterone in retinal vasculopathy and inflammation
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Renin; Angiotensin; Aldosterone; Retinopathy; Angiogenesis; Inflammation
ID ENDOTHELIAL GROWTH-FACTOR; PLASMA-RENIN ACTIVITY; CONVERTING ENZYME;
   MINERALOCORTICOID RECEPTOR; CELLULAR-LOCALIZATION; DIABETIC-RETINOPATHY;
   SIGNAL-TRANSDUCTION; VASCULAR PATHOLOGY; PIGMENT EPITHELIUM;
   MESSENGER-RNA
AB Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease. The localization of RAAS components within the retina has led to studies investigating the roles of angiotensin II, aldosterone and the counter regulatory arm of the pathway in vision-threatening retinopathies. This review will provide a brief overview of RAAS components as well as the vascular pathology that develops in the retinal diseases, retinopathy of prematurity, diabetic retinopathy and neovascular age-related macular degeneration. The review will discuss pre-clinical and clinical evidence that modulation of the RAAS alters the development of vasculopathy and inflammation in the aforementioned retinopathies, as well as the emerging role of aldosterone and the mineralocorticoid receptor in central serous chorioretinopathy.
C1 [Wilkinson-Berka, Jennifer L.; Suphapimol, Varaporn; Jerome, Jack R.; Deliyanti, Devy] Univ Melbourne, Dept Anat & Neurosci, Med Bldg 181,Grattan St, Parkville, Vic 3010, Australia.
   [Wilkinson-Berka, Jennifer L.; Suphapimol, Varaporn; Jerome, Jack R.; Deliyanti, Devy] Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic, Australia.
   [Allingham, Michael J.] Duke Univ, Med Ctr, Durham, NC USA.
C3 University of Melbourne; Monash University; Duke University
RP Wilkinson-Berka, JL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Med Bldg 181,Grattan St, Parkville, Vic 3010, Australia.
EM jennifer.wilkinsonberka@unimelb.edu.au
RI Deliyanti, Devy/I-1562-2014; Wilkinson-Berka, Jennifer/D-4232-2011
OI Deliyanti, Devy/0000-0002-0390-3454; Suphapimol,
   Varaporn/0000-0001-9581-803X; Wilkinson-Berka,
   Jennifer/0000-0003-3512-4030
FU National Health and Medical Research Council of Australia
   [3-PDF-2017-376-A-N]
FX This work was supported by the National Health and Medical Research
   Council of Australia. DD is a Juvenile Diabetes Research Foundation
   post-doctoral fellow (Grant ID: 3-PDF-2017-376-A-N).
CR Adair T. H, 2009, FASEB J, V23
   Allingham MJ, 2018, INVEST OPHTH VIS SCI, V59, P3355, DOI 10.1167/iovs.17-23073
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Barber AJ, 2017, VISION RES, V139, P82, DOI 10.1016/j.visres.2017.06.014
   Barrera-Chimal J, 2019, KIDNEY INT, V96, P302, DOI 10.1016/j.kint.2019.02.030
   Batenburg WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100954
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Bomback AS, 2007, NAT CLIN PRACT NEPHR, V3, P486, DOI 10.1038/ncpneph0575
   Bosnyak S, 2011, CLIN SCI, V121, P297, DOI 10.1042/CS20110036
   BRANDT CR, 1994, CURR EYE RES, V13, P755, DOI 10.3109/02713689409047011
   Brar VS, 2010, MOL VIS, V16, P1848
   Cannavo A, 2019, VITAM HORM, V109, P387, DOI 10.1016/bs.vh.2018.09.005
   Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   Chen P, 2006, EXP EYE RES, V83, P1041, DOI 10.1016/j.exer.2006.05.009
   Colafella KMM, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.020
   DANSER AHJ, 1988, CLIN EXP HYPERTENS A, V10, P1297, DOI 10.1080/07300077.1988.11878924
   DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160
   Darlow BA, 2009, BRIT J OPHTHALMOL, V93, P986, DOI 10.1136/bjo.2008.156208
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Daruich A, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.2
   DEINUM J, 1990, ENDOCRINOLOGY, V126, P1673, DOI 10.1210/endo-126-3-1673
   Deliyanti D, 2014, ARTERIOSCL THROM VAS, V34, P2033, DOI 10.1161/ATVBAHA.114.303792
   Deliyanti D, 2012, HYPERTENSION, V59, P607, DOI 10.1161/HYPERTENSIONAHA.111.188136
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Downie LE, 2009, NEUROSCIENCE, V161, P195, DOI 10.1016/j.neuroscience.2009.02.084
   Duan YQ, 2018, STEM CELLS, V36, P1430, DOI 10.1002/stem.2848
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Federation ID, 2015, DIABETES ATLAS
   FERRARIDILEO G, 1988, INVEST OPHTH VIS SCI, V29, P876
   FERRARIDILEO G, 1991, INVEST OPHTH VIS SCI, V32, P21
   Foureaux G, 2013, INVEST OPHTH VIS SCI, V54, P4296, DOI 10.1167/iovs.12-11427
   Frampton JE, 2007, DRUGS, V67, P1767, DOI 10.2165/00003495-200767120-00008
   Fu XY, 2017, INVEST OPHTH VIS SCI, V58, P3018, DOI 10.1167/iovs.17-21546
   Gilbert RE, 2000, DIABETOLOGIA, V43, P1360, DOI 10.1007/s001250051539
   Golestaneh N, 2001, GLIA, V33, P160, DOI 10.1002/1098-1136(200102)33:2<160::AID-GLIA1015>3.0.CO;2-4
   Good WV, 2006, BRIT J OPHTHALMOL, V90, P1378, DOI 10.1136/bjo.2006.098582
   Harindhanavudhi T, 2011, DIABETES CARE, V34, P1838, DOI 10.2337/dc11-0476
   Hartnett Mary Elizabeth, 2010, Trans Am Ophthalmol Soc, V108, P96
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Hildebrand GD, 2011, PEDIATRIC RETINA, P39, DOI 10.1007/978-3-642-12041-1_2
   Kanda A, 2019, J DIABETES INVEST, V10, P6, DOI 10.1111/jdi.12842
   Kaschina E, 2017, PHARMACOL RES, V125, P39, DOI 10.1016/j.phrs.2017.07.008
   Kawamura H, 2004, J PHYSIOL-LONDON, V561, P671, DOI 10.1113/jphysiol.2004.073098
   Kim SJ, 2018, SURV OPHTHALMOL, V63, P618, DOI 10.1016/j.survophthal.2018.04.002
   Klauber N, 1996, CIRCULATION, V94, P2566, DOI 10.1161/01.CIR.94.10.2566
   Kohler K, 1997, VISUAL NEUROSCI, V14, P63, DOI 10.1017/S0952523800008762
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lemarie CA, 2009, CIRC RES, V105, P852, DOI 10.1161/CIRCRESAHA.109.196576
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Lonchampt M, 2001, INVEST OPHTH VIS SCI, V42, P429
   MALLORGA P, 1989, CURR EYE RES, V8, P841, DOI 10.3109/02713688909000874
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   Mentz RJ, 2013, INT J CARDIOL, V167, P1677, DOI 10.1016/j.ijcard.2012.10.007
   Michel F, 2004, CIRCULATION, V109, P1933, DOI 10.1161/01.CIR.0000127112.36796.9B
   Milenkovic VM, 2010, AM J PHYSIOL-RENAL, V299, pF396, DOI 10.1152/ajprenal.00576.2009
   Miller AG, 2010, DIABETES, V59, P3208, DOI 10.2337/db10-0552
   Mintz-Hittner HA, 2009, CURR OPIN PEDIATR, V21, P182, DOI 10.1097/MOP.0b013e32832925f9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Montezano AC, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0431-2
   Moravski CJ, 2003, AM J PATHOL, V162, P151, DOI 10.1016/S0002-9440(10)63806-0
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Nadal JA, 1999, BIOCHEM BIOPH RES CO, V266, P382, DOI 10.1006/bbrc.1999.1834
   Nguyen G, 2010, J AM SOC NEPHROL, V21, P18, DOI 10.1681/ASN.2009030300
   Nitta E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.240
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   Otani A, 2000, INVEST OPHTH VIS SCI, V41, P1192
   Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Patz A, 1969, Surv Ophthalmol, V14, P1
   Pei H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010254
   Phipps JA, 2018, INVEST OPHTH VIS SCI, V59, P487, DOI 10.1167/iovs.17-22416
   Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207
   Pitt B, 2003, CIRCULATION, V108, P1831, DOI 10.1161/01.CIR.0000091405.00772.6E
   Prasad T, 2014, MOL VIS, V20, P1443
   Qiu YG, 2014, INVEST OPHTH VIS SCI, V55, P3809, DOI 10.1167/iovs.14-13883
   Rautureau Y, 2011, STEROIDS, V76, P834, DOI 10.1016/j.steroids.2011.02.015
   Rehman A, 2012, HYPERTENSION, V59, P291, DOI 10.1161/HYPERTENSIONAHA.111.180158
   Reichhart N, 2017, DIABETOLOGIA, V60, P202, DOI 10.1007/s00125-016-4115-0
   ROCKWOOD EJ, 1987, INVEST OPHTH VIS SCI, V28, P676
   Prestes TRR, 2017, CURR DRUG TARGETS, V18, P1301, DOI 10.2174/1389450117666160727142401
   Sampson AK, 2016, BRIT J PHARMACOL, V173, P729, DOI 10.1111/bph.13063
   Sarlos S, 2005, INVEST OPHTH VIS SCI, V46, P1069, DOI 10.1167/iovs.04-0885
   Satofuka S, 2009, DIABETES, V58, P1625, DOI 10.2337/db08-0254
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   Schefe JH, 2008, J MOL MED, V86, P623, DOI 10.1007/s00109-008-0320-8
   Senanayake PD, 2007, INVEST OPHTH VIS SCI, V48, P3301, DOI 10.1167/iovs.06-1024
   Simao S, 2017, ANGIOGENESIS, V20, P175, DOI 10.1007/s10456-016-9526-5
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Silva ACSE, 2016, PHARMACOL RES, V107, P154, DOI 10.1016/j.phrs.2016.03.018
   Sjolie AK, 2011, DIABETIC MED, V28, P345, DOI 10.1111/j.1464-5491.2010.03210.x
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Spannella F, 2017, J HYPERTENS, V35, P2315, DOI 10.1097/HJH.0000000000001438
   Sugiyama T, 2007, EXP EYE RES, V85, P406, DOI 10.1016/j.exer.2007.06.008
   Tenkumo K, 2014, EXP EYE RES, V122, P110, DOI 10.1016/j.exer.2014.03.011
   Vaduganathan M, 2018, EUR J HEART FAIL, V20, P677, DOI 10.1002/ejhf.973
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   Wallace DK, 2018, OPHTHALMOLOGY, V125, P1961, DOI 10.1016/j.ophtha.2018.05.001
   Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169
   WARD PE, 1979, LIFE SCI, V24, P1419, DOI 10.1016/0024-3205(79)90013-4
   Wheeler-Schilling TH, 1999, EUR J NEUROSCI, V11, P3387, DOI 10.1046/j.1460-9568.1999.00787.x
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   Wilkinson-Berka JL, 2011, DIABETOLOGIA, V54, P2724, DOI 10.1007/s00125-011-2239-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamagishi S, 2005, FEBS LETT, V579, P4265, DOI 10.1016/j.febslet.2005.06.058
   Zhang JZ, 2007, CURR EYE RES, V32, P883, DOI 10.1080/02713680701584123
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhao M, 2010, FASEB J, V24, P3405, DOI 10.1096/fj.09-154344
NR 112
TC 18
Z9 18
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2019
VL 187
AR 107766
DI 10.1016/j.exer.2019.107766
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB9FO
UT WOS:000488887100023
PM 31425690
DA 2022-11-30
ER

PT J
AU Singh, KK
   Krawczak, M
   Dawson, WW
   Schmidtke, J
AF Singh, Krishna K.
   Krawczak, Michael
   Dawson, William W.
   Schmidtke, Joerg
TI Association of HTRA1 and ARMS2 gene variation with drusen formation in
   rhesus macaques
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE rhesus macaque; macular degeneration; drusen formation; disease-gene
   association
ID MACULAR DEGENERATION; MACACA-MULATTA; SUSCEPTIBILITY; MONKEYS; DISEASE
AB Age-related macular degeneration (AMD) is a clinically heterogeneous disease and constitutes the major cause of visual impairment in the elderly population worldwide. Rhesus macaques also possess a macula and, like humans, develop drusen-associated, age-related macular pathologies. Susceptibility to AMD in humans and drusen formation in rhesus macaques both have been shown to be associated with variation in the HTRA1 and ARMS2 genes. To corroborate these results we genotyped a cohort of 116 rhesus macaques with and without macular drusen. Like in humans, markers in the two genes showed a significant association with drusen formation at the genotype level. joint haplotype analysis revealed, however, that the disease association observed in rhesus macaques was entirely attributable to a promoter polymorphism (-5586>T) of the HTRA1 gene. 2008 Elsevier Ltd. All rights reserved.
C1 [Schmidtke, Joerg] Hannover Med Sch, Inst Human Genet, Dept Human Genet, D-30625 Hannover, Germany.
   [Krawczak, Michael] Univ Kiel, Inst Med Informat & Stat, D-24098 Kiel, Germany.
   [Dawson, William W.] Univ Florida, JH Miller Hlth Sci Ctr, Gainesville, FL USA.
   [Singh, Krishna K.] St Michaels Hosp, Dept Cardiovasc Surg, Toronto, ON M5B 1W8, Canada.
C3 Hannover Medical School; University of Kiel; State University System of
   Florida; University of Florida; University of Toronto; University
   Toronto Affiliates; Saint Michaels Hospital Toronto
RP Schmidtke, J (通讯作者)，Hannover Med Sch, Inst Human Genet, Dept Human Genet, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM schmidtke.joerg@mh-hannover.de
RI Krawczak, Michael/A-8964-2010
OI Krawczak, Michael/0000-0003-2603-1502
FU NCRR (NIH) [P40 RR03640]; Caribbean Primate Research Center; Puerto
   Rico; Deutsche Forschungsgemeinschaft; NATIONAL CENTER FOR RESEARCH
   RESOURCES [P40RR003640] Funding Source: NIH RePORTER
FX This work was supported by NCRR (NIH) grant P40 RR03640, awarded to the
   Caribbean Primate Research Center, Puerto Rico, and by a grant of the
   Deutsche Forschungsgemeinschaft to J. S.
CR Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Dawson WW, 2008, VISION RES, V48, P360, DOI 10.1016/j.visres.2007.08.006
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Singh KK, 2005, EXP EYE RES, V81, P401, DOI 10.1016/j.exer.2005.02.011
   Singh KK, 2007, VET OPHTHALMOL, V10, P274, DOI 10.1111/j.1463-5224.2007.00549.x
   Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 14
TC 17
Z9 17
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2009
VL 88
IS 3
BP 479
EP 482
DI 10.1016/j.exer.2008.10.019
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 427MR
UT WOS:000264783900018
PM 19028492
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Liu, JS
AF Zhang, Yu
   Liu, Jun S.
TI Bayesian inference of epistatic interactions in case-control studies
SO NATURE GENETICS
LA English
DT Article
ID ASSOCIATION; STRATEGIES
AB Epistatic interactions among multiple genetic variants in the human genome may be important in determining individual susceptibility to common diseases. Although some existing computational methods for identifying genetic interactions have been effective for small- scale studies, we here propose a method, denoted ' bayesian epistasis association mapping' ( BEAM), for genome- wide case- control studies. BEAM treats the disease- associated markers and their interactions via a bayesian partitioning model and computes, via Markov chain Monte Carlo, the posterior probability that each marker set is associated with the disease. Testing this on an age- related macular degeneration genome- wide association data set, we demonstrate that the method is significantly more powerful than existing approaches and that genome- wide case- control epistasis mapping with many thousands of markers is both computationally and statistically feasible.
C1 Harvard Univ, Dept Stat, Sci Ctr 715, Cambridge, MA 02138 USA.
   Penn State Univ, Dept Stat, University Pk, PA 16802 USA.
C3 Harvard University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Pennsylvania State University -
   University Park
RP Liu, JS (通讯作者)，Harvard Univ, Dept Stat, Sci Ctr 715, 1 Oxford St, Cambridge, MA 02138 USA.
EM jliu@stat.harvard.edu
FU NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002518] Funding Source:
   NIH RePORTER; NHGRI NIH HHS [R01HG002518-06] Funding Source: Medline
CR Ccok NR, 2004, STAT MED, V23, P1439, DOI 10.1002/sim.1749
   Cho YM, 2004, DIABETOLOGIA, V47, P549, DOI 10.1007/s00125-003-1321-3
   Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173
   Culverhouse R, 2004, GENET EPIDEMIOL, V27, P141, DOI 10.1002/gepi.20006
   Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kooperberg C, 2005, GENET EPIDEMIOL, V28, P157, DOI 10.1002/gepi.20042
   Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642
   Liu JS., 2001, MONTE CARLO STRATEGI
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473
   Nelson MR, 2001, GENOME RES, V11, P458, DOI 10.1101/gr.172901
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26
   Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522
   Williams SM, 2004, HUM HERED, V57, P28, DOI 10.1159/000077387
   Zee R. Y. L., 2002, Pharmacogenomics Journal, V2, P197, DOI 10.1038/sj.tpj.6500101
   Zheng T, 2006, HUM HERED, V62, P196, DOI 10.1159/000096995
   Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270
NR 19
TC 351
Z9 368
U1 1
U2 30
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2007
VL 39
IS 9
BP 1167
EP 1173
DI 10.1038/ng2110
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 205OA
UT WOS:000249122400030
PM 17721534
DA 2022-11-30
ER

PT J
AU Allingham, MJ
   Nie, Q
   Lad, EM
   Izatt, DJ
   Mettu, PS
   Cousins, SW
   Farsiu, S
AF Allingham, Michael J.
   Nie, Qing
   Lad, Eleonora M.
   Izatt, Daniel J.
   Mettu, Priyatham S.
   Cousins, Scott W.
   Farsiu, Sina
TI Semiautomatic Segmentation of Rim Area Focal Hyperautofluorescence
   Predicts Progression of Geographic Atrophy Due to Dry Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; fundus autofluorescence; image analysis
ID OPTICAL-COHERENCE-TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; NATURAL-HISTORY; ENLARGEMENT; CLASSIFICATION;
   TUBULATION; LIPOFUSCIN; SECONDARY; EYES
AB PURPOSE. To develop image analysis software usable by nonexpert graders to segment geographic atrophy (GA) from dry AMD and to quantify rim area focal hyperautofluorescence (RAFH) surrounding GA on fundus autofluorescence (FAF) images. To compare the GA progression predictions based on RAFH with those of a validated qualitative classification system.
   METHODS. Retrospective analysis of serial FAF images from 49 eyes of 30 subjects with GA was performed using MATLAB-based software (MathWorks, Natick, MA, USA). Correlation between RAFH and progression of GA was analyzed using Spearman correlation. Comparisons of lesion growth rate between RAFH tertiles used generalized estimating equations and Kruskal-Wallis testing. Interobserver variability in lesion size, growth rate and RAFH were compared between two expert and one nonexpert grader using Bland-Altman statistics.
   RESULTS. Rim area focal hyperautofluorescence was positively correlated with GA progression rate (rho = 0.49, P < 0.001). Subjects in the middle or highest RAFH tertile were at greater risk of progression (P = 0.005 and P = 0.001, respectively). Mean difference in RAFH was 0.012 between expert and -0.005 to 0.017 between expert and nonexperts. Mean difference in lesion size (mm(2)) was 0.11 between expert and -0.29 to 0.41 between expert and nonexperts. Mean difference in lesion growth rate (mm(2)/mo) was 0.0098 between expert and -0.027 to 0.037 between expert and nonexperts. Risk stratification based on RAFH tertile was 96% identical across all graders.
   CONCLUSIONS. Our semiautomated image analysis software facilitates stratification of progression risk based on RAFH and enabled a nonexpert grader with minimal training to obtain results comparable to expert graders. Predictions based on RAFH were similar to those of a validated qualitative classification system.
C1 [Allingham, Michael J.; Lad, Eleonora M.; Mettu, Priyatham S.; Cousins, Scott W.; Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Nie, Qing] Beijing Inst Technol, Beijing 100081, Peoples R China.
   [Izatt, Daniel J.] Enloe High Sch, Raleigh, NC USA.
   [Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
C3 Duke University; Beijing Institute of Technology; Duke University
RP Allingham, MJ (通讯作者)，DUMC Box 3802, Durham, NC 27710 USA.
EM mike.allingham@dm.duke.edu
OI Farsiu, Sina/0000-0003-4872-2902
FU NEI NIH HHS [K12 EY016333, P30 EY005722] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [K12EY016333, P30EY005722] Funding Source: NIH
   RePORTER
CR Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Estrada R, 2012, BIOMED OPT EXPRESS, V3, P327, DOI 10.1364/BOE.3.000327
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nunes RP, OPHTHALMIC SURG LASE, V44, P344
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 36
TC 22
Z9 22
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 2283
EP 2289
DI 10.1167/iovs.15-19008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700091
PM 27127926
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Hollanders, K
   Van Bergen, T
   Kindt, N
   Castermans, K
   Leysen, D
   Vandewalle, E
   Moons, L
   Stalmans, I
AF Hollanders, Karolien
   Van Bergen, Tine
   Kindt, Nele
   Castermans, Karolien
   Leysen, Dirk
   Vandewalle, Evelien
   Moons, Lieve
   Stalmans, Ingeborg
TI The Effect of AMA0428, a Novel and Potent ROCK Inhibitor, in a Model of
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; rho kinase inhibition; anti-vascular
   endothelial growth factor
ID GLAUCOMA FILTRATION SURGERY; ENDOTHELIAL-CELL MIGRATION; TYROSINE KINASE
   INHIBITOR; PLACENTAL GROWTH-FACTOR; RHO-ASSOCIATED KINASE; CHOROIDAL
   NEOVASCULARIZATION; SCAR FORMATION; INTRAVITREAL INJECTION; MYOSIN
   PHOSPHATASE; ICAM-1 EXPRESSION
AB PURPOSE. Rho kinase (ROCK) is associated with VEGF-driven angiogenesis, as well as with inflammation and fibrosis. Therefore, the effect of AMA0428, a novel ROCK inhibitor, was studied in these processes, which highly contribute to the pathogenesis of neovascular AMD.
   METHODS. The effect of AMA0428 (0.5-5.0 mu M) on human umbilical vein endothelial cells (HUVECs), human brain microvascular endothelial cells (HBMECs), and human brain microvascular pericytes (HBVPs) was determined using cell viability (WST-1), apoptosis (caspase 3/7), and migration (scratch and under-agarose) assays. The in vivo response was investigated using a laser-induced choroidal neovascularization (CNV) mouse model, in which intravitreal injections of AMA0428, murine anti-VEGF-R2 mAb (DC101), or placebo was given. Outcome was assessed by analysis of inflammation (CD45), angiogenesis (FITC-dextran), vessel leakage (Texas Red-conjugated Dextran and FITC-labeled lectin) and fibrosis (Sirius Red/Collagen I).
   RESULTS. The AMA0428 dose-dependently reduced proliferation and VEGF-induced migration of HUVEC and HBMEC (P < 0.05). No significant effect was seen on HBVP proliferation; however, migration and pericyte recruitment were enhanced (P < 0.05) by AMA0428 administration. There was no apoptosis induction. The AMA0428 significantly reduced CNV and vessel leakage 2 weeks after laser treatment, comparable to DC101. In addition, AMA0428 inhibited inflammation on day 5 by 42% (P < 0.05) and collagen deposition on day 30 by 43% (P < 0. 05), whereas DC101 had no effect on inflammation nor on fibrosis.
   CONCLUSIONS. The results suggest that targeting ROCK with AMA0428 not only reduces neoangiogenesis, but also blocks inflammation and fibrosis (contrary to VEGF suppression). These results point to a potential therapeutic benefit of ROCK inhibition in neovascular AMD.
C1 [Hollanders, Karolien; Van Bergen, Tine; Vandewalle, Evelien; Moons, Lieve; Stalmans, Ingeborg] Katholieke Univ Leuven, Univ Leuven, Dept Neurosci, Lab Ophthalmol, Leuven, Belgium.
   [Kindt, Nele; Castermans, Karolien; Leysen, Dirk] Amakem Therapeut, Diepenbeek, Belgium.
   [Vandewalle, Evelien; Stalmans, Ingeborg] Katholieke Univ Leuven, Univ Leuven, Univ Hosp Leuven, Dept Ophthalmol, Leuven, Belgium.
   [Moons, Lieve] Katholieke Univ Leuven, Univ Leuven, Dept Biol, Leuven, Belgium.
C3 KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven
RP Stalmans, I (通讯作者)，Univ Hosp Leuven, Dept Ophthalmol, Kapucijnenvoer 33, B-3000 Louvain, Belgium.
EM Ingeborg.Stalmans@uzleuven.be
OI Vandewalle, Evelien/0000-0002-6525-4218; Moons, Lieve
   (Godelieve)/0000-0003-0186-1411
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623
   Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965
   Arita R, 2013, INVEST OPHTH VIS SCI, V54, P2373, DOI 10.1167/iovs.12-10757
   Arita R, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/175163
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bocci G, 2004, CANCER RES, V64, P6616, DOI 10.1158/0008-5472.CAN-04-0401
   Bocci G, 2004, EUR J PHARMACOL, V498, P9, DOI 10.1016/j.ejphar.2004.07.062
   Boland S, 2013, BIOORG MED CHEM LETT, V23, P6442, DOI 10.1016/j.bmcl.2013.09.040
   Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bryan BA, 2010, FASEB J, V24, P3186, DOI 10.1096/fj.09-145102
   Caballero S, 2011, INVEST OPHTH VIS SCI, V52, P2490, DOI 10.1167/iovs.10-6351
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Castermans K, 2008, BLOOD, V112, P4940, DOI 10.1182/blood-2007-09-113878
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Danen EHJ, 2005, J CELL BIOL, V169, P515, DOI 10.1083/jcb.200412081
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   de Velde SV, 2014, INVEST OPHTH VIS SCI, V55, P1006, DOI 10.1167/iovs.13-13157
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Doe C, 2007, J PHARMACOL EXP THER, V320, P89, DOI 10.1124/jpet.106.110635
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fazal F, 2009, J BIOL CHEM, V284, P21047, DOI 10.1074/jbc.M109.016444
   Fazal M A, 2007, J Orthop Surg (Hong Kong), V15, P9
   Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahmann C, 2010, CELL MOL LIFE SCI, V67, P171, DOI 10.1007/s00018-009-0189-x
   Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100
   Hollanders K, 2014, CURR EYE RES, V12, P1
   Honjo M, 2007, INVEST OPHTH VIS SCI, V48, P5549, DOI 10.1167/iovs.07-0878
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Lee HY, 2004, AM J PHYSIOL-CELL PH, V287, pC1657, DOI 10.1152/ajpcell.00172.2004
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Liu M, 2009, J SURG RES, V157, pE117, DOI 10.1016/j.jss.2008.10.018
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Mong PY, 2009, J IMMUNOL, V182, P2385, DOI 10.4049/jimmunol.0802811
   Montanez E, 2009, EMBO J, V28, P3132, DOI 10.1038/emboj.2009.295
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishikimi T, 2006, J PHARMACOL SCI, V100, P22, DOI 10.1254/jphs.FMJ05003X5
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobin Kathleen A, 2006, Insight, V31, P11
   Tsapara A, 2010, MOL BIOL CELL, V21, P860, DOI 10.1091/mbc.E09-07-0567
   Van Bergen T, 2013, J CELL MOL MED, V17, P1632, DOI 10.1111/jcmm.12151
   Van Bergen T, 2013, INVEST OPHTH VIS SCI, V54, P5788, DOI 10.1167/iovs.13-11696
   Van Bergen T, 2011, EXP EYE RES, V93, P689, DOI 10.1016/j.exer.2011.08.016
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   van der Meel R, 2011, DRUG DISCOV TODAY, V16, P219, DOI 10.1016/j.drudis.2011.01.005
   Wang SK, 2014, CLIN OPHTHALMOL, V8, P883, DOI 10.2147/OPTH.S41000
   Wang SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045499
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293
   Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200
   Zhang B, 2007, OPT EXPRESS, V15, P1878, DOI 10.1364/OE.15.001878
   Zheng YP, 2004, INVEST OPHTH VIS SCI, V45, P668, DOI 10.1167/iovs.02-0808
NR 82
TC 38
Z9 38
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2015
VL 56
IS 2
BP 1335
EP 1348
DI 10.1167/iovs.14-15681
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BC
UT WOS:000352137300080
PM 25626969
DA 2022-11-30
ER

PT J
AU Parravano, M
   Parisi, V
   Ziccardi, L
   Chiaravalloti, A
   Tedeschi, M
   Cacciamani, A
   Boccassini, B
   Boninfante, A
   Varano, M
AF Parravano, Mariacristina
   Parisi, Vincenzo
   Ziccardi, Lucia
   Chiaravalloti, Adele
   Tedeschi, Massimiliano
   Cacciamani, Andrea
   Boccassini, Barbara
   Boninfante, Antonluca
   Varano, Monica
TI Single-session photodynamic therapy combined with intravitreal
   ranibizumab for neovascular age-related macular degeneration: a
   comprehensive functional retinal assessment
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Choroidal neovascular
   membrane; Photodynamic therapy; mfERG; Ranibizumab
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SCANNING LASER OPHTHALMOSCOPE;
   COMBINATION THERAPY; VERTEPORFIN THERAPY; FUNDUS PERIMETRY; TRIAL;
   ELECTRORETINOGRAM; MICROPERIMETRY; MACULOPATHY; ANCHOR
AB To explore functional retinal changes in neovascular AMD patients (nAMD) treated with ranibizumab 0.5 mg combined with photodynamic therapy (PDT) 3 days after the first injection in the long term.
   Patients with no prior treatment for nAMD were treated with 3 injections of ranibizumab 0.5 mg 1 month apart and a single session of standard PDT 3 days after the first injection. Best-corrected visual acuity and time-domain OCT at baseline and every 28 +/- A 2 days were performed; microperimetry at 3, 6, and 12 months and multifocal electroretinogramm (mfERG) at 3 and 12 months were repeated. Fluorescein angiography and vision-related quality-of-life questionnaire were performed at baseline and 12 months.
   12/15 nAMD patients completed the 12 months study and received an average of 3.4 +/- A 0.7 injections. Mean VA changed from 54.67 +/- A 15.72 to 59.0 +/- A 24.77 letters (p = 0.371), while mean retinal sensitivity from 5.5 +/- A 4.8 to 6.6 +/- A 6.0 dB (p = 0.216). MfERG N1-P1 response amplitude densities (RADs) were significantly different from baseline (p < 0.01) in the central 0A degrees-2.5A degrees, whereas in the peripheral retinal areas (2.5A degrees-20A degrees), not significant (p > 0.01) changes in N1-P1 RADs were detected. The "general vision" VFQ-25 subscale showed a statistically significant improvement at 3 and 12 months.
   Ranibizumab 0.5 mg combined with standard PDT 3 days after the first injection determines an improvement of mfERG values in the retinal central area in nAMD patients in long-term follow-up.
C1 [Parravano, Mariacristina; Parisi, Vincenzo; Ziccardi, Lucia; Chiaravalloti, Adele; Tedeschi, Massimiliano; Cacciamani, Andrea; Boccassini, Barbara; Boninfante, Antonluca; Varano, Monica] Fdn GB Bietti IRCCS, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Parravano, M (通讯作者)，Fdn GB Bietti IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM criparra@tin.it
RI Parisi, Vincenzo/J-6137-2018; boninfante, antonluca/AAC-2198-2020;
   Cacciamani, Andrea/AAB-2154-2021; Ziccardi, Lucia/AAQ-9066-2020; Varano,
   Monica/K-8573-2016
OI Cacciamani, Andrea/0000-0003-1793-9842; Ziccardi,
   Lucia/0000-0002-5563-1243; Varano, Monica/0000-0002-6530-1563
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Bashshur ZF, 2011, RETINA, V24, P1561
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Mataix J, 2010, RETINA-J RET VIT DIS, V30, P1190, DOI 10.1097/IAE.0b013e3181d2f172
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Parisi V, 2008, OPHTHALMOLOGY, V115, pe2
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parisi V, 2010, CLIN NEUROPHYSIOL, V121, P380, DOI 10.1016/j.clinph.2009.09.032
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Tanga L, 2011, GRAEF ARCH CLIN EXP, V249, P715, DOI 10.1007/s00417-010-1612-6
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Varano M, 2005, INVEST OPHTH VIS SCI, V46, P1453, DOI 10.1167/iovs.04-0903
   2001, AM J OPHTHALMOL, V131, P541
NR 36
TC 6
Z9 6
U1 0
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD DEC
PY 2013
VL 127
IS 3
BP 217
EP 225
DI 10.1007/s10633-013-9404-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 244KW
UT WOS:000326388200004
PM 23943132
DA 2022-11-30
ER

PT J
AU Fu, ZF
   Gong, Y
   Lofqvist, C
   Hellstrom, A
   Smith, LEH
AF Fu, Zhongjie
   Gong, Yan
   Lofqvist, Chatarina
   Hellstrom, Ann
   Smith, Lois E. H.
TI Review: adiponectin in retinopathy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
ID TYPE-2 DIABETES-MELLITUS; OXYGEN-INDUCED RETINOPATHY; PANCREATIC
   BETA-CELLS; TERM-EQUIVALENT AGE; MACULAR DEGENERATION; FATTY-ACIDS;
   INSULIN-RESISTANCE; SERUM ADIPONECTIN; MEDIATED IMPROVEMENT; ENDOTHELIAL
   FUNCTION
AB Neovascular eye diseases are a major cause of blindness including retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration in which new vessel formation is driven by hypoxia or metabolic abnormalities affecting the fuel supply. White-adipose-tissue derived adipokines such as adiponectin modulate metabolic responses. Increasing evidence shows that lack of adiponectin may result in retinal neovascularization. Activation of the adiponectin pathway may in turn restore energy metabolism, to suppress the drive for compensatory but ultimately pathological neovessels of retinopathy. In this review, we will summarize our current knowledge of the role of adiponectin in eye diseases of premature infants, diabetic patients as well as the elderly. Further investigations in this field are likely to lead to new preventative approaches for these diseases. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Fu, Zhongjie; Gong, Yan; Smith, Lois E. H.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA USA.
   [Lofqvist, Chatarina; Hellstrom, Ann] Univ Gothenburg, Sahlgrenska Acad, Dept Ophthalmol, Gothenburg, Sweden.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Gothenburg
RP Smith, LEH (通讯作者)，Harvard Univ, Sch Med, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA USA.; Smith, LEH (通讯作者)，Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM lois.smith@childrens.harvard.edu
OI Lofqvist, Chatarina/0000-0003-4371-5164; Gong, Yan/0000-0002-4805-0459;
   FU, ZHONGJIE/0000-0002-8182-2983
FU EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
   DEVELOPMENT [P30HD018655, U54HD090255] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY017017, R01EY022275, R24EY024864] Funding
   Source: NIH RePORTER; NEI NIH HHS [R24 EY024864, R01 EY022275, R01
   EY017017] Funding Source: Medline; NICHD NIH HHS [U54 HD090255, P30
   HD018655] Funding Source: Medline
CR Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Antonopoulos AS, 2015, DIABETES, V64, P2207, DOI 10.2337/db14-1011
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Aslan M, 2014, TOXICOL APPL PHARM, V280, P389, DOI 10.1016/j.taap.2014.08.026
   Aslibekyan S, 2013, NUTR METAB CARDIOVAS, V23, P987, DOI 10.1016/j.numecd.2012.07.010
   Au SCL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09091
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bennett LD, 2014, INVEST OPHTH VIS SCI, V55, P3150, DOI 10.1167/iovs.14-13995
   Bjursell M, 2007, DIABETES, V56, P583, DOI 10.2337/db06-1432
   Bluher M, 2006, J CLIN ENDOCR METAB, V91, P2310, DOI 10.1210/jc.2005-2556
   Buldak L, 2012, INT J CLIN PHARM TH, V50, P805, DOI 10.5414/CP201735
   Cao GQ, 2015, BIOMARKERS, V20, P266, DOI 10.3109/1354750X.2015.1068857
   Chang Yo-Chen, 2013, Rev Diabet Stud, V10, P121, DOI 10.1900/RDS.2013.10.121
   Chavez-Valdez R, 2011, J PERINATOL, V31, P749, DOI 10.1038/jp.2011.19
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   Denzel MS, 2010, J CLIN INVEST, V120, P4342, DOI 10.1172/JCI43464
   Dorrell MI, 2006, PROG RETIN EYE RES, V25, P277, DOI 10.1016/j.preteyeres.2006.01.001
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Fu ZJ, 2012, INVEST OPHTH VIS SCI, V53, P5698, DOI 10.1167/iovs.12-10122
   Fu ZJ, 2015, GRAEF ARCH CLIN EXP, V253, P1503, DOI 10.1007/s00417-015-3024-0
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Fujimoto N, 2005, BBA-GENE STRUCT EXPR, V1731, P1, DOI 10.1016/j.bbaexp.2005.06.013
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Hadjadj S, 2005, DIABETOLOGIA, V48, P1088, DOI 10.1007/s00125-005-1747-x
   Harkewicz R, 2012, J BIOL CHEM, V287, P11469, DOI 10.1074/jbc.M111.256073
   Hebbard L, 2014, BEST PRACT RES CL EN, V28, P59, DOI 10.1016/j.beem.2013.11.005
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Higuchi A, 2009, CIRC RES, V104, P1058, DOI 10.1161/CIRCRESAHA.109.194506
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hojlund K, 2012, EUR J ENDOCRINOL, V166, P511, DOI 10.1530/EJE-11-0790
   Holland WL, 2013, CELL METAB, V17, P790, DOI 10.1016/j.cmet.2013.03.019
   Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Hulsmans M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062253
   Ito R, 2014, J ATHEROSCLER THROMB, V21, P248, DOI 10.5551/jat.19976
   Jalali S, 2013, ARCH DIS CHILD-FETAL, V98, pF327, DOI 10.1136/archdischild-2012-302365
   Jian L, 2013, HORM METAB RES, V45, P561, DOI 10.1055/s-0033-1341500
   Joyal J.S., 2016, NAT MED
   Jung CH, 2014, J DIABETES INVEST, V5, P333, DOI 10.1111/jdi.12144
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005
   Kanazawa I, 2011, GROWTH HORM IGF RES, V21, P268, DOI 10.1016/j.ghir.2011.07.004
   Kaser S, 2005, GUT, V54, P117, DOI 10.1136/gut.2003.037010
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kermorvant-Duchemin E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079545
   Kuda O, 2009, DIABETOLOGIA, V52, P941, DOI 10.1007/s00125-009-1305-z
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011
   Leskov Ilya, 2015, Int Ophthalmol Clin, V55, P81, DOI 10.1097/IIO.0000000000000090
   Lian K, 2015, DIABETES, V64, P49, DOI 10.2337/db14-0312
   Lin T, 2013, MOL VIS, V19, P1769
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Liu ML, 2010, BIOCHEM J, V425, P41, DOI 10.1042/BJ20091045
   Liu QQ, 2012, P NATL ACAD SCI USA, V109, P14568, DOI 10.1073/pnas.1211611109
   Lofqvist C, 2007, P NATL ACAD SCI USA, V104, P10589, DOI 10.1073/pnas.0702031104
   Long W, 2014, GEN COMP ENDOCR, V206, P1, DOI 10.1016/j.ygcen.2014.07.003
   Lyzogubov VV, 2012, BBA-MOL CELL RES, V1823, P1264, DOI 10.1016/j.bbamcr.2012.05.017
   Mao DN, 2012, CURR EYE RES, V37, P803, DOI 10.3109/02713683.2012.676700
   Nakano Y, 2014, EARLY HUM DEV, V90, P213, DOI 10.1016/j.earlhumdev.2014.02.009
   Oberthuer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038481
   Okada-Iwabu M, 2013, NATURE, V503, P493, DOI 10.1038/nature12656
   Olza J, 2010, CLIN NUTR, V29, P31, DOI 10.1016/j.clnu.2009.06.003
   Omae T, 2015, INVEST OPHTH VIS SCI, V56, P4143, DOI 10.1167/iovs.15-16447
   Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200
   Parker-Duffen JL, 2014, J BIOL CHEM, V289, P16200, DOI 10.1074/jbc.M114.548115
   Pawlik D, 2013, JPEN J PARENTER ENTE
   Pereira RI, 2012, J CLIN ENDOCR METAB, V97, pE642, DOI 10.1210/jc.2011-2542
   Prior SL, 2011, METABOLISM, V60, P173, DOI 10.1016/j.metabol.2009.12.008
   Prostek A, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-3
   Psilopanagioti A, 2009, NEUROENDOCRINOLOGY, V89, P38, DOI 10.1159/000151396
   Rahmouni Kamal, 2005, Curr Diab Rep, V5, P260, DOI 10.1007/s11892-005-0020-5
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Rosenson RS, 2009, OBESITY, V17, P504, DOI 10.1038/oby.2008.530
   Saito M, 2011, NEONATOLOGY, V100, P93, DOI 10.1159/000322654
   Sapieha P, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.10
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362
   Shao Z, 2014, ARTERIOSCL THROM VAS, V34, P581, DOI 10.1161/ATVBAHA.113.302927
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tao C, 2014, BEST PRACT RES CL EN, V28, P43, DOI 10.1016/j.beem.2013.11.003
   Terry T L, 1942, Trans Am Ophthalmol Soc, V40, P262
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Torigoe M, 2007, CLIN ENDOCRINOL, V67, P276, DOI 10.1111/j.1365-2265.2007.02876.x
   Wang M, 2013, ATHEROSCLEROSIS, V229, P62, DOI 10.1016/j.atherosclerosis.2013.01.017
   Wong WT, 2011, CELL METAB, V14, P104, DOI 10.1016/j.cmet.2011.05.009
   Yamauchi T, 2007, NAT MED, V13, P332, DOI 10.1038/nm1557
   Yamauchi T, 2013, CELL METAB, V17, P185, DOI 10.1016/j.cmet.2013.01.001
   Yilmaz MI, 2004, EUR J ENDOCRINOL, V151, P135, DOI 10.1530/eje.0.1510135
   Yokoyama H, 2006, J CLIN ENDOCR METAB, V91, P290, DOI 10.1210/jc.2004-2549
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yuan F, 2014, MOL MED REP, V9, P2293, DOI 10.3892/mmr.2014.2133
   Zhang J, 2012, BRIT J NUTR, V108, P1455, DOI 10.1017/S0007114511006866
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
   Zietz B, 2008, EXP CLIN ENDOCR DIAB, V116, P532, DOI 10.1055/s-2008-1058086
NR 100
TC 32
Z9 33
U1 0
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD AUG
PY 2016
VL 1862
IS 8
BP 1392
EP 1400
DI 10.1016/j.bbadis.2016.05.002
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DO5LA
UT WOS:000377823400003
PM 27155572
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Kim, EA
   Kim, BG
   Yi, CH
   Kim, IG
   Chae, CH
   Kang, SK
AF Kim, Eun A.
   Kim, Byung-Gyu
   Yi, Cheol-Ho
   Kim, Il Gon
   Chae, Chang-Ho
   Kang, Seong-Kyu
TI Macular degeneration in an arc welder
SO INDUSTRIAL HEALTH
LA English
DT Article
DE macular degeneration; welder; are welding infrared light
ID WELDING ARC; MACULOPATHY; PATHOGENESIS; INJURY
AB A male welder who had been working in an industrial machine plant for more than 20 years experienced acute intense pain in his left eye with continuous lacrimation while performing arc welding in 1997. Later in 1997, at the age of 39 yr, macular edema was found in his left eye. He was diagnosed with macular degeneration (MD) of the left eye in 2002, and with right eye MD in 2004. Radiation in the visible and near infrared (IR) spectra penetrates the eye and is absorbed by the retina, possibly causing thermal or photochemical damage. Such retinal damage may be permanent and, therefore, sight-threatening. The young age and history of an acute painful eye injury are not consistent with age related macular degeneration (AMD) but rather is likely maculopathy caused by welding arc exposure.
C1 Korea Occupat Safety & Hlth Agcy, Occupat Safety & Hlth Res Inst, Inchon 403711, South Korea.
   Sungkyunkwan Univ, Masan Samsung Med Ctr, Dept Occupat Med, Masan, South Korea.
   Chang Won Natl Univ, Dept Phys, Chang Won, South Korea.
   Korea Occupat Safety & Hlth Agcy, Dept Occupat Hlth, Inchon, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Changwon
   National University
RP Kim, EA (通讯作者)，Korea Occupat Safety & Hlth Agcy, Occupat Safety & Hlth Res Inst, 34-3 Gusan Dong, Inchon 403711, South Korea.
RI Kang, Seong-Kyu/F-1274-2018
OI Kang, Seong-Kyu/0000-0002-3205-2708
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BRITTAIN GPH, 1988, BRIT J OPHTHALMOL, V72, P570, DOI 10.1136/bjo.72.8.570
   FICH M, 1993, ACTA OPHTHALMOL, V71, P402
   Hanke C, 1990, Z Gesamte Hyg, V36, P110
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KOZIELEC GF, 1979, RETINA, V17, P558
   Lee MS, 2004, OPHTHAL RES, V36, P237, DOI 10.1159/000078784
   Magnavita N, 2002, OCCUP MED-OXFORD, V52, P223, DOI 10.1093/occmed/52.4.223
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   NAIDOFF MA, 1974, AM J OPHTHALMOL, V77, P663, DOI 10.1016/0002-9394(74)90528-5
   OKUNO T, 1986, Industrial Health, V24, P213
   ROMANCHUK KG, 1978, CAN J OPHTHALMOL, V13, P120
   Stokkermans T J, 1998, J Am Optom Assoc, V69, P625
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   UNIAT L, 1986, AM J OPHTHALMOL, V102, P394, DOI 10.1016/0002-9394(86)90021-8
NR 16
TC 13
Z9 15
U1 0
U2 2
PU NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN
PI KAWASAKI KANAGAWA
PA 21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN
SN 0019-8366
J9 IND HEALTH
JI Ind. Health
PD APR
PY 2007
VL 45
IS 2
BP 371
EP 373
DI 10.2486/indhealth.45.371
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 163XC
UT WOS:000246195500026
PM 17485886
OA Bronze
DA 2022-11-30
ER

PT J
AU Coco-Martin, MB
   Lopez-Miguel, A
   Cuadrado, R
   Mayo-Iscar, A
   Herrero, AJ
   Pastor, JC
   Maldonado, MJ
AF Coco-Martin, Maria B.
   Lopez-Miguel, Alberto
   Cuadrado, Ruben
   Mayo-Iscar, Agustin
   Herrero, Azael J.
   Pastor, Jose C.
   Maldonado, Miguel J.
TI Reading Performance Improvements in Patients with Central Vision Loss
   without Age-Related Macular Degeneration after Undergoing Personalized
   Rehabilitation Training
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Central vision loss; non-AMD; quality of life; reading performance;
   vision rehabilitation
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; STARGARDT-DISEASE; OPTICAL
   MAGNIFIERS; PREVALENCE; ADULTS; POPULATION; DYSTROPHY; BLINDNESS;
   FIXATION
AB Purpose: To evaluate the efficacy of a reading rehabilitation program (RRP) in patients with central visual loss (CVL) and assess the impact of the RRP on the quality of life (QoL).
   Methods: The RRP included four in-office and 39 in-home training sessions over 6 weeks. Reading speed, duration, and font size were evaluated during each in-office session. The subjective perception of the QoL was assessed before and after the RRP using the short version of a questionnaire (World Health Organization Quality of Life). A control group who received advice about ocular conditions and low-vision aids also was included.
   Results: Seventeen patients with Stargardt's disease (STGD), 11 with adult-onset foveomacular vitelliform dystrophy (AFVD), and eight with myopic macular degeneration (MMD) were included. The control group included five patients each with STGD, AFVD, and MMD. The respective mean corrected distance visual acuities (VAs) in patients with STGD, AFVD, MMD, and the control group were 0.57 +/- 0.38, 0.51 +/- 0.38, 0.49 +/- 0.24, and 0.55 +/- 0.25 logarithm of the minimum angle of resolution; the mean corrected near VAs were 0.89 +/- 0.20, 1.08 +/- 0.17, 0.99 +/- 0.34, and 1.18 +/- 0.37 (M notation) using low-vision aids. The reading speed, duration, and font size improved in all groups. The RRP groups obtained (p <= 0.01) greater improvements than the control group in each reading performance variable assessed. Patients with STGD obtained greater improvements in the subjective evaluation; the control group did not obtain noteworthy improvement in any domain.
   Conclusions: The RRP improved reading performance in patients with CVL and positively impacted the subjective perception of the QoL.
C1 [Coco-Martin, Maria B.; Lopez-Miguel, Alberto; Cuadrado, Ruben; Pastor, Jose C.; Maldonado, Miguel J.] Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Valladolid, Spain.
   [Coco-Martin, Maria B.; Herrero, Azael J.] European Univ Miguel Cervantes, Fac Hlth Sci, Valladolid, Spain.
   [Mayo-Iscar, Agustin] Univ Valladolid, Fac Sci, Dept Stat & Operat Res, Valladolid, Spain.
C3 Universidad de Valladolid; Miguel de Cervantes European University
   (UEMC); Universidad de Valladolid
RP Coco-Martin, MB (通讯作者)，IOBA, Paseo Belen 17, Valladolid 47011, Spain.
EM bego@ioba.med.uva.es
RI Jimeno, J Carlos Pastor/AAP-1156-2020; López-Miguel,
   Alberto/K-6117-2014; Mayo-Iscar, Agustin/L-7215-2014
OI Jimeno, J Carlos Pastor/0000-0001-5934-7306; López-Miguel,
   Alberto/0000-0001-9429-1571; Maldonado, Miguel J./0000-0002-1021-3275;
   Coco-Martin, Maria Begona/0000-0001-9977-429X; Mayo-Iscar,
   Agustin/0000-0003-0951-6508
FU Spanish Ministry of Economy and Competitiveness [RETICS RD12/0034/0001]
FX Supported in part by the Spanish Ministry of Economy and Competitiveness
   through Research Projects RETICS RD12/0034/0001 (Oftalmologia).
CR Beckmann PJ, 1996, VISION RES, V36, P3723, DOI 10.1016/0042-6989(96)00084-3
   Bowers A, 2007, OPTOMETRY VISION SCI, V84, P9, DOI 10.1097/01.opx.0000254035.39055.05
   Bowers AR, 2001, OPTOMETRY VISION SCI, V78, P325, DOI 10.1097/00006324-200105000-00016
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   Chung STL, 2011, INVEST OPHTH VIS SCI, V52, P1164, DOI 10.1167/iovs.10-6034
   Coco-Martin MB, 2013, OPHTHALMOLOGY, V120, P151, DOI 10.1016/j.ophtha.2012.07.035
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goldschmidt Mira, 2010, BMC Res Notes, V3, P15, DOI 10.1186/1756-0500-3-15
   Goodrich G L, 2001, Optometry, V72, P519
   GOODRICH GL, 1977, J VISUAL IMPAIR BLIN, V71, P377
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   LIM JI, 1994, AM J OPHTHALMOL, V117, P1
   Lovie-Kitchin Jan E, 1999, Clin Exp Optom, V82, P214
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   Nguyen NX, 2011, ACTA OPHTHALMOL, V89, pE82, DOI 10.1111/j.1755-3768.2010.02081.x
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00
   Stelmack JA, 2003, J VISUAL IMPAIR BLIN, V97, P521, DOI 10.1177/0145482X0309700904
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Trillo AH, 2012, INVEST OPHTH VIS SCI, V53, P4234, DOI 10.1167/iovs.12-9580
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Walter C, 2007, OPHTHAL EPIDEMIOL, V14, P103, DOI 10.1080/09286580601052167
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 31
TC 4
Z9 4
U1 2
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 9
BP 1260
EP 1268
DI 10.1080/02713683.2017.1315140
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FN8WV
UT WOS:000416309100009
PM 28632405
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Arias, L
   Figueroa, MS
   Araiz, J
   Ruiz-Moreno, JM
   Garcia-Arumi, J
   Gomez-Ulla, F
   Lopez-Galvez, MI
   Cabrera-Lopez, F
   Garcia-Campos, JM
   Mones, J
   Cervera, E
   Armada, F
   Gallego-Pinazo, R
   Pinero-Bustamante, A
   Serrano-Garcia, MA
AF Garcia-Layana, Alfredo
   Arias, Luis
   Figueroa, Marta S.
   Araiz, Javier
   Maria Ruiz-Moreno, Jose
   Garcia-Arumi, Jose
   Gomez-Ulla, Francisco
   Isabel Lopez-Galvez, Maria
   Cabrera-Lopez, Francisco
   Manuel Garcia-Campos, Jose
   Mones, Jordi
   Cervera, Enrique
   Armada, Felix
   Gallego-Pinazo, Roberto
   Pinero-Bustamante, Antonio
   Angel Serrano-Garcia, Miguel
TI A Delphi Study to Detect Deficiencies and Propose Actions in Real Life
   Treatment of Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   OUTCOMES; THERAPY; BEVACIZUMAB; AFLIBERCEPT; GUIDELINES; INJECTION;
   CONSENSUS
AB Purpose. Spanish retina specialists were surveyed in order to propose actions to decrease deficiencies in real-life neovascular age macular degeneration treatment (nv-AMD). Methods. One hundred experts, members of the Spanish Vitreoretinal Society (SERV), were invited to complete an online survey of 52 statements about nv-AMD management with a modified Delphi methodology. Four rounds were performed using a 5-point Linkert scale. Recommendations were developed after analyzing the differences between the results and the SERV guidelines recommendations. Results. Eighty-seven specialists completed all the Delphi rounds. Once major potential deficiencies in real-life nv-AMD treatment were identified, 15 recommendations were developed with a high level of agreement. Consensus statements to reduce the burden of the disease included the use of treat and extend regimen and to reduce the amount of diagnostic tests during the loading phase and training technical staff to perform these tests and reduce the time between relapse detection and reinjection, as well as establishing patient referral protocols to outside general ophthalmology clinics. Conclusion. The level of agreement with the final recommendations for nv-AMD treatment among Spanish retinal specialist was high indicating that some actions could be applied in order to reduce the deficiencies in real-life nv-AMD treatment.
C1 [Garcia-Layana, Alfredo] Univ Navarra Clin, Pamplona 31008, Spain.
   [Arias, Luis] Bellvitge Hosp, Barcelona 08907, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon y Cajal, Madrid 28034, Spain.
   [Figueroa, Marta S.] Vissum Madrid, Madrid 28002, Spain.
   [Araiz, Javier] Hosp San Eloy, Baracaldo 48902, Spain.
   [Maria Ruiz-Moreno, Jose] Hosp Univ Albacete, Albacete 02006, Spain.
   [Garcia-Arumi, Jose] Hosp VallDHebron, Barcelona 08035, Spain.
   [Gomez-Ulla, Francisco] Inst Oftalmol Gomez Ulla, Santiago De Compostela 15706, Spain.
   [Isabel Lopez-Galvez, Maria] Hosp Clin Univ Valladolid, IOBA, Valladolid 47011, Spain.
   [Cabrera-Lopez, Francisco] Complejo Hosp Univ Insular Materno Infantil Gran, Las Palmas Gran Canaria 35016, Spain.
   [Manuel Garcia-Campos, Jose] Hosp Univ Virgen de la Victoria, Malaga 29010, Spain.
   [Mones, Jordi] Inst Macula & Retina, Barcelona 08022, Spain.
   [Cervera, Enrique] Hosp Gen Valencia, Valencia 46014, Spain.
   [Armada, Felix] Hosp La Paz, Madrid 28046, Spain.
   [Gallego-Pinazo, Roberto] Hosp La Fe, Valencia 46026, Spain.
   [Pinero-Bustamante, Antonio] Hosp Univ Valme, Seville 41014, Spain.
   [Angel Serrano-Garcia, Miguel] Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife 38010, Spain.
C3 University of Navarra; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona;
   Hospital Universitario Ramon y Cajal; Hospital Universitari Vall
   d'Hebron; Universidad de Malaga; Hospital Universitario La Paz; Hospital
   Universitari i Politecnic La Fe; Hospital Valme
RP Garcia-Layana, A (通讯作者)，Univ Navarra Clin, Ave Pio XII 36, Pamplona 31008, Spain.
EM aglayana@unav.es
RI mones, jordi/CAJ-2963-2022; Ruiz-Moreno, José M/E-4644-2016; CABRERA
   LOPEZ, FRANCISCO/ABE-2892-2021
OI mones, jordi/0000-0003-3685-2160; Lopez-Guajardo,
   Lorenzo/0000-0002-8573-2555; Garcia-Arumi, Jose/0000-0001-8827-1160;
   Ruiz-Moreno, Jose M/0000-0001-9636-0788; CABRERA LOPEZ,
   FRANCISCO/0000-0002-5074-5102
CR Amoaku W., 2011, EYE, V25, P663
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Casaroli-Marano R, 2013, Arch Soc Esp Oftalmol, V88, P307, DOI 10.1016/j.oftal.2012.10.009
   Casparis H, 2014, RETINA-J RET VIT DIS, V34, P12, DOI 10.1097/IAE.0b013e31829f74b0
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979
   Gaudric A, 2010, AM J OPHTHALMOL, V149, P4, DOI 10.1016/j.ajo.2009.08.039
   Gómez-Ulla F., 2009, Arch Soc Esp Oftalmol, V84, P377
   Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Keane PA, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/752543
   Keeney S, 2006, J ADV NURS, V53, P205, DOI 10.1111/j.1365-2648.2006.03716.x
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lees NM, 2013, NEW ZEAL VET J, V61, P168, DOI 10.1080/00480169.2012.736131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nagpal K, 2010, ANN SURG, V252, P171, DOI 10.1097/SLA.0b013e3181dc3656
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh P, 2014, J AM COLL SURGEONS, V219, P346, DOI 10.1016/j.jamcollsurg.2014.03.051
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tolsgaard MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057687
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Zevin B, 2013, J AM COLL SURGEONS, V216, P955, DOI 10.1016/j.jamcollsurg.2013.01.003
NR 40
TC 8
Z9 8
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 595132
DI 10.1155/2014/595132
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY0WM
UT WOS:000347315000001
PM 25587438
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Fernandes, AR
   Sanchez-Lopez, E
   Santini, A
   dos Santos, T
   Garcia, ML
   Silva, AM
   Souto, EB
AF Fernandes, Ana R.
   Sanchez-Lopez, Elena
   Santini, Antonello
   dos Santos, Tiago
   Garcia, Maria L.
   Silva, Amelia M.
   Souto, Eliana B.
TI Mono- and Dicationic DABCO/Quinuclidine Composed Nanomaterials for the
   Loading of Steroidal Drug: 3(2) Factorial Design and Physicochemical
   Characterization
SO NANOMATERIALS
LA English
DT Article
DE cationic nanoemulsions; DABCO surfactants; quinuclidine surfactants;
   ocular administration; triamcinolone acetonide
ID SOLID LIPID NANOPARTICLES; TRIAMCINOLONE-ACETONIDE; OCULAR DELIVERY;
   IN-VITRO; CARRIERS; OPTIMIZATION; MANAGEMENT; STABILITY; EMULSION;
   SAFETY
AB Oil-in-water nanoemulsions (NEs) are considered a suitable nanotechnological approach to improve the eye-related bioavailability of lipophilic drugs. The potential of cationic NEs is prominent due to the electrostatic interaction that occurs between the positively charged droplets with the negatively charged mucins present in the tear film. This interaction offers prolonged NEs residence at the ocular surface, increasing the drug absorption. Triamcinolone acetonide (TA) is one of the first pharmacologic strategies applied as an intravitreal injection in the treatment of age-related macular degeneration (AMD). Newly synthesized quaternary derivatives of 1,4-diazabicyclo[2.2.2]octane (DABCO) and quinuclidine surfactants have been screened with the purpose to select the best compound to formulate long-term stable NEs that combine the best physicochemical properties for the loading of TA intended for ocular administration.
C1 [Fernandes, Ana R.; Souto, Eliana B.] Univ Coimbra, Fac Pharm, Dept Pharmaceut Technol, Polo Ciencias Saude, P-3000548 Coimbra, Portugal.
   [Fernandes, Ana R.; dos Santos, Tiago] Univ Porto, I3s Inst Invest & Inovacao Saude, R Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Fernandes, Ana R.; dos Santos, Tiago] Univ Porto, INEB Inst Engn Biomed, Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Fernandes, Ana R.] Univ Porto, Fac Engn, R Dr Roberto Frias, P-4200465 Porto, Portugal.
   [Fernandes, Ana R.; Sanchez-Lopez, Elena; Garcia, Maria L.] Univ Barcelona, Fac Pharm, Dept Pharm Pharmaceut Technol & Phys Chem, Barcelona 08028, Spain.
   [Sanchez-Lopez, Elena; Garcia, Maria L.] Univ Barcelona, Inst Nanosci & Nanotechnol IN2UB, Barcelona 08028, Spain.
   [Santini, Antonello] Univ Napoli Federico II, Dept Pharm, Via D Montesano 49, I-80131 Naples, Italy.
   [Silva, Amelia M.] Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, UTAD, P-5001801 Vila Real, Portugal.
   [Silva, Amelia M.] UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.
   [Souto, Eliana B.] Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.
C3 Universidade de Coimbra; Universidade do Porto; i3S - Instituto de
   Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do
   Porto; Universidade do Porto; University of Barcelona; University of
   Barcelona; University of Naples Federico II; University of
   Tras-os-Montes & Alto Douro; University of Tras-os-Montes & Alto Douro;
   Universidade do Minho
RP Souto, EB (通讯作者)，Univ Coimbra, Fac Pharm, Dept Pharmaceut Technol, Polo Ciencias Saude, P-3000548 Coimbra, Portugal.; Silva, AM (通讯作者)，Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, UTAD, P-5001801 Vila Real, Portugal.; Silva, AM (通讯作者)，UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.; Souto, EB (通讯作者)，Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.
EM anaritavfernandes@gmail.com; esanchezlopez@ub.edu; asantini@unina.it;
   tiago.f.santos@ineb.up.pt; marisagarcia@ub.edu; amsilva@utad.pt;
   eliana.souto@ceb.uminho.pt
RI Souto, Eliana/T-1645-2019; Silva, Amélia M/J-7128-2013; Souto,
   Eliana/GQZ-3071-2022; Sanchez Lopez, Elena/O-7645-2018
OI Souto, Eliana/0000-0002-9737-6017; Silva, Amélia M/0000-0002-7524-9914;
   Sanchez Lopez, Elena/0000-0003-2571-108X; SANTINI,
   Antonello/0000-0001-5505-3327; Fernandes, Ana/0000-0002-8787-7854
FU Portuguese Science and Technology Foundation (FCT) from the Ministry of
   Science and Technology (MCTES) [SFRH/BD/130555/2017]; European Social
   Fund (FSE) of EU [SFRH/BD/130555/2017]; CEB strategic fund
   [UIDB/04469/2020]; CITAB [UIDB/04033/2020]; European Funds
   (PRODER/COMPETE); FEDER, under the Partnership Agreement PT2020
FX This work was funded by the Portuguese Science and Technology Foundation
   (FCT) from the Ministry of Science and Technology (MCTES), European
   Social Fund (FSE) of EU, for the scholarship SFRH/BD/130555/2017 granted
   to A. R. Fernandes, and for the projects UIDB/04469/2020 (CEB strategic
   fund) and UIDB/04033/2020 (CITAB), co-funded by European Funds
   (PRODER/COMPETE) and FEDER, under the Partnership Agreement PT2020.
CR Aloisio C, 2015, J PHARM SCI-US, V104, P3535, DOI 10.1002/jps.24555
   [Anonymous], 2014, EUR J PHARM BIOPHARM, V87, P1, DOI 10.1016/j.ejpb.2014.02.005
   Araujo J, 2010, INT J PHARMACEUT, V393, P167, DOI 10.1016/j.ijpharm.2010.03.034
   Araujo J, 2009, COLLOID SURFACE B, V72, P48, DOI 10.1016/j.colsurfb.2009.03.028
   Araujo J, 2009, NANOMED-NANOTECHNOL, V5, P394, DOI 10.1016/j.nano.2009.02.003
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Caddeo C, 2013, COLLOID SURFACE B, V111, P327, DOI 10.1016/j.colsurfb.2013.06.016
   Cassir M, 2013, MOLTEN SALTS CHEMISTRY: FROM LAB TO APPLICATIONS, P355
   Cevc G, 2003, BBA-BIOMEMBRANES, V1614, P156, DOI 10.1016/s0005-2736(03)00172-X
   Chen WQ, 2015, J PHARMACOL SCI, V127, P332, DOI 10.1016/j.jphs.2015.01.008
   Detloff T., 2013, DISPERSION LETT TECH, V4, P1
   Doktorovova S, 2016, EUR J PHARM BIOPHARM, V108, P235, DOI 10.1016/j.ejpb.2016.08.001
   Doktorovova S, 2014, INT J PHARMACEUT, V471, P18, DOI 10.1016/j.ijpharm.2014.05.011
   Dukovski BJ, 2019, ACTA PHARMACEUT, V69, P621, DOI 10.2478/acph-2019-0054
   Dutescu RM, 2015, CORNEA, V34, P560, DOI 10.1097/ICO.0000000000000368
   Fangueiro JF, 2016, INT J PHARMACEUT, V502, P161, DOI 10.1016/j.ijpharm.2016.02.039
   Fangueiro JF, 2016, CURR PHARM DESIGN, V22, P1135, DOI 10.2174/1381612822666151216145900
   Fangueiro JF, 2015, EUR J PHARM BIOPHARM, V95, P307, DOI 10.1016/j.ejpb.2014.12.023
   Fangueiro JF, 2014, INT J PHARMACEUT, V461, P64, DOI 10.1016/j.ijpharm.2013.11.025
   Fangueiro JF, 2012, COLLOID SURFACE B, V100, P84, DOI 10.1016/j.colsurfb.2012.04.014
   Fedorova AA, 2016, ANTIVIR RES, V133, P73, DOI 10.1016/j.antiviral.2016.07.014
   Fernandes AR, 2017, SAUDI PHARM J, V25, P1117, DOI 10.1016/j.jsps.2017.07.004
   Fiscella R.G., 2008, CLIN OCULAR PHARM, V5th, P17
   Gan L, 2013, DRUG DISCOV TODAY, V18, P290, DOI 10.1016/j.drudis.2012.10.005
   Khachane PV, 2015, SAUDI PHARM J, V23, P188, DOI 10.1016/j.jsps.2014.07.007
   Lallemand F, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/604204
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Papa V, 2001, OPHTHALMOLOGICA, V215, P124, DOI 10.1159/000050842
   Pashirova TN, 2015, COLLOID SURFACE B, V127, P266, DOI 10.1016/j.colsurfb.2015.01.044
   PENNEY MD, 1987, ANN CLIN BIOCHEM, V24, P566, DOI 10.1177/000456328702400603
   Pickrell Aaron, 2012, Pharmaceutics, V4, P230, DOI 10.3390/pharmaceutics4010230
   da Silva ACR, 2012, MOLECULES, V17, P6305, DOI 10.3390/molecules17066305
   Santos BMS, 2003, FLUID PHASE EQUILIBR, V208, P1, DOI 10.1016/S0378-3812(02)00320-5
   Shah J, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050230
   Sharma N, 2016, ASIAN J PHARM SCI, V11, P404, DOI 10.1016/j.ajps.2015.09.004
   Souto EB, 2004, EUR J PHARM BIOPHARM, V58, P83, DOI 10.1016/j.ejpb.2004.02.015
   Tamilvanan S, 2004, EUR J PHARM BIOPHARM, V58, P357, DOI 10.1016/j.ejpb.2004.03.033
   Zakharova LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225534
   Zhang HJ, 2003, ARCH PHARM RES, V26, P768, DOI 10.1007/BF02976689
   Zhang JL, 2020, EUR J PHARM SCI, V144, DOI 10.1016/j.ejps.2020.105229
   Zielinska A, 2018, INT J PHARMACEUT, V553, P428, DOI 10.1016/j.ijpharm.2018.10.065
NR 41
TC 7
Z9 7
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-4991
J9 NANOMATERIALS-BASEL
JI Nanomaterials
PD OCT
PY 2021
VL 11
IS 10
AR 2758
DI 10.3390/nano11102758
PG 22
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 0B2HP
UT WOS:000774461600005
PM 34685199
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bonnel, S
   Mohand-Said, S
   Sahel, JA
AF Bonnel, S
   Mohand-Said, S
   Sahel, JA
TI The aging of the retina
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Review
DE age-related; retina; macular area
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; MULTIFOCAL
   ELECTRORETINOGRAM; CONE SURVIVAL; ROD; PIGMENT; LIPOFUSCIN;
   NEOVASCULARIZATION; VULNERABILITY; COMPONENT
AB This mini-review summarizes our current knowledge concerning the age-related changes that affect the retina. Over the last 10 years, our understanding of the genetics of hereditary retinal diseases has improved considerably. However, the modifications that occur in the retina as a result of aging are still under investigation. In this review, we place particular emphasis on the normal retinal alterations that occur with aging (gene modulation; psychophysical, structural and cellular alterations). We describe the events that occur during the pathological aging process, such as in age-related macular degeneration. Understanding these different modifications is essential if we are to find key players on which to base therapeutic interventions that may help to prevent the passage of normal aging process to the pathological aging process. (C) 2003 Elsevier Inc. All rights reserved.
C1 Ctr Hosp Natl Ophthalmol Quinze Vingts, F-75012 Paris, France.
   INSERM, U592, F-75654 Paris 13, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Sahel, JA (通讯作者)，Ctr Hosp Natl Ophthalmol Quinze Vingts, 28 Rue Charenton, F-75012 Paris, France.
EM j-sahel@quinze-vingts.fr
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103
   Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fintz AC, 2003, INVEST OPHTH VIS SCI, V44, P818, DOI 10.1167/iovs.01-1144
   Fortune B, 2002, J OPT SOC AM A, V19, P173, DOI 10.1364/JOSAA.19.000173
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   Guirao A, 1999, INVEST OPHTH VIS SCI, V40, P203
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hawkins BS, 1999, MOL VIS, V5
   Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071
   Jackson GR, 2002, J OPT SOC AM A, V19, P185, DOI 10.1364/JOSAA.19.000185
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/ng0501-21
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kurtenbach A, 2002, J OPT SOC AM A, V19, P190, DOI 10.1364/JOSAA.19.000190
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Petters RM, 1997, NAT BIOTECHNOL, V15, P965, DOI 10.1038/nbt1097-965
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WELEBER RG, 1981, INVEST OPHTH VIS SCI, V20, P392
   Winkler BS, 1999, MOL VIS, V5
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   YOUNG RW, 1971, J ULTRA MOL STRUCT R, V34, P190, DOI 10.1016/S0022-5320(71)90014-1
NR 51
TC 48
Z9 50
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD AUG
PY 2003
VL 38
IS 8
BP 825
EP 831
DI 10.1016/S0531-5565(03)00093-7
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 723VT
UT WOS:000185452800002
PM 12915204
DA 2022-11-30
ER

PT J
AU Hussain, RM
   Ciulla, LM
AF Hussain, Rehan M.
   Ciulla, Lauren M.
TI Avacincaptad pegol
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Avacincaptad pegol; ARC-1905; Zimura; Anti-C5 (complement 5); Aptamers;
   Geographic atrophy; Age-related macular degeneration; Stargardt disease
ID MACULAR DEGENERATION; VEGF SECRETION; COMPLEMENT; DISEASE; ACTIVATION
AB Dry age-related macular degeneration (AMD) and autosomal recessive Stargardt disease result in vision loss due to pro-gressive atrophy of the macula. Numerous studies have impli-cated complement-associated inflammation as a contributor to both diseases, which currently lack effective treatment options. The complement factor 5 inhibitor avacincaptad pegol is delivered by intravitreal injection and has been demonstrated to reduce geographic atrophy progression by 27% compared to sham injections in the phase II/III GATHER1 trial. It was generally well tolerated, though there was a dose-dependent increase in choroidal neovascular mem -brane formation, with a rate of 9% in the 2-mg group; this dose has advanced to the phase III GATHER2 trial for dry AMD. The phase IIb trial for autosomal recessive Stargardt disease is ongoing with expected completion in 2023.
C1 [Hussain, Rehan M.] Retina Hlth Inst, 1530 N Randall Rd,Ste 202, Elgin, IL 60123 USA.
   [Ciulla, Lauren M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA.
C3 Northwestern University; Feinberg School of Medicine
RP Hussain, RM (通讯作者)，Retina Hlth Inst, 1530 N Randall Rd,Ste 202, Elgin, IL 60123 USA.
EM rhussain27@gmail.com
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   [Anonymous], 2021, AGE RELATED MACULAR
   [Anonymous], 2021, AP ANN TOP LIN RES P
   [Anonymous], 2021, IV BIOC PAT ENR GATH
   [Anonymous], 2021, IVERIC BIOREPORTS 3
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Haggadone MD, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/1340156
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kunchithapautham K, 2012, ADV EXP MED BIOL, V723, P23, DOI 10.1007/978-1-4614-0631-0_4
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Melis JPM, 2015, MOL IMMUNOL, V67, P117, DOI 10.1016/j.molimm.2015.01.028
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 23
TC 0
Z9 0
U1 1
U2 3
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD MAR
PY 2022
VL 47
IS 3
BP 167
EP 172
DI 10.1358/dof.2022.47.3.3378053
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZS4WU
UT WOS:000768469200001
DA 2022-11-30
ER

PT J
AU Ellestad, G
   Zask, A
   Berova, N
AF Ellestad, George
   Zask, Arie
   Berova, Nina
TI The enduring legacy of Koji Nakanishi's research on bioorganic chemistry
   and natural products. Part 1: Isolation, structure determination and
   mode of action
SO CHIRALITY
LA English
DT Article
DE absolute configuration; CD; chemistry of vision; Nakanishi; natural
   products; porphyrin tweezers
ID ABSOLUTE CONFIGURATIONAL ASSIGNMENT; ACTIVATED MITOMYCIN-C; ZINC
   PORPHYRIN HOST; POINT-CHARGE MODEL; AGE PIGMENT A2-E; TERPENE
   TRILACTONES; CHIRAL RECOGNITION; CIRCULAR-DICHROISM; COUNTERCURRENT
   CHROMATOGRAPHY; LIPID-BILAYERS
AB In this brief review on Koji Nakanishi's remarkable career in natural products chemistry, we have highlighted a number of his accomplishments that illustrate the broad diversity of his interests. These include the isolation, structure determination, and biological mechanism of action of many natural products including the triterpenoid pristimerin; the diterpenoid ginkgolides; insect and crustacean molting hormones; phytoalexins; the toxic red tide principle brevetoxin; the vanadium tunicate pigments; philanthotoxin from killer wasps; antisickling agents; mitomycin DNA adducts; insect antifeedants; a mitotic hormone, the small molecule fish attractants from the sea anemone; new isolation and purification technologies; molecular chemistry of vision; age-related macular degeneration; and the development of the exciton circular dichroism (CD) chirality method for microscale determination of absolute configuration of natural products and chirality of other chiral molecules and supramolecular assembly.
C1 [Ellestad, George; Berova, Nina] Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
   [Zask, Arie] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.
C3 Columbia University; Columbia University
RP Ellestad, G (通讯作者)，Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM gae2104@columbia.edu
OI Zask, Arie/0000-0002-1991-1328; Berova, Nina/0000-0003-3792-6475
CR AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berova N., 2000, CIRCULAR DICHROISM P, P337
   Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209
   Borhan B, 1999, CHEM-EUR J, V5, P1172, DOI 10.1002/(SICI)1521-3765(19990401)5:4<1172::AID-CHEM1172>3.0.CO;2-Q
   BROUGHTON HB, 1986, J CHEM SOC CHEM COMM, P46, DOI 10.1039/c39860000046
   BRUENING RC, 1985, J AM CHEM SOC, V107, P5298, DOI 10.1021/ja00304a059
   CAI GL, 1993, J AM CHEM SOC, V115, P7192, DOI 10.1021/ja00069a016
   CHEN YQ, 1994, J AM CHEM SOC, V116, P2683, DOI 10.1021/ja00085a084
   CHOI SK, 1995, CHEM BIOL, V2, P23, DOI 10.1016/1074-5521(95)90077-2
   CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823
   DERGUINI F, 1979, TETRAHEDRON LETT, P4899
   DONG JG, 1995, PHYTOCHEMISTRY, V40, P1821, DOI 10.1016/0031-9422(95)00627-J
   EKONG DEU, 1975, NATURE, V258, P743, DOI 10.1038/258743a0
   ELDEFRAWI AT, 1988, P NATL ACAD SCI USA, V85, P4910, DOI 10.1073/pnas.85.13.4910
   EVANS LS, 1979, SCIENCE, V203, P1122, DOI 10.1126/science.203.4385.1122
   FANG JM, 1983, J AM CHEM SOC, V105, P5162, DOI 10.1021/ja00353a068
   FATOPE MO, 1987, J MED CHEM, V30, P1973, DOI 10.1021/jm00394a007
   Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084
   Fishkin N, 2003, ORG BIOMOL CHEM, V1, P1101, DOI 10.1039/b212213h
   FOSTER KW, 1984, NATURE, V311, P756, DOI 10.1038/311756a0
   FOUCAULT A, 1988, J LIQ CHROMATOGR, V11, P2455, DOI 10.1080/01483918808076740
   Fujimoto Y, 2002, J AM CHEM SOC, V124, P7294, DOI 10.1021/ja020083e
   Fujimoto Y, 2001, CHEM-EUR J, V7, P4198, DOI 10.1002/1521-3765(20011001)7:19<4198::AID-CHEM4198>3.0.CO;2-X
   GARGIULO D, 1989, TETRAHEDRON, V45, P5423, DOI 10.1016/S0040-4020(01)89488-6
   Giorgio E, 2005, BIOORGAN MED CHEM, V13, P5072, DOI 10.1016/j.bmc.2005.04.007
   Guo JS, 2000, CHIRALITY, V12, P43, DOI 10.1002/(SICI)1520-636X(2000)12:1<43::AID-CHIR8>3.0.CO;2-N
   Harada N, 1983, CIRCULAR DICHROIC SP, P460
   HARADA R, 1962, TETRAHEDRON LETT, P603
   HONIG B, 1979, J AM CHEM SOC, V101, P7084, DOI 10.1021/ja00517a060
   HOSTETTMANN K, 1979, J CHROMATOGR, V170, P355, DOI 10.1016/S0021-9673(00)95460-8
   HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004
   Huang XF, 1998, J AM CHEM SOC, V120, P6185, DOI 10.1021/ja973539e
   Huang XF, 2000, CHIRALITY, V12, P237, DOI 10.1002/(SICI)1520-636X(2000)12:4<237::AID-CHIR10>3.0.CO;2-6
   Ivic L, 2003, J BIOL CHEM, V278, P49279, DOI 10.1074/jbc.M304034200
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jiang H, 1999, TETRAHEDRON LETT, V40, P7645, DOI 10.1016/S0040-4039(99)01581-6
   Joshi D, 2013, J NAT PROD, V76, P450, DOI 10.1021/np300769c
   Kawamura A, 2017, CHEM BIOL DRUG DES, V89, P475, DOI 10.1111/cbdd.12883
   Klaic L, 2011, J AM CHEM SOC, V133, P19634, DOI 10.1021/ja208359a
   KRAUS W, 1985, TETRAHEDRON LETT, V26, P6435, DOI 10.1016/S0040-4039(00)99020-8
   Kubo I., 1979, International Union of Pure and applied Chemistry: Advances in pesticide science. Symposia papers presented at the Fourth International Congress of Pesticide Chemistry. Zurich, Switzerland, July 24-28, 1978. (In three parts). Part 2. Synthesis of pesticides. Chemical structure and biological activity. Natural products with biological activity., P284
   KURONO M, 1963, TETRAHEDRON LETT, P2153
   Kurtan T, 2001, J AM CHEM SOC, V123, P5974, DOI 10.1021/ja010250v
   Kurtan T, 2001, J AM CHEM SOC, V123, P5962, DOI 10.1021/ja010249w
   LEE MS, 1989, J AM CHEM SOC, V111, P6234, DOI 10.1021/ja00198a039
   Li J-J, 2019, FRONT PHARM, V12, DOI 10.3389/fphar.2019.00746
   LIN YY, 1981, J AM CHEM SOC, V103, P6773, DOI 10.1021/ja00412a053
   Matile S, 1996, CHEM BIOL, V3, P379, DOI 10.1016/S1074-5521(96)90121-0
   Matile S, 1996, ENANTIOMER, V1, P1
   Matile S, 1996, ANGEW CHEM INT EDIT, V35, P757, DOI 10.1002/anie.199607571
   Matile S, 1996, J AM CHEM SOC, V118, P5198, DOI 10.1021/ja960126p
   MURATA M, 1986, SCIENCE, V234, P585, DOI 10.1126/science.234.4776.585
   NAKANISHI K, 1992, STEROIDS, V57, P649, DOI 10.1016/0039-128X(92)90018-5
   NAKANISHI K, 1979, PHOTOCHEM PHOTOBIOL, V29, P657, DOI 10.1111/j.1751-1097.1979.tb07745.x
   Nakanishi K, 1995, ISRAEL J CHEM, V35, P253
   NAKANISHI K, 1966, CHEM COMMUN, P915, DOI 10.1039/c19660000915
   Nakanishi K, 2005, BIOORGAN MED CHEM, V13, P4987, DOI 10.1016/j.bmc.2005.06.014
   Nakanishi K., 1989, NATURAL PRODUCTS CHE, P13
   NAYA Y, 1989, P NATL ACAD SCI USA, V86, P6826, DOI 10.1073/pnas.86.17.6826
   OKABE K, 1967, J CHEM SOC C, P2201, DOI 10.1039/j39670002201
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PAWLAK J, 1987, J AM CHEM SOC, V109, P1144, DOI 10.1021/ja00238a025
   Pescitelli G, 2003, J AM CHEM SOC, V125, P7613, DOI 10.1021/ja030047v
   Pescitelli G, 2008, J AM CHEM SOC, V130, P6170, DOI 10.1021/ja711009y
   Proni G, 2002, CHEM COMMUN, P1590, DOI 10.1039/b204554k
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Rickman BH, 1998, TETRAHEDRON, V54, P5041, DOI 10.1016/S0040-4020(98)00221-X
   Ryan DE, 1996, BIOCHEMISTRY-US, V35, P8640, DOI 10.1021/bi9521506
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schneider J, 1983, CHEM COMMUN, P372
   SCHNEIDER JA, 1983, J CHEM SOC CHEM COMM, P353, DOI 10.1039/c39830000353
   SCHNEIDER JA, 1983, J CHEM SOC CHEM COMM, P352, DOI 10.1039/c39830000352
   Schwarz M, 1999, COMPREHENSIVE NATURA, V2, P367, DOI DOI 10.1016/B978-0-08-091283-7.00043-6
   SHIMIZU Y, 1986, J AM CHEM SOC, V108, P514, DOI 10.1021/ja00263a031
   SMITH MJ, 1991, ACCOUNTS CHEM RES, V24, P117, DOI 10.1021/ar00004a005
   SNYDER JK, 1984, J LIQ CHROMATOGR, V7, P243, DOI 10.1080/01483918408073965
   Stromgaard K, 2004, ANGEW CHEM INT EDIT, V43, P1640, DOI 10.1002/anie.200300601
   Sugumaran M, 2012, COMP BIOCHEM PHYS B, V163, P1, DOI 10.1016/j.cbpb.2012.05.005
   TACHIBANA K, 1985, TETRAHEDRON, V41, P1027, DOI 10.1016/S0040-4020(01)96470-1
   TAKAHASHI T, 1991, BIOCHEM BIOPH RES CO, V178, P1273, DOI 10.1016/0006-291X(91)91031-7
   Tan Q, 1998, J AM CHEM SOC, V120, P12357, DOI 10.1021/ja9827752
   Tanaka K, 2005, J AM CHEM SOC, V127, P9561, DOI 10.1021/ja0512677
   TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215
   TOMASZ M, 1986, P NATL ACAD SCI USA, V83, P6702, DOI 10.1073/pnas.83.18.6702
   TOMASZ M, 1987, BIOCHEMISTRY-US, V26, P2010, DOI 10.1021/bi00381a034
   Tomaz M, 1994, MOL ASPECTS ANTICANC, V2, P312
   TURNER CJ, 1987, TETRAHEDRON, V43, P2789, DOI 10.1016/S0040-4020(01)86885-X
   Usuki T, 2010, CHEM COMMUN, V46, P737, DOI 10.1039/b913414j
   Van Klink JW, 2004, CHIRALITY, V16, P549, DOI 10.1002/chir.20074
   VERDINE GL, 1985, J AM CHEM SOC, V107, P6118, DOI 10.1021/ja00307a056
   Vogensen SB, 2003, J MED CHEM, V46, P601, DOI 10.1021/jm0203985
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Yanase E, 2011, HETEROCYCLES, V82, P1151, DOI 10.3987/COM-10-S(E)102
   ZANNO PR, 1975, J AM CHEM SOC, V97, P1975, DOI 10.1021/ja00840a073
   ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040
   Zhao N, 1995, CHIRALITY, V7, P636, DOI 10.1002/chir.530070815
NR 97
TC 0
Z9 0
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-0042
EI 1520-636X
J9 CHIRALITY
JI Chirality
PD MAY
PY 2020
VL 32
IS 5
BP 632
EP 651
DI 10.1002/chir.23214
PG 20
WC Chemistry, Medicinal; Chemistry, Analytical; Chemistry, Organic;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA LD2LZ
UT WOS:000525865700014
PM 32157754
DA 2022-11-30
ER

PT J
AU Zhou, QB
   Gallagher, R
   Ufret-Vincenty, R
   Li, XY
   Olson, EN
   Wang, SS
AF Zhou, Qinbo
   Gallagher, Rachel
   Ufret-Vincenty, Rafael
   Li, Xinyu
   Olson, Eric N.
   Wang, Shusheng
TI Regulation of angiogenesis and choroidal neovascularization by members
   of microRNA-23 similar to 27 similar to 24 clusters
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE blindness; MAP kinase signaling; semaphorins; Akt; proangiogenic
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CELL-PROLIFERATION;
   IN-VIVO; MICRORNAS; MODEL; EXPRESSION; DISEASES; RETINA; INFLAMMATION
AB MicroRNAs (miRNAs) modulate complex physiological and pathological processes by repressing expression of multiple components of cellular regulatory networks. Here we demonstrate that miRNAs encoded by the miR-23 similar to 27 similar to 24 gene clusters are enriched in endothelial cells and highly vascularized tissues. Inhibition of miR-23 and miR-27 function by locked nucleic acid-modified anti-miRNAs represses angiogenesis in vitro and postnatal retinal vascular development in vivo. Moreover, miR-23 and miR-27 are required for pathological angiogenesis in a laser-induced choroidal neovascularization mouse model. MiR-23 and miR-27 enhance angiogenesis by promoting angiogenic signaling through targeting Sprouty2 and Sema6A proteins, which exert antiangiogenic activity. Manipulating miR-23/27 levels may have important therapeutic implications in neovascular age-related macular degeneration and other vascular disorders.
C1 [Zhou, Qinbo; Gallagher, Rachel; Ufret-Vincenty, Rafael; Li, Xinyu; Wang, Shusheng] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA.
   [Olson, Eric N.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
   [Wang, Shusheng] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Olson, EN (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
EM Eric.Olson@utsouthwestern.edu; Shusheng.Wang@utsouthwestern.edu
OI Zhou, Qinbo/0000-0002-7967-2138; Li, Xinyu/0000-0002-5908-6676
FU Department of Ophthalmology at UT Southwestern Medical Center; National
   Institutes of Health [EY020799]; Research to Prevent Blindness; Donald
   W. Reynolds Center for Clinical Cardiovascular Research; Robert A. Welch
   Foundation [I-0025]; Foundation Leducq's Transatlantic Network of
   Excellence in Cardiovascular Research Program; American Heart
   Association; Jon Holden DeHaan Foundation; NATIONAL EYE INSTITUTE
   [R01EY021862, P30EY020799] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL093039] Funding Source: NIH RePORTER
FX We thank Jose Cabrera for graphics. We are grateful to C. Kuo, C.
   Lowenstein, and W. Sessa for comments on the manuscript. S. W. was
   supported by a Startup fund from the Department of Ophthalmology at UT
   Southwestern Medical Center, National Institutes of Health Grant
   EY020799, and an unrestricted grant from Research to Prevent Blindness.
   E.N.O. was supported by grants from the National Institutes of Health,
   the Donald W. Reynolds Center for Clinical Cardiovascular Research, The
   Robert A. Welch Foundation (Grant I-0025), the Foundation Leducq's
   Transatlantic Network of Excellence in Cardiovascular Research Program,
   the American Heart Association, and the Jon Holden DeHaan Foundation.
CR Amrite A, 2010, EXPERT OPIN DRUG DEL, V7, P631, DOI 10.1517/17425241003663236
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Axton R, 2008, J CELL BIOCHEM, V103, P1171, DOI 10.1002/jcb.21497
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0
   Chhabra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-232
   Dhanabal M, 2005, CANCER BIOL THER, V4, P659, DOI 10.4161/cbt.4.6.1733
   Distler JHW, 2003, Q J NUCL MED, V47, P149
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jennewein C, 2010, J BIOL CHEM, V285, P11846, DOI 10.1074/jbc.M109.066399
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020
   Lee KS, 2006, BIOCHEM BIOPH RES CO, V346, P83, DOI 10.1016/j.bbrc.2006.05.069
   Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012
   Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299
   Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Suarez Y, 2007, CIRC RES, V100, P1164, DOI 10.1161/01.RES.0000265065.26744.17
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Yuan XY, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-65
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zhou R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000681
NR 43
TC 277
Z9 300
U1 3
U2 30
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 17
PY 2011
VL 108
IS 20
BP 8287
EP 8292
DI 10.1073/pnas.1105254108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 765OZ
UT WOS:000290719600045
PM 21536891
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Wells, LA
   Furukawa, S
   Sheardown, H
AF Wells, Laura A.
   Furukawa, Stephanie
   Sheardown, Heather
TI Photoresponsive PEG-Anthracene Grafted Hyaluronan as a
   Controlled-Delivery Biomaterial
SO BIOMACROMOLECULES
LA English
DT Article
ID TISSUE ENGINEERING SCAFFOLDS; DRUG-DELIVERY; MACULAR DEGENERATION;
   POSTERIOR SEGMENT; PROTEIN RELEASE; ACID HYDROGELS; SYSTEMS;
   PHARMACOKINETICS; RANIBIZUMAB; DEGRADATION
AB Ophthalmic drug delivery to the posterior segment of the eye could benefit from a responsive controlled drug-delivery system with. light or laser inducible changes. For example, the. delivery of age-related macular degeneration drugs requires invasive monthly injections-making long-term photoresponsive drug delivery a, desirable option. The feasibility of this may be facilitated by both the transparency of the eye and the advanced technology in ophthalmic lasers. Hyaluronic acid photogels that : are compatible with retinal pigment epithelial cell lines are shown here to deliver a variety of small and large model drugs over, the long term (months). Varying UV exposures resulted in decreases/increases or the turning off and on of delivery, potentially allowing the therapy to be tailored to suit the patient and the disease.
C1 [Sheardown, Heather] McMaster Univ, Dept Chem Engn, Hamilton, ON L8S 4L7, Canada.
   McMaster Univ, Sch Biomed Engn, Hamilton, ON L8S 4L7, Canada.
C3 McMaster University; McMaster University
RP Sheardown, H (通讯作者)，McMaster Univ, Dept Chem Engn, Hamilton, ON L8S 4L7, Canada.
EM sheardow@mcmaster.ca
OI Wells, Laura/0000-0002-7524-2798
FU NSERC; 20/20 NSERC Ophthalmic Materials Network
FX Funding support from NSERC and 20/20 NSERC Ophthalmic Materials Network
   is gratefully acknowledged. Dr. John Preston and Gabriel Devenyi are
   acknowledged for excimer laser expertise.
CR Ahmadi MA, 2008, EXPERT OPIN PHARMACO, V9, P3045, DOI [10.1517/14656560802473480, 10.1517/14656560802473480 ]
   Anderson OA, 2010, DRUG DISCOV TODAY, V15, P272, DOI 10.1016/j.drudis.2010.02.004
   Bhawalkar JD, 1996, REP PROG PHYS, V59, P1041, DOI 10.1088/0034-4885/59/9/001
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Bouas-Laurent H, 2001, CHEM SOC REV, V30, P248, DOI 10.1039/b006013p
   Bratschkov C, 2001, POLYM BULL, V46, P345, DOI 10.1007/s002890170041
   BRAY JC, 1973, J APPL POLYM SCI, V17, P3779, DOI 10.1002/app.1973.070171219
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   CHORNY RC, 1966, IND ENG CHEM PROC DD, V5, P206, DOI 10.1021/i260018a019
   de Jong SJ, 2001, J CONTROL RELEASE, V71, P261, DOI 10.1016/S0168-3659(01)00228-0
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Flory PJ, 1943, J CHEM PHYS, V11, P521, DOI 10.1063/1.1723792
   Garg HG., 2004, CHEM BIOL HYALURONAN
   Hartner S, 2007, J POLYM SCI POL CHEM, V45, P2443, DOI 10.1002/pola.22007
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Jaffe G.J., 2006, INTRAOCULAR DRUG DEL
   Jeon O, 2007, CARBOHYD POLYM, V70, P251, DOI 10.1016/j.carbpol.2007.04.002
   Kaur M, 2002, J MACROMOL SCI-POL R, VC42, P481, DOI 10.1081/MC-120015988
   KHORLIN AY, 1973, FEBS LETT, V31, P107, DOI 10.1016/0014-5793(73)80084-5
   KUMAR GS, 1989, CHEM REV, V89, P1915, DOI 10.1021/cr00098a012
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   LANG JC, 1995, ADV DRUG DELIVER REV, V16, P39, DOI 10.1016/0169-409X(95)00012-V
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Leach JB, 2003, BIOTECHNOL BIOENG, V82, P578, DOI 10.1002/bit.10605
   Leach JB, 2005, BIOMATERIALS, V26, P125, DOI 10.1016/j.biomaterials.2004.02.018
   Li CY, 2005, SOFT MATTER, V1, P238, DOI 10.1039/b506876b
   Molokhia SA, 2010, VISION RES, V50, P680, DOI 10.1016/j.visres.2009.10.013
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schwartz DM, 1996, CURR EYE RES, V15, P1156, DOI 10.3109/02713689608995150
   Skupinska K, 2006, ACTA BIOCHIM POL, V53, P101
   THOMPSON KP, 1992, P IEEE, V80, P838, DOI 10.1109/5.149448
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Weiner AL, 2008, OCULAR THERAPEUTICS: EYE ON NEW DISCOVERIES, P7, DOI 10.1016/B978-012370585-3.50004-2
   WELLS LA, 2011, EUR J PHARM BI UNPUB
   WELLS LA, 2011, MACROMOL BIOSC UNPUB
   Yasukawa T, 2005, ADV DRUG DELIVER REV, V57, P2033, DOI 10.1016/j.addr.2005.09.005
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
NR 44
TC 36
Z9 36
U1 0
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD APR
PY 2011
VL 12
IS 4
BP 923
EP 932
DI 10.1021/bm101233m
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 746DT
UT WOS:000289223500009
PM 21401018
DA 2022-11-30
ER

PT J
AU Viola, P
   Testa, V
   Desideri, LF
   Di Cello, L
   Rutigliani, C
   Vagge, A
   Nicolo, M
   Cian, R
   Traverso, CE
AF Viola, P.
   Testa, V
   Desideri, L. Ferro
   Di Cello, L.
   Rutigliani, C.
   Vagge, A.
   Nicolo, M.
   Cian, R.
   Traverso, C. E.
TI Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general
   overview
SO DRUGS OF TODAY
LA English
DT Review
DE Biosimilars; Ranibizumab; Aflibercept; Bevacizumab; Anti-vascular
   endothelial growth factor (VEGF) drugs; Macular degeneration;
   Intravitreal injections
ID VEGF
AB Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other-retinal vascular disorders, and their clinical use is associated with high financial burden. Biosimilars are a type of biological product highly similar to referral biologic drugs; they are increasing competition among biologics and have the potential to reduce the overall expenditures on biologics. In this comprehensive literature review, the current investigational biosimilars acting on retinal diseases are discussed. The authors review the results of clinical studies and highlight ongoing trials. Several biosimilar candidates are under evaluation and the pipeline will rapidly change in the future, as soon as each patent expires. Clinicians have to know these new-therapeutic agents, which might come in the mainstream clinical practice as a more cost-efficient option.
C1 [Viola, P.; Testa, V; Cian, R.] Osped San Bortolo, Vicenza, Italy.
   [Desideri, L. Ferro; Di Cello, L.; Vagge, A.; Nicolo, M.; Traverso, C. E.] Univ Genoa, Eye Clin, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Desideri, L. Ferro; Di Cello, L.; Vagge, A.; Nicolo, M.; Traverso, C. E.] Univ Eye Clin Genoa, IRCCS Osped Policlin San Martino, Genoa, Italy.
   [Rutigliani, C.] Univ Vita Salute, IRCCS Osped San Raffaele, Milan, Italy.
C3 ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Genoa;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Desideri, LF (通讯作者)，Univ Eye Clin Genoa, IRCCS Osped Policlin San Martino, Genoa, Italy.
EM lorenzoferrodes@gmail.com
CR [Anonymous], 2020, PHAS 3 STUD EV EQ EF
   [Anonymous], 2021, BYOOV RAN
   [Anonymous], 2021, RAND PHAS 3 DOUBL MA
   [Anonymous], 2021, PHAS 3 RAND DOUBL MA
   [Anonymous], 2021, POS ROAD AH BIOS
   [Anonymous], 2020, BIOS US 2020 2024
   [Anonymous], 2018, FED REGISTER
   [Anonymous], 2017, BIOS DEV REV APPR
   [Anonymous], 2020, PROSP MULT RAND DOUB
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Dandekar V., 2015, EC TIMES 0821
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Desideri LF, 2021, EXPERT OPIN BIOL TH, V21, P553, DOI 10.1080/14712598.2021.1915278
   FYB203, 2016, FYB203
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Griaud F, 2017, MABS-AUSTIN, V9, P1337, DOI 10.1080/19420862.2017.1366395
   Holz F.G., OPHTHALMOLOGY
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jose V, 2019, INDIAN J PHARMACOL, V51, P377, DOI 10.4103/ijp.IJP_413_19
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nicolo M, 2020, OPHTHALMOLOGICA, V243, P453, DOI 10.1159/000507711
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rathore Anurag, 2012, PDA J Pharm Sci Technol, V66, P393, DOI 10.5731/pdajpst.2012.00886
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sameera VV., 2016, KERALA J OPHTHALMOL, V28, P180, DOI [DOI 10.4103/KJO.KJO_18_17, 10.4103/kjo.kjo_18_17]
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P2, DOI 10.1136/bjophthalmol-2019-314443
   Sharma A, 2019, EYE, V33, P1359, DOI 10.1038/s41433-019-0434-y
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P377
   Sharma S., INT J RETINA VITREOU, V7, P24
   Sharma S, 2020, OPHTHALMOL THER, V9, P625, DOI 10.1007/s40123-020-00277-3
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Suh SK, 2011, BIOLOGICALS, V39, P336, DOI 10.1016/j.biologicals.2011.06.008
   Verma L, 2021, INDIAN J OPHTHALMOL, V69, P347, DOI 10.4103/ijo.IJO_2516_20
   Woo SJ, 2021, JAMA OPHTHALMOL, V139, P68, DOI 10.1001/jamaophthalmol.2020.5053
NR 42
TC 1
Z9 1
U1 1
U2 4
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD NOV
PY 2021
VL 57
IS 11
BP 689
EP 697
DI 10.1358/dot.2021.57.11.3331006
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XC0NV
UT WOS:000721718100004
PM 34821882
DA 2022-11-30
ER

PT J
AU Wang, G
   Yang, YN
   Ott, J
AF Wang, Gao
   Yang, Yaning
   Ott, Jurg
TI Genome-Wide Conditional Search for Epistatic Disease-Predisposing
   Variants in Human Association Studies
SO HUMAN HEREDITY
LA English
DT Article
DE Genome-wide association analysis; Conditional search; Epistatic
   disease-predisposing variants
ID DIABETES SUSCEPTIBILITY GENES; LINKAGE ANALYSIS; MACULAR DEGENERATION;
   STATISTICAL-METHODS; NUCLEAR FAMILIES; COMPLEX DISEASES; HIV-1
   INFECTION; POLYMORPHISM; STRATEGIES; TRAITS
AB Genome-wide search for new disease variants, based on well-established variants, has a long history in linkage analysis but is less well-known in genetic case-control association studies. We developed a simple yet highly efficient conditional search method that can find new variants, which are associated with a disease only through epistatic interaction with another variant and do not necessarily have a direct association effect. Our approach is analogous to partitioning of chi(2) in a hierarchical design, which is a well-established statistical technique. Applied to previously published data on age-related macular degeneration, our method found two single-nucleotide polymorphisms with genome-wide significant epistatic interaction that could not be found based only on direct main effects. Copyright (C) 2010 S. Karger AG, Basel
C1 [Wang, Gao; Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing 100029, Peoples R China.
   [Yang, Yaning] Univ Sci & Technol China, Dept Stat & Finance, Hefei 230026, Peoples R China.
   [Wang, Gao] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese
   Academy of Sciences; University of Science & Technology of China, CAS;
   Baylor College of Medicine
RP Ott, J (通讯作者)，Chinese Acad Sci, Beijing Inst Genom, 7 Bei Tu Cheng W Rd, Beijing 100029, Peoples R China.
EM ottjurg@yahoo.com
FU China Natural Science Foundation; NIH [AG026916, HL084410]; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTE [R01HL084410] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [U01AG016976, R01AG026916] Funding
   Source: NIH RePORTER
FX Grant support from the China Natural Science Foundation (to Y.Y. and
   J.O.) is gratefully acknowledged. This work was also supported in part
   by NIH grants AG026916 and HL084410.
CR Angquist L, 2008, HUM HERED, V66, P138, DOI 10.1159/000126049
   Armitage P, 2002, STAT METHODS MED RES, V4th
   Assmann G, 2009, CLIN EXP RHEUMATOL, V27, P615
   Bellone G, 2006, CANCER BIOL THER, V5, P1294, DOI 10.4161/cbt.5.10.3152
   Breslow NE, 1980, ANAL CASE CONTROL ST
   Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939
   Cichon S, 2009, AM J PSYCHIAT, V166, P540, DOI 10.1176/appi.ajp.2008.08091354
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759
   DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0
   Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Di YM, 2009, HUM HERED, V68, P139, DOI 10.1159/000218112
   DUPUIS J, 1995, GENETICS, V140, P843
   Escarceller M, 2000, DNA SEQUENCE, V11, P335, DOI 10.3109/10425170009033252
   Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371
   HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0
   Hoggart CJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000130
   Hoh J, 2001, GENOME RES, V11, P2115, DOI 10.1101/gr.204001
   Hoh J, 2000, ANN HUM GENET, V64, P413, DOI 10.1046/j.1469-1809.2000.6450413.x
   Kaur G, 2009, TISSUE ANTIGENS, V73, P289, DOI 10.1111/j.1399-0039.2009.01220.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kooperberg C, 2008, GENET EPIDEMIOL, V32, P255, DOI 10.1002/gepi.20300
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   LANDER ES, 1986, P NATL ACAD SCI USA, V83, P7353, DOI 10.1073/pnas.83.19.7353
   Long N, 2009, GENET SEL EVOL, V41, DOI 10.1186/1297-9686-41-18
   Long Q, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S1-S75
   Manolio TA, 2007, HUM HERED, V63, P63, DOI 10.1159/000099178
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Matthews AG, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1325
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Moore JH, 2009, AM J HUM GENET, V85, P309, DOI 10.1016/j.ajhg.2009.08.006
   Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735
   OTT J, 1982, HUM GENET, V62, P296, DOI 10.1007/BF00304542
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qiao Q, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-84
   Shah SH, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-S1-S148
   Snedecor G., 1989, AMES IOWA STATE U PR, V8
   Solberg TR, 2009, GENET SEL EVOL, V41, DOI 10.1186/1297-9686-41-29
   Thomson Glenys, 2007, BMC Proc, V1 Suppl 1, pS163
   Thomson G, 2008, ADV GENET, V60, P253, DOI 10.1016/S0065-2660(07)00411-7
   Wu CQ, 2009, STAT INTERFACE, V2, P161
   WU TT, 2009, BIOINFORMATICS, V28, P28
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
   Zheng G, 2006, IMS LECT NOTES MONOG, V49, P253
NR 46
TC 5
Z9 5
U1 1
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5652
EI 1423-0062
J9 HUM HERED
JI Hum. Hered.
PY 2010
VL 70
IS 1
BP 34
EP 41
DI 10.1159/000293722
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 619KC
UT WOS:000279428100004
PM 20413980
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ohba, N
   Nakao, K
   Isashiki, Y
   Ohba, A
AF Ohba, Norio
   Nakao, Kumiko
   Isashiki, Yasushi
   Ohba, Ayako
TI The 100 most frequently cited articles in ophthalmology journals
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Review
ID AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; IMMUNE-DEFICIENCY
   SYNDROME; OPTIC-NERVE DAMAGE; PHOTOREFRACTIVE KERATECTOMY;
   EXCIMER-LASER; CORNEAL ENDOTHELIUM; LENS OPACITIES; VISUAL-ACUITY;
   INTRAOCULAR-PRESSURE
AB We screened 46 ophthalmology journals to identify the most frequently cited articles using the Science Citation Index Expanded ( 1975 to 2006). The 100 most-cited articles were published in 13 journals, most in the Archives of Ophthalmology (n=30), followed by Ophthalmology (n=27) and the American Journal of Ophthalmology (n=11), and originated from 10 countries, led by the United States (n=86). The topics covered by these classic articles included epidemiology of age-related macular degeneration and glaucoma, description of new diseases including cytomegalovirus retinitis, optical coherence tomography, hypotensive medications in glaucoma, laser photocoagulation to treat diabetic retinopathy and subfoveal choroidal neovascularization, photorefractive surgery, and vitrectomy to treat idiopathic macular hole. The most frequently cited articles provide a historical perspective in the scientific advancement of ophthalmology during the last 3 decades.
C1 Aichi Shukutoku Univ, Div Orthopt & Visual Sci, Fac Med Welf, Chikusa Ku, Nagoya, Aichi 4648671, Japan.
   Kagoshima Univ, Grad Sch Med, Dept Ophthalmol, Kagoshima 890, Japan.
   Aichi Shukutoku Univ Clin, Dept Ophthalmol, Nagakute, Aichi, Japan.
   Aichi Shukutoku Univ, Dept Language Commun, Grad Sch Commun, Nagakute, Aichi, Japan.
C3 Aichi Shukutoku University; Kagoshima University; Aichi Shukutoku
   University
RP Ohba, N (通讯作者)，Aichi Shukutoku Univ, Div Orthopt & Visual Sci, Fac Med Welf, Chikusa Ku, Sakuragaoka 23, Nagoya, Aichi 4648671, Japan.
EM ohbanm@gctv.ne.jp
CR ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Alm A, 1995, OPHTHALMOLOGY, V102, P1743, DOI 10.1016/S0161-6420(95)30798-1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   APPLE DJ, 1992, SURV OPHTHALMOL, V37, P73, DOI 10.1016/0039-6257(92)90073-3
   APPLE DJ, 1984, SURV OPHTHALMOL, V29, P1, DOI 10.1016/0039-6257(84)90113-9
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BOURNE WM, 1976, AM J OPHTHALMOL, V81, P319, DOI 10.1016/0002-9394(76)90247-6
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CAMPBELL FM, 1990, B MED LIBR ASSOC, V78, P376
   Camras CB, 1996, OPHTHALMOLOGY, V103, P138, DOI 10.1016/S0161-6420(96)30749-5
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   FANTES FE, 1990, ARCH OPHTHALMOL-CHIC, V108, P665, DOI 10.1001/archopht.1990.01070070051034
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GARFIELD E, 1987, JAMA-J AM MED ASSOC, V257, P52, DOI 10.1001/jama.257.1.52
   GARTRY DS, 1992, OPHTHALMOLOGY, V99, P1209
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6
   HAYREH SS, 1994, AM J OPHTHALMOL, V117, P603, DOI 10.1016/S0002-9394(14)70067-4
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640
   HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859
   HOLLY FJ, 1977, SURV OPHTHALMOL, V22, P69, DOI 10.1016/0039-6257(77)90087-X
   JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031
   JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7
   KAMPIK A, 1981, ARCH OPHTHALMOL-CHIC, V99, P1445, DOI 10.1001/archopht.1981.03930020319025
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATTAN HM, 1991, OPHTHALMOLOGY, V98, P227
   KELLY NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P654, DOI 10.1001/archopht.1991.01080050068031
   KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
   KITAZAWA Y, 1991, ARCH OPHTHALMOL-CHIC, V109, P1693, DOI 10.1001/archopht.1991.01080120077030
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAING RA, 1976, EXP EYE RES, V22, P587, DOI 10.1016/0014-4835(76)90003-8
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Link AM, 1998, JAMA-J AM MED ASSOC, V280, P246, DOI 10.1001/jama.280.3.246
   LITTMANN H, 1982, KLIN MONATSBL AUGENH, V180, P286, DOI 10.1055/s-2008-1055068
   MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1
   MACHEMER R, 1978, AM J OPHTHALMOL, V85, P181, DOI 10.1016/S0002-9394(14)75946-X
   MARMOR MF, 1989, ARCH OPHTHALMOL-CHIC, V107, P816, DOI 10.1001/archopht.1989.01070010838024
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MUNNERLYN CR, 1988, J CATARACT REFR SURG, V14, P46, DOI 10.1016/S0886-3350(88)80063-4
   NUSSENBLATT RB, 1983, AM J OPHTHALMOL, V96, P275, DOI 10.1016/S0002-9394(14)77814-6
   PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092
   PALLIKARIS IG, 1994, J REFRACT CORNEAL S, V10, P498
   PALMER SS, 1991, OPHTHALMOLOGY, V98, P317
   PAVLIN CJ, 1991, OPHTHALMOLOGY, V98, P287
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   QUIGLEY HA, 1987, INVEST OPHTH VIS SCI, V28, P913
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   QUIGLEY HA, 1988, OPHTHALMOLOGY, V95, P357
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009
   QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   RUBINFELD RS, 1992, OPHTHALMOLOGY, V99, P1647
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCOTT AB, 1980, OPHTHALMOLOGY, V87, P1044
   SCOTT AB, 1985, ARCH OPHTHALMOL-CHIC, V103, P347
   SEILER T, 1991, OPHTHALMOLOGY, V98, P1156
   SKUTA GL, 1992, OPHTHALMOLOGY, V99, P438
   SKUTA GL, 1987, SURV OPHTHALMOL, V32, P149, DOI 10.1016/0039-6257(87)90091-9
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P77, DOI 10.1001/archopht.1991.01080010079037
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   *THOMS SCI, NEW FAC RES
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   TROKEL SL, 1983, AM J OPHTHALMOL, V96, P710, DOI 10.1016/S0002-9394(14)71911-7
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   WARING GO, 1982, OPHTHALMOLOGY, V89, P531
   Watson P, 1996, OPHTHALMOLOGY, V103, P126, DOI 10.1016/S0161-6420(96)30750-1
   WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386
   WISE JB, 1979, ARCH OPHTHALMOL-CHIC, V97, P319, DOI 10.1001/archopht.1979.01020010165017
   YABLONSKI ME, 1978, EXP EYE RES, V27, P135, DOI 10.1016/0014-4835(78)90083-0
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZIMMERMAN LE, 1978, BRIT J OPHTHALMOL, V62, P420, DOI 10.1136/bjo.62.6.420
   ZIMMERMAN TJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P601, DOI 10.1001/archopht.1977.04450040067008
NR 104
TC 75
Z9 77
U1 1
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2007
VL 125
IS 7
BP 952
EP 960
DI 10.1001/archopht.125.7.952
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 188BE
UT WOS:000247892600013
PM 17620577
OA Bronze
DA 2022-11-30
ER

PT J
AU Mainolfi, N
   Ehara, T
   Karki, RG
   Anderson, K
   Mac Sweeney, A
   Liao, SM
   Argikar, UA
   Jendza, K
   Zhang, C
   Powers, J
   Klosowski, DW
   Crowley, M
   Kawanami, T
   Ding, J
   April, M
   Forster, C
   Serrano-Wu, M
   Capparelli, M
   Ramqaj, R
   Solovay, C
   Cumin, F
   Smith, TM
   Ferrara, L
   Lee, W
   Long, D
   Prentiss, M
   De Erkenez, A
   Yang, L
   Liu, F
   Sellner, H
   Sirockin, F
   Valeur, E
   Erbel, P
   Ostermeier, D
   Ramage, P
   Gerhartz, B
   Schubart, A
   Flohr, S
   Gradoux, N
   Feifel, R
   Vogg, B
   Wiesmann, C
   Maibaum, J
   Eder, J
   Sedrani, R
   Harrison, RA
   Mogi, M
   Jaffee, BD
   Adams, CM
AF Mainolfi, Nello
   Ehara, Takeru
   Karki, Rajeshri G.
   Anderson, Karen
   Mac Sweeney, Aengus
   Liao, Sha-Mei
   Argikar, Upendra A.
   Jendza, Keith
   Zhang, Chun
   Powers, James
   Klosowski, Daniel W.
   Crowley, Maura
   Kawanami, Toshio
   Ding, Jian
   April, Myriam
   Forster, Cornelia
   Serrano-Wu, Michael
   Capparelli, Michael
   Ramqaj, Rrezarta
   Solovay, Catherine
   Cumin, Frederic
   Smith, Thomas M.
   Ferrara, Luciana
   Lee, Wendy
   Long, Debby
   Prentiss, Melissa
   De Erkenez, Andrea
   Yang, Louis
   Liu, Fang
   Sellner, Holger
   Sirockin, Finton
   Valeur, Eric
   Erbel, Paulus
   Ostermeier, Daniela
   Ramage, Paul
   Gerhartz, Bernd
   Schubart, Anna
   Flohr, Stefanie
   Gradoux, Nathalie
   Feifel, Roland
   Vogg, Barbara
   Wiesmann, Christian
   Maibaum, Juergen
   Eder, Joerg
   Sedrani, Richard
   Harrison, Richard A.
   Mogi, Muneto
   Jaffee, Bruce D.
   Adams, Christopher M.
TI Discovery of
   4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidi
   n-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed
   To Be Applicable to Treating a Diverse Array of Complement Mediated
   Diseases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID MACULAR DEGENERATION; ALTERNATIVE PATHWAY;
   2-CHLORO-1,3-DIMETHYLIMIDAZOLINIUM CHLORIDE; PLASMA-LEVELS; ACTIVATION;
   FRAGMENT; PROTEASE; SYSTEM; HYPOTHESIS; INSIGHTS
AB The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.
C1 [Mainolfi, Nello; Ehara, Takeru; Karki, Rajeshri G.; Anderson, Karen; Liao, Sha-Mei; Argikar, Upendra A.; Jendza, Keith; Zhang, Chun; Powers, James; Klosowski, Daniel W.; Crowley, Maura; Kawanami, Toshio; Ding, Jian; April, Myriam; Forster, Cornelia; Serrano-Wu, Michael; Capparelli, Michael; Solovay, Catherine; Smith, Thomas M.; Ferrara, Luciana; Lee, Wendy; Long, Debby; Prentiss, Melissa; De Erkenez, Andrea; Yang, Louis; Liu, Fang; Mogi, Muneto; Jaffee, Bruce D.; Adams, Christopher M.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
   [Mac Sweeney, Aengus; Ramqaj, Rrezarta; Cumin, Frederic; Sellner, Holger; Sirockin, Finton; Valeur, Eric; Erbel, Paulus; Ostermeier, Daniela; Ramage, Paul; Gerhartz, Bernd; Schubart, Anna; Flohr, Stefanie; Gradoux, Nathalie; Feifel, Roland; Vogg, Barbara; Wiesmann, Christian; Maibaum, Juergen; Eder, Joerg; Sedrani, Richard; Harrison, Richard A.] Novartis Pharma AG, Novartis Inst BioMed Res, CH-4056 Basel, Switzerland.
C3 Novartis; Novartis
RP Adams, CM (通讯作者)，Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
EM christopherM.adams@novartis.com
OI Argikar, Upendra/0000-0002-0939-0813; Karki,
   Rajeshri/0000-0003-2210-5789; Kawanami, Toshio/0000-0001-7721-366X;
   Harrison, Richard Alexander/0000-0002-2408-6043
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aronov AM, 2006, J MED CHEM, V49, P6917, DOI 10.1021/jm060500o
   Artman GD, 2010, TETRAHEDRON LETT, V51, P5319, DOI 10.1016/j.tetlet.2010.07.177
   Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128
   Chaplin H Jr, 2005, Immunohematology, V21, P85
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cui J, 2002, BIOORGAN MED CHEM, V10, P41, DOI 10.1016/S0968-0896(01)00259-0
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glazer LC, 2016, INVEST OPHTH VIS SCI, V57
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Grossman TR, 2017, MOL VIS, V23, P561
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Harrison RA, 2018, SEMIN IMMUNOPATHOL, V40, P15, DOI 10.1007/s00281-017-0661-x
   Henry R. T., 2000, U.S. Patent, Patent No. [US6162818, 6162818]
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   INAGI R, 1991, IMMUNOL LETT, V27, P49, DOI 10.1016/0165-2478(91)90243-4
   Isobe T, 1999, J ORG CHEM, V64, P6984, DOI 10.1021/jo990210y
   KAM CM, 1987, J BIOL CHEM, V262, P3444
   Karki RG, 2019, J MED CHEM, V62, P4656, DOI 10.1021/acs.jmedchem.9b00271
   Khan AR, 1998, PROTEIN SCI, V7, P815
   Klabunde T, 2005, CHEMBIOCHEM, V6, P876, DOI 10.1002/cbic.200400369
   Kock MA, 2004, J BIOL CHEM, V279, P30836, DOI 10.1074/jbc.M403196200
   LACHMANN PJ, 1984, SPRINGER SEMIN IMMUN, V7, P143, DOI 10.1007/BF01893018
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   Lukawska E, 2018, CLIN EXP MED, V18, P297, DOI 10.1007/s10238-018-0491-8
   Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Milder FJ, 2007, NAT STRUCT MOL BIOL, V14, P224, DOI 10.1038/nsmb1210
   Neumann P., 1983, U.S. Patent, Patent No. [US4398028, 4398028]
   ODA M, 1990, JPN J PHARMACOL, V52, P23, DOI 10.1254/jjp.52.23
   OPPERMANN M, 1991, KIDNEY INT, V40, P939, DOI 10.1038/ki.1991.298
   Ponnuraj K, 2004, MOL CELL, V14, P17, DOI 10.1016/S1097-2765(04)00160-1
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   de Cordoba SR, 2014, SEMIN THROMB HEMOST, V40, P422, DOI 10.1055/s-0034-1375296
   Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756
   Ruiz-Gomez G, 2009, J MED CHEM, V52, P6042, DOI 10.1021/jm900781m
   Rumthao S, 2004, BIOORG MED CHEM LETT, V14, P5165, DOI 10.1016/j.bmcl.2004.07.054
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schubart A, 2019, P NATL ACAD SCI USA, V116, P7926, DOI 10.1073/pnas.1820892116
   Sedrani R., 2014, 15 ANN DRUG DISC SUM
   Silva AS, 2012, MOL VIS, V18, P2288
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Vulpetti A, 2017, J MED CHEM, V60, P1946, DOI 10.1021/acs.jmedchem.6b01684
   Xu YY, 2000, J BIOL CHEM, V275, P378, DOI 10.1074/jbc.275.1.378
NR 48
TC 12
Z9 14
U1 2
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 11
PY 2020
VL 63
IS 11
BP 5697
EP 5722
DI 10.1021/acs.jmedchem.9b01870
PG 26
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA MA2IY
UT WOS:000541741100004
PM 32073845
DA 2022-11-30
ER

PT J
AU Borrillo, JL
   Sivalingam, A
   Martidis, A
   Federman, JL
AF Borrillo, JL
   Sivalingam, A
   Martidis, A
   Federman, JL
TI Surgical ablation of retinal angiomatous proliferation
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; ANASTOMOSES
AB Age-related macular degeneration (AMD) remains the leading cause of visual loss in adults older than 65 years. Retinal angiomatous proliferation (RAP) is a newly recognized manifestation of exudative AMD that has poor natural history and demonstrated resistence to resistence to treatment with conventional laser photocoagulation. A novel surgical technique has been developed in this pilot series that shows promise in the treatment of this subtype of neovascular lesions. Through specific surgical lysis of the feeding arteriole and draining venule of an RAP lesion, improvement in visual acuity has been noted. This has been correlated with resolution of intraretinal edema and flattening of associated pigment epithelia detachment, which was confirmed by fluorescein angiography, optical coherence tomography, and high-speed indo cyanine green angiography. Arc Ophthalmol. 2003;121:558-561.
C1 Thomas Jefferson Univ, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Sivalingam, A (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Retina Serv, 840 Walnut St,10th Floor, Philadelphia, PA 19107 USA.
CR Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 4
TC 51
Z9 54
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2003
VL 121
IS 4
BP 558
EP 561
DI 10.1001/archopht.121.4.558
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664QM
UT WOS:000182071800015
PM 12695253
OA Bronze
DA 2022-11-30
ER

PT J
AU Munch, IC
   Linneberg, A
   Larsen, M
AF Munch, Inger Christine
   Linneberg, Allan
   Larsen, Michael
TI Precursors of Age-Related Macular Degeneration: Associations With
   Physical Activity, Obesity, and Serum Lipids in the Inter99 Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; physical activity; drusen; small hard macular drusen
ID 15-YEAR CUMULATIVE INCIDENCE; CARDIOVASCULAR RISK-FACTORS; TERM
   INCIDENCE; MACULOPATHY; DRUSEN; PREVALENCE; PROGRESSION
AB PURPOSE. To investigate associations of small, hard macular drusen and larger macular drusen with obesity-related risk factors.
   METHODS. Cross-sectional study of 888 subjects aged 30 to 60 years characterized using anthropometric measurements and blood sample analyses. Physical activity was assessed by questionnaire. Digital grayscale fundus photographs were recorded in red-free illumination and graded for the presence of macular drusen > 63 mu m in either eye and the presence of 20 or more small, hard macular drusen as a mean of both eyes.
   RESULTS. Macular drusen > 63 mu m were associated with the level of physical activity, the age- and sex-adjusted odds ratio being 0.33 (95% confidence interval 0.13-0.82, P = 0.016) for participants who were physically active more than 7 hours/week compared with participants active 0 to 2 hours/week. In women, macular drusen > 63 mu m were associated with higher serum triglycerides (P = 0.0005). A waist circumference in the top quartile increased the odds for drusen > 63 mu m in men whereas in women, having a waist circumference in the middle quartiles reduced these odds. The presence of 20 or more small, hard macular drusen was associated with lower levels of serum high-density lipoprotein cholesterol (HDL; P 0.029) and with moderately elevated triglycerides.
   CONCLUSIONS. Precursors of AMD were associated with modifiable obesity-related risk factors; notably low physical activity with drusen > 63 mu m; and lower serum HDL and moderately elevated serum triglycerides with 20 or more small, hard macular drusen per eye. These findings support that a physically active, heart-healthy lifestyle prevents the earliest manifestation of AMD.
C1 [Munch, Inger Christine] Roskilde Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
   [Munch, Inger Christine; Linneberg, Allan; Larsen, Michael] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
   [Linneberg, Allan] Glostrup Cty Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
   [Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, Glostrup, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Munch, IC (通讯作者)，Roskilde Hosp, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM icm@dadlnet.dk
RI Munch, Inger Christine/E-9652-2010; Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891; Linneberg,
   Allan/0000-0002-0994-0184
FU Danish Medical Research Council; Danish Centre for Evaluation and Health
   Technology Assessment; Novo Nordisk; Copenhagen County; Danish Heart
   Foundation; Danish Diabetes Association; Danish Pharmaceutical
   Association; Augustinus Foundation; Ib Henriksen Foundation; Becket
   Foundation; Glaxo SmithKline; University of Copenhagen; Velux
   Foundation; Ojenforeningen
FX Supported by the Danish Medical Research Council, the Danish Centre for
   Evaluation and Health Technology Assessment, Novo Nordisk, Copenhagen
   County, the Danish Heart Foundation, the Danish Diabetes Association,
   the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib
   Henriksen Foundation, the Becket Foundation, Glaxo SmithKline, the
   University of Copenhagen, the Velux Foundation, and Ojenforeningen.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Engberg S, 2010, DIABETOLOGIA, V53, P70, DOI 10.1007/s00125-009-1587-1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jorgensen Torben, 2003, Eur J Cardiovasc Prev Rehabil, V10, P377
   Kessel L, 2004, ACTA OPHTHALMOL SCAN, V82, P19, DOI 10.1111/j.1395-3907.2004.0179.x
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   National Heart Lung and Blood Institute National Institutes of Health US Department of Health and Human Services, 2001, NIH PUBLICATION
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith LV, 2007, EUR J EPIDEMIOL, V22, P771, DOI 10.1007/s10654-007-9177-3
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 44
TC 36
Z9 37
U1 0
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2013
VL 54
IS 6
BP 3932
EP 3940
DI 10.1167/iovs.12-10785
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YW
UT WOS:000321120700014
PM 23652489
DA 2022-11-30
ER

PT J
AU Zhang, J
   Li, S
   Hu, SQ
   Yu, JG
   Xiang, Y
AF Zhang, Jun
   Li, Shuang
   Hu, Shuqiong
   Yu, Jiguo
   Xiang, Yi
TI Association between genetic variation of complement C3 and the
   susceptibility to advanced age-related macular degeneration: a
   meta-analysis
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; C3 gene; Polymorphism; Meta-analysis
ID GENOME-WIDE ASSOCIATION; FACTOR-H; COMPONENT 3; R102G POLYMORPHISM;
   RISK; VARIANT; DRUSEN; ACTIVATION; CFB; ALLELES
AB BackgroundThe purpose of this study is to discuss whether genetic variants (rs2230199, rs1047286, rs2230205, and rs2250656) in the C3 gene account for a significant risk of advanced AMD.MethodsWe performed a meta-analysis using electronic databases to search relevant articles. A total of 40 case-control studies from 38 available articles (20,673 cases and 20,025 controls) were included in our study.ResultsIn our meta-analysis, the pooled results showed that the carriage of G allele for rs2230199 and the T allele for rs1047286 had a tendency to the risk of advanced AMD (OR=1.49, 95% CI=1.39-1.59, P<0.001; OR=1.45, 95% CI=1.37-1.54, P<0.001). Moreover, in the subgroup analysis based on ethnicity, rs2230199 and rs1047286 polymorphisms were more likely to be a predictor of response for Caucasian region (OR=1.48, 95% CI=1.38-1.59, P<0.001; OR=1.45, 95% CI=1.37-1.54, P<0.001). Besides, pooled results suggested that the G allele of rs2230199 could confer susceptibility to advanced AMD in Middle East (OR=1.62, 95% CI=1.33-1.97, P<0.001).ConclusionIn our meta-analysis, C3 genetic polymorphisms unveiled a positive effect on the risk of advanced AMD, especially in Caucasians. Furthermore, numerous well-designed studies with large sample-size are required to validate this conclusion.
C1 [Zhang, Jun; Li, Shuang; Yu, Jiguo; Xiang, Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Ophthalmol, 26 Shengli St, Wuhan 430014, Hubei, Peoples R China.
   [Hu, Shuqiong] Jingzhou Aier Eye Hosp, Dept Ophthalmol, Jingzhou, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Xiang, Y (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Ophthalmol, 26 Shengli St, Wuhan 430014, Hubei, Peoples R China.
EM xyxyyanke@126.com
FU National Natural Science Foundation Project [81300761]; Key Project of
   Health and Family Planning Commission of Wuhan Municipality [WX18A08]
FX This work was supported by National Natural Science Foundation Project
   (81300761) and Key Project of Health and Family Planning Commission of
   Wuhan Municipality (WX18A08).
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P1, DOI [10.1080/13816810.2016.1275195, DOI 10.1080/13816810.2016.1275195]
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Contreras AV, 2014, MOL VIS, V20, P105
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Habibi I, 2017, KLIN MONATSBL AUGENH, V234, P478, DOI 10.1055/s-0043-104419
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Jaouni T, 2012, ARCH OPHTHALMOL-CHIC, V130, P987, DOI 10.1001/archophthalmol.2012.1483
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Little J, 2006, HUGENET HUGE REV HDB
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Losonczy G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050181
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Mckay GJ, 2010, MOL VIS, V16, P194
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
NR 64
TC 14
Z9 14
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 23
PY 2018
VL 18
AR 274
DI 10.1186/s12886-018-0945-5
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GX9ND
UT WOS:000448130000002
PM 30352574
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jehangir, N
   Mahmood, SMJ
   Mannis, T
   Moshirfar, M
AF Jehangir, Naz
   Mahmood, S. M. Jafar
   Mannis, Tova
   Moshirfar, Majid
TI Ocular dominance, coexistent retinal disease, and refractive errors in
   patients with cataract surgery
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE amblyopia; cataract; dominance; monovision
ID DIABETIC MACULAR EDEMA; AGE-RELATED MACULOPATHY; INTRAVITREAL
   BEVACIZUMAB INJECTION; PSEUDOPHAKIC MONOVISION; TRIAMCINOLONE ACETONIDE;
   NATURAL-HISTORY; LENS EXTRACTION; UNITED-STATES; EYE DISEASE; HIGH
   MYOPIA
AB Purpose of reviewThe purpose of this article is to highlight some common issues when planning cataract surgery in patients with preexisting ocular pathologies and to assess the role of ocular dominance in cataract surgery.Recent findingsIn addition to routine ocular examination, determination of ocular dominance and orthoptic evaluation for tropias, phorias, amblyopia, and diplopia can be helpful in planning for cataract surgery as these factors can affect postoperative outcomes. Although once controversial, cataract surgery by phacoemulsification is often a well tolerated and effective option for patients with coexistent retinal conditions including epiretinal membrane, age-related macular degeneration, diabetic retinopathy, and macular holes.SummaryIt is mandatory to recognize phorias, tropias, anisometropia, and amblyopia when planning cataract surgery. Visual potential, ocular dominance, refractive errors, and other retinal comorbidities influence cataract surgery planning and outcome.
C1 [Jehangir, Naz; Mannis, Tova; Moshirfar, Majid] Univ Calif San Francisco, Dept Ophthalmol, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
   [Mahmood, S. M. Jafar] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
C3 University of California System; University of California San Francisco;
   State University System of Florida; Florida Atlantic University
RP Moshirfar, M (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, Cornea & Refract Surg Div, Francis I Proctor Fdn, 10 Koret Way,K101, San Francisco, CA 94143 USA.
EM Majid.moshirfar@ucsf.edu
RI Moshirfar, Majid/AAG-8845-2021
OI Moshirfar, Majid/0000-0003-1024-6250
CR Alio J L, 1993, Eur J Ophthalmol, V3, P189
   American Academy of Ophthalmology Retina Panel, 2010, PREF PRACT PATT GUID
   Arevalo JF, 2014, CURR OPIN OPHTHALMOL, V25, P502, DOI 10.1097/ICU.0000000000000102
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Bandello F, 2012, EYE, V26, P485, DOI 10.1038/eye.2011.337
   Beauchamp GR, 2003, J AAPOS, V7, P233, DOI 10.1016/S1091-8531(03)00112-5
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Braun EHP, 2008, OPHTHALMOLOGY, V115, P1196, DOI 10.1016/j.ophtha.2007.09.018
   BROWN NAP, 1987, BRIT J OPHTHALMOL, V71, P405, DOI 10.1136/bjo.71.6.405
   Cheema RA, 2009, J CATARACT REFR SURG, V35, P18, DOI 10.1016/j.jcrs.2008.09.019
   Cheng CY, 2004, INVEST OPHTH VIS SCI, V45, P2856, DOI 10.1167/iovs.03-0878
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chew EY, 1999, ARCH OPHTHALMOL-CHIC, V117, P1600
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   DENATALE R, 1992, OPHTHALMOLOGICA, V205, P7, DOI 10.1159/000310303
   Fawcett SL, 2001, J AAPOS, V5, P342, DOI 10.1067/mpa.2001.119785
   Fernandez-Vega L, 2003, OPHTHALMOLOGY, V110, P2349, DOI 10.1016/S0161-6420(03)00794-2
   Fink WH, 1938, ARCH OPHTHALMOL-CHIC, V19, P555, DOI 10.1001/archopht.1938.00850160081005
   Funatsu H, 2002, J CATARACT REFR SURG, V28, P1355, DOI 10.1016/S0886-3350(02)01243-9
   Gobin L, 2008, J CATARACT REFR SURG, V34, P1353, DOI 10.1016/j.jcrs.2008.04.023
   Goldberg Damien F, 2011, Int Ophthalmol Clin, V51, P97, DOI 10.1097/IIO.0b013e31820f1f76
   Hale JE, 2006, BRIT J OPHTHALMOL, V90, P132, DOI 10.1136/bjo.2005.080689
   Handa T, 2005, J CATARACT REFR SURG, V31, P1588, DOI 10.1016/j.jcrs.2005.01.015
   Hayashi K, 2009, EYE, V23, P774, DOI 10.1038/eye.2008.161
   Heffez J, 2013, RETINA TODAY, P45
   Henderson BA, 2007, J CATARACT REFR SURG, V33, P1550, DOI 10.1016/j.jcrs.2007.05.013
   Hoshikawa R, 2013, STRABISMUS, V21, P110, DOI 10.3109/09273972.2013.786734
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Ito M, 2014, J CATARACT REFR SURG, V40, P1349, DOI 10.1016/j.jcrs.2013.11.038
   Ito M, 2012, J CATARACT REFR SURG, V38, P1440, DOI 10.1016/j.jcrs.2012.03.031
   Jahn CE, 2001, J CATARACT REFR SURG, V27, P753, DOI 10.1016/S0886-3350(00)00686-6
   Jain S, 1996, SURV OPHTHALMOL, V40, P491, DOI 10.1016/S0039-6257(96)82015-7
   Kim J, 2015, BRIT J OPHTHALMOL, V99, P391, DOI 10.1136/bjophthalmol-2014-305449
   Kim SH, 2007, J CATARACT REFR SURG, V30, P1721
   Kim SJ, 2007, OPHTHALMOLOGY, V114, P881, DOI 10.1016/j.ophtha.2006.08.053
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   la Cour M, 2002, ACTA OPHTHALMOL SCAN, V80, P579, DOI 10.1034/j.1600-0420.2002.800605.x
   Lahey JM, 2002, BRIT J OPHTHALMOL, V86, P876, DOI 10.1136/bjo.86.8.876
   Linke SJ, 2011, INVEST OPHTH VIS SCI, V52, P9166, DOI 10.1167/iovs.11-8131
   Lyle WA, 1996, J CATARACT REFR SURG, V22, P238, DOI 10.1016/S0886-3350(96)80225-2
   McGill E C, 1991, J Am Optom Assoc, V62, P738
   Murtha T, 2007, CURR OPIN OPHTHALMOL, V18, P13, DOI 10.1097/ICU.0b013e32801129fc
   Muselier A, 2010, AM J OPHTHALMOL, V150, P387, DOI 10.1016/j.ajo.2010.04.008
   Packard R, 2001, BRIT J OPHTHALMOL, V85, P1372, DOI 10.1136/bjo.85.11.1372
   Pollreisz A, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/608751
   Rajan MS, 2008, J CATARACT REFR SURG, V34, P76, DOI 10.1016/j.jcrs.2007.08.023
   Ripandelli G, 2003, OPHTHALMOLOGY, V110, P2355, DOI 10.1016/S0161-6420(03)00819-4
   Romero-Aroca P, 2006, J CATARACT REFR SURG, V32, P1438, DOI 10.1016/j.jcrs.2006.03.039
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Samuel Williams Gwyn, 2013, Ulster Med J, V82, P82
   SCHOR C, 1987, AM J OPTOM PHYS OPT, V64, P723
   Seijas O, 2007, AM J OPHTHALMOL, V144, P209, DOI 10.1016/j.ajo.2007.03.053
   Seward HC, 1998, BRIT J OPHTHALMOL, V82, P594, DOI 10.1136/bjo.82.6.594
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Simcock PR, 2000, ACTA OPHTHALMOL SCAN, V78, P684, DOI 10.1034/j.1600-0420.2000.078006684.x
   Squirrell D, 2002, BRIT J OPHTHALMOL, V86, P565, DOI 10.1136/bjo.86.5.565
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Takamura Y, 2009, OPHTHALMOLOGY, V116, P1151, DOI 10.1016/j.ophtha.2009.01.014
   Webber Ann L, 2005, Clin Exp Optom, V88, P365
   Zaidi Farhan, 2013, CATARACT SURG
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 64
TC 4
Z9 4
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JAN
PY 2016
VL 27
IS 1
BP 38
EP 44
DI 10.1097/ICU.0000000000000215
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CY4IP
UT WOS:000366372100006
PM 26632917
DA 2022-11-30
ER

PT J
AU Felipe, A
   Artigas, JM
   Gomez-Chova, J
   Garcia-Delpech, S
   Diaz-Llopis, M
AF Felipe, A.
   Artigas, J. M.
   Gomez-Chova, J.
   Garcia-Delpech, S.
   Diaz-Llopis, M.
TI Magnification of the retinal image through an intraocular Galilean
   telescope
SO JOURNAL OF MODERN OPTICS
LA English
DT Article
DE intraocular telescope; imaging eye; eye magnification
ID IMPLANTABLE MINIATURE TELESCOPE; CLOSED-CIRCUIT TELEVISION; MACULAR
   DEGENERATION; LOW-VISION; LENS SYSTEM; REHABILITATION; TECHNOLOGY;
   MAGNIFIER
AB The intraocular Galilean telescope is a good solution for incrementing the visual capabilities of patients with age-related macular degeneration. Nevertheless, some problems arise with the use of the intraocular telescopes available at present; these problems are originated by two main factors: the use of the same power values for the lenses in all types of eyes and the fact that the values of the distance between lenses into the eye are not the most suitable ones. As a result, a high residual refraction is produced in many implanted eyes. We propose a method for predicting outcomes in order to select patients for this technique and, moreover, for choosing the optimum power for the positive lens in the telescope in order to reach maximum values of magnification with minimum values of residual refraction.
C1 [Felipe, A.; Artigas, J. M.; Gomez-Chova, J.] Univ Valencia, Dept Opt, Fac Phys, Valencia, Spain.
   [Felipe, A.; Artigas, J. M.] FOM, Valencia, Spain.
   [Garcia-Delpech, S.; Diaz-Llopis, M.] Hosp Univ La Fe, Valencia, Spain.
   [Diaz-Llopis, M.] Univ Valencia, Fac Med, Dept Surg, Valencia, Spain.
C3 University of Valencia; Hospital Universitari i Politecnic La Fe;
   University of Valencia
RP Felipe, A (通讯作者)，Univ Valencia, Dept Opt, Fac Phys, Valencia, Spain.
EM adelina.felipe@uv.es
OI GARCIA-DELPECH, SALVADOR/0000-0002-6016-9284
FU Catedra Alcon-Universitat de Valencia
FX The study was partially funded by Catedra Alcon-Universitat de Valencia.
CR Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Faye E. E., 1976, CLIN LOW VISION
   Felipe A, 2007, J CATARACT REFR SURG, V33, P1781, DOI 10.1016/j.jcrs.2007.05.032
   FOWLER C, 1993, OPHTHAL PHYSL OPT, V13, P95, DOI 10.1111/j.1475-1313.1993.tb00432.x
   Goodrich G L, 2001, Optometry, V72, P519
   GOTTLOB H, 1984, MAGNIFYING VISUAL AI
   Harland S, 1998, OPTOMETRY VISION SCI, V75, P183, DOI 10.1097/00006324-199803000-00023
   Harper R, 1999, BRIT J OPHTHALMOL, V83, P495, DOI 10.1136/bjo.83.4.495
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Kaskaloglu M, 2001, J CATARACT REFR SURG, V27, P1751, DOI 10.1016/S0886-3350(01)00976-2
   KEATING MP, 1988, GEOMETRIC PHYS VISUA
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Lane SS, 2006, CURR OPIN OPHTHALMOL, V17, P94, DOI 10.1097/01.icu.0000193067.86627.a1
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   LOWE JB, 1990, OPHTHAL PHYSL OPT, V10, P225, DOI 10.1111/j.1475-1313.1990.tb00856.x
   Ortiz A, 1999, OPTOMETRY VISION SCI, V76, P755, DOI 10.1097/00006324-199911000-00024
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   SAFIR A, 1980, REFRACTION CLIN OPTI
   Uslan MM, 1996, J VISUAL IMPAIR BLIN, V90, P465
NR 23
TC 1
Z9 1
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0950-0340
J9 J MOD OPTIC
JI J. Mod. Opt.
PY 2010
VL 57
IS 2
SI SI
BP 152
EP 158
DI 10.1080/09500340902912910
PG 7
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 561QL
UT WOS:000274993400009
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Nitoda, E
AF Moschos, Marilita M.
   Nitoda, Eirini
TI The Role of mf-ERG in the Diagnosis and Treatment of Age-Related Macular
   Degeneration: Electrophysiological Features of AMD
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; diagnosis; electrophysiology;
   multifocal electroretinogram; treatment
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; OPTICAL COHERENCE TOMOGRAPHY;
   SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL-EVOKED POTENTIALS;
   RETINAL FUNCTION; PHOTODYNAMIC THERAPY; FOCAL ELECTRORETINOGRAMS; 2.0
   MG; RANIBIZUMAB; MACULOPATHY
AB Introduction: Age-related macular cegeneration (AMD) is the leading cause of visual dysfunction worldwide, affecting 9-25% of individuals between 65 and 75 years old. Methods: We have reviewed the published articles investigating the role of multifocal electroretinogram (mf-ERG) in the diagnosis and treatment of AMD. Results: Visual evoked potentials have revealed decreased amplitudes and higher latencies in patients with AMD, while the degeneration of photoreceptors and abnormalities of retinal pigment epithelium can be identified by electro-oculogram recordings. Moreover, ERG can detect the functional abnormalities observed in AMD and evaluate each therapeutic approach. The record of local electrophysiological responses coming from different retinal areas can be accurately performed by mfERG. Conclusion: The accuracy of mfERG in detecting the degeneration of photoreceptors, as well the disturbances of macular function, could be useful both in the early diagnosis of AMD and the assessment of treatment efficacy.
C1 [Moschos, Marilita M.; Nitoda, Eirini] Natl & Kapodistrian Univ Athens, Med Sch, Dept Ophthalmol 1, Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Moschos, MM (通讯作者)，Natl & Kapodistrian Univ Athens, Med Sch, Dept Ophthalmol 1, Ophthalmol, 6 Ikarias St, Athens 14578, Greece.
EM moschosmarilita@yahoo.fr
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   BIRCH DG, 1993, AM J OPHTHALMOL, V116, P148, DOI 10.1016/S0002-9394(14)71278-4
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Catalá-Mora J, 2005, Arch Soc Esp Oftalmol, V80, P395
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Chin MP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123480
   Creel DJ, WEBVISION ORG RETINA
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Fischer N, 2013, CLIN OPHTHALMOL, V7, P621, DOI 10.2147/OPTH.S42881
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Herbik A, 2014, OPHTHAL PHYSL OPT, V34, P540, DOI 10.1111/opo.12152
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P225, DOI 10.1097/00041327-200309000-00008
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Johnson TM, 2002, CLIN RETINA, P86
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kanski J., 2007, CLIN OPHTHALMOLOGY S
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kojima M, 2012, EUR J OPHTHALMOL, V22, P412, DOI 10.5301/ejo.5000031
   Kozak I, 2006, BRIT J OPHTHALMOL, V90, P1152, DOI 10.1136/bjo.2006.095141
   Lipski A, 2007, RETINA-J RET VIT DIS, V27, P864, DOI 10.1097/IAE.0b013e318154b9b9
   Liu Y, 2009, DOC OPHTHALMOL, V119, P163, DOI 10.1007/s10633-009-9189-2
   Mackay AM, 2008, DOC OPHTHALMOL, V116, P13, DOI 10.1007/s10633-007-9071-z
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P1, DOI 10.1007/s10633-006-9032-y
   Moschos MM, 2011, CLIN EXP OPTOM, V94, P268, DOI 10.1111/j.1444-0938.2011.00589.x
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Nemoto N, 2002, JPN J OPHTHALMOL, V46, P108, DOI 10.1016/S0021-5155(01)00456-7
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nitoda E, 2014, EXPERT OPIN THER TAR, V18, P987, DOI 10.1517/14728222.2014.930439
   Obata R, 2006, JPN J OPHTHALMOL, V50, P479, DOI 10.1007/s10384-006-0355-8
   Park Joo Youn, 2011, Korean J Ophthalmol, V25, P161, DOI 10.3341/kjo.2011.25.3.161
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Perlman Ido, 2001, Documenta Ophthalmologica, V102, P41, DOI 10.1023/A:1017539308389
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pirozzi E, 2006, ACTA OPHTHALMOL SCAN, V84, P27, DOI 10.1111/j.1600-0420.2005.00529.x
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabeti F, 2013, DOC OPHTHALMOL, V126, P125, DOI 10.1007/s10633-012-9366-6
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
   Tsuchihashi T, 2009, RETINA-J RET VIT DIS, V29, P1450, DOI 10.1097/IAE.0b013e3181ac2403
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vottonen P, 2015, ACTA OPHTHALMOL, V93, P621, DOI 10.1111/aos.12774
   Vottonen P, 2013, CLIN OPHTHALMOL, V7, P437, DOI 10.2147/OPTH.S40427
   Walter P, 2000, OPHTHALMOLOGICA, V214, P312, DOI 10.1159/000027512
   Wang Z, 1999, Zhonghua Yan Ke Za Zhi, V35, P430
   Wood A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096742
   Wu KHC, 2005, DOC OPHTHALMOL, V110, P237, DOI 10.1007/s10633-005-0649-z
   Wu L Z, 1991, Zhonghua Yan Ke Za Zhi, V27, P197
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
NR 79
TC 10
Z9 11
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 4
BP 461
EP 469
DI 10.1080/08820538.2017.1301496
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH6JW
UT WOS:000433551400004
PM 28328288
DA 2022-11-30
ER

PT J
AU Williams, AJ
   Fekrat, S
AF Williams, Adrienne J.
   Fekrat, Sharon
TI Progression of choroidal neovascularization following injection of
   pegaptanib sodium (Macugen) in two eyes with neovascular age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC-RETINOPATHY; OCCULT; LESIONS
AB PURPOSE: To describe two cases of neovascular aged related macular degeneration (AMD) that progressed despite a single intravitreal injection of pegaptanib sodium (Macugen) six weeks earlier.
   DESIGN: Interventional case report.
   METHODS: A 62,year old man and a 76,year old woman with occult and minimally classic lesions, respectively, each received a single injection of intravitreal pegaptanib.
   RESULTS: Within six weeks of an intravitreal pegaptanib injection, the choroidal neovascularization (CNV) progressed. In one eye, the chronic occult lesion developed subfoveal classic CNV. In the other eye, the classic component of the minimally classic lesion tripled in size.
   CONCLUSIONS: A single dose of intravitreal pegaptanib was not effective in these two patients at six weeks. This report reminds the ophthalmologist to consider obtaining a fluorescein angiogram during follow-up after an intravitreal pegaptanib injection to monitor CNV lesion characteristics, particularly if the visual acuity decreases.
C1 Duke Univ, Ctr Eye, Ctr Med, Albert Eye Res Inst, Durham, NC 27710 USA.
C3 Duke University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, Ctr Med, Albert Eye Res Inst, Box 3802, Durham, NC 27710 USA.
EM fekra001@mc.duke.edu
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 7
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2006
VL 142
IS 4
BP 683
EP 685
DI 10.1016/j.ajo.2006.04.032
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092LS
UT WOS:000241098900027
PM 17011868
DA 2022-11-30
ER

PT J
AU Liu, X
   Chen, JM
   Liu, Z
   Li, J
   Yao, K
   Wu, YL
AF Liu, Xin
   Chen, Jingmeng
   Liu, Zhe
   Li, Jie
   Yao, Ke
   Wu, Yalin
TI Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant
   Metabolism of Retinoids
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE retinoid visual cycle; retinoids; metabolism; visual chromophores;
   photoreceptor; gene therapy; retinylamine; RPE65; retinal pigment
   epithelium
ID LEBER-CONGENITAL-AMAUROSIS; CASSETTE TRANSPORTER ABCA4; HUMAN
   GENE-THERAPY; BINDING-PROTEIN 4; RETINYLIDENE-N-RETINYLETHANOLAMINE;
   PIGMENT EPITHELIAL-CELLS; VITAMIN-A METABOLISM; NERVE-FIBER LAYER; RCS
   RAT MODEL; MOUSE MODEL
AB The retinoid (visual) cycle is a complex enzymatic pathway that operates in the retina for the regeneration of 11-cis-retinal (11-cis-Ral), the inherent visual chromophore indispensable for vision. Deficiencies in the retinoid metabolism are involved in pathologic mechanisms of several forms of retinal diseases including age-related macular degeneration, Stargardt's disease, and Leber's congenital amaurosis, for which no effective cures presently exist. Nevertheless, the interference of abnormal retinoid metabolism with chemicals has been considered to be a promising strategy aimed at alleviating these retinal dysfunctions. Moreover, since gene therapy is gaining increasing importance in clinical practice, the modulation of key enzymes implicated with the retinoid cycle at a genetic level will hold great promise for the treatment of patients with degenerative diseases of the retina.
C1 [Liu, Xin; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Eye Ctr, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
   [Chen, Jingmeng] Zhejiang Univ City Coll, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Liu, Zhe] Zhejiang Prov Peoples Hosp, Dept Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
   [Li, Jie] Taizhou First Peoples Hosp, Taizhou, Zhejiang, Peoples R China.
   [Wu, Yalin] Xiamen Univ, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiangan South Rd, Xiamen 361102, Fujian Province, Peoples R China.
C3 Zhejiang University; Zhejiang University City College; Zhejiang
   Provincial People's Hospital; Xiamen University
RP Yao, K (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Eye Ctr, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.; Wu, YL (通讯作者)，Xiamen Univ, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiangan South Rd, Xiamen 361102, Fujian Province, Peoples R China.
EM xlren@zju.edu.cn; yalinw@xmu.edu.cn
RI Yao, Ke/AAM-6866-2021
OI Li, Jie/0000-0001-5463-3995; Yao, Ke/0000-0002-6764-7365
FU China National Natural Science Foundation [81570857, 81271018];
   Fundamental Research Funds for the Central Universities; Zhejiang Key
   Laboratory Funds of China [2011E10006]
FX Supported in part by China National Natural Science Foundation Grants
   81570857 (YW) and 81271018 (YW); the Fundamental Research Funds for the
   Central Universities grant (YW); and Zhejiang Key Laboratory Funds of
   China Grant 2011E10006 (KY).
CR Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200
   Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   ADAMS WR, 1995, P SOC EXP BIOL MED, V208, P178, DOI 10.3181/00379727-208-43849
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Banin E, 2010, HUM GENE THER, V21, P1749, DOI 10.1089/hum.2010.047
   Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Berkowitz BA, 2012, MOL VIS, V18, P372
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Biswas-Fiss EE, 2012, J BIOL CHEM, V287, P44097, DOI 10.1074/jbc.M112.409623
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Cai X, 2010, FASEB J, V24, P1178, DOI 10.1096/fj.09-139147
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   Chen CH, 2002, BIOPHYS J, V83, P1403, DOI 10.1016/S0006-3495(02)73911-8
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Cioffi CL, 2014, J MED CHEM, V57, P7731, DOI 10.1021/jm5010013
   Colella P, 2009, TRENDS MOL MED, V15, P23, DOI 10.1016/j.molmed.2008.11.003
   CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x
   Decensi A, 1997, EUR J CANCER, V33, P80, DOI 10.1016/S0959-8049(96)00351-6
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   den Hollander AI, 2010, J CLIN INVEST, V120, P3042, DOI 10.1172/JCI42258
   Deng WT, 2012, INVEST OPHTH VIS SCI, V53, P1895, DOI 10.1167/iovs.11-8831
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fan J, 2003, P NATL ACAD SCI USA, V100, P13662, DOI 10.1073/pnas.2234461100
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Chacon-Camacho OF, 2015, WORLD J CLIN CASES, V3, P112, DOI 10.12998/wjcc.v3.i2.112
   FRAUNFELDER FT, 1985, AM J OPHTHALMOL, V100, P534, DOI 10.1016/0002-9394(85)90676-2
   Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0
   GAMEL JW, 1993, ARCH OPHTHALMOL-CHIC, V111, P1462, DOI 10.1001/archopht.1993.01090110018006
   Gao SQ, 2012, INVEST OPHTH VIS SCI, V53, P6314, DOI 10.1167/iovs.12-10279
   Gearhart PM, 2010, ARCH OPHTHALMOL-CHIC, V128, P1442, DOI 10.1001/archophthalmol.2010.210
   Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Golczak M, 2010, METHODS MOL BIOL, V652, P229, DOI 10.1007/978-1-60327-325-1_13
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   Gorbatyuk M, 2007, EXP EYE RES, V84, P44, DOI 10.1016/j.exer.2006.08.014
   Gorbatyuk MS, 2005, MOL VIS, V11, P648
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HUBBARD R, 1958, P NATL ACAD SCI USA, V44, P130, DOI 10.1073/pnas.44.2.130
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Khan MA, 2015, RETINA-J RET VIT DIS, V35, P165, DOI 10.1097/IAE.0000000000000447
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Koenekoop RK, 2014, LANCET, V384, P1513, DOI 10.1016/S0140-6736(14)60153-7
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   LaVail MM, 2000, P NATL ACAD SCI USA, V97, P11488, DOI 10.1073/pnas.210319397
   LAW WC, 1989, BIOCHEM BIOPH RES CO, V161, P825, DOI 10.1016/0006-291X(89)92674-0
   Le Meur G, 2007, GENE THER, V14, P292, DOI 10.1038/sj.gt.3302861
   Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Li J, 2013, J BIOL CHEM, V288, P35671, DOI 10.1074/jbc.M113.511386
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, P314, DOI 10.1097/00006982-200603000-00010
   Liu HT, 2015, J BIOL CHEM, V290, P21568, DOI 10.1074/jbc.M115.655555
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2013, INVEST OPHTH VIS SCI, V54, P455, DOI 10.1167/iovs.12-11152
   Maeda T, 2011, MOL PHARMACOL, V80, P943, DOI 10.1124/mol.111.074732
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4368, DOI 10.1167/iovs.09-3700
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mandal MNA, 2011, J BIOL CHEM, V286, P32491, DOI 10.1074/jbc.M111.255877
   Mao HY, 2012, HUM GENE THER, V23, P356, DOI 10.1089/hum.2011.213
   Mao HY, 2011, HUM GENE THER, V22, P567, DOI 10.1089/hum.2010.140
   Mata JR, 1998, J LIPID RES, V39, P604
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   McCarthy NEM, 2000, BIOCHEM J, V347, P163, DOI 10.1042/0264-6021:3470163
   Millington-Ward S, 2011, MOL THER, V19, P642, DOI 10.1038/mt.2010.293
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Molday, 2000, Am J Ophthalmol, V130, P689, DOI 10.1016/S0002-9394(00)00756-X
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Molday RS, 2009, BBA-MOL CELL BIOL L, V1791, P573, DOI 10.1016/j.bbalip.2009.02.004
   Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200
   Narfstrom K, 2008, ADV EXP MED BIOL, V613, P139
   Narfstrom K, 2005, DOC OPHTHALMOL, V111, P39, DOI [10.1007/s10633-005-3159-0, 10.1007/S10633-005-3159-0]
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   NOBLE KG, 1979, ARCH OPHTHALMOL-CHIC, V97, P1281
   NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Orban T, 2011, J BIOL CHEM, V286, P17248, DOI 10.1074/jbc.M110.195198
   Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d
   Palczewski K, 2010, ARCH OPHTHALMOL-CHIC, V128, P1483, DOI 10.1001/archophthalmol.2010.245
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Palfi A, 2010, HUM GENE THER, V21, P311, DOI 10.1089/hum.2009.119
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   PECK GL, 1979, NEW ENGL J MED, V300, P329, DOI 10.1056/NEJM197902153000701
   PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609
   Perusek Lindsay, 2015, Methods Mol Biol, V1271, P345, DOI 10.1007/978-1-4939-2330-4_22
   Perusek L, 2013, NUTRIENTS, V5, P2646, DOI 10.3390/nu5072646
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Puntel A, 2015, BIOMATERIALS, V44, P103, DOI 10.1016/j.biomaterials.2014.12.019
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Ripps H, 2000, VISUAL NEUROSCI, V17, P97, DOI 10.1017/S095252380017110X
   Roosing S, 2014, J MED GENET, V51, P143, DOI 10.1136/jmedgenet-2013-102138
   Rotenstreich Y, 2013, JAMA OPHTHALMOL, V131, P985, DOI 10.1001/jamaophthalmol.2013.147
   Rotenstreich Y, 2010, BRIT J OPHTHALMOL, V94, P616, DOI 10.1136/bjo.2009.167049
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697
   SCHAFFER EM, 1993, J NUTR, V123, P1497, DOI 10.1093/jn/123.9.1497
   Sekeryapan B, 2013, INT OPHTHALMOL, V33, P481, DOI 10.1007/s10792-013-9726-6
   Sheffield VC, 2011, NEW ENGL J MED, V364, P1932, DOI 10.1056/NEJMra1012354
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sullivan JM, 2009, EXP EYE RES, V89, P602, DOI 10.1016/j.exer.2009.03.005
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Ucak H, 2014, J CUTAN MED SURG, V18, P236, DOI 10.2310/7750.2013.13168
   Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297
   Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wald G, 1935, J GEN PHYSIOL, V19, P351, DOI 10.1085/jgp.19.2.351
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wang YC, 2014, BIOORG MED CHEM LETT, V24, P2885, DOI 10.1016/j.bmcl.2014.04.089
   WELEBER RG, 1986, ARCH OPHTHALMOL-CHIC, V104, P831
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wolf G, 1999, NUTR REV, V57, P258
   Wu YL, 2014, BIOCHEM J, V460, P343, DOI 10.1042/BJ20140089
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yu GP, 2014, BIOMACROMOLECULES, V15, P4570, DOI 10.1021/bm501352s
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhang JY, 2015, MOL PHARMACOL, V87, P477, DOI 10.1124/mol.114.096560
   Zhao JL, 2014, INVEST OPHTH VIS SCI, V55, P8241, DOI 10.1167/iovs.14-15709
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 183
TC 11
Z9 11
U1 0
U2 24
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2016
VL 57
IS 3
BP 1017
EP 1030
DI 10.1167/iovs.15-18429
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK4BE
UT WOS:000374860600036
PM 26962698
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Cai, X
   McGinnis, JF
AF Cai, Xue
   McGinnis, James F.
TI Oxidative stress: The achilles' heel of neurodegenerative diseases of
   the retina
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Age-related macular degeneration; Mechanism; Risk factors; Animal
   models; Therapies; Reactive oxygen species; Nanoceria;
   Neovascularization; Review
ID DENSITY LIPOPROTEIN RECEPTOR; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT
   FACTOR-H; PIGMENTED EPITHELIAL-CELLS; MEMBRANE ATTACK COMPLEX; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; MOUSE MODEL; LIPOFUSCIN
   ACCUMULATION; SUBRETINAL NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness among adults in the developed countries. It is characterized by the progressive loss of central vision. AMD is classified into two forms: dry and wet. Dry AMD involves the accumulation of deposits in the RPE and Bruch's membrane; Wet AMD is characterized by neovascularization in the choroid. Whether the two forms of AMD share the same mechanism for the disease development is presently not clear. Oxidative stress, inflammation, and ER-stress are the common modes for the pathogenesis of AMD. In addition, other risk factors and several signaling pathways have been implicated as causative factors of AMD. In this paper, the mechanisms underlying AMD, risk factors involved in the pathology, representative animal models, and therapeutic treatment strategies are reviewed.
C1 [McGinnis, James F.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean McGee Eye Inst,Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [McGinnis, James F.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP McGinnis, JF (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean McGee Eye Inst,Dept Cell Biol, Oklahoma City, OK 73104 USA.
EM james-mcginnis@ouhsc.edu
FU NIH [P30-EY12190, COBRE-P20 RR017703, R21EY018306, R01EY018724]; FFB
   [C-NP-0707-0404-UOK08]; NSF [CBET-0708172]; OCAST [HR06-075];
   Presbyterian Health Foundation; Research to Prevent Blindness (RPB);
   NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R21EY018306, P30EY012190, R01EY022111,
   R01EY018724, P30EY021725] Funding Source: NIH RePORTER
FX This review was supported in part by grants from: NIH (P30-EY12190,
   COBRE-P20 RR017703, R21EY018306 and R01EY018724); FFB
   (C-NP-0707-0404-UOK08; NSF: CBET-0708172 and OCAST: HR06-075), and
   unrestricted funds from Presbyterian Health Foundation and Research to
   Prevent Blindness (RPB). JFM is a recipient of an RPB Senior Scientific
   Investigator Award.
CR Afzal A, 2010, BRAIN RES BULL, V81, P320, DOI 10.1016/j.brainresbull.2009.08.001
   Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhise NS, 2011, EXPERT OPIN DRUG DEL, V8, P485, DOI 10.1517/17425247.2011.558082
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   Bonomini F, 2010, EXP GERONTOL, V45, P149, DOI 10.1016/j.exger.2009.11.006
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Caputo M, 2011, CURR DRUG TARGETS, V12, P234, DOI 10.2174/138945011794182791
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen J, 2008, ADV EXP MED BIOL, V613, P53, DOI 10.1007/978-0-387-74904-4_5
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dias J. R., 2011, BR J OPHTHALMOL
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Ellis-Behnke R, 2011, ACTA OPHTHALMOL, V89, pE108, DOI 10.1111/j.1755-3768.2010.01982.x
   Enseleit F, 2010, CURR HYPERTENS REP, V12, P33, DOI 10.1007/s11906-009-0082-x
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedlander M, 2009, RETINA-J RET VIT DIS, V29, pS27, DOI 10.1097/IAE.0b013e3181ad2673
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Gridley T, 2010, CURR TOP DEV BIOL, V92, P277, DOI 10.1016/S0070-2153(10)92009-7
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7
   Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heckert EG, 2008, BIOMATERIALS, V29, P2705, DOI 10.1016/j.biomaterials.2008.03.014
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hou HY, 2010, MOL THER, V18, P1837, DOI 10.1038/mt.2010.144
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Karakoti AS, 2009, J AM CHEM SOC, V131, P14144, DOI 10.1021/ja9051087
   Karan G, 2005, MOL VIS, V11, P657
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lau LI, 2010, INVEST OPHTH VIS SCI, V51, P5486, DOI 10.1167/iovs.10-5663
   Lecomte J, 2011, CELL MOL LIFE SCI, V68, P677, DOI 10.1007/s00018-010-0476-6
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Link N, 2007, BIOTECHNOL BIOENG, V98, P1083, DOI 10.1002/bit.21525
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchetti V, 2010, J CLIN INVEST, V120, P3012, DOI 10.1172/JCI42951
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Medicherla B, 2008, J CELL BIOL, V182, P663, DOI 10.1083/jcb.200803022
   Mittag TW, 1999, EXP EYE RES, V69, P677, DOI 10.1006/exer.1999.0748
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Nagineni C. N., 2011, J CELL PHYSL
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Osborne NN, 2010, NEUROCHEM RES, V35, P2027, DOI 10.1007/s11064-010-0273-5
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Perez JM, 2008, SMALL, V4, P552, DOI 10.1002/smll.200700824
   Pierscionek BK, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/3/035102
   Plafker KS, 2010, J BIOL CHEM, V285, P23062, DOI 10.1074/jbc.M110.121913
   Plafker SM, 2010, ADV EXP MED BIOL, V664, P447, DOI 10.1007/978-1-4419-1399-9_51
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Prasad AS, 2009, J AM COLL NUTR, V28, P257, DOI 10.1080/07315724.2009.10719780
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rowland T. J., 2011, J CELL PHYSL
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   Shimazawa M, 2007, MOL VIS, V13, P578
   Silva GA, 2011, CURR STEM CELL RES T, V6, P255
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Suzuki M, 2007, MOL VIS, V13, P772
   Takahashi H, 2008, INVEST OPHTH VIS SCI, V49, P2143, DOI 10.1167/iovs.07-0523
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsunekawa S, 1999, APPL SURF SCI, V152, P53, DOI 10.1016/S0169-4332(99)00298-6
   Tuo J., 2011, NEUROBIOL AGING
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707
   Vincent A, 2010, LANGMUIR, V26, P7188, DOI 10.1021/la904285g
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Winkler BS, 1999, MOL VIS, V5
   Wong L. L., 2011, PHARMACOKINETICS EFF
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Wu WC, 2010, MOL VIS, V16, P1864
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhao L, 2008, AM J HEALTH-SYST PH, V65, P1232, DOI 10.2146/ahjp080052
   Zheng MH, 2010, J GENET GENOMICS, V37, P573, DOI 10.1016/S1673-8527(09)60077-1
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 161
TC 46
Z9 50
U1 1
U2 27
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2012
VL 17
BP 1976
EP 1995
DI 10.2741/4033
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 889DT
UT WOS:000300054400028
PM 22201850
DA 2022-11-30
ER

PT J
AU Dou, GR
   Wang, L
   Wang, YS
   Han, H
AF Dou, Guo-Rui
   Wang, Lin
   Wang, Yu-Sheng
   Han, Hua
TI Notch Signaling in Ocular Vasculature Development and Diseases
SO MOLECULAR MEDICINE
LA English
DT Article
ID ENDOTHELIAL PROGENITOR CELLS; TRANSCRIPTION FACTOR HESR1; INHIBITS
   TUMOR-GROWTH; TIP CELLS; IN-VITRO; BRANCHING MORPHOGENESIS; RETINAL
   ANGIOGENESIS; NEGATIVE REGULATOR; UP-REGULATION; MOUSE RETINA
AB Ocular angiogenesis, characterized by the formation of new blood vessels in the avascular area in eyes, is a highly coordinated process involved in retinal vasculature formation and several ocular diseases such as age-related macular degeneration, proliferative diabetic retinopathy and retinopathy of prematurity. This process is orchestrated by complicated cellular interactions and vascular growth factors, during which endothelial cells acquire heterogeneous phenotypes and distinct cellular destinations. To date, while the vascular endothelial growth factor has been identified as the most critical angiogenic agent with a remarkable therapeutic value, the Notch signaling pathway appears to be a similarly important regulator in several angiogenic steps. Recent progress has highlighted the involvement, mechanisms and therapeutic potential of Notch signaling in retinal vasculature development and pathological angiogenesis-related eye disorders, which may cause irreversible blindness.
C1 [Dou, Guo-Rui; Wang, Yu-Sheng] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Wang, Lin] Xijing Hosp, Dept Hepat Surg, Xian, Peoples R China.
   [Dou, Guo-Rui; Wang, Lin; Han, Hua] Fourth Mil Med Univ, Dept Med Genet & Dev Biol, Xian 710032, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University
RP Wang, YS (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
EM wangys@fmmu.edu.cn; huahan@fmmu.edu.cn
FU Ministry of Science and Technology of China [2011CB510200, 2009CB521706,
   2011ZXJ09101-02C]; National Natural Science Foundation of China (NSFC)
   [30872818, 30830067]; Natural Science of Shaanxi Province [2011K12-46,
   XJZT11M03]
FX This work was supported by grants from the Ministry of Science and
   Technology of China (2011CB510200, 2009CB521706, 2011ZXJ09101-02C),
   National Natural Science Foundation of China (NSFC) (30872818, 30830067)
   and Natural Science of Shaanxi Province (2011K12-46, XJZT11M03).
CR Ables JL, 2011, NAT REV NEUROSCI, V12, P269, DOI 10.1038/nrn3024
   Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Alev C, 2011, ANTIOXID REDOX SIGN, V15, P949, DOI 10.1089/ars.2010.3872
   Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940
   Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Cao L, 2010, BIOMATERIALS, V31, P9048, DOI 10.1016/j.biomaterials.2010.08.002
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   Carlson TR, 2005, P NATL ACAD SCI USA, V102, P9884, DOI 10.1073/pnas.0504391102
   Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Claxton S, 2004, GENE EXPR PATTERNS, V5, P123, DOI 10.1016/j.modgep.2004.05.004
   De Smet F, 2009, ARTERIOSCL THROM VAS, V29, P639, DOI 10.1161/ATVBAHA.109.185165
   del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819
   Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009
   Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493
   Djokovic D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-641
   Dong X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018481
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com
   Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949
   Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Friedlander Martin, 2007, Angiogenesis, V10, P89, DOI 10.1007/s10456-007-9070-4
   Funahashi Y, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-2
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Grego-Bessa J, 2007, DEV CELL, V12, P415, DOI 10.1016/j.devcel.2006.12.011
   Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184
   Gridley T, 2010, CURR TOP DEV BIOL, V92, P277, DOI 10.1016/S0070-2153(10)92009-7
   Hainaud P, 2006, CANCER RES, V66, P8501, DOI 10.1158/0008-5472.CAN-05-4226
   Han SY, 2011, STEM CELLS, V29, P217, DOI 10.1002/stem.576
   Harrington LS, 2008, MICROVASC RES, V75, P144, DOI 10.1016/j.mvr.2007.06.006
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200
   Hofmann JJ, 2007, GENE EXPR PATTERNS, V7, P461, DOI 10.1016/j.modgep.2006.11.002
   Hu YY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-82
   Iso T, 2006, BIOCHEM BIOPH RES CO, V341, P708, DOI 10.1016/j.bbrc.2006.01.020
   Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Jakobsson L, 2009, BIOCHEM SOC T, V37, P1233, DOI 10.1042/BST0371233
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kalen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018709
   Kent D, 2003, MOL VIS, V9, P747
   KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8
   Kikuchi R, 2011, LAB INVEST, V91, P691, DOI 10.1038/labinvest.2011.5
   Kim Ben J, 2007, Semin Ophthalmol, V22, P205, DOI 10.1080/08820530701745108
   Kim JH, 2009, J NEUROSCI RES, V87, P653, DOI 10.1002/jnr.21884
   Kinnunen K, 2011, ANN MED         0201
   Komine O, 2011, DEV BIOL, V354, P44, DOI 10.1016/j.ydbio.2011.03.020
   Krebs LT, 2000, GENE DEV, V14, P1343
   Krueger J, 2011, DEVELOPMENT, V138, P2111, DOI 10.1242/dev.063933
   Kwon SM, 2008, CIRCULATION, V118, P157, DOI 10.1161/CIRCULATIONAHA.107.754978
   Kwon SM, 2009, TRENDS CARDIOVAS MED, V19, P170, DOI 10.1016/j.tcm.2009.10.002
   Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   Li B, 2006, MICROVASC RES, V72, P146, DOI 10.1016/j.mvr.2006.07.002
   Li FF, 2011, DEV CELL, V20, P291, DOI 10.1016/j.devcel.2011.01.011
   Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969
   Liu H, 2010, CIRC RES, V107, P860, DOI 10.1161/CIRCRESAHA.110.218271
   Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846
   Liu ZJ, 2006, FASEB J, V20, P1009, DOI 10.1096/fj.05-4880fje
   Liu ZY, 2011, J CLIN INVEST, V121, P800, DOI 10.1172/JCI43114
   Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Lobov IB, 2011, BLOOD, V117, P6728, DOI 10.1182/blood-2010-08-302067
   Morello CA, 2007, AM J HEALTH-SYST PH, V64, pS3, DOI 10.2146/ajhp070330
   Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004
   Ohlmann A, 2010, J NEUROSCI, V30, P183, DOI 10.1523/JNEUROSCI.3210-09.2010
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pfister F, 2008, DIABETES, V57, P2495, DOI 10.2337/db08-0325
   Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015
   Phng LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009
   Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365
   Real C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018323
   Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Sainson RCA, 2005, FASEB J, V19, P1027, DOI 10.1096/fj.04-3172fje
   Sainson RCA, 2008, ANGIOGENESIS, V11, P41, DOI 10.1007/s10456-008-9098-0
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Sawamiphak S, 2010, NATURE, V465, P487, DOI 10.1038/nature08995
   Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood-2007-11-126045
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Shawber CJ, 2007, J CLIN INVEST, V117, P3369, DOI 10.1172/JCI24311
   Siekmann AF, 2008, BIOESSAYS, V30, P303, DOI 10.1002/bies.20736
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443
   Uemura AK, 2006, EXP CELL RES, V312, P676, DOI 10.1016/j.yexcr.2005.10.030
   Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5
   von Tell D, 2006, EXP CELL RES, V312, P623, DOI 10.1016/j.yexcr.2005.10.019
   Walshe TE, 2011, INVEST OPHTH VIS SCI, V52, P4472, DOI 10.1167/iovs.10-7061
   Wang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007572
   Wang L, 2009, HEPATOLOGY, V49, P268, DOI 10.1002/hep.22579
   Wang T, 2008, PROG BIOPHYS MOL BIO, V96, P499, DOI 10.1016/j.pbiomolbio.2007.07.006
   Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269
   Wei ZL, 2011, STROKE, V42, P2589, DOI 10.1161/STROKEAHA.111.614834
   Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751
   Zen AA, 2010, CIRC RES, V107, P283, DOI 10.1161/CIRCRESAHA.110.221663
   Zheng H, 2007, J CARDIOVASC PHARM, V50, P274, DOI 10.1097/FJC.0b013e318093ec8f
NR 115
TC 29
Z9 33
U1 0
U2 56
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD JAN
PY 2012
VL 18
IS 1
BP 47
EP 55
DI 10.2119/molmed.2011.00256
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 941KR
UT WOS:000303962600006
PM 21989947
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Azimipour, M
   Valente, D
   Vienola, KV
   Werner, JS
   Zawadzki, RJ
   Jonnal, RS
AF Azimipour, Mehdi
   Valente, Denise
   Vienola, Kari V.
   Werner, John S.
   Zawadzki, Robert J.
   Jonnal, Ravi S.
TI Optoretinogram: optical measurement of human cone and rod photoreceptor
   responses to light
SO OPTICS LETTERS
LA English
DT Article
ID COHERENCE TOMOGRAPHY; RETINAL PHYSIOLOGY; ADAPTIVE OPTICS;
   OPTOPHYSIOLOGY; OCT
AB Noninvasive, objective measurement of rod function is as significant as that of cone function, and for retinal diseases such as retinitis pigmentosa and age-related macular degeneration, rod function may be a more sensitive biomarker of disease progression and efficacy of treatment than cone function. Functional imaging of single human rod photoreceptors, however, has proven difficult because their small size and rapid functional response pose challenges for the resolution and speed of the imaging system. Here, we describe light-evoked, functional responses of human rods and cones, measured noninvasively using a synchronized. adaptive optics optical coherence tomography (OCT) and. scann ing light ophthalmoscopy (SW) system. The higher lateral resolution of the SW images made it possible to confirm the identity of rods in the corresponding OCT volumes. (C) 2020 Optical Society of America
C1 [Azimipour, Mehdi; Valente, Denise; Vienola, Kari V.; Werner, John S.; Zawadzki, Robert J.; Jonnal, Ravi S.] UC Davis Eye Ctr, Dept Ophthalmol & Vis Sci, Vis Sci & Adv Retinal Imaging Lab VSRI, Sacramento, CA 95817 USA.
   [Zawadzki, Robert J.] Univ Calif Davis, Dept Cell Biol & Human Anat, EyePod Smal & Anim Ocular Imaging Lab, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Azimipour, M (通讯作者)，UC Davis Eye Ctr, Dept Ophthalmol & Vis Sci, Vis Sci & Adv Retinal Imaging Lab VSRI, Sacramento, CA 95817 USA.
EM mazimipoure@ucdavis.edu
RI Zawadzki, Robert J./S-3236-2019; Vienola, Kari/ABE-7497-2021
OI Zawadzki, Robert J./0000-0002-9574-156X; Vienola,
   Kari/0000-0003-3390-392X; Jonnal, Ravi/0000-0002-9545-1837; Valente,
   Denise/0000-0002-1377-3585
FU National Eye Institute [R00-EY-026068, R01-EY-024239, R01-EY-026556]
FX National Eye Institute (R00-EY-026068, R01-EY-024239, R01-EY-026556).
CR ANSI, 2014, AM NATL STANDARD SAF
   Azimipour M., 2018, PLOS ONE, V113, P13138
   Azimipour M, 2019, OPT LETT, V44, P4219, DOI 10.1364/OL.44.004219
   Azimipour M, 2019, OPTICA, V6, P300, DOI 10.1364/OPTICA.6.000300
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   CHABRE M, 1973, NATURE-NEW BIOL, V244, P118, DOI 10.1038/newbio244118a0
   Cooper RF, 2017, BIOMED OPT EXPRESS, V8, P5098, DOI 10.1364/BOE.8.005098
   CORLESS JM, 1972, NATURE, V237, P229, DOI 10.1038/237229a0
   Hillmann D, 2016, P NATL ACAD SCI USA, V113, P13138, DOI 10.1073/pnas.1606428113
   Huber R, 2006, OPT EXPRESS, V14, P3225, DOI 10.1364/OE.14.003225
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   Jonnal RS, 2012, BIOMED OPT EXPRESS, V3, P104, DOI 10.1364/BOE.3.000104
   Lu CD, 2017, INVEST OPHTH VIS SCI, V58, P4632, DOI 10.1167/iovs.17-22171
   Migacz JV, 2019, BIOMED OPT EXPRESS, V10, P50, DOI 10.1364/BOE.10.000050
   RUSHTON WAH, 1968, VISION RES, V8, P617, DOI 10.1016/0042-6989(68)90040-0
   Sabesan R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144891
   Srinivasan VJ, 2006, OPT LETT, V31, P2308, DOI 10.1364/OL.31.002308
   Stevenson SB, 2005, PROC SPIE, V5688, P145, DOI 10.1117/12.591190
   Zhang FR, 2019, P NATL ACAD SCI USA, V116, P7951, DOI 10.1073/pnas.1816360116
   Zhang PF, 2017, P NATL ACAD SCI USA, V114, pE2937, DOI 10.1073/pnas.1620572114
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
NR 21
TC 28
Z9 29
U1 2
U2 13
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD SEP 1
PY 2020
VL 45
IS 17
BP 4658
EP 4661
DI 10.1364/OL.398868
PG 4
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA NH8NY
UT WOS:000564921500001
PM 32870829
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yang, XY
   Cheng, Y
   Su, GF
AF Yang, Xinyue
   Cheng, Yan
   Su, Guanfang
TI A review of the multifunctionality of angiopoietin-like 4 in eye disease
SO BIOSCIENCE REPORTS
LA English
DT Review
ID INDUCED ADIPOSE FACTOR; ENDOTHELIAL GROWTH-FACTOR;
   ACTIVATED-RECEPTOR-GAMMA; VASCULAR-PERMEABILITY; GENE-EXPRESSION;
   UP-REGULATION; ANGIOGENIC PHENOTYPE; ANOIKIS RESISTANCE;
   LIPOPROTEIN-LIPASE; EPITHELIAL-CELLS
AB Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional cytokine regulating vascular permeability, angiogenesis, and inflammation. Dysregulations in these responses contribute to the pathogenesis of ischemic retinopathies such as diabetic retinopathy (DR), age-related macular degeneration (AMD), retinal vein occlusion, and sickle cell retinopathy (SCR). However, the role of ANGPTL4 in these diseases remains controversial. Here, we summarize the functional mechanisms of ANGPTL4 in several diseases. We highlight original studies that provide detailed data about the mechanisms of action for ANGPTL4, its applications as a diagnostic or prognostic biomarker, and its use as a potential therapeutic target. Taken together, the discussions in this review will help us gain a better understanding of the molecular mechanisms by which ANGPTL4 functions in eye disease and will provide directions for future research.
C1 [Yang, Xinyue; Cheng, Yan; Su, Guanfang] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun 130041, Jilin, Peoples R China.
C3 Jilin University
RP Su, GF (通讯作者)，Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun 130041, Jilin, Peoples R China.
EM sugf2012@163.com
CR Aryal B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12313
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Baba K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11769-x
   Babapoor-Farrokhran S, 2017, CAN J OPHTHALMOL, V52, pE122, DOI 10.1016/j.jcjo.2017.01.010
   Babapoor-Farrokhran S, 2015, P NATL ACAD SCI USA, V112, pE3030, DOI 10.1073/pnas.1423765112
   Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Bahrami B, 2017, ASIA-PAC J OPHTHALMO, V6, P535, DOI 10.22608/APO.2017350
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Barz T, 2006, CANCER RES, V66, P11975, DOI 10.1158/0008-5472.CAN-06-1529
   Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021
   Biterova E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25237-7
   Blaedel T, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.38
   Bouleti C, 2018, INT J CARDIOL, V256, P2, DOI 10.1016/j.ijcard.2017.10.123
   Bouleti C, 2013, EUR HEART J, V34, P3657, DOI 10.1093/eurheartj/eht153
   Brown R, 2007, NEUROENDOCRINOLOGY, V85, P232, DOI 10.1159/000104248
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91
   Chi X, 2015, J BIOL CHEM, V290, P11865, DOI 10.1074/jbc.M114.623769
   Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170
   Chong HC, 2014, MOL THER, V22, P1593, DOI 10.1038/mt.2014.102
   Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396
   Cushing EM, 2017, MOL METAB, V6, P809, DOI 10.1016/j.molmet.2017.06.007
   Dewey FF, 2016, NEW ENGL J MED, V374, P1123, DOI 10.1056/NEJMoa1510926
   Dijk W, 2016, CURR OPIN LIPIDOL, V27, P249, DOI 10.1097/MOL.0000000000000290
   Dutton S, 2008, BRIT J NUTR, V100, P18, DOI 10.1017/S0007114507882961
   El-Shal AS, 2017, CYTOKINE, V96, P75, DOI 10.1016/j.cyto.2017.03.006
   Florea V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073146
   Frenzel E, 2015, J IMMUNOL, V195, P3605, DOI 10.4049/jimmunol.1500740
   Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103
   Gealekman O, 2008, AM J PHYSIOL-ENDOC M, V295, pE1056, DOI 10.1152/ajpendo.90345.2008
   Germain S, 2010, CURR OPIN HEMATOL, V17, P245, DOI 10.1097/MOH.0b013e32833865b9
   Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494
   Grootaert C, 2012, EXPERT REV PROTEOMIC, V9, P181, DOI [10.1586/EPR.12.12, 10.1586/epr.12.12]
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guo L, 2015, J CELL PHYSIOL, V230, P2390, DOI 10.1002/jcp.24969
   Hata S, 2017, ONCOL REP, V38, P120, DOI 10.3892/or.2017.5669
   Helgadottir A, 2016, NAT GENET, V48, P634, DOI 10.1038/ng.3561
   Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002
   Highet AR, 2015, EUR J CELL BIOL, V94, P589, DOI 10.1016/j.ejcb.2015.10.004
   Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868
   Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716
   Huang ZQ, 2016, ARCH ORAL BIOL, V71, P144, DOI 10.1016/j.archoralbio.2016.07.011
   Imran SA, 2010, DIABETES VASC DIS RE, V7, P231, DOI 10.1177/1479164110369848
   Inoue T, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r63
   Ioanna Z, 2018, GRAEF ARCH CLIN EXP, V256, P325, DOI 10.1007/s00417-017-3846-z
   Ito Y, 2003, CANCER RES, V63, P6651
   Izraely S, 2017, ONCOTARGET, V8, P75778, DOI 10.18632/oncotarget.19018
   Jabs M, 2018, CIRCULATION, V137, P2592, DOI 10.1161/CIRCULATIONAHA.117.029733
   Janjic K, 2018, ARCH ORAL BIOL, V85, P172, DOI 10.1016/j.archoralbio.2017.10.011
   Janson BJ, 2014, OCUL SURF, V12, P112, DOI 10.1016/j.jtos.2014.01.001
   Janssen AWF, 2017, BBA-MOL CELL BIOL L, V1862, P1056, DOI 10.1016/j.bbalip.2017.07.005
   Jee K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183320
   Jonker JT, 2013, AM J CLIN NUTR, V97, P255, DOI 10.3945/ajcn.112.043687
   Josephs T, 2007, J ENDOCRINOL, V194, P305, DOI 10.1677/JOE-07-0158
   Kaddatz K, 2010, J BIOL CHEM, V285, P29469, DOI 10.1074/jbc.M110.142018
   Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200
   Kersten S, 2009, ARTERIOSCL THROM VAS, V29, P969, DOI 10.1161/ATVBAHA.108.182147
   Kim HK, 2010, DIABETES, V59, P2772, DOI 10.2337/db10-0145
   Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kim JH, 2016, INVEST OPHTH VIS SCI, V57, P6, DOI 10.1167/iovs.15-18304
   Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262
   Kirsch N, 2017, DEV CELL, V43, P71, DOI 10.1016/j.devcel.2017.09.011
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10-162230
   Koliwad SK, 2009, J BIOL CHEM, V284, P25593, DOI 10.1074/jbc.M109.025452
   Kuo TY, 2014, J LIPID RES, V55, P919, DOI 10.1194/jlr.M047860
   Kwon SH, 2015, OPHTHALMOLOGY, V122, P968, DOI 10.1016/j.ophtha.2015.01.007
   Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X
   Li B, 2017, ONCOTARGET, V8, P54966, DOI 10.18632/oncotarget.18629
   Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479
   Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011
   Li XQ, 2015, BIOCHEM BIOPH RES CO, V467, P128, DOI 10.1016/j.bbrc.2015.09.104
   Lichtenstein L, 2010, CELL METAB, V12, P580, DOI 10.1016/j.cmet.2010.11.002
   Liu CQ, 2003, J BIOL CHEM, V278, P44857, DOI 10.1074/jbc.M304489200
   Liu DJ, 2017, NAT GENET, V49, P1758, DOI 10.1038/ng.3977
   Lu B, 2010, BIOCHEM BIOPH RES CO, V391, P1737, DOI 10.1016/j.bbrc.2009.12.145
   Lu QY, 2018, EXP EYE RES, V166, P140, DOI 10.1016/j.exer.2017.10.009
   Lu QY, 2016, GRAEF ARCH CLIN EXP, V254, P1281, DOI 10.1007/s00417-015-3187-8
   Lu RR, 2017, BIOMED PHARMACOTHER, V96, P137, DOI 10.1016/j.biopha.2017.09.105
   Luo F, 2018, INT J CARDIOL, V256, P1, DOI 10.1016/j.ijcard.2017.10.054
   Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107
   Makoveichuk E, 2017, BBA-MOL CELL BIOL L, V1862, P533, DOI 10.1016/j.bbalip.2017.02.005
   Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200
   Mathieu M, 2014, J BIOL CHEM, V289, P8402, DOI 10.1074/jbc.M113.539825
   McQueen AE, 2017, J BIOL CHEM, V292, P16122, DOI 10.1074/jbc.M117.803973
   Menaa F, 2017, J MULTIDISCIP HEALTH, V10, P335, DOI 10.2147/JMDH.S90630
   Meng QL, 2017, INVEST OPHTH VIS SCI, V58, P4514, DOI 10.1167/iovs.17-21974
   Muendlein A, 2014, ATHEROSCLEROSIS, V237, P632, DOI 10.1016/j.atherosclerosis.2014.10.028
   Nahon KJ, 2018, J CLIN LIPIDOL, V12, P56, DOI 10.1016/j.jacl.2017.10.016
   Ness C, 2017, MOL VIS, V23, P680
   Noh JM, 2015, EXP CLIN ENDOCR DIAB, V123, P455, DOI 10.1055/s-0035-1554624
   Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002
   Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pan DS, 2017, PPAR RES, V2017, DOI 10.1155/2017/4313561
   Perdiguero EG, 2016, J PATHOL, V240, P461, DOI 10.1002/path.4805
   Perdiguero EG, 2011, J BIOL CHEM, V286, P36841, DOI 10.1074/jbc.M111.220061
   Perez-Valencia JA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19010-5
   Phua T, 2017, SCI REP-UK, V7, DOI 10.1038/srep44351
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Sadeghabadi ZA, 2018, J ENDOCRINOL INVEST, V41, P241, DOI 10.1007/s40618-017-0730-y
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schumacher A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0152-2
   Schwartz SS, 2017, TRENDS ENDOCRIN MET, V28, P645, DOI 10.1016/j.tem.2017.05.005
   Shin SS, 2017, FOOD NUTR RES, V61, DOI 10.1080/16546628.2017.1338918
   Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040
   Staiger H, 2009, DIABETES, V58, P579, DOI 10.2337/db07-1438
   Stapleton CM, 2010, EXP CELL RES, V316, P507, DOI 10.1016/j.yexcr.2009.12.004
   Stitziel NO, 2016, NEW ENGL J MED, V374, P1134, DOI 10.1056/NEJMoa1507652
   Talmud PJ, 2008, ARTERIOSCL THROM VAS, V28, P2319, DOI 10.1161/ATVBAHA.108.176917
   Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519
   Tan ZW, 2017, BBA-MOL CELL RES, V1864, P1525, DOI 10.1016/j.bbamcr.2017.06.010
   Tarhoni Imad, 2018, J Immunoassay Immunochem, V39, P84, DOI 10.1080/15321819.2017.1407338
   Teo ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05869-x
   Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101
   Wang WY, 2016, GENE, V591, P43, DOI 10.1016/j.gene.2016.06.058
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
   Xu AM, 2005, P NATL ACAD SCI USA, V102, P6086, DOI 10.1073/pnas.0408452102
   Xu YT, 2018, J CELL MOL MED, V22, P1272, DOI 10.1111/jcmm.13405
   Yan Y.G., 2010, AM J PATHOL, V177, P2791, DOI [10.2353/ajpath.2010.100129, DOI 10.2353/AJPATH.2010.100129]
   Yang LY, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005973
   Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yin W, 2009, J BIOL CHEM, V284, P13213, DOI 10.1074/jbc.M900553200
   Yokouchi H, 2013, ACTA OPHTHALMOL, V91, pE289, DOI 10.1111/aos.12097
   Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000
   Yu XX, 2005, P NATL ACAD SCI USA, V102, P1767, DOI 10.1073/pnas.0409564102
   Zhang XY, 2009, INT J BIOCHEM CELL B, V41, P2368, DOI 10.1016/j.biocel.2009.07.011
   Zheng ZD, 2015, BIOMED REP, V3, P578, DOI 10.3892/br.2015.468
   Zhou L, 2018, MOL MED REP, V17, P3674, DOI 10.3892/mmr.2017.8306
   Zhu Hongxin, 2002, Zhonghua Yi Xue Za Zhi, V82, P94
   Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018
NR 133
TC 18
Z9 20
U1 1
U2 8
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD OCT 31
PY 2018
VL 38
AR BSR20180557
DI 10.1042/BSR20180557
PN 5
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GY8QO
UT WOS:000448897800040
PM 30049845
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ratnapriya, R
   Chew, EY
AF Ratnapriya, R.
   Chew, E. Y.
TI Age-related macular degenerationclinical review and genetics update
SO CLINICAL GENETICS
LA English
DT Review
DE age-related macular degeneration; disease management; exome-chip; GWAS;
   rare-variant association; risk prediction; whole-exome sequencing;
   whole-genome sequencing
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; FATTY-ACID INTAKE;
   SUSCEPTIBILITY LOCI; APOLIPOPROTEIN-E; RISK-FACTORS; VARIANT; DISEASE;
   CFH; POLYMORPHISM
AB Age-related macular degeneration (AMD) is the leading cause of central vision impairment in persons over the age of 50 years in developed countries. Both genetic and non-genetic (environmental) factors play major roles in AMD etiology, and multiple gene variants and lifestyle factors such as smoking have been associated with the disease. While dissecting the basic etiology of the disease remains a major challenge, current genetic knowledge has provided opportunities for improved risk assessment, molecular diagnosis and clinical testing of genetic variants in AMD treatment and management. This review addresses the potential of translating the wealth of genetic findings for improved risk prediction and therapeutic intervention in AMD patients. Finally, we discuss the recent advancement in genetics and genomics and the future prospective of personalized medicine in AMD patients.
C1 [Ratnapriya, R.] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Chew, E. Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Ratnapriya, Rinki/0000-0002-0469-4631
FU NATIONAL EYE INSTITUTE [ZIEEY000487] Funding Source: NIH RePORTER;
   Intramural NIH HHS [ZIA AT000018-02] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031
   Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Do R, 2012, HUM MOL GENET, V21, pR1, DOI 10.1093/hmg/dds387
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu WQ, 2013, NATURE, V493, P216, DOI 10.1038/nature11690
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Priya Rinki Ratna, 2012, Methods Mol Biol, V884, P335, DOI 10.1007/978-1-61779-848-1_24
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 71
TC 102
Z9 106
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD AUG
PY 2013
VL 84
IS 2
BP 160
EP 166
DI 10.1111/cge.12206
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 179CN
UT WOS:000321495800009
PM 23713713
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Gama, JJT
   de Sylos, CM
AF Torres Gama, Juliana Julian
   de Sylos, Celia Maria
TI Effect of thermal pasteurization and concentration on carotenoid
   composition of Brazilian Valencia orange juice
SO FOOD CHEMISTRY
LA English
DT Article
DE pasteurization; concentration; carotenoids; Valencia orange juice
ID VEGETABLES; ZEAXANTHIN; PRODUCTS; PIGMENTS; LUTEIN; COLOR
AB Changes in carotenoid pigment content of Brazilian Valencia orange juices due to thermal pasteurization and concentration were studied. Total carotenoid pigment content loss was not significant after thermal pasteurization and concentration. However, thermal effects on carotenoid pigment contents, especially violaxanthin and lutein, were clearly observed and significant (P < 0.05). Pasteurization reduced the content of violaxanthin by 38% and lutein by 20%. The concentration process resulted in loss of lutein (17%). With the loss of lutein, beta-cryptoxanthin became the major carotenoid in the pasteurized and concentrated juices. The provitarnin A content of the juice (beta-carotene, alpha-carotene and beta-cryptoxanthin) and the amount of zeaxanthin, which are considered to be active against age-related macular degeneration and cataracts, did not significantly decrease after pasteurization and concentration. (c) 2006 Elsevier Ltd. All rights reserved.
C1 UNESP, Dept Alimentos & Nutr, Fac Ciencias Farmaceut Araraquara, BR-14801902 Araraquara, SP, Brazil.
C3 Universidade Estadual Paulista
RP de Sylos, CM (通讯作者)，UNESP, Dept Alimentos & Nutr, Fac Ciencias Farmaceut Araraquara, BR-14801902 Araraquara, SP, Brazil.
EM syloscm@fcfar.unesp.br
CR Aman R, 2005, FOOD CHEM, V92, P753, DOI 10.1016/j.foodchem.2004.10.031
   *AOAC, 1990, OFF METH AN, P1271
   Britton G., 1997, NATURAL FOOD COLORAN, P197
   Britton G., 1995, CAROTENOIDS B, V1B, P13
   Davies B.H., 1976, CAROTENOIDS, P138
   Gama JJT, 2005, FOOD RES INT, V38, P899, DOI 10.1016/j.foodres.2005.03.008
   GROSSERT JS, 1972, CHEM SOC REV, V1, P1, DOI 10.1039/cs9720100001
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Kimura M, 2002, FOOD CHEM, V78, P389, DOI 10.1016/S0308-8146(02)00203-0
   Lee HS, 2003, LEBENSM-WISS TECHNOL, V36, P153, DOI 10.1016/S0023-6438(02)00087-7
   Lee HS, 2001, J AGR FOOD CHEM, V49, P877, DOI 10.1021/jf000654r
   Melendez-Martinez AJ, 2003, J AGR FOOD CHEM, V51, P7266, DOI 10.1021/jf034873z
   RODRIGUEZAMAYA DB, 1999, GUIDE CAROTENOID ANA, P59
   Rouseff R, 1996, J AGR FOOD CHEM, V44, P2176, DOI 10.1021/jf950631q
   Sanchez-Moreno C, 2003, J AGR FOOD CHEM, V51, P647, DOI 10.1021/jf020795o
   Subagio A, 2001, FOOD RES INT, V34, P183, DOI 10.1016/S0963-9969(00)00150-2
NR 16
TC 59
Z9 64
U1 2
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PY 2007
VL 100
IS 4
BP 1686
EP 1690
DI 10.1016/j.foodchem.2005.01.062
PG 5
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA 091BI
UT WOS:000241000300056
DA 2022-11-30
ER

PT J
AU Rodrigues, GA
   Lutz, D
   Shen, J
   Yuan, XD
   Shen, H
   Cunningham, J
   Rivers, HM
AF Rodrigues, Gerard A.
   Lutz, David
   Shen, Jie
   Yuan, Xiaoda
   Shen, Hong
   Cunningham, James
   Rivers, Hongwen M.
TI Topical Drug Delivery to the Posterior Segment of the Eye: Addressing
   the Challenge of Preclinical to Clinical Translation
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE formulation; in vivo evaluation; posterior segment; topical delivery;
   translation
ID CHOROIDAL NEOVASCULARIZATION; KINASE INHIBITOR; RABBIT;
   PHARMACOKINETICS; RETINA; PAZOPANIB; THERAPY; MODELS
AB Topical delivery of therapeutics to the posterior segment of the eye remains the holy grail of ocular drug delivery. As an example, anti-vascular endothelial growth factor biologics, such as ranibizumab, aflibercept, and bevacizumab, are delivered by intravitreal injection to treat neovascular age-related macular degeneration and, although these drugs have revolutionized treatment of the disease, less invasive alternatives to intravitreal injection are desired. Multiple reports in the literature have demonstrated topical delivery of both small and large molecules to the back of the eye in small animal models. Despite this progress, successful translation to larger species, and ultimately humans, has yet to be demonstrated. Selection of animal models with relevant ocular anatomy and physiology, along with appropriate experimental design, is critical to enable more relevant feasibility assessments and increased probability of successful translation.
C1 [Rodrigues, Gerard A.; Lutz, David] Allergan Plc, Biol Res, Irvine, CA 92612 USA.
   [Shen, Jie] Allergan Plc, Nonclin & Translat Sci, Irvine, CA 92612 USA.
   [Yuan, Xiaoda; Shen, Hong; Cunningham, James; Rivers, Hongwen M.] Allergan Plc, Pharmaceut Dev, Irvine, CA 92612 USA.
   [Rivers, Hongwen M.] Allergan Plc, 2525 Dupont Dr, Irvine, CA 92612 USA.
C3 AbbVie; Allergan; AbbVie; Allergan; AbbVie; Allergan; AbbVie; Allergan
RP Rivers, HM (通讯作者)，Allergan Plc, Pharmaceut Dev, Irvine, CA 92612 USA.; Rivers, HM (通讯作者)，Allergan Plc, 2525 Dupont Dr, Irvine, CA 92612 USA.
EM rivers_hongwen@allergan.com
CR Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Inoue J, 2004, J OCUL PHARMACOL TH, V20, P1, DOI 10.1089/108076804772745419
   Johnson LN, 2010, VISION RES, V50, P686, DOI 10.1016/j.visres.2009.08.028
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Owen GR, 2007, J OCUL PHARMACOL TH, V23, P335, DOI 10.1089/jop.2006.0123
   Ozaki T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130986
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Shen J, 2014, INVEST OPHTH VIS SCI, V55, P1056, DOI 10.1167/iovs.13-13650
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Singh R, 2014, RETINA-J RET VIT DIS, V34, P1787, DOI 10.1097/IAE.0000000000000179
   Wang Y, 2010, J CELL MOL MED, V14, P1998, DOI 10.1111/j.1582-4934.2009.00786.x
   Williams KA, 2005, EYE, V19, P910, DOI 10.1038/sj.eye.6701669
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Zernii EY, 2016, CNS NEUROL DISORD-DR, V15, P267, DOI 10.2174/1871527315666151110124957
NR 26
TC 44
Z9 45
U1 1
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD DEC
PY 2018
VL 35
IS 12
AR 245
DI 10.1007/s11095-018-2519-x
PG 5
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GY8BH
UT WOS:000448842900002
PM 30374744
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tan, YSE
   Shi, PJ
   Choo, CJ
   Laude, A
   Yeong, WY
AF Tan, Yong Sheng Edgar
   Shi, Pu Jiang
   Choo, Chang-J
   Laude, Augustinus
   Yeong, Wai Yee
TI Tissue engineering of retina and Bruch's membrane: a review of cells,
   materials and processes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; IN-VITRO;
   MECHANICAL-PROPERTIES; COLLAGEN MEMBRANES; AMNIOTIC MEMBRANE; PROGENITOR
   CELLS; GENE-THERAPY; SCAFFOLDS; RPE
AB The biological, structural and functional configuration of Bruch's membrane (BM) is significantly relevant to age-related macular degeneration (AMD) and other chorioretinal diseases, and AMD is one of the leading causes of blindness in the elderly worldwide. The configuration may worsen along with the ageing of retinal pigment epithelium and BM that finally leads to AMD. Thus, the scaffold-based tissue-engineered retina provides an innovative alternative for retinal tissue repair. The cell and material requirements for retinal repair are discussed including cell sheet engineering, decellularised membrane and tissue-engineered membranes. Further, the challenges and potential in realising a whole tissue model construct for retinal regeneration are highlighted herein. This review article provides a framework for future development of tissue-engineered retina as a preclinical model and possible treatments for AMD.
C1 [Tan, Yong Sheng Edgar; Shi, Pu Jiang; Yeong, Wai Yee] Nanyang Technol Univ, Singapore Ctr Printing 3D, Sch Mech & Aerosp Engn, 50 Nanyang Ave,Block N3, Singapore 639798, Singapore.
   [Choo, Chang-J; Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Tan Tock Seng Hospital
RP Yeong, WY (通讯作者)，Nanyang Technol Univ, Singapore Ctr Printing 3D, Sch Mech & Aerosp Engn, 50 Nanyang Ave,Block N3, Singapore 639798, Singapore.
EM WYYeong@ntu.edu.sg
RI Shi, Pujiang/K-3453-2019; Yeong, Wai Yee/G-2655-2013
OI Shi, Pujiang/0000-0002-8051-6773; Yeong, Wai Yee/0000-0003-3640-0877
FU Nanyang Technological University-National Healthcare Group Ageing
   Research Grant [ARG/14009]; Nanyang Technological University Start-Up
   Grant (SUG)
FX This work was supported by Nanyang Technological University-National
   Healthcare Group Ageing Research Grant ARG/14009 and Nanyang
   Technological University Start-Up Grant (SUG).
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Bhuthalingam R, 2015, INT J BIOPRINTING, V1, P57, DOI 10.18063/IJB.2015.01.008
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Caffe AR, 2001, J CHEM NEUROANAT, V22, P263
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Christiansen A., 2012, STEM CELLS INT, V2012, P1
   Chung L, 2017, ADV DRUG DELIVER REV, V114, P184, DOI 10.1016/j.addr.2017.07.006
   Desai SP, 2009, LAB CHIP, V9, P1631, DOI 10.1039/b822081f
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   Gaona LA, 2012, POLYM DEGRAD STABIL, V97, P1621, DOI 10.1016/j.polymdegradstab.2012.06.031
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Green DW, 2012, ADV HEALTHC MATER, V1, P140, DOI 10.1002/adhm.201100039
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Heffernan MJ, 2005, BIOCONJUGATE CHEM, V16, P1340, DOI 10.1021/bc050176w
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Holz F.G., 2013, AGE RELATED MACULAR
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsson A, 2017, NANOMED-NANOTECHNOL, V13, P1563, DOI 10.1016/j.nano.2016.12.023
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jorgenson E, 2013, CLIN MED RES, V11, P146
   Kang HW, 2016, NAT BIOTECHNOL, V34, P312, DOI 10.1038/nbt.3413
   Kurzepa K, 2013, POLIMERY-W, V58, P663, DOI 10.14314/polimery.2013.663
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Lee E, 2011, BRIT J OPHTHALMOL, V95, P445, DOI 10.1136/bjo.2009.171918
   Lee JE, 2001, YONSEI MED J, V42, P172, DOI 10.3349/ymj.2001.42.2.172
   Levinson R, 2003, SEMIN CELL DEV BIOL, V14, P225, DOI 10.1016/S1084-9521(03)00025-9
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Liu XH, 2009, BIOMATERIALS, V30, P4094, DOI 10.1016/j.biomaterials.2009.04.024
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Mironov V, 2006, TISSUE ENG, V12, P631, DOI 10.1089/ten.2006.12.631
   Naahidi S, 2017, BIOTECHNOL ADV, V35, P530, DOI 10.1016/j.biotechadv.2017.05.006
   Ng WL, 2016, INT J BIOPRINTING, V2, P53, DOI 10.18063/IJB.2016.01.009
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Perevedentsev A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6977
   Rahmani S, 2017, INT J POLYM MATER PO, V9, P1
   Recknor JB, 2006, BIOMATERIALS, V27, P4098, DOI 10.1016/j.biomaterials.2006.03.029
   Ren ZW, 2017, BIOFABRICATION, V9, DOI 10.1088/1758-5090/aa747f
   Roberts JJ, 2015, ACS BIOMATER SCI ENG, V1, P1267, DOI 10.1021/acsbiomaterials.5b00321
   Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904
   Schaner PJ, 2004, J VASC SURG, V40, P146, DOI 10.1016/j.jvs.2004.03.033
   Seo JM, 2004, MAT SCI ENG C-BIO S, V24, P185, DOI 10.1016/j.msec.2003.09.019
   Sheridan C, 2014, NAT BIOTECHNOL, V32, P1173, DOI 10.1038/nbt1214-1173
   Shi PJ, 2017, INT J BIOPRINTING, V3, P138, DOI 10.18063/IJB.2017.02.008
   Shim SH, 2017, JAMA OPHTHALMOL, V135, P287, DOI 10.1001/jamaophthalmol.2016.5824
   Shimizu T, 2006, FASEB J, V20, P708, DOI 10.1096/fj.05-4715fje
   Shin HJ, 2006, J BIOMAT SCI-POLYM E, V17, P103, DOI 10.1163/156856206774879126
   Soleimannejad M, 2017, MED HYPOTHESES, V101, P75, DOI 10.1016/j.mehy.2017.02.019
   Soman P, 2013, BIOTECHNOL BIOENG, V110, P3038, DOI 10.1002/bit.24957
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Suntornnond R, 2015, MACROMOL MATER ENG, V300, P858, DOI 10.1002/mame.201500028
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tan YJ, 2015, MATER LETT, V159, P424, DOI 10.1016/j.matlet.2015.07.061
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tian Y, 2017, ACS BIOMATER SCI ENG, V3, P890, DOI 10.1021/acsbiomaterials.6b00757
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Wade JS, 2014, BIOMED MICRODEVICES, V16, P629, DOI 10.1007/s10544-014-9865-1
   Yaji N, 2009, BIOMATERIALS, V30, P797, DOI 10.1016/j.biomaterials.2008.10.045
   Yamato M, 2004, MATER TODAY, V7, P42, DOI 10.1016/S1369-7021(04)00234-2
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Yasuo Kurimoto MT, 2015, RIKEN, P1
   Yeong WY, 2010, TISSUE ENG PART C-ME, V16, P1011, DOI [10.1089/ten.tec.2009.0604, 10.1089/ten.TEC.2009.0604]
   Yeong WY, 2005, VIRTUAL MODELING AND RAPID MANUFACTURING, P115
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 73
TC 12
Z9 12
U1 0
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2018
VL 102
IS 9
BP 1182
EP 1187
DI 10.1136/bjophthalmol-2017-311390
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GU2ON
UT WOS:000445109700002
PM 29453223
DA 2022-11-30
ER

PT J
AU Ung, L
   Pattamatta, U
   Carnt, N
   Wilkinson-Berka, JL
   Liew, G
   White, AJR
AF Ung, Lawson
   Pattamatta, Ushasree
   Carnt, Nicole
   Wilkinson-Berka, Jennifer L.
   Liew, Gerald
   White, Andrew J. R.
TI Oxidative stress and reactive oxygen species: a review of their role in
   ocular disease
SO CLINICAL SCIENCE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; RETINAL GANGLION-CELLS; RENIN-ANGIOTENSIN
   SYSTEM; OPTIC-NERVE HEAD; HUMAN TRABECULAR MESHWORK; INFLAMMATION
   IN-VITRO; OPEN-ANGLE GLAUCOMA; ALPHA-LIPOIC ACID; NADPH OXIDASE;
   DIABETIC-RETINOPATHY
AB For many years, oxidative stress arising from the ubiquitous production of reactive oxygen species (ROS) has been implicated in the pathogenesis of various eye diseases. While emerging research has provided some evidence of the important physiological role of ROS in normal cell function, disease may arise where the concentration of ROS exceeds and overwhelms the body's natural defence against them. Additionally, ROS may induce genomic aberrations which affect cellular homoeostasis and may result in disease. This literature review examines the current evidence for the role of oxidative stress in important ocular diseases with a view to identifying potential therapeutic targets for future study. The need is particularly pressing in developing treatments for conditions which remain notoriously difficult to treat, including glaucoma, diabetic retinopathy and age-related macular degeneration.
C1 [Ung, Lawson; White, Andrew J. R.] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
   [Pattamatta, Ushasree; Carnt, Nicole; Liew, Gerald; White, Andrew J. R.] Univ Sydney, Westmead Inst Med Res, Sydney, NSW 2145, Australia.
   [Wilkinson-Berka, Jennifer L.] Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic 3004, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Monash University
RP White, AJR (通讯作者)，Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.; White, AJR (通讯作者)，Univ Sydney, Westmead Inst Med Res, Sydney, NSW 2145, Australia.
EM andrew.white@sydney.edu.au
RI Carnt, Nicole/T-1585-2017; Liew, Gerald/AAB-6870-2022; White, Andrew
   JR/E-8462-2013; Wilkinson-Berka, Jennifer/D-4232-2011
OI Carnt, Nicole/0000-0002-5376-0885; Wilkinson-Berka,
   Jennifer/0000-0003-3512-4030
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Agarwal A, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0652-z
   Ahmed FAKM, 2001, BRAIN RES, V913, P133, DOI 10.1016/S0006-8993(01)02759-7
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730
   Altenhofer S., 2012, CELL MOL LIFE SCI, P1
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Babizhayev MA, 2016, BBA CLIN, V6, P49, DOI 10.1016/j.bbacli.2016.04.004
   Bajwa A, 2015, CLIN OPHTHALMOL, V9, P889, DOI 10.2147/OPTH.S80972
   Bartosz G, 2009, BIOCHEM PHARMACOL, V77, P1303, DOI 10.1016/j.bcp.2008.11.009
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bayir H, 2005, CRIT CARE MED, V33, pS498, DOI 10.1097/01.CCM.0000186787.64500.12
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benitez-del-Castillo JM, 2005, EYE, V19, P841, DOI 10.1038/sj.eye.6701689
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Bettaieb A, 2015, GASTROENTEROLOGY, V149, P468, DOI 10.1053/j.gastro.2015.04.009
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Borenshtein D, 2001, DIABETES-METAB RES, V17, P44, DOI 10.1002/1520-7560(0000)9999:9999&lt;::AID-DMRR153&gt;3.0.CO;2-
   Braun J, 2005, ARTHRITIS RHEUM, V52, P2447, DOI 10.1002/art.21197
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Bryan N, 2012, EUR CELLS MATER, V24, P249, DOI 10.22203/eCM.v024a18
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   Bull ND, 2011, INVEST OPHTH VIS SCI, V52, P3309, DOI 10.1167/iovs.10-6873
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chan EC, 2016, CLIN SCI, V130, P683, DOI 10.1042/CS20150103
   Chandra A, 2014, EYE, V28, P1066, DOI 10.1038/eye.2014.145
   Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901
   Cheung IMY, 2013, CLIN EXP OPTOM, V96, P188, DOI 10.1111/cxo.12025
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Cordero-Coma M, 2015, SURV OPHTHALMOL, V60, P575, DOI 10.1016/j.survophthal.2015.06.004
   Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024
   Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391
   Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104
   Deliyanti D., 2012, HYPERTENSION, V111
   Deliyanti D, 2016, CLIN SCI, V130, P1375, DOI 10.1042/CS20160068
   Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z
   Di Marco E, 2015, CLIN SCI, V129, P199, DOI 10.1042/CS20150093
   Dominguez JM, 2016, AM J PATHOL, V186, P1688, DOI 10.1016/j.ajpath.2016.01.023
   Dong CJ, 2010, INVEST OPHTH VIS SCI, V51, P4174, DOI 10.1167/iovs.09-4613
   Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403
   Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039
   Fang JH, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-31
   Feilchenfeld Z, 2008, EXP EYE RES, V87, P409, DOI 10.1016/j.exer.2008.07.011
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fletcher EL, 2007, CURR PHARM DESIGN, V13, P2699, DOI 10.2174/138161207781662920
   Fukumoto M, 2008, CURR EYE RES, V33, P885, DOI 10.1080/02713680802389851
   Galvis V, 2015, EYE, V29, P843, DOI 10.1038/eye.2015.63
   Gao H, 2002, ARCH OPHTHALMOL-CHIC, V120, P797
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gordillo GM, 2003, AM J SURG, V186, P259, DOI 10.1016/S0002-9610(03)00211-3
   Govindarajan B, 2009, MOL VIS, V15, P1079
   Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7
   Grassi MA, 2012, INVEST OPHTH VIS SCI, V53, P2377, DOI 10.1167/iovs.11-8068
   Gray SP, 2017, DIABETOLOGIA, V60, P927, DOI 10.1007/s00125-017-4215-5
   Gu XJ, 2016, INT J MOL MED, V38, P75, DOI 10.3892/ijmm.2016.2594
   Guha S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03654-4
   Guo L, 2006, INVEST OPHTH VIS SCI, V47, P626, DOI 10.1167/iovs.05-0754
   Huo YA, 2009, EXP EYE RES, V89, P876, DOI 10.1016/j.exer.2009.07.012
   Ilieva I, 2004, EXP EYE RES, V79, P181, DOI 10.1016/j.exer.2004.03.009
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jaffe GJ, 2016, NEW ENGL J MED, V375, P932, DOI 10.1056/NEJMoa1509852
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joseph A, 2003, OPHTHALMOLOGY, V110, P1449, DOI 10.1016/S0161-6420(03)00406-8
   Ju WK, 2007, INVEST OPHTH VIS SCI, V48, P2145, DOI 10.1167/iovs.06-0573
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   Kanamori A, 2010, BRAIN, V133, P2612, DOI 10.1093/brain/awq105
   Kang JH, 2016, JAMA OPHTHALMOL, V134, P294, DOI 10.1001/jamaophthalmol.2015.5601
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kau HC, 2006, EYE, V20, P826, DOI 10.1038/sj.eye.6702064
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kenney C.M., 2000, CLAO J, V26, P10
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kim J, 2012, FREE RADICAL BIO MED, V53, P357, DOI 10.1016/j.freeradbiomed.2012.04.030
   Kimura A., 2017, OXID MEDI CELL LONGE, V2017, P1
   Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x
   Kovacic P., 2008, CELL MEMBR FREE RADI, V1, P56, DOI DOI 10.3109/10799890903582578
   Kowluru R.A., 2007, EXP DIABETES RES, V2007, P1
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   Kowluru RA, 2012, EXPERT OPIN INV DRUG, V21, P797, DOI 10.1517/13543784.2012.681043
   Kowluru RA, 2009, FREE RADICAL BIO MED, V46, P1677, DOI 10.1016/j.freeradbiomed.2009.03.024
   Krupin T, 2011, AM J OPHTHALMOL, V151, P671, DOI 10.1016/j.ajo.2010.09.026
   Kuehn Markus H, 2005, Ophthalmol Clin North Am, V18, P383, DOI 10.1016/j.ohc.2005.04.002
   Kukner AS, 2004, CELL BIOCHEM FUNCT, V22, P299, DOI 10.1002/cbf.1105
   Kumar A, 2013, CRIT REV IMMUNOL, V33, P119, DOI 10.1615/CritRevImmunol.2013006618
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lafuente MP, 2002, EXP EYE RES, V74, P181, DOI 10.1006/exer.2001.1122
   Levin LA, 2003, SURV OPHTHALMOL, V48, pS21, DOI 10.1016/S0039-6257(03)00007-9
   Li AF, 2004, MOL VIS, V10, P750
   Li JM, 2010, DIABETES, V59, P1528, DOI 10.2337/db09-1057
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lieven CJ, 2006, INVEST OPHTH VIS SCI, V47, P1477, DOI 10.1167/iovs.05-0921
   Lieven CJ, 2003, ANTIOXID REDOX SIGN, V5, P641, DOI 10.1089/152308603770310310
   Lin J, 2006, DIABETOLOGIA, V49, P1089, DOI 10.1007/s00125-006-0174-y
   Lindsey JD, 2015, NEUROBIOL AGING, V36, P1969, DOI 10.1016/j.neurobiolaging.2014.12.021
   Lindstedt EW, 2005, BRIT J OPHTHALMOL, V89, P533, DOI 10.1136/bjo.2003.037192
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Liu XQ, 2013, J OCUL PHARMACOL TH, V29, P33, DOI 10.1089/jop.2012.0141
   Liu Y, 2012, FREE RADICAL BIO MED, V52, P909, DOI 10.1016/j.freeradbiomed.2011.12.013
   Lou M., 2011, ACTA OPHTHALMOL COPE, V89
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   Luna C, 2009, FOOD CHEM TOXICOL, V47, P198, DOI 10.1016/j.fct.2008.10.029
   Madsen-Bouterse SA, 2010, ANTIOXID REDOX SIGN, V13, P797, DOI 10.1089/ars.2009.2932
   Margis R, 2008, FEBS J, V275, P3959, DOI 10.1111/j.1742-4658.2008.06542.x
   Markus MA, 2008, CLIN INTERV AGING, V3, P331
   Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013
   MCCORD JM, 1985, NEW ENGL J MED, V312, P159
   McMonnies CW, 2015, OPTOMETRY VISION SCI, V92, pE35, DOI 10.1097/OPX.0000000000000455
   Merksamer PI, 2013, AGING-US, V5, P144, DOI 10.18632/aging.100544
   Miao L, 2009, FREE RADICAL BIO MED, V47, P344, DOI 10.1016/j.freeradbiomed.2009.05.018
   Miller AG, 2010, DIABETES, V59, P3208, DOI 10.2337/db10-0552
   Mohammad G, 2010, LAB INVEST, V90, P1365, DOI 10.1038/labinvest.2010.89
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187
   Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117
   Nguyen SM, 2003, ANTIOXID REDOX SIGN, V5, P629, DOI 10.1089/152308603770310293
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Noh YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.341
   Obrosova IG, 2000, EUR J PHARMACOL, V398, P139, DOI 10.1016/S0014-2999(00)00286-7
   Ohgami K, 2005, INVEST OPHTH VIS SCI, V46, P275, DOI 10.1167/iovs.04-0715
   Ohgami K, 2003, INVEST OPHTH VIS SCI, V44, P2694, DOI 10.1167/iovs.02-0822
   Osborne NN, 2009, ACTA OPHTHALMOL, V87, P450, DOI 10.1111/j.1755-3768.2008.01459.x
   Ozawa Y, 2013, JPN J OPHTHALMOL, V57, P126, DOI 10.1007/s10384-012-0204-x
   Ozdulger A, 2003, SHOCK, V19, P366, DOI 10.1097/00024382-200304000-00012
   Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014
   Pattamatta U, 2016, EXP EYE RES, V151, P38, DOI 10.1016/j.exer.2016.07.010
   Pirhan D, 2016, CURR EYE RES, V41, P59, DOI 10.3109/02713683.2015.1004719
   Nguyen QD, 2016, LANCET, V388, P1183, DOI 10.1016/S0140-6736(16)31339-3
   Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x
   Rojas M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020043
   Rojas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084357
   Roy S, 2015, CORNEA, V34, P668, DOI 10.1097/ICO.0000000000000421
   Russo MA, 2014, ENDOCR METAB IMMUNE, V14, P300, DOI 10.2174/1871530314666140709093305
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2016, J CELL PHYSIOL, V231, P1876, DOI 10.1002/jcp.25305
   Sadaka A, 2012, PROG RETIN EYE RES, V31, P316, DOI 10.1016/j.preteyeres.2012.03.004
   Sarlos S, 2005, INVEST OPHTH VIS SCI, V46, P1069, DOI 10.1167/iovs.04-0885
   Schafer M, 2008, PHARMACOL RES, V58, P165, DOI 10.1016/j.phrs.2008.06.004
   Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0
   Schmedt T, 2012, EXP EYE RES, V95, P24, DOI 10.1016/j.exer.2011.08.002
   Sedeek M, 2013, CLIN SCI, V124, P191, DOI 10.1042/CS20120330
   Sedeek M, 2012, J CARDIOVASC TRANSL, V5, P509, DOI 10.1007/s12265-012-9387-2
   Selmi C, 2014, AUTOIMMUN REV, V13, P591, DOI 10.1016/j.autrev.2014.01.006
   Semba K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.306
   Semba K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.296
   Sen CK, 2002, ANN NY ACAD SCI, V957, P239, DOI 10.1111/j.1749-6632.2002.tb02920.x
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shaw TJ, 2016, CURR OPIN CELL BIOL, V42, P29, DOI 10.1016/j.ceb.2016.04.001
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Singh PK, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-33
   Sjolie AK, 2011, DIABETIC MED, V28, P345, DOI 10.1111/j.1464-5491.2010.03210.x
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641
   Song HM, 2016, INVEST OPHTH VIS SCI, V57, P2864, DOI 10.1167/iovs.15-18974
   Spanier G, 2009, J PHYSIOL PHARMACOL, V60, P111
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   SuttorpSchulten MSA, 1996, BRIT J OPHTHALMOL, V80, P844, DOI 10.1136/bjo.80.9.844
   TALLEY AK, 1995, MOL CELL BIOL, V15, P2359
   Tallouzi M.O., 2017, ANTI TUMOUR NECROSIS
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Teixeira G., 2016, BR J PHARM
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P705, DOI 10.1167/iovs.06-0810
   The Writing Committee for the Normal Tension Glaucoma Genetic Study Group of Japan Glaucoma Society, 2010, OPHTHALMOLOGY, V117
   Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016
   Toppo S, 2008, ANTIOXID REDOX SIGN, V10, P1501, DOI 10.1089/ars.2008.2057
   Tsai YY, 2005, MOL VIS, V11, P71
   Tsang CK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4446
   Tugal-Tutkun I, 2005, ARTHRITIS RHEUM-US, V52, P2478, DOI 10.1002/art.21231
   Tynjala P, 2007, ANN RHEUM DIS, V66, P548, DOI 10.1136/ard.2006.058248
   Udar N, 2006, INVEST OPHTH VIS SCI, V47, P3345, DOI 10.1167/iovs.05-1500
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Veluthakal R, 2015, CELL PHYSIOL BIOCHEM, V36, P208, DOI 10.1159/000374065
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Vin AP, 2013, EXP EYE RES, V108, P72, DOI 10.1016/j.exer.2012.11.022
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   Wang FZ, 2014, J DRUG TARGET, V22, P849, DOI 10.3109/1061186X.2014.939983
   Wei YH, 2015, P NATL ACAD SCI USA, V112, pE6927, DOI 10.1073/pnas.1512683112
   Weinreb R.N., 2016, MED TREATMENT NEUROP, P259
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Wentz-Hunter K, 2004, EXP CELL RES, V297, P39, DOI 10.1016/j.yexcr.2004.02.024
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P1193, DOI 10.1177/1470320314566018
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   Wilkinson-Berka JL, 2011, DIABETOLOGIA, V54, P2724, DOI 10.1007/s00125-011-2239-9
   Wilkinson-Berka JL, 2014, ANTIOXID REDOX SIGN, V20, P2726, DOI 10.1089/ars.2013.5357
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Wilkinson-Berka JL, 2012, PEPTIDES, V36, P142, DOI 10.1016/j.peptides.2012.04.008
   Wojcik KA, 2013, INT J MOL SCI, V14, P19294, DOI 10.3390/ijms140919294
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Xu ZH, 2015, J NEUROCHEM, V133, P233, DOI 10.1111/jnc.13064
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yadav UCS, 2011, CURR MED CHEM, V18, P931
   Yang HW, 2009, INVEST OPHTH VIS SCI, V50, P5800, DOI 10.1167/iovs.09-3678
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
NR 223
TC 82
Z9 84
U1 1
U2 43
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD DEC 15
PY 2017
VL 131
IS 24
BP 2865
EP 2883
DI 10.1042/CS20171246
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FR2GG
UT WOS:000418884600002
PM 29203723
DA 2022-11-30
ER

PT J
AU D'Ambrosio, E
   Tortorella, P
   Iannetti, L
AF D'Ambrosio, Enzo
   Tortorella, Paolo
   Iannetti, Ludovico
TI Management of Uveitis-Related Choroidal Neovascularization: From the
   Pathogenesis to the Therapy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; PUNCTATE
   INNER CHOROIDOPATHY; PHOTODYNAMIC THERAPY; MULTIFOCAL CHOROIDITIS;
   MACULAR DEGENERATION; SECONDARY; RANIBIZUMAB; SUBFOVEAL; VERTEPORFIN
AB Inflammatory choroidal neovascularization is a severe but uncommon complication of uveitis, more frequent in posterior uveitis such as punctate inner choroidopathy, multifocal choroiditis, serpiginous choroiditis, and Vogt-Koyanagi-Harada syndrome. Its pathogenesis is supposed to be similar to the wet age related macular degeneration: hypoxia, release of vascular endothelial growth factor, stromal cell derived factor 1-alpha, and other mediators seem to be involved in the uveitis-related choroidal neovascularization. A review on the factors implicated so far in the pathogenesis of inflammatory choroidal neovascularization was performed. Also we reported the success rate of single studies concerning the therapies of choroidal neovascularization secondary to uveitis during the last decade: photodynamic therapy, intravitreal bevacizumab, and intravitreal ranibizumab, besides steroidal and immunosuppressive therapy. Hereby a standardization of the therapeutic approach is proposed.
C1 [D'Ambrosio, Enzo; Tortorella, Paolo; Iannetti, Ludovico] Univ Roma La Sapienza, Dept Ophthalmol, I-00161 Rome, Italy.
C3 Sapienza University Rome
RP Iannetti, L (通讯作者)，Univ Roma La Sapienza, Dept Ophthalmol, Viale Policlin 155, I-00161 Rome, Italy.
EM l.iannetti@policlinicoumberto1.it
OI Iannetti, Ludovico/0000-0003-1790-3532
CR Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Arevalo JF, 2011, RETINA-J RET VIT DIS, V31, P353, DOI 10.1097/IAE.0b013e3181ed8cec
   Baxter SL, 2013, AM J OPHTHALMOL, V156, P468, DOI 10.1016/j.ajo.2013.04.040
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P81, DOI 10.1159/000317908
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Coco RM, 2007, OCUL IMMUNOL INFLAMM, V15, P27, DOI 10.1080/09273940601174020
   Cornish KS, 2011, EUR J OPHTHALMOL, V21, P440, DOI 10.5301/EJO.2010.6117
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   Dees C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1456, DOI 10.1001/archopht.116.11.1456
   Doctor PP, 2009, OCUL IMMUNOL INFLAMM, V17, P118, DOI 10.1080/09273940802650406
   Ehrlich Rita, 2010, International Ophthalmology, V30, P345, DOI 10.1007/s10792-010-9346-3
   Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097/IAE.0b013e318187aff9
   Gerth C, 2006, EUR J OPHTHALMOL, V16, P111, DOI 10.1177/112067210601600118
   GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Gulati N, 2011, BRIT J OPHTHALMOL, V95, P162, DOI 10.1136/bjo.2009.177279
   Iannetti L, 2013, EUR J OPHTHALMOL, V23, P114, DOI 10.5301/ejo.5000192
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Julian K, 2011, ACTA OPHTHALMOL, V89, P179, DOI 10.1111/j.1755-3768.2010.02046.x
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Kramer M, 2010, RETINA-J RET VIT DIS, V30, P938, DOI 10.1097/IAE.0b013e3181c96a00
   Kuo IC, 2000, INT OPHTHALMOL CLIN, V40, P111, DOI 10.1097/00004397-200004000-00009
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Leslie T, 2005, BRIT J OPHTHALMOL, V89, P147, DOI 10.1136/bjo.2004.046623
   Lim JI, 2006, ANN ACAD MED SINGAP, V35, P198
   Lott MN, 2009, AM J OPHTHALMOL, V148, P711, DOI 10.1016/j.ajo.2009.06.010
   Mansour AM, 2012, CAN J OPHTHALMOL, V47, P269, DOI 10.1016/j.jcjo.2012.03.042
   Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097/00006982-200604000-00003
   Menezo V, 2010, RETINA-J RET VIT DIS, V30, P1400, DOI 10.1097/IAE.0b013e3181d374dc
   MOORTHY RS, 1993, AM J OPHTHALMOL, V116, P164, DOI 10.1016/S0002-9394(14)71280-2
   Nessi F, 2004, KLIN MONATSBL AUGENH, V221, P371, DOI 10.1055/s-2004-812860
   Nowilaty SR, 2006, BRIT J OPHTHALMOL, V90, P982, DOI 10.1136/bjo.2006.091538
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1100, DOI 10.1001/archophthalmol.2010.205
   Parodi MB, 2006, AM J OPHTHALMOL, V141, P123, DOI 10.1016/j.ajo.2005.07.045
   Rogers AH, 2003, OPHTHALMOLOGY, V110, P1315, DOI 10.1016/S0161-6420(03)00466-4
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Team RC, 2013, R LANG ENV STAT COMP
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P67, DOI 10.1111/j.1442-9071.2011.02719.x
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
NR 51
TC 33
Z9 33
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 450428
DI 10.1155/2014/450428
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8TS
UT WOS:000335691700001
PM 24868454
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ye, X
   Wang, YS
   Nathans, J
AF Ye, Xin
   Wang, Yanshu
   Nathans, Jeremy
TI The Norrin/Frizzled4 signaling pathway in retinal vascular development
   and disease
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
ID FAMILIAL EXUDATIVE VITREORETINOPATHY; RECEPTOR-RELATED PROTEIN-5;
   NORRIE-DISEASE; VENOUS INSUFFICIENCY; TARGETED DISRUPTION; OXYGEN
   DISTRIBUTION; REDUNDANT ROLES; FRIZZLED-4 GENE; ANGIOGENESIS; MUTATIONS
AB Disorders of retinal vascular growth and function are responsible for vision loss in a variety of diseases, including diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity and retinal artery or vein occlusion. Over the past decade, a new signaling pathway that controls retinal vascular development has emerged from the study of inherited disorders in both humans and mice - that are characterized by retinal hypovascularization. This pathway utilizes a glial-derived extracellular ligand, Norrin, that acts on a transmembrane receptor, Frizzled4, a coreceptor, Lrp5, and an auxiliary membrane protein, Tspan12, on the surface of developing endothelial cells. The resulting signal controls a transcriptional program that regulates endothelial growth and maturation. It will be of great interest to determine whether modulating this pathway could represent a therapeutic approach to human retinal vascular disease.
C1 [Ye, Xin; Wang, Yanshu; Nathans, Jeremy] Johns Hopkins Univ, Dept Mol Biol & Genet, Sch Med, Baltimore, MD 21205 USA.
   [Wang, Yanshu; Nathans, Jeremy] Johns Hopkins Univ, Howard Hughes Med Inst, Sch Med, Baltimore, MD 21205 USA.
   [Nathans, Jeremy] Johns Hopkins Univ, Dept Ophthalmol, Sch Med, Baltimore, MD 21205 USA.
   [Nathans, Jeremy] Johns Hopkins Univ, Dept Neurosci, Sch Med, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University
RP Nathans, J (通讯作者)，Johns Hopkins Univ, Dept Mol Biol & Genet, Sch Med, Baltimore, MD 21205 USA.
EM jnathans@jhmi.edu
OI Nathans, Jeremy/0000-0001-8106-5460
FU National Eye Institute (NIH); Howard Hughes Medical Institute; NATIONAL
   EYE INSTITUTE [R01EY018637] Funding Source: NIH RePORTER
FX The authors thank Hao Chang, Amir Rattner and Max Tischfield for
   comments on the manuscript; Edwin Stone and William Tasman for the
   fundus photographs; and Caroline Jones for assistance with preparing the
   figures. This research was supported by the National Eye Institute (NIH)
   and the Howard Hughes Medical Institute.
CR Ai MR, 2005, AM J HUM GENET, V77, P741, DOI 10.1086/497706
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Benson W E, 1995, Trans Am Ophthalmol Soc, V93, P473
   BERGER W, 2001, METABOLIC MOL BASES, P5977
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cioffi GA., 2003, ADLERS PHYSL EYE, V10th ed., P747
   CRISWICK VG, 1969, AM J OPHTHALMOL, V68, P578, DOI 10.1016/0002-9394(69)91237-9
   Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106
   Francois M, 2010, INT J BIOCHEM CELL B, V42, P445, DOI 10.1016/j.biocel.2009.08.017
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2
   Han C, 2005, DEVELOPMENT, V132, P667, DOI 10.1242/dev.01636
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739
   Ishikawa T, 2001, DEVELOPMENT, V128, P25
   Jiao XD, 2004, AM J HUM GENET, V75, P878, DOI 10.1086/425080
   Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081
   Kondo H, 2007, OPHTHALMIC GENET, V28, P220, DOI 10.1080/13816810701663543
   Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174
   LUHRNANN UF, 2005, GENESIS, V42, P253
   Matsui T, 2006, J CELL SCI, V119, P3513, DOI 10.1242/jcs.03081
   McLeod DS, 2006, DEV DYNAM, V235, P3336, DOI 10.1002/dvdy.20988
   Michaelides M, 2004, BRIT J OPHTHALMOL, V88, P1475, DOI 10.1136/bjo.2004.042556
   Monkley SJ, 1996, DEVELOPMENT, V122, P3343
   Nikopoulos K, 2010, HUM MUTAT, V31, P656, DOI 10.1002/humu.21250
   Nikopoulos K, 2010, AM J HUM GENET, V86, P240, DOI 10.1016/j.ajhg.2009.12.016
   Ohlmann A, 2005, J NEUROSCI, V25, P1701, DOI 10.1523/JNEUROSCI.4756-04.2005
   Ohlmann A, 2010, J NEUROSCI, V30, P183, DOI 10.1523/JNEUROSCI.3210-09.2010
   PARSONS MA, 1992, GRAEF ARCH CLIN EXP, V230, P248, DOI 10.1007/BF00176299
   Pendeville H, 2008, DEV BIOL, V317, P405, DOI 10.1016/j.ydbio.2008.01.028
   Poulter JA, 2010, AM J HUM GENET, V86, P248, DOI 10.1016/j.ajhg.2010.01.012
   Qin MH, 2005, HUM MUTAT, V26, P104, DOI 10.1002/humu.20191
   Rehm HL, 1997, HUM MUTAT, V9, P402
   Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   Robitaille JM, 2009, OPHTHALMIC GENET, V30, P23, DOI 10.1080/13816810802464312
   Sakamoto Y, 2007, BIOCHEM BIOPH RES CO, V360, P539, DOI 10.1016/j.bbrc.2007.06.093
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Shastry BS, 1997, ARCH OPHTHALMOL-CHIC, V115, P651, DOI 10.1001/archopht.1997.01100150653015
   Smallwood PM, 2007, J BIOL CHEM, V282, P4057, DOI 10.1074/jbc.M609618200
   Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Walshe TE, 2008, ANNU REV PATHOL-MECH, V3, P615, DOI 10.1146/annurev.pathmechdis.3.121806.151501
   Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001
   WARBURG O, 1928, BIOCHEM Z, V184, P484
   Xia CH, 2008, HUM MOL GENET, V17, P1605, DOI 10.1093/hmg/ddn047
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Yau KW, 2009, CELL, V139, P246, DOI 10.1016/j.cell.2009.09.029
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
NR 60
TC 115
Z9 117
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD SEP
PY 2010
VL 16
IS 9
BP 417
EP 425
DI 10.1016/j.molmed.2010.07.003
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 656QL
UT WOS:000282351500004
PM 20688566
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chung, STL
AF Chung, Susana T. L.
TI Enhancing Visual Performance for People with Central Vision Loss
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE low vision; central vision loss; age-related macular degeneration;
   reading; visual performance
ID READING SPEED; VERNIER ACUITY; LETTER-RECOGNITION; EYE-MOVEMENTS; AGE;
   PSYCHOPHYSICS; ORIENTATION; IMPROVEMENT; PREVALENCE; SPAN
AB People with central vision loss must use peripheral vision for visual tasks. It is well known that performance for almost all spatial tasks is worse in the normal periphery than in the normal fovea. The primary goal of my ongoing research is to understand the limiting factors and the potential for enhancing vision for people with central vision loss. Here I review my previous work related to understanding the limiting factors on reading, a task that is the primary complaint of many patients with age-related macular degeneration, the leading cause of visual impairment in the elderly. I also review my work related to enhancing visual functions in the normal periphery and how it may be applied to people with central vision loss. (Optom Vis Sci 2010;87:276-284)
C1 Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley
RP Chung, STL (通讯作者)，Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
EM s.chung@berkeley.edu
OI Chung, Susana/0000-0003-2729-1808
FU NIH [R01-EY012810]; NATIONAL EYE INSTITUTE [R01EY012810] Funding Source:
   NIH RePORTER
FX This work was supported by NIH grant R01-EY012810.
CR [Anonymous], 1990, EYE MOVEMENTS THEIR
   BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968
   BALL K, 1987, VISION RES, V27, P953, DOI 10.1016/0042-6989(87)90011-3
   BEARD BL, 1995, VISION RES, V35, P1679, DOI 10.1016/0042-6989(94)00267-P
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Chakravarthi R, 2007, J VISION, V7, DOI 10.1167/7.2.11
   CHAPARRO A, 1993, INVEST OPHTH VIS SCI, V34, P2341
   Cheong AMY, 2008, VISION RES, V48, P577, DOI 10.1016/j.visres.2007.11.022
   Chung STL, 2005, VISION RES, V45, P1399, DOI 10.1016/j.visres.2004.11.021
   Chung STL, 2004, VISION RES, V44, P695, DOI 10.1016/j.visres.2003.09.028
   Chung STL, 2002, INVEST OPHTH VIS SCI, V43, P1270
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   CHUNG STL, 2005, VISION 2005 LOND ENG
   Chung STL, 2008, OPTOMETRY VISION SCI, V85, P827, DOI 10.1097/OPX.0b013e31818527ea
   Chung STL, 2007, VISION RES, V47, P3150, DOI 10.1016/j.visres.2007.08.017
   Chung STL, 2009, VISION RES, V49, P2782, DOI 10.1016/j.visres.2009.08.013
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   FAHLE M, 1993, VISION RES, V33, P397, DOI 10.1016/0042-6989(93)90094-D
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Fine EM, 1999, VISION RES, V39, P747, DOI 10.1016/S0042-6989(98)00142-4
   FIORENTINI A, 1980, NATURE, V287, P43, DOI 10.1038/287043a0
   FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1
   FLOM MC, 1963, J OPT SOC AM, V53, P1026, DOI 10.1364/JOSA.53.001026
   FORSTER KI, 1970, PERCEPT PSYCHOPHYS, V8, P215, DOI 10.3758/BF03210208
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GIBSON EJ, 1963, ANNU REV PSYCHOL, V14, P29, DOI 10.1146/annurev.ps.14.020163.000333
   JACOBS RJ, 1979, VISION RES, V19, P1187, DOI 10.1016/0042-6989(79)90183-4
   KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   KOOI FL, 1994, SPATIAL VISION, V8, P255, DOI 10.1163/156856894X00350
   Latham K, 1996, VISION RES, V36, P2665, DOI 10.1016/0042-6989(96)00022-3
   Leat SJ, 1999, OPTOMETRY VISION SCI, V76, P198, DOI 10.1097/00006324-199904000-00023
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   LOOMIS JM, 1978, VISION RES, V18, P335, DOI 10.1016/0042-6989(78)90168-2
   MCCONKIE GW, 1975, PERCEPT PSYCHOPHYS, V17, P578, DOI 10.3758/BF03203972
   MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097
   ORegan J. K., 1991, IPO ANN PROGR REPORT, V26, P96
   POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770
   Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   Richards E, 2006, VISION RES, V46, P4217, DOI 10.1016/j.visres.2006.08.011
   RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   SAARINEN J, 1995, VISION RES, V35, P519, DOI 10.1016/0042-6989(94)00141-8
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   STUART JA, 1962, AM J OPHTHALMOL, V53, P471, DOI 10.1016/0002-9394(62)94878-X
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   TRUONG S, 2009, OPTOM VIS SCI, V86
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   WESTHEIMER G, 1979, INVEST OPHTH VIS SCI, V18, P893
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   Yu DY, 2007, J VISION, V7, DOI 10.1167/7.2.2
NR 56
TC 14
Z9 14
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD APR
PY 2010
VL 87
IS 4
BP 276
EP 284
DI 10.1097/OPX.0b013e3181c91347
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 577ZZ
UT WOS:000276264300008
PM 20010138
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cidlowski, JA
AF Cidlowski, John A.
TI GLUCOCORTICOIDS AND THEIR ACTIONS IN CELLS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE glucocorticoids; inflammation; receptors; steroid resistance
AB The biologic responses to the administration of exogenous glucocorticoids (GCs) appear to be specific to cell type. As a result, progress in understanding how to improve the benefit-to-risk ratio of GC therapies for the eye will depend on better characterization of both the receptors and the proteins induced when these receptors are stimulated. The complexity and diversity of the GC receptors in human tissue is underscored by evidence that up to 6,000 genes are expressed or suppressed within hours of GC exposure. The enormous potential to use exogenous GC agents to clownregulate processes involved in age-related macular degeneration must be balanced against a similar potential for counterproductive effects. Recent progress predicts an increasing precision with which GC steroids can be used to influence biologic functions. RETINA 29:S18-S20, 2009
C1 NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Cidlowski, JA (通讯作者)，NIEHS, Lab Signal Transduct, POB 12233, Res Triangle Pk, NC 27709 USA.
EM cidlows1@niehs.nih.gov
RI Cidlowski, John A/G-2548-2019
OI Cidlowski, John A/0000-0003-1420-0516
CR Lu NZ, 2007, MOL CELL BIOL, V27, P7143, DOI 10.1128/MCB.00253-07
   Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
NR 3
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S18
EP S20
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700007
DA 2022-11-30
ER

PT J
AU Grausgruber, H
   Miesenberger, S
   Schoenlechner, R
   Vollmann, J
AF Grausgruber, H.
   Miesenberger, S.
   Schoenlechner, R.
   Vollmann, J.
TI Influence of dough improvers on whole-grain bread quality of einkorn
   wheat
SO ACTA ALIMENTARIA
LA English
DT Article
DE ancient wheat; baking; emulsifier; enzyme; image analysis; texture
   analysis; Triticum monococcum
ID CELIAC-DISEASE; ALPHA-AMYLASES; TRANSGLUTAMINASE; BREADMAKING; BAKING;
   PERFORMANCE; MONOCOCCUM; FLOUR; BEHAVIOR; FRESH
AB Wholemeal products of einkorn wheat (Triticum monococcum L.) could help to elevate the daily uptake of both dietary fibre and lutein, compounds which can assist the prevention of coronary heart disease and age-related macular degeneration, respectively. However, gluten strength and rheological properties of einkorn wheat are low and bran particles are reported to decrease bread volume and crumb elasticity of flours. It was demonstrated that the application of individual enzymes and/or emulsifiers or their application in mixtures can significantly improve bread volume and crumb firmness of whole-grain einkorn breads. Crumb porosity characteristics, however, were not affected. Synergistic interactions between the dough improvers can be supposed. The antithesis between the application of dough conditioners and the organic production of einkorn wheat, and optional methods for optimisation of whole-grain einkorn bread are discussed.
C1 [Grausgruber, H.; Miesenberger, S.; Vollmann, J.] BOKU Univ Nat Resources & Appl Life Sci, Dept Appl Plant Sci & Plant Biotechnol, A-1180 Vienna, Austria.
   [Schoenlechner, R.] BOKU Univ Nat Resources & Appl Life Sci, Dept Food Sci & Technol, A-1190 Vienna, Austria.
C3 University of Natural Resources & Life Sciences, Vienna; University of
   Natural Resources & Life Sciences, Vienna
RP Grausgruber, H (通讯作者)，BOKU Univ Nat Resources & Appl Life Sci, Dept Appl Plant Sci & Plant Biotechnol, Gregor Mendel Str 33, A-1180 Vienna, Austria.
EM heinrich.grausgruber@boku.ac.at
RI Grausgruber, Heinrich/D-9776-2019
OI Grausgruber, Heinrich/0000-0003-4790-0922; Vollmann,
   Johann/0000-0003-2057-8347; Schoenlechner, Regine/0000-0002-2014-7187
CR AACC, 2004, APPR METH
   Blaszczak W, 2004, EUR FOOD RES TECHNOL, V219, P348, DOI 10.1007/s00217-004-0972-8
   Borghi B, 1996, CEREAL CHEM, V73, P208
   Collar C, 2005, EUR FOOD RES TECHNOL, V221, P298, DOI 10.1007/s00217-005-1162-z
   Collar C, 2001, FOOD SCI TECHNOL INT, V7, P501, DOI 10.1106/CPGA-20Q4-YXR7-64JA
   Curic D, 2002, INT J FOOD SCI TECH, V37, P673, DOI 10.1046/j.1365-2621.2002.00598.x
   DEGIDIO MG, 1993, CEREAL CHEM, V70, P298
   Fregaeu-Reid J., 2005, SPECIALTY GRAINS FOO, P37
   Friendly M, 1991, SAS SYSTEM STAT GRAP, p[437, 532]
   Gerrard JA, 2005, TRENDS FOOD SCI TECH, V16, P510, DOI 10.1016/j.tifs.2005.07.002
   Gomez M, 2004, EUR FOOD RES TECHNOL, V219, P145, DOI 10.1007/s00217-004-0937-y
   Haros M, 2002, EUR FOOD RES TECHNOL, V215, P425, DOI 10.1007/s00217-002-0580-4
   INOUE S, 1995, J JPN SOC FOOD SCI, V42, P634
   Kohler P, 1999, J AGR FOOD CHEM, V47, P1863, DOI 10.1021/jf980891i
   Larre C, 2000, CEREAL CHEM, V77, P121, DOI 10.1094/CCHEM.2000.77.2.121
   Leszczynska J, 2006, FOOD AGR IMMUNOL, V17, P105, DOI 10.1080/09540100600870279
   Loje H, 2003, J CEREAL SCI, V37, P231, DOI 10.1006/jcrs.2002.0498
   Maache-Rezzoug Z, 1998, J FOOD ENG, V35, P23, DOI 10.1016/S0260-8774(98)00017-X
   MARQUART L, 2002, WHOLE GRAIN FOODS HL, P382
   Molberg O, 2005, GASTROENTEROLOGY, V128, P393, DOI 10.1053/j.gastro.2004.11.003
   Nakamura A, 2005, J NUTR SCI VITAMINOL, V51, P204, DOI 10.3177/jnsv.51.204
   Poza OD, 2002, CEREAL FOOD WORLD, V47, P93
   Ribotta PD, 2004, FOOD HYDROCOLLOID, V18, P305, DOI 10.1016/S0268-005X(03)00086-9
   Rosell CM, 2001, J AGR FOOD CHEM, V49, P2973, DOI 10.1021/jf010012j
   *SAS I INC, 1999, SAS STAT US GUID VER, V2, P1467
   *SAS I INC, 1999, SAS PROC GUID VERS 8, V1, P273
   Vollmar A., 2005, Getreidetechnologie, V59, P57
NR 27
TC 12
Z9 12
U1 0
U2 49
PU AKADEMIAI KIADO
PI BUDAPEST
PA PRIELLE K U 19, H-1117 BUDAPEST, HUNGARY
SN 0139-3006
J9 ACTA ALIMENT HUNG
JI Acta Aliment.
PD SEP
PY 2008
VL 37
IS 3
BP 379
EP 390
DI 10.1556/AAlim.2008.0009
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 349RF
UT WOS:000259300300009
DA 2022-11-30
ER

PT J
AU Kosmadakis, G
AF Kosmadakis, George
TI Rheopheresis: A narrative review
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Review
DE Rheopheresis; haemorheopheresis; rheohaemapheresis
ID SUDDEN HEARING-LOSS; MACULAR DEGENERATION; THERAPEUTIC APHERESIS;
   FIBRINOGEN; HEMAPHERESIS; DISORDERS; SOCIETY; FORM
AB Introduction: Rheopheresis is an extracorporal selective double-filtration procedure with an initial separation of plasma from the whole blood and a further filtration of the plasma through a second filter in order to eliminate a certain number of high molecular weight proteins such LDL, Lp(a), fibrinogen, alpha 2-macroglobulin, Factor von Willebrand, and IgM Immunoglobulin. Methods: In this narrative review we discuss the available data on the effects of Rheopheresis in various clinical conditions. Results: Rheopheresis is considerd to exert a rapid effect on clinical conditions associated with seriously affected microcirculation and rheologic parameters such as, the dry age-related macular degeneration (AMD), sudden sensorineural hearing loss (SSHS), peripheral artery disease (PAD), calciphylaxis, systemic sclerosis and diabetic foot. Conclusions: Rheopheresis is a promising technique for conditions associated with affected microcirculatory rheologic parameters
C1 [Kosmadakis, George] AURA Sante, Pole Sante Republ, 105 Ave Republique, F-63009 Clermont Ferrand, France.
RP Kosmadakis, G (通讯作者)，AURA Sante, Pole Sante Republ, 105 Ave Republique, F-63009 Clermont Ferrand, France.
EM George.kosmadakis@gmail.com
OI Kosmadakis, G/0000-0001-7973-6915
CR Balletshofer BM, 2005, THER APHER DIAL, V9, P385, DOI 10.1111/j.1744-9987.2005.00316.x
   Bennani HN, 2019, J CLIN APHERESIS, V34, P631, DOI 10.1002/jca.21736
   Berrouschot J, 1999, STROKE, V30, P787, DOI 10.1161/01.STR.30.4.787
   Blaha M, 2015, ATHEROSCLEROSIS SUPP, V18, P140, DOI 10.1016/j.atherosclerosissup.2015.02.009
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Bouderlique E, 2018, THER APHER DIAL, V22, P413, DOI 10.1111/1744-9987.12666
   ClinicalTrials.gov, EFF TOL RHE OPH TREA
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P569, DOI 10.1097/IAE.0b013e3181a2f3fa
   Garcia-Lara AM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/857625
   Gonzalez-Vicent M, 2013, TRANSFUS APHER SCI, V49, P234, DOI 10.1016/j.transci.2013.05.004
   Hamich S, 2020, NEPHROL THER, V16, P431, DOI 10.1016/j.nephro.2020.09.002
   Keita AI, 2021, THER APHER DIAL, V25, P362, DOI 10.1111/1744-9987.13563
   Kirschkamp T, 2008, THER APHER DIAL, V12, P360, DOI 10.1111/j.1744-9987.2008.00610.x
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Klingel R, 2009, ATHEROSCLEROSIS SUPP, V10, P102, DOI 10.1016/S1567-5688(09)71821-5
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Korsten P, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00208
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Kostal M, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-017-0228-9
   Lutze S, 2017, CLIN HEMORHEOL MICRO, V67, P229, DOI 10.3233/CH-179204
   Maurizi-Balzan J, 2019, NEPHROL THER, V15, P439, DOI 10.1016/j.nephro.2019.01.005
   Melinda V, 2016, CLIN HEMORHEOL MICRO, V64, P977, DOI 10.3233/CH-168004
   Mosges R, 2008, OTOL NEUROTOL, V29, P769, DOI 10.1097/MAO.0b013e31817e5d03
   Mosges R, 2009, EUR ARCH OTO-RHINO-L, V266, P943, DOI 10.1007/s00405-008-0823-5
   Padmanabhan A, 2019, J CLIN APHERESIS, V34, P171, DOI 10.1002/jca.21705
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Ramunni A, 2007, BLOOD PURIFICAT, V25, P404, DOI 10.1159/000109101
   Ramunni A, 2013, ATHEROSCLEROSIS SUPP, V14, P83, DOI 10.1016/j.atherosclerosissup.2012.10.018
   Ramunni Alfonso, 2012, Clin Res Cardiol Suppl, V7, P41
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Robert T, 2020, NEPHROLOGY, V25, P298, DOI 10.1111/nep.13666
   Schuff-Werner P, 2002, ARTIF ORGANS, V26, P117, DOI 10.1046/j.1525-1594.2002.06879.x
   Ullrich H, 2004, J CLIN APHERESIS, V19, P71, DOI 10.1002/jca.20001
   Valbonesi M, 2004, INT J ARTIF ORGANS, V27, P806, DOI 10.1177/039139880402700911
   Worel N, 2019, TRANSFUS MED HEMOTH, V46, P394, DOI 10.1159/000503937
NR 39
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0391-3988
EI 1724-6040
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD MAY
PY 2022
VL 45
IS 5
BP 445
EP 454
AR 03913988221086597
DI 10.1177/03913988221086597
EA APR 2022
PG 10
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Transplantation
GA 0X7MI
UT WOS:000780170600001
PM 35389284
DA 2022-11-30
ER

PT J
AU Zhang, BS
   Chiu, CY
   Yuan, F
   Sang, T
   Cook, RJ
   Wilson, AF
   Bailey-Wilson, JE
   Chew, EY
   Xiong, MM
   Fan, RZ
AF Zhang, Bingsong
   Chiu, Chi-Yang
   Yuan, Fang
   Sang, Tian
   Cook, Richard J.
   Wilson, Alexander F.
   Bailey-Wilson, Joan E.
   Chew, Emily Y.
   Xiong, Momiao
   Fan, Ruzong
TI Gene-based analysis of bi-variate survival traits via functional
   regressions with applications to eye diseases
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE association study; common variants; complex diseases; functional data
   analysis; mixed effect Cox models; rare variants
AB Genetic studies of two related survival outcomes of a pleiotropic gene are commonly encountered but statistical models to analyze them are rarely developed. To analyze sequencing data, we propose mixed effect Cox proportional hazard models by functional regressions to perform gene-based joint association analysis of two survival traits motivated by our ongoing real studies. These models extend fixed effect Cox models of univariate survival traits by incorporating variations and correlation of multivariate survival traits into the models. The associations between genetic variants and two survival traits are tested by likelihood ratio test statistics. Extensive simulation studies suggest that type I error rates are well controlled and power performances are stable. The proposed models are applied to analyze bivariate survival traits of left and right eyes in the age-related macular degeneration progression.
C1 [Zhang, Bingsong; Sang, Tian; Fan, Ruzong] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA.
   [Chiu, Chi-Yang] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Div Biostat, Memphis, TN USA.
   [Chiu, Chi-Yang; Wilson, Alexander F.; Bailey-Wilson, Joan E.; Fan, Ruzong] NHGRI, Computat & Stat Genom Branch, NIH, Baltimore, MD 21224 USA.
   [Yuan, Fang] Kunming Med Univ, Sch Basic Med, Dept Biochem & Mol Biol, Kunming, Yunnan, Peoples R China.
   [Sang, Tian] Shanghai Univ Engn Sci, Sch Math Phys & Stat, Shanghai, Peoples R China.
   [Cook, Richard J.] Dept Stat & Actuarial Sci, Waterloo, ON, Canada.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Xiong, Momiao] Univ Texas Houston, Human Genet Ctr, Houston, TX 77025 USA.
C3 Georgetown University; University of Tennessee System; University of
   Tennessee Health Science Center; National Institutes of Health (NIH) -
   USA; NIH National Human Genome Research Institute (NHGRI); NIH National
   Institute on Aging (NIA); Kunming Medical University; Shanghai
   University of Engineering Science; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); University of Texas System;
   University of Texas Health Science Center Houston
RP Fan, RZ (通讯作者)，Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA.; Fan, RZ (通讯作者)，NHGRI, Computat & Stat Genom Branch, NIH, Baltimore, MD 21224 USA.
EM rf740@georgetown.edu
OI Zhang, Bingsong/0000-0002-4904-6961; Wilson,
   Alexander/0000-0002-6682-8156; Cook, Richard/0000-0002-1414-4908;
   Bailey-Wilson, Joan/0000-0002-9153-2920
FU U.S. National Science Foundation [DMS-1915904]
FX U.S. National Science Foundation, Grant/Award Number: DMS-1915904
CR [Anonymous], 2008, NAT METHODS, V5, P15, DOI 10.1038/NMETH1155
   Ansorge WJ, 2009, NEW BIOTECHNOL, V25, P195, DOI 10.1016/j.nbt.2008.12.009
   Bender R, 2005, STAT MED, V24, P1713, DOI 10.1002/sim.2059
   Broadaway KA, 2016, AM J HUM GENET, V98, P525, DOI 10.1016/j.ajhg.2016.01.017
   Chen H, 2014, GENET EPIDEMIOL, V38, P191, DOI 10.1002/gepi.21791
   Chien LC, 2017, GENET EPIDEMIOL, V41, P511, DOI 10.1002/gepi.22054
   Chiu CY, 2019, GENET EPIDEMIOL, V43, P952, DOI 10.1002/gepi.22254
   Chiu CY, 2019, GENET EPIDEMIOL, V43, P189, DOI 10.1002/gepi.22177
   Cox D. R., 1984, ANAL SURVIVAL DATA
   COX DR, 1972, J R STAT SOC B, V34, P187
   De Boor C., 2001, APPL MATH SCI, V27
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Fan R, 2016, GENET EPIDEMIOL, V40, P702, DOI 10.1002/gepi.21984
   Fan RZ, 2016, GENETICS, V202, P457, DOI 10.1534/genetics.115.180869
   Fan RZ, 2016, GENET EPIDEMIOL, V40, P133, DOI 10.1002/gepi.21947
   Fan RZ, 2015, GENETICS, V200, P1089, DOI 10.1534/genetics.115.178343
   Fan RZ, 2014, GENET EPIDEMIOL, V38, P622, DOI 10.1002/gepi.21840
   Fan RZ, 2013, GENET EPIDEMIOL, V37, P726, DOI 10.1002/gepi.21757
   Ferraty F, 2010, OXFORD HDB FUNCTIONA
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Horv?th L., 2012, INFERENCE FUNCTIONAL, DOI [10.1016/S0047-259X(02)00056-8, DOI 10.1007/978-1-4614-3655-3]
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Luo L, 2013, EUR J HUM GENET, V21, P217, DOI 10.1038/ejhg.2012.141
   Luo L, 2012, J MED GENET, V49, P513, DOI 10.1136/jmedgenet-2012-100798
   Luo L, 2011, GENOME RES, V21, P1099, DOI 10.1101/gr.115998.110
   Maity A, 2012, GENET EPIDEMIOL, V36, P686, DOI 10.1002/gepi.21663
   Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626
   Ramsay JO, 2009, USE R, P1, DOI 10.1007/978-0-387-98185-7_1
   Ramsay JO., 2005, FUNCTIONAL DATA ANAL, V2, DOI 10.1007/b98888
   Ross S., 1996, STOCHASTIC PROCESSES
   Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Stearns FW, 2010, GENETICS, V186, P767, DOI 10.1534/genetics.110.122549
   Therneau TM, 2019, MIXED EFFECTS COX MO
   THERNEAU TM, 2000, STAT BIOL HEALTH, pR7
   Vsevolozhskaya OA, 2016, GENET EPIDEMIOL, V40, P210, DOI 10.1002/gepi.21955
   Vsevolozhskaya OA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105074
   Wang YF, 2015, GENET EPIDEMIOL, V39, P259, DOI 10.1002/gepi.21895
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x
   Yuan F., 2021, GENET EPIDEMIOL, P1
NR 44
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
EI 1098-2272
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD JUL
PY 2021
VL 45
IS 5
BP 455
EP 470
DI 10.1002/gepi.22381
EA MAR 2021
PG 16
WC Genetics & Heredity; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Mathematical & Computational Biology
GA SW1KS
UT WOS:000623254500001
PM 33645812
DA 2022-11-30
ER

PT J
AU Bhosale, P
   Bernstein, PS
AF Bhosale, P
   Bernstein, PS
TI Microbial xanthophylls
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review
ID MICROALGA CHLORELLA-ZOFINGIENSIS; DIETARY BETA-CAROTENE; GREEN-ALGA;
   PHAFFIA-RHODOZYMA; PRELIMINARY IDENTIFICATION; HAEMATOCOCCUS-PLUVIALIS;
   ASTAXANTHIN PRODUCTION; ANTIOXIDANT ACTIVITY; ESCHERICHIA-COLI;
   MURIELLOPSIS SP
AB Xanthophylls are oxygenated carotenoids abundant in the human food supply. Lutein, zeaxanthin, and cryptoxanthin are major xanthophyll carotenoids in human plasma. The consumption of these xanthophylls is directly associated with reduction in the risk of,cancers, cardiovascular disease, age-related macular degeneration, and cataract formation. Canthaxanthin and astaxanthin also have considerable importance in aquaculture for salmonid and crustacean pigmentation, and are of commercial interest for the pharmaceutical and food industries. Chemical synthesis is a major source for the heavy demand of xanthophylls in the consumer market; however, microbial producers also have potential as commercial sources. In this review, we discuss the biosynthesis, commercial utility, and major microbial sources of xanthophylls. We also present a critical review of current research and technologies involved in promoting microbes as potential commercial sources for mass production.
C1 Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bhosale, P (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 75 N Med Dr, Salt Lake City, UT 84132 USA.
EM prakash.bhosale@hsc.utah.edu
FU NATIONAL EYE INSTITUTE [R29EY011600, R01EY011600] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY-11600] Funding Source: Medline
CR Albrecht M, 1997, J BIOTECHNOL, V58, P177, DOI 10.1016/S0168-1656(97)00151-X
   Alcantara S, 1999, J IND MICROBIOL BIOT, V23, P697, DOI 10.1038/sj.jim.2900688
   AN GH, 1990, ANTON LEEUW INT J G, V57, P91, DOI DOI 10.1007/BF00400151
   ANTIA NJ, 1983, PHYCOLOGIA, V22, P235, DOI 10.2216/i0031-8884-22-3-235.1
   ARAD S, 1993, PHYSIOL PLANTARUM, V87, P232, DOI 10.1034/j.1399-3054.1993.870217.x
   Armstrong GA, 1997, ANNU REV MICROBIOL, V51, P629, DOI 10.1146/annurev.micro.51.1.629
   Ausich RL, 1997, PURE APPL CHEM, V69, P2169, DOI 10.1351/pac199769102169
   Baker RTM, 2001, TRENDS FOOD SCI TECH, V12, P240, DOI 10.1016/S0924-2244(01)00091-7
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Berry A, 2003, INT J SYST EVOL MICR, V53, P231, DOI 10.1099/ijs.0.02368-0
   Bhosale P, 2004, J APPL MICROBIOL, V96, P623, DOI 10.1111/j.1365-2672.2004.02197.x
   Bhosale P, 2004, APPL MICROBIOL BIOT, V63, P351, DOI 10.1007/s00253-003-1441-1
   BINNS CW, 2004, ASIA PAC J CLIN NU S, V13, pS117
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BOUDREAULT G, 1983, CAN J OPHTHALMOL, V18, P325
   BOUSSIBA S, 1991, PLANT CELL PHYSIOL, V32, P1077, DOI 10.1093/oxfordjournals.pcp.a078171
   Boussiba S, 2000, PHYSIOL PLANTARUM, V108, P111, DOI 10.1034/j.1399-3054.2000.108002111x./
   BRITTON G, 1977, FEBS LETT, V79, P281, DOI 10.1016/0014-5793(77)80803-X
   Britton G., 1998, CAROTENOIDS BIOSYNTH, V3, P13
   CHANG JM, 1995, NUTR CANCER, V24, P325, DOI 10.1080/01635589509514421
   Chew BP, 1996, ANTICANCER RES, V16, P3689
   Chew BP, 1999, ANTICANCER RES, V19, P1849
   CHICHESTER C. O., 1967, PURE APPL CHEM, V14, P215, DOI 10.1351/pac196714020215
   COONEY JJ, 1966, J BACTERIOL, V92, P342, DOI 10.1128/JB.92.2.342-345.1966
   COONEY JJ, 1981, CAN J MICROBIOL, V27, P421, DOI 10.1139/m81-064
   Czeczuga-Semeniuk E, 2003, NEOPLASMA, V50, P280
   CZYGAN FC, 1964, EXPERIENTIA, V20, P573, DOI 10.1007/BF02150302
   de Miguel T, 2001, J AGR FOOD CHEM, V49, P1200, DOI 10.1021/jf001169z
   Del Campo JA, 2004, APPL MICROBIOL BIOT, V64, P848, DOI 10.1007/s00253-003-1510-5
   Del Campo JA, 2001, J BIOTECHNOL, V85, P289, DOI 10.1016/S0168-1656(00)00380-1
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   DelgadoVargas F, 1997, PLANT FOOD HUM NUTR, V50, P163, DOI 10.1007/BF02436035
   DI MASCIO P, 1990, BIOCHEM SOC T, V18, P1054
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   Ernst H, 2002, PURE APPL CHEM, V74, P1369, DOI 10.1351/pac200274081369
   FRANCIS GW, 1975, ARCH MICROBIOL, V104, P249, DOI 10.1007/BF00447333
   Fraser PD, 1997, J BIOL CHEM, V272, P6128, DOI 10.1074/jbc.272.10.6128
   FRESNEDO O, 1991, FEBS LETT, V282, P300, DOI 10.1016/0014-5793(91)80500-3
   GENSLER HL, 1990, CANCER LETT, V49, P231, DOI 10.1016/0304-3835(90)90164-S
   Goodwin T.W., 1980, BIOCH CAROTENOIDS, P33
   GOODWIN TW, 1993, METHOD ENZYMOL, V214, P330
   GORDON HT, 1982, CRC CR REV FOOD SCI, V18, P59, DOI 10.1080/10408398209527357
   GOSWAMI UC, 1981, INDIAN J BIOCHEM BIO, V18, P88
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204
   Grunewald K, 2001, J BIOL CHEM, V276, P6023, DOI 10.1074/jbc.M006400200
   Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7
   Guyomarc'h F, 2000, J IND MICROBIOL BIOT, V24, P64, DOI 10.1038/sj.jim.2900761
   Hadden WL, 1999, J AGR FOOD CHEM, V47, P4189, DOI 10.1021/jf990096k
   Hirschberg J, 1999, CURR OPIN BIOTECH, V10, P186, DOI 10.1016/S0958-1669(99)80033-0
   HOSHINO TO, 2004, Patent No. 20030923
   Humbelin M, 2002, GENE, V297, P129, DOI 10.1016/S0378-1119(02)00877-6
   Ip PF, 2005, PROCESS BIOCHEM, V40, P733, DOI 10.1016/j.procbio.2004.01.039
   Ip PF, 2004, PROCESS BIOCHEM, V39, P1761, DOI 10.1016/j.procbio.2003.08.003
   ITO M, 1992, METHOD ENZYMOL, V213, P13
   Jin ES, 2003, BIOTECHNOL BIOENG, V81, P115, DOI 10.1002/bit.10459
   Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119
   Johnson EA, 2003, INT MICROBIOL, V6, P169, DOI 10.1007/s10123-003-0130-3
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Jyonouchi H, 1996, NUTR CANCER, V26, P313, DOI 10.1080/01635589609514487
   JYONOUCHI H, 1994, NUTR CANCER, V21, P47, DOI 10.1080/01635589409514303
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 2003, Patent No. 2003066547
   Khachik F, 1995, US Patent, Patent No. [5,382,714, 5382714]
   KOBAYASHI M, 1992, J FERMENT BIOENG, V74, P61, DOI 10.1016/0922-338X(92)90271-U
   Kotake-Nara E, 2001, J NUTR, V131, P3303, DOI 10.1093/jn/131.12.3303
   KRINSKY NI, 1960, ARCH BIOCHEM BIOPHYS, V91, P271, DOI 10.1016/0003-9861(60)90501-4
   Lee PC, 2002, APPL MICROBIOL BIOT, V60, P1, DOI 10.1007/s00253-002-1101-x
   Lorenz RT, 2000, TRENDS BIOTECHNOL, V18, P160, DOI 10.1016/S0167-7799(00)01433-5
   LOTAN T, 1995, FEBS LETT, V364, P125, DOI 10.1016/0014-5793(95)00368-J
   MALAK NA, 1975, ANN NUTR ALIMENT, V29, P459
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Margalith PZ, 1999, APPL MICROBIOL BIOT, V51, P431, DOI 10.1007/s002530051413
   Masetto A, 2001, J BIOSCI BIOENG, V92, P55, DOI 10.1263/jbb.92.55
   MATHEWSROTH MM, 1987, PHOTOCHEM PHOTOBIOL, V46, P507, DOI 10.1111/j.1751-1097.1987.tb04803.x
   MAYNE ST, 1989, NUTR CANCER, V12, P225, DOI 10.1080/01635588909514022
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   McDermott J C, 1973, Pure Appl Chem, V35, P29, DOI 10.1351/pac197335010029
   Melendez-Martinez AJ, 2004, ARCH LATINOAM NUTR, V54, P149
   MEYER PS, 1994, SYST APPL MICROBIOL, V17, P24, DOI 10.1016/S0723-2020(11)80027-5
   Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   NELIS HJ, 1989, APPL ENVIRON MICROB, V55, P2505, DOI 10.1128/AEM.55.10.2505-2510.1989
   NELIS HJ, 1991, J APPL BACTERIOL, V70, P181, DOI 10.1111/j.1365-2672.1991.tb02922.x
   Nishino H, 2002, CANCER METAST REV, V21, P257, DOI 10.1023/A:1021206826750
   Okai Y, 1996, INT J IMMUNOPHARMACO, V18, P753, DOI 10.1016/S0192-0561(97)85558-0
   Olaizola M, 2000, J APPL PHYCOL, V12, P499, DOI 10.1023/A:1008159127672
   PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P291, DOI 10.1016/0003-9861(92)90675-M
   Pasamontes L, 1997, GENE, V185, P35, DOI 10.1016/S0378-1119(96)00624-5
   Pattison DJ, 2004, J RHEUMATOL, V31, P1310
   Pelah D, 2004, WORLD J MICROB BIOT, V20, P483, DOI 10.1023/B:WIBI.0000040398.93103.21
   PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0
   QUACKENBUSH FW, 1972, J ASSOC OFF ANA CHEM, V55, P617
   RODRIGUEZ DB, 1973, INT J BIOCHEM, V4, P213, DOI 10.1016/0020-711X(73)90042-6
   ROSENBERGER M, 1982, J ORG CHEM, V47, P2130, DOI 10.1021/jo00132a028
   Ruther A, 1997, APPL MICROBIOL BIOT, V48, P162, DOI 10.1007/s002530051032
   Salguero A, 2005, APPL MICROBIOL BIOT, V66, P506, DOI 10.1007/s00253-004-1711-6
   SANDMANN G, 1991, PHYSIOL PLANTARUM, V83, P186, DOI 10.1034/j.1399-3054.1991.830128.x
   Sandmann G, 2001, TRENDS PLANT SCI, V6, P14, DOI 10.1016/S1360-1385(00)01817-3
   Sandmann G, 2001, ARCH BIOCHEM BIOPHYS, V385, P4, DOI 10.1006/abbi.2000.2170
   SANDMANN G, 1994, EUR J BIOCHEM, V223, P7, DOI 10.1111/j.1432-1033.1994.tb18961.x
   Sanpietro LMD, 1998, YEAST, V14, P1007
   SANTAMARIA L, 1988, ANN NY ACAD SCI, V534, P584, DOI 10.1111/j.1749-6632.1988.tb30149.x
   SAPERSTEIN S, 1954, BIOCHEM J, V57, P273, DOI 10.1042/bj0570273
   Schmidt-Dannert C, 2000, CURR OPIN BIOTECH, V11, P255, DOI 10.1016/S0958-1669(00)00093-8
   Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shi XM, 2002, BIOTECHNOL PROGR, V18, P723, DOI 10.1021/bp0101987
   Shi XM, 1999, PROCESS BIOCHEM, V34, P341, DOI 10.1016/S0032-9592(98)00101-0
   Shi XM, 2000, ENZYME MICROB TECH, V27, P312, DOI 10.1016/S0141-0229(00)00208-8
   Shimada H, 1998, APPL ENVIRON MICROB, V64, P2676
   SIEIRO C, 2003, MICROORGANISMS HLTH, V1, P85
   SIMPSON KL, 1981, ANNU REV NUTR, V1, P351, DOI 10.1146/annurev.nu.01.070181.002031
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532
   Stahl W, 1996, ARCH BIOCHEM BIOPHYS, V336, P1, DOI 10.1006/abbi.1996.0525
   SUHONEN R, 1981, DERMATOLOGICA, V163, P172, DOI 10.1159/000250156
   SUMIDA T, 2002, SHOKUHIN KOGYO, V45, P18
   TERAO J, 1989, LIPIDS, V24, P659, DOI 10.1007/BF02535085
   Tsao R, 2004, J CHROMATOGR A, V1045, P65, DOI 10.1016/j.chroma.2004.06.020
   Uchiyama S, 2004, J HEALTH SCI, V50, P491, DOI 10.1248/jhs.50.491
   Vazquez M, 2001, FOOD TECHNOL BIOTECH, V39, P123
   Veiga-Crespo P, 2005, INT MICROBIOL, V8, P55
   Wang X, 2000, ANTIMICROB AGENTS CH, V44, P2452, DOI 10.1128/AAC.44.9.2452-2457.2000
   Wasileski J.M., 2000, Patent No. [6015684, US6015684A]
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   YAMAGUCHI M, 2004, Patent No. 2004037236
   Yamamoto HY, 1999, ADV PHOTOSYNTH, V8, P293
   YOKOYAMA A, 1994, BIOSCI BIOTECH BIOCH, V58, P1842, DOI 10.1271/bbb.58.1842
   YOUNG A, 1990, PHOTOSYNTH RES, V25, P129, DOI 10.1007/BF00035461
   Yuan JM, 2003, CANCER EPIDEM BIOMAR, V12, P890
   Yuan JM, 2001, CANCER EPIDEM BIOMAR, V10, P767
   Zhang XW, 1999, J IND MICROBIOL BIOT, V23, P691, DOI 10.1038/sj.jim.2900685
   1998, FED REG, V63, P14814
NR 134
TC 131
Z9 140
U1 5
U2 57
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD SEP
PY 2005
VL 68
IS 4
BP 445
EP 455
DI 10.1007/s00253-005-0032-8
PG 11
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 969GP
UT WOS:000232222900003
PM 16001255
DA 2022-11-30
ER

PT J
AU Zadeh, MA
   Khoder, M
   Ai-Kinani, AA
   Younes, HM
   Alany, RG
AF Zadeh, Maria Abedin
   Khoder, Mouhamad
   Ai-Kinani, Ali A.
   Younes, Husam M.
   Alany, Raid G.
TI Retinal cell regeneration using tissue engineered polymeric scaffolds
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; ANTERIOR LENS CAPSULE; MACULAR DEGENERATION;
   EXTRACELLULAR-MATRIX; PIGMENT EPITHELIUM; BRUCHS MEMBRANE; NANOFIBROUS
   SCAFFOLDS; IN-VITRO; ALGINATE; TRANSPLANTATION
AB Degenerative retinal diseases, such as age-related macular degeneration (AMD), can lead to permanent sight loss. Although intravitreal anti-vascular endothelial growth factor (VEGF) and steroid injections are effective for the management of early stages of wet and/or neovascular AMD (nAMD), no proven treatments currently exist for dry AMD or for the advanced geographic atrophy of the retina that follows. Tissue engineering (TE) has recently emerged as a promising alternative to repair retinal damaged and restore its functions. Here, we review recent advances in TE, with a particular emphasis on retinal regeneration. We provide an overview of retinal diseases, followed by a comprehensive review of TE techniques, cells, and polymers used in the fabrication of scaffolds for retinal cell regenerations, in particular the retinal pigment epithelium (RPE).
C1 [Zadeh, Maria Abedin; Khoder, Mouhamad; Ai-Kinani, Ali A.; Alany, Raid G.] Kingston Univ London, Sch Life Sci Pharm & Chem, Drug Discovery Delivery & Patient Care DDDPC Them, London, England.
   [Zadeh, Maria Abedin; Khoder, Mouhamad; Ai-Kinani, Ali A.; Younes, Husam M.; Alany, Raid G.] Qatar Univ, Coll Pharm, Pharmaceut & Polymer Drug Delivery Res Lab, Doha, Qatar.
   [Alany, Raid G.] Univ Auckland, Sch Pharm, Auckland, New Zealand.
   [Younes, Husam M.] Qatar Univ, Off Vice President Res & Grad Studies, Doha, Qatar.
C3 Kingston University; Qatar University; University of Auckland; Qatar
   University
RP Khoder, M; Alany, RG (通讯作者)，Kingston Univ London, Sch Life Sci Pharm & Chem, Drug Discovery Delivery & Patient Care DDDPC Them, London, England.; Khoder, M; Alany, RG (通讯作者)，Qatar Univ, Coll Pharm, Pharmaceut & Polymer Drug Delivery Res Lab, Doha, Qatar.; Alany, RG (通讯作者)，Univ Auckland, Sch Pharm, Auckland, New Zealand.
EM m.khoder@kingston.ac.uk; r.alany@kingston.ac.uk
RI Khoder, Mouhamad/AAD-3171-2021
OI Al-kinani, Ali Athab/0000-0003-4940-7648; Abedinzadeh,
   Maria/0000-0002-4903-0513; Khoder, Mouhamad/0000-0002-7640-471X
CR Achilli M, 2010, MACROMOL BIOSCI, V10, P307, DOI 10.1002/mabi.200900248
   Al Dalaty A, 2016, CARBOHYD POLYM, V140, P163, DOI 10.1016/j.carbpol.2015.12.010
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Azari P, 2015, INT J POLYM MATER PO, V64, P785, DOI 10.1080/00914037.2015.1030648
   Bandah-Rozenfeld D, 2010, AM J HUM GENET, V87, P199, DOI 10.1016/j.ajhg.2010.07.004
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bruzauskaite I, 2016, CYTOTECHNOLOGY, V68, P355, DOI 10.1007/s10616-015-9895-4
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Chen GN, 2015, BIOMED REP, V3, P749, DOI 10.3892/br.2015.522
   Chen HL, 2017, ACS APPL MATER INTER, V9, P38187, DOI 10.1021/acsami.7b07151
   Chen HL, 2011, INT J BIOL MACROMOL, V48, P13, DOI 10.1016/j.ijbiomac.2010.09.019
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chiono V, 2014, INTERFACE FOCUS, V4, DOI 10.1098/rsfs.2013.0045
   Daley WP, 2008, J CELL SCI, V121, P255, DOI 10.1242/jcs.006064
   de Valence S, 2013, EUR J PHARM BIOPHARM, V85, P78, DOI 10.1016/j.ejpb.2013.06.012
   Deshpande Pallavi, 2013, Methods Mol Biol, V1014, P179, DOI 10.1007/978-1-62703-432-6_12
   Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602
   Do AV, 2015, ADV HEALTHC MATER, V4, P1742, DOI 10.1002/adhm.201500168
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dutt K, 2009, TISSUE ENG PT A, V15, P1401, DOI 10.1089/ten.tea.2007.0358
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Freed LE, 2009, ADV MATER, V21, P3410, DOI 10.1002/adma.200900303
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Garg K, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3567097
   Ghassemi T, 2018, ARCH BONE JT SURG-AB, V6, P90
   Goncalves S, 2015, BIOMACROMOLECULES, V16, P1341, DOI 10.1021/acs.biomac.5b00129
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Haraguchi Y, 2012, RSC ADV, V2, P2184, DOI 10.1039/c2ra00704e
   Heidari R, 2015, APPL BIOCHEM BIOTECH, V175, P2399, DOI 10.1007/s12010-014-1431-z
   Hernon CA, 2006, REGEN MED, V1, P809, DOI 10.2217/17460751.1.6.809
   Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469-7580.2008.00878.x
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Isaacson A, 2018, EXP EYE RES, V173, P188, DOI 10.1016/j.exer.2018.05.010
   Jain A, 2015, J PHARM BIOALLIED SC, V7, P188, DOI 10.4103/0975-7406.160013
   Janik H, 2015, MAT SCI ENG C-MATER, V48, P586, DOI 10.1016/j.msec.2014.12.037
   Jeong Su Mi, 2011, Int J Stem Cells, V4, P105
   Karamichos D, 2015, J FUNCT BIOMATER, V6, P77, DOI 10.3390/jfb6010077
   Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003
   Kern TS, 2015, J DIABETES INVEST, V6, P371, DOI 10.1111/jdi.12312
   Kessler Michael W, 2008, Organogenesis, V4, P28
   Khan F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010017
   Kiilgaard Jens Folke, 2012, Stem Cells Int, V2012, P716968, DOI 10.1155/2012/716968
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Kim Y, 2016, INT NEUROUROL J, V20, pS23, DOI 10.5213/inj.1632600.318
   Kong B, 2016, MATERIALS, V9, DOI 10.3390/ma9080614
   Kozak I, 2015, SAUDI J OPHTHALMOL, V29, P137, DOI 10.1016/j.sjopt.2014.09.001
   Kramerov AA, 2016, EXP BIOL MED, V241, P559, DOI 10.1177/1535370215609692
   Kruse M, 2018, CURR EYE RES, V43, P1, DOI 10.1080/02713683.2017.1377258
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Kuijpers AJ, 2000, J BIOMAT SCI-POLYM E, V11, P225, DOI 10.1163/156856200743670
   Lai JY, 2010, INT J MOL SCI, V11, P5257, DOI 10.3390/ijms11125256
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Li YC, 2017, J THORAC DIS, V9, P455, DOI 10.21037/jtd.2017.02.77
   Lorber B, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/1/015001
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu TL, 2013, INT J NANOMED, V8, P337, DOI 10.2147/IJN.S38635
   Luo MY, 2018, INT J OPHTHALMOL-CHI, V11, P150, DOI 10.18240/ijo.2018.01.23
   Ma HS, 2018, ACTA BIOMATER, V79, P37, DOI 10.1016/j.actbio.2018.08.026
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   Mertens JP, 2014, REGEN MED, V9, P89, DOI [10.2217/RME.13.81, 10.2217/rme.13.81]
   Miller JW, 2008, NEW ENGL J MED, V358, P2282, DOI 10.1056/NEJMe0803081
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Najafabadi Hoda Shams, 2015, J Ophthalmic Vis Res, V10, P286, DOI 10.4103/2008-322X.170357
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369-7021(11)70058-X
   Oliveira HL, 2017, CALCIFIED TISSUE INT, V101, P341, DOI 10.1007/s00223-017-0294-z
   Oner A, 2018, TURK OFTALMOL DERG, V48, P33, DOI 10.4274/tjo.89972
   Ovsianikov A, 2018, TRENDS BIOTECHNOL, V36, P348, DOI 10.1016/j.tibtech.2018.01.005
   Phu D, 2009, IEEE ENG MED BIO, P4242, DOI 10.1109/IEMBS.2009.5332702
   Rahmani S, 2018, INT J POLYM MATER PO, V67, P27, DOI 10.1080/00914037.2017.1297939
   Reisman Miriam, 2014, P T, V39, P846
   Rohani L, 2018, STEM CELL TRANSL MED, V7, P867, DOI 10.1002/sctm.18-0087
   Samiy Nasrollah, 2014, J Ophthalmic Vis Res, V9, P506, DOI 10.4103/2008-322X.150831
   Sharma S, 2014, INVEST OPHTH VIS SCI, V55, P899, DOI 10.1167/iovs.13-12727
   Sharma S, 2011, MOL VIS, V17, P2898
   Shi P, 2017, JOURNAL, VXX
   Shi PJ, 2017, INT J BIOPRINTING, V3, P138, DOI 10.18063/IJB.2017.02.008
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Smith J, 2015, EYE, V29, P1131, DOI 10.1038/eye.2015.115
   Stratton S, 2016, BIOACT MATER, V1, P93, DOI 10.1016/j.bioactmat.2016.11.001
   Subia B, 2010, TISSUE ENGINEERING, P141
   Sun JC, 2013, MATERIALS, V6, P1285, DOI 10.3390/ma6041285
   Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tonsomboon K, 2013, J MECH BEHAV BIOMED, V21, P185, DOI 10.1016/j.jmbbm.2013.03.001
   Trese M, 2012, MATERIALS, V5, P108, DOI 10.3390/ma5010108
   Van Ba OL, 2015, ADV DRUG DELIVER REV, V82-83, P31, DOI 10.1016/j.addr.2014.11.013
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Wu ZJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24474
   Xie JW, 2008, MACROMOL RAPID COMM, V29, P1775, DOI 10.1002/marc.200800381
   Xu YY, 2016, BIOACT MATER, V1, P18, DOI 10.1016/j.bioactmat.2016.03.002
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
   Zhang WX, 2016, TISSUE ENG PART B-RE, V22, P193, DOI [10.1089/ten.teb.2015.0290, 10.1089/ten.TEB.2015.0290]
NR 108
TC 13
Z9 13
U1 2
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2019
VL 24
IS 8
SI SI
BP 1669
EP 1678
DI 10.1016/j.drudis.2019.04.009
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IX7GP
UT WOS:000485852100027
PM 31051266
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Akhtar-Schafer, I
   Wang, LP
   Krohne, TU
   Xu, HP
   Langmann, T
AF Akhtar-Schaefer, Isha
   Wang, Luping
   Krohne, Tim U.
   Xu, Heping
   Langmann, Thomas
TI Modulation of three key innate immune pathways for the most common
   retinal degenerative diseases
SO EMBO MOLECULAR MEDICINE
LA English
DT Review
DE complement; inflammasome; microglia; mononuclear phagocytes; retina
ID NLRP3 INFLAMMASOME ACTIVATION; PIGMENT EPITHELIAL-CELLS; OPTICAL
   COHERENCE TOMOGRAPHY; MEMBRANE ATTACK COMPLEX; ADENOSINE A(2A)
   RECEPTORS; NF-KAPPA-B; INDUCED CHOROIDAL NEOVASCULARIZATION;
   PROLIFERATIVE DIABETIC-RETINOPATHY; PATTERN-RECOGNITION RECEPTORS;
   NECROSIS-FACTOR-ALPHA
AB This review highlights the role of three key immune pathways in the pathophysiology of major retinal degenerative diseases including diabetic retinopathy, age-related macular degeneration, and rare retinal dystrophies. We first discuss the mechanisms how loss of retinal homeostasis evokes an unbalanced retinal immune reaction involving responses of local microglia and recruited macrophages, activity of the alternative complement system, and inflammasome assembly in the retinal pigment epithelium. Presenting these key mechanisms as complementary targets, we specifically emphasize the concept of immunomodulation as potential treatment strategy to prevent or delay vision loss. Promising molecules are ligands for phagocyte receptors, specific inhibitors of complement activation products, and inflammasome inhibitors. We comprehensively summarize the scientific evidence for this strategy from preclinical animal models, human ocular tissue analyses, and clinical trials evolving in the last few years.
C1 [Akhtar-Schaefer, Isha; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [Wang, Luping; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Langmann, Thomas] Univ Cologne, Ctr Mol Med, Cologne, Germany.
C3 University of Cologne; University of Bonn; Queens University Belfast;
   University of Cologne
RP Langmann, T (通讯作者)，Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.; Langmann, T (通讯作者)，Univ Cologne, Ctr Mol Med, Cologne, Germany.
EM thomas.langmann@uk-koeln.de
RI Krohne, Tim/D-1497-2013; Xu, Heping/A-4430-2008; Krohne,
   Tim/AAG-4412-2020
OI Krohne, Tim/0000-0003-2280-925X; Xu, Heping/0000-0003-4000-931X; 
FU DFG [LA1203/6-2, LA1203/9-1, LA1203/10-1, FOR2240]; ProRetina
   Foundation; Hans and Marlies Stock-Foundation; Diabetes UK [11/0004230,
   13/0004729]; European Union [722717]; Fight for Sight [1574/1575];
   Dunhill Medical Trust [R188/0211]
FX Research in the laboratory of T.L. is supported by the DFG (LA1203/6-2,
   LA1203/9-1, LA1203/10-1 and FOR2240), the ProRetina Foundation, and the
   Hans and Marlies Stock-Foundation. Research in Dr H. Xu's laboratory is
   supported by Diabetes UK (11/0004230, 13/0004729), European Union's
   Horizon 2020 (722717), Fight for Sight (1574/1575), and Dunhill Medical
   Trust (R188/0211).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Al-Gayyar MM, 2013, EUR CYTOKINE NETW, V24, P27, DOI 10.1684/ecn.2013.0334
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Amith SR, 2010, CELL SIGNAL, V22, P314, DOI 10.1016/j.cellsig.2009.09.038
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson JB, 2002, TRANSPLANT P, V34, P1083, DOI 10.1016/S0041-1345(02)02805-1
   Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200
   [Anonymous], 2018, RET INF NETW
   Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001
   Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Baumgartner WA, 2013, MED HYPOTHESES, V81, P720, DOI 10.1016/j.mehy.2013.07.036
   Behl Y, 2008, AM J PATHOL, V172, P1411, DOI 10.2353/ajpath.2008.071070
   Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Boss JD, 2017, INVEST OPHTH VIS SCI, V58, P5594, DOI 10.1167/iovs.17-21973
   Boulton M.E., 2013, AGE RELATED MACULAR, P45
   Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Brown GC, 2012, TRENDS BIOCHEM SCI, V37, P325, DOI 10.1016/j.tibs.2012.05.002
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Broz P, 2013, NAT REV IMMUNOL, V13, P551, DOI 10.1038/nri3479
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cai HL, 2018, PSYCHONEUROENDOCRINO, V90, P43, DOI 10.1016/j.psyneuen.2018.02.004
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131
   Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009
   Cantarini L, 2015, CLIN RHEUMATOL, V34, P1293, DOI 10.1007/s10067-013-2443-8
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Chan-Ling T, 2007, MICROCIRCULATION, V14, P63, DOI 10.1080/10739680601073451
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2018, AM J PATHOL, V188, P1007, DOI 10.1016/j.ajpath.2017.12.021
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Cheng LJ, 2013, INVEST OPHTH VIS SCI, V54, P8191, DOI 10.1167/iovs.13-12428
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chio CC, 2004, CELL SIGNAL, V16, P565, DOI 10.1016/j.cellsig.2003.10.003
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Choe JY, 2017, INFLAMMATION, V40, P980, DOI 10.1007/s10753-017-0542-4
   Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Cirino AC, 2006, RETINA-J RET VIT DIS, V26, P1091, DOI 10.1097/01.iae.0000254891.48272.13
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2007, AM J PATHOL, V171, P580, DOI 10.2353/ajpath.2007.070272
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Costa G, 2009, J NEUROSCI RES, V87, P1375, DOI 10.1002/jnr.21956
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cukras CA, 2012, INVEST OPHTH VIS SCI, V53, P3865, DOI 10.1167/iovs.11-9413
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Dang YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095548
   Das A, 2015, DIABETES OBES METAB, V17, P219, DOI 10.1111/dom.12384
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124
   De Benedetto U, 2015, RETINA-J RET VIT DIS, V35, P449, DOI 10.1097/IAE.0000000000000336
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Dempsey C, 2017, BRAIN BEHAV IMMUN, V61, P306, DOI 10.1016/j.bbi.2016.12.014
   Dentchev T, 2003, MOL VIS, V9, P184
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards JL, 2008, VACCINE, V26, pI56, DOI 10.1016/j.vaccine.2008.11.055
   Eldred JA, 2003, BIOCHEM SOC T, V31, P1213
   Emmi G, 2016, CLIN RHEUMATOL, V35, P1281, DOI 10.1007/s10067-015-3004-0
   Fabiani C, 2017, CLIN RHEUMATOL, V36, P191, DOI 10.1007/s10067-016-3506-4
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635
   Ferrer-Martin RM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135238
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Franceschini A, 2015, FASEB J, V29, P2450, DOI 10.1096/fj.14-268714
   Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200
   Franchi L, 2014, J IMMUNOL, V193, P4214, DOI 10.4049/jimmunol.1400582
   Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Gallagher MJ, 2007, BRIT J OPHTHALMOL, V91, P1680, DOI 10.1136/bjo.2007.124099
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Giatti S, 2009, NEUROSCIENCE, V164, P520, DOI 10.1016/j.neuroscience.2009.08.005
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x
   Giuliani AL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00123
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Goswami K, 2003, CLIN CHIM ACTA, V337, P163, DOI 10.1016/j.cccn.2003.08.009
   Graham DB, 2007, J EXP MED, V204, P2889, DOI 10.1084/jem.20071283
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001
   Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gul A, 2012, ANN RHEUM DIS, V71, P563, DOI 10.1136/annrheumdis-2011-155143
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haim M, 2002, ACTA OPHTHALMOL SCAN, V80, P5
   Halder SK, 2013, J NEUROCHEM, V126, P243, DOI 10.1111/jnc.12262
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hamerman JA, 2009, IMMUNOL REV, V232, P42, DOI 10.1111/j.1600-065X.2009.00841.x
   Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hasler J, 2007, CELL MOL LIFE SCI, V64, P1793, DOI 10.1007/s00018-007-7084-0
   Hatanaka E, 2006, CLIN EXP IMMUNOL, V146, P443, DOI 10.1111/j.1365-2249.2006.03229.x
   He YB, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0904-8
   He YX, 2015, CURR STEM CELL RES T, V10, P258, DOI 10.2174/1574888X09666141027103552
   Heeger PS, 2012, IMMUNOBIOLOGY, V217, P216, DOI 10.1016/j.imbio.2011.06.004
   HEREDIA CD, 1984, BRIT J OPHTHALMOL, V68, P811, DOI 10.1136/bjo.68.11.811
   Hildebrandt H, 2015, TOP CURR CHEM, V366, P55, DOI 10.1007/128_2013_446
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Hu ZZ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.363
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8
   Huang YB, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0011-8
   Huang ZJ, 2018, CELL DEATH DIFFER, V25, P180, DOI 10.1038/cdd.2017.141
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   Humphries MM, 2012, EUR J HUM GENET, V20, P64, DOI 10.1038/ejhg.2011.151
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jin S, 2007, BRAIN RES, V1179, P140, DOI 10.1016/j.brainres.2007.08.055
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Joyal JS, 2011, BLOOD, V117, P6024, DOI 10.1182/blood-2010-10-311589
   Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130
   Jurgens HA, 2012, EXP NEUROL, V233, P40, DOI 10.1016/j.expneurol.2010.11.014
   Kalda A, 2006, J NEUROL SCI, V248, P9, DOI 10.1016/j.jns.2006.05.003
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886
   Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001
   Kimoto T, 2002, JPN J OPHTHALMOL, V46, P160, DOI 10.1016/S0021-5155(01)00492-0
   Kimura A, 2005, P NATL ACAD SCI USA, V102, P17089, DOI 10.1073/pnas.0508517102
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kolev M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00001
   Kolev M, 2014, METHODS MOL BIOL, V1100, P347, DOI 10.1007/978-1-62703-724-2_29
   Koleva-Georgieva Desislava N, 2011, Folia Med (Plovdiv), V53, P44
   Korot E, 2016, JAMA OPHTHALMOL, V134, P15, DOI 10.1001/jamaophthalmol.2015.3949
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Kowluru Renu A, 2011, J Ocul Biol Dis Infor, V4, P3, DOI 10.1007/s12177-011-9074-6
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee JJ, 2015, INVEST OPHTH VIS SCI, V56, P3041, DOI 10.1167/iovs.15-16504
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li Y, 2012, INVEST OPHTH VIS SCI, V53, P5520, DOI 10.1167/iovs.12-10010
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Linnartz B, 2013, GLIA, V61, P37, DOI 10.1002/glia.22359
   Linnartz B, 2012, J NEUROSCI, V32, P946, DOI 10.1523/JNEUROSCI.3830-11.2012
   Linnartz-Gerlach B, 2014, NEUROSCIENCE, V275, P113, DOI 10.1016/j.neuroscience.2014.05.061
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luo C, 2011, MOL VIS, V17, P1588
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Madeira MH, 2016, TRANSL RES, V169, P112, DOI 10.1016/j.trsl.2015.11.005
   Madeira MH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0333-5
   Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Mathur A, 2018, J LEUKOCYTE BIOL, V103, P233, DOI 10.1189/jlb.3MR0617-250R
   Mazumdar B, 2013, J VIROL, V87, P7902, DOI [10.1128/JVI.00917-13, 10.1128/JVI.00174-13]
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   McCormick SM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00549
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mendiola AS, 2017, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00303
   Minghetti L, 2007, J NEUROPATH EXP NEUR, V66, P363, DOI 10.1097/nen.0b013e3180517477
   Mitchell CH, 2001, J PHYSIOL-LONDON, V534, P193, DOI 10.1111/j.1469-7793.2001.00193.x
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Mohammad MK, 2006, INT IMMUNOL, V18, P1101, DOI 10.1093/intimm/dxl045
   Moreau JL, 1999, BRAIN RES REV, V31, P65, DOI 10.1016/S0165-0173(99)00059-4
   Morgan J., 1995, WEBVISION ORG RETINA
   Morigiwa K, 2000, NEUROSCI LETT, V282, P153, DOI 10.1016/S0304-3940(00)00887-9
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Muramatsu D, 2013, GRAEF ARCH CLIN EXP, V251, P15, DOI 10.1007/s00417-012-2024-6
   Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097/IAE.0b013e31816576d5
   Nadal-Nicolas FM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38499
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   NEAL M, 1994, BRIT J PHARMACOL, V113, P1085, DOI 10.1111/j.1476-5381.1994.tb17106.x
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Neniskyte U, 2013, J NEUROCHEM, V126, P312, DOI 10.1111/jnc.12288
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Newman EA, 2003, J NEUROSCI, V23, P1659, DOI 10.1523/jneurosci.23-05-01659.2003
   Newman Eric A, 2006, Novartis Found Symp, V276, P193
   Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x
   Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x
   Niu SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01733-0
   Niyadurupola N, 2013, INVEST OPHTH VIS SCI, V54, P2163, DOI 10.1167/iovs.12-10968
   Nomura K, 2017, J IMMUNOL, V198, P4792, DOI 10.4049/jimmunol.1502532
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okada M, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.579961
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Patel JI, 2008, EYE, V22, P223, DOI 10.1038/sj.eye.6702584
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4
   Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Petrovic MG, 2010, ACTA OPHTHALMOL, V88, pe311, DOI 10.1111/j.1755-3768.2010.02030.x
   Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004
   Piano I, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00042
   Poon DCH, 2015, NEUROSCI BIOBEHAV R, V57, P30, DOI 10.1016/j.neubiorev.2015.07.015
   Potucek YD, 2006, NEUROCHEM INT, V49, P204, DOI 10.1016/j.neuint.2006.04.005
   Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011
   Pshezhetsky AV, 2011, GLYCOCONJUGATE J, V28, P441, DOI 10.1007/s10719-011-9350-5
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Rashid K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00176
   Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Reigada D, 2005, AM J PHYSIOL-CELL PH, V289, pC617, DOI 10.1152/ajpcell.00542.2004
   Reigada D, 2005, AM J PHYSIOL-CELL PH, V288, pC132, DOI 10.1152/ajpcell.00201.2004
   Reu P, 2017, CELL REP, V20, P779, DOI 10.1016/j.celrep.2017.07.004
   Reyes NJ, 2017, NAT REV IMMUNOL, V17, P322, DOI 10.1038/nri.2017.13
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Sanchez-Vallejo V, 2015, PHARMACOL RES, V99, P276, DOI 10.1016/j.phrs.2015.06.019
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Saura J, 2005, J NEUROCHEM, V95, P919, DOI 10.1111/j.1471-4159.2005.03395.x
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schmidt CQ, 2016, IMMUNOBIOLOGY, V221, P503, DOI 10.1016/j.imbio.2015.12.009
   Schnaar RL, 2014, PHYSIOL REV, V94, P461, DOI 10.1152/physrev.00033.2013
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schwarz F, 2017, EMBO J, V36, P751, DOI 10.15252/embj.201695581
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sfikakis PP, 2010, DIABETES CARE, V33, P1523, DOI 10.2337/dc09-2372
   Sfikakis PP, 2005, DIABETES CARE, V28, P445, DOI 10.2337/diacare.28.2.445
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Shahraz A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16800
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628
   Shiratori M, 2010, J NEUROCHEM, V114, P810, DOI 10.1111/j.1471-4159.2010.06809.x
   Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Sudharsan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18236-7
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Tobe Takao, 1995, Nippon Ganka Gakkai Zasshi, V99, P571
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomlinson DR, 2008, NAT REV NEUROSCI, V9, P36, DOI 10.1038/nrn2294
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Uckermann O, 2006, J NEUROSCI RES, V83, P538, DOI 10.1002/jnr.20760
   Uematsu S, 2006, J MOL MED-JMM, V84, P712, DOI 10.1007/s00109-006-0084-y
   Ugurlu S, 2012, ANN RHEUM DIS, V71, P1591, DOI 10.1136/annrheumdis-2012-201383
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vitale A, 2014, DERMATOLOGY, V228, P211, DOI 10.1159/000358125
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   von Moltke J, 2013, ANNU REV IMMUNOL, V31, P73, DOI 10.1146/annurev-immunol-032712-095944
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wang Y, 2010, J NEUROSCI, V30, P3482, DOI 10.1523/JNEUROSCI.3940-09.2010
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wilson HM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00357
   Wolf Y, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00026
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2015, MOL MED REP, V12, P4887, DOI 10.3892/mmr.2015.4064
   Wurm A, 2010, J NEUROCHEM, V112, P1261, DOI 10.1111/j.1471-4159.2009.06541.x
   Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Xiong SQ, 2017, J CELL BIOCHEM, V118, P4914, DOI 10.1002/jcb.26177
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2011, INVEST OPHTH VIS SCI, V52, P249, DOI 10.1167/iovs.10-6001
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Yu CR, 2011, INVEST OPHTH VIS SCI, V52, P6978, DOI 10.1167/iovs.11-7688
   Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang A, 2002, DIABETES, V51, P3499
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
   Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x
   Zhang LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20341
   Zhang X, 2015, ANTIOXID REDOX SIGN, V22, P848, DOI 10.1089/ars.2014.5868
   Zhang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.308
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhao MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131429
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   Zieger M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106562
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 385
TC 65
Z9 68
U1 3
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD OCT
PY 2018
VL 10
IS 10
AR e8259
DI 10.15252/emmm.201708259
PG 27
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GW7DM
UT WOS:000447125900001
PM 30224384
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Weichel, J
   Valtink, M
   Engelmann, K
   Richard, G
AF Weichel, J
   Valtink, M
   Engelmann, K
   Richard, G
TI Use of an oil-hydraulic microinjection pump for subretinal infusions
SO OPHTHALMIC SURGERY AND LASERS
LA English
DT Article
ID CELL TRANSPLANTATION; MACULAR DEGENERATION; PIGMENT
AB The injection of cell suspensions or drugs into the subretinal space is a new promising option of vitreoretinal surgery for the treatment of degenerative retinal disorders. We used a manual oil-hydraulic microinjection pump to subretinally inject suspensions of retinal pigment epithelial cells in Royal College of Surgeons rats and in patients suffering from age-related macular degeneration with geographic atrophy. The histological examination of the treated rat eyes showed that cell suspensions could be placed precisely in the subretinal space. Intra- and postoperative outcome of he patients in the clinical trial revealed no retinal complications during 6 months of follow up. We suggest the oil-hydraulic microinjection pump to be a valuable instrument for controlled and precisely dosed atraumatic infusion or aspiration of small volumes of cell suspensions, fluids or drugs in vitreoretinal surgery.
C1 Univ Hamburg, Dept Ophthalmol, D-20246 Hamburg, Germany.
C3 University of Hamburg
RP Weichel, J (通讯作者)，Univ Hamburg, Dept Ophthalmol, Martinistr 52,Cornea Bank, D-20246 Hamburg, Germany.
RI Valtink, Monika/I-1507-2013
OI Valtink, Monika/0000-0003-3205-1876
CR Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Saika S, 1998, GRAEF ARCH CLIN EXP, V236, P196, DOI 10.1007/s004170050064
   Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336
NR 5
TC 5
Z9 5
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0022-023X
J9 OPHTHALMIC SURG LAS
JI Ophthalmic Surg. Lasers
PD JUL-AUG
PY 2002
VL 33
IS 4
BP 340
EP 342
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 573KF
UT WOS:000176828100017
PM 12135000
DA 2022-11-30
ER

PT J
AU Breazzano, MP
   Bacci, T
   Wang, H
   Francis, JH
   Yannuzzi, LA
AF Breazzano, Mark P.
   Bacci, Tommaso
   Wang, Hao
   Francis, Jasmine H.
   Yannuzzi, Lawrence A.
TI Bacillary Layer Detachment in Bilateral Diffuse Uveal Melanocytic
   Proliferation Masquerading as Neovascular AMD
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare and unusual paraneoplastic ocular syndrome with generally poor prognosis. The authors present a case of BDUMP in a patient with bladder cancer, examined with current multimodal imaging. In the clinical setting with drusen and exudative macular detachments, the fundus simulated neovascular age-related macular degeneration, warranting standard-of-care therapy. The imaging actually showed the typical manifestations of BDUMP, but also newly recognized, associated manifestations, including the bacillary layer detachment, a gravitating retinal detachment, and multifocal choroidal hyperpermeability, but no evidence of neovascularization. Recognition of these associated manifestations is of value in appreciating the pathophysiology of this paraneoplastic disorder. Based on the imaging, the correct diagnosis was possible along with a better understanding of the nature of the clinical features in the posterior fundus.
C1 [Breazzano, Mark P.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Johns Hopkins Hosp, Baltimore, MD 21205 USA.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.] NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
   [Bacci, Tommaso] Univ Siena, Siena Univ Hosp, Dept Med Surg & Neurosci, Ophthalmol Unit, Siena, Italy.
   [Wang, Hao] Capital Reg Retina, Albany, NY USA.
   [Francis, Jasmine H.] Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10021 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Vitreous Retina Macula
   Consultants of New York; Columbia University; New York University;
   Manhattan Eye Ear & Throat Hospital; University of Siena; University
   Hospital of Siena; Memorial Sloan Kettering Cancer Center
RP Breazzano, MP (通讯作者)，Johns Hopkins Univ Hosp, 1800 Orleans St, Baltimore, MD 21287 USA.
EM mbreazz1@jhmi.edu
RI Bacci, Tommaso/GQA-8840-2022
OI Bacci, Tommaso/0000-0001-7477-2263; Breazzano, Mark/0000-0002-7093-965X;
   Francis, Jasmine/0000-0002-7637-3108
FU Macula Foundation Inc., New York, NY
FX Supported by The Macula Foundation Inc., New York, NY, which had no role
   in the study design, collection, analysis and interpretation of data,
   writing the report, or the decision to submit the report for
   publication.
CR Alrashidi Salah, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-204387
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P1541, DOI 10.1016/j.ophtha.2016.03.017
   Cicinelli MV, 2020, OPHTHALMOL RETINA, V4, P454, DOI 10.1016/j.oret.2019.12.003
   De Salvo G, 2011, EYE, V25, P1385, DOI 10.1038/eye.2011.180
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P216, DOI 10.1097/00006982-200502000-00018
   Fernandez-Avellaneda Pedro, 2022, Retin Cases Brief Rep, V16, P59, DOI 10.1097/ICB.0000000000000943
   GASS JDM, 1990, ARCH OPHTHALMOL-CHIC, V108, P527, DOI 10.1001/archopht.1990.01070060075053
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Klemp K, 2017, ACTA OPHTHALMOL, V95, P439, DOI 10.1111/aos.13481
   Rodriguez RHM, 2017, MED CLIN-BARCELONA, V149, P449, DOI 10.1016/j.medcli.2017.06.009
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Munipalli SB, 2019, GEN COMP ENDOCR, V281, P153, DOI 10.1016/j.ygcen.2019.06.003
   O'Day R, 2019, OSLI RETINA, V50, P525, DOI 10.3928/23258160-20190806-10
   Rahimy E, 2015, SEMIN OPHTHALMOL, V30, P206, DOI 10.3109/08820538.2013.835835
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
NR 16
TC 5
Z9 5
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2020
VL 51
IS 7
BP 413
EP 417
DI 10.3928/23258160-20200702-07
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA NJ1ZZ
UT WOS:000565846400007
PM 32706900
DA 2022-11-30
ER

PT J
AU Igic, R
AF Igic, Rajko
TI Four decades of ocular renin-angiotensin and kallikrein-kinin systems
   (1977-2017)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Renin-angiotensin system; Kallikrein-kinin system; Diabetic retinopathy;
   Diabetic macular edema; Age-related macular degeneration; Glaucoma;
   Uveitis; Cataract
ID I-CONVERTING-ENZYME; BRADYKININ-FORMING CASCADE; TISSUE KALLIKREIN;
   ENDOTHELIAL-CELLS; RECEPTOR; CARBOXYPEPTIDASE; INHIBITORS; EYE;
   ACTIVATION; EXPRESSION
AB This review offers a contemporary history of the renin-angiotensin (RAS) and kallikrein-kinin (KKS) systems with emphasis on how these complex systems affect the eye. It describes the types of communication (cross-talk) between the two systems and evaluates their potential role in the development of diabetic retinopathy, diabetic macular edema, age-related macular degeneration, glaucoma, and uveitis. In addition to detailing the important physiological actions of components of the RAS and KKS, possibilities are suggested for new therapeutic avenues in the treatment of common ocular diseases. Historical notes indicate the major events in this research area, marking four decades from the first publication on the discovery of renin and angiotensin converting enzyme in the eye to the present time. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Igic, Rajko] John H Stroger Jr Hosp Cook Cty, Dept Anesthesiol & Pain Management, Chicago, IL 60612 USA.
   [Igic, Rajko] Univ Banja Luka, Dept Pharmacol, Banja Luka 78000, Republic Of Srp, Bosnia & Herceg.
   [Igic, Rajko] Acad Arts & Sci, Banja Luka 7800, Republic Of Srp, Bosnia & Herceg.
C3 John H Stroger Junior Hospital Cook County; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; University of Banja Luka (UNIBL)
RP Igic, R (通讯作者)，Citaonicka 21, Sombor 25000, Serbia.
EM r.igic@excite.com
RI Igic, Rajko/AAA-7272-2019
CR Abelous JE, 1909, CR SOC BIOL, V66, P511
   AKTASHEVA YL, 1990, VESTN OFTALMOL, P50
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   BAKHLE YS, 1968, NATURE, V220, P919, DOI 10.1038/220919a0
   Benigni A, 2009, J CLIN INVEST, V119, P524, DOI 10.1172/JCI36703
   Bhat Menakshi, 2014, Prog Drug Res, V69, P111
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   BILL A, 1986, T OPHTHAL SOC UK, V105, P149
   Bolinger MT, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091498
   Braunger BM, 2015, EUR J PHARM BIOPHARM, V95, P173, DOI 10.1016/j.ejpb.2015.04.029
   BRAUNMENENDEZ E, 1958, SCIENCE, V127, P242, DOI 10.1126/science.127.3292.242-a
   Buharalioglu CK, 2011, AM J PHYSIOL-HEART C, V301, pH1043, DOI 10.1152/ajpheart.01018.2010
   BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008
   Chao Julie, 2014, World J Stem Cells, V6, P448, DOI 10.4252/wjsc.v6.i4.448
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   CUSHMAN DW, 1991, HYPERTENSION, V17, P589, DOI 10.1161/01.HYP.17.4.589
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   [丁德云 DING Deyun], 2007, [中华神经科杂志, Chinese Journal of Neurology], V40, P306
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dotsenko V, 1996, IMMUNOPHARMACOLOGY, V32, P141, DOI 10.1016/0162-3109(95)00076-3
   DZAU VJ, 1993, ARCH INTERN MED, V153, P937, DOI 10.1001/archinte.153.8.937
   Emanueli C, 2004, ARCH MAL COEUR VAISS, V97, P679
   Ferrao Fernanda M, 2014, World J Nephrol, V3, P64, DOI 10.5527/wjn.v3.i3.64
   FERRARIO CM, 1991, HYPERTENSION, V18, pS126, DOI 10.1161/01.HYP.18.5_Suppl.III126
   FERREIRA SH, 1965, EXPERIENTIA, V21, P347, DOI 10.1007/BF02144709
   Fisher M, 2002, THERAPIE, V57, P564
   Foureaux G, 2013, INVEST OPHTH VIS SCI, V54, P4296, DOI 10.1167/iovs.12-11427
   Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347
   Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507
   Haber PK, 2014, HYPERTENSION, V63, P774, DOI 10.1161/HYPERTENSIONAHA.113.02856
   Holappa M, 2015, OPEN OPHTHALMOL J, V9, P28, DOI 10.2174/1874364101509010028
   Igic R, 2003, CURR PHARM DESIGN, V9, P697, DOI 10.2174/1381612033455459
   IGIC R, 1985, EXP EYE RES, V41, P117, DOI 10.1016/0014-4835(85)90100-9
   IGIC R, 1972, CIRC RES, V31, pII51
   IGIC R, 1980, EXP EYE RES, V30, P299, DOI 10.1016/0014-4835(80)90010-X
   Igic R, 1977, Lijec Vjesn, V99, P482
   Igic R., 1975, 6 INT C PHARM HEIS A
   IGIC R, 1977, CENTRAL ACTIONS ANGI, P23
   Igic R, 2014, SRP ARK CELOK LEK, V142, P756, DOI 10.2298/SARH1412756I
   Jablecka A, 2009, MED SCI MONITOR, V15, pBR334
   JOHNSON AR, 1984, PEPTIDES, V5, P789, DOI 10.1016/0196-9781(84)90023-8
   Joseph K, 2002, INT IMMUNOPHARMACOL, V2, P1851, DOI 10.1016/S1567-5769(02)00186-8
   Kaplan AP, 2014, CHEM IMMUNOL ALLERGY, V100, P205, DOI 10.1159/000358739
   Kurihara T, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/581695
   LALIBERTE MF, 1988, LAB INVEST, V59, P263
   Linz W, 1997, CIRCULATION, V96, P3164, DOI 10.1161/01.CIR.96.9.3164
   Masuda T, 2015, EUR J PHARMACOL, V749, P161, DOI 10.1016/j.ejphar.2014.10.007
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   MIWA I, 1968, LIFE SCI PT 1 PHYSI, V7, P1339, DOI 10.1016/0024-3205(68)90265-8
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Navar LG, 1996, PHYSIOL REV, V76, P425, DOI 10.1152/physrev.1996.76.2.425
   Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276
   O'Callaghan J, 2017, HUM MOL GENET, V26, P1230, DOI 10.1093/hmg/ddx028
   ODYA CE, 1978, J BIOL CHEM, V253, P5927
   Pathak M, 2013, THROMB HAEMOSTASIS, V110, P423, DOI 10.1160/TH12-11-0840
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Prada JAH, 2008, HYPERTENSION, V51, P1312, DOI 10.1161/HYPERTENSIONAHA.107.108944
   Praddaude F, 2009, EXP EYE RES, V89, P109, DOI 10.1016/j.exer.2009.02.020
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Prosser HCG, 2009, CARDIOVASC RES, V82, P40, DOI 10.1093/cvr/cvp003
   Qiu YG, 2014, INVEST OPHTH VIS SCI, V55, P3809, DOI 10.1167/iovs.14-13883
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sangsree S, 2003, AM J PHYSIOL-HEART C, V284, pH1959, DOI 10.1152/ajpheart.00036.2003
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   Schmaier AH, 2014, THROMB RES, V133, pS41, DOI 10.1016/j.thromres.2014.03.018
   SEKI T, 1973, AM J PHYSIOL, V224, P1425, DOI 10.1152/ajplegacy.1973.224.6.1425
   SERNIA C, 1995, REGUL PEPTIDES, V57, P1, DOI 10.1016/0167-0115(95)00015-4
   Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200
   Sharif NA, 2015, J OCUL PHARMACOL TH, V31, P131, DOI 10.1089/jop.2014.0114
   SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261
   SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295
   Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10
   Skrbic R, 2009, PEPTIDES, V30, P1945, DOI 10.1016/j.peptides.2009.07.003
   Stone OA, 2009, ARTERIOSCL THROM VAS, V29, P657, DOI 10.1161/ATVBAHA.108.182139
   Strain WD, 2002, J RENIN-ANGIO-ALDO S, V3, P243, DOI 10.3317/jraas.2002.045
   Su JB, 2014, J RENIN-ANGIO-ALDO S, V15, P319, DOI 10.1177/1470320312474854
   Tigerstedt R., 1898, SKAND ARCH PHYSIOL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x, DOI 10.1111/J.1748-1716.1898.TB00272.X]
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tom B, 2003, INT J BIOCHEM CELL B, V35, P792, DOI 10.1016/S1357-2725(02)00273-X
   Vaajanen A., 2009, THESIS
   Vaajanen A, 2008, INVEST OPHTH VIS SCI, V49, P2557, DOI 10.1167/iovs.07-1399
   Vaajanen A, 2011, BASIC CLIN PHARMACOL, V109, P217, DOI 10.1111/j.1742-7843.2011.00729.x
   van der Meijden PEJ, 2012, J THROMB HAEMOST, V10, P1355, DOI 10.1111/j.1538-7836.2012.04758.x
   VanHaeringen NJ, 1996, BRIT J OPHTHALMOL, V80, P99, DOI 10.1136/bjo.80.2.99
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   Wang B, 2015, LANCET DIABETES ENDO, V3, P263, DOI 10.1016/S2213-8587(14)70256-6
   Wang J.H., 2017, PHARM THER
   WARD PE, 1979, LIFE SCI, V24, P1419, DOI 10.1016/0024-3205(79)90013-4
   Webb JG, 2009, EXP EYE RES, V89, P126, DOI 10.1016/j.exer.2009.02.016
   Werle E., 1970, HDB EXPT PHARM, V25, P1
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P59, DOI 10.1177/1470320314549791
   YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6
   Zhang XM, 2013, BIOL CHEM, V394, P335, DOI 10.1515/hsz-2012-0290
NR 94
TC 12
Z9 12
U1 1
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2018
VL 166
BP 74
EP 83
DI 10.1016/j.exer.2017.05.007
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT2YG
UT WOS:000423011300009
PM 28549900
DA 2022-11-30
ER

PT J
AU Wolkow, N
   Li, YF
   Maminishkis, A
   Song, Y
   Alekseev, O
   Iacovelli, J
   Song, DL
   Lee, JC
   Dunaief, JL
AF Wolkow, Natalie
   Li, Yafeng
   Maminishkis, Arvydas
   Song, Ying
   Alekseev, Oleg
   Iacovelli, Jared
   Song, Delu
   Lee, Jennifer C.
   Dunaief, Joshua L.
TI Iron upregulates melanogenesis in cultured retinal pigment epithelial
   cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Iron; Retinal pigment epithelium; Human fetal retinal pigment epithelial
   cells; ARPE-19 cells; Melanosome; MITF; LEF 1
ID TRANSCRIPTION FACTOR; MELANIN; EYE; HEMOCHROMATOSIS; DEGENERATION;
   MORPHOLOGY; INDUCTION; MEMBRANE; PROTEINS; MUTATION
AB The purpose of our studies was to examine the relationship between iron and melanogenesis in retinal pigment epithelial cells, as prior observations had suggested that iron may promote melanogenesis. This relationship has potential clinical importance, as both iron overload and hyperpigmentation are associated with age-related macular degeneration (AMD). Human fetal retinal pigment epithelial cells and ARPE-19 cells were treated with iron in the form of ferric ammonium citrate, after which quantitative RTPCR and electron microscopy were performed. Melanogenesis genes tyrosinase, tyrosinase-related protein 1, Hermansky-Pudlak Syndrome 3, premelanosome protein and dopachrome tautomerase were upregulated, as was the melanogenesis-controlling transcription factor, microphthalmia-associated transcription factor (MITF). Iron-treated cells had increased pigmentation and melanosome number. Multiple transcription factors upstream of MITF were upregulated by iron. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Wolkow, Natalie; Li, Yafeng; Song, Ying; Alekseev, Oleg; Iacovelli, Jared; Song, Delu; Lee, Jennifer C.; Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Maminishkis, Arvydas] NEI, Sect Epithelial & Retinal Physiol & Dis, MSC 1861, NIH, Bethesda, MD 20892 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Dunaief, JL (通讯作者)，Univ Penn, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, 305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
OI Wolkow, Natalie/0000-0003-1524-115X; Maminishkis,
   Arvydas/0000-0003-3345-3375
FU NIH/NEI [R01 EY015240]; FM Kirby Foundation; Research to Prevent
   Blindness; Paul and Evanina Bell MacKall Foundation Trust; NATIONAL EYE
   INSTITUTE [P30EY001583, ZIAEY000419, R01EY015240] Funding Source: NIH
   RePORTER
FX We thank Sheldon S. Miller, PhD for generously providing us with human
   fetal RPE cells. We thank Raymond Meade, MS of the Penn Electron
   Microscopy Resource Laboratory for exceptional technical assistance.
   Funding was provided by NIH/NEI R01 EY015240, Research to Prevent
   Blindness, the FM Kirby Foundation, a gift in honor of Dr. Lee F.
   Mauger, and the Paul and Evanina Bell MacKall Foundation Trust.
CR Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Biesemeier A, 2010, CELL TISSUE RES, V339, P551, DOI 10.1007/s00441-009-0920-9
   BREATHNA.AS, 1966, J ULTRA MOL STRUCT R, V16, P584, DOI 10.1016/S0022-5320(66)80008-4
   Brookes MJ, 2008, ONCOGENE, V27, P966, DOI 10.1038/sj.onc.1210711
   CAWLEY EP, 1969, ARCH DERMATOL, V100, P1, DOI 10.1001/archderm.100.1.1
   Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x
   Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045
   Di Pietro SM, 2004, TRAFFIC, V5, P276, DOI 10.1111/j.1600-0854.2004.0171.x
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Feeney-Burns L, 1980, Curr Top Eye Res, V2, P119
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Guillery RW, 1996, EYE, V10, P217, DOI 10.1038/eye.1996.49
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Harris ML, 2010, PIGM CELL MELANOMA R, V23, P496, DOI 10.1111/j.1755-148X.2010.00711.x
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   Kaczara P, 2012, PIGM CELL MELANOMA R, V25, P804, DOI 10.1111/pcmr.12008
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410
   Land M. F., 2004, ANIMAL EYES
   Liu JJ, 2010, PIGM CELL MELANOMA R, V23, P741, DOI 10.1111/j.1755-148X.2010.00775.x
   Maminishkis A., 2010, J VIS EXP, V45
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   McGlinchey RP, 2011, J BIOL CHEM, V286, P8385, DOI 10.1074/jbc.M110.197152
   Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521
   MUND ML, 1972, AM J OPHTHALMOL, V73, P167, DOI 10.1016/0002-9394(72)90130-4
   PERDRUP A, 1964, ARCH DERMATOL, V90, P34, DOI 10.1001/archderm.1964.01600010040010
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Sarna T, 2006, PIGMENTARY SYSTEM PH, P311
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STROEVA OG, 1983, INT REV CYTOL, V83, P221, DOI 10.1016/S0074-7696(08)61689-7
   Sznajer Y, 2008, AM J MED GENET A, V146A, P1038, DOI 10.1002/ajmg.a.32247
   Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200
   Tang KF, 2012, INT J MOL SCI, V13, P16769, DOI 10.3390/ijms131216769
   Theos AC, 2006, MOL BIOL CELL, V17, P3598, DOI 10.1091/mbc.E06-01-0081
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Waes JGV, 2008, EXP EYE RES, V86, P419, DOI 10.1016/j.exer.2007.11.015
   Wegner M, 2005, PIGM CELL RES, V18, P74, DOI 10.1111/j.1600-0749.2005.00218.x
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703
NR 45
TC 14
Z9 14
U1 1
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2014
VL 128
BP 92
EP 101
DI 10.1016/j.exer.2014.09.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS5LL
UT WOS:000344312300012
PM 25277027
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Grimaldo, S
   Garcia, M
   Zhang, H
   Chen, L
AF Grimaldo, S.
   Garcia, M.
   Zhang, H.
   Chen, L.
TI SPECIFIC ROLE OF LYMPHATIC MARKER PODOPLANIN IN RETINAL PIGMENT
   EPITHELIAL CELLS
SO LYMPHOLOGY
LA English
DT Article
DE podoplanin; retinal pigment epithelium; lymphatic; siRNA
ID PROLIFERATIVE VITREORETINOPATHY; MEMBRANE-PROTEIN; TIGHT JUNCTIONS;
   GROWTH-FACTOR; FLUOROURACIL; BLOOD
AB Podoplanin is a small transmembrane glycoprotein widely known to be a marker for lymphatic endothelial cells. In this study, we identify a novel localization of podoplanin in the retinal pigment epithelium (RPE), a cellular monolayer critically involved in the visual process. Using a small interfering RNA (siRNA)-mediated gene silencing approach, we have also demonstrated, for the first time, that podoplanin depletion in human RPE cells leads to a marked reduction of cell aggregates and tight junctions. Additionally, the podoplanin-depleted cells also exhibit a significantly lower rate of proliferation. These data together indicate that podoplanin plays a crucial role in RPE cell functions. Further investigation on this factor may reveal novel mechanisms and therapeutic strategies for RPE-related eye diseases, such as proliferative retinopathy and age-related macular degeneration.
C1 [Chen, L.] Univ Calif Berkeley, Ctr Eye Dis & Dev, Program Vis Sci, Berkeley, CA 94704 USA.
   Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94704 USA.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley
RP Chen, L (通讯作者)，Univ Calif Berkeley, Ctr Eye Dis & Dev, Program Vis Sci, Berkeley, CA 94704 USA.
EM chenlu@berkeley.edu
RI Zhang, Hui/F-9253-2011
FU National Institutes of Health; University of California at Berkeley;
   NATIONAL EYE INSTITUTE [R01EY017392] Funding Source: NIH RePORTER
FX This work is supported in part by research grants from National
   Institutes of Health and the Hellman Family Faculty Fund Award,
   University of California at Berkeley.
CR Abe T, 2003, INVEST OPHTH VIS SCI, V44, pU99
   BLUMENKRANZ MS, 1982, AM J OPHTHALMOL, V94, P458, DOI 10.1016/0002-9394(82)90239-2
   Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6
   BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141
   Campochiaro PA, 1997, ARCH OPHTHALMOL-CHIC, V115, P237, DOI 10.1001/archopht.1997.01100150239014
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   Chen L, 2009, LYMPHOLOGY, V42, P66
   Ecoiffier T, 2010, INVEST OPHTH VIS SCI, V51, P2436, DOI 10.1167/iovs.09-4505
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Esser P, 1997, EXP EYE RES, V65, P365, DOI 10.1006/exer.1997.0341
   Gonzalez RF, 1998, BBA-PROTEIN STRUCT M, V1429, P208, DOI 10.1016/S0167-4838(98)00231-3
   HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z
   Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782
   Matter K, 1999, INT REV CYTOL, V186, P117
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5
   Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342
   SIMO R, J BIOMED BIOTECHNOL
   STERN WH, 1983, AM J OPHTHALMOL, V96, P33, DOI 10.1016/0002-9394(83)90452-X
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186
   ZHANG H, 2010, INVEST OPHTHALM 0825
   ZHANG H, 2010, INVEST OPHTHALM 0804
NR 24
TC 8
Z9 8
U1 0
U2 1
PU LYMPHOLOGY
PI TUCSON
PA C/O C L WITTE MD 1501 N CAMPBELL AVE DEPT SURGERY, TUCSON, AZ 85724 USA
SN 0024-7766
J9 LYMPHOLOGY
JI Lymphology
PD SEP
PY 2010
VL 43
IS 3
BP 128
EP 134
PG 7
WC Immunology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Physiology
GA 694DK
UT WOS:000285275000004
PM 21226415
DA 2022-11-30
ER

PT J
AU Troger, J
   Kralinger, M
   Kieselbach, G
AF Troger, J.
   Kralinger, M.
   Kieselbach, G.
TI Surgery for peripapillar choroidal neovascularization
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
DE Vitrectomy; peripapillar CNV
ID MACULAR DEGENERATION; LASER TREATMENT; OCULAR HISTOPLASMOSIS;
   SURGICAL-TREATMENT; MEMBRANES; VERTEPORFIN
AB The therapy of choroidal neovascularizations (CNVs) in wet age-related macular degeneration (AMD) developed to an anti-vascular endothelial growth factor (VEGF) therapy. Peripapilar CNV (PPCNV) represents another manifestation of CNV which may treated additionally by surgical extraction of the membranes. METHODS: In this retrospective study, the morphological and visual outcome after surgery of 9 eyes of 9 patients with PPCNV was evaluated. RESULTS: Surgery was successful in each patient and visual acuity remaind stable or improved in each patient by two or more lines. Recurrence was observed in 6 eyes within three years. DISCUSSION: Hence, surgery may represent an alternative approach in the therapy of PPCNV although only a small number of cases were included. Randomized prospective trials comparing surgical excision of PPCNV with anti-VEGF therapy alone or in combination are needed.
C1 [Troger, J.; Kralinger, M.; Kieselbach, G.] Med Univ Innsbruck, Dept Ophthalmol & Optometry, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck
RP Kieselbach, G (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol & Optometry, Anichstr 35, A-6020 Innsbruck, Austria.
EM gerhard.kieselbach@i-med.ac.at
CR Aisenbrey S, 2007, BRIT J OPHTHALMOL, V91, P1027, DOI 10.1136/bjo.2006.108118
   Almony A, 2008, OPHTHALMOLOGY, V115, P540, DOI 10.1016/j.ophtha.2007.08.045
   Bains HS, 2003, RETINA-J RET VIT DIS, V23, P469, DOI 10.1097/00006982-200308000-00004
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CIALDINI AP, 1989, OPHTHALMIC SURG LAS, V20, P93
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Flaxel CJ, 1996, OPHTHALMOLOGY, V103, P1250, DOI 10.1016/S0161-6420(96)30513-7
   GASS DM, 1973, ARCH OPHTHALMOL-CHIC, V90, P201
   Gass JD, 1967, AM J OPHTHALMOL S, V63, P1
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Kokame GT, 2005, RETINA-J RET VIT DIS, V25, P564, DOI 10.1097/00006982-200507000-00004
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   LIM JI, 1993, AM J OPHTHALMOL, V116, P414, DOI 10.1016/S0002-9394(14)71398-4
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
NR 21
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
EI 1613-7523
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD DEC
PY 2008
VL 22
IS 6
BP 362
EP 364
DI 10.1007/s00717-008-0295-4
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 394XB
UT WOS:000262485400005
DA 2022-11-30
ER

PT J
AU Christaras, D
   Ginis, H
   Pennos, A
   Mompean, J
   Artal, P
AF Christaras, Dimitrios
   Ginis, Harilaos
   Pennos, Alexandros
   Mompean, Juan
   Artal, Pablo
TI Objective method for measuring the macular pigment optical density in
   the eye
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID FUNDUS REFLECTANCE; AGE; AUTOFLUORESCENCE; INSTRUMENT; MELANIN
AB Macular pigment is a yellowish pigment of purely dietary origin, which is thought to have a protective role in the retina. Recently, it was linked to age-related macular degeneration and Unproved Visual function. In this work, we present a method and a corresponding optical instrument for the rapid measurement of its optical density. The method is based on fundus rellectometry and features a photodetector for the measurement of reflectance at different wavelengths and retinal locations. The method has been tested against a commercially available instrument on a group of healthy volunteers and has shown good correlation. The proposed instrument can serve as a rapid, non-midriatic, low-cost tool for the measurement of macular pigment optical density. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Christaras, Dimitrios; Pennos, Alexandros; Mompean, Juan; Artal, Pablo] Univ Murcia, Inst Univ Invest Opt & Nanofis, Lab Opt, Campus Espinardo, E-30100 Murcia, Spain.
   [Christaras, Dimitrios; Ginis, Harilaos] Athens Eye Hosp, Dept Res, Leof Vouliagmenis 45, Glifadha 16675, Greece.
C3 University of Murcia
RP Christaras, D (通讯作者)，Univ Murcia, Inst Univ Invest Opt & Nanofis, Lab Opt, Campus Espinardo, E-30100 Murcia, Spain.; Christaras, D (通讯作者)，Athens Eye Hosp, Dept Res, Leof Vouliagmenis 45, Glifadha 16675, Greece.
EM dimitrios@um.es
RI Artal, Pablo/AAG-4485-2020; Artal, Pablo/AGV-7547-2022; Christaras,
   Dimitrios/AAZ-5867-2020; Mompean, Juan/H-1497-2015
OI Artal, Pablo/0000-0003-1284-6591; Artal, Pablo/0000-0003-1284-6591;
   Mompean, Juan/0000-0002-0192-2985
FU European Research Council (ERC) [AdG-2013-339228 SEECAT]; Secretaria de
   Estado e Investigacion, Desarrollo e Innovacion (SEIDI)
   [FIS2013-41237-R]; Fundacion Seneca Agencia de Ciencia y Tecnologia de
   la Region de Murcia [19897/GERM/15]
FX European Research Council (ERC) (AdG-2013-339228 SEECAT); Secretaria de
   Estado e Investigacion, Desarrollo e Innovacion (SEIDI)
   (FIS2013-41237-R); Fundacion Seneca Agencia de Ciencia y Tecnologia de
   la Region de Murcia (19897/GERM/15).
CR Artal P, 2014, ADV OPT PHOTONICS, V6, P340, DOI 10.1364/AOP.6.000340
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Christaras D., 2016, THESIS
   Christaras D, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.5.056001
   Christaras D, 2017, OPHTHAL PHYSL OPT, V37, P342, DOI 10.1111/opo.12375
   Christaras D, 2016, BIOMED OPT EXPRESS, V7, P3996, DOI 10.1364/BOE.7.003996
   Christaras D, 2015, J OPT SOC AM A, V32, P1723, DOI 10.1364/JOSAA.32.001723
   Ctori I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169520
   Davey PG, 2016, CLIN OPHTHALMOL, V10, P1671, DOI 10.2147/OPTH.S111708
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Ginis H, 2014, BIOMED OPT EXPRESS, V5, P3036, DOI 10.1364/BOE.5.003036
   Ginis H, 2012, J VISION, V12, DOI 10.1167/12.3.20
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Issa PC, 2009, EXP EYE RES, V89, P25, DOI 10.1016/j.exer.2009.02.006
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loughman J., 2010, J OPTOM, V3, P74
   Loughman J, 2012, ACTA OPHTHALMOL, V90, pe90, DOI 10.1111/j.1755-3768.2011.02294.x
   Moreland JD, 2004, ARCH BIOCHEM BIOPHYS, V430, P143, DOI 10.1016/j.abb.2004.06.024
   Muller S, 2018, AM J OPHTHALMOL, V194, P163, DOI 10.1016/j.ajo.2018.07.017
   Nolan J., 2003, OPTOM TODAY, V27, P39
   O'Brien A, 2013, APPL OPTICS, V52, P6201, DOI 10.1364/AO.52.006201
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SANTAMARIA J, 1987, J OPT SOC AM A, V4, P1109, DOI 10.1364/JOSAA.4.001109
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   van de Kraats J, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2398925
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 43
TC 4
Z9 4
U1 0
U2 0
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JUL 1
PY 2019
VL 10
IS 7
BP 3572
EP 3583
DI 10.1364/BOE.10.003572
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA IF8IW
UT WOS:000473334700034
PM 31467794
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yu, Y
   Moult, EM
   Chen, SY
   Ren, QS
   Rosenfeld, PJ
   Waheed, NK
   Fujimoto, JG
AF Yu, Yue
   Moult, Eric M.
   Chen, Siyu
   Ren, Qiushi
   Rosenfeld, Philip J.
   Waheed, Nadia K.
   Fujimoto, James G.
TI Developing a potential retinal OCT biomarker for local growth of
   geographic atrophy
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; MOTION CORRECTION;
   NATURAL-HISTORY; NUCLEAR LAYER; PROGRESSION; THICKNESS; EYES
AB Geographic atrophy (GA), the advanced stage of age-related macular degeneration, is a leading cause of blindness. GA lesions are characterized by anisotropic growth and the ability to predict growth patterns would be valuable in assessing potential therapeutics. In this study, we propose an OCT-based marker of local GA growth rate based on an axial projection of the OCT volume in the Henle fiber layer (HFL) and outer nuclear layer (ONL). We analyze the association between our proposed metric and local GA growth rates in a small longitudinal cohort of patients with AMD. These methods can potentially be used to identify risk markers, stratify patients, or assess response in future therapeutic studies. (C) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Yu, Yue; Ren, Qiushi] Peking Univ, Coll Engn, Dept Biomed Engn, Beijing 100871, Peoples R China.
   [Yu, Yue; Moult, Eric M.; Chen, Siyu; Fujimoto, James G.] MIT, Res Lab Elect, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Rosenfeld, Philip J.] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Miami, FL 33136 USA.
   [Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02116 USA.
C3 Peking University; Massachusetts Institute of Technology (MIT); Bascom
   Palmer Eye Institute; University of Miami; Tufts Medical Center
RP Fujimoto, JG (通讯作者)，MIT, Res Lab Elect, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI CHEN, SI/GZL-4800-2022
FU China Scholarship Council [201806010297]; National Institutes of Health
   [5-R01-EY011289-31]; Topcon Corporation; Retina Research Foundation;
   Beckman Argyros Award in Vision Research; Antonio Champalimaud Vision
   Award; Massachusetts Lions Eye Research Fund; Macula Vision Research
   Foundation
FX China Scholarship Council (201806010297); National Institutes of Health
   (5-R01-EY011289-31); Topcon Corporation; Retina Research Foundation;
   Beckman Argyros Award in Vision Research; Antonio Champalimaud Vision
   Award; Massachusetts Lions Eye Research Fund; Macula Vision Research
   Foundation.
CR [Anonymous], 2019, INVEST OPHTH VIS SCI
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lindner M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23203
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ploner SB, 2018, INVEST OPHTH VIS SCI, V59
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SchmidtErfurth U., 2020, AM J OPHTHALMOL
   SCHMIDTERFURTH U, 2019, INVEST OPHTH VIS SCI, V60
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   THULLIEZ M, 2019, IMAGING OPHTHALMOL R, V3, P478, DOI DOI 10.1016/j.oret.2019.01.024
   Viladomat J, 2014, BIOMETRICS, V70, P409, DOI 10.1111/biom.12139
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 35
TC 4
Z9 4
U1 0
U2 1
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2020
VL 11
IS 9
BP 5181
EP 5196
DI 10.1364/BOE.399506
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA NZ9YV
UT WOS:000577455500023
PM 33014607
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Malinin, NL
   West, XZ
   Byzova, TV
AF Malinin, Nikolay L.
   West, Xiaoxia Z.
   Byzova, Tatiana V.
TI Oxidation as "The Stress of Life"
SO AGING-US
LA English
DT Article
DE lipid oxidation; oxidative stress; aging; Toll-like receptor 2; AMD;
   angiogenesis; atherosclerosis
ID AGING ROS; INFLAMMATION; ACTIVATION; RECEPTOR; DISEASE; CANCER;
   ANGIOGENESIS; MECHANISMS; SENESCENCE; HYPOXIA
AB Multiple biological consequences of oxidative stress are known to contribute to aging and aging-related pathologies. It was recently shown that (carboxyalkyl)pyrroles (CAPs), the end products of phospholipid oxidation serve as a novel class of endogenous ligands for Toll-like receptors (TLRs) and promote the process of angiogenesis. In this review, we discuss implications of these findings in the context of age-related pathologies, including tumorigenesis. Accumulation of oxidation products in tissues of aging organisms might create conditions for uncontrolled pathological angiogenesis as seen in patients with age related macular degeneration. CAPs and their receptors, TLRs might also promote the progression of atherosclerotic lesions. Importantly, besides their role in a number of pathologies, oxidative products of phospholipids contribute to tissue repair processes thereby antagonizing the destructive effects of oxidation.
C1 [Malinin, Nikolay L.; West, Xiaoxia Z.; Byzova, Tatiana V.] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, JJ Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Byzova, TV (通讯作者)，Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, JJ Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA.
EM byzovat@ccf.org
RI Malinin, Nikolay/Z-5308-2019; Malinin, Nikolay/J-4271-2012
OI Malinin, Nikolay/0000-0002-2654-1783; Byzova,
   Tatiana/0000-0002-2615-875X
CR [Anonymous], 2000, LONGEVITY RECORDS LI
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Blagosklonny MV, 2008, CELL CYCLE, V7, P3344, DOI 10.4161/cc.7.21.6965
   Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986
   Coste I, 2010, J CLIN INVEST, V120, P3663, DOI 10.1172/JCI42771
   Courtois Y, 2010, AGING-US, V2, P888, DOI 10.18632/aging.100237
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Erusalimsky JD, 2009, J APPL PHYSIOL, V106, P326, DOI 10.1152/japplphysiol.91353.2008
   Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood-2009-05-224402
   Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hong S, 1999, J EXP MED, V190, P1197, DOI 10.1084/jem.190.9.1197
   Jun JI, 2010, AGING-US, V2, P627, DOI 10.18632/aging.100201
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Kryston TB, 2011, MUTAT RES-FUND MOL M, V711, P193, DOI 10.1016/j.mrfmmm.2010.12.016
   Lakatta EG, 2009, MED CLIN N AM, V93, P583, DOI 10.1016/j.mcna.2009.02.008
   Lang F, 2006, ANTIOXID REDOX SIGN, V8, P1183, DOI 10.1089/ars.2006.8.1183
   Lee SJ, 2010, CURR BIOL, V20, P2131, DOI 10.1016/j.cub.2010.10.057
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482
   NEUMANN HAM, 1981, BRIT J DERMATOL, V104, P383, DOI 10.1111/j.1365-2133.1981.tb15307.x
   Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43
   Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119
   Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599
   Ousset M, 2010, CELL CYCLE, V9, P2814, DOI 10.4161/cc.9.14.12253
   Pani G, 2010, AGING-US, V2, P514, DOI 10.18632/aging.100182
   Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488
   Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0
   Spirig R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010983
   Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284
   Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22
   Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548
   Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Yang W, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000556
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zuin A, 2010, AGING-US, V2, P231, DOI 10.18632/aging.100133
NR 46
TC 39
Z9 40
U1 2
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD SEP
PY 2011
VL 3
IS 9
BP 906
EP 910
DI 10.18632/aging.100385
PG 5
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 845BS
UT WOS:000296798400011
PM 21946568
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bhuiyan, A
   Wong, TY
   Ting, DSW
   Govindaiah, A
   Souied, EH
   Smith, RT
AF Bhuiyan, Alauddin
   Wong, Tien Yin
   Ting, Daniel Shu Wei
   Govindaiah, Arun
   Souied, Eric H.
   Smith, R. Theodore
TI Artificial Intelligence to Stratify Severity of Age-Related Macular
   Degeneration (AMD) and Predict Risk of Progression to Late AMD
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE deep learning; AMD prediction; dry AMD; wet AMD
ID EYE DISEASE; VITAMIN-C; AREDS; TRIAL
AB Purpose: To build and validate artificial intelligence (AI)-based models for AMD screening and for predicting late dry and wet AMD progression within 1 and 2 years.
   Methods: The dataset of the Age-related Eye Disease Study (AREDS) was used to train and validate our prediction model. External validation was performed on the Nutritional AMD Treatment-2 (NAT-2) study.
   First Step: An ensemble of deep learning screening methods was trained and validated on 116,875 color fundus photos from 4139 participants in the AREDS study to classify them as no, early, intermediate, or advanced AMD and further stratified them along the AREDS 12 level severity scale. Second step: the resulting AMD scores were combined with sociodemographic clinical data and other automatically extracted imaging data by a logistic model tree machine learning technique to predict risk for progression to late AMD within 1 or 2 years, with training and validation performed on 923 AREDS participants who progressed within 2 years, 901 who progressed within 1 year, and 2840 who did not progress within 2 years. For those found at risk of progression to late AMD, we further predicted the type (dry or wet) of the progression of late AMD.
   Results: For identification of early/none vs. intermediate/late (i.e., referral level) AMD, we achieved 99.2% accuracy. The prediction model for a 2-year incident late AMD (any) achieved 86.36% accuracy, with 66.88% for late dry and 67.15% for late wet AMD. For the NAT-2 dataset, the 2-year late AMD prediction accuracy was 84%.
   Conclusions: Validated color fundus photo-based models for AMD screening and risk prediction for late AMD are now ready for clinical testing and potential telemedical deployment.
   Translational Relevance: Noninvasive, highly accurate, and fast AI methods to screen for referral level AMD and to predict late AMD progression offer significant potential improvements in our care of this prevalent blinding disease.
C1 [Bhuiyan, Alauddin; Govindaiah, Arun] iHealthScreen Inc, New York, NY USA.
   [Bhuiyan, Alauddin] NYU, New York, NY USA.
   [Wong, Tien Yin; Ting, Daniel Shu Wei] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin; Ting, Daniel Shu Wei] DUKE NUS Sch Med, Singapore, Singapore.
   [Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Hop Intercommunal Creteil, Creteil, France.
   [Smith, R. Theodore] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 New York University; National University of Singapore; Singapore
   National Eye Center; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil; Icahn School of Medicine at Mount Sinai
RP Smith, RT (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY 10029 USA.
EM rts1md@gmail.com
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Bidwai, Pooja
   Vishal/0000-0002-3077-4395; smith, theodore/0000-0002-1693-943X
FU NIH SBIR project [R43EY026841]
FX This project is funded by NIH SBIR project number R43EY026841.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   [Anonymous], 2015, ANTI VEGF TREATMENT
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Bhuiyan A, 2018, INVEST OPHTH VIS SCI, V59
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bishop C. M., 2011, PATTERN RECOGN, DOI DOI 10.1038/nature11129
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Caruana R, P ICML 06
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Chollet F., 2017, P 2017 IEEE C COMP V, DOI [10.1109/CVPR.2017.195, DOI 10.1109/CVPR.2017.195]
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fox J, 2002, COX PROPORTIONAL HAZ
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Govindaiah A, 2017, P IEEE INT S BIOM IM, P1525, DOI [10.1109/ISBI.2018, DOI 10.1109/ISBI.2018.8363863]
   Govindaiah Arun, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P702, DOI 10.1109/EMBC.2018.8512379
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Hoeting JA, 1999, STAT SCI, V14, P382, DOI 10.1214/ss/1009212519
   Hussain A., 2018, 2018 IEEE International Magnetic Conference (INTERMAG), DOI 10.1109/INTMAG.2018.8508493
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Landwehr N, 2005, MACH LEARN, V59, P161, DOI 10.1007/s10994-005-0466-3
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Seddon J.M., 2011, INVESTIG OPHTHALMOL, V52, P5235
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Szegedy C., P IEEE C COMP VIS PA
   Szegedy C, 2017, P 31 AAAI C ART INT
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   Wong T. Y., 2007, LANCET, V370, P194
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   WT Y., 2007, AM J OPHTHALMOL, V144, P117
   Zoph B, IEEE C COMP VIS PATT
NR 43
TC 27
Z9 27
U1 7
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2020
VL 9
IS 2
AR 25
DI 10.1167/tvst.9.2.25
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG1FX
UT WOS:000599489500011
PM 32818086
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gil, JQ
   Marques, JP
   Hogg, R
   Rosina, C
   Cachulo, ML
   Santos, A
   Staurenghi, G
   Chakravarthy, U
   Silva, R
AF Gil, J. Q.
   Marques, J. P.
   Hogg, R.
   Rosina, C.
   Cachulo, M. L.
   Santos, A.
   Staurenghi, G.
   Chakravarthy, U.
   Silva, R.
TI Clinical features and long-term progression of reticular pseudodrusen in
   age-related macular degeneration: findings from a multicenter cohort
SO EYE
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RISK-FACTOR; PREVALENCE; DISEASE; EYE;
   MACULOPATHY
AB Purpose To determine whether reticular pseudodrusen (RPD) confer a long-term increased risk of progression to late agerelated macular degeneration (AMD) in the fellow eye of patients with unilateral wet-AMD.
   Patients and methods This was a multicenter, combined prospective and retrospective, longitudinal, observational, study. Patients with wet-AMD in one eye were recruited from two centers and evaluated on the risk of progression to late-AMD in the second eye (study eye). A minimum follow-up of 5 years was required, unless progression occurred first. Baseline retinal profile of patients was evaluated using multimodal imaging. Baseline images were graded by two separate centers.
   Results We recruited 88 patients (48 female) with a mean age of 75.6 +/- 7.1 years and mean follow-up of 65.7 +/- 20.9 months. Baseline prevalence of RPD was 58% (n=51). There was no statistically significant association of RPD with increased age (P=0.29) or sex distribution (P=0.39). The most sensitive image modality for RPD was IR (93%), followed by FAF (92%), OCT (74%, RF (33%) and CFP (29%). After 5 years, 54.50% (n=48) of the study eyes progressed to late-AMD. Of those, 81.25% (n=39) developed CNV and 18.75% (n=9) geographic atrophy. After correcting for age and sex, the presence of RPD was significantly associated with development of late-stage AMD (OR=2.55, P=0.03).
   Conclusion A multimodal approach is mandatory for RPD detection. RPD are highly prevalent in the fellow eyes of patients with unilateral neovascular AMD. Presence of RPD is associated with increased long-term risk of progression, highlighting the importance of comprehensive multimodal retinal imaging and careful monitoring of at-risk patients.
C1 [Gil, J. Q.; Marques, J. P.; Cachulo, M. L.; Santos, A.; Silva, R.] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Gil, J. Q.; Marques, J. P.; Cachulo, M. L.; Santos, A.; Silva, R.] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Hogg, R.; Chakravarthy, U.] Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland.
   [Rosina, C.; Staurenghi, G.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco Eye Clin, I-20122 Milan, Italy.
   [Cachulo, M. L.; Silva, R.] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Gil, J. Q.] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, P-3000075 Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Queens University Belfast; University
   of Milan; Luigi Sacco Hospital; Universidade de Coimbra; Universidade de
   Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)
RP Gil, JQ (通讯作者)，Ctr Hosp & Univ Coimbra, Dept Ophthalmol, P-3000075 Coimbra, Portugal.
EM joaomqgil@hotmail.com
RI santos, ana/GWV-5678-2022; Marques, João Pedro/J-3584-2012; Hogg, Ruth
   E./ABC-9602-2020; Silva, Rufino M/J-2817-2012; Staurenghi,
   Giovanni/K-4388-2017
OI Marques, João Pedro/0000-0002-1014-0483; Hogg, Ruth
   E./0000-0001-9413-2669; Silva, Rufino M/0000-0001-8676-0833; B M Santos,
   Ana Rita/0000-0003-3761-3292; Staurenghi, Giovanni/0000-0002-2299-5251;
   Cachulo, Maria Luz/0000-0002-0900-4548; Quadrado Gil,
   Joao/0000-0001-9032-1008; Chakravarthy, Usha/0000-0002-2606-3734
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Group A-REDSR, 2005, OPHTHALMOLOGY, V112, P533
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Institute NE, 2004, PREV BLINDN DAT
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 23
TC 24
Z9 25
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2017
VL 31
IS 3
BP 364
EP 371
DI 10.1038/eye.2016.207
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EN4QG
UT WOS:000395991400007
PM 27768118
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Isola, V
   Pece, A
   Brancato, R
AF Isola, V
   Pece, A
   Brancato, R
TI Circulatory changes in the choroidal vasculature after verteporfin-based
   photodynamic therapy for choroidal neovascularization in age-related
   macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE blindness; Bloch-Sulzberger; incontinentia pigmenti; phacomatosis;
   retinal avascularity; retinopathy of prematurity; retinal
   neovascularization
C1 Predabissi Hosp, Dept Ophthalmol, I-20070 Milan, Italy.
   San Raffaele Univ Hosp, Dept Ophthalmol & Visual Sci, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Isola, V (通讯作者)，Predabissi Hosp, Dept Ophthalmol, Via Pandina 1, I-20070 Milan, Italy.
EM isolav@tiscalinet.it
CR COHEN SMZ, 1983, RETINA-J RET VIT DIS, V3, P284, DOI 10.1097/00006982-198300340-00010
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
NR 5
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2004
VL 24
IS 4
BP 618
EP 620
DI 10.1097/00006982-200408000-00020
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 847QY
UT WOS:000223411200020
PM 15300088
DA 2022-11-30
ER

PT J
AU Pieramici, DJ
   Rabena, MD
AF Pieramici, D. J.
   Rabena, M. D.
TI Anti-VEGF therapy: comparison of current and future agents
SO EYE
LA English
DT Article
DE age-related macular degeneration; ranibizumab; bevacizumab; choroidal
   neovascularization; angiogenesis; anti-vegf
ID COHERENCE TOMOGRAPHY FINDINGS; VASCULAR-PERMEABILITY FACTOR;
   INTRAVITREAL INJECTION; BEVACIZUMAB AVASTIN(R); CELLS SECRETE;
   GROWTH-FACTOR; PHARMACOKINETICS; RANIBIZUMAB; SAFETY
AB With the identification of vascular endothelial growth factor (VEGF) and the confirmation of its pathophysiologic link to retinal and choroidal angiogenesis, numerous agents have been designed to inhibit its activity. It is noteworthy that anatomic and visual benefits have been associated with the use of anti-VEGF agents such as pegaptanib (Macugen) and to a greater extent, ranibizumab (Lucentis) and bevacizumab (Avastin), particularly in the management of neovascular age-related macular degeneration (AMD). Clinical trials and case series have confirmed the utility of these agents. However, shortcomings of the current drugs such as short half-life, intraocular dosing, limited effectiveness in some patients, and potential systemic side effects continue to drive the development of new agents. In this article, we review current anti-VEGF therapies and discuss future developments.
C1 [Pieramici, D. J.; Rabena, M. D.] Calif Retina Res Fdn, Calif Retina Consultants, Santa Barbara, CA 93103 USA.
RP Pieramici, DJ (通讯作者)，Calif Retina Res Fdn, Calif Retina Consultants, 515 E Micheltorena St, Santa Barbara, CA 93103 USA.
EM dpieramici@yahoo.com
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIDUSCHKA P, 2007, INVEST OPHTHALMOL, V482, P814
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michelson IC, 1948, EYE, P136
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 22
TC 74
Z9 77
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2008
VL 22
IS 10
BP 1330
EP 1336
DI 10.1038/eye.2008.88
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 361HI
UT WOS:000260118200017
PM 18497829
OA Bronze
DA 2022-11-30
ER

PT J
AU Nakanishi, H
   Tsujikawa, A
   Gotoh, N
   Hayashi, H
   Iwama, D
   Tamura, H
   Otani, A
   Yoshimura, N
AF Nakanishi, Hideo
   Tsujikawa, Akitaka
   Gotoh, Norimoto
   Hayashi, Hisako
   Iwama, Daisuke
   Tamura, Hiroshi
   Otani, Atsushi
   Yoshimura, Nagahisa
TI MACULAR COMPLICATIONS ON THE BORDER OF AN INFERIOR STAPHYLOMA ASSOCIATED
   WITH TILTED DISC SYNDROME
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; central serous chorioretinopathy;
   polypoidal choroidal vasculopathy; staphyloma; tilted disc syndrome
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   INDOCYANINE GREEN VIDEOANGIOGRAPHY; SUBRETINAL NEOVASCULARIZATION;
   CLINICAL CHARACTERISTICS; OPTIC DISK; DETACHMENT; DEGENERATION;
   FEATURES; LEAKAGE
AB Purpose: To describe the clinical characteristics of macular complications on the border of an inferior staphyloma associated with tilted disk syndrome.
   Methods: We reviewed retrospectively the medical records of 32 consecutive eyes of 20 patients with tilted disk syndrome and an inferior staphyloma lying across the macula.
   Results: In 21 (66%) eyes, fluorescein angiography showed window defects on the border of the staphyloma, where the early phase of indocyanine green angiography showed hypofluorescence due to atrophy of the choriocapillaris. On the late phase of indocyanine green angiography, 19 eyes (59%) showed hyperfluorescence along the border of the staphyloma, which often extended beyond the area of the window defect. Of the 32 eyes, 25 (78%) had macular complications: polypoidal choroidal vasculopathy in 7 (22%), classic choroidal neovascularization in 1 (3%), focal serous retinal detachment without polypoidal choroidal vasculopathy or choroidal neovascularization in 13 (41%), and atrophy of the retinal pigment epithelium alone in 4 (13%). Visual acuity in eyes with polypoidal choroidal vasculopathy or choroidal neovascularization was significantly worse than that in eyes with other complications (P < 0.001).
   Conclusions: Eyes with tilted disk syndrome often have macular complications on the border of the inferior staphyloma, which can cause severe visual loss.
C1 [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujiwaka@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR APPLE DJ, 1982, SURV OPHTHALMOL, V27, P3, DOI 10.1016/0039-6257(82)90111-4
   Cohen SY, 2006, GRAEF ARCH CLIN EXP, V244, P1536, DOI 10.1007/s00417-006-0302-x
   Cohen SY, 1998, OPHTHALMOLOGY, V105, P1831, DOI 10.1016/S0161-6420(98)91024-7
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   DORRELL D, 1978, BRIT J OPHTHALMOL, V62, P16, DOI 10.1136/bjo.62.1.16
   GIUFFRE G, 1993, GRAEF ARCH CLIN EXP, V231, P41, DOI 10.1007/BF01681699
   GIUFFRE G, 1991, INT OPHTHALMOL, V15, P1, DOI 10.1007/BF00150971
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Lafaut B A, 1996, Bull Soc Belge Ophtalmol, V262, P55
   Leys AM, 2002, RETINA-J RET VIT DIS, V22, P659, DOI 10.1097/00006982-200210000-00025
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   PROST M, 1988, INT OPHTHALMOL, V12, P131, DOI 10.1007/BF00137139
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Quaranta M, 1996, AM J OPHTHALMOL, V122, P663, DOI 10.1016/S0002-9394(14)70484-2
   Riise D, 1975, Acta Ophthalmol Suppl, P3
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STUR M, 1988, AM J OPHTHALMOL, V105, P98, DOI 10.1016/0002-9394(88)90135-3
   Theodossiadis PG, 2006, GRAEF ARCH CLIN EXP, V244, P122, DOI 10.1007/s00417-005-0018-3
   Tosti G, 1999, OPHTHALMOLOGY, V106, P1453, DOI 10.1016/S0161-6420(99)90472-4
   TSUBOI S, 1984, BRIT J OPHTHALMOL, V68, P869, DOI 10.1136/bjo.68.12.869
   Vongphanit J, 2002, AM J OPHTHALMOL, V133, P679, DOI 10.1016/S0002-9394(02)01339-9
   YOUNG SE, 1976, AM J OPHTHALMOL, V82, P16, DOI 10.1016/0002-9394(76)90658-9
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 29
TC 56
Z9 60
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1493
EP 1501
DI 10.1097/IAE.0b013e318183589c
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373LH
UT WOS:000260972600016
PM 18667957
DA 2022-11-30
ER

PT J
AU Lee, GW
   Roh, HC
   Kang, SW
   Kim, AY
   Noh, H
   Choi, KJ
AF Lee, Geun Woo
   Roh, Hyeon Cheol
   Kang, Se Woong
   Kim, A. Young
   Noh, Hoon
   Choi, Kyung Jun
TI The implications of subretinal fluid in pachychoroid neovasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
AB This study aimed to identify the clinical characteristics and longitudinal changes in exudative pachychoroid neovasculopathy (PNV) and non-exudative PNV. This retrospective cohort study involved 81 eyes of PNV diagnosed by multimodal imaging including optical coherence tomography angiography. At baseline, they were divided into exudative PNV group and non-exudative PNV group depending on the presence of subretinal fluid. The clinical features of both groups and the longitudinal changes were investigated and compared. There were 55 eyes with non-exudative PNV and 26 eyes with exudative PNV. Individuals with non-exudative PNV were older, more frequently asymptomatic and had a higher prevalence of polypoidal choroidal vasculopathy in the opposite eye (all P's<0.05). Whereas individuals with exudative PNV showed thicker choroid and more frequent history of central serous chorioretinopathy (all P's<0.001). During about 12 months of longitudinal observation, the transformation into polypoidal choroidal vasculopathy was noted in 4 eyes of non-exudative PNV group, whereas in none of the exudative PNV group. Exudative PNV and non-exudative PNV seem to be separate entities with different epidemiological parameters. Non-exudative PNV, which is frequently found without symptoms at an older age, is suspected to be the significant precursor lesion of polypoidal choroidal vasculopathy. In contrast, exudative PNV may share the same pathophysiology as central serous chorioretinopathy.
C1 [Lee, Geun Woo; Roh, Hyeon Cheol; Kang, Se Woong; Kim, A. Young; Noh, Hoon; Choi, Kyung Jun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Geun Woo] Catholic Univ, Daegu Sch Med, Dept Ophthalmol, Daegu, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Catholic
   University of Daegu
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM swkang@skku.edu
OI Roh, Hyeon Cheol/0000-0003-2157-6087
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Bae K, 2019, GRAEF ARCH CLIN EXP, V257, P279, DOI 10.1007/s00417-018-4201-8
   Bae SH, 2014, OPHTHALMOLOGY, V121, P558, DOI 10.1016/j.ophtha.2013.09.024
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Demirel S, 2017, GRAEF ARCH CLIN EXP, V255, P2317, DOI 10.1007/s00417-017-3793-8
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hwang S, 2019, RETINA-J RET VIT DIS, V39, P1117, DOI 10.1097/IAE.0000000000002108
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Schworm B, 2020, GRAEF ARCH CLIN EXP, V258, P1013, DOI 10.1007/s00417-020-04623-w
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
NR 24
TC 6
Z9 6
U1 2
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 18
PY 2021
VL 11
IS 1
AR 4066
DI 10.1038/s41598-021-83650-x
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QL9PI
UT WOS:000621412400021
PM 33603014
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Guryanov, I
   Tennikova, T
   Urtti, A
AF Guryanov, Ivan
   Tennikova, Tatiana
   Urtti, Arto
TI Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current
   Situation and Perspectives
SO PHARMACEUTICS
LA English
DT Review
DE VEGF; VEGFA; VEGFR; peptide; affinity; binding; angiogenesis
ID HEPARIN-BINDING DOMAIN; HIGH-AFFINITY; FACTOR VEGF; PROTEIN
   INTERACTIONS; ALPHA/BETA-PEPTIDES; TUMOR-GROWTH; COMPLEX; DESIGN;
   ANGIOGENESIS; RELEASE
AB Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs.
C1 [Guryanov, Ivan; Tennikova, Tatiana] St Petersburg State Univ, Inst Chem, Univ Sky Pr 26, St Petersburg 198504, Russia.
   [Urtti, Arto] Univ Helsinki, Div Pharmaceut Biosci, Viikinkaari 5 E, Helsinki 00014, Finland.
   [Urtti, Arto] Univ Eastern Finland, Sch Pharm, Yliopistonranta 1 C, Kuopio 70211, Finland.
C3 Saint Petersburg State University; University of Helsinki; University of
   Eastern Finland
RP Guryanov, I; Tennikova, T (通讯作者)，St Petersburg State Univ, Inst Chem, Univ Sky Pr 26, St Petersburg 198504, Russia.
EM ivan.guryanov1@gmail.com; tennikova@mail.ru; arto.urtti@helsinki.fi
RI Guryanov, Ivan/N-3117-2016; Tennikova, Tatiana/J-6840-2013
OI Guryanov, Ivan/0000-0001-6897-3528; Tennikova,
   Tatiana/0000-0002-9029-2056
FU Government of Russian Federation [075-15-2021-637]
FX This research was funded by Megagrant #075-15-2021-637 of the Government
   of Russian Federation.
CR Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540
   Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588
   Bayo-Puxan N, 2016, CHEMMEDCHEM, V11, P928, DOI 10.1002/cmdc.201500467
   Belair DG, 2016, BIOMATERIALS, V93, P27, DOI 10.1016/j.biomaterials.2016.03.021
   Belair DG, 2014, CHEM COMMUN, V50, P15651, DOI 10.1039/c4cc04317k
   Belair DG, 2014, BIOMACROMOLECULES, V15, P2038, DOI 10.1021/bm500177c
   Belair DG, 2013, ACTA BIOMATER, V9, P8823, DOI 10.1016/j.actbio.2013.06.033
   Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391
   Chan LY, 2016, SCI REP-UK, V6, DOI 10.1038/srep35347
   Chan SJ, 2020, STROKE, V51, P2844, DOI 10.1161/STROKEAHA.119.025304
   Checco JW, 2017, CHEMBIOCHEM, V18, P291, DOI 10.1002/cbic.201600545
   Checco JW, 2015, P NATL ACAD SCI USA, V112, P4552, DOI 10.1073/pnas.1420380112
   Chirio D, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040560
   Chittasupho C, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-019-1568-8
   Cole CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011644
   Coppock MB, 2017, BIOPOLYMERS, V108, DOI 10.1002/bip.22934
   Courtois F, 2016, MABS-AUSTIN, V8, P99, DOI 10.1080/19420862.2015.1112477
   Domingues A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050666
   Erdag B, 2007, MOL BIOTECHNOL, V35, P51, DOI 10.1385/MB:35:1:51
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e
   Fedorova A, 2011, CHEM BIOL, V18, P839, DOI 10.1016/j.chembiol.2011.05.011
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Gao F, 2020, CURR CANCER DRUG TAR, V20, P3, DOI 10.2174/1568009619666191114110359
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   Goncalves V, 2009, J PEPT SCI, V15, P417, DOI 10.1002/psc.1133
   Graaf MD, 2016, ACS CHEM BIOL, V11, P2829, DOI 10.1021/acschembio.6b00685
   Grunewald FS, 2010, BBA-PROTEINS PROTEOM, V1804, P567, DOI 10.1016/j.bbapap.2009.09.002
   Guryanov I, 2019, J PEPT SCI, V25, DOI 10.1002/psc.3142
   Guryanov I, 2021, J MED CHEM, V64, P10900, DOI 10.1021/acs.jmedchem.1c00219
   Guryanov I, 2016, MAT SCI ENG C-MATER, V68, P890, DOI 10.1016/j.msec.2016.07.072
   Haase HS, 2012, J AM CHEM SOC, V134, P7652, DOI 10.1021/ja302469a
   Hachim D, 2019, J CONTROL RELEASE, V313, P131, DOI 10.1016/j.jconrel.2019.10.018
   Hassan N, 2021, CELL SIGNAL, V77, DOI 10.1016/j.cellsig.2020.109822
   He C, 2019, J MATER CHEM B, V7, P1186, DOI 10.1039/c8tb02671h
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Impellitteri NA, 2012, BIOMATERIALS, V33, P3475, DOI 10.1016/j.biomaterials.2012.01.032
   Jeong KW, 2013, BIOCHEMISTRY-US, V52, P8823, DOI 10.1021/bi4011682
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kargozar S, 2020, CHEM SOC REV, V49, P5008, DOI 10.1039/c8cs01021h
   Kazerounian S, 2018, J CELL COMMUN SIGNAL, V12, P171, DOI 10.1007/s12079-017-0433-3
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kenrick SA, 2010, PROTEIN ENG DES SEL, V23, P9, DOI 10.1093/protein/gzp065
   Kim JW, 2010, EXP MOL MED, V42, P514, DOI 10.3858/emm.2010.42.7.052
   Kim SH, 2007, PEPTIDES, V28, P2125, DOI 10.1016/j.peptides.2007.08.010
   Kocabey S, 2013, ACTA BIOMATER, V9, P9075, DOI 10.1016/j.actbio.2013.07.007
   Koch S, 2012, BIOCHEM SOC T, V40, P20, DOI 10.1042/BST20110689
   Koehler L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54211-0
   Lee SS, 2017, NAT NANOTECHNOL, V12, P821, DOI [10.1038/nnano.2017.109, 10.1038/NNANO.2017.109]
   Liang XW, 2014, CURR MED CHEM, V21, P894, DOI 10.2174/09298673113206660264
   Mammadov R, 2011, BIOMACROMOLECULES, V12, P3508, DOI 10.1021/bm200957s
   Markovic-Mueller S, 2017, STRUCTURE, V25, P341, DOI 10.1016/j.str.2016.12.012
   Maslowska K, 2021, CANCERS, V13, DOI 10.3390/cancers13051072
   Maynard HD, 2005, ACTA BIOMATER, V1, P451, DOI 10.1016/j.actbio.2005.04.004
   Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0
   Muttenthaler M, 2021, NAT REV DRUG DISCOV, V20, P309, DOI 10.1038/s41573-020-00135-8
   Norrby K, 2000, INT J EXP PATHOL, V81, P191, DOI 10.1046/j.1365-2613.2000.00150.x
   Norton KA, 2014, ONCOTARGETS THER, V7, P1571, DOI 10.2147/OTT.S65055
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Pan B, 2002, J MOL BIOL, V316, P769, DOI 10.1006/jmbi.2001.5370
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   Pelay-Gimeno M, 2015, ANGEW CHEM INT EDIT, V54, P8896, DOI 10.1002/anie.201412070
   Peterson KJ, 2008, ANAL BIOCHEM, V378, P8, DOI 10.1016/j.ab.2008.03.043
   Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612
   Piossek C, 2003, THROMB HAEMOSTASIS, V90, P501, DOI 10.1160/TH03-02-0106
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Reille-Seroussi M, 2015, BIOCHEMISTRY-US, V54, P5147, DOI 10.1021/acs.biochem.5b00722
   Rouet R, 2014, FEBS LETT, V588, P269, DOI 10.1016/j.febslet.2013.11.029
   Rust R, 2019, FASEB J, V33, P34, DOI 10.1096/fj.201800640RR
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Shahsuvaryan ML, 2017, TRENDS PHARMACOL SCI, V38, P667, DOI 10.1016/j.tips.2017.05.004
   Shaik F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121673
   Shi DL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.639666
   Shim JW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010275
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Teran M, 2015, J BIOL CHEM, V290, P16451, DOI 10.1074/jbc.M114.627372
   Toepke MW, 2012, ADV HEALTHC MATER, V1, P457, DOI 10.1002/adhm.201200077
   Uzunalli G, 2017, ACS BIOMATER SCI ENG, V3, P1296, DOI 10.1021/acsbiomaterials.6b00165
   Wang MM, 2017, COLLOID SURFACE B, V150, P175, DOI 10.1016/j.colsurfb.2016.11.022
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wang XR, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.599281
   Wu G, 2013, J THEOR BIOL, V317, P293, DOI 10.1016/j.jtbi.2012.10.021
   Yasa O, 2017, J MATER CHEM B, V5, P4890, DOI 10.1039/c7tb00708f
   Yoo SA, 2005, J IMMUNOL, V174, P5846, DOI 10.4049/jimmunol.174.9.5846
   Zane D, 2021, INT J TOXICOL, V40, P108, DOI 10.1177/1091581820977846
   Zashikhina N, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010027
   Zheng K, 2011, MABS-AUSTIN, V3, P568, DOI 10.4161/mabs.3.6.17922
   Zirlik K, 2018, ONCOL RES TREAT, V41, P166, DOI 10.1159/000488087
NR 95
TC 4
Z9 4
U1 4
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD SEP
PY 2021
VL 13
IS 9
AR 1337
DI 10.3390/pharmaceutics13091337
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UY3KI
UT WOS:000701426200001
PM 34575413
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ly, A
   Phu, J
   Katalinic, P
   Kalloniatis, M
AF Ly, Angelica
   Phu, Jack
   Katalinic, Paula
   Kalloniatis, Michael
TI An evidence-based approach to the routine use of optical coherence
   tomography
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age&#8208; related macular degeneration; diabetic retinopathy; glaucoma;
   imaging; screening
ID NERVE-FIBER-LAYER; ANTERIOR-CHAMBER ANGLE; DIABETIC MACULAR EDEMA;
   MACHINE LEARNING CLASSIFIERS; GLAUCOMA DIAGNOSTIC ABILITY; ANGIOGRAPHY
   VESSEL DENSITY; VISUAL-FIELD PROGRESSION; TERM CLINICAL-COURSE; DISC
   MARGIN ANATOMY; LEAD-TIME BIAS
AB Optical coherence tomography is an imaging technology that has revolutionised the detection, assessment and management of ocular disease. It is now a mainstream technology in clinical practice and is performed by non-specialised personnel in some settings. This article provides a clinical perspective on the implications of that movement and describes best practice using multimodal imaging and an evidence-based approach. Practical, illustrative guides on the interpretation of optical coherence tomography are provided for three major diseases of the ocular fundus, in which optical coherence tomography is often crucial to management: age-related macular degeneration, diabetic retinopathy and glaucoma. Topics discussed include: cross-sectional and longitudinal signs in ocular disease, so-called 'red-green' disease whereby clinicians rely on machine/statistical comparisons for diagnosis in managing treatment-naive patients, and the utility of optical coherence tomography angiography and machine learning.
C1 [Ly, Angelica; Phu, Jack; Katalinic, Paula; Kalloniatis, Michael] Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Phu, Jack; Katalinic, Paula; Kalloniatis, Michael] Univ New South Wales, Fac Sci, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Kalloniatis, M (通讯作者)，Univ New South Wales, Ctr Eye Hlth, Sydney, NSW, Australia.; Kalloniatis, M (通讯作者)，Univ New South Wales, Fac Sci, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM m.kalloniatis@unsw.edu.au
OI Phu, Jack/0000-0002-9933-6780; Ly, Angelica/0000-0001-7881-1522;
   Kalloniatis, Michael/0000-0002-5264-4639
FU National Health and Medical Research Council (NHMRC) of Australia
   [1033224]; NHMRC
FX This work was supported, in part, by a grant from the National Health
   and Medical Research Council (NHMRC) of Australia (#1033224), Guide Dogs
   NSW/ACT is also a partner on the NHMRC grant and provided funding
   support for all the authors.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Akiyama H, 2018, JPN J OPHTHALMOL, V62, P286, DOI 10.1007/s10384-018-0571-z
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, AGE RELATED MACULAR
   Ang M, 2018, GRAEF ARCH CLIN EXP, V256, P237, DOI 10.1007/s00417-017-3896-2
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Asrani S, 2014, JAMA OPHTHALMOL, V132, P396, DOI 10.1001/jamaophthalmol.2013.7974
   Bartnik SE, 2018, CLIN EXP OPTOM, V101, P700, DOI 10.1111/cxo.12658
   Bathija R, 1998, J GLAUCOMA, V7, P165
   Bengtsson B, 2012, ACTA OPHTHALMOL, V90, P310, DOI 10.1111/j.1755-3768.2010.01977.x
   Bizios D, 2010, ACTA OPHTHALMOL, V88, P44, DOI 10.1111/j.1755-3768.2009.01784.x
   Blumberg DM, 2014, INVEST OPHTH VIS SCI, V55, P3491, DOI 10.1167/iovs.14-14014
   Bolz M, 2014, BRIT J OPHTHALMOL, V98, P1612, DOI 10.1136/bjophthalmol-2013-304564
   Bowd C, 2017, AM J OPHTHALMOL, V175, P37, DOI 10.1016/j.ajo.2016.11.010
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bressler NM, 2012, EYE, V26, P833, DOI 10.1038/eye.2012.53
   Burgansky-Eliash Z, 2005, INVEST OPHTH VIS SCI, V46, P4147, DOI 10.1167/iovs.05-0366
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x
   Chalam KV, 2012, INVEST OPHTH VIS SCI, V53, P8154, DOI 10.1167/iovs.12-10290
   Chartrand G, 2017, RADIOGRAPHICS, V37, P2113, DOI 10.1148/rg.2017170077
   Chauhan BC, 2013, OPHTHALMOLOGY, V120, P535, DOI 10.1016/j.ophtha.2012.09.055
   Chong GT, 2012, CURR OPIN OPHTHALMOL, V23, P79, DOI 10.1097/ICU.0b013e32834ff431
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chung JK, 2017, CURR EYE RES, V42, P1458, DOI 10.1080/02713683.2017.1337157
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Cucchetti Alessandro, 2014, J Hepatol, V61, P333, DOI 10.1016/j.jhep.2014.03.037
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dabasia PL, 2015, OPHTHALMOLOGY, V122, P2407, DOI 10.1016/j.ophtha.2015.08.019
   Danesh-Meyer HV, 2014, OPHTHALMOLOGY, V121, P1516, DOI 10.1016/j.ophtha.2014.02.020
   De Moraes CG, 2013, ACTA OPHTHALMOL, V91, pe86, DOI 10.1111/j.1755-3768.2012.02577.x
   De Niro JE, 2014, RETINA-J RET VIT DIS, V34, P1163, DOI 10.1097/IAE.0000000000000077
   Detry-Morel M, 2004, EUR J OPHTHALMOL, V14, P387, DOI 10.1177/112067210401400505
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Fang PP, 2019, RETINA-J RET VIT DIS, V39, P150, DOI 10.1097/IAE.0000000000001918
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flammer J, 1999, J GLAUCOMA, V8, P212
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Foreman J, 2018, JAMA OPHTHALMOL, V136, P240, DOI 10.1001/jamaophthalmol.2017.6457
   Fortune B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077831
   Fortune B, 2013, INVEST OPHTH VIS SCI, V54, P5653, DOI 10.1167/iovs.13-12219
   Fortune B, 2012, INVEST OPHTH VIS SCI, V53, P3939, DOI 10.1167/iovs.12-9979
   Francis BA, 2011, INVEST OPHTH VIS SCI, V52, P6257, DOI 10.1167/iovs.09-5126
   Garway-Heath DF, 2015, LANCET, V385, P1295, DOI 10.1016/S0140-6736(14)62111-5
   Glen FC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003996
   Hamada M, 2018, JPN J OPHTHALMOL, V62, P168, DOI 10.1007/s10384-018-0570-0
   Hanumunthadu D, 2017, CLIN OPHTHALMOL, V11, P2121, DOI 10.2147/OPTH.S148505
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Heijl A, 2013, ACTA OPHTHALMOL, V91, P406, DOI 10.1111/j.1755-3768.2012.02492.x
   Helmy YM, 2013, CLIN OPHTHALMOL, V7, P1731, DOI 10.2147/OPTH.S47987
   Hood DC, 2007, PROG RETIN EYE RES, V26, P688, DOI 10.1016/j.preteyeres.2007.08.001
   Hood DC, 2014, INVEST OPHTH VIS SCI, V55, P632, DOI 10.1167/iovs.13-13130
   Hood DC, 2013, INVEST OPHTH VIS SCI, V54, P7338, DOI 10.1167/iovs.13-12680
   Horii T, 2010, AM J OPHTHALMOL, V150, P840, DOI 10.1016/j.ajo.2010.06.015
   Hu CX, 2016, J GLAUCOMA, V25, P177, DOI 10.1097/IJG.0000000000000076
   Hua R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21743
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Hwang YH, 2012, INVEST OPHTH VIS SCI, V53, P2226, DOI 10.1167/iovs.11-8689
   Iverson SM, 2013, EYE, V27, P1180, DOI 10.1038/eye.2013.163
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Jansen RJ, 2013, ANN EPIDEMIOL, V23, P735, DOI 10.1016/j.annepidem.2013.07.021
   Jeong JH, 2014, ACTA OPHTHALMOL, V92, pE185, DOI 10.1111/aos.12277
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kalloniatis M, 2016, OPHTHAL PHYSL OPT, V36, P439, DOI 10.1111/opo.12295
   Kang SW, 2004, AM J OPHTHALMOL, V137, P313, DOI 10.1016/j.ajo.2003.09.016
   Kiely PM, 2015, CLIN EXP OPTOM, V98, P65, DOI 10.1111/cxo.12216
   Kim KE, 2015, OPHTHALMOLOGY, V122, P502, DOI 10.1016/j.ophtha.2014.09.031
   Kim KE, 2015, AM J OPHTHALMOL, V159, P160, DOI 10.1016/j.ajo.2014.10.010
   Kim M, 2013, INDIAN J OPHTHALMOL, V61, P213, DOI 10.4103/0301-4738.97075
   Kim SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177726
   Kim TW, 2013, CURR EYE RES, V38, P903, DOI 10.3109/02713683.2013.800888
   Knight OJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P312, DOI 10.1001/archopthalmol.2011.1576
   Kozak I, 2008, RETINA-J RET VIT DIS, V28, P538, DOI 10.1097/IAE.0b013e318167270b
   Krawitz BD, 2017, VISION RES, V139, P177, DOI 10.1016/j.visres.2016.09.019
   Krupin T, 2011, AM J OPHTHALMOL, V151, P671, DOI 10.1016/j.ajo.2010.09.026
   Lauermann JL, 2018, OPHTHALMOLOGICA, V239, P74, DOI 10.1159/000485261
   Leung CKS, 2010, OPHTHALMOLOGY, V117, P2337, DOI 10.1016/j.ophtha.2010.04.002
   Leung CKS, 2010, OPHTHALMOLOGY, V117, P1684, DOI 10.1016/j.ophtha.2010.01.026
   Leung CKS, 2012, OPHTHALMOLOGY, V119, P1858, DOI 10.1016/j.ophtha.2012.03.044
   Li G, 2010, OPHTHALMOLOGY, V117, P453, DOI 10.1016/j.ophtha.2009.07.033
   Lisboa R, 2013, INVEST OPHTH VIS SCI, V54, P3417, DOI 10.1167/iovs.13-11676
   Lisboa R, 2012, OPHTHALMOLOGY, V119, P2261, DOI 10.1016/j.ophtha.2012.06.009
   Liu MM, 2018, J GLAUCOMA, V27, P64, DOI 10.1097/IJG.0000000000000822
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Lupidi M, 2017, RETINA-J RET VIT DIS, V37, pE42, DOI 10.1097/IAE.0000000000001422
   Ly A, 2018, INVEST OPHTH VIS SCI, V59, P1790, DOI 10.1167/iovs.17-23076
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Malamos P, 2011, RETINA-J RET VIT DIS, V31, P453, DOI 10.1097/IAE.0b013e3181eef031
   Malik R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002067
   Masoodi H, 2014, CONTACT LENS ANTERIO, V37, P300, DOI 10.1016/j.clae.2014.04.002
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   McLeod SD, 2016, OPHTHALMOLOGY, V123, pP41, DOI 10.1016/j.ophtha.2015.10.053
   Medeiros FA, 2012, INVEST OPHTH VIS SCI, V53, P6939, DOI 10.1167/iovs.12-10345
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P339, DOI 10.1016/j.jcjo.2014.04.018
   Mozaffarieh M, 2013, CURR OPIN PHARMACOL, V13, P43, DOI 10.1016/j.coph.2012.10.001
   Musch DC, 2009, OPHTHALMOLOGY, V116, P200, DOI 10.1016/j.ophtha.2008.08.051
   Mwanza JC, 2015, INVEST OPHTH VIS SCI, V56, P6344, DOI 10.1167/iovs.15-17248
   Nakanishi H, 2015, GRAEF ARCH CLIN EXP, V253, P1143, DOI 10.1007/s00417-015-3026-y
   Nakano T, 2017, CLIN OPHTHALMOL, V11, P97, DOI 10.2147/OPTH.S115547
   Narayanaswamy A, 2010, ARCH OPHTHALMOL-CHIC, V128, P1321, DOI 10.1001/archophthalmol.2010.231
   National Collaborating Centre for Acute C. National Institute for Health and Clinical Excellence: Guidance, 2009, GLAUCOMA DIAGNOSIS M
   National Health and Medical Research Council (NHMRC), 2010, GUID SCREEN PROGN DI
   Nolan WP, 2007, OPHTHALMOLOGY, V114, P33, DOI 10.1016/j.ophtha.2006.05.073
   Ong HS, 2013, J GLAUCOMA, V22, P496, DOI 10.1097/IJG.0b013e3182447d58
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   Panozzo G, 2004, Semin Ophthalmol, V19, P13
   Park SB, 2011, JPN J OPHTHALMOL, V55, P343, DOI 10.1007/s10384-011-0036-0
   Park SC, 2012, OPHTHALMOLOGY, V119, P3, DOI 10.1016/j.ophtha.2011.07.012
   Parravano M, 2017, AM J OPHTHALMOL, V179, P90, DOI 10.1016/j.ajo.2017.04.021
   Phu J, 2018, OPTOMETRY VISION SCI, V95, P959, DOI 10.1097/OPX.0000000000001286
   Phu J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.17
   Phu J, 2017, CLIN EXP OPTOM, V100, P313, DOI 10.1111/cxo.12551
   Phu J, 2017, OPHTHAL PHYSL OPT, V37, P160, DOI 10.1111/opo.12355
   Porporato N, 2018, CLIN EXP OPHTHALMOL, V46, P147, DOI 10.1111/ceo.13120
   Prum Bruce E Jr, 2016, Ophthalmology, V123, pP112, DOI 10.1016/j.ophtha.2015.10.055
   Quek DT, 2012, INVEST OPHTH VIS SCI, V53, P5131, DOI 10.1167/iovs.12-10132
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7
   Quigley HA, 2015, PROG BRAIN RES, V220, P59, DOI 10.1016/bs.pbr.2015.04.003
   RADIUS RL, 1979, ARCH OPHTHALMOL-CHIC, V97, P948
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   Rao HL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173930
   Rao HL, 2016, AM J OPHTHALMOL, V171, P75, DOI 10.1016/j.ajo.2016.08.030
   Ravera V, 2019, RETINA-J RET VIT DIS, V39, P281, DOI 10.1097/IAE.0000000000001960
   Reis ASC, 2012, INVEST OPHTH VIS SCI, V53, P1852, DOI 10.1167/iovs.11-9309
   Reis ASC, 2012, OPHTHALMOLOGY, V119, P738, DOI 10.1016/j.ophtha.2011.09.054
   Rho S, 2014, INVEST OPHTH VIS SCI, V55, P5116, DOI 10.1167/iovs.14-14630
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rountree L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20480-4
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sakata LM, 2008, OPHTHALMOLOGY, V115, P769, DOI 10.1016/j.ophtha.2007.06.030
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Sawada A, 2017, BRIT J OPHTHALMOL, V101, P1649, DOI 10.1136/bjophthalmol-2016-309401
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schechet S, 2018, OSLI RETINA, V49, P80, DOI 10.3928/23258160-20180129-01
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shah SU, 2012, OPHTHALMOLOGY, V119, P1066, DOI 10.1016/j.ophtha.2011.11.001
   Sharma R, 2014, SURV OPHTHALMOL, V59, P311, DOI 10.1016/j.survophthal.2013.06.005
   Shelton RL, 2014, J BIOPHOTONICS, V7, P525, DOI 10.1002/jbio.201200243
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith SD, 2013, OPHTHALMOLOGY, V120, P1985, DOI 10.1016/j.ophtha.2013.05.034
   SOMMER A, 1977, ARCH OPHTHALMOL-CHIC, V95, P2149
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P77, DOI 10.1001/archopht.1991.01080010079037
   Song Y, 2012, RETINA-J RET VIT DIS, V32, P569, DOI 10.1097/IAE.0b013e31821f5d69
   Spaeth George L, 2002, Trans Am Ophthalmol Soc, V100, P181
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Strouthidis NG, 2014, BRIT J OPHTHALMOL, V98, P1605, DOI 10.1136/bjophthalmol-2013-304133
   The Royal College of Ophthalmologists, 2013, AGE RELATED MACULAR
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Vaz-Pereira S, 2017, RETINA-J RET VIT DIS, V37, P1287, DOI 10.1097/IAE.0000000000001336
   Vujosevic S, 2016, OPHTHALMIC RES, V55, P19, DOI 10.1159/000441110
   Wang B, 2013, INVEST OPHTH VIS SCI, V54, P8270, DOI 10.1167/iovs.13-13109
   Wang XL, 2015, GRAEF ARCH CLIN EXP, V253, P1557, DOI 10.1007/s00417-015-3095-y
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Wessel JM, 2013, INVEST OPHTH VIS SCI, V54, P3613, DOI 10.1167/iovs.12-9786
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Yapp M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190273
   Ye C, 2016, ACTA OPHTHALMOL, V94, pE211, DOI 10.1111/aos.12762
   Yu M, 2016, OPHTHALMOLOGY, V123, P1201, DOI 10.1016/j.ophtha.2016.02.017
   Zangerl B, 2017, CLIN EXP OPTOM, V100, P214, DOI 10.1111/cxo.12478
   Zhu HG, 2011, IEEE T MED IMAGING, V30, P1228, DOI 10.1109/TMI.2011.2109962
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 183
TC 14
Z9 16
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAY 1
PY 2019
VL 102
IS 3
BP 242
EP 259
DI 10.1111/cxo.12847
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA VJ8RP
UT WOS:000640473800006
PM 30560558
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Palczewska, G
   Dong, ZQ
   Golczak, M
   Hunter, JJ
   Williams, DR
   Alexander, NS
   Palczewski, K
AF Palczewska, Grazyna
   Dong, Zhiqian
   Golczak, Marcin
   Hunter, Jennifer J.
   Williams, David R.
   Alexander, Nathan S.
   Palczewski, Krzysztof
TI Noninvasive two-photon microscopy imaging of mouse retina and retinal
   pigment epithelium through the pupil of the eye
SO NATURE MEDICINE
LA English
DT Article
ID FLUORESCENCE; CHEMISTRY; MODELS
AB Two-photon excitation microscopy can image retinal molecular processes in vivo. Intrinsically fluorescent retinyl esters in subcellular structures called retinosomes are an integral part of the visual chromophore regeneration pathway. Fluorescent condensation products of all-trans-retinal accumulate in the eye with age and are also associated with age-related macular degeneration (AMD). Here, we report repetitive, dynamic imaging of these compounds in live mice through the pupil of the eye. By leveraging advanced adaptive optics, we developed a data acquisition algorithm that permitted the identification of retinosomes and condensation products in the retinal pigment epithelium by their characteristic localization, spectral properties and absence in genetically modified or drug-treated mice. This imaging approach has the potential to detect early molecular changes in retinoid metabolism that trigger light- and AMD-induced retinal defects and to assess the effectiveness of treatments for these conditions.
C1 [Palczewska, Grazyna; Dong, Zhiqian; Palczewski, Krzysztof] Polgenix, Cleveland, OH 44106 USA.
   [Golczak, Marcin; Alexander, Nathan S.; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Hunter, Jennifer J.; Williams, David R.] Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA.
   [Hunter, Jennifer J.] Univ Rochester, Flaum Eye Inst, Rochester, NY USA.
   [Hunter, Jennifer J.] Univ Rochester, Dept Biomed Engn, Rochester, NY USA.
   [Williams, David R.] Univ Rochester, Inst Opt, Rochester, NY 14627 USA.
C3 Case Western Reserve University; University of Rochester; University of
   Rochester; University of Rochester; University of Rochester
RP Palczewski, K (通讯作者)，Polgenix, Cleveland, OH 44106 USA.
EM kxp65@case.edu
OI DONG, ZHIQIAN/0000-0002-8748-4532; Hunter, Jennifer/0000-0001-5801-4737
FU National Eye Institute of the NIH [R01EY008061, R01EY009339,
   R24EY021126, P3OEY11373]; National Institute on Aging of the NIH
   [R44AG043645]; NIH institutional training [5T32EY007157, 5T32DK007319];
   NATIONAL EYE INSTITUTE [R01EY009339, P30EY011373, R24EY021126,
   T32EY007157, R01EY008061] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R44AG043645]
   Funding Source: NIH RePORTER
FX We thank M. Redmond (National Eye Institute of the US National
   Institutes of Health (NIH)) for Rpe65-1- mice and J. Wilson (Baylor
   College of Medicine) for GFP-rhodopsin mice. We also thank the team at
   Bioptigen for advice on preparation of mice for live animal imaging, D.
   Piston for stimulating discussion and L.T. Webster Jr. and members of
   K.E's laboratory and Polgenix's team for critical comments on the
   manuscript. Research reported in this publication was supported by the
   National Eye Institute of the NIH under award numbers R01EY008061,
   R01EY009339, R24EY021126 and P3OEY11373 and by the National Institute on
   Aging of the NIH under award number R44AG043645. N.S.A. was supported by
   NIH institutional training grants 5T32EY007157 and 5T32DK007319.
CR BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Bueno JM, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3505018
   Carroll J, 2012, INVEST OPHTH VIS SCI, V53, P8006, DOI 10.1167/iovs.12-11087
   Chan F, 2004, P NATL ACAD SCI USA, V101, P9109, DOI 10.1073/pnas.0403149101
   Chen CH, 2005, BIOPHYS J, V88, P2278, DOI 10.1529/biophysj.104.054254
   Delori F. o. C., 2007, J OPT SOC AM A, V24, P1250
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   Drabent R, 1997, J PHOTOCH PHOTOBIO B, V37, P254, DOI 10.1016/S1011-1344(96)07400-3
   Euler T, 2009, PFLUG ARCH EUR J PHY, V457, P1393, DOI 10.1007/s00424-008-0603-5
   Geng Y, 2012, BIOMED OPT EXPRESS, V3, P715, DOI 10.1364/BOE.3.000715
   Godara P, 2010, OPTOMETRY VISION SCI, V87, P930, DOI 10.1097/OPX.0b013e3181ff9a8b
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818
   Helmstaedter M, 2013, NATURE, V500, P168, DOI 10.1038/nature12346
   Huang SH, 2002, BIOPHYS J, V82, P2811, DOI 10.1016/S0006-3495(02)75621-X
   Hunter JJ, 2011, BIOMED OPT EXPRESS, V2, P139, DOI 10.1364/BOE.2.000139
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Kocaoglu OP, 2011, BIOMED OPT EXPRESS, V2, P748, DOI 10.1364/BOE.2.000748
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Lin B, 2004, NEURON, V43, P475, DOI 10.1016/j.neuron.2004.08.002
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2013, INVEST OPHTH VIS SCI, V54, P455, DOI 10.1167/iovs.12-11152
   Moroni L, 2000, J PHYS CHEM A, V104, P11063, DOI 10.1021/jp002098
   Padayatti P, 2012, BIOCHEMISTRY-US, V51, P1625, DOI 10.1021/bi201682q
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Rueckel M, 2006, P NATL ACAD SCI USA, V103, P17137, DOI 10.1073/pnas.0604791103
   Schmucker C, 2004, VISION RES, V44, P1857, DOI 10.1016/j.visres.2004.03.011
   Sharma R, 2013, BIOMED OPT EXPRESS, V4, P1285, DOI 10.1364/BOE.4.001285
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Spiess E, 2005, J MICROSC-OXFORD, V217, P200, DOI 10.1111/j.1365-2818.2005.01437.x
   Sun WZ, 2002, J COMP NEUROL, V451, P115, DOI 10.1002/cne.10323
   von Lintig J, 2010, TRENDS BIOCHEM SCI, V35, P400, DOI 10.1016/j.tibs.2010.01.005
   Xi P, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3059629
   Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899
NR 40
TC 78
Z9 78
U1 0
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUL
PY 2014
VL 20
IS 7
BP 785
EP 789
DI 10.1038/nm.3590
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA AK8PF
UT WOS:000338689500023
PM 24952647
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Maneu, V
   Noailles, A
   Megias, J
   Gomez-Vicente, V
   Carpena, N
   Gil, ML
   Gozalbo, D
   Cuenca, N
AF Maneu, Victoria
   Noailles, Agustina
   Megias, Javier
   Gomez-Vicente, Violeta
   Carpena, Nuria
   Luisa Gil, M.
   Gozalbo, Daniel
   Cuenca, Nicolas
TI Retinal Microglia Are Activated by Systemic Fungal Infection
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE microglial activation; retina; infection; candidiasis
ID MARROW-DERIVED MICROGLIA; CANDIDA-ALBICANS INFECTIONS;
   CENTRAL-NERVOUS-SYSTEM; MACULAR DEGENERATION; CYTOKINE PRODUCTION;
   PARKINSONS-DISEASE; IFN-GAMMA; CELLS; MICE; NEUROPROTECTION
AB PURPOSE. We determined whether systemic fungal infection could cause activation of retinal microglia and, therefore, could be potentially harmful for patients with retinal degenerative diseases.
   METHODS. Activation of retinal microglia was measured in a model of sublethal invasive candidiasis in C57BL/6J mice by confocal immunofluorescence and flow cytometry analysis, using anti-CD11b, anti-Iba1, anti-MHCII, and anti-CD45 antibodies.
   RESULTS. Systemic fungal infection causes activation of retinal microglia, with phenotypic changes in morphology, surface markers expression, and microglial relocation in retinal layers.
   CONCLUSIONS. As an excessive or prolonged microglial activation may lead to chronic inflammation with severe pathological side effects, causing or worsening the course of retinal dystrophies, a systemic infection may represent a risk factor to be considered in patients with ocular neurodegenerative diseases, such as diabetic retinopathy, glaucoma, age-related macular degeneration, or retinitis pigmentosa.
C1 [Maneu, Victoria] Univ Alicante, Dept Opt Farmacol & Anat, San Vicente Del Raspeig 03690, Alicante, Spain.
   [Maneu, Victoria] Univ Autonoma Madrid, Inst Teofilo Hernando ID Medicamento, Madrid, Spain.
   [Noailles, Agustina; Gomez-Vicente, Violeta; Cuenca, Nicolas] Univ Alicante, Dept Fisiol Genet & Microbiol, E-03080 Alicante, Spain.
   [Megias, Javier; Carpena, Nuria; Luisa Gil, M.; Gozalbo, Daniel] Univ Valencia, Dept Microbiol & Ecol, E-46100 Burjassot, Spain.
   [Cuenca, Nicolas] Univ Alicante, Inst Multidisciplinar Estudio Medio Ramon Margale, E-03080 Alicante, Spain.
C3 Universitat d'Alacant; Autonomous University of Madrid; Universitat
   d'Alacant; University of Valencia; Universitat d'Alacant
RP Maneu, V (通讯作者)，Univ Alicante, Dept Opt Farmacol & Anat, Pabellon 13, San Vicente Del Raspeig 03690, Alicante, Spain.
EM vmaneu@ua.es
RI Maneu, Victoria/N-4147-2014; Noailles, Agustina/G-9871-2015; Gil, María
   Luisa/M-2371-2014; Gozalbo, Daniel/ABF-5887-2021; Cuenca,
   Nicolas/I-2007-2015; Gómez-Vicente, Violeta/A-6089-2013
OI Maneu, Victoria/0000-0002-5265-1361; Noailles,
   Agustina/0000-0001-7898-137X; Gil, María Luisa/0000-0003-0319-5678;
   Cuenca, Nicolas/0000-0002-6767-5710; Gómez-Vicente,
   Violeta/0000-0002-5696-8673; Gozalbo, Daniel/0000-0001-5210-4117;
   CARPENA GARCIA, NURIA/0000-0002-1017-4499
FU Spanish Ministry of Economy and Competitiveness-FEDER [BFU2012-36845];
   Instituto de Salud Carlos III RETICS [RD12/0034/0010]; ONCE; Instituto
   de Salud Carlos III [PI080556]; MICINN-Juan de la Cierva Postdoctoral
   Fellowship [JCI-2009-05224]
FX Supported by project grants from the Spanish Ministry of Economy and
   Competitiveness-FEDER BFU2012-36845, Instituto de Salud Carlos III
   RETICS RD12/0034/0010, and ONCE (NCu); Instituto de Salud Carlos III
   PI080556 (DG); and MICINN-Juan de la Cierva Postdoctoral Fellowship
   JCI-2009-05224 (VG-V).
CR Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1
   Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4
   Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602
   Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989
   DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Goodridge Helen S., 2008, V183, P87
   Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0
   Gregerson DS, 2003, INVEST OPHTH VIS SCI, V44, P3083, DOI 10.1167/iovs.02-1014
   Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5
   Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Halder SK, 2013, J NEUROCHEM, V126, P243, DOI 10.1111/jnc.12262
   Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013
   Held J, 2013, J CLIN MICROBIOL, V51, P1158, DOI 10.1128/JCM.02473-12
   Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6
   Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kezic J, 2008, INVEST OPHTH VIS SCI, V49, P1599, DOI 10.1167/iovs.07-0953
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lionakis MS, 2011, J INNATE IMMUN, V3, P180, DOI 10.1159/000321157
   Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039
   Gil ML, 2009, FRONT BIOSCI-LANDMRK, V14, P570, DOI 10.2741/3263
   Magrone T, 2012, CURR PHARM DESIGN, V18, P34, DOI 10.2174/138161212798919057
   Maneu V, 2011, FEMS IMMUNOL MED MIC, V63, P148, DOI 10.1111/j.1574-695X.2011.00829.x
   Murciano C, 2006, MED MYCOL, V44, P149, DOI 10.1080/13693780500294733
   Murciano C, 2007, EUR CYTOKINE NETW, V18, P38
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Polazzi E, 2010, PROG NEUROBIOL, V92, P293, DOI 10.1016/j.pneurobio.2010.06.009
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438
   Shah VB, 2008, J IMMUNOL, V180, P2777, DOI 10.4049/jimmunol.180.5.2777
   Shah VB, 2009, NEUROSCI LETT, V458, P111, DOI 10.1016/j.neulet.2009.04.039
   Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022
   Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004
   Tremblay S, 2013, INVEST OPHTH VIS SCI, V54, P8125, DOI 10.1167/iovs.13-12496
   Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Yanez A, 2009, MICROBES INFECT, V11, P531, DOI 10.1016/j.micinf.2009.01.011
   Zinkernagel MS, 2013, AM J PATHOL, V182, P875, DOI 10.1016/j.ajpath.2012.11.031
NR 48
TC 21
Z9 22
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2014
VL 55
IS 6
BP 3578
EP 3585
DI 10.1167/iovs.14-14051
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9TX
UT WOS:000339485800027
PM 24833742
OA Green Published
DA 2022-11-30
ER

PT J
AU Chang, JH
   Garg, NK
   Lunde, E
   Han, KY
   Jain, S
   Azar, DT
AF Chang, Jin-Hong
   Garg, Nitin K.
   Lunde, Elisa
   Han, Kyu-Yeon
   Jain, Sandeep
   Azar, Dimitri T.
TI Corneal Neovascularization: An Anti-VEGF Therapy Review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE anti-VEGF therapy; corneal neovascularization; bevacizumab; ranibizumab;
   VEGF Trap; silencing RNA
ID ENDOTHELIAL GROWTH-FACTOR; HERPETIC STROMAL KERATITIS; FACTOR TRAP-EYE;
   SUBCONJUNCTIVAL BEVACIZUMAB INJECTION; DIABETIC MACULAR EDEMA;
   ACTIVATING-FACTOR PAF; TOPICAL BEVACIZUMAB; GRAFT-SURVIVAL; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION
AB Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors. (Surv Ophthalmol 57:415-429, 2012. (C) 2012 Elsevier Inc. All rights reserved.)
C1 [Chang, Jin-Hong; Garg, Nitin K.; Lunde, Elisa; Han, Kyu-Yeon; Jain, Sandeep; Azar, Dimitri T.] Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Chang, JH (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, 1855 W Taylor St, Chicago, IL 60612 USA.
EM changr@uic.edu
FU National Institute of Health [EY021886, EY10101, EY01792]; Research to
   Prevent Blindness, New-York; NATIONAL EYE INSTITUTE [P30EY001792,
   R29EY010101, R01EY010101, R21EY021886] Funding Source: NIH RePORTER
FX The authors report no proprietary or commercial interest in any product
   mentioned or concept discussed in this article. Publication for this
   article was supported by National Institute of Health (Bethesda, MD)
   grants EY021886 (JHC), EY10101 (DTA), EY01792 (DTA) and an unrestricted
   grant from Research to Prevent Blindness, New-York, NY.
CR Ahmed A, 2009, CLIN EXP OPHTHALMOL, V37, P730, DOI 10.1111/j.1442-9071.2009.02112.x
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avila MP, 2011, RETINA, V32, P10
   Avisar I, 2010, CURR EYE RES, V35, P108, DOI 10.3109/02713680903429007
   Awadein A, 2007, J CATARACT REFR SURG, V33, P1991, DOI 10.1016/j.jcrs.2007.07.012
   Bachmann BO, 2009, BRIT J OPHTHALMOL, V93, P1075, DOI 10.1136/bjo.2008.145128
   Bachmann BO, 2008, ARCH OPHTHALMOL-CHIC, V126, P71, DOI 10.1001/archopht.126.1.71
   Bachmann B, 2010, OPHTHALMOLOGY, V117, P1300, DOI 10.1016/j.ophtha.2010.01.039
   Bagri A, 2010, TRENDS MOL MED, V16, P122, DOI 10.1016/j.molmed.2010.01.004
   Bahar I, 2008, CURR EYE RES, V33, P23, DOI 10.1080/02713680701799101
   Bahar I, 2008, CORNEA, V27, P142, DOI 10.1097/ICO.0b013e318159019f
   Banifatemi M, 2011, J OCUL PHARMACOL TH, V27, P17, DOI 10.1089/jop.2010.0094
   Bayar SA, 2010, OCUL IMMUNOL INFLAMM, V18, P268, DOI 10.3109/09273948.2010.490630
   Bidot ML, 2011, J FR OPHTALMOL, V34, P376, DOI 10.1016/j.jfo.2011.03.004
   Biswas PS, 2006, EXP EYE RES, V82, P46, DOI 10.1016/j.exer.2005.05.001
   Bock F, 2007, OPHTHALMOLOGE, V104, P336, DOI 10.1007/s00347-007-1512-2
   Bock F, 2008, GRAEF ARCH CLIN EXP, V246, P281, DOI 10.1007/s00417-007-0684-4
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Carrasco MA, 2008, CORNEA, V27, P743, DOI 10.1097/QAI.0b013e31815b833a
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Chu HS, 2011, CORNEA, V30, P60, DOI 10.1097/ICO.0b013e3181e458c5
   Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P2666, DOI 10.1167/iovs.03-1380
   Cursiefen C, 2003, CORNEA, V22, P273, DOI 10.1097/00003226-200304000-00021
   Cursiefen C, 2003, BRIT J OPHTHALMOL, V87, P101, DOI 10.1136/bjo.87.1.101
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dastjerdi MH, 2011, INVEST OPHTH VIS SCI, V52, P8718, DOI 10.1167/iovs.11-7871
   Dastjerdi MH, 2010, INVEST OPHTH VIS SCI, V51, P2411, DOI 10.1167/iovs.09-3745
   Dastjerdi MH, 2009, ARCH OPHTHALMOL-CHIC, V127, P381, DOI 10.1001/archophthalmol.2009.18
   Dell S, 2006, INVEST OPHTH VIS SCI, V47, P1928, DOI 10.1167/iovs.05-1071
   DelMonte DW, 2011, J CATARACT REFR SURG, V37, P588, DOI 10.1016/j.jcrs.2010.12.037
   DeStafeno JJ, 2007, ARCH OPHTHALMOL-CHIC, V125, P834, DOI 10.1001/archopht.125.6.834
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Doctor PP, 2008, CORNEA, V27, P992, DOI 10.1097/ICO.0b013e31817786ad
   Dratviman-Storobinsky O, 2009, MOL VIS, V15, P2326
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Ellenberg D, 2010, PROG RETIN EYE RES, V29, P208, DOI 10.1016/j.preteyeres.2010.01.002
   Erdurmus M, 2007, GRAEF ARCH CLIN EXP, V245, P1577, DOI 10.1007/s00417-007-0587-4
   Fallah MR, 2010, CURR EYE RES, V35, P17, DOI 10.3109/02713680903395273
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gadkari Salil S., 2007, Indian Journal of Ophthalmology, V55, P103
   Gerten G, 2008, CORNEA, V27, P1195, DOI 10.1097/ICO.0b013e318180e50f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gueudry J, 2010, J FR OPHTALMOL, V33, P630, DOI 10.1016/j.jfo.2010.07.007
   Habot-Wilner Z, 2010, ACTA OPHTHALMOL, V88, P862, DOI 10.1111/j.1755-3768.2009.01571.x
   Hashemian MN, 2011, OPHTHALMIC RES, V46, P50, DOI 10.1159/000322061
   Hashemian MN, 2011, CORNEA, V30, P215, DOI 10.1097/ICO.0b013e3181e291a6
   Hashemian MN, 2009, OPHTHALMIC RES, V42, P90, DOI 10.1159/000224783
   He JC, 2010, CURR EYE RES, V35, P1063, DOI 10.3109/02713683.2010.513797
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hoffart L, 2010, CLIN EXP OPHTHALMOL, V38, P346, DOI 10.1111/j.1442-9071.2010.02252.x
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hos D, 2008, INVEST OPHTH VIS SCI, V49, P1836, DOI 10.1167/iovs.07-1314
   Hosseini H, 2007, CLIN EXP OPHTHALMOL, V35, P745, DOI 10.1111/j.1442-9071.2007.01572.x
   Hosseini H, 2007, MED HYPOTHESES, V69, P568, DOI 10.1016/j.mehy.2007.01.032
   Hosseini H, 2007, MED HYPOTHESES, V69, P925, DOI 10.1016/j.mehy.2007.01.047
   Hosseini H, 2007, MED HYPOTHESES, V68, P799, DOI 10.1016/j.mehy.2006.06.063
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kayikcioglu O, 1999, INT OPHTHALMOL, V23, P37, DOI 10.1023/A:1006486207583
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Keshavarz M, 2009, ARCH MED RES, V40, P59, DOI 10.1016/j.arcmed.2008.10.004
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim Sang Woo, 2008, Ophthalmology, V115, pe33, DOI 10.1016/j.ophtha.2008.02.013
   Kim TI, 2008, CORNEA, V27, P349, DOI 10.1097/ICO.0b013e31815cf67d
   Kim TI, 2009, INVEST OPHTH VIS SCI, V50, P4653, DOI 10.1167/iovs.08-2805
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Koenig Y, 2009, GRAEF ARCH CLIN EXP, V247, P1375, DOI 10.1007/s00417-009-1099-1
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lee S, 2002, J CLIN INVEST, V110, P1105, DOI 10.1172/JCI200215755
   Lee SH, 2009, BMB REP, V42, P800, DOI 10.5483/BMBRep.2009.42.12.800
   Lin CT, 2010, INVEST OPHTH VIS SCI, V51, P6277, DOI 10.1167/iovs.09-4571
   Lopez ES, 2011, CANCER CHEMOTH PHARM, V67, P723, DOI 10.1007/s00280-010-1457-z
   LOPEZ JS, 1991, ARCH OPHTHALMOL-CHIC, V109, P988, DOI 10.1001/archopht.1991.01080070100045
   LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994
   Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128
   MAGUIRE MG, 1994, OPHTHALMOLOGY, V101, P1536
   Mandalos A, 2010, CORNEA, V29, P1373, DOI 10.1097/ICO.0b013e3181d927b9
   Manzano RPA, 2007, BRIT J OPHTHALMOL, V91, P804, DOI 10.1136/bjo.2006.107912
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauro J, 2009, SEMIN OPHTHALMOL, V24, P130, DOI 10.1080/08820530902801106
   Murata M, 2006, CURR EYE RES, V31, P171, DOI 10.1080/02713680500514636
   Mwaikambo B. R., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P255, DOI 10.2174/187153008786848330
   Mwaikambo BR, 2008, CORNEA, V27, P1037, DOI 10.1097/ICO.0b013e31817780b6
   Natoli C, 2010, CURR CANCER DRUG TAR, V10, P462, DOI 10.2174/156800910791517208
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Oh JY, 2009, CORNEA, V28, P1070, DOI 10.1097/ICO.0b013e31819839f9
   Oh JY, 2009, CURR EYE RES, V34, P85, DOI 10.1080/02713680802607740
   Oliveira HB, 2010, EUR J OPHTHALMOL, V20, P48, DOI 10.1177/112067211002000106
   Papathanassiou M, 2008, AM J OPHTHALMOL, V145, P424, DOI 10.1016/j.ajo.2007.11.003
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Qian CXY, 2008, CORNEA, V27, P1090, DOI 10.1097/ICO.0b013e31817c41e3
   Rocher N, 2011, MOL VIS, V17, P104
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Saravia M, 2009, GRAEF ARCH CLIN EXP, V247, P1409, DOI 10.1007/s00417-009-1101-y
   Saxena S, 2009, EUR J OPHTHALMOL, V19, P870, DOI 10.1177/112067210901900530
   Schiffelers RM, 2006, EXPERT OPIN DRUG DEL, V3, P445, DOI 10.1517/17425247.3.3.445
   Shakiba Y, 2007, ARCH MED RES, V38, P789, DOI 10.1016/j.arcmed.2007.04.006
   Shakiba Y, 2009, RECENT PATENTS INFLA, V3, P221, DOI 10.2174/187221309789257450
   Shalam KV, 2009, CORNEA, V28, P328, DOI 10.1097/ICO.0b013e31818b8be0
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Singh N, 2007, CORNEA, V26, P65
   Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Symes RJ, 2010, CORNEA, V29, P691, DOI 10.1097/ICO.0b013e3181ba0ae2
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tshionyi M, 2012, CORNEA, V31, P74, DOI 10.1097/ICO.0b013e31821dd986
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Uy HS, 2008, CORNEA, V27, P70, DOI 10.1097/ICO.0b013e318158f6ad
   Vassileva PI, 2009, GRAEF ARCH CLIN EXP, V247, P1701, DOI 10.1007/s00417-009-1170-y
   VOLKERDIEBEN HJ, 1987, AUST NZ J OPHTHALMOL, V15, P11, DOI 10.1111/j.1442-9071.1987.tb00300.x
   Yan J, 2007, COLLOID SURFACE B, V60, P105, DOI 10.1016/j.colsurfb.2007.06.013
   Yatoh S, 1998, TRANSPLANTATION, V66, P1519, DOI 10.1097/00007890-199812150-00016
   Yeung SN, 2011, CORNEA, V30, P1110, DOI 10.1097/ICO.0b013e31821379aa
   Yoeruek E, 2008, ACTA OPHTHALMOL, V86, P322, DOI 10.1111/j.1600-0420.2007.01049.x
   Yoeruek E, 2007, CORNEA, V26, P977, DOI 10.1097/ICO.0b013e3180de1d0a
   Yoon KC, 2005, GENE THER, V12, P617, DOI 10.1038/sj.gt.3302442
   You IC, 2009, ACTA OPHTHALMOL, V87, P653, DOI 10.1111/j.1755-3768.2008.01399.x
   Yuan XY, 2009, MOL VIS, V15, P1988
   Zaki AA, 2010, ACTA OPHTHALMOL, V88, P868, DOI 10.1111/j.1755-3768.2009.01585.x
   Zhang CR, 2011, GRAEF ARCH CLIN EXP, V249, P1493, DOI 10.1007/s00417-011-1709-6
   Zheng M, 2001, J VIROL, V75, P9828, DOI 10.1128/JVI.75.20.9828-9835.2001
   Zuo L, 2010, CURR EYE RES, V35, P375, DOI 10.3109/02713681003597230
NR 142
TC 238
Z9 254
U1 2
U2 63
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2012
VL 57
IS 5
BP 415
EP 429
DI 10.1016/j.survophthal.2012.01.007
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 994DF
UT WOS:000307910400002
PM 22898649
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vakiti, A
   Singh, D
   Pilla, R
   Alhaj-Moustafa, M
   Fitzpatrick, KW
AF Vakiti, Anusha
   Singh, Daulath
   Pilla, Ravi
   Alhaj-Moustafa, Muhamad
   Fitzpatrick, Kelly W.
TI Bevacizumab-induced atypical hemolytic uremic syndrome and treatment
   with eculizumab
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE Bevacizumab; atypical hemolytic uremic syndrome; eculizumab; thrombotic
   microangiopathy; complement
ID THROMBOTIC MICROANGIOPATHY; DRUG; MECHANISMS; INHIBITION; TOXICITY
AB Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect. It encompasses the clinical triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure, without any association with Shiga toxins. Eculizumab is a terminal complement inhibitor used in the treatment of atypical hemolytic uremic syndrome. Herein, we present three cases of bevacizumab-induced atypical hemolytic syndrome treated successfully with eculizumab.
C1 [Vakiti, Anusha; Pilla, Ravi; Alhaj-Moustafa, Muhamad] MedStar Washington Hosp Ctr, Dept Internal Med, Washington, DC USA.
   [Singh, Daulath] Loyola Univ Med Ctr, Dept Hematol & Oncol, Maywood, IL 60153 USA.
   [Fitzpatrick, Kelly W.] MedStar Washington Hosp Ctr, Dept Internal Med, Div Hematol & Oncol, Washington, DC USA.
C3 MedStar Washington Hospital Center; Loyola University Chicago; MedStar
   Washington Hospital Center
RP Vakiti, A (通讯作者)，MedStar Washington Hosp Ctr, 110 Irving St NW, Washington, DC 20010 USA.
EM avakiti@gmail.com
RI Singh, Daulath/AAH-5015-2019; Moustafa, Muhamad Alhaj/AAH-3261-2019
OI Singh, Daulath/0000-0002-0346-8501; Moustafa, Muhamad
   Alhaj/0000-0001-8582-1219; Fitzpatrick, Kelly/0000-0002-3595-896X
CR Al-Nouri ZL, 2015, BLOOD, V125, P616, DOI 10.1182/blood-2014-11-611335
   Bollee G, 2009, NEPHROL DIAL TRANSPL, V24, P682, DOI 10.1093/ndt/gfn657
   Dhakal P, 2017, CLIN APPL THROMB-HEM, V23, P175, DOI 10.1177/1076029615599439
   El-Ghazal R, 2011, CLIN COLORECTAL CANC, V10, P142, DOI 10.1016/j.clcc.2011.03.012
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Faguer S, 2013, CLIN KIDNEY J, V6, P484, DOI 10.1093/ckj/sft078
   Jokiranta TS, 2017, BLOOD, V129, P2847, DOI 10.1182/blood-2016-11-709865
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kaplan BS, 2014, INTRACTABLE RARE DIS, V3, P34, DOI 10.5582/irdr.2014.01001
   Karkowsky MD, 2015, MED FORUM, V16, DOI [10.29046/TMF.016.1.007, DOI 10.29046/TMF.016.1.007]
   Kiuru M., 2014, DERMATOL ONLINE J, V20, P13030
   Lee HW, 2014, GUT LIVER, V8, P109, DOI 10.5009/gnl.2014.8.1.109
   Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
   Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Nester CM, 2012, HEMATOL-AM SOC HEMAT, P617, DOI 10.1182/asheducation-2012.1.617
   Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310
   Racca Patrizia, 2011, Tumori, V97, p31e, DOI 10.1700/989.10735
   Robinson Andrew, 2010, J Gastrointest Cancer, V41, P71, DOI 10.1007/s12029-009-9116-5
   Said T, 2010, TRANSPL P, V42, P814, DOI 10.1016/j.transproceed.2010.02.029
   Sawai T, 2014, CLIN EXP NEPHROL, V18, P4, DOI 10.1007/s10157-013-0911-8
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
NR 22
TC 11
Z9 11
U1 0
U2 761
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD JUN
PY 2019
VL 25
IS 4
BP 1011
EP 1015
DI 10.1177/1078155218774895
PG 5
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA HT4DE
UT WOS:000464512600038
PM 29768958
DA 2022-11-30
ER

PT S
AU Cho, C
   Duong, TT
   Mills, JA
AF Cho, Chloe
   Duong, Thu T.
   Mills, Jason A.
BE Rickman, CB
   Grimm, C
   Anderson, RE
   Ash, JD
   LaVail, MM
   Hollyfield, JG
TI A Mini Review: Moving iPSC-Derived Retinal Subtypes Forward for Clinical
   Applications for Retinal Degenerative Diseases
SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY
SE Advances in Experimental Medicine and Biology
LA English
DT Review
CT 18th International Symposium on Retinal Degeneration (RD)
CY SEP 03-08, 2018
CL Killarney, IRELAND
DE Human-induced pluripotent stem cells; Retinal degenerative diseases;
   Gene therapy; Retinal ganglion cells; Photoreceptor; Retinal pigmented
   epithelium; Age-related macular degeneration; Retinitis pigmentosa
ID PLURIPOTENT STEM-CELLS; GANGLION-CELLS; RETINITIS-PIGMENTOSA; PATIENT;
   DIFFERENTIATION; EPITHELIUM; GLAUCOMA; MODELS; LINES
AB Patient-derived human-induced pluripotent stem cells (iPSCs) have been critical in advancing our understanding of the underlying mechanisms of numerous retinal disorders. Many of these retinal disorders have no effective treatment and result in severe visual impairment and even blindness. Among the retinal degenerative diseases modeled by iPSCs are age-related macular degeneration (AMD), glaucoma, Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), and autosomal dominant retinitis pigmentosa (adRP). In addition to studying retinal disease ontogenesis and pathology, hiPSCs have clinical and pharmacological applications, such as developing drug screening and gene therapy approaches and new cell-based clinical treatments. Recent studies have primarily focused on three retinal cell fates - retinal pigmented epithelium cells (RPE), retinal ganglion cells (RGCs), and photoreceptor cells - and have demonstrated that hiPSCs have great potential for increasing our knowledge of and developing treatments for retinal degenerative disorders.
C1 [Cho, Chloe; Duong, Thu T.; Mills, Jason A.] Univ Penn, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Cho, Chloe; Duong, Thu T.; Mills, Jason A.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, CAROT, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Mills, JA (通讯作者)，Univ Penn, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.; Mills, JA (通讯作者)，Univ Penn, Scheie Eye Inst, Perelman Sch Med, CAROT, Philadelphia, PA 19104 USA.
EM millsja@pennmedicine.upenn.edu
CR Arno G, 2016, AM J HUM GENET, V99, P1305, DOI 10.1016/j.ajhg.2016.10.008
   Duong TT, 2018, STEM CELL RES, V27, P140, DOI 10.1016/j.scr.2018.01.009
   Gagliardi G, 2018, STEM CELL REP, V11, P665, DOI 10.1016/j.stemcr.2018.07.005
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Langer KB, 2018, STEM CELL REP, V10, P1282, DOI 10.1016/j.stemcr.2018.02.010
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Ohlemacher SK, 2016, STEM CELLS, V34, P1553, DOI 10.1002/stem.2356
   Oswald J, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418774433
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Schwarz N, 2017, HUM MOL GENET, V26, P2480, DOI 10.1093/hmg/ddx143
   Schwarz N, 2015, HUM MOL GENET, V24, P972, DOI 10.1093/hmg/ddu509
   Shimada H, 2017, CELL REP, V20, P384, DOI 10.1016/j.celrep.2017.06.045
   Sluch VM, 2017, STEM CELL TRANSL MED, V6, P1972, DOI 10.1002/sctm.17-0059
   Teotia P, 2017, STEM CELLS, V35, P2239, DOI 10.1002/stem.2675
   Teotia P, 2017, STEM CELLS, V35, P572, DOI 10.1002/stem.2513
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
   Weed Lindsey S, 2017, Stem Cell Investig, V4, P65, DOI 10.21037/sci.2017.07.02
   Wiley LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30742
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
NR 26
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-030-27378-1; 978-3-030-27377-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2019
VL 1185
BP 557
EP 561
DI 10.1007/978-3-030-27378-1_91
PG 5
WC Medicine, Research & Experimental; Ophthalmology
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Ophthalmology
GA BO4FI
UT WOS:000514087200092
PM 31884670
DA 2022-11-30
ER

PT J
AU Cheung, N
   Wong, TY
AF Cheung, Ning
   Wong, Tien Y.
TI Obesity and eye diseases
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related maculopathy; body mass index; cataract; eye disease
   glaucoma; obesity; pseudotumor celebri; retinal artery occlusion;
   retinal vein occlusion; retinopathy
ID BODY-MASS INDEX; OPEN-ANGLE GLAUCOMA; CARDIOVASCULAR RISK-FACTORS;
   ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; C-REACTIVE PROTEIN;
   TYPE-1 DIABETIC-PATIENTS; HUMAN TRABECULAR MESHWORK; SYSTEMIC
   BLOOD-PRESSURE; BLUE-MOUNTAINS-EYE
AB The prevalence of obesity has reached epidemic proportions in many countries. Although its impact on overall health is well documented, less is known about the ocular manifestations of obesity. Among different eye diseases, obesity has been linked with age-related cataract, glaucoma, age-related maculopathy, and diabetic retinopathy. Numerous population-based and prospective studies support an association between obesity and risk of age-related cataract. However, the nature and strength of these associations, particularly with the different cataract subtypes, remains to be determined. There is strong evidence that obesity is associated with elevated intraocular pressure, but there is no convincing data to support a more direct association between obesity and glaucomatous optic neuropathy. Studies to date have not found a consistent pattern of association between obesity and risk of age-related maculopathy or diabetic retinopathy. Thus, although obesity may be a risk factor for many ocular conditions, the present literature is inadequate to establish any convincing associations. Furthermore, whether weight loss reduces the risk of eye diseases remains unresolved. Because of the potential public health impact of obesity, there is a greater need to understand its ocular effects.
C1 Univ Melbourne, Ctr Eye Res Australia, Retinal Vasc Imaging Ctr, Melbourne, Vic 3002, Australia.
   Royal Melbourne Hosp, Melbourne, Vic, Australia.
   Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; Royal
   Melbourne Hospital; National University of Singapore; Singapore National
   Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Retinal Vasc Imaging Ctr, 32 Gisborne St, Melbourne, Vic 3002, Australia.
RI Cheung, Ning Danny/F-2043-2013; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU NHLBI NIH HHS [R21 HL077166-01, R21 HL077166, R21-HL077166] Funding
   Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077166]
   Funding Source: NIH RePORTER
CR Abramson N, 2001, SOUTHERN MED J, V94, P1013
   Agata J, 1997, AM J HYPERTENS, V10, P1171
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alam AA, 2004, SAUDI MED J, V25, P1593
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Backhouse O, 2000, EYE, V14, P13, DOI 10.1038/eye.2000.4
   BALLARD DJ, 1986, DIABETES CARE, V9, P334, DOI 10.2337/diacare.9.4.334
   Bengtsson B, 2005, J GLAUCOMA, V14, P135, DOI 10.1097/01.ijg.0000151683.04410.f3
   Bergman B, 2004, ACTA OPHTHALMOL SCAN, V82, P166, DOI 10.1111/j.1600-0420.2004.00182.x
   BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X
   Bianchini Franca, 2002, Obes Rev, V3, P5, DOI 10.1046/j.1467-789X.2002.00046.x
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231
   Brazis P W, 1998, Curr Opin Ophthalmol, V9, P27
   Broadway DC, 1998, BRIT J OPHTHALMOL, V82, P862, DOI 10.1136/bjo.82.8.862
   BULPITT CJ, 1975, BRIT J OPHTHALMOL, V59, P717, DOI 10.1136/bjo.59.12.717
   Caballero M, 2003, BIOCHEM BIOPH RES CO, V308, P346, DOI 10.1016/S0006-291X(03)01385-8
   Caldwell RB, 2005, CURR DRUG TARGETS, V6, P511, DOI 10.2174/1389450054021981
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Caulfield LE, 1999, AM J CLIN NUTR, V69, P237
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   CHATURVEDI N, 1995, DIABETES CARE, V18, P766, DOI 10.2337/diacare.18.6.766
   Chaturvedi N, 2001, DIABETES CARE, V24, P284, DOI 10.2337/diacare.24.2.284
   Chew E Y, 1997, Curr Opin Ophthalmol, V8, P59, DOI 10.1097/00055735-199706000-00011
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cohen RA, 1999, AM J MED, V107, P45, DOI 10.1016/S0002-9343(99)00165-5
   Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
   Cushman M, 1996, AM J EPIDEMIOL, V143, P665
   Cusick M, 2003, OPHTHALMOLOGY, V110, P2126, DOI 10.1016/j.ophtha.2003.01.001
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   De Block CEM, 2005, DIABETES CARE, V28, P1649, DOI 10.2337/diacare.28.7.1649
   de Rivera FJR, 2003, REV NEUROLOGIA, V37, P801, DOI 10.33588/rn.3709.2003282
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851
   DIELEMANS I, 1995, OPHTHALMOLOGY, V102, P54
   Dietz WH, 2004, NEW ENGL J MED, V350, P855, DOI 10.1056/NEJMp048008
   Dorchy H, 2002, DIABETES CARE, V25, P798, DOI 10.2337/diacare.25.4.798
   Dowse GK, 1998, AM J EPIDEMIOL, V147, P448, DOI 10.1093/oxfordjournals.aje.a009470
   Duntas LH, 2004, NUTR NEUROSCI, V7, P195, DOI 10.1080/10284150400009998
   Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   Fasshauer M, 2004, BIOCHIMIE, V86, P779, DOI 10.1016/j.biochi.2004.09.016
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Ferris FL, 2004, NEW ENGL J MED, V351, P2863, DOI 10.1056/NEJMe048316
   Ferris FL, 1996, DIABETES CARE, V19, P1291, DOI 10.2337/diacare.19.11.1291
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Ford ES, 1999, DIABETES CARE, V22, P1971, DOI 10.2337/diacare.22.12.1971
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Friedman Neal, 2004, Dis Manag, V7 Suppl 1, pS1
   Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V287, P1382, DOI 10.1001/jama.287.11.1382
   Frystyk J, 2005, DIABETOLOGIA, V48, P1911, DOI 10.1007/s00125-005-1850-z
   Gariano RF, 2000, INVEST OPHTH VIS SCI, V41, P3576
   GARNER MH, 1980, P NATL ACAD SCI-BIOL, V77, P1274, DOI 10.1073/pnas.77.3.1274
   Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472
   Gasser P, 1999, J GLAUCOMA, V8, P8
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Glowinska Barbara, 2004, Kardiol Pol, V61, P329
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Gomez-Ambrosi J, 2004, AM J CLIN NUTR, V79, P888
   Goodrich M E, 1999, Ophthalmic Epidemiol, V6, P279, DOI 10.1076/opep.6.4.279.4188
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grieshaber Matthias C, 2005, Curr Opin Ophthalmol, V16, P79, DOI 10.1097/01.icu.0000156134.38495.0b
   Grundy SM, 2000, ENDOCRINE, V13, P155, DOI 10.1385/ENDO:13:2:155
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P2329
   Hak AE, 1999, ARTERIOSCL THROM VAS, V19, P1986, DOI 10.1161/01.ATV.19.8.1986
   Halpern D Lynn, 2002, Ophthalmol Clin North Am, V15, P61, DOI 10.1016/S0896-1549(01)00012-8
   HANKINSON SE, 1993, ARCH OPHTHALMOL-CHIC, V111, P503, DOI 10.1001/archopht.1993.01090040095040
   Harding J J, 1997, Curr Opin Ophthalmol, V8, P46, DOI 10.1097/00055735-199708010-00010
   Harris A, 2003, AM J OPHTHALMOL, V135, P144, DOI 10.1016/S0002-9394(02)01927-X
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Hassink SG, 1996, PEDIATRICS, V98, P201
   Haynes WG, 2005, EXP PHYSIOL, V90, P683, DOI 10.1113/expphysiol.2005.031237
   Haynes WG, 1997, HYPERTENSION, V30, P619, DOI 10.1161/01.HYP.30.3.619
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Hennis A, 2003, OPHTHALMOLOGY, V110, P908, DOI 10.1016/S0161-6420(03)00075-7
   Henricsson M, 2003, DIABETES CARE, V26, P349, DOI 10.2337/diacare.26.2.349
   Hered R W, 1988, J Pediatr Ophthalmol Strabismus, V25, P145
   Hill JO, 2005, PSYCHIAT CLIN N AM, V28, P1, DOI 10.1016/j.psc.2004.09.010
   Hiller R, 1998, OPHTHALMOLOGY, V105, P1244, DOI 10.1016/S0161-6420(98)97029-4
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HORWITZ J, 1992, TXB OPHTHALMOLOGY 3, P50
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jacques PF, 2003, AM J CLIN NUTR, V78, P400, DOI 10.1093/ajcn/78.3.400
   Jaen Diaz J, 2001, Aten Primaria, V28, P23
   JAHN CE, 1986, OPHTHALMIC RES, V18, P112, DOI 10.1159/000265424
   James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123
   James PT, 2004, CLIN DERMATOL, V22, P276, DOI 10.1016/j.clindermatol.2004.01.010
   JONAS JB, 1989, AM J OPHTHALMOL, V107, P137, DOI 10.1016/0002-9394(89)90212-2
   KAISER HJ, 1995, GRAEF ARCH CLIN EXP, V233, P484, DOI 10.1007/BF00183429
   KARASIK A, 1984, DIABETES CARE, V7, P52, DOI 10.2337/diacare.7.1.52
   Kaur Harsohena, 2003, Treat Endocrinol, V2, P375, DOI 10.2165/00024677-200302060-00002
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Kennedy RL, 2004, CURR OPIN CLIN NUTR, V7, P3, DOI 10.1097/00075197-200401000-00002
   KITAZAWA Y, 1977, ARCH OPHTHALMOL-CHIC, V95, P1180, DOI 10.1001/archopht.1977.04450070078004
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN BE, 1981, ARCH OPHTHALMOL-CHIC, V99, P837
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Klein BEK, 1997, OPHTHALMOLOGY, V104, P573, DOI 10.1016/S0161-6420(97)30267-X
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, ARCH INTERN MED, V157, P650, DOI 10.1001/archinte.157.6.650
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kuang TM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1109, DOI 10.1001/archopht.123.8.1109
   Lahey JM, 2003, CURR OPIN PULM MED, V9, P385, DOI 10.1097/00063198-200309000-00008
   Lawrence VJ, 2004, CLIN DERMATOL, V22, P296, DOI 10.1016/j.clindermatol.2004.01.012
   LEE ET, 1992, DIABETES, V41, P359, DOI 10.2337/diabetes.41.3.359
   Lee JS, 2002, CLIN EXP OPHTHALMOL, V30, P237, DOI 10.1046/j.1442-9071.2002.00527.x
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   LESKE MC, 1983, AM J EPIDEMIOL, V118, P280, DOI 10.1093/oxfordjournals.aje.a113634
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P1113, DOI 10.1001/archopht.1995.01100090039020
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   LESSELL S, 1992, SURV OPHTHALMOL, V37, P155, DOI 10.1016/0039-6257(92)90134-F
   Lim HS, 2004, ARCH INTERN MED, V164, P1737, DOI 10.1001/archinte.164.16.1737
   Lobstein T., 2004, OBES REV S1, V5, P4, DOI [10.1111/j.1467-789X.2004.00133.x, DOI 10.1111/J.1467-789X.2004.00133.X]
   Maier PC, 2005, BMJ-BRIT MED J, V331, P134, DOI 10.1136/bmj.38506.594977.E0
   MAPSTONE R, 1985, BRIT MED J, V291, P93, DOI 10.1136/bmj.291.6488.93
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Matsuda M, 2004, DIABETIC MED, V21, P881, DOI 10.1111/j.1464-5491.2004.01261.x
   MCLEOD SD, 1990, INVEST OPHTH VIS SCI, V31, P2361
   McNab AA, 2005, CLIN EXP OPHTHALMOL, V33, P117, DOI 10.1111/j.1442-9071.2005.00969.x
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Miyazawa-Hoshimoto S, 2003, DIABETOLOGIA, V46, P1483, DOI 10.1007/s00125-003-1221-6
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Mori K, 2000, INT J EPIDEMIOL, V29, P661, DOI 10.1093/ije/29.4.661
   Nakamura M, 2005, OPHTHALMOLOGICA, V219, P1, DOI 10.1159/000081775
   Nakamura M, 1997, Nihon Jinzo Gakkai Shi, V39, P746
   Narin F, 2005, ANN SAUDI MED, V25, P209, DOI 10.5144/0256-4947.2005.209
   NELSON RG, 1989, DIABETES, V38, P435, DOI 10.2337/diabetes.38.4.435
   Nieuwdorp M, 2005, CURR OPIN PHARMACOL, V5, P155, DOI 10.1016/j.coph.2004.10.003
   Oh SW, 2005, DIABETES-METAB RES, V21, P434, DOI 10.1002/dmrr.529
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Olney J W, 1986, Adv Exp Med Biol, V203, P631
   PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006
   Polak Monika, 2004, Ann Univ Mariae Curie Sklodowska Med, V59, P434
   Prisco D, 2002, PATHOPHYSIOL HAEMO T, V32, P308, DOI 10.1159/000073587
   Purvin VA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1626, DOI 10.1001/archopht.118.12.1626
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   Raina J, 1996, AM J OPHTHALMOL, V122, P123, DOI 10.1016/S0002-9394(14)71978-6
   RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D
   ROBINSON MK, 1992, AM FAM PHYSICIAN, V45, P2661
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Savinova OV, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-12
   Schaumberg DA, 2000, AM J CLIN NUTR, V72, P1495
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   SCHOENFELD ER, 1993, J AM COLL NUTR, V12, P521, DOI 10.1080/07315724.1993.10718346
   Schorr U, 1998, J HYPERTENS, V16, P1475, DOI 10.1097/00004872-199816100-00011
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sheard NF, 2003, NUTR REV, V61, P76, DOI [10.1301/nr.2003.febr.76-79, 10.1031/nr.2003.febr.76-79]
   SHIOSE Y, 1990, SURV OPHTHALMOL, V34, P413, DOI 10.1016/0039-6257(90)90122-C
   SHIOSE Y, 1984, ARCH OPHTHALMOL-CHIC, V102, P883
   SHIOSE Y, 1986, AM J OPHTHALMOL, V101, P714, DOI 10.1016/0002-9394(86)90776-2
   Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683
   Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987
   Sjostrom CD, 1997, OBES RES, V5, P519
   Sjostrom CD, 1999, OBES RES, V7, P477
   Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMMER A, 1989, AM J OPHTHALMOL, V107, P186, DOI 10.1016/0002-9394(89)90221-3
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6
   SPECTOR A, 1993, EXP EYE RES, V57, P659, DOI 10.1006/exer.1993.1174
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   Su D. H. W., 2000, SMJ, V41, P295
   Suter PM, 1998, AM J HYPERTENS, V11, P1305, DOI 10.1016/S0895-7061(98)00162-9
   Tamburrino MB, 2002, PANMINERVA MED, V44, P301
   Tapp RJ, 2003, DIABETES CARE, V26, P1731, DOI 10.2337/diacare.26.6.1731
   Tavani Alessandra, 1995, Annals of Epidemiology, V5, P234, DOI 10.1016/1047-2797(94)00111-6
   Taylor A, 2000, INT OPHTHALMOL CLIN, V40, P17, DOI 10.1097/00004397-200010000-00003
   TEUSCHER AU, 1985, J NEUROL, V232, P144, DOI 10.1007/BF00313889
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038
   Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Uckaya G, 2000, J CLIN ENDOCR METAB, V85, P683, DOI 10.1210/jc.85.2.683
   Uckaya G, 2000, DIABETES CARE, V23, P371, DOI 10.2337/diacare.23.3.371
   Ughade Suresh N., 1998, Indian Journal of Ophthalmology, V46, P221
   Valle M, 2005, DIABETES METAB, V31, P55, DOI 10.1016/S1262-3636(07)70167-2
   van Leiden HA, 2003, ARCH OPHTHALMOL-CHIC, V121, P245, DOI 10.1001/archopht.121.2.245
   van Leiden HA, 2002, DIABETES CARE, V25, P1320, DOI 10.2337/diacare.25.8.1320
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI 10.1038/sj.ijo.0802158
   WEST SK, 1995, SURV OPHTHALMOL, V39, P323
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, INVEST OPHTH VIS SCI, V45, P2949, DOI 10.1167/iovs.04-0069
   WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yilmaz MI, 2004, EUR J ENDOCRINOL, V151, P135, DOI 10.1530/eje.0.1510135
   Yoshida M, 2003, JPN J OPHTHALMOL, V47, P191, DOI 10.1016/S0021-5155(02)00666-4
   Younan C, 2003, OPHTHALMIC EPIDEMIOL, V10, P227, DOI 10.1076/opep.10.4.227.15905
   Yudkin JS, 2005, LANCET, V365, P1817, DOI 10.1016/S0140-6736(05)66585-3
   Zanella MT, 2001, HYPERTENSION, V38, P705, DOI 10.1161/01.HYP.38.3.705
   ZANG EA, 1994, NUTR CANCER, V21, P247, DOI 10.1080/01635589409514323
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang FM, 2005, VITAM HORM, V71, P345, DOI 10.1016/S0083-6729(05)71012-8
   Zhang LY, 2001, DIABETES CARE, V24, P1275, DOI 10.2337/diacare.24.7.1275
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
NR 227
TC 202
Z9 209
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2007
VL 52
IS 2
BP 180
EP 195
DI 10.1016/j.survophthal.2006.12.003
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153EW
UT WOS:000245415800004
PM 17355856
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaczmarek, R
   Gajdzis, P
   Gajdzis, M
AF Kaczmarek, Radoslaw
   Gajdzis, Pawel
   Gajdzis, Malgorzata
TI Eph Receptors and Ephrins in Retinal Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE Eph; Eph receptors; ephrin; retina; diabetic retinopathy; proliferative
   vitreoretinopathy; retinopathy of prematurity; age-related macular
   degeneration; choroidal neovascularization
ID ANTI-VEGF THERAPY; PROLIFERATIVE VITREORETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; DIFFERENTIAL EXPRESSION; ANTITUMOR EFFICACY;
   ENDOTHELIAL-CELLS; TYROSINE KINASES; ANGIOGENESIS; PHARMACOKINETICS;
   INHIBITION
AB Retinal diseases are the leading cause of irreversible blindness. They affect people of all ages, from newborns in retinopathy of prematurity, through age-independent diabetic retinopathy and complications of retinal detachment, to age-related macular degeneration (AMD), which occurs mainly in the elderly. Generally speaking, the causes of all problems are disturbances in blood supply, hypoxia, the formation of abnormal blood vessels, and fibrosis. Although the detailed mechanisms underlying them are varied, the common point is the involvement of Eph receptors and ephrins in their pathogenesis. In our study, we briefly discussed the pathophysiology of the most common retinal diseases (diabetic retinopathy, retinopathy of prematurity, proliferative vitreoretinopathy, and choroidal neovascularization) and collected available research results on the role of Eph and ephrins. We also discussed the safety aspect of the use of drugs acting on Eph and ephrin for ophthalmic indications.
C1 [Kaczmarek, Radoslaw; Gajdzis, Malgorzata] Wroclaw Med Univ, Dept Ophthalmol, PL-50556 Wroclaw, Poland.
   [Gajdzis, Pawel] Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, PL-50556 Wroclaw, Poland.
C3 Wroclaw Medical University; Wroclaw Medical University
RP Gajdzis, M (通讯作者)，Wroclaw Med Univ, Dept Ophthalmol, PL-50556 Wroclaw, Poland.
EM radoslaw.kaczmarek@umed.wroc.pl; pawel.gajdzis@umed.wroc.pl;
   gosiagajdzis@gmail.com
RI Kaczmarek, Radosław/AAH-3117-2020; Gajdzis, Pawel/ABD-9439-2021
OI Kaczmarek, Radosław/0000-0001-9920-4406; Gajdzis,
   Pawel/0000-0003-3967-7169
CR Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Bahrami B, 2017, ASIA-PAC J OPHTHALMO, V6, P535, DOI 10.22608/APO.2017350
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Baudet S, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13070140
   Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175
   Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87
   Brar M, 2010, BRIT J OPHTHALMOL, V94, P1668, DOI 10.1136/bjo.2010.182881
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Carvalho RF, 2006, NAT NEUROSCI, V9, P322, DOI 10.1038/nn1655
   Chen G, 2010, ONCOL REP, V23, P563, DOI 10.3892/or_00000670
   Chen J, 2006, EXP EYE RES, V82, P664, DOI 10.1016/j.exer.2005.09.004
   Cheng N, 2002, MOL CANCER RES, V1, P2
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Chu ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19788-y
   Coucha M, 2020, VASC PHARMACOL, V131, DOI 10.1016/j.vph.2020.106761
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5
   Davies MH, 2009, MICROVASC RES, V77, P382, DOI 10.1016/j.mvr.2009.01.013
   DAVSON H, 1956, J PHYSIOL-LONDON, V132, P454, DOI 10.1113/jphysiol.1956.sp005537
   Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308
   Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2
   Dogra MR, 2017, INDIAN J PEDIATR, V84, P930, DOI 10.1007/s12098-017-2404-3
   Drescher U, 2002, CURR OPIN GENET DEV, V12, P397, DOI 10.1016/S0959-437X(02)00316-7
   Du EM, 2020, MOL BIOL REP, V47, P4681, DOI 10.1007/s11033-020-05470-y
   Du MR, 2018, VASC PHARMACOL, V108, P46, DOI 10.1016/j.vph.2018.05.004
   Du W, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7161027
   Du W, 2012, INVEST OPHTH VIS SCI, V53, P1990, DOI 10.1167/iovs.11-8788
   Ehlken C, 2011, ACTA OPHTHALMOL, V89, P82, DOI 10.1111/j.1755-3768.2009.01609.x
   Ejaz S, 2008, DIABETES OBES METAB, V10, P53, DOI 10.1111/j.1463-1326.2007.00795.x
   Fuller T, 2003, J CELL SCI, V116, P2461, DOI 10.1242/jcs.00426
   Garweg JG, 2013, SURV OPHTHALMOL, V58, P321, DOI 10.1016/j.survophthal.2012.12.004
   Groppa E, 2018, EMBO REP, V19, DOI 10.15252/embr.201745054
   Hamada K, 2003, ARTERIOSCL THROM VAS, V23, P190, DOI 10.1161/01.ATV.0000055440.89758.C2
   He SK, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-3810
   He SK, 2010, INVEST OPHTH VIS SCI, V51, P543, DOI 10.1167/iovs.09-3475
   He SK, 2005, INVEST OPHTH VIS SCI, V46, P4772, DOI 10.1167/iovs.05-0502
   Hellstrom A, 2019, EARLY HUM DEV, V138, DOI 10.1016/j.earlhumdev.2019.104846
   Huang H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197413
   Janes PW, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050088
   Janes PW, 2011, J CELL BIOL, V195, P1033, DOI 10.1083/jcb.201104037
   Kitahara H, 2018, EBIOMEDICINE, V31, P190, DOI 10.1016/j.ebiom.2018.04.021
   Kozulin P, 2009, MOL VIS, V15, P2649
   Kozulin P, 2009, MOL VIS, V15, P45
   Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003
   Lemke G, 2005, ANNU REV CELL DEV BI, V21, P551, DOI 10.1146/annurev.cellbio.20.022403.093702
   Li YP, 2019, INVEST OPHTH VIS SCI, V60, P4084, DOI 10.1167/iovs.19-26767
   Liang LY, 2019, ONCOGENE, V38, P6567, DOI 10.1038/s41388-019-0931-2
   Lim JI, 1999, SURV OPHTHALMOL, V44, P95, DOI 10.1016/S0039-6257(99)00077-6
   Lindauer Markus, 2018, Recent Results Cancer Res, V212, P29, DOI 10.1007/978-3-319-91439-8_2
   Liu ST, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0618-x
   Mao DN, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01580-0
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z
   McLaughlin T, 2014, MOL CELL NEUROSCI, V63, P24, DOI 10.1016/j.mcn.2014.05.005
   Medori M, 2020, NEURAL REGEN RES, V15, P382, DOI 10.4103/1673-5374.266044
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147
   Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6
   Nikolov DB, 2013, BBA-PROTEINS PROTEOM, V1834, P2160, DOI 10.1016/j.bbapap.2013.04.020
   Noberini R, 2012, SEMIN CELL DEV BIOL, V23, P51, DOI 10.1016/j.semcdb.2011.10.023
   Noh H, 2016, DEVELOPMENT, V143, P461, DOI 10.1242/dev.129478
   Oike Y, 2002, BLOOD, V100, P1326, DOI 10.1182/blood.V100.4.1326.h81602001326_1326_1333
   Ojima T, 2006, AM J PATHOL, V168, P331, DOI 10.2353/ajpath.2006.050435
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Provis J., 2007, J VISUAL-JAPAN, V7, P31, DOI [10.1167/7.15.31, DOI 10.1167/7.15.31]
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Salvucci O, 2006, BLOOD, V108, P2914, DOI 10.1182/blood-2006-05-023341
   Sankar MJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009734.pub3
   Scalia F, 2009, J COMP NEUROL, V514, P30, DOI 10.1002/cne.21968
   Schmidt JF, 2007, BRIT J OPHTHALMOL, V91, P1219, DOI 10.1136/bjo.2006.112185
   Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M
   Steinle JJ, 2003, CELL SIGNAL, V15, P1011, DOI 10.1016/S0898-6568(03)00072-X
   Su DF, 2013, EXP THER MED, V5, P1226, DOI 10.3892/etm.2013.962
   Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002
   Tognolini M, 2014, DRUG DISCOV TODAY, V19, P661, DOI 10.1016/j.drudis.2013.11.017
   Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P227, DOI 10.1007/978-3-319-95046-4_48
   Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621
   Umeda N, 2004, AM J OPHTHALMOL, V138, P270, DOI 10.1016/j.ajo.2004.04.006
   Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9
   Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu B, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926-019-0825-x
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yin Y, 2004, NEUROSCI RES, V48, P285, DOI 10.1016/j.neures.2003.11.009
   Yuukii T, 2006, J INT MED RES, V34, P485, DOI 10.1177/147323000603400505
   Zamora DO, 2005, INVEST OPHTH VIS SCI, V46, P2175, DOI 10.1167/iovs.04-0983
   Zhao JJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004891
   Zhou GM, 1999, OPTOMETRY VISION SCI, V76, P408, DOI 10.1097/00006324-199906000-00021
NR 94
TC 3
Z9 3
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 12
AR 6207
DI 10.3390/ijms22126207
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SZ2RV
UT WOS:000666419900001
PM 34201393
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Szarka, G
   Balogh, M
   Tengolics, AJ
   Ganczer, A
   Volgyi, B
   Kovacs-Oller, T
AF Szarka, Gergely
   Balogh, Marton
   Tengolics, Adam J.
   Ganczer, Alma
   Volgyi, Bela
   Kovacs-Oller, Tamas
TI The role of gap junctions in cell death and neuromodulation in the
   retina
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE age-related macular degeneration; bystander effect; connexin; diabetic
   retinopathy; gap junction; glaucoma; neuromodulation; retina; retinal
   disease; vision
ID ADENOASSOCIATED VIRAL VECTORS; PROTEIN CONNEXIN43 GJA1; INDUCED
   DOWN-REGULATION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MOUSE
   MODEL; INTERCELLULAR COMMUNICATION; GLOBAL PREVALENCE; TRANSGENE
   EXPRESSION; REDUCES INFLAMMATION
AB Vision altering diseases, such as glaucoma, diabetic retinopathy, age-related macular degeneration, myopia, retinal vascular disease, traumatic brain injuries and others cripple many lives and are projected to continue to cause anguish in the foreseeable future. Gap junctions serve as an emerging target for neuromodulation and possible regeneration as they directly connect healthy and/or diseased cells, thereby playing a crucial role in pathophysiology. Since they are permeable for macromolecules, able to cross the cellular barriers, they show duality in illness as a cause and as a therapeutic target. In this review, we take recent advancements in gap junction neuromodulation (pharmacological blockade, gene therapy, electrical and light stimulation) into account, to show the gap junction's role in neuronal cell death and the possible routes of rescuing neuronal and glial cells in the retina succeeding illness or injury.
C1 [Szarka, Gergely; Balogh, Marton; Tengolics, Adam J.; Ganczer, Alma; Volgyi, Bela; Kovacs-Oller, Tamas] Univ Pecs, Janos Szentgothai Res Ctr, Pecs, Hungary.
   [Szarka, Gergely; Balogh, Marton; Tengolics, Adam J.; Ganczer, Alma; Volgyi, Bela; Kovacs-Oller, Tamas] Hungarian Acad Sci, Natl Brain Res Program Nap 2 0, Retinal Elect Synapses Res Grp, Budapest, Hungary.
   [Szarka, Gergely; Balogh, Marton; Tengolics, Adam J.; Ganczer, Alma; Volgyi, Bela] Univ Pecs, Dept Expt Zool & Neurobiol, Pecs, Hungary.
   [Volgyi, Bela; Kovacs-Oller, Tamas] Univ Pecs, Med Sch, Pecs, Hungary.
C3 University of Pecs; Hungarian Academy of Sciences; University of Pecs;
   University of Pecs
RP Kovacs-Oller, T (通讯作者)，Univ Pecs, Janos Szentgothai Res Ctr, Pecs, Hungary.; Kovacs-Oller, T (通讯作者)，Hungarian Acad Sci, Natl Brain Res Program Nap 2 0, Retinal Elect Synapses Res Grp, Budapest, Hungary.; Kovacs-Oller, T (通讯作者)，Univ Pecs, Med Sch, Pecs, Hungary.
EM kovacstx@gmail.com
RI Volgyi, Bela/B-1016-2011; Kovács-Öller, Tamás/B-5530-2012
OI Kovács-Öller, Tamás/0000-0002-3353-4485; Szarka,
   Gergely/0000-0001-8121-2600
FU Hungarian Brain Research Program 2 [2017-1.2.1.-NKP-2017]; NKFI from the
   European Union [OTKA NN128293]; State of Hungary; European Social Fund
   [TAMOP-4.2.4.A/2-11/1-2012-0001]; New National Excellence Program of the
   Ministry for Innovation and Technology [UNKP-20-3-I-PTE-472]
FX This work was supported by the Hungarian Brain Research Program 2
   (2017-1.2.1.-NKP-2017) (to BV), by the NKFI (OTKA NN128293) from the
   European Union and the State of Hungary, co-financed by the European
   Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 National
   Excellence Program (to BV) and by the UNKP-20-3-I-PTE-472 New National
   Excellence Program of the Ministry for Innovation and Technology (to
   GS).
CR Ahmed A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14450-5
   Akopian A, 2017, J CLIN INVEST, V127, P2647, DOI 10.1172/JCI91948
   Akopian A, 2014, J NEUROSCI, V34, P10582, DOI 10.1523/JNEUROSCI.1912-14.2014
   Ali AAH, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0370-2
   Armstrong RA, 2018, CLIN EXP OPTOM, V101, P716, DOI 10.1111/cxo.12670
   Avci P, 2015, APPL NANOSCIENCE PHO, P331
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Ball AK, 1998, J COMP NEUROL, V393, P48, DOI 10.1002/(SICI)1096-9861(19980330)393:1<48::AID-CNE5>3.0.CO;2-Q
   Banerjee S, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00124
   Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Bassuk AG, 2016, SCI REP-UK, V6, DOI 10.1038/srep19969
   Belousov AB, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860-016-0120-x
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Berthoud VM, 2000, METHODS, V20, P180, DOI 10.1006/meth.1999.0935
   Bloomfield SA, 2004, VISION RES, V44, P3297, DOI 10.1016/j.visres.2004.07.012
   Borchers S, 2012, NAT REV NEUROSCI, V13, P63, DOI 10.1038/nrn3140
   Bosco A, 2015, JOVE-J VIS EXP, DOI 10.3791/52731
   Burke EG, 2019, NEURAL REGEN RES, V14, P593, DOI 10.4103/1673-5374.247463
   Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Caval-Holme F, 2019, CURR BIOL, V29, P4024, DOI 10.1016/j.cub.2019.10.025
   Ceelen PW, 2001, GLIA, V35, P1, DOI 10.1002/glia.1065
   Chen BN, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.770
   Chen YJ, 2017, ONCOTARGET, V8, P86924, DOI 10.18632/oncotarget.21008
   Christie KA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16279-4
   Ciolofan C, 2007, NEUROSCIENCE, V148, P473, DOI 10.1016/j.neuroscience.2007.06.003
   Coffin J.M., 1997, RETROVIRUSES
   Conley SM, 2010, PROG RETIN EYE RES, V29, P376, DOI 10.1016/j.preteyeres.2010.04.004
   Counsell JR, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-00152-5, 10.1038/srep44775]
   Cronin M, 2008, MOL CELL NEUROSCI, V39, P152, DOI 10.1016/j.mcn.2008.06.005
   Danesh-Meyer HV, 2016, PROG RETIN EYE RES, V51, P41, DOI 10.1016/j.preteyeres.2015.09.004
   Danesh-Meyer HV, 2012, BRAIN, V135, P506, DOI 10.1093/brain/awr338
   Darrow JJ, 2019, DRUG DISCOV TODAY, V24, P949, DOI 10.1016/j.drudis.2019.01.019
   Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2
   Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196
   Dedek K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001714
   Dedek K, 2006, EUR J NEUROSCI, V24, P1675, DOI 10.1111/j.1460-9568.2006.05052.x
   Dermietzel R, 2000, BRAIN RES REV, V32, P45, DOI 10.1016/S0165-0173(99)00067-3
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   Ding X, 2019, CRISPR J, V2, P51, DOI 10.1089/crispr.2018.0036
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Evans LP, 2018, ANN CLIN TRANSL NEUR, V5, P240, DOI 10.1002/acn3.523
   Evans WH, 2012, J MEMBRANE BIOL, V245, P437, DOI 10.1007/s00232-012-9488-5
   Fernandes R, 2004, J BIOL CHEM, V279, P27219, DOI 10.1074/jbc.M400446200
   Fernandez E., 2019, WEBVISION ORG RETINA
   Foo LC, 2011, NEURON, V71, P799, DOI 10.1016/j.neuron.2011.07.022
   Froes MM, 1999, P NATL ACAD SCI USA, V96, P7541, DOI 10.1073/pnas.96.13.7541
   Fu HY, 2003, MOL THER, V8, P911, DOI 10.1016/j.ymthe.2003.08.021
   Gajardo-Gomez R, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00086
   Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015
   Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200
   Goncalves MAFV, 2004, VIROLOGY, V321, P287, DOI 10.1016/j.virol.2004.01.007
   Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001
   Guo CX, 2016, INVEST OPHTH VIS SCI, V57, P3961, DOI 10.1167/iovs.15-16643
   Han XJ, 2015, INT J MOL MED, V35, P885, DOI 10.3892/ijmm.2015.2078
   Harper MM, 2019, INVEST OPHTH VIS SCI, V60, P2716, DOI 10.1167/iovs.18-26353
   Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Herve JC, 2005, CURR PHARM DESIGN, V11, P1941, DOI 10.2174/1381612054021060
   Hoffman LM, 1997, INVEST OPHTH VIS SCI, V38, P2224
   Hombach S, 2004, EUR J NEUROSCI, V19, P2633, DOI 10.1111/j.0953-816X.2004.03360.x
   Hu EH, 2010, J PHYSIOL-LONDON, V588, P4145, DOI 10.1113/jphysiol.2010.193268
   Ikeda Y, 1996, J GEN VIROL, V77, P1623, DOI 10.1099/0022-1317-77-8-1623
   Ishii M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.71
   Ivanova E, 2019, J COMP NEUROL, V527, P2675, DOI 10.1002/cne.24699
   Ivanova E, 2017, J NEUROSCI, V37, P7580, DOI 10.1523/JNEUROSCI.0187-17.2017
   Ivanova E, 2016, EXP EYE RES, V150, P81, DOI 10.1016/j.exer.2015.05.013
   Jacoby J, 2018, NEURON, V100, P1149, DOI 10.1016/j.neuron.2018.09.047
   Janssen-Bienhold U, 1998, J COMP NEUROL, V396, P310, DOI 10.1002/(SICI)1096-9861(19980706)396:3<310::AID-CNE3>3.0.CO;2-5
   Juttner J, 2019, NAT NEUROSCI, V22, P1345, DOI 10.1038/s41593-019-0431-2
   Kantor O, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00409
   Kantor O, 2017, BRAIN STRUCT FUNCT, V222, P2603, DOI 10.1007/s00429-016-1360-4
   Katakowski M, 2010, CANCER RES, V70, P8259, DOI 10.1158/0008-5472.CAN-10-0604
   Katti C, 2013, INVEST OPHTH VIS SCI, V54, P821, DOI 10.1167/iovs.12-10375
   Kerr NM, 2011, J CLIN NEUROSCI, V18, P102, DOI 10.1016/j.jocn.2010.06.002
   Kerr NM, 2010, INVEST OPHTH VIS SCI, V51, P4028, DOI 10.1167/iovs.09-4847
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Koo J, 2015, ENDOCRINOL METAB, V30, P361, DOI 10.3803/EnM.2015.30.3.361
   Kovacs-Oller T, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0180-0
   Lai Y, 2009, J CLIN INVEST, V119, P624, DOI 10.1172/JCI36612
   Ledford H, 2020, NATURE, V579, P185, DOI 10.1038/d41586-020-00655-8
   LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213
   Li AF, 2003, INVEST OPHTH VIS SCI, V44, P5376, DOI 10.1167/iovs.03-0360
   Li AF, 2009, INVEST OPHTH VIS SCI, V50, P1400, DOI 10.1167/iovs.07-1519
   Li X, 2008, J NEUROSCI, V28, P9769, DOI 10.1523/JNEUROSCI.2137-08.2008
   Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372
   Liu CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020649
   Loizos K, 2018, IEEE T NEUR SYS REH, V26, P1111, DOI 10.1109/TNSRE.2018.2832055
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Ma Y, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9274
   Manasson J, 2013, INVEST OPHTH VIS SCI, V54, P2361, DOI 10.1167/iovs.12-10815
   Manjarrez-Marmolejo J, 2016, CURR NEUROPHARMACOL, V14, P759, DOI 10.2174/1570159X14666160603115942
   Massey SC, 2003, CELL COMMUN ADHES, V10, P425, DOI 10.1080/15419060390264343
   Mast TC, 2010, VACCINE, V28, P950, DOI 10.1016/j.vaccine.2009.10.145
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Maxeiner S, 2005, J NEUROSCI, V25, P566, DOI 10.1523/JNEUROSCI.3232-04.2005
   Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522
   Muller LPD, 2010, VISUAL NEUROSCI, V27, P91, DOI 10.1017/S0952523810000131
   Muir ER, 2012, INVEST OPHTH VIS SCI, V53, P6488, DOI 10.1167/iovs.12-9758
   Murlidharan G, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00076
   Muto T, 2014, INVEST OPHTH VIS SCI, V55, P4327, DOI 10.1167/iovs.14-14606
   Nakai H, 2001, J VIROL, V75, P6969, DOI 10.1128/JVI.75.15.6969-6976.2001
   Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290
   NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173
   O'Brien J, 2018, ANNU REV VIS SCI, V4, P79, DOI 10.1146/annurev-vision-091517-034133
   O'Carroll SJ, 2008, CELL COMMUN ADHES, V15, P27, DOI 10.1080/15419060802014164
   Oku H, 2001, INVEST OPHTH VIS SCI, V42, P1915
   Orellana JA, 2009, ANTIOXID REDOX SIGN, V11, P369, DOI 10.1089/ars.2008.2130
   Ormonde S, 2012, J MEMBRANE BIOL, V245, P381, DOI 10.1007/s00232-012-9460-4
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Pearson RA, 2004, EUR J NEUROSCI, V19, P2435, DOI 10.1111/j.0953-816X.2004.03338.x
   Pereda AE, 2013, BBA-BIOMEMBRANES, V1828, P134, DOI 10.1016/j.bbamem.2012.05.026
   Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014
   Pocrnich CE, 2012, GRAEF ARCH CLIN EXP, V250, P515, DOI 10.1007/s00417-011-1871-x
   Prochnow N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00031
   Puller C, 2020, J NEUROSCI, V40, P1302, DOI 10.1523/JNEUROSCI.1374-19.2019
   Qiu C, 2003, CURR BIOL, V13, P1697, DOI 10.1016/j.cub.2003.09.007
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Rash JE, 2004, J NEUROCYTOL, V33, P131, DOI 10.1023/B:NEUR.0000029653.34094.0b
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Reichenbach A, 1995, PROG RETIN EYE RES, V15, P139, DOI 10.1016/1350-9462(95)00008-9
   Rieke C, 2020, BIORXIV, DOI [10.1101/2020.01.23.917096, DOI 10.1101/2020.01.23.917096]
   Ripps H, 2002, EXP EYE RES, V74, P327, DOI 10.1006/exer.2002.1155
   ROBINSON SR, 1993, SCIENCE, V262, P1072
   Roy K, 2017, P NATL ACAD SCI USA, V114, pE10484, DOI 10.1073/pnas.1708261114
   Roy S, 2017, VISION RES, V139, P115, DOI 10.1016/j.visres.2017.04.014
   Roy S, 2017, PROG RETIN EYE RES, V61, P35, DOI 10.1016/j.preteyeres.2017.06.001
   Saenz DT, 2004, J VIROL, V78, P2906, DOI 10.1128/JVI.78.6.2906-2920.2004
   Sato T, 2002, DIABETES, V51, P1565, DOI 10.2337/diabetes.51.5.1565
   Schubert T, 2005, J COMP NEUROL, V490, P29, DOI 10.1002/cne.20621
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Shelley J, 2006, EUR J NEUROSCI, V23, P3176, DOI 10.1111/j.1460-9568.2006.04848.x
   Shimojima M, 2004, SCIENCE, V303, P1192, DOI 10.1126/science.1092124
   Sigulinsky CL, 2020, J NEUROSCI, V40, P4483, DOI 10.1523/JNEUROSCI.1810-19.2020
   Singer O, 2008, CURR GENE THER, V8, P483, DOI 10.2174/156652308786848067
   Slavi N, 2018, P NATL ACAD SCI USA, V115, pE5934, DOI 10.1073/pnas.1803907115
   Smedowski A, 2020, ACTA OPHTHALMOL, V98, P408, DOI 10.1111/aos.14272
   Srinivas M, 2018, BBA-BIOMEMBRANES, V1860, P192, DOI 10.1016/j.bbamem.2017.04.024
   Striedinger K, 2005, EUR J NEUROSCI, V22, P605, DOI 10.1111/j.1460-9568.2005.04228.x
   Swiech L, 2015, NAT BIOTECHNOL, V33, P102, DOI 10.1038/nbt.3055
   Taymans JM, 2007, HUM GENE THER, V18, P195, DOI 10.1089/hum.2006.178
   Tengolics AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51756-y
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thuringer D, 2016, ONCOTARGET, V7, P28160, DOI 10.18632/oncotarget.8583
   Tien T, 2016, EXP EYE RES, V146, P103, DOI 10.1016/j.exer.2015.12.011
   Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013
   Tsai D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14357-1
   Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985
   Valiunas V, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12286
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Volgyi B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069426
   Volgyi B, 2013, PROG RETIN EYE RES, V34, P1, DOI 10.1016/j.preteyeres.2012.12.002
   Vogt VM, 1999, J VIROL, V73, P7050, DOI 10.1128/JVI.73.8.7050-7055.1999
   Wang N, 2013, NEUROPHARMACOLOGY, V75, P506, DOI 10.1016/j.neuropharm.2013.08.021
   Weiland JD, 2014, IEEE T BIO-MED ENG, V61, P1412, DOI 10.1109/TBME.2014.2314733
   Wilson AM, 2018, NANO LETT, V18, P6981, DOI 10.1021/acs.nanolett.8b02896
   Wolvetang EJ, 2007, BIOCHEM BIOPH RES CO, V363, P610, DOI 10.1016/j.bbrc.2007.09.035
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2018, WHOHISIERGHE20184
   Yang GY, 2019, CHINESE MED J-PEKING, V132, P1700, DOI 10.1097/CM9.0000000000000319
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yu Q, 2014, GENE THER, V21, P71, DOI 10.1038/gt.2013.59
   Yuan L, 2016, SCI REP-UK, V6, DOI 10.1038/srep22024
   Yungher BJ, 2017, INVEST OPHTH VIS SCI, V58, P1743, DOI 10.1167/iovs.16-19873
   Zahs KR, 2006, VISUAL NEUROSCI, V23, P1, DOI 10.1017/S0952523806231018
   Zahs KR, 2003, J COMP NEUROL, V455, P531, DOI 10.1002/cne.10524
   Zhang L, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000692
   Zhu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep15647
   Zong L, 2016, SCI REP-UK, V6, DOI 10.1038/srep19884
NR 176
TC 4
Z9 4
U1 3
U2 19
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD OCT
PY 2021
VL 16
IS 10
BP 1911
EP 1920
DI 10.4103/1673-5374.308069
PG 10
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA QP3UM
UT WOS:000623762600002
PM 33642359
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Telias, M
   Nawy, S
   Kramer, RH
AF Telias, Michael
   Nawy, Scott
   Kramer, Richard H.
TI Degeneration-Dependent Retinal Remodeling: Looking for the Molecular
   Trigger
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE retinal degeneration; retinal remodeling; synaptic plasticity; retinoic
   acid; retinal ganglion cell; retinitis pigmentosa; age-related macular
   degeneration
ID GANGLION-CELLS; RESPONSES; MODEL
AB Vision impairment and blindness in humans are most frequently caused by the degeneration and loss of photoreceptor cells in the outer retina, as is the case for age-related macular degeneration, retinitis pigmentosa, retinal detachment and many other diseases. While inner retinal neurons survive degeneration, they undergo fundamental pathophysiological changes, collectively known as "remodeling." Inner retinal remodeling downstream to photoreceptor death occurs across mammalian retinas from mice to humans, independently of the cause of degeneration. It results in pervasive spontaneous hyperactivity and membrane hyperpermeability in retinal ganglion cells, which funnel all retinal signals to the brain. Remodeling reduces light detection in vision-impaired patients and precludes meaningful vision restoration in blind individuals. In this review, we summarize current hypotheses proposed to explain remodeling and their potential medical significance highlighting the important role played by retinoic acid and its receptor.
C1 [Telias, Michael; Nawy, Scott; Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
   [Kramer, Richard H.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley
RP Kramer, RH (通讯作者)，Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.; Kramer, RH (通讯作者)，Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
EM rhkramer@berkeley.edu
FU National Eye Institute [R01EY024334, R24EY023937, P30EY003176]
FX This work was supported by grants from the National Eye Institute
   (R01EY024334, R24EY023937, and P30EY003176).
CR Aplin FP, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00046
   Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Baker CK, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00316
   Barrett JM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00330
   Borowska J, 2011, J NEUROSCI, V31, P5000, DOI 10.1523/JNEUROSCI.5800-10.2011
   Collin GB, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040931
   Daruwalla A, 2018, BIOCHEM J, V475, P3171, DOI 10.1042/BCJ20180193
   Denlinger B, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132114
   Euler T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00444
   Garcia-Ayuso D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184649
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Goldberg AFX, 2016, PROG RETIN EYE RES, V55, P52, DOI 10.1016/j.preteyeres.2016.05.003
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Haq W, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00108
   Harper AR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122008
   Iandiev I, 2006, INVEST OPHTH VIS SCI, V47, P2161, DOI 10.1167/iovs.05-0595
   Ivanova E, 2016, EXP EYE RES, V150, P81, DOI 10.1016/j.exer.2015.05.013
   Jones, 2016, WEBVISION ORG RETINA, P1511
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kolb H., 2005, WEBVISION ORG RETINA
   Kolb H., 1995, WEBVISION ORG RETINA
   Kreissig Ingrid, 2016, Taiwan J Ophthalmol, V6, P161, DOI 10.1016/j.tjo.2016.04.006
   Lin YH, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-7
   Lin YH, 2012, FASEB J, V26, P81, DOI 10.1096/fj.11-192914
   Llonch S, 2018, DEV BIOL, V433, P132, DOI 10.1016/j.ydbio.2017.09.028
   Luo TL, 2006, J NEUROBIOL, V66, P677, DOI 10.1002/neu.20239
   Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Mirochnik RM, 2019, MILITARY MED RES, V6, DOI 10.1186/s40779-019-0206-9
   Nakazawa M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8276140
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Saha S, 2016, NEUROSCIENCE, V329, P1, DOI 10.1016/j.neuroscience.2016.04.032
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stasheff SF, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00298
   Takahashi VKL, 2018, OPHTHALMIC GENET, V39, P560, DOI 10.1080/13816810.2018.1495745
   Telias M, 2019, NEURON, V102, P574, DOI 10.1016/j.neuron.2019.02.015
   Tochitsky I, 2018, CHEM REV, V118, P10748, DOI 10.1021/acs.chemrev.7b00723
   Tochitsky I, 2016, NEURON, V92, P100, DOI 10.1016/j.neuron.2016.08.038
   Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013
   Trenholm S, 2012, J PHYSIOL-LONDON, V590, P2501, DOI 10.1113/jphysiol.2011.225060
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Winkler PA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040882
   Wiseman EM, 2017, CRIT REV FOOD SCI, V57, P3703, DOI 10.1080/10408398.2016.1160362
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 53
TC 3
Z9 4
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD DEC 18
PY 2020
VL 14
AR 618019
DI 10.3389/fnins.2020.618019
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA PM8KU
UT WOS:000604041500001
PM 33390897
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hosoda, Y
   Miyake, M
   Schellevis, RL
   Boon, CJF
   Hoyng, CB
   Miki, A
   Meguro, A
   Sakurada, Y
   Yoneyama, S
   Takasago, Y
   Hata, M
   Muraoka, Y
   Nakanishi, H
   Oishi, A
   Ooto, S
   Tamura, H
   Uji, A
   Miyata, M
   Takahashi, A
   Ueda-Arakawa, N
   Tajima, A
   Sato, T
   Mizuki, N
   Shiragami, C
   Iida, T
   Khor, CC
   Wong, TY
   Yamada, R
   Honda, S
   de Jong, EK
   den Hollander, AI
   Matsuda, F
   Yamashiro, K
   Tsujikawa, A
AF Hosoda, Yoshikatsu
   Miyake, Masahiro
   Schellevis, Rosa L.
   Boon, Camiel J. F.
   Hoyng, Carel B.
   Miki, Akiko
   Meguro, Akira
   Sakurada, Yoichi
   Yoneyama, Seigo
   Takasago, Yukari
   Hata, Masayuki
   Muraoka, Yuki
   Nakanishi, Hideo
   Oishi, Akio
   Ooto, Sotaro
   Tamura, Hiroshi
   Uji, Akihito
   Miyata, Manabu
   Takahashi, Ayako
   Ueda-Arakawa, Naoko
   Tajima, Atsushi
   Sato, Takehiro
   Mizuki, Nobuhisa
   Shiragami, Chieko
   Iida, Tomohiro
   Khor, Chiea Chuen
   Wong, Tien Yin
   Yamada, Ryo
   Honda, Shigeru
   de Jong, Eiko K.
   den Hollander, Anneke, I
   Matsuda, Fumihiko
   Yamashiro, Kenji
   Tsujikawa, Akitaka
TI Genome-wide association analyses identify two susceptibility loci for
   pachychoroid disease central serous chorioretinopathy
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; GATA5; GENE; NEOVASCULOPATHY; VARIANTS; UPDATE;
   HEART
AB The recently emerged pachychoroid concept has changed the understanding of age-related macular degeneration (AMD), which is a major cause of blindness; recent studies attributed AMD in part to pachychoroid disease central serous chorioretinopathy (CSC), suggesting the importance of elucidating the CSC pathogenesis. Our large genome-wide association study followed by validation studies in three independent Japanese and European cohorts, consisting of 1546 CSC samples and 13,029 controls, identified two novel CSC susceptibility loci: TNFRSF10A-LOC389641 and near GATA5 (rs13278062, odds ratio =1.35, P =1.26 x 10(-13); rs6061548, odds ratio = 1.63, P = 5.36 x 10(-15)). A T allele at TNFRSF10A-LOC389641 rs13278062, a risk allele for CSC, is known to be a risk allele for AMD. This study not only identified new susceptibility genes for CSC, but also improves the understanding of the pathogenesis of AMD.
C1 [Hosoda, Yoshikatsu; Miyake, Masahiro; Hata, Masayuki; Muraoka, Yuki; Nakanishi, Hideo; Oishi, Akio; Ooto, Sotaro; Tamura, Hiroshi; Uji, Akihito; Miyata, Manabu; Takahashi, Ayako; Ueda-Arakawa, Naoko; Yamashiro, Kenji; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Hosoda, Yoshikatsu; Miyake, Masahiro; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto, Japan.
   [Schellevis, Rosa L.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Boon, Camiel J. F.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands.
   [Miki, Akiko; Honda, Shigeru] Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med, Kobe, Hyogo, Japan.
   [Meguro, Akira; Mizuki, Nobuhisa] Yokohama City Univ, Dept Ophthalmol & Visual Sci, Sch Med, Yokohama, Kanagawa, Japan.
   [Sakurada, Yoichi; Yoneyama, Seigo] Univ Yamanashi, Dept Ophthalmol, Fac Med, Kofu, Yamanashi, Japan.
   [Takasago, Yukari; Shiragami, Chieko] Kagawa Univ, Fac Med, Dept Ophthalmol, Takamatsu, Kagawa, Japan.
   [Tajima, Atsushi; Sato, Takehiro] Kanazawa Univ, Grad Sch Adv Prevent Med Sci, Dept Bioinformat & Genom, Kanazawa, Ishikawa, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Khor, Chiea Chuen; Wong, Tien Yin] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Khor, Chiea Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
   [Wong, Tien Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Wong, Tien Yin] Natl Univ Hlth Syst, Singapore, Singapore.
   [Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Honda, Shigeru] Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka, Japan.
   [Yamashiro, Kenji] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
C3 Kyoto University; Kyoto University; Radboud University Nijmegen; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; Kobe University; Yokohama City University; University of
   Yamanashi; Kagawa University; Kanazawa University; Tokyo Women's Medical
   University; National University of Singapore; Singapore National Eye
   Center; Agency for Science Technology & Research (A*STAR); A*STAR -
   Genome Institute of Singapore (GIS); National University of Singapore;
   National University of Singapore; National University of Singapore;
   Osaka Metropolitan University
RP Miyake, M (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.; Miyake, M (通讯作者)，Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto, Japan.
EM miyakem@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Tajima, Atsushi/C-1053-2008; Miyata,
   Manabu/U-9008-2018; Wong, Tien Yin/AAC-9724-2020; Oishi,
   Akio/AAE-9996-2020; Boon, CJF/P-7534-2014
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tajima,
   Atsushi/0000-0001-6808-5491; Wong, Tien Yin/0000-0002-8448-1264; Oishi,
   Akio/0000-0002-0977-9458; Yamada, Ryo/0000-0002-1587-630X; Boon,
   CJF/0000-0002-6737-7932; Tsujikawa, Akitaka/0000-0003-0779-7799; Miyata,
   Manabu/0000-0002-7574-1749
CR Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Aung T, 2015, NAT GENET, V47, P387, DOI 10.1038/ng.3226
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Bagheri Masood, 2017, Med Hypothesis Discov Innov Ophthalmol, V6, P118
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Breukink MB, 2017, CLIN OPHTHALMOL, V11, P39, DOI 10.2147/OPTH.S115685
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   Cakir B, 2019, OPHTHALMOL THER, V8, P75, DOI 10.1007/s40123-018-0159-1
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukuda K, 2005, DEV GROWTH DIFFER, V47, P375
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gallego-Pinazo R, 2017, CHOROIDAL DISORDERS, P161, DOI 10.1016/B978-0-12-805313-3.00010-7
   GASS JDM, 1995, OPHTHALMOLOGY, V102, P737, DOI 10.1016/S0161-6420(95)30960-8
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Higasa K, 2016, J HUM GENET, V61, P547, DOI 10.1038/jhg.2016.12
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Jiang JQ, 2013, INT J CARDIOL, V165, P570, DOI 10.1016/j.ijcard.2012.09.039
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuriyama S, 2016, J EPIDEMIOL, V26, P493, DOI 10.2188/jea.JE20150268
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Mateo-Montoya Aranzazu, 2014, World J Gastrointest Pathophysiol, V5, P355, DOI 10.4291/wjgp.v5.i3.355
   Messaoudi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9835
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Mishra A, 2017, TWIN RES HUM GENET, V20, P1, DOI 10.1017/thg.2016.100
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mohabati D, 2019, RETINA-J RET VIT DIS, V39, P2303, DOI 10.1097/IAE.0000000000002333
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Nagasaki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9018
   Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Sobota RS, 2016, HUM GENET, V135, P895, DOI 10.1007/s00439-016-1687-1
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Stennard FA, 2003, DEV BIOL, V262, P206, DOI 10.1016/S0012-1606(03)00385-3
   Sun YY, 2013, INVEST OPHTH VIS SCI, V54, P8199, DOI 10.1167/iovs.13-12867
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wang XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025985
   Weenink AC, 2001, OPHTHALMOLOGICA, V215, P183, DOI 10.1159/000050855
   Wen XZ, 2010, WORLD J GASTROENTERO, V16, P1201, DOI 10.3748/wjg.v16.i10.1201
   Yamaguchi-Kabata Yumi, 2015, Hum Genome Var, V2, P15050, DOI 10.1038/hgv.2015.50
   YANNUZZI LA, 1987, RETINA-J RET VIT DIS, V7, P111, DOI 10.1097/00006982-198700720-00009
   Zavoloka O, 2016, GRAEF ARCH CLIN EXP, V254, P2071, DOI 10.1007/s00417-016-3419-6
NR 58
TC 19
Z9 19
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD DEC 12
PY 2019
VL 2
AR 468
DI 10.1038/s42003-019-0712-z
PG 9
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA JV5AL
UT WOS:000502376700002
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU He, YM
   Qu, YQ
   Zhu, J
   Zhang, Y
   Saidi, A
   Ma, T
   Zhou, QF
   Chen, ZP
AF He, Youmin
   Qu, Yueqiao
   Zhu, Jiang
   Zhang, Yi
   Saidi, Arya
   Ma, Teng
   Zhou, Qifa
   Chen, Zhongping
TI Confocal Shear Wave Acoustic Radiation Force Optical Coherence
   Elastography for Imaging and Quantification of the In Vivo Posterior Eye
SO IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS
LA English
DT Article
DE Shear wave elastography; ARF; OCT; retina; in vivo study
ID ELASTIC PROPERTIES; TOMOGRAPHY; ULTRASOUND; MODULUS; RETINA; OCT
AB Retinal diseases, such as age-related macular degeneration (AMD), are the leading cause of blindness in the elderly population. Since no known cures are currently present, it is crucial to diagnose the condition in its early stages so that disease progression is monitored. Recent advances show that the mechanical elasticity of the posterior eye changes with the onset of AMD. In this paper, we present a quantitative method of mapping the mechanical elasticity of the posterior eye using confocal shear wave acoustic radiation force optical coherence elastography. This technique has been developed and validated with both an ex-vivo porcine tissue model and a customized in vivo rabbit model, which both showed the quantified elasticity variations between different layers. This study verifies the feasibility of using this technology for the quantification and diagnosis of retinal diseases from the in vivo posterior eye.
C1 [He, Youmin; Qu, Yueqiao; Zhu, Jiang; Chen, Zhongping] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.
   [He, Youmin; Qu, Yueqiao; Zhu, Jiang; Chen, Zhongping] Univ Calif Irvine, Beckman Laser Inst, Irvine, CA 92697 USA.
   [Zhang, Yi; Ma, Teng; Zhou, Qifa] Univ Southern California, Dept Ophthalmol & Biomed Engn, Roski Eye Inst, Los Angeles, CA 90089 USA.
   [Saidi, Arya] Marshall B Ketchum Univ, Southern Calif Coll Optometry, Fullerton, CA 92831 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Chen, ZP (通讯作者)，Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.; Chen, ZP (通讯作者)，Univ Calif Irvine, Beckman Laser Inst, Irvine, CA 92697 USA.; Zhou, QF (通讯作者)，Univ Southern California, Dept Ophthalmol & Biomed Engn, Roski Eye Inst, Los Angeles, CA 90089 USA.
EM youminh1@uci.edu; yueqiaoq@uci.edu; jzhumail@gmail.com;
   zhangyi5757@hotmail.com; aryasaidi@gmail.com; mt880501@gmail.com;
   qifazhou@usc.edu; z2chen@uci.edu
RI Zhu, Jiang/O-4869-2016
OI Zhu, Jiang/0000-0002-2601-4967
FU National Institutes of Health [R01HL-125084, R01HL-127271, R01EY-026091,
   R01EY-021529, P41EB-015890, F31EY-027666, R01EY-028662]; Air Force
   Office of Scientific Research [FA9550-14-1-0034]; NATIONAL EYE INSTITUTE
   [F31EY027666, R01EY026091] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL125084, R01HL127271] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [P41EB015890] Funding Source: NIH RePORTER
FX This work was supported in part by the National Institutes of Health
   under Grant R01HL-125084, Grant R01HL-127271, Grant R01EY-026091, Grant
   R01EY-021529, Grant P41EB-015890, Grant F31EY-027666, and Grant
   R01EY-028662, and in part by the Air Force Office of Scientific Research
   under Grant FA9550-14-1-0034. (Y. H. and Y. Q contributed equally to
   this work and are treated as cofirst authors.) (Corresponding authors:
   Zhongping Chen and Qifa Zhou.)
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   Cohen E, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056017
   Cour L., 2002, DRUGS AGING, V19, P101
   Detorakis ET, 2010, OPHTHAL SURG LAS IM, V41, P135, DOI 10.3928/15428877-20091230-24
   Ford MR, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3526701
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   Gennisson J-L, 2013, Diagn Interv Imaging, V94, P487, DOI 10.1016/j.diii.2013.01.022
   Han ZL, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.2.020501
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Huang SH, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.7.076003
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JONES IL, 1992, EYE, V6, P556, DOI 10.1038/eye.1992.121
   Krishnan L, 2007, AM J PHYSIOL-HEART C, V293, pH3650, DOI 10.1152/ajpheart.00772.2007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litwiller DV, 2010, J MAGN RESON IMAGING, V32, P44, DOI 10.1002/jmri.22217
   Qu Y, 2016, IEEE J SEL TOP QUANT, V22, P288
   Qu YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05077-7
   Razani M, 2012, BIOMED OPT EXPRESS, V3, P972, DOI 10.1364/BOE.3.000972
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Song SZ, 2015, OPT LETT, V40, P5007, DOI 10.1364/OL.40.005007
   Usha Chakravarthy J.E., 2010, BMJ-BRIT MED J, V340, P526
   Wang S, 2014, BIOMED OPT EXPRESS, V5, P3807, DOI 10.1364/BOE.5.003807
   Wang S, 2014, OPT LETT, V39, P41, DOI 10.1364/OL.39.000041
   Zhang J, 2009, OPT LETT, V34, P3442, DOI 10.1364/OL.34.003442
   Zhu JA, 2017, APPL PHYS LETT, V110, DOI 10.1063/1.4983292
   Zhu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep35499
   Zhu J, 2015, OPT LETT, V40, P2099, DOI 10.1364/OL.40.002099
NR 28
TC 13
Z9 13
U1 4
U2 60
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1077-260X
EI 1558-4542
J9 IEEE J SEL TOP QUANT
JI IEEE J. Sel. Top. Quantum Electron.
PD JAN-FEB
PY 2019
VL 25
IS 1
AR 7200107
DI 10.1109/JSTQE.2018.2834435
PG 7
WC Engineering, Electrical & Electronic; Quantum Science & Technology;
   Optics; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Physics; Optics
GA GJ3TU
UT WOS:000435222400001
PM 32042240
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Sahoo, M
   Pal, S
   Mitra, M
AF Sahoo, M.
   Pal, S.
   Mitra, M.
TI Automatic segmentation of accumulated fluid inside the retinal layers
   from optical coherence tomography images
SO MEASUREMENT
LA English
DT Article
DE Optical Coherence Tomography (OCT); K-mean Clustering; Sub-retinal
   fluid; Retinal Fluid Automatic Detection (RFAD)
ID MACULAR EDEMA
AB Visual impairments are mostly associated with the retinal diseases such as glaucoma, age related macular degeneration, fluid accumulation inside the retinal layers and other diseases. To evaluate the visual loss associated with the sub-retinal fluid accumulation, OCT images are widely used. So long, the effected retinal segment is visually estimated from the images. In this paper, we have proposed a novel Retinal Fluid Automatic Detection (RFAD) algorithm for automatically extracting the affected retinal segment due to fluid accumulation and thereby noticeably increasing the visual impact of the affected area than earlier by proper edge detection. The proposed method is validated qualitatively and quantitatively against 25 OCT images including both normal and different types of abnormal conditions. Good sensitivity and specificity is achieved as indicated in the result section. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Sahoo, M.] Haldia Inst Technol, Dept Appl Elect & Instrumentat Engn, Haldia, W Bengal, India.
   [Pal, S.; Mitra, M.] Univ Calcutta, Dept Appl Phys, Kolkata, W Bengal, India.
C3 Haldia Institute of Technology; University of Calcutta
RP Sahoo, M (通讯作者)，Haldia Inst Technol, Dept Appl Elect & Instrumentat Engn, Haldia, W Bengal, India.
EM mou.sahoo@gmail.com
OI Pal, Saurabh/0000-0002-5139-6573
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   BOVIK AC, 1987, IEEE T PATTERN ANAL, V9, P181, DOI 10.1109/TPAMI.1987.4767894
   Catier A, 2005, AM J OPHTHALMOL, V140, P200, DOI 10.1016/j.ajo.2005.02.053
   Ding WG, 2013, IEEE ENG MED BIO, P7388, DOI 10.1109/EMBC.2013.6611265
   Dubes B. C., 1988, ALGORITHMS CLUSTERIN
   FERCHER AF, 1988, OPT LETT, V13, P186, DOI 10.1364/OL.13.000186
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Jayaraman S., 2010, DIGITAL IMAGE PROCES
   Jun JJ, 2010, RETINA-J RET VIT DIS, V30, P917, DOI 10.1097/IAE.0b013e3181cbd9e5
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   TAKADA K, 1987, APPL OPTICS, V26, P1603, DOI 10.1364/AO.26.001603
   Tian J., 2005, TSINGHUA SCI TECHNOL, V10, P277
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   YOUNGQUIST RC, 1987, OPT LETT, V12, P158, DOI 10.1364/OL.12.000158
NR 20
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0263-2241
EI 1873-412X
J9 MEASUREMENT
JI Measurement
PD APR
PY 2017
VL 101
BP 138
EP 144
DI 10.1016/j.measurement.2017.01.027
PG 7
WC Engineering, Multidisciplinary; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Instruments & Instrumentation
GA EM3LJ
UT WOS:000395216100017
DA 2022-11-30
ER

PT J
AU Nair, AG
   Nair, AG
   Shah, BR
   Gandhi, RA
AF Nair, Aditya Gopinathan
   Nair, Akshay Gopinathan
   Shah, Bharat R.
   Gandhi, Rashmin Anilkumar
TI Seeing the unseen: Charles Bonnet syndrome revisited
SO PSYCHOGERIATRICS
LA English
DT Article
DE Charles Bonnet syndrome; dementia; glaucoma; macular degeneration;
   visual hallucinations; visual impairment
ID COMPLEX VISUAL HALLUCINATIONS; BONNET,CHARLES SYNDROME; MACULAR
   DEGENERATION; BLINDNESS; VISION
AB Charles Bonnet syndrome (CBS) is a rare condition that encompasses three clinical features: complex visual hallucinations, ocular pathology causing visual deterioration, and preserved cognitive status. Common associated ocular pathologies include age-related macular degeneration, glaucoma, and cataracts. Several theories have been proposed to try to explain the visual hallucinations. However, the pathophysiology remains poorly understood, and treatment is largely based on anecdotal data. The lack of awareness of CBS among medical professionals often leads to inappropriate diagnosis and medication. In a country like India, where awareness of mental health is not widespread, cultural myths and stigma prevent patients from seeking professional help. Here we describe two cases of CBS and revisit different ocular morbidities that have been reported to occur in conjunction with CBS. Psychiatrists and ophthalmologists alike must be sensitive to this clinical condition to ensure prompt diagnosis and treatment.
C1 [Nair, Aditya Gopinathan; Shah, Bharat R.] Disha Psychiat Clin, Bombay, Maharashtra, India.
   [Nair, Aditya Gopinathan] Natl Burns Inst, Mumbai, Maharashtra, India.
   [Nair, Akshay Gopinathan] Adv Eye Hosp & Inst, Dept Neuroophthalmol, Sanpada 400705, Navi Mumbai, India.
   [Nair, Akshay Gopinathan] Adv Eye Hosp & Inst, Dept Ophthalm Plast Surg, Sanpada 400705, Navi Mumbai, India.
   [Nair, Akshay Gopinathan] Adv Eye Hosp & Inst, Dept Ocular Oncol, Sanpada 400705, Navi Mumbai, India.
   [Gandhi, Rashmin Anilkumar] Beyond Eye Care, Hyderabad, Andhra Pradesh, India.
   [Gandhi, Rashmin Anilkumar] Ctr Sight, Neuroophthalmol Serv, Hyderabad, Andhra Pradesh, India.
RP Nair, AG (通讯作者)，Adv Eye Hosp & Inst, Dept Neuroophthalmol, 30 Affaires,Sect 17, Sanpada 400705, Navi Mumbai, India.
EM akshaygn@gmail.com
CR Aydin OF, 2012, PEDIATR NEUROL, V46, P250, DOI 10.1016/j.pediatrneurol.2012.02.010
   BARTLET JEA, 1951, BRAIN, V74, P363, DOI 10.1093/brain/74.3.363
   Chen CS, 2001, AM J PSYCHIAT, V158, P1158, DOI 10.1176/appi.ajp.158.7.1158-a
   COLE MG, 1992, CAN J PSYCHIAT, V37, P267, DOI 10.1177/070674379203700411
   DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584
   de Morsier G, 1938, REV OTONEUROOPHTALMO, V16, P244
   Dodd J, 1999, IRISH MED J, V92, P344
   DUKEELDER S, 1971, SYSTEM OPHTHALMOLOGY, V12, P562
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P664
   Fong SYY, 1997, AUST NZ J PSYCHIAT, V31, P769, DOI 10.3109/00048679709062694
   HART CT, 1967, BRIT MED J, V3, P643, DOI 10.1136/bmj.3.5566.643
   HARTMANN PM, 1995, J NERV MENT DIS, V183, P549, DOI 10.1097/00005053-199508000-00009
   Hashemi N, 2012, CAN J OPHTHALMOL, V47, pE5, DOI 10.1016/j.jcjo.2012.03.029
   HAUGE T, 1954, Acta Radiol Suppl, V109, P1
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Jan T, 2012, WEST J EMERG MED, V13, P544, DOI 10.5811/westjem.2012.7.12891
   Kishore Jugal, 2011, Indian J Psychiatry, V53, P324, DOI 10.4103/0019-5545.91906
   Lang UE, 2007, J PSYCHOPHARMACOL, V21, P553, DOI 10.1177/0269881106075275
   MCNAMARA ME, 1982, INT J NEUROSCI, V17, P13, DOI 10.3109/00207458208985083
   MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Moja MC, 2005, NEUROL SCI, V26, P168, DOI 10.1007/s10072-005-0455-0
   NORTONWILLSON L, 1987, FAM PRACT, V4, P27, DOI 10.1093/fampra/4.1.27
   Paulig M, 2001, J NEUROL NEUROSUR PS, V70, P813, DOI 10.1136/jnnp.70.6.813
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   Rovner BW, 2006, CURR OPIN OPHTHALMOL, V17, P275, DOI 10.1097/01.icu.0000193100.13551.ac
   Santos-Bueso E, 2013, Arch Soc Esp Oftalmol, V88, P369, DOI 10.1016/j.oftal.2012.12.008
   Schadlu AP, 2009, CURR OPIN OPHTHALMOL, V20, P219, DOI 10.1097/ICU.0b013e328329b643
   SYMONDS C, 1957, BRAIN, V80, P415, DOI 10.1093/brain/80.4.415
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   WHITE NJ, 1980, BRIT J PSYCHIAT, V136, P284, DOI 10.1192/bjp.136.3.284
   Zhang J, 2013, MIDDLE EAST AFR J OP, V20, P369, DOI 10.4103/0974-9233.119997
NR 33
TC 9
Z9 9
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1346-3500
EI 1479-8301
J9 PSYCHOGERIATRICS
JI Psychogeriatrics
PD SEP
PY 2015
VL 15
IS 3
BP 204
EP 208
DI 10.1111/psyg.12091
PG 5
WC Geriatrics & Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Psychiatry
GA CV9FA
UT WOS:000364591600007
PM 25515178
DA 2022-11-30
ER

PT J
AU Billick, SB
   Garakani, A
AF Billick, Stephen B.
   Garakani, Amir
TI Ophthalmologic Screening in 25 Consecutive Geriatric Psychiatric
   Inpatient Admissions
SO PSYCHIATRIC QUARTERLY
LA English
DT Article
DE Vision; Visual problems; Aging; Eye exam; Quality assurance
ID VISION LOSS
AB In the aging process, people are at increasing risk of visual abnormalities such as cataracts, glaucoma, age-related macular degeneration, and other retinal defects. This holds true for geriatric psychiatric patients as well. These ophthalmic problems may increase risk of falls or increase the comorbidity from dementing processes and depression. Geriatric patients presenting for psychiatric treatment may also be misdiagnosed or under-diagnosed as a result of these visual problems. This quality assurance review of 25 consecutive geriatric psychiatric inpatients demonstrated discrepancies between chart documentation and actual ophthalmologic pathology present in the patients. Doing a simple but complete ophthalmologic screening as part of the general physical examination on admission to an inpatient psychiatric unit can identify those patients who will need more in depth examination of their eyes and promote more accurate differential diagnoses for the patients.
C1 [Billick, Stephen B.] New York Med Coll, New York, NY 10065 USA.
   [Garakani, Amir] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 New York Medical College; Icahn School of Medicine at Mount Sinai
RP Garakani, A (通讯作者)，128 East Ave, Norwalk, CT 06851 USA.
EM amir.garakani@mssm.edu
RI Garakani, Amir/A-3936-2013
OI Garakani, Amir/0000-0002-9749-8372
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890423349
   Bickley LS, 2003, BATES GUIDE PHYS EXA, P144
   Eichenbaum JW, 2012, MT SINAI J MED, V79, P276, DOI 10.1002/msj.21303
   Huang CQ, 2010, AGEING RES REV, V9, P131, DOI 10.1016/j.arr.2009.05.005
   Jackson GR, 2003, NEUROL CLIN, V21, P709, DOI 10.1016/S0733-8619(02)00107-X
   Jefferis JM, 2012, AGE AGEING, V41, P565, DOI 10.1093/ageing/afs042
   Kaplan HI, 1995, COMPREHENSIVE TXB PS
   KATZ B, 1989, SURV OPHTHALMOL, V34, P31, DOI 10.1016/0039-6257(89)90127-6
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Pelletier AL, 2009, AM FAM PHYSICIAN, V79, P963
   Salonen L, 2012, CURR GERONTOL GERIAT, V2012
   WEINSTOCK FJ, 1983, GERIATRICS, V38, P117
   Yanoff M., 2009, OPHTHALMOLOGY
NR 13
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-2720
EI 1573-6709
J9 PSYCHIAT QUART
JI Psychiatr. Q.
PD MAR
PY 2014
VL 85
IS 1
BP 49
EP 56
DI 10.1007/s11126-013-9269-z
PG 8
WC Psychiatry
WE Social Science Citation Index (SSCI)
SC Psychiatry
GA AC4KS
UT WOS:000332490500005
PM 23963654
DA 2022-11-30
ER

PT J
AU Huynh, TP
   Mann, SN
   Mandal, NA
AF Tuan-Phat Huynh
   Mann, Shivani N.
   Mandal, Nawajes A.
TI Botanical Compounds: Effects on Major Eye Diseases
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; EXTRACT EGB-761 PROTECTS; RED WINE
   CONSTITUENT; GINKGO-BILOBA; OXIDATIVE STRESS; DNA-DAMAGE; ZEAXANTHIN
   SUPPLEMENTATION; MACULAR PIGMENT; (-)-EPIGALLOCATECHIN GALLATE; INDUCED
   CATARACTOGENESIS
AB Botanical compounds have been widely used throughout history as cures for various diseases and ailments. Many of these compounds exhibit strong antioxidative, anti-inflammatory, and antiapoptotic properties. These are also common damaging mechanisms apparent in several ocular diseases, including age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract, and retinitis pigmentosa. In recent years, there have been many epidemiological and clinical studies that have demonstrated the beneficial effects of plant-derived compounds, such as curcumin, lutein and zeaxanthin, danshen, ginseng, and many more, on these ocular pathologies. Studies in cell cultures and animal models showed promising results for their uses in eye diseases. While there are many apparent significant correlations, further investigation is needed to uncover the mechanistic pathways of these botanical compounds in order to reach widespread pharmaceutical use and provide noninvasive alternatives for prevention and treatments of the major eye diseases.
C1 [Tuan-Phat Huynh; Mann, Shivani N.; Mandal, Nawajes A.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Tuan-Phat Huynh; Mann, Shivani N.; Mandal, Nawajes A.] Dean McGee Eye Inst, Oklahoma City, OK 73104 USA.
   [Tuan-Phat Huynh] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73104 USA.
   [Mandal, Nawajes A.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
   [Mandal, Nawajes A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Mandal, NA (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
EM mmandal@ouhsc.edu
FU Bright Focus Foundation; National Eye Institute [EY022071]; National
   Center for Research Resources [RR17703]; Foundation Fighting Blindness;
   Research to Prevent Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES
   [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY022071] Funding Source: NIH RePORTER
FX The paper was supported by grants from the American Health Assistance
   Foundation (is currently known as "Bright Focus Foundation"), National
   Eye Institute (EY022071), National Center for Research Resources
   (RR17703), Foundation Fighting Blindness, and unrestricted grant from
   Research to Prevent Blindness to the Department of Ophthalmology, OUHSC.
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V119, P1417
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Ahsan H, 1998, CANCER LETT, V124, P23, DOI 10.1016/S0304-3835(97)00442-4
   Alex AF, 2010, CURR EYE RES, V35, P1021, DOI 10.3109/02713683.2010.506970
   Anderson D.R., 2009, DUANES OPHTHALMOLOGY, VVolume 48
   Areias FM, 2001, BIOCHEM PHARMACOL, V62, P111, DOI 10.1016/S0006-2952(01)00621-9
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bian QN, 2012, ADV EXP MED BIOL, V723, P43, DOI 10.1007/978-1-4614-0631-0_7
   Blasiak Janusz, 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P271
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249
   Burgos-Moron E, 2010, INT J CANCER, V126, P1771, DOI 10.1002/ijc.24967
   Cao J, 2006, TOXICOL SCI, V91, P476, DOI 10.1093/toxsci/kfj153
   Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1
   Chan CM, 2010, MOL VIS, V16, P586
   Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035
   Chen YH, 2001, J CELL BIOCHEM, V82, P512, DOI 10.1002/jcb.1176
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho JY, 2001, PLANTA MED, V67, P213, DOI 10.1055/s-2001-12005
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Corder R, 2001, NATURE, V414, P863, DOI 10.1038/414863a
   Cragg GM, 2005, PURE APPL CHEM, V77, P7, DOI 10.1351/pac200577010007
   Cybulska-Heinrich AK, 2012, MOL VIS, V18, P390
   da Costa BLDA, 2008, BRAIN RES BULL, V76, P412, DOI 10.1016/j.brainresbull.2008.01.022
   Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   FARNSWORTH NR, 1985, B WORLD HEALTH ORGAN, V63, P965
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Gacche RN, 2011, FOOD CHEM TOXICOL, V49, P1806, DOI 10.1016/j.fct.2011.04.032
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   GIRI AK, 1990, CYTOBIOS, V62, P111
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   GOODPASTURE CE, 1976, FOOD COSMET TOXICOL, V14, P9, DOI 10.1016/S0015-6264(76)80356-2
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Holden J.M., 2011, USDA DATABASE FLAVON
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Ishii Y, 2003, INVEST OPHTH VIS SCI, V44, P1982, DOI 10.1167/iovs.02-0912
   Izzo AA, 2012, MED PRIN PRACT, V21, P404, DOI 10.1159/000334488
   Janssens D, 2000, FUND CLIN PHARMACOL, V14, P193, DOI 10.1111/j.1472-8206.2000.tb00016.x
   Kelly MR, 2001, MUTAT RES-DNA REPAIR, V485, P309, DOI 10.1016/S0921-8777(01)00066-0
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kim NR, 2010, J GINSENG RES, V34, P237, DOI 10.5142/jgr.2010.34.3.237
   Kim S, 2002, BIOCHEM BIOPH RES CO, V296, P247, DOI 10.1016/S0006-291X(02)00870-7
   Kim YC, 1998, J NEUROSCI RES, V53, P426, DOI 10.1002/(SICI)1097-4547(19980815)53:4<426::AID-JNR4>3.3.CO;2-K
   Kim YH, 2012, ACTA OPHTHALMOL, V90, pE31, DOI 10.1111/j.1755-3768.2011.02243.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kumar PA, 2005, MOL VIS, V11, P561
   Lamson D W, 2000, Altern Med Rev, V5, P196
   Lee SR, 2003, PHYTOTHER RES, V17, P206, DOI 10.1002/ptr.1090
   Lee Sung Min, 2010, Korean J Ophthalmol, V24, P101, DOI 10.3341/kjo.2010.24.2.101
   Lee WK, 2006, CLIN EXP PHARMACOL P, V33, P27, DOI 10.1111/j.1440-1681.2006.04319.x
   Li CZ, 2012, INVEST OPHTH VIS SCI, V53, P3241, DOI 10.1167/iovs.11-8406
   Losa GA, 2003, EUR J CLIN INVEST, V33, P818, DOI 10.1046/j.1365-2362.2003.01219.x
   Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q
   Luo JZQ, 2006, EVID-BASED COMPL ALT, V3, P365, DOI 10.1093/ecam/nel026
   Ma K, 2010, ACTA OPHTHALMOL, V88, P553, DOI 10.1111/j.1755-3768.2008.01486.x
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Maclennan KM, 2002, PROG NEUROBIOL, V67, P235, DOI 10.1016/S0301-0082(02)00015-1
   Makri O. E., 2012, ACTA OPHTHALMOLOGICA, V90
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mandelcorn E., 2009, DUANES OPHTHALMOLOGY
   Manikandan R, 2010, CURR EYE RES, V35, P122, DOI 10.3109/02713680903447884
   MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764
   Nair J, 2005, CARCINOGENESIS, V26, P1307, DOI 10.1093/carcin/bgi073
   Ochiai T, 2004, NEUROCHEM INT, V44, P321, DOI 10.1016/S0197-0186(03)00174-8
   Osborne NN, 2008, PROG BRAIN RES, V173, P339, DOI 10.1016/S0079-6123(08)01124-2
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Pandya U, 2000, TOXICOL LETT, V115, P195, DOI 10.1016/S0378-4274(00)00191-0
   Pierre S, 2002, CELL MOL BIOL, V48, P671
   Pignatelli P, 2000, AM J CLIN NUTR, V72, P1150
   Qiu QH, 2012, CHINESE MED J-PEKING, V125, P2306, DOI 10.3760/cma.j.issn.0366-6999.2012.13.012
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Raju T. N., 2006, Indian Journal of Experimental Biology, V44, P733
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Ritch R, 2007, CAN J OPHTHALMOL, V42, P425, DOI 10.3129/i07-044
   Russo P, 2001, NUTR METAB CARDIOVAS, V11, P25
   Sakano K, 2002, ARCH BIOCHEM BIOPHYS, V405, P223, DOI 10.1016/S0003-9861(02)00302-8
   SANNGMOK LEE，, 2010, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V51, P733
   Sastre J, 2002, CELL MOL BIOL, V48, P685
   Sen S, 2013, PHYTOTHER RES, V27, P290, DOI 10.1002/ptr.4719
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shetty AK, 2004, NUTR RES, V24, P373, DOI 10.1016/j.nutres.2003.11.010
   Shigematsu S, 2003, FREE RADICAL BIO MED, V34, P810, DOI 10.1016/S0891-5849(02)01430-2
   Sieving PA, 2008, OPHTHALMOLOGY
   Siu AW, 2008, NEUROSCI LETT, V432, P193, DOI 10.1016/j.neulet.2007.12.046
   SLANE PR, 1994, CLIN RES, V42, pA162
   Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stefek M, 2011, REJUV RES, V14, P525, DOI 10.1089/rej.2011.1170
   Stewart LK, 2008, METABOLISM, V57, pS39, DOI 10.1016/j.metabol.2008.03.003
   Sun XR, 2003, NEUROSIGNALS, V12, P31, DOI 10.1159/000068913
   Suryanarayana P, 2005, INVEST OPHTH VIS SCI, V46, P2092, DOI 10.1167/iovs.04-1304
   Tilak JC, 2004, PHYTOTHER RES, V18, P798, DOI 10.1002/ptr.1553
   Urbina-Cano P, 2006, J APPL GENET, V47, P377, DOI 10.1007/BF03194648
   Verschoyle RD, 2007, NUTR CANCER, V59, P152, DOI 10.1080/01635580701458186
   Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9
   Woo JM, 2012, MOL VIS, V18, P901
   Wu YJ, 1998, ARTERIOSCL THROM VAS, V18, P481, DOI 10.1161/01.ATV.18.3.481
   WU ZZ, 1983, CHINESE MED J-PEKING, V96, P445
   Xiong Y, 2010, DIABETES, V59, P2505, DOI 10.2337/db10-0315
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yar AS, 2012, J MED FOOD, V15, P391, DOI 10.1089/jmf.2011.0135
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
   Zhang B, 2008, BRAIN RES, V1198, P141, DOI 10.1016/j.brainres.2007.12.015
   Zhang L, 2013, ASIAN PAC J TROP MED, V6, P145, DOI 10.1016/S1995-7645(13)60011-5
   ZHU MD, 1993, CHINESE MED J-PEKING, V106, P922
   Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
   Zigler Jr J.S., 2011, DUANES OPHTHALMOLOGY
NR 129
TC 31
Z9 33
U1 0
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
VL 2013
AR 549174
DI 10.1155/2013/549174
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 177SV
UT WOS:000321396600001
PM 23843879
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lehmann, GL
   Ginsberg, M
   Nolan, DJ
   Rodriguez, C
   Martinez-Gonzalez, J
   Zeng, SM
   Voigt, AP
   Mullins, RF
   Rafii, S
   Rodriguez-Boulan, E
   Benedicto, I
AF Lehmann, Guillermo L.
   Ginsberg, Michael
   Nolan, Daniel J.
   Rodriguez, Cristina
   Martinez-Gonzalez, Jose
   Zeng, Shemin
   Voigt, Andrew P.
   Mullins, Robert F.
   Rafii, Shahin
   Rodriguez-Boulan, Enrique
   Benedicto, Ignacio
TI Retinal Pigment Epithelium-Secreted VEGF-A Induces Alpha-2-Macroglobulin
   Expression in Endothelial Cells
SO CELLS
LA English
DT Article
DE Alpha-2-macroglobulin (A2M); retinal pigment epithelium (RPE); vascular
   endothelial growth factor-A (VEGF-A); endothelial cells (ECs);
   extracellular matrix (ECM); matrix metalloproteinase-2 (MMP-2); protease
   inhibitor; age-related macular degeneration (AMD); Bruch's membrane
ID RECEPTOR-RELATED PROTEIN-1; GROWTH-FACTOR EXPRESSION; BETA-AMYLOID
   PEPTIDE; C-REACTIVE PROTEIN; MACULAR DEGENERATION; MULTIFUNCTIONAL
   BINDING; OXIDATIVE STRESS; BRUCHS MEMBRANE; ALPHA(2)-MACROGLOBULIN;
   CHORIOCAPILLARIS
AB Alpha-2-macroglobulin (A2M) is a protease inhibitor that regulates extracellular matrix (ECM) stability and turnover. Here, we show that A2M is expressed by endothelial cells (ECs) from human eye choroid. We demonstrate that retinal pigment epithelium (RPE)-conditioned medium induces A2M expression specifically in ECs. Experiments using chemical inhibitors, blocking antibodies, and recombinant proteins revealed a key role of VEGF-A in RPE-mediated A2M induction in ECs. Furthermore, incubation of ECs with RPE-conditioned medium reduces matrix metalloproteinase-2 gelatinase activity of culture supernatants, which is partially restored after A2M knockdown in ECs. We propose that dysfunctional RPE or choroidal blood vessels, as observed in retinal diseases such as age-related macular degeneration, may disrupt the crosstalk mechanism we describe here leading to alterations in the homeostasis of choroidal ECM, Bruch's membrane and visual function.
C1 [Lehmann, Guillermo L.; Rodriguez-Boulan, Enrique; Benedicto, Ignacio] Weill Cornell Med, Dept Ophthalmol, Margaret Dyson Vis Res Inst, New York, NY 10065 USA.
   [Lehmann, Guillermo L.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Ginsberg, Michael; Nolan, Daniel J.] Angiocrine Biosci Inc, San Diego, CA 92121 USA.
   [Rodriguez, Cristina] Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona 08041, Spain.
   [Rodriguez, Cristina; Martinez-Gonzalez, Jose] Inst Invest Biomed St Pau IIB ST PAU, Barcelona 08041, Spain.
   [Rodriguez, Cristina; Martinez-Gonzalez, Jose] Inst Salud Carlos III, CIBER Enfermedades Cardiovasc CIBERCV, Madrid 28029, Spain.
   [Martinez-Gonzalez, Jose] Consejo Super Invest Cient IIBB CSIC, Inst Invest Biomed Barcelona, Barcelona 08036, Spain.
   [Zeng, Shemin; Voigt, Andrew P.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA 52246 USA.
   [Rafii, Shahin] Weill Cornell Med, Dept Med, Div Regenerat Med, Ansary Stem Cell Inst, New York, NY 10065 USA.
   [Benedicto, Ignacio] Univ Complutense Madrid, Fac Med, Dept Inmunol Oftalmol & ORL, Madrid 28040, Spain.
   [Benedicto, Ignacio] Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain.
C3 Cornell University; Regeneron; Autonomous University of Barcelona;
   Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca
   (VHIR); Hospital of Santa Creu i Sant Pau; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERCV; Instituto de Salud Carlos III;
   Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Investigaciones Biomedicas de Barcelona (IIBB); University of
   Barcelona; University of Iowa; Cornell University; Complutense
   University of Madrid; Centro Nacional de Investigaciones
   Cardiovasculares (CNIC)
RP Benedicto, I (通讯作者)，Weill Cornell Med, Dept Ophthalmol, Margaret Dyson Vis Res Inst, New York, NY 10065 USA.; Benedicto, I (通讯作者)，Univ Complutense Madrid, Fac Med, Dept Inmunol Oftalmol & ORL, Madrid 28040, Spain.; Benedicto, I (通讯作者)，Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain.
EM ibened01@ucm.es
FU NIH [EY08538, GM34107, EY024605]; Tri-Institutional Stem Cell Initiative
   by Starr Foundation [2013-028]; Research to Prevent Blindness; Dyson
   Foundations; Comunidad Autonoma de Madrid [2017-T1/BMD-5247,
   2021-5A/BMD20944]; Ministerio de Ciencia e Innovacion (MCIN); Instituto
   de Salud Carlos III; Pro-CNIC Foundation; MCIN/AEI [CEX2020-001041-S,
   RTI2018-094727-B-100]
FX This work was funded by grants EY08538 and GM34107 from NIH, award
   2013-028 by the Tri-Institutional Stem Cell Initiative established by a
   grant from The Starr Foundation and by Departmental grants from Research
   to Prevent Blindness and Dyson Foundations (E.R.-B.). I.B. was supported
   by the Comunidad Autonoma de Madrid (grants 2017-T1/BMD-5247 and
   2021-5A/BMD20944). The CNIC is supported by the Ministerio de Ciencia e
   Innovacion (MCIN), the Instituto de Salud Carlos III, and the Pro-CNIC
   Foundation and is a Severo Ochoa Center of Excellence (grant
   CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033). R.F.M. and
   S.Z. were supported by grant EY024605 from NIH. J.M.-G. was supported by
   grant RTI2018-094727-B-100 funded by MCIN/AEI/10.13039/501100011033.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arbelaez LF, 1997, ARCH BIOCHEM BIOPHYS, V347, P62, DOI 10.1006/abbi.1997.0309
   Armstrong PB, 1999, DEV COMP IMMUNOL, V23, P375, DOI 10.1016/S0145-305X(99)00018-X
   Barcelona PF, 2010, EXP EYE RES, V91, P264, DOI 10.1016/j.exer.2010.05.017
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   BORTH W, 1994, ANN NY ACAD SCI, V737, P267, DOI 10.1111/j.1749-6632.1994.tb44317.x
   BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   CHU CT, 1994, ANN NY ACAD SCI, V737, P291, DOI 10.1111/j.1749-6632.1994.tb44319.x
   Dammalli M, 2017, OMICS, V21, P114, DOI 10.1089/omi.2016.0170
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2
   Du YS, 1998, J NEUROCHEM, V70, P1182
   Evans CH, 2014, NAT REV RHEUMATOL, V10, P11, DOI 10.1038/nrrheum.2013.159
   Ford KM, 2012, MOL VIS, V18, P519
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Frankowski H, 2012, METHODS MOL BIOL, V814, P221, DOI 10.1007/978-1-61779-452-0_15
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fukuoka Y, 2004, BIOCHEMISTRY-US, V43, P10757, DOI 10.1021/bi049486c
   Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275
   IMBER MJ, 1981, J BIOL CHEM, V256, P8134
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kannan R, 2006, MOL VIS, V12, P1649
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mantuano E, 2016, P NATL ACAD SCI USA, V113, P1369, DOI 10.1073/pnas.1515480113
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   May CA, 1999, HISTOCHEM CELL BIOL, V112, P381, DOI 10.1007/s004180050420
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046
   NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x
   Nagase H, 1998, Cell Res, V8, P179
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017
   OHLSSON K, 1971, ACTA PHYSIOL SCAND, V81, P269, DOI 10.1111/j.1748-1716.1971.tb04900.x
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   PINO RM, 1985, AM J ANAT, V172, P279, DOI 10.1002/aja.1001720403
   PINO RM, 1981, J HISTOCHEM CYTOCHEM, V29, P281, DOI 10.1177/29.2.7252121
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Rehman AA, 2013, J CELL PHYSIOL, V228, P1665, DOI 10.1002/jcp.24266
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   ROCHE PA, 1988, BIOCHEMISTRY-US, V27, P7876, DOI 10.1021/bi00420a044
   Rodriguez-Calvo R, 2015, THROMB HAEMOSTASIS, V113, P1323, DOI 10.1160/TH14-07-0645
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sambri I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141932
   Seandel M, 2008, P NATL ACAD SCI USA, V105, P19288, DOI 10.1073/pnas.0805980105
   Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Shirasawa M, 2013, EXP EYE RES, V110, P59, DOI 10.1016/j.exer.2013.02.012
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Troeberg Linda, 2003, Methods Mol Biol, V225, P77
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Voigt AP, 2021, HUM MOL GENET, V30, P1543, DOI 10.1093/hmg/ddab140
   Voigt AP, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108204
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Voigt AP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020438
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Yan L, 2000, J CELL SCI, V113, P3979
   Yanez-Mo M, 2008, BLOOD, V112, P3217, DOI 10.1182/blood-2008-02-139394
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 82
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2022
VL 11
IS 19
AR 2975
DI 10.3390/cells11192975
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5H9NE
UT WOS:000867996500001
PM 36230937
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dissopa, J
   Kansomkeat, S
   Intajag, S
AF Dissopa, Jessada
   Kansomkeat, Supaporn
   Intajag, Sathit
TI Enhance Contrast and Balance Color of Retinal Image
SO SYMMETRY-BASEL
LA English
DT Article
DE color retinal image; color balance; contrast enhancement; Rayleigh
   CLAHE; age-related macular degeneration
ID HISTOGRAM EQUALIZATION
AB This paper proposes a simple and effective retinal fundus image simulation modeling to enhance contrast and adjust the color balance for symmetric information in biomedicine. The aim of the study is for reliable diagnosis of AMD (age-related macular degeneration) screening. The method consists of a few simple steps. Firstly, local image contrast is refined with the CLAHE (Contrast Limited Adaptive Histogram Equalization) technique by operating CIE L*a*b* color space. Then, the contrast-enhanced image is stretched and rescaled by a histogram scaling equation to adjust the overall brightness offsets of the image and standardize it to Hubbard's retinal image brightness range. The proposed method was assessed with retinal images from the DiaretDB0 and STARE datasets. The findings in the experimentation section indicate that the proposed method results in delightful color naturalness along with a standard color of retinal lesions.
C1 [Dissopa, Jessada; Kansomkeat, Supaporn; Intajag, Sathit] Prince Songkla Univ, Div Computat Sci, Fac Sci, Hat Yai 90110, Thailand.
C3 Prince of Songkla University
RP Intajag, S (通讯作者)，Prince Songkla Univ, Div Computat Sci, Fac Sci, Hat Yai 90110, Thailand.
EM 6110220125@email.psu.ac.th; supaporn.k@psu.ac.th; sathit.i@psu.ac.th
FU Faculty of Science Research Fund, Prince of Songkla University
   [2-2561-02-017]
FX This work was supported by the Faculty of Science Research Fund, Prince
   of Songkla University, Contract no. 2-2561-02-017.
CR Bala AA, 2021, INT J IMAG SYST TECH, V31, P1050, DOI 10.1002/ima.22504
   Cao LC, 2020, SIGNAL PROCESS, V170, DOI 10.1016/j.sigpro.2019.107445
   Cao LC, 2020, MED BIOL ENG COMPUT, V58, P483, DOI 10.1007/s11517-019-02106-7
   Cheng HD, 2004, DIGIT SIGNAL PROCESS, V14, P158, DOI 10.1016/j.dsp.2003.07.002
   Gaudio A., 2020, INT C IM AN REC, P299, DOI DOI 10.1007/978-3-030-50516-5_26
   Ghosh SK, 2020, PROCEDIA COMPUT SCI, V167, P1300, DOI 10.1016/j.procs.2020.03.446
   Hasler D, 2003, P SOC PHOTO-OPT INS, V5007, P87, DOI 10.1117/12.477378
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hubbard L.D., 2009, J OPHTHALMIC PHOTOGR, V31, P15
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Hunt RWG, 2011, WILEY-ISTE, P41
   Isselmou A., 2020, INT J CIRCUITS, V14, P1096
   Jin K, 2018, ACTA OPHTHALMOL, V96, pE320, DOI 10.1111/aos.13573
   Jintasuttisak T., 2014, P 14 INT C CONTR AUT
   Kandpal A., 2020, P INT C SIGN PROC IN
   Kauppi T., 2006, DIARETDB0 EVALUATION
   Kolaman A, 2012, IEEE T IMAGE PROCESS, V21, P1526, DOI 10.1109/TIP.2011.2181522
   Matkovic K., 2005, P 1 EUR C COMP AESTH
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Pratt WK, 2007, DIGITAL IMAGE PROCES
   Sawssen B., 2020, INT J AP MAT COM-POL, V2, P92
   Setiawan AW, 2013, INT CONF ICT SMART S, P215
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Vetova S., 2021, WSEAS T INT J ELECT, V3, P109
   Wang JL, 2021, COMPUT BIOL MED, V128, DOI 10.1016/j.compbiomed.2020.104116
   Wang SH, 2013, IEEE T IMAGE PROCESS, V22, P3538, DOI 10.1109/TIP.2013.2261309
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao L., 2020, INT J CIRCUITS, V14, P1034
   Zhou M, 2018, IEEE T BIO-MED ENG, V65, P521, DOI 10.1109/TBME.2017.2700627
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 30
TC 0
Z9 0
U1 5
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-8994
J9 SYMMETRY-BASEL
JI Symmetry-Basel
PD NOV
PY 2021
VL 13
IS 11
AR 2089
DI 10.3390/sym13112089
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XG7RP
UT WOS:000724946600001
OA gold
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Vagge, A
   Nicolo, M
   Traverso, CE
AF Desideri, L. Ferro
   Vagge, A.
   Nicolo, M.
   Traverso, C. E.
TI An overview of gene therapies in the pipeline for ocular disorders
SO DRUGS OF THE FUTURE
LA English
DT Review
DE Gene therapy; Ocular gene therapy; Luxturna; Inherited retinal
   dystrophies; Macular degeneration; Voretigene neparvovec
ID HEREDITARY OPTIC NEUROPATHY; VORETIGENE NEPARVOVEC; MACULAR
   DEGENERATION; RETINITIS-PIGMENTOSA; MOLECULAR-GENETICS; INITIAL
   FINDINGS; CLINICAL-TRIAL; OPEN-LABEL; MUTATIONS; INJECTION
AB Recently, ocular gene therapy has been proven to be a promising emerging treatment option for ocular disorders, considering the encouraging clinical outcomes and safety profile. In particular, ocular gene therapy has been introduced for the treatment of several inherited retinal diseases mostly by implementing an adeno-associated virus vector. In 2017, voretigene neparvovec was the first gene therapy approved by the U.S. Food and Drug Administration for the treatment RPE65-related Leber congenital amaurosis and retinitis pigmentosa. Moreover, gene therapy is being examined in several different nonhereditary diseases, including wet age-related macular degeneration, diabetic retinopathy and glaucoma. In this review article, we discuss the current approaches investigating the role of gene therapy for ocular disorders. Nonetheless, we will discuss its potential clinical benefit for patients and the reduction of the treatment burden due to the longer duration.
C1 [Desideri, L. Ferro; Vagge, A.; Nicolo, M.; Traverso, C. E.] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
   [Vagge, A.; Nicolo, M.; Traverso, C. E.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Nicolo, M.] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Desideri, LF (通讯作者)，IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
EM lorenzoferrodes@gmail.com
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Banin E, 2015, MOL THER, V23, P1423, DOI 10.1038/mt.2015.114
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Bonnet C, 2007, REJUV RES, V10, P127, DOI 10.1089/rej.2006.0526
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Bruewer AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060218
   Busskamp V, 2011, CURR OPIN NEUROBIOL, V21, P942, DOI 10.1016/j.conb.2011.06.001
   Byrne LC, 2014, GENE THER, V21, P585, DOI 10.1038/gt.2014.31
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cehajic-Kapetanovic J, 2020, NAT MED, V26, P354, DOI 10.1038/s41591-020-0763-1
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cukras C, 2018, MOL THER, V26, P2282, DOI 10.1016/j.ymthe.2018.05.025
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   de Moraes CG, 2016, SURV OPHTHALMOL, V61, P597, DOI 10.1016/j.survophthal.2016.03.006
   Desideri LF, 2020, DRUG TODAY, V56, P311, DOI 10.1358/dot.2020.56.5.3137164
   Desideri LF, 2019, DRUG TODAY, V55, P377, DOI 10.1358/dot.2019.55.6.2984806
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Desideri LF, 2019, PARKINSONISM RELAT D, V61, P234, DOI 10.1016/j.parkreldis.2018.11.004
   Fahim A, 2018, CURR OPIN PEDIATR, V30, P725, DOI 10.1097/MOP.0000000000000690
   Ferro Desideri L., 2019, DRUGS FUTURE, V44
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025
   Fischer MD, 2020, JAMA OPHTHALMOL, V138, P643, DOI 10.1001/jamaophthalmol.2020.1032
   Fischer MD, 2017, MOL THER, V25, P1854, DOI 10.1016/j.ymthe.2017.05.005
   Gao J, 2020, CLIN OPHTHALMOL, V14, P3855, DOI 10.2147/OPTH.S231804
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873
   Guy J, 2017, OPHTHALMOLOGY, V124, P1621, DOI 10.1016/j.ophtha.2017.05.016
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   High KA, 2019, NEW ENGL J MED, V381, P455, DOI 10.1056/NEJMra1706910
   Hirji N, 2018, OPHTHALMIC GENET, V39, P149, DOI 10.1080/13816810.2017.1418389
   Imani S, 2018, MUTAT RES-REV MUTAT, V775, P39, DOI 10.1016/j.mrrev.2018.02.001
   Jiang JJ, 2021, FUND CLIN PHARMACOL, V35, P4, DOI 10.1111/fcp.12561
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kang C, 2020, MOL DIAGN THER, V24, P487, DOI 10.1007/s40291-020-00475-6
   Kim CK, 2017, NAT REV NEUROSCI, V18, P222, DOI 10.1038/nrn.2017.15
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Komaromy AM, 2010, HUM MOL GENET, V19, P2581, DOI 10.1093/hmg/ddq136
   Lam BL, 2019, AM J OPHTHALMOL, V197, P65, DOI 10.1016/j.ajo.2018.09.012
   Landau Klara, 2011, Handb Clin Neurol, V102, P97, DOI 10.1016/B978-0-444-52903-9.00010-8
   Lee JH, 2019, PROG RETIN EYE RES, V68, P31, DOI 10.1016/j.preteyeres.2018.08.003
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Manickam AH, 2017, INDIAN J OPHTHALMOL, V65, P1087, DOI 10.4103/ijo.IJO_358_17
   Mokhles P, 2017, ACTA OPHTHALMOL, V95, P10, DOI 10.1111/aos.12933
   Moore NA, 2018, EXPERT OPIN BIOL TH, V18, P37, DOI 10.1080/14712598.2018.1389886
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217
   Petit L, 2016, HUM GENE THER, V27, P563, DOI 10.1089/hum.2016.040
   Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Rodrigues GA, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2554-7
   Rosenberg T, 2016, INVEST OPHTH VIS SCI, V57, P1370, DOI 10.1167/iovs.15-18306
   Rubio RG, 2016, DEV OPHTHALMOL, V55, P28, DOI 10.1159/000431129
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sanchez-Alcudia R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151943
   Schon C, 2015, EUR J PHARM BIOPHARM, V95, P343, DOI 10.1016/j.ejpb.2015.01.009
   Sudharsan R, 2019, ADV EXP MED BIOL, V1185, P113, DOI 10.1007/978-3-030-27378-1_19
   Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293
   Trapani I, 2018, TRENDS MOL MED, V24, P669, DOI 10.1016/j.molmed.2018.06.006
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P139, DOI 10.1007/978-3-319-95046-4_27
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P43, DOI 10.1007/978-3-319-95046-4_10
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P125, DOI 10.1007/978-3-319-95046-4_25
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P131, DOI 10.1007/978-3-319-95046-4_26
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P167, DOI 10.1007/978-3-319-95046-4_32
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Vignal C, 2018, OPHTHALMOLOGY, V125, P945, DOI 10.1016/j.ophtha.2017.12.036
   Wallace DC, 2017, HANDB EXP PHARMACOL, V240, P339, DOI 10.1007/164_2017_2
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yang S, 2016, EBIOMEDICINE, V10, P258, DOI 10.1016/j.ebiom.2016.07.002
   Ziccardi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225722
   Zobor D, 2015, OPHTHALMIC RES, V54, P103, DOI 10.1159/000435957
NR 77
TC 2
Z9 2
U1 1
U2 9
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD MAY
PY 2021
VL 46
IS 5
BP 383
EP 390
DI 10.1358/dof.2021.46.5.3273779
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SA8SQ
UT WOS:000649573500004
DA 2022-11-30
ER

PT J
AU Kazamel, M
   Lopez, MA
   Bebin, M
   Bowling, K
   Korf, BR
   Barsh, GS
   Cooper, GM
   Hurst, ACE
   Ubogu, EE
AF Kazamel, Mohamed
   Lopez, Michael A.
   Bebin, Martina
   Bowling, Kevin
   Korf, Bruce R.
   Barsh, Gregory S.
   Cooper, Gregory M.
   Hurst, Anna C. E.
   Ubogu, Eroboghene E.
TI Fibulin-5 mutation featuring Charcot-Marie-Tooth disease, joint
   hyperlaxity, and scoliosis
SO NEUROLOGY-GENETICS
LA English
DT Article
ID MACULAR DEGENERATION
AB Fibulin-5 (FBLN5) is an extracellular matrix glycoprotein expressed in elastic fiber-rich tissues.(1) Mutations affecting the first epidermal growth factor domain feature a spinal Charcot-Marie-Tooth (CMT) phenotype, whereas the C-terminus c.1117C>T variant causes demyelinating sensorimotor polyneuropathy.(2) Besides CMT, FBLN5 mutations also feature age-related macular degeneration and cutis laxa.(3) FBLN5-associated CMT was reported in 6 families from Austria,(2) the Czech Republic,(4) and China,(5) with 4 possessing the c.1117C>T (p.Arg373Cys) mutation.(2,4,5) Joint hyperlaxity and scoliosis were reported in 1 spinal CMT Austrian family due to a p.Gly90Ser mutation, but never with p.Arg373Cys-associated CMT-1.(2) We describe the phenotype of a family with FBLN5-associated CMT-1 featuring younger symptom onset, joint hyperlaxity, and scoliosis.
C1 [Kazamel, Mohamed; Bebin, Martina; Ubogu, Eroboghene E.] Univ Alabama Birmingham UAB, Dept Neurol, Birmingham, AL 35294 USA.
   [Lopez, Michael A.; Bebin, Martina] UAB, Childrens Alabama, Dept Pediat, Birmingham, AL USA.
   [Bowling, Kevin; Barsh, Gregory S.; Cooper, Gregory M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA.
   [Korf, Bruce R.; Hurst, Anna C. E.] UAB, Dept Genet, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   HudsonAlpha Institute for Biotechnology; University of Alabama System;
   University of Alabama Birmingham
RP Kazamel, M (通讯作者)，Univ Alabama Birmingham UAB, Dept Neurol, Birmingham, AL 35294 USA.
EM mkazamel@uabmc.edu
RI Hurst, Anna CE/AAL-2889-2021; Lopez, Michael A./AAT-2145-2021
OI Hurst, Anna CE/0000-0002-9765-9703; Lopez, Michael
   A./0000-0002-3029-0761
FU State of Alabama
FX The authors acknowledge the Alabama Genomic Health Initiative (AGHI),
   funded by the State of Alabama, for making the whole-genome sequencing
   diagnosis possible.
CR Auer-Grumbach M, 2011, BRAIN, V134, P1839, DOI 10.1093/brain/awr076
   Brozkova DS, 2013, BRAIN, V136, DOI 10.1093/brain/aws333
   Cheng S, 2017, CLIN NEUROPATHOL, V36, P171, DOI 10.5414/NP301011
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Yanagisawa H, 2009, J CELL COMMUN SIGNAL, V3, P337, DOI 10.1007/s12079-009-0065-3
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2376-7839
J9 NEUROL-GENET
JI Neurol.-Genet.
PD AUG
PY 2020
VL 6
IS 4
AR e476
DI 10.1212/NXG.0000000000000476
PG 3
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA ON2IO
UT WOS:000586531700001
PM 32802946
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shu, XH
   Luhmann, UFO
   Aleman, TS
   Barker, SE
   Lennon, A
   Tulloch, B
   Chen, M
   Xu, HP
   Jacobson, SG
   Ali, R
   Wright, AF
AF Shu, Xinhua
   Luhmann, Ulrich F. O.
   Aleman, Tomas S.
   Barker, Susan E.
   Lennon, Alan
   Tulloch, Brian
   Chen, Mei
   Xu, Heping
   Jacobson, Samuel G.
   Ali, Robin
   Wright, Alan F.
TI Characterisation of a C1qtnf5 Ser163Arg Knock-In Mouse Model of
   Late-Onset Retinal Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID ANTERIOR LENS ZONULES; CYSTIC-FIBROSIS; LIPOFUSCIN ACCUMULATION; GENETIC
   MODEL; MICE; MODIFIER; PHENOTYPE; MUTATION; DISEASE; IDENTIFICATION
AB A single founder mutation resulting in a Ser163Arg substitution in the C1QTNF5 gene product causes autosomal dominant late-onset retinal macular degeneration (L-ORMD) in humans, which has clinical and pathological features resembling age-related macular degeneration. We generated and characterised a mouse "knock-in" model carrying the Ser163Arg mutation in the orthologous murine C1qtnf5 gene by site-directed mutagenesis and homologous recombination into mouse embryonic stem cells. Biochemical, immunological, electron microscopic, fundus autofluorescence, electroretinography and laser photocoagulation analyses were used to characterise the mouse model. Heterozygous and homozygous knock-in mice showed no significant abnormality in any of the above measures at time points up to 2 years. This result contrasts with another C1qtnf5 Ser163Arg knock-in mouse which showed most of the features of L-ORMD but differed in genetic background and targeting construct.
C1 [Shu, Xinhua; Lennon, Alan; Tulloch, Brian; Wright, Alan F.] Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Luhmann, Ulrich F. O.; Barker, Susan E.; Ali, Robin] UCL Inst Ophthalmol, London, England.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Aleman, Tomas S.; Jacobson, Samuel G.] Univ Penn, Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Chen, Mei; Xu, Heping] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
C3 University of Edinburgh; University of London; University College
   London; Glasgow Caledonian University; Glasgow Caledonian University;
   University of Pennsylvania; Pennsylvania Medicine; Queens University
   Belfast
RP Shu, XH (通讯作者)，Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland.
EM alan.wright@hgu.mrc.ac.uk
RI Xu, Heping/A-4430-2008; Luhmann, Ulrich/D-8905-2012
OI Xu, Heping/0000-0003-4000-931X; Jacobson, Samuel/0000-0003-2122-169X;
   Ali, Robin/0000-0003-3126-6517
FU European Commission [FP7]; EVI GENORET [LSHG-CT-2005-512036]; Medical
   Research Council (UK); Macula Vision Research Foundation; RP Fighting
   Blindness; TENOVUS Scotland; Vision Research Trust; W.H. Ross
   Foundation; National Eye Research Centre; Carnegie Trust for the
   Universities of Scotland; MRC [MC_U127584475] Funding Source: UKRI;
   Medical Research Council [MC_U127584475, MC_PC_U127584475] Funding
   Source: researchfish
FX This work was supported by The European Commission (FP7), Integrated
   project "EVI GENORET" (LSHG-CT-2005-512036), Medical Research Council
   (UK), Macula Vision Research Foundation, RP Fighting Blindness, TENOVUS
   Scotland, Vision Research Trust, W.H. Ross Foundation, National Eye
   Research Centre, and Carnegie Trust for the Universities of Scotland.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   BRUNNER S, INVEST OPHTHALMOL VI, V51, P1106
   CHAVALI VR, 2011, HUM MOL GENET
   Danciger M, 2007, MOL VIS, V13, P79
   Demaison C, 2000, HUM GENE THER, V11, P91, DOI 10.1089/10430340050016184
   DICKINSON P, 1995, MOL MED TODAY, V1, P140, DOI 10.1016/S1357-4310(95)80092-1
   DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8
   Elsea Sarah H, 2002, ILAR J, V43, P66
   Gerido DA, 2003, INVEST OPHTH VIS SCI, V44, P2669, DOI 10.1167/iovs.02-1311
   Haston CK, 2002, MAMM GENOME, V13, P605, DOI 10.1007/s00335-002-2190-7
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kiernan AE, 2007, GENETICS, V177, P307, DOI 10.1534/genetics.107.075960
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lima BL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014136
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Montagutelli X, 2000, J AM SOC NEPHROL, V11, pS101
   Park SY, 2009, J BIOL CHEM, V284, P27780, DOI 10.1074/jbc.M109.005611
   Pierce EA, 2001, BIOESSAYS, V23, P605, DOI 10.1002/bies.1086
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Robson MG, 2003, CLIN EXP IMMUNOL, V133, P326, DOI 10.1046/j.1365-2249.2003.02233.x
   Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280
   Samardzija M, 2006, EUR J NEUROSCI, V23, P1028, DOI 10.1111/j.1460-9568.2006.04639.x
   Shu XH, 2006, ADV EXP MED BIOL, V572, P41
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Shu XH, 2006, INVEST OPHTH VIS SCI, V47, P348, DOI 10.1167/iovs.05-0858
   Silverman KA, 2002, GENOME RES, V12, P88, DOI 10.1101/gr.206002
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Stone EM, 2009, CURR OPIN GENET DEV, V19, P283, DOI 10.1016/j.gde.2009.03.006
   Subrayan V, 2005, AM J OPHTHALMOL, V140, P1127, DOI 10.1016/j.ajo.2005.06.023
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   Van Raamsdonk JM, 2007, NEUROBIOL DIS, V26, P189, DOI 10.1016/j.nbd.2006.12.010
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Wheeler FC, 2005, MAMM GENOME, V16, P414, DOI 10.1007/s00335-005-2468-7
   Wheeler FC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000647
   Williams DS, 2009, INVEST OPHTH VIS SCI, V50, P3881, DOI 10.1167/iovs.08-3358
   Wong GW, 2008, BIOCHEM J, V416, P161, DOI 10.1042/BJ20081240
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
   Yang TX, 2005, AM J PHYSIOL-RENAL, V288, pF1125, DOI 10.1152/ajprenal.00219.2004
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 47
TC 12
Z9 12
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 16
PY 2011
VL 6
IS 11
AR e27433
DI 10.1371/journal.pone.0027433
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 855HV
UT WOS:000297555400045
PM 22110650
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UH
   Schlichtenbrede, F
AF Jonas, Jost B.
   Spandau, Ulrich H.
   Schlichtenbrede, Frank
TI Intravitreal bevacizumab for filtering surgery
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE intravitreal bevacizumab; avastin; exudative age-related macular
   degeneration; intraocular antiangiogenesis; iris neovascularization;
   neovascular glaucoma; ischemic retinopathy
ID PROLIFERATIVE DIABETIC-RETINOPATHY; INJECTION; RUBEOSIS
AB Background: It was the aim of this study to report on the intravitreal use of bevacizumab as antiproliferative agent in combination with filtering surgery. Methods: The clinical interventional case series study included 2 patients (2 eyes) who underwent standard antiglaucomatous penetrating filtering surgery combined with an intravitreal application of 1.5 mg bevacizumab. The intraocular pressure was elevated due to an intravitreal triamcinolone injection as treatment of exudative age-related macular degeneration (patient No. 1) or due to neovascular glaucoma (patient No. 2) after an ischemic retinal branch vein occlusion. Results: At 4 and 12 weeks after surgery, intraocular pressure was reduced in both patients to 10 and 14 mm Hg with functioning filtering blebs. Conclusions: Intravitreal bevacizumab may potentially be helpful as addition to antiglaucomatous filtering surgery, particularly in neovascular glaucoma. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Heidelberg, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
CR Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P148, DOI 10.3928/1542-8877-20060301-12
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
NR 7
TC 45
Z9 52
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHAL RES
JI Ophthalmic Res.
PY 2007
VL 39
IS 2
BP 121
EP 122
DI 10.1159/000099248
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151DU
UT WOS:000245270000012
PM 17284939
DA 2022-11-30
ER

PT J
AU Pasqualetti, G
   Danesi, R
   Del Tacca, M
   Bocci, G
AF Pasqualetti, Giuseppe
   Danesi, Romano
   Del Tacca, Mario
   Bocci, Guido
TI Vascular endothelial growth factor pharmacogenetics: a new perspective
   for anti-angiogenic therapy
SO PHARMACOGENOMICS
LA English
DT Review
DE bevacizumab; pharmacogenetics; single nucleotide polymorphism; tyrosine
   kinase inhibitors; vascular endothelial growth factor; vascular
   endothelial growth factor receptor-2
ID CELL LUNG-CANCER; SINGLE NUCLEOTIDE POLYMORPHISMS; METASTATIC
   COLORECTAL-CANCER; FACTOR GENE POLYMORPHISMS; RECEPTOR TYROSINE KINASE;
   SORSBYS FUNDUS DYSTROPHY; INDUCIBLE FACTOR 1-ALPHA; FACTOR
   MESSENGER-RNA; BREAST-CANCER; VEGF GENE
AB The pharmacogenetic approach to anti-angiogenic therapy should be considered a possible strategy for many pathological conditions with high incidence in Western countries, including solid tumors, age-related macular degeneration or endometriosis. While pharmacogenetic studies are building stronger foundations for the systematic investigations of phenotype-genotype relationships in many research and clinical fields of medicine, pharmacogenetic data regarding anti-angiogenic drugs are still lacking. Here we review preclinical and clinical genetic studies on angiogenic determinants such as vascular endothelial growth factor and vascular endothelial growth factor receptor-2. We suggest that pharmacogenetic profiling of patients who are candidates for the currently available anti-angiogenic agents targeting vascular endothelial growth factor and vascular endothelial growth factor receptor-2 may aid the selection of patients on the basis of their likelihood of responding to the drugs or suffering from toxicity.
C1 Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, I-56126 Pisa, Italy.
C3 University of Pisa
RP Bocci, G (通讯作者)，Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Via Roma 55, I-56126 Pisa, Italy.
EM g.bocci@med.unipi.it
RI Danesi, Romano/J-7239-2018; Danesi, Romano/AAC-9410-2019; Bocci,
   Guido/AAC-7515-2022
OI Danesi, Romano/0000-0002-4414-8934; Danesi, Romano/0000-0002-4414-8934; 
CR AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bamberger ES, 2002, J CLIN PATHOL-MOL PA, V55, P348, DOI 10.1136/mp.55.6.348
   Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596
   Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971
   Bhanoori M, 2005, HUM REPROD, V20, P1844, DOI 10.1093/humrep/deh852
   Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6
   Bocci G, 2004, CANCER RES, V64, P6616, DOI 10.1158/0008-5472.CAN-04-0401
   Boiardi L, 2003, J RHEUMATOL, V30, P2160
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6
   Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chau CH, 2005, CANCER BIOL THER, V4, P1222, DOI 10.4161/cbt.4.11.2091
   Choi JY, 2006, BREAST CANCER RES TR, V100, P213, DOI 10.1007/s10549-006-9245-5
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciardiello F, 2006, ANN ONCOL, V17, pVII109, DOI 10.1093/annonc/mdl962
   Clarke M, 2001, BRIT J OPHTHALMOL, V85, P1429, DOI 10.1136/bjo.85.12.1429
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819
   Dales JP, 2003, ANN PATHOL, V23, P297
   Danesi R, 2003, PHARMACOL REV, V55, P57, DOI 10.1124/pr.55.1.4
   Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001
   Ebos JML, 2004, MOL CANCER RES, V2, P315
   Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141
   EISEN T, 2006, P AN M AM SOC CLIN, V24, P4524
   Feinbloom D, 2005, ARTERIOSCL THROM VAS, V25, P2043, DOI 10.1161/01.ATV.0000181762.31694.da
   Ferrante M, 2006, INFLAMM BOWEL DIS, V12, P870, DOI 10.1097/01.mib.0000235095.01608.10
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fontanini G, 1997, JNCI-J NATL CANCER I, V89, P881, DOI 10.1093/jnci/89.12.881
   Fontanini G, 2002, BRIT J CANCER, V86, P558, DOI 10.1038/sj.bjc.6600130
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Giatromanolaki A, 2006, MODERN PATHOL, V19, P701, DOI 10.1038/modpathol.3800579
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gu ZP, 2004, WORLD J GASTROENTERO, V10, P1495
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Han SW, 2004, RHEUMATOLOGY, V43, P1173, DOI 10.1093/rheumatology/keh281
   Harris AL, 2001, CLIN CANCER RES, V7, P1992
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hasegawa Y, 2005, INTERNAL MED, V44, P26, DOI 10.2169/internalmedicine.44.26
   Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440
   HECHT JR, 2005, P AM SOC CLIN ONCOL, V23
   Herbst RS, 2005, J CLIN ONCOL, V23, P3243, DOI 10.1200/JCO.2005.18.853
   Hiramatsu A, 2006, LEUKEMIA LYMPHOMA, V47, P89, DOI 10.1080/10428190500270386
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Howell WM, 2002, GENES IMMUN, V3, P229, DOI 10.1038/sj.gene.6363851
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Ikeda N, 2001, CANCER-AM CANCER SOC, V92, P488, DOI 10.1002/1097-0142(20010801)92:3<488::AID-CNCR1347>3.0.CO;2-F
   IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672
   Itakura J, 1997, CLIN CANCER RES, V3, P1309
   Jacobs EJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1400
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848
   Jin QR, 2005, CLIN CANCER RES, V11, P3647, DOI 10.1158/1078-0432.CCR-04-1803
   Johnson JA, 2005, EXP PHYSIOL, V90, P283, DOI 10.1113/expphysiol.2004.028506
   Kariyazono H, 2004, PEDIATR RES, V56, P953, DOI 10.1203/01.PDR.0000145280.26284.B9
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950
   Kim Y, 2006, AM J MED GENET B, V141B, P332, DOI 10.1002/ajmg.b.30317
   Koukourakis MI, 2004, LUNG CANCER, V46, P293, DOI 10.1016/j.lungcan.2004.04.037
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Kyzas PA, 2005, J CANCER RES CLIN, V131, P624, DOI 10.1007/s00432-005-0003-6
   Lacal PM, 2005, INT J ONCOL, V27, P1625
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045
   Lu H, 2005, CANCER RES, V65, P5015, DOI 10.1158/0008-5472.CAN-04-2786
   Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Lyseng-Williamson KA, 2006, AM J CANC, V5, P43
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   Mazure NM, 1996, CANCER RES, V56, P3436
   McCarron SL, 2002, CANCER RES, V62, P3369
   Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103
   Mezquita P, 2005, ONCOGENE, V24, P889, DOI 10.1038/sj.onc.1208251
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016
   Mooser V, 2003, J THROMB HAEMOST, V1, P1398, DOI 10.1046/j.1538-7836.2003.00272.x
   Morabito A, 2006, ONCOLOGIST, V11, P753, DOI 10.1634/theoncologist.11-7-753
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516
   Narendran A, 2003, EXP HEMATOL, V31, P693, DOI 10.1016/S0301-472X(03)00159-0
   Park HW, 2006, J ALLERGY CLIN IMMUN, V117, P774, DOI 10.1016/j.jaci.2005.12.1328
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Prior SJ, 2003, PHYSIOL GENOMICS, V15, P20, DOI 10.1152/physiolgenomics.00061.2003
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   RAK J, 1995, CANCER RES, V55, P4575
   Ravi R, 2000, GENE DEV, V14, P34
   Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Rini Brian I, 2006, Curr Oncol Rep, V8, P85, DOI 10.1007/s11912-006-0041-5
   Rogers MS, 2006, EXP CELL RES, V312, P561, DOI 10.1016/j.yexcr.2005.10.021
   Rueda B, 2006, J RHEUMATOL, V33, P69
   Rugo HS, 2004, ONCOLOGIST, V9, P43, DOI 10.1634/theoncologist.9-suppl_1-43
   Saif MW, 2006, EXPERT OPIN DRUG SAF, V5, P553, DOI 10.1517/14740338.5.4.553
   Salmon JS, 2005, CANCER INVEST, V23, P712, DOI 10.1080/07357900500360024
   Sawada T, 1999, Brain Tumor Pathol, V16, P23, DOI 10.1007/BF02478898
   Scandurro AB, 1998, BIOCHEM BIOPH RES CO, V246, P436, DOI 10.1006/bbrc.1998.8639
   Schneider BP, 2006, BREAST CANCER RES TR, V96, P209, DOI 10.1007/s10549-005-9003-0
   SENGER DR, 1986, CANCER RES, V46, P5629
   Sfar S, 2006, CYTOKINE, V35, P21, DOI 10.1016/j.cyto.2006.07.003
   Shahbazi M, 2002, J AM SOC NEPHROL, V13, P260, DOI 10.1681/ASN.V131260
   Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023
   Shaked Y, 2005, CURR CANCER DRUG TAR, V5, P551, DOI 10.2174/156800905774574020
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SHEN H, 1993, BLOOD, V81, P2767
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shibuya M, 2006, ENDOTHELIUM-J ENDOTH, V13, P63, DOI 10.1080/10623320600697955
   Siest G, 2005, EUR J PHARMACOL, V527, P1, DOI 10.1016/j.ejphar.2005.10.011
   Stadler WM, 2005, CANCER-AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453
   Stevens A, 2003, CANCER RES, V63, P812
   Suganthalakshmi B, 2006, MOL VIS, V12, P336
   Sund M, 2005, GASTROENTEROLOGY, V129, P2076, DOI 10.1053/j.gastro.2005.06.023
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Takeshima H, 2003, SURG NEUROL, V60, P321, DOI 10.1016/S0090-3019(03)00430-0
   Talbot SG, 2004, ANN SURG ONCOL, V11, P530, DOI 10.1245/ASO.2004.03.014
   Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605
   Tanimoto K, 2003, CARCINOGENESIS, V24, P1779, DOI 10.1093/carcin/bgg132
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
   Troiani T, 2006, MOL CANCER THER, V5, P1883, DOI 10.1158/1535-7163.MCT-06-0055
   Tzanakis N, 2006, J SURG ONCOL, V94, P624, DOI 10.1002/jso.20619
   Ushijima C, 2001, LUNG CANCER-J IASLC, V34, P233, DOI 10.1016/S0169-5002(01)00246-X
   Uthoff SMS, 2002, INT J CANCER, V101, P32, DOI 10.1002/ijc.10552
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
   Van Der Meer P, 2005, J CARD FAIL, V11, P279, DOI 10.1016/j.cardfail.2004.11.006
   Vieira JM, 2005, EUR J ENDOCRINOL, V153, P701, DOI 10.1530/eje.1.02009
   Viloria-Petit AM, 2004, INT J RADIAT ONCOL, V58, P914, DOI 10.1016/j.ijrobp.2003.09.091
   Walter JW, 2002, GENE CHROMOSOME CANC, V33, P295, DOI 10.1002/gcc.10028
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0
   Wey JS, 2005, CANCER-AM CANCER SOC, V104, P427, DOI 10.1002/cncr.21145
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Yamada N, 2005, J CLIN ENDOCR METAB, V90, P5841, DOI 10.1210/jc.2005-0991
   Yasuda E, 2005, BIOCHEM BIOPH RES CO, V328, P137, DOI 10.1016/j.bbrc.2004.12.163
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
   Zhong XS, 2004, INT J ONCOL, V25, P445
NR 158
TC 44
Z9 54
U1 0
U2 3
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JAN
PY 2007
VL 8
IS 1
BP 49
EP 66
DI 10.2217/14622416.8.1.49
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 129YJ
UT WOS:000243765700013
PM 17187509
DA 2022-11-30
ER

PT J
AU Gorham, RD
   Forest, DL
   Tamamis, P
   Lopez de Victoria, A
   Kraszni, M
   Kieslich, CA
   Banna, CD
   Bellows-Peterson, ML
   Larive, CK
   Floudas, CA
   Archontis, G
   Johnson, LV
   Morikis, D
AF Gorham, Ronald D., Jr.
   Forest, David L.
   Tamamis, Phanourios
   Lopez de Victoria, Aliana
   Kraszni, Marta
   Kieslich, Chris A.
   Banna, Christopher D.
   Bellows-Peterson, Meghan L.
   Larive, Cynthia K.
   Floudas, Christodoulos A.
   Archontis, Georgios
   Johnson, Lincoln V.
   Morikis, Dimitrios
TI Novel compstatin family peptides inhibit complement activation by
   drusen-like deposits in human retinal pigmented epithelial cell cultures
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular degeneration; drusen; retinal pigmented epithelium; complement
   system; complement inhibitors; compstatin family peptides; molecular
   dynamics
ID MOLECULAR-DYNAMICS SIMULATIONS; MACULAR DEGENERATION; STRUCTURAL BASIS;
   C3 ACTIVATION; FORCE-FIELDS; AMINO-ACIDS; DRUG DESIGN; ANALOGS; PROTEIN;
   MODEL
AB We have used a novel human retinal pigmented epithelial (RPE) cell-based model that mimics drusen biogenesis and the pathobiology of age-related macular degeneration to evaluate the efficacy of newly designed peptide inhibitors of the complement system. The peptides belong to the compstatin family and, compared to existing compstatin analogs, have been optimized to promote binding to their target, complement protein C3, and to enhance solubility by improving their polarity/hydrophobicity ratios. Based on analysis of molecular dynamics simulation data of peptide C3 complexes, novel binding features were designed by introducing intermolecular salt bridge-forming arginines at the N-terminus and at position -1 of N-terminal dipeptide extensions. Our study demonstrates that the RPE cell assay has discriminatory capability for measuring the efficacy and potency of inhibitory peptides in a macular disease environment. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Gorham, Ronald D., Jr.; Lopez de Victoria, Aliana; Kieslich, Chris A.; Morikis, Dimitrios] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Forest, David L.; Banna, Christopher D.; Johnson, Lincoln V.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Tamamis, Phanourios; Archontis, Georgios] Univ Cyprus, Dept Phys, Nicosia, Cyprus.
   [Kraszni, Marta; Larive, Cynthia K.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.
   [Bellows-Peterson, Meghan L.; Floudas, Christodoulos A.] Princeton Univ, Dept Chem & Biol Engn, Princeton, NJ 08544 USA.
C3 University of California System; University of California Riverside;
   University of California System; University of California Santa Barbara;
   University of Cyprus; University of California System; University of
   California Riverside; Princeton University
RP Morikis, D (通讯作者)，Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
EM l_johnso@lifesci.ucsb.edu; dmorikis@ucr.edu
RI Larive, Cynthia K/E-4640-2012; Kraszni, Marta/Q-5315-2017; Morikis,
   Dimitrios/L-8527-2013
OI Kraszni, Marta/0000-0003-4364-9486; Morikis,
   Dimitrios/0000-0003-0083-4665; Gorham, Ronald/0000-0002-0261-6699;
   Kieslich, Chris/0000-0002-1845-6589; Larive,
   Cynthia/0000-0003-3458-0771; Tamamis, Phanourios/0000-0002-3342-2651
FU Beckman Initiative for Macular Research (BIMR) [1112]; Center for the
   Study of Macular Degeneration at UC Santa Barbara; NIH [R01-GM052032];
   University of Cyprus; Cyprus Research Promotion Foundation
   [INFRASTRUCTURE/STRA-TEGIC/0308/31]; European Regional Development fund;
   UCR Dissertation Year Fellowship Award; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [R01GM052032] Funding Source: NIH RePORTER
FX This work was funded by a grant from the Beckman Initiative for Macular
   Research (BIMR Grant 1112 to DM and LVJ), and by the generous
   benefactors of the Center for the Study of Macular Degeneration at UC
   Santa Barbara. CAF acknowledges support from NIH R01-GM052032. GA and PT
   acknowledge financial support from a University of Cyprus grant, and use
   of computational resources at the Biophysics clusters of the University
   of Cyprus and at an IBM cluster of the Cyprus Institute (financed by the
   Cyprus Research Promotion Foundation grant
   INFRASTRUCTURE/STRA-TEGIC/0308/31 that is co-funded by the European
   Regional Development fund). RDG acknowledges support from the UCR
   Dissertation Year Fellowship Award. DM, RDG, ALdV, and CAK thank David
   Lo for continuous help with the ELISA experiments.
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bellows ML, 2010, BIOPHYS J, V99, P3445, DOI 10.1016/j.bpj.2010.09.050
   Bellows ML, 2010, BIOPHYS J, V98, P2337, DOI 10.1016/j.bpj.2010.01.057
   Bellows-Peterson ML, 2012, J MED CHEM, V55, P4159, DOI 10.1021/jm201609k
   Berthod A, 2004, J CHROMATOGR A, V1037, P3, DOI 10.1016/j.chroma.2004.01.001
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Furlong ST, 2000, IMMUNOPHARMACOLOGY, V48, P199, DOI 10.1016/S0162-3109(00)00205-8
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Henchoz Y, 2009, ANAL BIOANAL CHEM, V394, P707, DOI 10.1007/s00216-009-2634-y
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Katragadda M, 2006, J MED CHEM, V49, P4616, DOI 10.1021/jm0603419
   Kieslich CA, 2012, CURR PHYS CHEM, V2, P324
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klepeis JL, 2004, IND ENG CHEM RES, V43, P3817, DOI 10.1021/ie0340995
   Klepeis JL, 2003, J AM CHEM SOC, V125, P8422, DOI 10.1021/ja034846p
   Krivov GG, 2009, PROTEINS, V77, P778, DOI 10.1002/prot.22488
   Lopez de Victoria A, 2011, CHEM BIOL DRUG DES, V77, P431, DOI 10.1111/j.1747-0285.2011.01111.x
   Macias AT, 2005, J COMPUT CHEM, V26, P1452, DOI 10.1002/jcc.20281
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Magotti P, 2009, J MOL RECOGNIT, V22, P495, DOI 10.1002/jmr.972
   Mallik B, 2005, J AM CHEM SOC, V127, P10967, DOI 10.1021/ja051004c
   Mallik B, 2005, J MED CHEM, V48, P274, DOI 10.1021/jm0495531
   Mallik B, 2003, PROTEINS, V53, P130, DOI 10.1002/prot.10491
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922
   Morikis D, 2005, LECT NOTES COMPUT SC, V3515, P680
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   Morikis D, 2004, BIOCHEM SOC T, V32, P28, DOI 10.1042/BST0320028
   Morikis D, 2002, BIOCHEM SOC T, V30, P1026, DOI 10.1042/BST0301026
   Morikis D, 2002, J BIOL CHEM, V277, P14942, DOI 10.1074/jbc.M200021200
   MORIKIS D, 2005, STRUCTURE DYNAMICS A
   Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003
   Qu H, 2009, MOL IMMUNOL, V47, P185, DOI 10.1016/j.molimm.2009.08.032
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sahu A, 1996, J IMMUNOL, V157, P884
   Sahu A, 2003, MOL IMMUNOL, V39, P557, DOI 10.1016/S0161-5890(02)00212-2
   Sahu A, 2000, J IMMUNOL, V165, P2491, DOI 10.4049/jimmunol.165.5.2491
   Song MK, 2005, BIOPHYS CHEM, V115, P201, DOI 10.1016/j.bpc.2004.12.039
   Soulika AM, 2003, J IMMUNOL, V171, P1881, DOI 10.4049/jimmunol.171.4.1881
   Tamamis P, 2007, J MOL GRAPH MODEL, V26, P571, DOI 10.1016/j.jmgm.2007.03.014
   Tamamis P, 2012, CHEM BIOL DRUG DES, V79, P703, DOI 10.1111/j.1747-0285.2012.01324.x
   Tamamis P, 2011, PROTEINS, V79, P3166, DOI 10.1002/prot.23149
   Tamamis P, 2010, PROTEINS, V78, P2655, DOI 10.1002/prot.22780
   Valko K, 2004, J CHROMATOGR A, V1037, P299, DOI 10.1016/j.chroma.2003.10.084
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yesselman JD, 2012, J COMPUT CHEM, V33, P189, DOI 10.1002/jcc.21963
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 57
TC 21
Z9 22
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2013
VL 116
BP 96
EP 108
DI 10.1016/j.exer.2013.07.023
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 259YP
UT WOS:000327562500013
PM 23954241
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chun, DW
   Heier, JS
   Raizman, MB
AF Chun, Dal W.
   Heier, Jeffrey S.
   Raizman, Michael B.
TI Visual prosthetic device for bilateral end-stage macular degeneration
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Article
DE AMD; macular degeneration; visual prosthesis
AB Age-related macular degeneration is the leading cause of blindness in the USA. For the 1.8 million patients in the most advanced stages, there are currently no available treatments to improve vision. A visual prosthetic device that provides one eye with an enlarged retinal image of the central visual field has been developed with the goal of improving central vision In patients with bilateral end-stage macular degeneration. The other eye is left unimplanted to provide peripheral vision. This device is designed for implantation in the posterior chamber of the eye during an outpatient surgical procedure. In US Food and Drug Administration clinical trials, 72% of patients experienced an improvement in their level of visual impairment (profound or severe, to severe or moderate). This was accompanied by a clinically significant improvement in quality of life.
C1 Tufts New England Eye Ctr, Ophthalm Consultants Boston, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Ophthalm Consultants Boston, Boston, MA 02114 USA.
   Tufts Univ, Sch Med, Ophthalm Consultants Boston, Boston, MA 02114 USA.
   New England Eye Ctr, Cornea & Cataract Serv, Boston, MA 02114 USA.
C3 Ophthalmic Consultants of Boston; Harvard University; Harvard Medical
   School; Ophthalmic Consultants of Boston; Ophthalmic Consultants of
   Boston; Tufts University
RP Chun, DW (通讯作者)，Tufts New England Eye Ctr, Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM chundak@yahoo.com
CR Adams E., 2003, OPTICAL DEVICES ADUL
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sunness JS, 1999, MOL VIS, V5
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 23
TC 4
Z9 4
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD NOV
PY 2005
VL 2
IS 6
BP 657
EP 665
DI 10.1586/17434440.2.6.657
PG 9
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 089YS
UT WOS:000240918400006
PM 16293092
DA 2022-11-30
ER

PT J
AU Trotta, MC
   Gesualdo, C
   Petrillo, F
   Lepre, CC
   Della Corte, A
   Cavasso, G
   Maggiore, G
   Hermenean, A
   Simonelli, F
   D'Amico, M
   Rossi, S
AF Trotta, Maria Consiglia
   Gesualdo, Carlo
   Petrillo, Francesco
   Lepre, Caterina Claudia
   Della Corte, Alberto
   Cavasso, Giancuomo
   Maggiore, Giulia
   Hermenean, Anca
   Simonelli, Francesca
   D'Amico, Michele
   Rossi, Settimio
TI Resolution of Inflammation in Retinal Disorders: Briefly the State
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinopathy; inflammation; pro-resolving mediators; lipoxins; resolvins;
   protectins; maresins; annexins; galectins
ID PIGMENT EPITHELIAL-CELLS; DOCOSAHEXAENOIC ACID; NEUROPROTECTIN D1;
   CHOROIDAL NEOVASCULARIZATION; FATTY-ACIDS; ANNEXIN; MECHANISMS;
   RESOLVINS; MODEL; GALECTIN-1
AB The most frequent retinal diseases, such as diabetic retinopathy, age-related macular degeneration and posterior uveitis, are underlined by oxidative stress or aging-induced retinal inflammation, which contributes to vision impairing or loss. Resolution of inflammation is emerging as a critical phase able to counteract the inflammatory process leading to the progression of retinal damage. Particularly, pro-resolving mediators (PMs) play a key role in the modulation of inflammatory exudates and could be considered a new target to be investigated in different inflammatory-autoimmune pathologies. Here, we highlight the most recent studies concerning the role of the main PMs (lipoxins, resolvins, prtectins, maresins and annexins) in retinal inflammation, in order to collect the best evidence in the field of inflammatory retinal damage resolution and to propose novel pharmacological approaches in the management of the most common retinal diseases.
C1 [Trotta, Maria Consiglia; Petrillo, Francesco; Lepre, Caterina Claudia; D'Amico, Michele] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Santa Maria Costantinopoli 16, I-80138 Naples, Italy.
   [Gesualdo, Carlo; Della Corte, Alberto; Cavasso, Giancuomo; Simonelli, Francesca; Rossi, Settimio] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Via Luigi Crecchio 6, I-80131 Naples, Italy.
   [Maggiore, Giulia] Univ Foggia, Dept Ophthalmol, Viale Luigi Pinto 1, I-71122 Foggia, Italy.
   [Hermenean, Anca] Vasile Goldis Western Univ Arad, Aurel Ardelean Inst Life Sci, 86 Revolutiei Av, Arad 310414, Romania.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; University of Foggia; Vasile Goldis Western University of
   Arad
RP Rossi, S (通讯作者)，Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, Via Luigi Crecchio 6, I-80131 Naples, Italy.
EM mariaconsiglia.trotta2@unicampania.it; carlo.gesualdo@unicampania.it;
   francesco.petrillo@unicampania.it; caterinac.lepre@gmail.com;
   albertodellacorte@live.it; giancuomo.cavasso@studenti.unicampania.it;
   giuliamaggiore@icloud.com; anca.hermenean@gmail.com;
   francesca.simonelli@unicampania.it; michele.damico@unicampania.it;
   settimio.rossi@unicampania.it
OI Hermenean, Anca/0000-0001-8510-6653; d'amico,
   michele/0000-0002-6899-0595; Trotta, Maria
   Consiglia/0000-0001-9813-5955; Petrillo, Francesco/0000-0003-0446-2846
FU ITALIAN MINISTRY OF EDUCATION; UNIVERSITY AND RESEARCH
   [PRIN-2017TSHBXZ]; CNCS/CCCDI-UEFISCDI [PN-III-P4-ID-PCE-2020-1772]
FX This research was funded by ITALIAN MINISTRY OF EDUCATION, UNIVERSITY
   AND RESEARCH, grant number PRIN-2017TSHBXZ and by ROMANIAN MINISTRY OF
   RESEARCH, INNOVATION AND DIGITIZATION, CNCS/CCCDI-UEFISCDI, project
   number PN-III-P4-ID-PCE-2020-1772, within PNCDI III.
CR Abdolmaleki F, 2020, CLIN REV ALLERG IMMU, V58, P82, DOI 10.1007/s12016-019-08754-9
   Al-Obaidi N, 2019, FASEB J, V33, P373, DOI 10.1096/fj.201800555RR
   Aleo D., 2015, U.S. Patent, Patent No. [20120010280A1, 20120010280]
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2016, ADV EXP MED BIOL, V854, P385, DOI 10.1007/978-3-319-17121-0_51
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Bogdanov P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097302
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988
   Canning P, 2007, EXP DIABETES RES, DOI 10.1155/2007/51837
   Caridi B, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.687495
   Chandrasekharan JA, 2015, J INFLAMM RES, V8, P181, DOI 10.2147/JIR.S90380
   Chiang N, 2019, J CLIN INVEST, V129, P5294, DOI 10.1172/JCI129448
   Christensen MV, 2018, INT J ONCOL, V52, P5, DOI 10.3892/ijo.2017.4197
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cooray Sadani N, 2013, Proc Natl Acad Sci U S A, V110, P18232, DOI 10.1073/pnas.1308253110
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dalli J, 2013, J IMMUNOL, V190, P6478, DOI 10.4049/jimmunol.1203000
   Davis BM, 2017, MITOCHONDRION, V36, P114, DOI 10.1016/j.mito.2017.05.010
   Galecto Biotech A.B., SYNEOS HLTH BIORASI
   Gardner PJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.10
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Gesualdo C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.718902
   Hansen TV, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01582
   Ji RR, 2011, TRENDS NEUROSCI, V34, P599, DOI 10.1016/j.tins.2011.08.005
   Qi-Hui J, 2013, CHINESE MED J-PEKING, V126, P2109, DOI 10.3760/cma.j.issn.0366-6999.20130217
   Kaviarasan K, 2015, METABOLISM, V64, P958, DOI 10.1016/j.metabol.2015.04.005
   Kohli P, 2009, BRIT J PHARMACOL, V158, P960, DOI 10.1111/j.1476-5381.2009.00290.x
   Li CR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00612
   Liclican EL, 2010, THESCIENTIFICWORLDJO, V10, P1029, DOI 10.1100/tsw.2010.99
   LIN HH, 1987, J PEDIATR-US, V111, P877, DOI 10.1016/S0022-3476(87)80210-X
   Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684
   Liu XJ, 2009, J PROTEOME RES, V8, P1255, DOI 10.1021/pr800850a
   Livne-Bar I, 2017, J CLIN INVEST, V127, P4403, DOI 10.1172/JCI77398
   Lopez-Vicario C, 2016, EUR J PHARMACOL, V785, P133, DOI 10.1016/j.ejphar.2015.03.092
   Lu ZY, 2019, BIOCHEM BIOPH RES CO, V516, P900, DOI 10.1016/j.bbrc.2019.06.137
   Maisto R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00235
   Marcheselli VL, 2010, PROSTAG LEUKOTR ESS, V82, P27, DOI 10.1016/j.plefa.2009.10.010
   Medeiros R, 2008, MOL PHARMACOL, V74, P154, DOI 10.1124/mol.108.046870
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Olsen MV, 2021, J CELL PHYSIOL, V236, P340, DOI 10.1002/jcp.29846
   Palacios-Pelaez R, 2010, MOL NEUROBIOL, V41, P367, DOI 10.1007/s12035-010-8139-z
   Rashid S, 2008, ARCH OPHTHALMOL-CHIC, V126, P219, DOI 10.1001/archophthalmol.2007.61
   Rossi S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/126408
   Rossi S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/149381
   Rostoker R, 2013, PROSTAG OTH LIPID M, V107, P85, DOI 10.1016/j.prostaglandins.2013.08.001
   Roy S, 2016, EXP EYE RES, V142, P71, DOI 10.1016/j.exer.2015.04.004
   Schoenberger SD, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/281981
   Serhan C.N., 2013, U.S. Patent, Patent No. [7759395B2, 7759395]
   Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197
   Seve P, 2017, AUTOIMMUN REV, V16, P1254, DOI 10.1016/j.autrev.2017.10.010
   Shaw LC, 2018, INVEST OPHTH VIS SCI, V59, P858, DOI 10.1167/iovs.17-23034
   Sheets KG, 2010, MOL VIS, V16, P320
   Slack RJ, 2021, INT J BIOCHEM CELL B, V130, DOI 10.1016/j.biocel.2020.105881
   Tang S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/2380319
   Tian H., 2008, INVESTIG OPHTHALMOL, V49, P5414
   Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146
   Trotta MC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126280
   Trotta MC, 2020, J CELL PHYSIOL, V235, P4256, DOI 10.1002/jcp.29303
   University of Edinburgh University of Oxford Latus Therapeutics, DEFINEEVALUATING THE
   Wang Meng, 2013, Zhonghua Yan Ke Za Zhi, V49, P642
   Weinstein JE, 2018, CURR OPIN OPHTHALMOL, V29, P267, DOI 10.1097/ICU.0000000000000466
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   Xi YF, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110591
   Xie TH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3390
   Xu H., 2022, FRONT OPHTHALMOL, V2, DOI [10.3389/fopht.2022.756689, DOI 10.3389/FOPHT.2022.756689]
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Zhao SH, 2010, CHINESE MED J-PEKING, V123, P713, DOI 10.3760/cma.j.issn.0366-6999.2010.06.014
   Zhao SH, 2009, MOL VIS, V15, P1231
   Zhou MW, 2018, INT J MOL MED, V42, P13, DOI 10.3892/ijmm.2018.3623
   Zhu MH, 2022, INFLAMMATION, V45, P414, DOI 10.1007/s10753-021-01555-3
NR 79
TC 2
Z9 2
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2022
VL 23
IS 9
AR 4501
DI 10.3390/ijms23094501
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 1F8LF
UT WOS:000795412800001
PM 35562891
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cleaver, N
   Ramirez, J
   Gildenberg, S
AF Cleaver, Nathan
   Ramirez, James
   Gildenberg, Stuart
TI Cutaneous Lupus Erythematosus in a Patient Undergoing Intravitreal
   Bevacizumab Injections: Case Report and Review of the Literature
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Review
AB Introduction: Bevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF). It is approved by the Food and Drug Administration (FDA) for metastatic colorectal cancer, advanced non-small cell lung cancer, metastatic renal cell cancer and glioblastoma. Bevacizumab has also been used off label in ophthalmology for age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and other chorioretinal vascular disorders. Numerous case reports have described various cutaneous reactions in response to bevacizumab therapy including acneiform eruptions and exfoliative dermatitis.
   Case Presentation: We report a case of a 63 year-old Caucasian female who presented with subacute cutaneous lupus erythematosus six weeks after initiating two intravitreal injections of bevacizumab for central serous choroidopathy.
   Conclusion: We report the first documented case of a cutaneous lupus erythematosus eruption following bevacizumab administration as a monotherapy.
C1 [Cleaver, Nathan; Gildenberg, Stuart] St Joseph Mercy Hosp, Dept Dermatol, Ann Arbor, MI 48104 USA.
   [Ramirez, James] St Joseph Mercy Hosp, Dept Dermatopathol, Ann Arbor, MI 48104 USA.
C3 Saint Joseph Mercy Health System (SJMHS); Saint Joseph Mercy Health
   System (SJMHS)
RP Cleaver, N (通讯作者)，St Joseph Mercy Hosp, Dept Dermatol, Ann Arbor, MI 48104 USA.
EM Nathan.cleaver@gmail.com
CR Amselem L, 2009, ACTA OPHTHALMOL, V87, P110, DOI 10.1111/j.1755-3768.2007.01154.x
   Fourcade S, 2011, ARCH DERMATOL, V147, P1227, DOI 10.1001/archdermatol.2011.311
   Genentech, AV PRESCR INF
   Gotlib V, 2006, ANTI-CANCER DRUG, V17, P1227, DOI 10.1097/01.cad.0000231481.07654.fc
   Gressett SM, 2009, ANN PHARMACOTHER, V43, P490, DOI 10.1345/aph.1L426
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Keenan BP, 2010, ARCH DERMATOL, V146, P577, DOI 10.1001/archdermatol.2010.68
   Ladas ID, 2009, CLIN OPHTHALMOL, V3, P129
   Nguyen A, 2009, J AM ACAD DERMATOL, V61, P921, DOI 10.1016/j.jaad.2009.05.052
   Saif MW, 2008, CLIN COLORECTAL CANC, V7, P144, DOI 10.3816/CCC.2008.n.020
   Srivastava M, 2003, ARCH DERMATOL, V139, P45, DOI 10.1001/archderm.139.1.45
   Sugrue MM, 2008, J CLIN ONCOL, V25, P4105
   Vano-Galvan S, 2009, J EUR ACAD DERMATOL, V23, P972, DOI 10.1111/j.1468-3083.2008.03078.x
   Vihinen Pia, 2011, J Med Case Rep, V5, P243, DOI 10.1186/1752-1947-5-243
   Wozel G, 2010, J DTSCH DERMATOL GES, V8, P243, DOI 10.1111/j.1610-0387.2009.07268.x
NR 16
TC 13
Z9 13
U1 2
U2 6
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD SEP
PY 2013
VL 12
IS 9
BP 1052
EP 1055
PG 4
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 297QS
UT WOS:000330270600015
PM 24002156
DA 2022-11-30
ER

PT J
AU Wu, YL
   Li, J
   Yao, K
AF Wu, Ya-lin
   Li, Jie
   Yao, Ke
TI Structures and biogenetic analysis of lipofuscin bis-retinoids
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Review
DE Age-related macular degeneration (AMD); Lipofuscin; Retinal pigment
   epithelial (RPE); Bis-retinoids; Structures; Biogenesis; Conversion
   relationships
ID RETINAL-PIGMENT EPITHELIUM; TRANSPORTER GENE ABCR; AGE-RELATED
   MACULOPATHY; LIGHT-INDUCED DAMAGE; CONE-ROD DYSTROPHY; MACULAR
   DEGENERATION; STARGARDT-DISEASE; FUNDUS FLAVIMACULATUS;
   RETINITIS-PIGMENTOSA; VISUAL CYCLE
AB Age-related macular degeneration (AMD) is still an incurable blinding eye disease because of complex pathogenic mechanisms and unusual diseased regions. With the use of chemical biology tools, great progress has been achieved in improving the understanding of AMD pathogenesis. The severity of AMD is, at least in part, linked to the non-degradable lipofuscin bis-retinoids in retinal pigment epithelial (RPE). This material is thought to result from the lifelong accumulation of lysosomal residual bodies containing the end products derived from the daily phagocytosis of rod outer segments by RPE cells. Here, we present previously recognized bis-retinoids with focus on structures and biosynthetic pathways. In addition to a brief discussion on the mutual conversion relationships of bis-retinoids, future perspectives and the medical relevance of such studies on these lipofuscin constituents are also highlighted.
C1 [Wu, Ya-lin; Li, Jie] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wu, Ya-lin; Yao, Ke] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Wu, YL (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM yalinw@zju.edu.cn
RI Yao, Ke/AAM-6866-2021
OI Li, Jie/0000-0001-5463-3995; Yao, Ke/0000-0002-6764-7365
FU National Natural Science Foundation of China [21202146, 81271018];
   Fundamental Research Funds for the Central Universities, China; Zhejiang
   Key Laboratory Fund of China [2011E10006]
FX Project supported by the National Natural Science Foundation of China
   (Nos. 21202146 and 81271018), the Fundamental Research Funds for the
   Central Universities, China, and the Zhejiang Key Laboratory Fund of
   China (No. 2011E10006)
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Broniec A, 2005, FREE RADICAL BIO MED, V38, P1037, DOI 10.1016/j.freeradbiomed.2004.12.023
   Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779
   Clancy CMR, 2000, J PHYS CHEM B, V104, P12098, DOI 10.1021/jp0030544
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Ducroq D, 2002, AM J HUM GENET, V71, P1480, DOI 10.1086/344829
   DUHAMEL L, 1991, TETRAHEDRON LETT, V32, P4495, DOI 10.1016/0040-4039(91)80021-W
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Feeney-Burns L, 1980, Curr Top Eye Res, V2, P119
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Fukui T, 2002, INVEST OPHTH VIS SCI, V43, P2819
   Gelasco A, 2000, BIOCHEMISTRY-US, V39, P4907, DOI 10.1021/bi992736i
   Gerber S, 1998, GENOMICS, V48, P139, DOI 10.1006/geno.1997.5164
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Isin B, 2006, PROTEINS, V65, P970, DOI 10.1002/prot.21158
   Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim SR, 2007, BIOCHEMISTRY-US, V46, P10122, DOI 10.1021/bi7009635
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liu J, 2011, J BIOL CHEM, V286, P27622, DOI 10.1074/jbc.M111.233312
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Mannich C., 1912, ARCH PHARM, V250, P647, DOI [DOI 10.1002/ARDP.19122500151, 10.1002/ardp.19122500151]
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mather BD, 2006, PROG POLYM SCI, V31, P487, DOI 10.1016/j.progpolymsci.2006.03.001
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Michael A., 1887, AM CHEM J, V9, P112
   Molday RS, 2006, ADV EXP MED BIOL, V572, P465
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rando RR, 1996, CHEM BIOL, V3, P255, DOI 10.1016/S1074-5521(96)90105-2
   Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414
   Rozet JM, 1999, J MED GENET, V36, P447
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SAKMAR TP, 1997, PROG NUCL ACID RES M, V59, P1, DOI DOI 10.1016/S0079-6603(08)61027-2]
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JR, 2010, METHODS MOL BIOL, V652, P315, DOI 10.1007/978-1-60327-325-1_18
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   THOMAS AF, 1976, HELV CHIM ACTA, V59, P2261, DOI 10.1002/hlca.19760590642
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wu YL, 2011, J AM CHEM SOC, V133, P849, DOI 10.1021/ja107195u
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
NR 78
TC 7
Z9 7
U1 0
U2 13
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD SEP
PY 2013
VL 14
IS 9
BP 763
EP 773
DI 10.1631/jzus.B1300051
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 231ZV
UT WOS:000325458100001
PM 24009196
OA Green Published
DA 2022-11-30
ER

PT J
AU Chen, P
   Pan, D
   Fan, CH
   Chen, JH
   Huang, K
   Wang, DF
   Zhang, HL
   Li, Y
   Feng, GY
   Liang, PJ
   He, L
   Shi, YY
AF Chen, Peng
   Pan, Dun
   Fan, Chunhai
   Chen, Jianhua
   Huang, Ke
   Wang, Dongfang
   Zhang, Honglu
   Li, You
   Feng, Guoyin
   Liang, Peiji
   He, Lin
   Shi, Yongyong
TI Gold nanoparticles for high-throughput genotyping of long-range
   haplotypes
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID DNA; POLYMORPHISM; DIAGNOSTICS; EFFICIENCY; HTRA1; MAP; PCR
AB Completion of the Human Genome Project(1) and the HapMap Project(2) has led to increasing demands for mapping complex traits in humans to understand the aetiology of diseases(3). Identifying variations in the DNA sequence, which affect how we develop disease and respond to pathogens and drugs, is important for this purpose, but it is difficult to identify these variations in large sample sets(3-5). Here we show that through a combination of capillary sequencing and polymerase chain reaction assisted by gold nanoparticles, it is possible to identify several DNA variations that are associated with age-related macular degeneration(6-8) and psoriasis(9) on significant regions of human genomic DNA. Our method is accurate and promising for large-scale and high-throughput genetic analysis of susceptibility towards disease and drug resistance(10-12).
C1 [Chen, Peng; Fan, Chunhai; Chen, Jianhua; Huang, Ke; Li, You; Feng, Guoyin; He, Lin; Shi, Yongyong] Shanghai Jiao Tong Univ, Bio X Inst, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
   [Pan, Dun; Fan, Chunhai; Wang, Dongfang; Zhang, Honglu] Chinese Acad Sci, Shanghai Inst Appl Phys, Phys Biol Lab, Shanghai 201800, Peoples R China.
   [Liang, Peiji] Shanghai Jiao Tong Univ, Sch Life Sci & Technol, Shanghai 200030, Peoples R China.
   [He, Lin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China.
   [He, Lin] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Shi, Yongyong] Changning Mental Hlth Ctr, Shanghai 200042, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Applied Physics, CAS; Shanghai Jiao Tong University;
   Chinese Academy of Sciences; Shanghai Institutes for Biological
   Sciences, CAS; Fudan University
RP Shi, YY (通讯作者)，Shanghai Jiao Tong Univ, Bio X Inst, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
EM fchh@sinap.ac.cn; shiyongyong@gmail.com
RI Zhang, Honglu/K-2275-2017; Chen, Peng/H-6539-2011; Fan,
   Chunhai/A-7569-2011; Chen, Jianhua/AAS-8417-2020; Zhang,
   Honglu/V-3403-2019; Chen, Peng/E-5546-2015; Shi, Yongyong/GSO-1627-2022
OI Zhang, Honglu/0000-0003-3930-6739; Fan, Chunhai/0000-0002-7171-7338;
   Zhang, Honglu/0000-0003-3930-6739; Chen, Peng/0000-0002-1422-4641; Shi,
   Yongyong/0000-0003-1710-1505; Wang, Dongfang/0000-0001-8112-3149
FU National 863 Program [2009AA022701]; National 973 Program [2010CB529602,
   2007CB936000, 2012CB932600]; Natural Science Foundation of China
   [20725516, 31000553, 90913014, 20902096]; Foundation for the Author of
   National Excellent Doctoral Dissertation of PR China [201026]; Program
   for New Century Excellent Talents in University [NCET-09-0550]; Shanghai
   Changning Health Bureau Program [2008406002]; Shanghai Municipal Health
   Bureau Program [2008095]; Shanghai Leading Academic Discipline Project
   [B205]; CAS [KJCX2-EW-N03]; Major ST Program [2009ZX10004-301]
FX This work was supported by the National 863 Program (2009AA022701), the
   National 973 Program (2010CB529602, 2007CB936000, 2012CB932600), the
   Natural Science Foundation of China (20725516, 31000553, 90913014,
   20902096), the Foundation for the Author of National Excellent Doctoral
   Dissertation of PR China (201026), the Program for New Century Excellent
   Talents in University (NCET-09-0550), the Shanghai Changning Health
   Bureau Program (2008406002), the Shanghai Municipal Health Bureau
   Program (2008095), the Shanghai Leading Academic Discipline Project
   (B205), CAS (KJCX2-EW-N03) and the Major S&T Program (2009ZX10004-301).
CR Beaudet AL, 2008, ANNU REV MED, V59, P113, DOI 10.1146/annurev.med.59.012907.101800
   Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580
   Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Douglas JA, 2001, NAT GENET, V28, P361, DOI 10.1038/ng582
   Fan HC, 2011, NAT BIOTECHNOL, V29, P51, DOI 10.1038/nbt.1739
   FOLSTEIN S, 1977, NATURE, V265, P726, DOI 10.1038/265726a0
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Herdt AR, 2006, COLLOID SURFACE B, V51, P130, DOI 10.1016/j.colsurfb.2006.06.006
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kitzman JO, 2011, NAT BIOTECHNOL, V29, P59, DOI 10.1038/nbt.1740
   Kwok PY, 2004, HUM MUTAT, V23, P442, DOI 10.1002/humu.20020
   Kwok PY, 2001, ANNU REV GENOM HUM G, V2, P235, DOI 10.1146/annurev.genom.2.1.235
   Levenstien MA, 2006, PLOS GENET, V2, P1156, DOI 10.1371/journal.pgen.0020127
   Li HK, 2005, ANGEW CHEM INT EDIT, V44, P5100, DOI 10.1002/anie.200500403
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni183
   Lu Y, 2007, ACCOUNTS CHEM RES, V40, P315, DOI 10.1021/ar600053g
   McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157
   Mi LJ, 2009, SMALL, V5, P2597, DOI 10.1002/smll.200901147
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Sharma J, 2009, SCIENCE, V323, P112, DOI 10.1126/science.1165831
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Tost J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf095
   Voelkerding KV, 2010, J MOL DIAGN, V12, P539, DOI 10.2353/jmoldx.2010.100043
   Xiao M, 2009, NAT METHODS, V6, P199, DOI [10.1038/nmeth.1301, 10.1038/NMETH.1301]
   Zhang XJ, 2009, NAT GENET, V41, P205, DOI 10.1038/ng.310
NR 30
TC 102
Z9 105
U1 1
U2 180
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD OCT
PY 2011
VL 6
IS 10
BP 639
EP 644
DI 10.1038/NNANO.2011.141
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA 833ZD
UT WOS:000295923800012
PM 21892166
DA 2022-11-30
ER

PT J
AU Clark, LN
   Haamer, E
   Mejia-Santana, H
   Harris, J
   Lesage, S
   Durr, A
   Janin, S
   Hedrich, K
   Louis, ED
   Cote, LJ
   Andrews, H
   Fahn, S
   Waters, C
   Ford, B
   Frucht, S
   Scott, W
   Klein, C
   Brice, A
   Roomere, H
   Ottman, R
   Marder, K
AF Clark, Lorraine N.
   Haamer, Eneli
   Mejia-Santana, Helen
   Harris, Juliette
   Lesage, Suzanne
   Durr, Alexandra
   Janin, Sabine
   Hedrich, Katja
   Louis, Elan D.
   Cote, Lucien J.
   Andrews, Howard
   Fahn, Stanley
   Waters, Cheryl
   Ford, Blair
   Frucht, Steven
   Scott, William
   Klein, Christine
   Brice, Alexis
   Roomere, Hanno
   Ottman, Ruth
   Marder, Karen
TI Construction and validation of a Parkinson's disease mutation genotyping
   array for the Parkin gene
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkin; Parkinson's disease; mutation; genotyping array; chip; genetic
   epidemiology
ID EARLY-ONSET PARKINSONISM; PRIMER EXTENSION; HETEROZYGOSITY; FAMILIES;
   FREQUENT; ALLELES; EUROPE; ORIGIN; CHIP
AB Parkin mutations account for the majority of familial and sporadic early onset Parkinson's disease (EOPD) cases with a known genetic association. More than 100 mutations have been described in the Parkin gene that includes homozygous, compound heterozygous, and single heterozygous mutations. We have designed a Parkin mutation genotyping array (gene chip) that includes published Parkin sequence variants and allows their simultaneous detection. The chip was validated by screening 85 PD cases and 47 controls previously tested for Parkin mutations. Similar genotyping microarrays have been developed for other genetically heterogeneous diseases including age-related macular degeneration. Here, we show the utility of a genotyping array for Parkinson's disease by analysis of 60 subjects from the Genetic Epidemiology of Parkinson Disease (GEPD) study that includes 15 early-onset PD case probands and 45 relatives. (C) 2007 Movement Disorder Society.
C1 Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA.
   Asper Biotech, Tartu, Estonia.
   Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Hop La Pitie Salpetriere, INSERM, U679, AP HP, Paris, France.
   Univ Paris 06, Fac Med, Paris, France.
   Univ Lubeck, Dept Neurol, Lubeck, Germany.
   Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   Hop La Pitie Salpetriere, Dept Genet Cytogenet & Embryol, AP HP, Paris, France.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   Columbia Univ, Dept Epidemiol Brain Disorders, New York State Psychiat Inst, New York, NY USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; UDICE-French Research Universities; Sorbonne
   Universite; Universite de Franche-Comte; University of Lubeck; Columbia
   University; Duke University; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research
   Universities; Sorbonne Universite; Columbia University; Columbia
   University; New York State Psychiatry Institute
RP Clark, LN (通讯作者)，Columbia Univ, Dept Pathol, Black Bldg BB513,650 W 168th St, New York, NY 10032 USA.
EM LC654@columbia.edu
RI brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; Klein,
   Christine/AGK-8003-2022; Ottman, Ruth/O-2371-2013
OI brice, alexis/0000-0002-0941-3990; Ottman, Ruth/0000-0001-7074-242X;
   Frucht, Steven/0000-0002-4653-0491; Scott, William/0000-0001-9336-6404;
   Klein, Christine/0000-0003-2102-3431; Scott, W.
   Norman/0000-0002-1051-9952
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
   [R56NS036630, R01NS032527, R01NS041723, R01NS036630] Funding Source: NIH
   RePORTER; NCRR NIH HHS [RR00645] Funding Source: Medline; NINDS NIH HHS
   [NS41723-01A1, NS36630, NS32527] Funding Source: Medline
CR Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567
   Bertoli-Avella AM, 2005, MOVEMENT DISORD, V20, P424, DOI 10.1002/mds.20343
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Clark LN, 2006, ARCH NEUROL-CHICAGO, V63, P548, DOI 10.1001/archneur.63.4.548
   Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172
   Foroud T, 2003, NEUROLOGY, V60, P796, DOI 10.1212/01.WNL.0000049470.00180.07
   HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503
   Hedrich K, 2004, MOVEMENT DISORD, V19, P1146, DOI 10.1002/mds.20234
   Hedrich K, 2005, MOVEMENT DISORD, V20, P1060, DOI 10.1002/mds.20512
   Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88
   Hedrich K, 2002, NEUROLOGY, V58, P1239, DOI 10.1212/WNL.58.8.1239
   Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Khan NL, 2005, MOVEMENT DISORD, V20, P479, DOI 10.1002/mds.20335
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   Kurg A, 2000, GENET TEST, V4, P1, DOI 10.1089/109065700316408
   LAWSON E, 2002, NATURE, V418, P544
   Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652
   Lincoln SJ, 2003, MOVEMENT DISORD, V18, P1306, DOI 10.1002/mds.10601
   Lohmann E, 2003, ANN NEUROL, V54, P176, DOI 10.1002/ana.10613
   Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103
   Lwin A, 2004, MOL GENET METAB, V81, P70, DOI 10.1016/j.ymgme.2003.11.004
   Marder K, 2003, ANN NEUROL, V54, P507, DOI 10.1002/ana.10711
   Marder K, 2003, NEUROLOGY, V61, P18, DOI 10.1212/01.WNL.0000074784.35961.C0
   Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524
   Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023
   Periquet M, 2003, BRAIN, V126, P1271, DOI 10.1093/brain/awg136
   Periquet M, 2001, AM J HUM GENET, V68, P617, DOI 10.1086/318791
   Pigullo S, 2004, PARKINSONISM RELAT D, V10, P357, DOI 10.1016/j.parkreldis.2004.04.012
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Poorkaj P, 2004, AM J MED GENET A, V129A, P44, DOI 10.1002/ajmg.a.30157
   Simonelli F, 2005, OPHTHALMIC RES, V37, P159, DOI 10.1159/000086073
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278
   Sun M, 2006, ARCH NEUROL-CHICAGO, V63, P826, DOI 10.1001/archneur.63.6.826
   Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525
   Wu RM, 2005, ARCH NEUROL-CHICAGO, V62, P82, DOI 10.1001/archneur.62.1.82
   Zernant J, 2005, INVEST OPHTH VIS SCI, V46, P3052, DOI 10.1167/iovs.05-0111
   Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005
NR 40
TC 13
Z9 13
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY 15
PY 2007
VL 22
IS 7
BP 932
EP 937
DI 10.1002/mds.21419
PG 6
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 174BU
UT WOS:000246917000004
PM 17415800
DA 2022-11-30
ER

PT J
AU Blick, SKA
   Keating, GM
   Wagstaff, AJ
AF Blick, Stephanie K. A.
   Keating, Gillian M.
   Wagstaff, Antona J.
TI Ranibizumab
SO DRUGS
LA English
DT Article
ID MACULAR DEGENERATION; ANGIOGENESIS; VERTEPORFIN; THERAPY
AB Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation.
   Well designed, phase III trials in patients with neo-vascular (wet) age-related macular degeneration (AMD) indicated that monthly intravitreal injections of ranibizurnab 0.3 or 0.5mg for up to 2 years maintained or improved visual acuity to a greater extent than sham injection, verteporfin photodynamic therapy or sham photodynamic therapy.
   In patients with predominantly classic wet AMD who received ranibizurnab in combination with verteporfin therapy, preliminary results indicate that combination therapy is superior to that of verteporfin therapy alone.
   Most serious ocular adverse events, which were uncommon, were associated with either the injection procedure or ranibizumab.
C1 Wolters Kluwer Hlth Adis, Auckland, New Zealand.
C3 Adis International
RP Blick, SKA (通讯作者)，Wolters Kluwer Hlth Adis, 41 Centorian Dr,Private Bag 65901,Mairangi Bay, Auckland, New Zealand.
EM demail@adis.co.nz
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN DM, ANN M ASS RES VIS OP
   BROWN DM, 2007, ANN M ASS RES VIS OP
   CHANG TS, 2006, ANN M ASS RES VIS OP
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haughney PC, 2005, INVEST OPHTH VIS SCI, P46
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2005, INVEST OPHTHALMOL VI
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   KOROTKIN A, 2006, ANN M ASS RES VIS OP
   Lalwani G, 2006, ANN M ASS RES VIS OP
   LOWE J, 2003, INVEST OPHTH VIS SCI, P44
   Melnikova I, 2005, NAT REV DRUG DISCOV, V4, P711, DOI 10.1038/nrd1827
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   ROSENFELD PJ, 2006, ANN M ASS RES VIS OP
   SCHMIDTERFURTH U, 2006, ASIAN J OPHTHALMO S1, V8, P176
   Sorbera LA, 2003, DRUG FUTURE, V28, P541, DOI 10.1358/dof.2003.028.06.738510
   *US FDA, RANB FULL PRESCR INF
   *US FDA, 2007, SAF AL DRUGS BIOL ME
NR 27
TC 44
Z9 48
U1 0
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PY 2007
VL 67
IS 8
BP 1199
EP 1206
DI 10.2165/00003495-200767080-00007
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 181JX
UT WOS:000247434100008
PM 17521219
DA 2022-11-30
ER

PT J
AU Singh, C
AF Singh, Charandeep
TI Metabolism and Vascular Retinopathies: Current Perspectives and Future
   Directions
SO DIAGNOSTICS
LA English
DT Review
DE metabolism; ROP; AMD; DR; HIF; mitochondria; retinal metabolism
ID ENDOTHELIAL-CELL METABOLISM; HYPOXIA-INDUCIBLE FACTOR; MULLER CELLS;
   QUANTITATIVE HISTOCHEMISTRY; DIABETIC-RETINOPATHY; PLASMA METABOLOMICS;
   DISEASE; GLUCOSE; RETINA; OXYGEN
AB The retina is one of the most metabolically active organs in the body. Although it is an extension of the brain, the metabolic needs of the retina and metabolic exchanges between the different cell types in the retina are not the same as that of the brain. Retinal photoreceptors convert most of the glucose into lactate via aerobic glycolysis which takes place in their cytosol, yet there are immense numbers of mitochondria in photoreceptors. The present article is a focused review of the metabolic dysregulation seen in retinopathies with underlying vascular abnormalities with aberrant mitochondrial metabolism and Hypoxia-inducible factor (HIF) dependent pathogenesis. Special emphasis has been paid to metabolic exchanges between different cell types in retinopathy of prematurity (ROP), age-related macular degeneration (AMD), and diabetic retinopathy (DR). Metabolic similarities between these proliferative retinopathies have been discussed.
C1 [Singh, Charandeep] Mass Gen Hosp, Liver Ctr, Div Gastroenterol, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts General Hospital
RP Singh, C (通讯作者)，Mass Gen Hosp, Liver Ctr, Div Gastroenterol, Boston, MA 02114 USA.
EM csingh3@mgh.harvard.edu
OI Singh, Charandeep/0000-0003-4015-0591
FU R21 grant from National Eye Institute [R21 EY033046 01]
FX My research is supported by R21 grant from National Eye Institute grant
   number R21 EY033046 01.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Akita T, 2003, LAB INVEST, V83, P65, DOI 10.1097/01.LAB.0000050761.67879.E4
   Atsuzawa K, 2010, HISTOCHEM CELL BIOL, V134, P565, DOI 10.1007/s00418-010-0752-4
   Bringmann A, 2001, FRONT BIOSCI-LANDMRK, V6, pE77, DOI 10.2741/Bringman
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De Bock K, 2013, CELL METAB, V18, P634, DOI 10.1016/j.cmet.2013.08.001
   DESCHAEPDRIJVER L, 1989, RES VET SCI, V47, P34
   Du JH, 2021, AMINO ACIDS, V53, P1789, DOI 10.1007/s00726-021-02981-1
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Duncan JL, 2005, BRIT J OPHTHALMOL, V89, P1549, DOI 10.1136/bjo.2005.077370
   Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Fligor CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32871-8
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Germer A, 1998, J NEUROCYTOL, V27, P329, DOI 10.1023/A:1006934724566
   GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   Hartnett ME, 2013, J AAPOS, V17, P229, DOI 10.1016/j.jaapos.2012.12.155
   Hartnett ME, 2012, NEW ENGL J MED, V367, P2515, DOI 10.1056/NEJMra1208129
   Heckel E, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.154174
   Hellstrom A, 2021, JAMA PEDIATR, V175, P359, DOI 10.1001/jamapediatrics.2020.5653
   Holoman NC, 2021, J NEUROSCI, V41, P3275, DOI 10.1523/JNEUROSCI.2010-20.2021
   Hoppe G, 2016, P NATL ACAD SCI USA, V113, pE2516, DOI 10.1073/pnas.1523005113
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003
   Hurley JB, 2021, ANNU REV VIS SCI, V7, P665, DOI 10.1146/annurev-vision-100419-115156
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Jr MAB, 2022, AM J OPHTHALMOL, V235, P154, DOI 10.1016/j.ajo.2021.09.021
   Kim B, 2017, EMBO J, V36, P2321, DOI 10.15252/embj.201796436
   Kim S, 2019, P NATL ACAD SCI USA, V116, P10824, DOI 10.1073/pnas.1901572116
   Kumar A, 2013, CRIT REV IMMUNOL, V33, P119, DOI 10.1615/CritRevImmunol.2013006618
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lofqvist CA, 2018, JAMA OPHTHALMOL, V136, P271, DOI 10.1001/jamaophthalmol.2017.6658
   LOWRY OH, 1961, J BIOL CHEM, V236, P2813
   LOWRY OH, 1956, J BIOL CHEM, V220, P879
   Madan A, 2003, FRONT BIOSCI-LANDMRK, V8, pD1030, DOI 10.2741/1056
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell SL, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10113141
   Mora-Ortiz M, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1548-8
   Narayanan SP, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.23
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Ostergaard JR, 2016, DEGENER NEUROL NEURO, V6, P73, DOI 10.2147/DNND.S111967
   PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428
   Paris LP, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-015-0877-5
   Patrick AT, 2020, J DIABETES METAB DIS, V19, P829, DOI 10.1007/s40200-020-00570-9
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Qi JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53433-6
   Sears JE, 2008, P NATL ACAD SCI USA, V105, P19898, DOI 10.1073/pnas.0805817105
   Singh C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070614
   Singh C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15066-6
   Singh C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129398
   Singh C, 2018, INVEST OPHTH VIS SCI, V59, P3440, DOI 10.1167/iovs.18-24120
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Smith LEH, 2008, INVEST OPHTH VIS SCI, V49, P5177, DOI 10.1167/iovs.08-2584
   Sumarriva K, 2019, INVEST OPHTH VIS SCI, V60, P3119, DOI 10.1167/iovs.19-27321
   Sun Y, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.757088
   Swarup A, 2019, AM J PHYSIOL-CELL PH, V316, pC121, DOI 10.1152/ajpcell.00410.2018
   Tojo Y, 2015, MOL CELL BIOL, V35, P2658, DOI 10.1128/MCB.00161-15
   Tomita Y, 2021, LIFE-BASEL, V11, DOI 10.3390/life11111119
   Tomita Y, 2021, DIABETOLOGIA, V64, P70, DOI 10.1007/s00125-020-05309-y
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Wong BW, 2017, EMBO J, V36, P2187, DOI 10.15252/embj.201696150
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Yamashita T, 2013, INT J BIOCHEM CELL B, V45, P1042, DOI 10.1016/j.biocel.2013.02.021
   Yan WJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66092-9
   Yun JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241365
   Zhou YD, 2021, INT J MED SCI, V18, P3581, DOI 10.7150/ijms.63603
   Zhou YD, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.9
   Zhu XR, 2019, NUTR METAB, V16, DOI 10.1186/s12986-019-0358-3
NR 83
TC 1
Z9 1
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD APR
PY 2022
VL 12
IS 4
AR 903
DI 10.3390/diagnostics12040903
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0Q9BP
UT WOS:000785204900001
PM 35453951
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Merkle, CW
   Augustin, M
   Harper, DJ
   Gesperger, J
   Lichtenegger, A
   Eugui, P
   Garhofer, G
   Glosmann, M
   Baumann, B
AF Merkle, Conrad W.
   Augustin, Marco
   Harper, Danielle J.
   Gesperger, Johanna
   Lichtenegger, Antonia
   Eugui, Pablo
   Garhofer, Gerhard
   Glosmann, Martin
   Baumann, Bernhard
TI High-resolution, depth-resolved vascular leakage measurements using
   contrast-enhanced, correlation-gated optical coherence tomography in
   mice
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
AB Vascular leakage plays a key role in vision-threatening retinal diseases such as diabetic retinopathy and age-related macular degeneration. Fluorescence angiography is the current gold standard for identification of leaky vasculature in vivo, however it lacks depth resolution, providing only 2D images that complicate precise identification and localization of pathological vessels. Optical coherence tomography (OCT) has been widely adopted for clinical ophthalmology due to its high, micron-scale resolution and rapid volumetric scanning capabilities. Nevertheless, OCT cannot currently identify leaky blood vessels. To address this need, we have developed a new method called exogenous contrast-enhanced leakage OCT (ExCEL-OCT) which identifies the diffusion of tracer particles around leaky vasculature following injection of a contrast agent. We apply this method to a mouse model of retinal neovascularization and demonstrate high-resolution 3D vascular leakage measurements in vivo for the first time.
C1 [Merkle, Conrad W.; Augustin, Marco; Harper, Danielle J.; Gesperger, Johanna; Lichtenegger, Antonia; Eugui, Pablo; Baumann, Bernhard] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Gesperger, Johanna] Med Univ Vienna, Div Neuropathol & Neurochem, Dept Neurol, Vienna, Austria.
   [Garhofer, Gerhard] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Glosmann, Martin] Univ Vet Med Vienna, Core Facil Res & Technol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; University of Veterinary Medicine Vienna
RP Merkle, CW (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
EM conrad.merkle@meduniwien.ac.at
RI Glösmann, Martin/F-9349-2019
OI Glösmann, Martin/0000-0002-2094-3247; Baumann,
   Bernhard/0000-0001-6419-1932; Merkle, Conrad/0000-0002-2465-4100; Eugui,
   Pablo/0000-0002-3007-2385; Harper, Danielle J./0000-0003-2768-3684
FU European Research Council [640396 OPTIMALZ]; Austrian Science Fund
   [P25823-B24]
FX European Research Council (640396 OPTIMALZ); Austrian Science Fund
   (P25823-B24).
CR Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011
   Augustin M., 2018, LNCS
   Augustin M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164419
   Avila FJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46568-z
   Bernucci MT, 2018, BIOMED OPT EXPRESS, V9, P1020, DOI 10.1364/BOE.9.001020
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cunha-Vaz J, 2016, INVEST OPHTH VIS SCI, V57, P6776, DOI 10.1167/iovs.16-19999
   CUNHAVAZ J, 1979, SURV OPHTHALMOL, V23, P279, DOI 10.1016/0039-6257(79)90158-9
   de la Zerda A, 2015, CLIN EXP OPHTHALMOL, V43, P358, DOI 10.1111/ceo.12299
   Fanea L, 2012, MOL VIS, V18, P2538
   Fialova S, 2016, BIOMED OPT EXPRESS, V7, P1479, DOI 10.1364/BOE.7.001479
   Hagag Ahmed M, 2017, Taiwan J Ophthalmol, V7, P115, DOI 10.4103/tjo.tjo_31_17
   Harper DJ, 2020, NEUROPHOTONICS, V7, DOI 10.1117/1.NPh.7.1.015006
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heye AK, 2014, NEUROIMAGE-CLIN, V6, P262, DOI 10.1016/j.nicl.2014.09.002
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   International Diabetes Federation, 2015, IDF DIABETES ATLAS 7
   Kim WH, 2015, OPT LETT, V40, P1426, DOI 10.1364/OL.40.001426
   Kodach VM, 2011, OPT EXPRESS, V19, P6131, DOI 10.1364/OE.19.006131
   Kollias AN, 2010, DTSCH ARZTEBL INT, V107, P75, DOI 10.3238/arztebl.2010.0075
   Lee J, 2012, OPT EXPRESS, V20, P22262, DOI 10.1364/OE.20.022262
   Lee J, 2011, OPT EXPRESS, V19, P21258, DOI 10.1364/OE.19.021258
   Lee TM, 2003, OPT LETT, V28, P1546, DOI 10.1364/OL.28.001546
   Liba O, 2016, SCI REP-UK, V6, DOI 10.1038/srep23337
   Liu L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16293-6
   Merkle C. W., 2019, PROC SPIE, V10858
   Merkle CW, 2020, OPT LETT, V45, P2359, DOI 10.1364/OL.380051
   Merkle CW, 2019, NEUROIMAGE, V202, DOI 10.1016/j.neuroimage.2019.116067
   Merkle CW, 2016, BIOMED OPT EXPRESS, V7, P4289, DOI 10.1364/BOE.7.004289
   Merkle CW, 2016, NEUROIMAGE, V125, P350, DOI 10.1016/j.neuroimage.2015.10.017
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oldenburg AL, 2008, OPT EXPRESS, V16, P11525, DOI 10.1364/OE.16.011525
   Palczewska G, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121555
   Pan YT, 2014, NEUROIMAGE, V103, P492, DOI 10.1016/j.neuroimage.2014.08.051
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Rao KD, 2003, OPT LETT, V28, P340, DOI 10.1364/OL.28.000340
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Shih YYI, 2012, RADIOLOGY, V264, P234, DOI 10.1148/radiol.12112033
   Si P, 2020, NANO LETT, V20, P101, DOI 10.1021/acs.nanolett.9b03344
   Song W., 2018, J VISUALIZED EXP, V138
   Song WY, 2019, BIOMED OPT EXPRESS, V10, P4907, DOI 10.1364/BOE.10.004907
   Srinivasan VJ, 2012, BIOMED OPT EXPRESS, V3, P612, DOI 10.1364/BOE.3.000612
   Srinivasan VJ, 2010, OPT LETT, V35, P43, DOI 10.1364/OL.35.000043
   Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752
   Winkelmann JA, 2019, LIGHT-SCI APPL, V8, DOI 10.1038/s41377-018-0117-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu CY, 2004, OPT LETT, V29, P1647, DOI 10.1364/OL.29.001647
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
   Zhang J, 2017, J BIOPHOTONICS, V10, P878, DOI 10.1002/jbio.201600047
   Zhu J, 2020, J BIOPHOTONICS, V13, DOI 10.1002/jbio.202000090
NR 55
TC 0
Z9 0
U1 4
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD APR 1
PY 2021
VL 12
IS 4
BP 1774
EP 1791
DI 10.1364/BOE.415227
PG 18
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA RI8YG
UT WOS:000637192000001
PM 33996197
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Xue, J
   Yan, S
   Wang, Y
   Liu, TT
   Qi, F
   Zhang, HY
   Qiu, CG
   Qu, JH
   Liu, XY
   Li, DW
AF Xue, Jie
   Yan, Shuo
   Wang, Yuan
   Liu, Tingting
   Qi, Feng
   Zhang, Hongyan
   Qiu, Chenggong
   Qu, Jianhua
   Liu, Xiyu
   Li, Dengwang
TI Unsupervised Segmentation of Choroidal Neovascularization for Optical
   Coherence Tomography Angiography by Grid Tissue-Like Membrane Systems
SO IEEE ACCESS
LA English
DT Article
DE GTM systems; unsupervised segmentation; choroidal neovascularization;
   OCTA
ID P SYSTEMS; OCT ANGIOGRAPHY; ALGORITHM; POWER
AB Accurate segmentation of choroidal neovascularization (CNV) patterns is vital for precise lesion size quantification in age-related macular degeneration. In this paper, we develop a method for unsupervised and parallel segmentation of CNV in optical coherence tomography based on a grid tissuelike membrane (GTM) system. A GTM system incorporates a modified Clustering In QUEst (CLIQUE) algorithm into tissue-like membrane systems. Exploiting CLIQUE's aptitude for unsupervised clustering, GTM systems can detect CNV of different shapes, positions and density without the need of a training stage. The average dice ratio is 0.84 +/- 0.04, outperforms both baseline and the state-of-the-art methods. Besides, being a parallel computational paradigm, GTM systems can handle all scans under analysis simultaneously and therefore they are less time consuming, completing CNV detection on 48 scans in 0.56 seconds.
C1 [Xue, Jie; Yan, Shuo; Wang, Yuan; Qi, Feng; Zhang, Hongyan; Qiu, Chenggong; Qu, Jianhua; Liu, Xiyu] Shandong Normal Univ, Business Sch, Jinan 250014, Peoples R China.
   [Liu, Tingting] Shandong Acad Med Sci, Shandong Eye Hosp, Shandong Eye Inst, Jinan 250014, Peoples R China.
   [Li, Dengwang] Shandong Normal Univ, Shandong Prov Engn & Tech Ctr Light Manipulat, Sch Phys & Elect, Shandong Key Lab Med Phys & Image Proc, Jinan 250014, Peoples R China.
C3 Shandong Normal University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; University of Jinan; Shandong Normal
   University
RP Qu, JH; Liu, XY (通讯作者)，Shandong Normal Univ, Business Sch, Jinan 250014, Peoples R China.; Li, DW (通讯作者)，Shandong Normal Univ, Shandong Prov Engn & Tech Ctr Light Manipulat, Sch Phys & Elect, Shandong Key Lab Med Phys & Image Proc, Jinan 250014, Peoples R China.
EM qjh@sdnu.edu.cn; xyliu@sdnu.edu.cn; lidengwang@sdnu.edu.cn
RI liu, ting/GZM-3326-2022; Xue, Jie/ABC-2905-2021
OI Xue, Jie/0000-0002-4952-5583
FU National Natural Science Foundation of China [61802234, 61876101,
   61971271]; Natural Science Foundation of Shandong Province
   [ZR2019QF007]; China Postdoctoral Project [2017M612339]; Natural Science
   Foundation for Distinguished Young Scholars of Shandong Province
   [JQ201516]; Taishan Scholars Project of Shandong Province, Primary
   Research and Development Plan of Shandong Province [2018GGX101018]
FX This work was supported in part by the National Natural Science
   Foundation of China under Grant 61802234, Grant 61876101, and Grant
   61971271, in part by the Natural Science Foundation of Shandong Province
   under Grant ZR2019QF007, in part by the China Postdoctoral Project under
   Grant 2017M612339, in part by the Natural Science Foundation for
   Distinguished Young Scholars of Shandong Province under Grant JQ201516,
   and in part by the Taishan Scholars Project of Shandong Province,
   Primary Research and Development Plan of Shandong Province, under Grant
   2018GGX101018.
CR Barros A., 2018, VIS PAN AM PANAMER J, V17, P31
   Campos M, 2019, MBIO, V10, DOI 10.1128/mBio.02460-18
   Christinal HA, 2009, LECT NOTES COMPUT SC, V5856, P169, DOI 10.1007/978-3-642-10268-4_20
   Diaz-Pernil D, 2019, J MEMBRANE COMPUT, V1, P58, DOI 10.1007/s41965-018-00002-x
   Huang L, 2011, INFORM SCIENCES, V181, P2370, DOI 10.1016/j.ins.2010.12.015
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain AK, 1999, ACM COMPUT SURV, V31, P264, DOI 10.1145/331499.331504
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jie X., 2016, J COMPUT THEOR NANOS, V13, P3895
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Liu XY, 2017, NEURAL PROCESS LETT, V46, P171, DOI 10.1007/s11063-016-9577-z
   Martin-Vide C, 2003, THEOR COMPUT SCI, V296, P295, DOI 10.1016/S0304-3975(02)00659-X
   Orellana-Martin D, 2019, THEOR COMPUT SCI, V777, P443, DOI 10.1016/j.tcs.2018.12.024
   Paun G, 2000, J COMPUT SYST SCI, V61, P108, DOI 10.1006/jcss.1999.1693
   Peng H, 2018, IEEE T SMART GRID, V9, P4777, DOI 10.1109/TSG.2017.2670602
   Peng H, 2017, KNOWL-BASED SYST, V125, P74, DOI 10.1016/j.knosys.2017.03.024
   Prabhakar S, 1998, PROC INT CONF DATA, P94, DOI 10.1109/ICDE.1998.655763
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Subramanian KG, 2018, EMERGENCE COMPLEX CO, V30, P333, DOI 10.1007/978-3-319-73216-9_16
   Xie M, 2019, ENERGIES, V12, DOI 10.3390/en12030486
   Xue J, 2019, KNOWL-BASED SYST, V183, DOI 10.1016/j.knosys.2019.104887
   Xue J, 2018, BIOMED OPT EXPRESS, V9, P3208, DOI 10.1364/BOE.9.003208
   Xue J, 2014, SOFT COMPUT, V18, P1425, DOI 10.1007/s00500-013-1155-y
   Yu CY, 2018, J PARALLEL DISTR COM, V111, P136, DOI 10.1016/j.jpdc.2017.08.005
   Zhang GX, 2013, APPL SOFT COMPUT, V13, P1528, DOI 10.1016/j.asoc.2012.05.032
   Zhang HY, 2011, BIOSYSTEMS, V105, P73, DOI 10.1016/j.biosystems.2011.03.004
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhang XY, 2014, INFORM SCIENCES, V278, P285, DOI 10.1016/j.ins.2014.03.053
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
NR 32
TC 3
Z9 4
U1 2
U2 10
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2019
VL 7
BP 143058
EP 143066
DI 10.1109/ACCESS.2019.2943186
PG 9
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Telecommunications
GA VJ6TW
UT WOS:000617355800001
OA gold
DA 2022-11-30
ER

PT J
AU Peet, DJ
   Kittipassorn, T
   Wood, JP
   Chidlow, G
   Casson, RJ
AF Peet, D. J.
   Kittipassorn, T.
   Wood, J. P.
   Chidlow, G.
   Casson, R. J.
TI HIF signalling: The eyes have it
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Hypoxia; Hypoxia inducible factors; Oxygen; Eye; Retina; Ischemia;
   Vasculature; Vascular endothelial growth factor
ID HYPOXIA-INDUCIBLE FACTOR-1; RETINAL MULLER CELLS; PAS DOMAIN PROTEIN;
   TRANSCRIPTIONAL REGULATION; NEGATIVE REGULATOR; FACTOR-I; OXYGEN;
   ISCHEMIA; RETINOPATHY; METABOLISM
AB The hypoxia inducible factors (HIFs) promote changes in gene expression in response to hypoxia, and mediate key physiological responses such as angiogenesis. They play important roles in development and normal physiology, as well as in ischaemic and other pathologies. The human eye is a complex organ, with tight regulation of vascularisation and oxygen delivery, with the highly specialised retina containing both highly vascularised and avascular regions. This review, written to honour the significant contribution of Lorenz Poellinger to this field, covers the role of the HIFs in normal development of the eye, specifically the vasculature, as well as their roles in numerous retinal pathologies, including ischaemic retinopathies, and age-related macular degeneration (AMD). The characterisation of the HIFs in the eye has improved our understanding of the development, function, and numerous pathologies of the eye, and should inform future therapeutic approaches.
C1 [Peet, D. J.; Kittipassorn, T.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia.
   [Kittipassorn, T.] Mahidol Univ, Dept Physiol, Fac Med, Siriraj Hosp, Bangkok, Thailand.
   [Wood, J. P.; Chidlow, G.; Casson, R. J.] Univ Adelaide, South Australian Inst Ophthalmol, Adelaide, SA, Australia.
C3 University of Adelaide; Mahidol University; University of Adelaide
RP Peet, DJ (通讯作者)，Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia.
EM daniel.peet@adelaide.edu.au
RI Peet, Daniel/AAE-6698-2020
OI Peet, Daniel/0000-0002-6085-8936; Kittipassorn,
   Thaksaon/0000-0001-9854-2905
FU National Health and Medical Research Council of Australia [1099932];
   Ophthalmic Research Institute of Australia
FX This review was written in memory of Lorenz Poellinger, a close
   colleague and collaborator, who made a major contribution to this field
   and will be sadly missed. Supported by National Health and Medical
   Research Council of Australia grant 1099932 and the Ophthalmic Research
   Institute of Australia. The authors declare they have no conflicts of
   interest.
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   ANDERSON B, 1964, ARCH OPHTHALMOL-CHIC, V72, P792
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Casson RJ, 2004, BRIT J OPHTHALMOL, V88, P816, DOI 10.1136/bjo.2003.024661
   Casson RJ, 2004, ARCH OPHTHALMOL-CHIC, V122, P361, DOI 10.1001/archopht.122.3.361
   Chan MC, 2016, MOL ASPECTS MED, V47-48, P54, DOI 10.1016/j.mam.2016.01.001
   Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999
   Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Hartnett M. E., 2016, SURV OPHTHALMOL
   HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P818, DOI 10.1136/bjo.64.11.818
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   LANDERS MB, 1982, RETINA-J RET VIT DIS, V2, P167, DOI 10.1097/00006982-198200230-00007
   Lin M, 2011, DIABETOLOGIA, V54, P1554, DOI 10.1007/s00125-011-2081-0
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lindsay KJ, 2014, P NATL ACAD SCI USA, V111, P15579, DOI 10.1073/pnas.1412441111
   Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200
   Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423
   Maynard MA, 2005, FASEB J, V19, P1396, DOI 10.1096/fj.05-3788com
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Ng SK, 2015, CLIN EXP OPHTHALMOL, V43, P367, DOI 10.1111/ceo.12462
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Wind F., 1930, METABOLISM TUMORS IN
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
NR 44
TC 14
Z9 15
U1 0
U2 15
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUL 15
PY 2017
VL 356
IS 2
SI SI
BP 136
EP 140
DI 10.1016/j.yexcr.2017.03.030
PG 5
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EY9KX
UT WOS:000404318600005
PM 28315667
DA 2022-11-30
ER

PT J
AU Basavarajappa, HD
   Sulaiman, RS
   Qi, XP
   Shetty, T
   Babu, SSP
   Sishtla, KL
   Lee, B
   Quigley, J
   Alkhairy, S
   Briggs, CM
   Gupta, K
   Tang, B
   Shadmand, M
   Grant, MB
   Boulton, ME
   Seo, SY
   Corson, TW
AF Basavarajappa, Halesha D.
   Sulaiman, Rania S.
   Qi, Xiaoping
   Shetty, Trupti
   Babu, Sardar Sheik Pran
   Sishtla, Kamakshi L.
   Lee, Bit
   Quigley, Judith
   Alkhairy, Sameerah
   Briggs, Christian M.
   Gupta, Kamna
   Tang, Buyun
   Shadmand, Mehdi
   Grant, Maria B.
   Boulton, Michael E.
   Seo, Seung-Yong
   Corson, Timothy W.
TI Ferrochelatase is a therapeutic target for ocular neovascularization
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; angiogenesis; ferrochelatase;
   griseofulvin; heme synthesis
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION;
   GENE-EXPRESSION; ERYTHROPOIETIC PROTOPORPHYRIA; BIOLOGICAL EVALUATION;
   MACULAR DEGENERATION; BINDING-PROTEINS; NITRIC-OXIDE; GRISEOFULVIN;
   HOMOISOFLAVANONE
AB Ocular neovascularization underlies major blinding eye diseases such as "wet" age-related macular degeneration (AMD). Despite the successes of treatments targeting the vascular endothelial growth factor (VEGF) pathway, resistant and refractory patient populations necessitate discovery of new therapeutic targets. Using a forward chemical genetic approach, we identified the heme synthesis enzyme ferrochelatase (FECH) as necessary for angiogenesis in vitro and in vivo. FECH is overexpressed in wet AMD eyes and murine choroidal neovascularization; siRNA knockdown of Fech or partial loss of enzymatic function in the Fech(m1Pas) mouse model reduces choroidal neovascularization. FECH depletion modulates endothelial nitric oxide synthase function and VEGF receptor 2 levels. FECH is inhibited by the oral antifungal drug griseofulvin, and this compound ameliorates choroidal neovascularization in mice when delivered intravitreally or orally. Thus, FECH inhibition could be used therapeutically to block ocular neovascularization.
C1 [Basavarajappa, Halesha D.; Sulaiman, Rania S.; Qi, Xiaoping; Shetty, Trupti; Babu, Sardar Sheik Pran; Sishtla, Kamakshi L.; Quigley, Judith; Alkhairy, Sameerah; Briggs, Christian M.; Gupta, Kamna; Shadmand, Mehdi; Grant, Maria B.; Boulton, Michael E.; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Sulaiman, Rania S.; Qi, Xiaoping; Shetty, Trupti; Babu, Sardar Sheik Pran; Sishtla, Kamakshi L.; Quigley, Judith; Alkhairy, Sameerah; Briggs, Christian M.; Gupta, Kamna; Shadmand, Mehdi; Grant, Maria B.; Boulton, Michael E.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Tang, Buyun; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.; Shetty, Trupti; Grant, Maria B.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.] Cairo Univ, Fac Pharm, Dept Biochem, Cairo, Egypt.
   [Lee, Bit; Seo, Seung-Yong] Gachon Univ, Coll Pharm, Incheon, South Korea.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Egyptian Knowledge Bank (EKB); Cairo
   University; Gachon University
RP Corson, TW (通讯作者)，Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
EM tcorson@iu.edu
RI Pasha, Pran Babu Sardar/AAH-8388-2019; PASHA, PRAN BABU
   SARDAR/AAS-7266-2020; Basavarajappa, Halesha Dhurvigere/V-2038-2019;
   Corson, Timothy W./B-6851-2009
OI PASHA, PRAN BABU SARDAR/0000-0001-8974-7562; Basavarajappa, Halesha
   Dhurvigere/0000-0002-2840-5937; Corson, Timothy W./0000-0002-1402-7875
FU International Retinal Research Foundation; Retina Research Foundation;
   Carl Marshall & Mildred Almen Reeves Foundation, Inc.; Ralph W. and
   Grace M. Showalter Research Trust Fund; NIH/NCATS [KL2TR001106,
   UL1TR001108]; NIH/NEI [R01EY025641]; Ausich Graduate Scholarship from
   Kemin Health; Basic Science Research Program through National Research
   Foundation of Korea (NRF) - Ministry of Education
   [NRF-2013R1A1A2007151]; Pioneer Research Center Program through NRF -
   Ministry of Science, ICT & Future Planning [2014M3C1A3001556]; Research
   to Prevent Blindness, Inc.;  [R01EY012601];  [R01EY007739]; 
   [R01HL110170];  [R01DK090730];  [R01EY025383];  [R01EY018358];  [JDRF
   2-SRA-2014-146-Q-R]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001108, KL2TR001106] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY025383, R01EY012601, R01EY007739,
   R01EY025641, R01EY018358] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [T35HL110854, R01HL110170] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK090730] Funding Source: NIH RePORTER
FX We thank Michael Sturek for the porcine brain and Harry Dailey for the
   FECH expression plasmid and protein production advice. This work was
   supported by grants from the International Retinal Research Foundation,
   the Retina Research Foundation, the Carl Marshall & Mildred Almen Reeves
   Foundation, Inc., the Ralph W. and Grace M. Showalter Research Trust
   Fund, NIH/NCATS KL2TR001106 and UL1TR001108, and NIH/NEI R01EY025641
   (T.W.C.); the Ausich Graduate Scholarship from Kemin Health (H.D.B.);
   R01EY012601, R01EY007739, R01HL110170, R01DK090730, and R01EY025383
   (M.B.G.); R01EY025383, R01EY018358, and JDRF 2-SRA-2014-146-Q-R
   (M.E.B.); the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF-2013R1A1A2007151) and the Pioneer Research Center Program through
   the NRF funded by the Ministry of Science, ICT & Future Planning
   (2014M3C1A3001556) (S.-Y.S.); and an unrestricted grant from Research to
   Prevent Blindness, Inc. (T.W.C., M.B.G., and M.E.B.).
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   Basavarajappa HD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095694
   BORGERS M, 1980, REV INFECT DIS, V2, P520
   BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242
   BRADY AM, 1992, ARCH TOXICOL, V66, P175, DOI 10.1007/BF01974011
   COLE SPC, 1984, MOL CELL BIOCHEM, V64, P127
   Corson TW, 2011, CHEMBIOCHEM, V12, P1767, DOI 10.1002/cbic.201100007
   DAILEY HA, 1994, J BIOL CHEM, V269, P390
   Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316
   Elewski Boni, 2005, Ther Clin Risk Manag, V1, P299
   EPSTEIN WL, 1972, ARCH DERMATOL, V106, P344, DOI 10.1001/archderm.106.3.344
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532
   Grover C, 2012, INT J DERMATOL, V51, P455, DOI 10.1111/j.1365-4632.2011.05341.x
   Gupta V, 2013, MOL PHARMACOL, V84, P824, DOI 10.1124/mol.113.087940
   Hamza I, 2012, BBA-MOL CELL RES, V1823, P1617, DOI 10.1016/j.bbamcr.2012.04.009
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   HOLLEY A, 1990, J BIOCHEM TOXICOL, V5, P175, DOI 10.1002/jbt.2570050307
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kim JH, 2008, MOL VIS, V14, P556
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lecha M, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-19
   Lee B, 2016, BIOORG MED CHEM LETT, V26, P4277, DOI 10.1016/j.bmcl.2016.07.043
   Lee B, 2014, ORG BIOMOL CHEM, V12, P7673, DOI 10.1039/c4ob01604a
   Liu K, 2015, BIOCHEM PHARMACOL, V98, P493, DOI 10.1016/j.bcp.2015.09.002
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOCHHEAD AC, 1967, BRIT J DERMATOL, V79, P96, DOI 10.1111/j.1365-2133.1967.tb11463.x
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martinez MDC, 2009, CELL MOL BIOL, V55, P127, DOI 10.1170/T862
   Mense SM, 2006, CELL RES, V16, P681, DOI 10.1038/sj.cr.7310086
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   Niphakis MJ, 2015, CELL, V161, P1668, DOI 10.1016/j.cell.2015.05.045
   Park J, 2016, ACS CHEM BIOL, V11, P44, DOI 10.1021/acschembio.5b00671
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Petersen AB, 2014, CHEM REV, V114, P12088, DOI 10.1021/cr400368e
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Rathel Thomas R., 2003, Biol Proced Online, V5, P136, DOI 10.1251/bpo55
   Rezzola S, 2013, EXP EYE RES, V112, P51, DOI 10.1016/j.exer.2013.04.014
   Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009
   Savitski MM, 2014, SCIENCE, V346, P55, DOI 10.1126/science.1255784
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P1311
   Tsuboi H, 2007, J DERMATOL, V34, P790, DOI 10.1111/j.1346-8138.2007.00386.x
   TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858
   TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491
   Wenzel Andrea A, 2015, Mol Vis, V21, P515
   Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841
NR 57
TC 27
Z9 28
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD JUN
PY 2017
VL 9
IS 6
BP 786
EP 801
DI 10.15252/emmm.201606561
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EW5EC
UT WOS:000402527000006
PM 28377496
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Whitehead, AJ
   Mares, JA
   Danis, RP
AF Whitehead, A. Jeffrey
   Mares, Julie A.
   Danis, Ronald P.
TI Macular pigment - A review of current knowledge
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Review
ID AGE-RELATED MACULOPATHY; LONGITUDINAL CHROMATIC ABERRATION; SERUM
   CONCENTRATIONS; OPTICAL-DENSITY; SINGLET OXYGEN; NUTRITIONAL
   MANIPULATION; LUTEIN SUPPLEMENTATION; TISSUE CONCENTRATIONS;
   EPITHELIAL-CELLS; PRIMATE RETINAS
AB The existence of the macula lutea of the human retina has been known for more than 200 years. It is established that the xanthophylls lutein and zeaxanthin are responsible for the yellow color. The effect of macular photopigments on blue-light filtration and color perception is well established. It has been postulated that the pigment might serve to reduce chromatic aberration and to improve visual acuity. The antioxidant capabilities of these xanthophylls combined with their ability to trap short-wavelength light may serve to protect the outer retina, retinal pigment epithelium, and choriocapillaris from oxidative damage. Current ideas on the pathophysiology of age-related macular degeneration may be compatible with the proposed function of lutein and zeaxanthin. This review will summarize our knowledge about macular pigment regarding current efforts in research and the epidemiology of age-related eye disease.
C1 Univ Wisconsin, Dept Ophthalmol, Fundus Photo Reading Ctr, Madison, WI 53711 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Danis, RP (通讯作者)，Univ Wisconsin, Dept Ophthalmol, Fundus Photo Reading Ctr, Pk West 1,Suite 400,406 Sci Dr, Madison, WI 53711 USA.
EM danis@rc.ophth.wisc.edu
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Barker F. M., 1991, DIRECT SPECTRAL TRAN
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   BONE RA, 2001, INVEST OPHTH VIS SCI, V42, P548
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   BROWN PK, 1963, NATURE, V200, P37, DOI 10.1038/200037a0
   Buzzi F., 1782, OPUSCOLI SCELTI SCI, V5, P87
   BYNOE LA, 1992, PHOTOCHEM PHOTOBIOL, V56, P353, DOI 10.1111/j.1751-1097.1992.tb02170.x
   CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CONN PF, 1991, J PHOTOCH PHOTOBIO B, V11, P41, DOI 10.1016/1011-1344(91)80266-K
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   ERDMAN JW, 1993, N Y ACAD SCI, V691, P76
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   FOOTE CS, 1970, ANN NY ACAD SCI, V171, P139, DOI 10.1111/j.1749-6632.1970.tb39317.x
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GILMARTIN B, 1985, VISION RES, V25, P1747, DOI 10.1016/0042-6989(85)90148-8
   Goodwin T, 1980, BIOGEOCHEMISTRY CARO, P346
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HARTRIDGE H, 1951, NATURE, V167, P77
   Hof KHV, 2000, J NUTR, V130, P503
   Home E., 1798, PHILOS T R SOC LON 2, P332
   HOWARTH PA, 1986, VISION RES, V26, P361, DOI 10.1016/0042-6989(86)90034-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Liebler DC, 1997, ARCH BIOCHEM BIOPHYS, V338, P244, DOI 10.1006/abbi.1996.9822
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   MARES J, 2004, CAROTENOIDS HLTH DIS
   Mares JA, 2004, ARCH OPHTHALMOL-CHIC, V122, P628, DOI 10.1001/archopht.122.4.628
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Muller H, 1996, Z ERNAHRUNGSWISS, V35, P45, DOI 10.1007/BF01612027
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Robson AG, 2005, PERCEPTION, V34, P1029, DOI 10.1068/p5196
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   RUDDOCK K. H., 1963, VISION RES, V3, P417, DOI 10.1016/0042-6989(63)90093-2
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Soemmering S., 1799, COMMENT SOC REG SCI, P13
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Sujak A, 2000, BBA-BIOMEMBRANES, V1509, P255, DOI 10.1016/S0005-2736(00)00299-6
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WALLS G. L., 1933, BRIT JOUR OPHTHALMOL, V17, P641, DOI 10.1136/bjo.17.11.641
   WEALE RA, 1951, J PHYSIOL-LONDON, V113, P115, DOI 10.1113/jphysiol.1951.sp004559
   WEISER H, 1993, ANN NY ACAD SCI, V691, P213, DOI 10.1111/j.1749-6632.1993.tb26174.x
   WERNER JS, 1990, OPTOMETRY VISION SCI, V67, P214, DOI 10.1097/00006324-199003000-00013
   Winkler BS, 1999, MOL VIS, V5
   WOLIN LR, 1967, J ANAT, V101, P693
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   YOUNG RW, 1994, OPTOMETRY VISION SCI, V71, P125, DOI 10.1097/00006324-199402000-00013
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
NR 104
TC 143
Z9 150
U1 0
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2006
VL 124
IS 7
BP 1038
EP 1045
DI 10.1001/archopht.124.7.1038
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064XE
UT WOS:000239123200015
PM 16832030
OA Bronze
DA 2022-11-30
ER

PT J
AU Flaxman, SR
   Bourne, RRA
   Resnikoff, S
   Ackland, P
   Braithwaite, T
   Cicinelli, MV
   Das, A
   Jonas, JB
   Keeffe, J
   Kempen, JH
   Leasher, J
   Limburg, H
   Naidoo, K
   Pesudovs, K
   Silvester, A
   Stevens, GA
   Tahhan, N
   Wong, TY
   Taylor, HR
AF Flaxman, Seth R.
   Bourne, Rupert R. A.
   Resnikoff, Serge
   Ackland, Peter
   Braithwaite, Tasanee
   Cicinelli, Maria V.
   Das, Aditi
   Jonas, Jost B.
   Keeffe, Jill
   Kempen, John H.
   Leasher, Janet
   Limburg, Hans
   Naidoo, Kovin
   Pesudovs, Konrad
   Silvester, Alex
   Stevens, Gretchen A.
   Tahhan, Nina
   Wong, Tien Y.
   Taylor, Hugh R.
CA Vision Loss Expert Grp Global Burd
TI Global causes of blindness and distance vision impairment 1990-2020: a
   systematic review and meta-analysis
SO LANCET GLOBAL HEALTH
LA English
DT Review
ID VISUAL IMPAIRMENT; PREVALENCE; PROJECTIONS; BURDEN
AB Background Contemporary data for causes of vision impairment and blindness form an important basis of recommendations in public health policies. Refreshment of the Global Vision Database with recently published data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregation by cause, and forecasts to 2020.
   Methods In this systematic review and meta-analysis, we analysed published and unpublished population-based data for the causes of vision impairment and blindness from 1980 to 2014. We identified population-based studies published before July 8, 2014, by searching online databases with no language restrictions (MEDLINE from Jan 1, 1946, and Embase from Jan 1, 1974, and the WHO Library Database). We fitted a series of regression models to estimate the proportion of moderate or severe vision impairment (defined as presenting visual acuity of <6/18 but >= 3/60 in the better eye) and blindness (presenting visual acuity of <3/60 in the better eye) by cause, age, region, and year.
   Findings We identified 288 studies of 3 983 541 participants contributing data from 98 countries. Among the global population with moderate or severe vision impairment in 2015 (216.6 million [80% uncertainty interval 98.5 million to 359.1 million]), the leading causes were uncorrected refractive error (116.3 million [49.4 million to 202.1 million]), cataract (52.6 million [18.2 million to 109.6 million]), age-related macular degeneration (8.4 million [0.9 million to 29.5 million]), glaucoma (4.0 million [0.6 million to 13.3 million]), and diabetic retinopathy (2.6 million [0.2 million to 9.9 million]). Among the global population who were blind in 2015 (36.0 million [12.9 million to 65.4 million]), the leading causes were cataract (12.6 million [3.4 million to 28.7 million]), uncorrected refractive error (7.4 million [2.4 million to 14.8 million]), and glaucoma (2.9 million [0.4 million to 9.9 million]). By 2020, among the global population with moderate or severe vision impairment (237.1 million [101.5 million to 399.0 million]), the number of people affected by uncorrected refractive error is anticipated to rise to 127.7 million (51.0 million to 225.3 million), by cataract to 57.1 million (17.9 million to 124.1 million), by age-related macular degeneration to 8.8 million (0.8 million to 32.1 million), by glaucoma to 4.5 million (0.5 million to 15.4 million), and by diabetic retinopathy to 3.2 million (0.2 million to 12.9 million). By 2020, among the global population who are blind (38.5 million [13.2 million to 70.9 million]), the number of patients blind because of cataract is anticipated to rise to 13.4 million (3.3 million to 31.6 million), because of uncorrected refractive error to 8.0 million (2.5 million to 16.3 million), and because of glaucoma to 3.2 million (0.4 million to 11.0 million). Cataract and uncorrected refractive error combined contributed to 55% of blindness and 77% of vision impairment in adults aged 50 years and older in 2015. World regions varied markedly in the causes of blindness and vision impairment in this age group, with a low prevalence of cataract (<22% for blindness and 14.1-15.9% for vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as causes in the high-income subregions. Blindness and vision impairment at all ages in 2015 due to diabetic retinopathy (odds ratio 2.52 [1.48-3.73]) and cataract (1.21 [1.17-1.25]) were more common among women than among men, whereas blindness and vision impairment due to glaucoma (0.71 [0.57-0.86]) and corneal opacity (0.54 [0.43-0.66]) were more common among men than among women, with no sex difference related to age-related macular degeneration (0.91 [0.70-1.14]).
   Interpretation The number of people affected by the common causes of vision loss has increased substantially as the population increases and ages. Preventable vision loss due to cataract (reversible with surgery) and refractive error (reversible with spectacle correction) continue to cause most cases of blindness and moderate or severe vision impairment in adults aged 50 years and older. A large scale-up of eye care provision to cope with the increasing numbers is needed to address avoidable vision loss. Copyright (C) The Author(s). Published by Elsevier Ltd.
C1 [Flaxman, Seth R.] Imperial Coll London, Dept Math, London, England.
   [Flaxman, Seth R.] Imperial Coll London, Data Sci Inst, London, England.
   [Bourne, Rupert R. A.] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge CB1 1PT, England.
   [Resnikoff, Serge; Naidoo, Kovin; Tahhan, Nina] Brien Holden Vis Inst, Sydney, NSW, Australia.
   [Resnikoff, Serge; Tahhan, Nina] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Ackland, Peter] Int Agcy Prevent Blindness, London, England.
   [Braithwaite, Tasanee] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Cicinelli, Maria V.] Ist Sci San Raffaele, Milan, Italy.
   [Das, Aditi] York Hosp, York, N Yorkshire, England.
   [Jonas, Jost B.] Univ Med, Dept Ophthalmol, Mannheim, Germany.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany.
   [Keeffe, Jill] LV Prasad Eye Inst, Hyderabad, Andhra Prades, India.
   [Kempen, John H.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA.
   [Kempen, John H.] Discovery Eye Ctr, Addis Ababa, Ethiopia.
   [Kempen, John H.] MyungSung Christian Med Ctr, Addis Ababa, Ethiopia.
   [Leasher, Janet] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Naidoo, Kovin] Univ Kwazulu Natal, African Vis Res Inst, Durban, South Africa.
   [Pesudovs, Konrad] Flinders Univ S Australia, Ctr Clin Eye Res, Natl Hlth & Med Res Council, Adelaide, SA, Australia.
   [Silvester, Alex] SpaMed Res Inst, Bolton, England.
   [Stevens, Gretchen A.] WHO, Dept Informat Evidence & Res, Geneva, Switzerland.
   [Wong, Tien Y.] Natl Univ Singapore, Duke Natl Univ Singapore, Grad Med Sch, Singapore Eye Res Inst, Singapore, Singapore.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
C3 Imperial College London; Imperial College London; Anglia Ruskin
   University; Brien Holden Vision Institute; University of New South Wales
   Sydney; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; Ruprecht Karls University Heidelberg;
   Ruprecht Karls University Heidelberg; L. V. Prasad Eye Institute;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Nova Southeastern University; University of Kwazulu Natal;
   Flinders University South Australia; World Health Organization; National
   University of Singapore; Singapore National Eye Center; University of
   Melbourne
RP Bourne, RRA (通讯作者)，Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge CB1 1PT, England.
EM rb@rupertbourne.co.uk
RI Wong, Tien Yin/AAC-9724-2020; cicinelli, maria vittoria/M-1611-2019;
   Braithwaite, Tasanee/AAZ-1118-2020; Naidoo, Kovin
   Shunmugam/AAF-5914-2020; Silva, Juan Carlos/N-9113-2019; Pesudovs,
   Konrad/T-9403-2019; Tejedor, Jaime/G-7728-2015; bozkurt,
   banu/ACI-1564-2022; Resnikoff, Serge/N-2355-2019; Leasher,
   Janet/B-8889-2016; Virgili, Gianni/P-6607-2014; Lansingh,
   Van/C-8672-2018
OI Wong, Tien Yin/0000-0002-8448-1264; cicinelli, maria
   vittoria/0000-0003-2938-0409; Braithwaite, Tasanee/0000-0002-3025-4066;
   Silva, Juan Carlos/0000-0003-4855-5008; Pesudovs,
   Konrad/0000-0002-6322-9369; bozkurt, banu/0000-0002-9847-3521;
   Resnikoff, Serge/0000-0002-5866-4446; Frick, Kevin/0000-0002-0178-5319;
   Tejedor Fraile, Jaime/0000-0001-5507-5622; Kempen,
   John/0000-0002-2967-4792; Gazzard, Gus/0000-0003-1982-5005; Furtado,
   Joao M./0000-0003-2490-5747; Gichuhi, Stephen/0000-0002-7062-4869;
   Chakravarthy, Usha/0000-0002-2606-3734; Dreer,
   Laura/0000-0002-4728-5467; Dandona, Rakhi/0000-0003-0926-788X; Battaglia
   Parodi, Maurizio/0000-0002-0385-7961; Morse, Alan
   R./0000-0002-5285-7626; Leasher, Janet/0000-0002-8779-5162; Virgili,
   Gianni/0000-0002-9960-2989; george, ronnie/0000-0001-7368-0252; Musch,
   David/0000-0002-4164-3841; Lansingh, Van/0000-0002-0090-4195; Del Monte,
   Monte/0000-0002-3153-959X; Hammond, Billy/0000-0002-5762-0206
FU Brien Holden Vision Institute
FX Brien Holden Vision Institute.
CR Ahmad O.B., AGE STANDARDIZATION
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P359
   Bhutta Z, 2011, LANCET, V377, P969, DOI 10.1016/S0140-6736(11)60169-4
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Burton Matthew J, 2009, Community Eye Health, V22, P33
   Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3
   Gilbert C E, 1999, Ophthalmic Epidemiol, V6, P73
   Kempen JH, 2011, OPHTHAL EPIDEMIOL, V18, P99, DOI 10.3109/09286586.2011.588908
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   UN, 2015, ESAPWP241 UN
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization (WHO), 2013, UN EYE HLTH GLOB ACT
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 20
TC 1334
Z9 1388
U1 28
U2 185
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD DEC
PY 2017
VL 5
IS 12
BP E1221
EP E1234
DI 10.1016/S2214-109X(17)30393-5
PG 14
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA FM2YO
UT WOS:000414869500022
PM 29032195
OA Green Published, Green Accepted, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wu, NS
   Yi, M
   Guan, CZ
   Wang, MY
   Zhang, Z
   Yang, XL
   Li, HY
   Han, DA
   Zeng, YG
   Tang, ZL
AF Wu, Nanshou
   Yi, Min
   Guan, Caizhong
   Wang, Mingyi
   Zhang, Zhang
   Yang, Xulun
   Li, Hongyi
   Han, Dingan
   Zeng, Yaguang
   Tang, Zhilie
TI Retinal cross-section motion correction in three-dimensional retinal
   optical coherence tomography
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
DE boundary segmentation; motion correction; optical coherence tomography;
   retinal imaging
AB Motion correction is an important issue in ophthalmic optical coherence tomography (OCT), and can improve the ability of data sets to reflect the physiological structures of tissues and make visualization and subsequent analysis easier. In this study, we present a novel method to correct the cross-sectional motion artifacts in retinal OCT volumes. Motion along the x-direction (fast-scan direction) is corrected through the normalized cross-correlation algorithm, while axial motion compensation is performed using the polynomial fitting method on the inner segment/outer segment (IS/OS) layer segmented by the shortest path faster algorithm (SPFA). The results of volunteers with central serous chorioretinopathy demonstrate that the proposed method effectively corrects motion artifacts in OCT volumes and may have potential application value in the evaluation of ophthalmic diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration.
C1 [Wu, Nanshou; Tang, Zhilie] South China Normal Univ, Sch Phys & Telecommun Engn, Guangzhou 510006, Peoples R China.
   [Yi, Min; Guan, Caizhong; Wang, Mingyi; Li, Hongyi; Han, Dingan; Zeng, Yaguang] Foshan Univ, Sch Phys & Optoelect Engn, Foshan 528200, Peoples R China.
   [Zhang, Zhang; Yang, Xulun] Foshan Univ, Sch Mech & Elect Engn & Automat, Foshan, Peoples R China.
C3 South China Normal University; Foshan University; Foshan University
RP Tang, ZL (通讯作者)，South China Normal Univ, Sch Phys & Telecommun Engn, Guangzhou 510006, Peoples R China.; Zeng, YG (通讯作者)，Foshan Univ, Sch Phys & Optoelect Engn, Foshan 528200, Peoples R China.
EM zeng.yg@163.com; tangzhl@scnu.edu.cn
RI 本, 公/GXN-1428-2022
OI Guan, Caizhong/0000-0003-1190-0576; Wang, Mingyi/0000-0002-0784-296X
FU National Key Research and Development Program of China [2018YFC1406600];
   National Natural Science Foundation of China [61771139, 61605026,
   62075042, 61575067, 51603069]; Natural Science Foundation of Guangdong
   Province [2017A030313386]; Guangdong Development Project of Science and
   Technology [2020B1111040001]
FX National Key Research and Development Program of China, Grant/Award
   Number: 2018YFC1406600; National Natural Science Foundation of China,
   Grant/Award Numbers: 61771139, 61605026, 62075042, 61575067, 51603069;
   Natural Science Foundation of Guangdong Province, Grant/Award Number:
   2017A030313386; the Guangdong Development Project of Science and
   Technology, Grant/Award Number: 2020B1111040001
CR Baghaie A, 2017, MED IMAGE ANAL, V37, P129, DOI 10.1016/j.media.2017.02.002
   Chen YW, 2018, BIOMED OPT EXPRESS, V9, P1111, DOI 10.1364/BOE.9.001111
   Chen Y, 2017, BIOMED OPT EXPRESS, V8, P1783, DOI 10.1364/BOE.8.001783
   de Kinkelder R, 2011, INVEST OPHTH VIS SCI, V52, P3908, DOI 10.1167/iovs.10-6738
   Huang Z, 2013, BIOMATERIALS, V34, P746, DOI 10.1016/j.biomaterials.2012.09.062
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   LaRocca F, 2013, BIOMED OPT EXPRESS, V4, P2307, DOI 10.1364/BOE.4.002307
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Onishi AC, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419840249
   Rajabi H, 2016, BIOMED PHYS ENG EXPR, V2, DOI 10.1088/2057-1976/2/3/035012
   Shilyagin PA, 2018, RADIOPHYS QUANT EL+, V60, P769, DOI 10.1007/s11141-018-9845-z
   Singh S, 2020, J ALLOY COMPD, V823, DOI 10.1016/j.jallcom.2020.153780
   Stokes A, 2014, PLANT SOIL, V377, P1, DOI 10.1007/s11104-014-2044-6
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Tang PJ, 2018, APPL PHYS LETT, V113, DOI 10.1063/1.5050208
   Yarmohammadi A, 2016, OPHTHALMOLOGY, V123, P2498, DOI 10.1016/j.ophtha.2016.08.041
NR 18
TC 0
Z9 0
U1 4
U2 17
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD JUN
PY 2021
VL 14
IS 6
AR e202000443
DI 10.1002/jbio.202000443
EA MAR 2021
PG 10
WC Biochemical Research Methods; Biophysics; Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA SM2ZN
UT WOS:000625998500001
PM 33576160
DA 2022-11-30
ER

PT J
AU Liu, G
   Zhang, CD
   Wang, J
   Jia, WC
AF Liu, Gang
   Zhang, Chun-Di
   Wang, Jing
   Jia, Wan-Cheng
TI Inhibition of the oxidative stress-induced miR-125b protects glucose
   metabolic disorders of human retinal pigment epithelium (RPE) cells
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Retinal pigment epithelium; miR-125b; Age-related macular degeneration;
   Oxidative stress
ID MACULAR DEGENERATION; MICRORNA EXPRESSION; ARPE-19 CELLS; GLYCOLYSIS;
   BIOGENESIS; AMD
AB The dysfunction of retinal pigment epithelium (RPE) with aging leads to age-related macular degeneration (AMD). Oxidative stress has been demonstrated as one of the causes of retinal pathological conditions. This study was conducted to investigate the mechanism of hydrogen peroxide (H2O2) induced human retinal pigment epithelial (RPE) cell dysfunction. We report miR-125b is induced by H2O2 treatments in RPE cells. In addition, we observed inhibited glucose metabolism under oxidative stress. Overexpression of miR-125b promotes the disorders of cellular glucose metabolism through direct targeting Hexokinase 2 (HK2). Restoration of HK2 in H2O2 treated RPE cells prevents the oxidative stress-suppressed glucose metabolism. Inhibition of the H2O2-induced miR-125b by inhibitor significantly prevented disorders of glucose metabolism. This study will contribute to the development of the miRNA based therapeutic approaches for against the oxidative stress-mediated human AMD.
C1 [Liu, Gang; Zhang, Chun-Di; Wang, Jing; Jia, Wan-Cheng] Shanghai Jiao Tong Univ, Dept Ophthalmol, Affiliated Peoples Hosp 6, South Campus, Shanghai 201400, Peoples R China.
C3 Shanghai Jiao Tong University
RP Jia, WC (通讯作者)，Shanghai Jiao Tong Univ, Dept Ophthalmol, Affiliated Peoples Hosp 6, South Campus, Shanghai 201400, Peoples R China.
EM wchengjia109@163.com
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bowes RC, 2013, INVEST OPHTH VIS SCI, V54, pF68
   Chu H, 2015, WORLD J TRADIT CHIN, V1, P203
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Howell JC, 2013, MOL VIS, V19, P544
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Roberts DJ, 2015, CELL DEATH DIFFER, V22, P364, DOI 10.1038/cdd.2014.208
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 22
TC 8
Z9 10
U1 0
U2 17
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2018
VL 64
IS 4
BP 1
EP 5
DI 10.14715/cmb/2018.64.4.1
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GC0SN
UT WOS:000429488200001
PM 29631677
DA 2022-11-30
ER

PT J
AU Sripathi, SR
   Sylvester, O
   He, WL
   Moser, T
   Um, JY
   Lamoke, F
   Ramakrishna, W
   Bernstein, PS
   Bartoli, M
   Jahng, WJ
AF Sripathi, Srinivas R.
   Sylvester, O'Donnell
   He, Weilue
   Moser, Trevor
   Um, Ji-Yeon
   Lamoke, Folami
   Ramakrishna, Wusirika
   Bernstein, Paul S.
   Bartoli, Manuela
   Jahng, Wan Jin
TI Prohibitin as the Molecular Binding Switch in the Retinal Pigment
   Epithelium
SO PROTEIN JOURNAL
LA English
DT Article
DE Prohibitin; Retinal pigment epithelium; Oxidative stress; Macular
   degeneration; Mitochondria
ID HUMAN RPE CELLS; MACULAR DEGENERATION; OXIDATIVE STRESS; PROGRESSIVE
   STAGES; PROTEOME ANALYSIS; PROTEINS; MITOCHONDRIA; COMPLEX;
   STABILIZATION; ORGANIZATION
AB Previously, our molecular binding study showed that prohibitin interacts with phospholipids, including phosphatidylinositide and cardiolipin. Under stress conditions, prohibitin interacts with cardiolipin as a retrograde response to activate mitochondrial proliferation. The lipid-binding switch mechanism of prohibitin with phosphatidylinositol-3,4,5-triphosphate and cardiolipin may suggest the role of prohibitin effects on energy metabolism and age-related diseases. The current study examined the region-specific expressions of prohibitin with respect to the retina and retinal pigment epithelium (RPE) in age-related macular degeneration (AMD). A detailed understanding of prohibitin binding with lipids, nucleotides, and proteins shown in the current study may suggest how molecular interactions control apoptosis and how we can intervene against the apoptotic pathway in AMD. Our data imply that decreased prohibitin in the peripheral RPE is a significant step leading to mitochondrial dysfunction that may promote AMD progression.
C1 [Sripathi, Srinivas R.; He, Weilue; Moser, Trevor; Um, Ji-Yeon; Ramakrishna, Wusirika] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA.
   [Sripathi, Srinivas R.] Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol, Sch Med, Baltimore, MD 21287 USA.
   [Sylvester, O'Donnell; Jahng, Wan Jin] Amer Univ Nigeria, Dept Petr Chem, Retina Prote Lab, Yola, Nigeria.
   [Lamoke, Folami; Bartoli, Manuela] Georgia Regents Univ, Dept Ophthalmol, Augusta, GA 30912 USA.
   [Bernstein, Paul S.] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Sch Med, Salt Lake City, UT 84132 USA.
C3 Michigan Technological University; Johns Hopkins University; Johns
   Hopkins Medicine; American University of Nigeria; University System of
   Georgia; Augusta University; Utah System of Higher Education; University
   of Utah
RP Jahng, WJ (通讯作者)，Amer Univ Nigeria, Dept Petr Chem, Retina Prote Lab, Yola, Nigeria.
EM wan.jahng@aun.edu.ng
RI He, Weilue/AAP-1748-2020; Wusirika, Ramakrishna/O-9116-2019; Jahng, Wan
   Jin/C-1236-2018; Ramakrishna, Wusirika/M-6646-2017
OI Jahng, Wan Jin/0000-0001-8241-7739; Ramakrishna,
   Wusirika/0000-0002-8571-5827; Moser, Trevor/0000-0001-9399-0514
FU Century II Equipment fund; Research Excellence Fund from Michigan
   Technological University; American University of Nigeria; NATIONAL EYE
   INSTITUTE [R01EY022416, R01EY011600] Funding Source: NIH RePORTER
FX The authors thank Jeremy Goldman and Mike Gibson for insightful
   discussions and sharing equipment. Matthew Durocher and Dr. Tristan
   Purvis are acknowledged for their suggestions and critical reading. This
   study was supported by the Century II Equipment fund and the Research
   Excellence Fund from Michigan Technological University, Research
   Assistantship and Teaching Assistantship from American University of
   Nigeria.
CR Alge CS, 2006, J PROTEOME RES, V5, P862, DOI 10.1021/pr050420t
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Ande SR, 2009, BIOCHEM BIOPH RES CO, V390, P1023, DOI 10.1016/j.bbrc.2009.10.101
   Arnouk H, 2011, J PROTEOMICS, V74, P254, DOI 10.1016/j.jprot.2010.11.004
   Artal-Sanz M, 2003, J BIOL CHEM, V278, P40416
   Artal-Sanz M, 2009, NATURE, V461, P793, DOI 10.1038/nature08466
   Back JW, 2002, PROTEIN SCI, V11, P2471, DOI 10.1110/ps.0212602
   Bonilha VL, 2004, MOL CELL PROTEOMICS, V3, P1119, DOI 10.1074/mcp.M400106-MCP200
   Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   Cottingham Katie, 2006, J Proteome Res, V5, P2501, DOI 10.1021/pr062762k
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200
   Gregory-Bass RC, 2008, INT J CANCER, V122, P1923, DOI 10.1002/ijc.23351
   He F, 2009, APOPTOSIS, V14, P1212, DOI 10.1007/s10495-009-0380-4
   He J, 2012, NUCLEIC ACIDS RES, V40, P6109, DOI 10.1093/nar/gks266
   Jahng WJ, 2012, OCULAR DIS, P121, DOI [10.5772/48785, DOI 10.5772/48785.INTECH]
   Kasashima K, 2008, EXP CELL RES, V314, P988, DOI 10.1016/j.yexcr.2008.01.005
   Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048
   Kutsyi MP, 2005, MITOCHONDRION, V5, P35, DOI 10.1016/j.mito.2004.09.002
   Lee H, 2010, INT J BIOL MACROMOL, V47, P685, DOI 10.1016/j.ijbiomac.2010.08.018
   Lee H, 2010, INT J BIOL MACROMOL, V47, P104, DOI 10.1016/j.ijbiomac.2010.05.014
   Liu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034315
   MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0
   Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372
   Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283
   Rivera-Milla E, 2006, CELL MOL LIFE SCI, V63, P343, DOI 10.1007/s00018-005-5434-3
   Sharma A, 2004, P NATL ACAD SCI USA, V101, P17492, DOI 10.1073/pnas.0407536101
   Sripathi Srinivas R, 2012, Adv Biosci Biotechnol, V3, P1167, DOI 10.4236/abb.2012.38143
   Sripathi SR, 2011, BIOCHEMISTRY-US, V50, P8342, DOI 10.1021/bi2008933
   Steglich G, 1999, MOL CELL BIOL, V19, P3435
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com
   Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhang RN, 2010, INT J BIOL MACROMOL, V47, P255, DOI 10.1016/j.ijbiomac.2010.04.013
NR 43
TC 13
Z9 14
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1572-3887
EI 1573-4943
J9 PROTEIN J
JI Protein J.
PD FEB
PY 2016
VL 35
IS 1
BP 1
EP 16
DI 10.1007/s10930-015-9641-y
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DJ3PQ
UT WOS:000374118300001
PM 26661103
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Araujo, RS
   Santos, DF
   Silva, GA
AF Araujo, Rute S.
   Santos, Daniela F.
   Silva, Gabriela A.
TI The role of the retinal pigment epithelium and Muller cells secretome in
   neovascular retinal pathologies
SO BIOCHIMIE
LA English
DT Review
DE Retina; Retinal pigment epithelium (RPE); Muller cells; Secretome;
   Neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF EXPRESSION; DIABETIC-RETINOPATHY;
   MATRIX METALLOPROTEINASE-2; INTERPHOTORECEPTOR MATRIX; BRUCHS MEMBRANE;
   INHIBITION; DEGENERATION; THERAPY; MMP-2
AB Secreted trophic factors are key to maintain the structural and functional integrity of the retina, as they regulate cellular pathways responsible for survival, function, and response to injury. Nevertheless, these same factors can also be involved in retinal pathologies, as a consequence of the impairment of the secretory function of cells. The cells considered as major contributors to the retinal secretome are the retinal pigmented epithelium (RPE) and Muller cells. Their role in the pathophysiology of the most common neovascular pathologies in the retina - Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Retinopathy of Prematurity (ROP) - is highlighted in this short review, together with current trophic factor-based therapies, which are mainly focused on controlling inflammation, cell survival, and angiogenesis. (c) 2018 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Araujo, Rute S.; Santos, Daniela F.; Silva, Gabriela A.] Univ Nova Lisboa, NOVA Med Sch, CEDOC Chron Dis Ctr, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.
   [Araujo, Rute S.] Univ Nova Lisboa, NOVA Med Sch, Bioengn Cell Therapies & Regenerat Med PhD Progra, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.
   [Santos, Daniela F.] Univ Nova Lisboa, NOVA Med Sch, ProRegeM PhD Programme Mech Dis & Regenerat Med, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.
C3 Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade
   Nova de Lisboa
RP Silva, GA (通讯作者)，Univ Nova Lisboa, NOVA Med Sch, CEDOC Chron Dis Ctr, Campo Martires Patria 130, P-1169056 Lisbon, Portugal.
EM gabriela.silva@nms.unl.pt
RI Santos, Daniela/GZK-5367-2022; Silva, Gabriela/AAJ-2440-2021; Silva,
   Gabriela/F-4409-2012
OI Araujo, Rute/0000-0003-4996-4938; Silva, Gabriela/0000-0001-5946-1918;
   Santos, Daniela/0000-0001-6855-1763
FU Fundacao para a Ciencia e a Tecnologia [PD/BD/114251/2016,
   SFRH/BD/114051/2016]; Marie Curie Reintegration Grant under the FP7
   program [PIRG-GA-2009-249314]; FCT/Ministerio Educacao e Ciencia; FEDER
   under the PT2020 Partnership Agreement; iNOVA4Health
   [UID/Multi/04462/2013]
FX The authors acknowledge the financial support of Fundacao para a Ciencia
   e a Tecnologia for fellowships to Daniela F. Santos (PD/BD/114251/2016)
   and Rute S. Araujo (SFRH/BD/114051/2016), the Marie Curie Reintegration
   Grant (PIRG-GA-2009-249314) to Gabriela A. Silva, under the FP7 program,
   and iNOVA4Health - UID/Multi/04462/2013, a program supported by
   FCT/Ministerio Educacao e Ciencia, through national funds and co-funded
   by FEDER under the PT2020 Partnership Agreement.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Angulo J, 2011, EUR J PHARMACOL, V667, P153, DOI 10.1016/j.ejphar.2011.06.015
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bhatt LK, 2010, AM J TRANSL RES, V2, P181
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Calado S., 2016, PEPITO DRIVEN PEDF E, DOI [10.1089/hgtb.2015.169, DOI 10.1089/HGTB.2015.169]
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chong D. Y., 2013, INVEST OPHTH VIS SCI, V49, P3193, DOI [10.1167/iovs.07-1641.Interleukin-6, DOI 10.1167/IOVS.07-1641.INTERLEUKIN-6]
   Ciombor KK, 2013, CLIN CANCER RES, V19, P1920, DOI 10.1158/1078-0432.CCR-12-2911
   Cislo-Pakuluk A, 2017, STEM CELL REV REP, V13, P598, DOI 10.1007/s12015-017-9750-4
   Coughlin BA, 2017, VISION RES, V139, P93, DOI 10.1016/j.visres.2017.03.013
   Cuevas P., 2012, BMJ CASE REP, V2012, DOI [10.1136/bcr.02.2012.5942bcr0220125942, DOI 10.1136/BCR.02.2012.5942BCR0220125942]
   Cuevas P., 2012, BMJ CASE REP, V2012, DOI [10.1136/bcr-2012-006619bcr2012006619, DOI 10.1136/BCR-2012-006619BCR2012006619]
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   Eichler W, 2004, EXP CELL RES, V299, P68, DOI 10.1016/j.yexcr.2004.05.020
   Fiori A, 2018, IMMUNOBIOLOGY, V223, P729, DOI 10.1016/j.imbio.2018.01.001
   Folkman J, 1997, EXS, V79, P1
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Fu SH, 2015, DIABETES, V64, P3554, DOI 10.2337/db15-0180
   Greene WA, 2016, INVEST OPHTH VIS SCI, V57, P4428, DOI 10.1167/iovs.16-19192
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hirsch L, 2015, CYTOKINE, V71, P394, DOI 10.1016/j.cyto.2014.11.014
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Ip MS, 2015, OPHTHALMOLOGY, V122, P367, DOI 10.1016/j.ophtha.2014.08.048
   Jan Sanaullah, 2016, J Ayub Med Coll Abbottabad, V28, P364
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Ke M, 2012, BIO-MED MATER ENG, V22, P113, DOI 10.3233/BME-2012-0696
   Kitaoka T, 1997, CURR EYE RES, V16, P396, DOI 10.1076/ceyr.16.4.396.10685
   Klettner A, 2015, MOL VIS, V21, P736
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Konopatskaya O, 2006, MOL VIS, V12, P626
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mitamura Y, 2002, DIABETES CARE, V25, P2352, DOI 10.2337/diacare.25.12.2352
   Murugeswari P, 2017, CYTOKINE, V95, P126, DOI 10.1016/j.cyto.2017.02.013
   Nishikiori N, 2007, DIABETES, V56, P1333, DOI 10.2337/db06-1431
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619
   Praidou A, 2011, ACTA OPHTHALMOL, V89, P248, DOI 10.1111/j.1755-3768.2009.01661.x
   Rodrigues M, 2013, DIABETES, V62, P3863, DOI 10.2337/db13-0014
   Rodriguez IR, 2000, INVEST OPHTH VIS SCI, V41, P2438
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   Simao S., 2016, NEW FRONTIERS OPHTHA, V2, P77, DOI [10.15761/NFO.1000119, DOI 10.15761/NFO.1000119]
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tolentino M, 2012, CURR DRUG THER, V7, P131, DOI 10.2174/157488512800675959
   Van Bergen T, 2017, EXP EYE RES, V165, P136, DOI 10.1016/j.exer.2017.09.012
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Wang HB, 2013, AM J PATHOL, V183, P964, DOI 10.1016/j.ajpath.2013.05.011
   Wang Jia-Kang, 2015, Eye Sci, V30, P176
   Wang Jia-Kang, 2015, Eye Sci, V30, P198
   Wang JJ, 2015, WORLD J DIABETES, V6, P726, DOI 10.4239/wjd.v6.i5.726
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Xu WQ, 2016, INT J OPHTHALMOL-CHI, V9, P1343, DOI 10.18240/ijo.2016.09.19
   Yafai Y, 2014, OPHTHALMIC RES, V52, P81, DOI 10.1159/000362371
   Yego ECK, 2009, INVEST OPHTH VIS SCI, V50, P1920, DOI 10.1167/iovs.08-2082
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 73
TC 11
Z9 11
U1 1
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD DEC
PY 2018
VL 155
SI SI
BP 104
EP 108
DI 10.1016/j.biochi.2018.06.019
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HB2VP
UT WOS:000450903000012
PM 29960032
DA 2022-11-30
ER

PT J
AU Yan, YJ
   Bao, LL
   Zhang, LJ
   Bian, J
   Hu, TS
   Zheng, MZ
   Chen, DY
   Yu, XH
   Chen, ZL
AF Yan, Yi-Jia
   Bao, Lei-Lei
   Zhang, Li-Jun
   Bian, Jun
   Hu, Tai-shan
   Zheng, Mei-zhen
   Chen, Dan-Ye
   Yu, Xin-hai
   Chen, Zhi-Long
TI Inhibition of Laser-Induced Choroidal Neovascularization by
   Hematoporphyrin Dimethylether-Mediated Photodynamic Therapy in Rats
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE photodynamic therapy; hematoporphyrin dimethylether; choroidal
   neovascularization; age-related macular degeneration
ID MACULAR DEGENERATION; PATHOLOGICAL MYOPIA; TRANSPUPILLARY THERMOTHERAPY;
   VERTEPORFIN THERAPY; BRUCH MEMBRANE; KRYPTON LASER; BEVACIZUMAB;
   RADIOSENSITIZATION; RANIBIZUMAB; TUMORS
AB This study aimed to investigate the effect of hematoporphyrin dimethylether (HDME)-mediated photo dynamic therapy for laser-induced choroidal neovascularization (CNV) in adult Brown Norway rats. HDME was administered via tail vein at 14d after the laser photocoagulation, and the rats received irradiance with a laser light at 570 nm at 15 min after injection. CNV was evaluated by fundus photography, fundus fluorescein angiography, optical coherence tomography, and hematoxylin and eosin staining. We found that CNV was occurred at 7d after photocoagulation and reaching peak activity at 14d after photocoagulation. There is a significant reduction in the total area of the fluorescein leakage and the number of strong fluorescein leakage spots on 7d after HDME-mediated photodynamic therapy (PDT). The results suggest that HDME-mediated PDT inhibits laser-induced CNV in rats, representing a promising therapy for wet age-related macular degeneration.
C1 [Yan, Yi-Jia; Zhang, Li-Jun; Chen, Dan-Ye; Yu, Xin-hai; Chen, Zhi-Long] Donghua Univ, Coll Chem & Biol, Dept Pharmaceut Sci & Technol, Shanghai 201620, Peoples R China.
   [Yan, Yi-Jia; Hu, Tai-shan; Zheng, Mei-zhen] Shanghai Xianhui Pharmaceut Co Ltd, Dept Pharmacol, Shanghai 200433, Peoples R China.
   [Bao, Lei-Lei; Bian, Jun] 411 Hosp, Shanghai 200081, Peoples R China.
C3 Donghua University
RP Yu, XH; Chen, ZL (通讯作者)，Donghua Univ, Coll Chem & Biol, Dept Pharmaceut Sci & Technol, Shanghai 201620, Peoples R China.
EM yuxinhai@dhu.edu.cn; zlchen1967@qq.com
RI Chen, Zhi-long/AGF-6157-2022
FU National Natural Science Foundation of China [21402236, 21372042];
   Foundation of Science and Technology Commission of Shanghai Municipality
   [14431906200, 15431904100, 15XD1523400, 14ZR1439800, 14ZR1439900,
   15ZR1439900]; Fundamental Research Funds for the Central Universities
   [17D110513]; Foundation of Science and Technology Commission of
   Songjiang District [16SJGG20]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 21402236, 21372042), Foundation of Science and Technology
   Commission of Shanghai Municipality (No. 14431906200, 15431904100,
   15XD1523400, 14ZR1439800, 14ZR1439900, 15ZR1439900), Fundamental
   Research Funds for the Central Universities (17D110513), Foundation of
   Science and Technology Commission of Songjiang District (16SJGG20).
CR Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Barak Y, 2012, MIDDLE EAST AFR J OP, V19, P43, DOI 10.4103/0974-9233.92115
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   BAURMANN H, 1975, A GRAEF ARCH KLIN EX, V193, P245, DOI 10.1007/BF00417573
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Costagliola C, 2008, EUR J OPHTHALMOL, V18, P955, DOI 10.1177/112067210801800616
   Cruess A, 2009, CAN J OPHTHALMOL, V44, P548, DOI 10.3129/i09-140
   Cui J, 2014, PHOTOMED LASER SURG, V32, P30, DOI 10.1089/pho.2013.3588
   Deng H, 2013, DYES PIGMENTS, V99, P930, DOI 10.1016/j.dyepig.2013.06.037
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   HAWKINS BS, 1989, ARCH OPHTHALMOL-CHIC, V107, P344, DOI 10.1001/archopht.1989.01070010354023
   Hussain N, 2008, INDIAN J OPHTHALMOL, V56, P465, DOI 10.4103/0301-4738.43366
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Kent D, 2003, MOL VIS, V9, P747
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Li FL, 2015, EXP EYE RES, V136, P78, DOI 10.1016/j.exer.2015.05.004
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Luksiene Z, 2006, CANCER LETT, V235, P40, DOI 10.1016/j.canlet.2005.03.041
   Luksiene Z, 2006, J ENVIRON PATHOL TOX, V25, P293, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.190
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Master A, 2013, J CONTROL RELEASE, V168, P88, DOI 10.1016/j.jconrel.2013.02.020
   Miller DG, 2006, OPTOMETRY VISION SCI, V83, P316, DOI 10.1097/01.opx.0000216019.88256.eb
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   OHKUMA H, 1983, ARCH OPHTHALMOL-CHIC, V101, P1102, DOI 10.1001/archopht.1983.01040020104018
   PERRY DD, 1982, AM J OPHTHALMOL, V93, P787, DOI 10.1016/0002-9394(82)90475-5
   POLLACK A, 1986, OPHTHALMOLOGY, V93, P1113
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Singh B, 2012, RETINA-J RET VIT DIS, V32, P206, DOI 10.1097/IAE.0B013E318236E84C
   Singh SP, 2014, PHOTODIAGN PHOTODYN, V11, P156, DOI 10.1016/j.pdpdt.2014.02.011
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Tomanova P, 2015, STEROIDS, V97, P8, DOI 10.1016/j.steroids.2014.08.024
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Valmaggia C, 2008, KLIN MONATSBL AUGENH, V225, P380, DOI 10.1055/s-2008-1027266
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   VANDERZYPEN E, 1986, ARCH OPHTHALMOL-CHIC, V104, P1070, DOI 10.1001/archopht.1986.01050190128052
   Vasquez Lopez G, 2000, Arch Soc Esp Oftalmol, V75, P675
   Wang L, 2014, EXP EYE RES, V127, P117, DOI 10.1016/j.exer.2014.07.006
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
   Zhao Shi-hong, 2003, Zhonghua Yan Ke Za Zhi, V39, P298
NR 51
TC 3
Z9 3
U1 1
U2 11
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD DEC
PY 2017
VL 40
IS 12
BP 2088
EP 2095
DI 10.1248/bpb.b17-00319
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FO6XE
UT WOS:000417011700011
PM 29199233
OA gold
DA 2022-11-30
ER

PT J
AU Lambert, V
   Munaut, C
   Jost, M
   Noel, A
   Werb, Z
   Foidart, JM
   Rakic, JM
AF Lambert, V
   Munaut, C
   Jost, M
   Noel, A
   Werb, Z
   Foidart, JM
   Rakic, JM
TI Matrix metalloproteinase-9 contributes to choroidal neovascularization
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY;
   RETINAL-PIGMENT EPITHELIUM; ANGIOGENIC SWITCH; MURINE MODEL;
   MATRIX-METALLOPROTEINASE-9; EXPRESSION; MEMBRANES; INHIBITORS; TISSUE
AB Age-related macular degeneration (AMD) is the primary cause of irreversible photoreceptors loss in adult patients and current therapies are limited. increased levels of matrix metalloproteinases (MMPs) have been documented in neovascularization of severe ocular pathologies such as AMD and proliferative diabetic retinopathy. We report here that MMP-9 (gelatinase B) expression is induced and temporally regulated in the course of experimental choroidal neovascularization. We used transgenic mice expressing,6-galactosidase reporter gene under the dependence of MMP-9 promoter and RT-PCR analysis on choroidal neovascular structures microdissected from serial sections by laser pressure catapulting to show that MMP-9 expression is up-regulated concomitantly with the appearance of inflammatory cells in the subretinal lesion. in mice deficient in MMP-9 expression the development of choroidal neovascularization induced by laser photocoagulation still occurred, but at a reduced level.
C1 Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.
   Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   Univ Hosp, Dept Ophthalmol, Liege, Belgium.
C3 University of Liege; University of California System; University of
   California San Francisco; University of Liege
RP Lambert, V (通讯作者)，Univ Liege, Lab Tumor & Dev Biol, Pathol Tower B23, B-4000 Liege, Belgium.
RI Munaut, Carine/K-8138-2019
OI Noel, Agnes/0000-0002-7670-6179
CR BEHRINGER RR, 1993, DEVELOPMENT, V117, P823
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bohm M, 1997, AM J PATHOL, V151, P63
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1
   Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fini ME, 1996, AM J PATHOL, V149, P1287
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Itoh T, 1998, CANCER RES, V58, P1048
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kosano H, 1999, LIFE SCI, V64, P2307, DOI 10.1016/S0024-3205(99)00184-8
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Majka S, 2001, INVEST OPHTH VIS SCI, V42, P210
   Mandriota SJ, 1997, J CELL SCI, V110, P2293
   Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935
   Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903
   Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588
   Munaut C, 1995, INVAS METAST, V15, P169
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Salzmann J, 2000, BRIT J OPHTHALMOL, V84, P1091, DOI 10.1136/bjo.84.10.1091
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87
NR 34
TC 86
Z9 91
U1 0
U2 2
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2002
VL 161
IS 4
BP 1247
EP 1253
DI 10.1016/S0002-9440(10)64401-X
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 601NQ
UT WOS:000178453000017
PM 12368198
OA Green Published
DA 2022-11-30
ER

PT J
AU D'Souza, YB
   Jones, CJP
   Bonshek, RE
AF D'Souza, Yvonne B.
   Jones, Carolyn J. P.
   Bonshek, Richard E.
TI Comparison of lectin binding of drusen, RPE, Bruch's membrane, and
   photoreceptors
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; GLYCOSYLATION;
   GLYCOSIDASES; LOCALIZATION; GLYCOPROTEIN; PATHOGENESIS; RHODOPSIN;
   EVOLUTION; CELLS
AB Purpose: Drusen are deposits located between the retinal pigment epithelium and Bruch's membrane in age-related maculopathy. They are believed to be photoreceptor byproducts that are incompletely metabolized by the retinal pigment epithelium. This study therefore compares the lectin histochemistry of drusen, photoreceptors, retinal pigment epithelium, and Bruch's membrane.
   Methods: Semithin sections of three eyes with age-related maculopathy were studied using 19 biotinylated lectins and an avidin-peroxidase-revealing system with and without neuraminidase pretreatment.
   Results: High mannose, bi and tri-antennary nonbisected and bisected complex N-glycan, N-acetyl glucosamine and galactose were expressed by drusen, retinal pigment epithelium, Bruch's membrane, and photoreceptors while N-acetyl galactosamine and fucose were absent; treatment with neuraminidase exposed subterminal galactose in both sites and sparse N-acetyl galactosamine residues in drusen alone. Overall, there were striking similarities between the lectin binding of drusen, retinal pigment epithelium, and the photoreceptor outer segments, though cone outer segments were distinct in some features of their O-linked glycosylation.
   Conclusions: The results suggest that the pathogenesis of drusen is a combined mechanism, involving photoreceptors, Bruch's membrane, and the retinal pigment epithelium.
C1 [D'Souza, Yvonne B.; Bonshek, Richard E.] Manchester Royal Eye Hosp, Acad Unit, Manchester M13 9WH, Lancs, England.
   [Jones, Carolyn J. P.] Univ Manchester, Maternal & Fetal Hlth Res Ctr, Manchester, Lancs, England.
   [Bonshek, Richard E.] Manchester Royal Infirm, NSOPS, Manchester M13 9WL, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester
RP D'Souza, YB (通讯作者)，Manchester Royal Eye Hosp, Acad Unit, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM yvonnedsouza@fsmail.net
OI Jones, Carolyn/0000-0002-0026-9494
FU Manchester Academic Health Sciences Centre (MAHSC); NIHR Manchester
   Biomedical Research Centre
FX The Maternal and Fetal Health Research Group is supported by the
   Manchester Academic Health Sciences Centre (MAHSC) and the NIHR
   Manchester Biomedical Research Centre.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   BISHOP PN, 1993, GLYCOBIOLOGY, V3, P403, DOI 10.1093/glycob/3.4.403
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   D'souza Y, 2008, J MOL HISTOL, V39, P77, DOI 10.1007/s10735-007-9130-5
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FISCHER E, 1995, GLYCOCONJUGATE J, V12, P707, DOI 10.1007/BF00731268
   FONG SL, 1984, J NEUROCHEM, V42, P1667, DOI 10.1111/j.1471-4159.1984.tb12758.x
   FUJITA S, 1994, GLYCOBIOLOGY, V4, P633, DOI 10.1093/glycob/4.5.633
   Jones CJP, 2007, CELLS TISSUES ORGANS, V185, P269, DOI 10.1159/000102175
   JONES CJP, 1992, HISTOCHEM J, V24, P327, DOI 10.1007/BF01046164
   JONES CJP, 1987, HISTOCHEM J, V19, P264, DOI 10.1007/BF01675685
   KIVELA T, 1990, CURR EYE RES, V9, P1195, DOI 10.3109/02713689009003476
   LENTRICHIA BB, 1978, INVEST OPHTH VIS SCI, V17, P884
   Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Nakagawa M, 2001, FEBS LETT, V496, P19, DOI 10.1016/S0014-5793(01)02392-4
   PILLER V, 1990, EUR J BIOCHEM, V191, P461, DOI 10.1111/j.1432-1033.1990.tb19144.x
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Uehara F, 2000, INVEST OPHTH VIS SCI, V41, P2759
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 20
TC 5
Z9 5
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 4
PY 2009
VL 15
IS 94-96
BP 906
EP 911
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 450OS
UT WOS:000266411300001
PM 19421409
DA 2022-11-30
ER

PT J
AU Camino, A
   Jia, YL
   Yu, J
   Wang, J
   Liu, L
   Huang, D
AF Camino, Acner
   Jia, Yali
   Yu, Jeffrey
   Wang, Jie
   Liu, Liang
   Huang, David
TI Automated detection of shadow artifacts in optical coherence tomography
   angiography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID MOTION CORRECTION; VISUALIZATION; INTENSITY
AB Frequently, when imaging retinal vasculature with optical coherence tomography angiography (OCTA) in diseased eyes, there are unavoidable obstacles to the propagation of light such as vitreous floaters or the pupil boundary. These obstacles can block the optical coherence tomography (OCT) beam and impede the visualization of the underlying retinal microcirculation. Detecting these shadow artifacts is especially important in the quantification of metrics that assess retinal disease progression because they might masquerade as regional perfusion loss. In this work, we present an algorithm to identify shadowed areas in OCTA of healthy subjects as well as patients with diabetic retinopathy, uveitis and age-related macular degeneration. The aim is to exclude these areas from analysis so that the overall OCTA parameters are minimally affected by shadow artifacts. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Camino, Acner; Jia, Yali; Yu, Jeffrey; Wang, Jie; Liu, Liang; Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Jia, Yali; Wang, Jie] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Oregon Health & Science University
RP Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.; Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.
EM jiaya@ohsu.edu
OI Jia, Yali/0000-0002-2784-1905
FU National Institutes of Health (Bethesda, MD) [R01EY027833, DP3 DK104397,
   R01 EY024544, P30 EY010572]; William & Mary Greve Special Scholar Award
   from Research to Prevent Blindness (New York, NY); Research to Prevent
   Blindness (New York, NY); NATIONAL EYE INSTITUTE [R01EY027833,
   P30EY010572, R01EY024544] Funding Source: NIH RePORTER
FX This work was supported by grants R01EY027833, DP3 DK104397, R01
   EY024544, P30 EY010572 from the National Institutes of Health (Bethesda,
   MD) and an unrestricted departmental funding grant and William & Mary
   Greve Special Scholar Award from Research to Prevent Blindness (New
   York, NY).
CR Camino A, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.20
   Camino A, 2017, BIOMED OPT EXPRESS, V8, P3053, DOI 10.1364/BOE.8.003053
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, P4485, DOI 10.1167/iovs.16-20080
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Karamata B, 2005, J OPT SOC AM A, V22, P593, DOI 10.1364/JOSAA.22.000593
   Kelly-Perez I, 2013, J OPT SOC AM A, V30, P2585, DOI 10.1364/JOSAA.30.002585
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Mariampillai A, 2010, OPT LETT, V35, P1257, DOI 10.1364/OL.35.001257
   Motaghiannezam R, 2012, BIOMED OPT EXPRESS, V3, P503, DOI 10.1364/BOE.3.000503
   Motaghiannezam S. M. R., 2012, SPIE, P6
   Park SS, 2016, JAMA OPHTHALMOL, V134, P943, DOI 10.1001/jamaophthalmol.2016.1645
   Poddar R, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.12.126010
   Rodolfo M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40763
   Shi WS, 2017, J BIOPHOTONICS, V10, P1597, DOI 10.1002/jbio.201600264
   Tomlinson A, 2018, OPHTHALMOL RETINA, V2, P748, DOI 10.1016/j.oret.2018.01.012
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 29
TC 18
Z9 18
U1 0
U2 3
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2019
VL 10
IS 3
BP 1514
EP 1531
DI 10.1364/BOE.10.001514
PG 18
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA HN4EY
UT WOS:000460138400036
PM 30891364
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Friedlander, M
AF Friedlander, Martin
TI COMBINATION ANGIOSTATIC THERAPIES Targeting Multiple Angiogenic Pathways
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE combination angiostatic therapies; antiangiogenesis; neovascular eye
   disease
ID MACULAR DEGENERATION; RETINAL ANGIOGENESIS
AB The multiplicity of signaling pathways for new blood vessel formation is suggested by the modest antiangiogenic effects achieved when any single pathway or molecular step is blocked. In an experimental model of neovascularization in newborn mice, highly significant improvements in an antiangiogenic effect are achieved when inhibitors of different pathways of new vessel formation are combined. In this model, neovascularization can be completely inhibited in the majority of animals when at least three pathways are inhibited. When only two pathways are blocked, complete inhibition of neovascularization is less commonly observed but still far more common than when a single pathway is inhibited. For the prevention of new blood vessel formation in neovascular eye diseases like age-related macular degeneration, the experimental evidence supports combination therapies that inhibit more than one molecular pathway. RETINA 29:S27-S29, 2009
C1 [Friedlander, Martin] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
   [Friedlander, Martin] Scripps Clin, Div Ophthalmol, Retina Serv, La Jolla, CA USA.
C3 Scripps Research Institute; Scripps Research Institute
RP Friedlander, M (通讯作者)，10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM friedlan@scripps.edu
CR Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
NR 7
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S27
EP S29
DI 10.1097/IAE.0b013e3181ad2673
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700010
PM 19553794
DA 2022-11-30
ER

PT J
AU Wieghofer, P
   Hagemeyer, N
   Sankowski, R
   Schlecht, A
   Staszewski, O
   Amann, L
   Gruber, M
   Koch, J
   Hausmann, A
   Zhang, PP
   Boneva, S
   Masuda, T
   Hilgendorf, I
   Goldmann, T
   Bottcher, C
   Priller, J
   Rossi, FMV
   Lange, C
   Prinz, M
AF Wieghofer, Peter
   Hagemeyer, Nora
   Sankowski, Roman
   Schlecht, Anja
   Staszewski, Ori
   Amann, Lukas
   Gruber, Markus
   Koch, Jana
   Hausmann, Annika
   Zhang, Peipei
   Boneva, Stefaniya
   Masuda, Takahiro
   Hilgendorf, Ingo
   Goldmann, Tobias
   Boettcher, Chotima
   Priller, Josef
   Rossi, Fabio M., V
   Lange, Clemens
   Prinz, Marco
TI Mapping the origin and fate of myeloid cells in distinct compartments of
   the eye by single-cell profiling
SO EMBO JOURNAL
LA English
DT Article
DE cornea; macrophages; microglia; retina; single&#8208; cell RNA&#8208;
   seq
AB Similar to the brain, the eye is considered an immune-privileged organ where tissue-resident macrophages provide the major immune cell constituents. However, little is known about spatially restricted macrophage subsets within different eye compartments with regard to their origin, function, and fate during health and disease. Here, we combined single-cell analysis, fate mapping, parabiosis, and computational modeling to comprehensively examine myeloid subsets in distinct parts of the eye during homeostasis. This approach allowed us to identify myeloid subsets displaying diverse transcriptional states. During choroidal neovascularization, a typical hallmark of neovascular age-related macular degeneration (AMD), we recognized disease-specific macrophage subpopulations with distinct molecular signatures. Our results highlight the heterogeneity of myeloid subsets and their dynamics in the eye that provide new insights into the innate immune system in this organ which may offer new therapeutic targets for ophthalmological diseases.
C1 [Wieghofer, Peter; Hagemeyer, Nora; Sankowski, Roman; Staszewski, Ori; Amann, Lukas; Koch, Jana; Hausmann, Annika; Masuda, Takahiro; Goldmann, Tobias; Prinz, Marco] Univ Freiburg, Fac Med, Inst Neuropathol, Freiburg, Germany.
   [Wieghofer, Peter] Univ Leipzig, Inst Anat, Leipzig, Germany.
   [Sankowski, Roman; Staszewski, Ori] Univ Freiburg, Fac Med, Freiburg, Germany.
   [Schlecht, Anja; Gruber, Markus; Koch, Jana; Zhang, Peipei; Boneva, Stefaniya; Lange, Clemens] Univ Freiburg, Fac Med, Ctr Eye, Med Ctr, Freiburg, Germany.
   [Amann, Lukas] Univ Freiburg, Fac Biol, Freiburg, Germany.
   [Hilgendorf, Ingo] Univ Freiburg, Univ Heart Ctr Freiburg, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Boettcher, Chotima; Priller, Josef] Charite Univ Med Berlin, Dept Neuropsychiat, Berlin, Germany.
   [Boettcher, Chotima; Priller, Josef] Charite Univ Med Berlin, Lab Mol Psychiat, Berlin, Germany.
   [Priller, Josef] DZNE, Berlin, Germany.
   [Priller, Josef] BIH, Berlin, Germany.
   [Priller, Josef] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Priller, Josef] UK DRI, Edinburgh, Midlothian, Scotland.
   [Rossi, Fabio M., V] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada.
   [Rossi, Fabio M., V] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
   [Prinz, Marco] Univ Freiburg, Signalling Res Ctr BIOSS, Freiburg, Germany.
   [Prinz, Marco] Univ Freiburg, Signalling Res Ctr CIBSS, Freiburg, Germany.
   [Prinz, Marco] Univ Freiburg, Fac Med, Ctr Basics NeuroModulat NeuroModulBasics, Freiburg, Germany.
C3 University of Freiburg; Leipzig University; University of Freiburg;
   University of Freiburg; University of Freiburg; Universitats Herzzentrum
   Freiburg; University of Freiburg; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Helmholtz Association; German Center for
   Neurodegenerative Diseases (DZNE); Berlin Institute of Health;
   University of Edinburgh; University of British Columbia; University of
   British Columbia; University of Freiburg; University of Freiburg;
   University of Freiburg
RP Wieghofer, P; Prinz, M (通讯作者)，Univ Freiburg, Fac Med, Inst Neuropathol, Freiburg, Germany.; Wieghofer, P (通讯作者)，Univ Leipzig, Inst Anat, Leipzig, Germany.; Lange, C (通讯作者)，Univ Freiburg, Fac Med, Ctr Eye, Med Ctr, Freiburg, Germany.; Prinz, M (通讯作者)，Univ Freiburg, Signalling Res Ctr BIOSS, Freiburg, Germany.; Prinz, M (通讯作者)，Univ Freiburg, Signalling Res Ctr CIBSS, Freiburg, Germany.; Prinz, M (通讯作者)，Univ Freiburg, Fac Med, Ctr Basics NeuroModulat NeuroModulBasics, Freiburg, Germany.
EM peter.wieghofer@medizin.uni-leipzig.de;
   clemens.lange@uniklinik-freiburg.de; marco.prinz@uniklinik-freiburg.de
RI Wieghofer, Peter/AAV-9572-2020; Hilgendorf, Ingo/AFM-6379-2022; Priller,
   Josef/ABW-3835-2022
OI Hilgendorf, Ingo/0000-0002-0024-1643; Boneva,
   Stefaniya/0000-0002-9811-2160; Hausmann, Annika/0000-0001-8852-3444;
   Bottcher, Chotima/0000-0002-6226-586X; Koch, Jana/0000-0002-7552-6088;
   Amann, Lukas/0000-0002-8363-373X; Sankowski, Roman/0000-0001-9215-8021;
   Priller, Josef/0000-0001-7596-0979
FU Sobek Foundation; Ernst-Jung Foundation; German Research Foundation [SFB
   992, SFB1160]; Ministry of Science, Research and Arts,
   Baden-Wuerttemberg (Sonderlinie "Neuroinflammation"); German Research
   Foundation (DFG) under Germany's Excellence Strategy (CIBSS EXC-2189)
   [390939984]; Berlin Institute of Health [CRG2aSP6]; DFG [SFB/TRR265]; UK
   DRI (Momentum Award); ProjektDEAL;  [SFB/TRR167]; MRC [MC_PC_16031]
   Funding Source: UKRI
FX The authors thank Marc Leinweber, Gabriele Prinz, Maria Oberle, Johannes
   Baumann, Katrin Seidel, Eileen Barleon, Constance Hobusch, Angela
   Ehrlich, Heidrun Kuhrt, and Sylvia Zeitler for excellent technical
   assistance, M. Folio and team at lighthouse fluorescence technologies
   core Facility, University Medical Center, Freiburg for cell sorting,
   CEMT at University of Freiburg for excellent animal care, KFB, Center of
   Excellence for Fluorescent Bioanalytics, Regensburg for bulk RNA-seq
   analysis, Jonas Neher, Tubingen (Ccr2-RFP), Frederic Geissmann, New York
   for providing Flt3<SUP>cre</SUP> :Rosa26-YFP mice. Special thanks to
   Sagar and Dominic Grun, MPI-IE, Freiburg, for providing excellent
   support for scRNA-seq. M.P. is supported by the Sobek Foundation, the
   Ernst-Jung Foundation, the German Research Foundation (SFB 992, SFB1160,
   Reinhart-Koselleck-Grant, Gottfried Wilhelm Leibniz Prize) and the
   Ministry of Science, Research and Arts, Baden-Wuerttemberg (Sonderlinie
   "Neuroinflammation"). His research is supported by the German Research
   Foundation (DFG) under Germany's Excellence Strategy (CIBSS EXC-2189
   Project ID 390939984). J.P. received additional funding from the Berlin
   Institute of Health (CRG2aSP6), DFG (SFB/TRR265), and the UK DRI
   (Momentum Award). CL, MP, JP, CB and IH are supported by the SFB/TRR167.
   Open Access funding enabled and organized by ProjektDEAL.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ajami B, 2018, NAT NEUROSCI, V21, P541, DOI 10.1038/s41593-018-0100-x
   Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Andrews S., 2010, BABRAHAM BIOINFORMAT
   Baker SC, 2005, NAT METHODS, V2, P731, DOI 10.1038/nmeth1005-731
   Bechmann I, 2005, NEUROMOL MED, V7, P217, DOI 10.1385/NMM:7:3:217
   Benz C, 2008, J EXP MED, V205, P1187, DOI 10.1084/jem.20072168
   Boeck M, 2020, GLIA, V68, P1859, DOI 10.1002/glia.23810
   Boettcher C, 2008, BRIT J OPHTHALMOL, V92, P272, DOI 10.1136/bjo.2007.126318
   Boneva S, 2020, LAB INVEST, V100, P1345, DOI 10.1038/s41374-020-0446-z
   Boyer SW, 2011, CELL STEM CELL, V9, P64, DOI 10.1016/j.stem.2011.04.021
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Chappell-Maor L, 2020, EUR J IMMUNOL, V50, P353, DOI 10.1002/eji.201948342
   Chinnery HR, 2008, IMMUNOLOGY, V125, P541, DOI 10.1111/j.1365-2567.2008.02868.x
   Jordao MJC, 2019, SCIENCE, V363, P365, DOI 10.1126/science.aat7554
   Dando SJ, 2016, GLIA, V64, P1331, DOI 10.1002/glia.23005
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ensan S, 2016, NAT IMMUNOL, V17, P159, DOI 10.1038/ni.3343
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   GLOOR B P, 1969, Albrecht Von Graefes Archiv fuer Klinische und Experimentelle Ophthalmologie, V179, P105, DOI 10.1007/BF00410377
   Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Grun D, 2016, CELL STEM CELL, V19, P266, DOI 10.1016/j.stem.2016.05.010
   Grun D, 2014, NAT METHODS, V11, P637, DOI [10.1038/NMETH.2930, 10.1038/nmeth.2930]
   Hagemeyer N, 2016, EMBO J, V35, P1730, DOI 10.15252/embj.201693801
   Hamrah P, 2003, J LEUKOCYTE BIOL, V74, P172, DOI 10.1189/jlb.1102544
   Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8
   Herman JS, 2018, NAT METHODS, V15, P379, DOI 10.1038/nmeth.4662
   Huang YB, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0011-8
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kezic J, 2008, INVEST OPHTH VIS SCI, V49, P1599, DOI 10.1167/iovs.07-0953
   Kierdorf K, 2019, NAT REV NEUROSCI, V20, P547, DOI 10.1038/s41583-019-0201-x
   Kierdorf K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058544
   Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu J, 2017, MUCOSAL IMMUNOL, V10, P1145, DOI 10.1038/mi.2016.139
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Magnusson A., 2016, VARIOUS R PROGRAMMIN
   Masuda T, 2020, NAT IMMUNOL, V21, P802, DOI 10.1038/s41590-020-0707-4
   Masuda T, 2019, NATURE, V566, P388, DOI 10.1038/s41586-019-0924-x
   Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015
   Molawi K, 2014, J EXP MED, V211, P2151, DOI 10.1084/jem.20140639
   Mudge JM, 2015, MAMM GENOME, V26, P366, DOI 10.1007/s00335-015-9583-x
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Pitulescu ME, 2010, NAT PROTOC, V5, P1518, DOI 10.1038/nprot.2010.113
   Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Sankowski R, 2019, NAT NEUROSCI, V22, P2098, DOI 10.1038/s41593-019-0532-y
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schlecht A, 2020, AM J PATHOL, V190, P1632, DOI 10.1016/j.ajpath.2020.04.004
   Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179
   Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Tay TL, 2017, NAT NEUROSCI, V20, P793, DOI 10.1038/nn.4547
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   van de Laar L, 2016, IMMUNITY, V44, P755, DOI 10.1016/j.immuni.2016.02.017
   Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220
   Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wieghofer P, 2016, BBA-MOL BASIS DIS, V1862, P299, DOI 10.1016/j.bbadis.2015.09.019
   Wieghofer P, 2015, GLIA, V63, P1, DOI 10.1002/glia.22727
   Winget S., 2011, FASTQ SCREEN ALLOWS
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Zajac BK, 2015, FORENSIC SCI INT-GEN, V15, P137, DOI 10.1016/j.fsigen.2014.11.013
NR 75
TC 32
Z9 31
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD MAR 15
PY 2021
VL 40
IS 6
AR e105123
DI 10.15252/embj.2020105123
EA FEB 2021
PG 27
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QX9VV
UT WOS:000615872400001
PM 33555074
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Hutchinson, CV
   Walker, JA
   Davidson, C
AF Hutchinson, Claire V.
   Walker, James A.
   Davidson, Colin
TI Oestrogen, ocular function and low-level vision: a review
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Review
DE oestrogen; menopause; eye; vision
ID HORMONE REPLACEMENT THERAPY; WAVELENGTH-SENSITIVE CONES; OPEN-ANGLE
   GLAUCOMA; INTRAOCULAR-PRESSURE; BLOOD-FLOW; RECEPTOR-ALPHA; DRY EYE;
   HYPERTENSION TREATMENT; CONTRAST SENSITIVITY; REPRODUCTIVE FACTORS
AB Over the past 10 years, a literature has emerged concerning the sex steroid hormone oestrogen and its role in human vision. Herein, we review evidence that oestrogen (oestradiol) levels may significantly affect ocular function and low-level vision, particularly in older females. In doing so, we have examined a number of vision-related disorders including dry eye, cataract, increased intraocular pressure, glaucoma, age-related macular degeneration and Leber's hereditary optic neuropathy. In each case, we have found oestrogen, or lack thereof, to have a role. We have also included discussion of how oestrogen-related pharmacological treatments for menopause and breast cancer can impact the pathology of the eye and a number of psychophysical aspects of vision. Finally, we have reviewed oestrogen's pharmacology and suggest potential mechanisms underlying its beneficial effects, with particular emphasis on anti-apoptotic and vascular effects.
C1 [Hutchinson, Claire V.] Univ Leicester, Coll Med Biol Sci & Psychol, Leicester LE1 9HN, Leics, England.
   [Walker, James A.] Harvard Univ, Sch Med, Ctr Human Genet Res, Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Davidson, Colin] Univ London, St Georges Med Sch, Div Biomed Sci, London SW17 0RE, England.
C3 University of Leicester; Harvard University; Harvard Medical School;
   Massachusetts General Hospital; St Georges University London; University
   of London
RP Hutchinson, CV (通讯作者)，Univ Leicester, Coll Med Biol Sci & Psychol, Leicester LE1 9HN, Leics, England.
EM ch190@le.ac.uk
RI Davidson, Colin/J-6256-2019
OI Davidson, Colin/0000-0002-8180-7943
CR Abramov Y, 2005, J GLAUCOMA, V14, P271, DOI 10.1097/01.ijg.0000169390.17427.b7
   Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806
   Affinito P, 2003, MENOPAUSE, V10, P482, DOI 10.1097/01.GME.0000063568.84134.35
   Akar Y, 2005, CAN J OPHTHALMOL, V40, P487, DOI 10.1016/S0008-4182(05)80011-0
   Altinas O, 2004, OPHTHALMOLOGICA, V218, P120, DOI 10.1159/000076148
   Arevalo MA, 2011, J MOL ENDOCRINOL, V46, pR1, DOI 10.1677/JME-10-0122
   Azcoitia I, 2011, TRENDS ENDOCRIN MET, V22, P467, DOI 10.1016/j.tem.2011.08.002
   Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2
   Carlson LE, 2000, MENOPAUSE, V7, P168, DOI 10.1097/00042192-200007030-00007
   Chen ZG, 2004, EXP EYE RES, V78, P67, DOI 10.1016/j.exer.2003.09.015
   Cheng GJ, 2005, J CLIN ENDOCR METAB, V90, P435, DOI 10.1210/jc.2004-0861
   Coksuer H, 2011, CLIMACTERIC, V14, P482, DOI 10.3109/13697137.2010.539724
   Colley SM, 2004, CLIN EXP OPHTHALMOL, V32, P105, DOI 10.1046/j.1442-9071.2004.00769.x
   Crawford DK, 2010, BRAIN, V133, P2999, DOI 10.1093/brain/awq237
   de Ronde W, 2003, CLIN ENDOCRINOL, V58, P529, DOI 10.1046/j.1365-2265.2003.01669.x
   de Voogd S, 2008, ARCH OPHTHALMOL-CHIC, V126, P110, DOI 10.1001/archopht.126.1.110
   Deschenes MC, 2010, INVEST OPHTH VIS SCI, V51, P2587, DOI 10.1167/iovs.09-3710
   Eisner A, 2006, VISION RES, V46, P1816, DOI 10.1016/j.visres.2005.11.003
   Eisner A, 2004, BRIT J OPHTHALMOL, V88, P125, DOI 10.1136/bjo.88.1.125
   Eisner A, 2007, BREAST CANCER RES TR, V106, P161, DOI 10.1007/s10549-006-9486-3
   Eisner A, 2011, CURR EYE RES, V36, P867, DOI 10.3109/02713683.2011.594202
   Eisner A, 2011, ACTA OPHTHALMOL, V89, pe217, DOI 10.1111/j.1755-3768.2009.01799.x
   Eisner A, 2009, BREAST CANCER RES TR, V117, P9, DOI 10.1007/s10549-008-0156-5
   Eisner A, 2008, VISION RES, V48, P2663, DOI 10.1016/j.visres.2008.01.029
   Erb C, 2008, GRAEF ARCH CLIN EXP, V246, P1593, DOI 10.1007/s00417-008-0881-9
   Espeland MA, 2010, J WOMENS HEALTH, V19, P371, DOI 10.1089/jwh.2009.1605
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Filardo EJ, 2012, ENDOCRINOLOGY, V153, P2953, DOI 10.1210/en.2012-1061
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Foster TC, 2012, HIPPOCAMPUS, V22, P656, DOI 10.1002/hipo.20935
   GANLEY JP, 1980, SURV OPHTHALMOL, V25, P130, DOI 10.1016/0039-6257(80)90087-9
   Gharaibeh A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005431.pub2
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Guaschino S, 2003, MENOPAUSE, V10, P53, DOI 10.1097/01.GME.0000030663.97769.FE
   Gupta PD, 2005, SURV OPHTHALMOL, V50, P274, DOI 10.1016/j.survophthal.2005.02.005
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hales AM, 1997, J EXP MED, V185, P273, DOI 10.1084/jem.185.2.273
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hatsumi T, 2006, EXP BIOL MED, V231, P311
   Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hulsman CAA, 2001, AM J EPIDEMIOL, V154, P138, DOI 10.1093/aje/154.2.138
   Irwin RW, 2011, ENDOCRINOLOGY, V152, P556, DOI 10.1210/en.2010-1061
   Ishunina TA, 2008, GYNECOL ENDOCRINOL, V24, P93, DOI 10.1080/09513590701705148
   JOHNSON N, 1987, PERCEPT MOTOR SKILL, V64, P587, DOI 10.2466/pms.1987.64.2.587
   Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137
   Kamalden TA, 2011, OPHTHALMIC RES, V45, P65, DOI 10.1159/000313985
   Kanthan GL, 2010, ACTA OPHTHALMOL, V88, P773, DOI 10.1111/j.1755-3768.2009.01565.x
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kavroulaki D, 2010, ACTA OPHTHALMOL, V88, P850, DOI 10.1111/j.1755-3768.2009.01607.x
   Khurana RN, 2006, AM J OPHTHALMOL, V142, P494, DOI 10.1016/j.ajo.2006.04.018
   Klinge CM, 2008, J CELL BIOCHEM, V105, P1342, DOI 10.1002/jcb.21936
   Lee SM, 2004, MED HYPOTHESES, V63, P494, DOI 10.1016/j.mehy.2004.02.044
   Mabuchi F, 2010, AM J OPHTHALMOL, V149, P826, DOI 10.1016/j.ajo.2009.12.030
   Maki PM, 2011, BRAIN RES, V1379, P232, DOI 10.1016/j.brainres.2010.11.030
   Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551
   Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084
   Navarro A, 2013, AGE, V35, P821, DOI 10.1007/s11357-012-9415-9
   Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018
   Neumann F, 2010, NEUROCHEM RES, V35, P522, DOI 10.1007/s11064-009-0092-8
   Nixon E, 2012, INVEST OPHTH VIS SCI, V53, P4739, DOI 10.1167/iovs.12-9517
   Noureddin BN, 1999, EYE, V13, P729, DOI 10.1038/eye.1999.217
   Orwoll E, 2006, J CLIN ENDOCR METAB, V91, P1336, DOI 10.1210/jc.2005-1830
   Ozcura F, 2012, INT J OPHTHALMOL-CHI, V5, P64, DOI 10.3980/j.issn.2222-3959.2012.01.13
   Paganini-Hill A, 2000, BREAST CANCER RES TR, V60, P167, DOI 10.1023/A:1006342300291
   Pasquale LR, 2007, J GLAUCOMA, V16, P598, DOI 10.1097/IJG.0b013e318064c82d
   Pinto LA, 2012, ACTA OPHTHALMOL, V90, pe214, DOI 10.1111/j.1755-3768.2011.02335.x
   Pointer JS, 2000, OPHTHAL PHYSL OPT, V20, P131, DOI 10.1016/S0275-5408(99)00042-3
   Quesada A, 2008, DEV NEUROBIOL, V68, P632, DOI 10.1002/dneu.20609
   Qureshi I A, 1997, Proc Natl Sci Counc Repub China B, V21, P49
   Rossouw JE, 2002, LANCET, V360, P1996, DOI 10.1016/S0140-6736(02)12030-7
   Russo R, 2008, PROG BRAIN RES, V173, P583, DOI 10.1016/S0079-6123(08)01144-8
   Salomao SR, 2007, CURR EYE RES, V32, P345, DOI 10.1080/02713680701229638
   Salvati AL, 1923, ANN OCUL, V160, P568
   Sanchez AM, 2010, STEROIDS, V75, P528, DOI 10.1016/j.steroids.2009.12.003
   Sator MO, 1998, BRIT J OBSTET GYNAEC, V105, P100, DOI 10.1111/j.1471-0528.1998.tb09358.x
   Schaumberg DA, 2001, JAMA-J AM MED ASSOC, V286, P2114, DOI 10.1001/jama.286.17.2114
   Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010
   Seymenoglu G, 2011, CURR EYE RES, V36, P399, DOI 10.3109/02713683.2011.553307
   Sherwin BB, 2006, NEUROSCIENCE, V138, P1021, DOI 10.1016/j.neuroscience.2005.07.051
   Shoshani YZ, 2011, ACTA OPHTHALMOL, V89, pE382, DOI 10.1111/j.1755-3768.2011.02130.x
   Siesky BA, 2008, EUR J OPHTHALMOL, V18, P320, DOI 10.1177/112067210801800228
   Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013
   Taner P, 2004, OPHTHALMOLOGICA, V218, P257, DOI 10.1159/000078616
   Tint NL, 2010, MENOPAUSE, V17, P157, DOI 10.1097/gme.0b013e3181b82fb4
   Tiwari-Woodruff S, 2009, J NEUROL SCI, V223, P15
   Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919
   van der Spuy WJ, 2012, REV NEUROSCIENCE, V23, P269, DOI 10.1515/revneuro-2012-0028
   Vasconsuelo A, 2011, STEROIDS, V76, P1223, DOI 10.1016/j.steroids.2011.08.001
   Versura P, 2005, GYNECOL ENDOCRINOL, V20, P289, DOI 10.1080/09513590400027257
   Wang CJ, 2012, MOL VIS, V18, P1115
   Wei X, 2012, MED HYPOTHESES, V79, P377, DOI 10.1016/j.mehy.2012.05.041
   Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x
   Worzala K, 2001, ARCH INTERN MED, V161, P1448, DOI 10.1001/archinte.161.11.1448
   Xie WK, 2011, MOL VIS, V17, P3512
   Yamashita H, 2011, EXP EYE RES, V93, P75, DOI 10.1016/j.exer.2011.04.006
   Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851
NR 99
TC 20
Z9 21
U1 0
U2 19
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022-0795
EI 1479-6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD NOV
PY 2014
VL 223
IS 2
BP R9
EP R18
DI 10.1530/JOE-14-0349
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AR5YT
UT WOS:000343659000001
PM 25143633
OA Bronze
DA 2022-11-30
ER

PT J
AU Filho, CADG
   Penha, FM
   Gregori, G
   Rosenfeld, PJ
AF Filho, Carlos Alexandre de Amorim Garcia
   Penha, Fernando Marcondes
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Increasing Volume of a Retinal Pigmented Epithelial Detachment as a
   Predictor of Submacular Hemorrhage During Anti-VEGF Therapy
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; CLASSIFICATION
AB Vascularized retinal pigment epithelium detachments (PEDs) are part of the spectrum of neovascular age-related macular degeneration (AMD). These patients with vascularized PEDs are at a higher risk of experiencing severe vision loss. This case report demonstrates the use of a new spectral-domain optical coherence tomography (SD-OCT) algorithm to measure the area and volume of PEDs. When this algorithm was applied to the scans from a patient with a vascularized PED who developed a large submacular hemorrhage while undergoing ranibizumab therapy, the authors found that the algorithm measured an increase in the area and volume of the PED that preceded the macular hemorrhage. Although further studies are needed, the increase in the volume of a PED may serve as a useful predictor of disease progression and the need for more aggressive anti-VEGF therapy.
C1 [Filho, Carlos Alexandre de Amorim Garcia; Penha, Fernando Marcondes; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
FU Carl Zeiss Meditec
FX Drs. Garcia Filho and Rosenfeld received research support from Carl
   Zeiss Meditec. Dr. Gregori and the University of Miami co-own a patent
   that is licensed to Carl Zeiss Meditec. Dr. Rosenfeld has received
   honoraria for lectures from Carl Zeiss Meditec.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 11
TC 8
Z9 8
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2013
VL 44
IS 2
BP 204
EP 207
DI 10.3928/23258160-20130313-12
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 172PS
UT WOS:000321017200021
PM 23510045
DA 2022-11-30
ER

PT J
AU Weismann, D
   Hartvigsen, K
   Lauer, N
   Bennett, KL
   Scholl, HPN
   Issa, PC
   Cano, M
   Brandstatter, H
   Tsimikas, S
   Skerka, C
   Superti-Furga, G
   Handa, JT
   Zipfel, PF
   Witztum, JL
   Binder, CJ
AF Weismann, David
   Hartvigsen, Karsten
   Lauer, Nadine
   Bennett, Keiryn L.
   Scholl, Hendrik P. N.
   Issa, Peter Charbel
   Cano, Marisol
   Brandstaetter, Hubert
   Tsimikas, Sotirios
   Skerka, Christine
   Superti-Furga, Giulio
   Handa, James T.
   Zipfel, Peter F.
   Witztum, Joseph L.
   Binder, Christoph J.
TI Complement factor H binds malondialdehyde epitopes and protects from
   oxidative stress
SO NATURE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; APOPTOTIC CELLS;
   INNATE IMMUNITY; END-PRODUCTS; AGE; PHAGOCYTOSIS; PROTEINS; RISK;
   PHOSPHOLIPIDS
AB Oxidative stress and enhanced lipid peroxidation are linked to many chronic inflammatory diseases, including age-related macular degeneration (AMD). AMD is the leading cause of blindness in Western societies, but its aetiology remains largely unknown. Malondialdehyde (MDA) is a common lipid peroxidation product that accumulates in many pathophysiological processes, including AMD. Here we identify complement factor H (CFH) as a major MDA-binding protein that can block both the uptake of MDA-modified proteins by macrophages and MDA-induced proinflammatory effects in vivo in mice. The CFH polymorphism H402, which is strongly associated with AMD, markedly reduces the ability of CFH to bind MDA, indicating a causal link to disease aetiology. Our findings provide important mechanistic insights into innate immune responses to oxidative stress, which may be exploited in the prevention of and therapy for AMD and other chronic inflammatory diseases.
C1 [Weismann, David; Hartvigsen, Karsten; Bennett, Keiryn L.; Superti-Furga, Giulio; Binder, Christoph J.] Austrian Acad Sci, CeMM, A-1090 Vienna, Austria.
   [Weismann, David; Hartvigsen, Karsten; Brandstaetter, Hubert; Binder, Christoph J.] Med Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria.
   [Hartvigsen, Karsten; Tsimikas, Sotirios; Witztum, Joseph L.; Binder, Christoph J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Lauer, Nadine; Skerka, Christine; Zipfel, Peter F.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany.
   [Lauer, Nadine; Skerka, Christine; Zipfel, Peter F.] Univ Jena, D-07745 Jena, Germany.
   [Scholl, Hendrik P. N.; Cano, Marisol; Handa, James T.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Issa, Peter Charbel] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [Brandstaetter, Hubert] Octapharma PPGmbH, Res & Dev, A-1100 Vienna, Austria.
C3 Austrian Academy of Sciences; CeMM Research Center for Molecular
   Medicine of the Austrian Academy of Sciences; Medical University of
   Vienna; University of California System; University of California San
   Diego; Hans Knoll Institute (HKI); Friedrich Schiller University of
   Jena; Johns Hopkins University; Johns Hopkins Medicine; University of
   Oxford; Octapharma
RP Binder, CJ (通讯作者)，Austrian Acad Sci, CeMM, A-1090 Vienna, Austria.
EM christoph.binder@meduniwien.ac.at
RI Superti-Furga, Giulio/AAE-5681-2019; Issa, Peter Charbel/E-8935-2018;
   Issa, Peter Charbel/O-2580-2019; Superti-Furga, Giulio/F-4755-2015
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Superti-Furga, Giulio/0000-0002-0570-1768;
   Bennett, Keiryn L./0000-0001-9356-7708; Binder, Christoph
   J./0000-0001-8313-7050
FU Austrian Academy of Sciences; Austrian Research Promotion Agency; SFB
   Lipotox F30 of the Austrian Science Fund; NIH [HL088093, RO1 HL086599,
   EY14005, EY019044]; Edward N. & Della L. Thome Memorial Foundation;
   Research to Prevent Blindness (Wilmer Eye institute); Deutsche
   Forschungsgemeinschaft; ProRetina Foundation; Fondation Leducq;
   Wynn-Gund Translational Research Acceleration Program Enhanced Research
   and Clinical Training Award; National Neurovision Research Institute -
   Foundation Fighting Blindness; Macular Degeneration Research Award;
   American Health Assistance Foundation; European Commission; European
   Community; American Heart Association [0630228N]; NATIONAL EYE INSTITUTE
   [R01EY019904, R01EY014005] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [P01HL088093] Funding Source: NIH RePORTER
FX We are indebted to M. Ozsvar-Kozma for technical assistance, S. Halbich
   for performing the surface plasmon resonance analysis, A. Hartmann for
   purification of CFH variants from patient plasma, C. Mannhalter for help
   with genotyping, and E. N. Montano. This work was supported by the
   Austrian Academy of Sciences, a BRIDGE grant from the Austrian Research
   Promotion Agency, the SFB Lipotox F30 of the Austrian Science Fund
   (C.J.B.); NIH grants HL088093 (C.J.B., S. T., J.L.W.), RO1 HL086599 (K.
   H., J.L.W.), EY14005, EY019044 (J.T.H.); the Edward N. & Della L. Thome
   Memorial Foundation Awards Program in AMD Research, Research to Prevent
   Blindness (Wilmer Eye institute) (J.T.H.); the Deutsche
   Forschungsgemeinschaft (P.F.Z., C. S.); the ProRetina Foundation (N. L.,
   P.F.Z., C. S.); the Fondation Leducq (C.J.B., S. T., J.L.W.); the
   Wynn-Gund Translational Research Acceleration Program Enhanced Research
   and Clinical Training Award, National Neurovision Research Institute -
   Foundation Fighting Blindness, Macular Degeneration Research Award,
   American Health Assistance Foundation (H. P. N. S.); European Commission
   and the Seventh European Community Framework Program, Marie Curie
   Intra-European Fellowship (P. C. I.). K. H. was supported by the
   Scientist Development Grant 0630228N of the American Heart Association.
   J. T. H. is the Robert Bond Welch Professor. We thank all patients for
   participation.
CR Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951
   Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763
   Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Flierman R, 2007, IMMUNOBIOLOGY, V212, P363, DOI 10.1016/j.imbio.2006.11.005
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shanmugam N, 2008, DIABETES, V57, P879, DOI 10.2337/db07-1204
   SHECHTER I, 1981, J LIPID RES, V22, P63
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Suzuki M, 2007, MOL VIS, V13, P772
   Takizawa F, 1996, FEBS LETT, V397, P269, DOI 10.1016/S0014-5793(96)01197-0
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thiele Geoffrey M, 2004, Comp Hepatol, V3 Suppl 1, pS25, DOI 10.1186/1476-5926-2-S1-S25
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Xu DS, 1997, CHEM RES TOXICOL, V10, P978, DOI 10.1021/tx970069t
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 42
TC 394
Z9 412
U1 5
U2 97
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 6
PY 2011
VL 478
IS 7367
BP 76
EP 81
DI 10.1038/nature10449
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 829JN
UT WOS:000295575400037
PM 21979047
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Montero, JA
   Ruiz-Moreno, JM
   De la Vega, C
AF Montero, J. A.
   Ruiz-Moreno, J. M.
   De la Vega, C.
TI Intravitreal bevacizumab for adult-onset vitelliform dystrophy: A case
   report
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE adult-onset foveomacular vitelliform dystrophy; age-related macular
   degeneration; bevacizumab; choroidal neovascularization; retinal pigment
   epithelium dystrophy
ID DEGENERATION
AB PURPOSE. Adult-onset foveomacular vitelliform dystrophy (AFVD) is often misdiagnosed as occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The authors report the anatomic and functional outcome of intravitreal bevacizumab in a case of AFVD associated with a suspected occult CNV.
   METHODS. Prospective, interventional, single case report. One female patient with decreased visual acuity (VA) and metamorphopsia secondary to AFVD received one single intravitreal injection of bevacizumab 1.25 mg.
   RESULTS. The patient reported unchanged VA and decreased metamorphopsia 6 weeks after the injection. Fluorescein angiography (FA) and optical coherence tomography (OCT) showed progressive decrease of subretinal fluid until complete disappearance. VA, OCT, and FA remained unchanged during 10 months follow-up.
   CONCLUSIONS. Intravitreal bevacizumab showed a morphologic improvement and stable VA in a patient with AFVD. Further case series are required to confirm this observation.
C1 [Montero, J. A.] Pio Rio Hortega Univ Hosp, Ophthalmol Unit, E-47010 Valladolid, Spain.
   [Montero, J. A.; Ruiz-Moreno, J. M.; De la Vega, C.] VISSUM, Alicante Inst Ophthalmol, Alicante, Spain.
   [Ruiz-Moreno, J. M.] Miguel Hernandez Univ, Dept Ophthalmol, Alicante, Spain.
C3 Universidad Miguel Hernandez de Elche
RP Montero, JA (通讯作者)，Pio Rio Hortega Univ Hosp, Ophthalmol Unit, Avenida Santa Teresa S-N, E-47010 Valladolid, Spain.
EM javmonmor@hotmail.com
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR Benhamou N, 2003, AM J OPHTHALMOL, V135, P362, DOI 10.1016/S0002-9394(02)01946-3
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P399, DOI 10.1097/00006982-200406000-00010
   GLACETBERNARD A, 1990, J FR OPHTALMOL, V13, P407
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   PICCOLINO FC, 1988, INT OPHTHALMOL, V11, P207
NR 5
TC 18
Z9 21
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2007
VL 17
IS 6
BP 983
EP 986
DI 10.1177/112067210701700620
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265UO
UT WOS:000253386800020
PM 18050129
DA 2022-11-30
ER

PT J
AU Caporossi, T
   Tartaro, R
   Bacherini, D
   Pacini, B
   De Angelis, L
   Governatori, L
   Di Leo, L
   Oliverio, L
   Rizzo, S
AF Caporossi, Tomaso
   Tartaro, Ruggero
   Bacherini, Daniela
   Pacini, Bianca
   De Angelis, Lorenzo
   Governatori, Lorenzo
   Di Leo, Laura
   Oliverio, Leandro
   Rizzo, Stanislao
TI Applications of the Amniotic Membrane in Vitreoretinal Surgery
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE vitreoretinal surgery; amniotic membrane; vitrectomy; macular hole;
   retinal detachment; age related macular degeneration; optic pit
   maculopathy
ID INTERNAL LIMITING MEMBRANE; CAPSULAR FLAP TRANSPLANTATION; OPTICAL
   COHERENCE TOMOGRAPHY; REFRACTORY MACULAR HOLE; RETINAL FREE-FLAP;
   STEM-CELLS; SURGICAL TECHNIQUES; AUTOLOGOUS BLOOD; NERVE HEAD;
   DETACHMENT
AB Recently, the use of the human amniotic membrane (hAM) has been extended to treat retinal disorders, such as macular holes that failed to close and retinal tears. The hAM has demonstrated the induction of a recovery process of the external retinal layers involving the external limiting membrane (ELM) and the ellipsoid zone (EZ). After that, the application of the hAM for retinal pathologies was extended to large macular tears, high myopic retinal detachment associated with MH, paravascular tears, serous macular detachment associated with optic pit, complicated retinal detachment and advanced age-related macular degeneration (AMD). The hAM has shown a potential in repairing retinal tissue through a regeneration process. This review aims to highlight the use of the hAM in various vitreo-retinal surgical fields, and to confront it with other cutting-edge surgical techniques used to treat challenging vitreo-retinal pathologies.
C1 [Caporossi, Tomaso; Tartaro, Ruggero; Bacherini, Daniela; Pacini, Bianca; De Angelis, Lorenzo; Governatori, Lorenzo; Di Leo, Laura; Oliverio, Leandro] Univ Florence, Dept NEUROFARBA, Ophthalmol, I-50134 Florence, Italy.
   [Rizzo, Stanislao] Catholic Univ Sacred Hearth, Dept Ophthalmol, Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy.
C3 University of Florence; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli
RP Caporossi, T (通讯作者)，Univ Florence, Dept NEUROFARBA, Ophthalmol, I-50134 Florence, Italy.
EM tomaso.caporossi@gmail.com; ruggero.tartaro@gmail.com;
   daniela.bacherini@unifi.it; pacinibianca@gmail.com;
   lor.deangelis89@gmail.com; lorenzo.gov@gmail.com;
   laura.dileo82@gmail.com; leandro.oliverio92@gmail.com;
   stanislao.rizzo@gmail.com
RI de Angelis, Lorenzo/AAE-5613-2019
OI de Angelis, Lorenzo/0000-0001-6969-1979; caporossi,
   tomaso/0000-0002-6902-2983
CR BONNET M, 1991, GRAEF ARCH CLIN EXP, V229, P526, DOI 10.1007/BF00203315
   Bovey EH, 1999, RETINA-J RET VIT DIS, V19, P489, DOI 10.1097/00006982-199911000-00001
   BROWN GC, 1980, CAN J OPHTHALMOL, V15, P144
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Caporossi T, 2020, ACTA OPHTHALMOL, V98, pE526, DOI 10.1111/aos.14334
   Caporossi T, 2020, EUR J OPHTHALMOL, V30, P392, DOI 10.1177/1120672119891415
   Caporossi T, 2020, ACTA OPHTHALMOL, V98, pE252, DOI 10.1111/aos.14174
   Caporossi T, 2019, ACTA OPHTHALMOL, V97, P821, DOI 10.1111/aos.14109
   Chen SN, 2018, OPHTHALMOLOGICA, V240, P143, DOI 10.1159/000487337
   Chen SN, 2016, RETINA-J RET VIT DIS, V36, P163, DOI 10.1097/IAE.0000000000000674
   Cheng AMS, 2016, CORNEA, V35, P736, DOI 10.1097/ICO.0000000000000784
   Coppola Michele, 2017, Int J Retina Vitreous, V3, P37, DOI 10.1186/s40942-017-0090-y
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Deihim T, 2016, CORNEA, V35, P997, DOI 10.1097/ICO.0000000000000867
   Garcia-Arumi J, 2004, GRAEF ARCH CLIN EXP, V242, P819, DOI 10.1007/s00417-004-0897-8
   Grewal DS, 2019, OPHTHALMOLOGY, V126, P1399, DOI 10.1016/j.ophtha.2019.01.027
   Grewal DS, 2016, JAMA OPHTHALMOL, V134, P229, DOI 10.1001/jamaophthalmol.2015.5237
   Gupta A, 2015, INT J BIOMATER, V2015, DOI 10.1155/2015/274082
   Gupta K, 2015, J RADIOL CASE REP, V9, P12, DOI 10.3941/jrcr.v9i3.2115
   Heerema-McKenney A, 2018, APMIS, V126, P570, DOI 10.1111/apm.12847
   Hirakata A, 2005, OPHTHALMOLOGY, V112, P1430, DOI 10.1016/j.ophtha.2005.02.013
   Imai M, 1999, AM J OPHTHALMOL, V128, P621, DOI 10.1016/S0002-9394(99)00200-7
   Kang SW, 2003, BRIT J OPHTHALMOL, V87, P1015, DOI 10.1136/bjo.87.8.1015
   Kaur Jaspreet, 2018, J Indian Soc Periodontol, V22, P235, DOI 10.4103/jisp.jisp_119_18
   Kheirkhah A, 2008, AM J OPHTHALMOL, V146, P266, DOI 10.1016/j.ajo.2008.03.028
   Kiilgaard Jens Folke, 2012, Stem Cells Int, V2012, P716968, DOI 10.1155/2012/716968
   Kumagai K, 2010, AM J OPHTHALMOL, V149, P127, DOI 10.1016/j.ajo.2009.08.002
   KURIYAMA S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1559, DOI 10.1001/archopht.1990.01070130061031
   Lai CC, 2015, OPHTHALMOLOGY, V122, P1889, DOI 10.1016/j.ophtha.2015.05.040
   Lee SM, 2018, ACTA OPHTHALMOL, V96, pE406, DOI 10.1111/aos.13504
   Li W, 2008, J CELL PHYSIOL, V215, P657, DOI 10.1002/jcp.21345
   Lim LS, 2014, OPHTHALMOLOGY, V121, P305, DOI 10.1016/j.ophtha.2013.08.033
   Liu PK, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0909-9
   Marcus AJ, 2008, J CELL MOL MED, V12, P1256, DOI 10.1111/j.1582-4934.2008.00180.x
   Marcus AJ, 2008, J CELL MOL MED, V12, P730, DOI 10.1111/j.1582-4934.2008.00221.x
   Marcus AJ, 2008, DIFFERENTIATION, V76, P130, DOI 10.1111/j.1432-0436.2007.00194.x
   MATSUMURA M, 1992, OPHTHALMOLOGICA, V204, P122, DOI 10.1159/000310281
   Meng H, 2011, NEUROSCI LETT, V496, P48, DOI 10.1016/j.neulet.2011.03.090
   Mohammed OA, 2013, MIDDLE EAST AFR J OP, V20, P357, DOI 10.4103/0974-9233.120008
   Morizane Y, 2014, AM J OPHTHALMOL, V157, P861, DOI 10.1016/j.ajo.2013.12.028
   Murri MS, 2018, CLIN OPHTHALMOL, V12, P1105, DOI 10.2147/OPTH.S165553
   Niknejad H, 2016, CELL TISSUE RES, V363, P599, DOI 10.1007/s00441-016-2364-3
   Niknejad H, 2015, MED HYPOTHESES, V85, P197, DOI 10.1016/j.mehy.2015.04.030
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Olaya-C M, 2019, J Neonatal Perinatal Med, V12, P47, DOI 10.3233/NPM-1795
   Otani T, 2019, PEDIATR RES, V85, P97, DOI 10.1038/s41390-018-0131-8
   Parolini B, 2018, RETINA-J RET VIT DIS, V38, pS12, DOI 10.1097/IAE.0000000000001914
   Peng J, 2018, RETINA-J RET VIT DIS, V38, P2177, DOI 10.1097/IAE.0000000000001830
   Postel E A, 1998, Trans Am Ophthalmol Soc, V96, P73
   Postel EA, 1998, T AM OPHTHAL SOC, V96, P88
   Riccio M, 2019, J CELL PHYSIOL, V234, P3362, DOI 10.1002/jcp.27299
   Rizzo S, 2020, OPHTHALMOL RETINA, V4, P996, DOI 10.1016/j.oret.2020.04.017
   Rizzo Stanislao, 2020, Retina, DOI 10.1097/IAE.0000000000002753
   Rizzo S, 2019, RETINA-J RET VIT DIS, V39, P95, DOI 10.1097/IAE.0000000000002320
   Rizzo S, 2018, RETINA-J RET VIT DIS, V38, P198, DOI 10.1097/IAE.0000000000001636
   Sadraie SH, 2016, ARCH IRAN MED, V19, P612, DOI 0161909/AIM.003
   Sane MS, 2018, REGEN MED, V13, P689, DOI 10.2217/rme-2018-0085
   Shah PK, 2017, OSLI RETINA, V48, P251, DOI 10.3928/23258160-20170301-09
   Tehrani FA, 2013, CRYOBIOLOGY, V67, P293, DOI 10.1016/j.cryobiol.2013.08.010
   Tosi GM, 2005, J CELL PHYSIOL, V202, P849, DOI 10.1002/jcp.20181
   Tosi GM, 2005, J CELL PHYSIOL, V202, P852, DOI 10.1002/jcp.20180
   Travassos AS, 2013, RETINA-J RET VIT DIS, V33, P1708, DOI 10.1097/IAE.0b013e31828e699c
   Tseng SCG, 2001, BIOSCIENCE REP, V21, P481, DOI 10.1023/A:1017995810755
   Tseng Scheffer C G, 2004, Ocul Surf, V2, P177
   Waked Naji, 2005, J Med Liban, V53, P39
   Wu AL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0898-8
NR 66
TC 1
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2675
DI 10.3390/jcm9082675
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NL2UL
UT WOS:000567276800001
PM 32824838
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sennlaub, F
   Auvynet, C
   Calippe, B
   Lavalette, S
   Poupel, L
   Hu, SJ
   Dominguez, E
   Camelo, S
   Levy, O
   Guyon, E
   Saederup, N
   Charo, IF
   Van Rooijen, N
   Nandrot, E
   Bourges, JL
   Behar-Cohen, F
   Sahel, JA
   Guillonneau, X
   Raoul, W
   Combadiere, C
AF Sennlaub, Florian
   Auvynet, Constance
   Calippe, Bertrand
   Lavalette, Sophie
   Poupel, Lucie
   Hu, Shulong J.
   Dominguez, Elisa
   Camelo, Serge
   Levy, Olivier
   Guyon, Elodie
   Saederup, Noah
   Charo, Israel F.
   Van Rooijen, Nico
   Nandrot, Emeline
   Bourges, Jean-Louis
   Behar-Cohen, Francine
   Sahel, Jose-Alain
   Guillonneau, Xavier
   Raoul, William
   Combadiere, Christophe
TI CCR2(+) monocytes infiltrate atrophic lesions in age-related macular
   disease and mediate photoreceptor degeneration in experimental
   subretinal inflammation in Cx3cr1 deficient mice
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular disease; chemokines; monocyte; neurodegeneration;
   neuroinflammation
ID FACTOR-H POLYMORPHISM; CHEMOATTRACTANT PROTEIN-1; RETINAL DEGENERATION;
   BONE-MARROW; GEOGRAPHIC ATROPHY; MYELOID CELLS; MICROGLIA; RECEPTOR;
   EXPRESSION; CHEMOKINE
AB Atrophic age-related macular degeneration (AMD) is associated with the subretinal accumulation of mononuclear phagocytes (MPs). Their role in promoting or inhibiting retinal degeneration is unknown. We here show that atrophic AMD is associated with increased intraocular CCL2 levels and subretinal CCR2(+) inflammatory monocyte infiltration in patients. Using age- and light-induced subretinal inflammation and photoreceptor degeneration in Cx3cr1 knockout mice, we show that subretinal Cx3cr1 deficient MPs overexpress CCL2 and that both the genetic deletion of CCL2 or CCR2 and the pharmacological inhibition of CCR2 prevent inflammatory monocyte recruitment, MP accumulation and photoreceptor degeneration in vivo. Our study shows that contrary to CCR2 and CCL2, CX3CR1 is constitutively expressed in the retina where it represses the expression of CCL2 and the recruitment of neurotoxic inflammatory CCR2(+) monocytes. CCL2/CCR2 inhibition might represent a powerful tool for controlling inflammation and neurodegeneration in AMD.
C1 [Sennlaub, Florian; Auvynet, Constance; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Dominguez, Elisa; Camelo, Serge; Levy, Olivier; Guyon, Elodie; Nandrot, Emeline; Sahel, Jose-Alain; Guillonneau, Xavier; Raoul, William] INSERM, U 968, Paris, France.
   [Sennlaub, Florian; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Dominguez, Elisa; Camelo, Serge; Levy, Olivier; Nandrot, Emeline; Sahel, Jose-Alain; Guillonneau, Xavier; Raoul, William] Univ Paris 06, UPMC, UMR S 968, Inst Vis, Paris, France.
   [Sennlaub, Florian; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Dominguez, Elisa; Camelo, Serge; Levy, Olivier; Nandrot, Emeline; Sahel, Jose-Alain; Guillonneau, Xavier; Raoul, William] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM, DHOS CIC 503, Paris, France.
   [Sennlaub, Florian; Bourges, Jean-Louis; Behar-Cohen, Francine] Ctr Rech Ophtalmol, Hotel Dieu, Serv Ophtalmol, Paris, France.
   [Auvynet, Constance; Poupel, Lucie; Guyon, Elodie; Combadiere, Christophe] Lab Immunite & Infect, INSERM, UMR S 945, Paris, France.
   [Auvynet, Constance; Poupel, Lucie; Guyon, Elodie; Combadiere, Christophe] Univ Paris 06, UPMC, UMR S 945, Paris, France.
   [Saederup, Noah; Charo, Israel F.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA.
   [Saederup, Noah; Charo, Israel F.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.
   [Van Rooijen, Nico] Free Univ Amsterdam, Dept Mol Cell Biol, Med Ctr, Amsterdam, Netherlands.
   [Bourges, Jean-Louis; Behar-Cohen, Francine] Ctr Rech Cordeliers, INSERM, UMR S 872, Paris, France.
   [Bourges, Jean-Louis; Behar-Cohen, Francine] Univ Paris 05, Ctr Rech Cordeliers, UMR S 872, Paris, France.
   [Bourges, Jean-Louis; Behar-Cohen, Francine] Univ Paris 06, UPMC, UMR S 872, Paris, France.
   [Combadiere, Christophe] Grp Hosp Pitie Salpetriere, AP HP, Serv Immunol, F-75634 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; University of California System; University of California
   San Francisco; The J David Gladstone Institutes; University of
   California System; University of California San Francisco; Vrije
   Universiteit Amsterdam; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP; UDICE-French Research Universities; Sorbonne Universite
RP Sennlaub, F (通讯作者)，INSERM, U 968, Paris, France.
EM florian.sennlaub@inserm.fr; christophe.combadiere@upmc.fr
RI Combadiere, Christophe/I-5639-2013; Sahel, Jose-Alain/F-3172-2017;
   guillonneau, xavier/AAF-9495-2021; Nandrot, Emeline F./AAN-3925-2020;
   Raoul, William/H-2118-2018; Sennlaub, Florian/F-2756-2017; Van Rooijen,
   Nico/Z-1578-2019; Guillonneau, xavier/E-3995-2017
OI Combadiere, Christophe/0000-0002-1755-4531; Sahel,
   Jose-Alain/0000-0002-4831-1153; guillonneau, xavier/0000-0001-7379-3935;
   Raoul, William/0000-0002-5040-3372; Sennlaub,
   Florian/0000-0003-4412-1341; Guillonneau, xavier/0000-0001-7379-3935;
   Nandrot, Emeline/0000-0003-3087-078X; Camelo, Serge/0000-0001-8733-8503;
   BOURGES, Jean-Louis/0000-0002-7016-9819; Poupel,
   Lucie/0000-0001-7015-8450
FU INSERM; ANR blanc [AO5120DD]; ANR Maladies Neurologiques et
   Psychiatriques [ANR-08-MNPS-003]; ANR Geno [R09099DS]; ANR Programme
   Emergence [ANR-EMMA-050]; ERC starting Grant [ERC-2007 St.G. 210345];
   Assistance Publique-Hopitaux de Paris; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTE [R01HL102475] Funding Source: NIH RePORTER
FX The authors wish to thank Christopher Brent Murray for critical review
   of the manuscript, Estelle Devevre from the Plateforme d'imagerie,
   Centre de Recherche des Cordeliers, Universite Pierre et Marie Curie,
   UMR S 872, Paris, France and Anne-Marie Faussat from the Plateformes
   Cytometrie et Imagerie, IFR65, Faculte de medecine Saint-Antoine, Paris.
   This work was supported by grants from INSERM, ANR blanc (AO5120DD), ANR
   Maladies Neurologiques et Psychiatriques (ANR-08-MNPS-003), ANR Geno
   2009 (R09099DS), ANR Programme Emergence 2012 (ANR-EMMA-050), and ERC
   starting Grant (ERC-2007 St.G. 210345) FS and CC are recipients of a
   contract 'Interface' from Assistance Publique-Hopitaux de Paris.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chen M., 2011, PLOS ONE, V6
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hisatomi T, 2003, AM J PATHOL, V162, P1869, DOI 10.1016/S0002-9440(10)64321-0
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Levy OE, 2011, ARVO M, V52, P968
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Paques M, 2006, VISION RES, V46, P1336, DOI 10.1016/j.visres.2005.09.037
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7
   Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yang X, 2010, BR J OPHTHALMOL
NR 76
TC 190
Z9 198
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD NOV
PY 2013
VL 5
IS 11
BP 1775
EP 1793
DI 10.1002/emmm.201302692
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 245KT
UT WOS:000326463300010
PM 24142887
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Truong, A
   Wong, TY
   Khachigian, LM
AF An Truong
   Wong, Tien Y.
   Khachigian, Levon M.
TI Emerging therapeutic approaches in the management of retinal
   angiogenesis and edema
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE Retinal angiogenesis; Retinal edema; Age-related macular degeneration
   (AMD); Diabetic retinopathy (DR); Neuronal degeneration; Anti-VEGF
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; CILIARY
   NEUROTROPHIC FACTOR; PIGMENT EPITHELIAL TEAR; COMPLEMENT FACTOR-H;
   MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; DIABETIC-RETINOPATHY; VISUAL IMPAIRMENT
AB Conditions resulting in retinal angiogenesis and edema (exudative age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and retinopathy of prematurity) are major causes of visual impairment, with significant impact on quality of life. There has been increasing clinical usage of anti-vascular endothelial growth factor (anti-VEGF) agents to stop retinal angiogenesis and resolve intraretinal fluid arising from these conditions. However, anti-VEGFs have not been completely successful in curing these conditions, and a range of emerging treatments aimed at supplementing or competing with anti-VEGF agents are being developed. We will discuss the proposed merits these emerging agents bring to the treatment arsenal and how they compare with anti-VEGFs with regards to therapeutic activity, potency, specificity and safety. This review will also highlight recent pre-clinical research findings and suggest where future research might be directed.
C1 [An Truong; Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 University of New South Wales Sydney; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; National
   University of Singapore; Singapore National Eye Center
RP Khachigian, LM (通讯作者)，Univ New S Wales, Ctr Vasc Res, Lowy Canc Res Ctr, 3rd Floor, Sydney, NSW 2052, Australia.
EM L.Khachigian@unsw.edu.au
RI Khachigian, Levon/AAZ-7458-2020; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Khachigian,
   Levon/0000-0003-3446-0323
FU NHMRC; Allergan; Bayer; Novartis; Pfizer; Solvay
FX This work was supported in part by a funding from the NHMRC.; TW reports
   receiving consulting and speaking fees and travel support from Allergan,
   Bayer, Novartis, Pfizer and Solvay. LK reports UNSW has IP interests
   surrounding Dz13.
CR Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arimura N, 2009, OPHTHALMOLOGY, V116, P921, DOI 10.1016/j.ophtha.2008.12.024
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Blumenkranz MS, 2010, EYE, V24, P428, DOI 10.1038/eye.2009.335
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Bush RA, 2004, INVEST OPHTH VIS SCI, V45, P2420, DOI 10.1167/iovs.03-1342
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   CUNHAVAZ J, 1979, SURV OPHTHALMOL, V23, P279, DOI 10.1016/0039-6257(79)90158-9
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Davuluri G, 2009, ARCH OPHTHALMOL-CHIC, V127, P613, DOI 10.1001/archophthalmol.2009.88
   Dejneka NS, 2004, MOL VIS, V10, P964
   Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8
   Donello JE, 2001, J PHARMACOL EXP THER, V296, P216
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ejaz S, 2008, DIABETES OBES METAB, V10, P53, DOI 10.1111/j.1463-1326.2007.00795.x
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Essex RW, 2007, BRIT J OPHTHALMOL, V91, P649, DOI 10.1136/bjo.2005.089458
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fahmy RG, 2006, NAT BIOTECHNOL, V24, P856, DOI 10.1038/nbt1225
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   FOROOGHIAN F, 2009, ACTA OPHTHA IN PRESS
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   FRAMME C, 2009, INVEST OPHTH VIS SCI, V51, P1671
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Gamulescu MA, 2007, EXPERT OPIN THER PAT, V17, P1351, DOI 10.1517/13543776.17.11.1351
   Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gibbons James J, 2009, Semin Oncol, V36 Suppl 3, pS3, DOI 10.1053/j.seminoncol.2009.10.011
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Honda S, 2008, GRAEF ARCH CLIN EXP, V246, P1061, DOI 10.1007/s00417-008-0786-7
   Houde VP, 2010, DIABETES, V59, P1338, DOI 10.2337/db09-1324
   Ignoffo RJ, 2004, AM J HEALTH-SYST PH, V61, pS21, DOI 10.1093/ajhp/61.suppl_5.S21
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Jiang GM, 2009, INVEST OPHTH VIS SCI, V50, P4769, DOI 10.1167/iovs.08-3303
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Johnston DA, 2009, GENE, V435, P36, DOI 10.1016/j.gene.2009.01.003
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kay MA, 2007, NAT BIOTECHNOL, V25, P1111, DOI 10.1038/nbt1007-1111
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kowluru RA, 2004, DIABETES, V53, P775, DOI 10.2337/diabetes.53.3.775
   Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Kusari J, 2010, INVEST OPHTH VIS SCI, V51, P1044, DOI 10.1167/iovs.08-3293
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal EC, 2005, CNS NEUROL DISORD-DR, V4, P421, DOI 10.2174/1568007054546162
   Ledwith BJ, 2000, INTERVIROLOGY, V43, P258, DOI 10.1159/000053993
   Lee BH, 2005, J CELL BIOCHEM, V95, P1214, DOI 10.1002/jcb.20488
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Luo X, 2009, ARTERIOSCL THROM VAS, V29, P1836, DOI 10.1161/ATVBAHA.109.189753
   MACRON D, 2009, GENOME WEB RNAI 0611
   *MACUSIGHT, 2009, OPH INN SUMM PRES
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Manam S, 2000, INTERVIROLOGY, V43, P273, DOI 10.1159/000053994
   Mayor-Torroglosa S, 2005, INVEST OPHTH VIS SCI, V46, P3825, DOI 10.1167/iovs.05-0392
   McCarty DM, 2004, ANNU REV GENET, V38, P819, DOI 10.1146/annurev.genet.37.110801.143717
   MCLAUGHLIN M, 2010, GTCBIO 2 ANN OC DIS
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mitamura Y, 2005, CURR DIABETES REV, V1, P73, DOI 10.2174/1573399052952596
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Nakai H, 2005, J VIROL, V79, P3606, DOI 10.1128/JVI.79.6.3606-3614.2005
   *NCT, NCT00712491
   *NCT, 2010, NCT00509548
   *NCT, NCT00656643
   *NCT, NCT00612456
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   *NEUR, 2009, RES NEUR NT 501 PHAS
   *NEUR, POS RES NEUR NT 501
   *NEUR, RES NEUR NT 501 PHAS
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nichols WW, 1995, ANN NY ACAD SCI, V772, P30, DOI 10.1111/j.1749-6632.1995.tb44729.x
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   *NT, NT503
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Porteus MH, 2006, PLOS GENET, V2, P1285, DOI 10.1371/journal.pgen.0020133
   *POT PHARM, 2009, POT PHARM POT 4 DRUG
   PRAIDOU A, 2009, ACTA OPHTHA IN PRESS
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   ROBERTS D, 2008, NEW ANTIPDGF APTAMER
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Roh MI, 2009, OPHTHALMOLOGY, V116, P80, DOI 10.1016/j.ophtha.2008.09.036
   Romano G, 2009, DRUG NEWS PERSPECT, V22, P185, DOI 10.1358/dnp.2009.22.4.1367704
   ROSENFELD P, 2010, OPHTHALMOLO IN PRESS
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   RYAN GB, 1977, AM J PATHOL, V86, P183
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai K, 2009, INVEST OPHTH VIS SCI, V50, P4905, DOI 10.1167/iovs.07-1542
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   SCHULZ M, 1987, J VIROL, V61, P344, DOI 10.1128/JVI.61.2.344-353.1987
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shinohara K, 1996, HEART VESSELS, V11, P113, DOI 10.1007/BF01745169
   Shojaei F, 2007, CANCER J, V13, P345, DOI 10.1097/PPO.0b013e31815a7b69
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   SZABO, 2009, BRIT J PHARMACOL, V156, P714
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Valenzuela CF, 1997, BRAIN RES REV, V24, P77
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Vidal-Sanz M, 2001, SURV OPHTHALMOL, V45, pS261, DOI 10.1016/S0039-6257(01)00205-3
   *VITPS GROUP, 2001, AM J OPHTHALMOL, V131, P541
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   WALTER DK, 2004, BR J CLIN PHARM, V58, P601
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213
   WEI L, 2007, AM SOC GEN THER ANN
   WEI L, 2004, ARVO 2004 M
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726
   Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120
   Zhang GS, 2006, J CELL SCI, V119, P3219, DOI 10.1242/jcs.03059
   Zhang XY, 2009, INT J BIOCHEM CELL B, V41, P2368, DOI 10.1016/j.biocel.2009.07.011
   2010, INVEST OPHTHALMOL VI, V51, P1606
NR 183
TC 23
Z9 25
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD APR
PY 2011
VL 89
IS 4
BP 343
EP 361
DI 10.1007/s00109-010-0709-z
PG 19
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 752KD
UT WOS:000289689200004
PM 21170513
DA 2022-11-30
ER

PT J
AU Shen, DF
   Wen, R
   Tuo, JS
   Bojanowski, CM
   Chan, CC
AF Shen, DF
   Wen, R
   Tuo, JS
   Bojanowski, CM
   Chan, CC
TI Exacerbation of retinal degeneration and choroidal neovascularization
   induced by subretinal injection of matrigel in CCL2/MCP-1-deficient mice
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE neovascularization; retinal degeneration; CCL2; matrigel; macular
   degeneration, age-related
ID MACULAR DEGENERATION; GROWTH-FACTOR; MODEL; PATHOGENESIS; MEMBRANE
AB This study presents a mouse model for human age-related macular degeneration (AMD) as characterized by subretinal deposit and choroidal neovascularization. Matrigel, a basement membrane extract, solidifies after implantation in tissue and can stimulate local angiogenesis. This study demonstrates the induction of neovascularization and focal retinal degeneration following subretinal Matrigel injection in mice. In senescent mice, the normal functioning of CC chemokine CCL2/MCP-1 and its receptor CCR2 confers protection against age-related retinal degeneration, a disease that shares many similar features with human AMD. Our data shows that CCL2-deficient mice develop more severe disease as compared to the wild-type controls. These findings suggest that Matrigel subretinal injection could be used to generate AMD-like pathological changes. The data support the previously proposed role of CCL2 in AMD pathogenesis. Copyright (C) 2006 S. Karger AG, Basel.
C1 NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Pennsylvania
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10,Rm 10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810
FU Intramural NIH HHS [Z01 EY000222-22] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [Z01EY000418, Z01EY000222] Funding Source: NIH RePORTER
CR AKHTAR N, 2000, ANGIOGENESIS, V5, P75
   Albini A, 2004, INT J DEV BIOL, V48, P563, DOI 10.1387/ijdb.041822aa
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BAFFI J, 2004, INVEST OPHTH VIS SCI, V1, P3582
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Miller JW, 1997, AM J PATHOL, V151, P13
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Tuaillon N, 2002, INVEST OPHTH VIS SCI, V43, P1493
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 17
TC 25
Z9 26
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2006
VL 38
IS 2
BP 71
EP 73
DI 10.1159/000090266
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 018YP
UT WOS:000235801600004
PM 16352919
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Kim, J
   Han, SY
   Min, H
AF Kim, Jisu
   Han, Su-Young
   Min, Hyeyoung
TI Ginseng for an eye: effects of ginseng on ocular diseases
SO JOURNAL OF GINSENG RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Cataract; Diabetic retinopathy;
   Ginseng; Glaucoma
ID ENDOPLASMIC-RETICULUM STRESS; RETINAL-PIGMENT EPITHELIUM; PROCESSED
   PANAX-GINSENG; DIABETIC-RETINOPATHY; DOUBLE-BLIND; SUN GINSENG; ANATOMY;
   DAMAGE; DRUG; PERMEABILITY
AB The sense of vision is the primary means by which we gather information from our surroundings, and vision loss, therefore, severely compromises the life of the affected individuals, their families, and society. Loss of vision becomes more frequent with age, and diabetic retinopathy, age-related macular degeneration, cataracts, and glaucoma are the major causes of vision impairment. To find active pharmacological compounds that might prevent or ameliorate the vision-threatening eye diseases, numerous studies have been performed, and some botanical compounds, including those extracted from ginseng, have been shown to possess beneficial effects in the treatment or prevention of common ocular diseases. In this review, we summarize the recent reports investigating the therapeutic effects of ginseng and ginsenosides on diverse ocular diseases and discuss their therapeutic potential. (C) 2019 The Korean Society of Ginseng. Publishing services by Elsevier B.V.
C1 [Kim, Jisu; Han, Su-Young; Min, Hyeyoung] Chung Ang Univ, Coll Pharm, 84 Heukseokro, Seoul 06974, South Korea.
C3 Chung Ang University
RP Min, H (通讯作者)，Chung Ang Univ, Coll Pharm, 84 Heukseokro, Seoul 06974, South Korea.
EM hymin@cau.ac.kr
FU National Research Foundation (NRF) - Ministry of Science, ICT, and
   Future Planning [2015R1C1A2A01054457]; Chung-Ang University
FX This work was supported by the National Research Foundation (NRF) funded
   by the Ministry of Science, ICT, and Future Planning
   (2015R1C1A2A01054457 to H.M.), and by the Chung-Ang University Research
   Scholarship Grants in 2018 (S.H.).
CR [Anonymous], 2008, CHIN J INTEGR MED, V14, P33, DOI [10.1007/s11655-007-9002, 10.1007/s11655-007-9002-6]
   Bae HW, 2015, J GINSENG RES, V39, P7, DOI 10.1016/j.jgr.2014.07.002
   BEEBE DC, 1986, T OPHTHAL SOC UK, V105, P123
   Betts Brandi S., 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P3643
   Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brzezinski JA, 2015, DEVELOPMENT, V142, P3263, DOI 10.1242/dev.127043
   Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y
   Chang WH, 2015, J INT SOC SPORT NUTR, V12, DOI 10.1186/s12970-015-0095-6
   Chang ZY, 2016, SCI CHINA LIFE SCI, V59, P81, DOI 10.1007/s11427-015-4988-z
   Chen JC, 2001, AM J CHINESE MED, V29, P155, DOI 10.1142/S0192415X01000174
   Chen SY, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3183805
   Chen Zhe-Jing, 2007, Zhonghua Wei Chang Wai Ke Za Zhi, V10, P64
   Das A, 2016, INVEST OPHTH VIS SCI, V57, P6669, DOI 10.1167/iovs.16-21031
   Doozandeh Azadeh, 2016, J Ophthalmic Vis Res, V11, P209, DOI 10.4103/2008-322X.183923
   Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035
   Fan CL, 2017, DRUG DES DEV THER, V11, P3343, DOI 10.2147/DDDT.S149700
   Fan Y, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/5326382
   Feder RS, 2016, OPHTHALMOLOGY, V123, pP152, DOI 10.1016/j.ophtha.2015.10.048
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gao DH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/578165
   Jian WJ, 2016, J ETHNOPHARMACOL, V182, P50, DOI 10.1016/j.jep.2015.11.021
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kim SH, 2015, PHYTOTHER RES, V29, P1910, DOI 10.1002/ptr.5480
   Kim WY, 2000, J NAT PROD, V63, P1702, DOI 10.1021/np990152b
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   Lee H, 2012, J GINSENG RES, V36, P248, DOI 10.5142/jgr.2012.36.3.248
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Li Y, 2016, ONCOTARGET, V7, P70535, DOI 10.18632/oncotarget.12059
   Lian FM, 2015, J ETHNOPHARMACOL, V164, P71, DOI 10.1016/j.jep.2015.01.048
   Lin JB, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.3
   Lu JM, 2009, CURR VASC PHARMACOL, V7, P293, DOI 10.2174/157016109788340767
   Maeng YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068659
   Malhotra A, 2011, SEMIN ULTRASOUND CT, V32, P2, DOI 10.1053/j.sult.2010.10.009
   Mathenge Wanjiku, 2014, Community Eye Health, V27, P49
   Mathur S, 2017, BIOMED REP, V6, P612, DOI 10.3892/br.2017.909
   MCCAA CS, 1982, ENVIRON HEALTH PERSP, V44, P1, DOI 10.2307/3429469
   Moreau KL, 2012, TRENDS MOL MED, V18, P273, DOI 10.1016/j.molmed.2012.03.005
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   SANNGMOK LEE，, 2010, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V51, P733
   Sen S, 2013, PHYTOTHER RES, V27, P290, DOI 10.1002/ptr.4719
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Smerdon D, 2000, CURR ANAESTH CRIT CA, V11, P286
   Song KC, 2012, J GINSENG RES, V36, P61, DOI 10.5142/jgr.2012.36.1.61
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun HQ, 2010, INT J OPHTHALMOL-CHI, V3, P220, DOI 10.3980/j.issn.2222-3959.2010.03.09
   Sun Yan, 2006, Zhongguo Fei Ai Za Zhi, V9, P254, DOI 10.3779/j.issn.1009-3419.2006.03.09
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Truscott RJW, 2016, BBA-GEN SUBJECTS, V1860, P192, DOI 10.1016/j.bbagen.2015.08.016
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Wang DD, 2016, J AGR FOOD CHEM, V64, P1528, DOI 10.1021/acs.jafc.5b05864
   Wang LF, 2018, EXP THER MED, V15, P300, DOI 10.3892/etm.2017.5386
   WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Yang H, 2016, J GINSENG RES, V40, P1, DOI 10.1016/j.jgr.2015.03.003
NR 59
TC 5
Z9 5
U1 3
U2 15
PU KOREAN SOC GINSENG
PI SEOCHO-GU
PA 1807 SEOCHO WORLD OFFICETEL, 1355-3 SEOCHO-DONG, SEOCHO-GU, SEOUL
   137-862, SOUTH KOREA
SN 1226-8453
EI 2093-4947
J9 J GINSENG RES
JI J. Ginseng Res.
PD JAN
PY 2020
VL 44
IS 1
BP 1
EP 7
DI 10.1016/j.jgr.2018.11.006
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA JZ4CC
UT WOS:000505047900001
PM 32095091
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kanellopoulos, JM
   Delarasse, C
AF Kanellopoulos, Jean M.
   Delarasse, Cecile
TI Pleiotropic Roles of P2X7 in the Central Nervous System
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE purinergic receptor; P2X7; ATP; nervous system; neurodegenerative
   disease; neurologic disease; demyelinating disease; animal model
ID GENOME-WIDE ASSOCIATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   P2X(7) RECEPTOR EXPRESSION; AMYLOID PRECURSOR PROTEIN; PORE FORMATION;
   MULTIPLE-SCLEROSIS; NLRP3 INFLAMMASOME; GASDERMIN-D; IL-1-BETA
   SECRETION; ALZHEIMERS-DISEASE
AB The purinergic receptor P2X7 is expressed in neural and immune cells known to be involved in neurological diseases. Its ligand, ATP, is a signaling molecule that can act as a neurotransmitter in physiological conditions or as a danger signal when released in high amount by damaged/dying cells or activated glial cells. Thus, ATP is a danger-associated molecular pattern. Binding of ATP by P2X7 leads to the activation of different biochemical pathways, depending on the physiological or pathological environment. The aim of this review is to discuss various functions of P2X7 in the immune and central nervous systems. We present evidence that P2X7 may have a detrimental or beneficial role in the nervous system, in the context of neurological pathologies: epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, age-related macular degeneration and cerebral artery occlusion.
C1 [Kanellopoulos, Jean M.] Univ Paris Saclay, CNRS, I2BC, Orsay, France.
   [Delarasse, Cecile] Sorbonne Univ, Inst Vis, CNRS, Inserm, Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite Paris Saclay; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite
RP Delarasse, C (通讯作者)，Sorbonne Univ, Inst Vis, CNRS, Inserm, Paris, France.
EM cecile.dektrasse@upmc.fr
RI Delarasse, Cecile/K-8234-2017
OI Delarasse, Cecile/0000-0001-9739-4306
FU Agence Nationale de la Recherche [ANR-12-MALZ-0003-02-P2X7RAD]; Inserm;
   CNRS; Sorbonne Universite; Universite Paris-Saclay
FX This work was supported by grant from the Agence Nationale de la
   Recherche (ANR-12-MALZ-0003-02-P2X7RAD). CD's laboratory is also
   supported by Inserm, CNRS and Sorbonne Universite. JK is funded by CNRS
   and Universite Paris-Saclay.
CR Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025
   Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947
   Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601
   Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Alberto AVP, 2013, N-S ARCH PHARMACOL, V386, P775, DOI 10.1007/s00210-013-0868-x
   Amadio S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01529
   Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105
   Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101
   Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463
   Apolloni S, 2013, HUM MOL GENET, V22, P4102, DOI 10.1093/hmg/ddt259
   Apolloni S, 2013, J IMMUNOL, V190, P5187, DOI 10.4049/jimmunol.1203262
   Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200
   Bahlo M, 2009, NAT GENET, V41, P824, DOI 10.1038/ng.396
   Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206
   Barros-Barbosa AR, 2016, EPILEPSIA, V57, P99, DOI 10.1111/epi.13263
   Barth K, 2007, FEBS J, V274, P3021, DOI 10.1111/j.1742-4658.2007.05830.x
   Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003
   Beamer E, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00021
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   BEYER EC, 1991, J BIOL CHEM, V266, P7971
   Bianco F, 2006, J NEUROCHEM, V99, P745, DOI 10.1111/j.1471-4159.2006.04101.x
   BURNSTOCK G, 1972, BRIT J PHARMACOL, V46, P234, DOI 10.1111/j.1476-5381.1972.tb06868.x
   BURNSTOCK G, 1972, PHARMACOL REV, V24, P509
   Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chen LF, 2006, J IMMUNOL, V176, P3115, DOI 10.4049/jimmunol.176.5.3115
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Christy AL, 2013, J AUTOIMMUN, V42, P50, DOI 10.1016/j.jaut.2012.11.003
   Cotsapas C, 2018, CELL, V175, P1679, DOI 10.1016/j.cell.2018.09.049
   Cruchaga C, 2013, NEURON, V78, P256, DOI 10.1016/j.neuron.2013.02.026
   Csoka B, 2015, FASEB J, V29, P3626, DOI 10.1096/fj.15-272450
   Cullen SP, 2015, CELL REP, V11, P1535, DOI 10.1016/j.celrep.2015.05.003
   D'Souza CS, 2018, J NEUROPATH EXP NEUR, V77, P567, DOI 10.1093/jnen/nly032
   Damotte V, 2014, GENES IMMUN, V15, P126, DOI 10.1038/gene.2013.70
   Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033
   Danquah W, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8463
   Darmellah A, 2012, J BIOL CHEM, V287, P34583, DOI 10.1074/jbc.M112.400010
   Delarasse C, 2011, J BIOL CHEM, V286, P2596, DOI 10.1074/jbc.M110.200618
   Delarasse C, 2009, J NEUROCHEM, V109, P846, DOI 10.1111/j.1471-4159.2009.06008.x
   Di AK, 2018, IMMUNITY, V49, P56, DOI 10.1016/j.immuni.2018.04.032
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Di Virgilio F, 2018, TRENDS CELL BIOL, V28, P392, DOI 10.1016/j.tcb.2018.01.005
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Domercq M, 2019, CURR OPIN PHARMACOL, V47, P119, DOI 10.1016/j.coph.2019.03.010
   Domingo-Fernandez R, 2017, J BIOL CHEM, V292, P12077, DOI 10.1074/jbc.M117.797126
   Donnelly-Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476-5381.2009.00233.x
   Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600
   Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089
   Evavold CL, 2018, IMMUNITY, V48, P35, DOI 10.1016/j.immuni.2017.11.013
   Evavold CL, 2018, J MOL BIOL, V430, P217, DOI 10.1016/j.jmb.2017.09.019
   Fabbrizio P, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00249
   Faivre E, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00235
   Faria RX, 2005, AM J PHYSIOL-CELL PH, V288, pC260, DOI 10.1152/ajpcell.00215.2004
   Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Garcia-Marcos M, 2006, J LIPID RES, V47, P705, DOI 10.1194/jlr.M500408-JLR200
   Gonnord P, 2009, FASEB J, V23, P795, DOI 10.1096/fj.08-114637
   Green JP, 2018, P NATL ACAD SCI USA, V115, pE9371, DOI 10.1073/pnas.1812744115
   Gu BJ, 2018, BRIT J PHARMACOL, V175, P4195, DOI 10.1111/bph.14470
   Gu BJ, 2015, HUM MOL GENET, V24, P5644, DOI 10.1093/hmg/ddv278
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Habbas S, 2011, GLIA, V59, P1800, DOI 10.1002/glia.21224
   Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Harkat M, 2017, P NATL ACAD SCI USA, V114, pE3786, DOI 10.1073/pnas.1701379114
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Hashimoto-Hill S, 2017, MUCOSAL IMMUNOL, V10, P912, DOI 10.1038/mi.2016.109
   Hattori M, 2012, NATURE, V485, P207, DOI 10.1038/nature11010
   He YB, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0904-8
   He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959
   Hechler B, 2011, PURINERG SIGNAL, V7, P293, DOI 10.1007/s11302-011-9247-6
   Heilig R, 2018, EUR J IMMUNOL, V48, P584, DOI 10.1002/eji.201747404
   Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729
   Hill LM, 2010, J IMMUNOL, V185, P3028, DOI 10.4049/jimmunol.1001298
   Hirayama Y, 2015, J NEUROSCI, V35, P3794, DOI 10.1523/JNEUROSCI.4218-14.2015
   Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Diaz-Hernandez JI, 2012, NEUROBIOL AGING, V33, P1816, DOI 10.1016/j.neurobiolaging.2011.09.040
   Illes P, 2019, EXPERT OPIN THER TAR, V23, P165, DOI 10.1080/14728222.2019.1575811
   Illes P, 2017, J NEUROSCI, V37, P7049, DOI 10.1523/JNEUROSCI.3103-16.2017
   Janks L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1353-8
   Jansen IE, 2019, NAT GENET, V51, P404, DOI 10.1038/s41588-018-0311-9
   Jimenez-Pacheco A, 2016, J NEUROSCI, V36, P5920, DOI 10.1523/JNEUROSCI.4009-15.2016
   Jun G, 2010, ARCH NEUROL-CHICAGO, V67, P1473, DOI 10.1001/archneurol.2010.201
   Kaczmarek-Hajek K, 2018, ELIFE, V7, DOI 10.7554/eLife.36217
   Kahner BN, 2006, J THROMB HAEMOST, V4, P2317, DOI 10.1111/j.1538-7836.2006.02192.x
   Karasawa A, 2017, ELIFE, V6, DOI 10.7554/eLife.31186
   Karasawa A, 2016, ELIFE, V5, DOI 10.7554/eLife.22153
   Kasuya G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00887-9
   Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x
   Kawate T, 2009, NATURE, V460, P592, DOI 10.1038/nature08198
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khadra A, 2013, BIOPHYS J, V104, P2612, DOI 10.1016/j.bpj.2013.05.006
   Kim JE, 2011, J CLIN INVEST, V121, P2037, DOI 10.1172/JCI44818
   Koch-Nolte F, 2019, CURR OPIN PHARMACOL, V47, P110, DOI 10.1016/j.coph.2019.03.001
   Kong Qiongman, 2005, Purinergic Signal, V1, P337, DOI 10.1007/s11302-005-7145-5
   Kunkle BW, 2019, NAT GENET, V51, P414, DOI 10.1038/s41588-019-0358-2
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Langer HF, 2012, CIRC RES, V110, P1202, DOI 10.1161/CIRCRESAHA.111.256370
   Le Feuvre RA, 2003, J CEREBR BLOOD F MET, V23, P381, DOI 10.1097/01.WCB.0000048519.34839.97
   Leeson HC, 2018, STEM CELLS, V36, P1764, DOI 10.1002/stem.2894
   Leon-Otegui M, 2011, FEBS LETT, V585, P2255, DOI 10.1016/j.febslet.2011.05.048
   Liu T, 2014, CELL REP, V8, P974, DOI 10.1016/j.celrep.2014.07.012
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Lorden G, 2017, J EXP MED, V214, P511, DOI 10.1084/jem.20161452
   Lovelace MD, 2015, STEM CELLS, V33, P526, DOI 10.1002/stem.1864
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Mahaut-Smith MP, 2011, PURINERG SIGNAL, V7, P341, DOI 10.1007/s11302-011-9224-0
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Marioni RE, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0150-6
   Martin E, 2019, MOL PSYCHIATR, V24, P108, DOI 10.1038/s41380-018-0108-3
   Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868
   Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081
   Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007
   McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3
   Mellouk A, 2019, FASEB J, V33, P3225, DOI 10.1096/fj.201800867R
   Messemer N, 2013, NEUROPHARMACOLOGY, V73, P122, DOI 10.1016/j.neuropharm.2013.05.017
   Metzger MW, 2017, PURINERG SIGNAL, V13, P153, DOI 10.1007/s11302-016-9546-z
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009
   Morciano G, 2017, NAT PROTOC, V12, P1542, DOI 10.1038/nprot.2017.052
   Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801
   Narcisse L, 2005, GLIA, V49, P245, DOI 10.1002/glia.20110
   Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134
   Ousingsawat J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7245
   Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Peverini L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00265
   Pippel A, 2017, P NATL ACAD SCI USA, V114, pE2156, DOI 10.1073/pnas.1610414114
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913
   Qu Y, 2011, J IMMUNOL, V186, P6553, DOI 10.4049/jimmunol.1100478
   Qu Y, 2009, PURINERG SIGNAL, V5, P163, DOI 10.1007/s11302-009-9132-8
   Ramanan Vijay K, 2013, Am J Neurodegener Dis, V2, P145
   Rampe D, 2004, J NEUROIMMUNOL, V147, P56, DOI 10.1016/j.jneuroim.2003.10.014
   Rassendren F, 2016, J NEUROSCI RES, V94, P781, DOI 10.1002/jnr.23770
   Riedel T, 2007, BIOPHYS J, V93, P846, DOI 10.1529/biophysj.106.103614
   Rigato C, 2012, J NEUROSCI, V32, P11559, DOI 10.1523/JNEUROSCI.1042-12.2012
   Rissiek B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00204
   Robinson LE, 2014, J BIOL CHEM, V289, P31983, DOI 10.1074/jbc.M114.574699
   Rodrigues RJ, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00148
   Rozmer K, 2017, CEREB CORTEX, V27, P3568, DOI 10.1093/cercor/bhw178
   Ruhl S, 2018, SCIENCE, V362, P956, DOI 10.1126/science.aar7607
   Russi AE, 2016, J AUTOIMMUN, V73, P100, DOI 10.1016/j.jaut.2016.06.015
   Sabelko-Downes KA, 1999, J NEUROIMMUNOL, V100, P42, DOI 10.1016/S0165-5728(99)00191-5
   Sadovnick AD, 2017, HUM MUTAT, V38, P736, DOI 10.1002/humu.23218
   Safya H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00360
   Sanz JM, 2009, J IMMUNOL, V182, P4378, DOI 10.4049/jimmunol.0803612
   Savio LEB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00052
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696
   Schachter J, 2008, J CELL SCI, V121, P3261, DOI 10.1242/jcs.029991
   Schmid-Burgk JL, 2016, J BIOL CHEM, V291, P103, DOI 10.1074/jbc.C115.700492
   Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813
   Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8
   Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z
   Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33
   Shi HX, 2016, NAT IMMUNOL, V17, P250, DOI 10.1038/ni.3333
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Starossom SC, 2015, CIRC RES, V117, P779, DOI 10.1161/CIRCRESAHA.115.306847
   STEINBERG TH, 1987, J BIOL CHEM, V262, P8884
   Tang TT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00227-x
   Taylor JP, 2016, NATURE, V539, P197, DOI 10.1038/nature20413
   Taylor SRJ, 2009, J LEUKOCYTE BIOL, V85, P978, DOI 10.1189/jlb.0408251
   Miras-Portugal MT, 2017, J NEUROSCI, V37, P7063, DOI 10.1523/JNEUROSCI.3104-16.2017
   Tsao HK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.274
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Witting A, 2006, P NATL ACAD SCI USA, V103, P6362, DOI 10.1073/pnas.0510418103
   Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101
   Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12
   Yip L, 2009, FASEB J, V23, P1685, DOI 10.1096/fj.08-126458
   Young CNJ, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00248
   Zanoni I, 2017, IMMUNITY, V47, P697, DOI 10.1016/j.immuni.2017.09.010
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 182
TC 25
Z9 25
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD SEP 4
PY 2019
VL 13
AR 401
DI 10.3389/fncel.2019.00401
PG 18
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA IU7XW
UT WOS:000483797600001
PM 31551714
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Feng, YJ
   Liang, J
   Zhai, YQ
   Sun, JR
   Wang, J
   She, XJ
   Gu, Q
   Liu, Y
   Zhu, H
   Luo, XT
   Sun, XD
AF Feng, Yiji
   Liang, Jian
   Zhai, Yuanqi
   Sun, Junran
   Wang, Jing
   She, Xiangjun
   Gu, Qing
   Liu, Yang
   Zhu, Hong
   Luo, Xueting
   Sun, Xiaodong
TI Autophagy activated by SIRT6 regulates A beta induced inflammatory
   response in RPEs
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE RPE cells; A beta; Inflammation; SIRT6; Autophagy
ID MACULAR DEGENERATION; RETINAL DEGENERATION; CELL SENESCENCE;
   AMYLOID-BETA; MECHANISMS; DRUSEN; DISEASE
AB Age-associated dysfunction of retinal pigment epithelial cells (RPEs) is considered to be the initial trigger of retinal diseases such as age-related macular degeneration. Although autophagy is upregulated in RPEs during the course of aging, little is known about how autophagy is regulated and its functional role in RPEs. In this study, we found that expression of Sirtuin 6 (SIRT6) and autophagic markers are upregulated in RPEs of aged mice where subretinal deposition of amyloid-beta is accumulated and in amyloid-beta stimulated RPEs. In addition, gain and loss-of-function studies confirmed the positive role of SIRT6 in regulating autophagy. Interesting, inhibition of autophagy attenuates amyloid-beta stimulated inflammatory response in RPEs. Collectively, our findings uncover the autophagy modulated by SIRT6 may be a proinflammatory mechanism for amyloid-beta induced RPE dysfunction. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Feng, Yiji; Liang, Jian; Zhai, Yuanqi; Sun, Junran; Wang, Jing; She, Xiangjun; Liu, Yang; Zhu, Hong; Luo, Xueting; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.
   [Liang, Jian; Gu, Qing; Liu, Yang; Zhu, Hong; Luo, Xueting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Zhai, Yuanqi; Zhu, Hong; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Luo, XT; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xtluo@sjtu.edu.cn; xdsun@sjtu.edu.cn
RI she, xiangjun/AAH-5955-2019
OI Jing, Wang/0000-0003-4477-9442
FU National Natural Science Foundation of China [81730026, 81700828,
   81400413]; Science and Technology Commission of Shanghai Municipality
   [16140900800]; Creative Foundation for Translational Medicine from
   Shanghai Jiao Tong University School of Medicine [15ZH4005]; Program for
   Eastern Young Scholar at Shanghai Institutions of Higher Learning
   [QD2016003]; Shanghai Rising-Star Program [17QA1402800]; Shanghai
   Pujiang Program [16PJ1408500]
FX This work was funded by the National Natural Science Foundation of China
   (81730026, 81700828, 81400413), Science and Technology Commission of
   Shanghai Municipality (16140900800), Creative Foundation for
   Translational Medicine from Shanghai Jiao Tong University School of
   Medicine (15ZH4005), Program for Eastern Young Scholar at Shanghai
   Institutions of Higher Learning (QD2016003), Shanghai Rising-Star
   Program (17QA1402800) and Shanghai Pujiang Program (16PJ1408500).
CR Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Huang N, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317708532
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Lu J, 2016, TRANSL RES, V172, P96, DOI 10.1016/j.trsl.2016.03.002
   Pillai VB, 2014, CIRC RES, V114, P368, DOI 10.1161/CIRCRESAHA.113.300536
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Sun JR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.502
   Takasaka N, 2014, J IMMUNOL, V192, P958, DOI 10.4049/jimmunol.1302341
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Xiao CY, 2012, J BIOL CHEM, V287, P41903, DOI 10.1074/jbc.M112.415182
   ZHANG J, 2015, CELL DEATH DIS, V6
NR 35
TC 13
Z9 15
U1 0
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 19
PY 2018
VL 496
IS 4
BP 1148
EP 1154
DI 10.1016/j.bbrc.2018.01.159
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FX8IT
UT WOS:000426336400021
PM 29402409
DA 2022-11-30
ER

PT J
AU Tan, PL
   Rickman, CB
   Katsanis, N
AF Tan, Perciliz L.
   Rickman, Catherine Bowes
   Katsanis, Nicholas
TI AMD and the alternative complement pathway: genetics and functional
   implications
SO HUMAN GENOMICS
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; AGE-RELATED MACULOPATHY;
   LOW-DENSITY-LIPOPROTEIN; FACTOR-H POLYMORPHISM; MACULAR-DEGENERATION;
   SUSCEPTIBILITY LOCI; BRUCHS MEMBRANE; RARE VARIANTS; HIGH-RISK;
   SPONTANEOUS HYDROLYSIS
AB Age-related macular degeneration (AMD) is an ocular neurodegenerative disorder and is the leading cause of legal blindness in Western societies, with a prevalence of up to 8 % over the age of 60, which continues to increase with age. AMD is characterized by the progressive breakdown of the macula (the central region of the retina), resulting in the loss of central vision including visual acuity. While its molecular etiology remains unclear, advances in genetics and genomics have illuminated the genetic architecture of the disease and have generated attractive pathomechanistic hypotheses. Here, we review the genetic architecture of AMD, considering the contribution of both common and rare alleles to susceptibility, and we explore the possible mechanistic links between photoreceptor degeneration and the alternative complement pathway, a cascade that has emerged as the most potent genetic driver of this disorder.
C1 [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Med Ctr, Ctr Human Dis Modeling, Durham, NC 27710 USA.
   [Tan, Perciliz L.; Rickman, Catherine Bowes; Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Ophthalmol, Duke Eye Ctr, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Katsanis, N (通讯作者)，Duke Univ, Med Ctr, Ctr Human Dis Modeling, Durham, NC 27710 USA.; Katsanis, N (通讯作者)，Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
EM Nicholas.Katsanis@duke.edu
RI Mitchell, Paul/P-1498-2014
OI Bowes Rickman, Catherine/0000-0002-8555-9596
FU NEI NIH HHS [P30 EY005722, R01 EY026161] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [P30EY005722, R01EY026161] Funding Source: NIH
   RePORTER
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   deVillena FPM, 1996, CYTOGENET CELL GENET, V72, P339
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   Emison ES, 2005, NATURE, V434, P857, DOI 10.1038/nature03467
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Flint J, 2009, GENOME RES, V19, P723, DOI 10.1101/gr.086660.108
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hanssen R, 1930, Z AUGENHEILKD, P360
   Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hobbs Ronald P, 2014, J Ophthalmic Vis Res, V9, P487, DOI 10.4103/2008-322X.150829
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Ji WZ, 2008, NAT GENET, V40, P592, DOI 10.1038/ng.118
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jordan DM, 2015, NATURE, V524, P225, DOI 10.1038/nature14497
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NILSSON UR, 1984, J IMMUNOL METHODS, V72, P49, DOI 10.1016/0022-1759(84)90432-0
   Pagenstecher H. a. G., 1875, ATLAS PATHOLOGISCHEN
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schork NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/j.gde.2009.04.010
   Schulte EC, 2014, AM J HUM GENET, V95, P85, DOI 10.1016/j.ajhg.2014.06.005
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yoshida Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124655
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang K, 1999, GENOMICS, V60, P234, DOI 10.1006/geno.1999.5896
NR 135
TC 44
Z9 50
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD JUN 21
PY 2016
VL 10
AR 23
DI 10.1186/s40246-016-0079-x
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DT6BO
UT WOS:000381568000001
PM 27329102
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, H
   Guo, JH
   West, XXZ
   Bid, HK
   Lu, L
   Hong, L
   Jang, GF
   Zhang, L
   Crabb, JW
   Linetsky, M
   Salomon, RG
AF Wang, Hua
   Guo, Junhong
   West, Xiaoxia Z.
   Bid, Hemant K.
   Lu, Liang
   Hong, Li
   Jang, Geeng-Fu
   Zhang, Lei
   Crabb, John W.
   Linetsky, Mikhail
   Salomon, Robert G.
CA Clinical Genomic Proteomic AMD
TI Detection and Biological Activities of Carboxyethylpyrrole Ethanolamine
   Phospholipids (CEP-EPs)
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; IN-VITRO; PHOSPHATIDYLETHANOLAMINE; PROTEIN;
   CELLS; BIOMARKERS; ADDUCTS; TLR2; ANGIOGENESIS; CHEMISTRY
AB Oxidation of docosahexaenoate phospholipids produces 4-hydroxy-7-oxo-hept-5-eonyl phospholipids (HOHA-PLs) that react with protein lysyl epsilon-amino residues to generate 2-omega-carboxyethylpyrrole (CEP) derivatives, endogenous factors that induce angiogenesis in the retina and tumors. It seemed likely, but remained unproven, that HOHA-PLs react with ethanolamine phospholipids (EPs) in vivo to generate CEP-EPs. We now show that CEP-EPs are present in human blood at 4.6-fold higher levels in age-related macular degeneration plasma than in normal plasma. We also show that CEP-EPs are pro-angiogenic, inducing tube formation by human umbilical vein endothelial cells by activating Toll-like receptor 2. CEP-EP levels may be a useful biomarker for clinical assessment of AMD risk and CEP-associated tumor progression and a tool for monitoring the efficacy of therapeutic interventions.
C1 [Wang, Hua; Guo, Junhong; West, Xiaoxia Z.; Lu, Liang; Hong, Li; Linetsky, Mikhail; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Bid, Hemant K.] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43205 USA.
   [Jang, Geeng-Fu; Zhang, Lei; Crabb, John W.; Clinical Genomic Proteomic AMD] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; University System of Ohio; Ohio State
   University; Nationwide Childrens Hospital; Research Institute at
   Nationwide Children's Hospital; Cleveland Clinic Foundation
RP Salomon, RG (通讯作者)，Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
EM rgs@case.edu
RI Wang, Hua/N-9400-2015; Guo, Junhong/O-6316-2017
OI Wang, Hua/0000-0002-2109-5497; Guo, Junhong/0000-0003-0005-4837;
   Salomon, Robert/0000-0001-9456-3557
FU NIH [EY016813, GM21249, EY 021840, EY022647]; Foundation Fighting
   Blindness Center Grant; NATIONAL EYE INSTITUTE [R21EY021840,
   P30EY011373, R01EY016813] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH
   RePORTER
FX This work was supported by NIH Grants EY016813 (R.G.S.) and GM21249
   (R.G.S.), EY 021840 (J.W.C.), and EY022647 (J.W.C.) and a Foundation
   Fighting Blindness Center Grant to the Cole Eye Insititue.
CR Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Berry KAZ, 2007, CHEM RES TOXICOL, V20, P1342, DOI 10.1021/tx700102n
   BHUYAN KC, 1986, MECH AGEING DEV, V34, P289, DOI 10.1016/0047-6374(86)90080-1
   BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434
   Crabb J. W, 2014, COLD SPRING HARBOR P, DOI [10.1101/cshperspect.a01719, DOI 10.1101/CSHPERSPECT.A01719]
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Erridge C, 2008, J BIOL CHEM, V283, P24748, DOI 10.1074/jbc.M800352200
   ESTERBAUER H, 1986, BIOCHEM J, V239, P405, DOI 10.1042/bj2390405
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   JUNEJA LR, 1988, BIOCHIM BIOPHYS ACTA, V960, P334, DOI 10.1016/0005-2760(88)90041-0
   Lertsiri S, 1998, BIOSCI BIOTECH BIOCH, V62, P893, DOI 10.1271/bbb.62.893
   Li W, 2009, FREE RADICAL BIO MED, V47, P1539, DOI 10.1016/j.freeradbiomed.2009.09.003
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Oak JH, 2003, FEBS LETT, V555, P419, DOI 10.1016/S0014-5793(03)01237-7
   Pamplona R, 1998, EUR J BIOCHEM, V255, P685, DOI 10.1046/j.1432-1327.1998.2550685.x
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Shin HS, 2011, J IMMUNOL, V186, P1119, DOI 10.4049/jimmunol.1001647
   Sullivan CB, 2010, J LIPID RES, V51, P999, DOI 10.1194/jlr.M001040
   Vance JE, 2013, BBA-MOL CELL BIOL L, V1831, P543, DOI 10.1016/j.bbalip.2012.08.016
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
NR 27
TC 23
Z9 23
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
EI 1520-5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD DEC
PY 2014
VL 27
IS 12
BP 2015
EP 2022
DI 10.1021/tx500216a
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA AW8XZ
UT WOS:000346543900003
PM 25380349
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Blagosklonny, MV
AF Blagosklonny, Mikhail V.
TI Prospective Treatment of Age-Related Diseases by Slowing Down Aging
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Review
ID GENETICALLY HETEROGENEOUS MICE; RENAL-TRANSPLANT RECIPIENTS; EXTENDS
   LIFE-SPAN; CELL-CYCLE ARREST; CALORIE RESTRICTION; INSULIN-RESISTANCE;
   MTOR INHIBITOR; ORAL RAPAMYCIN; SENESCENCE; HUMANS
AB Atherosclerosis, hypertension, obesity, diabetic complications, cancer, benign prostate hyperplasia, Alzheimer and Parkinson diseases, age-related macular degeneration, osteoarthritis, osteoporosis, and seborrheic keratosis are strongly associated with aging, implying a common underlying process. Each disease is treated separately and, in most cases, symptomatically. Suppression of aging itself should delay or treat all age-related diseases, thus increasing healthy life span and maximal longevity. But, is it possible to slow down aging? Recent evidence indicates that the target of rapamycin signaling pathway is involved in cellular senescence and organismal aging. Preclinical and clinical studies demonstrated the therapeutic effects of rapamycin in diverse age-related diseases. One simple reason why a single drug is indicated for so many age-related diseases is that it inhibits the aging process. (Am J Pathol 2012, 181:1142-1146; http://dx.doi.org/10.1016/j.ajpath.2012.06.024)
C1 Roswell Pk Canc Inst, Dept of Cell Stress Biol, Buffalo, NY 14263 USA.
C3 Roswell Park Cancer Institute
RP Blagosklonny, MV (通讯作者)，Roswell Pk Canc Inst, Dept of Cell Stress Biol, Elm & Carlton St, Buffalo, NY 14263 USA.
EM blagosklonny@oncotarget.com
CR Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486
   Anisimov VN, 2010, AM J PATHOL, V176, P2092, DOI 10.2353/ajpath.2010.091050
   Baetta R, 2009, J PHARMACOL EXP THER, V328, P419, DOI 10.1124/jpet.108.144147
   Bartke A, 2008, CELL CYCLE, V7, P3338, DOI 10.4161/cc.7.21.7012
   Barzilai N, 2012, DIABETES, V61, P1315, DOI 10.2337/db11-1300
   Berstein LM, 2009, FUTURE ONCOL, V5, P309, DOI [10.2217/fon.09.2, 10.2217/FON.09.2]
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   Blagosklonny MV, 2008, CANCER BIOL THER, V7, P1520, DOI 10.4161/cbt.7.10.6663
   Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288
   Blagosklonny MV, 2012, AGING-US, V4, P159, DOI 10.18632/aging.100443
   Blagosklonny MV, 2011, CELL CYCLE, V10, P4217, DOI 10.4161/cc.10.24.18595
   Blagosklonny MV, 2010, CELL CYCLE, V9, P683, DOI 10.4161/cc.9.4.10766
   Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068
   Campistol JM, 2006, J AM SOC NEPHROL, V17, P581, DOI 10.1681/ASN.2005090993
   Cao K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002346
   Carames B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis-2011-200557
   Chang GR, 2009, J PHARMACOL SCI, V109, P496, DOI 10.1254/jphs.08215FP
   Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919
   Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105
   Gao XM, 2006, J HYPERTENS, V24, P1663, DOI 10.1097/01.hjh.0000239304.01496.83
   Granville CA, 2007, CLIN CANCER RES, V13, P2281, DOI 10.1158/1078-0432.CCR-06-2570
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   HENRICSSON M, 1995, DIABETES CARE, V18, P1571, DOI 10.2337/diacare.18.12.1571
   Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Keogh A, 2004, CIRCULATION, V110, P2694, DOI 10.1161/01.CIR.0000136812.90177.94
   Khamzina L, 2005, ENDOCRINOLOGY, V146, P1473, DOI 10.1210/en.2004-0921
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135
   Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265
   Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584
   Li ZP, 2012, NUTR REV, V70, P57, DOI 10.1111/j.1753-4887.2011.00453.x
   Majumder S, 2012, AGING CELL, V11, P326, DOI 10.1111/j.1474-9726.2011.00791.x
   Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5
   Mathew T, 2004, CLIN TRANSPLANT, V18, P446, DOI 10.1111/j.1399-0012.2004.00188.x
   Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Moskalev AA, 2010, REJUV RES, V13, P246, DOI 10.1089/rej.2009.0903
   Mueller MA, 2008, ATHEROSCLEROSIS, V198, P39, DOI 10.1016/j.atherosclerosis.2007.09.019
   Muzumdar R, 2008, AGING CELL, V7, P438, DOI 10.1111/j.1474-9726.2008.00391.x
   Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407
   Neef M, 2006, J HEPATOL, V45, P786, DOI 10.1016/j.jhep.2006.07.030
   Orlandi A, 2006, ATHEROSCLEROSIS, V188, P221, DOI 10.1016/j.atherosclerosis.2006.01.018
   Pakala R, 2005, J CARDIOVASC PHARM, V46, P481, DOI 10.1097/01.fjc.0000177985.14305.15
   Rodriguez AE, 2006, J AM COLL CARDIOL, V47, P1522, DOI 10.1016/j.jacc.2005.12.052
   Rovira J, 2008, TRANSPL INT, V21, P992, DOI 10.1111/j.1432-2277.2008.00710.x
   Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221
   Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584
   Siegel-Axel D, 2008, CARDIOVASC RES, V78, P8, DOI 10.1093/cvr/cvn015
   Soare A, 2010, AGING ALBANY NY, V3, P374
   Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831
   Stipp D, 2012, SCI AM, V306, P32
   Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674
   Wang CF, 2010, AGING-US, V2, P555, DOI 10.18632/aging.100196
   Williamson DL, 2011, AGING-US, V3, P83, DOI 10.18632/aging.100290
   Witte AV, 2009, P NATL ACAD SCI USA, V106, P1255, DOI 10.1073/pnas.0808587106
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
NR 63
TC 75
Z9 77
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2012
VL 181
IS 4
BP 1142
EP 1146
DI 10.1016/j.ajpath.2012.06.024
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 017DK
UT WOS:000309570100003
PM 22841821
OA Bronze
DA 2022-11-30
ER

PT J
AU Matthaei, M
   Zeitz, O
   Keseru, M
   Wagenfeld, L
   Hornig, R
   Post, N
   Richard, G
AF Matthaei, Mario
   Zeitz, Oliver
   Keserue, Matthias
   Wagenfeld, Lars
   Hornig, Ralf
   Post, Nils
   Richard, Gisbert
TI Progress in the Development of Vision Prostheses
SO OPHTHALMOLOGICA
LA English
DT Review
DE Retina; Visual prosthesis; Electrophysiology
ID SILICON RETINA MICROCHIP; ELECTRICAL-STIMULATION; SUBRETINAL
   IMPLANTATION; MORPHOMETRIC ANALYSIS; ARTIFICIAL VISION; FILM ELECTRODES;
   VISUAL-SYSTEM; PIGMENTOSA; BLIND; PHOTORECEPTORS
AB Degenerative retinal diseases like retinitis pigmentosa and age-related macular degeneration are among the most common causes of blindness worldwide. Electronic visual prostheses represent a potential therapeutic option of increasing importance in otherwise incurably impaired patients. Based on extensive animal experiments, several devices are now being tested in clinical trials. According to the placement of the electrodes, possible stimulation sites are located subretinally, epiretinally, along the optic nerve or cortically. Anatomical, physiological and pathophysiological aspects must be considered in development and clinical application. To provide an appropriate retinal substitute, the optimal integration and adaptation of the prosthesis into the highly complex system of the visual pathway is important. This article aims to summarize the relevant studies and provides an overview of the current status of developments and challenges that still need to be mastered. Copyright (C) 2011 S. Karger AG, Basel
C1 [Matthaei, Mario; Zeitz, Oliver; Keserue, Matthias; Wagenfeld, Lars; Richard, Gisbert] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, DE-20246 Hamburg, Germany.
   [Hornig, Ralf; Post, Nils] IMI Intelligent Med Implants GmbH, Bonn, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Richard, G (通讯作者)，Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, Martinistr 52, DE-20246 Hamburg, Germany.
EM augenklinik@uke.uni-hamburg.de
RI Keserü, Matthias/AAM-7020-2020; Zeitz, Oliver/AAJ-9728-2021
CR Brelen ME, 2006, J NEUROSURG, V104, P593, DOI 10.3171/jns.2006.104.4.593
   Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Chow AY, 1997, NEUROSCI LETT, V225, P13, DOI 10.1016/S0304-3940(97)00185-7
   Chow AY, 2002, J REHABIL RES DEV, V39, P313
   CHOW AY, 2005, INVEST OPHTH VIS S S, V46, pNI218
   Cohen ED, 2007, J NEURAL ENG, V4, pR14, DOI 10.1088/1741-2560/4/2/R02
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   ECKMILLER RE, 2008, INVEST OPHTHALMOL VI, V49
   Eckmiller R, 2005, J NEURAL ENG, V2, pS91, DOI 10.1088/1741-2560/2/1/011
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Feucht M, 2005, OPHTHALMOLOGE, V102, P688, DOI 10.1007/s00347-005-1186-6
   FRIED SI, 2008, INVEST OPHTHALMOL VI, V49
   Gerding H, 2007, J NEURAL ENG, V4, pS30, DOI 10.1088/1741-2560/4/1/S05
   HUMAYUN M, 1994, ARCH OPHTHALMOL-CHIC, V112, P110, DOI 10.1001/archopht.1994.01090130120028
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2009, INVEST OPHTH VIS SCI, V50
   Javaheri M, 2006, ANN ACAD MED SINGAP, V35, P137
   KESERUE M, 2008, INVEST OPHTHALMOL VI, V49
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Knauer C, 2006, OPHTHALMOLOGE, V103, P735, DOI 10.1007/s00347-006-1411-y
   LeRoy C, 1755, HIST ACAD ROY SCI PA, V60, P87
   LI ZY, 1995, J NEUROSCI, V15, P5429
   LOUDIN J, 2008, INVEST OPHTHALMOL VI, V49
   Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0
   Pardue MT, 2005, J NEURAL ENG, V2, pS39, DOI 10.1088/1741-2560/2/1/006
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   Ren Q, 2007, ARTIFICIAL SIGHT BAS, P187
   RICHARD G, 2008, INVEST OPHTHALMOL VI, V49
   Sachs HG, 2005, GRAEF ARCH CLIN EXP, V243, P464, DOI 10.1007/s00417-004-1049-x
   Schanze T, 2006, EXP EYE RES, V82, P332, DOI 10.1016/j.exer.2005.07.007
   Shah S, 2007, J NEURAL ENG, V4, pS24, DOI 10.1088/1741-2560/4/1/S04
   SOMMERHALDER JR, 2008, INVEST OPHTHALMOL VI, V49
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Troyk PR, 2005, P ANN INT IEEE EMBS, P7376, DOI 10.1109/IEMBS.2005.1616216
   Uhlig CE, 2001, OPHTHALMOLOGE, V98, P1089, DOI 10.1007/s003470170031
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   WALTER P, 2008, INVEST OPHTHALMOL VI, V49
   Warren DJ, 2003, BIOMED EN S, P261
   Wilke R, 2009, INVEST OPHTHALMOL VI, V50
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
   Zrenner E, 2007, INVEST OPHTHALMOL VI, V48
NR 43
TC 23
Z9 24
U1 0
U2 16
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 4
BP 187
EP 192
DI 10.1159/000318042
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YO
UT WOS:000289508200001
PM 21293161
OA Bronze
DA 2022-11-30
ER

PT J
AU Weinstock, C
AF Weinstock, Christof
TI Association of Blood Group Antigen CD59 with Disease
SO TRANSFUSION MEDICINE AND HEMOTHERAPY
LA English
DT Review
DE CD59; Blood group; Deficiency; Disease
ID MEMBRANE ATTACK COMPLEX; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA;
   DECAY-ACCELERATING FACTOR; REGULATORY PROTEINS CD46; INHIBITOR
   ECULIZUMAB; GROUP SYSTEM; MACULAR-DEGENERATION; SURFACE EXPRESSION;
   HUMAN-ERYTHROCYTES; ENDOTHELIAL-CELLS
AB In 2014, the membrane-bound protein CD59 became a blood group antigen. CD59 has been known for decades as an inhibitor of the complement system, located on erythrocytes and on many other cell types. In paroxysmal nocturnal haemoglobinuria (PNH), a stem cell clone with acquired deficiency to express GPI-anchored molecules, including the complement inhibitor CD59, causes severe and life-threatening disease. The lack of CD59, which is the only membrane-bound inhibitor of the membrane attack complex, contributes a major part of the intravascular haemolysis observed in PNH patients. This crucial effect of CD59 in PNH disease prompted studies to investigate its role in other diseases. In this review, the role of CD59 in inflammation, rheumatic disease, and age-related macular degeneration is investigated. Further, the pivotal role of CD59 in PNH and congenital CD59 deficiency is reviewed.
C1 [Weinstock, Christof] Inst Ulm, German Red Cross Blood Serv Baden Wurttemberg Hes, Ulm, Germany.
   [Weinstock, Christof] Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany.
   [Weinstock, Christof] Ulm Univ, Inst Transfus Med, Ulm, Germany.
C3 Ulm University
RP Weinstock, C (通讯作者)，Inst Ulm, German Red Cross Blood Serv Baden Wurttemberg Hes, Ulm, Germany.; Weinstock, C (通讯作者)，Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany.; Weinstock, C (通讯作者)，Ulm Univ, Inst Transfus Med, Ulm, Germany.
EM c.weinstock@blutspende.de
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anliker M, 2014, TRANSFUSION, V54, P1817, DOI 10.1111/trf.12531
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ardicli D, 2017, NEUROPEDIATRICS, V48, P477, DOI 10.1055/s-0037-1604483
   Ben-Zeev B, 2015, EUR J PAEDIATR NEURO, V19, P688, DOI 10.1016/j.ejpn.2015.07.001
   BJORGE L, 1995, SCAND J IMMUNOL, V41, P350, DOI 10.1111/j.1365-3083.1995.tb03578.x
   BLAAS P, 1988, J IMMUNOL, V140, P3045
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Brandlein S, 2003, CANCER RES, V63, P7995
   Brodsky RA, 2008, BLOOD, V111, P1840, DOI 10.1182/blood-2007-06-094136
   Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128
   BUDZKO DB, 1976, CELL IMMUNOL, V22, P98, DOI 10.1016/0008-8749(76)90011-3
   BURGE J, 1981, J IMMUNOL, V126, P232
   Christmas SE, 2006, IMMUNOLOGY, V119, P522, DOI 10.1111/j.1365-2567.2006.02467.x
   DAVIES ME, 1994, SCAND J RHEUMATOL, V23, P316, DOI 10.3109/03009749409099280
   Devarapu SK, 2016, INT J CANCER, V138, P2963, DOI 10.1002/ijc.30025
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El Nemer W, 1998, J BIOL CHEM, V273, P16686
   Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200
   Fust A, 2012, SCI WORLD J, DOI 10.1100/2012/815615
   FUJITA T, 1995, JPN J CANCER RES, V86, P187, DOI 10.1111/j.1349-7006.1995.tb03038.x
   GUC D, 1993, RHEUMATOL INT, V13, P139, DOI 10.1007/BF00301260
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Haliloglu G, 2015, NEUROLOGY, V84, P1220, DOI 10.1212/WNL.0000000000001391
   Helias V, 2012, NAT GENET, V44, P170, DOI 10.1038/ng.1069
   Hillmen P, 2007, BLOOD, V110, P4123, DOI 10.1182/blood-2007-06-095646
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Hochsmann B, 2014, NEW ENGL J MED, V370, P90, DOI 10.1056/NEJMc1308104
   HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250
   Huang YX, 2007, ACTA CRYSTALLOGR D, V63, P714, DOI 10.1107/S0907444907015557
   IIDA K, 1983, J IMMUNOL, V130, P1876
   International Society of Blood Transfusion (ISBT), BLOOD GROUP SYST CD5
   International Society of Blood Transfusion (ISBT), CLASS BLOOD GROUP TE
   ISSITT PD, 1973, MED LAB TECHNOL, V30, P95
   Janeway CA, 2005, IMMUNOBIOLOGY
   Parvaneh VJ, 2020, AUTOIMMUN HIGHLIGHTS, V11, DOI 10.1186/s13317-020-00132-2
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Karbian N, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000280
   Kinderlerer AR, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2019
   Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X
   Klemann C, 2018, EUR J PAEDIATR NEURO, V22, P870, DOI 10.1016/j.ejpn.2018.04.003
   Koch N, 2009, J LEUKOCYTE BIOL, V86, P155, DOI [10.1189/JLB.0708443, 10.1189/jlb.0708443]
   Konttinen YT, 1996, ANN RHEUM DIS, V55, P888, DOI 10.1136/ard.55.12.888
   Lee JW, 2019, BLOOD, V133, P530, DOI 10.1182/blood-2018-09-876136
   LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353
   Lepik K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005766
   Li K, 2011, MOL IMMUNOL, V48, P1121, DOI 10.1016/j.molimm.2011.02.003
   Li XF, 2018, TRANSFUSION, V58, P3033, DOI 10.1111/trf.14960
   Lidington EA, 2000, BLOOD, V96, P2784
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linton SM, 1999, MOL IMMUNOL, V36, P905, DOI 10.1016/S0161-5890(99)00113-3
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lupo D, 2007, P NATL ACAD SCI USA, V104, P19303, DOI 10.1073/pnas.0706563104
   Mahtout H, 2011, FEMS IMMUNOL MED MIC, V62, P295, DOI 10.1111/j.1574-695X.2011.00813.x
   Mannes M, 2021, BLOOD, V137, P443, DOI 10.1182/blood.2020005959
   Mason JC, 2001, ARTHRITIS RHEUM, V44, P138, DOI 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G
   MCGEER PL, 1991, BRAIN RES, V544, P315, DOI 10.1016/0006-8993(91)90071-3
   Mevorach D, 2016, ANN NEUROL, V80, P708, DOI 10.1002/ana.24770
   Miyaji K, 2014, J NEUROIMMUNOL, V276, P172, DOI 10.1016/j.jneuroim.2014.08.004
   Mizuno M, 1997, ARTHRITIS RHEUM, V40, P527, DOI 10.1002/art.1780400319
   MOTOYAMA N, 1992, EUR J IMMUNOL, V22, P2669, DOI 10.1002/eji.1830221029
   MOUTABARRIK A, 1993, LYMPHOKINE CYTOK RES, V12, P167
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x
   Navenot JM, 1997, MUSCLE NERVE, V20, P92, DOI 10.1002/(SICI)1097-4598(199701)20:1<92::AID-MUS12>3.0.CO;2-3
   Nevo Y, 2013, BLOOD, V121, P129, DOI 10.1182/blood-2012-07-441857
   NOSE M, 1990, IMMUNOLOGY, V70, P145
   Okroj M, 2007, ANN MED, V39, P517, DOI 10.1080/07853890701477546
   OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607
   Ouyang QW, 2016, INT J ONCOL, V48, P2015, DOI 10.3892/ijo.2016.3408
   Pasch MC, 1999, EUR J IMMUNOL, V29, P100, DOI 10.1002/(SICI)1521-4141(199901)29:01<100::AID-IMMU100>3.0.CO;2-R
   Rautemaa R, 1996, J DENT RES, V75, P568, DOI 10.1177/00220345960750010901
   Ravindranath NMH, 2006, J ORAL PATHOL MED, V35, P560, DOI 10.1111/j.1600-0714.2006.00466.x
   Roth A, 2020, BLOOD, V135, P912, DOI 10.1182/blood.2019003399
   Saison C, 2012, NAT GENET, V44, P174, DOI 10.1038/ng.1070
   Sayama K, 1988, Trans Assoc Am Physicians, V101, P270
   Schmidt CQ, 2016, IMMUNOL REV, V274, P152, DOI 10.1111/imr.12475
   Schmidt CQ., 2021, BLOOD
   Schmitt CA, 1999, EUR J CANCER, V35, P117, DOI 10.1016/S0959-8049(98)00290-1
   Schnabolk G, 2017, J OCUL PHARMACOL TH, V33, P400, DOI 10.1089/jop.2016.0101
   SCHONERMARK S, 1988, IMMUNOLOGY, V63, P585
   Schrezenmeier H, 2020, THER ADV HEMATOL, V11, DOI 10.1177/2040620720966137
   Schrezenmeier H, 2020, ANN HEMATOL, V99, P1505, DOI 10.1007/s00277-020-04052-z
   Schrezenmeier H, 2014, HAEMATOLOGICA, V99, P922, DOI 10.3324/haematol.2013.093161
   SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837
   Shang YL, 2014, ARCH PATHOL LAB MED, V138, P910, DOI 10.5858/arpa.2013-0064-OA
   Singh A, 2014, DAN MED J, V61
   Singhrao SK, 1999, LAB INVEST, V79, P1247
   SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418
   Solmaz I, 2020, NEUROPEDIATRICS, V51, P206, DOI 10.1055/s-0039-3399583
   Spiller OB, 2000, CLIN EXP IMMUNOL, V121, P234, DOI 10.1046/j.1365-2249.2000.01305.x
   SPRING FA, 1992, BLOOD, V80, P2136
   Struglics A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1123-x
   Takahashi K, 2006, CURR OPIN IMMUNOL, V18, P16, DOI 10.1016/j.coi.2005.11.014
   TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T
   TANDON N, 1992, IMMUNOLOGY, V75, P372
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Ueda M, 2019, MOL CELL ENDOCRINOL, V490, P57, DOI 10.1016/j.mce.2019.04.006
   VENNEKER GT, 1994, J PATHOL, V172, P189, DOI 10.1002/path.1711720206
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   VOGT W, 1978, IMMUNOLOGY, V34, P29
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Weinstock Christof, 2019, Immunohematology, V35, P7
   Williams AS, 2004, ARTHRITIS RHEUM-US, V50, P3035, DOI 10.1002/art.20478
   YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707
   YEFENOF E, 1991, INT IMMUNOL, V3, P395, DOI 10.1093/intimm/3.4.395
   Yin HP, 2015, J INFECT CHEMOTHER, V21, P8, DOI 10.1016/j.jiac.2014.08.020
   Yuksel D, 2018, NEUROL-CLIN PRACT, V8, pE18, DOI 10.1212/CPJ.0000000000000511
   ZALMAN LS, 1987, J EXP MED, V166, P947, DOI 10.1084/jem.166.4.947
   Zelek WM, 2019, MULT SCLER J, V25, P523, DOI 10.1177/1352458518758927
   Zhou YZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0895-0
NR 115
TC 2
Z9 2
U1 7
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1660-3796
EI 1660-3818
J9 TRANSFUS MED HEMOTH
JI Transfus. Med. Hemother.
PD FEB
PY 2022
VL 49
IS 1
BP 13
EP 24
DI 10.1159/000521174
PG 12
WC Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Immunology
GA YY3DE
UT WOS:000754670800003
PM 35221864
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hong, YW
   Luo, Y
AF Hong, Yiwen
   Luo, Yan
TI Zebrafish Model in Ophthalmology to Study Disease Mechanism and Drug
   Discovery
SO PHARMACEUTICALS
LA English
DT Review
DE zebrafish; eye; disease model; mechanism; drug candidate
ID CATARACT FORMATION; PHOTORECEPTOR DEGENERATION; RETINAL DEVELOPMENT;
   MOLECULAR-GENETICS; LENS DEVELOPMENT; CONE DYSTROPHY; VISUAL-SYSTEM;
   HUMAN EYE; MUTANT; MUTATION
AB Visual impairment and blindness are common and seriously affect people's work and quality of life in the world. Therefore, the effective therapies for eye diseases are of high priority. Zebrafish (Danio rerio) is an alternative vertebrate model as a useful tool for the mechanism elucidation and drug discovery of various eye disorders, such as cataracts, glaucoma, diabetic retinopathy, age-related macular degeneration, photoreceptor degeneration, etc. The genetic and embryonic accessibility of zebrafish in combination with a behavioral assessment of visual function has made it a very popular model in ophthalmology. Zebrafish has also been widely used in ocular drug discovery, such as the screening of new anti-angiogenic compounds or neuroprotective drugs, and the oculotoxicity test. In this review, we summarized the applications of zebrafish as the models of eye disorders to study disease mechanism and investigate novel drug treatments.
C1 [Hong, Yiwen; Luo, Yan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
C3 Sun Yat Sen University
RP Luo, Y (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
EM hongyw@mail2.sysu.edu.cn; luoyan2@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81770971]; Natural Science
   Foundation of Guangdong Province, China [2020A1515010617]
FX This work was supported by the National Natural Science Foundation of
   China to Y.L (81770971); and the Natural Science Foundation of Guangdong
   Province, China to Y.L (2020A1515010617).
CR Ablain J, 2013, TRENDS CELL BIOL, V23, P584, DOI 10.1016/j.tcb.2013.09.009
   Ali Z, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.43
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Alvarez Y, 2010, DIS MODEL MECH, V3, P236, DOI 10.1242/dmm.003772
   Alvarez Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007867
   Anand D, 2018, HUM MUTAT, V39, P471, DOI 10.1002/humu.23395
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Aryal S, 2020, HUM GENET, V139, P1541, DOI 10.1007/s00439-020-02195-7
   Aslan M, 2008, FREE RADICAL BIO MED, V45, P367, DOI 10.1016/j.freeradbiomed.2008.04.026
   Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482
   Baye LM, 2011, HUM MOL GENET, V20, P1467, DOI 10.1093/hmg/ddr025
   Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326
   Bibliowicz J, 2011, PROG MOL BIOL TRANSL, V100, P287, DOI 10.1016/B978-0-12-384878-9.00007-8
   Biehlmaier O, 2003, INVEST OPHTH VIS SCI, V44, P1287, DOI 10.1167/iovs.02-0363
   Blanco-Sanchez B, 2017, METHOD CELL BIOL, V138, P415, DOI 10.1016/bs.mcb.2016.10.006
   Boisset G, 2008, GENE EXPR PATTERNS, V8, P404, DOI 10.1016/j.gep.2008.04.007
   Bollmann JH, 2019, ANNU REV VIS SCI, V5, P269, DOI 10.1146/annurev-vision-091718-014723
   Bonet-Fernandez JM, 2020, HUM GENET, V139, P1209, DOI 10.1007/s00439-020-02164-0
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Bujakowska KM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028274
   Cao ZQ, 2010, NAT PROTOC, V5, P1903, DOI 10.1038/nprot.2010.149
   Carnes MU, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004372
   Cassar S, 2020, CHEM RES TOXICOL, V33, P95, DOI 10.1021/acs.chemrestox.9b00335
   Chen CC, 2008, CURR EYE RES, V33, P59, DOI 10.1080/02713680701795026
   Choi J, 2007, DEV BIOL, V304, P735, DOI 10.1016/j.ydbio.2007.01.023
   Coomer CE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68172-2
   Dahm R, 2007, EXP EYE RES, V85, P74, DOI 10.1016/j.exer.2007.02.015
   Daly C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11513-5
   Das BC, 2013, FUTURE MED CHEM, V5, P2103, DOI 10.4155/fmc.13.170
   Deeti S, 2014, J PHARMACOL TOX MET, V69, P1, DOI 10.1016/j.vascn.2013.09.002
   Easter SS, 1996, DEV BIOL, V180, P646
   Eroglul AU, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00088
   Feng D, 2017, J BIOL CHEM, V292, P17375, DOI 10.1074/jbc.M117.784017
   Ferre-Fernandez JJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46175
   Gallenberger M, 2011, HUM MOL GENET, V20, P422, DOI 10.1093/hmg/ddq478
   Ganzen L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89482-z
   Ganzen L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061185
   Gao M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.478
   Gath N, 2019, DEV DYNAM, V248, P514, DOI 10.1002/dvdy.44
   Gestri G, 2012, DEV NEUROBIOL, V72, P302, DOI 10.1002/dneu.20919
   Giannaccini M, 2018, CELL MOL LIFE SCI, V75, P1255, DOI 10.1007/s00018-017-2691-x
   Gleeson M, 2007, ACTA DIABETOL, V44, P157, DOI 10.1007/s00592-007-0257-3
   Goishi K, 2006, DEVELOPMENT, V133, P2585, DOI 10.1242/dev.02424
   Gray MP, 2009, INVEST OPHTH VIS SCI, V50, P1515, DOI 10.1167/iovs.08-3010
   Greiling TMS, 2010, INVEST OPHTH VIS SCI, V51, P1540, DOI 10.1167/iovs.09-4388
   Greiling TMS, 2009, MOL VIS, V15, P2313
   Greiling TMS, 2009, DEV DYNAM, V238, P2254, DOI 10.1002/dvdy.21997
   Han SS, 2018, HUM GENET, V137, P779, DOI 10.1007/s00439-018-1936-6
   Harding P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042190
   Hartsock A, 2014, DEV BIOL, V394, P327, DOI 10.1016/j.ydbio.2014.07.024
   Heckler K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092002
   Heisenberg CP, 1996, DEVELOPMENT, V123, P191
   Hendee KE, 2018, HUM MOL GENET, V27, P1675, DOI 10.1093/hmg/ddy074
   Hoshijima K, 2019, DEV CELL, V51, P645, DOI 10.1016/j.devcel.2019.10.004
   Huang WJ, 2018, EXP EYE RES, V172, P112, DOI 10.1016/j.exer.2018.03.019
   Hubshman MW, 2018, HUM MOL GENET, V27, P614, DOI 10.1093/hmg/ddx428
   Iglesias AI, 2014, HUM MOL GENET, V23, P1320, DOI 10.1093/hmg/ddt522
   Jones JL, 2021, EUR J HUM GENET, V29, P1206, DOI 10.1038/s41431-021-00889-8
   Jung SH, 2016, BRIT J PHARMACOL, V173, P15, DOI 10.1111/bph.13279
   Kawase R, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00126
   Kitambi SS, 2009, MECH DEVELOP, V126, P464, DOI 10.1016/j.mod.2009.01.002
   Kokel D, 2010, NAT CHEM BIOL, V6, P231, DOI 10.1038/NCHEMBIO.307
   Kondkar AA, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107834
   Krall M, 2018, HUM GENET, V137, P315, DOI 10.1007/s00439-018-1884-1
   Krock BL, 2008, J CELL SCI, V121, P1907, DOI 10.1242/jcs.029397
   Kumaran N, 2017, BRIT J OPHTHALMOL, V101, P1147, DOI 10.1136/bjophthalmol-2016-309975
   Lahola-Chomiak AA, 2019, HUM MOL GENET, V28, P1298, DOI 10.1093/hmg/ddy429
   Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711
   Lee CJ, 2014, INVEST OPHTH VIS SCI, V55, P4585, DOI 10.1167/iovs.14-14888
   Lee Y, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2020.111201
   Leyk J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.415
   Li JZ, 2021, NUCLEIC ACIDS RES, V49, P2027, DOI 10.1093/nar/gkab003
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Li XQ, 2012, HUM MUTAT, V33, P391, DOI 10.1002/humu.21648
   Link BA, 2004, INVEST OPHTH VIS SCI, V45, P4415, DOI 10.1167/iovs.04-0557
   Lisch W, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107715
   Liu F, 2015, HUM MOL GENET, V24, P4648, DOI 10.1093/hmg/ddv197
   Liu YT, 2017, EXP EYE RES, V160, P62, DOI 10.1016/j.exer.2017.05.002
   Lu J, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108207
   Lu ZJ, 2019, J BIOL CHEM, V294, P13953, DOI 10.1074/jbc.RA119.008618
   Lu ZJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46098
   Luo N, 2012, HUM MOL GENET, V21, P3333, DOI 10.1093/hmg/dds163
   Lyraki R, 2016, BIOCHEM SOC T, V44, P1235, DOI 10.1042/BST20160148
   MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627
   Merrigan SL, 2017, BRIT J PHARMACOL, V174, P2636, DOI 10.1111/bph.13875
   Mishra S, 2018, J BIOL CHEM, V293, P740, DOI 10.1074/jbc.M117.808634
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mochizuki T, 2017, DEVELOPMENT, V144, P708, DOI 10.1242/dev.138909
   Morales-Camara S, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050550
   Nakao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032472
   Noel NCL, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010078
   Noel NCL, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102214
   Ohnesorge N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00508
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Oliver VF, 2016, OPHTHALMOLOGY, V123, P709, DOI 10.1016/j.ophtha.2015.12.008
   Oura Y, 2018, AM J PATHOL, V188, P2729, DOI 10.1016/j.ajpath.2018.08.012
   Peschek J, 2013, P NATL ACAD SCI USA, V110, pE3780, DOI 10.1073/pnas.1308898110
   Ping XY, 2021, GENE, V786, DOI 10.1016/j.gene.2021.145621
   Ping XY, 2021, AUTOPHAGY, V17, P3323, DOI 10.1080/15548627.2021.1872188
   Pooranachandran N, 2016, GENETICS, V203, P771, DOI 10.1534/genetics.115.180943
   Portugues R, 2009, CURR OPIN NEUROBIOL, V19, P644, DOI 10.1016/j.conb.2009.10.007
   Protas ME, 2017, HUM MOL GENET, V26, P3630, DOI 10.1093/hmg/ddx251
   Puzzolo D, 2018, CURR EYE RES, V43, P175, DOI 10.1080/02713683.2017.1385087
   Qu Z, 2019, BBA-MOL BASIS DIS, V1865, P2694, DOI 10.1016/j.bbadis.2019.07.009
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Richardson R, 2017, EYE, V31, P68, DOI 10.1038/eye.2016.198
   Rihel J, 2010, SCIENCE, V327, P348, DOI 10.1126/science.1183090
   Sadamoto K, 2018, J VET MED SCI, V80, P901, DOI 10.1292/jvms.17-0613
   Salehpour A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.652061
   Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4
   SCHMITT EA, 1994, J COMP NEUROL, V344, P532, DOI 10.1002/cne.903440404
   Semina EV, 2006, DEV BIOL, V299, P63, DOI 10.1016/j.ydbio.2006.07.005
   Sen P, 2020, EYE, V34, P632, DOI 10.1038/s41433-019-0643-4
   Shah MH, 2017, MOL GENET GENOM MED, V5, P323, DOI 10.1002/mgg3.290
   Shao M, 2020, P NATL ACAD SCI USA, V117, P7245, DOI 10.1073/pnas.1917922117
   Sheng WW, 2018, INVEST OPHTH VIS SCI, V59, P4542, DOI 10.1167/iovs.18-24539
   Sherpa T, 2008, DEV NEUROBIOL, V68, P166, DOI 10.1002/dneu.20568
   Shi WJ, 2020, ECOTOX ENVIRON SAFE, V193, DOI 10.1016/j.ecoenv.2020.110371
   Shi XH, 2005, MECH DEVELOP, V122, P513, DOI 10.1016/j.mod.2004.11.012
   Shi XH, 2006, MECH DEVELOP, V123, P761, DOI 10.1016/j.mod.2006.07.004
   Shiels A, 2019, ANNU REV VIS SCI, V5, P123, DOI 10.1146/annurev-vision-091517-034346
   Shiels A, 2017, EXP EYE RES, V156, P95, DOI 10.1016/j.exer.2016.06.011
   Shiels A, 2010, MOL VIS, V16, P2007
   Shu XH, 2011, INVEST OPHTH VIS SCI, V52, P2960, DOI 10.1167/iovs.10-6800
   Shu XH, 2010, HUM MOL GENET, V19, P657, DOI 10.1093/hmg/ddp533
   Siddam AD, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007278
   Skarie JM, 2009, INVEST OPHTH VIS SCI, V50, P5026, DOI 10.1167/iovs.09-3447
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stella SL, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030633
   Stujenske JM, 2011, INVEST OPHTH VIS SCI, V52, P4200, DOI 10.1167/iovs.10-6434
   Sukumaran S, 2009, VISION RES, V49, P479, DOI 10.1016/j.visres.2008.12.009
   Sundaramurthi H, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00689
   Swindell EC, 2008, GENESIS, V46, P177, DOI 10.1002/dvg.20380
   Taler K, 2020, DEV BIOL, V458, P177, DOI 10.1016/j.ydbio.2019.10.020
   Tanvir Z, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035220
   Umali J, 2019, VISION RES, V156, P66, DOI 10.1016/j.visres.2019.01.008
   van Rooijen E, 2010, DIS MODEL MECH, V3, P343, DOI 10.1242/dmm.004036
   Veth KN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001310
   Vihtelic TS, 2008, INT REV CEL MOL BIO, V269, P341, DOI 10.1016/S1937-6448(08)01006-X
   Vorontsova I, 2018, INVEST OPHTH VIS SCI, V59, P2869, DOI 10.1167/iovs.18-24044
   Wasfy MM, 2014, EXP EYE RES, V122, P65, DOI 10.1016/j.exer.2014.03.007
   Williams AL, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20235
   Wu SY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207540
   Wu SY, 2016, J BIOL CHEM, V291, P25387, DOI 10.1074/jbc.M116.749606
   Wu YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126750
   Xie J, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-76
   Yeh LK, 2008, J BIOL CHEM, V283, P506, DOI 10.1074/jbc.M707656200
   Yi Z, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102792
   Yoshimatsu T, 2020, NEURON, V107, P320, DOI 10.1016/j.neuron.2020.04.021
   Youngblood H, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107795
   Yu SS, 2017, HUM MOL GENET, V26, P2335, DOI 10.1093/hmg/ddx137
   Zelinka CP, 2018, MOL VIS, V24, P587
   Zhang J, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165724
   Zhang JL, 2016, HUM GENET, V135, P1375, DOI 10.1007/s00439-016-1730-2
   Zhang LY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149663
   Zhang T, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.588991
   Zhao XPC, 2006, INVEST OPHTH VIS SCI, V47, P4341, DOI 10.1167/iovs.05-1611
   Zhuang YY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00333
NR 159
TC 2
Z9 2
U1 7
U2 24
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD AUG
PY 2021
VL 14
IS 8
AR 716
DI 10.3390/ph14080716
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UH2GF
UT WOS:000689755700001
PM 34451814
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Smith, KN
   Katchinskiy, N
   Elezzabi, AY
AF Smith, Katherine N.
   Katchinskiy, Nir
   Elezzabi, Abdulhakem Y.
TI Femtosecond Laser Pulse Ablation of Sub-Cellular Drusen-Like Deposits
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; PROPHYLACTIC TREATMENT; PHOTODYNAMIC THERAPY;
   810-NANOMETER LASER; HUMAN MELANIN; MEMBRANE; EYES
AB Age-related macular degeneration (AMD) is a condition affecting the retina and is the leading cause of vision loss. Dry AMD is caused by the accumulation of lipid deposits called drusen, which form under the retina. This work demonstrates, for the first time, the removal of drusen-like deposits underneath ARPE-19 cell layers using femtosecond laser pulses. A novel cell culture model was created in response to the limited access to primary cell lines and the absence of animal models that recapitulate all aspects of AMD. In the cell culture model, deposits were identified with fluorescent stains specific to known deposit constituents. Trains of sub-10 femtosecond laser pulses from a Ti:Sapphire laser were used to successfully ablate the deposits without causing damage to surrounding cells. This drusen removal method can be used as a potential treatment for dry-stage AMD.
C1 [Smith, Katherine N.; Katchinskiy, Nir; Elezzabi, Abdulhakem Y.] Univ Alberta, Ultrafast Opt & Nanophoton Lab, Dept Elect & Comp Engn, Edmonton, AB T6G 1H9, Canada.
C3 University of Alberta
RP Katchinskiy, N; Elezzabi, AY (通讯作者)，Univ Alberta, Ultrafast Opt & Nanophoton Lab, Dept Elect & Comp Engn, Edmonton, AB T6G 1H9, Canada.
EM katchins@ualberta.ca; elezzabi@ualberta.ca
FU Olive Young Fund of the University of Alberta Hospitals Foundation;
   Queen Elizabeth II Scholarship
FX The authors would like to thank Dr. Ian MacDonald and Alina Radziwon for
   their support and technical expertise during this research. The authors
   would also like to thank Woo Jung Cho for the electron microscopy sample
   preparation and image acquisition, as well as the University of Alberta
   Faculty of Medicine and Dentistry's Imaging Core Facility for all their
   expertise and assistance in the work. The project was supported by the
   Olive Young Fund of the University of Alberta Hospitals Foundation.
   K.N.S. was supported by the Queen Elizabeth II Scholarship.
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bauerle D., 2000, ADV TEXTS PHYS
   Bird A.C., 2004, AGE RELATED MACULAR
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Burles K, 2014, VIROLOGY, V456, P108, DOI 10.1016/j.virol.2014.03.019
   Campbell Matthew, 2012, Adv Exp Med Biol, V763, P70
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Kallitsis A, 2007, IN VIVO, V21, P1049
   Katchinskiy N, 2016, SCI REP-UK, V6, DOI 10.1038/srep20529
   Katchinskiy N, 2014, LASER SURG MED, V46, P335, DOI 10.1002/lsm.22230
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   Kohli V, 2005, BIOTECHNOL BIOENG, V92, P889, DOI 10.1002/bit.20689
   Kohli V, 2005, LASER SURG MED, V37, P227, DOI 10.1002/lsm.20220
   Kohli V, 2007, BIOTECHNOL BIOENG, V98, P1230, DOI 10.1002/bit.21564
   Kohli V, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-7
   KOLLIAS N, 1988, J SOC COSMET CHEM, V39, P347
   KOLLIAS N, 1987, J INVEST DERMATOL, V89, P384, DOI 10.1111/1523-1747.ep12471764
   Konig K, 2001, OPT LETT, V26, P819, DOI 10.1364/OL.26.000819
   Niemz, 2002, LASER TISSUE INTERAC
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Shin OR, 2013, TISSUE ENG REGEN MED, V10, P164, DOI 10.1007/s13770-012-0374-0
   Tirlapur UK, 2002, PLANT J, V31, P365, DOI 10.1046/j.1365-313X.2002.01346.x
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Watanabe W, 2004, OPT EXPRESS, V12, P4203, DOI 10.1364/OPEX.12.004203
   Zhu L, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2898832
   Zonios G, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2844710
NR 34
TC 0
Z9 0
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 30
PY 2019
VL 9
AR 15633
DI 10.1038/s41598-019-52137-1
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JI2EP
UT WOS:000493276600064
PM 31666658
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wooff, Y
   Man, SM
   Aggio-Bruce, R
   Natoli, R
   Fernando, N
AF Wooff, Yvette
   Man, Si Ming
   Aggio-Bruce, Riemke
   Natoli, Riccardo
   Fernando, Nilisha
TI IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in
   Retinal Degenerative Diseases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE retinal degeneration; IL-1 (interleukin-1); age-related macular
   degeneration (AMD); inflammation; cytokine; inflammasome; IL-1b;
   photoreceptor cell death
ID PIGMENT EPITHELIAL-CELLS; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS;
   ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; SENILE MACULAR
   DEGENERATION; AMYLOID-BETA STIMULATION; COMPLEMENT FACTOR-H;
   FACTOR-KAPPA-B; NLRP3 INFLAMMASOME; PHOTORECEPTOR DEGENERATION
AB Inflammation underpins and contributes to the pathogenesis of many retinal degenerative diseases. The recruitment and activation of both resident microglia and recruited macrophages, as well as the production of cytokines, are key contributing factors for progressive cell death in these diseases. In particular, the interleukin 1 (IL-1) family consisting of both pro- and anti-inflammatory cytokines has been shown to be pivotal in the mediation of innate immunity and contribute directly to a number of retinal degenerations, including Age-Related Macular Degeneration (AMD), diabetic retinopathy, retinitis pigmentosa, glaucoma, and retinopathy of prematurity (ROP). In this review, we will discuss the role of IL-1 family members and inflammasome signaling in retinal degenerative diseases, piecing together their contribution to retinal disease pathology, and identifying areas of research expansion required to further elucidate their function in the retina.
C1 [Wooff, Yvette; Man, Si Ming; Aggio-Bruce, Riemke; Natoli, Riccardo; Fernando, Nilisha] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
   [Wooff, Yvette; Natoli, Riccardo] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University
RP Fernando, N (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
EM nilisha.fernando@anu.edu.au
RI Wooff, Yvette/AAS-4835-2020; Man, Si Ming/AAE-9168-2019; Aggio-Bruce,
   Riemke/AAX-4522-2020
OI Man, Si Ming/0000-0002-5079-2857; Fernando, Nilisha/0000-0002-8488-1348;
   Aggio-Bruce, Riemke/0000-0003-3086-2739; Natoli,
   Riccardo/0000-0002-9350-0439
CR Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003
   Agarwal RK, 2004, METH MOLEC MED, V102, P395
   Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033
   Albalawi F, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00227
   Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
   Altinova AE, 2008, CYTOKINE, V42, P217, DOI 10.1016/j.cyto.2008.02.006
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Bamforth SD, 1997, INVEST OPHTH VIS SCI, V38, P25
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Beaudry-Richard A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30087-4
   Benitez-del-Castillo J, 2019, EUR J OPHTHALMOL, V29, P437, DOI 10.1177/1120672118795399
   Berglof E, 2003, J NEUROIMMUNOL, V139, P36, DOI 10.1016/S0165-5728(03)00130-9
   Bian ZM, 2018, EXP EYE RES, V172, P10, DOI 10.1016/j.exer.2018.03.015
   Blank T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01930
   Blumberg H, 2007, J EXP MED, V204, P2603, DOI 10.1084/jem.20070157
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Bozoyan L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0392-7
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   Bulau AM, 2011, THESCIENTIFICWORLDJO, V11, P2480, DOI 10.1100/2011/968479
   Burke SJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE715, DOI 10.1152/ajpendo.00153.2015
   Campbell M, 2014, EXPERT REV CLIN IMMU, V10, P1273, DOI 10.1586/1744666X.2014.950231
   Campbell M, 2014, ADV EXP MED BIOL, V801, P409, DOI 10.1007/978-1-4614-3209-8_52
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cao SJ, 2013, MOL VIS, V19, P718
   Carmo A, 2000, MEDIAT INFLAMM, V9, P243, DOI 10.1080/09629350020025764
   CASPI RR, 1988, J IMMUNOL, V140, P1490
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Chatziralli I, 2017, INVEST OPHTH VIS SCI, V58, pBIO99, DOI 10.1167/iovs.17-21713
   Chaurasia SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21198-z
   Chen H, 2018, INVEST OPHTH VIS SCI, V59, P978, DOI 10.1167/iovs.17-22816
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Ciccia F, 2015, CLIN EXP IMMUNOL, V181, P230, DOI 10.1111/cei.12644
   Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   D'Amico AG, 2017, PEPTIDES, V97, P64, DOI 10.1016/j.peptides.2017.09.014
   Da Cunha AP, 2018, CURR EYE RES, V43, P553, DOI 10.1080/02713683.2017.1410180
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Ding LP, 2018, ONCOTARGET, V9, P2895, DOI 10.18632/oncotarget.22814
   Dong N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/126984
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Ebneter A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20474
   Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284
   El-Azab MF, 2014, BRIT J PHARMACOL, V171, P1299, DOI 10.1111/bph.12535
   El-Barbary AM, 2019, JCR-J CLIN RHEUMATOL, V25, P85, DOI 10.1097/RHU.0000000000000779
   ELASRAR AM, 1992, AM J OPHTHALMOL, V114, P731, DOI 10.1016/S0002-9394(14)74052-8
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fernando N, 2018, INVEST OPHTH VIS SCI, V59, P4362, DOI 10.1167/iovs.18-24627
   Fernando N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0514-x
   Frey S, 2013, ANN RHEUM DIS, V72, P1569, DOI 10.1136/annrheumdis-2012-202264
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Fujinami K, 2015, OPHTHALMOLOGY, V122, P326, DOI 10.1016/j.ophtha.2014.08.012
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gao N, 2018, J IMMUNOL, V201, P688, DOI 10.4049/jimmunol.1800046
   Gao Y, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00423
   Ghazi NG, 2002, EYE, V16, P411, DOI 10.1038/sj.eye.6700197
   GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3
   GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611
   Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Gupta VK, 2016, NEUROSCI LETT, V623, P52, DOI 10.1016/j.neulet.2016.04.059
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hang H, 2014, MOL VIS, V20, P1137
   Hao JF, 2019, OCUL IMMUNOL INFLAMM, V27, P836, DOI 10.1080/09273948.2018.1450516
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Holtkamp GM, 1999, EUR J IMMUNOL, V29, P215, DOI 10.1002/(SICI)1521-4141(199901)29:01<215::AID-IMMU215>3.0.CO;2-#
   How ACS, 2007, INVEST OPHTH VIS SCI, V48, P2123, DOI 10.1167/iovs.06-1213
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Jablonska-Trypuc A, 2016, J ENZYM INHIB MED CH, V31, P177, DOI 10.3109/14756366.2016.1161620
   Jiang K, 2013, J CLIN EXP OPHTHAL S, V2, DOI 10.4172/2155-9570.S2-007
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jung SH, 2014, INVEST OPHTH VIS SCI, V55, P2290, DOI 10.1167/iovs.13-13587
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kataoka K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.73
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kaur C, 2014, BRAIN STRUCT FUNCT, V219, P151, DOI 10.1007/s00429-012-0491-5
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kiang L, 2018, INVEST OPHTH VIS SCI, V59, P3767, DOI 10.1167/iovs.18-24489
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Kitaoka Y, 2007, BRAIN RES, V1142, P247, DOI 10.1016/j.brainres.2007.01.097
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Koprich JB, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-8
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kowluru RA, 2004, INVEST OPHTH VIS SCI, V45, P4161, DOI 10.1167/iovs.04-0633
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0616-y
   Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95
   Lin HJ, 2003, OPHTHALMOLOGICA, V217, P358, DOI 10.1159/000071352
   Liu JF, 2010, MOL VIS, V16, P2931
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Liu XF, 2015, EXP CELL RES, V331, P223, DOI 10.1016/j.yexcr.2014.08.040
   Liu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144460
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Luna JD, 1997, J NEUROSCI RES, V49, P268, DOI 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A
   Mai SZ, 2018, INT IMMUNOPHARMACOL, V58, P103, DOI 10.1016/j.intimp.2018.03.011
   Malik AN, 2015, DIABETES RES CLIN PR, V110, P257, DOI 10.1016/j.diabres.2015.10.006
   Mao CJ, 2014, INDIAN J OPHTHALMOL, V62, P699, DOI 10.4103/0301-4738.136220
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin-Sanchez F, 2016, CELL DEATH DIFFER, V23, P1219, DOI 10.1038/cdd.2015.176
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mateos MV., 2015, INT J OPHTHALMOL CLI, V2, P33, DOI DOI 10.23937/2378-346X/1410033
   McGeer PL, 2002, NEUROSCI LETT, V326, P67, DOI 10.1016/S0304-3940(02)00300-2
   McGeough MD, 2012, J IMMUNOL, V189, P2707, DOI 10.4049/jimmunol.1101737
   McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9
   McMurtrey JJ, 2018, SURV OPHTHALMOL, V63, P769, DOI 10.1016/j.survophthal.2018.03.002
   McNamee EN, 2011, P NATL ACAD SCI USA, V108, P16711, DOI 10.1073/pnas.1111982108
   Mendiola AS, 2018, J NEURAL TRANSM, V125, P781, DOI 10.1007/s00702-017-1732-9
   Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22
   Mitra S, 2018, AM J RESP CELL MOL, V59, P56, DOI 10.1165/rcmb.2017-0393OC
   Mookherjee S, 2016, GENET TEST MOL BIOMA, V20, P633, DOI 10.1089/gtmb.2015.0344
   Mookherjee S, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-99
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Murphy MP, 2010, J ALZHEIMERS DIS, V19, P311, DOI [10.3233/JAD-2009-1221, 10.3233/JAD-2010-1221]
   Mutamba S, 2012, EUR J IMMUNOL, V42, P607, DOI 10.1002/eji.201142035
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nishida A, 2016, INFLAMM BOWEL DIS, V22, P303, DOI 10.1097/MIB.0000000000000654
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Ozacmak HS, 2014, J SURG RES, V191, P350, DOI 10.1016/j.jss.2014.04.040
   Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x
   Patel JI, 2008, EYE, V22, P223, DOI 10.1038/sj.eye.6702584
   Patel MN, 2017, TRENDS MOL MED, V23, P165, DOI 10.1016/j.molmed.2016.12.007
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Qiao H, 2004, LAB INVEST, V84, P973, DOI 10.1038/labinvest.3700115
   Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Rao NA, 2003, INVEST OPHTH VIS SCI, V44, P22, DOI 10.1167/iovs.02-0199
   Rathi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01868
   Ratnapriya R, 2013, GENOME MED, V5, DOI 10.1186/gm488
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rochet E, 2015, INFECT IMMUN, V83, P2109, DOI 10.1128/IAI.02985-14
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Samardzija M, 2012, EXP EYE RES, V99, P17, DOI 10.1016/j.exer.2012.04.004
   Sarkar A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007140
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Scheibe K, 2017, GUT, V66, P823, DOI 10.1136/gutjnl-2015-310374
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Scuderi S, 2015, J MOL NEUROSCI, V56, P431, DOI 10.1007/s12031-015-0505-x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sena DF, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006539.pub2
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7
   Shah Parag K, 2016, World J Clin Pediatr, V5, P35, DOI 10.5409/wjcp.v5.i1.35
   Shchuko AG, 2015, INDIAN J OPHTHALMOL, V63, P905, DOI 10.4103/0301-4738.176031
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Skopinski P, 2005, J DIABETES COMPLICAT, V19, P335, DOI 10.1016/j.jdiacomp.2005.02.008
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Song ZM, 2014, GRAEF ARCH CLIN EXP, V252, P1229, DOI 10.1007/s00417-014-2586-6
   Sood BG, 2010, PEDIATR RES, V67, P394, DOI 10.1203/PDR.0b013e3181d01a36
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Squadrito ML, 2014, CELL REP, V8, P1432, DOI 10.1016/j.celrep.2014.07.035
   Srividya G, 2018, EYE, V32, P820, DOI 10.1038/eye.2017.285
   Stahel M, 2016, RETINA-J RET VIT DIS, V36, P385, DOI 10.1097/IAE.0000000000000701
   Strauss O, 1998, ACTA ANAT, V162, P101
   Sugita S, 2013, INVEST OPHTH VIS SCI, V54, P3240, DOI 10.1167/iovs.12-11483
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Suzuki Y, 2014, RETINA-J RET VIT DIS, V34, P165, DOI 10.1097/IAE.0b013e3182979df6
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Swindell WR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00080
   Takahashi S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4256183
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Towne JE, 2012, CURR OPIN PHARMACOL, V12, P486, DOI 10.1016/j.coph.2012.02.009
   Tsai T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194603
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vigne S, 2011, BLOOD, V118, P5813, DOI 10.1182/blood-2011-05-356873
   Viringipurampeer IA, 2016, HUM MOL GENET, V25, P1501, DOI 10.1093/hmg/ddw029
   Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Walsh PT, 2018, ANN NY ACAD SCI, V1417, P23, DOI 10.1111/nyas.13280
   Wan CK, 2016, J IMMUNOL, V196, P543, DOI 10.4049/jimmunol.1502080
   Wang CY, 2007, MOL VIS, V13, P719
   Wang CY, 2007, J GLAUCOMA, V16, P230, DOI 10.1097/IJG.0b013e3180300818
   Wang CY, 2006, MOL VIS, V12, P1380
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wang M, 2016, CELL MOL BIOL, V62, P31, DOI 10.14715/cmb/2016.62.4.6
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   Wang PL, 2005, CYTOKINE, V29, P245, DOI 10.1016/j.cyto.2004.12.002
   Wang XL, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0886-6
   Watanabe T, 2016, BRIT J OPHTHALMOL, V100, P425, DOI 10.1136/bjophthalmol-2015-306924
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Whiteley SJO, 2001, EXP EYE RES, V73, P557, DOI 10.1006/exer.2001.1066
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/9402198
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu WD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01462
   Yang TS, 2015, ARTERIOSCL THROM VAS, V35, P2638, DOI 10.1161/ATVBAHA.115.306543
   Yazdi AS, 2013, ANN RHEUM DIS, V72, P96, DOI 10.1136/annrheumdis-2012-202252
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Yoshimoto T, 1998, J IMMUNOL, V161, P3400
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zeng HL, 2018, INT J OPHTHALMOL-CHI, V11, P143, DOI 10.18240/ijo.2018.01.22
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03079-z
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhang W, 2018, WIRELESS COMMUNICATI, V2018, P1, DOI DOI 10.1080/02713683.2018.1518458
   Zhang X, 2004, EXP EYE RES, V78, P849, DOI 10.1016/j.exer.2003.10.018
   Zhao B, 2017, CURR MOL MED, V17, P460, DOI 10.2174/1566524018666180207152941
   Zhao BB, 2015, EXP EYE RES, V138, P80, DOI 10.1016/j.exer.2015.06.018
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhao MM, 2016, INVEST OPHTH VIS SCI, V57, P2955, DOI 10.1167/iovs.15-18505
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhao RJ, 2014, INT IMMUNOPHARMACOL, V22, P285, DOI 10.1016/j.intimp.2014.06.041
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
   Zhou XH, 2005, J BIOL CHEM, V280, P31240, DOI 10.1074/jbc.M502641200
NR 289
TC 85
Z9 90
U1 2
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 16
PY 2019
VL 10
AR 1618
DI 10.3389/fimmu.2019.01618
PG 21
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA IJ3SC
UT WOS:000475823800001
PM 31379825
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Saito, Y
   Tsuruma, K
   Shimazawa, M
   Nishimura, Y
   Tanaka, T
   Hara, H
AF Saito, Yuichi
   Tsuruma, Kazuhiro
   Shimazawa, Masamitsu
   Nishimura, Yuhei
   Tanaka, Toshio
   Hara, Hideaki
TI Establishment of a drug evaluation model against light-induced retinal
   degeneration using adult pigmented zebrafish
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Dry age-related macular degeneration; Pigmented retina; Zebrafish
ID PHOTOOXIDATIVE DAMAGE; GROWTH-FACTOR; REGENERATION
AB Age-related macular degeneration (AMD) is a major cause of irreversible loss of central vision in the elderly. Zebrafish is an attractive animal model in some respects, lower cost, smaller housing facilities and easier genetic manipulation compared to rodents. The present study aimed to establish a drug evaluation method against light irradiation, as a dry AMD disease model, using adult pigmented zebrafish. Intravitreal administration of an antioxidant, N-acetylcysteine, protected against light-induced retinal degeneration in a concentration-dependent manner. We established a new drug evaluation model against light-induced retinal degeneration that can provide new knowledge about dry AMD pathology and therapy. (C) 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Saito, Yuichi; Tsuruma, Kazuhiro; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan.
   [Nishimura, Yuhei; Tanaka, Toshio] Mie Univ, Grad Sch Med, Dept Mol & Cellular Pharmacol Pharmacogen & Pharm, Tsu, Mie 514, Japan.
C3 Gifu Pharmaceutical University; Mie University
RP Tsuruma, K; Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan.
EM tsuruma@gifu-pu.ac.jp; hidehara@gifu-pu.ac.jp
OI Nishimura, Yuhei/0000-0003-1901-8799; Hara, Hideaki/0000-0003-2046-9001;
   Saito, Yuichi/0000-0002-7738-276X
FU Gifu Prefectural Promotion Agency for Healthy Longevity and Drug
   Discovery
FX This study was conducted with support from the Gifu Prefectural
   Promotion Agency for Healthy Longevity and Drug Discovery. Professor
   Tetsuya Yamamoto at the Department of Ophthalmology, Gifu University
   Graduate School of Medicine, and Dr. Kenji Ichihara at the Nagaragawa
   Research Center, Api Co., Ltd., provided excellent assistance. Api Co.,
   Ltd. collaborated on this research.
CR Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fimbel SM, 2007, J NEUROSCI, V27, P1712, DOI 10.1523/JNEUROSCI.5317-06.2007
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Inoue Y, 2013, INVEST OPHTH VIS SCI, V54, P3815, DOI 10.1167/iovs.12-11236
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Link BA, 2015, ANNU REV VIS SCI, V1, P125, DOI 10.1146/annurev-vision-082114-035717
   Rajaram K, 2014, MOL VIS, V20, P1075
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Thomas JL, 2012, EXP EYE RES, V97, P105, DOI 10.1016/j.exer.2012.02.004
   Thummel R, 2011, JOVE-J VIS EXP, P1
   Thummel R, 2008, EXP EYE RES, V87, P433, DOI 10.1016/j.exer.2008.07.009
   Vihtelic TS, 2000, J NEUROBIOL, V44, P289, DOI 10.1002/1097-4695(20000905)44:3<289::AID-NEU1>3.0.CO;2-H
   Westerfield M., 2007, ZEBRAFISH BOOK GUIDE
NR 14
TC 9
Z9 10
U1 2
U2 9
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JUL
PY 2016
VL 131
IS 3
BP 215
EP 218
DI 10.1016/j.jphs.2016.05.009
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DS9HT
UT WOS:000381094400008
PM 27430989
OA gold
DA 2022-11-30
ER

PT J
AU Intajag, S
   Kansomkeat, S
   Bhurayanontachai, P
AF Intajag, S.
   Kansomkeat, S.
   Bhurayanontachai, P.
TI Histogram specification with generalised extreme value distribution to
   enhance retinal images
SO ELECTRONICS LETTERS
LA English
DT Article
DE image enhancement; image colour analysis; data analysis; histogram
   specification; generalised extreme value distribution; luminance
   channel; digital colour retina images; colour bands; visual diagnosis;
   age-related macular degeneration; brightness; contrast; colour balance;
   location parameter; shape parameters; algorithm performance; image
   datasets
AB Histogram specification usually deals with greyscale image enhancements, although, it can apply to colour images; however, generally manipulating only the luminance channel. A method for automatic enhancement of digital colour retina images by specifying all colour bands of the histograms is designed to adjust brightness, contrast, and colour balance for visual diagnosis of age-related macular degeneration. The proposed algorithm employs a generalised extreme value distribution consisting of three parameters to adjust brightness and colour balance by the location parameter, contrast and tone tuned by the scale, and shape parameters, respectively. The algorithm performance is evaluated with two image datasets: structured analysis of the retina and automated retinal image analysis. The improved results show that the specified histograms based on the generalised extreme value have been provided with important features to characterise the symptoms of a macular degeneration.
C1 [Intajag, S.; Kansomkeat, S.] Prince Songkla Univ, Fac Sci, Dept Comp Sci, Hat Yai, Songkhla, Thailand.
   [Bhurayanontachai, P.] Prince Songkla Univ, Fac Med, Dept Ophthalmol, Hat Yai, Songkhla, Thailand.
C3 Prince of Songkla University; Prince of Songkla University
RP Intajag, S (通讯作者)，Prince Songkla Univ, Fac Sci, Dept Comp Sci, Hat Yai, Songkhla, Thailand.
EM sathit.i@psu.ac.th
FU Faculty of Science Research Fund, Prince of Songkla University [157006]
FX This work was supported by Faculty of Science Research Fund (157006),
   Prince of Songkla University.
CR Celik T, 2012, IEEE T IMAGE PROCESS, V21, P145, DOI 10.1109/TIP.2011.2162419
   Gonzalez R. C., 2009, DIGITAL IMAGE PROCES
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Kotz S., 2000, EXTERME VALUES DISTR
   KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694
NR 5
TC 0
Z9 0
U1 0
U2 21
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 0013-5194
EI 1350-911X
J9 ELECTRON LETT
JI Electron. Lett.
PD APR 14
PY 2016
VL 52
IS 8
BP 596
EP 597
DI 10.1049/el.2015.3746
PG 2
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA DJ1GE
UT WOS:000373950500014
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Sharma, K
   Gupta, A
   Prabhakar, S
   Singh, R
   Gupta, PK
   Anand, A
AF Sharma, Neel Kamal
   Sharma, Kaushal
   Gupta, Amod
   Prabhakar, Sudesh
   Singh, Ramandeep
   Gupta, Pawan Kumar
   Anand, Akshay
TI Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype?
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; TLR3; Single nucleotide polymorphism;
   Signaling; Genotype; Allele frequency
ID PATTERN-RECOGNITION RECEPTORS; DOUBLE-STRANDED-RNA; MACULAR
   DEGENERATION; FUNCTIONAL ANALYSES; INNATE IMMUNITY; CELL-DEATH; AGE;
   DISEASE; SUSCEPTIBILITY; POLYMORPHISMS
AB Age-related macular degeneration (AMD) is a devastating disease that results in irreversible central vision loss. TLRs signaling pathway has been found to play an important role in AMD pathogenesis as evidenced by several studies. The objective of the study was to determine the single nucleotide polymorphism (SNP) changes in TLR3 in North Indian AMD patients. We recruited 176 patients comprising 115 AMD patients and 61 controls. Real time PCR was used to evaluate the SNP changes at rs3775291 locus. Pearson's chi (2) test was used evaluate association between various groups. No significant association in genotype and allele frequency was found in AMD patients as compared to control. The results suggest that AMD pathology in North Indian AMD patients is not affected by TLR3 signaling but it could be influenced by other genetic or environmental factors unique to North India.
C1 [Sharma, Neel Kamal; Sharma, Kaushal; Prabhakar, Sudesh; Gupta, Pawan Kumar; Anand, Akshay] Post Grad Inst Med Educ & Res, Neurosci Res Lab, Dept Neurol, Chandigarh, India.
   [Gupta, Amod; Singh, Ramandeep] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Neurosci Res Lab, Dept Neurol, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI anand, Akshay/AAI-1586-2019; Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU ICMR, India
FX The study was carried out at Neuroscience Research Lab, Department of
   Neurology, Post graduate Institute of Medical Education and Research,
   Chandigarh, India. We acknowledge ICMR, India for providing funds. We
   are grateful to Mr. Sumit Rana who carried out the quality assurance of
   study.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253
   de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1
   Gorin MB, 2005, EUR J HUM GENET, V13, P793, DOI 10.1038/sj.ejhg.5201431
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   McAllister CS, 2013, J IMMUNOL, V190, P418, DOI 10.4049/jimmunol.1202756
   Park DW, 2007, BIOCHEM BIOPH RES CO, V362, P1090, DOI 10.1016/j.bbrc.2007.08.119
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tohgi H, 1999, MOL BRAIN RES, V65, P124, DOI 10.1016/S0169-328X(98)00351-9
   van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5
   Wornle M, 2011, IOVS, V52, P10
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 40
TC 10
Z9 10
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD AUG
PY 2014
VL 393
IS 1-2
BP 1
EP 8
DI 10.1007/s11010-014-2040-4
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AK3TX
UT WOS:000338348700001
PM 24682730
DA 2022-11-30
ER

PT J
AU Otto, J
AF Otto, Juergen
TI Rheohaemapheresis
SO TRANSFUSION AND APHERESIS SCIENCE
LA English
DT Article
ID SUDDEN HEARING-LOSS; MEMBRANE DIFFERENTIAL FILTRATION; MACULAR
   DEGENERATION; FOLLOW-UP; TRIAL; RHEOPHERESIS; MULTICENTER; FIBRINOGEN
AB The rheology of the blood as description of the flow characteristics approves conclusions to the perfusion of the different tissues. Many pathological processes influence the rheological qualities of the blood or the characteristics of the vessels, especially the capillaries. In both cases the perfusion of the tissue can be to a great extent disturbed. The rheological qualities of the blood can be ameliorated in different ways. Rheohaemapheresis is a very effective and save method to reduce high molecular plasma proteins. In the last decades in the meantime rheohaemapheresis was very successfully applied to treat age-related macular degeneration (AMD), idiopathic sudden hearing loss (ISHL), diabetic complications, coronary heart disease, small vessel disease, uveal effusion syndrome, central vein thrombosis of the eye and all other disorders of the microcirculatory system. (C) 2010 Elsevier Ltd. All rights reserved.
C1 Deutsch Haemapherese Zentrum, D-50825 Cologne, Germany.
RP Otto, J (通讯作者)，Deutsch Haemapherese Zentrum, Maarweg 165, D-50825 Cologne, Germany.
EM med@dhzcologne.de
CR Balletshofer BM, 2005, THER APHER DIAL, V9, P385, DOI 10.1111/j.1744-9987.2005.00316.x
   *BAS DOC GEIG, 1966, DOC GEIG SCI TABL, P557
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P51, DOI 10.1016/j.transci.2005.11.001
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   FARWICK A, 2009, INVEST OPHTH VIS SCI, P24
   Kirschkamp T, 2008, THER APHER DIAL, V12, P360, DOI 10.1111/j.1744-9987.2008.00610.x
   Klemm E, 2009, LARYNGO RHINO OTOL, V88, P524, DOI 10.1055/s-0028-1128133
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   KOSS MJ, 2009, GRAEFES ARCH CLIN EX
   LEVEEN HH, 1980, SURG GYNECOL OBSTET, V150, P139
   Lin HC, 2008, STROKE, V39, P2744, DOI 10.1161/STROKEAHA.108.519090
   Luke C, 2001, J CLIN APHERESIS, V16, P23, DOI 10.1002/jca.1004
   Mosges R, 2008, OTOL NEUROTOL, V29, P769, DOI 10.1097/MAO.0b013e31817e5d03
   Mosges R, 2009, EUR ARCH OTO-RHINO-L, V266, P943, DOI 10.1007/s00405-008-0823-5
   Olzowy B, 2005, MMW Fortschr Med, V147, P37
   Rencova E, 2009, Cesk Slov Oftalmol, V65, P43
   Rietzsch H, 2008, HORM METAB RES, V40, P487, DOI 10.1055/s-2008-1077071
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Suckfull M, 2009, DTSCH ARZTEBL INT, V106, P669, DOI 10.3238/arztebl.2009.0669
   Suckfull M, 2002, LANCET, V360, P1811, DOI 10.1016/S0140-6736(02)11768-5
   UYGUNKIEHNE S, 2007, K NEPHR MUNCH
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, pU819
   WIDDER RA, 1997, ASS RES VIS OPTH 1 1, V38, P1
NR 24
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1473-0502
J9 TRANSFUS APHER SCI
JI Transfus. Apher. Sci.
PD OCT
PY 2010
VL 43
IS 2
BP 217
EP 222
DI 10.1016/j.transci.2010.07.021
PG 6
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 684QF
UT WOS:000284563700020
PM 20705512
DA 2022-11-30
ER

PT J
AU Grigoropoulos, V
   Emfietzoglou, J
   Nikolaidis, P
   Theodossiadis, G
   Theodossiadis, P
AF Grigoropoulos, Vlassis
   Emfietzoglou, John
   Nikolaidis, Pantelis
   Theodossiadis, George
   Theodossiadis, Panagiotis
TI Full-thickness macular hole after intravitreal injection of ranibizumab
   in a patient with retinal pigment epithelium detachment and tear
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascular membrane;
   Macular hole; Ranibizumab; Retinal pigment epithelium detachment;
   Retinal pigment epithelium tear
ID DEGENERATION
AB PURPOSE. To report a case of full-thickness macular hole (FTMH) after intravitreal injection of ranibizumab in a patient with retinal pigment epithelium detachment (PED) and tear.
   METHODS. A 67-year-old woman with PED and retinal pigment epithelium (RPE) tear due to age-related macular degeneration was studied by biomicroscopy, fluorescein and indocyanine green angiography, and optical coherence tomography and was treated with intravitreal ranibizumab.
   RESULTS. The patient developed a FTMH that was observed 1 month after the ranibizumab injection.
   CONCLUSIONS. Intravitreal ranibizumab may create focal sites of tractional forces on the retinal surface while contraction of the choroidal neovascular membrane may also place forces on the RPE and outer retina. Both actions may have as a result contraction and tearing of the retina leading to the formation of a FTMH. (Eur J Ophthalmol 2010; 20: 469-72)
C1 [Grigoropoulos, Vlassis; Emfietzoglou, John; Nikolaidis, Pantelis; Theodossiadis, George] Henry Dunant Hosp, Dept Ophthalmol 2, Athens, Greece.
   [Theodossiadis, Panagiotis] Univ Athens, Dept Ophthalmol 2, Athens, Greece.
C3 Henry Dunant Hospital; National & Kapodistrian University of Athens
RP Grigoropoulos, V (通讯作者)，1 Semitelou St, Athens 11528, Greece.
EM elgrigo@doctors.org.uk
CR Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Emerson GG, 2005, AM J OPHTHALMOL, V140, P316, DOI 10.1016/j.ajo.2005.01.028
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 8
TC 15
Z9 17
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2010
VL 20
IS 2
BP 469
EP 472
DI 10.1177/112067211002000235
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 611ED
UT WOS:000278793200035
PM 20037902
DA 2022-11-30
ER

PT J
AU Konerding, MA
AF Konerding, MA
TI Ocular angiogenesis: translating preclinical indications to successful
   clinical development
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Article
DE age-related macular degeneration (AMD); antiangiogenesis; choroidal
   neovascularisation (CNV); gene therapy; ocular angiogenesis; small
   interfering RNA (siRNA); vascular endothelial growth factor (VEGF)
ID NEOVASCULARIZATION; MODEL
AB Angiogenesis-related ocular diseases such as age-related macular degeneration (AMD) or diabetic retinopathy have a high socioeconomic impact in western countries and are the leading causes of blindness. Conventional treatment modalities for AMD are of limited success. Inhibition of new vessel formation and targeting of pathological vessels seem to be the best choice in AMD. A variety of animal models mimic the relevant aspects of choroidal neovascularisation (CNV) and allow for therapy screening. Preclinical and clinical studies show that a variety of different strategies are very promising. Stategies include inhibition or blocking of vascular endothelial growth factor, a key player in angiogenesis), blocking specific receptors, application of naturally occurring angiogenesis inhibitors and gene therapy. However, the multistep pathways involved in ocular angiogenesis suggest that a cocktail approach is required for effective long-term treatment and prevention of CNV.
C1 Univ Mainz, Dept Anat, D-55099 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz
RP Konerding, MA (通讯作者)，Univ Mainz, Dept Anat, D-55099 Mainz, Germany.
EM konerdin@uni-mainz.de
CR Aiello LM, 2003, AM J OPHTHALMOL, V136, P122, DOI 10.1016/S0002-9394(03)00219-8
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
NR 7
TC 8
Z9 10
U1 0
U2 1
PU ASHLEY PUBLICATIONS LTD
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD JUN
PY 2004
VL 8
IS 3
BP 255
EP 258
DI 10.1517/14728222.8.3.255
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 830TO
UT WOS:000222146500007
PM 15161431
DA 2022-11-30
ER

PT J
AU Hall, JC
   Paull, D
   Pebay, A
   Lidgerwood, GE
AF Hall, Jenna C.
   Paull, Daniel
   Pebay, Alice
   Lidgerwood, Grace E.
TI Human pluripotent stem cells for the modelling of retinal pigment
   epithelium homeostasis and disease: A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE human pluripotent stem cells; retinal disease; disease modelling;
   retinal pigment epithelium
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; MACULAR DEGENERATION;
   DIRECTED DIFFERENTIATION; HUMAN FIBROBLASTS; NEURAL RETINA;
   BEST-DISEASE; OPTIC-NERVE; GENE; ABCA4
AB Human pluripotent stem cells (hPSCs), which include induced pluripotent stem cells and embryonic stem cells, are powerful tools for studying human development, physiology and disease, including those affecting the retina. Cells from selected individuals, or specific genetic backgrounds, can be differentiated into distinct cell types allowing the modelling of diseases in a dish for therapeutic development. hPSC-derived retinal cultures have already been used to successfully model retinal pigment epithelium (RPE) degeneration for various retinal diseases including monogenic conditions and complex disease such as age-related macular degeneration. Here, we will review the current knowledge gained in understanding the molecular events involved in retinal disease using hPSC-derived retinal models, in particular RPE models. We will provide examples of various conditions to illustrate the scope of applications associated with the use of hPSC-derived RPE models.
C1 [Hall, Jenna C.; Pebay, Alice; Lidgerwood, Grace E.] Univ Melbourne, Dept Anat & Physiol, Parkville, Vic 3010, Australia.
   [Paull, Daniel] New York Stem Cell Fdn Res Inst, New York, NY USA.
   [Pebay, Alice] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia.
C3 University of Melbourne; Royal Melbourne Hospital; University of
   Melbourne
RP Lidgerwood, GE (通讯作者)，Univ Melbourne, Dept Anat & Physiol, Parkville, Vic 3010, Australia.
EM grace.lidgerwood@unimelb.edu.au
RI Lidgerwood, Grace/AAS-7439-2020
OI Lidgerwood, Grace/0000-0002-1774-5944; Pebay, Alice/0000-0002-7408-9453;
   Hall, Jenna/0000-0003-4540-7798; Paull, Daniel/0000-0002-9004-794X
FU Victorian Government; Dementia Australia Research Foundation [039305];
   Medical Research Future Fund - Stem Cell Therapies Mission [MRF1200678];
   DHB Foundation; NHMRC Synergy [1181010]; National Health and Medical
   Research Council (NHMRC) Senior Research Fellowship [1154389];
   Australian Research Council (ARC) Training Centre for Personalised
   Therapeutics Technologies [IC170100016]
FX Victorian Government; Dementia Australia Research Foundation,
   Grant/Award Number: 039305; Medical Research Future Fund -Stem Cell
   Therapies Mission, Grant/Award Number: MRF1200678; DHB Foundation; NHMRC
   Synergy, Grant/Award Number: 1181010; National Health and Medical
   Research Council (NHMRC) Senior Research Fellowship, Grant/Award Number:
   1154389; Australian Research Council (ARC) Training Centre for
   Personalised Therapeutics Technologies, Grant/Award Number: IC170100016
CR Ahmad I, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100824
   Allison TF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04011-3
   [Anonymous], 2020, NAT BIOTECHNOL, V38, P382, DOI 10.1038/s41587-020-0493-4
   Benati D, 2020, J MED GENET, V57, P437, DOI 10.1136/jmedgenet-2019-106473
   Braun TA, 2013, HUM MOL GENET, V22, P5136, DOI 10.1093/hmg/ddt367
   Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Chen XY, 2020, CURR EYE RES, V45, P1390, DOI 10.1080/02713683.2020.1740744
   Christensen DRG, 2017, EXP EYE RES, V165, P35, DOI 10.1016/j.exer.2017.08.014
   Claassen JN, 2019, STEM CELL RES, V34, DOI 10.1016/j.scr.2018.11.013
   Cornelis SS, 2017, HUM MUTAT, V38, P400, DOI 10.1002/humu.23165
   D'Antonio-Chronowska A, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3469
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dickson VK, 2014, NATURE, V516, P213, DOI 10.1038/nature13913
   Ebeling MC, 2022, PHARMACEUTICALS-BASE, V15, DOI 10.3390/ph15010062
   Elitt MS, 2018, HUM MOL GENET, V27, pR89, DOI 10.1093/hmg/ddy186
   Engel AL, 2022, EXP EYE RES, V215, DOI 10.1016/j.exer.2021.108899
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Guo MH, 2016, AM J HUM GENET, V99, P527, DOI 10.1016/j.ajhg.2016.06.031
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hallam D, 2018, STEM CELLS, V36, P1535, DOI 10.1002/stem.2883
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hata M, 2018, P NATL ACAD SCI USA, V115, P3936, DOI 10.1073/pnas.1717338115
   Hau Kwan-Leong, 2022, Methods Mol Biol, V2434, P245, DOI 10.1007/978-1-0716-2010-6_16
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Hongisto H, 2020, J PATHOL, V252, P138, DOI 10.1002/path.5506
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jang SY, 2012, J BIOL CHEM, V287, P19304, DOI 10.1074/jbc.M112.363747
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kashani AH, 2022, STEM CELL REP, V17, P448, DOI 10.1016/j.stemcr.2022.01.001
   Kashani AH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.13
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimova N, 2019, J NEUROSCI RES, V97, P975, DOI 10.1002/jnr.24397
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lane A, 2020, STEM CELL REP, V15, P67, DOI 10.1016/j.stemcr.2020.05.007
   Lee JH, 2020, YONSEI MED J, V61, P816, DOI 10.3349/ymj.2020.61.9.816
   Levkovitch-Verbin H, 2004, EYE, V18, P1066, DOI 10.1038/sj.eye.6701576
   Li SY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13100
   Lidgerwood GE, 2019, CURR OPIN PHARMACOL, V48, P114, DOI 10.1016/j.coph.2019.09.003
   Lidgerwood GE, 2016, STEM CELL REV REP, V12, P179, DOI 10.1007/s12015-015-9636-2
   Lo B, 2009, ENDOCR REV, V30, P204, DOI 10.1210/er.2008-0031
   Maeda T, 2022, TRENDS MOL MED, V28, P388, DOI 10.1016/j.molmed.2022.03.001
   Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Manian KV, 2021, CELL STEM CELL, V28, P846, DOI 10.1016/j.stem.2021.02.006
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Matynia Anna, 2022, Transl Vis Sci Technol, V11, P33, DOI 10.1167/tvst.11.3.33
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mellough CB, 2019, STEM CELL TRANSL MED, V8, P694, DOI 10.1002/sctm.18-0267
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Tran MTN, 2019, MOL VIS, V25, P174
   Moshfegh Y, 2016, HUM MOL GENET, V25, P2672, DOI 10.1093/hmg/ddw126
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nash BM, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/4536382
   Ng DSC, 2016, ASIA-PAC J OPHTHALMO, V5, P245, DOI 10.1097/APO.0000000000000209
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   PAIGEN K, 1995, NAT MED, V1, P215, DOI 10.1038/nm0395-215
   Peng SM, 2013, STEM CELL TRANSL MED, V2, P534, DOI 10.5966/sctm.2012-0134
   Pugazhendhi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031170
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Riera M, 2019, STEM CELL RES, V36, DOI 10.1016/j.scr.2019.101389
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Senabouth A., 2021, BIORXIV, DOI [10.1101/2021.08.19.457044, DOI 10.1101/2021.08.19.457044]
   Shang P, 2018, JOVE-J VIS EXP, DOI 10.3791/56997
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sinha D, 2020, AM J HUM GENET, V107, P278, DOI 10.1016/j.ajhg.2020.06.011
   Soldner F, 2018, CELL, V175, P615, DOI 10.1016/j.cell.2018.09.010
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sterneckert JL, 2014, NAT REV GENET, V15, P625, DOI 10.1038/nrg3764
   Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sung Y, 2021, BRIT J OPHTHALMOL, V105, P829, DOI 10.1136/bjophthalmol-2020-316225
   Tagawa M, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108503
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tan LX, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101781
   Teo AKK, 2011, GENE DEV, V25, P238, DOI 10.1101/gad.607311
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Wang JH, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-12210-8
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Waterston RH, 2002, P NATL ACAD SCI USA, V99, P3712, DOI 10.1073/pnas.042692499
   Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 102
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 50
IS 6
BP 667
EP 677
DI 10.1111/ceo.14128
EA JUL 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3O4UV
UT WOS:000825843300001
PM 35739648
OA Green Published
DA 2022-11-30
ER

PT J
AU Liu, XY
   Zheng, F
   Li, S
   Wang, ZT
   Wang, XY
   Wen, LK
   He, Y
AF Liu, Xinyao
   Zheng, Fei
   Li, Sheng
   Wang, Zhitong
   Wang, Xinyuan
   Wen, Liankui
   He, Yang
TI Malvidin and its derivatives exhibit antioxidant properties by
   inhibiting MAPK signaling pathways to reduce endoplasmic reticulum
   stress in ARPE-19 cells
SO FOOD & FUNCTION
LA English
DT Article
ID NF-KAPPA-B; ER STRESS; P38 MAPK; ANTHOCYANINS; PROTECTS; PHENOLICS;
   PIGMENTS; INJURY
AB Malvidin (MV) and its derivatives, such as malvidin-3-O-guaiacol (Mv3C) and malvidin-3-O-6-(acrylic acid-(2-hydroxy,4-carboxy-cyclohexanol)ester)-guaiacol (Mv3ACEC), are natural compounds with antioxidant properties. However, the basic mechanisms underlying their functional activities are unclear. In this study, we show that MV, Mv3C, and Mv3ACEC inhibit reactive oxygen species production and malondialdehyde content, promote glutathione peroxidase activity, and increase superoxide dismutase levels in ARPE-19 cells treated with H2O2. Western blotting and immunofluorescence analysis revealed that MV, Mv3C, and Mv3ACEC regulate mitogen-activated protein kinase signal transduction pathways related to endoplasmic reticulum stress. Interestingly, Mv3C and Mv3ACEC showed greater beneficial properties than MV. Our results show that MV and its derivatives have potential as therapeutic compounds for ocular diseases associated with oxidative stress, such as age-related macular degeneration.
C1 [Liu, Xinyao; Li, Sheng; Wang, Zhitong; Wang, Xinyuan; Wen, Liankui; He, Yang] Jilin Agr Univ, Coll Food Sci & Engn, Changchun 130118, Peoples R China.
   [Zheng, Fei] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Peoples R China.
C3 Jilin Agricultural University; Changchun University of Chinese Medicine
RP Wen, LK; He, Y (通讯作者)，Jilin Agr Univ, Coll Food Sci & Engn, Changchun 130118, Peoples R China.
EM wenliankui@163.com; heyang200704@jlau.edu.cn
OI He, Yang/0000-0001-7245-8369; Wen, Liankui/0000-0003-1258-8721
FU Natural Science Foundation of the Department of Science and Technology
   of Jilin Province [20180201054NY]
FX This research was supported by the Natural Science Foundation of the
   Department of Science and Technology of Jilin Province (No.
   20180201054NY).
CR Adachi T, 2012, ARCH BIOCHEM BIOPHYS, V520, P30, DOI 10.1016/j.abb.2012.01.014
   Afsar E, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2020.101430
   Azevedo J, 2010, FOOD CHEM, V119, P518, DOI 10.1016/j.foodchem.2009.06.050
   Bardak H, 2018, CUTAN OCUL TOXICOL, V37, P112, DOI 10.1080/15569527.2017.1354218
   Chen LJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08133
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313
   Dong Y, 2020, MOL THER-NUCL ACIDS, V19, P42, DOI 10.1016/j.omtn.2019.10.026
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandes I, 2010, J AGR FOOD CHEM, V58, P3785, DOI 10.1021/jf903714z
   Garcia-Alonso M, 2005, MOL NUTR FOOD RES, V49, P1112, DOI 10.1002/mnfr.200500100
   Gil TY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031277
   Giorgio Marco, 2007, Nat Rev Mol Cell Biol, V8, P722, DOI 10.1038/nrm2240
   Goncalves GL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36933-9
   Goupy P, 2009, J AGR FOOD CHEM, V57, P5762, DOI 10.1021/jf900841b
   He Y, 2018, FOOD CHEM, V268, P15, DOI 10.1016/j.foodchem.2018.06.052
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Hwang Narae, 2016, Korean J Ophthalmol, V30, P468
   Jin XL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5604610
   Jin X, 2014, MOL NUTR FOOD RES, V58, P1941, DOI 10.1002/mnfr.201400161
   Lee SH, 2020, ONCOL REP, V44, P1136, DOI 10.3892/or.2020.7662
   Li RL, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3481758
   Li XZ, 2013, DIABETES, V62, P599, DOI 10.2337/db12-0026
   Liu JN, 2020, LWT-FOOD SCI TECHNOL, V130, DOI 10.1016/j.lwt.2020.109673
   Liu XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111835
   Oliveira H, 2016, FOOD FUNCT, V7, P2462, DOI [10.1039/c6fo00445h, 10.1039/C6FO00445H]
   Park JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179048
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Pesonen M, 2012, TOXICOL LETT, V211, P239, DOI 10.1016/j.toxlet.2012.04.002
   Pirker KF, 2011, J AGR FOOD CHEM, V59, P11833, DOI 10.1021/jf2033126
   Quan JH, 2020, TOXICOLOGY, V442, DOI 10.1016/j.tox.2020.152540
   Shivarudrappa AH, 2020, J CELL COMMUN SIGNAL, V14, P207, DOI 10.1007/s12079-019-00539-1
   Song QT, 2021, TOXICOL APPL PHARM, V410, DOI 10.1016/j.taap.2020.115361
   Strugala P, 2016, J AGR FOOD CHEM, V64, P7414, DOI 10.1021/acs.jafc.6b03066
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Wang YQ, 2019, AM J TRANSL RES, V11, P418
   Wang Y, 2016, MOL NUTR FOOD RES, V60, P1564, DOI 10.1002/mnfr.201501048
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Weng SS, 2017, MOL MED REP, V16, P3461, DOI 10.3892/mmr.2017.6964
   Woo JM, 2012, MOL VIS, V18, P901
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xu XR, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4378461
   Yang LG, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02938-4
   Yang W, 2019, FOOD CHEM, V281, P189, DOI 10.1016/j.foodchem.2018.12.111
   Yu JJ, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/6655372
   Zhang YY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102146
   Zheng F, 2019, XENOBIOTICA, V49, P1025, DOI 10.1080/00498254.2018.1532132
   Zhu X, 2018, ARCH PHARM RES, V41, P1009, DOI 10.1007/s12272-018-1059-6
NR 48
TC 2
Z9 4
U1 5
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PD AUG 21
PY 2021
VL 12
IS 16
BP 7198
EP 7213
DI 10.1039/d1fo01345a
EA JUL 2021
PG 16
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA UD1MF
UT WOS:000670369100001
PM 34232243
DA 2022-11-30
ER

PT J
AU Ryu, J
   Seong, H
   Yoon, N
   Seo, SW
   Park, JW
   Kang, SS
   Park, JM
   Han, YS
AF Ryu, Jinhyun
   Seong, Hyemin
   Yoon, Nalae
   Seo, Seong Wook
   Park, Jeong Woo
   Kang, Sang Soo
   Park, Jong Moon
   Han, Yong Seop
TI Tristetraprolin regulates the decay of the hypoxia-induced vascular
   endothelial growth factor mRNA in ARPE-19 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ARPE-19 cells; hypoxia; neovascular age-related macular degeneration;
   tristetraprolin; vascular endothelial growth factor
ID HUMAN COLON-CANCER; ANTI-VEGF THERAPY; MACULAR DEGENERATION;
   PLASMINOGEN-ACTIVATOR; UNTRANSLATED REGION; RANIBIZUMAB; EXPRESSION;
   STABILITY; AFLIBERCEPT; GENE
AB The aim of the present study was to investigate the effects of tristetraprolin (TTP) on the vascular endothelial growth factor (VEGF) mRNA and protein expression levels in retinal pigment epithelial cells under hypoxic conditions, and to consider the possibility of using TTP as a novel treatment tool for neovascular age-related macular degeneration (AMD). Overexpression of TTP reduced the expression and secretion levels of VEGF in ARPE-19 cells under hypoxic conditions. TTP destabilized the VEGF mRNA by binding to adenosine and uridine-rich elements regions in its 3'-untranslated region. Furthermore, conditioned medium (CM) from TTP-overexpressing ARPE-19 cells suppressed the tube formation in human umbilical vein endothelial cells compared with hypoxic CM. These findings indicate that regulation of TTP expression may be a promising therapeutic tool for neovascular AMD, however, further research is required.
C1 [Ryu, Jinhyun; Seong, Hyemin; Yoon, Nalae; Kang, Sang Soo] Gyeongsang Natl Univ, Sch Med, Dept Anat & Convergence Med Sci, Jinju 52727, Gyeongnam, South Korea.
   [Seo, Seong Wook; Park, Jong Moon; Han, Yong Seop] Gyeongsang Natl Univ, Sch Med, Ophthalmol, Inst Hlth Sci, Jinju Daero 816 Beon Gil 15, Jinju 52727, Gyeongnam, South Korea.
   [Seo, Seong Wook; Park, Jong Moon; Han, Yong Seop] Gyeongsang Natl Univ, Dept Ophthalmol, Jinju 52727, Gyeongnam, South Korea.
   [Park, Jeong Woo] Univ Ulsan, Dept Biol Sci, Ulsan 44610, South Korea.
C3 Gyeongsang National University; Gyeongsang National University;
   Gyeongsang National University; University of Ulsan
RP Han, YS (通讯作者)，Gyeongsang Natl Univ, Sch Med, Ophthalmol, Inst Hlth Sci, Jinju Daero 816 Beon Gil 15, Jinju 52727, Gyeongnam, South Korea.
EM medcabin@naver.com
FU Biomedical Research Institute Fund of Gyeongsang National University
   Hospital (Jinju, Korea) [GNUHBRIF-2013-0002]
FX The present study was supported by the Biomedical Research Institute
   Fund (grant no. GNUHBRIF-2013-0002) of Gyeongsang National University
   Hospital (Jinju, Korea).
CR Arcondeguy T, 2013, NUCLEIC ACIDS RES, V41, P7997, DOI 10.1093/nar/gkt539
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Baou M, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/634520
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238
   Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003
   Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001
   Cha HJ, 2011, HEPATO-GASTROENTEROL, V58, P790
   Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883
   Cherradi N, 2006, MOL ENDOCRINOL, V20, P916, DOI 10.1210/me.2005-0121
   Ciulla, 1999, Expert Opin Investig Drugs, V8, P2173, DOI 10.1517/13543784.8.12.2173
   Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Engelmann D, 2013, J MOL CELL BIOL, V5, P391, DOI 10.1093/jmcb/mjt035
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hacker C, 2010, GROWTH FACTORS, V28, P178, DOI 10.3109/08977190903578660
   Hau HH, 2007, J CELL BIOCHEM, V100, P1477, DOI 10.1002/jcb.21130
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Lee HH, 2010, J BIOL CHEM, V285, P17329, DOI 10.1074/jbc.M109.094235
   Lee HH, 2010, INT J CANCER, V126, P1817, DOI 10.1002/ijc.24847
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Ma JF, 2013, EUR REV MED PHARMACO, V17, P1345
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0
   NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
NR 35
TC 3
Z9 4
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2016
VL 14
IS 6
BP 5395
EP 5400
DI 10.3892/mmr.2016.5890
PN A
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EG5HY
UT WOS:000391076100061
PM 27840917
OA Bronze
DA 2022-11-30
ER

PT J
AU Arias, L
   Caminal, JM
   Rubio, M
   Pujol, O
   Arruga, J
AF Arias, L.
   Caminal, J. M.
   Rubio, M.
   Pujol, O.
   Arruga, J.
TI Retinal pigment epithelial tears after intravitreal bevacizumab
   injection for predominantly classic choroidal neovascularization
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE intravitreal bevacizumab; retinal pigment epithelial tear; predominantly
   classic choroidal neovascularization
ID MACULAR DEGENERATION; AVASTIN; SECONDARY; THERAPY
AB PURPOSE. To detect retinal pigment epithelium (RPE) tears in predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) treated with intravitreal bevacizumab injections.
   METHODS. Forty consecutive patients with predominantly classic CNV secondary to AMD were treated with 1.25 mg of intravitreal bevacizumab. Patients were evaluated with visual acuity (VA) measured with Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography.
   RESULTS. Three patients developed a RPE tear after the first injection. The first patient had been treated with verteporfin therapy and VA remained unchanged. In the other two cases the CNV was naive and VA improved since the foveal center was not involved by the tear and macular edema was reduced.
   CONCLUSIONS. RPE tears can occur following intravitreal bevacizumab injections in patients with predominantly classic CNV although VA is not always affected.
C1 [Arias, L.; Caminal, J. M.; Rubio, M.; Pujol, O.; Arruga, J.] Bellvitge Univ Hosp, Dept Ophthalmol, E-08907 Barcelona, Spain.
   [Arias, L.] USP Hosp, Ophthalmol Inst Barcelona, Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona
RP Arias, L (通讯作者)，Bellvitge Univ Hosp, Dept Ophthalmol, C Feixa Llarga, S-N, E-08907 Barcelona, Spain.
EM luisarias@telefonica.net
RI Rubio Caso, Marcos Javier/L-6866-2013
OI Rubio Caso, Marcos Javier/0000-0002-7072-9855; ARIAS,
   LUIS/0000-0001-7041-5576; Caminal, JM/0000-0001-9563-0344
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
NR 8
TC 23
Z9 23
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2007
VL 17
IS 6
BP 992
EP 995
DI 10.1177/112067210701700622
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265UO
UT WOS:000253386800022
PM 18050131
DA 2022-11-30
ER

PT J
AU Domenech, EB
   Marfany, G
AF B. Domenech, Elena
   Marfany, Gemma
TI The Relevance of Oxidative Stress in the Pathogenesis and Therapy of
   Retinal Dystrophies
SO ANTIOXIDANTS
LA English
DT Review
DE oxidative stress damage; oxidative stress response; photoreceptors;
   retina; age-related macular degeneration (AMD); glaucoma; retinitis
   pigmentosa; leber hereditary optic neuropathy (LHON)
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS;
   RNA-BINDING PROTEINS; RETINITIS-PIGMENTOSA; EYE DEVELOPMENT; ER STRESS;
   AGE; AUTOPHAGY; DEGENERATION
AB Retinal cell survival requires an equilibrium between oxygen, reactive oxygen species, and antioxidant molecules that counteract oxidative stress damage. Oxidative stress alters cell homeostasis and elicits a protective cell response, which is most relevant in photoreceptors and retinal ganglion cells, neurons with a high metabolic rate that are continuously subject to light/oxidative stress insults. We analyze how the alteration of cellular endogenous pathways for protection against oxidative stress leads to retinal dysfunction in prevalent (age-related macular degeneration, glaucoma) as well as in rare genetic visual disorders (Retinitis pigmentosa, Leber hereditary optic neuropathy). We also highlight some of the key molecular actors and discuss potential therapies using antioxidants agents, modulators of gene expression and inducers of cytoprotective signaling pathways to treat damaging oxidative stress effects and ameliorate severe phenotypic symptoms in multifactorial and rare retinal dystrophies.
C1 [B. Domenech, Elena; Marfany, Gemma] Univ Barcelona, Dept Genet Microbiol & Estadist, Avda Diagonal 643, Barcelona 08028, Spain.
   [B. Domenech, Elena; Marfany, Gemma] Univ Barcelona, CIBERER, ISCIII, Barcelona 08028, Spain.
   [Marfany, Gemma] Univ Barcelona, Inst Biomed IBUB, IBUB IRSJD, Barcelona 08028, Spain.
C3 University of Barcelona; CIBER - Centro de Investigacion Biomedica en
   Red; CIBERER; Instituto de Salud Carlos III; University of Barcelona;
   University of Barcelona
RP Marfany, G (通讯作者)，Univ Barcelona, Dept Genet Microbiol & Estadist, Avda Diagonal 643, Barcelona 08028, Spain.; Marfany, G (通讯作者)，Univ Barcelona, CIBERER, ISCIII, Barcelona 08028, Spain.; Marfany, G (通讯作者)，Univ Barcelona, Inst Biomed IBUB, IBUB IRSJD, Barcelona 08028, Spain.
EM elenabdomenech@ub.edu; gmarfany@ub.edu
RI Marfany, Gemma/I-5668-2015
OI Marfany, Gemma/0000-0001-7941-983X
FU Ministerio de Economia y Competitividad/FEDER [SAF2016-80937-R];
   Generalitat de Catalunya [2017 SGR 738]
FX This research was supported by grants SAF2016-80937-R (Ministerio de
   Economia y Competitividad/FEDER) and 2017 SGR 738 (Generalitat de
   Catalunya) to G.M. E.B.D. is a fellow of the FI-2017 (Generalitat de
   Catalunya).
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Adornetto A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00121
   Aguirre JD, 2012, J BIOL CHEM, V287, P13541, DOI 10.1074/jbc.R111.312181
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Anderson P, 2009, CURR BIOL, V19, pR397, DOI 10.1016/j.cub.2009.03.013
   Augustine G.J., 2004, SENSATION SENSORY PR
   Baksheeva VE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8010003
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Benhar M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040309
   Berkowitz BA, 2015, INVEST OPHTH VIS SCI, V56, P6294, DOI 10.1167/iovs.15-16990
   Berson EL, 2012, ARCH OPHTHALMOL-CHIC, V130, P707, DOI 10.1001/archophthalmol.2011.2580
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Boya P, 2017, EYE, V31, P185, DOI 10.1038/eye.2016.278
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Brune B, 2005, ANTIOXID REDOX SIGN, V7, P497, DOI 10.1089/ars.2005.7.497
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cecilia OM, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8562408
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Charkoudian LK, 2008, J INORG BIOCHEM, V102, P2130, DOI 10.1016/j.jinorgbio.2008.08.001
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chua SYL, 2019, INVEST OPHTH VIS SCI, V60, P4915, DOI 10.1167/iovs.19-28346
   Conlon EG, 2017, GENE DEV, V31, P1509, DOI 10.1101/gad.304055.117
   Cortina MS, 2005, EXP EYE RES, V81, P742, DOI 10.1016/j.exer.2005.04.017
   Courchaine EM, 2016, EMBO J, V35, P1603, DOI 10.15252/embj.201593517
   Dash S, 2016, WIRES RNA, V7, P527, DOI 10.1002/wrna.1355
   Datilo MN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32553-5
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Marco N, 2006, J BIOL CHEM, V281, P16147, DOI 10.1074/jbc.M601467200
   Detrick B, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P101, DOI 10.1007/978-3-030-28384-1_6
   Dinkova-Kostova AT, 2015, BIOCHEM SOC T, V43, P602, DOI 10.1042/BST20150003
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Donato L, 2018, MOL BIOL REP, V45, P1349, DOI 10.1007/s11033-018-4295-4
   Donato L, 2018, INVEST OPHTH VIS SCI, V59, P843, DOI 10.1167/iovs.17-22962
   Donato L, 2018, FEBS OPEN BIO, V8, P219, DOI 10.1002/2211-5463.12360
   Downie LE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.1
   Du YP, 2010, INVEST OPHTH VIS SCI, V51, P2158, DOI 10.1167/iovs.09-3674
   Farajipour H, 2019, J CELL BIOCHEM, V120, P6886, DOI 10.1002/jcb.28068
   Fathinajafabadi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087898
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Garanto A, 2011, INVEST OPHTH VIS SCI, V52, P5202, DOI 10.1167/iovs.10-7101
   Genestra M, 2007, CELL SIGNAL, V19, P1807, DOI 10.1016/j.cellsig.2007.04.009
   George AK, 2018, INT J OPHTHALMOL-CHI, V11, P881, DOI 10.18240/ijo.2018.05.26
   Gorbatyuk MS, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100860
   Gu L, 2018, NEUROSCI LETT, V670, P89, DOI 10.1016/j.neulet.2018.01.043
   Hass DT, 2019, J NEUROSCI, V39, P3582, DOI 10.1523/JNEUROSCI.2702-18.2019
   He JN, 2019, MOL NEUROBIOL, V56, P6586, DOI 10.1007/s12035-019-1559-5
   Hernandez-Rabaza V, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8030053
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Huang CX, 2013, INVEST OPHTH VIS SCI, V54
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Jarosz M, 2017, INFLAMMOPHARMACOLOGY, V25, P11, DOI 10.1007/s10787-017-0309-4
   Jensen SJK, 2003, J MOL STRUC-THEOCHEM, V666, P387, DOI 10.1016/j.theochem.2003.08.037
   Jiang WM, 2016, AM J TRANSL RES, V8, P799
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221
   Kroeber M, 2006, EXP EYE RES, V82, P1075, DOI 10.1016/j.exer.2005.11.004
   Kroeger H, 2019, FEBS J, V286, P399, DOI 10.1111/febs.14522
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Li C, 2014, BBA-MOL BASIS DIS, V1842, P1121, DOI 10.1016/j.bbadis.2014.04.009
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Lingappan Krithika, 2018, Current Opinion in Toxicology, V7, P81, DOI 10.1016/j.cotox.2017.11.002
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015
   Martinez T, 2014, MOL THER, V22, P81, DOI 10.1038/mt.2013.216
   de la Camara CMF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0172-9
   de la Camara CMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074223
   Mian MF, 2008, CHEM-BIOL INTERACT, V171, P57, DOI 10.1016/j.cbi.2007.08.009
   Milani A, 2017, BRIT J PHARMACOL, V174, P1290, DOI 10.1111/bph.13625
   Miller WP, 2019, INVEST OPHTH VIS SCI, V60, P2369, DOI 10.1167/iovs.19-26606
   Mirra S, 2019, ADV EXP MED BIOL, V1185, P513, DOI 10.1007/978-3-030-27378-1_84
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Mulfaul K, 2020, CELL REP, V30, P2209, DOI 10.1016/j.celrep.2020.01.064
   Nagar S, 2017, P NATL ACAD SCI USA, V114, pE4048, DOI 10.1073/pnas.1613067114
   Namkoong S, 2018, MOL CELL, V70, P175, DOI 10.1016/j.molcel.2018.02.025
   Neelam K, 2017, BRIT J OPHTHALMOL, V101, P551, DOI 10.1136/bjophthalmol-2016-309814
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Noro T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.93
   Olchawa MM, 2013, INVEST OPHTH VIS SCI, V54, P2276, DOI 10.1167/iovs.12-11154
   Park HYL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30165-7
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Prokai-Tatrai K, 2013, MOL PHARMACEUT, V10, P3253, DOI 10.1021/mp400313u
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Sacca SC, 2013, MUTAT RES-REV MUTAT, V752, P153, DOI 10.1016/j.mrrev.2013.01.001
   Sala-Vila A, 2016, JAMA OPHTHALMOL, V134, P1142, DOI 10.1001/jamaophthalmol.2016.2906
   Samardzija M, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107719
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schmidl D, 2011, EXP EYE RES, V93, P141, DOI 10.1016/j.exer.2010.09.002
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Shibuki H, 2000, INVEST OPHTH VIS SCI, V41, P3607
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073
   Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subirada PV, 2018, EUR J NEUROSCI, V47, P1429, DOI 10.1111/ejn.13965
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tew W, 2019, AM J RESP CRIT CARE, V199
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   Trachsel-Moncho L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0855-8
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P6729, DOI 10.1167/iovs.11-9378
   Tuson M, 2004, AM J HUM GENET, V74, P128, DOI 10.1086/381055
   Tuson M, 2009, MOL VIS, V15, P168
   van Leeuwen W, 2019, TRAFFIC, V20, P623, DOI 10.1111/tra.12669
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Vittitow JL, 2002, BIOCHEM BIOPH RES CO, V298, P67, DOI 10.1016/S0006-291X(02)02395-1
   Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yang PM, 2016, LIFE SCI, V155, P94, DOI 10.1016/j.lfs.2016.05.006
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhang X, 2017, CURR MED CHEM, V24, P4329, DOI 10.2174/0929867324666170801100516
   Zhao Y, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/8524607
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong YM, 2012, DIABETES, V61, P492, DOI 10.2337/db11-0315
   Zhuo YH, 2012, P NATL ACAD SCI USA, V109, P19882, DOI 10.1073/pnas.1218953109
NR 141
TC 67
Z9 67
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2020
VL 9
IS 4
AR 347
DI 10.3390/antiox9040347
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA LT3HG
UT WOS:000536961200071
PM 32340220
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Berger, M
   Welchowski, T
   Schmitz-Valckenberg, S
   Schmid, M
AF Berger, Moritz
   Welchowski, Thomas
   Schmitz-Valckenberg, Steffen
   Schmid, Matthias
TI A classification tree approach for the modeling of competing risks in
   discrete time
SO ADVANCES IN DATA ANALYSIS AND CLASSIFICATION
LA English
DT Article
DE Discrete time-to-event data; Competing risks; Recursive partitioning;
   Cause-specific hazards; Regression modeling
ID VARIABLE SELECTION; REGRESSION-MODELS; DECISION TREES; FORESTS
AB Cause-specific hazard models are a popular tool for the analysis of competing risks data. The classical modeling approach in discrete time consists of fitting parametric multinomial logit models. A drawback of this method is that the focus is on main effects only, and that higher order interactions are hard to handle. Moreover, the resulting models contain a large number of parameters, which may cause numerical problems when estimating coefficients. To overcome these problems, a tree-based model is proposed that extends the survival tree methodology developed previously for time-to-event models with one single type of event. The performance of the method, compared with several competitors, is investigated in simulations. The usefulness of the proposed approach is demonstrated by an analysis of age-related macular degeneration among elderly people that were monitored by annual study visits.
C1 [Berger, Moritz; Welchowski, Thomas; Schmid, Matthias] Univ Hosp Bonn, Dept Med Biometry Informat & Epidemiol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Eye Hosp Bonn, Sigmund Freud Str 25, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Berger, M (通讯作者)，Univ Hosp Bonn, Dept Med Biometry Informat & Epidemiol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM Moritz.Berger@imbie.uni-bonn.de
RI Berger, Moritz/ABD-2233-2021
OI Welchowski, Thomas/0000-0003-2940-647X; Schmid,
   Matthias/0000-0002-0788-0317
CR Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719
   Berger M, 2018, STAT MODEL, V18, P322, DOI 10.1177/1471082X17748084
   Beyersmann J., 2011, COMPETING RISKS MULT
   Binder H, 2009, BIOINFORMATICS, V25, P890, DOI 10.1093/bioinformatics/btp088
   Bou-Hamad I, 2011, STAT MODEL, V11, P429, DOI 10.1177/1471082X1001100503
   Bou-Hamad I, 2009, CAN J STAT, V37, P17, DOI 10.1002/cjs.10007
   Breiman L, 1996, MACH LEARN, V24, P41, DOI 10.1023/A:1018094028462
   Breiman L., 1984, CLASSICATION REGRESS
   Cieslak DA, 2008, LECT NOTES ARTIF INT, V5211, P241, DOI 10.1007/978-3-540-87479-9_34
   Cieslak DA, 2012, DATA MIN KNOWL DISC, V24, P136, DOI 10.1007/s10618-011-0222-1
   COX DR, 1972, J R STAT SOC B, V34, P187
   Doove LL, 2014, ADV DATA ANAL CLASSI, V8, P403, DOI 10.1007/s11634-013-0159-x
   Ferri U, 2003, LECT NOTES ARTIF INT, V2837, P121
   Hastie T., 2011, ELEMENTS STAT LEARNI
   Hoens T. Ryan, 2012, Advances in Knowledge Discovery and Data Mining. Proceedings 16th Pacific-Asia Conference (PAKDD 2012), P122, DOI 10.1007/978-3-642-30217-6_11
   Ibrahim NA, 2008, INT J BIOL MED SCI, V3, P25
   Ishwaran H, 2014, BIOSTATISTICS, V15, P757, DOI 10.1093/biostatistics/kxu010
   Janitza S, 2015, PREDICTION MODELS TI, P177
   Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107
   Luo SR, 2016, EUR J OPER RES, V253, P869, DOI 10.1016/j.ejor.2016.02.050
   Meggiolaro S, 2017, STUD HIGH EDUC, V42, P1259, DOI 10.1080/03075079.2015.1087995
   Mingers J., 1989, Machine Learning, V4, P227, DOI 10.1023/A:1022604100933
   Most S, 2016, QUAL QUANT, V50, P1589, DOI 10.1007/s11135-015-0222-0
   PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374
   Provost F, 2003, MACH LEARN, V52, P199, DOI 10.1023/A:1024099825458
   Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712
   Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1023/A:1022643204877
   Ripley B. D., 1996, PATTERN RECOGNITION
   Schmid M, 2018, ECONOMET STAT, V7, P153, DOI 10.1016/j.ecosta.2017.03.008
   Schmid M, 2016, STAT MED, V35, P734, DOI 10.1002/sim.6729
   Steinberg JS, 2016, RETINA-J RET VIT DIS, V36, P1548, DOI 10.1097/IAE.0000000000000951
   Tapak L, 2015, GENOM PROTEOM BIOINF, V13, P169, DOI 10.1016/j.gpb.2015.04.001
   Tutz G, 2016, SPRINGER SER STAT, P1, DOI 10.1007/978-3-319-28158-2
   TUTZ G, 1995, QUAL QUANT, V29, P405, DOI 10.1007/BF01106065
   Tutz G., 2012, REGRESSION CATEGORIC
   Tutz G, 2015, COMPUT STAT DATA AN, V82, P207, DOI 10.1016/j.csda.2014.09.009
   Vallejos CA, 2017, J R STAT SOC A STAT, V180, P613, DOI 10.1111/rssa.12211
   Xu W, 2016, CANC INFORM
   Yee TW, 2010, J STAT SOFTW, V32, P1
   Zahid FM, 2013, ADV DATA ANAL CLASSI, V7, P393, DOI 10.1007/s11634-013-0136-4
NR 40
TC 4
Z9 4
U1 0
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1862-5347
EI 1862-5355
J9 ADV DATA ANAL CLASSI
JI Adv. Data Anal. Classif.
PD DEC
PY 2019
VL 13
IS 4
BP 965
EP 990
DI 10.1007/s11634-018-0345-y
PG 26
WC Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA JM9ZZ
UT WOS:000496565800007
DA 2022-11-30
ER

PT J
AU Priyadarshani, AMB
AF Priyadarshani, A. M. B.
TI A review on factors influencing bioaccessibility and bioefficacy of
   carotenoids
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Carotenoids; bioavailability; bioaccessibility; bioefficacy;
   bioconversion; dietary factors
ID TRANS-BETA-CAROTENE; RICH LIPOPROTEIN FRACTION; VITAMIN-A STATUS; LEAFY
   VEGETABLES; DARK-GREEN; ALL-TRANS; IN-VITRO; LUTEIN BIOAVAILABILITY;
   DIETARY CAROTENOIDS; LIPID DROPLETS
AB Vitamin A deficiency is one of the most prevalent deficiency disorders in the world. As shown by many studies plant food based approaches have a real potential on prevention of vitamin A deficiency in a sustainable way. Carotenoids are important as precursors of vitamin A as well as for prevention of cancers, coronary heart diseases, age-related macular degeneration, cataract etc. Bioaccessibility and bioefficacy of carotenoids are known to be influenced by numerous factors including dietary factors such as fat, fiber, dosage of carotenoid, location of carotenoid in the plant tissue, heat treatment, particle size of food, carotenoid species, interactions among carotenoids, isomeric form and molecular linkage and subject characteristics. Therefore even when carotenoids are found in high quantities in plant foods their utilization may be unsatisfactory because some factors are known to interfere as negative effectors.
C1 [Priyadarshani, A. M. B.] Univ Sri Jayewardenepura, Fac Med Sci, Med Lab Sci Unit, Dept Allied Hlth Sci, Nugegoda, Sri Lanka.
C3 University Sri Jayewardenepura
RP Priyadarshani, AMB (通讯作者)，Univ Sri Jayewardenepura, Fac Med Sci, Med Lab Sci Unit, Dept Allied Hlth Sci, Nugegoda, Sri Lanka.
EM buddhiathapaththu@yahoo.com
CR Asai A, 2004, J NUTR, V134, P2237, DOI 10.1093/jn/134.9.2237
   Boileau TWM, 2002, EXP BIOL MED, V227, P914, DOI 10.1177/153537020222701012
   Borel P, 1996, J LIPID RES, V37, P250
   Borel P, 1998, J NUTR, V128, P1361, DOI 10.1093/jn/128.8.1361
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Brown MJ, 2004, AM J CLIN NUTR, V80, P396, DOI 10.1093/ajcn/80.2.396
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Charoenkiatkul S., 1985, Food and Nutrition Bulletin, V7, P72
   Chitchumroonchokchai C, 2004, J NUTR, V134, P2280, DOI 10.1093/jn/134.9.2280
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058
   Deming DM, 2002, J NUTR, V132, P2709, DOI 10.1093/jn/132.9.2709
   Deming DM, 2000, J NUTR, V130, P2789, DOI 10.1093/jn/130.11.2789
   dePee S, 1996, EUR J CLIN NUTR, V50, pS38
   DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7
   DIMITROV NV, 1988, AM J CLIN NUTR, V48, P298, DOI 10.1093/ajcn/48.2.298
   Drammeh BS, 2002, J NUTR, V132, P3693, DOI 10.1093/jn/132.12.3693
   ERDMAN JW, 1988, FOOD TECHNOL-CHICAGO, V42, P214
   Furr HC, 1997, J NUTR BIOCHEM, V8, P364, DOI 10.1016/S0955-2863(97)00060-0
   Gartner C, 1997, AM J CLIN NUTR, V66, P116
   GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248
   Goni I, 2006, J AGR FOOD CHEM, V54, P5382, DOI 10.1021/jf0609835
   GOODWIN TW, 1986, ANNU REV NUTR, V6, P273, DOI 10.1146/annurev.nu.06.070186.001421
   Halliwell B, 1997, NUTR REV, V55, pS44, DOI 10.1111/j.1753-4887.1997.tb06100.x
   Hedren E, 2002, EUR J CLIN NUTR, V56, P425, DOI 10.1038/sj.ejcn.1601329
   Hedren E., 2004, THESIS
   Hof KHV, 1999, BRIT J NUTR, V82, P203, DOI 10.1017/S0007114599001385
   International Vitamin A Consultative Group (IVACG) XXI Meeting, 2003, 21 M IMPR VIT A STAT
   International Vitamin A Consultative Group (IVACG) XXII Meeting, 2004, 22 M VIT A COMM AG M
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   KRINSKY NI, 1989, PREV MED, V18, P592, DOI 10.1016/0091-7435(89)90032-7
   Kritchevsky SB, 1999, J NUTR, V129, P5, DOI 10.1093/jn/129.1.5
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mason J., 2004, FOOD NUTR BULL, V25, P3
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   Noakes M, 2002, AM J CLIN NUTR, V75, P79, DOI 10.1093/ajcn/75.1.79
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   Ornelas-Paz JDJ, 2008, J AGR FOOD CHEM, V56, P1511, DOI 10.1021/jf072751r
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   PRINCE MR, 1993, AM J CLIN NUTR, V57, P175, DOI 10.1093/ajcn/57.2.175
   Priyadarshani AMB, 2007, INT J FOOD SCI NUTR, V58, P659, DOI 10.1080/09637480701395580
   Ribaya-Mercado JD, 2002, NUTR REV, V60, P104, DOI 10.1301/00296640260085831
   Richelle M, 2004, AM J CLIN NUTR, V80, P171
   Riedl J, 1999, J NUTR, V129, P2170, DOI 10.1093/jn/129.12.2170
   Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5
   Rock CL, 1998, J NUTR, V128, P913, DOI 10.1093/jn/128.5.913
   ROCK CL, 1992, AM J CLIN NUTR, V55, P96, DOI 10.1093/ajcn/55.1.96
   Rodriguez-Amaya D.B., 1999, GUIDE CAROTENOID ANA
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   STAHL W, 1995, J NUTR, V125, P2128, DOI 10.1093/jn/125.8.2128
   STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161
   Takyi EEK, 1999, J NUTR, V129, P1549, DOI 10.1093/jn/129.8.1549
   Tang G, 1999, AM J CLIN NUTR, V70, P1069
   Torronen R, 1996, NUTR RES, V16, P565, DOI 10.1016/0271-5317(96)00035-8
   Tyssandier V, 2002, AM J CLIN NUTR, V75, P526, DOI 10.1093/ajcn/75.3.526
   Tyssandier V, 2001, BBA-MOL CELL BIOL L, V1533, P285, DOI 10.1016/S1388-1981(01)00163-9
   Unlu NZ, 2005, J NUTR, V135, P431, DOI 10.1093/jn/135.3.431
   van den Berg H, 2000, J SCI FOOD AGR, V80, P880, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;880::AID-JSFA646&gt;3.0.CO;2-1
   van den Berg H, 1998, AM J CLIN NUTR, V68, P82, DOI 10.1093/ajcn/68.1.82
   van het Hof KH, 2000, J NUTR, V130, P1189
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
   van Lieshout M, 2003, AM J CLIN NUTR, V77, P12, DOI 10.1093/ajcn/77.1.12
   van Lieshout M, 2001, AM J CLIN NUTR, V73, P949
   vanVliet T, 1996, INT J VITAM NUTR RES, V66, P77
   vanVliet T, 1996, EUR J CLIN NUTR, V50, pS32
   Wasantwisut Emorn, 2000, Food and Nutrition Bulletin, V21, P157
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zhi JG, 1996, J CLIN PHARMACOL, V36, P152, DOI 10.1002/j.1552-4604.1996.tb04180.x
   Zhou JR, 1996, J AM COLL NUTR, V15, P84
   [No title captured]
NR 72
TC 44
Z9 47
U1 5
U2 86
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2017
VL 57
IS 8
BP 1710
EP 1717
DI 10.1080/10408398.2015.1023431
PG 8
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA EO6BU
UT WOS:000396777500015
PM 26168011
DA 2022-11-30
ER

PT J
AU Wu, N
   Wang, Y
   Yang, LB
   Cho, KS
AF Wu, Nan
   Wang, Yi
   Yang, Lanbo
   Cho, Kin-Sang
TI Signaling Networks of Retinal Ganglion Cell Formation and the Potential
   Application of Stem Cell-Based Therapy in Retinal Degenerative Diseases
SO HUMAN GENE THERAPY
LA English
DT Article
ID NEURAL PROGENITOR CELLS; DEVELOPING MOUSE RETINA; ROD PHOTORECEPTOR
   DEVELOPMENT; IN-VITRO DIFFERENTIATION; TRANSCRIPTION FACTOR NRL; DOMAIN
   FACTOR BRN-3B; LEUCINE-ZIPPER NRL; CRX-DEFICIENT MICE; VERTEBRATE
   RETINA; SONIC HEDGEHOG
AB Retinal degenerative diseases such as age-related macular degeneration, retinitis pigmentosa, and glaucoma result in permanent loss of retinal neurons and vision. Stem cell therapy could be a novel treatment strategy to restore visual function. In an ideal situation, a homogenous population of stem cell-derived retinal neurons with high purity is used for replacement therapy. Thus, it is crucial to elucidate the molecular mechanisms that regulate the development of retinal progenitor cells and subsequent generation of specific retinal neurons. Here, recent findings concerning the intrinsic and extrinsic factors that regulate retinal progenitor cell maintenance and differentiation are summarized, especially transcriptional factors and extrinsic signals. Understanding these mechanisms is indispensable because they have potential clinical applications, chiefly the generation of specific retinal cells such as retinal ganglion cells to treat glaucoma and other optic neuropathy diseases.
C1 [Wu, Nan; Wang, Yi] Third Mil Med Univ, Southwest Hosp, Southwest Eye Hosp, Dept Ophthalmol, Chongqing, Peoples R China.
   [Yang, Lanbo; Cho, Kin-Sang] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA USA.
C3 Army Medical University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute
RP Cho, KS (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM kinsang_cho@meei.harvard.edu
OI Yang, Lanbo Z./0000-0003-3260-635X; Cho, Kin-Sang/0000-0003-4285-615X
FU National Natural Science Foundation of China [30901645]; Youth
   Innovation Fund of the Third Military Medical University [2009XQN29]
FX The study was supported by grants from National Natural Science
   Foundation of China (grant no. 30901645) and the Youth Innovation Fund
   of the Third Military Medical University (grant no. 2009XQN29).
CR Agarwal R, 2009, INDIAN J OPHTHALMOL, V57, P257, DOI 10.4103/0301-4738.53049
   Agathocleous M, 2009, ANNU REV CELL DEV BI, V25, P45, DOI 10.1146/annurev.cellbio.042308.113259
   Aoki H, 2008, GRAEF ARCH CLIN EXP, V246, P255, DOI 10.1007/s00417-007-0710-6
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Atkinson-Leadbeater K, 2010, J NEUROSCI, V30, P685, DOI 10.1523/JNEUROSCI.4165-09.2010
   AUSTIN CP, 1995, DEVELOPMENT, V121, P3637
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bassett EA, 2012, TRENDS NEUROSCI, V35, P565, DOI 10.1016/j.tins.2012.05.004
   BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293
   Ben-Hur T, 2004, STEM CELLS, V22, P1246, DOI 10.1634/stemcells.2004-0094
   Bongso A, 2008, J CELL BIOCHEM, V105, P1352, DOI 10.1002/jcb.21957
   Brown NL, 1998, DEVELOPMENT, V125, P4821
   Brown NL, 2001, DEVELOPMENT, V128, P2497
   Brzezinski JA, 2012, DEV BIOL, V365, P395, DOI 10.1016/j.ydbio.2012.03.006
   Brzezinski JA, 2011, DEVELOPMENT, V138, P3519, DOI 10.1242/dev.064006
   Brzezinski JA, 2010, DEVELOPMENT, V137, P619, DOI 10.1242/dev.043968
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Cao F, 2006, CIRCULATION, V113, P1005, DOI 10.1161/CIRCULATIONAHA.105.588954
   Cayouette M, 2003, NEURON, V40, P897, DOI 10.1016/S0896-6273(03)00756-6
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251
   Cwinn MA, 2011, J NEUROSCI, V31, P5169, DOI 10.1523/JNEUROSCI.5495-10.2011
   de Lima S, 2012, P NATL ACAD SCI USA, V109, P9149, DOI 10.1073/pnas.1119449109
   Decembrini S, 2009, P NATL ACAD SCI USA, V106, P21179, DOI 10.1073/pnas.0909167106
   Ding Q, 2009, J NEUROSCI, V29, P3992, DOI 10.1523/JNEUROSCI.5237-08.2009
   Doroquez DB, 2006, CRIT REV BIOCHEM MOL, V41, P339, DOI 10.1080/10409230600914344
   Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0
   Elliott J, 2008, NEURON, V60, P26, DOI 10.1016/j.neuron.2008.08.008
   Englund-Johansson U, 2010, EXP EYE RES, V90, P292, DOI 10.1016/j.exer.2009.11.005
   Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7
   Fang IM, 2013, EXP EYE RES, V113, P49, DOI 10.1016/j.exer.2013.05.007
   Feng L, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-36
   Fischer AJ, 2002, DEVELOPMENT, V129, P2283
   Forrest D, 2012, MOL ENDOCRINOL, V26, P905, DOI 10.1210/me.2012-1010
   Fujikawa T, 2005, AM J PATHOL, V166, P1781, DOI 10.1016/S0002-9440(10)62488-1
   Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Gan L, 1999, DEV BIOL, V210, P469, DOI 10.1006/dbio.1999.9280
   Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920
   Georgi SA, 2011, DEV NEUROBIOL, V71, P1153, DOI 10.1002/dneu.20899
   Georgi SA, 2010, J NEUROSCI, V30, P4048, DOI 10.1523/JNEUROSCI.4982-09.2010
   Gruen L, 2006, STEM CELLS, V24, P2162, DOI 10.1634/stemcells.2006-0105
   Guo Y, 2003, INVEST OPHTH VIS SCI, V44, P3194, DOI 10.1167/iovs.02-0875
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Hafler BP, 2012, P NATL ACAD SCI USA, V109, P7882, DOI 10.1073/pnas.1203138109
   Hao H, 2012, PLOS GENET, V8, P380, DOI 10.1371/journal.pgen.1002649
   Harper MM, 2011, INVEST OPHTH VIS SCI, V52, P4506, DOI 10.1167/iovs.11-7346
   Hashimoto T, 2006, DEVELOPMENT, V133, P2201, DOI 10.1242/dev.02385
   Hegde GV, 2007, EXP EYE RES, V84, P577, DOI 10.1016/j.exer.2006.11.012
   Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010
   Hertz J, 2014, CELL TRANSPLANT, V23, P855, DOI 10.3727/096368913X667024
   Horndli CS, 2012, DEVELOPMENT, V139, P2604, DOI 10.1242/dev.077594
   Jagatha B, 2009, BIOCHEM BIOPH RES CO, V380, P230, DOI 10.1016/j.bbrc.2009.01.038
   Jain V, 2012, J COMP NEUROL, V520, P742, DOI 10.1002/cne.22765
   Jia L, 2009, P NATL ACAD SCI USA, V106, P17534, DOI 10.1073/pnas.0902425106
   Johnson TV, 2011, EXP EYE RES, V93, P196, DOI 10.1016/j.exer.2010.05.016
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Kageyama R, 2008, DEV GROWTH DIFFER, V50, pS97, DOI 10.1111/j.1440-169X.2008.00993.x
   Kautzmann MAI, 2011, J BIOL CHEM, V286, P28247, DOI 10.1074/jbc.M111.257246
   Kayama M, 2010, OPHTHALMIC RES, V43, P79, DOI 10.1159/000247592
   Khanna H, 2006, J BIOL CHEM, V281, P27327, DOI 10.1074/jbc.M605500200
   Kim JW, 2012, MOL CELL BIOL, V32, P1720, DOI 10.1128/MCB.06440-11
   Kiyama T, 2011, VISION RES, V51, P251, DOI 10.1016/j.visres.2010.10.016
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Lad EM, 2009, STEM CELLS DEV, V18, P7, DOI 10.1089/scd.2008.0169
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107
   Lee DA, 2005, AM J HEALTH-SYST PH, V62, P691, DOI 10.1093/ajhp/62.7.691
   Levine EM, 1997, J NEUROSCI, V17, P6277
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Ma WX, 2006, MOL CELL NEUROSCI, V31, P463, DOI 10.1016/j.mcn.2005.10.018
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mao CA, 2008, DEVELOPMENT, V135, P3379, DOI 10.1242/dev.024612
   Mao CA, 2011, DEV BIOL, V349, P90, DOI 10.1016/j.ydbio.2010.10.008
   Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Martinez-Morales JR, 2005, DEV CELL, V8, P565, DOI 10.1016/j.devcel.2005.01.022
   Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178
   McCabe KL, 1999, DEVELOPMENT, V126, P5713
   McFarlane S, 1998, DEVELOPMENT, V125, P3967
   McNeill B, 2012, MOL CELL NEUROSCI, V49, P333, DOI 10.1016/j.mcn.2011.12.008
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Mellough CB, 2004, EXP NEUROL, V186, P6, DOI 10.1016/j.expneurol.2003.10.021
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Meyer JS, 2004, BRAIN RES, V1014, P131, DOI 10.1016/j.brainres.2004.04.019
   Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200
   Montana CL, 2011, J BIOL CHEM, V286, P36921, DOI 10.1074/jbc.M111.279026
   Mu XQ, 2008, P NATL ACAD SCI USA, V105, P6942, DOI 10.1073/pnas.0802627105
   Mu XQ, 2005, DEV BIOL, V280, P467, DOI 10.1016/j.ydbio.2005.01.028
   Mu XQ, 2004, DEVELOPMENT, V131, P1197, DOI 10.1242/dev.01010
   Munemasa Y, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00060
   Nelson BR, 2007, DEV BIOL, V304, P479, DOI 10.1016/j.ydbio.2007.01.001
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Ng L, 2011, J NEUROSCI, V31, P11118, DOI 10.1523/JNEUROSCI.1709-11.2011
   Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155
   Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028
   Oh ECT, 2007, P NATL ACAD SCI USA, V104, P1679, DOI 10.1073/pnas.0605934104
   Omori Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019685
   Oron-Karni V, 2008, DEVELOPMENT, V135, P4037, DOI 10.1242/dev.028308
   Pan L, 2008, DEVELOPMENT, V135, P1981, DOI 10.1242/dev.010751
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   PRADA C, 1991, EUR J NEUROSCI, V3, P1187
   Qiu F, 2008, J NEUROSCI, V28, P3392, DOI 10.1523/JNEUROSCI.0043-08.2008
   Rapaport DH, 2001, J NEUROBIOL, V49, P129, DOI 10.1002/neu.1070
   Riesenberg AN, 2009, J NEUROSCI, V29, P12865, DOI 10.1523/JNEUROSCI.3382-09.2009
   Riesenberg AN, 2009, GENESIS, V47, P175, DOI 10.1002/dvg.20479
   Roger JE, 2010, J BIOL CHEM, V285, P25637, DOI 10.1074/jbc.M110.142810
   Rouskova Lucie, 2008, Acta Medica (Hradec Kralove), V51, P121
   Sakagami K, 2009, J NEUROSCI, V29, P6932, DOI 10.1523/JNEUROSCI.0289-09.2009
   Sanchez-Camacho C, 2008, DEVELOPMENT, V135, P3531, DOI 10.1242/dev.023663
   Satarian L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071855
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Skowronska-Krawczyk D, 2009, DEVELOPMENT, V136, P3767, DOI 10.1242/dev.033449
   STIEMKE MM, 1995, DIFFERENTIATION, V58, P189, DOI 10.1046/j.1432-0436.1995.5830189.x
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906
   Trimarchi JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001588
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   Vinothkumar S, 2008, DEV BIOL, V314, P200, DOI 10.1016/j.ydbio.2007.11.034
   Wallace VA, 2008, BRAIN RES, V1192, P61, DOI 10.1016/j.brainres.2007.06.018
   Walland MJ, 2006, CLIN EXP OPHTHALMOL, V34, P827, DOI 10.1111/j.1442-9071.2006.01368.x
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SW, 2001, GENE DEV, V15, P24, DOI 10.1101/gad.855301
   Wang SW, 2000, MOL CELL NEUROSCI, V16, P141, DOI 10.1006/mcne.2000.0860
   Wang YP, 2005, DEVELOPMENT, V132, P5103, DOI 10.1242/dev.02096
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Willardsen MI, 2009, DEV BIOL, V326, P471, DOI 10.1016/j.ydbio.2008.10.046
   XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7
   XIANG MQ, 1995, J NEUROSCI, V15, P4762
   Yang ZY, 2003, DEV BIOL, V264, P240, DOI 10.1016/j.ydbio.2003.08.005
   Yao J, 2007, MOL VIS, V13, P1066
   Yaron O, 2006, DEVELOPMENT, V133, P1367, DOI 10.1242/dev.02311
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215
   Yu S, 2006, BIOCHEM BIOPH RES CO, V344, P1071, DOI 10.1016/j.bbrc.2006.03.231
   Zaghloul NA, 2005, BIOL CELL, V97, P321, DOI 10.1042/BC2004/0521
   Zarzeczny A, 2009, CELL, V139, P1032, DOI 10.1016/j.cell.2009.11.039
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
   Zhang XM, 2001, DEVELOPMENT, V128, P943
NR 150
TC 2
Z9 2
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD AUG
PY 2016
VL 27
IS 8
BP 609
EP 620
DI 10.1089/hum.2016.083
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA DU6AQ
UT WOS:000382295500005
PM 27466076
DA 2022-11-30
ER

PT J
AU Belgio, B
   Salvetti, AP
   Mantero, S
   Boschetti, F
AF Belgio, Beatrice
   Salvetti, Anna Paola
   Mantero, Sara
   Boschetti, Federica
TI The Evolution of Fabrication Methods in Human Retina Regeneration
SO APPLIED SCIENCES-BASEL
LA English
DT Review
DE retina; tissue engineering; retina regeneration; biofabrication; 3D
   bioprinting; electrospinning; ophthalmology
ID PIGMENT EPITHELIAL-CELLS; PLURIPOTENT STEM-CELLS; SILK FIBROIN
   MEMBRANES; BRUCHS MEMBRANE; NANOFIBROUS SCAFFOLDS; POLYMER SCAFFOLDS;
   GANGLION-CELLS; DIFFERENTIATION; RPE; CULTURE
AB Optic nerve and retinal diseases such as age-related macular degeneration and inherited retinal dystrophies (IRDs) often cause permanent sight loss. Currently, a limited number of retinal diseases can be treated. Hence, new strategies are needed. Regenerative medicine and especially tissue engineering have recently emerged as promising alternatives to repair retinal degeneration and recover vision. Here, we provide an overview of retinal anatomy and diseases and a comprehensive review of retinal regeneration approaches. In the first part of the review, we present scaffold-free approaches such as gene therapy and cell sheet technology while in the second part, we focus on fabrication techniques to produce a retinal scaffold with a particular emphasis on recent trends and advances in fabrication techniques. To this end, the use of electrospinning, 3D bioprinting and lithography in retinal regeneration was explored.
C1 [Belgio, Beatrice; Mantero, Sara; Boschetti, Federica] Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20133 Milan, Italy.
   [Salvetti, Anna Paola] Univ Milan, Fatebenefratelli & Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, I-20157 Milan, Italy.
   [Salvetti, Anna Paola] Casa Cura Beato Palazzolo, Dept Ophthalmol, I-24122 Bergamo, Italy.
C3 Polytechnic University of Milan; University of Milan; Luigi Sacco
   Hospital
RP Belgio, B (通讯作者)，Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20133 Milan, Italy.
EM beatrice.belgio@polimi.it; paola.anna.salvetti@gmail.com;
   sara.mantero@polimi.it; federica.boschetti@polimi.it
RI ; BOSCHETTI, FEDERICA/I-8623-2018
OI Salvetti, Anna Paola/0000-0002-5513-2241; BOSCHETTI,
   FEDERICA/0000-0002-1932-7535; MANTERO, SARA/0000-0002-1264-0465; Belgio,
   Beatrice/0000-0002-7964-9122
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Aimar A, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/5340616
   Akbarzadeh R, 2014, J BIOMED MATER RES B, V102, P1304, DOI 10.1002/jbm.b.33101
   Asnaghi MA, 2011, J APPL BIOMATER BIOM, V9, P73, DOI 10.5301/JABB.2011.8562
   Beachley V, 2009, MAT SCI ENG C-BIO S, V29, P663, DOI 10.1016/j.msec.2008.10.037
   Belgio B, 2021, BIOENGINEERING-BASEL, V8, DOI 10.3390/bioengineering8020018
   Bhardwaj N, 2010, BIOTECHNOL ADV, V28, P325, DOI 10.1016/j.biotechadv.2010.01.004
   Bird A.C., 2013, RETINA-J RET VIT DIS, V5th, P1145, DOI [10.1016/C2010-1-69566-1, DOI 10.1016/C2010-1-69566-1]
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brennan CM, 2019, BIOMED MATER, V14, DOI 10.1088/1748-605X/ab49f2
   Brucato, 2017, ARCH CHEM RES, V01, P1, DOI DOI 10.21767/2572-4657.100012
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Chaudhari AA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121974
   Chen GN, 2015, BIOMED REP, V3, P749, DOI 10.3892/br.2015.522
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Chirila TV, 2008, TISSUE ENG PT A, V14, P1203, DOI [10.1089/ten.tea.2007.0224, 10.1089/tea.2007.0224]
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curtis MW, 2009, J CARDIOVASC NURS, V24, P87, DOI 10.1097/01.JCN.0000343562.06614.49
   Da Silva GR, 2015, EUR J PHARM SCI, V73, P9, DOI 10.1016/j.ejps.2015.03.003
   Dalton PD, 2017, CURR OPIN BIOMED ENG, V2, P49, DOI 10.1016/j.cobme.2017.05.007
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dutt K, 2009, TISSUE ENG PT A, V15, P1401, DOI 10.1089/ten.tea.2007.0358
   El-Sherbiny Ibrahim M, 2013, Glob Cardiol Sci Pract, V2013, P316, DOI 10.5339/gcsp.2013.38
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fu Lin, 2019, Biomed Res Int, V2019, P8397521, DOI 10.1155/2019/8397521
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   Georgiou M, 2021, CLIN EXP OPHTHALMOL, V49, P270, DOI 10.1111/ceo.13917
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gleadall A, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038-018-0121-4
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Haraguchi Y, 2012, RSC ADV, V2, P2184, DOI 10.1039/c2ra00704e
   Hasan A, 2014, ACTA BIOMATER, V10, P11, DOI 10.1016/j.actbio.2013.08.022
   He P, 2018, BURNS TRAUMA, V6, DOI 10.1186/s41038-017-0104-x
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hertz J, 2013, ACTA BIOMATER, V9, P7622, DOI 10.1016/j.actbio.2013.04.048
   Hewitt E, 2019, BIOMED MATER, V14, DOI 10.1088/1748-605X/ab3344
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Janik H, 2015, MAT SCI ENG C-MATER, V48, P586, DOI 10.1016/j.msec.2014.12.037
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Kador KE, 2016, TISSUE ENG PT A, V22, P286, DOI [10.1089/ten.tea.2015.0373, 10.1089/ten.TEA.2015.0373]
   Kador KE, 2014, ACTA BIOMATER, V10, P4939, DOI 10.1016/j.actbio.2014.08.032
   Kador KE, 2013, BIOMATERIALS, V34, P4242, DOI 10.1016/j.biomaterials.2013.02.027
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kessler Michael W, 2008, Organogenesis, V4, P28
   Kim HS, 2019, INT J BIOL MACROMOL, V130, P220, DOI 10.1016/j.ijbiomac.2019.01.078
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kitsara M, 2017, ACTA BIOMATER, V48, P20, DOI 10.1016/j.actbio.2016.11.014
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Lai JY, 2013, J MATER SCI-MATER M, V24, P2201, DOI 10.1007/s10856-013-4961-y
   Lai JY, 2010, MAT SCI ENG C-MATER, V30, P677, DOI 10.1016/j.msec.2010.02.024
   Langer R, 2016, J PEDIATR SURG, V51, P8, DOI 10.1016/j.jpedsurg.2015.10.022
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Li JP, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1028-0
   Li KJ, 2017, ACTA BIOMATER, V54, P117, DOI 10.1016/j.actbio.2017.02.032
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lorber B, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/1/015001
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu TL, 2013, INT J NANOMED, V8, P337, DOI 10.2147/IJN.S38635
   Maitra J., 2014, AM J POLYM SCI, V4, P25, DOI DOI 10.5923/J.AJPS.20140402.01
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mannoor MS, 2013, NANO LETT, V13, P2634, DOI 10.1021/nl4007744
   Mantero S, 2007, J APPL BIOMATER BIOM, V5, P107
   Martinez-Perez CA, 2011, ADVANCES IN REGENERATIVE MEDICINE, P275
   Masaeli E, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/ab4a20
   McGill TJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.43
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Mertens JP, 2014, REGEN MED, V9, P89, DOI [10.2217/RME.13.81, 10.2217/rme.13.81]
   Moroni L, 2018, NAT REV MATER, V3, P21, DOI 10.1038/s41578-018-0006-y
   Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001
   Nadri S, 2013, MOL BIOL REP, V40, P3883, DOI 10.1007/s11033-012-2360-y
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Noorani B, 2018, INT J POLYM MATER PO, V67, P754, DOI 10.1080/00914037.2017.1362639
   Park JH, 2018, INT J BIOL MACROMOL, V117, P546, DOI 10.1016/j.ijbiomac.2018.05.127
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Prasad A, 2017, MATER TODAY-PROC, V4, P898, DOI 10.1016/j.matpr.2017.01.101
   Rahmani S, 2018, INT J POLYM MATER PO, V67, P27, DOI 10.1080/00914037.2017.1297939
   Rahmati M, 2021, PROG MATER SCI, V117, DOI 10.1016/j.pmatsci.2020.100721
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Roozafzoon R, 2015, BIOCHEM BIOPH RES CO, V457, P154, DOI 10.1016/j.bbrc.2014.12.069
   Sahle FF, 2019, ADV DRUG DELIVER REV, V148, P290, DOI 10.1016/j.addr.2019.10.006
   Saidy NT, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00793
   Schwab A, 2020, CHEM REV, V120, P10850, DOI 10.1021/acs.chemrev.0c00084
   Shadforth AMA, 2015, J FUNCT BIOMATER, V6, P946, DOI 10.3390/jfb6030946
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Shafiee A, 2017, ANNU REV MED, V68, P29, DOI 10.1146/annurev-med-102715-092331
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shi PJ, 2018, J TISSUE ENG REGEN M, V12, P1297, DOI 10.1002/term.2661
   Shi PJ, 2017, INT J BIOPRINTING, V3, P138, DOI 10.18063/IJB.2017.02.008
   Siemann U, 2005, PROG COLL POL SCI S, V130, P1
   Singh AK, 2014, J BIOMED MATER RES A, V102, P639, DOI 10.1002/jbm.a.34726
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Soleimannejad M, 2018, ARTIF CELL NANOMED B, V46, P805, DOI 10.1080/21691401.2017.1345922
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subia B, 2010, TISSUE ENGINEERING, P141
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Tian Y, 2017, ACS BIOMATER SCI ENG, V3, P890, DOI 10.1021/acsbiomaterials.6b00757
   Tran KTM, 2017, J SCI-ADV MATER DEV, V2, P1, DOI 10.1016/j.jsamd.2016.12.001
   Turnbull G, 2018, BIOACT MATER, V3, P278, DOI 10.1016/j.bioactmat.2017.10.001
   Van Ba OL, 2015, ADV DRUG DELIVER REV, V82-83, P31, DOI 10.1016/j.addr.2014.11.013
   Vukicevic M, 2017, JACC-CARDIOVASC IMAG, V10, P171, DOI 10.1016/j.jcmg.2016.12.001
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worthington KS, 2016, J OCUL PHARMACOL TH, V32, P310, DOI 10.1089/jop.2015.0126
   Wubneh A, 2018, ACTA BIOMATER, V80, P1, DOI 10.1016/j.actbio.2018.09.031
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xie JW, 2010, NANOSCALE, V2, P35, DOI 10.1039/b9nr00243j
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
   Zorlutuna P, 2007, BIOMATERIALS, V28, P3489, DOI 10.1016/j.biomaterials.2007.04.013
NR 130
TC 2
Z9 2
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD MAY
PY 2021
VL 11
IS 9
AR 4102
DI 10.3390/app11094102
PG 15
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA SB4MR
UT WOS:000649971000001
OA gold
DA 2022-11-30
ER

PT J
AU Yu, HL
   Li, JY
   Hu, XL
   Feng, JH
   Wang, H
   Xiong, F
AF Yu, Haoli
   Li, Junyan
   Hu, Xiaolong
   Feng, Jiahao
   Wang, Hao
   Xiong, Fei
TI Protective effects of cynaroside on oxidative stress in retinal pigment
   epithelial cells
SO JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
LA English
DT Article
DE age-related macular degeneration; cynaroside; oxidative stress; p-Akt;
   retinal pigment epithelial cells
ID ANTIOXIDANT ACTIVITY; MACULAR DEGENERATION; GENERATION; PREVALENCE;
   MECHANISMS; APOPTOSIS
AB Cynaroside is a flavonoid compound proved to possess antioxidant activity, but its protective effect on age-related macular degeneration still remains unclear. In this study, the protective effects of cynaroside on oxidative stress and apoptosis in retinal pigment epithelial (RPE) cells induced by hydrogen peroxide (H2O2) were investigated. Results showed that cynaroside effectively attenuated the decrease of cell activity induced by H2O2. The total reactive oxygen species can be remitted by decreasing malondialdehyde level, as well as increasing glutathione level, and superoxide dismutase and catalase activities. In addition, Western blot analysis indicated that cynaroside protected ARPE-19 cells from apoptosis through downregulation of caspase-3 protein activation which was controlled by the upstream proteins Bcl-2 and Bax. It was finally proved that cynaroside could enhance the antioxidant and antiapoptotic ability in ARPE-19 cells by promoting the expression of p-Akt.
C1 [Yu, Haoli; Xiong, Fei] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Lab Biomat & Devices, Nanjing 210096, Jiangsu, Peoples R China.
   [Li, Junyan; Hu, Xiaolong; Feng, Jiahao; Wang, Hao] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Dept TCMs Pharmaceut, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.
C3 Southeast University - China; China Pharmaceutical University
RP Xiong, F (通讯作者)，Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Lab Biomat & Devices, Nanjing 210096, Jiangsu, Peoples R China.; Wang, H (通讯作者)，China Pharmaceut Univ, Sch Tradit Chinese Pharm, Dept TCMs Pharmaceut, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.
EM wanghao@cpu.edu.cn; xiongfei@seu.edu.cn
FU Fundamental Research Funds for the Central Universities [2242018K3DN30]
   Funding Source: Medline; National Natural Science Foundation of China
   [81473160] Funding Source: Medline; National Key Research and
   Development Program of China [2017YFA0205502, 2017YFA0104301] Funding
   Source: Medline; Major National Science and Technology Projects of the
   Chinese thirteen five-year Plan [2017ZX09309024] Funding Source:
   Medline; Joint Research Fund for State Key Laboratory of Bioelectronics
   and Zhongda Hospital and Qinglan project Funding Source: Medline
CR Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chen S, 2014, NEUROPATH APPL NEURO, V40, P759, DOI 10.1111/nan.12103
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hu W, 2015, CHIN J NAT MEDICINES, V13, P445, DOI 10.1016/S1875-5364(15)30038-8
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004
   Liu LB, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22052
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spirlandeli AL, 2014, INT J SPORTS MED, V35, P14, DOI 10.1055/s-0033-1345132
   Sun X, 2011, J CELL BIOCHEM, V112, P2019, DOI 10.1002/jcb.23121
   Trushina E, 2007, NEUROSCIENCE, V145, P1233, DOI 10.1016/j.neuroscience.2006.10.056
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
   Wu MJ, 2005, J AGR FOOD CHEM, V53, P6305, DOI 10.1021/jf050511a
   Zha X, 2015, CELL PHYSIOL BIOCHEM, V36, P2217, DOI 10.1159/000430186
NR 23
TC 3
Z9 3
U1 3
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1095-6670
EI 1099-0461
J9 J BIOCHEM MOL TOXIC
JI J. Biochem. Mol. Toxicol.
PD AUG
PY 2019
VL 33
IS 8
AR e22352
DI 10.1002/jbt.22352
PG 7
WC Biochemistry & Molecular Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Toxicology
GA IQ3BK
UT WOS:000480625200013
PM 31157476
DA 2022-11-30
ER

PT J
AU Celkova, L
   Doyle, SL
   Campbell, M
AF Celkova, Lucia
   Doyle, Sarah L.
   Campbell, Matthew
TI NLRP3 Inflammasome and Pathobiology in AMD
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; NLRP3 inflammasome; IL-18; geographic
   atrophy; choroidal neovascularization; retinal pigment epithelium;
   pyroptosis; autophagy
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; MACULAR DEGENERATION; NALP3
   INFLAMMASOME; OXIDATIVE STRESS; TOLL-LIKE; PROINFLAMMATORY CYTOKINES;
   DANGER SIGNAL; AMYLOID-BETA; ACTIVATION
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss and blindness in the elderly. It is characterized by a progressive loss of photoreceptors in the macula due to damage to the retinal pigment epithelium (RPE). Clinically, it is manifested by drusen deposition between the RPE and underlying choroid and accumulation of lipofuscin in the RPE. End-stage disease is characterized by geographic atrophy (dry AMD) or choroidal neovascularization (wet AMD). The NLRP3 inflammasome has recently been implicated in the disease pathology. Here we review the current knowledge on the involvement of this multiprotein complex and its effector cytokines interleukin-1 beta (IL-1 beta) and IL-18 in AMD progression. We also describe cell death mechanisms that have been proposed to underlie RPE degeneration in AMD and discuss the role of autophagy in the regulation of disease progression.
C1 [Celkova, Lucia; Campbell, Matthew] Trinity Coll Dublin, Smurfit Inst Genet, Neurovasc Genet Lab, Lincoln Pl Gate, Dublin 2, Ireland.
   [Doyle, Sarah L.] Trinity Coll Dublin, Dept Clin Med, Sch Med, Dublin 2, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP Campbell, M (通讯作者)，Trinity Coll Dublin, Smurfit Inst Genet, Neurovasc Genet Lab, Lincoln Pl Gate, Dublin 2, Ireland.
EM celkoval@tcd.ie; doyles8@tcd.ie; matthew.campbell@tcd.ie
OI Doyle, Sarah/0000-0002-6294-9380
FU Science Foundation Ireland (SFI); Health Research Board (HRB) of
   Ireland; GlaxoSmithKline (GSK); Enterprise Ireland (EI); Bright Focus
   Foundation; ARVO Foundation for Eye Research (AFER)
FX The authors acknowledge funding support from Science Foundation Ireland
   (SFI), the Health Research Board (HRB) of Ireland, GlaxoSmithKline
   (GSK), Enterprise Ireland (EI), Bright Focus Foundation and the ARVO
   Foundation for Eye Research (AFER).
CR Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Babelova A, 2009, J BIOL CHEM, V284, P24035, DOI 10.1074/jbc.M109.014266
   Bamias G, 2012, CYTOKINE, V59, P451, DOI 10.1016/j.cyto.2012.06.014
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019
   Boraschi D, 2006, EUR CYTOKINE NETW, V17, P224
   Byrne B. G., 2013, MBIO, V4, DOI [10.1128/mBio.00620-12, DOI 10.1128/MBIO.0620-12]
   Cai X, 2014, CELL, V156, P1207, DOI 10.1016/j.cell.2014.01.063
   Compan V, 2012, IMMUNITY, V37, P487, DOI 10.1016/j.immuni.2012.06.013
   Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844
   Doyle SL, 2014, NAT MED, V20, P1376, DOI 10.1038/nm.3741
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   El Awad B, 2000, KIDNEY INT, V58, P43, DOI 10.1046/j.1523-1755.2000.00139.x
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Grunwald G. B., 2006, DUANES OPHTHALMOLOGY
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Harris J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00083
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones SA, 2013, IMMUNOL CELL BIOL, V91, P250, DOI 10.1038/icb.2012.82
   Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723
   Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez-Castejon G, 2013, J BIOL CHEM, V288, P2721, DOI 10.1074/jbc.M112.422238
   Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008
   Mallat Z, 2002, CIRC RES, V91, P441, DOI 10.1161/01.RES.0000033592.11674.D8
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0
   National Council for the Blind of Ireland, COST BLINDN REP IR 2
   National Council for the Blind of Ireland, EC IMP VIS IMP BLIND
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256
   Qiao H, 2004, LAB INVEST, V84, P973, DOI 10.1038/labinvest.3700115
   Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342
   Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamasaki K, 2009, J BIOL CHEM, V284, P12762, DOI 10.1074/jbc.M806084200
   Yano S, 2003, CANCER SCI, V94, P244, DOI 10.1111/j.1349-7006.2003.tb01428.x
   Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 110
TC 54
Z9 57
U1 2
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2015
VL 4
IS 1
BP 172
EP 192
DI 10.3390/jcm4010172
PG 21
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9II
UT WOS:000363130100012
PM 26237026
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, SJ
   Flach, AJ
   Jampol, LM
AF Kim, Stephen J.
   Flach, Allan J.
   Jampol, Lee M.
TI Nonsteroidal Anti-inflammatory Drugs in Ophthalmology
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; allergic conjunctivitis; cataract
   surgery; cyclooxygenase inhibitors; cystoid macular edema; diabetic
   retinopathy; mydriasis; nonsteroidal anti-inflammatory drugs; NSAIDs;
   postoperative inflammation; prostaglandins
ID CYSTOID MACULAR EDEMA; KETOROLAC TROMETHAMINE 0.5-PERCENT; DICLOFENAC
   SODIUM 0.1-PERCENT; ENDOTHELIAL GROWTH-FACTOR; PREDNISOLONE ACETATE
   1-PERCENT; RANDOMIZED CLINICAL-TRIAL; BLOOD-AQUEOUS BARRIER;
   DOUBLE-MASKED TRIAL; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR;
   INTRAOCULAR-PRESSURE RESPONSE
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) arc increasingly employed in ophthalmology to reduce miosis and inflammation, manage scleritis, and prevent and treat cystoid macular edema associated with cataract surgery. In addition, the), may decrease postoperative pain and photophobia associated with refractive surgery and may reduce the itching associated with allergic conjunctivitis. In recent years, the U.S. Food and Drug Administration has approved new topical NSAIDs, and previously approved NSAIDs have been reformulated. These additions and changes result ill different pharmacokinetics and closing intervals, which may offer therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide all updated review oil NSAIDs and a summary of their current uses in ophthalmology with attention to potential future applications. (Surv Ophthalmol 55:108-133, 2010. (C) 2010 Elsevier Inc. All rights reserved.)
C1 [Kim, Stephen J.] Vanderbilt Univ, Dept Ophthalmol, Nashville, TN 37232 USA.
   [Flach, Allan J.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Flach, Allan J.] Vet Adm, San Francisco, CA USA.
   [Jampol, Lee M.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Vanderbilt University; University of California System; University of
   California San Francisco; Northwestern University; Feinberg School of
   Medicine
RP Kim, SJ (通讯作者)，Vanderbilt Univ, Dept Ophthalmol, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM skim30@gmail.com
CR ABELSON MB, 1993, SURV OPHTHALMOL, V38, P115, DOI 10.1016/0039-6257(93)90036-7
   ABELSON MB, 1983, AM J OPHTHALMOL, V95, P502, DOI 10.1016/0002-9394(83)90272-6
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Ahuja M, 2008, AAPS J, V10, P229, DOI 10.1208/s12248-008-9024-9
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Akpek EK, 1999, OPHTHALMOLOGY, V106, P729, DOI 10.1016/S0161-6420(99)90157-4
   ALLANSMITH MR, 1986, SURV OPHTHALMOL, V30, P229, DOI 10.1016/0039-6257(86)90119-0
   Almeida DRP, 2008, J CATARACT REFR SURG, V34, P64, DOI 10.1016/j.jcrs.2007.08.034
   Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531
   Amrite AC, 2008, J PHARMACOL EXP THER, V324, P749, DOI 10.1124/jpet.107.128918
   [Anonymous], 1991, Ophthalmology, V98, P757
   [Anonymous], 1997, J Cataract Refract Surg, V23, P1183
   Apt L, 1998, OPHTHALMOLOGY, V105, P1448, DOI 10.1016/S0161-6420(98)98026-5
   Ares JJ, 1998, CURR PHARM DESIGN, V4, P17
   ARMALY MF, 1965, FED PROC, V24, P1274
   ARMALY MF, 1966, ARCH OPHTHALMOL-CHIC, V75, P776, DOI 10.1001/archopht.1966.00970050778013
   Asai T, 2006, CORNEA, V25, P224, DOI 10.1097/01.ico.0000177835.93130.d4
   Avunduk AM, 2003, AM J OPHTHALMOL, V136, P593, DOI 10.1016/S0002-9394(03)00326-X
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Baklayan GA, 2008, J OCUL PHARMACOL TH, V24, P392, DOI 10.1089/jop.2007.0082
   BALLAS Z, 1993, SURV OPHTHALMOL, V38, P141, DOI 10.1016/0039-6257(93)90038-9
   Baron JA, 2008, LANCET, V372, P1756, DOI 10.1016/S0140-6736(08)61490-7
   BAUDOIN C, 1989, DIABETES, V38, P491
   Bauer AM, 2005, AM J OPHTHALMOL, V139, P1086, DOI 10.1016/j.ajo.2005.01.030
   Beehler C, 1998, OPHTHALMOLOGY, V105, P1780
   Bekendam PD, 2007, CORNEA, V26, P1002, DOI 10.1097/ICO.0b013e3180cfe626
   Benson SE, 2009, RETINA-J RET VIT DIS, V29, P387, DOI 10.1097/IAE.0b013e318192f4d8
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bielohuby M, 2008, OBES METAB-MILAN, V4, P1
   Birt CM, 2003, OPHTHAL SURG LAS IM, V34, P381
   Biswas Jyotirmay, 2004, International Ophthalmology, V25, P147, DOI 10.1007/s10792-004-5195-2
   BLAYDES JE, 1993, J CATARACT REFR SURG, V19, P481, DOI 10.1016/S0886-3350(13)80611-6
   BLUMENTHAL M, 1987, OPHTHALMIC LASER THE, V2, P249
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brint SF, 1999, J CATARACT REFR SURG, V25, P41, DOI 10.1016/S0886-3350(99)80009-1
   BROOKS CD, 1985, ANN ALLERGY, V55, P557
   BROOKS CD, 1984, J ALLERGY CLIN IMMUN, V73, P584, DOI 10.1016/0091-6749(84)90515-3
   BROOKS CD, 1988, J ALLERGY CLIN IMMUN, V81, P1110, DOI 10.1016/0091-6749(88)90877-9
   BROOKS PM, 1988, MED J AUSTRALIA, V148, P249
   BROWN SI, 1970, AM J OPHTHALMOL, V70, P744, DOI 10.1016/0002-9394(70)90494-0
   Bucci FA, 2007, AM J OPHTHALMOL, V144, P146, DOI 10.1016/j.ajo.2007.02.034
   BURNETT J, 1983, OPHTHALMIC SURG LAS, V14, P150
   Caldwell M, 2008, J REFRACT SURG, V24, P377, DOI 10.3928/1081597X-20080401-11
   Carmo A, 2000, MEDIAT INFLAMM, V9, P243, DOI 10.1080/09629350020025764
   Chan CKM, 2004, AM J OPHTHALMOL, V137, P1157, DOI 10.1016/j.ajo.2004.01.038
   Chang DF, 1999, OPHTHALMOLOGY, V106, P1172, DOI 10.1016/S0161-6420(99)90262-2
   Cheng HF, 2005, CURR PHARM DESIGN, V11, P1795, DOI 10.2174/1381612053764922
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Chiolero Arnaud, 2002, Expert Opin Drug Saf, V1, P45, DOI 10.1517/14740338.1.1.45
   Congdon NG, 2001, J CATARACT REFR SURG, V27, P622, DOI 10.1016/S0886-3350(01)00801-X
   Costagliola C, 2005, EXP EYE RES, V81, P610, DOI 10.1016/j.exer.2005.03.020
   Costagliola C, 2008, CURR EYE RES, V33, P477, DOI 10.1080/02713680802100845
   Crofford LJ, 2002, CURR OPIN RHEUMATOL, V14, P225, DOI 10.1097/00002281-200205000-00005
   Cryan LM, 2008, CURR EYE RES, V33, P177, DOI 10.1080/02713680701867908
   D'Angelo G, 2003, GRAEF ARCH CLIN EXP, V241, P192, DOI 10.1007/s00417-002-0612-6
   Dadeya S, 2002, J PEDIAT OPHTH STRAB, V39, P166, DOI 10.3928/0191-3913-20020501-08
   Dai WD, 2004, J CARDIOVASC PHARM T, V9, P51, DOI 10.1177/107424840400900i108
   Davies NM, 2004, J PHARM PHARM SCI, V7, P217
   DAVIES T, 1974, THROMB RES, V5, P667, DOI 10.1016/0049-3848(74)90056-5
   de Souza JP, 2006, EYE, V20, P598, DOI 10.1038/sj.eye.6701938
   DELAMAZA MS, 1995, OPHTHALMOLOGY, V102, P687, DOI 10.1016/S0161-6420(95)30970-0
   DEUTSCH TA, 1979, AM J OPHTHALMOL, V87, P536, DOI 10.1016/0002-9394(79)90245-9
   DHIR SP, 1979, AM J OPHTHALMOL, V87, P403, DOI 10.1016/0002-9394(79)90084-9
   Diestelhorst M, 1996, J CATARACT REFR SURG, V22, P788, DOI 10.1016/S0886-3350(96)80163-5
   Donnenfeld ED, 2007, OPHTHALMOLOGY, V114, P1653, DOI 10.1016/j.ophtha.2006.12.029
   Donnenfeld ED, 2007, ADV THER, V24, P852, DOI 10.1007/BF02849978
   Donnenfeld ED, 2006, J CATARACT REFR SURG, V32, P1474, DOI 10.1016/j.jcrs.2006.04.009
   Du YP, 2004, AM J PHYSIOL-REG I, V287, pR735, DOI 10.1152/ajpregu.00080.2003
   DUNNE JA, 1985, BRIT J OPHTHALMOL, V69, P120, DOI 10.1136/bjo.69.2.120
   Duong HVQ, 2007, J CATARACT REFR SURG, V33, P1925, DOI 10.1016/j.jcrs.2007.07.017
   Durrie DS, 2007, ADV THER, V24, P1278, DOI 10.1007/BF02877774
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EIFERMAN RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P1022, DOI 10.1001/archopht.1993.01090080016002
   El-Harazi SM, 1998, OPHTHALMIC SURG LAS, V29, P539
   ELLIS PP, 1994, J OCUL PHARMACOL, V10, P677, DOI 10.1089/jop.1994.10.677
   Esgin H, 2006, J OCUL PHARMACOL TH, V22, P460, DOI 10.1089/jop.2006.22.460
   Fan DSP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1716, DOI 10.1001/archopht.121.12.1716
   Fan DSP, 2001, OPHTHALMOLOGY, V108, P1973, DOI 10.1016/S0161-6420(01)00781-3
   Yavas GF, 2007, J CATARACT REFR SURG, V33, P804, DOI 10.1016/j.jcrs.2007.01.033
   Fekrat S, 2003, RETINA-J RET VIT DIS, V23, P8, DOI 10.1097/00006982-200302000-00002
   Fernandes BF, 2008, EYE, V22, P701, DOI 10.1038/sj.eye.6703042
   Figueiredo A, 2003, CAN J OPHTHALMOL, V38, P352, DOI 10.1016/S0008-4182(03)80045-5
   Flach A, 2000, OPHTHALMOLOGY, V107, P1224, DOI 10.1016/S0161-6420(00)00223-2
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   Flach A J, 2001, Trans Am Ophthalmol Soc, V99, P205
   Flach A J, 2000, Trans Am Ophthalmol Soc, V98, P101
   FLACH AJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P344, DOI 10.1001/archopht.1988.01060130370024
   FLACH AJ, 1988, OPHTHALMOLOGY, V95, P1279
   Flach AJ, 1998, OPHTHALMOLOGY, V105, P1775, DOI 10.1016/S0161-6420(98)99053-4
   Flach AJ, 2000, OPHTHALMOLOGY, V107, P2039, DOI 10.1016/S0161-6420(00)00366-3
   FLACH AJ, 1987, AM J OPHTHALMOL, V103, P479, DOI 10.1016/S0002-9394(14)74268-0
   FLACH AJ, 1990, OPHTHALMOLOGY, V97, P1253
   FLACH AJ, 1992, SURV OPHTHALMOL, V36, P259, DOI 10.1016/0039-6257(92)90095-B
   FLACH AJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P480
   FLACH AJ, 1991, AM J OPHTHALMOL, V112, P514, DOI 10.1016/S0002-9394(14)76851-5
   FLACH AJ, 1991, J TOXICOL-CUTAN OCUL, V10, P253, DOI 10.3109/15569529109052135
   Flach AJ, 2008, T AM OPHTHAL SOC, V106, P145
   FLACH AJ, 2000, T AM OPHTHAL SOC, V98, P105
   FLACH AJ, 1994, DUANES FDN CLIN OPHT, V2, P1
   Flach AJ., 2001, T AM OPHTHAL SOC, V99, P210
   Flach AJ, 2006, CORNEA, V25, P1265, DOI 10.1097/01.ico.0000240100.92055.89
   Flach Allan J, 2008, Trans Am Ophthalmol Soc, V106, P138
   Flach Allan Joseph, 2002, International Ophthalmology Clinics, V42, P1
   FRASERSMITH EB, 1988, J OCUL PHARMACOL, V4, P321, DOI 10.1089/jop.1988.4.321
   FRASERSMITH EB, 1987, ARCH OPHTHALMOL-CHIC, V105, P264, DOI 10.1001/archopht.1987.01060020118042
   Fraunfelder F T, 1976, Trans Am Ophthalmol Soc, V74, P457
   FRIEDLAENDER MH, 1993, SURV OPHTHALMOL, V38, P105, DOI 10.1016/0039-6257(93)90035-6
   Frota ACA, 2007, CAN J OPHTHALMOL, V42, P145, DOI 10.3129/canjophthalmol.06-109
   Frucht-Pery J, 1999, AM J OPHTHALMOL, V127, P148, DOI 10.1016/S0002-9394(98)00327-4
   FruchtPery J, 1997, CORNEA, V16, P42
   FRY LL, 1995, J CATARACT REFR SURG, V21, P187, DOI 10.1016/S0886-3350(13)80508-1
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   GASS JDM, 1966, ARCH OPHTHALMOL-CHIC, V76, P646, DOI 10.1001/archopht.1966.03850010648005
   GIESER DK, 1981, ANN OPHTHALMOL, V13, P831
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   GILLS JP, 1994, J CATARACT REFR SURG, V20, P110, DOI 10.1016/S0886-3350(13)80063-6
   GOETHALS M, 1994, DOC OPHTHALMOL, V85, P287, DOI 10.1007/BF01664937
   Goldkind L, 2006, PHARMACOEPIDEM DR S, V15, P213, DOI 10.1002/pds.1207
   Gordon YJ, 1998, ARCH OPHTHALMOL-CHIC, V116, P900, DOI 10.1001/archopht.116.7.900
   GREAVES MW, 1973, BRIT MED J, V3, P608, DOI 10.1136/bmj.3.5881.608
   GREEN K, 1983, ARCH OPHTHALMOL-CHIC, V101, P284
   Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Guadagni F, 2007, ANTICANCER RES, V27, P3147
   GUPTA S, 1991, ACTA OPHTHALMOL, V69, P95
   Gwon Arlene, 1994, CLAO Journal, V20, P131
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hankey GJ, 2003, STROKE, V34, P2736, DOI 10.1161/01.STR.0000097301.50041.6E
   HANNA C, 1972, ARCH OPHTHALMOL-CHIC, V88, P196
   Hariprasad SM, 2007, J OCUL PHARMACOL TH, V23, P585, DOI 10.1089/jop.2007.0062
   Hattori Y, 2007, CURR MED RES OPIN, V23, P1913, DOI 10.1185/030079907X218770
   Heier J, 1999, AM J OPHTHALMOL, V127, P253, DOI 10.1016/S0002-9394(98)00413-9
   Heier JS, 2000, OPHTHALMOLOGY, V107, P2034, DOI 10.1016/S0161-6420(00)00365-1
   HENDRICKS RL, 1990, INVEST OPHTH VIS SCI, V31, P1503
   HENRICH WL, 1983, AM J KIDNEY DIS, V2, P478, DOI 10.1016/S0272-6386(83)80083-3
   HERBORT CP, 1993, ARCH OPHTHALMOL-CHIC, V111, P481, DOI 10.1001/archopht.1993.01090040073033
   HERSH PS, 1990, ARCH OPHTHALMOL-CHIC, V108, P577, DOI 10.1001/archopht.1990.01070060125062
   Hirneiss C, 2005, GRAEF ARCH CLIN EXP, V243, P768, DOI 10.1007/s00417-005-1126-9
   HOSKINS HD, 1983, OPHTHALMOLOGY, V90, P796
   HOTCHKISS ML, 1984, OPHTHALMOLOGY, V91, P969
   Hu WZ, 2005, RETINA-J RET VIT DIS, V25, P1054, DOI 10.1097/00006982-200512000-00015
   HURVITZ LM, 1984, OPHTHALMIC SURG LAS, V15, P394
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   IRVINE SR, 1953, AM J OPHTHALMOL, V36, P599, DOI 10.1016/0002-9394(53)90302-X
   Isawi H, 2007, J CATARACT REFR SURG, V33, P1644, DOI 10.1016/j.jcrs.2007.04.041
   Ismail RA, 2008, EUR J OPHTHALMOL, V18, P1011, DOI 10.1177/112067210801800626
   Jabs DA, 2000, AM J OPHTHALMOL, V130, P469, DOI 10.1016/S0002-9394(00)00710-8
   JACKSON WB, 1993, SURV OPHTHALMOL, V38, P91, DOI 10.1016/0039-6257(93)90034-5
   JACOBSON DR, 1974, AM J OPHTHALMOL, V77, P445, DOI 10.1016/0002-9394(74)90451-6
   JAMPOL LM, 1982, OPHTHALMOLOGY, V89, P891
   JAMPOL LM, 1985, OPHTHALMOLOGY, V92, P807
   JAROS PA, 1988, SURV OPHTHALMOL, V33, P41, DOI 10.1016/0039-6257(88)90071-9
   Johnson EIM, 1999, CURR EYE RES, V18, P79, DOI 10.1076/ceyr.18.2.79.5386
   Johnson MW, 2009, AM J OPHTHALMOL, V147, P11, DOI 10.1016/j.ajo.2008.07.024
   Jones MK, 1999, NAT MED, V5, P1418
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kahaly GJ, 1999, EXP CLIN ENDOCR DIAB, V107, pS201, DOI 10.1055/s-0029-1212186
   Kaiser PK, 1997, OPHTHALMOLOGY, V104, P1353, DOI 10.1016/S0161-6420(97)30135-3
   Kapin MA, 2003, INFLAMMATION, V27, P281, DOI 10.1023/A:1026024409826
   Karim MM, 2000, AM J OPHTHALMOL, V129, P398, DOI 10.1016/S0002-9394(99)00355-4
   KAWAGUCHI T, 2003, FOLIA OPHTHALMOL JPN, V54, P276
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Kent AR, 1998, OPHTHALMIC SURG LAS, V29, P562
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   Khan Hayat A., 2007, Indian Journal of Ophthalmology, V55, P271
   KHOSRAVI E, 1995, INFLAMM RES, V44, P47, DOI 10.1007/BF01630487
   Kim A, 2008, AM J OPHTHALMOL, V146, P483, DOI 10.1016/j.ajo.2008.07.027
   Kim SJ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1203, DOI 10.1001/archopht.126.9.1203
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P870, DOI 10.1097/IAE.0b013e318169d04e
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P595, DOI 10.1097/IAE.0b013e31815e98a5
   Kim SJ, 2007, OPHTHALMOLOGY, V114, P881, DOI 10.1016/j.ophtha.2006.08.053
   Kim SJ, 2009, OPHTHALMOLOGY, V116, P1531, DOI 10.1016/j.ophtha.2009.02.008
   KITAO N, 2005, ATARASHII GANKA, V22, P1299
   Klein BEK, 2001, OPHTHALMOLOGY, V108, P1670, DOI 10.1016/S0161-6420(01)00656-X
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOTHARI HV, 1987, BIOCHIM BIOPHYS ACTA, V921, P502, DOI 10.1016/0005-2760(87)90078-6
   KRAFF MC, 1982, OPHTHALMOLOGY, V89, P885
   KRAFF MC, 1994, J CATARACT REFR SURG, V20, P138, DOI 10.1016/S0886-3350(13)80153-8
   KU EC, 1986, AM J MED, V80, P18, DOI 10.1016/0002-9343(86)90074-4
   Kulshrestha MK, 2000, RETINA-J RET VIT DIS, V20, P46, DOI 10.1097/00006982-200001000-00009
   Kwok AKH, 1997, OPHTHALMOLOGY, V104, P2112, DOI 10.1016/S0161-6420(97)30052-9
   LAIBOVITZ RA, 1995, J OCUL PHARMACOL TH, V11, P361, DOI 10.1089/jop.1995.11.361
   LAM S, 1989, OPHTHALMOLOGY, V96, P589
   LANE LS, 1982, OPHTHALMOLOGY, V89, P763
   Lane SS, 2007, J CATARACT REFR SURG, V33, P53, DOI 10.1016/j.jcrs.2006.08.043
   Laurell CG, 2002, BRIT J OPHTHALMOL, V86, P1380, DOI 10.1136/bjo.86.12.1380
   Leibowitz HM, 1996, ARCH OPHTHALMOL-CHIC, V114, P933, DOI 10.1001/archopht.1996.01100140141005
   LEOPOLD IH, 1974, AM J OPHTHALMOL, V78, P759, DOI 10.1016/0002-9394(74)90298-0
   Lewis R A, 1981, Kroc Found Ser, V14, P239
   Lin JC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1129
   LING TL, 1987, J PHARM SCI, V76, P289, DOI 10.1002/jps.2600760405
   LOBES LA, 1980, ARCH OPHTHALMOL-CHIC, V98, P1230
   Lobo CL, 2004, J CATARACT REFR SURG, V30, P752, DOI 10.1016/S0886-3350(03)00582-0
   LYONS CJ, 1990, EYE, V4, P521, DOI 10.1038/eye.1990.69
   MAHONEY JM, 1983, INVEST OPHTH VIS SCI, V24, P151
   Maier TJ, 2008, BIOCHEM PHARMACOL, V76, P862, DOI 10.1016/j.bcp.2008.07.009
   Malhotra M, 2006, AAPS PHARMSCITECH, V7
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Margalit E, 2006, INVEST OPHTH VIS SCI, V47, P2093, DOI 10.1167/iovs.05-0764
   Marshall JCA, 2007, CARCINOGENESIS, V28, P2053, DOI 10.1093/carcin/bgm091
   MASUDA K, 1984, PHARM EYE, P539
   MCDONALD HR, 1986, OPHTHALMOLOGY, V93, P978
   McGeer E G, 2001, Mol Interv, V1, P22
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Mentes J, 2003, OPHTHALMOLOGICA, V217, P408, DOI 10.1159/000073070
   MEREDITH TA, 1980, OPHTHALMOLOGY, V87, P1090
   MERMOUD A, 1992, ARCH OPHTHALMOL-CHIC, V110, P368, DOI 10.1001/archopht.1992.01080150066030
   MEYER E, 1987, BRIT J OPHTHALMOL, V71, P497, DOI 10.1136/bjo.71.7.497
   MILLER D, 1981, ARCH OPHTHALMOL-CHIC, V99, P681, DOI 10.1001/archopht.1981.03930010681016
   Mirshahi A, 2008, RETINA-J RET VIT DIS, V28, P1215, DOI 10.1097/IAE.0b013e31817b6afa
   Missotten L, 2001, OPHTHALMOLOGICA, V215, P43, DOI 10.1159/000050825
   MIYAKE K, 1980, BRIT J OPHTHALMOL, V64, P324, DOI 10.1136/bjo.64.5.324
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Miyake K, 2000, JPN J OPHTHALMOL, V44, P58, DOI 10.1016/S0021-5155(99)00176-8
   MIYAKE K, 1984, SURV OPHTHALMOL, V28, P554, DOI 10.1016/0039-6257(84)90239-X
   MIYAKE Y, 1993, ARCH OPHTHALMOL-CHIC, V111, P1605, DOI 10.1001/archopht.1993.01090120027008
   Miyake-Kashima M, 2004, JPN J OPHTHALMOL, V48, P587, DOI 10.1007/s10384-004-0127-2
   Mombaerts I, 1996, SURV OPHTHALMOL, V41, P66, DOI 10.1016/S0039-6257(97)81996-0
   Monnier Yan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P31, DOI 10.2174/1568010053622975
   MOREIRA H, 1991, OPHTHALMOLOGY, V98, P1693
   Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954
   NAPOLI SA, 1990, ANN OPHTHALMOL, V22, P30
   NAVEH N, 1990, OPHTHALMIC RES, V22, P3, DOI 10.1159/000266995
   NAVEHFLOMAN N, 1982, METAB PEDIATR SYST O, V6, P321
   Needleman P, 1997, J RHEUMATOL, V24, P6
   NESBURN AB, 1979, IMMUNOLOGY EYE, P21
   NEUFELD AH, 1973, PROSTAG OTH LIPID M, V4, P157, DOI 10.1016/0090-6980(73)90036-1
   NOBLE AG, 1989, AM J OPHTHALMOL, V108, P336, DOI 10.1016/0002-9394(89)90135-9
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   O'Brien TP, 2001, OPHTHALMOLOGY, V108, P656, DOI 10.1016/S0161-6420(00)00590-X
   OBRIEN WM, 1983, AM J MED, V75, P32, DOI 10.1016/0002-9343(83)90326-1
   OHARA K, 2004, JPN J CATARACT REFRA, V18, P168
   Ohara K OA, 2004, JPN J CLIN OPHTHAL, V58, P1325
   OHJI M, 1991, AM J OPHTHALMOL, V112, P450
   Okhravi N, 2005, SURV OPHTHALMOL, V50, P351, DOI 10.1016/j.survophthal.2005.04.001
   OLSON NY, 1988, AM J DIS CHILD, V142, P1289, DOI 10.1001/archpedi.1988.02150120043036
   PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X
   Papa V, 2002, EYE, V16, P292, DOI 10.1038/sj.eye.6700124
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Peterson WL, 1999, JAMA-J AM MED ASSOC, V282, P1961, DOI 10.1001/jama.282.20.1961
   PFISTER RR, 1980, ARCH OPHTHALMOL-CHIC, V98, P89
   POWELL EDU, 1964, LANCET, V2, P17
   Price MO, 2004, CURR MED RES OPIN, V20, P2015, DOI 10.1185/030079904X16759
   Rabiah PK, 1996, INVEST OPHTH VIS SCI, V37, P613
   RADTKE N, 1978, ARCH OPHTHALMOL-CHIC, V96, P51
   Raizman M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1000, DOI 10.1001/archopht.1996.01100140208016
   Rao CV, 2004, CURR CANCER DRUG TAR, V4, P29, DOI 10.2174/1568009043481632
   RAO NA, 1987, ARCH OPHTHALMOL-CHIC, V105, P413
   Ray Subhransu, 2002, Semin Ophthalmol, V17, P167, DOI 10.1076/soph.17.3.167.14794
   REISS GR, 1991, SURV OPHTHALMOL, V35, P407, DOI 10.1016/0039-6257(91)90106-P
   Rho DS, 2006, CORNEA, V25, P1266, DOI 10.1097/01.ico.0000235942.10279.c4
   Rho DS, 2003, J CATARACT REFR SURG, V29, P2378, DOI 10.1016/S0886-3350(03)00233-5
   Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp-75-9-1088
   Roberts CW, 1996, J CATARACT REFR SURG, V22, P780, DOI 10.1016/S0886-3350(96)80162-3
   ROBERTS CW, 1995, ARCH OPHTHALMOL-CHIC, V113, P725, DOI 10.1001/archopht.1995.01100060051031
   ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0
   ROSENBAUM JT, 1993, RETINA-J RET VIT DIS, V13, P17, DOI 10.1097/00006982-199313010-00005
   Rossetti L, 1998, OPHTHALMOLOGY, V105, P397, DOI 10.1016/S0161-6420(98)93018-4
   SABATES NR, 1989, AM J OPHTHALMOL, V108, P22, DOI 10.1016/S0002-9394(14)73255-6
   SALZ JJ, 1994, J REFRACT CORNEAL S, V10, P640
   Samiy N, 1996, INT OPHTHALMOL CLIN, V36, P195, DOI 10.1097/00004397-199603610-00019
   Samuelsson B, 1980, Adv Prostaglandin Thromboxane Res, V6, P1
   SANDERS DR, 1983, ARCH OPHTHALMOL-CHIC, V101, P1614
   SANDERS DR, 1982, ARCH OPHTHALMOL-CHIC, V100, P588
   Sandoval HP, 2006, J OCUL PHARMACOL TH, V22, P251, DOI 10.1089/jop.2006.22.251
   Sawaoka H, 1999, LAB INVEST, V79, P1469
   Schalnus R, 2003, OPHTHALMOLOGICA, V217, P89, DOI 10.1159/000068563
   SCHWARTZ B, 1980, CORTICOSTEROIDS EYE, P753
   Seitz B, 1996, ARCH OPHTHALMOL-CHIC, V114, P921, DOI 10.1001/archopht.1996.01100140129002
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Sharma Ashok, 1997, Indian Journal of Ophthalmology, V45, P177
   Shen WY, 2000, GRAEF ARCH CLIN EXP, V238, P273, DOI 10.1007/s004170050353
   SHER NA, 1994, J REFRACT CORNEAL S, V10, P587
   Shimazaki J, 1996, OPHTHALMOLOGY, V103, P50, DOI 10.1016/S0161-6420(96)30732-X
   SHIMAZAKI J, 1995, CORNEA, V14, P623
   Shiuey Y, 2000, OPHTHALMOLOGY, V107, P1512, DOI 10.1016/S0161-6420(00)00177-9
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   SIMON LS, 1980, NEW ENGL J MED, V302, P1237
   Simone JN, 1999, J CATARACT REFR SURG, V25, P699, DOI 10.1016/S0886-3350(99)00023-1
   Singal N, 2004, CAN J OPHTHALMOL, V39, P245, DOI 10.1016/S0008-4182(04)80121-2
   Sitenga GL, 1996, OPHTHALMOLOGY, V103, P890, DOI 10.1016/S0161-6420(96)30591-5
   Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8
   SMIDDY WE, 1990, RETINA-J RET VIT DIS, V10, P42, DOI 10.1097/00006982-199001010-00007
   Snir M, 2000, OPHTHALMOLOGY, V107, P1884, DOI 10.1016/S0161-6420(00)00350-X
   Solomon KD, 1997, ARCH OPHTHALMOL-CHIC, V115, P1119, DOI 10.1001/archopht.1997.01100160289004
   Solomon KD, 2004, J CATARACT REFR SURG, V30, P1653, DOI 10.1016/j.jcrs.2004.05.019
   Solomon KD, 2001, J CATARACT REFR SURG, V27, P1232, DOI 10.1016/S0886-3350(00)00832-4
   Solomon KD, 2001, OPHTHALMOLOGY, V108, P331, DOI 10.1016/S0161-6420(00)00543-1
   SOLOMON LD, 1995, J CATARACT REFR SURG, V21, P73, DOI 10.1016/S0886-3350(13)80484-1
   Souza JP, 2006, AM J OPHTHALMOL, V142, P625, DOI 10.1016/j.ajo.2006.05.053
   Spaeth G L, 1977, Trans Am Ophthalmol Soc, V75, P353
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Srinivasan R, 2002, J CATARACT REFR SURG, V28, P517, DOI 10.1016/S0886-3350(01)01115-4
   Staudt S, 2003, OPHTHALMOLOGE, V100, P702, DOI 10.1007/s00347-003-0821-3
   STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5
   STEWART RH, 1979, ARCH OPHTHALMOL-CHIC, V97, P2139
   Stewart RH, 2007, J OCUL PHARMACOL TH, V23, P601, DOI 10.1089/jop.2007.0040
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   STJERNSCHANTZ J, 1984, PHARM EYE, P311
   Stjernschantz JW, 2001, INVEST OPHTH VIS SCI, V42, P1134
   STRELOW SA, 1992, OPHTHALMIC SURG LAS, V23, P170
   SZERENYI K, 1994, AM J OPHTHALMOL, V118, P312, DOI 10.1016/S0002-9394(14)72954-X
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Takamatsu Futoshi, 2003, Rinsho Ganka, V57, P1233
   Tan DTH, 1999, OPHTHALMOLOGY, V106, P223, DOI 10.1016/S0161-6420(99)90060-X
   Tauber J, 1998, J OCUL PHARMACOL TH, V14, P137, DOI 10.1089/jop.1998.14.137
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thaller VT, 2000, EYE, V14, P642, DOI 10.1038/eye.2000.157
   Thomas MC, 2000, MED J AUSTRALIA, V172, P184, DOI 10.5694/j.1326-5377.2000.tb125548.x
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Thygeson P, 1977, CONTROVERSY OPHTHALM, P450
   TINKELMAN DG, 1993, SURV OPHTHALMOL, V38, P133, DOI 10.1016/0039-6257(93)90037-8
   Toker MI, 2006, AM J OPHTHALMOL, V141, P902, DOI 10.1016/j.ajo.2005.12.004
   Tranos PG, 2004, SURV OPHTHALMOL, V49, P470, DOI 10.1016/j.survophthal.2004.06.002
   Trattler W, 2007, CORNEA, V26, P665, DOI 10.1097/ICO.0b013e31805290ce
   Trinquand C., 1996, Investigative Ophthalmology and Visual Science, V37, pS590
   TUFT SJ, 1991, OPHTHALMOLOGY, V98, P467
   Uchio E, 2007, OPHTHALMOLOGICA, V221, P153, DOI 10.1159/000099294
   URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9
   Ursell PG, 1999, J CATARACT REFR SURG, V25, P1492, DOI 10.1016/S0886-3350(99)00196-0
   VANDER JF, 1989, AM J OPHTHALMOL, V108, P288, DOI 10.1016/0002-9394(89)90119-0
   Vlajkovic G, 2007, INT J CLIN PHARM TH, V45, P259
   WAITZMAN MB, 1967, AM J PHYSIOL, V212, P329, DOI 10.1152/ajplegacy.1967.212.2.329
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Walters T, 2007, J CATARACT REFR SURG, V33, P1539, DOI 10.1016/j.jcrs.2007.05.015
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471
   Waterbury LD, 2004, J OCUL PHARMACOL TH, V20, P345, DOI 10.1089/1080768041725380
   WATSON PG, 1976, BRIT J OPHTHALMOL, V60, P163, DOI 10.1136/bjo.60.3.163
   Weinberger D, 2000, BRIT J OPHTHALMOL, V84, P135, DOI 10.1136/bjo.84.2.135
   WEINREB RN, 1984, ARCH OPHTHALMOL-CHIC, V102, P1629
   Weisz JM, 1999, OPHTHALMOLOGY, V106, P1656, DOI 10.1016/S0161-6420(99)90366-4
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Williams CPR, 2005, EYE, V19, P739, DOI 10.1038/sj.eye.6701632
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wittpenn JR, 2008, AM J OPHTHALMOL, V146, P554, DOI 10.1016/j.ajo.2008.04.036
   Wolf EJ, 2007, J CATARACT REFR SURG, V33, P1974, DOI 10.1016/j.jcrs.2007.06.043
   WOOD TS, 1988, OPHTHALMOLOGY, V95, P822
   Wright M, 1997, BRIT J OPHTHALMOL, V81, P299, DOI 10.1136/bjo.81.4.299
   YABLONSKI ME, 1978, ARCH OPHTHALMOL-CHIC, V96, P474
   Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301
   YANNUZZI LA, 1977, AM J OPHTHALMOL, V84, P517, DOI 10.1016/0002-9394(77)90444-5
   YANNUZZI LA, 1984, SURV OPHTHALMOL, V28, P540, DOI 10.1016/0039-6257(84)90238-8
   YANNUZZI LA, 1981, OPHTHALMOLOGY, V88, P947
   Yasojima K, 1999, AM J PATHOL, V154, P927, DOI 10.1016/S0002-9440(10)65340-0
   Yee RW, 1998, AM J OPHTHALMOL, V125, P472, DOI 10.1016/S0002-9394(99)80187-1
   YOUNG BJ, 1982, BRIT J OPHTHALMOL, V66, P389, DOI 10.1136/bjo.66.6.389
   Yuen SJA, 2003, ARCH OPHTHALMOL-CHIC, V121, P491, DOI 10.1001/archopht.121.4.491
   ZIMMERMAN TJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P551
   1984, SURV OPHTHALMOL S, V28, P131
NR 362
TC 236
Z9 254
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2010
VL 55
IS 2
BP 108
EP 133
DI 10.1016/j.survophthal.2009.07.005
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 564KA
UT WOS:000275211700002
PM 20159228
DA 2022-11-30
ER

PT J
AU Makrynioti, D
   Zagoriti, Z
   Koutsojannis, C
   Morgan, PB
   Lagoumintzis, G
AF Makrynioti, Dimitra
   Zagoriti, Zoi
   Koutsojannis, Constantinos
   Morgan, Philip B.
   Lagoumintzis, George
TI Ocular conditions and dry eye due to traditional and new forms of
   smoking: A review
SO CONTACT LENS & ANTERIOR EYE
LA English
DT Review
DE Electronic cigarettes; Conventional cigarettes; Nicotine uptake; Dry eye
   disease; Smoking; Vaping
ID OPEN-ANGLE GLAUCOMA; CORNEAL INFILTRATIVE EVENTS; TOBACCO CIGARETTE
   SUBSTITUTES; LITHIUM-ION BATTERIES; RISK-FACTORS; ELECTRONIC CIGARETTES;
   MACULAR DEGENERATION; MICROBIAL KERATITIS; GRAVES OPHTHALMOPATHY;
   ANTIOXIDANT STATUS
AB Addiction to cigarette smoking has high prevalence rates recorded worldwide. Smoking has been linked to several life-threatening systemic conditions such as cancer, heart attack and stroke, in addition to a range of ocular pathologies. In recent years, electronic cigarettes (EC) have emerged as alternatives to smoking. ECs are nicotine delivery devices which produce an aerosol by heating, rather than combusting, a liquid which contains nicotine, flavours and preservatives. This review focuses on the association of traditional and new forms of smoking with dry eye disease, contact lens wear and four other common ocular diseases: cataract, age-related macular degeneration, glaucoma and Graves' ophthalmopathy. It is concluded that smoking and vaping appear as a risk factor for the aforementioned ocular conditions. An evidence-based, clear link between cigarette smoking, or EC vaping and ocular problems is yet to be discovered.
C1 [Makrynioti, Dimitra; Lagoumintzis, George] Univ Patras, Sch Hlth Rehabil Sci, Psaron 6, GR-25100 Aigio, Greece.
   [Zagoriti, Zoi; Lagoumintzis, George] Univ Patras, Dept Pharm, Lab Mol Biol & Immunol, Univ Campus, GR-26504 Patras, Greece.
   [Koutsojannis, Constantinos] Univ Patras, Sch Hlth Rehabil Sci, Dept Physiotherapy, Lab Hlth Phys & Computat Intelligence, Psaron 6, GR-25100 Aigio, Greece.
   [Morgan, Philip B.] Univ Manchester, Div Pharm & Optometry, Eurolens Res, Carys Bannister Bldg,Dover St, Manchester M13 9PL, Lancs, England.
C3 University of Patras; University of Patras; University of Patras;
   University of Manchester
RP Makrynioti, D (通讯作者)，Univ Patras, Sch Hlth Rehabil Sci, Psaron 6, GR-25100 Aigio, Greece.
EM dmakrynioti@upatras.gr; zoizag@upatras.gr; ckoustog@upatras.gr;
   philip.morgan@manchester.ac.uk; glagoum@upatras.gr
RI Kappaomicronupsilontausigmaomicrongammaiotaάnunuetasigma,
   Kappaomeganusigmataualphanutauίnuomicronsigma/V-2039-2019
OI Kappaomicronupsilontausigmaomicrongammaiotaάnunuetasigma,
   Kappaomeganusigmataualphanutauίnuomicronsigma/0000-0003-2664-2127;
   Morgan, Philip/0000-0003-0680-8169; Lagoumintzis,
   George/0000-0002-0441-9023
CR Abrams DB, 2014, JAMA-J AM MED ASSOC, V311, P135, DOI 10.1001/jama.2013.285347
   Acar DE, 2017, CUTAN OCUL TOXICOL, V36, P1, DOI 10.3109/15569527.2015.1136828
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alshamrani AA, 2017, MIDDLE EAST AFR J OP, V24, P67, DOI 10.4103/meajo.MEAJO_281_16
   [Anonymous], 2014, LANCET, V384, P829, DOI 10.1016/S0140-6736(14)61470-7
   [Anonymous], 2015, E CIGARETTES EVIDENC
   [Anonymous], 2004, IARC MONOGR EVAL CAR, V83, P1
   Anton-Lopez A, 2018, Arch Soc Esp Oftalmol (Engl Ed), V93, P76, DOI 10.1016/j.oftal.2017.10.001
   Asfar T, 2015, INVEST OPHTH VIS SCI, V56, P1120, DOI 10.1167/iovs.15-16479
   Bahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750
   Bahn RS, 2000, ENDOCRIN METAB CLIN, V29, P287, DOI 10.1016/S0889-8529(05)70132-8
   Barrio-Barrio J, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/249125
   Bartalena L, 2000, ENDOCR REV, V21, P168, DOI 10.1210/er.21.2.168
   Baumung C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35577
   Becmeur PH, 2017, J FR OPHTALMOL, V40, P224, DOI 10.1016/j.jfo.2016.10.008
   Behar RZ, 2018, TOB CONTROL, V27, P325, DOI 10.1136/tobaccocontrol-2016-053472
   Bekki K, 2014, INT J ENV RES PUB HE, V11, P11192, DOI 10.3390/ijerph111111192
   Beltran-Zambrano E, 2019, Arch Soc Esp Oftalmol (Engl Ed), V94, P60, DOI 10.1016/j.oftal.2018.10.020
   Ben-Eli H, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9060842
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Bilano V, 2015, LANCET, V385, P966, DOI 10.1016/S0140-6736(15)60264-1
   Britton J., 2014, ELECT CIGARETTES REP
   Brown CJ, 2014, TOB CONTROL, V23, P4, DOI 10.1136/tobaccocontrol-2013-051476
   Brozek GM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43324-1
   Brozek GM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16132297
   Burton Matthew J, 2009, Community Eye Health, V22, P33
   Cai H, 2017, REDOX BIOL, V13, P402, DOI 10.1016/j.redox.2017.05.013
   Cantrell FL, 2014, J COMMUN HEALTH, V39, P614, DOI 10.1007/s10900-013-9807-5
   Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317
   Cawood TJ, 2007, J CLIN ENDOCR METAB, V92, P59, DOI 10.1210/jc.2006-1824
   Cekic O, 1998, BRIT J OPHTHALMOL, V82, P186, DOI 10.1136/bjo.82.2.186
   Centers for Disease Control and Prevention, 2010, TOB SMOK CAUS DIS BI
   Chalmers RL, 2007, OPTOMETRY VISION SCI, V84, P573, DOI 10.1097/OPX.0b013e3180dc9a12
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chang K, 2014, INT J MOL SCI, V15, P22279, DOI 10.3390/ijms151222279
   Chapman S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5512
   Chen YY, 2019, INT J COLORECTAL DIS, V34, P2023, DOI 10.1007/s00384-019-03441-9
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Cheng TR, 2014, TOB CONTROL, V23, P11, DOI 10.1136/tobaccocontrol-2013-051482
   Chia EM, 2003, CLIN EXP OPHTHALMOL, V31, P229, DOI 10.1046/j.1442-9071.2003.00634.x
   Chiam N, 2018, CLIN EXP OPHTHALMOL, V46, P25, DOI 10.1111/ceo.13008
   Corey Catherine G, 2018, Inj Epidemiol, V5, P4, DOI 10.1186/s40621-018-0135-1
   Cornish KS, 2013, SEMIN OPHTHALMOL, V28, P11, DOI 10.3109/08820538.2012.719565
   Costenbader KH, 2006, LUPUS, V15, P737, DOI 10.1177/0961203306069344
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Cui YH, 2013, AM J CLIN NUTR, V98, P778, DOI 10.3945/ajcn.112.053835
   Dana R, 2019, AM J OPHTHALMOL, V202, P47, DOI 10.1016/j.ajo.2019.01.026
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Donma O, 2002, CURR EYE RES, V25, P9, DOI 10.1076/ceyr.25.1.9.9960
   Edwards R, 2008, J GLAUCOMA, V17, P558, DOI 10.1097/IJG.0b013e31815f530c
   Efron N, 2007, CORNEA, V26, P793, DOI 10.1097/ICO.0b013e31806c79dc
   Efron N, 2006, CLIN EXP OPTOM, V89, P280, DOI 10.1111/j.1444-0938.2006.00069.x
   El Mubarak MA, 2018, FOOD CHEM TOXICOL, V116, P147, DOI 10.1016/j.fct.2018.04.021
   El-Shazly AAF, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/130159
   Elmazar HM, 2018, J CATARACT REFR SURG, V44, P134, DOI 10.1016/j.jcrs.2017.10.051
   Erhardt L, 2009, ATHEROSCLEROSIS, V205, P23, DOI 10.1016/j.atherosclerosis.2009.01.007
   F.E.M.A. (FEMA), 2017, EL CIG FIR EXPL US 2
   Fang SJ, 2017, J CLIN ENDOCR METAB, V102, P4273, DOI 10.1210/jc.2017-01349
   Farsalinos KE, 2016, ADDICTION, V111, P2032, DOI 10.1111/add.13506
   Farsalinos KE, 2014, THER ADV DRUG SAF, V5, P67, DOI 10.1177/2042098614524430
   Farsalinos KE, 2014, INT J ENV RES PUB HE, V11, P4356, DOI 10.3390/ijerph110404356
   Flouris AD, 2012, FOOD CHEM TOXICOL, V50, P3600, DOI 10.1016/j.fct.2012.07.025
   G. United States Public Health Service, 2010, OFF SURG TOB SMOK CA
   Gabela Merino MI, 2003, Arch Soc Esp Oftalmol, V78, P543
   Galor A, 2011, CURR OPIN OPHTHALMOL, V22, P477, DOI 10.1097/ICU.0b013e32834bbe7a
   Galvez-Rosas A, 2018, GAC MED MEX, V154, P42, DOI 10.24875/GMM.17002663
   Ganapathy V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177780
   Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859
   Grana R, 2014, CIRCULATION, V129, P1972, DOI 10.1161/CIRCULATIONAHA.114.007667
   Grus FH, 2002, GRAEF ARCH CLIN EXP, V240, P889, DOI 10.1007/s00417-002-0539-y
   Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779
   Hajek P, 2014, ADDICTION, V109, P1801, DOI 10.1111/add.12659
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Handa S, 2011, EYE, V25, P1170, DOI 10.1038/eye.2011.143
   Harding J., 1991, CATARACT BIOCH EPIDE
   Harshman J, 2018, CAN J EMERG MED, V20, pS20, DOI 10.1017/cem.2017.32
   Hartmann-Boyce Jamie, 2016, Cochrane Database Syst Rev, V9, pCD010216, DOI 10.1002/14651858.CD010216.pub3
   Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829
   Herrington J.S., 2015, ANAL NICOTINE IMPURI
   Higuchi A, 2011, FREE RADICAL BIO MED, V51, P2210, DOI 10.1016/j.freeradbiomed.2011.09.025
   Hughes A, 2019, CLIN TOXICOL, V57, P287, DOI 10.1080/15563650.2018.1510503
   Ivashynka A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00866
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain V, 2017, INT OPHTHALMOL, V37, P291, DOI 10.1007/s10792-016-0245-0
   Jankowski M., 2019, INT J ENV RES PUBLIC, V16
   Jankowski M, 2019, INT J OCCUP MED ENV, V32, P595, DOI 10.13075/ijomeh.1896.01433
   Jiang Y, 2014, EYE CONTACT LENS, V40, P148, DOI 10.1097/ICL.0000000000000026
   Jiwani AZ, 2017, INT J BURNS TRAUMA, V7, P1
   Jonas JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202132
   Jones L, 2017, OCUL SURF, V15, P575, DOI 10.1016/j.jtos.2017.05.006
   Kandel ER, 2014, NEW ENGL J MED, V371, P932, DOI 10.1056/NEJMsa1405092
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawada T, 2017, PUBLIC HEALTH, V147, P153, DOI 10.1016/j.puhe.2017.01.017
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Kennedy RD, 2011, OPTOMETRY, V82, P310, DOI 10.1016/j.optm.2010.10.014
   Khairudin Muhammad Najmi, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-214964
   Kim KH, 2016, J ENVIRON SCI HEAL C, V34, P262, DOI 10.1080/10590501.2016.1236604
   Kim KI, 2019, KOREAN J FAM MED, V40, P22, DOI 10.4082/kjfm.17.0058
   King AC, 2016, PSYCHOL ADDICT BEHAV, V30, P106, DOI 10.1037/adb0000123
   Kisic B, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/467130
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Kobashi H, 2018, INT J OPHTHALMOL-CHI, V11, P1926, DOI 10.18240/ijo.2018.12.08
   Kosmider L, 2014, NICOTINE TOB RES, V16, P1319, DOI 10.1093/ntr/ntu078
   Kriebel D.L., 2001, REENERGIZING PUBLIC
   Kumetz EA, 2016, AM J EMERG MED, V34, DOI 10.1016/j.ajem.2016.04.010
   Kuo YK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081227
   Laan M, 2004, J IMMUNOL, V173, P4164, DOI 10.4049/jimmunol.173.6.4164
   Lacheta D, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7453260
   Lam DCL, 2014, RESPIROLOGY, V19, P945, DOI 10.1111/resp.12374
   Law SM, 2018, EYE, V32, P716, DOI 10.1038/eye.2017.292
   Leduc C, 2016, THER ADV RESPIR DIS, V10, P130, DOI 10.1177/1753465815621233
   Lee SY, 2012, OPHTHAL PHYSL OPT, V32, P518, DOI 10.1111/j.1475-1313.2012.00931.x
   Lindblom EN, 2015, FOOD DRUG LAW J, V70, P55
   Lois N, 2008, BRIT J OPHTHALMOL, V92, P1304, DOI 10.1136/bjo.2008.141168
   Maideen N.M.P., 2019, WORLD J PHARM, V8, P14, DOI 10.5497/wjp.v8.i2.14
   Markidan J, 2018, STROKE, V49, P1276, DOI 10.1161/STROKEAHA.117.018859
   Matsumoto Y, 2008, EYE, V22, P961, DOI 10.1038/eye.2008.78
   Md Isa NA, 2019, OPTOMETRY VISION SCI, V96, P678, DOI 10.1097/OPX.0000000000001422
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morgan PB, 2005, INVEST OPHTH VIS SCI, V46, P3136, DOI 10.1167/iovs.05-0133
   Morgan PB, 2005, BRIT J OPHTHALMOL, V89, P430, DOI 10.1136/bjo.2004.052688
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Motooka Y., 2018, SAGE OPEN MED
   Mouhamed DH, 2013, IMMUNO-ANAL BIOL SPE, V28, P195, DOI 10.1016/j.immbio.2013.03.004
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   N.C. f.C.D.P.a.H.P.U.O.o.S.a. Health CfDCaP (US), 2016, E CIG US YOUTH YOUNG
   Nelson JD, 2017, OCUL SURF, V15, P269, DOI 10.1016/j.jtos.2017.05.005
   Nicoll KJ, 2016, BURNS, V42, pE42, DOI 10.1016/j.burns.2016.03.027
   Niven TCS, 2019, J GLAUCOMA, V28, P7, DOI 10.1097/IJG.0000000000001120
   Norii T, 2017, J EMERG MED, V52, P86, DOI 10.1016/j.jemermed.2016.08.010
   Oh AY, 2014, LARYNGOSCOPE, V124, P2702, DOI 10.1002/lary.24750
   Paley GL, 2016, CORNEA, V35, P1015, DOI 10.1097/ICO.0000000000000881
   Perez CI, 2019, CURR OPIN OPHTHALMOL, V30, P82, DOI 10.1097/ICU.0000000000000553
   Perez-de-Arcelus M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005761
   PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479
   Radford CF, 2009, OPHTHALMOLOGY, V116, P385, DOI 10.1016/j.ophtha.2008.09.053
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Ramirez JI, 2017, J BURN CARE RES, V38, P220, DOI 10.1097/BCR.0000000000000472
   Rossheim ME, 2019, TOB CONTROL, V28, P472, DOI 10.1136/tobaccocontrol-2018-054518
   Rummenie VT, 2008, CYTOKINE, V43, P200, DOI 10.1016/j.cyto.2008.05.011
   Russo C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040581
   Salvi M, 2015, J CLIN ENDOCR METAB, V100, P422, DOI 10.1210/jc.2014-3014
   Satici A, 2003, ACTA OPHTHALMOL SCAN, V81, P583, DOI 10.1111/j.1395-3907.2003.00158.x
   Sauer A, 2016, EYE CONTACT LENS, V42, P158, DOI 10.1097/ICL.0000000000000180
   Sheckter C, 2016, BURNS TRAUMA, V4, DOI 10.1186/s41038-016-0061-9
   Simonavicius E, 2019, TOB CONTROL, V28, P582, DOI 10.1136/tobaccocontrol-2018-054419
   Smith CJ, 2001, ATHEROSCLEROSIS, V158, P257, DOI 10.1016/S0021-9150(01)00570-6
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Stapleton F., 2003, EYE CONTACT LENS S1, V29, pS192
   Stapleton F., 2003, EYE CONTACT LENS, V29, pS115
   Stapleton F, 2008, OPHTHALMOLOGY, V115, P1655, DOI 10.1016/j.ophtha.2008.04.002
   Stapleton F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181343
   Stapleton F, 2017, OCUL SURF, V15, P334, DOI 10.1016/j.jtos.2017.05.003
   Stapleton Fiona, 2003, Eye Contact Lens, V29, pS85
   Stapleton F, 2012, OPHTHALMOLOGY, V119, P1516, DOI 10.1016/j.ophtha.2012.01.052
   Szczotka-Flynn L, 2010, INVEST OPHTH VIS SCI, V51, P5421, DOI 10.1167/iovs.10-5456
   Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613
   Tan XJ, 2008, J CLIN LAB ANAL, V22, P159, DOI 10.1002/jcla.20235
   TAYLOR A, 1995, AM J CLIN NUTR, V62, P1439, DOI 10.1093/ajcn/62.6.1439S
   Thomas J, 2012, AUSTRALAS MED J, V5, P221, DOI 10.4066/AMJ.2012.1035
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Titiyal JS, 2018, INDIAN J OPHTHALMOL, V66, P207, DOI 10.4103/ijo.IJO_698_17
   Treitl D, 2017, J EMERG MED, V53, P121, DOI 10.1016/j.jemermed.2017.03.031
   Um SB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199131
   Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang S., 2016, PLOS ONE, V11
   Wang ZM, 2019, INT J OPHTHALMOL-CHI, V12, P1209, DOI 10.18240/ijo.2019.07.24
   Ward SK, 2010, OPTOMETRY VISION SCI, V87, P367, DOI 10.1097/OPX.0b013e3181d95188
   WEBER A, 1984, PREV MED, V13, P618, DOI 10.1016/S0091-7435(84)80012-2
   West R, 2017, PSYCHOL HEALTH, V32, P1018, DOI 10.1080/08870446.2017.1325890
   Westenberger B, 2009, EVALUATION E CIGARET
   Wieslander G, 2001, OCCUP ENVIRON MED, V58, P649, DOI 10.1136/oem.58.10.649
   World Health Organization ( WHO), 2019, WHO REP GLOB TOB EP
   Xu L, 2016, INT J OPHTHALMOL-CHI, V9, P1480, DOI 10.18240/ijo.2016.10.19
   Yoon Kyung-Chul, 2005, Korean J Ophthalmol, V19, P18
   Zapp D, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0777-3
   Zhao S., 2019, MEDICINE, V98
NR 179
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1367-0484
EI 1476-5411
J9 CONTACT LENS ANTERIO
JI Contact Lens Anterior Eye
PD JUN
PY 2020
VL 43
IS 3
BP 277
EP 284
DI 10.1016/j.clae.2020.02.009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA LS7RB
UT WOS:000536577600021
PM 32111452
DA 2022-11-30
ER

PT J
AU Kang-Mieler, JJ
   Rudeen, KM
   Liu, WQ
   Mieler, WF
AF Kang-Mieler, Jennifer J.
   Rudeen, Kayla M.
   Liu, Wenqiang
   Mieler, William F.
TI Advances in ocular drug delivery systems
SO EYE
LA English
DT Review
ID CILIARY NEUROTROPHIC FACTOR; FLUOCINOLONE ACETONIDE IMPLANT;
   EXTENDED-RELEASE; THERMORESPONSIVE HYDROGELS; INTRAVITREAL INJECTIONS;
   PLGA NANOPARTICLES; BEVACIZUMAB; MICROSPHERES; PHARMACOKINETICS; TRIAL
AB Recent advances in pharmacological agents have led to successful treatment of a variety of retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vascular occlusions (RVO). These treatments often require repeated drug injections for an extended period of time. To reduce these repeated treatment burdens, minimally invasive drug delivery systems are needed. An ideal therapy should maintain effective levels of drug for the intended duration of treatment following a single application, recognising that a significant number of months of therapy may be required. There are numerous approaches under investigation to improve treatment options. This review will highlight the advantages and limitations of selected drug delivery systems of novel biomaterial implants and depots. The main emphasis will be placed on less invasive, longer acting, sustained release formulations for the treatment of retinal disorders.
C1 [Kang-Mieler, Jennifer J.; Rudeen, Kayla M.; Liu, Wenqiang] IIT, Dept Biomed Engn, Chicago, IL 60616 USA.
   [Mieler, William F.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60680 USA.
C3 Illinois Institute of Technology; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Kang-Mieler, JJ (通讯作者)，IIT, Dept Biomed Engn, Chicago, IL 60616 USA.; Mieler, WF (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60680 USA.
EM kang-mieler@iit.edu; wmieler@uic.edu
RI Liu, Wenqiang/AAS-9154-2020; Liu, Wenqiang/AAH-2473-2021; Liu,
   Wenqiang/ABE-8502-2020
OI Liu, Wenqiang/0000-0002-1752-9838; Kang-Mieler,
   Jennifer/0000-0002-2844-5066
FU NIH [EY025434, EY029298]
FX We would like to acknowledge NIH Research Grants (EY025434 and
   EY029298). Jennifer J. Kang-Mieler: NIH Research Grants (EY025434;
   EY029298). Kayla M. Rudeen, Wenqiang Liu, William F. Mieler: None
CR Agrawal AK, 2012, EXPERT OPIN DRUG DEL, V9, P383, DOI 10.1517/17425247.2012.665367
   [Anonymous], EYEWIRE NEWS
   [Anonymous], 2014, RET FLUOC AC INTR IM
   [Anonymous], OTX IVT ANTIVEGF ANT
   [Anonymous], GB102 GAR VIS
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bucolo C, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00188
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Drapala PW, 2014, PHARM RES-DORDR, V31, P742, DOI 10.1007/s11095-013-1195-0
   Drapala PW, 2011, J BIOMAT SCI-POLYM E, V22, P59, DOI 10.1163/092050609X12578498952315
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   El Rayes En, 2013, RETINA TODAY, V8, P49
   El Rayes EN, 2018, RETIN TODAY, V13, P28
   Elhayek RF, 2017, INVEST OPHTH VIS SCI, V58
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   Ho AC, 2011, RETINA TODAY, V7, P59
   Ip MS, 2019, SUPRACHOROIDAL CLS T
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kang SJ, 2011, ASS RES VIS OPHTH AN
   Kang-Mieler JJ, 2017, EXPERT OPIN DRUG DEL, V14, P611, DOI 10.1080/17425247.2016.1227785
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kang-Mieler JJ, 2011, DUANES OPHTHALMOLOGY
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Klouda L, 2015, EUR J PHARM BIOPHARM, V97, P338, DOI 10.1016/j.ejpb.2015.05.017
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Lewis RA, 2009, J CATARACT REFR SURG, V35, P814, DOI 10.1016/j.jcrs.2009.01.010
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Liu WQ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.12
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Manoharan C, 2009, J PHARM SCI-US, V98, P529, DOI 10.1002/jps.21445
   Mi FL, 2002, BIOMATERIALS, V23, P3257, DOI 10.1016/S0142-9612(02)00084-4
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rizzo S, 2012, RETINA-J RET VIT DIS, V32, P776, DOI 10.1097/IAE.0b013e3182278b0e
   Rubio R.G., 2014, RETINA TODAY, P78
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Yang C, 2001, EXPERT OPIN BIOL TH, V1, P159, DOI 10.1517/14712598.1.2.159
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yeh S, 2018, AM SOC RETINA SPECIA
   Yeo Y, 2004, ARCH PHARM RES, V27, P1, DOI 10.1007/BF02980037
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
NR 65
TC 33
Z9 33
U1 1
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2020
VL 34
IS 8
BP 1371
EP 1379
DI 10.1038/s41433-020-0809-0
EA FEB 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MO4WR
UT WOS:000514261500001
PM 32071402
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU de Jorge, EG
   Caesar, JJE
   Malik, TH
   Patel, M
   Colledge, M
   Johnson, S
   Hakobyan, S
   Morgan, BP
   Harris, CL
   Pickering, MC
   Lea, SM
AF de Jorge, Elena Goicoechea
   Caesar, Joseph J. E.
   Malik, Talat H.
   Patel, Mitali
   Colledge, Matthew
   Johnson, Steven
   Hakobyan, Svetlana
   Morgan, B. Paul
   Harris, Claire L.
   Pickering, Matthew C.
   Lea, Susan M.
TI Dimerization of complement factor H-related proteins modulates
   complement activation in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE deregulation; structure; innate immunity
ID MACULAR DEGENERATION; C3B; GLOMERULONEPHRITIS; HEPARIN; GENES; CFHR1;
   RISK
AB The complement system is a key component regulation influences susceptibility to age-related macular degeneration, meningitis, and kidney disease. Variation includes genomic rearrangements within the complement factor H-related (CFHR) locus. Elucidating the mechanism underlying these associations has been hindered by the lack of understanding of the biological role of CFHR proteins. Here we present unique structural data demonstrating that three of the CFHR proteins contain a shared dimerization motif and that this hitherto unrecognized structural property enables formation of both homodimers and heterodimers. Dimerization confers avidity for tissue-bound complement fragments and enables these proteins to efficiently compete with the physiological complement inhibitor, complement factor H (CFH), for ligand binding. Our data demonstrate that these CFHR proteins function as competitive antagonists of CFH to modulate complement activation in vivo and explain why variation in the CFHRs predisposes to disease.
C1 [de Jorge, Elena Goicoechea; Malik, Talat H.; Patel, Mitali; Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Complement & Inflammat Res, London W12 0NN, England.
   [Caesar, Joseph J. E.; Colledge, Matthew; Johnson, Steven; Lea, Susan M.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   [Hakobyan, Svetlana; Morgan, B. Paul; Harris, Claire L.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4YU, S Glam, Wales.
C3 Imperial College London; University of Oxford; Cardiff University
RP Pickering, MC (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Complement & Inflammat Res, London W12 0NN, England.
EM matthew.pickering@imperial.ac.uk; susan.lea@path.ox.ac.uk
RI Johnson, Steven J/F-9182-2016; de Jorge, Elena Goicoechea/L-4580-2016;
   Lea, Susan M/B-7678-2009
OI Johnson, Steven J/0000-0002-7877-3543; de Jorge, Elena
   Goicoechea/0000-0002-4978-2483; Lea, Susan M/0000-0001-9287-8053;
   Morgan, Paul/0000-0003-4075-7676; Pickering, Matthew/0000-0002-1153-0192
FU Medical Research Council United Kingdom studentship; Medical Research
   Council [G0701298]; Wellcome Trust Senior Fellowship in Clinical Science
   [WT098476MA]; Medical Research Council Programme [RWIX0]; Wellcome Trust
   [098476/Z/12/Z] Funding Source: researchfish; MRC [G0701298] Funding
   Source: UKRI
FX We thank Dr. J. McRae for the rabbit anti-human complement factor
   H-related 5 antibody. This work was supported in part by a Medical
   Research Council United Kingdom studentship (to J.J.E.C.); Medical
   Research Council Grant G0701298 (to C.L.H.); and Wellcome Trust Senior
   Fellowship in Clinical Science WT098476MA (to M.C.P.). E.G.d.J. is an
   Imperial College Junior Research Fellow, and S.J. is supported by
   Medical Research Council Programme Grant RWIX0 (to S.M.L.).
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Malik TH, 2012, J AM SOC NEPHROL, V23, P1155, DOI 10.1681/ASN.2012020166
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Narkio-Makela M, 2001, CLIN IMMUNOL, V100, P118, DOI 10.1006/clim.2001.5043
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
NR 20
TC 188
Z9 196
U1 1
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 19
PY 2013
VL 110
IS 12
BP 4685
EP 4690
DI 10.1073/pnas.1219260110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 125EK
UT WOS:000317521600061
PM 23487775
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Canfield, AE
   Hadfield, KD
   Rock, CF
   Wylie, EC
   Wilkinson, FL
AF Canfield, A. E.
   Hadfield, K. D.
   Rock, C. F.
   Wylie, E. C.
   Wilkinson, F. L.
TI HtrA1: a novel regulator of physiological and pathological matrix
   mineralization?
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE differentiation; high-temperature requirement protein A1 (HtrA1);
   mineralization; osteoarthritis; osteoblast; vascular smooth muscle cell
ID SERINE-PROTEASE; MACULAR DEGENERATION; EXPRESSION; CARTILAGE; PROTEINS;
   FAMILY
AB HtrAl (high-temperature requirement protein A1) is a secreted multiclomain protein with proven serine protease activity and the ability to regulate TGF-beta (transforming growth factor-beta)/BMP (bone morphogenetic protein) signalling. There is increasing evidence that HtrA1 regulates several pathological processes, including tumour development, Alzheimer's disease, age-related macular degeneration and osteoarthritis, although the mechanism(s) by which it regulates these processes have not been fully elucidated. Using overexpression and knock-down strategies, we have evidence demonstrating that HtrAl is also a key regulator of physiological and pathological matrix mineralization in vitro. We propose that HtrAl regulates mineralization by inhibiting TGF-beta/BMP signalling and/or by cleaving specific matrix proteins, including decorin and MGP (matrix Gla protein). Taken together, these studies suggest that HtrA1 may be a novel therapeutic target for several diseases.
C1 Univ Manchester, Fac Med & Human Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
C3 University of Manchester
RP Canfield, AE (通讯作者)，Univ Manchester, Fac Med & Human Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM ann.canfield@manchester.ac.uk
OI Canfield, Ann/0000-0002-8983-5674; Wilkinson, Fiona/0000-0002-0358-3489
FU Wellcome Trust Funding Source: Medline
CR Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DOHERTY M, 1998, BIOCHEM SOC T, V26, pS410
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 15
TC 40
Z9 44
U1 2
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD AUG
PY 2007
VL 35
BP 669
EP 671
DI 10.1042/BST0350669
PN 4
PG 3
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 204OG
UT WOS:000249053300007
PM 17635117
DA 2022-11-30
ER

PT J
AU Saunders, RE
   Perkins, SJ
AF Saunders, RE
   Perkins, SJ
TI A user's guide to the interactive web database of factor H-associated
   hemolytic uremic syndrome
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article
DE factor H; hemolytic uremic syndrome; mutation; factor I; membrane
   cofactor protein
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; MOLECULAR-BASIS; MUTATIONS;
   GENE; DISEASE; POLYMORPHISM; RECOGNITION; DEFICIENCY; HEPARIN
AB Atypical hemolytic uremic syndrome (aHUS) mutations have been reported in the complement regulatory proteins factor H, factor I, and membrane cofactor protein (MCP). Mutations within factor H are also associated with membranoproliferative glomerulonephritis and age-related macular degeneration. The increasing amount of information on aHUS requires organization if it is to be usable. Accordingly, an interactive factor H aHUS Web database has been developed (littp://www.fh-hus.org) that integrates genotypic, phenotypic, and structural information for mutations within human factor H. This provides a valuable tool for the interpretation of previously reported aHUS mutations, and provides prediction and analysis tools for new mutations. It will be extended to include mutations in factor I and MCP. Here, we describe how to use this Web database as a research tool, and indicate possible future directions depending on feedback from the clinical community.
C1 UCL, Dept Biochem & Mol Biol, Royal Free & Univ Coll Med Sch, London WC1E 6BT, England.
C3 University of London; University College London
RP Perkins, SJ (通讯作者)，UCL, Dept Biochem & Mol Biol, Royal Free & Univ Coll Med Sch, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Ballermann BJ, 1998, KIDNEY INT, V53, P1810, DOI 10.1046/j.1523-1755.1998.00943.x
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Remuzzi G, 2002, LANCET, V359, P1671, DOI 10.1016/S0140-6736(02)08560-4
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Sanchez-Corral P, 2000, IMMUNOGENETICS, V51, P366, DOI 10.1007/s002510050631
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
NR 27
TC 5
Z9 5
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0094-6176
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PD MAR
PY 2006
VL 32
IS 2
BP 160
EP 167
DI 10.1055/s-2006-939772
PG 8
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 029JN
UT WOS:000236558600011
PM 16575691
DA 2022-11-30
ER

PT J
AU Damian, I
   Nicoara, SD
AF Damian, Ioana
   Nicoara, Simona Delia
TI SD-OCT Biomarkers and the Current Status of Artificial Intelligence in
   Predicting Progression from Intermediate to Advanced AMD
SO LIFE-BASEL
LA English
DT Article
DE intermediate age-related macular degeneration progression; SD-OCT;
   artificial intelligence; imaging biomarkers; deep learning
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; GEOGRAPHIC-ATROPHY;
   RETICULAR PSEUDODRUSEN; COMPLEMENT ACTIVATION; PREVALENCE; MORPHOLOGY;
   RPE
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness in the Western World. Optical coherence tomography (OCT) has revolutionized the diagnosis and follow-up of AMD patients. This review focuses on SD-OCT imaging biomarkers which were identified as predictors for progression in intermediate AMD to late AMD, either geographic atrophy (GA) or choroidal neovascularization (CNV). Structural OCT remains the most compelling modality to study AMD features related to the progression such as drusen characteristics, hyperreflective foci (HRF), reticular pseudo-drusen (RPD), sub-RPE hyper-reflective columns and their impact on retinal layers. Further on, we reviewed articles that attempted to integrate biomarkers that have already proven their involvement in intermediate AMD progression, in their models of artificial intelligence (AI). By combining structural biomarkers with genetic risk and lifestyle the predictive ability becomes more accurate.
C1 [Damian, Ioana; Nicoara, Simona Delia] Iuliu Hatieganu Univ Med & Pharm, Dept Ophthalmol, 8 Victor Babes St, Cluj Napoca 400012, Romania.
   [Nicoara, Simona Delia] Emergency Cty Hosp, Clin Ophthalmol, 3-5 Clin St, Cluj Napoca 40006, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy
RP Nicoara, SD (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Ophthalmol, 8 Victor Babes St, Cluj Napoca 400012, Romania.; Nicoara, SD (通讯作者)，Emergency Cty Hosp, Clin Ophthalmol, 3-5 Clin St, Cluj Napoca 40006, Romania.
EM ioana.damian@umicluj.ro; stalu@umfcluj.ro
RI Nicoara, Simona Delia/D-3353-2016
OI Nicoara, Simona Delia/0000-0002-7886-2044
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bilc S, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12010022
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Brinkmann MP, 2021, INVEST OPHTH VIS SCI, V62
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Ivert L, 2003, GRAEF ARCH CLIN EXP, V241, P656, DOI 10.1007/s00417-003-0653-5
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Saade C, 2016, INVEST OPHTH VIS SCI, V57
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Tepelus TC, 2017, OSLI RETINA, V48, P312, DOI 10.3928/23258160-20170329-05
   Toprak I, 2017, INT OPHTHALMOL, V37, P801, DOI 10.1007/s10792-016-0331-3
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 63
TC 1
Z9 1
U1 3
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD MAR
PY 2022
VL 12
IS 3
AR 454
DI 10.3390/life12030454
PG 14
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA 0C3EM
UT WOS:000775200600001
PM 35330205
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Caston, RA
   Gampala, S
   Armstrong, L
   Messmann, RA
   Fishel, ML
   Kelly, MR
AF Caston, Rachel A.
   Gampala, Silpa
   Armstrong, Lee
   Messmann, Richard A.
   Fishel, Melissa L.
   Kelly, Mark R.
TI The multifunctional APE1 DNA repair- redox signaling protein as a drug
   target in human disease
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE-1; BASE-EXCISION-REPAIR;
   COLORECTAL-CANCER SUSCEPTIBILITY; ASP148GLU POLYMORPHISM;
   PROSTATE-CANCER; THERAPEUTIC TARGET; APE1/REF-1; INHIBITION; EXPRESSION;
   XRCC1
AB Apurinic/apyrimidinic (AP) endonuclease?reduction/oxidation factor 1 (APE1/Ref-1, also called APE1) is a multifunctional enzyme with crucial roles in DNA repair and reduction/oxidation (redox) signaling. APE1 was originally described as an endonuclease in the Base Excision Repair (BER) pathway. Further study revealed it to be a redox signaling hub regulating critical transcription factors (TFs). Although a significant amount of focus has been on the role of APE1 in cancer, recent findings support APE1 as a target in other indications, including ocular diseases [diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD)], inflammatory bowel disease (IBD) and others, where APE1 regulation of crucial TFs impacts important pathways in these diseases. The central responsibilities of APE1 in DNA repair and redox signaling make it an attractive therapeutic target for cancer and other diseases.
C1 [Caston, Rachel A.; Gampala, Silpa; Armstrong, Lee; Fishel, Melissa L.; Kelly, Mark R.] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, 1044 W Walnut, Indianapolis, IN 46202 USA.
   [Messmann, Richard A.] Apexian Pharmaceut, 20 N Meridian St, Indianapolis, IN 46204 USA.
   [Fishel, Melissa L.; Kelly, Mark R.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1044 W Walnut, Indianapolis, IN 46202 USA.
   [Fishel, Melissa L.; Kelly, Mark R.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1044 W Walnut, Indianapolis, IN 46202 USA.
   [Fishel, Melissa L.; Kelly, Mark R.] Indiana Univ Sch Med, Indiana Univ Simon Comprehens Canc Ctr, 1044 W Walnut, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Kelly, MR (通讯作者)，Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, 1044 W Walnut, Indianapolis, IN 46202 USA.; Kelly, MR (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1044 W Walnut, Indianapolis, IN 46202 USA.; Kelly, MR (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1044 W Walnut, Indianapolis, IN 46202 USA.; Kelly, MR (通讯作者)，Indiana Univ Sch Med, Indiana Univ Simon Comprehens Canc Ctr, 1044 W Walnut, Indianapolis, IN 46202 USA.
EM mkelley@iu.edu
OI Messmann, Richard/0000-0002-2112-0277; Kelley, Mark/0000-0001-9472-1826;
   Fishel, Melissa/0000-0002-9436-6382; Gampala, Silpa/0000-0001-9928-3941
FU National Institute of Health; National Cancer Institute [R01CA167291,
   R01CA167291-S1]; DOD [W81XWH1910217]; NIH/NCI [R01CA205166, R01CA231267,
   R01EY031939, R01HL140961, U01HL143403, R01CA211098, R01NF180045]; Riley
   Children's Foundation; Tom Wood Lexus Foundation
FX M.R.K. and M.L.F. were supported by grants from the National Institute
   of Health and National Cancer InstituteR01CA167291, R01CA167291-S1 and
   DOD grant W81XWH1910217. M.R.K. was also supported by NIH/NCI grants
   R01CA205166, R01CA231267, R01EY031939 and R01HL140961 and M.L.F. was
   supported by NIH/NCI grants U01HL143403, R01CA211098 and R01NF180045.
   M.R.K. and M.L.F. were additionally supported by the Riley Children's
   Foundation and the Tom Wood Lexus Foundation.
CR Abdel-Fatah TMA, 2014, BREAST CANCER RES TR, V143, P411, DOI 10.1007/s10549-013-2820-7
   AlMutairi F, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/869512
   Antoniali G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00842-8
   Banuelos S, 2013, FEBS LETT, V587, P2254, DOI 10.1016/j.febslet.2013.05.055
   Bapat A, 2010, J PHARMACOL EXP THER, V334, P988, DOI 10.1124/jpet.110.169128
   Barchiesi A, 2015, NUCLEIC ACIDS RES, V43, P5451, DOI 10.1093/nar/gkv433
   Bardia A, 2012, INFLAMM RES, V61, P359, DOI 10.1007/s00011-011-0418-2
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bin Samsuddin Muhamad Fairuz, 2019, Asian J Neurosurg, V14, P283, DOI 10.4103/ajns.AJNS_332_17
   Box JK, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0073-9
   Canbay E, 2011, CURR MED RES OPIN, V27, P1295, DOI 10.1185/03007995.2011.573544
   Cesaratto L, 2007, J MOL MED, V85, P1099, DOI 10.1007/s00109-007-0204-3
   Chang-Claude J, 2005, CLIN CANCER RES, V11, P4802, DOI 10.1158/1078-0432.CCR-04-2657
   Chattopadhyay R, 2006, NUCLEIC ACIDS RES, V34, P2067, DOI 10.1093/nar/gkl177
   Chen L, 2006, J UROLOGY, V175, P108, DOI 10.1016/S0022-5347(05)00042-X
   Chiarella S, 2013, NUCLEIC ACIDS RES, V41, P3228, DOI 10.1093/nar/gkt001
   Choi S, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7276502
   Cholia RP, 2018, METAB BRAIN DIS, V33, P1307, DOI 10.1007/s11011-018-0233-3
   Chu L, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e14531
   Cocchiola R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081815
   Codrich M, 2019, DNA REPAIR, V82, DOI 10.1016/j.dnarep.2019.102675
   Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646
   Ding JX, 2017, MOL CANCER THER, V16, P1401, DOI 10.1158/1535-7163.MCT-17-0099
   ERLANDSON RA, 1985, ULTRASTRUCT PATHOL, V9, P113, DOI 10.3109/01913128509055493
   Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X
   Feng Zhiwei, 2015, Journal of Chemical Biology, V8, P79, DOI 10.1007/s12154-015-0131-7
   Fishel M, 2019, MOL CANCER THER, V18, P1947, DOI 10.1158/1535-7163.MCT-18-1166
   Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005
   Fishel ML, 2011, MOL CANCER THER, V10, P1698, DOI 10.1158/1535-7163.MCT-11-0107
   Frossi B, 2019, J BIOL CHEM, V294, P5198, DOI 10.1074/jbc.RA118.006601
   Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170
   Gros L, 2004, NUCLEIC ACIDS RES, V32, P73, DOI 10.1093/nar/gkh165
   Hadi MZ, 2000, NUCLEIC ACIDS RES, V28, P3871, DOI 10.1093/nar/28.20.3871
   Heath EM, 2017, LEUKEMIA, V31, P798, DOI 10.1038/leu.2017.30
   Hu JJ, 2001, CARCINOGENESIS, V22, P917, DOI 10.1093/carcin/22.6.917
   Huang HI, 2019, HEAD NECK-J SCI SPEC, V41, P1557, DOI 10.1002/hed.25576
   Illuzzi JL, 2017, ENVIRON MOL MUTAGEN, V58, P84, DOI 10.1002/em.22074
   Ishchenko AA, 2006, P NATL ACAD SCI USA, V103, P2564, DOI 10.1073/pnas.0508582103
   Jiang AH, 2011, VISION RES, V51, P93, DOI 10.1016/j.visres.2010.10.008
   Kaur A, 2016, NATURE, V532, P250, DOI 10.1038/nature17392
   Kelley MR, 2016, J PHARMACOL EXP THER, V359, P300, DOI 10.1124/jpet.116.235283
   Kim Wan-Cheol, 2010, Int J Biochem Mol Biol, V1, P12
   Laev SS, 2017, BIOORGAN MED CHEM, V25, P2531, DOI 10.1016/j.bmc.2017.01.028
   Lai YJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24030449
   Lee In Won, 2017, Genomics & Informatics, V15, P147, DOI 10.5808/GI.2017.15.4.147
   Lee YR, 2016, INT NEUROUROL J, V20, pS30, DOI 10.5213/inj.1632600.300
   Lee YR, 2015, ONCOTARGET, V6, P23383, DOI 10.18632/oncotarget.4345
   Li MX, 2018, NUCLEIC ACIDS RES, V46, P5664, DOI 10.1093/nar/gky326
   Li Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0452-x
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Li Y, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0505-z
   Li Y, 2014, INVEST OPHTH VIS SCI, V55, P4461, DOI 10.1167/iovs.14-14451
   Li Z, 2011, ARCH MED RES, V42, P226, DOI 10.1016/j.arcmed.2011.04.005
   Li ZW, 2006, IUBMB LIFE, V58, P581, DOI 10.1080/15216540600946456
   Lirussi L, 2016, ONCOTARGET, V7, P26293, DOI 10.18632/oncotarget.8477
   Liu YF, 2020, CELL BIOCHEM FUNCT, V38, P195, DOI 10.1002/cbf.3461
   LIUZZI M, 1987, BIOCHEMISTRY-US, V26, P3315, DOI 10.1021/bi00386a011
   Logsdon DP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32034-9
   Logsdon DP, 2016, MOL CANCER THER, V15, P2722, DOI 10.1158/1535-7163.MCT-16-0253
   Lu H, 2019, CANCER RES, V79, P4426, DOI 10.1158/0008-5472.CAN-19-0237
   Lu J, 2009, FASEB J, V23, P3459, DOI 10.1096/fj.09-136549
   Luo M, 2008, ANTIOXID REDOX SIGN, V10, P1853, DOI 10.1089/ars.2008.2120
   Luo MH, 2012, BIOCHEMISTRY-US, V51, P695, DOI 10.1021/bi201034z
   Ma XB, 2019, BREAST CANCER RES TR, V176, P109, DOI 10.1007/s10549-019-05189-w
   Madala HR, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-5825
   Madlener S, 2013, P NATL ACAD SCI USA, V110, P17844, DOI 10.1073/pnas.1304784110
   Malfatti MC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1294-9
   McIlwain David W, 2018, Oncotarget, V9, P10962, DOI 10.18632/oncotarget.23493
   McNeill DR, 2020, MUTAGENESIS, V35, P27, DOI 10.1093/mutage/gez046
   Nassour H, 2016, SCI REP-UK, V6, DOI 10.1038/srep29389
   Pascut Devis, 2019, Oncotarget, V10, P383, DOI 10.18632/oncotarget.26555
   Pasha SPBS, 2018, J PHARMACOL EXP THER, V367, P108, DOI 10.1124/jpet.118.248088
   Poletto M, 2016, MOL CARCINOGEN, V55, P688, DOI 10.1002/mc.22313
   Poletto M, 2014, MOL BIOL CELL, V25, P1641, DOI 10.1091/mbc.E13-12-0717
   Poletto M, 2012, BIOCHEM BIOPH RES CO, V424, P34, DOI 10.1016/j.bbrc.2012.06.039
   Rai G, 2012, J MED CHEM, V55, P3101, DOI 10.1021/jm201537d
   Rees MG, 2016, NAT CHEM BIOL, V12, P109, DOI [10.1038/nchembio.1986, 10.1038/NCHEMBIO.1986]
   Sahakian L., 2020, J INFLAMM BOWEL DIS, DOI DOI 10.1093/IBD/IZAA161
   Santos JC, 2014, INT J MOL SCI, V15, P17333, DOI 10.3390/ijms151017333
   Seiple LA, 2008, MOL PHARMACOL, V73, P669, DOI 10.1124/mol.107.042622
   Shah F, 2019, MOL CANCER THER, V18, DOI 10.1158/1535-7163.TARG-19-C017
   Shah F, 2017, MOL ONCOL, V11, P1711, DOI 10.1002/1878-0261.12138
   Shah F, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0023-0
   SHAHDA S, 2019, J CLIN ONCOL, V0037
   Shao YF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699125
   Shen ED, 2014, TUMOR BIOL, V35, P2529, DOI 10.1007/s13277-013-1334-6
   Shin JH, 2015, CANCER RES TREAT, V47, P823, DOI 10.4143/crt.2014.074
   Tell G, 2002, J BIOL CHEM, V277, P14564, DOI 10.1074/jbc.M200582200
   Tell G, 2010, MOL CELL BIOL, V30, P366, DOI 10.1128/MCB.01174-09
   Trilles R, 2019, J MED CHEM, V62, P1971, DOI 10.1021/acs.jmedchem.8b01529
   Wallace SS, 2014, DNA REPAIR, V19, P14, DOI 10.1016/j.dnarep.2014.03.030
   Wan CL, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz655
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Whitaker AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02175-y
   Woo J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099528
   Wurtmann EJ, 2009, CRIT REV BIOCHEM MOL, V44, P34, DOI [10.1080/10409230802594043, 10.1080/10409230802594043 ]
   Xie JL, 2019, J ORAL MAXIL SURG, V77, P859, DOI 10.1016/j.joms.2018.11.034
   Yan LWL, 2019, J BIOL CHEM, V294, P15158, DOI 10.1074/jbc.REV119.006513
   Yang X, 2018, CANCER MED-US, V7, P4406, DOI 10.1002/cam4.1717
   Zawahir Z, 2009, J MED CHEM, V52, P20, DOI 10.1021/jm800739m
   Zhang SH, 2014, WORLD J GASTROENTERO, V20, P8700, DOI 10.3748/wjg.v20.i26.8700
   Zhou X, 2015, MOL GENET GENOMICS, V290, P281, DOI 10.1007/s00438-014-0916-3
NR 102
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD JAN
PY 2020
VL 26
IS 1
BP 218
EP 228
DI 10.1016/j.drudis.2020.10.015
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RC2SV
UT WOS:000632655700010
PM 33148489
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Eberhardt, HU
   Buhlmann, D
   Hortschansky, P
   Chen, Q
   Bohm, S
   Kemper, MJ
   Wallich, R
   Hartmann, A
   Hallstrom, T
   Zipfel, PF
   Skerka, C
AF Eberhardt, Hannes U.
   Buhlmann, Denise
   Hortschansky, Peter
   Chen, Qian
   Boehm, Sascha
   Kemper, Markus J.
   Wallich, Reinhard
   Hartmann, Andrea
   Hallstroem, Teresia
   Zipfel, Peter F.
   Skerka, Christine
TI Human Factor H-Related Protein 2 (CFHR2) Regulates Complement Activation
SO PLOS ONE
LA English
DT Article
ID ALTERNATIVE PATHWAY; MUTATION; GENES; RISK
AB Mutations and deletions within the human CFHR gene cluster on chromosome 1 are associated with diseases, such as dense deposit disease, CFHR nephropathy or age-related macular degeneration. Resulting mutant CFHR proteins can affect complement regulation. Here we identify human CFHR2 as a novel alternative pathway complement regulator that inhibits the C3 alternative pathway convertase and terminal pathway assembly. CFHR2 is composed of four short consensus repeat domains (SCRs). Two CFHR2 molecules form a dimer through their N-terminal SCRs, and each of the two C-terminal ends can bind C3b. C3b bound CFHR2 still allows C3 convertase formation but the CFHR2 bound convertases do not cleave the substrate C3. Interestingly CFHR2 hardly competes off factor H from C3b. Thus CFHR2 likely acts in concert with factor H, as CFHR2 inhibits convertases while simultaneously allowing factor H assisted degradation by factor I.
C1 [Eberhardt, Hannes U.; Buhlmann, Denise; Chen, Qian; Boehm, Sascha; Hartmann, Andrea; Hallstroem, Teresia; Zipfel, Peter F.; Skerka, Christine] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany.
   [Hortschansky, Peter] Leibniz Inst Nat Prod Res & Infect Biol, Dept Mol & Appl Microbiol, Jena, Germany.
   [Kemper, Markus J.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
   [Wallich, Reinhard] Heidelberg Univ, Inst Immunol, Heidelberg, Germany.
   [Zipfel, Peter F.] Univ Jena, Jena, Germany.
C3 Hans Knoll Institute (HKI); Hans Knoll Institute (HKI); University of
   Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls
   University Heidelberg; Friedrich Schiller University of Jena
RP Skerka, C (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany.
EM christine.skerka@hki-jena.de
FU Deutsche Forschungsgemeinschaft (DFG) [Sk 46, Zi 432]; International
   Leibniz Research School (ILRS); Jena school of Microbial Communication
   (JSMC), Jena, Germany
FX This work was supported by the Deutsche Forschungsgemeinschaft (DFG, Sk
   46, Zi 432), Germany. HUE, DB and QC are doctoral researchers at the
   International Leibniz Research School (ILRS), part of the Jena school of
   Microbial Communication (JSMC), Jena, Germany. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Eberhardt HU, 2009, MED 2 EUR C IMM
   Eyler SJ, 2013, PEDIAT NEPH IN PRESS
   Francis NJ, 2012, BLOOD, V119, P591, DOI 10.1182/blood-2011-03-339903
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kubista KE, 2011, MOL VIS, V17, P2080
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Roos A, 2003, MOL IMMUNOL, V39, P655, DOI 10.1016/S0161-5890(02)00254-7
   Sethi S, 2011, CLIN J AM SOC NEPHRO, V6, P1009, DOI 10.2215/CJN.07110810
   SKERKA C, 1992, J IMMUNOL, V148, P3313
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 25
TC 48
Z9 50
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2013
VL 8
IS 11
AR e78617
DI 10.1371/journal.pone.0078617
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 256KH
UT WOS:000327308500007
PM 24260121
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, YT
   Kang, SW
   Lee, JH
   Chung, SE
AF Kim, Yun Taek
   Kang, Se Woong
   Lee, Jeong-Hee
   Chung, Song Ee
TI Peripheral exudative hemorrhagic chorioretinopathy in Korean patients
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE PEHCR; peripheral choroidal neovascularization; pseudomelanoma
ID RETINAL-PIGMENT EPITHELIUM
AB Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is a rare condition characterized by either subretinal exudates or subretinal hemorrhage outside the macula. The objective of this case report is to describe PEHCR lesions in Korean patients.
   Five eyes of four patients are reviewed.
   All cases were characterized by either peripheral subretinal exudates or hemorrhage with age-related degeneration. Four of the lesions appeared as subretinal masses, and the other manifested as a large retinal pigment epithelial alteration combined with subretinal exudates and subretinal fibrosis. Two of the patients evidenced serious visual impairment induced by massive subretinal hemorrhage extending to the fovea. Visual acuity in the other three eyes studied remained stable.
   PEHCR appears to be a variant of age-related macular degeneration that occurs in Asians. Although PEHCR is known to be self-limiting, it frequently causes subfoveal extensions of subretinal blood and fluid.
C1 [Kim, Yun Taek; Kang, Se Woong; Chung, Song Ee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Lee, Jeong-Hee] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Ewha Womans
   University
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
OI Kim, Yun Taek/0000-0001-9104-4241
CR Annesley W H Jr, 1980, Trans Am Ophthalmol Soc, V78, P321
   BLOOME MA, 1978, AM J OPHTHALMOL, V86, P630, DOI 10.1016/0002-9394(78)90181-2
   Collaer N, 2007, Bull Soc Belge Ophtalmol, P23
   REESE AB, 1962, AM J OPHTHALMOL, V53, P897, DOI 10.1016/0002-9394(62)93009-X
   Shields CL, 2009, OPHTHALMOLOGY, V116, P529, DOI 10.1016/j.ophtha.2008.10.015
   SILVA VB, 1976, ARCH OPHTHALMOL-CHIC, V94, P1295
   Tsui I, 2009, SEMIN OPHTHALMOL, V24, P25, DOI 10.1080/08820530802520178
NR 7
TC 6
Z9 6
U1 1
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2010
VL 54
IS 3
BP 227
EP 231
DI 10.1007/s10384-009-0794-0
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 616GG
UT WOS:000279196400011
PM 20577857
DA 2022-11-30
ER

PT J
AU Silva, JTD
   da Silva, AC
   Geiss, JMT
   de Araujo, PHH
   Becker, D
   Bracht, L
   Leimann, FV
   Bona, E
   Guerra, GP
   Goncalves, OH
AF do Prado Silva, Jessica Thais
   da Silva, Anderson Clayton
   Tonin Geiss, Julia Maria
   Hermes de Araujo, Pedro Henrique
   Becker, Daniela
   Bracht, Livia
   Leimann, Fernanda Vitoria
   Bona, Evandro
   Guerra, Gustavo Petri
   Goncalves, Odinei Hess
TI Analytical validation of an ultraviolet-visible procedure for
   determining lutein concentration and application to lutein-loaded
   nanoparticles
SO FOOD CHEMISTRY
LA English
DT Article
DE Xanthophyll; UV-Vis; Nanoparticles; Nanoprecipitation; Bioactive
   quantification
ID CAROTENOIDS; PERFORMANCE; CHROMATOGRAPHY; BIOAVAILABILITY; SOLUBILITY;
   PARTICLES
AB Lutein is a carotenoid presenting known anti-inflammatory and antioxidant properties. Lutein-rich diets have been associated with neurological improvement as well as reduction of the risk of vision loss due to Age-Related Macular Degeneration (AMD). Micro and nanoencapsulation have demonstrated to be effective techniques in protecting lutein against degradation and also in improving its bioavailability. However, actual lutein concentration inside the capsules and encapsulation efficiency are key parameters that must be precisely known when designing in vitro and in vivo tests. In this work an analytical procedure was validated for the determination of the actual lutein content in zein nanoparticles using ultraviolet -visible spectroscopy. Method validation followed the International Conference on Harmonisation (ICH) guidelines which evaluate linearity, detection limit, quantification limit, accuracy and precision. The validated methodology was applied to characterize lutein-loaded nanoparticles. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [do Prado Silva, Jessica Thais; da Silva, Anderson Clayton; Leimann, Fernanda Vitoria; Bona, Evandro; Goncalves, Odinei Hess] Fed Univ Technol Parana UTFPR, Postgrad Program Food Technol PPGTA, POB 271,BR 369,Km 0-5, BR-87301006 Campo Mourao, PR, Brazil.
   [Tonin Geiss, Julia Maria; Guerra, Gustavo Petri] Fed Univ Technol Parana UTFPR, Postgrad Program Food Technol PPGTA, POB 271,Ave Brasil,4232, BR-85884000 Medianeira, PR, Brazil.
   [Hermes de Araujo, Pedro Henrique] Fed Univ Santa Catarina UFSC, Dept Chem & Food Engn EQA, POB 476,Campus Bettor Joao David Ferreira Lima, BR-88040970 Florianopolis, SC, Brazil.
   [Becker, Daniela] State Univ Santa Catarina UDESC, Ctr Technol Sci, BR-89223100 Joinville, SC, Brazil.
   [Bracht, Livia] State Univ Maringa UEM, BR-87020900 Maringa, PR, Brazil.
C3 Universidade Tecnologica Federal do Parana; Universidade Tecnologica
   Federal do Parana
RP Goncalves, OH (通讯作者)，Fed Univ Technol Parana UTFPR, Postgrad Program Food Technol PPGTA, POB 271,BR 369,Km 0-5, BR-87301006 Campo Mourao, PR, Brazil.
EM odinei@utfpr.edu.br
RI Gonçalves, Odinei Hess/AAT-4805-2021; Araújo, Pedro H. H./Q-9549-2019;
   Bona, Evandro/F-8225-2012; Petri Guerra, Gustavo/AGQ-7865-2022; Becker,
   Daniela/D-4635-2013; Leimann, Fernanda V/O-5001-2016; Guerra, Gustavo
   Petri/AAU-2862-2021
OI Gonçalves, Odinei Hess/0000-0002-9528-8187; Araújo, Pedro H.
   H./0000-0001-5905-0158; Bona, Evandro/0000-0001-8557-7527; Becker,
   Daniela/0000-0003-3250-576X; Leimann, Fernanda V/0000-0001-6230-9597;
   Guerra, Gustavo Petri/0000-0001-6995-5348; da Silva Abreu, Anderson
   Clayton/0000-0002-6488-1906; Silva, Jessica/0000-0002-0235-940X
FU CAPES; CNPq
FX Authors thank CAPES and CNPq for the financial support and LCME -
   Federal University of Santa Catarina for the TEM images.
CR Abrahamsson V, 2012, J CHROMATOGR A, V1250, P63, DOI 10.1016/j.chroma.2012.05.069
   Amorim-Carrilho KT, 2014, TRAC-TREND ANAL CHEM, V56, P49, DOI 10.1016/j.trac.2013.12.011
   Araujo P, 2009, J CHROMATOGR B, V877, P2224, DOI 10.1016/j.jchromb.2008.09.030
   Arunkumar R, 2015, J PHARM SCI-US, V104, P2085, DOI 10.1002/jps.24436
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   da Silva-Buzanello RA, 2015, FOOD CHEM, V172, P99, DOI 10.1016/j.foodchem.2014.09.016
   de Vos P, 2010, INT DAIRY J, V20, P292, DOI 10.1016/j.idairyj.2009.11.008
   Dias MG, 2008, FOOD CHEM, V109, P815, DOI 10.1016/j.foodchem.2007.12.026
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Gonzalez AG, 2010, TALANTA, V82, P1995, DOI 10.1016/j.talanta.2010.07.071
   Hu DD, 2012, J FOOD ENG, V109, P545, DOI 10.1016/j.jfoodeng.2011.10.025
   Hu K, 2015, FOOD CHEM, V182, P275, DOI 10.1016/j.foodchem.2015.03.009
   ICH, 2005, VAL AN PROC TEXT MET
   Indyk HE, 2014, INT DAIRY J, V37, P82, DOI 10.1016/j.idairyj.2014.02.010
   Kamil A, 2016, FOOD CHEM, V192, P915, DOI 10.1016/j.foodchem.2015.07.106
   Karlsen A, 2003, J CHROMATOGR B, V795, P17, DOI 10.1016/S1570-0232(03)00483-5
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Koh W.-P., 2011, NUTR METAB CARDIOVAS, V9, P685
   Lacatusu I, 2013, J FUNCT FOODS, V5, P1260, DOI 10.1016/j.jff.2013.04.010
   Lepeltier E, 2014, ADV DRUG DELIVER REV, V71, P86, DOI 10.1016/j.addr.2013.12.009
   Li B, 2015, J CHROMATOGR A, V1425, P287, DOI 10.1016/j.chroma.2015.11.029
   Li HY, 2012, FOOD CHEM, V132, P508, DOI [10.1016/j.foodchem.2011.10.017, 10.1016/j.foodchem.2011.09.014]
   Lieblein-Boff JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136904
   Liu CH, 2010, COLLOID SURFACE A, V353, P149, DOI 10.1016/j.colsurfa.2009.11.006
   Marinova D, 2007, J FOOD COMPOS ANAL, V20, P370, DOI 10.1016/j.jfca.2006.09.007
   Miguel F, 2008, CHEM ENG PROCESS, V47, P1594, DOI 10.1016/j.cep.2007.07.008
   Nalawade P, 2015, J INCL PHENOM MACRO, V83, P77, DOI 10.1007/s10847-015-0542-7
   Patel AR, 2010, J AGR FOOD CHEM, V58, P12497, DOI 10.1021/jf102959b
   Peng ML, 2016, J FUNCT FOODS, V24, P122, DOI 10.1016/j.jff.2016.04.006
   Podaralla S, 2012, AAPS PHARMSCITECH, V13, P919, DOI 10.1208/s12249-012-9816-1
   Serpeloni JM, 2012, TOXICOL IN VITRO, V26, P288, DOI 10.1016/j.tiv.2011.11.011
   Silva J. T., 2016, CURCUMIN CLIN USES H, P25
   Stinco CM, 2014, J CHROMATOGR A, V1370, P162, DOI 10.1016/j.chroma.2014.10.044
   Wang MX, 2013, ATHEROSCLEROSIS, V227, P380, DOI 10.1016/j.atherosclerosis.2013.01.021
   Zhang Y, 2013, FOOD HYDROCOLLOID, V33, P1, DOI 10.1016/j.foodhyd.2013.02.009
   Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086
NR 36
TC 22
Z9 23
U1 4
U2 73
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD SEP 1
PY 2017
VL 230
BP 336
EP 342
DI 10.1016/j.foodchem.2017.03.059
PG 7
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA ET8FA
UT WOS:000400533200040
PM 28407919
DA 2022-11-30
ER

PT J
AU Taylor, A
AF Taylor, Allen
TI Mechanistically linking age-related diseases and dietary carbohydrate
   via autophagy and the ubiquitin proteolytic systems
SO AUTOPHAGY
LA English
DT Article
DE aging; carbohydrate; disease; ubiquitin; autophagy; proteolysis; diet;
   glycemic index; glycation; sugar; lysosome
AB Epidemiological data indicate that consuming diets that deliver sugar to the blood rapidly (called high glycemic index, GI) is associated with enhanced risk for age-related diseases such as cardiovascular disease, type 2 diabetes, cataract and age-related macular degeneration (AMD). These debilities are associated with accumulation of toxic protein aggregates as observed in other protein precipitation or amyloid diseases including Alzheimer, Parkinson and Huntington diseases and encephalopathies. Barriers to recommending lower-GI diets to promote health include the absence of established intracellular biochemical mechanisms that link high-GI diets to compromised homeostasis. The data herein corroborate the epidemiological findings and provide platforms to elucidate additional mechanistic aspects of salutary effects of consuming diets of different GIs. They are also useful for testing drugs, including autophagy enhancers, glycemia regulators, or nutraceuticals, which can be exploited to extend health.
C1 Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, JM USDA, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Taylor, A (通讯作者)，Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, JM USDA, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
FU NIH [RO1 EY 13250, RO1 EY21212]; USDA [1950-510000-060-01A]; NATIONAL
   EYE INSTITUTE [R01EY021212, R01EY013250] Funding Source: NIH RePORTER
FX Funding for this work was provided by NIH RO1 EY 13250, RO1 EY21212 and
   USDA contract 1950-510000-060-01A.
NR 0
TC 18
Z9 19
U1 0
U2 10
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD SEP
PY 2012
VL 8
IS 9
BP 1404
EP 1406
DI 10.4161/auto.21150
PG 3
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 003TO
UT WOS:000308634400018
PM 22906982
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Polosukhina, A
   Litt, J
   Tochitsky, I
   Nemargut, J
   Sychev, Y
   De Kouchkovsky, I
   Huang, T
   Borges, K
   Trauner, D
   Van Gelder, RN
   Kramer, RH
AF Polosukhina, Aleksandra
   Litt, Jeffrey
   Tochitsky, Ivan
   Nemargut, Joseph
   Sychev, Yivgeny
   De Kouchkovsky, Ivan
   Huang, Tracy
   Borges, Katharine
   Trauner, Dirk
   Van Gelder, Russell N.
   Kramer, Richard H.
TI Photochemical Restoration of Visual Responses in Blind Mice
SO NEURON
LA English
DT Article
ID GANGLION-CELLS; PHOTORECEPTOR DEGENERATION; RETINAL PROSTHESIS; ECTOPIC
   EXPRESSION; MOUSE MODEL; MELANOPSIN; RESTORES; CHANNELS; PERFORMANCE;
   MECHANISMS
AB Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are degenerative blinding diseases caused by the death of rods and cones, leaving the remainder of the visual system intact but largely unable to respond to light. Here, we show that AAQ, a synthetic small molecule photoswitch, can restore light sensitivity to the retina and behavioral responses in vivo in mouse models of RP, without exogenous gene delivery. Brief application of AAQ bestows prolonged light sensitivity on multiple types of retinal neurons, resulting in synaptically amplified responses and center-surround antagonism in arrays of retinal ganglion cells (RGCs). Intraocular injection of AAQ restores the pupillary light reflex and locomotory light avoidance behavior in mice lacking retinal photoreceptors, indicating reconstitution of light signaling to brain circuits. AAQ and related photoswitch molecules present a potential drug strategy for restoring retinal function in degenerative blinding diseases.
C1 [Polosukhina, Aleksandra; Huang, Tracy; Kramer, Richard H.] Univ Calif Berkeley, Vis Sci Grad Grp, Berkeley, CA 94720 USA.
   [Litt, Jeffrey; Tochitsky, Ivan; De Kouchkovsky, Ivan; Borges, Katharine; Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   [Nemargut, Joseph; Sychev, Yivgeny; Van Gelder, Russell N.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Van Gelder, Russell N.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.
   [Trauner, Dirk] Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley;
   University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of Munich
RP Kramer, RH (通讯作者)，Univ Calif Berkeley, Vis Sci Grad Grp, Berkeley, CA 94720 USA.
EM rhkramer@berkeley.edu
RI Van Gelder, Russell/ABB-4225-2021
OI Van Gelder, Russell/0000-0001-5368-3659; Tochitsky,
   Ivan/0000-0003-0650-9193; Nemargut, Joseph/0000-0001-6274-6172
FU National Eye Institute (NEI) [EY018957, P30 EY003176, P30 EY001730];
   Beckman Foundation for Macular Research; Research to Prevent Blindness
   award; Ezell Fellowship; Nanomedicine Development Center [PN2 EY018241];
   NATIONAL EYE INSTITUTE [P30EY003176, R01EY018957, P30EY001730,
   PN2EY018241, R21EY016249, R01EY015514] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232,
   T32GM066698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTH [R01MH088484] Funding Source: NIH RePORTER
FX We thank A. Anishchenko and J. Elstrott for helpful comments and
   discussions; Trevor Lee, Andrew Noblet, R. Montpetit, T. Lamprecht, and
   X. Qiu for technical and experimental assistance; and J. Flannery and K.
   Greenberg for valuable suggestions. This work was supported by the
   National Eye Institute (NEI), which provided research Grant EY018957 to
   R.H.K., Core Grant P30 EY003176 to R.H.K., and Core Grant P30 EY001730
   to R.V.G. This work was also supported by Beckman Foundation for Macular
   Research (R.H.K.) and a Research to Prevent Blindness award to Y.S. and
   R.V.G. and an Ezell Fellowship to A.P. The NEI also funded the
   Nanomedicine Development Center (PN2 EY018241), which supported this
   interdisciplinary project. R.H.K. and D.T. are SAB members and
   consultants of Photoswitch Bioscience, Inc., which is developing
   commercial uses for chemical photoswitches. A.P., J.L., I.T., J.N.,
   Y.S., T.H., I.D.K., and K.B. conducted the in vitro and in vivo
   experiments. D.T. designed and synthesized chemical reagents. R.H.K. and
   R.V.G. coordinated the research and wrote the manuscript. R.H.K.
   initiated the research and supervised the program.
CR Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Banghart MR, 2009, ANGEW CHEM INT EDIT, V48, P9097, DOI 10.1002/anie.200904504
   Beltran WA, 2010, GENE THER, V17, P1162, DOI 10.1038/gt.2010.56
   Benav H, 2010, IEEE ENG MED BIO, P5919, DOI 10.1109/IEMBS.2010.5627549
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Caporale N, 2011, MOL THER, V19, P1212, DOI 10.1038/mt.2011.103
   Carcieri SM, 2003, J NEUROPHYSIOL, V90, P1704, DOI 10.1152/jn.00127.2003
   Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Degenaar P, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035007
   Ecker JL, 2010, NEURON, V67, P49, DOI 10.1016/j.neuron.2010.05.023
   Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]
   Farrow K, 2011, J NEUROPHYSIOL, V105, P1516, DOI 10.1152/jn.00331.2010
   Feldbauer K, 2009, P NATL ACAD SCI USA, V106, P12317, DOI 10.1073/pnas.0905852106
   Fortin DL, 2008, NAT METHODS, V5, P331, DOI [10.1038/NMETH.1187, 10.1038/nmeth.1187]
   Gerding H, 2007, J NEURAL ENG, V4, pS38, DOI 10.1088/1741-2560/4/1/S06
   Govorunova EG, 2011, MBIO, V2, DOI 10.1128/mBio.00115-11
   Greenberg KP, 2011, NEURON, V69, P713, DOI 10.1016/j.neuron.2011.01.024
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Huberman AD, 2008, ANNU REV NEUROSCI, V31, P479, DOI 10.1146/annurev.neuro.31.060407.125533
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Ivanova E, 2010, INVEST OPHTH VIS SCI, V51, P5288, DOI 10.1167/iovs.10-5389
   Jimenez AJ, 1996, CELL TISSUE RES, V284, P193, DOI 10.1007/s004410050579
   Johnson J, 2010, P NATL ACAD SCI USA, V107, P17374, DOI 10.1073/pnas.1008533107
   KANDEL GL, 1987, CLIN VISION SCI, V1, P357
   Kessel L, 2010, J CATARACT REFR SURG, V36, P308, DOI 10.1016/j.jcrs.2009.08.035
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   London NJS, 2011, ADV THER, V28, P351, DOI 10.1007/s12325-011-0019-z
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Mourot A., 2011, ACS CHEM NE IN PRESS
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179
   Punzo C, 2007, INVEST OPHTH VIS SCI, V48, P849, DOI 10.1167/iovs.05-1555
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Shire DB, 2009, IEEE T BIO-MED ENG, V56, P2502, DOI 10.1109/TBME.2009.2021401
   Sjulson L, 2008, CHEM REV, V108, P1588, DOI 10.1021/cr078221b
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Vandenberghe L. H., 2011, SCI TRANSL MED, V3
   Winter JO, 2007, J BIOMAT SCI-POLYM E, V18, P1031, DOI 10.1163/156856207781494403
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
   Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744
NR 53
TC 163
Z9 171
U1 4
U2 55
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD JUL 26
PY 2012
VL 75
IS 2
BP 271
EP 282
DI 10.1016/j.neuron.2012.05.022
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 982HH
UT WOS:000307033200012
PM 22841312
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Gune, S
   Abdelfattah, NS
   Karamat, A
   Balasubramanian, S
   Marion, KM
   Morgenthien, E
   Sadda, SR
AF Gune, Shamika
   Abdelfattah, Nizar Saleh
   Karamat, Ayesha
   Balasubramanian, Siva
   Marion, Kenneth M.
   Morgenthien, Elizabeth
   Sadda, SriniVas R.
TI Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy
   in the HARBOR Study for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN;
   NATURAL-HISTORY; GROWTH; BEVACIZUMAB; EFFICACY; SAFETY; RISK
AB Purpose: Previous studies of macular atrophy (MA) in HARBOR analyzed color fundus photography and fluorescein angiography image data. This study performed a longitudinal assessment of monthly spectral-domain (SD) OCT scans to determine MA prevalence, incidence, and progression in HARBOR.
   Design: Post hoc analysis of SD OCT images from HARBOR (ClincalTrials.gov identifier, NCT00891735), a phase 3 multicenter, prospective, randomized, double-blind, active treatment-controlled clinical trial.
   Participants: Patients (n = 1097) with subfoveal choroidal neovascularization secondary to neovascular agerelated macular degeneration (nAMD) treated with ranibizumab 0.5 mg monthly (n = 275), 0.5 mg pro re nata (PRN) after 3 loading doses (n = 275), 2.0 mg monthly (n = 274), or 2.0 mg PRN (n = 273).
   Methods: Evaluable SD OCT macular cube scans from patients with 24 months of follow-up (N = 941) were examined by masked reading center-trained graders monthly from baseline to month 24. Atrophy diagnosis criteria were consistent with those proposed by the Classification of Atrophy Meetings (CAM) group: hypertransmission of light into the choroid, retinal pigment epithelium loss, and loss of outer retinal layers. Macular atrophy was considered Definite if all 3 criteria were met and Questionable if 2 were met. Study arms were compared for time to MA detection (log-rank test) and enlargement rates (time x arm interaction test).
   Main Outcome Measures: Prevalence, incidence, and enlargement rates of MA.
   Results: At baseline, imbalance in MA rates across ranibizumab arms was evident (0.5 mg monthly, 19.1%; 0.5 mg PRN, 16.1%; 2.0 mg monthly, 10.1%; 2.0 mg PRN, 10.5%). At month 24, new MA development rates in eyes without baseline MA were similar between ranibizumab doses (0.5 mg, 25.9%; 2.0 mg, 25.4%) and treatment regimens (monthly, 26.4%; PRN, 25.0%). No significant differences in enlargement rate of new atrophy area (P = 0.479, square-root transformed) or time to detection of new MA (P = 0.997) were evident among study arms.
   Conclusions: In this analysis of a major nAMD trial using CAM atrophy criteria, no differences were observed in incidence or progression rates of new MA among study arms, ranibizumab doses, or treatment regimens. Monthly versus PRN treatment did not influence MA incidence or progression. (C) 2019 by the American Academy of Ophthalmology.
C1 [Gune, Shamika; Morgenthien, Elizabeth] Genentech Inc, San Francisco, CA 94080 USA.
   [Abdelfattah, Nizar Saleh; Karamat, Ayesha; Balasubramanian, Siva; Marion, Kenneth M.; Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Abdelfattah, Nizar Saleh; Sadda, SriniVas R.] UCLA, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Roche Holding; Genentech; Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054
FU Genentech, Inc., South San Francisco, California
FX Supported by Genentech, Inc., South San Francisco, California. The
   sponsor participated in the study design; data management, analysis, and
   interpretation; and preparation, review, and approval of the manuscript.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 18
Z9 20
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2020
VL 127
IS 4
BP 523
EP 532
DI 10.1016/j.ophtha.2019.09.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW0VD
UT WOS:000520890400023
PM 31718842
OA hybrid
DA 2022-11-30
ER

PT J
AU Gao, Y
   Yu, T
   Zhang, Y
   Dang, GF
AF Gao, Yang
   Yu, Tao
   Zhang, Yue
   Dang, Guangfu
TI Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF
   Combination Treatment for Neovascular Age-Related Macular Degeneration:
   A Meta-Analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; photodynamic therapy; meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PLUS RANIBIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; FLUENCE; TRIALS;
   VISUDYNE(R); INHIBITORS; EFFICACY; PDT
AB PURPOSE. The purpose of this study was to compare the efficacy and safety of anti-VEGF monotherapy with verteporfin photodynamic therapy (PDT) and anti-VEGF combination treatment in neovascular AMD.
   METHODS. This study used a meta-analysis of randomized controlled trials.
   RESULTS. We included a total of 16 studies that included 587 patients in the monotherapy group and 673 in the combination treatment group. There was no statistical difference between best corrected visual acuity (BCVA) and central retinal thickness (CRT) at end of the study and the proportions of patients who gained >= 15 BCVA letters between the two treatment groups. Nevertheless, combination therapy required fewer anti-VEGF injections than monotherapy. Subgroup analyses showed that CRT at end of the study was thinner in the standard-fluence (SF) PDT combination therapy group than in the monotherapy group (weighted mean difference [WMD]: 17.256; 95% confidence interval [CI]: 5.423 similar to 29.089; P = 0.004). The reduced-fluence (RF) PDT combination therapy group required fewer anti-VEGF injections than the monotherapy group (WMD: 3.217; 95% CI: 2.798 similar to 3.636; P < 0.001), while the number of anti-VEGF treatments between the SF PDT combination therapy and monotherapy groups was not statistically different (WMD: 0.23; 95% CI: -0.016 similar to 0.475; P = 0.067). In the combination therapy group, there was no difference between the PDT thorn anti-VEGF versus anti-VEGF retreatment regimens.
   CONCLUSIONS. This study indicates that verteporfin PDT and anti-VEGF combination therapy is effective for achieving BCVA gain and CRT reduction comparable with that of anti-VEGF monotherapy. Combination therapy with RF PDT can potentially decrease the number of antiVEGF injections needed.
C1 [Gao, Yang; Yu, Tao; Zhang, Yue; Dang, Guangfu] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Ophthalmol, Jinan, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University
RP Dang, GF (通讯作者)，Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
EM dangguangfu@126.com
OI GAO, YANG/0000-0002-1631-1239
CR Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Datseris I, 2015, SEMIN OPHTHALMOL, V30, P112, DOI 10.3109/08820538.2013.833268
   Debefve E, 2008, ANGIOGENESIS, V11, P235, DOI 10.1007/s10456-008-9106-4
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Giustolisi Rosalia, 2011, Digit J Ophthalmol, V17, P23, DOI 10.5693/djo.01.2011.05.003
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Nowak MS, 2012, MED SCI MONITOR, V18, pCR374, DOI 10.12659/MSM.882907
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Saviano Sandro, 2016, Digit J Ophthalmol, V22, P46, DOI 10.5693/djo.01.2014.01.004
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Weidle UH, 2012, CANCER GENOM PROTEOM, V9, P357
   Weingessel B, 2016, WIEN KLIN WOCHENSCHR, V128, P560, DOI 10.1007/s00508-015-0772-0
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
NR 37
TC 26
Z9 27
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2018
VL 59
IS 10
BP 4307
EP 4317
DI 10.1167/iovs.17-23747
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR7EB
UT WOS:000442849800021
PM 30372759
OA gold
DA 2022-11-30
ER

PT J
AU Tawfik, A
   Elsherbiny, NM
   Zaidi, Y
   Rajpurohit, P
AF Tawfik, Amany
   Elsherbiny, Nehal M.
   Zaidi, Yusra
   Rajpurohit, Pragya
TI Homocysteine and Age-Related Central Nervous System Diseases: Role of
   Inflammation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE hyperhomocysteinemia; Alzheimer's disease; age-related macular
   degeneration; diabetic retinopathy; inflammation
ID BLOOD-BRAIN-BARRIER; SMOOTH-MUSCLE-CELLS; INDUCED ENDOPLASMIC-RETICULUM;
   ALZHEIMERS-DISEASE; PLASMA HOMOCYSTEINE; ENDOTHELIAL DYSFUNCTION;
   COGNITIVE IMPAIRMENT; NMDA RECEPTORS; NITRIC-OXIDE; MOUSE MODEL
AB Hyperhomocysteinemia (HHcy) is remarkably common among the aging population. The relation between HHcy and the development of neurodegenerative diseases, such as Alzheimer's disease (AD) and eye diseases, and age-related macular degeneration (AMD) and diabetic retinopathy (DR) in elderly people, has been established. Disruption of the blood barrier function of the brain and retina is one of the most important underlying mechanisms associated with HHcy-induced neurodegenerative and retinal disorders. Impairment of the barrier function triggers inflammatory events that worsen disease pathology. Studies have shown that AD patients also suffer from visual impairments. As an extension of the central nervous system, the retina has been suggested as a prominent site of AD pathology. This review highlights inflammation as a possible underlying mechanism of HHcy-induced barrier dysfunction and neurovascular injury in aging diseases accompanied by HHcy, focusing on AD.
C1 [Tawfik, Amany; Elsherbiny, Nehal M.; Zaidi, Yusra; Rajpurohit, Pragya] Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.
   [Tawfik, Amany; Elsherbiny, Nehal M.; Zaidi, Yusra; Rajpurohit, Pragya] Augusta Univ, James & Jean Culver Vis Discovery Inst, MCG, Augusta, GA 30912 USA.
   [Tawfik, Amany] Augusta Univ, Med Coll Georgia MCG, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   [Tawfik, Amany] Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.
   [Tawfik, Amany] Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA.
   [Elsherbiny, Nehal M.] Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; Oakland
   University; Egyptian Knowledge Bank (EKB); Mansoura University
RP Tawfik, A (通讯作者)，Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, James & Jean Culver Vis Discovery Inst, MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Med Coll Georgia MCG, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA.
EM amtawfik@augusta.edu; drnehal@hotmail.com; yzaidi@augusta.edu;
   prajpurohit@augusta.edu
RI Elsherbiny, Nehal/AAF-9206-2019
OI Elsherbiny, Nehal/0000-0001-5167-3377; Tawfik, Amany/0000-0002-0245-8256
FU American Heart Association (AHA) Scientist Development Grant
   [16SDG3070001]; NEI [1R01EY029751-02, P30EY031631]
FX This research was funded by the American Heart Association (AHA)
   Scientist Development Grant award #16SDG3070001, and NEI grant awards
   1R01EY029751-02 and P30EY031631.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Ajith TA, 2015, CLIN CHIM ACTA, V450, P316, DOI 10.1016/j.cca.2015.09.007
   Akalin A, 2008, EUR J ENDOCRINOL, V158, P47, DOI 10.1530/EJE-07-0470
   Delfino VDA, 2007, NUTRITION, V23, P242, DOI 10.1016/j.nut.2007.01.002
   Alvarez-Sanchez N, 2020, J GERONTOL A-BIOL, V75, P1488, DOI 10.1093/gerona/glz168
   An Y, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0741-y
   AnandBabu K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216899
   Andrieu S, 2009, J ALZHEIMERS DIS, V16, P235, DOI 10.3233/JAD-2009-0971
   Anggono V, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8256196
   Ataie A, 2012, INT J MOL CELL MED, V1, P145
   Aydin E, 2008, EUR J OPHTHALMOL, V18, P226, DOI 10.1177/112067210801800210
   Azzini E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041421
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Baydas G, 2005, NEUROSCIENCE, V135, P879, DOI 10.1016/j.neuroscience.2005.05.048
   Baydas G, 2005, BRAIN RES, V1046, P187, DOI 10.1016/j.brainres.2005.04.011
   Beard RS, 2011, AM J PHYSIOL-HEART C, V300, pH13, DOI 10.1152/ajpheart.00598.2010
   Beard RS, 2011, BLOOD, V118, P2007, DOI 10.1182/blood-2011-02-338269
   Bescond A, 1999, BIOCHEM BIOPH RES CO, V263, P498, DOI 10.1006/bbrc.1999.1391
   Bevan RJ, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01094-2
   Beydoun MA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-643
   Boldyrev AA, 2007, J ALZHEIMERS DIS, V11, P219
   Braun DJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01938-7
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Chang CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082676
   Chen H, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5912146
   Chen S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0963-x
   Cheng ZJ, 2009, CURR HYPERTENS REV, V5, P158, DOI 10.2174/157340209788166940
   Christen WG, 2018, OPHTHALMOL RETINA, V2, P508, DOI 10.1016/j.oret.2017.10.001
   Christen WG, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2017.1362009
   Cunha-Vaz J, 2017, OPHTHALMOLOGICA, V237, P1, DOI 10.1159/000455809
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Danysz W, 2012, BRIT J PHARMACOL, V167, P324, DOI 10.1111/j.1476-5381.2012.02057.x
   de Jager CA, 2012, INT J GERIATR PSYCH, V27, P592, DOI 10.1002/gps.2758
   den Heijer T, 2003, BRAIN, V126, P170, DOI 10.1093/brain/awg006
   Dobrynina L A, 2017, Zh Nevrol Psikhiatr Im S S Korsakova, V117, P25, DOI 10.17116/jnevro201711712225-33
   Dong N, 2018, INT OPHTHALMOL, V38, P737, DOI 10.1007/s10792-017-0528-0
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Elsherbiny NM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030393
   Endres M, 2005, STROKE, V36, P321, DOI 10.1161/01.STR.0000153008.60517.ab
   Erickson MA, 2013, J CEREBR BLOOD F MET, V33, P1500, DOI 10.1038/jcbfm.2013.135
   Fang P, 2019, ARTERIOSCL THROM VAS, V39, P2097, DOI 10.1161/ATVBAHA.119.313138
   Fawzi AA, 2020, OPHTHALMOLOGY, V127, P119, DOI 10.1016/j.ophtha.2019.07.025
   Fridman O, 1999, Acta Physiol Pharmacol Ther Latinoam, V49, P21
   Gao LB, 2016, MINERVA MED, V107, P108
   Gerard F, 2012, BRAIN RES, V1473, P1, DOI 10.1016/j.brainres.2012.07.032
   Gokkusu C, 2010, CYTOKINE, V50, P15, DOI 10.1016/j.cyto.2009.12.015
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gu SX, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013368
   Hansson O, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0485-0
   Hasegawa T, 2005, J NEUROSCI RES, V80, P869, DOI 10.1002/jnr.20514
   Hayden MR, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-4
   Hayden MR, 2002, CARDIOVASC DIABETOL, V1, DOI 10.1186/1475-2840-1-3
   Ho PI, 2002, J NEUROSCI RES, V70, P694, DOI 10.1002/jnr.10416
   Ho PI, 2001, J NEUROCHEM, V78, P249, DOI 10.1046/j.1471-4159.2001.00384.x
   Holven KB, 2001, AM J MED, V110, P536, DOI 10.1016/S0002-9343(01)00696-9
   Hu HM, 2019, INFLAMMATION, V42, P64, DOI 10.1007/s10753-018-0873-9
   Hu HM, 2016, BIOMED PHARMACOTHER, V80, P63, DOI 10.1016/j.biopha.2016.02.022
   Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007
   Iacobazzi V, 2013, MOL GENET METAB, V110, P25, DOI 10.1016/j.ymgme.2013.07.012
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Irizarry MC, 2005, NEUROLOGY, V65, P1402, DOI 10.1212/01.wnl.0000183063.99107.5c
   Jara-Prado A, 2003, NEUROTOX RES, V5, P237, DOI 10.1007/BF03033381
   Jaul E, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00335
   Jeong SO, 2017, BIOCHEM BIOPH RES CO, V493, P164, DOI 10.1016/j.bbrc.2017.09.054
   Jiang XH, 2005, ARTERIOSCL THROM VAS, V25, P2515, DOI 10.1161/01.ATV.0000189559.87328.e4
   Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626
   Kalani A, 2014, J CEREBR BLOOD F MET, V34, P1212, DOI 10.1038/jcbfm.2014.74
   Kamat P K, 2015, Open Neurol J, V9, P9, DOI 10.2174/1874205X01509010009
   Kamat PK, 2013, NEUROSCIENCE, V252, P302, DOI 10.1016/j.neuroscience.2013.07.051
   Kamat PK, 2016, ALCOHOL CLIN EXP RES, V40, P2474, DOI 10.1111/acer.13234
   Kamat PK, 2016, MOL NEUROBIOL, V53, P2451, DOI 10.1007/s12035-015-9212-4
   Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood-2005-06-2506
   Kaur D, 2019, INFLAMMOPHARMACOLOGY, V27, P663, DOI 10.1007/s10787-019-00580-x
   Koller A, 2018, CURR PHARM DESIGN, V24, P2911, DOI 10.2174/1381612824666180625125450
   Kowluru RA, 2020, EYE VISION, V7, DOI 10.1186/s40662-019-0167-9
   Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000
   Kumar K, 2018, BIOMED PHARMACOTHER, V98, P297, DOI 10.1016/j.biopha.2017.12.053
   Kumar M, 2019, NITRIC OXIDE-BIOL CH, V90, P15, DOI 10.1016/j.niox.2019.05.008
   Kundu S, 2009, MOL CELL BIOCHEM, V332, P215, DOI 10.1007/s11010-009-0194-2
   Lazzerini PE, 2007, AUTOIMMUN REV, V6, P503, DOI 10.1016/j.autrev.2007.03.008
   Le Stunff H, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00807
   Lee JC, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0250-2
   Lehotsky J, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00538
   Lei X.W., 2019, OPHTHALM RES, P1, DOI [10.1159/000499020, DOI 10.1159/000499020]
   Lei XW, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0362-1
   Li JJ, 2015, INT J MOL SCI, V16, P12560, DOI 10.3390/ijms160612560
   Li W, 2020, FRONT BIOSCI-LANDMRK, V25, P536, DOI 10.2741/4819
   Liu ZY, 2012, CIRC RES, V111, P1261, DOI [10.1161/CIRCRESAHA.112.270520, 10.1161/circresaha.112.270520]
   Lominadze D, 2006, AM J PHYSIOL-HEART C, V290, pH1206, DOI 10.1152/ajpheart.00376.2005
   Luchowska E, 2005, J NEUROSCI RES, V79, P375, DOI 10.1002/jnr.20359
   Luchsinger JA, 2007, ARCH NEUROL-CHICAGO, V64, P86, DOI 10.1001/archneur.64.1.86
   Lyros E, 2014, CURR ALZHEIMER RES, V11, P18, DOI 10.2174/1567205010666131119235254
   Maccioni Ricardo B, 2018, Open Neurol J, V12, P50, DOI 10.2174/1874205X01812010050
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Mohammad G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051771
   Mok SS, 2002, EUR J BIOCHEM, V269, P3014, DOI 10.1046/j.1432-1033.2002.02976.x
   Moretti R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010231
   Morris MS, 2003, LANCET NEUROL, V2, P425, DOI 10.1016/S1474-4422(03)00438-1
   Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088
   Olivares D, 2012, CURR ALZHEIMER RES, V9, P746
   Ortega-Gutierrez S, 2007, J CELL BIOCHEM, V102, P729, DOI 10.1002/jcb.21327
   Osuna C, 2002, PHARMACOL TOXICOL, V90, P32, DOI 10.1034/j.1600-0773.2002.900107.x
   Pacheco-Quinto J, 2006, NEUROBIOL DIS, V22, P651, DOI 10.1016/j.nbd.2006.01.005
   Pang XM, 2014, ATHEROSCLEROSIS, V236, P73, DOI 10.1016/j.atherosclerosis.2014.06.021
   Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013
   Perla-Kajan J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133140
   Petras M, 2014, J PHYSIOL PHARMACOL, V65, P15
   Phelip JM, 2008, INFLAMM BOWEL DIS, V14, P242, DOI 10.1002/ibd.20309
   Poddar R, 2009, J NEUROCHEM, V110, P1095, DOI 10.1111/j.1471-4159.2009.06207.x
   Price BR, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00350
   Robinson N, 2018, MECH AGEING DEV, V174, P86, DOI 10.1016/j.mad.2017.10.001
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200
   Scarpa S, 2003, FEBS LETT, V541, P145, DOI 10.1016/S0014-5793(03)00277-1
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
   Shen XN, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12104
   Shi YF, 2013, J ZHEJIANG UNIV-SC B, V14, P696, DOI 10.1631/jzus.BQICC703
   Smith AD, 2021, J INTERN MED, V290, P826, DOI 10.1111/joim.13279
   Smith AD, 2018, J ALZHEIMERS DIS, V62, P561, DOI 10.3233/JAD-171042
   Sontag E, 2007, J NEUROSCI, V27, P2751, DOI 10.1523/JNEUROSCI.3316-06.2007
   Streck EL, 2003, METAB BRAIN DIS, V18, P147, DOI 10.1023/A:1023815119931
   Sun JY, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22090
   Takeda S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00171
   Tawfik A, 2021, J MOL MED, V99, P119, DOI 10.1007/s00109-020-02000-y
   Tawfik A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081119
   Tawfik Amany, 2014, Austin J Clin Ophthalmol, V1, P1023
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Tawfik A, 2013, INVEST OPHTH VIS SCI, V54, P939, DOI 10.1167/iovs.12-10536
   Troen AM, 2008, P NATL ACAD SCI USA, V105, P12474, DOI 10.1073/pnas.0805350105
   Ukinc K, 2009, ENDOCRINE, V36, P255, DOI 10.1007/s12020-009-9218-7
   Vaccaro O, 2000, NUTR METAB CARDIOVAS, V10, P297
   van den Kommer TN, 2010, NEUROBIOL AGING, V31, P1700, DOI 10.1016/j.neurobiolaging.2008.09.009
   Wakkee M, 2007, ATHEROSCLEROSIS, V190, P1, DOI 10.1016/j.atherosclerosis.2006.07.011
   Wang R, 2017, J ALZHEIMERS DIS, V57, P1041, DOI 10.3233/JAD-160763
   Wang XC, 2015, ATHEROSCLEROSIS, V242, P191, DOI 10.1016/j.atherosclerosis.2015.07.021
   Wang ZS, 2016, ASIAN PAC J TROP MED, V9, P475, DOI 10.1016/j.apjtm.2016.03.023
   Weiss N, 2002, VASC MED, V7, P227, DOI 10.1191/1358863x02vm428ra
   Weiss N, 2002, ARTERIOSCL THROM VAS, V22, P34, DOI 10.1161/hq1201.100456
   Yang Guoqing, 2002, Zhonghua Nei Ke Za Zhi, V41, P34
   Zenaro E, 2017, NEUROBIOL DIS, V107, P41, DOI 10.1016/j.nbd.2016.07.007
   Zhang HS, 2005, PHARMACOLOGY, V74, P57, DOI 10.1159/000083684
   Zhang Y, 2016, NEUROL SCI, V37, P1039, DOI 10.1007/s10072-016-2546-5
   Zhang Y, 2021, TRANSL NEURODEGENER, V10, DOI 10.1186/s40035-021-00230-9
   Zhuo JM, 2010, CURR ALZHEIMER RES, V7, P140, DOI 10.2174/156720510790691326
   Zhuo JM, 2011, TRENDS PHARMACOL SCI, V32, P562, DOI 10.1016/j.tips.2011.05.003
   Zieminska E, 2003, NEUROCHEM INT, V43, P481, DOI 10.1016/S0197-0186(03)00038-X
   Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114
   Zlokovic BV, 2004, J NEUROCHEM, V89, P807, DOI 10.1111/j.1471-4159.2004.02385.x
   Zou CG, 2010, NEUROBIOL AGING, V31, P2069, DOI 10.1016/j.neurobiolaging.2008.11.007
NR 150
TC 4
Z9 4
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 12
AR 6259
DI 10.3390/ijms22126259
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SZ0KB
UT WOS:000666264500001
PM 34200792
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rimpela, AK
   Kiiski, I
   Deng, F
   Kidron, H
   Urtti, A
AF Rimpela, Anna-Kaisa
   Kiiski, Iiro
   Deng, Feng
   Kidron, Heidi
   Urtti, Arto
TI Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug
   Delivery to the Posterior and Anterior Segments
SO PHARMACEUTICS
LA English
DT Article
DE intravitreal injection; ocular drug delivery; bevacizumab; ranibizumab;
   aflibercept; controlled release
ID BEVACIZUMAB; RABBIT; VOLUME; RANIBIZUMAB; CLEARANCE; RITUXIMAB; THERAPY;
   PROTEIN
AB Biologicals are important ocular drugs that are be delivered using monthly and bimonthly intravitreal injections to treat retinal diseases, such as age-related macular degeneration. Long acting delivery systems are needed for prolongation of their dosing interval. Intravitreal biologicals are eliminated from the eye via the aqueous humor outflow. Thus, the anterior and posterior segments are exposed to the drug. We utilized a kinetic simulation model to estimate protein drug concentrations in the vitreous and aqueous humor after bolus injection and controlled release administration to the vitreous. The simulations predicted accurately the experimental levels of 5 biologicals in the vitreous and aqueous humor. The good match between the simulations and experimental data demonstrated almost complete anterior segment bioavailability, and major dose sparing with ocular controlled release systems. Overall, the model is a useful tool in the design of intraocular delivery of biologicals.
C1 [Rimpela, Anna-Kaisa; Kiiski, Iiro; Deng, Feng; Kidron, Heidi; Urtti, Arto] Univ Helsinki, Drug Res Program, Fac Pharm, Viikinkaari 5 E, Helsinki 00790, Finland.
   [Urtti, Arto] St Petersburg State Univ, Lab Biohybrid Technol, Inst Chem, Univ Skii Pr 26, St Petersburg 198504, Russia.
   [Urtti, Arto] Univ Eastern Finland, Sch Pharm, Yliopistonranta 1, Kuopio 70211, Finland.
C3 University of Helsinki; Saint Petersburg State University; University of
   Eastern Finland
RP Urtti, A (通讯作者)，Univ Helsinki, Drug Res Program, Fac Pharm, Viikinkaari 5 E, Helsinki 00790, Finland.; Urtti, A (通讯作者)，St Petersburg State Univ, Lab Biohybrid Technol, Inst Chem, Univ Skii Pr 26, St Petersburg 198504, Russia.; Urtti, A (通讯作者)，Univ Eastern Finland, Sch Pharm, Yliopistonranta 1, Kuopio 70211, Finland.
EM anna-kaisa.rimpela@helsinki.fi; iiro.kiiski@helsinki.fi;
   feng.deng@helsinki.fi; heidi.kidron@helsinki.fi; arto.urtti@uef.fi
RI Kiiski, Iiro/AAG-5805-2019; Kidron, Heidi/A-5826-2015
OI Kiiski, Iiro/0000-0001-8677-9032; Deng, Feng/0000-0002-9173-6923;
   Kidron, Heidi/0000-0001-6427-8042; Rimpela,
   Anna-Kaisa/0000-0003-4093-3465
FU Government of Russian Federation [14.W03.031.0025]
FX This research was supported from the Government of Russian Federation
   Mega-Grant 14.W03.031.0025 "Biohybrid Technologies for Modern
   Biomedicine".
CR ARAIE M, 1991, EXP EYE RES, V52, P27, DOI 10.1016/0014-4835(91)90125-X
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316 , 10.1517/13543780902855316]
   BARANY E, 1949, AM J OPHTHALMOL, V32, P177, DOI 10.1016/S0002-9394(14)78371-0
   Bhatt N, 2016, DEV OPHTHALMOL, V55, P252, DOI 10.1159/000431201
   CONRAD JM, 1977, J PHARM SCI, V66, P219, DOI 10.1002/jps.2600660222
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   GAUL GR, 1986, INVEST OPHTH VIS SCI, V27, P1331
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hutton-Smith LA, 2017, MOL PHARMACEUT, V14, P2690, DOI 10.1021/acs.molpharmaceut.7b00164
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   Kholdebarin R, 2008, CAN J OPHTHALMOL, V43, P454, DOI [10.3129/i08-076, 10.1139/i08-076]
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim H, 2006, EXP EYE RES, V82, P760, DOI 10.1016/j.exer.2005.09.018
   Kim J, 2018, J CONTROL RELEASE, V269, P45, DOI 10.1016/j.jconrel.2017.11.008
   Lamminsalo M, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2435-0
   Lau CML, 2018, ADV DRUG DELIVER REV, V126, P145, DOI 10.1016/j.addr.2018.03.013
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Loyet KM, 2019, MOL PHARMACEUT, V16, P86, DOI 10.1021/acs.molpharmaceut.8b00871
   Maurice D.M., 1984, HDB EXPT PHARM, P16
   MILLER SC, 1980, J PHARM SCI, V69, P615, DOI 10.1002/jps.2600690544
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Tesar D, 2017, MABS-AUSTIN, V9, P1297, DOI 10.1080/19420862.2017.1372078
NR 34
TC 22
Z9 22
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JAN
PY 2019
VL 11
IS 1
AR 9
DI 10.3390/pharmaceutics11010009
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HM8LI
UT WOS:000459732200009
PM 30598037
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Fanjul-Moles, ML
   Lopez-Riquelme, GO
AF Luisa Fanjul-Moles, Maria
   Octavio Lopez-Riquelme, German
TI Relationship between Oxidative Stress, Circadian Rhythms, and AMD
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ROD OUTER SEGMENT; RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL
   GROWTH-FACTOR; SUCCINATE-UBIQUINONE OXIDOREDUCTASE; MITOCHONDRIAL
   COMPLEX II; MACULAR DEGENERATION; BLUE-LIGHT; PHOTOCHEMICAL DAMAGE;
   LOCOMOTOR-ACTIVITY; ELECTRON-TRANSFER
AB This work reviews concepts regarding oxidative stress and the mechanisms by which endogenous and exogenous factors produce reactive oxygen species (ROS). It also surveys the relationships between oxidative stress, circadian rhythms, and retinal damage in humans, particularly those related to light and photodamage. In the first section, the production of ROS by different cell organelles and biomolecules and the antioxidant mechanisms that antagonize this damage are reviewed. The second section includes a brief review of circadian clocks and their relationship with the cellular redox state. In the third part of this work, the relationship between retinal damage and ROS is described. The last part of this work focuses on retinal degenerative pathology, age-related macular degeneration, and the relationships between this pathology, ROS, and light. Finally, the possible interactions between the retinal pigment epithelium (RPE), circadian rhythms, and this pathology are discussed.
C1 [Luisa Fanjul-Moles, Maria] Univ Nacl Autonoma Mexico, Fac Ciencias, Ciudad Univ, Mexico City 04510, DF, Mexico.
   [Octavio Lopez-Riquelme, German] Univ Autonoma Estado Morelos, Fac Humanidades, Posgrad Ciencias Cognit, Ave Univ 1001, Cuernavaca 62209, Morelos, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Universidad Autonoma del Estado
   de Morelos
RP Fanjul-Moles, ML (通讯作者)，Univ Nacl Autonoma Mexico, Fac Ciencias, Ciudad Univ, Mexico City 04510, DF, Mexico.
EM mfajul@gmail.com
RI López-Riquelme, Germán Octavio/AAN-3337-2021
OI López-Riquelme, Germán Octavio/0000-0002-8031-4522
CR AcunaCastroviejo D, 1996, LIFE SCI, V60, pPL23, DOI 10.1016/S0024-3205(96)00606-6
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson RF, 2005, J BIOL CHEM, V280, P33331, DOI 10.1074/jbc.M506002200
   [Anonymous], 2006, POL J ENV STUD
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bae YS, 2011, MOL CELLS, V32, P491, DOI 10.1007/s10059-011-0276-3
   BALZER I, 1991, SCIENCE, V253, P795, DOI 10.1126/science.1876838
   Banks G, 2015, NEUROBIOL AGING, V36, P380, DOI 10.1016/j.neurobiolaging.2014.07.040
   Barzilai N, 2010, J CLIN ENDOCR METAB, V95, P4493, DOI 10.1210/jc.2010-0859
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bednarova A, 2013, INT J MOL SCI, V14, P3026, DOI 10.3390/ijms14023026
   Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633
   BERGIANNAKI JD, 1995, J PINEAL RES, V18, P159, DOI 10.1111/j.1600-079X.1995.tb00155.x
   Bhatt L, 2010, MOL VIS, V16, P283
   Bhatwadekar AD, 2013, DIABETES, V62, P273, DOI 10.2337/db12-0172
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bloch G, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0035
   Bobu C, 2006, INVEST OPHTH VIS SCI, V47, P3109, DOI 10.1167/iovs.05-1397
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Brandes N, 2009, ANTIOXID REDOX SIGN, V11, P997, DOI [10.1089/ars.2008.2285, 10.1089/ARS.2008.2285]
   Buettner G. R., 2011, PHOTOBIOLOGY SCI LIN
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Carneiro BTS, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00083
   CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Chong SJF, 2014, MITOCHONDRION, V19, P39, DOI 10.1016/j.mito.2014.06.002
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821
   Do JY, 2015, BIOCHEM BIOPH RES CO, V460, P457, DOI 10.1016/j.bbrc.2015.03.055
   Doyle SE, 2002, VISUAL NEUROSCI, V19, P593, DOI 10.1017/S0952523802195058
   Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Ferrari E, 2008, EXP GERONTOL, V43, P88, DOI 10.1016/j.exger.2007.06.010
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Finkel T, 2012, J BIOL CHEM, V287, P4434, DOI 10.1074/jbc.R111.271999
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fu Y, 2012, FRONT BIOSCI-LANDMRK, V17, P1461, DOI 10.2741/3997
   Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Gleason C, 2011, P NATL ACAD SCI USA, V108, P10768, DOI 10.1073/pnas.1016060108
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDMAN AI, 1980, INVEST OPHTH VIS SCI, V19, P1257
   GROF E, 1985, PROG NEURO-PSYCHOPH, V9, P609, DOI 10.1016/0278-5846(85)90026-0
   Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200
   Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4
   Halliwell B, 2013, BRIT J CLIN PHARMACO, V75, P637, DOI 10.1111/j.1365-2125.2012.04272.x
   Hardeland R, 2003, CHRONOBIOL INT, V20, P921, DOI 10.1081/CBI-120025245
   Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119
   Hardin PE, 2005, CURR BIOL, V15, pR714, DOI 10.1016/j.cub.2005.08.019
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hill BG, 2010, J BIOL CHEM, V285, P19699, DOI 10.1074/jbc.R110.101618
   Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jensen LD, 2013, CELL CYCLE, V12, P405, DOI 10.4161/cc.23596
   Jensen LD, 2012, CELL REP, V2, P231, DOI 10.1016/j.celrep.2012.07.005
   Johnson CH, 2003, CHRONOBIOL INT, V20, P741, DOI 10.1081/CBI-120024211
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kanofsky JR, 2011, PHOTOCHEM PHOTOBIOL, V87, P14, DOI 10.1111/j.1751-1097.2010.00855.x
   Khan MA, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0151-1
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klomsiri C, 2011, ANTIOXID REDOX SIGN, V14, P1065, DOI 10.1089/ars.2010.3376
   Koyanagi S, 2003, CANCER RES, V63, P7277
   Kruft BI, 2011, PHOTOCHEM PHOTOBIOL, V87, P1204, DOI 10.1111/j.1751-1097.2011.00993.x
   KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880
   Lai AG, 2012, P NATL ACAD SCI USA, V109, P17129, DOI 10.1073/pnas.1209148109
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Li JM, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/963289
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liebel F, 2012, J INVEST DERMATOL, V132, P1901, DOI 10.1038/jid.2011.476
   Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x
   Long YC, 2014, AM J PHYSIOL-ENDOC M, V306, pE581, DOI 10.1152/ajpendo.00665.2013
   Fanjul-Moles ML, 2013, FRONT BIOSCI-LANDMRK, V18, P665, DOI 10.2741/4129
   Mackey SR, 2011, ADV GENET, V74, P13, DOI 10.1016/B978-0-12-387690-4.00002-7
   Malkus KA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-24
   McConnell V, 2005, Ulster Med J, V74, P82
   Merrow M, 2001, CELL, V106, P141, DOI 10.1016/S0092-8674(01)00443-3
   Metzger CS, 2015, CYTOKINE, V76, P519, DOI 10.1016/j.cyto.2015.07.015
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128
   Mrosovsky N, 1996, BIOL REV, V71, P343, DOI 10.1111/j.1469-185X.1996.tb01278.x
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Pagan C, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-17
   Palma-Anzures I, 2012, BIOL RHYTHM RES, V43, P15, DOI 10.1080/09291016.2011.638116
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   Pandi-Perumal SR, 2002, AGEING RES REV, V1, P559, DOI 10.1016/S1568-1637(02)00014-4
   Paranagama MP, 2010, MITOCHONDRION, V10, P158, DOI 10.1016/j.mito.2009.12.145
   Pittendrigh CS, 1981, HDB BEHAV NEUROBIOLO, V4, P95, DOI DOI 10.1007/978-1-4615-6552-9_7
   Pospisil P, 2014, J PHOTOCH PHOTOBIO B, V139, P11, DOI 10.1016/j.jphotobiol.2014.02.008
   Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011
   Quinlan CL, 2014, J BIOL CHEM, V289, P8312, DOI 10.1074/jbc.M113.545301
   Quinlan CL, 2012, J BIOL CHEM, V287, P27255, DOI 10.1074/jbc.M112.374629
   Rahman K, 2007, CLIN INTERV AGING, V2, P219
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   Roehlecke C, 2011, MOL VIS, V17, P876
   Rosen R, 2009, MOL VIS, V15, P1673
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Sahar S, 2007, CELL CYCLE, V6, P1329, DOI 10.4161/cc.6.11.4295
   Sarkar C, 2004, AM J PHYSIOL-HEART C, V287, pH1554, DOI 10.1152/ajpheart.00272.2004
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Schutt F, 2000, OPHTHALMOLOGE, V97, P682, DOI 10.1007/s003470070037
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581
   Sinha S, 2009, J CELL SCI, V122, P3385, DOI 10.1242/jcs.053124
   Skene DJ, 2003, EXP GERONTOL, V38, P199, DOI 10.1016/S0531-5565(02)00198-5
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Sohal RS, 2012, FREE RADICAL BIO MED, V52, P539, DOI 10.1016/j.freeradbiomed.2011.10.445
   Somanath PR, 2009, ANGIOGENESIS, V12, P177, DOI 10.1007/s10456-009-9141-9
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   TEIRSTEIN PS, 1980, INVEST OPHTH VIS SCI, V19, P1268
   TERMAN JS, 1993, BRAIN RES, V605, P256
   Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419
   Tosini G, 2000, NEUROSCI LETT, V286, P119, DOI 10.1016/S0304-3940(00)01117-4
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Travis RC, 2003, CANCER EPIDEM BIOMAR, V12, P806
   Turner PL, 2008, BRIT J OPHTHALMOL, V92, P1439, DOI 10.1136/bjo.2008.141747
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887
   Uchino Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045805
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Vanselow JT, 2010, PROTEIN REV, V12, P79, DOI 10.1007/978-1-4419-1262-6_3
   Vinores SA, 1997, HISTOL HISTOPATHOL, V12, P99
   Wagner GC, 2007, EUR J NEUROSCI, V25, P485, DOI 10.1111/j.1460-9568.2006.05291.x
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang TA, 2012, SCIENCE, V337, P839, DOI 10.1126/science.1222826
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEAVER DR, 1993, J CLIN ENDOCR METAB, V76, P295, DOI 10.1210/jc.76.2.295
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu YH, 2007, SLEEP MED, V8, P623, DOI 10.1016/j.sleep.2006.11.010
   Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yoshida Y, 2009, DIABETES-METAB RES, V25, P678, DOI 10.1002/dmrr.1007
   Yoshida Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028227
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
   Zhang J, 2006, P NATL ACAD SCI USA, V103, P16212, DOI 10.1073/pnas.0604567103
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
   Zipfel PF, 2013, ADV EXP MED BIOL, V735, P173, DOI 10.1007/978-1-4614-4118-2_11
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 187
TC 52
Z9 55
U1 6
U2 40
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 7420637
DI 10.1155/2016/7420637
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DF6XX
UT WOS:000371502600001
PM 26885250
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Shoughy, SS
   Arevalo, JF
   Kozak, I
AF Shoughy, Samir S.
   Arevalo, J. Fernando
   Kozak, Igor
TI Update on wide- and ultra-widefield retinal imaging
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; ultra-widefield retinal imaging; widefield retinal imaging
ID SCANNING LASER OPHTHALMOSCOPY; ENDOTHELIAL GROWTH-FACTOR; DIABETIC
   MACULAR EDEMA; HIPPEL-LINDAU-DISEASE; FLUORESCEIN ANGIOGRAPHY;
   RISK-FACTORS; RETINOPATHY; AUTOFLUORESCENCE; MANAGEMENT; DEGENERATION
AB The peripheral retina is the site of pathology in many ocular diseases and ultra-widefield (UWF) imaging is one of the new technologies available to ophthalmologists to manage some of these diseases. Currently, there are several imaging systems used in practice for the purpose of diagnostic, monitoring disease progression or response to therapy, and telemedicine. These include modalities for both adults and pediatric patients. The current systems are capable of producing wide-and UWF color fundus photographs, fluorescein and indocyanine green angiograms, and autofluorescence images. Using this technology, important clinical observations have been made in diseases such as diabetic retinopathy, uveitides, retinal vascular occlusions and tumors, intraocular tumors, retinopathy of prematurity, and age-related macular degeneration. Widefield imaging offers excellent postoperative documentation of retinal detachment surgery. New applications will soon be available to integrate this technology into large volume routine clinical practice.
C1 [Shoughy, Samir S.] Ctr Eye, Riyadh, Saudi Arabia.
   [Shoughy, Samir S.] Eye Fdn Res Ophthalmol, Riyadh, Saudi Arabia.
   [Arevalo, J. Fernando; Kozak, Igor] King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia.
   [Arevalo, J. Fernando] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Baltimore, MD 21218 USA.
C3 The Eye Center - Riyadh; King Khaled Eye Specialist Hospital; Johns
   Hopkins University; Johns Hopkins Medicine
RP Kozak, I (通讯作者)，King Khalid Eye Specialist Hosp, Vitreoretinal & Uveitis Div, POB 7191, Riyadh 11462, Saudi Arabia.
EM ikozak@kkesh.med.sa
RI Kozak, Igor/AAC-4645-2019; Shoughy, Samir/J-2882-2019
OI Shoughy, Samir/0000-0002-9655-0669; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 2007, GLOB IN EL AV BLIND
   Beare N., 2014, SCI WORLD J, V2014
   Bell Darren J, 2004, Cancer Control, V11, P296
   Campbell JP, 2012, AM J OPHTHALMOL, V154, P908, DOI 10.1016/j.ajo.2012.05.019
   Chan RVP, 2010, RETINA-J RET VIT DIS, V30, P958, DOI 10.1097/IAE.0b013e3181c9696a
   Chew Emily Ying, 2005, Trans Am Ophthalmol Soc, V103, P495
   Ciardella A, 2007, FUNDUS FLUORESCEIN I, P79
   Do DV, 2006, RETINA, P1417
   Fijalkowski N, 2014, OSLI RETINA, V45, P106, DOI 10.3928/23258160-20140122-01
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gregori NZ, 2013, OPHTHALMOLOGY, V120, P169, DOI 10.1016/j.ophtha.2012.07.051
   Gupta V, 2014, SAUDI J OPHTHALMOL, V28, P95, DOI 10.1016/j.sjopt.2014.02.008
   Haddad NMN, 2013, SEMIN OPHTHALMOL, V28, P377, DOI 10.3109/08820538.2013.825281
   Kaines Andrew, 2009, Int Ophthalmol Clin, V49, P53, DOI 10.1097/IIO.0b013e31819fd471
   Kang KB, 2013, J PEDIAT OPHTH STRAB, V50, P282, DOI 10.3928/01913913-20130528-04
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Klein R, 1996, ANNU REV PUBL HEALTH, V17, P137
   Leder HA, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-30
   Lee B R, 2000, Korean J Ophthalmol, V14, P74
   Maamari RN, 2014, BRIT J OPHTHALMOL, V98, P438, DOI 10.1136/bjophthalmol-2013-303797
   Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827
   Mesquida M, 2014, RETINA-J RET VIT DIS, V34, P2121, DOI 10.1097/IAE.0000000000000197
   Muqit MMK, 2013, ACTA OPHTHALMOL, V91, P251, DOI 10.1111/j.1755-3768.2011.02307.x
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Oliver SCN, 2009, RETINAL ANGIOGRAPHY, P407
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Patel CK, 2013, EYE, V27, P589, DOI 10.1038/eye.2013.45
   Patel RD, 2013, AM J OPHTHALMOL, V155, P1038, DOI 10.1016/j.ajo.2013.01.007
   POMERANTZEFF O, 1975, INVEST OPHTH VISUAL, V14, P401
   Prasad PS, 2010, OPHTHALMOLOGY, V117, P780, DOI 10.1016/j.ophtha.2009.09.019
   Reznicek L, 2014, INT J OPHTHALMOL-CHI, V7, P697, DOI 10.3980/j.issn.2222-3959.2014.04.21
   Roth DB, 2001, ARCH OPHTHALMOL-CHIC, V119, P268
   Seidensticker F, 2011, CLIN OPHTHALMOL, V5, P1667, DOI 10.2147/OPTH.S26224
   SHIELDS CL, 1995, OPHTHALMOLOGY, V102, P1351, DOI 10.1016/S0161-6420(95)30864-0
   Shields JA, 2001, AM J OPHTHALMOL, V131, P561, DOI 10.1016/S0002-9394(00)00883-7
   Staurenghi G, 2005, ARCH OPHTHALMOL-CHIC, V123, P244, DOI 10.1001/archopht.123.2.244
   Tan CS, 2014, OSLI RETINA, V45, P363, DOI 10.3928/23258160-20140909-07
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tsui I, 2011, RETINA-J RET VIT DIS, V31, P105, DOI 10.1097/IAE.0b013e3181e36c6d
   Wessel MM, 2012, BRIT J OPHTHALMOL, V96, P694, DOI 10.1136/bjophthalmol-2011-300774
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
   Witmer MT, 2012, EYE, V26, P1209, DOI 10.1038/eye.2012.122
   Witmer MT, 2013, CLIN OPHTHALMOL, V7, P389, DOI 10.2147/OPTH.S41731
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   1981, INVEST OPHTHALMOL 2, V21, P1
NR 48
TC 25
Z9 25
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2015
VL 63
IS 7
BP 575
EP 581
DI 10.4103/0301-4738.167122
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU0YX
UT WOS:000363246700005
PM 26458474
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Craig, JE
   Hewitt, AW
   McMellon, AE
   Henders, AK
   Ma, LJ
   Wallace, L
   Sharma, S
   Burdon, KP
   Visscher, PM
   Montgomery, GW
   MacGregor, S
AF Craig, Jamie E.
   Hewitt, Alex W.
   McMellon, Amy E.
   Henders, Anjali K.
   Ma, Lingjun
   Wallace, Leanne
   Sharma, Shiwani
   Burdon, Kathryn P.
   Visscher, Peter M.
   Montgomery, Grant W.
   MacGregor, Stuart
TI Rapid inexpensive genome-wide association using pooled whole blood
SO GENOME RESEARCH
LA English
DT Article
ID COMMON SEQUENCE VARIANTS; FACTOR-H POLYMORPHISM; SKIN PIGMENTATION; DNA
   POOLS; GENE; HAPLOTYPE; EYE; SUSCEPTIBILITY; SAMPLES; SNP
AB Genome-wide association studies (GWAS) have now successfully identified important genetic variants associated with many human traits and diseases. The high cost of genotyping arrays in large data sets remains the major barrier to wider utilization of GWAS. We have developed a novel method in which whole blood from cases and controls, respectively, is pooled prior to DNA extraction for genotyping. We demonstrate proof of principle by clearly identifying the associated variants for eye color, age-related macular degeneration, and pseudoexfoliation syndrome in cohorts not previously studied. Blood pooling has the potential to reduce GWAS cost by several orders of magnitude and dramatically shorten gene discovery time. This method has profound implications for translation of modern genetic approaches to a multitude of diseases and traits yet to be analyzed by GWAS, and will enable developing nations to participate in GWAS.
C1 [Craig, Jamie E.; Hewitt, Alex W.; McMellon, Amy E.; Ma, Lingjun; Sharma, Shiwani; Burdon, Kathryn P.] Flinders Univ S Australia, Dept Ophthalmol, Bedford Pk, SA 5042, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Henders, Anjali K.; Wallace, Leanne; Visscher, Peter M.; Montgomery, Grant W.; MacGregor, Stuart] Queensland Inst Med Res, Genet & Populat Hlth, Herston, Qld 4029, Australia.
C3 Flinders University South Australia; Centre for Eye Research Australia;
   University of Melbourne; QIMR Berghofer Medical Research Institute
RP Craig, JE (通讯作者)，Flinders Univ S Australia, Dept Ophthalmol, Bedford Pk, SA 5042, Australia.
EM jamie.craig@flinders.edu.au; hewitt.alex@gmail.com
RI Macgregor, Stuart/C-6442-2009; Wallace, Leanne/V-2097-2018; Hewitt, Alex
   W/D-1936-2013; Burdon, Kathryn/A-5026-2009; Montgomery, Grant
   W/B-7148-2008; Burdon, Kathryn/AAD-2334-2022; Visscher,
   Peter/ABB-6151-2020; Henders, Anjali/E-3126-2017
OI Macgregor, Stuart/0000-0001-6731-8142; Wallace,
   Leanne/0000-0003-4310-7572; Hewitt, Alex W/0000-0002-5123-5999; Burdon,
   Kathryn/0000-0001-8217-1249; Montgomery, Grant W/0000-0002-4140-8139;
   Burdon, Kathryn/0000-0001-8217-1249; Visscher,
   Peter/0000-0002-2143-8760; Craig, Jamie/0000-0001-9955-9696; Sharma,
   Shiwani/0000-0002-0828-025X; Henders, Anjali/0000-0003-3672-1451
FU Ophthalmic Research Institute of Australia; Glaucoma Research
   Foundation; American Health Assistance Foundation; Australian National
   Health and Medical Research Council
FX The Ophthalmic Research Institute of Australia, the Glaucoma Research
   Foundation, the American Health Assistance Foundation, and the
   Australian National Health and Medical Research Council provided
   financial assistance. We thank Jozef Gecz and Nicholas Hayward for their
   helpful comments.
CR Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664
   Brown KM, 2008, NAT GENET, V40, P838, DOI 10.1038/ng.163
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Docherty SJ, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-3
   Duffy DL, 2007, AM J HUM GENET, V80, P241, DOI 10.1086/510885
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Graf J, 2007, HUM MUTAT, V28, P710, DOI 10.1002/humu.20504
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hewitt AW, 2008, HUM MOL GENET, V17, P710, DOI 10.1093/hmg/ddm342
   Homer N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000167
   Homer N, 2008, BIOINFORMATICS, V24, P1896, DOI 10.1093/bioinformatics/btn333
   Jawaid A, 2009, ANN HUM GENET, V73, P118, DOI 10.1111/j.1469-1809.2008.00486.x
   Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102
   Kirkpatrick B, 2007, BIOINFORMATICS, V23, P3048, DOI 10.1093/bioinformatics/btm435
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Macgregor S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl136
   Macgregor S, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1060
   Macgregor S, 2007, EUR J HUM GENET, V15, P501, DOI 10.1038/sj.ejhg.5201768
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Pearson JV, 2007, AM J HUM GENET, V80, P126, DOI 10.1086/510686
   Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6
   Sham P, 2002, NAT REV GENET, V3, P862, DOI 10.1038/nrg930
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Stokowski RP, 2007, AM J HUM GENET, V81, P1119, DOI 10.1086/522235
   Sturm RA, 2008, AM J HUM GENET, V82, P424, DOI 10.1016/j.ajhg.2007.11.005
   Sulem P, 2007, NAT GENET, V39, P1443, DOI 10.1038/ng.2007.13
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang H, 2008, BIOINFORMATICS, V24, P1942, DOI 10.1093/bioinformatics/btn324
NR 30
TC 34
Z9 35
U1 0
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD NOV
PY 2009
VL 19
IS 11
BP 2075
EP 2080
DI 10.1101/gr.094680.109
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 514WK
UT WOS:000271426600015
PM 19801603
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ferrara, N
   Damico, L
   Shams, N
   Lowman, H
   Kim, R
AF Ferrara, Napoleone
   Damico, Lisa
   Shams, Naveed
   Lowman, Henry
   Kim, Robert
TI Development of ranibizumab, an anti-vascular endothelial growth factor
   antigen binding fragment, as therapy for neovascular age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE vascular endothelial growth factor; monoclonal antibody; endothelium;
   angiogenesis; age-related macular degeneration; retinopathy
ID VASCULAR-PERMEABILITY FACTOR; HUMAN TUMOR XENOGRAFTS; FACTOR VEGF;
   CHOROIDAL NEOVASCULARIZATION; FACTOR ANTIBODY; CELL GROWTH; RETINAL
   NEOVASCULARIZATION; INTRAVITREAL INJECTION; BEVACIZUMAB AVASTIN;
   CRYSTAL-STRUCTURE
AB Background: Angiogenesis is a key aspect of the wet form of age-related neovascular (AMD), the leading cause of blindness in the elderly population. Substantial evidence indicated that vascular endothelial growth factor (VEGF)-A is a major mediator of angiogenesis and vascular leakage in wet AMD. VEGF-A is the prototype member of a gene family that includes also PIGF, VEGF-B, VEGF-C, VEGF-D and the orf virus-encoded VEGF-E. Several isoforms of VEGF-A can be generated due to alternative mRNA splicing. Various VEGF inhibitors have been clinically developed. Among these, ranibizumab is a high affinity recombinant Fab that neutralizes all isoforms of VEGF-A. The article briefly reviews the biology of VEGF and then focuses on the path that led to clinical development of ranibizumab.
   Results: The safety and efficacy of ranibizumab in the treatment of neovascular AMD have been evaluated in two large phase III, multicenter, randomized, double-masked, controlled pivotal trials in different neovascular AMD patient populations. Combined, the trial results indicate that ranibizumab results not only in a slowing down of vision loss but also in a significant proportion of patients experiencing a clinically meaningful vision gain. The visual acuity benefit over control was observed regardless of CNV lesion type. Furthermore, the benefit was associated with a low rate of serious adverse events.
   Conclusions: Ranibizumab represents a novel therapy that, for the first time, appears to have the potential to enable many AMD patients to obtain a meaningful and sustained gain of vision. On June 30 2006, ranibizurnab was approved by the US Food and Drug Administration for the treatment of wet AMD.
C1 Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baca M, 1997, J BIOL CHEM, V272, P10678
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRARA N, 1995, LAB INVEST, V72, P615
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Garner Alec, 1994, P1625
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Goldenberg DM, 2002, J NUCL MED, V43, P693
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, IN PRESS OPHTHALMOLO
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Klagsbrun M, 2005, CYTOKINE GROWTH F R, V16, P535, DOI 10.1016/j.cytogfr.2005.05.002
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUWABARA T, 1988, CELL TISSUE BIOL, P1069
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Matsumoto T., 2001, SCI STKE, V112, P1
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Morea V, 2000, METHODS, V20, P267, DOI 10.1006/meth.1999.0921
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133
   Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x
   Presta LG, 1997, CANCER RES, V57, P4593
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181
   Reff Mitchell E, 2002, Cancer Control, V9, P152
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROSENFELD PJ, 2006, IN PRESS N ENGL J ME
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   SMELSER G, 1965, EYE STRUCTURE
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
NR 117
TC 611
Z9 661
U1 1
U2 58
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2006
VL 26
IS 8
BP 859
EP 870
DI 10.1097/01.iae.0000242842.14624.e7
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AW
UT WOS:000246985400002
PM 17031284
DA 2022-11-30
ER

PT J
AU Lachmann, PJ
AF Lachmann, Peter J.
TI The story of complement factor I
SO IMMUNOBIOLOGY
LA English
DT Article
DE Complement; Conglutinin; Factor I; C3b feedback cycle; C3b breakdown
   cycle; Age related degeneration
ID NEPHRITIC FACTOR; ALTERNATIVE PATHWAY; C3B INACTIVATOR; FACTOR-H;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; INITIATING FACTOR;
   DOWN-REGULATION; 3RD COMPONENT; HUMAN SERUM; PURIFICATION
AB Factor I was first discovered in 1966. Its importance became apparent with the description of the original Factor I deficient patient in Boston in 1967. This patient presented with a hyperactive alternative complement pathway resulting in secondary complement deficiency due to continuous complement consumption. On the basis of these findings, the mechanism of the alternative pathway was worked out. In 1975, the surprise finding was made that elevating levels of Factor I in plasma down-regulated the alternative pathway. Attempts to exploit this finding for clinical use had a long and frustrating history and it was not until 2019 that the first patient was treated with the gene therapy vector for age related macular degeneration by Professor Sir Robert MacLaren in Oxford. This review follows the long and contorted course from initial observations to clinical use of complement Factor I.
C1 [Lachmann, Peter J.] Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.
C3 University of Cambridge
RP Lachmann, PJ (通讯作者)，Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.
EM pjl1000@cam.ac.uk
CR Ahmad A., 2017, MODULATION IMMUNE RE
   Alba-Dominguez M, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-42
   ALPER CA, 1970, J CLIN INVEST, V49, P1975, DOI 10.1172/JCI106417
   BAATRUP G, 1987, SCAND J IMMUNOL, V26, P355, DOI 10.1111/j.1365-3083.1987.tb02267.x
   Bordet J, 1909, ZENTR BAKTERIOL PARA, V49, P260
   CATTERALL CF, 1987, BIOCHEM J, V242, P849, DOI 10.1042/bj2420849
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Coombs R. A., 1961, SEROLOGY CONGLUTINAT
   COOMBS RRA, 1945, BRIT J EXP PATHOL, V26, P255
   DAVIS AE, 1977, NEW ENGL J MED, V297, P144, DOI 10.1056/NEJM197707212970306
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   FISHELSON Z, 1983, J BIOL CHEM, V258, P7411
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   HARRISON RA, 1980, MOL IMMUNOL, V17, P219, DOI 10.1016/0161-5890(80)90074-7
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   HSIUNG L, 1982, BIOCHEM J, V203, P293, DOI 10.1042/bj2030293
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Lachmann PJ, 2016, CLIN EXP IMMUNOL, V183, P150, DOI 10.1111/cei.12714
   LACHMANN P. J., 1965, CIBA FOUND SYMP, P242, DOI 10.1002/9780470719381.ch12
   Lachmann P. J., 1967, PROTIDES BIOL FLUIDS, V15, P469
   Lachmann P. J., 1974, SCHER S IMM 1973 PER, V12, P262
   Lachmann P. J., 1973, P 5 INT COMPL WORKSH, V111, P22289
   Lachmann PJ, 2018, J IMMUNOL METHODS, V457, P30, DOI 10.1016/j.jim.2018.03.013
   Lachmann PJ, 2018, IMMUNOBIOLOGY, V223, P519, DOI 10.1016/j.imbio.2018.02.001
   Lachmann PJ, 2018, FASEB J, V32, P123, DOI 10.1096/fj.201700734
   LACHMANN PJ, 1971, IMMUNOCHEMISTRY, V8, P81, DOI 10.1016/0019-2791(71)90423-X
   LACHMANN PJ, 1962, J EXP MED, V115, P63, DOI 10.1084/jem.115.1.63
   LACHMANN PJ, 1973, LANCET, V1, P465
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   LACHMANN PJ, 1968, J IMMUNOL, V100, P691
   Lay E, 2015, CLIN EXP IMMUNOL, V181, P314, DOI 10.1111/cei.12437
   LEVY LR, 1959, P SOC EXP BIOL MED, V101, P608
   LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109
   MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827
   MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739
   MULLEREBERHARD HJ, 1960, J EXP MED, V111, P201, DOI 10.1084/jem.111.2.201
   NICOL PAE, 1973, IMMUNOLOGY, V24, P259
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Sadallah S, 1999, AM J KIDNEY DIS, V33, P1153, DOI 10.1016/S0272-6386(99)70155-1
   Scholl HPN, 2007, MOL VIS, V13, P196
   SCHREIBER RD, 1976, SCAND J IMMUNOL, V5, P705, DOI 10.1111/j.1365-3083.1976.tb03020.x
   SCHREIBER RD, 1976, J EXP MED, V144, P1062, DOI 10.1084/jem.144.4.1062
   SCOTT DM, 1978, CLIN EXP IMMUNOL, V32, P12
   SCOTT DM, 1981, CLIN EXP IMMUNOL, V46, P120
   SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   SPITZER RE, 1969, SCIENCE, V164, P436, DOI 10.1126/science.164.3878.436
   TAMURA N, 1967, J IMMUNOL, V99, P582
   THOMPSON RA, 1972, BRIT MED J, V1, P282, DOI 10.1136/bmj.1.5795.282
   THOMPSON RA, 1977, CLIN EXP IMMUNOL, V27, P23
   TORISU M, 1968, NATURE, V218, P1163, DOI 10.1038/2181163a0
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Yaseen S, 2017, FASEB J, V31, P2210, DOI 10.1096/fj.201601306R
   ZIEGLER JB, 1975, J CLIN INVEST, V55, P668, DOI 10.1172/JCI107975
NR 61
TC 15
Z9 15
U1 0
U2 3
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD JUL
PY 2019
VL 224
IS 4
BP 511
EP 517
DI 10.1016/j.imbio.2019.05.003
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA IQ5XQ
UT WOS:000480826300006
PM 31109748
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nguyen, HV
   Li, Y
   Tsang, SH
AF Nguyen, Huy V.
   Li, Yao
   Tsang, Stephen H.
TI Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE retinal disease; induced pluripotent stem cells; gene therapy
ID PLURIPOTENT STEM-CELLS; FRIZZLED-RELATED PROTEIN; DIRECTED
   DIFFERENTIATION; PRECLINICAL MODEL; TRANSPLANTATION; MACROPHAGES;
   INDUCTION; MOUSE; FORM; CAS9
AB Inherited retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world. Currently, treatments for these conditions are limited. Recently, considerable attention has been given to the possibility of using patient-specific induced pluripotent stem cells (iPSCs) as a treatment for these conditions. iPSCs reprogrammed from adult somatic cells offer the possibility of generating patient-specific cell lines in vitro. In this review, we will discuss the current literature pertaining to iPSC modeling of retinal disease, gene therapy of iPSC-derived retinal pigmented epithelium (RPE) cells, and retinal transplantation. We will focus on the use of iPSCs created from patients with inherited eye diseases for testing the efficacy of gene or drug-based therapies, elucidating previously unknown mechanisms and pathways of disease, and as a source of autologous cells for cell replacement.
C1 [Nguyen, Huy V.] Columbia Univ, Coll Phys & Surg, 100 Haven Ave,Apt 14B, New York, NY 10032 USA.
   [Li, Yao; Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Nguyen, HV (通讯作者)，Columbia Univ, Coll Phys & Surg, 100 Haven Ave,Apt 14B, New York, NY 10032 USA.
EM hvnguyen10@gmail.com; yl2635@columbia.edu; sht2@columbia.edu
FU Tistou and Charlotte Kerstan Foundation; NIH [R01EY018213]; Research to
   Prevent Blindness Physician-Scientist Award; Schneeweiss Stem Cell Fund;
   New York State [N09G-302, N13G-275]; Foundation Fighting Blindness New
   York Regional Research Center Grant [C-NY05-0705-0312]; Joel Hoffman
   Fund; Gale and Richard Siegel Stem Cell Fund; Charles Culpeper
   Scholarship; Laszlo Bito and Olivia Carino Foundation; Irma T. Hirschl
   Charitable Trust; Bernard and Anne Spitzer Stem Cell Fund; Gertrude
   Rothschild Stem Cell Foundation; Gebroe Family Foundation; RPB Medical
   Student Fellowship
FX Stephen H. Tsang is a member of the RD-CURE Consortium and is supported
   by Tistou and Charlotte Kerstan Foundation, NIH R01EY018213, the
   Research to Prevent Blindness Physician-Scientist Award, the Schneeweiss
   Stem Cell Fund, New York State (N09G-302 and N13G-275), and the
   Foundation Fighting Blindness New York Regional Research Center Grant
   (C-NY05-0705-0312), the Joel Hoffman Fund, Gale and Richard Siegel Stem
   Cell Fund, Charles Culpeper Scholarship, Laszlo Bito and Olivia Carino
   Foundation, Irma T. Hirschl Charitable Trust, Bernard and Anne Spitzer
   Stem Cell Fund, Gertrude Rothschild Stem Cell Foundation, and Gebroe
   Family Foundation. Huy V. Nguyen is supported by the RPB Medical Student
   Fellowship.
CR Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108
   Bilic J, 2012, STEM CELLS, V30, P33, DOI 10.1002/stem.700
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cereso N, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.11
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Cyranoski D, 2013, NATURE, V494, P413, DOI 10.1038/494413a
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006
   Hou ZG, 2013, P NATL ACAD SCI USA, V110, P15644, DOI 10.1073/pnas.1313587110
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Liu ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066369
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Minegishi Y, 2013, HUM MOL GENET, V22, P3559, DOI 10.1093/hmg/ddt210
   Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001
   Morizane A, 2013, STEM CELL REP, V1, P283, DOI 10.1016/j.stemcr.2013.08.007
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Phillips CO, 2009, ARCH INTERN MED, V169, P1180, DOI 10.1001/archinternmed.2009.195
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tsuji O, 2010, P NATL ACAD SCI USA, V107, P12704, DOI 10.1073/pnas.0910106107
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   Tucker BA, 2014, HUM MOL GENET, V23, pR9, DOI 10.1093/hmg/ddu124
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023
   Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788
NR 49
TC 23
Z9 24
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2015
VL 4
IS 4
BP 567
EP 578
DI 10.3390/jcm4040567
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9LQ
UT WOS:000363138900004
PM 26239347
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Bayar, SA
   Altinors, DD
   Kucukerdonmez, C
   Akova, YA
AF Bayar, Sezin Akca
   Altinors, Dilek D.
   Kucukerdonmez, Cem
   Akova, Yonca A.
TI Severe Corneal Changes following Intravitreal Injection of Bevacizumab
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE avastin; bevacizumab; cornea; changes; intravitreal injection
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; AVASTIN INJECTION;
   POVIDONE-IODINE; FACTOR THERAPY; SAFETY; DISEASE; CELLS
AB Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration.
   Design: Retrospective noncomparative case series.
   Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab.
   Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period.
   Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.
C1 [Bayar, Sezin Akca; Altinors, Dilek D.; Kucukerdonmez, Cem; Akova, Yonca A.] Baskent Univ Hosp, Dept Ophthalmol, TR-06490 Ankara, Turkey.
C3 Baskent University
RP Bayar, SA (通讯作者)，Baskent Univ Hosp, Dept Ophthalmol, Fevzi Cakmak Cad 10, TR-06490 Ankara, Turkey.
EM sezinakca@gmail.com
RI Altınörs, Dilek Dursun/AAK-8077-2021; Bayar, Sezin Akca/AAJ-2406-2021;
   Akova, Yonca/AAD-1036-2020
OI Altınörs, Dilek Dursun/0000-0001-5223-0279; Bayar, Sezin
   Akca/0000-0001-5109-755X; 
CR Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Alp BN, 2000, CORNEA, V19, P546, DOI 10.1097/00003226-200007000-00028
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Khalili MR, 2009, CORNEA, V28, P360, DOI 10.1097/ICO.0b013e318189137a
   KIM TI, 2009, INVEST OPHTHALM 0520
   Lerhaupt KE, 2006, CUTAN OCUL TOXICOL, V25, P63, DOI 10.1080/15569520600695512
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Noar J, 2001, J CATARACT REFR SURG, V27, P941, DOI 10.1016/S0886-3350(00)00750-1
   Park HY, 2008, CORNEA, V27, P1151, DOI 10.1097/ICO.0b013e318180e572
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shalam KV, 2009, CORNEA, V28, P328, DOI 10.1097/ICO.0b013e31818b8be0
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   van Setten GB, 1997, ACTA OPHTHALMOL SCAN, V75, P649
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yu CQ, 2008, INVEST OPHTH VIS SCI, V49, P3870, DOI 10.1167/iovs.07-1418
NR 27
TC 15
Z9 15
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD AUG
PY 2010
VL 18
IS 4
BP 268
EP 274
DI 10.3109/09273948.2010.490630
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 638ZD
UT WOS:000280939000006
PM 20662658
DA 2022-11-30
ER

PT J
AU Das, UN
AF Das, Undurti N.
TI Pathological retinal angiogenesis and polyunsaturated fatty acids
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; RETINOPATHY; PERSISTENT; VESSELS
AB Retinopathy of prematurity in children, diabetic retinopathy, and age-related macular degeneration (AMD) are characterized by vessel loss followed by hypoxia-driven destructive neovascularization. Damage to the retinal pigment epithelium and a chronic aberrant inflammatory, response increase the expression of vascular endothelial growth factor (VEGF) and tumour necrosis factor-alpha (TNF-alpha) that initiate and perpetuate pathological retinal angiogenesis. Anti-VEGF approaches are of limited benefit in the treatment of AMD, diabetic retinopathy, and retinopathy of prematurity. Polyunsaturated fatty acids (PUFAs): arachidonic (AA), eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), and their products lipoxins, resolvins, and protectins play an important role in the pathogenesis of pathological retinopathy in view of their anti-inflammatory; wound healing, and neuroprotective actions. Lipoxins, resolvins and protectins prevented hyperoxia-induced retinopathy in experimental animals suggesting that they are useful in the prevention and treatment of destructive angiogenesis.
C1 [Das, Undurti N.] UND Life Sci, Shaker Hts, OH 44120 USA.
   [Das, Undurti N.] Bharati Vidyapeeth Univ, Coll Med, Dept Med, Pune, Maharashtra, India.
   [Das, Undurti N.] IKP Ctr Technol Publ Hlth, Hyderabad 500078, Andhra Pradesh, India.
C3 Bharati Vidyapeeth Deemed University
RP Das, UN (通讯作者)，UND Life Sci, 13800 Fairhill Rd,321, Shaker Hts, OH 44120 USA.
FU Department of Biotechnology, New Delhi, India
FX UND was in receipt of Ramalingaswami Fellowship of Department of
   Biotechnology, New Delhi, India during the tenure of this study.
CR Acevedo LM, 2008, NAT MED, V14, P372, DOI 10.1038/nm0408-372
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Das UN, 2005, MED SCI MONITOR, V11, pRA233
   Das Undurti N., 2006, Biotechnology Journal, V1, P420, DOI 10.1002/biot.200600012
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kermorvant-Duchemin E, 2005, NAT MED, V11, P1339, DOI 10.1038/nm1336
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
NR 13
TC 8
Z9 8
U1 0
U2 2
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD NOV-DEC
PY 2008
VL 19
IS 6
BP 44
EP 49
PG 6
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 404QV
UT WOS:000263169000012
DA 2022-11-30
ER

PT J
AU Kim, ES
   Lee, MS
   Jeong, H
   Lim, SY
   Kim, D
   Kim, D
   Jung, J
   Lyu, S
   Cho, HJ
   Kim, DM
   Suh, W
   Jeong, JH
AF Kim, E. Seul
   Lee, Min Sang
   Jeong, Hayoung
   Lim, Su Yeon
   Kim, Doha
   Kim, Dahwun
   Jung, Jaeback
   Lyu, Siyan
   Cho, Hee Joo
   Kim, Dong Min
   Suh, Wonhee
   Jeong, Ji Hoon
TI Sustained-Release Microspheres of Rivoceranib for the Treatment of
   Subfoveal Choroidal Neovascularization
SO PHARMACEUTICS
LA English
DT Article
DE rivoceranib; drug repositioning; microsphere; subfoveal choroidal
   neovascularization; macular degeneration
ID BIODEGRADABLE MICROSPHERES; OCULAR NEOVASCULARIZATION; MACULAR
   DEGENERATION; LOADED NANOPARTICLES; RETINAL DISEASES; DELIVERY; VEGF;
   APATINIB
AB The wet type of age-related macular degeneration (AMD) accompanies the subfoveal choroidal neovascularization (CNV) caused by the abnormal extension or remodeling of blood vessels to the macula and retinal pigment epithelium (RPE). Vascular endothelial growth factor (VEGF) is known to play a crucial role in the pathogenesis of the disease. In this study, we tried to repurpose an investigational anticancer drug, rivoceranib, which is a selective inhibitor of VEGF receptor-2 (VEGFR2), and evaluate the therapeutic potential of the drug for the treatment of wet-type AMD in a laser-induced CNV mouse model using microsphere-based sustained drug release formulations. The PLGA-based rivoceranib microsphere can carry out a sustained delivery of rivoceranib for 50 days. When administered intravitreally, the sustained microsphere formulation of rivoceranib effectively inhibited the formation of subfoveal neovascular lesions in mice.
C1 [Kim, E. Seul; Lee, Min Sang; Lim, Su Yeon; Kim, Dahwun; Jung, Jaeback; Lyu, Siyan; Cho, Hee Joo; Kim, Dong Min; Jeong, Ji Hoon] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.
   [Jeong, Hayoung; Kim, Doha; Suh, Wonhee] Chung Ang Univ, Dept Global Innovat Drug, Grad Sch, Seoul 06974, South Korea.
   [Jeong, Hayoung; Kim, Doha; Suh, Wonhee] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
C3 Sungkyunkwan University (SKKU); Chung Ang University; Chung Ang
   University
RP Jeong, JH (通讯作者)，Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea.; Suh, W (通讯作者)，Chung Ang Univ, Dept Global Innovat Drug, Grad Sch, Seoul 06974, South Korea.; Suh, W (通讯作者)，Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
EM seul4146@skku.edu; lminsa@skku.edu; gkdud819@naver.com;
   kally37@naver.com; summerflow02@gmail.com; gnjs0219@naver.com;
   domonde@naver.com; lsy2018dd@hotmail.com; chohj823@naver.com;
   eastjade@g.skku.edu; wsuh@cau.ac.kr; jhjeong@skku.edu
OI suh, wonhee/0000-0001-5811-0833; Jeong, Ji Hoon/0000-0002-4836-3551
FU National Research Foundation of Korea (NRF) [2018M3A9B502131913,
   2020R1A4A4079931, 2020R1A2C2010449]; Ministry of Science and ICT (MSIT)
FX This research was supported by the National Research Foundation of Korea
   (NRF) grants (2018M3A9B502131913, 2020R1A4A4079931, 2020R1A2C2010449)
   funded by the Ministry of Science and ICT (MSIT).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOTHA SA, 1990, DRUG DEV IND PHARM, V16, P673, DOI 10.3109/03639049009104410
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chen WL, 2017, MOL PHARMACEUT, V14, P459, DOI 10.1021/acs.molpharmaceut.6b00896
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeong JH, 2016, INT J NANOMED, V11, P3101, DOI 10.2147/IJN.S108452
   Kang H, 2020, J CLIN ONCOL, V38
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kumar N, 2014, J THERM ANAL CALORIM, V115, P2375, DOI 10.1007/s10973-013-3237-6
   Lee JE, 2017, INT J NANOMED, V12, P4813, DOI 10.2147/IJN.S135133
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mietzner R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080706
   Mohamed AI, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010007
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Prajapati VD, 2015, EXPERT OPIN DRUG DEL, V12, P1283, DOI 10.1517/17425247.2015.1015985
   Qiao MX, 2005, INT J PHARM, V294, P103, DOI 10.1016/j.ijpharm.2005.01.017
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Zhang ZR, 2018, DRUG DELIV, V25, P166, DOI 10.1080/10717544.2017.1422296
NR 30
TC 0
Z9 0
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD OCT
PY 2021
VL 13
IS 10
AR 1548
DI 10.3390/pharmaceutics13101548
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA YC1UU
UT WOS:000739484000001
PM 34683841
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Alizadeh, E
   Mammadzada, P
   Andre, H
AF Alizadeh, Effat
   Mammadzada, Parviz
   Andre, Helder
TI The Different Facades of Retinal and Choroidal Endothelial Cells in
   Response to Hypoxia
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE choroidal endothelial cells; retinal endothelial cells; hypoxia;
   angiogenesis; differential expression
ID INDUCIBLE FACTOR-I; GLUCOCORTICOID-RECEPTOR AGONIST; GROWTH-FACTOR
   EXPRESSION; DIABETIC MACULAR EDEMA; ANTI-VEGF; PIGMENT EPITHELIUM;
   GENE-EXPRESSION; TISSUE FACTOR; INTUSSUSCEPTIVE ANGIOGENESIS;
   FACTOR-1-ALPHA AND-2-ALPHA
AB Ocular angiogenic diseases, such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, are associated with severe loss of vision. These pathologies originate from different vascular beds, retinal and choroidal microvasculatures, respectively. The activation of endothelial cells (EC) plays pivotal roles in angiogenesis, often triggered by oxygen deficiency. Hypoxia-inducible factors in ECs mediate the transcription of multiple angiogenic genes, including the canonical vascular endothelial growth factors. ECs show notable heterogeneity in function, structure, and disease, therefore the understanding of retinal/choroidal ECs (REC; CEC) biochemical and molecular responses to hypoxia may offer key insights into tissue-specific vascular targeting treatments. The aim of this review is to discuss the differences spanning between REC and CEC, with focus on their response to hypoxia, which could provide innovative and sustainable strategies for site specific targeting of ocular neovascularization.
C1 [Alizadeh, Effat; Mammadzada, Parviz; Andre, Helder] Karolinska Inst, St Erik Eye Hosp, Dept Clin Neurosci, S-11282 Stockholm, Sweden.
   [Alizadeh, Effat] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz 516615731, Iran.
C3 Karolinska Institutet; Tabriz University of Medical Science
RP Andre, H (通讯作者)，Karolinska Inst, St Erik Eye Hosp, Dept Clin Neurosci, S-11282 Stockholm, Sweden.
EM alizadehe@tbzmed.ac.ir; Parviz.Mammadzada@ki.se; Helder.Andre@ki.se
RI Andre, Helder/AAC-5220-2019
OI Andre, Helder/0000-0002-2926-2376; Mammadzada,
   Parviz/0000-0003-4171-5291
FU Karolinska Institutet Foundations; University of Medical Sciences,
   Tabriz, Iran
FX This research was supported by the Karolinska Institutet Foundations.
   E.A. was partly supported by a personal grant from the University of
   Medical Sciences, Tabriz, Iran.
CR Abu El-Asrar AM, 2007, BRIT J OPHTHALMOL, V91, P822, DOI 10.1136/bjo.2006.109876
   Adair T.H., 2010, ANGIOGENESIS
   Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   AMES A, 1992, CAN J PHYSIOL PHARM, V70, pS158, DOI 10.1139/y92-257
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Anand-Apte B., 2010, DEV ANATOMY RETINAL
   Andre H, 2008, J BIOL CHEM, V283, P29375, DOI 10.1074/jbc.M805919200
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Armbruster NS, 2016, J IMMUNOL, V196, P1284, DOI 10.4049/jimmunol.1502232
   Atkuri KR, 2007, P NATL ACAD SCI USA, V104, P4547, DOI 10.1073/pnas.0611732104
   Azhdari M, 2013, STEM CELL RES, V10, P288, DOI 10.1016/j.scr.2012.12.004
   Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3
   Baharivand N, 2012, CLIN OPHTHALMOL, V6, P185, DOI 10.2147/OPTH.S27423
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Barben M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0243-y
   Bharadwaj AS, 2013, PROG RETIN EYE RES, V32, P102, DOI 10.1016/j.preteyeres.2012.08.004
   Biswal MR, 2018, J MOL MED, V96, P1107, DOI 10.1007/s00109-018-1683-0
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   Browning AC, 2005, BRIT J OPHTHALMOL, V89, P1343, DOI 10.1136/bjo.2004.063602
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, P128, DOI 10.1136/bjophthalmol-2011-300572
   Brylla E, 2003, EXP EYE RES, V77, P527, DOI 10.1016/S0014-4835(03)00219-7
   Burri PH, 2004, DEV DYNAM, V231, P474, DOI 10.1002/dvdy.20184
   Byrne MB, 2014, TRENDS BIOTECHNOL, V32, P556, DOI 10.1016/j.tibtech.2014.09.006
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cammalleri M, 2017, INVEST OPHTH VIS SCI, V58, P3138, DOI 10.1167/iovs.17-21593
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Caprara V, 2014, LIFE SCI, V118, P185, DOI 10.1016/j.lfs.2014.02.030
   Carneiro A, 2009, ACTA OPHTHALMOL, V87, P517, DOI 10.1111/j.1755-3768.2008.01257.x
   Cartwright S, 2014, SEMIN CELL DEV BIOL, V29, P169, DOI 10.1016/j.semcdb.2013.12.010
   Cattaneo F, 2010, NEUROCHEM RES, V35, P2018, DOI 10.1007/s11064-010-0301-5
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Curren RD, 2002, ATLA-ALTERN LAB ANIM, V30, P69, DOI 10.1177/026119290203002S10
   Dal Monte M, 2015, INVEST OPHTH VIS SCI, V56, P2392, DOI 10.1167/iovs.14-16323
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286
   Dougherty CJ, 2008, MOL VIS, V14, P471
   Dubail J, 2015, MATRIX BIOL, V44-46, P24, DOI 10.1016/j.matbio.2015.03.001
   Dus D, 2003, IMMUNOL LETT, V86, P163, DOI 10.1016/S0165-2478(03)00018-X
   Eden G, 2011, CURR PHARM DESIGN, V17, P1874, DOI 10.2174/138161211796718215
   Elliott NT, 2011, J PHARM SCI-US, V100, P59, DOI 10.1002/jps.22257
   Ergul A, 2011, PHARMACOL RES, V63, P477, DOI 10.1016/j.phrs.2011.01.012
   Evans JR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011234.pub2
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Formenti F, 2010, P NATL ACAD SCI USA, V107, P12722, DOI 10.1073/pnas.1002339107
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fraser HM, 2008, ENDOCRINOLOGY, V149, P4413, DOI 10.1210/en.2008-0325
   Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0
   Gerhardt H, 2008, ORGANOGENESIS, V4, P241, DOI [DOI 10.4161/0RG.4.4.7414, DOI 10.4161/org.4.4.7414]
   Ghasemi M, 2018, ARTIF CELL NANOMED B, V46, P1694, DOI 10.1080/21691401.2017.1391820
   GITLIN JD, 1983, MICROVASC RES, V26, P74, DOI 10.1016/0026-2862(83)90056-0
   Giurdanella G, 2017, BIOCHEM PHARMACOL, V142, P145, DOI 10.1016/j.bcp.2017.06.130
   Grimsey NJ, 2015, J CELL BIOL, V210, P1117, DOI 10.1083/jcb.201504007
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hoang S, 2009, J CEREBR BLOOD F MET, V29, P385, DOI 10.1038/jcbfm.2008.128
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Holekamp NM, 2006, AM J OPHTHALMOL, V141, P1027, DOI 10.1016/j.ajo.2006.01.016
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099
   Jimenez N, 2013, CYTOTECHNOLOGY, V65, P1, DOI 10.1007/s10616-012-9459-9
   Kaufman PL, 2011, ADLERS PHYSL EYE
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lambert E, 2012, J BIOL CHEM, V287, P3987, DOI 10.1074/jbc.M111.289371
   Lange J, 2012, GLIA, V60, P1567, DOI 10.1002/glia.22376
   Larrieu-Lahargue F, 2012, TRENDS CARDIOVAS MED, V22, P44, DOI 10.1016/j.tcm.2012.06.010
   Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X
   Lee YC, 2018, MOL NEUROBIOL, V55, P7743, DOI 10.1007/s12035-018-0867-5
   Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105
   Leonard SS, 2004, FREE RADICAL BIO MED, V37, P1921, DOI 10.1016/j.freeradbiomed.2004.09.010
   Li YM, 2017, J CELL MOL MED, V21, P1555, DOI 10.1111/jcmm.13086
   Lim JI, 2010, RETINA-J RET VIT DIS, V30, P1472, DOI 10.1097/IAE.0b013e3181d6df09
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002
   Loboda A, 2006, VASC PHARMACOL, V44, P206, DOI 10.1016/j.vph.2005.11.007
   Lupo G, 2013, BIOCHEM PHARMACOL, V86, P1603, DOI 10.1016/j.bcp.2013.09.008
   Mammadzada P, 2016, ACTA OPHTHALMOL, V94, P805, DOI [10.1111/aos.13119, 10.1111/j.1755-3768.2016.0399]
   MARUYAMA Y, 1963, Z ZELLFORSCH MIK ANA, V60, P69, DOI 10.1007/BF00329383
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McLeod LL, 1997, FREE RADICAL BIO MED, V23, P680, DOI 10.1016/S0891-5849(97)00055-5
   McLeod LL, 1999, AM J PHYSIOL-HEART C, V277, pH92, DOI 10.1152/ajpheart.1999.277.1.H92
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mirshahi A, 2008, EUR J OPHTHALMOL, V18, P263, DOI 10.1177/112067210801800215
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231
   Nagle DG, 2006, CURR PHARM DESIGN, V12, P2673, DOI 10.2174/138161206777698783
   Newsam JM, 2005, J MATER CHEM, V15, P3061, DOI 10.1039/b416210b
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Neill CL, 2016, CARDIOVASC RES, V112, P677, DOI 10.1093/cvr/cvw209
   Patel C, 2014, AM J PATHOL, V184, P3040, DOI 10.1016/j.ajpath.2014.07.012
   Paternotte E, 2008, BIO-MED MATER ENG, V18, P295, DOI 10.3233/BME-2008-0541
   Peet DJ, 2017, EXP CELL RES, V356, P136, DOI 10.1016/j.yexcr.2017.03.030
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7
   Piekny AJ, 2010, SEMIN CELL DEV BIOL, V21, P881, DOI 10.1016/j.semcdb.2010.08.002
   Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x
   Prevete N, 2015, PHARMACOL RES, V102, P184, DOI 10.1016/j.phrs.2015.09.017
   Proksch JW, 2011, DRUG METAB DISPOS, V39, P1181, DOI 10.1124/dmd.111.039099
   Querques G, 2015, OPHTHALMIC RES, V53, P194, DOI 10.1159/000379754
   Rong Y, 2006, CANCER RES, V66, P7067, DOI 10.1158/0008-5472.CAN-06-0346
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   RYMASZEWSKI Z, 1992, P SOC EXP BIOL MED, V199, P183
   SAKAMOTO T, 1995, CURR EYE RES, V14, P621, DOI 10.3109/02713689508998488
   Saker S, 2014, EXP EYE RES, V121, P161, DOI 10.1016/j.exer.2014.02.016
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Sears Jonathan E, 2013, Trans Am Ophthalmol Soc, V111, P169
   Shafaie S, 2016, BIORESEARCH OPEN ACC, V5, DOI 10.1089/biores.2016.0008
   Shafiee A, 2011, INVEST OPHTH VIS SCI, V52, P1422, DOI 10.1167/iovs.10-5598
   Sheibani Nader, 2013, J Ophthalmic Vis Res, V8, P1
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Skeie J.M., 2010, THESIS
   Smith JR, 2007, INVEST OPHTH VIS SCI, V48, P2676, DOI 10.1167/iovs.06-0598
   Smith JR, 2018, AM J OPHTHALMOL, V193, P197, DOI 10.1016/j.ajo.2018.03.020
   Sorenson CM, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.S12-005
   Sprague LD, 2007, ONCOL REP, V17, P1259
   Staton CA, 2009, INT J EXP PATHOL, V90, P195, DOI 10.1111/j.1365-2613.2008.00633.x
   Staurenghi G, 2015, OPHTHALMOLOGY, V122, P990, DOI 10.1016/j.ophtha.2014.12.014
   Stenger C, 2011, INT J ONCOL, V39, P601, DOI 10.3892/ijo.2011.1083
   Stewart EA, 2011, EXP EYE RES, V93, P761, DOI 10.1016/j.exer.2011.09.010
   Sugioka K, 2013, EXP EYE RES, V115, P13, DOI 10.1016/j.exer.2013.06.020
   Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028
   Takei A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42546
   Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026
   Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669
   Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188
   Tsutsui K, 2010, J BIOL CHEM, V285, P4870, DOI 10.1074/jbc.M109.076919
   Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013
   Tudisco L, 2017, ONCOTARGET, V8, P32873, DOI 10.18632/oncotarget.15861
   Ubels JL, 2005, OCUL SURF, V3, P126, DOI 10.1016/S1542-0124(12)70195-7
   Uhrin P, 2013, CELL ADHES MIGR, V7, P23, DOI 10.4161/cam.22124
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034
   Wang B, 2003, J OCUL PHARMACOL TH, V19, P457, DOI 10.1089/108076803322473015
   Wang L, 2014, EXP EYE RES, V127, P117, DOI 10.1016/j.exer.2014.07.006
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weckbach LT, 2012, AM J PHYSIOL-HEART C, V303, pH429, DOI 10.1152/ajpheart.00934.2011
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Whitcup SM, 2018, INVEST OPHTH VIS SCI, V59, P1, DOI 10.1167/iovs.17-22259
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   WOJTA J, 1988, BLOOD, V71, P1703
   Wroblewski JJ, 2010, AM J OPHTHALMOL, V149, P147, DOI 10.1016/j.ajo.2009.08.005
   WU DL, 2011, JOVE J VIS EXP AUG, DOI DOI 10.3791/2899
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
   Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200
   Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200
   Yan HT, 2014, ASIAN PAC J TROP MED, V7, P237, DOI 10.1016/S1995-7645(14)60028-6
   Yang JS, 2005, J BIOL CHEM, V280, P36047, DOI 10.1074/jbc.M501755200
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhu J, 2012, CANCER SCI, V103, P2092, DOI 10.1111/cas.12020
   Zhu YL, 2013, MOL VIS, V19, P2360
NR 166
TC 24
Z9 24
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2018
VL 19
IS 12
AR 3846
DI 10.3390/ijms19123846
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HG9JM
UT WOS:000455323500148
PM 30513885
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Re, RN
AF Re, Richard N.
TI A Pathogenic Mechanism Potentially Operative in Multiple Progressive
   Diseases and Its Therapeutic Implications
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE Intracrine; Chronic renal disease; Heart failure; Age-related macular
   degeneration; Neurodegenerative diseases; Renin-angiotensin system
ID RENIN-ANGIOTENSIN SYSTEM; GROWTH-FACTOR-BETA; EPITHELIAL-CELLS;
   INTRACELLULAR RENIN; MESSENGER-RNA; UP-REGULATION; IN-VITRO; MESENCHYMAL
   TRANSITION; INTRACRINE HYPOTHESIS; PARKINSONS-DISEASE
AB A variety of peptide signaling moieties that we have termed intracrines can act in the interiors of their cells of synthesis or of target cells after internalization. These intracrine factors are known to be upregulated in such disorders as diabetic nephropathy, systolic heart failure, and age-related macular degeneration. Indeed, a similar set of intracrines is upregulated in each of these disorders, suggesting a commonality of mechanism. In addition, several chronic neurodegenerative disorders such as Alzheimer disease and Parkinson disease involve intercellular trafficking of intracellular disease-causing proteins. These disorders can be considered intracrine-like. Here the mechanistic and therapeutic implications of these observations, and of the relevant modes of intracrine action, are discussed, including the possibility that similar therapeutic approaches could be effective in multiple progressive disorders and the implications of these observations for intracrine pharmacology in general.
C1 [Re, Richard N.] Ochsner Clin Fdn, Div Acad Res, 1514 Jefferson Highway, New Orleans, LA 70121 USA.
C3 Ochsner Health System
RP Re, RN (通讯作者)，Ochsner Clin Fdn, Div Acad Res, 1514 Jefferson Highway, New Orleans, LA 70121 USA.
EM rre@ochsner.org
FU Ochsner Clinic Foundation
FX This work was supported by the Ochsner Clinic Foundation.
CR Abadir PM, 2011, P NATL ACAD SCI USA, V108, P14849, DOI 10.1073/pnas.1101507108
   Abeyrathna P, 2016, AM J PHYSIOL-CELL PH, V311, pC24, DOI 10.1152/ajpcell.00295.2015
   Ahmad S, 2016, BIOCHEM BIOPH RES CO, V478, P559, DOI 10.1016/j.bbrc.2016.07.100
   Alzayadneh EM, 2015, J RENIN-ANGIO-ALDO S, V16, P1135, DOI 10.1177/1470320313515039
   Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200
   Borges FT, 2013, J AM SOC NEPHROL, V24, P385, DOI 10.1681/ASN.2012101031
   Brezniceanu ML, 2006, KIDNEY INT, V69, P1977, DOI 10.1038/sj.ki.5000396
   Cervio E, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/482171
   Chen JC, 2012, MOL CELL BIOL, V32, P981, DOI 10.1128/MCB.06410-11
   Colby DW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a006833
   Concha-Marambio L, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6188
   Cook JL, 2002, J MOL CELL CARDIOL, V34, P1525, DOI 10.1006/jmcc.2002.2106
   Cook JL, 2001, CIRC RES, V89, P1138, DOI 10.1161/hh2401.101270
   Cook JL, 2012, AM J PHYSIOL-REG I, V302, pR482, DOI 10.1152/ajpregu.00493.2011
   Dachsel JC, 2007, MOVEMENT DISORD, V22, P293, DOI 10.1002/mds.21223
   Dagher Z, 2017, AM J PATHOL, V187, P627, DOI 10.1016/j.ajpath.2016.11.007
   Dai LC, 2009, WORLD J GASTROENTERO, V15, P412, DOI 10.3748/wjg.15.412
   Danzer KM, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-42
   De Mello WC, 2016, MOL CELL BIOCHEM, V422, P31, DOI 10.1007/s11010-016-2801-3
   De Mello W, 2016, PEPTIDES, V84, P36, DOI 10.1016/j.peptides.2016.08.005
   Deliu E, 2011, AM J PHYSIOL-CELL PH, V301, pC559, DOI 10.1152/ajpcell.00123.2011
   Eggena P, 1996, J HYPERTENS, V14, P961
   Epstein M, 2015, LANCET DIABETES ENDO, V3, P993, DOI 10.1016/S2213-8587(15)00289-2
   Epstein M, 2014, LANCET DIABETES ENDO, V2, P925, DOI 10.1016/S2213-8587(14)70216-5
   Ferrario CM, 2016, AM J PHYSIOL-HEART C, V311, pH404, DOI 10.1152/ajpheart.00219.2016
   Fiordaliso F, 2000, LAB INVEST, V80, P513, DOI 10.1038/labinvest.3780057
   Florea VG, 2014, CIRC RES, V114, P1815, DOI 10.1161/CIRCRESAHA.114.302589
   Fu LW, 2016, J MOL CELL CARDIOL, V92, P1, DOI 10.1016/j.yjmcc.2016.01.019
   Gerdes HH, 2013, MECH DEVELOP, V130, P381, DOI 10.1016/j.mod.2012.11.006
   Giles K, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a023747
   Gonzalez JE, 2006, MICROBIOL MOL BIOL R, V70, P859, DOI 10.1128/MMBR.00002-06
   Gore B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100310
   Grundemann J, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn084
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Gwathmey TM, 2012, AM J PHYSIOL-REG I, V302, pR518, DOI 10.1152/ajpregu.00525.2011
   Hoang TT, 2017, NUCLEIC ACIDS RES, V45, P818, DOI 10.1093/nar/gkw1192
   Hollborn M, 2005, MOL VIS, V11, P397
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Ishigami T, 2014, HYPERTENSION, V64, P125, DOI 10.1161/HYPERTENSIONAHA.114.03394
   Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jowaed A, 2010, J NEUROSCI, V30, P6355, DOI 10.1523/JNEUROSCI.6119-09.2010
   Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371
   Kingsbury AE, 2004, MOVEMENT DISORD, V19, P162, DOI 10.1002/mds.10683
   Kubota S, 2000, FEBS LETT, V474, P58, DOI 10.1016/S0014-5793(00)01573-8
   Kumar R, 2012, CLIN SCI, V123, P273, DOI 10.1042/CS20120089
   Kumar R, 2012, AM J PHYSIOL-REG I, V302, pR510, DOI 10.1152/ajpregu.00512.2011
   Lee S, 2015, EXP NEUROBIOL, V24, P1, DOI 10.5607/en.2015.24.1.1
   Leri A, 2000, AM J PATHOL, V156, P1663, DOI 10.1016/S0002-9440(10)65037-7
   Li XC, 2008, AM J PHYSIOL-CELL PH, V294, pC1034, DOI 10.1152/ajpcell.00432.2007
   Li Z, 2017, J AM SOC NEPHROL, V28, P2393, DOI 10.1681/ASN.2016070811
   Lorenzo O, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015622.33198.BF
   Lumley JS, 2008, ANN ROY COLL SURG, V90, P91, DOI 10.1308/003588408X261726
   Lyu LM, 2015, J MOL CELL CARDIOL, V89, P268, DOI 10.1016/j.yjmcc.2015.10.022
   Malm T, 2016, NEUROCHEM INT, V97, P193, DOI 10.1016/j.neuint.2016.04.011
   Maquigussa E, 2015, FASEB J, V29
   Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165
   Nanba D, 2004, CYTOKINE GROWTH F R, V15, P13, DOI 10.1016/j.cytogfr.2003.10.002
   Olanow CW, 2009, P NATL ACAD SCI USA, V106, P12571, DOI 10.1073/pnas.0906759106
   Ortega A, 2005, J AM SOC NEPHROL, V16, P939, DOI 10.1681/ASN.2004040328
   Penco S, 2001, BIOTECHNOL APPL BIOC, V34, P151, DOI 10.1042/BA20010038
   Peters J., PRORENIN RECEPTOR IT
   Pironti G, 2015, CIRCULATION, V131, P2120, DOI 10.1161/CIRCULATIONAHA.115.015687
   Planque Nathalie, 2006, Cell Commun Signal, V4, P7, DOI 10.1186/1478-811X-4-7
   Przedborski S, 2003, J CLIN INVEST, V111, P3, DOI 10.1172/JCI200317522
   Public Health Reviews, 2003, B WHO, V81
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   RE R, 1984, LIFE SCI, V34, P647, DOI 10.1016/0024-3205(84)90228-5
   RE R, 1984, CLIN EXP HYPERTENS A, V6, P1739, DOI 10.3109/10641968409046069
   Re RN, 2008, J CLIN PHARMACOL, V48, P344, DOI 10.1177/0091270007312155
   Re RN, 2008, AM J PHYSIOL-HEART C, V295, pH447, DOI 10.1152/ajpheart.00461.2008
   Re RN, 2006, BIOESSAYS, V28, P943, DOI 10.1002/bies.20459
   Re RN, 2017, MED CLIN N AM, V101, P103, DOI 10.1016/j.mcna.2016.08.007
   Re RN, 2016, OCHSNER J, V16, P502
   Re RN, 2016, AM J MED SCI, V351, P626, DOI 10.1016/j.amjms.2016.03.006
   Re RN, 2015, J AM SOC HYPERTENS, V9, P586, DOI 10.1016/j.jash.2015.05.002
   Re RN, 2015, J AM SOC HYPERTENS, V9, P54, DOI 10.1016/j.jash.2014.09.016
   Re RN, 2014, OCHSNER J, V14, P673
   Re RN, 2014, AM J MED SCI, V347, P312, DOI 10.1097/MAJ.0b013e3182a28af3
   Re RN, 2011, J AM SOC HYPERTENS, V5, P435, DOI 10.1016/j.jash.2011.07.001
   Re RN, 2009, AM J PHYSIOL-HEART C, V297, pH893, DOI 10.1152/ajpheart.00414.2009
   RE RN, 1984, BIOCHEM BIOPH RES CO, V119, P220, DOI 10.1016/0006-291X(84)91641-3
   Re RN, 2006, REGUL PEPTIDES, V133, P1, DOI 10.1016/j.regpep.2005.09.012
   RE RN, 1984, ARCH INTERN MED, V144, P2037, DOI 10.1001/archinte.144.10.2037
   RE RN, 1983, BIOCHEM BIOPH RES CO, V110, P61, DOI 10.1016/0006-291X(83)91260-3
   Re RN, 2003, HYPERTENSION, V42, P117, DOI 10.1161/01.HYP.0000082495.93495.5B
   Re RN, 2003, BIOESSAYS, V25, P401, DOI 10.1002/bies.10248
   Re RN, 2002, REGUL PEPTIDES, V106, P1, DOI 10.1016/S0167-0115(02)00031-9
   Re RN, 2002, AM J MED SCI, V323, P43, DOI 10.1097/00000441-200201000-00008
   RE RN, 1982, CLIN SCI, V63, pS191, DOI 10.1042/cs063191s
   RE RN, 1981, CLIN SCI, V61, pS245, DOI 10.1042/cs061245s
   Re RN, 2015, THESIS, V13, pe2
   Re RN, 2010, AM J PHYSIOL-HEART C, V297, pH893
   Re RN, 2015, J PARKINSONS DIS ALZ, V2, P8
   Redding KM, 2010, AM J PHYSIOL-HEART C, V298, pH1807, DOI 10.1152/ajpheart.00027.2010
   Reyes S, 2017, CURR HYPERTENS REP, V19, DOI 10.1007/s11906-017-0708-3
   Romero M, 2010, NEPHROL DIAL TRANSPL, V25, P2447, DOI 10.1093/ndt/gfq104
   Roth-Eichhorn S, 1998, HEPATOLOGY, V28, P1588, DOI 10.1002/hep.510280619
   Sato M, 2006, ACTA DERM-VENEREOL, V86, P300, DOI 10.2340/00015555-0101
   Sato W, 2014, BRIT J PHARMACOL, V171, P879, DOI 10.1111/bph.12418
   Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200
   Shinohara K, 2016, HYPERTENSION, V68, P1385, DOI 10.1161/HYPERTENSIONAHA.116.08242
   Singh VP, 2008, AM J PHYSIOL-HEART C, V294, pH1675, DOI 10.1152/ajpheart.91493.2007
   Siragy HM, 2008, EXP PHYSIOL, V93, P817, DOI 10.1113/expphysiol.2008.042085
   Siragy HM, 2010, AM J NEPHROL, V31, P541, DOI 10.1159/000313363
   Tadevosyan A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004965
   Tan RJ, 2014, KIDNEY INT SUPPL, V4, P84, DOI 10.1038/kisup.2014.16
   Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x
   Watts J. C., 2017, COLD SPRING HARB PER
   Wilson BA, 2017, AM J PHYSIOL-RENAL, V312, pF879, DOI 10.1152/ajprenal.00246.2016
   Woerman A. L., 2017, COLD SPRING HARB PER, DOI [10.1101/cshperspecta024588, DOI 10.1101/CSHPERSPECTA024588]
   Xue BJ, 2012, HYPERTENSION, V59, P459, DOI 10.1161/HYPERTENSIONAHA.111.185116
   Xue C, 2005, HYPERTENSION, V46, P584, DOI 10.1161/01.HYP.0000175814.18550.c0
   Yang PY, 2016, METHODS MOL BIOL, V1344, P325, DOI 10.1007/978-1-4939-2966-5_21
   Yeung BHY, 2012, MOL CELL ENDOCRINOL, V349, P272, DOI 10.1016/j.mce.2011.11.007
   Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   Zhou LL, 2016, CURR OPIN NEPHROL HY, V25, P100, DOI 10.1097/MNH.0000000000000205
   Zhou LL, 2015, AM J PATHOL, V185, P3211, DOI 10.1016/j.ajpath.2015.08.004
NR 119
TC 2
Z9 2
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0091-2700
EI 1552-4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD DEC
PY 2017
VL 57
IS 12
BP 1507
EP 1518
DI 10.1002/jcph.997
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FM4GU
UT WOS:000414973300001
PM 28884862
DA 2022-11-30
ER

PT J
AU Inoue, Y
   Shimazawa, M
   Noda, Y
   Nagano, R
   Otsuka, T
   Kuse, Y
   Nakano, Y
   Tsuruma, K
   Nakagami, Y
   Hara, H
AF Inoue, Yuki
   Shimazawa, Masamitsu
   Noda, Yasuhiro
   Nagano, Ryota
   Otsuka, Tomohiro
   Kuse, Yoshiki
   Nakano, Yukimichi
   Tsuruma, Kazuhiro
   Nakagami, Yasuhiro
   Hara, Hideaki
TI RS9, a novel Nrf2 activator, attenuates light-induced death of cells of
   photoreceptor cells and Muller glia cells
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE AMD; HO-1; light-induced retinal degeneration; Nrf2; photoreceptor;
   retina
ID OXIDATIVE STRESS; MACULAR DEGENERATION; RETINAL DEGENERATION;
   ISCHEMIA-REPERFUSION; HUMAN-DISEASE; BRAIN-INJURY; BLUE-LIGHT; IN-VITRO;
   PROTECTION; NEUROPROTECTION
AB The retina is highly sensitive to oxidative stress because of its high consumption of oxygen associated with the phototransductional processes. Recent findings have suggested that oxidative stress is involved in the pathology of age-related macular degeneration, a progressive degeneration of the central retina. A well-known environmental risk factor is light exposure, as excessive and continuous light exposure can damage photoreceptors. Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a transcriptional factor that controls antioxidative responses and phase 2 enzymes. Thus, we hypothesized that RS9, a specific activator of Nrf2, decreases light-induced retinal cell death in vivo and in vitro. Nrf2 was detected in the nucleus of the 661W cells exposed to RS9 and also after light exposure, and the Nrf2-antioxidant response element binding was increased in 661W cells after exposure to
C1 [Inoue, Yuki; Shimazawa, Masamitsu; Noda, Yasuhiro; Nagano, Ryota; Otsuka, Tomohiro; Kuse, Yoshiki; Nakano, Yukimichi; Tsuruma, Kazuhiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
   [Nakagami, Yasuhiro] Daiichi Sankyo Co Ltd, Tokyo, Japan.
C3 Gifu Pharmaceutical University; Daiichi Sankyo Company Limited
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Kuse, Yoshiki/AAB-7445-2021
OI Hara, Hideaki/0000-0003-2046-9001; Nakagami,
   Yasuhiro/0000-0003-3618-1715
FU Daiichi Sankyo Co., Ltd.; Gifu Pharmaceutical University
FX This study was supported by Daiichi Sankyo Co., Ltd. and conducted as a
   collaboration between Gifu Pharmaceutical University and Daiichi Sankyo
   Co., Ltd. Dr. Hideaki Hara and Dr. Yasuhiro Nakagami had grants and the
   other authors declared no competing financial interest.
CR Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2
   Arroba AI, 2014, ADV EXP MED BIOL, V801, P373, DOI 10.1007/978-1-4614-3209-8_47
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Catino S, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00305
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Dang J, 2012, J MOL NEUROSCI, V46, P578, DOI 10.1007/s12031-011-9645-9
   Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016
   DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x
   Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102
   Gu DM, 2015, BIOCHEM BIOPH RES CO, V457, P391, DOI 10.1016/j.bbrc.2015.01.002
   Guo C, 2017, MOL NEUROBIOL, V54, P833, DOI 10.1007/s12035-016-9690-z
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Himori N, 2013, J NEUROCHEM, V127, P669, DOI 10.1111/jnc.12325
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Imai T, 2016, NEUROBIOL DIS, V89, P136, DOI 10.1016/j.nbd.2016.02.001
   Imamura T, 2014, EXP EYE RES, V129, P24, DOI 10.1016/j.exer.2014.10.019
   Imuta N, 2007, ANTIOXID REDOX SIGN, V9, P543, DOI 10.1089/ars.2006.1519
   Izawa H, 2016, FREE RADICAL BIO MED, V96, P304, DOI 10.1016/j.freeradbiomed.2016.03.036
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Liby KT, 2012, PHARMACOL REV, V64, P972, DOI 10.1124/pr.111.004846
   Matteucci A, 2014, EXP EYE RES, V125, P20, DOI 10.1016/j.exer.2014.05.011
   Mikami Y, 2011, J BIOL CHEM, V286, P39379, DOI 10.1074/jbc.M111.298208
   Nakagami Y., 2015, CURR EYE RES, P1
   Nakagami Y, 2015, BRIT J PHARMACOL, V172, P1237, DOI 10.1111/bph.12999
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rhee KD, 2013, P NATL ACAD SCI USA, V110, pE4520, DOI 10.1073/pnas.1303604110
   Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419
   Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3
   Takagi T, 2014, FREE RADICAL BIO MED, V72, P124, DOI 10.1016/j.freeradbiomed.2014.04.009
   Tan SM, 2015, EXP EYE RES, V136, P1, DOI 10.1016/j.exer.2015.04.015
   Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102
   Tsuruma K, 2011, MOL VIS, V17, P3556
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wang J, 2015, FREE RADICAL BIO MED, V86, P25, DOI 10.1016/j.freeradbiomed.2015.04.009
   Wei YH, 2015, P NATL ACAD SCI USA, V112, pE6927, DOI 10.1073/pnas.1512683112
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yamauchi K, 2016, NEUROSCIENCE, V333, P302, DOI 10.1016/j.neuroscience.2016.07.035
   Yang JH, 2003, INVEST OPHTH VIS SCI, V44, P1312, DOI 10.1167/iovs.02-0768
   Yin XP, 2015, INT J CLIN EXP PATHO, V8, P10156
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou Z, 2015, CELL DEATH DIFFER, V22, P488, DOI 10.1038/cdd.2014.229
NR 52
TC 27
Z9 28
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2017
VL 141
IS 5
BP 750
EP 765
DI 10.1111/jnc.14029
PG 16
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA EU7AL
UT WOS:000401187000009
PM 28345128
OA Bronze
DA 2022-11-30
ER

PT J
AU Soloway, AH
   Curley, RW
   Soloway, SM
AF Soloway, Albert H.
   Curley, Robert W., Jr.
   Soloway, Scott M.
TI Macular degeneration: A possible biochemical mechanism
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; EPOXIDE HYDROLASES; RETINOIC ACID; LIPOFUSCIN;
   RPE
AB The possible role of labile endogenous metabolites in the cause of various chronic debilitating diseases such as macular degeneration has not been adequately explored. In the metabolism of the various retinoids, namely retinal (vitamin A aldehyde), retinol (vitamin A alcohol) and retinoic acid, each has the potential for generating labile intermediates, such as their corresponding 5,6-epoxides by the action of various cytochrome P(450)s. Such retinoid epoxides may well have the capacity for acting as toxins upon the neurons in the macula unless they are rapidly hydrolyzed by epoxide hydrolases. Since the cytochrome P(450)s responsible for epoxide formation and the various epoxide hydrolases involved in their hydrolysis are determined genetically, this may serve to explain a genetic component being involved in the causation of age-related macular degeneration. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Soloway, Albert H.; Curley, Robert W., Jr.] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA.
   [Soloway, Scott M.] Yale Univ, Sch Med, Dept Ophthalmol, New Haven, CT 06510 USA.
C3 Ohio State University; Yale University
RP Soloway, AH (通讯作者)，Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500 W 12th Ave, Columbus, OH 43210 USA.
EM soloway.1@osu.edu
CR Arand M, 2003, EXCLI J, V2, P22
   Boyd DR, 2000, CHEM COMMUN, P1481, DOI 10.1039/b004314l
   Collins FS, 2010, LANGUAGE LIFE DNA RE, P67
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Decker M, 2009, ARCH TOXICOL, V83, P297, DOI 10.1007/s00204-009-0416-0
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   MCCORMICK AM, 1980, BIOCHEM J, V186, P475, DOI 10.1042/bj1860475
   Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920
   Pietz J, 1999, J CLIN INVEST, V103, P1169, DOI 10.1172/JCI5017
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Soloway AH, 2009, MED HYPOTHESES RES, V5, P19
   Soloway AH, 2007, MED HYPOTHESES, V69, P1225, DOI 10.1016/j.mehy.2007.04.023
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   THOMAS H, 1990, ENVIRON HEALTH PERSP, V88, P49, DOI 10.2307/3431050
   Weinberg RA, 2007, BIOL CANC, P488
   Zurfluh MR, 2008, HUM MUTAT, V29, P167, DOI 10.1002/humu.20637
   Zusterzeel PLM, 2001, J MED GENET, V38, P234, DOI 10.1136/jmg.38.4.234
NR 21
TC 1
Z9 1
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY
PY 2011
VL 76
IS 5
BP 729
EP 732
DI 10.1016/j.mehy.2011.02.009
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 757KT
UT WOS:000290084600032
PM 21349651
DA 2022-11-30
ER

PT J
AU Mucke, HAM
   Mucke, PM
AF Mucke, Hermann A. M.
   Mucke, Peter M.
TI Current drug patenting for retinal diseases: Beyond VEGF inhibitors
SO IDRUGS
LA English
DT Review
DE Diabetic retinopathy; macular degeneration; patent; retinal disease;
   retinopathy of prematurity
ID MACULAR DEGENERATION; DRUSEN
AB An analysis of patent applications that address strategies for the pharmacological treatment of retinal diseases that are not directly related to VEGF inhibition, published under the PCT during the 18-month period from January 2008 to June 2009, is presented. The largest number of therapeutic patent applications focused on attempts to correct visual cycle dysfunctions, complement overactivation or beta-amyloid deposition in drusen to control age-related macular degeneration (AMD). Biomarker-based and genetic diagnostic modalities that assess AMD risk were also frequently claimed in the patent applications, and have become a significant factor in patenting for ocular disorders. The fields of both visual cycle therapy and AMD biomarkers were dominated by non-corporate patent assignees. Diabetic retinopathy has not received as much attention from inventors compared with AMD; retinopathy of prematurity remains a field in which little specific patenting occurs.
C1 [Mucke, Hermann A. M.; Mucke, Peter M.] HM Pharma Consultancy, A-1160 Vienna, Austria.
RP Mucke, HAM (通讯作者)，HM Pharma Consultancy, Enenkelstr 28-32, A-1160 Vienna, Austria.
EM h.mucke@hmpharmacon.com
OI Mucke, Hermann/0000-0002-1491-6250
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Brandies R, 2008, NEUROSCI BIOBEHAV R, V32, P611, DOI 10.1016/j.neubiorev.2007.09.004
   Cantsilieris Stuart, 2009, Recent Pat DNA Gene Seq, V3, P102
   Heidary G, 2009, SEMIN OPHTHALMOL, V24, P77, DOI 10.1080/08820530902800314
   Galvez MIL, 2009, CURR DIABETES REV, V5, P14, DOI 10.2174/157339909787314167
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mucke HAM, 2009, CLIN OPHTHALMOL, V3, P103
   Schwartz SG, 2009, EXPERT OPIN PHARMACO, V10, P1123, DOI [10.1517/14656560902910092, 10.1517/14656560902910092 ]
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 11
TC 4
Z9 4
U1 0
U2 1
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1369-7056
J9 IDRUGS
JI IDrugs
PD JAN
PY 2010
VL 13
IS 1
BP 30
EP 37
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 533QO
UT WOS:000272839500009
PM 20024845
DA 2022-11-30
ER

PT J
AU Mansoor, S
   Kuppermann, BD
   Kenney, MC
AF Mansoor, Saffar
   Kuppermann, Baruch D.
   Kenney, M. Cristina
TI Intraocular Sustained-Release Delivery Systems for Triamcinolone
   Acetonide
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE conjugates/codrugs; drug delivery system; microcannulation; ocular
   implants; triamcinolone
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; RANDOMIZED
   CLINICAL-TRIAL; DRUG-DELIVERY; INTRAVITREAL TRIAMCINOLONE; FLUOCINOLONE
   ACETONIDE; PHOTODYNAMIC THERAPY; MACULAR EDEMA; GANCICLOVIR IMPLANT;
   CHOROIDAL NEOVASCULARIZATION
AB Recently, the use of triamcinolone acetonide (TA) injection has increased dramatically in treatment for several ocular diseases. Among them, macular diseases such as macular edema due to diabetic retinopathy, venous occlusive diseases, ocular inflammation and age-related macular degeneration (AMD) are very common vision threatening disorders and are great challenges to treat. In these types of chronic retinal diseases, repeated intraocular injections of TA are often required which increases the likelihood of complications. In order to achieve sustained-release, maintain therapeutic levels of TA over longer times and reduce frequency of intravitreal injections, researchers are investigating different implantable devices or injectable systems. However, as of yet, there is no sustained-release product for TA available on the commercial market. This review discusses and compares different sustained-release devices or injectable systems that are currently being developed.
C1 [Mansoor, Saffar; Kuppermann, Baruch D.; Kenney, M. Cristina] Univ Calif Irvine, Sch Med, Dept Ophthalmol, Irvine, CA 92717 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Ophthalmol, Med Ctr, Orange, CA 92868 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Sch Med, Dept Ophthalmol, Irvine, CA 92717 USA.
EM mkenney@uci.edu
FU Discovery Eye Foundation; Henry L. Guenther Foundation; Iris and B.
   Gerald Cantor Foundation; Research to Prevent Blindness Foundation
FX Supported by the Discovery Eye Foundation, Henry L. Guenther Foundation,
   Iris and B. Gerald Cantor Foundation and the Research to Prevent
   Blindness Foundation.
CR ADLER RA, 1994, LIFE SCI, V55, P1823, DOI 10.1016/0024-3205(94)90093-0
   ALI F, 2002, DIGIT J OPHTHALMOL
   Andrade RE, 2004, AM J OPHTHALMOL, V137, P572, DOI 10.1016/j.ajo.2003.08.035
   Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Argenti D, 2000, J CLIN PHARMACOL, V40, P770, DOI 10.1177/00912700022009413
   Audren F, 2006, ACTA OPHTHALMOL SCAN, V84, P624, DOI 10.1111/j.1600-0420.2006.00700.x
   Aukunuru JV, 2001, PHARM RES-DORDR, V18, P565, DOI 10.1023/A:1011060705599
   Bandello F, 2003, Semin Ophthalmol, V18, P251
   Bashshur ZF, 2004, ARCH OPHTHALMOL-CHIC, V122, P1137, DOI 10.1001/archopht.122.8.1137
   Beeley NRF, 2006, J BIOMED MATER RES A, V76A, P690, DOI 10.1002/jbm.a.30567
   Beeley NRF, 2005, J BIOMED MATER RES A, V73A, P437, DOI 10.1002/jbm.a.30294
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Berger AS, 1996, INVEST OPHTH VIS SCI, V37, P2318
   BESSLER M, 1981, AM J OPHTHALMOL, V91, P785
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   BOYD A, 1992, CURR EYE RES S, V11, P153
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   BRETON P, 1994, NANOPARTICLES RECENT, V4, P161
   Burk SE, 2003, J CATARACT REFR SURG, V29, P645, DOI 10.1016/S0886-3350(03)00016-6
   Cardillo J.A., 2006, Arch Soc Esp Oftalmol, V81, P679
   Cardillo J A, 2006, Arch Soc Esp Oftalmol, V81, P675
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Durairaj C, 2009, PHARM RES-DORDR, V26, P1236, DOI 10.1007/s11095-008-9728-7
   Ebner R, 2004, BRIT J OPHTHALMOL, V88, P1380, DOI 10.1136/bjo.2004.046193
   Eperon S, 2008, INT J PHARMACEUT, V352, P240, DOI 10.1016/j.ijpharm.2007.10.054
   Felinski EA, 2005, CURR EYE RES, V30, P949, DOI 10.1080/02713680500263598
   Felt-Baeyens O, 2006, INT J PHARMACEUT, V322, P6, DOI 10.1016/j.ijpharm.2006.05.053
   FRIMPONGBOATENG A, 2008, ACTA OPHTHALMOL, P1
   Furino C, 2003, RETINA-J RET VIT DIS, V23, P771, DOI 10.1097/00006982-200312000-00004
   Gilger Brian C., 2000, Veterinary Ophthalmology, V3, P105, DOI 10.1046/j.1463-5224.2000.00117.x
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Herrero-Vanrell R, 2000, PHARMACEUT RES, V17, P1323, DOI 10.1023/A:1026464124412
   Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Ip MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1131, DOI 10.1001/archopht.122.8.1131
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   KHOOBEHI B, 1991, OPHTHALMIC SURG LAS, V22, P175
   Kim H, 2006, RETINA-J RET VIT DIS, V26, P523, DOI 10.1097/00006982-200605000-00005
   KIMURA H, 1994, CURR EYE RES, V13, P353, DOI 10.3109/02713689409167299
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   KOONER K, 1997, TXB OCULAR PHARM
   Kreines K, 1975, Ohio State Med J, V71, P703
   KREINES K, 1975, OHIO STATE MED J, V71, P703
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   KUPPERMANN BD, 2007, RETINA TODAY, P27
   LEE VHL, 1998, DRUG DELIVERY POSTER
   LESCURE F, 1994, PHARMACEUT RES, V11, P1270, DOI 10.1023/A:1018986226557
   Lewis DH, 1990, BIODEGRADABLE POLYM
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Macky TA, 2002, J MED CHEM, V45, P1122, DOI 10.1021/jm010511b
   MANGINI NJ, 2002, ARVO ANN M
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   Martin DF, 1997, ARCH OPHTHALMOL-CHIC, V115, P1389, DOI 10.1001/archopht.1997.01100160559005
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   Meyer CH, 2007, OPHTHALMOLOGICA, V221, P118, DOI 10.1159/000098257
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   MORITERA T, 1994, CURR EYE RES, V13, P171, DOI 10.3109/02713689408995774
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   OGURA Y, 1995, SURV OPHTHALMOL, V39, pS17, DOI 10.1016/S0039-6257(05)80069-4
   Okada AA, 2003, BRIT J OPHTHALMOL, V87, P968, DOI 10.1136/bjo.87.8.968
   Olejnik O, 2005, ADV DRUG DELIVER REV, V57, P1991, DOI 10.1016/j.addr.2005.09.002
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   PIZZARELLO LD, 1978, AM J OPHTHALMOL, V85, P818, DOI 10.1016/S0002-9394(14)78111-5
   QUIROGA P, 1993, ARCH DOC ESP OFTALMO, V65, P491
   Rechtman E, 2003, AM J OPHTHALMOL, V136, P739, DOI 10.1016/S0002-9394(03)00389-1
   SANDER B, 2006, ACTA OPHTHALMOL SCAN, V84, P90, DOI DOI 10.1111/J.1600-0420.2006.00712_39.X
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Seah SKL, 2005, AM J OPHTHALMOL, V139, P927, DOI 10.1016/j.ajo.2004.10.052
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   SINGH S, 2001, IND J OPHTHALMOL, V50, P160
   SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Sommer A, 1998, ACTA DERM-VENEREOL, V78, P15
   Sosnowski J, 1997, J UROLOGY, V158, P269, DOI 10.1097/00005392-199707000-00084
   Suggs LJ, 1996, PHYS PROPERTIES POLY, P615
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tan DTH, 1999, OPHTHALMOLOGY, V106, P223, DOI 10.1016/S0161-6420(99)90060-X
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Tielsch JA, 1994, VISION PROBLEMS US R
   VARNER S, 2005, MDDI ARCHIVE
   Veloso AAS, 1997, INVEST OPHTH VIS SCI, V38, P665
   Wadood AC, 2004, J CATARACT REFR SURG, V30, P761, DOI 10.1016/j.jcrs.2003.08.028
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Wise DL., 2000, HDB PHARM CONTROLLED, P329
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yasukawa T, 2005, ADV DRUG DELIVER REV, V57, P2033, DOI 10.1016/j.addr.2005.09.005
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Zamir E, 2002, OPHTHALMOLOGY, V109, P798, DOI 10.1016/S0161-6420(01)01018-1
   Zhou TH, 1998, J CONTROL RELEASE, V55, P281, DOI 10.1016/S0168-3659(98)00061-3
NR 111
TC 50
Z9 58
U1 0
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD APR
PY 2009
VL 26
IS 4
BP 770
EP 784
DI 10.1007/s11095-008-9812-z
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 413NE
UT WOS:000263799000003
PM 19184374
OA hybrid
DA 2022-11-30
ER

PT J
AU Wilson, BC
   Patterson, MS
AF Wilson, Brian C.
   Patterson, Michael S.
TI The physics, biophysics and technology of photodynamic therapy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Review
ID SINGLET OXYGEN LUMINESCENCE; SPHERICAL-HARMONICS METHOD; IN-VIVO;
   OPTICAL-PROPERTIES; LIGHT-SCATTERING; TUMOR OXYGENATION; FLUENCE RATE;
   BLOOD-FLOW; PHOTOSENSITIZER DOSIMETRY; PHOTOBLEACHING KINETICS
AB Photodynamic therapy (PDT) uses light-activated drugs to treat diseases ranging from cancer to age-related macular degeneration and antibiotic-resistant infections. This paper reviews the current status of PDT with an emphasis on the contributions of physics, biophysics and technology, and the challenges remaining in the optimization and adoption of this treatment modality. A theme of the review is the complexity of PDT dosimetry due to the dynamic nature of the three essential components-light, photosensitizer and oxygen. Considerable progress has been made in understanding the problem and in developing instruments to measure all three, so that optimization of individual PDT treatments is becoming a feasible target. The final section of the review introduces some new frontiers of research including low dose rate (metronomic) PDT, two-photon PDT, activatable PDT molecular beacons and nanoparticle-based PDT.
C1 [Wilson, Brian C.] Univ Toronto, Ontario Canc Inst, Div Biophys & Bioimaging, Toronto, ON M5G 2M9, Canada.
   [Wilson, Brian C.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
   [Patterson, Michael S.] McMaster Univ, Juravinski Canc Ctr, Dept Med Phys, Hamilton, ON L8V 5CS, Canada.
   [Patterson, Michael S.] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8V 5CS, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; University of Toronto; McMaster University; McMaster
   University
RP Wilson, BC (通讯作者)，Univ Toronto, Ontario Canc Inst, Div Biophys & Bioimaging, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.
EM wilson@uhnres.utoronto.ca; mike.patterson@jcc.hhsc.ca
RI Patterson, Michael S/A-9882-2010
OI Patterson, Michael S/0000-0002-6398-0742; Wilson, Brian
   C./0000-0001-5543-666X
FU NATIONAL CANCER INSTITUTE [P01CA043892] Funding Source: NIH RePORTER
CR Alexandrakis G, 1998, APPL OPTICS, V37, P7401, DOI 10.1364/AO.37.007401
   [Anonymous], [No title captured]
   ARRIDGE SR, 1993, MED PHYS, V20, P299, DOI 10.1118/1.597069
   Arridge SR, 2000, INT J IMAG SYST TECH, V11, P2
   BARR H, 1987, PHOTOCHEM PHOTOBIOL, V46, P795, DOI 10.1111/j.1751-1097.1987.tb04850.x
   Beek JF, 1997, PHYS MED BIOL, V42, P2255, DOI 10.1088/0031-9155/42/11/017
   Berard V, 2006, J ENVIRON PATHOL TOX, V25, P239, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.150
   Betz CS, 2007, LASER SURG MED, V39, P571, DOI 10.1002/lsm.20535
   Biel M, 2006, LASER SURG MED, V38, P349, DOI 10.1002/lsm.20368
   Bisland SK, 2004, PHOTOCHEM PHOTOBIOL, V80, P22, DOI 10.1562/2004-03-05-RA-100.1
   Boere IA, 2006, PHOTOCHEM PHOTOBIOL, V82, P1638, DOI 10.1562/2006-01-03-RA-763
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   Brandis A, 2005, PHOTOCHEM PHOTOBIOL, V81, P983, DOI 10.1562/2004-12-01-RA-389R1.1
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3
   Buerk DG, 2004, METHOD ENZYMOL, V381, P665
   Burch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1921887
   Busch TM, 2006, LASER SURG MED, V38, P494, DOI 10.1002/lsm.20355
   Cengel K A, 2007, Cancer Treat Res, V134, P493, DOI 10.1007/978-0-387-48993-3_34
   Chabrier-Rosello Y, 2005, ANTIMICROB AGENTS CH, V49, P4288, DOI 10.1128/AAC.49.10.4288-4295.2005
   Chen J, 2004, J AM CHEM SOC, V126, P11450, DOI 10.1021/ja047392k
   Chen J, 2002, CANCER J, V8, P154, DOI 10.1097/00130404-200203000-00009
   Chen Q, 1996, PHOTOCHEM PHOTOBIOL, V63, P128, DOI 10.1111/j.1751-1097.1996.tb03003.x
   Chen Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P197, DOI 10.1562/0031-8655(2002)076<0197:IOTRBM>2.0.CO;2
   Chen ZP, 1998, PHOTOCHEM PHOTOBIOL, V67, P56, DOI 10.1111/j.1751-1097.1998.tb05165.x
   CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354
   Chou TM, 2002, CATHETER CARDIO INTE, V57, P387, DOI 10.1002/ccd.10336
   Conover DL, 2000, PHYS MED BIOL, V45, P2685, DOI 10.1088/0031-9155/45/9/318
   Coutier S, 2002, RADIAT RES, V158, P339, DOI 10.1667/0033-7587(2002)158[0339:EOIFRO]2.0.CO;2
   Czarnota GJ, 1999, BRIT J CANCER, V81, P520, DOI 10.1038/sj.bjc.6690724
   DAVIES N, 2006, THESIS U TORONTO
   DEHAAS ERM, 2007, J EUR ACAD DERMATOL, DOI DOI 10.1111/J.1468-3083.200702445X
   DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008
   Demidova TN, 2004, INT J IMMUNOPATH PH, V17, P245, DOI 10.1177/039463200401700304
   Diamond KR, 2003, PHYS MED BIOL, V48, P4135, DOI 10.1088/0031-9155/48/24/011
   Diamond KR, 2003, APPL OPTICS, V42, P2436, DOI 10.1364/AO.42.002436
   DOUGHERTY TJ, 1979, J NATL CANCER I, V62, P231
   DOUGHERTY TJ, 1978, CANCER RES, V38, P2628
   Du KL, 2006, LASER SURG MED, V38, P427, DOI 10.1002/lsm.20341
   Dysart JS, 2006, PHOTOCH PHOTOBIO SCI, V5, P73, DOI 10.1039/b511807g
   Dysart JS, 2005, PHYS MED BIOL, V50, P2597, DOI 10.1088/0031-9155/50/11/011
   Dysart JS, 2005, PHOTOCHEM PHOTOBIOL, V81, P196, DOI 10.1562/2004-07-23-RA-244.1
   Eggener SE, 2007, J UROLOGY, V178, P2260, DOI 10.1016/j.juro.2007.08.072
   Farrell TJ, 1998, PHOTOCHEM PHOTOBIOL, V68, P394, DOI 10.1111/j.1751-1097.1998.tb09698.x
   FARRELL TJ, 1994, SPIE P, V2135, P117
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Fien Sari M, 2007, J Natl Compr Canc Netw, V5, P531
   Finlay JC, 2004, PHYS MED BIOL, V49, P4837, DOI 10.1088/0031-9155/49/21/001
   Finlay JC, 2004, MED PHYS, V31, P1949, DOI 10.1118/1.1760188
   FIRBANK M, 1993, PHYS MED BIOL, V38, P503, DOI 10.1088/0031-9155/38/4/002
   Fischer HC, 2006, ADV FUNCT MATER, V16, P1299, DOI 10.1002/adfm.200500529
   FLOCK ST, 1987, MED PHYS, V14, P835, DOI 10.1118/1.596010
   FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x
   Forrer M, 1995, P SOC PHOTO-OPT INS, V2627, P33, DOI 10.1117/12.228901
   FOSTER TH, 1991, RADIAT RES, V126, P296, DOI 10.2307/3577919
   FOSTER TH, 1992, RADIAT RES, V130, P379, DOI 10.2307/3578385
   Funke B, 2006, LASER SURG MED, V38, P866, DOI 10.1002/lsm.20391
   Gersing E, 2003, PHYSIOL MEAS, V24, P625, DOI 10.1088/0967-3334/24/2/370
   Ghosh N, 2001, APPL OPTICS, V40, P176, DOI 10.1364/AO.40.000176
   Gibson AP, 2005, PHYS MED BIOL, V50, pR1, DOI 10.1088/0031-9155/50/4/R01
   Gold MH, 2007, LASER MED SCI, V22, P67, DOI 10.1007/s10103-006-0420-z
   Gomer C J, 1996, J Clin Laser Med Surg, V14, P315
   GORMAN AA, 1992, J PHOTOCH PHOTOBIO B, V14, P159, DOI 10.1016/1011-1344(92)85095-C
   Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940
   Hahn SM, 2006, CLIN CANCER RES, V12, P5464, DOI 10.1158/1078-0432.CCR-06-0953
   Haider MA, 2007, RADIOLOGY, V244, P196, DOI 10.1148/radiol.2441060398
   Henderson BW, 2006, LASER SURG MED, V38, P489, DOI 10.1002/lsm.20327
   Henderson BW, 2000, CANCER RES, V60, P525
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008-5472.CAN-03-3513
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hirano T. K. E., 2002, J JPN SOC LASER SURG, V22, P99
   Hirschberg H, 1999, J NEURO-ONCOL, V44, P15, DOI 10.1023/A:1006215002764
   Hopper C, 2004, INT J CANCER, V111, P138, DOI 10.1002/ijc.20209
   Huang Z, 2005, LASER SURG MED, V36, P390, DOI 10.1002/lsm.20177
   HUR EB, 1998, MED HLTH R I, V81, P396
   Jacques SL, 1998, PHOTOCHEM PHOTOBIOL, V67, P23
   Jarvi MT, 2006, PHOTOCHEM PHOTOBIOL, V82, P1198, DOI 10.1562/2006-05-03-IR-891
   JEEVES WP, 1985, ADV EXP MED BIOL, V193, P51
   Johansson A, 2007, MED PHYS, V34, P4309, DOI 10.1118/1.2790585
   Jori G, 2004, PHOTOCH PHOTOBIO SCI, V3, P403, DOI 10.1039/b311904c
   KEY H, 1991, PHYS MED BIOL, V36, P579, DOI 10.1088/0031-9155/36/5/002
   Khurana M, 2007, PHOTOCHEM PHOTOBIOL, V83, P1441, DOI 10.1111/j.1751-1097.2007.00185.x
   Kovalev D, 2005, ADV MATER, V17, P2531, DOI 10.1002/adma.200500328
   Lilge L, 2000, BRIT J CANCER, V83, P1110, DOI 10.1054/bjoc.2000.1426
   LUNA MC, 1994, CANCER RES, V54, P1374
   Luo Y, 2004, NAT MATER, V3, P249, DOI 10.1038/nmat1092
   Marijnissen JPA, 1996, PHYS MED BIOL, V41, P1191, DOI 10.1088/0031-9155/41/7/008
   Marijnissen JPA, 2002, PHYS MED BIOL, V47, P2049, DOI 10.1088/0031-9155/47/12/304
   Markel VA, 2004, WAVE RANDOM MEDIA, V14, pL13, DOI 10.1088/0959-7174/14/1/L02
   Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922
   Mir Y, 2008, LASER MED SCI, V23, P19, DOI 10.1007/s10103-007-0446-x
   Mir Y, 2006, PHOTOCH PHOTOBIO SCI, V5, P1024, DOI 10.1039/b607113a
   Mitra S, 2003, PHOTOCHEM PHOTOBIOL, V78, P615, DOI 10.1562/0031-8655(2003)078<0615:AOHSPP>2.0.CO;2
   Miyagi K, 2003, J PHOTOCH PHOTOBIO B, V70, P133, DOI 10.1016/S1011-1344(03)00073-3
   MOAN J, 1985, CANCER RES, V45, P1608
   Moan J, 2003, ANTICANCER RES, V23, P3591
   Molckovsky A, 2001, PHYS MED BIOL, V46, P983, DOI 10.1088/0031-9155/46/4/306
   MOORE RB, 1992, BRIT J CANCER, V65, P491, DOI 10.1038/bjc.1992.102
   Moriyama EH, 2004, PHOTOCHEM PHOTOBIOL, V80, P242, DOI 10.1562/2004-02-20-RA-088.1
   Moseley H, 2006, BRIT J DERMATOL, V154, P747, DOI 10.1111/j.1365-2133.2006.07145.x
   Nestor Mark S, 2006, J Drugs Dermatol, V5, P140
   Niedre M, 2002, PHOTOCHEM PHOTOBIOL, V75, P382, DOI 10.1562/0031-8655(2002)075<0382:DNILDO>2.0.CO;2
   Niedre MJ, 2005, BRIT J CANCER, V92, P298, DOI 10.1038/sj.bjc.6602331
   Niedre MJ, 2003, CANCER RES, V63, P7986
   Nseyo UO, 1998, J CLIN LASER MED SUR, V16, P61, DOI 10.1089/clm.1998.16.61
   Nyst HJ, 2007, LASER SURG MED, V39, P647, DOI 10.1002/lsm.20536
   Ohlerth S, 2006, LASER SURG MED, V38, P229, DOI 10.1002/lsm.20282
   Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816
   Overholt BF, 2007, GASTROINTEST ENDOSC, V66, P460, DOI 10.1016/j.gie.2006.12.037
   Pandey SK, 2005, J MED CHEM, V48, P6286, DOI 10.1021/jm050427m
   PANJEHPOUR M, 1993, LASER SURG MED, V13, P296, DOI 10.1002/lsm.1900130306
   Papkovsky DB, 2004, METHOD ENZYMOL, V381, P715
   PATTERSON M S, 1991, Lasers in Medical Science, V6, P155, DOI 10.1007/BF02032543
   PATTERSON MS, 1990, PHOTOCHEM PHOTOBIOL, V51, P343, DOI 10.1111/j.1751-1097.1990.tb01720.x
   PATTERSON MS, 1990, J PHOTOCH PHOTOBIO B, V5, P69, DOI 10.1016/1011-1344(90)85006-I
   PETERS VG, 1990, PHYS MED BIOL, V35, P1317, DOI 10.1088/0031-9155/35/9/010
   PICKERING JW, 1993, APPL OPTICS, V32, P399, DOI 10.1364/AO.32.000399
   Pogue BW, 2001, APPL OPTICS, V40, P588, DOI 10.1364/AO.40.000588
   Pogue BW, 1998, APPL OPTICS, V37, P7429, DOI 10.1364/AO.37.007429
   Popp AK, 2003, APPL OPTICS, V42, P2871, DOI 10.1364/AO.42.002871
   Rendon A, 2006, PHYS MED BIOL, V51, P5967, DOI 10.1088/0031-9155/51/23/001
   Robinson DJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P140, DOI 10.1562/0031-8655(1998)067<0140:FPOAIP>2.3.CO;2
   RODGERS MAJ, 1988, J PHOTOCH PHOTOBIO B, V1, P371, DOI 10.1016/1011-1344(88)85024-3
   Rogers DWO, 2006, PHYS MED BIOL, V51, pR287, DOI 10.1088/0031-9155/51/13/R17
   Roth Y, 2004, RADIOLOGY, V232, P685, DOI 10.1148/radiol.2322030778
   Samia ACS, 2006, PHOTOCHEM PHOTOBIOL, V82, P617, DOI 10.1562/2005-05-11-IR-525
   Samkoe KS, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2750663
   SAMUEL I, 2007, MAT WORLD       0828
   Schmitt JM, 1998, APPL OPTICS, V37, P2788, DOI 10.1364/AO.37.002788
   SEE KL, 1984, PHOTOCHEM PHOTOBIOL, V39, P631, DOI 10.1111/j.1751-1097.1984.tb03902.x
   Sheng C, 2004, PHOTOCHEM PHOTOBIOL, V79, P520, DOI 10.1562/MU-03-33.1
   Sheppard CJR, 2007, OPT LETT, V32, P142, DOI 10.1364/OL.32.000142
   Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031-9155/43/9/003
   SMITH G, 1994, PHOTOCHEM PHOTOBIOL, V59, P135, DOI 10.1111/j.1751-1097.1994.tb05012.x
   Smits T, 2006, BRIT J DERMATOL, V155, P429, DOI 10.1111/j.1365-2133.2006.07290.x
   SPANGLER JW, 2006, SPIE P, V6139
   Standish BA, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2744068
   Standish BA, 2007, GASTROINTEST ENDOSC, V66, P326, DOI 10.1016/j.gie.2007.02.040
   STAR WM, 1987, PHOTOCHEM PHOTOBIOL, V46, P619, DOI 10.1111/j.1751-1097.1987.tb04822.x
   Stefflova K, 2007, CURR MED CHEM, V14, P2110
   Sterenborg HJCM, 1996, PHYS MED BIOL, V41, P835, DOI 10.1088/0031-9155/41/5/002
   Stylli SS, 2006, J CLIN NEUROSCI, V13, P709, DOI 10.1016/j.jocn.2005.11.012
   Synytsya A, 2004, PHOTOCHEM PHOTOBIOL, V79, P453, DOI 10.1562/HE-03-05.1
   Tang Hi M., 2007, Journal of Infection and Chemotherapy, V13, P87, DOI 10.1007/s10156-006-0501-8
   Thompson MS, 2005, APPL OPTICS, V44, P4023, DOI 10.1364/AO.44.004023
   Trachtenberg J, 2007, J UROLOGY, V178, P1974, DOI 10.1016/j.juro.2007.07.036
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   TROMBERG BJ, 1990, PHOTOCHEM PHOTOBIOL, V52, P375, DOI 10.1111/j.1751-1097.1990.tb04193.x
   Tschen EH, 2006, BRIT J DERMATOL, V155, P1262, DOI 10.1111/j.1365-2133.2006.07520.x
   Usuda J, 2006, J THORAC ONCOL, V1, P489, DOI 10.1097/01243894-200606000-00018
   Van Dyk J, 1999, MODERN TECHNOLOGY OF RADIATION ONCOLOGY, P1
   van Veen RLP, 2006, GASTROINTEST ENDOSC, V64, P786, DOI 10.1016/j.gie.2006.06.056
   VanStaveren HJ, 1995, LASER MED SCI, V10, P137, DOI 10.1007/BF02150852
   VANSTAVEREN HJ, 1991, APPL OPTICS, V30, P4507, DOI 10.1364/AO.30.004507
   VEENHUIZEN RB, 1995, RADIOTHER ONCOL, V37, P131, DOI 10.1016/0167-8140(95)01626-R
   Vesselov L, 2005, APPL OPTICS, V44, P2754, DOI 10.1364/AO.44.002754
   Wang I, 1997, BRIT J DERMATOL, V136, P184
   Wang KKH, 2007, MED PHYS, V34, P282, DOI 10.1118/1.2401041
   WANG LH, 1995, COMPUT METH PROG BIO, V47, P131, DOI 10.1016/0169-2607(95)01640-F
   Weersink RA, 2005, J PHOTOCH PHOTOBIO B, V79, P211, DOI 10.1016/j.jphotobiol.2005.01.008
   Weersink RA, 1997, PHOTOCHEM PHOTOBIOL, V66, P326, DOI 10.1111/j.1751-1097.1997.tb03155.x
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Wilson BC, 1997, LASER MED SCI, V12, P182, DOI 10.1007/BF02765099
   WILSON BC, 1989, J PHOTOCH PHOTOBIO B, V3, P459, DOI 10.1016/1011-1344(89)80052-1
   WILSON BC, 1986, PHYS MED BIOL, V31, P327, DOI 10.1088/0031-9155/31/4/001
   Wilson BC, 2006, NATO SCI SER II-MATH, V239, P121
   Wilson M, 2004, PHOTOCH PHOTOBIO SCI, V3, P412, DOI 10.1039/b211266c
   Woodhams JH, 2004, BRIT J CANCER, V91, P788, DOI 10.1038/sj.bjc.6602036
   Xu HP, 2006, PHYS MED BIOL, V51, pN247, DOI 10.1088/0031-9155/51/12/N03
   Xu M, 2005, OPT LETT, V30, P3051, DOI 10.1364/OL.30.003051
   Yamamoto J, 2006, CLIN CANCER RES, V12, P7132, DOI 10.1158/1078-0432.CCR-06-0786
   Yu C, 2005, J MATER CHEM, V15, P1857, DOI 10.1039/b500369e
   Yu GQ, 2005, CLIN CANCER RES, V11, P3543, DOI 10.1158/1078-0432.CCR-04-2582
   Yu GQ, 2006, PHOTOCHEM PHOTOBIOL, V82, P1279, DOI 10.1562/2005-10-19-RA-721
   Yuan J, 1997, RADIAT RES, V148, P386, DOI 10.2307/3579524
   Zelickson B, 2005, DERMATOL SURG, V31, P375, DOI 10.1097/00042728-200503000-00025
   Zeng HS, 2002, PHOTOCHEM PHOTOBIOL, V75, P398, DOI 10.1562/0031-8655(2002)075<0398:MPFAPB>2.0.CO;2
   Zheng G, 2007, P NATL ACAD SCI USA, V104, P8989, DOI 10.1073/pnas.0611142104
   Zhou XD, 2006, INT J RADIAT ONCOL, V64, P1211, DOI 10.1016/j.ijrobp.2005.11.019
   Zhu TC, 2005, J PHOTOCH PHOTOBIO B, V79, P231, DOI 10.1016/j.jphotobiol.2004.09.013
NR 180
TC 708
Z9 732
U1 10
U2 244
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD MAY 7
PY 2008
VL 53
IS 9
BP R61
EP R109
DI 10.1088/0031-9155/53/9/R01
PG 49
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 290JW
UT WOS:000255120100001
PM 18401068
DA 2022-11-30
ER

PT J
AU Heo, M
   Lee, B
   Sishda, K
   Fei, X
   Lee, S
   Park, S
   Yuan, Y
   Lee, S
   Kwon, S
   Lee, J
   Kim, S
   Corson, TW
   Seo, SY
AF Heo, Myunghoe
   Lee, Bit
   Sishda, Kamakshi
   Fei, Xiang
   Lee, Sanha
   Park, Soojun
   Yuan, Yue
   Lee, Seul
   Kwon, Sangil
   Lee, Jungeun
   Kim, Sanghee
   Corson, Timothy W.
   Seo, Seung-Yong
TI Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer
   Hydrogenation and Their Biological Evaluation for Antiangiogenic
   Activity
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID DYNAMIC KINETIC RESOLUTION; MACULAR DEGENERATION; RETINAL
   NEOVASCULARIZATION; THERAPEUTIC TARGET; HOMOISOFLAVONOIDS;
   ISOFLAVANONES; RACEMIZATION; RANIBIZUMAB
AB Neovascular eye diseases are a major cause of blindness. Excessive angiogenesis is a feature of several conditions, including wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity. Development of novel antiangiogenic small molecules for the treatment of neovascular eye disease is essential to provide new therapeutic leads for these diseases. We have previously reported the therapeutic potential of anti-angiogenic homoisoflavanone derivatives with efficacy in retinal and choroidal neovascularization models, although these are racemic compounds due to the C3-stereogenic center in the molecules. This work presents asymmetric synthesis and structural determination of anti-angiogenic homoisoflavanones and pharmacological characterization of the stereoisomers. We describe an enantioselective synthesis of homoisoflavanones by virtue of ruthenium-catalyzed asymmetric transfer hydrogenation accompanying dynamic kinetic resolution, providing a basis for the further development of these compounds into novel experimental therapeutics for neovascular eye diseases.
C1 [Heo, Myunghoe; Lee, Bit; Fei, Xiang; Lee, Sanha; Yuan, Yue; Lee, Seul; Kwon, Sangil; Lee, Jungeun; Seo, Seung-Yong] Gachon Univ, Coll Pharm, Incheon 21936, South Korea.
   [Sishda, Kamakshi; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Sishda, Kamakshi; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Corson, Timothy W.] Indiana Univ Sch Med, Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.
   [Park, Soojun; Kim, Sanghee] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.
C3 Gachon University; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Seoul National University (SNU)
RP Seo, SY (通讯作者)，Gachon Univ, Coll Pharm, Incheon 21936, South Korea.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.
EM tcorson@iu.edu; syseo@gachon.ac.kr
RI Corson, Timothy W./B-6851-2009; Fei, Xiang/Z-1378-2019
OI Corson, Timothy W./0000-0002-1402-7875; Fei, Xiang/0000-0001-9637-1989;
   Kwon, Sangil/0000-0002-5672-6690; Lee, Sanha/0000-0001-6163-0231
FU National Eye Institute [R01EY025641]; BrightFocus Foundation [M2015301];
   Bio & Medical Technology Development Program of the National Research
   Foundation - Korean government, MSIP [NRF-2017M3A9C8027781,
   NRF-2014M3C1A3054139]; Korea Health Technology R&D Project through the
   Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   Welfare [HI14C1135]; NATIONAL EYE INSTITUTE [R01EY025641] Funding
   Source: NIH RePORTER
FX We thank Emily Sims and the Indiana University AngioBioCore for training
   on and assistance with the IncuCyte, and Rakshin Kharwadkar for
   assistance with proliferation assays. This work was supported by grants
   from the National Eye Institute (grant number R01EY025641) and the
   BrightFocus Foundation (grant number M2015301) to TWC, and grants from
   the Bio & Medical Technology Development Program of the National
   Research Foundation funded by the Korean government, MSIP
   (NRF-2017M3A9C8027781 and NRF-2014M3C1A3054139) and the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare (grant
   number HI14C1135) to S.-Y.S.
CR Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   ADINOLFI M, 1990, TETRAHEDRON, V46, P6565, DOI 10.1016/S0040-4020(01)96021-1
   ADINOLFI M, 1987, PHYTOCHEMISTRY, V26, P285, DOI 10.1016/S0031-9422(00)81529-0
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   An HC, 2018, J MED CHEM, V61, P9266, DOI 10.1021/acs.jmedchem.8b00971
   Ashley ER, 2017, ACS CATAL, V7, P1446, DOI 10.1021/acscatal.6b03191
   Basavarajappa HD, 2017, EMBO MOL MED, V9, P786, DOI 10.15252/emmm.201606561
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   Basavarajappa HD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095694
   Blagg J, 2017, CANCER CELL, V32, P9, DOI 10.1016/j.ccell.2017.06.005
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Castelli MV, 2017, STUD NAT PROD CHEM, V54, P315, DOI 10.1016/B978-0-444-63929-5.00009-7
   CORSARO MM, 1992, PHYTOCHEMISTRY, V31, P1395, DOI 10.1016/0031-9422(92)80299-T
   Crouch NR, 1999, PHYTOCHEMISTRY, V51, P943, DOI 10.1016/S0031-9422(99)00154-5
   Drewes G, 2018, TRENDS BIOTECHNOL, V36, P1275, DOI 10.1016/j.tibtech.2018.06.008
   du Toit K, 2005, BIOORGAN MED CHEM, V13, P2561, DOI 10.1016/j.bmc.2005.01.036
   du Toit K, 2010, NAT PROD RES, V24, P457, DOI 10.1080/14786410903335174
   Emami S, 2015, EUR J MED CHEM, V93, P539, DOI 10.1016/j.ejmech.2015.02.048
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fallah A, 2019, BIOMED PHARMACOTHER, V110, P775, DOI 10.1016/j.biopha.2018.12.022
   Fernandez R, 2007, TETRAHEDRON, V63, P6755, DOI 10.1016/j.tet.2007.04.075
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Foubelo F, 2015, TETRAHEDRON-ASYMMETR, V26, P769, DOI 10.1016/j.tetasy.2015.06.016
   Fujii A, 1996, J AM CHEM SOC, V118, P2521, DOI 10.1021/ja954126l
   Gaspar A, 2014, CHEM REV, V114, P4960, DOI 10.1021/cr400265z
   GOMIS M, 1990, TETRAHEDRON, V46, P1849, DOI 10.1016/S0040-4020(01)89754-4
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Huerta FF, 2001, CHEM SOC REV, V30, P321, DOI 10.1039/b105464n
   Jo DH, 2014, J MOL MED, V92, P1083, DOI 10.1007/s00109-014-1168-8
   Kawasaki M, 2005, HETEROCYCLES, V65, P761, DOI 10.3987/COM-05-10347
   Kessberg A, 2018, ORG LETT, V20, P3006, DOI 10.1021/acs.orglett.8b01034
   Kim JH, 2008, MOL VIS, V14, P556
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Lee B, 2016, BIOORG MED CHEM LETT, V26, P4277, DOI 10.1016/j.bmcl.2016.07.043
   Lee B, 2014, ORG BIOMOL CHEM, V12, P7673, DOI 10.1039/c4ob01604a
   Lee H, 2016, MOLECULES, V21, DOI 10.3390/molecules21081058
   Lemke MK, 2013, ANGEW CHEM INT EDIT, V52, P11651, DOI 10.1002/anie.201306500
   Li ZY, 2014, CHINESE J CHEM, V32, P783, DOI 10.1002/cjoc.201400361
   Lin LG, 2014, PLANTA MED, V80, P1053, DOI 10.1055/s-0034-1383026
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mohr JT, 2016, BEILSTEIN J ORG CHEM, V12, P2038, DOI 10.3762/bjoc.12.192
   Mulholland DA, 2013, NAT PROD REP, V30, P1165, DOI 10.1039/c3np70008a
   Ohkuma T, 2000, J AM CHEM SOC, V122, P6510, DOI 10.1021/ja001098k
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Peach P, 2006, TETRAHEDRON, V62, P1864, DOI 10.1016/j.tet.2005.11.036
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Poisson T, 2010, J ORG CHEM, V75, P7704, DOI 10.1021/jo101585t
   Qin T, 2017, ORG LETT, V19, P2981, DOI 10.1021/acs.orglett.7b01218
   Salakka AK, 2006, BEILSTEIN J ORG CHEM, V2, DOI 10.1186/1860-5397-2-16
   Schwikkard S, 2019, J NAT PROD, V82, P1227, DOI 10.1021/acs.jnatprod.8b00989
   Seo SY, 2019, METHOD ENZYMOL, V622, P347, DOI 10.1016/bs.mie.2019.02.028
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   Sulaiman RS, 2018, ACS CHEM BIOL, V13, P45, DOI 10.1021/acschembio.7b00854
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Yu YC, 2015, EUR J ORG CHEM, V2015, P4964, DOI 10.1002/ejoc.201500579
   ZANOTTIGEROSA A, 2005, MET REV, V49, P158, DOI DOI 10.1595/147106705X75421
   Ziegler S, 2013, ANGEW CHEM INT EDIT, V52, P2744, DOI 10.1002/anie.201208749
NR 60
TC 13
Z9 13
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
EI 1520-6904
J9 J ORG CHEM
JI J. Org. Chem.
PD AUG 16
PY 2019
VL 84
IS 16
BP 9995
EP 10011
DI 10.1021/acs.joc.9b01134
PG 17
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)
SC Chemistry
GA IS2JP
UT WOS:000481979200015
PM 31381339
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Ng, WY
   Lee, SY
   Cheung, CMG
AF Teo, Kelvin Yi Chong
   Ng, Wei Yan
   Lee, Shu Yen
   Cheung, Chui Ming Gemmy
TI Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF
   Therapy
SO DRUGS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; PUNCTATE INNER
   CHOROIDOPATHY; INTRAVITREAL BEVACIZUMAB INJECTION; LACQUER CRACK
   FORMATION; PATHOLOGICAL MYOPIA; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; BEIJING-EYE; FOLLOW-UP
AB Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.
C1 [Teo, Kelvin Yi Chong; Ng, Wei Yan; Lee, Shu Yen; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Lee, Shu Yen; Cheung, Chui Ming Gemmy] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Lee, Shu Yen; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.; Cheung, CMG (通讯作者)，Duke NUS Grad Med Sch, Singapore, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
OI Teo, Kelvin/0000-0002-7458-7081; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
CR ADELBERG DA, 1995, RETINA-J RET VIT DIS, V15, P198, DOI 10.1097/00006982-199515030-00003
   Ahn SJ, 2015, INVEST OPHTH VIS SCI, V56, P5794, DOI 10.1167/iovs.14-16006
   Ahn SJ, 2013, INVEST OPHTH VIS SCI, V54, P2115, DOI 10.1167/iovs.12-11542
   Amoaku WM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128403
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baba T, 2002, ACTA OPHTHALMOL SCAN, V80, P82, DOI 10.1034/j.1600-0420.2002.800116.x
   BALDWIN WR, 1981, AM J OPTOM PHYS OPT, V58, P516
   Bennett MD, 2007, GRAEF ARCH CLIN EXP, V245, P903, DOI 10.1007/s00417-006-0472-6
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Bruyere E, 2015, AM J OPHTHALMOL, V160, P749, DOI 10.1016/j.ajo.2015.07.004
   Caillaux V, 2013, AM J OPHTHALMOL, V156, P958, DOI 10.1016/j.ajo.2013.06.032
   Calvo-Gonzalez C, 2011, AM J OPHTHALMOL, V151, P529, DOI 10.1016/j.ajo.2010.09.021
   Chan WM, 2009, BRIT J OPHTHALMOL, V93, P150, DOI 10.1136/bjo.2008.145797
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Chen L, 2011, RETINA-J RET VIT DIS, V31, P2078, DOI 10.1097/IAE.0b013e3182109074
   Cheung CMG, 2013, ACTA OPHTHALMOL, V91, pE580, DOI 10.1111/aos.12117
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   CURTIN BJ, 1979, OPHTHALMOLOGY, V86, P681
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   Farinha CL, 2013, EUR J OPHTHALMOL, V23, P887, DOI 10.5301/ejo.5000323
   Franqueira N, 2012, OPHTHALMOLOGICA, V227, P39, DOI 10.1159/000333213
   Gharbiya M, 2010, CLIN TER, V161, pE87
   Gharbiya M, 2012, BRIT J OPHTHALMOL, V96, P1068, DOI 10.1136/bjophthalmol-2012-301639
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   Hamelin N, 2002, AM J OPHTHALMOL, V133, P530, DOI 10.1016/S0002-9394(02)01335-1
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Iacono P, 2012, RETINA-J RET VIT DIS, V32, P1539, DOI 10.1097/IAE.0b013e31826956b7
   Iacono P, 2011, RETINA-J RET VIT DIS, V31, P1841, DOI 10.1097/IAE.0b013e31821800a4
   Ikuno Y, 2008, RETINA-J RET VIT DIS, V28, P1124, DOI 10.1097/IAE.0b013e318174417a
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Ikuno Y, 2010, AM J OPHTHALMOL, V149, P140, DOI 10.1016/j.ajo.2009.08.008
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Kang HM, 2014, AM J OPHTHALMOL, V157, P378, DOI 10.1016/j.ajo.2013.09.018
   Kim YM, 2011, EYE, V25, P936, DOI 10.1038/eye.2011.94
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kojima A, 2006, GRAEF ARCH CLIN EXP, V244, P1474, DOI 10.1007/s00417-006-0324-4
   Kung YH, 2014, ACTA OPHTHALMOL, V92, pe615, DOI 10.1111/aos.12457
   Lai TYY, 2012, EYE, V26, P1004, DOI 10.1038/eye.2012.97
   Lai TYY, 2012, RETINA-J RET VIT DIS, V32, P1443, DOI 10.1097/IAE.0b013e31826956e4
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Leung TG, 2014, RETINA-J RET VIT DIS, V34, P1666, DOI 10.1097/IAE.0000000000000125
   Liu HH, 2010, OPHTHALMOLOGY, V117, P1763, DOI 10.1016/j.ophtha.2010.01.020
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Milani P, 2014, OPHTHALMOLOGICA, V232, P28, DOI 10.1159/000357980
   Milani P, 2012, CLIN OPHTHALMOL, V6, P1885, DOI 10.2147/OPTH.S34649
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Moriyama M, 2007, OPHTHALMOLOGY, V114, P1755, DOI 10.1016/j.ophtha.2006.11.034
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Nakanishi H, 2011, EYE, V25, P375, DOI 10.1038/eye.2010.226
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Niwa Y, 2012, OPHTHALMIC RES, V47, P135, DOI 10.1159/000330499
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui Kyoko, 2004, Curr Opin Ophthalmol, V15, P197, DOI 10.1097/01.icu.0000120709.35941.e9
   Ohno-Matsui K, 2016, AM J OPHTHALMOL, V166, P22, DOI 10.1016/j.ajo.2016.03.019
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-012-2022-8
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Pan CW, 2013, AM J OPHTHALMOL, V156, P1021, DOI 10.1016/j.ajo.2013.06.005
   Parodi MB, 2013, RETINA-J RET VIT DIS, V33, P593, DOI 10.1097/IAE.0b013e31826b6731
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Peiretti E, 2012, CAN J OPHTHALMOL, V47, P28, DOI 10.1016/j.jcjo.2011.12.009
   Petrou P, 2010, ACTA OPHTHALMOL, V88, pe136, DOI 10.1111/j.1755-3768.2009.01572.x
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Rosen E, 2009, EYE, V23, P1479, DOI 10.1038/eye.2008.218
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Ruiz-Moreno JM, 2009, EYE, V23, P334, DOI 10.1038/sj.eye.6703052
   Ruiz-Moreno JM, 2015, RETINA-J RET VIT DIS, V35, P2450, DOI 10.1097/IAE.0000000000000632
   Ruiz-Moreno JM, 2013, BRIT J OPHTHALMOL, V97, P1447, DOI 10.1136/bjophthalmol-2012-302973
   Ruiz-Moreno JM, 2011, OPHTHALMOLOGY, V118, P2521, DOI 10.1016/j.ophtha.2011.07.029
   Ruiz-Moreno JM, 2011, GRAEF ARCH CLIN EXP, V249, P595, DOI 10.1007/s00417-010-1599-z
   Sarao V, 2016, GRAEF ARCH CLIN EXP, V254, P445, DOI 10.1007/s00417-015-3076-1
   Saviano S, 2014, INT J OPHTHALMOL-CHI, V7, P335, DOI 10.3980/j.issn.2222-3959.2014.02.26
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Teo K, 2014, WORLD J OPHTHALMOL, V4, P35
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Tokoro T, 1988, Acta Ophthalmol Suppl, V185, P107
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tufail A, 2013, OPHTHALMOLOGY, V120, P1944, DOI 10.1016/j.ophtha.2013.06.010
   Uemoto R, 2012, GRAEF ARCH CLIN EXP, V250, P989, DOI 10.1007/s00417-011-1921-4
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P344, DOI 10.1001/archopht.118.3.344
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P717, DOI 10.1097/IAE.0b013e318203c1ef
   Voykov B, 2010, GRAEF ARCH CLIN EXP, V248, P543, DOI 10.1007/s00417-009-1285-1
   Wakabayashi T, 2011, RETINA-J RET VIT DIS, V31, P880, DOI 10.1097/IAE.0b013e3181f2a293
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Wang EQ, 2013, RETINA-J RET VIT DIS, V33, P1375, DOI 10.1097/IAE.0b013e31827d260a
   Wang JH, 2012, GRAEF ARCH CLIN EXP, V250, P1717, DOI 10.1007/s00417-012-2159-5
   WATZKE RC, 1984, AM J OPHTHALMOL, V98, P572, DOI 10.1016/0002-9394(84)90243-5
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wolfram C, 2014, BRIT J OPHTHALMOL, V98, P857, DOI 10.1136/bjophthalmol-2013-304228
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Yang HS, 2013, AM J OPHTHALMOL, V156, DOI DOI 10.1016/J.AJO.2013.08.002
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   You QS, 2014, OPHTHALMOLOGY, V121, P220, DOI 10.1016/j.ophtha.2013.06.013
   Young Terri L, 2004, Trans Am Ophthalmol Soc, V102, P423
NR 107
TC 5
Z9 6
U1 0
U2 11
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD JUL
PY 2016
VL 76
IS 11
BP 1119
EP 1133
DI 10.1007/s40265-016-0605-0
PG 15
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA DQ8YG
UT WOS:000379497000004
PM 27364753
DA 2022-11-30
ER

PT J
AU Manikandan, R
   Thiagarajan, R
   Goutham, G
   Arumugam, M
   Beulaja, M
   Rastrelli, L
   Skalicka-Wozniak, K
   Habtemariam, S
   Orhan, IE
   Nabavi, SF
   Nabavi, SM
AF Manikandan, Ramar
   Thiagarajan, Raman
   Goutham, Ganesh
   Arumugam, Munusamy
   Beulaja, Manikandan
   Rastrelli, Luca
   Skalicka-Wozniak, Krystyna
   Habtemariam, Solomon
   Orhan, Ilkay Erdogan
   Nabavi, Seyed Fazel
   Nabavi, Seyed Mohammad
TI Zeaxanthin and ocular health, from bench to bedside
SO FITOTERAPIA
LA English
DT Review
DE Age-related macular degeneration; Cataract; Ocular problems; Oxidative
   stress; Zeaxanthin
ID MACULAR PIGMENT; DIETARY CAROTENOIDS; BETA-CAROTENE; LUTEIN; CATARACT;
   RISK; DAMAGE; SERUM; ANTIOXIDANTS; BIOACCESSIBILITY
AB Cataracts, glaucoma, and age-related macular degeneration are knownas major ocular problems which cause blindness among the elderly population worldwide. Oxidative stress plays an important role in both the initiation and progression of ocular problems and with respect to this; dietary antioxidants can serve as a therapeutic strategy for the improvement of ocular health. Zeaxanthin is known as one of the most important and common xanthophyll carotenoids, possessing multiple therapeutic effects such as strong antioxidant and pro-oxidant behaviour as well as anti-inflammatory effects. A growing body of literature shows that zeaxanthin mitigates ocular problems and suppresses oxidative stress in the Tetinal tissues. This paper aims to critically review the available literature regarding the beneficial effects of zeaxanthin on ocular problems with emphasis on its chemistry, bioavailability, and sources. (C) 2015 ElsevierB.V. All rights reserved.
C1 [Manikandan, Ramar; Goutham, Ganesh; Arumugam, Munusamy] Univ Madras, Dept Zool, Guindy Campus, Madras 600025, Tamil Nadu, India.
   [Thiagarajan, Raman] SASTRA Univ, Sch Chem & Biotechnol, Dept Biotechnol, Thanjavur 613401, India.
   [Beulaja, Manikandan] Annai Veilankannis Coll Women, Dept Biochem, Madras 600015, Tamil Nadu, India.
   [Rastrelli, Luca] Univ Salerno, Dipartimento Farm, Via Giovanni Paolo 2,132, I-84084 Fisciano, SA, Italy.
   [Skalicka-Wozniak, Krystyna] Med Univ Lublin, Dept Pharmacognosy, Med Plants Unit, Lublin, Poland.
   [Habtemariam, Solomon] Univ Greenwich, Medway Sch Sci, Pharmacognosy Res Labs, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Orhan, Ilkay Erdogan] Gazi Univ, Fac Pharm, Dept Pharmacognosy, TR-06330 Ankara, Turkey.
   [Nabavi, Seyed Fazel; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
C3 University of Madras; Shanmugha Arts, Science, Technology & Research
   Academy (SASTRA); University of Salerno; Medical University of Lublin;
   University of Greenwich; Gazi University; Baqiyatallah University of
   Medical Sciences (BMSU)
RP Thiagarajan, R (通讯作者)，SASTRA Univ, Sch Chem & Biotechnol, Dept Biotechnol, Thanjavur 613401, India.; Nabavi, SM (通讯作者)，Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
EM raman@biotech.sastra.edu; Nabavi208@gmail.com
RI Rastrelli, Luca/A-4159-2011; Nabavi, Seyed Mohammad/G-5335-2010; ORHAN,
   ILKAY ERDOGAN/H-6092-2011; nabavi, seyed fazel/A-2223-2010; Raman,
   Thiagarajan/AAP-6638-2021; Skalicka-Woźniak, Krystyna/AAJ-5579-2020
OI Rastrelli, Luca/0000-0001-6102-2762; Nabavi, Seyed
   Mohammad/0000-0001-8859-5675; Skalicka-Wozniak,
   Krystyna/0000-0002-9313-5929; Rastrelli, Luca/0000-0003-0718-5450
CR Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169
   Alvarez R, 2014, CHEM REV, V114, P1, DOI 10.1021/cr400126u
   Aman R, 2005, FOOD CHEM, V92, P753, DOI 10.1016/j.foodchem.2004.10.031
   Baudelet PH, 2013, MAR DRUGS, V11, P4390, DOI 10.3390/md11114390
   Bernstein P.S., 2015, PROG RAIN EYE RES
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Cardoso PC, 2011, FOOD CHEM, V126, P411, DOI 10.1016/j.foodchem.2010.10.109
   Cenedella RJ, 2003, J LIPID RES, V44, P198, DOI 10.1194/jlr.M200002-JLR200
   CHANDLER LA, 1988, J AGR FOOD CHEM, V36, P129, DOI 10.1021/jf00079a033
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chitchumroonchokcai C, 2006, J NUTR, V136, P588, DOI 10.1093/jn/136.3.588
   Cocate PG, 2015, BRIT J NUTR, V114, P257, DOI 10.1017/S0007114515001622
   Cross H.G., 1975, EUR J BIOCHEM, V57, P317
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dai ZL, 2014, J BONE MINER RES, V29, P408, DOI 10.1002/jbmr.2041
   Raposo MFD, 2013, LIFE SCI, V93, P479, DOI 10.1016/j.lfs.2013.08.002
   Delgado-Vargas F, 2000, CRIT REV FOOD SCI, V40, P173, DOI 10.1080/10408690091189257
   Dias IHK, 2014, J ALZHEIMERS DIS, V40, P399, DOI 10.3233/JAD-131964
   Dugo P, 2008, J AGR FOOD CHEM, V56, P3478, DOI 10.1021/jf800144v
   Dwyer JH, 2004, ARTERIOSCL THROM VAS, V24, P313, DOI 10.1161/01.ATV.0000109955.80818.8a
   Ernst H, 2002, PURE APPL CHEM, V74, P2213, DOI 10.1351/pac200274112213
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hollborn M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059603
   Huo T, 2007, J AGR FOOD CHEM, V55, P8950, DOI 10.1021/jf071687a
   Jin ES, 2003, BIOTECHNOL BIOENG, V81, P115, DOI 10.1002/bit.10459
   Jomova K, 2013, EUR J MED CHEM, V70, P102, DOI 10.1016/j.ejmech.2013.09.054
   Kljak K, 2015, FOOD CHEM, V167, P402, DOI 10.1016/j.foodchem.2014.07.002
   Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1948, DOI 10.1021/jf981029d
   Leoncini E., 2015, EUR J EPIDEMIOL
   Lewinsohn E, 2005, TRENDS FOOD SCI TECH, V16, P407, DOI 10.1016/j.tifs.2005.04.004
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li XR, 2015, J IND MICROBIOL BIOT, V42, P627, DOI 10.1007/s10295-014-1565-6
   Liu J, 2014, BRIT J NUTR, V112, P2041, DOI 10.1017/S000711451400316X
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Liu XH, 2014, NUTRIENTS, V6, P452, DOI 10.3390/nu6010452
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Manayi A., 2015, CRIT REV BIOTECHNOL
   Maurer MM, 2014, FOOD CHEM, V165, P475, DOI 10.1016/j.foodchem.2014.05.038
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Miranda JM, 2015, NUTRIENTS, V7, P706, DOI 10.3390/nu7010706
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Mori M, 2006, J CLIN INVEST, V116, P395, DOI 10.1172/JCI20797
   Nagao A, 2014, JARQ-JPN AGR RES Q, V48, P385, DOI 10.6090/jarq.48.385
   Nakajima E, 2014, EYE, V28, P85, DOI 10.1038/eye.2013.239
   Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408
   Nimalaratne C, 2015, J AGR FOOD CHEM, V63, P2956, DOI 10.1021/jf505615w
   Nolan JM, 2015, J ALZHEIMERS DIS, V44, P1157, DOI 10.3233/JAD-142265
   Oliver J, 2000, J CHROMATOGR A, V881, P543, DOI 10.1016/S0021-9673(00)00329-0
   Penicaud C, 2011, FRUITS, V66, P417, DOI 10.1051/fruits/2011058
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pugliese A, 2014, EUR J NUTR, V53, P501, DOI 10.1007/s00394-013-0555-1
   Rivera SM, 2012, J CHROMATOGR A, V1224, P1, DOI 10.1016/j.chroma.2011.12.025
   Rodriguez-Amaya D.B., 2004, HARVESTPLUS HDB CARO
   Rodriguez-Amaya DB, 2008, J FOOD COMPOS ANAL, V21, P445, DOI 10.1016/j.jfca.2008.04.001
   Sajilata MG, 2008, COMPR REV FOOD SCI F, V7, P29, DOI 10.1111/j.1541-4337.2007.00028.x
   Sandmann G, 2015, ADV BIOCHEM ENG BIOT, V148, P449, DOI 10.1007/10_2014_277
   Santocono M, 2006, J PHOTOCH PHOTOBIO B, V85, P205, DOI 10.1016/j.jphotobiol.2006.07.009
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Song SH, 2011, CELL STRESS CHAPERON, V16, P475, DOI 10.1007/s12192-011-0259-5
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Stengel DB, 2015, METHODS MOL BIOL, V1308, P1, DOI 10.1007/978-1-4939-2684-8_1
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Umeno D, 2005, MICROBIOL MOL BIOL R, V69, P51, DOI 10.1128/MMBR.69.1.51-78.2005
   van der Veen RLP, 2010, OPHTHALMOLOGY, V117, P966, DOI 10.1016/j.ophtha.2009.10.019
   Vaz B, 2005, ORG LETT, V7, P545, DOI 10.1021/ol0478281
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Wang CC, 2010, FOOD CHEM, V120, P184, DOI 10.1016/j.foodchem.2009.10.005
   Wang L, 2014, BRIT J NUTR, V111, P1686, DOI 10.1017/S000711451300411X
   Wegner A, 2011, MED HYPOTHESES, V76, P741, DOI 10.1016/j.mehy.2011.02.013
   Weikel KA, 2014, NUTR REV, V72, P30, DOI 10.1111/nure.12077
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Williams S., 1984, OFFICIAL METHODS ANA
   Woodside JV, 2015, MATURITAS, V80, P63, DOI 10.1016/j.maturitas.2014.10.012
   Woutersen RA, 1999, CRIT REV TOXICOL, V29, P515, DOI 10.1080/10408449991349267
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   Yu BL, 2012, BRIT J NUTR, V108, P611, DOI 10.1017/S0007114511005885
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zhao L, 2015, NATURE, V523, P607, DOI 10.1038/nature14650
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 86
TC 16
Z9 16
U1 0
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0367-326X
EI 1873-6971
J9 FITOTERAPIA
JI Fitoterapia
PD MAR
PY 2016
VL 109
BP 58
EP 66
DI 10.1016/j.fitote.2015.12.009
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DH3KH
UT WOS:000372685400010
PM 26705841
DA 2022-11-30
ER

PT J
AU Dou, XZ
   Duerfeldt, AS
AF Dou, Xiaozheng
   Duerfeldt, Adam S.
TI Small-Molecule Modulation of PPARs for the Treatment of Prevalent
   Vascular Retinal Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE diabetic retinopathy; age-related macular degeneration; retinopathy of
   prematurity; peroxisome proliferator-activated receptor; drug discovery
ID ENDOTHELIAL GROWTH-FACTOR; ACID-BINDING PROTEIN; ACTIVATED
   RECEPTOR-ALPHA; DIABETIC-RETINOPATHY; X-RECEPTOR; NUCLEAR RECEPTORS;
   TNF-ALPHA; MACULAR DEGENERATION; GLOBAL PREVALENCE; GENE-EXPRESSION
AB Vascular-related retinal diseases dramatically impact quality of life and create a substantial burden on the healthcare system. Age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity are leading causes of irreversible blindness. In recent years, the scientific community has made great progress in understanding the pathology of these diseases and recent discoveries have identified promising new treatment strategies. Specifically, compelling biochemical and clinical evidence is arising that small-molecule modulation of peroxisome proliferator-activated receptors (PPARs) represents a promising approach to simultaneously address many of the pathological drivers of these vascular-related retinal diseases. This has excited academic and pharmaceutical researchers towards developing new and potent PPAR ligands. This review highlights recent developments in PPAR ligand discovery and discusses the downstream effects of targeting PPARs as a therapeutic approach to treating retinal vascular diseases.
C1 [Dou, Xiaozheng] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46656 USA.
   [Duerfeldt, Adam S.] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
C3 University of Notre Dame; University of Oklahoma System; University of
   Oklahoma - Norman
RP Duerfeldt, AS (通讯作者)，Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
EM xdou@nd.edu; adam.duerfeldt@ou.edu
OI Duerfeldt, Adam/0000-0002-3130-9890; Dou, Xiaozheng/0000-0001-9897-381X
FU National Eye Institute of the National Institutes of Health
   [R21EY028279, R01EY030472]
FX This work was supported by the National Eye Institute of the National
   Institutes of Health under award numbers R21EY028279 (A.S.D.) and
   R01EY030472 (A.S.D.).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ansquer JC, 2009, CURR PHARM DESIGN, V15, P537, DOI 10.2174/138161209787315701
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Aranda JV, 2019, SEMIN PERINATOL, V43, P360, DOI 10.1053/j.semperi.2019.05.009
   BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007
   Banyard P., 2019, ESSENTIAL PSYCHOL
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018
   BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014
   Bressler NM, 2011, NEW ENGL J MED, V365, P1520, DOI 10.1056/NEJMct0908432
   Cai X, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3789217
   Cano MD, 2008, PPAR RES, V2008, DOI 10.1155/2008/821592
   Capozzi ME, 2013, INVEST OPHTH VIS SCI, V54, P4197, DOI 10.1167/iovs.13-11608
   Chandraratna RAS, 2016, AM J TRANSL RES, V8, P1016
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2443, DOI 10.1016/j.ophtha.2014.07.019
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Choudhary M, 2016, J BIOMOL SCREEN, V21, P1007, DOI 10.1177/1087057116659856
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Ciudin A, 2013, PPAR RES, V2013, DOI 10.1155/2013/686525
   Cummings JL, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0173-2
   Dawson MI, 2012, BBA-MOL CELL BIOL L, V1821, P21, DOI 10.1016/j.bbalip.2011.09.014
   de Carvalho JER, 2018, BIOCHEM BIOPHYS REP, V13, P83, DOI 10.1016/j.bbrep.2018.01.005
   Deng GT, 2017, INVEST OPHTH VIS SCI, V58, P5030, DOI 10.1167/iovs.16-21402
   Ding LX, 2014, AM J PATHOL, V184, P2709, DOI 10.1016/j.ajpath.2014.06.021
   Dou XZ, 2018, BIOORG MED CHEM LETT, V28, P2717, DOI 10.1016/j.bmcl.2018.03.010
   Dou XZ, 2020, J MED CHEM, V63, P2854, DOI 10.1021/acs.jmedchem.9b01189
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Farol Len T, 2004, Expert Rev Anticancer Ther, V4, P180, DOI 10.1586/14737140.4.2.180
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fievet C, 2006, CURR OPIN PHARMACOL, V6, P606, DOI 10.1016/j.coph.2006.06.009
   Floresta G, 2017, EUR J MED CHEM, V138, P854, DOI 10.1016/j.ejmech.2017.07.022
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fruchart JC, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0602-y
   Fruchart JC, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-82
   Furuhashi M., 2017, BIOGENESIS FATTY ACI, DOI [10.1007/978-3-319-43676-0_15-1, DOI 10.1007/978-3-319-43676-0_15-1]
   Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589
   Geloneck MM, 2014, JAMA OPHTHALMOL, V132, P1327, DOI 10.1001/jamaophthalmol.2014.2772
   Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
   Han E, 2017, AM J OPHTHALMOL, V182, P133, DOI 10.1016/j.ajo.2017.07.022
   Hanafy KA, 2011, FEBS LETT, V585, P3821, DOI 10.1016/j.febslet.2011.03.048
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   HARROLD BP, 1969, DIABETES, V18, P285, DOI 10.2337/diab.18.5.285
   Hennuyer N, 2016, ATHEROSCLEROSIS, V249, P200, DOI 10.1016/j.atherosclerosis.2016.03.003
   Hinnah K, 2020, J MED CHEM, V63, P10908, DOI 10.1021/acs.jmedchem.0c00654
   Ho SY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124403
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Hong F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082189
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Huang JK, 2011, NAT NEUROSCI, V14, P45, DOI 10.1038/nn.2702
   Hughes MLR, 2015, J BIOL CHEM, V290, P13895, DOI 10.1074/jbc.M114.605998
   Ishibashi S, 2018, J CLIN LIPIDOL, V12, P173, DOI 10.1016/j.jacl.2017.10.006
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jain M, 2017, Dual PPAR Modulators for the Treatment of Diabetic Retinopathy and Diabetic Eye Diseases, Patent No. [WO 2017/089980 Al, 2017089980]
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Falomir-Lockhart LJ, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00162
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kaiser AB, 2018, DIABETES, V67, DOI 10.2337/db18-202-LB
   Kawasaki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010361
   Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kiss M, 2017, P NATL ACAD SCI USA, V114, P10725, DOI 10.1073/pnas.1700785114
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757
   KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0
   Knickelbein JE, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0786-7
   Kojetin DJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9013
   Krezel W, 2019, MOL CELL ENDOCRINOL, V491, DOI 10.1016/j.mce.2019.04.016
   Larsen AK, 1996, INVEST OPHTH VIS SCI, V37, P2603
   Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168
   Liu RZ, 2008, GENOMICS, V92, P436, DOI 10.1016/j.ygeno.2008.08.003
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu HX, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00783
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCloskey M, 2013, INVEST OPHTH VIS SCI, V54, P2020, DOI 10.1167/iovs.13-11625
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Motojima K, 2000, INT J BIOCHEM CELL B, V32, P1085, DOI 10.1016/S1357-2725(00)00046-7
   Mukherjee R, 2002, J STEROID BIOCHEM, V81, P217, DOI 10.1016/S0960-0760(02)00066-3
   Nakano Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24010114
   National Academies of Sciences Engineering and Medicine, 2016, MAK EYE HLTH POP HLT
   Nissen SE, 2005, JAMA-J AM MED ASSOC, V294, P2581, DOI 10.1001/JAMA.294.20.JOC50147
   Nunez V, 2010, P NATL ACAD SCI USA, V107, P10626, DOI 10.1073/pnas.0913545107
   Oleksiewicz MB, 2008, PPAR RES, V2008, DOI 10.1155/2008/103167
   Painter SL, 2015, BRIT J OPHTHALMOL, V99, P807, DOI 10.1136/bjophthalmol-2014-305561
   Park CW, 2006, DIABETES, V55, P885, DOI 10.2337/diabetes.55.04.06.db05-1329
   Patil R, 2019, J BIOL CHEM, V294, P3720, DOI 10.1074/jbc.RA118.006848
   Pertl L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129383
   Pirat C, 2012, J MED CHEM, V55, P4027, DOI 10.1021/jm101360s
   Pollinger J, 2019, J MED CHEM, V62, P2112, DOI 10.1021/acs.jmedchem.8b01848
   Pradhan AD, 2018, AM HEART J, V206, P80, DOI 10.1016/j.ahj.2018.09.011
   Raza-Iqbal S, 2015, J ATHEROSCLER THROMB, V22, P754, DOI 10.5551/jat.28720
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   Rivera JC, 2011, NEONATOLOGY, V100, P343, DOI 10.1159/000330174
   Sankar MJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009734.pub3
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Sasaki Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225682
   Savage SR, 2015, MOL VIS, V21, P568
   Schachtrup C, 2004, BIOCHEM J, V382, P239, DOI 10.1042/BJ20031340
   Schroeder F, 2008, LIPIDS, V43, P1, DOI 10.1007/s11745-007-3111-z
   Shiono A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67579-1
   Simo R, 2015, PROG RETIN EYE RES, V48, P160, DOI 10.1016/j.preteyeres.2015.04.003
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Singh Ajay, 2009, Int Ophthalmol Clin, V49, P1, DOI 10.1097/IIO.0b013e31819fd164
   Song MK, 2012, BRIT J PHARMACOL, V165, P4, DOI 10.1111/j.1476-5381.2011.01411.x
   Stone W.L., 2020, RETINOPATHY
   Su XY, 2016, INVEST OPHTH VIS SCI, V57, P3397, DOI 10.1167/iovs.15-18542
   Suarez S, 2014, INVEST OPHTH VIS SCI, V55, P8232, DOI 10.1167/iovs.14-14217
   Tajnsek S, 2020, PPAR RES, V2020, DOI 10.1155/2020/1783564
   Takada I, 2020, EXPERT OPIN THER PAT, V30, P1, DOI 10.1080/13543776.2020.1703952
   Takei K, 2017, J PHARMACOL SCI, V133, P214, DOI 10.1016/j.jphs.2017.02.003
   Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002
   Tobita Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155296
   Tomita Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235878
   Treacy MP, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-46
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Velkov T, 2013, PPAR RES, V2013, DOI 10.1155/2013/938401
   Wang L, 2015, NEUROCHEM RES, V40, P713, DOI 10.1007/s11064-015-1517-1
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.16
   Wang YT, 2016, EXPERT OPIN THER PAT, V26, P767, DOI 10.1080/13543776.2016.1182500
   WHO, CALLS GLOB ACT HALT
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamamoto Y, 2018, BIOCHEM BIOPH RES CO, V499, P239, DOI 10.1016/j.bbrc.2018.03.135
   Yamazaki Y, 2007, BIOORG MED CHEM LETT, V17, P4689, DOI 10.1016/j.bmcl.2007.05.066
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang S, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/275435
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 142
TC 4
Z9 4
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 23
AR 9251
DI 10.3390/ijms21239251
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PD4EI
UT WOS:000597639500001
PM 33291567
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Braun, PX
   Mehta, N
   Gendelman, I
   Alibhai, AY
   Baumal, CR
   Duker, JS
   Waheed, NK
AF Braun, Phillip X.
   Mehta, Nihaal
   Gendelman, Isaac
   Alibhai, A. Yasin
   Baumal, Caroline R.
   Duker, Jay S.
   Waheed, Nadia K.
TI Using the Pathophysiology of Dry AMD to Guide Binarization of the
   Choriocapillaris on OCTA: A Model
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE binarization; quantification; choriocapillaris; OCTA; AMD
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MACULAR DEGENERATION; FLOW DEFICITS;
   FEATURES; DENSITY; DRUSEN; EYES
AB Especially since the incorporation of swept laser sources, optical coherence tomography angiography (OCTA) has enabled quantification of choriocapillaris perfusion. A critical step in this process is binarization, which makes angiographic images quantifiable in terms of perfusion metrics. It remains challenging to have confidence that choriocapillaris perfusion metrics reflect the reality of pathophysiologic flow, largely because choice of binarization method can result in significantly different perfusion metric outcomes. This commentary discusses a proof-of-concept case involving comparative assessment of binarization methods for a set of dry age-related macular degeneration OCTA data. One of these methods was deemed preferable based on superior agreement with suspected physiologic and pathophysiologic characteristics, thus demonstrating the principle that, in the absence of gold standards for measurement of choriocapillaris perfusion, the best available approximations of pathophysiology may be used to guide choice of binarization method.
C1 [Braun, Phillip X.] Univ Rochester, Med Ctr, Flaum Eye Inst, Rochester, NY 14642 USA.
   [Mehta, Nihaal] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Gendelman, Isaac] Tufts Med Ctr, Dept Surg, Boston, MA 02116 USA.
   [Alibhai, A. Yasin; Baumal, Caroline R.; Duker, Jay S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, 260 Tremont St, Boston, MA 02116 USA.
C3 University of Rochester; University of Colorado System; University of
   Colorado Denver; Tufts Medical Center; Tufts Medical Center
RP Waheed, NK (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 260 Tremont St, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
FU Macula Vision Research Foundation (West Conshohocken, PA); National
   Institutes of Health [5-R01-EY011289-31]; Air Force Office of Scientific
   Research [FA9550-15-1-0473]; Champalimaud Vision Award (Lisbon,
   Portugal); Beckman-Argyros Award in Vision Research (Irvine, CA); Yale
   School of Medicine Medical Student Fellowship (New Haven, CT); National
   Institutes of Health-National Institute of Diabetes and Digestive and
   Kidney Medical Student Research Fellowship; National Institutes of
   Health Clinical and Translational Science Award Multidisciplinary
   Pre-Doctoral Training Program in Translational Research (New Haven, CT);
   Research to Prevent Blindness Challenge Grant (NewYork, NY);
   Massachusetts Lions Clubs (Belmont, MA)
FX Supported by the Macula Vision Research Foundation (West Conshohocken,
   PA), Massachusetts Lions Clubs (Belmont, MA), National Institutes of
   Health (grant no. 5-R01-EY011289-31), Air Force Office of Scientific
   Research (grant no. FA9550-15-1-0473), Champalimaud Vision Award
   (Lisbon, Portugal), Beckman-Argyros Award in Vision Research (Irvine,
   CA), Yale School of Medicine Medical Student Fellowship (New Haven, CT),
   National Institutes of Health-National Institute of Diabetes and
   Digestive and Kidney Medical Student Research Fellowship, National
   Institutes of Health Clinical and Translational Science Award
   Multidisciplinary Pre-Doctoral Training Program in Translational
   Research (New Haven, CT), and Research to Prevent Blindness Challenge
   Grant (NewYork, NY). The funding organizations had no role in the design
   or conduct of this research.
CR Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Arya M, 2018, OSLI RETINA, V49, pS5, DOI 10.3928/23258160-20180814-02
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Braun PX, 2019, INVEST OPHTH VIS SCI, V60, P4985, DOI 10.1167/iovs.19-27861
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2018, QUANT IMAG MED SURG, V8, P1102, DOI 10.21037/qims.2018.12.09
   Mehta N, 2019, AM J OPHTHALMOL, V205, P54, DOI 10.1016/j.ajo.2019.03.008
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Rabiolo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205773
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shi YY, 2020, AM J OPHTHALMOL, V209, P18, DOI 10.1016/j.ajo.2019.09.017
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2020
VL 9
IS 8
AR 44
DI 10.1167/tvst.9.8.44
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MY9IV
UT WOS:000558734000018
PM 32855890
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xie, MZ
   Li, J
   Jiang, T
AF Xie, Minzhu
   Li, Jing
   Jiang, Tao
TI Detecting genome-wide epistases based on the clustering of relatively
   frequent items
SO BIOINFORMATICS
LA English
DT Article
ID MULTIFACTOR-DIMENSIONALITY REDUCTION; GENE-GENE INTERACTIONS;
   ASSOCIATION ANALYSIS; SUSCEPTIBILITY LOCI; HUMAN-DISEASES; MODELS;
   INFERENCE; CANCER
AB Motivation: In genome-wide association studies (GWAS), up to millions of single nucleotide polymorphisms (SNPs) are genotyped for thousands of individuals. However, conventional single locus-based approaches are usually unable to detect gene-gene interactions underlying complex diseases. Due to the huge search space for complicated high order interactions, many existing multi-locus approaches are slow and may suffer from low detection power for GWAS.
   Results: In this article, we develop a simple, fast and effective algorithm to detect genome-wide multi-locus epistatic interactions based on the clustering of relatively frequent items. Extensive experiments on simulated data show that our algorithm is fast and more powerful in general than some recently proposed methods. On a real genome-wide case-control dataset for age-related macular degeneration (AMD), the algorithm has identified genotype combinations that are significantly enriched in the cases.
C1 [Xie, Minzhu; Jiang, Tao] Univ Calif Riverside, Dept Comp Sci & Engn, Riverside, CA 92521 USA.
   [Xie, Minzhu] Hunan Normal Univ, Coll Phys & Informat Sci, Changsha 410081, Hunan, Peoples R China.
   [Li, Jing] Case Western Reserve Univ, Dept Elect Engn & Comp Sci, Cleveland, OH 44106 USA.
C3 University of California System; University of California Riverside;
   Hunan Normal University; Case Western Reserve University
RP Xie, MZ (通讯作者)，Univ Calif Riverside, Dept Comp Sci & Engn, Riverside, CA 92521 USA.
EM minzhux@cs.ucr.edu; jingli@cwru.edu
RI Jiang, Tao/AGX-8391-2022; jiang, tao/GWC-7108-2022
OI Jiang, Tao/0000-0003-3833-4498; Li, Jing/0000-0003-1160-6959
FU National Institutes of Health/National Library of Medicine [2R01LM008
   991]; National Natural Science Foundation of China [61070145]; NATIONAL
   LIBRARY OF MEDICINE [R01LM008991] Funding Source: NIH RePORTER
FX National Institutes of Health/National Library of Medicine grant
   (2R01LM008 991); National Natural Science Foundation of China grant
   (61070145) in part.
CR Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cattaert T, 2011, ANN HUM GENET, V75, P78, DOI 10.1111/j.1469-1809.2010.00604.x
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759
   Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521
   Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284
   Gui J, 2011, ANN HUM GENET, V75, P20, DOI 10.1111/j.1469-1809.2010.00624.x
   Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700
   He QC, 2011, BIOINFORMATICS, V27, P1, DOI 10.1093/bioinformatics/btq600
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li JH, 2011, BIOINFORMATICS, V27, P516, DOI 10.1093/bioinformatics/btq688
   Li J, 2011, BIOINFORMATICS, V27, pI222, DOI 10.1093/bioinformatics/btr227
   Li Jing, 2008, Int J Bioinform Res Appl, V4, P150, DOI 10.1504/IJBRA.2008.018342
   Li WT, 2000, HUM HERED, V50, P334, DOI 10.1159/000022939
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Melum E, 2011, NAT GENET, V43, P17, DOI 10.1038/ng.728
   Moore JH, 2010, BIOINFORMATICS, V26, P445, DOI 10.1093/bioinformatics/btp713
   Nelson MR, 2001, GENOME RES, V11, P458, DOI 10.1101/gr.172901
   NEUMAN RJ, 1992, GENET EPIDEMIOL, V9, P347, DOI 10.1002/gepi.1370090506
   OORD EJ, 2008, ARCH GEN PSYCHIAT, V65, P1062
   Park MY, 2008, BIOSTATISTICS, V9, P30, DOI 10.1093/biostatistics/kxm010
   Phillips PC, 2008, NAT REV GENET, V9, P855, DOI 10.1038/nrg2452
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Ritchie MD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-28
   Schwarz DF, 2010, BIOINFORMATICS, V26, P1752, DOI 10.1093/bioinformatics/btq257
   Stuart PE, 2010, NAT GENET, V42, P1000, DOI 10.1038/ng.693
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Wan XA, 2010, BIOINFORMATICS, V26, P2517, DOI 10.1093/bioinformatics/btq486
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   Wan X, 2010, BIOINFORMATICS, V26, P30, DOI 10.1093/bioinformatics/btp622
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
NR 34
TC 60
Z9 61
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD JAN 1
PY 2012
VL 28
IS 1
BP 5
EP 12
DI 10.1093/bioinformatics/btr603
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA 866MA
UT WOS:000298383800002
PM 22053078
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Chen, L
   Bai, YJ
   Zhao, M
   Jiang, YR
AF Chen, Li
   Bai, Yujing
   Zhao, Min
   Jiang, Yanrong
TI TLR4 inhibitor attenuates amyloid-beta-induced angiogenic and
   inflammatory factors in ARPE-19 cells: Implications for age-related
   macular degeneration
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE toll-like receptor 4; amyloid-beta; angiogenic factors; inflammatory
   factors; retinal pigment epithelial
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; CYTOKINE PRODUCTION;
   ALZHEIMERS-DISEASE; IN-VITRO; ACTIVATION; EXPRESSION; PROTEIN;
   PATHOGENESIS; PEPTIDE
AB Subretinally-deposited amyloid-beta (A beta) is an important factor in age-related macular degradation (AMD) often leading to irreversible blindness in the elderly population. The molecular mechanism underlying A beta deposition during AMD remains unclear. The expression of inflammatory and angiogenic factors was examined by treatment of retinal pigment epithelial (RPE) cells with the oligomeric form of A beta (OA beta 1-42). Changes in the mRNA expression levels of various cytokines was detected by the QuantiGenePlex 6.0 Reagent system, and the protein expression level was determined by western blotting. Culture supernatants were detected using a multiplex cytokine assay and enzyme-linked immunosorbent assays. The in vitro tube formation was evaluated by a Matrigel assay. The present study highlights that OA beta 1-42 activates the toll-like receptor 4 (TLR4), myeloid differentiation factor 88 and phosphorylation nuclear factor-kappa B signaling pathway in RPE cells. Additionally, it increased the mRNA and protein expression of interleukin (IL)-6, IL-8, IL-33, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiopoietin 2. Furthermore, the TLR4 inhibitor (COBRA) attenuated the expression of inflammatory and angiogenesis factors, particularly IL-6, IL-8, IL-33, bFGF and VEGF. When human umbilical vein endothelial cells (HUVECs) were co-cultured with the COBRA-treated RPE cell culture supernatant the length of the endothelial cell network (measured by calculating tip cell lengths of endothelial cells) was impaired when compared with the HUVECs that were co-cultured with the cell supernatant exposed to OA beta 1-42. These results suggest that the TLR4-associated pathway may be a potential target for the treatment of AMD.
C1 [Chen, Li; Bai, Yujing; Zhao, Min; Jiang, Yanrong] Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Chen, Li; Bai, Yujing; Zhao, Min; Jiang, Yanrong] Minist Educ, Key Lab Vis Loss & Restorat, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Chen, Li; Bai, Yujing; Zhao, Min; Jiang, Yanrong] Beijing Key Lab Diag & Therapy Retinal & Choroid, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Chen, Li] Xian 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi, Peoples R China.
C3 Peking University
RP Bai, YJ; Jiang, YR (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen South St, Beijing 100044, Peoples R China.; Bai, YJ; Jiang, YR (通讯作者)，Minist Educ, Key Lab Vis Loss & Restorat, 11 Xizhimen South St, Beijing 100044, Peoples R China.; Bai, YJ; Jiang, YR (通讯作者)，Beijing Key Lab Diag & Therapy Retinal & Choroid, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM baiyujing93@gmail.com; drjyr@gmail.com
OI Zhao, Min/0000-0003-0521-9186
FU Beijing Nova Program [Z131102000413004]
FX The present study was supported by the Beijing Nova Program (grant no.
   Z131102000413004).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Bryant CE, 2010, NAT REV MICROBIOL, V8, P8, DOI 10.1038/nrmicro2266
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882
   Fioravanzo L, 2010, CURR ALZHEIMER RES, V7, P591, DOI 10.2174/156720510793499020
   Gouras GK, 2015, NEUROTHERAPEUTICS, V12, P3, DOI 10.1007/s13311-014-0313-y
   Hoyer W, 2008, P NATL ACAD SCI USA, V105, P5099, DOI 10.1073/pnas.0711731105
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jantaratnotai N, 2013, J ALZHEIMERS DIS, V37, P367, DOI 10.3233/JAD-122191
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mohr T, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-231
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Park MY, 2014, NUTR RES PRACT, V8, P516, DOI 10.4162/nrp.2014.8.5.516
   Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935
   Qi Y, 2014, INVEST OPHTH VIS SCI, V55, P5466, DOI 10.1167/iovs.14-14380
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Smith PD, 2014, J IMMUNOL, V193, P5604, DOI 10.4049/jimmunol.1302608
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Teplow DB, 2006, ACCOUNTS CHEM RES, V39, P635, DOI 10.1021/ar050063s
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhou X, 2014, NUTRITION, V30, P90, DOI 10.1016/j.nut.2013.06.006
NR 37
TC 19
Z9 20
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2016
VL 13
IS 4
BP 3249
EP 3256
DI 10.3892/mmr.2016.4890
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DI6AR
UT WOS:000373582100040
PM 26936827
OA Bronze
DA 2022-11-30
ER

PT J
AU Fan, H
   Song, JT
AF Fan, Hua
   Song, Jian-Tao
TI Potential mechanisms of macular degeneration protection by fatty fish
   consumption
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID LONG-CHAIN; DOCOSAHEXAENOIC ACID; DISEASE; OMEGA-3; PHOSPHOLIPIDS;
   PREVALENCE; METABOLISM; RETINA; RISK; N-3
AB Age-related macular degeneration (AMD) is a progressive retinal disease that is a leading cause of visual impairment and severe vision loss. The number of people affected by AMD is increasing and constitutes a huge worldwide health problem. The beneficial effects of fish consumption on AMD have been revealed over the past decades, and in this review, we summarizes the beneficial effects of fatty fish on AMD and its mechanism of action. Fatty fish affects the development of AMD by inhibiting neovascularization, interacting with retinal pigment epithelial (RPE) cells, displacing Omega-6, and inducing cellular responses. It is recommended that people at high risk or with moderate or more severe AMD should consider eating more fatty fish in addition to maintaining a healthy lifestyle of weight control and smoking cessation and the need to promote new models of personalized AMD prevention and treatment.
C1 [Fan, Hua; Song, Jian-Tao] China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Eye Hospital, CACMS
RP Song, JT (通讯作者)，China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
EM Jangts@163.com
OI Fan, Hua/0000-0003-2942-9495
FU Capital Health Development Scientific Research Project [2016-2-4138];
   Eye Hospital of China Academy of Chinese Medical Sciences Scientific
   Research fund [202001]
FX This work was supported by grants from Capital Health Development
   Scientific Research Project (2016-2-4138), Eye Hospital of China Academy
   of Chinese Medical Sciences Scientific Research fund (202001). We
   greatly appreciate Prof. Joshua Dunaief Scheie Eye Institute, University
   of Pennsylvania for his correction and great comments on this
   manuscript.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Arslan S, 2019, J AM COLL NUTR, V38, P424, DOI 10.1080/07315724.2018.1538830
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   deTurco EBR, 1997, J BIOL CHEM, V272, P10491
   DETURCO EBR, 1990, J NEUROSCI RES, V27, P522, DOI 10.1002/jnr.490270413
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Harris MA, 2001, PROSTAG LEUKOTR ESS, V65, P23, DOI 10.1054/plef.2001.0283
   Ibuki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238940
   Jacob J, 2021, OPHTHALMOL THER, V10, P299, DOI 10.1007/s40123-021-00335-4
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Juhee Kim, 2021, FRONT CELL NEUROSCI, V15, P638098
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Leung HH, 2020, NEUROCHEM RES, V45, P1007, DOI 10.1007/s11064-020-02994-4
   Leung HH, 2019, FREE RADICAL BIO MED, V145, P349, DOI 10.1016/j.freeradbiomed.2019.10.007
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Lorente-Cebrian S, 2015, J PHYSIOL BIOCHEM, V71, P341, DOI 10.1007/s13105-015-0395-y
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Merle BMJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062047
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Montserrat-de la Paz S, 2016, FOOD FUNCT, V7, P1345, DOI [10.1039/c6fo00136j, 10.1039/C6FO00136J]
   Nelson G. J., 2000, Fatty acids in foods and their health implications., P481
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Paez-Escamilla M, 2021, SURV OPHTHALMOL, V66, P153, DOI 10.1016/j.survophthal.2020.08.005
   Paraoan L, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100859
   Rutledge GA, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01742-0
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Santos FF, 1995, INT OPHTHALMOL, V19, P149, DOI 10.1007/BF00133731
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Simon E, 2011, EXP EYE RES, V93, P628, DOI 10.1016/j.exer.2011.07.016
   Singh JE, 2020, CURR NUTR REP, V9, P264, DOI 10.1007/s13668-020-00329-x
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753-4887.2010.00287.x
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang AC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041179
   Zhang TT, 2019, PROG LIPID RES, V75, DOI 10.1016/j.plipres.2019.100997
NR 56
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD APR
PY 2022
VL 63
AR 102186
DI 10.1016/j.coph.2022.102186
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2P7PA
UT WOS:000819926800005
PM 35217394
OA hybrid
DA 2022-11-30
ER

PT J
AU Stallivieri, A
   Baros, F
   Jetpisbayeva, G
   Myrzakhmetov, B
   Frochot, C
AF Stallivieri, Aurelie
   Baros, Francis
   Jetpisbayeva, Gulim
   Myrzakhmetov, Bauyrzhan
   Frochot, Celine
TI The Interest of Folic Acid in Targeted Photodynamic Therapy
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Folic acid; nanoparticle; photodynamic therapy; photosensitizer; singlet
   oxygen
ID FOLATE BINDING-PROTEIN; CANCER; RECEPTOR; DELIVERY; PHOTOSENSITIZERS;
   NANOPARTICLES; CELLS; LIPOSOMES; ALPHA; NANOCARRIERS
AB Photodynamic therapy is an alternative to chemotherapy and radiotherapy for cancer treatment. PDT is clinically applied to treat age-related macular degeneration and several types of cancer. Most of the time, the selectivity of the treatment is brought about by the application of light. Another strategy to improve selectivity is to design and synthesize targeted photosensitizers or nanoparticles, which can identify and selectively accumulate within tumor tissues. This review presents our inventory of all the data concerning the use of folic acid as a promising targeting unit to improve the selectivity of photosensitizers to folic acid receptors. We will discuss the strategies that are developed to couple folic acid to photosensitizers or nanoparticles as well as the influence of the presence of folic acid on the objects' photophysical properties and their effects on selectivity and phototoxicity in vitro and in vivo.
C1 [Stallivieri, Aurelie; Baros, Francis; Jetpisbayeva, Gulim; Myrzakhmetov, Bauyrzhan; Frochot, Celine] Univ Lorraine, CNRS, UMR 7274, Lab React & Genie Proc, F-54001 Nancy, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute
   for Engineering & Systems Sciences (INSIS); Universite de Lorraine
RP Frochot, C (通讯作者)，GDR 3049 Medicaments Photoactivables Photochimiot, Nancy, France.
EM celine.frochot@univ-lorraine.fr
RI Myrzakhmetov, Bauyrzhan/AAW-8260-2020; Myrzakhmetov,
   Bauyrzhan/GZG-7925-2022
OI Myrzakhmetov, Bauyrzhan/0000-0002-6828-0649; 
CR Amiji MM, 2006, NANOTECHNOLOGY CANC
   Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441
   Azais H., INT J GYNEC IN PRESS
   Azais H, 2014, B CANCER, V101, P1109, DOI 10.1684/bdc.2014.1977
   Bae BC, 2010, BIOMATERIALS, V31, P6325, DOI 10.1016/j.biomaterials.2010.04.030
   Bugaj AM, 2011, PHOTOCH PHOTOBIO SCI, V10, P1097, DOI 10.1039/c0pp00147c
   Bulin AL, 2013, J PHYS CHEM C, V117, P21583, DOI 10.1021/jp4077189
   Chatterjee DK, 2008, NANOMEDICINE-UK, V3, P73, DOI 10.2217/17435889.3.1.73
   Chen W., 2007, Nanoparticles based photodynamic therapy and methods of making and using some, Patent No. [US 20070218049, 20070218049]
   Cui SS, 2013, ACS NANO, V7, P676, DOI 10.1021/nn304872n
   de Nonancourt-Didion M, 2001, CANCER LETT, V171, P139, DOI 10.1016/S0304-3835(01)00552-3
   Fan JQ, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1911-z
   Fan JQ, 2013, SMALL, V9, P613, DOI 10.1002/smll.201201456
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   Garcia Diaz M., 2012, THESIS U RAMON LLULL
   Gravier J, 2008, J MED CHEM, V51, P3867, DOI 10.1021/jm800125a
   Hilgenbrink AR, 2005, J PHARM SCI-US, V94, P2135, DOI 10.1002/jps.20457
   Hu Z, 2013, J MATER CHEM B, V1, P5003, DOI 10.1039/c3tb20849d
   Huang P, 2011, THERANOSTICS, V1, P240, DOI 10.7150/thno/v01p0240
   KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983
   Ke MR, 2013, J MED CHEM, V56, P8475, DOI 10.1021/jm4009168
   Khoza P, 2013, J LUMIN, V134, P784, DOI 10.1016/j.jlumin.2012.06.048
   Kim SH, 2008, EUR J PHARM BIOPHARM, V68, P618, DOI 10.1016/j.ejpb.2007.08.010
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Li DH, 2013, J PHOTOCH PHOTOBIO B, V127, P28, DOI 10.1016/j.jphotobiol.2013.06.008
   Li L, 2011, CARBOHYD POLYM, V86, P708, DOI 10.1016/j.carbpol.2011.05.011
   Ling D, 2012, BIOMATERIALS, V33, P5478, DOI 10.1016/j.biomaterials.2012.04.023
   Lo YL, 2015, J BIOMED NANOTECHNOL, V11, P1385, DOI 10.1166/jbn.2015.2081
   Low PS, 2008, ACCOUNTS CHEM RES, V41, P120, DOI 10.1021/ar7000815
   LUHRS CA, 1989, J BIOL CHEM, V264, P21446
   MANTOVANI LT, 1994, EUR J CANCER, V30A, P363, DOI 10.1016/0959-8049(94)90257-7
   Moret F, 2013, PHOTOCH PHOTOBIO SCI, V12, P823, DOI 10.1039/c3pp25384h
   Morosini V, 2011, PHOTOCH PHOTOBIO SCI, V10, P842, DOI 10.1039/c0pp00380h
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   Qualls MM, 2001, INT J CANCER, V93, P384, DOI 10.1002/ijc.1339
   Reddy JA, 2005, CURR PHARM BIOTECHNO, V6, P131, DOI 10.2174/1389201053642376
   Salazar MD, 2007, CANCER METAST REV, V26, P141, DOI 10.1007/s10555-007-9048-0
   Saul JM, 2003, J CONTROL RELEASE, V92, P49, DOI 10.1016/S0168-3659(03)00295-5
   Schneider RL, 2005, BIOORGAN MED CHEM, V13, P2799, DOI 10.1016/j.bmc.2005.02.025
   Sega EI, 2008, CANCER METAST REV, V27, P655, DOI 10.1007/s10555-008-9155-6
   Selvestrel F, 2013, NANOSCALE, V5, P6106, DOI 10.1039/c3nr00402c
   Shahnaz K, 2015, RES J BIOTECHNOL, V10, P27
   Shanmugam V, 2014, ACS APPL MATER INTER, V6, P4382, DOI 10.1021/am5000905
   Shi JJ, 2014, BIOMATERIALS, V35, P5771, DOI 10.1016/j.biomaterials.2014.03.071
   Stefflova K, 2006, MOL IMAGING, V5, P520, DOI 10.2310/7290.2006.00027
   Stefflova K, 2007, BIOCONJUGATE CHEM, V18, P379, DOI 10.1021/bc0602578
   Syu WJ, 2012, SMALL, V8, P2060, DOI 10.1002/smll.201102695
   Teng IT, 2013, BIOMATERIALS, V34, P7462, DOI 10.1016/j.biomaterials.2013.06.001
   Tran TH, 2013, CARBOHYD POLYM, V92, P1615, DOI 10.1016/j.carbpol.2012.10.075
   Tian JW, 2013, J AM CHEM SOC, V135, P18850, DOI 10.1021/ja408286k
   van Dam GM, 2011, NAT MED, V17, P1315, DOI 10.1038/nm.2472
   Wang F., 2010, J MATER CHEM, V22, P24597
   Wang HJ, 2014, ACS APPL MATER INTER, V6, P3219, DOI 10.1021/am500097f
   Wang S, 1996, BIOCONJUGATE CHEM, V7, P56, DOI 10.1021/bc9500709
   Wang S, 2014, J MATER CHEM B, V2, P1594, DOI 10.1039/c3tb21620a
   Yang XJ, 2013, J MATER CHEM B, V1, P2757, DOI 10.1039/c3tb00575e
   Zhang YR, 2014, ANAL CHEM, V86, P3092, DOI 10.1021/ac404201s
   Zhao L, 2013, J MATER CHEM B, V1, P5806, DOI 10.1039/c3tb20933d
   Zhao LL, 2013, J BIOMATER APPL, V28, P434, DOI 10.1177/0885328212459777
   Zheng G., 2010, U.S. Patent, Patent No. [2010/0075899 A1, 20100075899]
NR 60
TC 21
Z9 21
U1 1
U2 50
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2015
VL 22
IS 27
BP 3185
EP 3207
DI 10.2174/0929867322666150729113912
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CS5JF
UT WOS:000362113600005
PM 26219395
DA 2022-11-30
ER

PT J
AU Baltmr, A
   Lightman, S
   Tomkins-Netzer, O
AF Baltmr, Abeir
   Lightman, Sue
   Tomkins-Netzer, Oren
TI Examining the Choroid in Ocular Inflammation: A Focus on Enhanced Depth
   Imaging
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY;
   KOYANAGI-HARADA-DISEASE; BIRDSHOT CHORIORETINOPATHY; GLOBAL
   REASSESSMENT; MEMORIAL-LECTURE; THICKNESS; TOXOPLASMOSIS; MANAGEMENT;
   DIAGNOSIS
AB The choroid is the vascular layer that supplies the outer retina and is involved in the pathogenesis of several ocular conditions including choroidal tumors, age related macular degeneration, central serous chorioretinopathy, diabetic retinopathy, and uveitis. Nevertheless, difficulties in the visualization of the choroid have limited our understanding of its exact role in ocular pathology. Enhanced depth imaging optical coherent topography (EDI-OCT) is a novel, noninvasive technique that is used to evaluate choroidal thickness and morphology in these diseases. The technique provides detailed objective in vivo visualization of the choroid and can be used to characterize posterior segment inflammatory disorders, monitor disease activity, and evaluate efficacy of treatment. In this review we summarize the current application of this technique in ocular inflammatory disorders and highlight its utility as an additional tool in monitoring choroidal involvement in ocular inflammation.
C1 [Baltmr, Abeir; Lightman, Sue; Tomkins-Netzer, Oren] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Lightman, Sue; Tomkins-Netzer, Oren] UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Baltmr, A (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
EM a.baltmr@alumni.ucl.ac.uk
OI Tomkins-Netzer, Oren/0000-0002-1015-1641
CR Atmaca LS, 2006, GRAEF ARCH CLIN EXP, V244, P1688, DOI 10.1007/s00417-006-0345-z
   Auer C, 1998, AM J OPHTHALMOL, V126, P471, DOI 10.1016/S0002-9394(98)00119-6
   Bansal R, 2010, INDIAN J OPHTHALMOL, V58, P45, DOI 10.4103/0301-4738.58471
   CHARTERIS DG, 1992, AUTOIMMUNITY, V12, P201, DOI 10.3109/08916939209148460
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coskun E, 2013, OCUL IMMUNOL INFLAMM, V21, P440, DOI 10.3109/09273948.2013.817591
   da Silva FT, 2013, BRIT J OPHTHALMOL, V97, P70, DOI 10.1136/bjophthalmol-2012-302089
   Desai UR, 2001, RETINA-J RET VIT DIS, V21, P40, DOI 10.1097/00006982-200102000-00007
   Fardeau C, 1999, OPHTHALMOLOGY, V106, P1928, DOI 10.1016/S0161-6420(99)90403-7
   Fleischman D, 2012, OCUL IMMUNOL INFLAMM, V20, P300, DOI 10.3109/09273948.2012.682637
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Fonollosa A, 2008, OCUL IMMUNOL INFLAMM, V16, P242, DOI 10.1080/09273940802311769
   Fuchs E., 1905, GRAEFES ARCH CLIN EX, V61, P365, DOI 10.1007/BF01969717
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Goldenberg D, 2013, GRAEF ARCH CLIN EXP, V251, P2037, DOI 10.1007/s00417-013-2334-3
   Gross NE, 2006, ARCH OPHTHALMOL-CHIC, V124, P493, DOI 10.1001/archopht.124.4.493
   HAKIN KN, 1992, EYE, V6, P453, DOI 10.1038/eye.1992.95
   Hirukawa K, 2013, GRAEF ARCH CLIN EXP, V251, P2273, DOI 10.1007/s00417-013-2265-z
   Holland GN, 2004, AM J OPHTHALMOL, V137, P1, DOI 10.1016/j.ajo.2003.10.032
   Holland GN, 2003, AM J OPHTHALMOL, V136, P973, DOI 10.1016/j.ajo.2003.09.040
   Howe LJ, 1997, EYE, V11, P554, DOI 10.1038/eye.1997.142
   Iaccarino G, 2009, OPHTHALMOLOGICA, V223, P250, DOI 10.1159/000209274
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ishibazawa A, 2014, INT OPHTHALMOL, V34, P679, DOI 10.1007/s10792-013-9849-9
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Karampelas M, 2013, GRAEF ARCH CLIN EXP, V251, P2029, DOI 10.1007/s00417-013-2330-7
   Keane PA, 2013, JAMA OPHTHALMOL, V131, P341, DOI 10.1001/jamaophthalmol.2013.1724
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim M, 2013, INVEST OPHTH VIS SCI, V54, P6033, DOI 10.1167/iovs.13-12231
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lingappan A, 2012, AM J OPHTHALMOL, V153, P162, DOI 10.1016/j.ajo.2011.06.020
   Lobo A, 2003, CLIN EXP OPHTHALMOL, V31, P310, DOI 10.1046/j.1442-9071.2003.00666.x
   Mahendradas P, 2010, OCUL IMMUNOL INFLAMM, V18, P408, DOI 10.3109/09273948.2010.498656
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   McCluskey PJ, 1999, OPHTHALMOLOGY, V106, P2380, DOI 10.1016/S0161-6420(99)90543-2
   Modi YS, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-58
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mrejen Sarah, 2012, Int Ophthalmol Clin, V52, P67, DOI 10.1097/IIO.0b013e318265f676
   Muhaya M, 2000, OCUL IMMUNOL INFLAMM, V8, P141, DOI 10.1076/0927-3948(200009)8:3;1-K;FT141
   Nakayama M, 2012, RETINA-J RET VIT DIS, V32, P2061, DOI 10.1097/IAE.0b013e318256205a
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   OLK RJ, 1983, BRIT J OPHTHALMOL, V67, P826, DOI 10.1136/bjo.67.12.826
   Park SC, 2012, OPHTHALMOLOGY, V119, P3, DOI 10.1016/j.ophtha.2011.07.012
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Rao Narsing A., 2007, International Ophthalmology, V27, P81, DOI 10.1007/s10792-006-9029-2
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Sallam A, 2012, RETINA-J RET VIT DIS, V32, P1129, DOI 10.1097/IAE.0b013e31822d3a34
   Schmidt KG, 2001, BRIT J OPHTHALMOL, V85, P678, DOI 10.1136/bjo.85.6.678
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   SPALTON DJ, 1981, BRIT J OPHTHALMOL, V65, P348, DOI 10.1136/bjo.65.5.348
   Takahashi H, 2014, RETINA-J RET VIT DIS, V34, P775, DOI 10.1097/IAE.0b013e3182a6b3f6
   Taki W, 2013, GRAEF ARCH CLIN EXP, V251, P1003, DOI 10.1007/s00417-012-1972-1
   Tian J, 2013, BIOMED OPT EXPRESS, V4, P397, DOI 10.1364/BOE.4.000397
   Torres VLL, 2011, AM J OPHTHALMOL, V151, P586, DOI 10.1016/j.ajo.2010.09.028
   Yannuzzi L. A., 2012, RETINA, V32
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
NR 59
TC 36
Z9 37
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 459136
DI 10.1155/2014/459136
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ9TB
UT WOS:000338054500001
PM 25024846
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
AF Schmitz-Valckenberg, Steffen
TI The Journey of "Geographic Atrophy" through Past, Present, and Future
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Terminology; Nomenclature; History;
   Evolution
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE IMAGES; MACULAR
   DEGENERATION; EYE DISEASE; PROGRESSION; SECONDARY; PHOTOGRAPHS;
   MACULOPATHY; DRUSEN
AB "Geographic atrophy" is a concise term that has been firmly established for the description of the end-stage manifestation of nonexudative age-related macular degeneration (AMD). "Geographic lesions" resembling sharply demarcated continents on a map have been originally described in the German literature in 1854 (landkartenartiger/inselformiger Zungenfratt) for a manifestation later called "geographic tongue" in English. In 1970, Gass was the first to describe "geographic areas of atrophy" in "senile macular choroidal degeneration." Within a decade, the disease itself was named "geographic atrophy." Today, various meanings of the term are used in parallel both in research and in routine clinical care. Currently, we are on the verge of better understanding the different forms of atrophy development, manifestation, and progression in AMD, which will pave the way for a more rational approach to their nomenclature and classification. (C) 2017 S. Karger AG, Basel
C1 [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
CR Abdelfattah NS, 2016, OPHTHALMOLOGY
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DM, 2013, MOSBYS DICT MED NURS
   [Anonymous], 2011, DORLANDS ILLUSTRATED, V32
   BAARSMA GS, 1976, DOC OPHTHALMOL, V40, P269, DOI 10.1007/BF00155041
   Behr C, 1920, MONATSBLATTER AUGENH, V65, P465
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dimmer F, 1927, ATLAS PHOTOGRAPHISCH, V75
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FRANCOIS J, 1952, Ann Ocul (Paris), V185, P136
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   HAMILTON AM, 1974, BRIT J OPHTHALMOL, V58, P784, DOI 10.1136/bjo.58.9.784
   Harms C, 1904, KLIN MONATSBL AUGENH, V42, P448
   Hollwich F, 1963, DER AUGENARZT, VV, P683
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Junius P, 1926, SCHEIBENFORMIGE ENTA
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   KRAFFEL G, 1955, Klin Monbl Augenheilkd Augenarztl Fortbild, V127, P664
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   Prinz H., 1927, DENT COSMOS, V69, P272
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Santlus, 1854, J KINDERKRANKHEITEN, V23, P161
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schlaegel TJ, 1969, ESSENTIALS UVEITIS
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Spehlmann O, 1892, BEITRAGE KENNTNIS LI
   Steinberg JS, 2015, RETINA, V36, P1548
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   THYGESON P, 1956, ARCH OPHTHALMOL-CHIC, V56, P375
   Varoni E, 2016, NEW ENGL J MED, V374, P670, DOI 10.1056/NEJMicm1502932
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 56
TC 9
Z9 9
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 1
BP 11
EP 20
DI 10.1159/000455074
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM5MW
UT WOS:000395356700002
PM 28076857
OA Bronze
DA 2022-11-30
ER

PT J
AU Enseleit, F
   Michels, S
   Ruschitzka, F
AF Enseleit, Frank
   Michels, Stephan
   Ruschitzka, Frank
TI Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye
SO CURRENT HYPERTENSION REPORTS
LA English
DT Article
DE Vascular endothelial growth factor; Age-related macular degeneration;
   Cardiovascular disease; Ranibizumab; Bevacizumab; Pegaptanib
ID INTRAVITREAL BEVACIZUMAB AVASTIN; SENILE MACULAR DEGENERATION;
   AGE-RELATED MACULOPATHY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SYSTEMIC
   BEVACIZUMAB; PHOTODYNAMIC THERAPY; RANIBIZUMAB; ATHEROSCLEROSIS;
   VERTEPORFIN
AB "Wet" (also called neovascular) age-related macular degeneration (AMD) is a chronic progressive disease characterized by leakage of fluid or blood from choroidal neovascularization. It remains the leading cause of blindness in the developed world. Vascular endothelial growth factor (VEGF), which plays a key role in the pathogenesis of retinal neovascularization and vessel leakage leading to central vision loss, has emerged as a potential target in the treatment of wet AMD. Importantly, large-scale clinical trials have demonstrated that intravitreal VEGF antagonism prevents vision loss and may even improve visual acuity in patients with neovascular AMD. Because VEGF and its downstream mediator nitric oxide have a well-established cardioprotective role, however, it can be argued that the beneficial effects of VEGF antagonism in the eye may come at the cost of adverse systemic effects, particularly myocardial infarction and stroke.
C1 [Enseleit, Frank; Ruschitzka, Frank] Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
   [Michels, Stephan] Triemli Hosp Zurich, Dept Ophthalmol, CH-8063 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; Triemli Hospital
RP Ruschitzka, F (通讯作者)，Univ Zurich Hosp, Ramistr 100, CH-8091 Zurich, Switzerland.
EM frank.ruschitzka@usz.ch
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P352, DOI 10.1111/j.1755-3768.2008.01317.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   *CATT, 2008, LUC AV TRIAL
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   DellaCroce JT, 2008, CURR OPIN OPHTHALMOL, V19, P493, DOI 10.1097/ICU.0b013e3283129779
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   *EMEA, 2007, RAN LUC SUMM PROD CH
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geitzenauer W, 2008, RETINA-J RET VIT DIS, V28, P1375, DOI 10.1097/IAE.0b013e3181863f96
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gunn R, 1892, T OPHTHAL SOC UK, V12, P124
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705
   LUSCHER TF, 1990, ENDOTHELIUM MODULATO
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MOSHFEGHI AA, 2002, OPHTHALMOLOGY, V113
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   *U BRIST, 2009, RAND CONTR TRIAL ALT
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
NR 54
TC 10
Z9 10
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1522-6417
EI 1534-3111
J9 CURR HYPERTENS REP
JI Curr. Hypertens. Rep.
PD FEB
PY 2010
VL 12
IS 1
BP 33
EP 38
DI 10.1007/s11906-009-0082-x
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 554VA
UT WOS:000274462100006
PM 20425156
DA 2022-11-30
ER

PT J
AU Shahbazi, S
   Mokhtari-Dizaji, M
   Mansori, MR
AF Shahbazi, Shahriar
   Mokhtari-Dizaji, Manijhe
   Mansori, Mohamad Reza
TI Noninvasive estimation of the ocular elastic modulus for age-related
   macular degeneration in the human eye using sequential ultrasound
   imaging
SO ULTRASONICS
LA English
DT Article
DE Sonography; Elasticity; Ocular; Age-related macular degeneration (AMD)
ID RISK; PATHOGENESIS; RIGIDITY; SMOKING
AB Introduction: Elastic modulus estimation may be an important clinical criterion, as it seems to affect such eye parameters as intraocular pressure, ocular pulsation, blood flow, effect of topical medications, and post-refractive surgery complications. The purpose of this study was to examine the differences in elasticity in the ocular axial length, posterior wall thickness (posterior pole), and retina-choroid thickness under normal and aged-related macular degeneration (AMD) conditions in the human eye by directly estimating the elastic modulus with sequential and noninvasive ultrasound image processing.
   Materials and Methods: In this study, 25 healthy subjects and 20 patients with non-neovascular AMD participated in the experiment. The deformation of the ocular axial length, posterior wall thickness and retina-choroid complex thickness was captured using high-resolution ultrasonography before and after loading. The B-mode (20 MHz) and A-mode (8 MHz) frames were obtained and processed with an echo tracking technique. The elastic modulus was estimated using changes in ocular axial length, posterior wall thickness and retina-choroid complex thickness and with applied stress measurements.
   Results: There was a significant difference (p < 0.05) in the ocular axial length elastic modulus between the AMD and healthy subjects (AMD patients: 95.165 +/- 26.431 kPa, vs. healthy subjects: 49.539 +/- 25.867 kPa). Moreover, there was a statistically significant difference (p < 0.05) in the posterior wall thickness elastic modulus between AMD patients and healthy subjects (AMD patients: 50.519 +/- 12.295 kPa, vs. healthy subjects: 20.519 +/- 11.827 kPa). However, no statistically significant difference (p-value > 0.05) was found in the retina-choroid complex elastic modulus between the two groups (AMD patients: 20.134 +/- 3.898 kPa, vs. healthy subjects: 15.630 +/- 4.250 kPa).
   Conclusion: Although the results were obtained examining a relatively low number of patients, it would appear that noninvasive ultrasound estimation of the local elastic moduli of ocular axial length and posterior wall thickness is suited to aid in detection of the non-exudative AMD thus manifesting its potential as a screening tool in symptom-free individuals. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Shahbazi, Shahriar; Mokhtari-Dizaji, Manijhe] Tarbiat Modares Univ, Dept Med Phys, Tehran, Iran.
   [Mansori, Mohamad Reza] Tehran Med Sci Univ, Farabi Hosp, Tehran, Iran.
C3 Tarbiat Modares University; Tehran University of Medical Sciences
RP Mokhtari-Dizaji, M (通讯作者)，Tarbiat Modares Univ, Dept Med Phys, Tehran, Iran.
EM mokhtarm@modares.ac.ir
RI Dizaji, Manijhe Mokhtari/AAW-3224-2020
OI Dizaji, Manijhe Mokhtari/0000-0003-1598-2038
FU Tarbiat Modares University
FX The authors would like to thank Mr. M. Zarin from Tehran Medical
   Sciences University for imaging protocols. This study was funded by
   Tarbiat Modares University.
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Coleman DJ, 2004, OPHTHALMOLOGY, V111, P1344, DOI 10.1016/j.ophtha.2003.10.029
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Downs J.C., 2009, GLAUCOMA MEDICAL DIA, P67
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedenwald J.S., 1937, AM J OPHTHALMOL, V20, P985, DOI [10.1016/s0002-9394(37)90425-2, DOI 10.1016/S0002-9394(37)90425-2, 10.1016/S0002-9394(37)90425-2]
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Kallel F, 1998, ULTRASOUND MED BIOL, V24, P409, DOI 10.1016/S0301-5629(97)00287-1
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krouskop TA, 1998, ULTRASONIC IMAGING, V20, P260, DOI 10.1177/016173469802000403
   Mokhtari-Dizaji M, 2006, ULTRASOUND MED BIOL, V32, P1493, DOI 10.1016/j.ultrasmedbio.2006.05.023
   Ophir J, 2001, CR ACAD SCI IV-PHYS, V2, P1193, DOI 10.1016/S1296-2147(01)01255-0
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Saada A.S., 1983, ELASTICITY THEORY AP
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Southern Simon, 2009, Australas J Ultrasound Med, V12, P32, DOI 10.1002/j.2205-0140.2009.tb00005.x
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Verhoeff FH, 1937, ARCH OPHTHALMOL-CHIC, V18, P561
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 29
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0041-624X
EI 1874-9968
J9 ULTRASONICS
JI Ultrasonics
PD FEB
PY 2012
VL 52
IS 2
BP 208
EP 214
DI 10.1016/j.ultras.2011.08.004
PG 7
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 852EQ
UT WOS:000297335200002
PM 21944993
DA 2022-11-30
ER

PT J
AU Sever, O
   Mercan, R
AF Sever, Ozkan
   Mercan, Ridvan
TI The effect of long-term systemic immunosuppressive drug use on druse
   formation: a new perspective to age-related macular degeneration
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Druse; systemic immunosuppression; inflammation; age-related macular
   degeneration
ID COMPLEMENT FACTOR-H; BRUCHS MEMBRANE; ACTIVATION; INFLAMMATION;
   INDIVIDUALS; MECHANISM; VARIANT; COMMON
AB Background/aim: To evaluate the effect of the long-term use of systemic immunosuppressive drugs on druse formation in patients aged over 50 years.
   Materials and methods: The current retrospective cohort study includes 420 eyes of 420 patients. 210 eyes of 210 patients who used immunosuppressive drugs (Group 1) at least for the last 5 years and 210 eyes of 210 control patients (Group 2) who did not use any drugs were compared. All patients were older than 50 years and selected among patients who were followed by rheumatology and ophthalmology clinic at a tertiary university hospital. All patients had complete ophthalmic examination, fundus photography and optical coherence tomography (OCT). The primary outcome of this study is the difference in macular and paramacular druse formation rates between two groups.
   Results: Small, intermediate, large, soft, and paramacular druse formation rates were significantly lower in Group 1 than those in Group 2 (P = 0.028, P = 0.001, P = 0.001, P = 0.001, and P = 0.001, respectively).
   Conclusion: Patients who used long-term systemic immunosuppressive drugs had significantly lower hard and soft druse formation rate than age and sex matched control subjects.
C1 [Sever, Ozkan] Namik Kemal Univ, Fac Med, Dept Ophthalmol, Tekirdag, Turkey.
   [Mercan, Ridvan] Namik Kemal Univ, Fac Med, Dept Rheumatol, Tekirdag, Turkey.
C3 Namik Kemal University; Namik Kemal University
RP Sever, O (通讯作者)，Namik Kemal Univ, Fac Med, Dept Ophthalmol, Tekirdag, Turkey.
EM sever_ozkan@hotmail.com
RI mercan, ridvan/W-3342-2017
OI mercan, ridvan/0000-0003-1537-2192; Sever, Ozkan/0000-0003-0829-3912
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Choudhary M, 2018, BBA-MOL BASIS DIS, V1864, P1583, DOI 10.1016/j.bbadis.2018.02.015
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Fox AR, 2017, BRIT J OPHTHALMOL, V101, P342, DOI 10.1136/bjophthalmol-2016-308587
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lesher AM, 2013, MOL IMMUNOL, V56, P191, DOI 10.1016/j.molimm.2013.06.002
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li JQ., 2017, RETINAL DIS EUROPE
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Montesinos MC, 2007, ARTHRITIS RHEUM-US, V56, P1440, DOI 10.1002/art.22643
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Reich O, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0617-x
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Schnabolk G, 2019, INVEST OPHTH VIS SCI, V60, P3520, DOI 10.1167/iovs.18-26444
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Souliotis K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226287
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Becerri EV, 2009, CELL MOL IMMUNOL, V6, P303, DOI 10.1038/cmi.2009.40
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 36
TC 0
Z9 0
U1 0
U2 3
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2020
VL 50
IS 8
BP 1963
EP 1969
DI 10.3906/sag-2001-36
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PH9PR
UT WOS:000600735500027
PM 33128358
OA Green Published
DA 2022-11-30
ER

PT J
AU Owsley, C
   Clark, ME
   Huisingh, CE
   Curcio, CA
   McGwin, G
AF Owsley, Cynthia
   Clark, Mark E.
   Huisingh, Carrie E.
   Curcio, Christine A.
   McGwin, Gerald, Jr.
TI Visual Function in Older Eyes in Normal Macular Health: Association with
   Incident Early Age-Related Macular Degeneration 3 Years Later
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; risk factors; visual function
ID MEDIATED DARK-ADAPTATION; CHEMISTRY STANDARDIZATION PROJECT; CONTRAST
   SENSITIVITY TEST; GEOGRAPHIC ATROPHY; INTERNATIONAL-FEDERATION; A-I;
   ACUITY; MACULOPATHY; IMPAIRMENT; ABNORMALITIES
AB PURPOSE. In older eyes in normal macular health, we examined associations between impaired photopic acuity, mesopic acuity, spatial contrast sensitivity, light sensitivity, and the presence of low luminance deficit (difference between photopic and mesopic acuity) at baseline and incident AMD 3 years later. Associations were compared with an association between delayed rod-mediated dark adaptation and incident AMD, previously reported for this cohort.
   METHODS. Enrollees were 60 years or older. Eyes at step 1 in the AREDS nine-step classification system based on masked grading of color fundus photographs were included. Photopic and mesopic acuity, contrast sensitivity, and light sensitivity, and the presence of low luminance deficit, were measured at baseline. Demographic, lifestyle, general health, and blood markers were assessed at baseline as potential confounders. Three years later fundus grading was repeated to determine AMD presence.
   RESULTS. For the analysis, 827 eyes of 467 persons were eligible. Impaired mesopic acuity at baseline was associated with incident AMD, age-adjusted rate ratio (RR) 1.57 (95% confidence interval [CI] 1.04-2.35), whereas impaired photopic acuity, contrast sensitivity and macular light sensitivity, and the presence of a low luminance deficit were not. The mesopic acuity association was slightly weaker than the association between abnormal dark adaptation and incident AMD (RR 1.85, 95% CI 1.07-3.20).
   CONCLUSIONS. Impaired mesopic acuity in eyes in normal macular health is a risk factor for incident early AMD 3 years later, however, photopic acuity, contrast sensitivity, and light sensitivity, and the presence of a low luminance deficit are not risk factors.
C1 [Owsley, Cynthia; Clark, Mark E.; Huisingh, Carrie E.; Curcio, Christine A.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Huisingh, Carrie/0000-0002-7010-2024
FU National Institutes of Health (Bethesda, MD, USA) [R01AG04212,
   R01EY6109]; Research to Prevent Blindness (New York, NY, USA); Eyesight
   Foundation of Alabama (Birmingham, AL, USA); Alfreda J. Schueler Trust
   (Chicago, IL, USA); NATIONAL EYE INSTITUTE [R01EY006109] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212] Funding Source:
   NIH RePORTER
FX This research was supported by the National Institutes of Health
   (R01AG04212, R01EY6109; Bethesda, MD, USA), Research to Prevent
   Blindness (New York, NY, USA), the Eyesight Foundation of Alabama
   (Birmingham, AL, USA), and the Alfreda J. Schueler Trust (Chicago, IL,
   USA).
CR ALBERS JJ, 1992, CLIN CHEM, V38, P658
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1824
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Feigl B, 2006, VISUAL NEUROSCI, V23, P863, DOI 10.1017/S0952523806230190
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   MARCOVINA SM, 1993, CLIN CHEM, V39, P773
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   National Health Interview Survey, QUEST DAT REL DOC 19
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 1990, CLIN VISION SCI, V5, P325
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Szalai AJ, 2000, J IMMUNOL, V165, P1030, DOI 10.4049/jimmunol.165.2.1030
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zheng DD, 2012, INVEST OPHTH VIS SCI, V53, P2685, DOI 10.1167/iovs.11-8794
NR 47
TC 24
Z9 24
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1782
EP 1789
DI 10.1167/iovs.15-18962
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700035
PM 27074381
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fukuyama, H
   Huang, BB
   BouGhanem, G
   Fawzi, AA
AF Fukuyama, Hisashi
   Huang, Bonnie Bertha
   BouGhanem, Ghazi
   Fawzi, Amani A.
TI The Fovea-Protective Impact of Double-Layer Sign in Eyes With
   Foveal-Sparing Geographic Atrophy and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE double-layer sign (DLS); geographic atrophy (GA); foveal sparing;
   age-related macular degeneration (AMD)
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION;
   NATURAL-HISTORY; PROGRESSION; SECONDARY; RISK; PREVALENCE; RATES; VEGF
AB PURPOSE. The purpose of this study was to investigate the impact of double-layer sign (DLS) on geographic atrophy (GA) progression in eyes with foveal-sparing GA and agerelated macular degeneration (AMD).
   METHODS. This is a retrospective, consecutive case series of eyes with foveal-sparing GA secondary to AMD with more than 6 months of follow-up. The size of the foveal-sparing area was measured on the fundus autofluorescence images at the first and last visits. Each eye was evaluated for the presence or absence of DLS inside the foveal-sparing area. We graded eyes based on the presence of DLS within the foveal-sparing area and compared the progression of GA between two groups (DLS (+) versus DLS (-)).
   RESULTS. We identified 25 eyes with foveal-sparing GA with at least 2 follow-up visits (average interval = 22.7 +/- 11.8 months between visits). The mean foveal sparing area was 1.74 +/- 0.87 mm(2) (range = 0.42-4.14 mm(2)) at baseline and 1.26 +/- 0.75 mm(2) (range = 0.25-2.92 mm(2)) at the last visit. Seventeen eyes (65.3%) were graded as DLS (+) within the foveal-sparing area. Square root progression of GA toward the fovea was significantly faster in the DLS (-) eyes (0.149 +/- 0.078 mm/year) compared to the DLS (+) group (0.088 +/- 0.052 mm/year; P = 0.04).
   CONCLUSIONS. The DLS (-) group showed significantly faster centripetal GA progression than the DLS (+) group. Our data suggest that the presence of DLS in the spared foveal area could be a protective factor against foveal progression of GA in eyes with AMD.
C1 [Fukuyama, Hisashi; Huang, Bonnie Bertha; BouGhanem, Ghazi; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 N Michigan Ave,Suite 440, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
FU Boehringer Ingelheim
FX Supported by Boehringer Ingelheim. The sponsor or NIH R01EY31815 had no
   role in the design or conduct of this research.
CR Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chan CK, 2022, OPHTHALMOL RETINA, V6, P484, DOI 10.1016/j.oret.2022.01.019
   Colijn JM, 2021, JAMA OPHTHALMOL, V139, P743, DOI 10.1001/jamaophthalmol.2021.1407
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Eshtiaghi A, 2021, RETINA-J RET VIT DIS, V41, P2424, DOI 10.1097/IAE.0000000000003207
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Ghanchi FD, 2021, EYE, V35, P134, DOI 10.1038/s41433-020-01285-0
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Heier JS, 2021, JAMA OPHTHALMOL, V139, P542, DOI 10.1001/jamaophthalmol.2021.0221
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shen MX, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.6.14
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Trivizki O, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.1.20
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   You QS, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.15.28
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2022
VL 63
IS 11
AR 4
DI 10.1167/iovs.63.11.4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5U2GI
UT WOS:000876370500005
PM 36201174
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Said, YA
   Dewilde, E
   Stalmans, P
AF Ali Said, Yasmin
   Dewilde, Evelien
   Stalmans, Peter
TI Visual Outcome after Vitrectomy with Subretinal tPA Injection to Treat
   Submacular Hemorrhage Secondary to Age-Related Macular Degeneration or
   Macroaneurysm
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; NATIONAL OPHTHALMOLOGY DATABASE;
   PARS-PLANA VITRECTOMY; INTRAVITREAL INJECTION; PNEUMATIC DISPLACEMENT;
   VITREOMACULAR ADHESION; GAS INJECTION; EXPANSILE GAS; MANAGEMENT;
   SURGERY
AB Purpose. To determine the efficacy and safety of 23G transconjunctival sutureless vitrectomy, subretinal injection of tissue plasminogen activator using the EVA Surgical System, and pneumatic displacement with air to treat submacular hemorrhages. Methods. Retrospective analysis of 93 eyes surgically treated for submacular hemorrhage caused by neovascular AMD or retinal macroaneurysms. Main Outcome Measures. Postoperative visual acuity and surgical complications. Results. After surgery, visual acuity improved after 6 weeks but decreased again at the final postoperative visit at 8 months due to progression of the underlying disease. Complications consisted of 2 cases of retinal pigment epithelial tear, 7 vitreous hemorrhages, 4 hyphema, 6 cases of retinal detachment, and 2 subchoroidal hemorrhages during the follow-up period. Conclusions. This study suggests that a surgical approach with 23G vitrectomy, subretinal tPA injection, and pneumatic displacement using air may be an effective procedure for submacular hemorrhage displacement in patients with AMD and retinal macroaneurysms. However, visual outcome is limited by the underlying macular pathology. Larger multicenter randomized controlled studies are warranted to determine the therapeutic effect of this surgical approach.
C1 [Ali Said, Yasmin; Dewilde, Evelien; Stalmans, Peter] UZ Leuven, Dept Ophthalmol, Herestr 49, B-3000 Leuven, Belgium.
C3 KU Leuven; University Hospital Leuven
RP Stalmans, P (通讯作者)，UZ Leuven, Dept Ophthalmol, Herestr 49, B-3000 Leuven, Belgium.
EM yasmin.alisaid@uzleuven.be; dewilde_evelien@hotmail.com;
   peter.stalmans@uzleuven.be
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   DOFT BH, 1985, OPHTHALMOLOGY, V92, P1601, DOI 10.1016/S0161-6420(85)33838-1
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 2002, ARCH OPHTHALMOL-CHIC, V120, P102
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Jackson TL, 2016, JAMA OPHTHALMOL, V134, P79, DOI 10.1001/jamaophthalmol.2015.4587
   Jackson TL, 2014, OPHTHALMOLOGY, V121, P643, DOI 10.1016/j.ophtha.2013.07.015
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P2012, DOI 10.1097/IAE.0b013e3182a6b3e2
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P629, DOI 10.1016/j.ophtha.2012.09.003
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Leguay JM, 2000, J FR OPHTALMOL, V23, P797
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Lincoff H, 2001, RETINA-J RET VIT DIS, V21, P191, DOI 10.1097/00006982-200104000-00021
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Ratanasukon M, 2005, EYE, V19, P1328, DOI 10.1038/sj.eye.6701769
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Schurmans A, 2009, AM J OPHTHALMOL, V147, P495, DOI 10.1016/j.ajo.2008.09.003
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Steller A, 2004, OPHTHALMOLOGE, V101, P500, DOI 10.1007/s00347-003-0924-x
   Tranos P, 2021, INT OPHTHALMOL, V41, P4037, DOI 10.1007/s10792-021-01976-x
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Verbeke G., 2000, SPRINGER SERIES STAT
   Williamson TH, 2009, GRAEF ARCH CLIN EXP, V247, P1019, DOI 10.1007/s00417-009-1072-z
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 47
TC 2
Z9 2
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 30
PY 2021
VL 2021
AR 3160963
DI 10.1155/2021/3160963
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YE5CX
UT WOS:000741144600001
PM 35003789
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Garhoefer, G
   Aslam, TM
   Silva, R
   Delcourt, C
   Klaver, CCW
   Seddon, JM
   Minnella, AM
AF Garcia-Layana, Alfredo
   Garhoefer, Gerhard
   Aslam, Tariq M.
   Silva, Rufino
   Delcourt, Cecile
   Klaver, Caroline C. W.
   Seddon, Johanna M.
   Minnella, Angelo M.
TI Exploring Consensus on Preventive Measures and Identification of
   Patients at Risk of Age-Related Macular Degeneration Using the Delphi
   Process
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; prevention; identification; risk;
   Delphi; STARS(R); food supplement
ID LIFE-STYLE FACTORS; EYE DISEASE; GENETIC SUSCEPTIBILITY; VISION LOSS;
   VITAMIN-C; PROGRESSION; PREDICTION; OMEGA-3-FATTY-ACIDS; MANAGEMENT;
   ASSOCIATION
AB Background: Early identification of AMD can lead to prompt and more effective treatment, better outcomes, and better final visual acuity; several risk scores have been devised to determine the individual level of risk for developing AMD. Herein, the Delphi method was used to provide recommendations for daily practice regarding preventive measures and follow-up required for subjects at low, moderate, and high risk of AMD evaluated with the Simplified Test AMD Risk-assessment Scale (STARS(R)) questionnaire. Methods: A steering committee of three experts drafted and refined 25 statements on the approach to be recommended in different clinical situations [general recommendations (n = 2), use of evaluation tools (n = 4), general lifestyle advice (n = 3), and AREDS-based nutritional supplementation (n = 5)] with the help of a group of international experts, all co-authors of this paper. Thirty retinal specialists from Europe and the US were chosen based on relevant publications, clinical expertise, and experience in AMD, who then provided their level of agreement with the statements. Statements for which consensus was not reached were modified and voted upon again. Results: In the first round of voting, consensus was reached for 24 statements. After modification, consensus was then reached for the remaining statement. Conclusion: An interprofessional guideline to support preventive measures in patients at risk of AMD based on STARS(R) scoring has been developed to aid clinicians in daily practice, which will help to optimize preventive care of patients at risk of AMD.
C1 [Garcia-Layana, Alfredo] Univ Navarra Clin, Inst Invest Sanitaria Navarra, Pamplona 31009, Spain.
   [Garhoefer, Gerhard] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Aslam, Tariq M.] Univ Manchester, Fac Biol Med & Hlth, Sch Pharm & Optometry, Manchester M13 9PL, Lancs, England.
   [Aslam, Tariq M.] Manchester Royal Eye Hosp, Manchester Univ NHS Fdn Trust, Manchester M13 9WL, Lancs, England.
   [Silva, Rufino] Univ Coimbra, ICBR FMUC, Fac Med, P-3000548 Coimbra, Portugal.
   [Silva, Rufino] CHUC, Ophthalmol Dept, P-3004561 Coimbra, Portugal.
   [Silva, Rufino] AIBILI, P-3000548 Coimbra, Portugal.
   [Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team LEHA,UMR 1219, F-33000 Bordeaux, France.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Epidmiol, NL-3000 CA Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, CH-4031 Basel, Switzerland.
   [Seddon, Johanna M.] Univ Massachusetts Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
   [Minnella, Angelo M.] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, UOC Oculist, IRCCS, I-00168 Rome, Italy.
C3 University of Navarra; Medical University of Vienna; University of
   Manchester; Manchester Royal Eye Hospital; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Coimbra; Institut National de
   la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University
   Nijmegen; University of Massachusetts System; University of
   Massachusetts Worcester; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli
RP Garhoefer, G (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
EM aglayana@unav.es; gerhard.garhoefer@meduniwien.ac.at;
   tariq.aslam@manchester.ac.uk; rufino.silva@oftalmologia.co.pt;
   cecile.delcourt@u-bordeaux.fr; c.c.w.klaver@erasmusmc.nl;
   johanna.seddon@umassmed.edu; angelomaria.minnella@unicatt.it
RI Delcourt, Cecile/I-2627-2013; Aslam, Tariq/A-8532-2016
OI Delcourt, Cecile/0000-0002-2099-0481; Silva, Rufino/0000-0001-8676-0833;
   /0000-0001-5896-5313; Aslam, Tariq/0000-0002-9739-7280
FU Laboratoires Thea
FX The APC was funded by Laboratoires Thea.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Ajana S, 2021, OPHTHALMOLOGY, V128, P587, DOI 10.1016/j.ophtha.2020.08.031
   American Academy of Ophthalmology, PREF PRACT PATT GUID
   Androudi S, 2016, ADV THER, V33, P715, DOI 10.1007/s12325-016-0332-7
   Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Barrios M, 2011, SOC SCI COMPUT REV, V29, P208, DOI 10.1177/0894439310368031
   Bennett C, 2012, GASTROENTEROLOGY, V143, P336, DOI 10.1053/j.gastro.2012.04.032
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458
   DALKEY N, 1969, FUTURES, V1, P408, DOI 10.1016/S0016-3287(69)80025-X
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Delcourt C, 2017, INVEST OPHTH VIS SCI, V58, P6399, DOI 10.1167/iovs.17-21819
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Engelman D, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006549
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Fitch K., 2001, RANDUCLA APPROPRIATE
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Lawrenson JG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040823
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lee AY, 2018, BRIT J OPHTHALMOL, V102, P465, DOI 10.1136/bjophthalmol-2017-310939
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Merle BMJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.17
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Meshkat B., 2014, J HOSP ADM, V3, P1, DOI [10.5430/jha.v3n4p1, DOI 10.5430/JHA.V3N4P1]
   Minnella AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.28
   Murphy M K, 1998, Health Technol Assess, V2, pi
   Parodi MB, 2018, EUR OPHTHALMIC REV, V12, P39, DOI DOI 10.17925/EOR.2018.12.1.39
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 63
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2021
VL 10
IS 22
AR 5432
DI 10.3390/jcm10225432
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA XF6AR
UT WOS:000724152200001
PM 34830713
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Eadie, JA
   Gottlieb, JL
   Ip, MS
   Blodi, BA
   Danis, RP
   Chandra, SR
   Nork, TM
   Altaweel, MM
   Stern-Hogan, BS
AF Eadie, James A.
   Gottlieb, Justin L.
   Ip, Michael S.
   Blodi, Barbara A.
   Danis, Ronald P.
   Chandra, Suresh R.
   Nork, T. Michael
   Altaweel, Michael M.
   Stern-Hogan, Brendan S.
TI Response to Aflibercept in Patients With Persistent Exudation Despite
   Prior Treatment With Bevacizumab or Ranibizumab for Age-Related Macular
   Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VEGF-TRAP; THERAPY
AB BACKGROUND AND OBJECTIVE: This study examines the clinical response of patients transitioned to aflibercept, the newest anti-VEGF medication, due to persistent evidence of exudation on optical coherence tomography (OCT) despite regular treatment with bevacizumab and/or ranibizumab.
   PATIENTS AND METHODS: Aflibercept was administered to 111 patients considered for study inclusion. Eyes were included if they were transitioned to aflibercept for treatment of persistent exudation on OCT despite regular treatment with at least three injections of ranibizumab or bevacizumab. Retrospective data were collected from medical records.
   RESULTS: Complete resolution of exudation was seen in 34% of eyes at final follow-up. Clear improvement in exudation amount or severity without complete resolution was seen in 25%. No improvement was seen in 34%, and 6% demonstrated worsening of exudation. Snellen visual acuity at the time of transition versus final follow-up after aflibercept injection did not appreciably change (logMAR 0.494 to 0.505, Snellen equivalent 20/62 to 20/64; P = .84). The mean center point neurosensory retina thickness decreased from 228.6 to 176.9 mu m (P = .001).
   CONCLUSION: Aflibercept may decrease the amount of exudation in a significant number of patients. However, this reduction did not result in an improvement in Snellen visual acuity.
C1 [Eadie, James A.; Gottlieb, Justin L.; Ip, Michael S.; Blodi, Barbara A.; Danis, Ronald P.; Chandra, Suresh R.; Nork, T. Michael; Altaweel, Michael M.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Eadie, James A.] Retina Vitreous Consultants, Pittsburgh, PA USA.
   [Stern-Hogan, Brendan S.] Southeast Permanente Med Grp, Atlanta, GA USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   Permanente Medical Groups
RP Eadie, JA (通讯作者)，2880 Univ Ave, Madison, WI 53705 USA.
EM JamesED523@gmail.com
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 10
TC 8
Z9 9
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP-OCT
PY 2014
VL 45
IS 5
BP 394
EP 397
DI 10.3928/23258160-20140909-03
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0OY
UT WOS:000347297300005
PM 25230402
DA 2022-11-30
ER

PT J
AU Konstantinidis, L
   Ambresin, A
   Zografos, L
   Mantel, I
AF Konstantinidis, Lazaros
   Ambresin, Aude
   Zografos, Leonidas
   Mantel, Irmela
TI Retinal pigment epithelium tears after intravitreal injection of
   ranibizumab for predominantly classic neovascular membranes secondary to
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; intravitreal ranibizumab;
   predominantly classic choroidal neovascularization; retinal pigment
   epithelial tear
ID BEVACIZUMAB INJECTION; PHOTODYNAMIC THERAPY; DETACHMENTS; VERTEPORFIN;
   RIP
AB Purpose:
   Retinal pigment epithelium (RPE) tear is an extremely rare complication in patients with classic neovascular membranes without RPE detachment. We evaluate their incidence and functional outcome following treatment with intravitreal ranibizumab.
   Methods:
   Observational study of 72 consecutive patients (74 eyes) treated at Jules Gonin University Eye Hospital, Lausanne, with intravitreal ranibizumab 0.5 mg for classic choroidal neovascularization (CNV) between March 2006 and February 2008. Best-corrected visual acuity (BCVA), fundus examination and optical coherence tomography were recorded monthly; fluorescein angiography was performed at baseline and repeated at least every 3 months.
   Results:
   RPE tears occurred in four (5.4%) eyes temporal to the fovea, after a mean of four injections (range 3-6). Mean baseline BCVA was 0.25 decimal equivalent (logMAR 0.67) and improved despite the RPE tear to 0.6 decimal equivalent (logMAR 0.22).
   Conclusion:
   RPE tears following intravitreal ranibizumab injections for classic CNV can occur in about 5% of patients, even in the absence of baseline RPE detachment. Nevertheless, vision may improve provided the fovea is not involved.
C1 [Konstantinidis, Lazaros; Ambresin, Aude; Zografos, Leonidas; Mantel, Irmela] Jules Gonin Univ Eye Hosp, CH-1004 Lausanne, Switzerland.
RP Mantel, I (通讯作者)，Jules Gonin Univ Eye Hosp, Av France 15, CH-1004 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Apte Rajendra S., 2007, International Ophthalmology, V27, P59, DOI 10.1007/s10792-007-9066-5
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fasolino G, 2007, ACTA OPHTHALMOL SCAN, V85, P575, DOI 10.1111/j.1600-0420.2007.00897.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 43
TC 21
Z9 21
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2010
VL 88
IS 7
BP 736
EP 741
DI 10.1111/j.1755-3768.2009.01547.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672OQ
UT WOS:000283596200027
PM 19604160
OA Bronze
DA 2022-11-30
ER

PT J
AU Boltz, A
   Luksch, A
   Wimpissinger, B
   Maar, N
   Weigert, G
   Frantal, S
   Brannath, W
   Garhofer, G
   Ergun, E
   Stur, M
   Schmetterer, L
AF Boltz, Agnes
   Luksch, Alexandra
   Wimpissinger, Barbara
   Maar, Noemi
   Weigert, Guenther
   Frantal, Sophie
   Brannath, Werner
   Garhoefer, Gerhard
   Ergun, Erdem
   Stur, Michael
   Schmetterer, Leopold
TI Choroidal Blood Flow and Progression of Age-Related Macular Degeneration
   in the Fellow Eye in Patients with Unilateral Choroidal
   Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; LASER INTERFEROMETRIC MEASUREMENT; BRUCH MEMBRANE
   CHANGE; BLUE MOUNTAINS EYE; PNEUMOTONOMETRIC MEASUREMENT;
   CARDIOVASCULAR-DISEASE; FUNDUS PULSATION; TERM INCIDENCE; FOVEAL REGION;
   RISK-FACTORS
AB PURPOSE. Cardiovascular risk factors such as smoking, hypertension, and atherosclerosis seem to play an important role in the development of choroidal neovascularization (CNV). Recent studies have also provided evidence suggesting that choroidal and retinal blood flow is decreased in patients with AMD. On the basis of these results, the hypothesis for this study was that lower choroidal blood flow is associated with an increased risk of CNV in patients with AMD.
   METHODS. Forty-one patients with unilateral choroidal neovascular AMD were included in this observational longitudinal study. The fellow eyes of the patients served as study eyes. Subfoveal choroidal blood flow (FLOW) and fundus pulsation amplitude (FPA) were assessed with laser Doppler flowmetry and laser interferometry, respectively. A multivariate COX-regression model was used to test the hypothesis that low choroidal perfusion parameters are associated with the development of CNV.
   RESULTS. Of the 37 patients that were followed up until the end of the study, 17 developed CNV and 20 did not. The univariate COX-regression analysis shows that lower FLOW, systolic blood pressure, intraocular pressure, and FPA are risk factors for development of CNV. Moreover, the more advanced the AMD in the study eye, the higher the risk for CNV to develop in the fellow eye. Multivariate COX regression analysis indicated that only FLOW (P = 0.0071), FPA (P = 0.0068), and staging (P = 0.031) had statistically significant influences on the progression to CNV.
   CONCLUSIONS. The present study indicates that lower choroidal perfusion is a risk factor for the development of CNV in the fellow eye of patients with unilateral CNV. (Invest Ophthalmol Vis Sci. 2010; 51: 4220-4225) DOI:10.1167/iovs.09-4968
C1 [Boltz, Agnes; Luksch, Alexandra; Weigert, Guenther; Garhoefer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Luksch, Alexandra; Maar, Noemi; Weigert, Guenther; Stur, Michael] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Frantal, Sophie; Brannath, Werner] Med Univ Vienna, Dept Med Stat & Informat, A-1090 Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Biomed Engn & Phys, A-1090 Vienna, Austria.
   [Wimpissinger, Barbara] Rudolph Fdn Hosp, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Vienna, Austria.
   [Ergun, Erdem] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
   [Ergun, Erdem] KA Sanat Hera, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna; Ludwig Boltzmann
   Institute; Medical University of Graz
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
OI Schmetterer, Leopold/0000-0002-7189-1707
CR BONNER RF, 1990, PRINCIPLES LASER DOP, P73
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duke-Elder S., 1966, DIS UVEAL TRACT SYST, P740
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Geiser MH, 1999, KLIN MONATSBL AUGENH, V214, P285, DOI 10.1055/s-2008-1034795
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hommer A, 2008, INVEST OPHTH VIS SCI, V49, P4046, DOI 10.1167/iovs.07-1342
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Pemp B, 2009, GRAEF ARCH CLIN EXP, V247, P67, DOI 10.1007/s00417-008-0942-0
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   Polska E, 2002, CURR EYE RES, V24, P318, DOI 10.1076/ceyr.24.4.318.8413
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Riva C E, 2006, Bull Soc Belge Ophtalmol, P185
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   RIVA CE, ACTA OPHTHALMOL
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmetterer L, 2000, EYE, V14, P39, DOI 10.1038/eye.2000.9
   Schmetterer L, 2000, EYE, V14, P46, DOI 10.1038/eye.2000.10
   Schmetterer L, 2007, SURV OPHTHALMOL, V52, pS134, DOI 10.1016/j.survophthal.2007.08.008
   SCHMETTERER LF, 1995, OPT ENG, V34, P711, DOI 10.1117/12.193292
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 48
TC 83
Z9 84
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4220
EP 4225
DI 10.1167/iovs.09-4968
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100055
PM 20484590
DA 2022-11-30
ER

PT J
AU Garrott, HM
   Haynes, RJ
AF Garrott, Helen M.
   Haynes, Richard J.
TI Blindness from suprachoroidal haemorrhage in two patients with
   age-related macular degeneration on systemic anticoagulation therapy or
   an antiplatelet agent
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
ID INTRAOCULAR HEMORRHAGE; COMPLICATIONS; MACULOPATHY
C1 [Garrott, Helen M.; Haynes, Richard J.] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital
RP Haynes, RJ (通讯作者)，Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
EM Richard.Haynes@bristol.ac.uk
CR Alexandrakis G, 1998, RETINA-J RET VIT DIS, V18, P485, DOI 10.1097/00006982-199805000-00023
   Chalasani R, 2010, MED J AUSTRALIA, V192, P228, DOI 10.5694/j.1326-5377.2010.tb03485.x
   Chorich LJ, 1998, OPHTHALMOLOGY, V105, P428, DOI 10.1016/S0161-6420(98)93023-8
   Edwards P, 1996, J Am Optom Assoc, V67, P223
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Khawly JA, 1996, AM J OPHTHALMOL, V121, P577, DOI 10.1016/S0002-9394(14)75438-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Knox FA, 2002, EYE, V16, P669, DOI 10.1038/sj.eye.6700109
   Kowal LM, 2002, MED J AUSTRALIA, V176, P351, DOI 10.5694/j.1326-5377.2002.tb04439.x
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Ung T., 2003, Heart (London), V89, P985, DOI 10.1136/heart.89.9.985
   Wong JS, 1999, AUST NZ J OPHTHALMOL, V27, P433
NR 12
TC 5
Z9 5
U1 0
U2 0
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD MAR 15
PY 2010
VL 192
IS 6
BP 346
EP 347
DI 10.5694/j.1326-5377.2010.tb03536.x
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 579NO
UT WOS:000276378500013
PM 20230354
DA 2022-11-30
ER

PT J
AU Meyer, CH
   Mennel, S
   Schmidt, JC
   Kroll, P
AF Meyer, C. H.
   Mennel, S.
   Schmidt, J. C.
   Kroll, P.
TI Acute retinal pigment epithelial tear following intravitreal bevacizumab
   (Avastin) injection for occult choroidal neovascularisation secondary to
   age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
C1 Univ Marburg, Dept Ophthalmol, D-35037 Marburg, Germany.
C3 Philipps University Marburg
RP Meyer, CH (通讯作者)，Univ Marburg, Dept Ophthalmol, Robert Koch Str 4, D-35037 Marburg, Germany.
EM meyer_eye@yahoo.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hesse L, 1997, OPHTHALMOLOGE, V94, P366
   Kroll P, 2006, BRIT J OPHTHALMOL, V90, P128, DOI 10.1136/bjo.2005.083337
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 6
TC 91
Z9 98
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1207
EP 1208
DI 10.1136/bjo.2006.093732
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700038
PM 16929069
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhang, QT
   Miller, JML
AF Zhang, Qitao
   Miller, Jason M. L.
TI Basic-science observations explain how outer retinal hyperreflective
   foci predict drusen regression and geographic atrophy in age-related
   macular degeneration
SO EYE
LA English
DT Article
ID PIGMENT-EPITHELIUM; PROGRESSION
C1 [Zhang, Qitao; Miller, Jason M. L.] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Zhang, QT; Miller, JML (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
EM qitaoz@med.umich.edu; miljason@med.umich.edu
OI Miller, Jason/0000-0002-2784-9560
FU Kellogg Eye Center's Pre-Residency Fellowship program
FX The authors acknowledge the Kellogg Eye Center's Pre-Residency
   Fellowship program for funding the basic science aspects of this study.
   The authors also gratefully acknowledge philanthropic donations from
   Barbara Dunn as well as Dee and Dickson Brown.
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Miller JML, 2021, GRAEF ARCH CLIN EXP, V259, P2051, DOI 10.1007/s00417-021-05101-7
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Zhang QT, 2019, EXP EYE RES, V178, P212, DOI 10.1016/j.exer.2018.10.008
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 17
TC 0
Z9 0
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2022
VL 36
IS 5
BP 1115
EP 1118
DI 10.1038/s41433-021-01748-y
EA AUG 2021
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V6DU
UT WOS:000686867400001
PM 34417566
DA 2022-11-30
ER

PT J
AU Costagliola, C
   Morescalchi, F
   Duse, S
   Romano, D
   Mazza, G
   Parmeggiani, F
   Bartollino, S
   Semeraro, F
AF Costagliola, Ciro
   Morescalchi, Francesco
   Duse, Sarah
   Romano, Davide
   Mazza, Giuseppina
   Parmeggiani, Francesco
   Bartollino, Silvia
   Semeraro, Francesco
TI Systemic thromboembolic adverse events in patients treated with
   intravitreal anti-VEGF drugs for neovascular age-related macular
   degeneration: an update
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE Abicipar; aflibercept; age-related macular degeneration; anti-VEGF;
   bevacizumab; conbercept; ranibizumab; thromboembolic adverse events
ID ENDOTHELIAL GROWTH-FACTOR; ANKYRIN REPEAT PROTEIN; QUALITY-OF-LIFE;
   CHOROIDAL NEOVASCULARIZATION; PEGAPTANIB SODIUM; OCULAR
   NEOVASCULARIZATION; RANIBIZUMAB TREATMENT; PLASMA-LEVELS; BEVACIZUMAB;
   INJECTION
AB Introduction: Intravitreal anti-VEGF is the most effective therapy for wet AMD, although systemic effects on the endothelium cannot be excluded. Areas covered: The purpose of this review was to evaluate risk of thromboembolic events associated with intravitreal anti-VEGF. Expert opinion: Current data are insufficient to confirm the safety of these compounds, due to the paucity of specific studies. Thus, pharmacovigilance for all anti-VEGF should be improved to verify the true role of anti-VEGF in the occurrence of systemic adverse events.
C1 [Costagliola, Ciro; Bartollino, Silvia] Univ Molise, Dept Med & Hlth Sci V Tiberio, Via Santis, I-86100 Campobasso, Italy.
   [Morescalchi, Francesco; Duse, Sarah; Romano, Davide; Mazza, Giuseppina; Semeraro, Francesco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
C3 University of Molise; University of Brescia; University of Ferrara
RP Bartollino, S (通讯作者)，Univ Molise, Dept Med & Hlth Sci V Tiberio, Via Santis, I-86100 Campobasso, Italy.
EM silvia.bartollino@unimol.it
RI Bartollino, Silvia/M-6271-2019; SEMERARO, Francesco/K-8667-2016
OI Bartollino, Silvia/0000-0001-7105-6392; SEMERARO,
   Francesco/0000-0002-2275-4917; Romano, Davide/0000-0002-8961-242X
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   [Anonymous], 2006, INITIAL US APPROVAL, P4
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   CAMPBELL RJ, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E4203
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHMP, RAN LUC ANN I SUMM P
   Chong NV, 2009, EYE, V23, P1250, DOI 10.1038/eye.2009.84
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Etulain J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096402
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gentile Ronald, 2007, Surv Ophthalmol, V52, P551, DOI 10.1016/j.survophthal.2007.06.002
   Goldbaum M., 2010, RETIN PHARMACOTHER, P265
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hwang DJ, 2012, J KOREAN MED SCI, V27, P1580, DOI 10.3346/jkms.2012.27.12.1580
   Igaki T, 2018, TNS OPINION SOCIAL S
   Kazazi-Hyseni F, 2010, ONCOLOGIST, V15, P819, DOI 10.1634/theoncologist.2009-0317
   Ko J, 2005, J SURG RES, V129, P251, DOI 10.1016/j.jss.2005.05.006
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Maguire MG, 2017, OPHTHALMOL RETINA, V1, P375, DOI 10.1016/j.oret.2016.12.015
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Mikacic I, 2016, DRUG SAFETY, V39, P517, DOI 10.1007/s40264-016-0408-y
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parodi MB, 2018, EUR J OPHTHALMOL, V28, P58, DOI 10.5301/ejo.5001060
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rinaldi M, 2013, RETINA-J RET VIT DIS, V33, P397, DOI 10.1097/IAE.0b013e318261a73c
   Rinaldi M, 2012, BRIT J CLIN PHARMACO, V74, P940, DOI 10.1111/j.1365-2125.2012.04291.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sangroongruangsri S, 2018, CLIN DRUG INVEST, V38, P853, DOI 10.1007/s40261-018-0678-5
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart MW, 2012, RETINA, V32, P343
   Ueta T., 2014, OPHTHALMOLOGY, V121, pe5
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vazquez-Lombardi R, 2015, DRUG DISCOV TODAY, V20, P1271, DOI 10.1016/j.drudis.2015.09.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zarbin MA, 2018, ASIA-PAC J OPHTHALMO, V7, P63, DOI 10.22608/APO.2017495
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 86
TC 9
Z9 10
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD SEP 2
PY 2019
VL 18
IS 9
BP 803
EP 815
DI 10.1080/14740338.2019.1643838
EA JUL 2019
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IS0YI
UT WOS:000477515400001
PM 31309853
OA Green Published
DA 2022-11-30
ER

PT J
AU Rebolleda, G
   Puerto, B
   de Juan, V
   Gomez-Mariscal, M
   Munoz-Negrete, FJ
   Casado, A
AF Rebolleda, Gema
   Puerto, Beatriz
   de Juan, Victoria
   Gomez-Mariscal, Marta
   Jose Munoz-Negrete, Francisco
   Casado, Alfonso
TI Optic Nerve Head Biomechanic and IOP Changes Before and After the
   Injection of Aflibercept for Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Bruch's membrane opening; intraocular pressure; lamina cribrosa; optic
   nerve head
ID INTRAOCULAR-PRESSURE ELEVATION; GROWTH-FACTOR AGENTS; HUMAN
   LAMINA-CRIBROSA; OPEN-ANGLE GLAUCOMA; INTRAVITREAL INJECTIONS; OCULAR
   HYPERTENSION; RANIBIZUMAB LUCENTIS; SUSTAINED ELEVATION; FACTOR THERAPY;
   HUMAN EYES
AB PURPOSE. We investigated the early effects of intravitreal aflibercept injection (IAI) on optic nerve head (ONH) morphology.
   METHODS. All of the participants underwent applanation tonometry and enhanced depth imaging by spectral-domain optical coherence tomography immediately before injection, and within 5 and 30 minutes after IAI. Changes in the anterior lamina cribrosa surface depth, prelaminar tissue thickness (PTT), optic cup width, optic cup depth, and Bruch's membrane opening (BMO) were assessed.
   RESULTS. The study included 30 eyes of 30 subjects with a mean age of 77.4 +/- 6 6.8 years (range, 65-89 years) following IAI (2 mg in 0.05 ml). Within 5 minutes after injection, the mean cup depth, mean cup width, and BMO were significantly increased (P = 0.013, P = 0.000, and P = 0.004, respectively), whereas the mean PTT was thinned (P= 0.009). These morphologic changes returned to near baseline values 30 minutes after injection. Cup widening and BMO expansion (P = 0.000; r, 0.668), as well as cup deepening and prelaminar thinning (P = 0.000; r, -0.838), were significantly correlated. The magnitude of cup deepening and prelaminar tissue thinning correlated with the IOP change in the opposite direction than expected (P = 0.039; r, -0.379 and P = 0.377; r, 0.040).
   CONCLUSIONS. A significant widening and deepening of the optic cup, BMO expansion, and prelaminar tissue thinning occurred following IAI for neovascular AMD. Eyes having greater optic disc cup deepening and prelaminar tissue condensation after IAI, associated with a lower IOP increase after injection, suggesting that ONH compliance might buffer the effect of additional intravitreal fluid injection on IOP values.
C1 [Rebolleda, Gema; Puerto, Beatriz; de Juan, Victoria; Gomez-Mariscal, Marta; Jose Munoz-Negrete, Francisco] Hosp Univ Ramon y Cajal, Dept Ophthalmol, Madrid, Spain.
   [Casado, Alfonso] Hosp Sierrallana, Dept Ophthalmol, Barrio Ganzo S-N, Torrelavega 39300, Cantabria, Spain.
C3 Hospital Universitario Ramon y Cajal
RP Casado, A (通讯作者)，Hosp Sierrallana, Dept Ophthalmol, Barrio Ganzo S-N, Torrelavega 39300, Cantabria, Spain.
EM casadorojo@hotmail.es
RI Gomez, Marta/ADJ-7912-2022; Casado, Alfonso/AAI-9951-2020
OI Casado, Alfonso/0000-0002-3402-7311
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Agard E, 2015, CAN J OPHTHALMOL, V50, P127, DOI 10.1016/j.jcjo.2014.11.004
   Agoumi Y, 2011, OPHTHALMOLOGY, V118, P52, DOI 10.1016/j.ophtha.2010.05.016
   Albon J, 2000, BRIT J OPHTHALMOL, V84, P318, DOI 10.1136/bjo.84.3.318
   Aref AA, 2012, CURR OPIN OPHTHALMOL, V23, P105, DOI 10.1097/ICU.0b013e32834ff41d
   Azuara-Blanco A, 1998, BRIT J OPHTHALMOL, V82, P880, DOI 10.1136/bjo.82.8.880
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bellezza AJ, 2003, INVEST OPHTH VIS SCI, V44, P623, DOI 10.1167/iovs.01-1282
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   COLEMAN AL, 1991, OPHTHALMOLOGY, V98, P35
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Downs JC, 2008, OPTOMETRY VISION SCI, V85, P425, DOI 10.1097/OPX.0b013e31817841cb
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Han JC, 2016, INVEST OPHTH VIS SCI, V57, P486, DOI 10.1167/iovs.15-17722
   Hohn F, 2010, GRAEF ARCH CLIN EXP, V248, P1371, DOI 10.1007/s00417-010-1382-1
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jiang R, 2015, OPHTHALMOLOGY, V122, P730, DOI 10.1016/j.ophtha.2014.11.008
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kotecha A, 2006, BRIT J OPHTHALMOL, V90, P1531, DOI 10.1136/bjo.2006.100388
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Leung Leo K K, 2012, Mol Cell Biomech, V9, P157
   LEVY NS, 1984, ARCH OPHTHALMOL-CHIC, V102, P782
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Morshedi RG, 2016, J GLAUCOMA, V25, P291, DOI 10.1097/IJG.0000000000000173
   Omay E, 2016, INT OPHTHALMOL, V36, P665, DOI 10.1007/s10792-016-0171-1
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1401, DOI 10.1097/IAE.0000000000000476
   Rebolleda G, 2017, BRIT J OPHTHALMOL, V101, P143, DOI 10.1136/bjophthalmol-2015-307945
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rusu IM, 2014, RETINA-J RET VIT DIS, V34, P2161, DOI 10.1097/IAE.0000000000000264
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Seth RK, 2009, RETINA-J RET VIT DIS, V29, P956, DOI 10.1097/IAE.0b013e3181a91dfd
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sigal IA, 2014, INVEST OPHTH VIS SCI, V55, P1, DOI 10.1167/iovs.13-12724
   Strouthidis NG, 2011, INVEST OPHTH VIS SCI, V52, P9431, DOI 10.1167/iovs.11-7922
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wen JC, 2016, RETINA-J RET VIT DIS, V36, P1874, DOI 10.1097/IAE.0000000000001018
   Yang HL, 2011, INVEST OPHTH VIS SCI, V52, P7109, DOI 10.1167/iovs.11-7448
   Yun SC, 2015, GRAEF ARCH CLIN EXP, V253, P2247, DOI 10.1007/s00417-015-3131-y
NR 45
TC 7
Z9 7
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5688
EP 5695
DI 10.1167/iovs.16-20111
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600084
PM 27784074
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lee, Y
   Hussain, AA
   Seok, JH
   Kim, SH
   Marshall, J
AF Lee, Yunhee
   Hussain, Ali A.
   Seok, Jae-Hwan
   Kim, Suhn-Hee
   Marshall, John
TI Modulating the Transport Characteristics of Bruch's Membrane With
   Steroidal Glycosides and its Relevance to Age-Related Macular
   Degeneration (AMD)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Bruch's membrane; macular degeneration; steroidal glycosides; supplement
   therapies
ID RETINAL-PIGMENT EPITHELIUM; MATRIX METALLOPROTEINASES; HYDRAULIC
   CONDUCTIVITY; DARK-ADAPTATION; PANAX-GINSENG; GINSENOSIDES;
   ACCUMULATION; CHOLESTEROL; METABOLISM; SAPONINS
AB PURPOSE. Beneficial expectations of supplement therapies to increase the transport of nutrients, vitamins, and antioxidants across Bruch's membrane in AMD, by mass action alone, remain inconclusive. Therefore, the potential for targeting the transport pathways themselves to improve bidirectional exchange using amphipathic steroidal glycosides (ginsenosides) has been investigated.
   METHODS. Bruch's choroid preparations were mounted in modified Ussing chambers and basal levels of hydraulic conductivity (23 donors, age range, 12-89 years) and diffusional transport of FITC-albumin (21 donors, age range, 12-92 years) quantified. Then, following a 24-hour incubation with ginsenoside preparations, the transport parameters were re-evaluated and the resulting data analyzed with respect to aging and modulation by ginsenosides.
   RESULTS. Basal hydraulic conductivity of Bruch's showed an age-related exponential decline with a half-life of 19 years. Incubation with ginsenosides improved hydraulic conductivity with levels equivalent to donors 19 years younger. Across the age range examined, hydraulic conductivities were increased to 2.05-fold +/- 0.38 (P < 0.001) of basal values. Diffusional transport of albumin across Bruch's also showed an age-related exponential decline with a half-life of 18 years. The decay curves were elevated on incubation with ginsenosides and diffusional rates were equivalent to donors 15 years younger. Diffusional rates were elevated 2.01-fold 6 0.49 over basal values (P < 0.001).
   CONCLUSIONS. Transport characteristics of human Bruch's can be improved by ginsenosides, facilitating the bidirectional exchange of nutrients and waste products across the membrane. With improved transport pathways, the need for supplement therapies becomes redundant. Slowed aging of Bruch's is expected to delay the onset and/or progression of AMD.
C1 [Lee, Yunhee; Hussain, Ali A.; Marshall, John] Univ London, Inst Ophthalmol, Univ Coll London, Dept Genet, London, England.
   [Seok, Jae-Hwan] Chungnam Natl Univ, Dept Appl Biol Sci, Daejeon, South Korea.
   [Kim, Suhn-Hee] Chonbuk Natl Univ, Sch Med, Dept Physiol, Jeonju 561756, South Korea.
C3 University of London; University College London; Chungnam National
   University; Jeonbuk National University
RP Hussain, AA (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM alyhussain@aol.com
FU GBioMix Ltd., (JeonJu, Korea); Department of Health through National
   Institute for Health Research to Moorfields Eye Hospital NHS Foundation
   Trust (London, UK); UCL Institute of Ophthalmology for a Biomedical
   Research Centre for Ophthalmology (London, UK); Fight for Sight [1374]
   Funding Source: researchfish
FX Supported by grants from GBioMix Ltd., (JeonJu, Korea), the Department
   of Health through the award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust (London, UK)
   and UCL Institute of Ophthalmology for a Biomedical Research Centre for
   Ophthalmology (London, UK). The views expressed in this publication are
   those of the authors and not necessarily those of the Department of
   Health.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bae EA, 2002, BIOL PHARM BULL, V25, P743, DOI 10.1248/bpb.25.743
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043-4526(08)00401-4
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hasegawa H, 1997, PLANTA MED, V63, P436, DOI 10.1055/s-2006-957729
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2004, FOCUS ON MACULAR DEGENERATION RESEARCH, P59
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussain AA, 2010, INVEST OPHTH VIS SCI, V51, P2363, DOI 10.1167/iovs.09-4259
   Jackson GR, 1999, VISION RES, V38, P3655
   Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
   Kang KS, 2007, BIOL PHARM BULL, V30, P917, DOI 10.1248/bpb.30.917
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kitts DD, 2000, MOL CELL BIOCHEM, V203, P1, DOI 10.1023/A:1007078414639
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Kwon HY, 2008, ARCH PHARM RES, V31, P171, DOI 10.1007/s12272-001-1137-y
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lee SJ, 1985, KOREAN BIOCH J, V14, P1
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   MURPHY G, 1995, METHOD ENZYMOL, V248, P470
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAI JK, 1988, J BIOL CHEM, V263, P12472
   Plekhanov AY, 1999, ANAL BIOCHEM, V271, P186, DOI 10.1006/abio.1999.4127
   Qiu J, 2014, GENET MOL RES, V13, P3586, DOI 10.4238/2014.May.9.2
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SEGAL R, 1978, BIOCHIM BIOPHYS ACTA, V512, P223, DOI 10.1016/0005-2736(78)90233-X
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sun BS, 2009, J PHARMACEUT BIOMED, V50, P15, DOI 10.1016/j.jpba.2009.03.025
   Tawab MA, 2003, DRUG METAB DISPOS, V31, P1065, DOI 10.1124/dmd.31.8.1065
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   YU BS, 1984, CHEM-BIOL INTERACT, V52, P185, DOI 10.1016/0009-2797(84)90072-3
   YU BS, 1985, CHEM-BIOL INTERACT, V56, P303, DOI 10.1016/0009-2797(85)90013-4
   Yun UJ, 2013, BIOCHEM PHARMACOL, V85, P1441, DOI 10.1016/j.bcp.2013.02.025
NR 62
TC 11
Z9 12
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2015
VL 56
IS 13
BP 8403
EP 8418
DI 10.1167/iovs.15-16936
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB1BU
UT WOS:000368243800098
PM 26747771
DA 2022-11-30
ER

PT J
AU Abdolrahimzadeh, S
   Di Pippo, M
   Sordi, E
   Zweifel, SA
AF Abdolrahimzadeh, Solmaz
   Di Pippo, Mariachiara
   Sordi, Edoardo
   Zweifel, Sandrine Anne
TI Inner Retinal Layer Thickness Alterations in Early Age Related Macular
   Degeneration in Eyes with Subretinal Drusenoid Deposits or Conventional
   Drusen
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE subretinal drusenoid deposits; reticular pseudodrusen; conventional
   drusen; age related macular degeneration; inner retina
ID GANGLION-CELL COMPLEX; NERVE-FIBER LAYER; RETICULAR PSEUDODRUSEN;
   PLEXIFORM LAYER; PREVALENCE; TOPOGRAPHY
AB The purpose of this study was to evaluate central and parafoveal inner retinal layer thickness in patients with subretinal drusenoid deposits (SDD) or conventional drusen (CD). Participants underwent comprehensive ophthalmoscopic examination. Evidence of SDD or CD was evaluated with near infrared reflectance and spectral domain optical coherence tomography. Quantification of subfoveal lesions was made through a qualitative analysis of vertical and horizontal SD-OCT scans centered on the fovea. Inner retinal layer macular thickness measurements were obtained for central circles with 1, 3, and 5 mm diameter. Continuous variables were compared by the analysis of covariance (ANCOVA) with post-hoc Tukey HSD correction for multiple comparison analysis. Fifty-five patients were included in the study; 18 eyes with SDD alone, 19 eyes with CD alone, and 18 eyes of healthy age-matched subjects. Eight eyes with SDD (44%) and 13 eyes with CD (68%) had subfoveal lesions. There was significant reduction in the inner retinal layer thickness in the central 1mm area and in the superior 3 mm area in the SDD and CD group compared to controls. In conclusion the inner retinal layer is thinner in the central macula and in the superior parafovea in eyes.
C1 [Abdolrahimzadeh, Solmaz; Di Pippo, Mariachiara; Sordi, Edoardo] Univ Rome Sapienza, Fac Med & Psychol, Neurosci Mental Hlth & Sense Organs NESMOS Dept, Ophthalmol Unit,St Andrea Hosp, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
   [Zweifel, Sandrine Anne] Univ Hosp Zurich, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
   [Zweifel, Sandrine Anne] Univ Zurich, Ramistr 71, CH-8006 Zurich, Switzerland.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of
   Zurich; University Zurich Hospital; University of Zurich
RP Abdolrahimzadeh, S (通讯作者)，Univ Rome Sapienza, Fac Med & Psychol, Neurosci Mental Hlth & Sense Organs NESMOS Dept, Ophthalmol Unit,St Andrea Hosp, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
EM solmaz.abdolrahimzadeh@uniroma1.it; mariachiara.dipippo@gmail.com;
   edosordi@hotmail.com; sandrine.zweifel@usz.ch
OI Di Pippo, Mariachiara/0000-0002-1089-2060
CR Abdolrahimzadeh S, 2019, EYE, V33, P1290, DOI 10.1038/s41433-019-0405-3
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Chiang TTK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.59
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Gass J.D.M., 1987, STEREOSCOPIC ATLAS M, V1, P3
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee MW, 2020, AM J OPHTHALMOL, V212, P17, DOI 10.1016/j.ajo.2019.12.003
   Lee SE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239555
   Lim HB, 2019, AM J OPHTHALMOL, V199, P167, DOI 10.1016/j.ajo.2018.11.016
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ozcaliskan S, 2020, PHOTODIAGN PHOTODYN, V32, DOI 10.1016/j.pdpdt.2020.102030
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P12, DOI 10.1097/IAE.0000000000002362
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Trinh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.2
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2021
VL 10
IS 21
AR 5136
DI 10.3390/jcm10215136
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XB2KX
UT WOS:000721162200001
PM 34768654
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Hollyfield, JG
AF Hollyfield, Joe G.
TI Age-Related Macular Degeneration: The Molecular Link between Oxidative
   Damage, Tissue-Specific Inflammation and Outer Retinal Disease The
   Proctor Lecture
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE; CIGARETTE-SMOKING; COMPLEMENT
   ACTIVATION; DRUSEN; RISK; MACULOPATHY; VARIANT; ASSOCIATION; PREVALENCE
C1 [Hollyfield, Joe G.] Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation
RP Hollyfield, JG (通讯作者)，Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cole Eye Inst I31, Cleveland, OH 44195 USA.
EM hollyfj@ccf.org
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bando H, 2007, EXP EYE RES, V84, P135, DOI 10.1016/j.exer.2006.09.008
   BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   GASS JDM, 1987, STEREOSCOPIC ATLAS M, P60
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   PEAKMAN M, 1989, J CLIN PATHOL, V42, P1018, DOI 10.1136/jcp.42.10.1018
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
NR 48
TC 79
Z9 83
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2010
VL 51
IS 3
BP 1276
EP 1281
DI 10.1167/iovs.09-4478
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 563VW
UT WOS:000275164300006
PM 20185837
DA 2022-11-30
ER

PT J
AU Alfaar, AS
   Sturzbecher, L
   Diedrichs-Mohring, M
   Lam, M
   Roubeix, C
   Ritter, J
   Schumann, K
   Annamalai, B
   Pompos, IM
   Rohrer, B
   Sennlaub, F
   Reichhart, N
   Wildner, G
   Strauss, O
AF Alfaar, Ahmad Samir
   Stuerzbecher, Lucas
   Diedrichs-Moehring, Maria
   Lam, Marion
   Roubeix, Christophe
   Ritter, Julia
   Schumann, Kathrin
   Annamalai, Balasubramaniam
   Pompoes, Inga-Marie
   Rohrer, Baerbel
   Sennlaub, Florian
   Reichhart, Nadine
   Wildner, Gerhild
   Strauss, Olaf
TI FoxP3 expression by retinal pigment epithelial cells: transcription
   factor with potential relevance for the pathology of age-related macular
   degeneration
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE IL-1 beta; Ca-channels; CRISPR; Cas9; Phosphorylation; RPE; Age-related
   macular degeneration; FoxP3; Immune barrier; Immune privilege of the
   retina
ID REGULATORY T-CELLS; COMPLEMENT EXPRESSION; RECEPTOR ANTAGONIST; RPE;
   INFLAMMATION; C5A; GENE; INTERLEUKIN-1-BETA; STIMULATION; RECRUITMENT
AB Background: Forkhead-Box-Protein P3 (FoxP3) is a transcription factor and marker of regulatory T cells, converting naive T cells into Tregs that can downregulate the effector function of other T cells. We previously detected the expression of FoxP3 in retinal pigment epithelial (RPE) cells, forming the outer blood-retina barrier of the immune privileged eye.
   Methods: We investigated the expression, subcellular localization, and phosphorylation of FoxP3 in RPE cells in vivo and in vitro after treatment with various stressors including age, retinal laser burn, autoimmune inflammation, exposure to cigarette smoke, in addition of IL-1 beta and mechanical cell monolayer destruction. Eye tissue from humans, mouse models of retinal degeneration and rats, and ARPE-19, a human RPE cell line for in vitro experiments, underwent immunohistochemical, immunofluorescence staining, and PCR or immunoblot analysis to determine the intracellular localization and phosphorylation of FoxP3. Cytokine expression of stressed cultured RPE cells was investigated by multiplex bead analysis. Depletion of the FoxP3 gene was performed with CRISPR/Cas9 editing.
   Results: RPE in vivo displayed increased nuclear FoxP3-expression with increases in age and inflammation, long-term exposure of mice to cigarette smoke, or after laser burn injury. The human RPE cell line ARPE-19 constitutively expressed nuclear FoxP3 under non-confluent culture conditions, representing a regulatory phenotype under chronic stress. Confluently grown cells expressed cytosolic FoxP3 that was translocated to the nucleus after treatment with IL-1 beta to imitate activated macrophages or after mechanical destruction of the monolayer. Moreover, with depletion of FoxP3, but not of a control gene, by CRISPR/Cas9 gene editing decreased stress resistance of RPE cells.
   Conclusion: Our data suggest that FoxP3 is upregulated by age and under cellular stress and might be important for RPE function.
C1 [Alfaar, Ahmad Samir; Stuerzbecher, Lucas; Pompoes, Inga-Marie; Reichhart, Nadine; Strauss, Olaf] Charite Univ Med Berlin, Dept Ophthalmol, Expt Ophthalmol, D-10117 Berlin, Germany.
   [Alfaar, Ahmad Samir; Stuerzbecher, Lucas; Pompoes, Inga-Marie; Reichhart, Nadine; Strauss, Olaf] Freie Univ, D-10117 Berlin, Germany.
   [Alfaar, Ahmad Samir; Stuerzbecher, Lucas; Pompoes, Inga-Marie; Reichhart, Nadine; Strauss, Olaf] Humboldt Univ, Berlin Inst Hlth, D-10117 Berlin, Germany.
   [Alfaar, Ahmad Samir] Univ Hosp Ulm, Dept Ophthalmol, D-89075 Ulm, Germany.
   [Diedrichs-Moehring, Maria; Wildner, Gerhild] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Sect Immunobiol, Univ Hosp, D-80336 Munich, Germany.
   [Lam, Marion; Roubeix, Christophe; Sennlaub, Florian] Sorbonne Univ, Inst Vis, CNRS, INSERM, F-75012 Paris, France.
   [Ritter, Julia; Schumann, Kathrin] Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-81675 Munich, Germany.
   [Annamalai, Balasubramaniam; Rohrer, Baerbel] Med Univ South Carolina, Coll Med, Dept Ophthalmol, Charleston, SC 29425 USA.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Berlin Institute
   of Health; Humboldt University of Berlin; Ulm University; University of
   Munich; Centre National de la Recherche Scientifique (CNRS); Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite;
   Technical University of Munich; Medical University of South Carolina
RP Strauss, O (通讯作者)，Charite Univ Med Berlin, Dept Ophthalmol, Expt Ophthalmol, D-10117 Berlin, Germany.; Strauss, O (通讯作者)，Freie Univ, D-10117 Berlin, Germany.; Strauss, O (通讯作者)，Humboldt Univ, Berlin Inst Hlth, D-10117 Berlin, Germany.; Wildner, G (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Sect Immunobiol, Univ Hosp, D-80336 Munich, Germany.
EM njreichhart@gmail.com; wildner@med.uni-muenchen.de;
   Olaf.strauss@charite.de
RI Alfaar, Ahmad Samir/C-8483-2011
OI Alfaar, Ahmad Samir/0000-0002-0930-4583
FU Dr. Werner Jackstaedt-Stiftung Stiftung; Einstein Foundation/BIH
   Visiting Fellow Program
FX Open Access funding enabled and organized by Projekt DEAL. We are very
   thankful for the financial support by the Dr. Werner Jackstaedt-Stiftung
   Stiftung and by the Einstein Foundation/BIH Visiting Fellow Program.
   There is no role of the funding institutions in the study design, data
   collection/analysis, interpretation and writing of the manuscript.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ando Y, 2020, MOL MED REP, V22, P582, DOI 10.3892/mmr.2020.11115
   Beskina O, 2007, AM J PHYSIOL-CELL PH, V293, pC1103, DOI 10.1152/ajpcell.00249.2007
   BOZIC CR, 1994, J BIOL CHEM, V269, P29355
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Camelo S, 2015, MOL VIS, V21, P1051
   Catalioto RM, 2015, BIOCHEM PHARMACOL, V97, P189, DOI 10.1016/j.bcp.2015.07.034
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crespo-Garcia Sergio, 2017, Invest Ophthalmol Vis Sci, V58, P4997, DOI 10.1167/iovs.16-21283
   Dabouz R, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02032-8
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Deng GP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02486
   Diedrichs-Mohring M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1088-6
   Diedrichs-Mohring M, 2005, J NEUROIMMUNOL, V164, P22, DOI 10.1016/j.jneuroim.2005.02.023
   Dietrich L, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108167
   Dong Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626172
   Efstathiou NE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244307
   Ehlken C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126859
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Georgiev P, 2019, J CLIN IMMUNOL, V39, P623, DOI 10.1007/s10875-019-00684-7
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Housset M, 2015, J OCUL PHARMACOL TH, V31, P406, DOI 10.1089/jop.2015.0023
   Hu MJ, 2011, BRIT J OPHTHALMOL, V95, P1738, DOI 10.1136/bjophthalmol-2011-300235
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Hultquist JF, 2016, CELL REP, V17, P1438, DOI 10.1016/j.celrep.2016.09.080
   Imai A, 2012, INVEST OPHTH VIS SCI, V53, P7299, DOI 10.1167/iovs.12-10182
   JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z
   Jasielska M, 2010, INVEST OPHTH VIS SCI, V51, P3874, DOI 10.1167/iovs.09-5003
   Jo DH, 2019, GLIA, V67, P321, DOI 10.1002/glia.23542
   Kasprowicz DJ, 2003, J IMMUNOL, V171, P1216, DOI 10.4049/jimmunol.171.3.1216
   Kim H, 2014, NAT REV GENET, V15, P321, DOI 10.1038/nrg3686
   Klettner A, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108214
   Klettner A, 2014, ACTA OPHTHALMOL, V92, pe621, DOI 10.1111/aos.12472
   Kmieciak M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-89
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li W, 2019, EUR J PHARMACOL, V853, P289, DOI 10.1016/j.ejphar.2019.04.012
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Lingeman Emily, 2017, Curr Protoc Mol Biol, V120, DOI 10.1002/cpmb.43
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Lucas K, 2012, J IMMUNOL, V189, P1237, DOI 10.4049/jimmunol.1103264
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Magg T, 2012, EUR J IMMUNOL, V42, P1627, DOI 10.1002/eji.201141838
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Mulfaul K, 2020, CELL REP, V30, P2209, DOI 10.1016/j.celrep.2020.01.064
   Munoz-Rojas AR, 2021, NAT REV IMMUNOL, V21, P597, DOI 10.1038/s41577-021-00519-w
   Nie H, 2013, NAT MED, V19, P322, DOI 10.1038/nm.3085
   Obert E, 2017, J MOL MED, V95, P535, DOI 10.1007/s00109-017-1506-8
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014
   Redpath M, 2011, MOL ONCOL, V5, P156, DOI 10.1016/j.molonc.2011.03.001
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rossi Oriana, 2013, BMC Res Notes, V6, P431, DOI 10.1186/1756-0500-6-431
   Rovai LE, 1998, J LEUKOCYTE BIOL, V64, P494, DOI 10.1002/jlb.64.4.494
   Samuel W, 2017, MOL VIS, V23, P60
   Schafer N, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00197
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schumann K, 2020, NAT IMMUNOL, V21, P1456, DOI 10.1038/s41590-020-0784-4
   Schumann K, 2015, P NATL ACAD SCI USA, V112, P10437, DOI 10.1073/pnas.1512503112
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss O, 2016, EUR J PHARMACOL, V787, P84, DOI 10.1016/j.ejphar.2016.03.066
   Streilein J W, 1999, Chem Immunol, V73, P11
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sun Q, 2020, FREE RADICAL BIO MED, V147, P271, DOI 10.1016/j.freeradbiomed.2019.12.029
   Tallon B, 2010, J CUTAN PATHOL, V37, P1184, DOI 10.1111/j.1600-0560.2009.01482.x
   Tan BS, 2012, PIGM CELL MELANOMA R, V25, P398, DOI 10.1111/j.1755-148X.2012.00993.x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terheyden L, 2021, GRAEF ARCH CLIN EXP, V259, P413, DOI 10.1007/s00417-020-04930-2
   Thurau SR, 2004, INT IMMUNOL, V16, P1573, DOI 10.1093/intimm/dxh158
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Tran DQ, 2012, J MOL CELL BIOL, V4, P29, DOI 10.1093/jmcb/mjr033
   van Bilsen K, 2011, BRIT J OPHTHALMOL, V95, P864, DOI 10.1136/bjo.2010.187930
   Vega JL, 2010, OCUL IMMUNOL INFLAMM, V18, P459, DOI 10.3109/09273948.2010.509532
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016
   Wang Yun-Peng, 2003, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V19, P221
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Wildner G, 2019, IMMUNOBIOLOGY, V224, P172, DOI 10.1016/j.imbio.2018.09.002
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zhang HY, 2010, CANCER LETT, V287, P91, DOI 10.1016/j.canlet.2009.06.001
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129945
   Zhu Y, 2015, MOL VIS, V21, P1122
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 108
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD OCT 22
PY 2022
VL 19
IS 1
AR 260
DI 10.1186/s12974-022-02620-w
PG 23
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 5M6FU
UT WOS:000871189200001
PM 36273134
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Au, A
   Hou, K
   Davila, JP
   Gunnemann, F
   Fragiotta, S
   Arya, M
   Sacconi, R
   Pauleikhoff, D
   Querques, G
   Waheed, N
   Freund, KB
   Sadda, S
   Sarraf, D
AF Au, Adrian
   Hou, Kirk
   Davila, Juan Pablo
   Gunnemann, Frederic
   Fragiotta, Serena
   Arya, Malvika
   Sacconi, Riccardo
   Pauleikhoff, Daniel
   Querques, Giuseppe
   Waheed, Nadia
   Freund, K. Bailey
   Sadda, SriniVas
   Sarraf, David
TI Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment
   Progression in Neovascular Age-Related Macular Degeneration Using
   Optical Coherence Tomography Angiography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE vascularized serous pigment epithelial detachment; age-related macular
   degeneration; anti-VEGF
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INDOCYANINE-GREEN VIDEOANGIOGRAPHY;
   TYPE-1 NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; TEARS;
   THERAPY; SUBTYPES; TRIALS; RISK
AB PURPOSE. To analyze the evolution of type 1 neovascularization associated with vascularized serous pigment epithelial detachment (vsPED) using three-dimensional, volumetric, en face optical coherence tomography angiography (OCTA).
   METHODS. This was a retrospective case series from four tertiary medical centers. OCTA images were analyzed at baseline and at the 3-, 6-, 12-, 18-, and 24-month follow-up visit when available. Visual acuity, number of injections, PED maximal height and PED area and volume, and choroidal neovascularization (CNV) flow area and progression were determined at each visit. Qualitative and quantitative analysis of CNV progression (including CNV/PED flow area) and final PED morphology was performed to determine anatomic outcomes.
   RESULTS. Twenty-four eyes in 22 patients were studied. Median follow-up was 20 months. Across all eyes, maximum PED height decreased from 395.5 to 369.5 lm while CNV/PED flow ratio increased from 27.3% to 40.2%. Median visual acuity was unchanged at 20/40. Final PED outcomes included filled fibrovascular versus persistent vsPED. Filled vsPEDs decreased in PED height and volume and displayed a multilayered morphology in contrast to persistent vsPEDs. Fibrovascular PEDs received on average seven less injections as compared to persistent vsPEDs.
   CONCLUSIONS. Three-dimensional, volumetric, en face OCTA analysis of vsPED progression illustrated two anatomic outcomes: filled, typically multilayered fibrovascular PED versus persistent vsPED. The filled multilayered PED displayed a reduction in PED height and volume, greater CNV/PED flow ratio, and fewer anti-VEGF injections versus the persistent vsPED and may represent a more stable anatomic outcome while the persistent vsPED may indicate a more unstable morphology.
C1 [Au, Adrian; Hou, Kirk; Davila, Juan Pablo; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retina Disorders & Ophthalm Genet, Los Angeles, CA USA.
   [Gunnemann, Frederic; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Fragiotta, Serena; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Arya, Malvika; Waheed, Nadia] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Sacconi, Riccardo; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
   [Sadda, SriniVas] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   St. Franziskus-Hospital; Vitreous Retina Macula Consultants of New York;
   Tufts Medical Center; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele; Doheny Eye Institute; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System
RP Sarraf, D (通讯作者)，Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM sarraf@jsei.ucla.edu
RI Fragiotta, Serena/I-5227-2016; Au, Adrian/AAE-9654-2019; Freund, K.
   Bailey/V-7488-2018
OI Fragiotta, Serena/0000-0002-6214-6270; Au, Adrian/0000-0001-8110-9988;
   Sacconi, Riccardo/0000-0003-2891-2012; Freund, K.
   Bailey/0000-0002-7888-9773
FU Research to Prevent Blindness (New York, NY, USA); Macula Foundation,
   Inc. (New York, NY, USA)
FX Supported by funding from Research to Prevent Blindness (DS) (New York,
   NY, USA) and the Macula Foundation, Inc. (DS) (New York, NY, USA).
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Clemens CR, 2017, ACTA OPHTHALMOL, V95, P683, DOI 10.1111/aos.13359
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kang H, 2019, RETINA-J RET VIT DIS, V39, P1551, DOI 10.1097/IAE.0000000000002201
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Lam D, 2018, RETINA-J RET VIT DIS, V38, P1100, DOI 10.1097/IAE.0000000000001698
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Nagiel Aaron, 2015, Retin Cases Brief Rep, V9, P269, DOI 10.1097/ICB.0000000000000184
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2181, DOI 10.1097/IAE.0000000000000764
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yuksel H, 2013, ARQ BRAS OFTALMOL, V76, P209, DOI 10.1590/S0004-27492013000400002
NR 41
TC 6
Z9 6
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2019
VL 60
IS 10
BP 3310
EP 3319
DI 10.1167/iovs.18-26478
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS2FS
UT WOS:000481969000005
PM 31369033
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Barakat, A
   Rufin, V
   Tran, THC
AF Barakat, A.
   Rufin, V.
   Tran, T. H. C.
TI Two year outcome in treatment-naive patients with neovascular
   age-related macular degeneration (nAMD) using an individualized regimen
   of Aflibercept
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Aflibercept; Individualized
   regimen
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   EXTEND INTRAVITREAL THERAPY; RANIBIZUMAB; EFFICACY; VEGF; EYES; AMD
AB Purpose. - To evaluate the 2 year visual and anatomical results of intravitreal aflibercept injection (IAI) in nAMD in treatment-naive eyes in real life using a flexible regimen combining a PRN and modified treat-and-extend (TAE) regimen.
   Patients and methods. - This is a retrospective study including 48 eyes of 38 patients with nAMD treated with aflibercept as first line therapy. The modified T&E protocol consisted of a loading phase with 3 monthly IAI followed by an adaptation phase during which patients were monitored and treated as needed at the same visit from week 12 to week 32, then a T&E phase per se, for which the treatment interval was determined based on history of disease recurrence.
   Results. - A total of 48 eyes were included. Visual acuity at baseline was 57.3 +/- 16 letters. Visual gain was 6 +/- 12 letters at 1 year and 5.2 +/- 11 letters at 2 years. At the 2-year end point, 94.3% of eyes maintained visual acuity and 71.4% of eyes had >= 70 letters. Reduction of central macular thickness, macular volume and pigment epithelium detachment height was observed after the loading phase, at 1 and 2 years compared to baseline. Complete resolution of fluid was obtained in 78% of eyes after the loading phase, in 68% of eyes at 1 year and in 62.8% of eyes at 2 years. Subfoveal choroidal thickness remained stable during the study. The surface area of the neovascular lesion was reduced at 1 year. The mean number of IAI was 6 IVT (3-11) during the first year and 3.2 IVT (0-13) during the second year. Conclusion Aflibercept is effective in real life in treatment-naive eyes at two years. A personalized regimen of IAI for neovascular AMD produced good functional and anatomical outcome over 2 years, with a lower number of injections than in the pivotal studies. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Barakat, A.; Rufin, V.; Tran, T. H. C.] Lille Catholic Univ, St Vincent de Paul Hosp, Lille Catholic Hosp, Dept Ophthalmol, Blvd Belfort,BP387, F-59020 Lille, France.
RP Tran, THC (通讯作者)，St Vincent de Paul Hosp, Dept Ophthalmol, Blvd Belfort,BP387, F-59020 Lille, France.
EM tran.hachau@ghicl.net
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   European Medicines Agency, 2012, EYL 40MG ML SOL INJ
   Gelman SK, 2014, RETINA-J RET VIT DIS, V34, P2088, DOI 10.1097/IAE.0000000000000207
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kodjikian L, 2015, J FR OPHTALMOL, V38, P639, DOI 10.1016/j.jfo.2015.06.001
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Maringe E, 2016, J FR OPHTALMOL, V39, P255, DOI 10.1016/j.jfo.2015.10.009
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Moyal L, 2015, J FR OPHTALMOL, V38, P573, DOI 10.1016/j.jfo.2015.01.011
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 26
TC 5
Z9 5
U1 0
U2 2
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD SEP
PY 2018
VL 41
IS 7
BP 603
EP 610
DI 10.1016/j.jfo.2018.01.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT9YC
UT WOS:000444902500011
PM 30166233
DA 2022-11-30
ER

PT J
AU Gong, JW
   Yu, SQ
   Gong, YY
   Wang, FH
   Sun, XD
AF Gong, Jingwen
   Yu, Suqin
   Gong, Yuanyuan
   Wang, Fenghua
   Sun, Xiaodong
TI The Diagnostic Accuracy of Optical Coherence Tomography Angiography for
   Neovascular Age-Related Macular Degeneration: A Comparison with Fundus
   Fluorescein Angiography
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; THERAPY
AB Purpose. To describe the morphological characteristics and efficacy of OCTA in detecting CNV in nAMD. We retrospectively reviewed 53 patients (86 eyes) with suspected CNV secondary to wet AMD. All the patients underwent a multimodal assessment for CNV. Two independent readers calculated the sensitivity and specificity of OCTA in detecting CNV compared with FA. A qualitative analysis of OCTA was also performed to describe the morphological appearance of CNV. Among 86 eyes of 53 patients, 52 eyes were diagnosed as having CNV based on the FA imaging analysis. According to FA, CNV was classified as classic in 28 eyes, predominantly classic in 6 eyes, minimally classic in 9 eyes, and occult in 9 eyes. In 56 eyes, CNV was visualized on OCTA and corresponding OCT B-scans. In total, 46.4% (26/56) had well-circumscribed vessels, and 53.6% (30/56) showed poorly circumscribed vessels. There were 11 false positives and 7 false negatives using OCTA. The specificity of OCTA for the detection of CNV was 67.6%, with sensitivity of 86.5%. OCTA may help in the noninvasive diagnosis of CNV and may provide a method for monitoring the evolution of CNV.
C1 [Gong, Jingwen; Sun, Xiaodong] Nanjing Med Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Gong, Jingwen] Zhejiang Prov Peoples Hosp, Dept Ophthalmol, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
   [Yu, Suqin; Gong, Yuanyuan; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
C3 Nanjing Medical University; Zhejiang Provincial People's Hospital;
   Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Nanjing Med Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
RI 俞, 素勤/HDO-8369-2022
FU Health and Family Planning Commission of Zhejiang Province of China
   [2011ZHB001]; major scientific and technological project of Science
   Technology Department of Zhejiang Province [2013C03048-1]
FX This study was supported by Health and Family Planning Commission of
   Zhejiang Province of China (no. 2011ZHB001) and by major scientific and
   technological project of Science Technology Department of Zhejiang
   Province (no. 2013C03048-1).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bellou S, 2013, CANCER LETT, V338, P219, DOI 10.1016/j.canlet.2013.05.015
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Coscas G., 2009, OCT IN AMD
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
NR 21
TC 69
Z9 72
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 7521478
DI 10.1155/2016/7521478
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI4IT
UT WOS:000373464300001
PM 27110394
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lu, F
   Shi, Y
   Qu, C
   Zhao, PQ
   Liu, XQ
   Gong, B
   Ma, S
   Zhou, Y
   Zhang, Q
   Fei, P
   Xu, Y
   Hu, JB
   Fan, YC
   Lin, Y
   Zhu, XJ
   Yang, ZL
AF Lu, Fang
   Shi, Yi
   Qu, Chao
   Zhao, Peiquan
   Liu, Xiaoqi
   Gong, Bo
   Ma, Shi
   Zhou, Yu
   Zhang, Qi
   Fei, Ping
   Xu, Yu
   Hu, Jianbin
   Fan, Yingchuan
   Lin, Ying
   Zhu, Xianjun
   Yang, Zhenglin
TI A Genetic Variant in the SKIV2L Gene Is Significantly Associated With
   Age-Related Macular Degeneration in a Han Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; SKIV2L; single nucleotide polymorphism
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; HTRA1 PROMOTER
   POLYMORPHISM; GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; FACTOR-B;
   JAPANESE POPULATION; COMPONENT 2; ENVIRONMENTAL ASSOCIATIONS;
   SUSCEPTIBILITY
AB PURPOSE. Previous studies have shown that genetic variants in the complement component 2 (C2)/complement factor B (BF) gene are associated with AMD in Caucasians, but not in Han Chinese. Recent studies have indicated that genetic variants in the neighboring superkiller viralicidic activity 2-like (SKIV2L) gene showed significant association with AMD. We conducted this study to investigate whether genetic variants in the SKIV2L gene are associated with AMD in a Han Chinese population.
   METHODS. Thirteen single nucleotide polymorphisms (SNPs) in the C2-BF-RDBP-SKIV2L-STK19 region were genotyped by the SNaPshot method in a cohort composed of 449 patients with choriodal neovascularization (CNV) AMD and 1025 healthy controls of Han Chinese descent.
   RESULTS. Among the SNPs genotyped, P values of seven SNPs were less than 0.05; however, only rs429608 was found to be significantly associated with AMD after correction for multiple testing. The minor allele (A) frequency of rs429608 was 0.050 in cases and 0.089 in controls, and the P value was 3.76 x 10(-4) (0.00489 after Bonferroni correction), with an odds ratio of 0.55 (95% confidence interval, 0.40-0.77). The SKIV2L gene was expressed in the human RPE, retina, and D407 (human RPE) cells, and in mouse retinas and RPE.
   CONCLUSIONS. We demonstrated that the rs429608 genetic variant in the SKIV2L gene was significantly associated with AMD in a Han Chinese population. SKIV2L may play an important role in the development of AMD.
C1 [Lu, Fang; Shi, Yi; Liu, Xiaoqi; Gong, Bo; Ma, Shi; Zhou, Yu; Lin, Ying; Zhu, Xianjun; Yang, Zhenglin] Sichuan Acad Med Sci, Inst Lab Med, Sichuan Key Lab Human Dis Gene Study, Chengdu 610072, Sichuan, Peoples R China.
   [Lu, Fang; Shi, Yi; Qu, Chao; Liu, Xiaoqi; Gong, Bo; Ma, Shi; Zhou, Yu; Hu, Jianbin; Fan, Yingchuan; Lin, Ying; Zhu, Xianjun; Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China.
   [Qu, Chao; Hu, Jianbin; Fan, Yingchuan] Sichuan Acad Med Sci, Dept Ophthalmol, Chengdu 610072, Sichuan, Peoples R China.
   [Zhao, Peiquan; Zhang, Qi; Fei, Ping; Xu, Yu] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Sichuan Provincial People's Hospital; Shanghai Jiao Tong
   University
RP Yang, ZL (通讯作者)，Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, 32 1st Ring Rd West 2, Chengdu 610072, Sichuan, Peoples R China.
EM zliny@yahoo.com
OI Zhu, Xianjun/0000-0002-2531-7552
FU Natural Science Foundation of China [81025006, 81070761, 81100693,
   81170882]; Department of Science and Technology of Sichuan Province
   [2011JTD0020, 2010JQ0055, 2012JQ0023]
FX Supported by grants from the Natural Science Foundation of China
   (81025006 [ZY], 81070761 [FL], 81100693 [CQ], and 81170882 [YS]), and
   the Department of Science and Technology of Sichuan Province
   (2011JTD0020 [ZY], 2010JQ0055 [FL], and 2012JQ0023 [YS]). The authors
   alone are responsible for the content and the writing of the paper.
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Lu F, 2010, MOL VIS, V16, P1
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 42
TC 13
Z9 15
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2911
EP 2917
DI 10.1167/iovs.12-11381
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 156KV
UT WOS:000319821700060
PM 23557739
DA 2022-11-30
ER

PT J
AU Eklund, K
   Sonn, U
   Nystedt, P
   Dahlin-Ivanoff, S
AF Eklund, K
   Sonn, U
   Nystedt, P
   Dahlin-Ivanoff, S
TI A cost-effectiveness analysis of a health education programme for
   elderly persons with age-related macular degeneration: A longitudinal
   study
SO DISABILITY AND REHABILITATION
LA English
DT Article
DE occupational therapy; health promotion; evaluation
ID BEAVER-DAM EYE; OCCUPATIONAL-THERAPY; VISUAL IMPAIRMENT; POPULATION;
   ACUITY; ADULTS
AB Purpose: To analyse the cost-effectiveness of the activity-based Health Education Programme 'Discovering New Ways' versus a standard Individual Programme.
   Method: Two-hundred and twenty-nine persons were randomized to either the Health Education Programme or an Individual Programme. The present study is based on 131 persons who participated in the 28-month follow-up. Costs for the low vision clinic were documented prospectively along with external costs. A cost-effectiveness analysis was done using cases with an improved level of perceived security in daily activities as the effectiveness measure.
   Results: The Health Education Programme led to significantly more cases with an improved level of perceived security ( 45 vs. 10%, CI 95%: 21-49, p value < 0.001) and the total social cost per treatment was lower ( 28 004 vs. 36 341 SEK). Taken separately the low vision clinic costs were slightly higher due to a higher prescription of assistive devices, but external costs were lower for the Health Education Programme compared to the Individual Programme, though neither of these differences was statistically significant.
   Conclusion: The results suggest that replacing the standard Individual Programme with the Health Education Programme 'Discovering New Ways' is cost-effective as more persons experience increased security to a lesser total cost.
C1 Univ Gothenburg, Sahlgrenska Acad, Inst Occupat Therapy & Physiotherapy, SE-40530 Gothenburg, Sweden.
   Univ Gothenburg, Sahlgrenska Acad, Dept Geriatr Med, SE-40530 Gothenburg, Sweden.
   Linkoping Univ, Dept Econ & Management, Linkoping, Sweden.
   Univ Gothenburg, Sahlgrenska Acad, Vardal Inst, SE-40530 Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg; Linkoping
   University; University of Gothenburg
RP Eklund, K (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Occupat Therapy & Physiotherapy, Box 455, SE-40530 Gothenburg, Sweden.
EM kajsa.eklund@fhs.gu.se
RI Dahlin-Ivanoff, Synneve/U-9819-2018
CR Altman DG, 1991, PRACTICAL STAT MED R
   Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Claesson L, 2000, STROKE, V31, P2569, DOI 10.1161/01.STR.31.11.2569
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Donaldson C, 1998, PHARMACOECONOMICS, V13, P389, DOI 10.2165/00019053-199813040-00002
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Hay J, 2002, J AM GERIATR SOC, V50, P1381, DOI 10.1046/j.1532-5415.2002.50359.x
   Ivanoff SD, 2002, AM J OCCUP THER, V56, P322, DOI 10.5014/ajot.56.3.322
   Ivanoff SD, 1996, DISABIL REHABIL, V18, P515, DOI 10.3109/09638289609166038
   Ivanoff SD, 2000, SCAND J OCCUP THER, V7, P148
   IVANOFF SD, 2001, DISABILTIY REHABILIT, V23, P69
   IVANOFF SD, 2000, THESIS GOTEBORG U
   Jackson J, 1998, AM J OCCUP THER, V52, P326, DOI 10.5014/ajot.52.5.326
   JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   LACHMAN R, 1982, AGING COGNITIVE PROC
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Ovretveit J, 1998, EVALUATING HLTH INTE
   Russell W, 2001, OPHTHAL PHYSL OPT, V21, P36, DOI 10.1046/j.1475-1313.2001.00569.x
   Sonntag SK, 1996, J COMMONW COMP POLIT, V34, P1
   Ungar WJ, 1998, J CLIN EPIDEMIOL, V51, P1335, DOI 10.1016/S0895-4356(98)00117-6
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   Wang KM, 1999, BRAIN TOPOGR, V12, P19, DOI 10.1023/A:1022225522447
   Wilcock A.A., 1998, BRIT J OCCUPATIONAL, V61, P340, DOI DOI 10.1177/030802269806100801
   Yerxa EJ, 1998, AM J OCCUP THER, V52, P412, DOI 10.5014/ajot.52.6.412
   Young B., 1998, J OCCUPATIONAL SCI, V5, P107, DOI [https://doi.org/10.1080/14427591.1998.9686438, DOI 10.1080/14427591.1998.9686438]
NR 31
TC 17
Z9 17
U1 0
U2 26
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-8288
EI 1464-5165
J9 DISABIL REHABIL
JI Disabil. Rehabil.
PY 2005
VL 27
IS 20
BP 1203
EP 1212
DI 10.1080/09638280500052716
PG 10
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA 986IS
UT WOS:000233443900001
PM 16298922
DA 2022-11-30
ER

PT J
AU Vercellin, ACV
   Harris, A
   Chiaravalli, G
   Sacco, R
   Siesky, B
   Ciulla, T
   Guidoboni, G
AF Vercellin, Alice C. Verticchio
   Harris, Alon
   Chiaravalli, Greta
   Sacco, Riccardo
   Siesky, Brent
   Ciulla, Thomas
   Guidoboni, Giovanna
TI Physics-based modeling of Age-related Macular Degeneration-A theoretical
   approach to quantify retinal and choroidal contributions to macular
   oxygenation
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Macula; Retina
ID BLOOD-FLOW; RISK-FACTORS; AUTOREGULATION; CONSUMPTION; RETROBULBAR;
   MECHANISMS
AB We developed a mathematical model to characterize how macular oxygenation may be affected by abnormalities in the retinal and choroidal oxygen supplies. The macular region is modeled as a layered structure including: ganglion cell and nerve fiber layers, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, inner segment of photoreceptors layer and retinal pigmented epithelium. Each layer is characterized by specific levels of oxygen consumption. The vitreous and the choroid are located at the macula boundary and provide oxygen via boundary conditions of Dirichlet type. The three capillary plexi (superficial, intermediate, and deep) of the retinal circulation pierce the macular layers and provide oxygen via a volumetric source that depends on the retinal blood flow. Oxygen profiles through the macular tissue are calculated by simulating the balance among oxygen supply, consumption and diffusion in: (a) physiological baseline conditions; (b) retinal blood flow reduced by 10%, 30% and 50% with respect to baseline; (c) choroidal oxygen level diminished by 10%, 30% and 50% with respect to baseline. Model simulations predict that: (1) the oxygenation of the foveal avascular zone is not affected by reduction in retinal blood flow; (2) a reduction in choroidal oxygen supply significantly affects the outer layers, especially the photoreceptors and outer nuclear layers; (3) the impact of reduction in choroidal oxygen supply is larger in the region more proximal to the macular center; (4) the impact of reduction in retinal blood flow is larger in the region more proximal to the macular periphery. The proposed mathematical model suggests that changes in retinal and choroidal oxygen supplies impact the oxygenation of the macular tissue differentially. These results may help better understand the pathogenesis of macular degeneration.
C1 [Vercellin, Alice C. Verticchio; Harris, Alon; Siesky, Brent] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY 10029 USA.
   [Chiaravalli, Greta] Italian Inst Technol, Milan, Italy.
   [Chiaravalli, Greta] Politecn Milan, Dipartimento Fis, Milan, Italy.
   [Sacco, Riccardo] Politecn Milan, Dipartimento Matemat, Milan, Italy.
   [Ciulla, Thomas] Midwest Eye Inst, Vitreoretinal Med & Surg, Indianapolis, IN 46290 USA.
   [Guidoboni, Giovanna] Univ Missouri, Dept Math, Dept Elect Engn & Comp Sci, Columbia, MO 65211 USA.
   [Harris, Alon] Mt Sinai Hosp, Ophthalmol, New York, NY 10029 USA.
   [Harris, Alon] Mt Sinai Hosp, Int Res & Acad Affairs, New York, NY 10029 USA.
   [Harris, Alon] Mt Sinai Hosp, Ophthalm Vasc Diagnost & Res Program, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Istituto Italiano di Tecnologia
   - IIT; Polytechnic University of Milan; Polytechnic University of Milan;
   University of Missouri System; University of Missouri Columbia; Icahn
   School of Medicine at Mount Sinai; Icahn School of Medicine at Mount
   Sinai; Icahn School of Medicine at Mount Sinai
RP Harris, A (通讯作者)，Icahn Sch Med Mt Sinai, 1468 Madison Ave,Annenberg 22-86, New York, NY 10029 USA.; Harris, A (通讯作者)，Mt Sinai Hosp, Ophthalmol, New York, NY 10029 USA.; Harris, A (通讯作者)，Mt Sinai Hosp, Int Res & Acad Affairs, New York, NY 10029 USA.; Harris, A (通讯作者)，Mt Sinai Hosp, Ophthalm Vasc Diagnost & Res Program, New York, NY 10029 USA.
EM alon.harris@mssm.edu
OI Ciulla, Thomas/0000-0001-5557-6777; Chiaravalli,
   Greta/0000-0003-4979-3446
FU NIH [R01EY030851]; NSF [DMS 1853222/2021192]; Research to Prevent
   Blindness
FX Y This work was supported by NIH grant R01EY030851 (Alon Harris), NSF
   DMS 1853222/2021192 (Giovanna Guidoboni and Alon Harris), a Challenge
   Grant award from Research to Prevent Blindness, NY (Alon Harris).
CR Arciero J, 2019, MODEL SIMUL SCI ENG, P101, DOI 10.1007/978-3-030-25886-3_5
   Arciero J, 2013, INVEST OPHTH VIS SCI, V54, P5584, DOI 10.1167/iovs.12-11543
   Arciero JC, 2008, AM J PHYSIOL-HEART C, V295, pH1562, DOI 10.1152/ajpheart.00261.2008
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brendan C., 2020, MATH BIOSCI, V329
   Burgansky-Eliash Z, 2014, CURR EYE RES, V39, P304, DOI 10.3109/02713683.2013.840384
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Carichino L., 2016, MODEL ARTIF INTELL O, V1, P64
   Cassani S, 2015, J COUPLED SYST MULTI, V3, P38, DOI 10.1166/jcsmd.2015.1063
   Causin P, 2016, BIOMECH MODEL MECHAN, V15, P525, DOI 10.1007/s10237-015-0708-7
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan KKW, 2016, BMJ OPEN OPHTHALMOL, V1, DOI 10.1136/bmjophth-2016-000032
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chiaravalli G., 2018, THESIS POLITECNICO M THESIS POLITECNICO M
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Cringle SJ, 2002, COMP BIOCHEM PHYS A, V132, P61, DOI 10.1016/S1095-6433(01)00530-X
   GANFIELD RA, 1970, AM J PHYSIOL, V219, P814, DOI 10.1152/ajplegacy.1970.219.3.814
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Guidoboni G., 2020, ANN M ASS RES VIS OP ANN M ASS RES VIS OP
   Guidoboni G, 2014, INVEST OPHTH VIS SCI, V55, P4105, DOI 10.1167/iovs.13-13611
   Harris A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1076, DOI 10.1001/archopht.118.8.1076
   Harris A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100841
   Hayreh SS, 2006, EYE, V20, P1130, DOI 10.1038/sj.eye.6702377
   Hecht F, 2012, J NUMER MATH, V20, P251, DOI 10.1515/jnum-2012-0013
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   John D, 2011, INDIAN J OPHTHALMOL, V59, P9, DOI 10.4103/0301-4738.73706
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Pappelis K, 2020, AM J PHYSIOL-HEART C, V319, pH1253, DOI 10.1152/ajpheart.00404.2020
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pogue BW, 2001, RADIAT RES, V155, P15, DOI 10.1667/0033-7587(2001)155[0015:EOODIR]2.0.CO;2
   Prada D, 2016, SURV OPHTHALMOL, V61, P164, DOI 10.1016/j.survophthal.2015.10.004
   Quarteroni A., 1994, NUMERICAL APPROXIMAT, V23
   Rahimy E, 2015, RETINA-J RET VIT DIS, V35, P1921, DOI 10.1097/IAE.0000000000000785
   Rechtman E, 2007, OPHTHAL SURG LAS IM, V38, P219, DOI 10.3928/15428877-20070501-06
   Reynolds J.D., 2011, PEDIAT RETINA, DOI [10.1007/978-3-642-12041-1, DOI 10.1007/978-3-642-12041-1]
   Roos MW, 2007, COMPUT BIOL MED, V37, P890, DOI 10.1016/j.compbiomed.2006.09.005
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
NR 48
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD SEP
PY 2021
VL 339
AR 108650
DI 10.1016/j.mbs.2021.108650
EA JUL 2021
PG 12
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA TX8QG
UT WOS:000683350700002
PM 34197878
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Kay, P
   Yang, YC
   Hiscott, P
   Gray, D
   Maminishkis, A
   Paraoan, L
AF Kay, Paul
   Yang, Yit C.
   Hiscott, Paul
   Gray, Donna
   Maminishkis, Arvydas
   Paraoan, Luminita
TI Age-Related Changes of Cystatin C Expression and Polarized Secretion by
   Retinal Pigment Epithelium: Potential Age-Related Macular Degeneration
   Links
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cystatin C; secretion; aging; retinal pigment epithelium
ID GLYCATION END-PRODUCTS; BRUCHS MEMBRANE; EXTRACELLULAR-MATRIX; G73A
   POLYMORPHISM; PROTEIN; CELLS; LOCALIZATION; PRECURSOR; DYSFUNCTION;
   ACTIVATION
AB PURPOSE. Cystatin C, a potent cysteine proteinase inhibitor, is abundantly secreted by the RPE and may contribute to regulating protein turnover in the Bruch's membrane (BrM). A cystatin C variant associated with increased risk of developing AMD and Alzheimer's disease (AD) presents reduced secretion levels from RPE. The purpose of this study was to analyze the effects of age and the accumulation of advanced glycation end-products (AGEs) on the expression and secretion of cystatin C by the RPE.
   METHODS. Confluent monolayers of human fetal RPE (hfRPE) cells were cultured using an in vitro model mimicking extracellular AGE accumulation. Cystatin C expression, secretion, and its polarity were analyzed following culture on AGE-containing BrM mimics (AGEd versus nonAGEd). Monolayer barrier properties were assessed by transepithelial resistance measurements. The relative level of cystatin C protein expression in human RPE in situ was assessed immunohistochemically in relation to age.
   RESULTS. Advanced glycation end product-exposed RPE monolayers presented significantly decreased cystatin C expression and secretion. Basolateral secretion was fully established by week 8 in non-AGEd conditions. In AGEd cultures, polarity of secretion was impaired despite maintenance of physiological barrier properties of the monolayer. In the macula region of RPE/choroid segments from human eyes, the level of cystatin C protein was reduced with increasing donor age.
   CONCLUSIONS. Exposure to AGEs reduces expression of cystatin C and affects its normal secretion in cultured RPE. Age-related changes of cystatin C in the RPE from the posterior pole may compromise its extracellular functions, potentially contributing to AMD pathogenesis.
C1 [Kay, Paul; Hiscott, Paul; Gray, Donna; Paraoan, Luminita] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3GA, Merseyside, England.
   [Yang, Yit C.] Royal Wolverhampton NHS Trust, Dept Ophthalmol, Wolverhampton, W Midlands, England.
   [Maminishkis, Arvydas] NEI, NIH, Bethesda, MD 20892 USA.
C3 University of Liverpool; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Paraoan, L (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM lparaoan@liv.ac.uk
RI Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Maminishkis,
   Arvydas/0000-0003-3345-3375
FU R & D Royal Wolverhampton NHS Trust; AgeUK; NATIONAL EYE INSTITUTE
   [ZIAEY000419] Funding Source: NIH RePORTER
FX Supported by a grant from R & D Royal Wolverhampton NHS Trust (LP). Work
   in Luminita Paraoan's lab is supported by AgeUK.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6
   ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1363
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   BJARNADOTTIR M, 1995, SCAND J CLIN LAB INV, V55, P617, DOI 10.3109/00365519509110261
   Bondeva T, 2011, AM J PHYSIOL-RENAL, V301, pF852, DOI 10.1152/ajprenal.00575.2010
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Dahrouj M, 2013, J PHARMACOL EXP THER, V344, P96, DOI 10.1124/jpet.112.199307
   Davies L, 2009, J CELL MOL MED, V13, P1995, DOI 10.1111/j.1582-4934.2008.00590.x
   El-Sukkari D, 2003, J IMMUNOL, V171, P5003, DOI 10.4049/jimmunol.171.10.5003
   Ghidoni R, 2011, NEUROBIOL AGING, V32, P1435, DOI 10.1016/j.neurobiolaging.2009.08.013
   GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Howard C, 2010, HISTOL HISTOPATHOL, V25, P1163, DOI 10.14670/HH-25.1163
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu PF, 2012, INT J MOL MED, V29, P613, DOI 10.3892/ijmm.2012.891
   Hua Y, 2012, INT J NEUROSCI, V122, P431, DOI 10.3109/00207454.2012.672502
   Ida H, 2004, MOL VIS, V10, P439
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kaur G, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00079
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   LI W, 1984, EXP EYE RES, V38, P291, DOI 10.1016/0014-4835(84)90167-2
   Liu YY, 2010, ATHEROSCLEROSIS, V208, P34, DOI 10.1016/j.atherosclerosis.2009.06.007
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Min C, 1999, DIABETES RES CLIN PR, V46, P197, DOI 10.1016/S0168-8227(99)00094-7
   MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Scivittaro V, 2000, AM J PHYSIOL-RENAL, V278, pF676, DOI 10.1152/ajprenal.2000.278.4.F676
   Sheikpranbabu S, 2010, BIOCHIMIE, V92, P1040, DOI 10.1016/j.biochi.2010.05.004
   SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stitt AW, 2004, DIABETOLOGIA, V47, P1735, DOI 10.1007/s00125-004-1523-3
   SUGAHARA K, 1993, VIRCHOWS ARCH B, V64, P115, DOI 10.1007/BF02915103
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1341
   TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C
   van Soest SS, 2007, MOL VIS, V13, P1608
   Whitcomb EA, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12808
   Wistow G, 2002, MOL VIS, V8, P205
   Wittchen ES, 2011, INVEST OPHTH VIS SCI, V52, P7455, DOI 10.1167/iovs.11-7295
   Xu YK, 2011, J IMMUNOL, V186, P3666, DOI 10.4049/jimmunol.1001934
   Yamamoto-Watanabe Y, 2010, BRAIN RES, V1361, P140, DOI 10.1016/j.brainres.2010.09.033
   Yim MB, 2001, ANN NY ACAD SCI, V928, P48, DOI 10.1111/j.1749-6632.2001.tb05634.x
   Zhong XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055328
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 65
TC 15
Z9 15
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2014
VL 55
IS 2
BP 926
EP 934
DI 10.1167/iovs.13-13239
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6IU
UT WOS:000331891700037
PM 24458156
DA 2022-11-30
ER

PT J
AU Ghoshal, R
   Kaur, S
   Fadzil, NM
   Ghosh, S
   Ngah, N
   Abd Aziz, RAB
AF Ghoshal, Rituparna
   Kaur, Sharanjeet
   Fadzil, Norliza Mohamad
   Ghosh, Somnath
   Ngah, Norfariza
   Abd Aziz, Roslin Azni Binti
TI Quality of Life in Patients with Neovascular Age Related Macular
   Degeneration (n-AMD) Seen in a Public Hospital of Malaysia
SO SAINS MALAYSIANA
LA English
DT Article
DE Neovascular AMD (n-AMD); visual functions (VF); vision targeted quality
   of life (VTQOL)
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VISUAL FUNCTION QUESTIONNAIRE;
   PSYCHOMETRIC PROPERTIES; POPULATION; RANIBIZUMAB; PREVALENCE; PATTERNS;
   IMPACT
AB The purpose of the present study was to assess quality of life (QOL) in n-AMD patients seen in a Malaysian public hospital and to further identify visual and demographic factors that may contribute to QOL scores of these patients. Patients with any form of n-AMD in at least one eye were recruited from hospital's ophthalmology department. Bahasa Malaysia version of National Eye Institute Visual function questionnaire-25 (NEI-VFQ-25) was administered to all participants. Demographics, visual functions (VF) including best corrected distance visual acuity (BCDVA), contrast sensitivity (CS), near visual acuity (NVA) and reading speed (RS) were recorded. Eighty-six patients (Malay=26, Indian=23, Chinese=37) aged 52 to 85 years, diagnosed with n-AMD were chosen to participate. Their mean NEI-VFQ composite score (NEI-VFQ CS) was 66.91 +/- 13.07. However, no significant difference in NEI-VFQ CS between gender, races and between the two sub groups of n-AMD were observed (p>0.05). NEI-VFQ CS showed a significant association with RS (correlation coefficient (rho) = 0.627), NVA (rho = -.660), BCDVA (rho = -.586), CS (rho = .0.515). A linear model showed that a combination of BCDVA, NVA, CS is accounted for a significant 38 % variability of NEI-VFQ CS (R-2 = 0.382, p<0.001). In conclusion, the QOL of Malaysian n-AMD patients were found to be low. Thus, the study results indicated the need of developing necessary management strategies to address this QOL issues in n-AMD patients in Malaysia. Furthermore, the present study suggested incorporating appropriate VF such as near acuity, contrast sensitivity, reading speed in clinical settings while assessing n-AMD patients as these VF explain the patient's perception about the impact of this disease.
C1 [Ghoshal, Rituparna; Kaur, Sharanjeet; Fadzil, Norliza Mohamad; Ghosh, Somnath; Ngah, Norfariza] Univ Kebangsaan Malaysia, Fac Hlth Sci, Sch Healthcare Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abd Aziz, Kuala Lumpur 50300, Federal Territo, Malaysia.
   [Abd Aziz, Roslin Azni Binti] Hosp Shah Alam, Dept Ophthalmol, Seksyen 7, Shah Alam 40000, Selangor Darul, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Kaur, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Sch Healthcare Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abd Aziz, Kuala Lumpur 50300, Federal Territo, Malaysia.
EM sharanjeet@ukm.edu.my
CR Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bertelmann T, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0536-1
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, P606
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Buari NH, 2015, BANGLADESH J MED SCI, V14, P236, DOI 10.3329/bjms.v14i3.18964
   Centers for Disease Control and Prevention, 2020, DIS IMP ALL US
   Chandramohan H., 2017, INT MED J, V24, P61
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Fenwick EK, 2017, JAMA OPHTHALMOL, V135, P469, DOI 10.1001/jamaophthalmol.2017.0266
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Li Y., 2008, AM J OPHTHALMOL, V146, P172
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mohamad NA, 2017, INT J OPHTHALMOL-CHI, V10, P1889, DOI 10.18240/ijo.2017.12.16
   Nazima SA, 2016, MED HEALTH-KUALA LUM, V11, P245, DOI 10.17576/MH.2016.1102.13
   Omar Rokiah, 2014, BMC Res Notes, V7, P667, DOI 10.1186/1756-0500-7-667
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Rahman M., 2015, THESIS
   Rebollo P., 2001, INT UROL NEPHROL, V33, P195
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rizal A. M., 2007, JURNAL KESIHATAN MAS, V13, P32
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tabachnick BG., 2014, USING MULTIVARIATE S, V6
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   World Health Organization, 2014, VIS IMP BLIND
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
NR 38
TC 5
Z9 5
U1 0
U2 0
PU UNIV KEBANGSAAN MALAYSIA
PI SELANGOR
PA FACULTY SCIENCE & TECHNOLOGY, BANGI, SELANGOR, 43600, MALAYSIA
SN 0126-6039
J9 SAINS MALAYS
JI Sains Malays.
PD OCT
PY 2018
VL 47
IS 10
BP 2447
EP 2454
DI 10.17576/jsm-2018-4710-21
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HC2NY
UT WOS:000451640100021
OA gold
DA 2022-11-30
ER

PT J
AU Hjelmqvist, L
   Lindberg, C
   Kanulf, P
   Dahlgren, H
   Johansson, I
   Siewert, A
AF Hjelmqvist, Lars
   Lindberg, Charlotte
   Kanulf, Par
   Dahlgren, Henrik
   Johansson, Ingrid
   Siewert, Annica
TI One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular
   Degeneration: Results of a Prospective and Retrospective Observational
   Multicentre Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT; DOSING REGIMEN; TRIAL;
   PHARMACOKINETICS; LUCENTIS; FRAGMENT
AB The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46-93 years). In total, a mean of 4.7 +/- 1.6 injections per patient (range 1-10) was given to month 12. Mean VA score was 58.3 +/- 12.2 letters before treatment, 63.3 +/- 12.5 after 3 injections (Delta 4.9 +/- 10.1 letters from baseline), and 59.3 +/- 16.2 at 12 months (Delta 1.0 +/- 13.6). VA score from baseline to month 12 was stable in 74.4% of patients, improved by 15 letters/3 lines or more in 14.7%, and decreased by >= 15 letters/3 lines in 10.9% of patients. With a mean of 4.7 ranibizumab injections per patient per year, mean VA was stabilised but not increased. To maintain the initial gain seen after the first three injections, an average of 1.8 +/- 1.5 additional injections does not appear to be adequate.
C1 [Hjelmqvist, Lars] Karolinska Inst, St Eriks Eye Hosp, S-11282 Stockholm, Sweden.
   [Lindberg, Charlotte] Univ Lund Hosp, Dept Ophthalmol, S-22185 Lund, Sweden.
   [Lindberg, Charlotte] Helsingborg Hosp, Dept Ophthalmol, S-25187 Helsingborg, Sweden.
   Ryhov Hosp, Dept Ophthalmol, S-55185 Jonkoping, Sweden.
   [Dahlgren, Henrik] Soder Sjukhuset, Dept Ophthalm Pathol, S-11883 Stockholm, Sweden.
   [Johansson, Ingrid] Orebro Univ Hosp, Dept Ophthalmol, S-70185 Orebro, Sweden.
   [Siewert, Annica] Novartis Sweden AB, Dept Med, S-18311 Taby, Sweden.
C3 Karolinska Institutet; Lund University; Skane University Hospital;
   Helsingborgs Hospital; Sodersjukhuset Hospital; Orebro University;
   Novartis
RP Hjelmqvist, L (通讯作者)，Karolinska Inst, St Eriks Eye Hosp, Polhemsgatan 50, S-11282 Stockholm, Sweden.
EM lars.hjelmqvist@sankterik.se
FU Novartis Sweden AB
FX The Swedish Lucentis Quality Registry is funded by Novartis Sweden AB.
CR Abraham P., 2010, AM J OPHTHALMOL, V150
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bolz M., 2008, P 8 EUR SOC RET SPEC
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ernst Benjamin J., 2010, International Ophthalmology, V30, P267, DOI 10.1007/s10792-009-9324-9
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   SHESKIN DJ, 1996, HDB PARAMETRIC NONPA
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 38
TC 47
Z9 47
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 405724
DI 10.1155/2011/405724
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100013
PM 22174994
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Miskala, PH
   Bressler, NM
   Meinert, CL
AF Miskala, PH
   Bressler, NM
   Meinert, CL
TI Relative contributions of reduced vision and general health to NEI-VFQ
   scores in patients with neovascular age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; FUNCTIONAL STATUS;
   MACULOPATHY; ACUITY
AB Objective: To estimate the relative contributions of central vision loss and general health to vision-targeted quality of life as measured by the National Eye Institute Visual Function Questionnaire (NEI-VFQ).
   Methods: Data on quality of life (NEI-VFQ and the 36-Item Short-Form Health Survey [SF-36]) and visual acuity were collected as part of the Submacular Surgery Trials Pilot Study. Information on medical conditions was collected by patient chart review. Twenty-four-month data for 120 patients were analyzed using linear regression methods.
   Results: Median patient age at the 24-month examination was 77 years; 60% were women, and 98% were non-Hispanic whites. A 3-line decrement in visual acuity in the better-seeing eye was associated with a 5.1- to 17.1-point decrement in NEI-VFQ scores after adjustment for general health (SF-36 physical component summary [PCS] and mental component summary [MCS] scores). A 10-point decrement in the PCS score was associated with a 4- to 9-point decrement in NEI-VFQ scores after adjustment for visual acuity in the better-seeing eye and MCS score. A 10-point decrement in the MCS score was associated with a 4- to 8-point decrement in NEI-VFQ scores after adjustment for visual acuity in the better-seeing eye and PCS score. Diabetes, arthritis/rheumatism, and hypertension also had large effects on NEI-VFQ scores in the adjusted analysis.
   Conclusions: The NEI-VFQ is sensitive to differences in visual acuity in the better-seeing eye, as expected, and to differences in general health. Adjustment for general health should be considered when comparing NEI-VFQ scores between patient groups.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health
RP Miskala, PH (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM pmiskala@jhmi.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR ADAMS PF, 1999, VITAL HLTH STAT, V200, P81
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Globe D, 2003, INVEST OPHTH VIS SCI, V44, P1470, DOI 10.1167/iovs.02-0292
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MISKALA PH, 2002, VISUAL ACUITY QUALIT
   Musch DC, 1997, AM J OPHTHALMOL, V124, P1
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Schiffman RM, 2001, ARCH OPHTHALMOL-CHIC, V119, P841
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907
   *SUBM SURG TRAIL R, 1998, PB98166648 NTIS
   *SUBR SURG TRIAL R, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   WARE JE, 1994, SF3L PHYS MENTAL HLT
   WARE JE, 1993, SF36 HLTH SURV MANAU
   Wilson MR, 1998, OPHTHALMOLOGY, V105, P2112, DOI 10.1016/S0161-6420(98)91135-6
   VFQ50 RAND
NR 26
TC 38
Z9 40
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2004
VL 122
IS 5
BP 758
EP 766
DI 10.1001/archopht.122.5.758
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 819TU
UT WOS:000221339400011
PM 15136325
OA Bronze
DA 2022-11-30
ER

PT J
AU Fukushima, A
   Maruko, I
   Chujo, K
   Hasegawa, T
   Arakawa, H
   Iida, T
AF Fukushima, Akira
   Maruko, Ichiro
   Chujo, Kyoko
   Hasegawa, Taiji
   Arakawa, Hisaya
   Iida, Tomohiro
TI Characteristics of treatment-naive quiescent choroidal
   neovascularization detected by optical coherence tomography angiography
   in patients with age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE OCTA; CNV; Subretinal fluid; Natural resolution
ID NATURAL-HISTORY
AB Purpose To determine the characteristics of eyes with treatment-naive quiescent choroidal neovascularization (CNV) detected by optical coherence tomography angiography (OCTA). Methods Thirty-eight eyes of 37 treatment-naive consecutive patients (30 men, 7 women, average 69.8 years) were studied. Quiescent CNVs were detected by OCTA (RTVue XR Avanti, Optovue, Fremont, CA) in all eyes. Swept-source OCT (SS-OCT; DRI-OCT, Topcon, Japan) confirmed the absence of exudation. The symptoms, visual acuity, CNV size, and status of the fellow eye were evaluated. Patients were followed longitudinally and the length of follow-up period and development of exudation were recorded for each patient. We also investigated patients' medical records from their referral hospitals in search of prior exudation. Results All eyes with quiescent CNV were diagnosed at the initial visit with sub-retinal pigment epithelium CNVs, i.e., type 1 CNV, from the OCT and OCTA images. Prior exudation was confirmed in 15 eyes (39.5%) from their medical records of the referral hospitals. Symptoms were present in 18 eyes (47.3%). An exudative CNV was present in 12 of the fellow eyes. Exudation developed in 12 eyes (31.6%) during an average follow-up period of 25.1 months. One-half of the eyes had a prior exudation. The CNV at the baseline in eyes that developed exudation during the follow-up period was larger than eyes without exudation; however, the difference was not significant (0.59 +/- 0.47 vs 0.48 +/- 0.32 mm(2), P = 0.50). Conclusion Quiescent CNVs will develop exudation in approximately 30% of the eyes during a mean 2-year follow-up period. These findings must be remembered when investigating quiescent CNVs that could not be distinguished from eyes with former active CNV and naturally deactivate CNV.
C1 [Fukushima, Akira; Maruko, Ichiro; Chujo, Kyoko; Hasegawa, Taiji; Arakawa, Hisaya; Iida, Tomohiro] Tokyo Womens Med Univ, Tokyo Womens Med Univ Sch Med, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.
C3 Tokyo Women's Medical University
RP Maruko, I (通讯作者)，Tokyo Womens Med Univ, Tokyo Womens Med Univ Sch Med, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.
EM imaruko@twmu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Hasegawa, Taiji/ABG-8260-2021
OI Maruko, Ichiro/0000-0001-5647-6372; 
CR Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Solecki L, 2021, EYE, V35, P644, DOI 10.1038/s41433-020-0936-7
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
NR 14
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2671
EP 2677
DI 10.1007/s00417-021-05127-x
EA MAR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000623724400001
PM 33649916
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Nikkhah, H
   Bonyadi, M
   Nazari, R
   Soheilian, M
AF Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Nikkhah, Homayoun
   Bonyadi, Mortaza
   Nazari, Rahman
   Soheilian, Masoud
TI Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type
   age-related macular degeneration: a meta-analysis
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE ARMS2; LOC387715 A69S; CFH Y402H; Wet-type age-related macular
   degeneration; Meta-analysis
ID COMPLEMENT FACTOR-H; GENE POLYMORPHISMS; ASSOCIATION; SUSCEPTIBILITY;
   LOC387715; VARIANTS; MACULOPATHY; ARMS2
AB PurposeWe designed this meta-analysis to pool studies which have analyzed both CFH (Y402H or I62V) and ARMS2 A69S in the same samples to compare the effect of CFH and ARMS2 in neovascular AMD.MethodsRelevant studies identified and reviewed separately in order to select those for inclusion. Included studies had genotype data of studied groups for both ARMS2 A69S and CFH. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA. Funnel plot and Egger's regression test used for evaluation of the possible publication bias. ResultsOverall, we included 6676 neovascular AMD cases and 7668 controls. Pooled overall odds ratios (ORs) (95% CI) for neovascular AMD/control were ARMS2 A69S: OR=2.35 (2.01-2.75) for GT versus GG; OR=8.57 (6.91-10.64) for TT versus GG; CFH Y402H: OR=1.94 (1.73-2.18) for CT versus TT; OR=4.89 (3.96-6.05) for CC versus TT. ARMS2 A69S genotype OR/CFH Y402H genotype OR (homogeneous genotypes): Asia=2.14, Europe: 1.87, America: 1.82, Middle East: 3.56, pooled: 1.75. ARMS2 A69S genotype OR/CFH Y402H genotype OR (heterogeneous genotypes): Asia=0.93, Europe: 1.39, America: 2.06, Middle East: 1.20, pooled: 1.21. ARMS2 A69S risk genotypes have stronger predisposing effect on neovascular AMD compared to CFH Y402H risk genotypes. ConclusionOur inclusion criteria to select those studies which have analyzed the effect of these two loci in the same case-control samples showed much stronger effect of ARMS2 A69S in neovascular AMD compared to the CFH Y402H.
C1 [Bonyadi, Mohammad Hossein Jabbarpoor; Nikkhah, Homayoun; Nazari, Rahman; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; University of Tabriz
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Hossein, Jabbarpoor Bonyadi Mohammad/A-1886-2014; Nikkhah,
   Homayoun/AAW-4663-2020; Javadzadeh, Alireza/L-6424-2017; Soheilian,
   Masoud/AAW-4743-2020; Yaseri, Mehdi/I-1645-2018
OI Nikkhah, Homayoun/0000-0002-2414-4661; Javadzadeh,
   Alireza/0000-0002-5151-6125; Yaseri, Mehdi/0000-0002-4066-873X;
   Soheilian, Masoud/0000-0001-7508-426X
FU Center of Excellence for Biodiversity
FX Center of Excellence for Biodiversity sponsored this study. The sponsor
   had no role in the design or conduct of this research.
CR Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Fang K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/821918
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jabbarpoor Bonyadi MH, 2017, ACTA OPHTHALMOL
   Jabbarpoor Bonyadi MH, 2016, INT OPHTHALMOL
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Losonczy G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050181
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tong Y, 2010, MOL VIS, V16, P1958
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Xu YL, 2008, MOL VIS, V14, P1373
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zerbib J, 2010, MOL VIS, V16, P1324
NR 30
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2019
VL 39
IS 4
BP 949
EP 956
DI 10.1007/s10792-018-0853-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HR2NR
UT WOS:000462974200029
PM 29423786
DA 2022-11-30
ER

PT J
AU Sayegh, RG
   Sacu, S
   Dunavolgyi, R
   Kroh, ME
   Roberts, P
   Mitsch, C
   Montuoro, A
   Ehrenmuller, M
   Schmidt-Erfurth, U
AF Sayegh, Ramzi Gilbert
   Sacu, Stefan
   Dunavoelgyi, Roman
   Kroh, Maria Elisabeth
   Roberts, Philipp
   Mitsch, Christoph
   Montuoro, Alessio
   Ehrenmueller, Margit
   Schmidt-Erfurth, Ursula
TI Geographic Atrophy and Foveal-Sparing Changes Related to Visual Acuity
   in Patients With Dry Age-Related Macular Degeneration Over Time
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE; IN-VIVO; PROGRESSION; MACULOPATHY; SECONDARY; EYE;
   SEGMENTATION; TOPOGRAPHY
AB PURPOSE: To correlate the area of geographic atrophy (GA) and residual foveal sparing (FS), and to identify the minimum FS and maximum GA area allowing sufficient visual acuity (VA) for daily tasks.
   DESIGN: Prospective cohort study.
   METHODS: Thirty-six eyes of 25 patients with GA and FS were followed for 18 months using spectral domain optical coherence tomography and VA tests. Volume scans were imported into software enabling grading of areas in B-scans and computing of planimetric measurements in complete volume scans. Correlation of areas 1 (complete atrophy), 2 (FS in the central millimeter), and 3 (FS in the central 3 mm) with each other and with best-corrected VA (BCVA) were evaluated.
   RESULTS: Baseline means of areas 1, 2, and 3 were 6.15 mm(2), 0.49 mm(2), and 3.08 mm(2), respectively. At 1 year, area 1 increased by a mean of 1.33 mm2, while areas 2 and 3 were decreased by 0.12 mm(2) and 0.65 mm(2), respectively. From baseline to 18 months and from visit to visit, all areas.and BCVA changed progressively (P <.001). Significant thresholds in GA size and FS for achieving a BCVA >= 70 ETDRS letters were detected (area 1: <= 6 mm(2); area 2: >= 0.48 mm(2); and area 3: >= 28 mm(2)).
   CONCLUSION: GA and FS changed inversely over time. In general, FS highly correlated with BCVA, while GA progression correlated with the central 3-mm FS regression, but not with BCVA. A threshold in GA and FS area could be determined for BCVA necessary for daily activity. (C) 2017 The Author(s). Published by Elsevier Inc.
C1 [Sayegh, Ramzi Gilbert; Sacu, Stefan; Dunavoelgyi, Roman; Kroh, Maria Elisabeth; Roberts, Philipp; Mitsch, Christoph; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
   [Montuoro, Alessio] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Vienna, Austria.
   [Ehrenmueller, Margit] Univ Appl Sci Upper Austria, Dept Hlth Proc Management, Steyr, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Mitsch, Christoph/0000-0002-5361-5418; Dunavoelgyi,
   Roman/0000-0002-1842-240X; Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR [Anonymous], 1987, STEREOSCOPIC ATLAS M
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Coren S., 1999, SENSATION PERCEPTION
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Daien V, 2014, ACTA OPHTHALMOL, V92, pe500, DOI 10.1111/aos.12335
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   Gullstrand A., 1924, HELMHOLTZS TREATISE, V1, P350
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Mones J, 2013, OPHTHALMOLOGY, V120, P829, DOI 10.1016/j.ophtha.2012.09.054
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques G, 2015, RETINA, V36, P247
   Ritter M, 2013, INVEST OPHTH VIS SCI, V54, P6416, DOI 10.1167/iovs.12-11550
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schutze C, 2013, INVEST OPHTH VIS SCI, V54, P739, DOI 10.1167/iovs.11-7877
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 1999, MOL VIS, V5
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 45
TC 30
Z9 30
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2017
VL 179
BP 118
EP 128
DI 10.1016/j.ajo.2017.03.031
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA0YY
UT WOS:000405163900014
PM 28385474
OA hybrid
DA 2022-11-30
ER

PT J
AU Murinello, S
   Mullins, RF
   Lotery, AJ
   Perry, VH
   Teeling, JL
AF Murinello, Salome
   Mullins, Robert F.
   Lotery, Andrew J.
   Perry, V. Hugh
   Teeling, Jessica L.
TI Fc gamma Receptor Upregulation Is Associated With Immune Complex
   Inflammation in the Mouse Retina and Early Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE immune complex; immunoglobulin; Fc receptor; macular degeneration;
   inflammation
ID FACTOR-H POLYMORPHISM; ARTHUS REACTION; DRUSEN; EXPRESSION; ANTIBODIES;
   MICROGLIA; CHORIOCAPILLARIS; AUTOANTIBODIES; ACCUMULATION; AUTOIMMUNITY
AB PURPOSE. Several lines of evidence suggest the involvement of antibodies and immune complex inflammation in AMD, a blinding disease with a strong inflammatory component. To examine this further, we developed a novel experimental mouse model of retinal inflammation and evaluated whether inflammation associated with immune complex formation was present in eyes of AMD donors.
   METHODS. A localized immune complex-mediated reaction was induced in the retina of wild-type (WT), Fc receptor gamma chain-deficient (gamma(-/-)), and C1q-deficient (C1q(-/-)) mice, and donor eyes were obtained after death from donors with early or wet AMD and from healthy control subjects. The presence of immune complexes, Fc gamma receptors (Fc gamma Rs), and markers of macrophage/microglia activation was investigated by immunohistochemistry.
   RESULTS. In WT and C1q(-/-) mice, immune complex deposition in the retina led to a robust inflammatory response with activation of microglia, recruitment of myeloid cells, and increased expression of Fc gamma RI through Fc gamma RIV and major histocompatibility complex class II. This response was not observed in gamma(-/-) mice lacking activating Fc gamma Rs. We found that early AMD was associated with deposition of IgG, C1q, and membrane attack complex in the choriocapillaris and with increased numbers of CD45 vertical bar cells expressing Fc gamma RIIa and Fc gamma RIIb. Furthermore, Fc gamma RIIa and Fc gamma RIIb were observed in eyes of donors with wet AMD.
   CONCLUSIONS. Our studies suggest that immune complexes may contribute to AMD pathogenesis through interaction of IgG with Fc gamma Rs and might inform about possible adverse effects associated with therapeutic antibodies.
C1 [Murinello, Salome; Perry, V. Hugh; Teeling, Jessica L.] Univ Southampton, Southampton Gen Hosp, Ctr Biol Sci, Southampton SO16 6YD, Hants, England.
   [Mullins, Robert F.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Lotery, Andrew J.] Univ Southampton, Southampton Gen Hosp, Fac Med, Clin Neurosci Res Grp, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Iowa; University of Southampton
RP Murinello, S (通讯作者)，Univ Southampton, Southampton Gen Hosp, Ctr Biol Sci, South Lab & Path Block,MP840,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM scm1v07@soton.ac.uk; jt8@soton.ac.uk
RI Teeling, Jessica/C-4390-2016; Perry, V. Hugh/Y-2935-2019; Mullins,
   Robert F/I-6717-2013
OI Murinello, Salome/0000-0002-9694-2160; Mullins,
   Robert/0000-0002-5006-0891; Lotery, Andrew/0000-0001-5541-4305; Teeling,
   Jessica/0000-0003-4004-7391
FU Fight for Sight (UK); Brian Mercer Charitable Trust; National Institutes
   of Health [EY-017451]; Wellcome Trust; Fight for Sight [1820/21] Funding
   Source: researchfish; NATIONAL EYE INSTITUTE [R01EY017451] Funding
   Source: NIH RePORTER
FX Supported by Fight for Sight (UK), The Brian Mercer Charitable Trust,
   and Grant EY-017451 from the National Institutes of Health. Salome
   Murinello's studentship is supported by Fight for Sight (UK). The
   Wellcome Trust provided additional funding.
CR Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Baglio V, 2011, J NEPHROL, V24, P522, DOI 10.5301/JN.2011.6244
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CRAWFORD JP, 1985, EXP MOL PATHOL, V42, P175, DOI 10.1016/0014-4800(85)90026-7
   D'souza Y, 2008, BRIT J OPHTHALMOL, V92, P950, DOI 10.1136/bjo.2007.130138
   De Haas AH, 2008, GLIA, V56, P888, DOI 10.1002/glia.20663
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Han DP, 2009, ARCH OPHTHALMOL-CHIC, V127, P577, DOI 10.1001/archophthalmol.2009.38
   Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klejnberg Tatiana, 2006, Arq. Bras. Oftalmol., V69, P233, DOI 10.1590/S0004-27492006000200018
   Kumar V, 2006, J CLIN INVEST, V116, P512, DOI 10.1172/JCI25536
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lunnon K, 2011, J IMMUNOL, V186, P7215, DOI 10.4049/jimmunol.0903833
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206
   OKADA M, 1980, INVEST OPHTH VIS SCI, V19, P169
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385
   SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448
   Teeling JL, 2012, ACTA NEUROPATHOL, V124, P479, DOI 10.1007/s00401-012-0995-3
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   WALKER BAM, 1991, J IMMUNOL, V146, P735
NR 52
TC 30
Z9 30
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 247
EP 258
DI 10.1167/iovs.13-11821
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200029
PM 24334446
OA Green Published
DA 2022-11-30
ER

PT J
AU Nury, T
   Yammine, A
   Ghzaiel, I
   Sassi, K
   Zarrouk, A
   Brahmi, F
   Samadi, M
   Rup-Jacques, S
   Vervandier-Fasseur, D
   de Barros, JPP
   Bergas, V
   Ghosh, S
   Majeed, M
   Pande, A
   Atanasov, A
   Hammami, S
   Hammami, M
   Mackrill, J
   Nasser, B
   Andreoletti, P
   Cherkaoui-Malki, M
   Vejux, A
   Lizard, G
AF Nury, T.
   Yammine, A.
   Ghzaiel, I
   Sassi, K.
   Zarrouk, A.
   Brahmi, F.
   Samadi, M.
   Rup-Jacques, S.
   Vervandier-Fasseur, D.
   de Barros, J. P. Pais
   Bergas, V
   Ghosh, S.
   Majeed, M.
   Pande, A.
   Atanasov, A.
   Hammami, S.
   Hammami, M.
   Mackrill, J.
   Nasser, B.
   Andreoletti, P.
   Cherkaoui-Malki, M.
   Vejux, A.
   Lizard, G.
TI Attenuation of 7-ketocholesterol- and 7 beta-hydroxycholesterol-induced
   oxiapoptophagy by nutrients, synthetic molecules and oils: Potential for
   the prevention of age-related diseases
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Age-related diseases; Endoplasmic reticulum; 7-Ketocholesterol; 7
   beta-Hydroxycholesterol; Lysosome; Mitochondria; Nutrients; Oxysterol;
   Oxiapoptophagy; Peroxisome
ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; ENDOPLASMIC-RETICULUM
   STRESS; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; DOCOSAHEXAENOIC ACID DHA;
   CHOLESTEROL OXIDATION; ALPHA-TOCOPHEROL; FATTY-ACIDS; MEDICAL
   BIOREMEDIATION; ALZHEIMERS-DISEASE
AB Age-related diseases for which there are no effective treatments include cardiovascular diseases; neurodegenerative diseases such as Alzheimer's disease; eye disorders such as cataract and age-related macular degeneration; and, more recently, Severe Acute Respiratory Syndrome (SARS-CoV-2). These diseases are associated with plasma and/or tissue increases in cholesterol derivatives mainly formed by auto-oxidation: 7-ketocholesterol, also known as 7-oxo-cholesterol, and 7 beta-hydroxycholesterol. The formation of these oxysterols can be considered as a consequence of mitochondrial and peroxisomal dysfunction, leading to increased in oxidative stress, which is accentuated with age. 7-ketocholesterol and 7 beta-hydroxycholesterol cause a specific form of cytotoxic activity defined as oxiapoptophagy, including oxidative stress and induction of death by apoptosis associated with autophagic criteria. Oxiaptophagy is associated with organelle dysfunction and in particular with mitochondrial and peroxisomal alterations involved in the induction of cell death and in the rupture of redox balance. As the criteria characterizing 7-ketocholesterol- and 7 beta-hydroxycholesterol-induced cytotoxicity are often simultaneously observed in major age-related diseases (cardiovascular diseases, age-related macular degeneration, Alzheimer's disease) the involvement of these oxysterols in the pathophysiology of the latter seems increasingly likely. It is therefore important to better understand the signalling pathways associated with the toxicity of 7-ketocholesterol and 7 beta-hydroxycholesterol in order to identify pharmacological targets, nutrients and synthetic molecules attenuating or inhibiting the cytotoxic activities of these oxysterols. Numerous natural cytoprotective compounds have been identified: vitamins, fatty acids, polyphenols, terpenes, vegetal pigments, antioxidants, mixtures of compounds (oils, plant extracts) and bacterial enzymes. However, few synthetic molecules are able to prevent 7-ketocholesterol- and/or 7 beta-hydroxycholesterol-induced cytotoxicity: dimethyl fumarate, monomethyl fumarate, the tyrosine kinase inhibitor AG126, memantine, simvastatine, Trolox, dimethylsufoxide, mangafodipir and mitochondrial permeability transition pore (MPTP) inhibitors. The effectiveness of these compounds, several of which are already in use in humans, makes it possible to consider using them for the treatment of certain age-related diseases associated with increased plasma and/or tissue levels of 7-ketocholesterol and/or 7 beta-hydroxycholesterol.
C1 [Nury, T.; Yammine, A.; Ghzaiel, I; Sassi, K.; Andreoletti, P.; Cherkaoui-Malki, M.; Vejux, A.; Lizard, G.] Univ Bourgogne Franche Comte UBFC, INSERM, Team BioPeroxIL Biochem Peroxisome Inflammat & Li, EA 7270, Dijon, France.
   [Yammine, A.] Lebanese Univ, Fac Sci, Doctoral Sch Sci & Technol, Bioact Mol Res Lab, Fanar, Lebanon.
   [Ghzaiel, I; Zarrouk, A.; Hammami, S.; Hammami, M.] Univ Monastir, Fac Med, LR12ES05, Lab NAFS Nutr Funct Food & Vasc Hlth, Monastir, Tunisia.
   [Sassi, K.] Univ Tunis El Manar, Fac Med, Lab Onco Hematol LRO5ES05, Tunis 1007, Tunisia.
   [Zarrouk, A.] Univ Sousse, Fac Med, Sousse, Tunisia.
   [Brahmi, F.] Univ Abderrahmane Mira Bejaia, Fac Nat & Life Sci, Dept Food Sci, Lab Biophys Biochem Biomath & Scientometry 3B5, Bejaia, Algeria.
   [Samadi, M.; Rup-Jacques, S.] Univ Lorraine, Dept Chem, ICPM, LCPMC A2, Metz Technopole, Metz, France.
   [Vervandier-Fasseur, D.] Univ Bourgogne Franche Comte, Univ Burgundy ICMUB UMR CNRS 6302, Inst Mol Chem, Team OCS, Dijon, France.
   [de Barros, J. P. Pais; Bergas, V] Univ Bourgogne, UFR Sci Sante, LabEx LipSTIC, Plateforme Lipidom,Inserm,UMR1231, Dijon, France.
   [Ghosh, S.] Indian Inst Technol Delhi, Dept Chem, New Delhi, India.
   [Majeed, M.; Pande, A.] Sabinsa Corp, 20 Lake Dr, East Windsor, NJ USA.
   [Atanasov, A.] Univ Vienna, Dept Pharmacognosy, Vienna, Austria.
   [Atanasov, A.] Med Univ Vienna, Ludwig Boltzmann Inst Digital Hlth & Patient Safe, Vienna, Austria.
   [Atanasov, A.] Polish Acad Sci, Inst Genet & Anim Biotechnol, Jastrzebiec, Poland.
   [Atanasov, A.] Bulgarian Acad Sci, Inst Neurobiol, Sofia, Bulgaria.
   [Mackrill, J.] Univ Coll Cork, Sch Med, Dept Physiol, Cork, Ireland.
   [Nasser, B.] Univ Hassan I, Dept Biol, Lab Biochem & Neurosci, Settat 26000, Morocco.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bourgogne; Lebanese University; Universite de Monastir;
   Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT);
   Universite de Sousse; Universite de Bejaia; Universite de Lorraine;
   Universite de Bourgogne; Institut Agro; AgroSup Dijon; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite de
   Bourgogne; Universite de Franche-Comte; Indian Institute of Technology
   System (IIT System); Indian Institute of Technology (IIT) - Delhi;
   University of Vienna; Medical University of Vienna; Institute of
   Genetics & Animal Biotechnology, Polish Academy of Sciences; Polish
   Academy of Sciences; Bulgarian Academy of Sciences; University College
   Cork; Hassan First University of Settat
RP Vejux, A; Lizard, G (通讯作者)，Univ Bourgogne, Fac Sci Gabriel, Lab BioPeroxlL, INSERM, 6 Blvd Gabriel, F-21000 Dijon, France.
EM anne.vejux@u-bourgogne.fr; gerard.lizard@u-bourgogne.fr
RI ANDREOLETTI, PIERRE/B-5245-2012; Atanasov, Atanas G./C-5535-2013
OI ANDREOLETTI, PIERRE/0000-0003-2118-7858; Atanasov, Atanas
   G./0000-0003-2545-0967; PAIS DE BARROS, Jean-Paul/0000-0002-5124-2283;
   SASSI, Khouloud/0000-0003-3372-0242
FU University of Bourgogne (Dijon, France); Universite Libanaise
   (Beirut/Fanar, Lebanon; Research Funding Program at the Lebanese
   University (2020-2022) ); University of Monastir (Monastir, Tunisia);
   University Tunis El Manar (Tunis, Tunisia); University of Bejaia
   (Bejaia, Algeria); Faculty of Sciences & Techniques" (FST) (Settat,
   Morocco); Nutrition Mediterraneenne Sante (NMS); Association
   Bourguignonne pour les Applications des Sciences de l'Information en
   Medecine (ABASIM); COST (European Cooperation in Science and Technology)
   [NutRedOx-CA16112]; Ministry of Europe and Foreign Affairs, Ministry of
   Higher Education, Research and Innovation; French Institute of Rabat
   (PHC TOUBKAL 2019) [TBK 19/92, 41501RJ]; department of Neurology (Pr
   Thibault Moreau, University Hospital, Dijon, France; EMATSEP project)
FX This work was funded by University of Bourgogne (Dijon, France) ,
   Universite Libanaise (Beirut/Fanar, Lebanon; Research Funding Program at
   the Lebanese University (20202022) ) , University of Monastir (Monastir,
   Tunisia) , University Tunis El Manar (Tunis, Tunisia) , University of
   Bejaia (Bejaia, Algeria) , Faculty of Sciences & Techniques" (FST)
   (Settat, Morocco) , Yammine A and Ghzaiel I received a financial support
   from Nutrition Mediterraneenne & Sante (NMS) . Ghzaiel I and Sassi K
   received a financial support from the Association Bourguignonne pour les
   Applications des Sciences de l'Information en Medecine (ABASIM) . This
   article/publication is also based upon work from COST Action
   NutRedOxCA16112 (Personalized nutrition in ageing society: redox control
   of major agerelated diseases) supported by COST (European Cooperation in
   Science and Technology) . This project was financially supported by
   Ministry of Europe and Foreign Affairs, Ministry of Higher Education,
   Research and Innovation and the French Institute of Rabat (PHC TOUBKAL
   2019, n?TBK 19/92 (FrenchMorocco bilateral program) ; Grant Number:
   41501RJ) . This project was also supported by the department of
   Neurology (Pr Thibault Moreau, University Hospital, Dijon, France;
   EMATSEP project) and the authors also thank the international network of
   the UNESCO Chair 'Culture and tradition of wine'
   (http://chaireunescovinetculture.ubourgogne.fr/) . Nury T, Ghzaiel I,
   Sassi K, Zarrouk A, Samadi M, Mackrill J, Vejux A and Lizard G are
   members of the European Network for Oxysterols Research (ENOR; htt
   p://oxysterols.net) . Zarrouk A, Pande A, Atanasov A, Hammami S, Hammami
   M and Lizard G are members of the International Natural Product Sciences
   Taskforce (INPST; https://inpst.net/) .
CR Alba G, 2016, EUR J NUTR, V55, P2485, DOI 10.1007/s00394-015-1142-4
   Alhouayek M, 2021, BBA-MOL CELL BIOL L, V1866, DOI 10.1016/j.bbalip.2020.158854
   Anand PK, 2020, IMMUNOL REV, V297, P108, DOI 10.1111/imr.12891
   Anderson A, 2020, REDOX BIOL, V29, DOI 10.1016/j.redox.2019.101380
   Aon MA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00282
   Arnal-Levron M, 2019, BBA-MOL CELL BIOL L, V1864, P1247, DOI 10.1016/j.bbalip.2019.05.011
   Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065
   Atanasov AG, 2021, NAT REV DRUG DISCOV, V20, P200, DOI 10.1038/s41573-020-00114-z
   Atzeri A, 2016, FOOD FUNCT, V7, P337, DOI [10.1039/c5fo00074b, 10.1039/C5FO00074B]
   Baarine M, 2012, NEUROSCIENCE, V213, P1, DOI 10.1016/j.neuroscience.2012.03.058
   Badreddine A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102220
   Barja G, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.05.016
   Beck KR, 2019, J STEROID BIOCHEM, V190, P19, DOI 10.1016/j.jsbmb.2019.03.011
   Beck LR, 2019, J LIPID RES, V60, P1535, DOI 10.1194/jlr.M092908
   Bezine M, 2018, BIOCHIMIE, V153, P46, DOI 10.1016/j.biochi.2018.04.013
   Bezine M, 2018, BIOCHIMIE, V153, P56, DOI 10.1016/j.biochi.2018.02.008
   Biasi F, 2014, REDOX BIOL, V2, P795, DOI 10.1016/j.redox.2014.06.008
   Bjorkhem I, 2014, J LIPID RES, V55, P1165, DOI 10.1194/jlr.P048603
   Boumhras M, 2014, ENVIRON TOXICOL, V29, P1245, DOI 10.1002/tox.21855
   Brahmi F, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7120184
   Brahmi F, 2019, CRIT REV FOOD SCI, V59, P3179, DOI 10.1080/10408398.2018.1491828
   Brown AJ, 1996, J LIPID RES, V37, P320
   Brown AJ, 2021, BRIT J PHARMACOL, V178, P3089, DOI 10.1111/bph.15073
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Butler D, 2006, ANTIOXID REDOX SIGN, V8, P185, DOI 10.1089/ars.2006.8.185
   Buttari B, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/257543
   Cenini G, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2105607
   Chang MC, 2016, ONCOTARGET, V7, P74473, DOI 10.18632/oncotarget.12578
   Cilla A, 2017, CHEM PHYS LIPIDS, V207, P192, DOI 10.1016/j.chemphyslip.2017.03.001
   Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2
   Corsinovi L, 2011, MOL NUTR FOOD RES, V55, pS161, DOI 10.1002/mnfr.201100208
   Dammann C, 2019, CHEM-BIOL INTERACT, V303, P57, DOI 10.1016/j.cbi.2019.02.018
   de Medina P, 2021, BRIT J PHARMACOL, V178, P3248, DOI 10.1111/bph.15205
   de Medina P, 2010, P NATL ACAD SCI USA, V107, P13520, DOI 10.1073/pnas.1002922107
   Debbabi M, 2017, CHEM PHYS LIPIDS, V207, P151, DOI 10.1016/j.chemphyslip.2017.04.002
   Debbabi M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121973
   Deckert V, 2002, ATHEROSCLEROSIS, V165, P41, DOI 10.1016/S0021-9150(02)00189-2
   DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323
   Deiana M, 2012, FOOD CHEM, V134, P2105, DOI 10.1016/j.foodchem.2012.04.014
   Deiana M, 2010, FOOD CHEM TOXICOL, V48, P3008, DOI 10.1016/j.fct.2010.07.041
   Deon M, 2016, CELL MOL NEUROBIOL, V36, P497, DOI 10.1007/s10571-015-0234-2
   Dias IHK, 2019, J STEROID BIOCHEM, V193, DOI 10.1016/j.jsbmb.2019.105426
   Doria M, 2019, FREE RADICAL BIO MED, V137, P46, DOI 10.1016/j.freeradbiomed.2019.04.016
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Duran M.J., 2010, CELL MOL BIOL NOISY, V56, P1434
   Erridge C, 2007, FREE RADICAL RES, V41, P260, DOI 10.1080/10715760601070091
   Faust PL, 2014, BIOCHIMIE, V98, P75, DOI 10.1016/j.biochi.2013.10.019
   Fransen M, 2020, ADV EXP MED BIOL, V1299, P19, DOI 10.1007/978-3-030-60204-8_2
   Fransen M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061126
   Fransen Marc, 2013, Subcell Biochem, V69, P45, DOI 10.1007/978-94-007-6889-5_3
   Fu XD, 2014, FREE RADICAL BIO MED, V71, P1, DOI 10.1016/j.freeradbiomed.2014.03.010
   Fuda H, 2007, J LIPID RES, V48, P1343, DOI 10.1194/jlr.M700018-JLR200
   Fujiki Y, 2020, J CELL SCI, V133, DOI 10.1242/jcs.236943
   Gabaldon T, 2010, PHILOS T R SOC B, V365, P765, DOI 10.1098/rstb.2009.0240
   Gallucci G, 2020, J THORAC DIS, V12, P3866, DOI 10.21037/jtd.2020.02.47
   Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004
   Gargiulo S, 2016, J PHYSIOL-LONDON, V594, P2095, DOI 10.1113/JP271168
   Ghosh S, 2018, BIORESOURCE TECHNOL, V254, P91, DOI 10.1016/j.biortech.2018.01.030
   Ghosh S, 2017, CHEM PHYS LIPIDS, V207, P253, DOI 10.1016/j.chemphyslip.2017.05.008
   Ghosh S, 2016, BIORESOURCE TECHNOL, V213, P44, DOI 10.1016/j.biortech.2016.03.079
   Girao H, 1998, EXP EYE RES, V66, P645, DOI 10.1006/exer.1998.0465
   Griffiths WJ, 2020, PROSTAG OTH LIPID M, V147, DOI 10.1016/j.prostaglandins.2019.106381
   Griffiths WJ, 2019, FREE RADICAL BIO MED, V144, P124, DOI 10.1016/j.freeradbiomed.2019.04.020
   Hamer I, 2012, CURR DRUG METAB, V13, P1371, DOI 10.2174/138920012803762684
   Hammoud Y, 2013, BIOCHIMIE, V95, P568, DOI 10.1016/j.biochi.2012.08.003
   Han JH, 2007, BRAIN RES, V1137, P11, DOI 10.1016/j.brainres.2006.12.041
   He AY, 2021, TRENDS CELL BIOL, V31, P656, DOI 10.1016/j.tcb.2021.02.005
   He CY, 2013, AM J PATHOL, V183, P626, DOI 10.1016/j.ajpath.2013.04.028
   Heo GY, 2011, J LIPID RES, V52, P1117, DOI 10.1194/jlr.M014217
   HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177
   Hullin-Matsuda F, 2009, PROSTAG LEUKOTR ESS, V81, P313, DOI 10.1016/j.plefa.2009.09.006
   Iaia N, 2020, ARCH BIOCHEM BIOPHYS, V694, DOI 10.1016/j.abb.2020.108591
   Inpanathan S, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00113
   Islinger M, 2012, HISTOCHEM CELL BIOL, V137, P547, DOI 10.1007/s00418-012-0941-4
   Iuliano L, 2011, CHEM PHYS LIPIDS, V164, P457, DOI 10.1016/j.chemphyslip.2011.06.006
   Jang ER, 2011, NEUROCHEM INT, V58, P52, DOI 10.1016/j.neuint.2010.10.012
   Keenan SN, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01300-4
   Kemp S, 2012, BBA-MOL BASIS DIS, V1822, P1465, DOI 10.1016/j.bbadis.2012.03.012
   Kim A, 2017, BRAIN RES BULL, V134, P63, DOI 10.1016/j.brainresbull.2017.07.008
   Kim YJ, 2010, NEUROCHEM RES, V35, P603, DOI 10.1007/s11064-009-0105-7
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koh SS, 2021, NEUROMOL MED, V23, P184, DOI 10.1007/s12017-020-08620-4
   Kohno M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65673-y
   Koka S, 2017, REDOX BIOL, V13, P336, DOI 10.1016/j.redox.2017.06.004
   Kuo X, 2021, NEUROMOL MED, V23, P176, DOI 10.1007/s12017-020-08621-3
   Laskar A, 2010, J CARDIOVASC PHARM, V56, P263, DOI 10.1097/FJC.0b013e3181eb3063
   Laskar A, 2010, EUR J PHARMACOL, V640, P124, DOI 10.1016/j.ejphar.2010.04.046
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lee JW, 2015, BBA-MOL CELL BIOL L, V1851, P605, DOI 10.1016/j.bbalip.2015.01.007
   Lemaire-Ewing S, 2012, ATHEROSCLEROSIS, V221, P303, DOI 10.1016/j.atherosclerosis.2011.10.016
   Leonarduzzi G, 2006, ANTIOXID REDOX SIGN, V8, P375, DOI 10.1089/ars.2006.8.375
   Leoni V, 2017, J STEROID BIOCHEM, V169, P96, DOI 10.1016/j.jsbmb.2016.03.029
   Levy D, 2019, BIOCHEM BIOPHYS REP, V19, DOI 10.1016/j.bbrep.2018.12.008
   Li W, 2012, FREE RADICAL BIO MED, V53, P2054, DOI 10.1016/j.freeradbiomed.2012.09.007
   Li W, 2011, BIOCHEM BIOPH RES CO, V409, P711, DOI 10.1016/j.bbrc.2011.05.071
   Li X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087552, 10.1371/journal.pone.0089666]
   Lismont C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00035
   Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5
   Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651
   Lordan S, 2008, BRIT J NUTR, V100, P287, DOI 10.1017/S0007114507898643
   Lordan S, 2009, J BIOCHEM MOL TOXIC, V23, P324, DOI 10.1002/jbt.20295
   Luchetti F, 2017, REDOX BIOL, V13, P581, DOI 10.1016/j.redox.2017.07.014
   Luchetti F, 2015, STEROIDS, V99, P204, DOI 10.1016/j.steroids.2015.02.008
   Luquain-Costaz C, 2020, BIOCHIMIE, V179, P247, DOI 10.1016/j.biochi.2020.10.018
   Lyons NM, 2001, FREE RADICAL RES, V35, P329, DOI 10.1080/10715760100300861
   Macho-Gonzalez A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9070638
   Mackrill JJ, 2011, CHEM PHYS LIPIDS, V164, P488, DOI 10.1016/j.chemphyslip.2011.04.001
   Marcello A, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101682
   Martinet W, 2008, BRIT J PHARMACOL, V154, P1236, DOI 10.1038/bjp.2008.181
   Mascia C, 2010, FREE RADICAL BIO MED, V49, P2049, DOI 10.1016/j.freeradbiomed.2010.09.033
   Mast N, 2005, BIOCHEMISTRY-US, V44, P3259, DOI 10.1021/bi047566a
   Mathieu J, 2008, BIODEGRADATION, V19, P807, DOI 10.1007/s10532-008-9183-5
   Mathieu JM, 2012, BIOTECHNOL BIOENG, V109, P2409, DOI 10.1002/bit.24506
   Mathieu JM, 2010, APPL ENVIRON MICROB, V76, P352, DOI 10.1128/AEM.02538-09
   Mathieu JM, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-21
   Meddeb W, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7070095
   Miguet-Alfonsi C, 2002, BIOCHEM PHARMACOL, V64, P527, DOI 10.1016/S0006-2952(02)01110-3
   Mitic T, 2013, BIOCHIMIE, V95, P548, DOI 10.1016/j.biochi.2012.08.007
   Mitic T, 2013, BIOCHEM PHARMACOL, V86, P146, DOI 10.1016/j.bcp.2013.02.002
   Monier S, 2003, BIOCHEM BIOPH RES CO, V303, P814, DOI 10.1016/S0006-291X(03)00412-1
   Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002
   Nagy G, 2007, FREE RADICAL BIO MED, V42, P1625, DOI 10.1016/j.freeradbiomed.2007.02.026
   Naito Y, 2004, BIOL RES, V37, P231, DOI 10.4067/S0716-97602004000200009
   Navas-Madronal M, 2019, CLIN SCI, V133, P1421, DOI 10.1042/CS20190399
   Neekhra A, 2020, J OPHTHAL VIS RES, V15, P470, DOI 10.18502/jovr.v15i4.7781
   Nordgren M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00145
   Nury T, 2020, ADV EXP MED BIOL, V1299, P31, DOI 10.1007/978-3-030-60204-8_3
   Nury T, 2021, BRIT J PHARMACOL, V178, P3115, DOI 10.1111/bph.15173
   Nury T, 2018, BIOCHIMIE, V153, P181, DOI 10.1016/j.biochi.2018.07.009
   Nury T, 2017, J STEROID BIOCHEM, V169, P123, DOI 10.1016/j.jsbmb.2016.03.037
   Nury T, 2015, STEROIDS, V99, P194, DOI 10.1016/j.steroids.2015.02.003
   Nury T, 2014, BIOCHEM BIOPH RES CO, V446, P714, DOI 10.1016/j.bbrc.2013.11.081
   O'Sullivan AJ, 2003, J APPL TOXICOL, V23, P191, DOI 10.1002/jat.906
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Olkkonen VM, 2009, MOL ASPECTS MED, V30, P123, DOI 10.1016/j.mam.2009.02.004
   Palozza P, 2011, J NUTR BIOCHEM, V22, P259, DOI 10.1016/j.jnutbio.2010.02.003
   Palozza P, 2010, J NUTR BIOCHEM, V21, P34, DOI 10.1016/j.jnutbio.2008.10.002
   Panov AV, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1323028
   Park SH, 2016, MOL NUTR FOOD RES, V60, P1033, DOI 10.1002/mnfr.201500750
   Paz JL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050482
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Perveen I, 2018, APPL BIOCHEM MICRO+, V54, P262, DOI 10.1134/S0003683818030110
   Plattner H, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0419
   Prunet C, 2006, CYTOM PART A, V69A, P359, DOI 10.1002/cyto.a.20272
   Ragot K, 2013, BIOCHEM PHARMACOL, V86, P67, DOI 10.1016/j.bcp.2013.02.028
   Ragot K, 2011, CHEM PHYS LIPIDS, V164, P469, DOI 10.1016/j.chemphyslip.2011.04.014
   Raleigh DR, 2018, MOL CELL, V72, P316, DOI 10.1016/j.molcel.2018.08.034
   Ribeiro D, 2012, HISTOL HISTOPATHOL, V27, P661, DOI 10.14670/HH-27.661
   Ricciardi CA, 2020, J CELL MOL MED, V24, P12910, DOI 10.1111/jcmm.15999
   Rimbach G, 2002, P NUTR SOC, V61, P415, DOI 10.1079/PNS2002183
   Rittmann BE, 2007, REJUV RES, V10, P359, DOI 10.1089/rej.2007.0594
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rogers MA, 2015, J STEROID BIOCHEM, V151, P102, DOI 10.1016/j.jsbmb.2014.09.008
   Roman GC, 2019, REV NEUROL-FRANCE, V175, P724, DOI 10.1016/j.neurol.2019.08.005
   Rosenblat M, 2002, ATHEROSCLEROSIS, V160, P69, DOI 10.1016/S0021-9150(01)00563-9
   Rossin D, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060151
   Royer MC, 2009, J BIOL CHEM, V284, P15826, DOI 10.1074/jbc.M808641200
   Rusinol AE, 2004, J BIOL CHEM, V279, P1392, DOI 10.1074/jbc.M308619200
   Ryan L, 2004, CELL BIOL TOXICOL, V20, P313, DOI 10.1007/s10565-004-5066-7
   Ryan L, 2005, BRIT J NUTR, V94, P519, DOI 10.1079/BJN20051524
   Sallem F, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9020287
   Samadi A, 2021, CURR MED CHEM, V28, P110, DOI 10.2174/0929867327666200316142659
   Sanchez LD, 2021, BRIT J PHARMACOL, V178, P3327, DOI 10.1111/bph.15227
   Sassi K, 2019, J STEROID BIOCHEM, V191, DOI 10.1016/j.jsbmb.2019.04.020
   Sato Y, 2017, MOL GENET METAB REP, V10, P56, DOI 10.1016/j.ymgmr.2017.01.006
   Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200
   Schloendorn J, 2009, REJUV RES, V12, P411, DOI 10.1089/rej.2009.0917
   Schrader M, 2015, J INHERIT METAB DIS, V38, P681, DOI 10.1007/s10545-015-9819-7
   Seet RCS, 2011, FREE RADICAL BIO MED, V50, P1787, DOI 10.1016/j.freeradbiomed.2011.03.019
   Sghaier R, 2019, J STEROID BIOCHEM, V194, DOI 10.1016/j.jsbmb.2019.105432
   Sghaier R, 2019, FREE RADICAL RES, V53, P535, DOI 10.1080/10715762.2019.1612891
   Shannon OM, 2021, EUR J CLIN NUTR, V75, P1176, DOI 10.1038/s41430-020-00841-x
   Shen LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188841
   Silvente-Poirot S, 2012, CURR OPIN PHARMACOL, V12, P696, DOI 10.1016/j.coph.2012.07.007
   Singh N, 2020, ACS OMEGA, V5, P16165, DOI 10.1021/acsomega.0c01747
   Smith JJ, 2013, NAT REV MOL CELL BIO, V14, P803, DOI 10.1038/nrm3700
   Sudo R, 2015, GENES CELLS, V20, P982, DOI 10.1111/gtc.12301
   Tarasiuk A, 2019, EXPERT REV CLIN PHAR, V12, P921, DOI 10.1080/17512433.2019.1670058
   Terlecky SR, 2006, BBA-MOL CELL RES, V1763, P1749, DOI 10.1016/j.bbamcr.2006.08.017
   Tesoriere L, 2015, BRIT J NUTR, V114, P368, DOI 10.1017/S0007114515002111
   Tesoriere L, 2013, BRIT J NUTR, V110, P230, DOI 10.1017/S000711451200493X
   Testa G, 2018, BIOCHIMIE, V153, P220, DOI 10.1016/j.biochi.2018.06.006
   Testa G, 2016, REDOX BIOL, V10, P24, DOI 10.1016/j.redox.2016.09.001
   Tian L, 2011, J AGR FOOD CHEM, V59, P6453, DOI 10.1021/jf200544r
   Trivedi PC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051131
   Trompier D, 2014, BIOCHIMIE, V98, P102, DOI 10.1016/j.biochi.2013.09.009
   Vamecq J, 2014, BIOCHIMIE, V98, P4, DOI 10.1016/j.biochi.2013.09.019
   Vejux A, 2009, J NUTR BIOCHEM, V20, P45, DOI 10.1016/j.jnutbio.2007.12.001
   Vejux A, 2007, HISTOCHEM CELL BIOL, V127, P609, DOI 10.1007/s00418-006-0268-0
   Vejux A, 2020, BIOCHEM PHARMACOL, V173, DOI 10.1016/j.bcp.2019.113648
   Vejux A, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/471947
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wanders RJA, 2014, BIOCHIMIE, V98, P36, DOI 10.1016/j.biochi.2013.08.022
   Wang YQ, 2018, CURR OPIN CLIN NUTR, V21, P90, DOI 10.1097/MCO.0000000000000442
   Warraich UEA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04107
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Willcox DC, 2014, MECH AGEING DEV, V136, P148, DOI 10.1016/j.mad.2014.01.002
   Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017
   Xue QL, 2011, CLIN GERIATR MED, V27, P1, DOI 10.1016/j.cger.2010.08.009
   Yamagata K, 2013, MICROVASC RES, V88, P25, DOI 10.1016/j.mvr.2013.03.006
   Yammine A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112346
   Yeolekar M E, 2014, J Assoc Physicians India, V62, P34
   Yeung AWK, 2021, ANTIOXID REDOX SIGN, V34, P402, DOI 10.1089/ars.2019.7952
   Yin DZ, 2005, EXP GERONTOL, V40, P455, DOI 10.1016/j.exger.2005.03.012
   Yuan Xi-Ming, 2016, J Cell Death, V9, P1, DOI 10.4137/JCD.S37841
   Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8
   Zahm JM, 2003, CYTOM PART A, V52A, P57, DOI 10.1002/cyto.a.10027
   Zapolska-Downar D, 2008, ANN NUTR METAB, V53, P283, DOI 10.1159/000191290
   Zarrouk A, 2020, CURR ALZHEIMER RES, V17, P823, DOI 10.2174/1567205017666201203123046
   Zarrouk A, 2019, BIOMED ENVIRON SCI, V32, P291, DOI 10.3967/bes2019.039
   Zarrouk A, 2018, BIOCHIMIE, V153, P210, DOI 10.1016/j.biochi.2018.06.027
   Zarrouk A, 2017, J STEROID BIOCHEM, V169, P29, DOI 10.1016/j.jsbmb.2016.02.024
   Zarrouk A, 2015, STEROIDS, V99, P238, DOI 10.1016/j.steroids.2015.01.018
   Zarrouk A, 2014, AGEING RES REV, V18, P148, DOI 10.1016/j.arr.2014.09.006
   Zarrouk A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/623257
   Zarroulc A, 2019, CURR PHARM DESIGN, V25, P1791, DOI 10.2174/1381612825666190705192902
   Zerbinati C, 2017, FREE RADICAL BIO MED, V111, P151, DOI 10.1016/j.freeradbiomed.2017.04.013
   Zhang HB, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.143420
   ZHANG X, 2021, BRIT J PHARMACOL
NR 222
TC 24
Z9 24
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD JUL
PY 2021
VL 68
AR 101324
DI 10.1016/j.arr.2021.101324
EA APR 2021
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA SU3YM
UT WOS:000663077400001
PM 33774195
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Cao, XG
   Shen, DF
   Wang, YJ
   Zhang, J
   Oh, JY
   Prockop, DJ
   Chan, CC
AF Tuo, Jingsheng
   Cao, Xiaoguang
   Shen, Defen
   Wang, Yujuan
   Zhang, Jun
   Oh, Joo Youn
   Prockop, Darwin J.
   Chan, Chi-Chao
TI Anti-inflammatory recombinant TSG-6 stabilizes the progression of focal
   retinal degeneration in a murine model
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; Animal model; IL-17a; TNF-alpha;
   TSG-6; Treatment
ID PIGMENT EPITHELIAL-CELLS; INTER-ALPHA-INHIBITOR; MACULAR DEGENERATION;
   EXPRESSION; MICE; LESIONS; AUTOIMMUNITY; HYALURONAN; LIPOFUSCIN; MSCS
AB Background: Inflammatory responses are detected in the retina of patients with age-related macular degeneration and Ccl2(-/-)/Cx3cr1(-/-) mice on rd8 background,(Ccl2(-/-)/Cx3cr1(-/-) mice) a model that develops progressive age-related macular degeneration-like retinal lesions including focal photoreceptor degeneration, abnormal retinal pigment epithelium and A2E accumulation. Tumor necrosis factor-inducible gene 6 protein is an anti-inflammatory protein and has been shown to improve myocardial infarction outcome and chemically injured cornea in mice by suppressing inflammation. In this study, we evaluated the effect of an intravitreous injection of recombinant TSG-6 on the retinal lesions of Ccl2(-/-)/Cx3cr1(-/-) mice.
   Methods: Recombinant TSG-6 (400 ng) was administered by intravitreous injection into the right eye of six-week-old Ccl2(-/-)/Cx3cr1(-/-) mice. Their left eye was injected with phosphate-buffered saline as a control. Funduscopic pictures were taken before injection and sequentially once a month after injection. The mice were killed two months after injection and the ocular histology examined. Retinal A2E, a major component of lipofuscin, was measured by high performance liquid chromatography. The microarray of ocular mRNA of 92 immunological genes was performed. The genes showing differentiated expression in microarray were further compared between the injected right eye and the contralateral (control) eye by [real-time quantitative reverse transcription polymerase chain reaction] qRT-PCR.
   Results: The continuous monitoring of the fundus for two months showed a slower progression or alleviation of retinal lesions in the treated right eyes as compared with the untreated left eyes. Among 23 pairs of eyes, the lesion levels improved in 78.3%, stayed the same in 8.7% and progressed in 13.0%. Histology confirmed the clinical observation. Even though there was no difference in the level of A2E between the treated and the untreated eyes, microarray analysis of 92 immune genes showed that IL-17a was substantially decreased after the treatment. Expression of TNF-alpha showed a similar pattern to IL-17a. The results were consistent in duplicated arrays and confirmed by qRT-PCR.
   Conclusions: We concluded that intravitreous administration of recombinant TSG-6 might stabilize retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice on rd8 background. Modulation of ocular immunological gene expressions, especially IL-17a, could be one of the mechanisms.
C1 [Tuo, Jingsheng; Cao, Xiaoguang; Shen, Defen; Wang, Yujuan; Zhang, Jun; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Oh, Joo Youn; Prockop, Darwin J.] Scott & White Mem Hosp & Clin, Inst Regenerat Med, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Scott & White Medical Center; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Zhang, Jun/K-2424-2012; wang, yujuan/C-8428-2016
OI Tuo, Jingsheng/0000-0002-1372-7810
FU National Eye Institute, National Institutes of Health; NATIONAL EYE
   INSTITUTE [ZIAEY000418, ZICEY000461, ZIAEY000222] Funding Source: NIH
   RePORTER
FX This work was carried out in the National Eye Institute, National
   Institutes of Health, Bethesda, MD, USA and supported by the Intramural
   Research Program of National Eye Institute, National Institutes of
   Health.
CR Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Caspi R, 2008, IMMUNOL RES, V42, P41, DOI 10.1007/s12026-008-8031-3
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Fries E, 2003, ACTA BIOCHIM POL, V50, P735
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kehlen A, 2003, ARTHRITIS RES THER, V5, pR186, DOI 10.1186/ar762
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446
   Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107
   Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   Smith TC, 2007, AUST FAM PHYSICIAN, V36, P359
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tanigawa S, 2011, CYTOKINE, V56, P376, DOI 10.1016/j.cyto.2011.08.015
   Tuo J, 2011, NEUROBIOL AGING, V33, P433
   Tuo J, 2011, NEUROBIOL AGING, V33, pe1
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Verma V, 2008, CURR EYE RES, V33, P701, DOI 10.1080/02713680802236185
   Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7
   Wisniewski Hans-Georg, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR225, DOI 10.1007/BF02346350
   Wisniewski HG, 1996, J IMMUNOL, V156, P1609
   Zhou YD, 2011, EXP EYE RES, V93, P636, DOI 10.1016/j.exer.2011.07.017
NR 42
TC 25
Z9 28
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD MAR 27
PY 2012
VL 9
AR 59
DI 10.1186/1742-2094-9-59
PG 8
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 949EM
UT WOS:000304559100001
PM 22452753
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zatreanu, L
   Freund, KB
   Leong, BCS
   Yu, HG
   Teke, MY
   Yzer, S
   Sadda, SR
   Sarraf, D
AF Zatreanu, Luca
   Freund, K. Bailey
   Leong, Belinda C. S.
   Yu, Hyeong G.
   Teke, Mehmet Y.
   Yzer, Suzanne
   Sadda, SriniVas R.
   Sarraf, David
TI SEROUS MACULAR DETACHMENT IN BEST DISEASE A Masquerade Syndrome
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE best disease; choroidal thickness; intravitreal anti-VEGF injections;
   masquerade; misdiagnosis; serous macular detachment; subretinal fluid
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL THICKNESS PROFILE;
   RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; CLINICAL SPECTRUM;
   GENETIC-ANALYSIS; VITELLIFORM; DYSTROPHY; FAMILY; MUTATIONS
AB Purpose: To describe the clinical and multimodal imaging findings of a series of cases of serous macular detachment (SMD) caused by Best disease (BD) masquerading as neovascular age-related macular degeneration or central serous chorioretinopathy that were inappropriately treated with intravitreal anti-vascular endothelial growth factor or laser therapy. This study will also present data to support age-related progressive choroidal thickening in BD patients, which may play a role in the development of SMD in this population. Methods: Clinical examination and multimodal imaging findings, including color fundus photography, spectral-domain optical coherence tomography, fundus autofluorescence, fluorescein angiography, and optical coherence tomography-angiography, were reviewed and analyzed. Subfoveal choroidal thickness was also formally measured, and an age-related choroidal thickness analysis was performed and compared with a normal population. Results: Twenty-six eyes of 13 patients (5 women) were included. Median age was 44 years. Nine patients presented with a history of SMD and subretinal fluid recalcitrant to various therapies, including intravitreal anti-vascular endothelial growth factor injections and photodynamic therapy. Best disease was subsequently diagnosed genetically in six patients and by detailed family history in seven. Mean logarithm of the minimum angle of resolution best-corrected visual acuity for all 26 eyes at last follow-up was +0.36 (Snellen equivalent of 20/46). Subfoveal choroidal thickness positively correlated with age for our cohort, increasing linearly at a rate of 25.6 mu m per decade (R-2= 0.64;P< 0.001). Choroidal neovascularization was identified in four eyes on optical coherence tomography angiography, but these eyes did not respond to anti-vascular endothelial growth factor treatment. Conclusion: The diagnosis of BD should be considered in patients presenting with SMD and recalcitrant subretinal fluid masquerading as neovascular age-related macular degeneration or chronic central serous chorioretinopathy to avoid unnecessary treatment procedures. The positive correlation of subfoveal choroidal thickness with age in BD patients may be a factor in the pathogenesis and development of SMD in this population. Recognizing the multimodal imaging features of SMD associated with BD, described in detail in this study, will guide practitioners to the accurate diagnosis of BD and reduce the risk of unnecessary intraocular procedures with potential complications.
C1 [Zatreanu, Luca; Sarraf, David] UCLA, Div Retinal Disorders & Ophthalm Genet, Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA.
   [Zatreanu, Luca; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Zatreanu, Luca; Sadda, SriniVas R.] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Freund, K. Bailey; Leong, Belinda C. S.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Leong, Belinda C. S.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Leong, Belinda C. S.] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Yu, Hyeong G.] Seoul Natl Univ Hosp, Seoul, South Korea.
   [Yu, Hyeong G.] Seoul Natl Univ, Coll Med, Seoul, South Korea.
   [Teke, Mehmet Y.] Ulucanlar Eye Res & Training Hosp, Retina Dept, Ankara, Turkey.
   [Yzer, Suzanne] Rotterdam Eye Hosp, Rotterdam, Netherlands.
C3 University of California System; University of California Los Angeles;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System; Doheny Eye Institute;
   University of California System; University of California Los Angeles;
   Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; Seoul National University (SNU);
   Seoul National University Hospital; Seoul National University (SNU);
   Ankara Ulucanlar Eye Training & Research Hospital; Rotterdam Eye
   Hospital
RP Sarraf, D (通讯作者)，UCLA, Div Retinal Disorders & Ophthalm Genet, Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA.
EM sarraf@jsei.ucla.edu
RI Yzer, Suzanne/ABB-6929-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Research To Prevent Blindness, Inc, New York, NY; The Macula Foundation,
   Inc, New York, NY
FX Supported by research funding from the Research To Prevent Blindness,
   Inc (D.S.), New York, NY and The Macula Foundation, Inc (D.S., K.B.F.),
   New York, NY.
CR Alfonso-Munoz EA, 2018, OPHTHALMOL RETINA, V2, P857, DOI 10.1016/j.oret.2018.04.021
   [Anonymous], 2012, BMC OPHTHALMOL, DOI DOI 10.1186/1471-2415-12-25
   Arora R, 2007, CLIN EXP OPHTHALMOL, V35, P287, DOI 10.1111/j.1442-9071.2007.01464.x
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Bakall B, 2007, EXP EYE RES, V85, P34, DOI 10.1016/j.exer.2007.02.018
   Barbazetto I, 2018, OPHTHALMOLOGY, V125, P75, DOI 10.1016/j.ophtha.2017.07.020
   Bard LA, 1975, T SECT OPHTHALMOL AM, V79, pOP865
   Best II F, 1905, OPHTHALMOLOGICA, V13, P199
   Boon CJF, 2009, RETINA-J RET VIT DIS, V29, P835, DOI 10.1097/IAE.0b013e31819d4fda
   Cakir M, 2009, J AAPOS, V13, P94, DOI 10.1016/j.jaapos.2008.06.014
   Caldwell GM, 1999, GENOMICS, V58, P98, DOI 10.1006/geno.1999.5808
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P391, DOI 10.4103/0301-4738.159862
   Chhablani J, 2014, INDIAN J OPHTHALMOL, V62, P1060, DOI 10.4103/0301-4738.146711
   Chowers I, 2015, PROG RETIN EYE RES, V47, P64, DOI 10.1016/j.preteyeres.2015.02.001
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   Eagle RC, 2011, EYE PATHOLOGY ATLAS, V2nd, P149
   Feiner L, 2017, RETIN CASES BRIEF RE, V11, pS191
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P238, DOI 10.1111/aos.12142
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Gass JDM, 1997, STEREOSCOPIC ATLAS M, V2
   Glavac D, 2016, ACTA OPHTHALMOL, V94, pE786, DOI 10.1111/aos.13202
   Govetto A, 2017, AM J OPHTHALMOL, V184, P167, DOI 10.1016/j.ajo.2017.10.011
   Grenga PL, 2016, EUR J OPHTHALMOL, V26, P145, DOI 10.5301/ejo.5000687
   Guziewicz KE, 2018, P NATL ACAD SCI USA, V115, pE2839, DOI 10.1073/pnas.1720662115
   Hartzell HC, 2008, PHYSIOL REV, V88, P639, DOI 10.1152/physrev.00022.2007
   Iannaccone A, 2011, ARCH OPHTHALMOL-CHIC, V129, P211, DOI 10.1001/archophthalmol.2010.367
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kausar A, 2016, J AYUB MED COLL ABBO, V28, P404
   Kramer Franziska, 2003, Hum Mutat, V22, P418, DOI 10.1002/humu.9189
   KRILL AE, 1966, AM J OPHTHALMOL, V61, P1405, DOI 10.1016/0002-9394(66)90478-8
   Kubicka-Trzaska A, 2008, KLIN OCZNA, V110, P183
   Leu J, 2007, GRAEF ARCH CLIN EXP, V245, P1723, DOI 10.1007/s00417-007-0604-7
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Lin CF, 2014, RETIN CASES BRIEF RE, V8, P247
   Low S, 2011, MOL VIS, V17, P2272
   Makati R, 2014, OPTOMETRY VISION SCI, V91, pE274, DOI 10.1097/OPX.0000000000000403
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MARMOR MF, 1979, ANN OPHTHALMOL, V11, P1705
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688
   Mrejen-Uretsky S, 2016, RETINA-J RET VIT DIS, V36, P1111, DOI 10.1097/IAE.0000000000000831
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Palacios RM, 2016, INT J RETINA VITREOU, V2, P5
   Parodi MB, 2016, RETINA-J RET VIT DIS, V36, P764, DOI 10.1097/IAE.0000000000000759
   Parodi MB, 2014, OPHTHALMIC SURG LASE, V45, pe8
   Pece A, 2007, SEMIN OPHTHALMOL, V22, P99
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Qian CX, 2017, OPHTHALMOLOGY, V124, P456, DOI 10.1016/j.ophtha.2016.11.022
   Querques G, 2008, AM J OPHTHALMOL, V146, P501, DOI 10.1016/j.ajo.2008.05.029
   Querques G, 2016, BRIT J OPHTHALMOL, V100, P1724, DOI 10.1136/bjophthalmol-2016-308370
   Ruiz-Moreno JM, 2013, INVEST OPHTH VIS SCI, V54, P353, DOI 10.1167/iovs.12-10863
   Schatz P, 2016, GRAEF ARCH CLIN EXP, V254, P215, DOI 10.1007/s00417-015-3025-z
   Shin Joong Won, 2012, Korean J Ophthalmol, V26, P255, DOI 10.3341/kjo.2012.26.4.255
   Singh S, 2017, DELHI J OPHTHALMOL, V27, P255
   Sodi A, 2015, OPHTHALMIC GENET, V36, P168, DOI 10.3109/13816810.2015.1009121
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Stattin M, 2017, RETIN CASES BRIEF RE
   STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246
   Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999
   Testa F, 2008, BRIT J OPHTHALMOL, V92, P1467, DOI 10.1136/bjo.2008.143776
   Toto L, 2018, RETINA-J RET VIT DIS, V38, P731, DOI 10.1097/IAE.0000000000001615
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yardley J, 2004, INVEST OPHTH VIS SCI, V45, P3683, DOI 10.1167/iovs.04-0550
   Zhang Q, 2011, GRAEF ARCH CLIN EXP, V249, P745, DOI 10.1007/s00417-010-1587-3
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
NR 74
TC 9
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1456
EP 1470
DI 10.1097/IAE.0000000000002659
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400014
PM 31613838
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chen, J
   Sapieha, P
   Aderman, CM
   Stahl, A
   Clemons, TE
   Chew, EY
   Smith, LEH
AF SanGiovanni, John Paul
   Chen, Jing
   Sapieha, Przemyslaw
   Aderman, Christopher M.
   Stahl, Andreas
   Clemons, Traci E.
   Chew, Emily Y.
   Smith, Lois E. H.
TI DNA Sequence Variants in PPARGC1A, a Gene Encoding a Coactivator of the
   omega-3 LCPUFA Sensing PPAR-RXR Transcription Complex, Are Associated
   with NV AMD and AMD-Associated Loci in Genes of Complement and VEGF
   Signaling Pathways
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ACTIVATED-RECEPTOR-GAMMA; GENOME-WIDE
   ASSOCIATION; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   MESSENGER-RNA; FATTY-ACIDS; POLYMORPHISMS; RISK; EXPRESSION
AB Background: Increased intake of omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) and use of peroxisome proliferator activator receptor (PPAR)-activating drugs are associated with attenuation of pathologic retinal angiogenesis. omega-3 LCPUFAs are endogenous agonists of PPARs. We postulated that DNA sequence variation in PPAR gamma (PPARG) co-activator 1 alpha (PPARGC1A), a gene encoding a co-activator of the LCPUFA-sensing PPARG-retinoid X receptor (RXR) transcription complex, may influence neovascularization (NV) in age-related macular degeneration (AMD).
   Methods: We applied exact testing methods to examine distributions of DNA sequence variants in PPARGC1A for association with NV AMD and interaction of AMD-associated loci in genes of complement, lipid metabolism, and VEGF signaling systems. Our sample contained 1858 people from 3 elderly cohorts of western European ancestry. We concurrently investigated retinal gene expression profiles in 17-day-old neonatal mice on a 2% LCPUFA feeding paradigm to identify LCPUFA-regulated genes both associated with pathologic retinal angiogenesis and known to interact with PPARs or PPARGC1A.
   Results: A DNA coding variant (rs3736265) and a 3'UTR-resident regulatory variant (rs3774923) in PPARGC1A were independently associated with NV AMD (exact P = 0.003, both SNPs). SNP-SNP interactions existed for NV AMD (P<0.005) with rs3736265 and a AMD-associated variant in complement factor B (CFB, rs512559). PPARGC1A influences activation of the AMD-associated complement component 3 (C3) promoter fragment and CFB influences activation and proteolysis of C3. We observed interaction (P <= 0.003) of rs3736265 with a variant in vascular endothelial growth factor A (VEGFA, rs3025033), a key molecule in retinal angiogenesis. Another PPARGC1A coding variant (rs8192678) showed statistical interaction with a SNP in the VEGFA receptor fms-related tyrosine kinase 1 (FLT1, rs10507386; P <= 0.003). C3 expression was down-regulated 2-fold in retinas of omega-3 LCPUFA-fed mice - these animals also showed 70% reduction in retinal NV (P <= 0.001).
   Conclusion: Ligands and co-activators of the omega-3 LCPUFA sensing PPAR-RXR axis may influence retinal angiogenesis in NV AMD via the complement and VEGF signaling systems. We have linked the co-activator of a lipid-sensing transcription factor (PPARG co-activator 1 alpha, PPARGC1A) to age-related macular degeneration (AMD) and AMD-associated genes.
C1 [SanGiovanni, John Paul; Chew, Emily Y.] NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Chen, Jing; Aderman, Christopher M.; Smith, Lois E. H.] Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   [Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.
   [Stahl, Andreas] Univ Eye Hosp Freiburg, Dept Ophthalmol, Freiburg, Germany.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Harvard University; Boston Children's Hospital; Harvard Medical
   School; Universite de Montreal; University of Freiburg; Emmes
   Corporation
RP SanGiovanni, JP (通讯作者)，NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020
FU National Eye Institute; Research to Prevent Blindness; Children's
   Hospital Ophthalmology Foundation; Charles H. Hood Foundation; Canadian
   Institues of Health Research (Institute of Nutrition, Metabolism and
   Diabetes); Deutsche Forschungsgemeinschaft; Freifrau von Nauendorf
   Stiftung; Deutsche Ophthalmologische Gesellschaft; National Institutes
   of Health [NIH-P50-NS40828, NIH-P30-HD18655];  [EY017017]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY022275, R01EY017017] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040828] Funding
   Source: NIH RePORTER
FX Funding support for NEI-AMD was provided by the National Eye Institute
   (JPSG); EY017017 and Research to Prevent Blindness (RPB) Senior
   Investigator Award (LEHS). Additional support was provided by Children's
   Hospital Ophthalmology Foundation and Charles H. Hood Foundation (JC),
   the Canadian Institues of Health Research (Institute of Nutrition,
   Metabolism and Diabetes) (PS) and the Deutsche Forschungsgemeinschaft,
   Freifrau von Nauendorf Stiftung and Deutsche Ophthalmologische
   Gesellschaft (AS). Mouse microarray studies were performed by the
   Molecular Genetics Core Facility at Children's Hospital Boston supported
   by National Institutes of Health NIH-P50-NS40828, and NIH-P30-HD18655.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson SP, 2004, MOL PHARMACOL, V66, P1440, DOI 10.1124/mol.104.005496
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Cano MD, 2008, PPAR RES, V2008, DOI 10.1155/2008/821592
   Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Fauconnet S, 2002, J BIOL CHEM, V277, P23534, DOI 10.1074/jbc.M200172200
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Halapin NA, 2010, NEUROCHEM RES, V35, P1944, DOI 10.1007/s11064-010-0351-8
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200
   Lee Y, 2002, P NATL ACAD SCI USA, V99, P11848, DOI 10.1073/pnas.182420899
   Leuenberger N, 2009, J CLIN INVEST, V119, P3138, DOI 10.1172/JCI39019
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Miura S, 2003, J BIOL CHEM, V278, P31385, DOI 10.1074/jbc.M304312200
   Miura S, 2008, ENDOCRINOLOGY, V149, P4527, DOI 10.1210/en.2008-0466
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pershadsingh HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/164273
   Prevent Blindness America [PBA], 2017, EC IMPACT VISION PRO
   Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rufibach LE, 2006, J LIPID RES, V47, P1463, DOI 10.1194/jlr.M600082-JLR200
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Sheets KG, 2010, MOL VIS, V16, P320
   Smailhodzic D, 2012, OPHTHALMOLOGY
   Son NH, 2007, J CLIN INVEST, V117, P2791, DOI 10.1172/JCI30335
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Vanden Heuvel JP, 2012, PROG MOL BIOL TRANSL, V108, P75, DOI 10.1016/B978-0-12-398397-8.00004-6
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Yano M, 2007, CIRC RES, V100, P1442, DOI 10.1161/01.RES.0000268411.49545.9c
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 61
TC 23
Z9 25
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2013
VL 8
IS 1
AR e53155
DI 10.1371/journal.pone.0053155
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086SQ
UT WOS:000314707700012
PM 23335958
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ryhanen, T
   Mannermaa, E
   Oksala, N
   Viiri, J
   Paimela, T
   Salminen, A
   Atalay, M
   Kaarniranta, K
AF Ryhanen, Tuornas
   Mannermaa, Ehisa
   Oksala, Niku
   Viiri, Johanna
   Paimela, Tuomas
   Salminen, Antero
   Atalay, Mustafa
   Kaarniranta, Kai
TI Radicicol but not geldanamycin evokes oxidative stress response and
   efflux protein inhibition in ARPE-19 human retinal pigment epithelial
   cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE geldanamycin; heat shock protein; oxidative stress; radicicol; retinal
   pigment epithelium
ID NITRIC-OXIDE SYNTHASE; MACULAR DEGENERATION; GENE-TRANSCRIPTION; HSP90;
   ACTIVATION; BINDING; PHOSPHORYLATION; TOXICITY; COMPLEX; DEATH
AB Drug delivery to retinal cells has represented a major challenge for ophthalmologists for many decades. However, drug targeting to the retina is essential in therapies against retinal diseases such as age-related macular degeneration, the most common reason of blindness in the developed countries. Retinal cells are chronically exposed to oxidative stress that contributes to cellular senescence and may cause neovascularization in the most severe age-related macular degeneration cases. Various pre- and clinical studies have revealed that heat shock protein 90 (HSP90) inhibitors, such as geldanamycin and radicicol, are promising drugs in the treatment of different malignant processes. In this study, our goal was to compare the effects of 0.1 mu M, 1 mu M or 5 mu M geldanamycin or radicicol on the oxidative stress response, cytotoxicity, and efflux protein activity (a protein pump which removes drugs from cells) in ARPE-19 (human retinal pigment epithelial, RPE) cells. Our findings indicate that geldanamycin and radicicol increased HSP70 and HSP27 expression analyzed by western blotting. Cellular levels of protein carbonyls were increased in response to 0.1 mu M (P= 0.048 for 24 h, P= 0.018 for 48 h) or 5 mu M (P= 0.030 for 24 h, P= 0.046 for 48 h) radicicol but not to geldanamycin analyzed by ELISA assay. In addition, HNE-protein adducts were accumulated in the RPE cells exposed to 0.1 M or 5 mu M radicicol but not to geldanamycin analyzed by western blotting. However, MTT assay revealed that 5 mu M geldanamycin reduced cellular viability 20-30% (P<0.05 for 24 h, P<0.01 for 48 h), but this was not observed at any radicicol concentration in RPE cells. Interestingly, the increased oxidative stress response was associated with efflux protein inhibition (20-30%) when the cells were exposed to 1 mu M or 5 mu M (P<0.05) radicicol, but not in geldanamycin-treated RPE cells. These novel findings help in understanding the influence of HSP90 inhibition and regulatory mechanisms of drug delivery to retinal cells. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Ryhanen, Tuornas; Viiri, Johanna; Paimela, Tuomas; Kaarniranta, Kai] Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Mannermaa, Ehisa] Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland.
   [Oksala, Niku] Univ Tampere, Dept Surg, Div Vasc Surg, FIN-33101 Tampere, Finland.
   [Salminen, Antero] Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland.
   [Atalay, Mustafa] Univ Kuopio, Dept Physiol, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; Tampere University;
   University of Eastern Finland; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
EM kaamira@messi.uku.fi
OI Kaarniranta, Kai/0000-0003-2600-8679
CR Atalay Mustafa, 2002, J Sports Sci Med, V1, P1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8
   Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200
   Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4
   CAJONE F, 1988, CHEM-BIOL INTERACT, V65, P235, DOI 10.1016/0009-2797(88)90109-3
   Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8
   Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dey A, 2006, J PHARMACOL EXP THER, V317, P1391, DOI 10.1124/jpet.106.101808
   Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200
   Fantappie O, 2004, FREE RADICAL RES, V38, P751, DOI 10.1080/10715760410001705140
   Hadden MK, 2006, CURR TOP MED CHEM, V6, P1173
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102
   Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800
   HOLZ FG, 2004, GENETICS AMD, V2, P24
   Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kinnunen S, 2005, EUR J APPL PHYSIOL, V95, P550, DOI 10.1007/s00421-005-0034-3
   Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7
   NEGRESALVAYRE A, 2007, BRIT J PHARMACOL, P1
   Piper P W, 2001, Curr Opin Investig Drugs, V2, P1606
   Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131
   SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392
   Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688
   Sreedhar AS, 2003, J BIOL CHEM, V278, P35231, DOI 10.1074/jbc.M301371200
   Vellonen KS, 2004, EUR J PHARM SCI, V23, P181, DOI 10.1016/j.ejps.2004.07.006
   Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3
NR 33
TC 21
Z9 23
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 28
PY 2008
VL 584
IS 2-3
BP 229
EP 236
DI 10.1016/j.ejphar.2008.02.010
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 300KC
UT WOS:000255821700003
PM 18313664
DA 2022-11-30
ER

PT J
AU Jobling, AI
   Fang, ZP
   Koleski, D
   Tymms, MJ
AF Jobling, AI
   Fang, ZP
   Koleski, D
   Tymms, MJ
TI Expression of the ETS transcription factor ELF3 in the retinal pigment
   epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SORSBYS FUNDUS DYSTROPHY; TISSUE INHIBITOR; GENOMIC ORGANIZATION;
   CELL-LINES; GENE; FAMILY; DIFFERENTIATION; RECEPTOR; PROTEIN; BINDING
AB PURPOSE. The ETS family of transcription factors regulate several critical cellular functions. They have also been implicated in invertebrate ocular development. This work was undertaken to determine whether epithelium-specific ETS transcription factors are expressed in the retinal pigment epithelium and to investigate the possible role of these factors in retinal diseases such as age-related macular degeneration.
   METHODS. The expression of the epithelial ETS transcription factors ELF5, ESE3, and ELF3 was assessed by RT-PCR in the human RPE cell lines D407 and hTERT-RPE1. The full-length coding sequence of rat Elf`3 was isolated with 3' rapid amplification of cDNA ends (RACE) and degenerative primers, and its expression was determined in various rat tissues, by RT-PCR and real-time PCR. A polyclonal ELF3 antibody produced from a C-terminal peptide was used to observe the distribution of the transcription factor within the retina. To assess the possible ELF3 regulation of the TIMP3 promoter, transient transfection assays were performed. Promoter activity was determined with a firefly luciferase reporter gene construct.
   RESULTS. The epithelium-specific ETS transcription factor ELF3 was expressed in the D407 and hTERT-RPE1 cell lines. Neither ESE3 nor ELF5 was detected in the RPE. The cloning of rat Elf3 produced two splice variants, designated Elf3a (1786 bp) and Elf3b (1855 bp). The larger form, Elf3b, contained a 69-bp insert in the coding sequence, which showed high homology to a similar insert previously identified in murine Elf3. Both splice variants were expressed in rat lung, kidney, liver, and retina, but were absent in heart tissue. Real-time PCR analysis showed the retina to contain high levels of Elf3, which was subsequently localized to the RPE. Elf3 upregulated the TIMP3 promoter, with Elf3a and -3b inducing an approximate sixfold increase in activity.
   CONCLUSIONS. The ELF3 transcription factor is highly expressed in the RPE and can regulate important ocular genes, such as TIMP3, in vitro. The specific expression of ELF3 in the RPE may reflect an important role for this transcription factor in retinal function. Furthermore, its regulation of TIMP3 may have implications for degenerative retinal diseases, such as age-related macular degeneration.
C1 Natl Vis Res Inst Australia, Carlton, Vic 3053, Australia.
   Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
C3 University of Melbourne
RP Jobling, AI (通讯作者)，Natl Vis Res Inst Australia, 386 Cardigan St, Carlton, Vic 3053, Australia.
RI Jobling, Andrew/C-8221-2015
OI Jobling, Andrew/0000-0002-7827-3135
CR Albagli O, 1996, MECH DEVELOP, V59, P29, DOI 10.1016/0925-4773(96)00568-0
   APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313
   Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4
   Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404
   BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020
   Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441
   BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321
   Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978
   Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110
   CUHNAVAZ J, 1979, SURV OPHTHALMOL, V23, P279
   Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810
   Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2
   FLOOD MT, 1983, INVEST OPHTH VIS SCI, V24, P1227
   Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7
   Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1
   Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x
   GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0
   He L, 1998, Mol Vis, V4, P32
   Hsu T, 2000, ONCOGENE, V19, P6409, DOI 10.1038/sj.onc.1204033
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986
   KOIZUMI S, 1990, ONCOGENE, V5, P675
   KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9
   Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774
   Mimeault M, 2000, CRIT REV ONCOGENESIS, V11, P227
   Mochii M, 1998, DEV BIOL, V193, P47, DOI 10.1006/dbio.1997.8800
   Nagase H, 1996, ZINC METALLOPROTEASE, P153
   Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541
   NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0
   Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216
   Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419
   Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439
   ONEAL EM, 1994, CELL, V78, P137
   Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297
   RAO VN, 1993, CANCER RES, V53, P215
   SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170
   SIDDIQUE HR, 1993, ONCOGENE, V8, P1751
   Simpson D, 2000, MOL VIS, V6, P178
   Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0
   TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2
   Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427
   Venanzoni MC, 1996, ONCOGENE, V12, P1199
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WERNERT N, 1992, AM J PATHOL, V140, P119
   Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9
   Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6
   Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198
NR 51
TC 12
Z9 12
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2002
VL 43
IS 11
BP 3530
EP 3537
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 609AB
UT WOS:000178879500023
PM 12407165
DA 2022-11-30
ER

PT J
AU Liu, HH
   Xu, LA
   Wang, YX
   Wang, SA
   You, QS
   Jonas, JB
AF Liu, Hai Hua
   Xu, Liang
   Wang, Ya Xing
   Wang, Shuang
   You, Qi Sheng
   Jonas, Jost B.
TI Prevalence and Progression of Myopic Retinopathy in Chinese Adults: The
   Beijing Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL CORNEAL THICKNESS; AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE;
   OPTIC-NERVE HEAD; REFRACTIVE ERRORS; RISK-FACTORS; MACULAR DEGENERATION;
   PATHOLOGICAL MYOPIA; VISUAL IMPAIRMENT; OLDER POPULATION
AB Purpose: To determine the prevalence and progression of myopic retinopathy in Chinese adults.
   Design: Population-based cross-sectional study.
   Participants: The Beijing Eye Study 2001 included 4439 subjects of 5324 individuals who were invited to participate (response rate, 83.4%); the eligibility criterion was an age of 40+ years. The study was repeated in 2006, with 3251 subjects (73.2%) participating.
   Methods: The participants underwent a detailed eye examination, including fundus photography. Myopic retinopathy was defined by posterior staphylomata, lacquer cracks, Fuchs' spot of the macula, and myopic chorioretinal atrophy at the posterior pole. Parapapillary atrophy was assessed separately.
   Main Outcome Measures: Prevalence of myopic retinopathy and its change during a follow-up of 5 years.
   Results: After exclusion of pseudophakic or aphakic eyes, and eyes without assessable fundus photographs, 4319 subjects (97.3%) were included in the present study. Myopic retinopathy was present in 198 eyes (2.3% +/- 0.2%; 95% confidence interval [CI], 2.0-2.6) of 132 participants (3.1%). Myopic retinopathy was significantly associated with higher age (P<0.001), worse best-corrected visual acuity (P<0.001), deeper anterior chamber (P=0.04), larger optic disc (P<0.001), less age-related macular degeneration (P=0.02; odds ratio [OR] 0.90), and greater prevalence of open-angle glaucoma (P<0.001; OR 4.42). Myopic retinopathy was not associated significantly (P>0.20) with body height and weight, gender, rural versus urban region of residence, level of education, intraocular pressure, or central corneal thickness. The prevalence of myopic retinopathy increased significantly (P<0.001) with increasing myopic refractive error, from 3.8% in eyes with a myopic refractive error of < -4.0 diopters to 89.6% in eyes with a myopic refractive error of at least -10.0 diopters. At the 5-year follow-up examination, enlargement of the chorioretinal atrophy at the posterior fundus was observed in 9% of the eyes.
   Conclusions: Myopic retinopathy was present in 3.1% of subjects aged 40+ years who resided in the Greater Beijing area. Myopic retinopathy was associated with increased age, worse best-corrected visual acuity, deeper anterior chamber, larger optic disc, less age-related macular degeneration, and higher prevalence of open-angle glaucoma.
C1 [Liu, Hai Hua; Xu, Liang; Wang, Ya Xing; Wang, Shuang; You, Qi Sheng; Jonas, Jost B.] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.] Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
RI You, Qisheng/AAG-7153-2020; You, Qisheng/A-3619-2014; wang, YA
   XING/K-9671-2016
OI You, Qisheng/0000-0003-0743-7320; You, Qisheng/0000-0003-0743-7320;
   wang, YA XING/0000-0003-2749-7793
FU National Key Laboratory Fund, Beijing, China
FX Funded with a grant from the National Key Laboratory Fund, Beijing,
   China.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Burgoyne CF, 2001, J GLAUCOMA, V10, pS16, DOI 10.1097/00061198-200110001-00007
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cheng CY, 2003, INVEST OPHTH VIS SCI, V44, P4630, DOI 10.1167/iovs.03-0169
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   Fam HB, 2006, BRIT J OPHTHALMOL, V90, P1451, DOI 10.1136/bjo.2006.101170
   FUCHS A, 1960, AM J OPHTHALMOL, V49, P1418, DOI 10.1016/0002-9394(60)91369-6
   Gozum N, 1997, Eur J Ophthalmol, V7, P277
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   HU DN, 1987, J MED GENET, V24, P584, DOI 10.1136/jmg.24.10.584
   HYAMS SW, 1977, BRIT J OPHTHALMOL, V61, P428, DOI 10.1136/bjo.61.6.428
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P346, DOI 10.1016/j.ajo.2004.07.047
   Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2660, DOI 10.1167/iovs.03-1363
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334
   KLEIN RM, 1975, AM J OPHTHALMOL, V79, P386, DOI 10.1016/0002-9394(75)90611-X
   Lai TYY, 2008, EYE, V22, P209, DOI 10.1038/sj.eye.6702573
   LITTMANN H, 1982, KLIN MONATSBL AUGENH, V180, P286, DOI 10.1055/s-2008-1055068
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Pedersen L, 2005, ACTA OPHTHALMOL SCAN, V83, P539, DOI 10.1111/j.1600-0420.2005.00498.x
   Saw SM, 2008, OPHTHALMOLOGY, V115, P1713, DOI 10.1016/j.ophtha.2008.03.016
   Sawada A, 2008, OPHTHALMOLOGY, V115, P363, DOI 10.1016/j.ophtha.2007.03.075
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Steidl SM, 1997, AM J OPHTHALMOL, V123, P181, DOI 10.1016/S0002-9394(14)71034-7
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Tarczy-Hornoch K, 2006, INVEST OPHTH VIS SCI, V47, P1845, DOI 10.1167/iovs.05-1153
   Tokoro T, 1988, Acta Ophthalmol Suppl, V185, P107
   Van Newkirk M R, 1997, Trans Am Ophthalmol Soc, V95, P715
   Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   XIE X, 2009, INT OPHTHALMOL  0217
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
   Zhang HT, 2008, GRAEF ARCH CLIN EXP, V246, P587, DOI 10.1007/s00417-007-0760-9
NR 45
TC 209
Z9 229
U1 1
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2010
VL 117
IS 9
BP 1763
EP 1768
DI 10.1016/j.ophtha.2010.01.020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646DY
UT WOS:000281518100015
PM 20447693
DA 2022-11-30
ER

PT J
AU Calejo, MT
   Ilmarinen, T
   Vuorimaa-Laukkanen, E
   Talvitie, E
   Hakola, HM
   Skottman, H
   Kellomaki, M
AF Calejo, Maria Teresa
   Ilmarinen, Tanja
   Vuorimaa-Laukkanen, Elina
   Talvitie, Elina
   Hakola, Hanna M.
   Skottman, Heli
   Kellomaki, Minna
TI Langmuir-Schaefer film deposition onto honeycomb porous films for
   retinal tissue engineering
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Retinal pigment epithelium; Pluripotent stem cells; Tissue engineering;
   Honeycomb films; Langmuir-Schaefer films
ID PIGMENT EPITHELIUM; BRUCHS MEMBRANE; CELL-ADHESION; STEM-CELLS;
   POLYETHYLENE TEREPHTHALATE; MACULAR DEGENERATION; POLY(LACTIC ACID);
   TIGHT JUNCTIONS; RPE CELLS; SURFACES
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in senior citizens in the developed world. The disease is characterised by the degeneration of a specific cell layer at the back of the eye - the retinal pigment epithelium (RPE), which is essential in retinal function. The most promising therapeutic option to restore the lost vision is considered to be RPE cell transplantation. This work focuses on the development of biodegradable biomaterials with similar properties to the native Bruch's membrane as carriers for RPE cells. In particular, the breath figure (BF) method was used to create semi-permeable microporous films, which were thereafter used as the substrate for the consecutive Langmuir-Schaefer (LS) deposition of highly organised layers of collagen type I and collagen type IV. The newly developed biomaterials were further characterised in terms of surface porosity, roughness, hydrophilicity, collagen distribution, diffusion properties and hydrolytic stability. Human embryonic stem cell-derived RPE cells (hESC-RPE) cultured on the biomaterials showed good adhesion, spreading and morphology, as well as the expression of specific protein markers. Cell function was additionally confirmed by the assessment of the phagocytic capacity of hESC-RPE. Throughout the study, microporous films consistently showed better results as cell culture materials for hESC-RPE than dip-coated controls. This work demonstrates the potential of the BF-LS combined technologies to create biomimetic prosthetic Bruch's membranes for hESC-RPE transplantation.
   Statement of Significance
   Age-related macular degeneration (AMD) is a leading cause of central blindness in developed countries, associated with the degeneration of the retinal pigment epithelium (RPE), a specific cell layer at the back of the eye. Transplantation of RPE cells derived from stem cells is considered the best option to treat these patients. In this work, we developed a cell carrier for human embryonic stem cell-derived RPE that resembled the upper layers of the membrane that naturally supports the RPE cells in the retina. The new combination of technologies employed in this study resulted in very promising materials as confirmed by our studies on cell proliferation, morphology and function. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Calejo, Maria Teresa; Talvitie, Elina; Kellomaki, Minna] Tampere Univ Technol, Fac Biomed Sci & Engn, Tampere, Finland.
   [Calejo, Maria Teresa; Talvitie, Elina; Kellomaki, Minna] Tampere Univ Technol, BioMediTech Inst, Tampere, Finland.
   [Ilmarinen, Tanja; Skottman, Heli] Univ Tampere, Fac Med & Life Sci, Tampere, Finland.
   [Ilmarinen, Tanja; Skottman, Heli] Univ Tampere, BioMediTech Inst, Tampere, Finland.
   [Vuorimaa-Laukkanen, Elina; Hakola, Hanna M.] Tampere Univ Technol, Lab Chem & Bioengn, Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University; Tampere
   University; Tampere University
RP Calejo, MT (通讯作者)，Tampere Univ Technol, Fac Biomed Sci & Engn, Tampere, Finland.; Calejo, MT (通讯作者)，Tampere Univ Technol, BioMediTech Inst, Tampere, Finland.
EM teresa.calejo@tut.fi
RI Kellomäki, Minna/G-6190-2010
OI Kellomäki, Minna/0000-0003-4321-1820; Skottman,
   Heli/0000-0002-4127-8792; Vuorimaa-Laukkanen, Elina/0000-0002-3610-785X;
   Ilmarinen, Tanja/0000-0002-4609-8897
FU Finnish funding agency of innovation (Tekes) Human Spare Parts program;
   Academy of Finland [304909, 253134, 218050, 272808, 133879]; Finnish
   Cultural Foundation; Paivikki and Sakari Sohlberg Foundation
FX This study was supported by the Finnish funding agency of innovation
   (Tekes) Human Spare Parts program, the Academy of Finland (grant numbers
   304909, 253134, 218050, 272808, 133879), the Finnish Cultural Foundation
   and Paivikki and Sakari Sohlberg Foundation. Suvi Heinamaki, Outi Melin,
   Hanna Pekkanen and Outi Heikkila are thanked for technical assistance.
CR Ahn JI, 2013, ACTA BIOMATER, V9, P7796, DOI 10.1016/j.actbio.2013.04.014
   [Anonymous], TISSUE ENG A
   Barthes J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/921905
   Biesalski MA, 2006, BIOMATERIALS, V27, P1259, DOI 10.1016/j.biomaterials.2005.08.002
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Carbonaro A, 2004, J MEMBRANE SCI, V241, P249, DOI 10.1016/j.memsci.2004.04.039
   Chang CW, 1997, J NEUROCHEM, V69, P859
   Chen QB, 2007, J COLLOID INTERF SCI, V316, P1, DOI 10.1016/j.jcis.2007.07.059
   Chollet C, 2009, BIOMATERIALS, V30, P711, DOI 10.1016/j.biomaterials.2008.10.033
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Donelli I, 2009, BIOTECHNOL BIOENG, V103, P845, DOI 10.1002/bit.22316
   Du MC, 2011, CHEM-EUR J, V17, P4238, DOI 10.1002/chem.201003021
   Fagerholm P, 2014, BIOMATERIALS, V35, P2420, DOI 10.1016/j.biomaterials.2013.11.079
   Fang Z, 2013, IEEE T PLASMA SCI, V41, P1627, DOI 10.1109/TPS.2013.2259508
   Foldberg S, 2012, COLLOID SURFACE B, V93, P92, DOI 10.1016/j.colsurfb.2011.12.018
   Fukuhira Y, 2006, BIOMATERIALS, V27, P1797, DOI 10.1016/j.biomaterials.2005.10.019
   Gessner A, 2000, INT J PHARM, V196, P245, DOI 10.1016/S0378-5173(99)00432-9
   Goffin AJJ, 2010, LANGMUIR, V26, P3514, DOI 10.1021/la9031317
   Gonzalez-Fernandez F, 2002, J ENDOCRINOL, V175, P75, DOI 10.1677/joe.0.1750075
   Hayat MA, 2012, STEM CELLS CANC STEM, V7, P187
   Inagaki N, 2004, J POLYM SCI POL PHYS, V42, P3727, DOI 10.1002/polb.20234
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Juuti-Uusitalo K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030089
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Komez A, 2016, J BIOMED MATER RES A, V104, P2166, DOI 10.1002/jbm.a.35756
   KONARI K, 1995, EXP EYE RES, V61, P99, DOI 10.1016/S0014-4835(95)80063-8
   Langmuir I, 1938, J AM CHEM SOC, V60, P1351, DOI 10.1021/ja01273a023
   Lodish H., 2000, MOL CELL BIOL, V4th
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 1999, BIOMATERIALS, V20, P2351, DOI 10.1016/S0142-9612(99)00164-7
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Marmur A, 2003, LANGMUIR, V19, P8343, DOI 10.1021/la0344682
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Munoz-Bonilla A, 2014, PROG POLYM SCI, V39, P510, DOI 10.1016/j.progpolymsci.2013.08.006
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Pastorino L, 2014, COLLOID SURFACE B, V114, P372, DOI 10.1016/j.colsurfb.2013.10.026
   Phaechamud T, 2016, MAT SCI ENG C-MATER, V61, P744, DOI 10.1016/j.msec.2016.01.014
   Rahmany MB, 2013, ACTA BIOMATER, V9, P5431, DOI 10.1016/j.actbio.2012.11.019
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Riera M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.10
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Sakuma M, 2014, J BIOMAT SCI-POLYM E, V25, P431, DOI 10.1080/09205063.2013.866761
   Savolainen V, 2011, ANN BIOMED ENG, V39, P3055, DOI 10.1007/s10439-011-0387-1
   Skottman H, 2010, IN VITRO CELL DEV-AN, V46, P206, DOI 10.1007/s11626-010-9286-2
   Sorkio AE, 2015, BIOMATERIALS, V51, P257, DOI 10.1016/j.biomaterials.2015.02.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Tenboll A, 2010, LANGMUIR, V26, P12165, DOI 10.1021/la1018136
   Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Wang XH, 2011, J BIOMAT SCI-POLYM E, V22, P1917, DOI 10.1163/092050610X529155
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   WHO, 2016, PRIOR EYE DIS
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang AJ, 2015, CHEM REV, V115, P9801, DOI 10.1021/acs.chemrev.5b00069
NR 61
TC 28
Z9 28
U1 1
U2 49
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD APR 24
PY 2017
VL 54
BP 138
EP 149
DI 10.1016/j.actbio.2017.02.035
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA EW2QZ
UT WOS:000402342400012
PM 28223209
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Semeraro, F
   Morescalchi, F
   Duse, S
   Parmeggiani, F
   Gambicorti, E
   Costagliola, C
AF Semeraro, F.
   Morescalchi, F.
   Duse, S.
   Parmeggiani, F.
   Gambicorti, E.
   Costagliola, C.
TI Aflibercept in wet AMD: specific role and optimal use
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE aflibercept; AMD; neovascularization; VEGF; VEGF inhibition; VEGF-Trap
   eye
ID ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP-EYE; MACULAR EDEMA SECONDARY;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; TYROSINE KINASE; INTRAVITREAL
   BEVACIZUMAB; VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY; PEGAPTANIB
   SODIUM; DA VINCI
AB Background: Vascular endothelial growth factor (VEGF) is a naturally occurring glycoprotein in the body that acts as a growth factor for endothelial cells. It regulates angiogenesis, enhances vascular permeability, and plays a major role in wet age-related macular degeneration. The consistent association between choroidal neovascularization and increased VEGF expression provides a strong reason for exploring the therapeutic potential of anti-VEGF agents in the treatment of this disorder. Blockade of VEGF activity is currently the most effective strategy for arresting choroidal angiogenesis and reducing vascular permeability, which is frequently the main cause of visual acuity deterioration. In recent years, a number of other molecules have been developed to increase the efficacy and to prolong the durability of the anti-VEGF effect. Aflibercept (EYLEA (R); Regeneron Pharmaceutical Inc and Bayer), also named VEGF Trap-eye, is the most recent member of the anti-VEGF armamentarium that was approved by the US Food and Drug Administration in November 2011. Because of its high binding affinity and long duration of action, this drug is considered to be a promising clinically proven anti-VEGF agent for the treatment of wet maculopathy.
   Objective: This article reviews the current literature and clinical trial data regarding the efficacy and the pharmacological properties of VEGF-Trap eye and describes the possible advantages of its use over the currently used "older" anti-VEGF drugs.
   Methods: For this review, a search of PubMed from January 1989 to May 2013 was performed using the following terms (or combination of terms): vascular endothelial growth factors, VEGF, age-related macular degeneration, VEGF-Trap eye in wet AMD, VEGF-Trap eye in diabetic retinopathy, VEGF-Trap eye in retinal vein occlusions, aflibercept. Studies were limited to those published in English.
   Results and conclusion: Two Phase III clini-cal trials, VEGF Trap-eye Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2, comparing VEGF Trap-eye to ranibizumab demonstrated the noninferiority of this novel compound. The clinical equivalence of this compound against ranibizumab is maintained even when the injections are administered at 8-week intervals, which indicates the potential to reduce the risk of monthly intravitreal injections and the burden of monthly monitoring.
C1 [Semeraro, F.; Morescalchi, F.; Duse, S.; Gambicorti, E.] Univ Brescia, Ophthalmol Clin, Dept Med & Surg Specialties Radiol Specialties &, Brescia, Italy.
   [Parmeggiani, F.] Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
   [Costagliola, C.] Univ Molise, Dept Hlth Sci, Ophthalmol Clin, Campobasso, Italy.
C3 University of Brescia; University of Ferrara; University of Molise
RP Semeraro, F (通讯作者)，Spedali Civil Brescia, Ophthalmol Clin, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
EM semeraro@med.unibs.it
RI Costagliola, Ciro/G-5707-2012; Semeraro, Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   [Anonymous], 2008, DRUGS R&D, V9, P261
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Boyer DS, 2012, 45 ANN SCI M RET SOC
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   CANTRILL HL, 1984, INT OPHTHALMOL CLIN, V24, P13, DOI 10.1097/00004397-198402440-00004
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Do DV, 2007, IOVS, V48
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, PNAS, V99, P11392
   Holz FG, INTRAVITREAL AFLIBER
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Michels M, 2008, 26 ANN M AM SOC RET
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Monsky WL, 1999, CANCER RES, V59, P4129
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   PAJUSOLA K, 1992, CANCER RES, V52, P5738
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Regeneron Pharmaceuticals Inc, REG BAYER IN PHAS 3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rinaldi M, 2012, BRIT J CLIN PHARMACO, V74, P940, DOI 10.1111/j.1365-2125.2012.04291.x
   Roberts WG, 1997, CANCER RES, V57, P765
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Squirrell DM, 2009, CLIN EXP OPHTHALMOL, V37, P368, DOI 10.1111/j.1442-9071.2009.02044.x
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   US Food and Drug Administration, 2011, FDA APPR EYL EY DIS
   US Food and Drug Administration, EYL
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
NR 86
TC 88
Z9 94
U1 1
U2 31
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 711
EP 722
DI 10.2147/DDDT.S40215
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 194MQ
UT WOS:000322637800001
PM 23990705
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Dervisogullan, MS
   Totan, Y
   Tenlik, A
   Yuce, A
AF Dervisogullan, Mehmet Serdar
   Totan, Yuksel
   Tenlik, Aylin
   Yuce, Aslihan
TI Effects of cigarette smoking on choroidal and retinal thickness and
   ocular pulse amplitude
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Choroidal thickness; ocular pulse amplitude; smoking
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   BLOOD-FLOW; MACULAR DEGENERATION; HEALTHY-SUBJECTS; SMOKERS; EYES;
   REPRODUCIBILITY; CIRCULATION; TONOMETER
AB Background: In our study, we aimed to show the effects of smoking on choroidal thickness and ocular pulse amplitude. It is known that the anatomy and physiologic functions of the choroid is important in ocular diseases like glaucoma and age-related macular degeneration. Choroidal thickness is measured by the spectral domain optical coherence tomography (SD-OCT). The ocular pulse amplitude (OPA) is the difference between the systolic and diastolic intraocular pressure (IOP) and it is an index of choroidal perfusion.
   Design: This was a cross-sectional prospective observational study at the Turgut Ozal University Hospital setting.
   Participants: The test subjects were divided into two groups: the smokers group which consisted in 24 participants (20 male, 4 female) and the control group with 22 participants (16 male, 6 female).
   Methods: The participants underwent full ophthalmological examination including best-corrected visual acuity (BCVA), spherical equivalent (SE) values of refractive errors, intraocular pressure (IOP), ocular pulse amplitude (OPA), central corneal thickness (CCT), axial length (AL) and choroidal thickness. The IOP and the OPA were measured with the dynamic contour tonometer. The CCT and the AL were measured with the Nidek AL-Scan (Nidek Co., Ltd., Gamagori, Japan). The choroidal thickness was measured by the Cirrus high-definition optical coherence tomography (Cirrus Version 6.0; Carl Zeiss Meditec, Dublin, CA).
   Results: Gender did not differ significantly between the groups (p = 0.12). The age, SE, IOP, OPA, CCT and AL did not differ significantly in smokers and control groups (p = 0.12, p = 0.37, p = 0.54, p = 0.80, p = 0.56 and p = 0.82, respectively). The nasal, temporal, central retinal (p = 021, p = 021, p = 0.11) and nasal, temporal, central choroidal thicknesses (p = 0.80, p = 0.39, p = 0.75) did not differ significantly between smokers and control groups.
   Conclusions: We could not find a significant difference in OPA, retinal and choroidal thicknesses between smokers and non smokers. Further studies including histopathological changes in larger groups are needed to show the effect of smoking on choroidal thickness especially in patients with ocular diseases like age-related macular degeneration.
C1 [Dervisogullan, Mehmet Serdar; Totan, Yuksel; Tenlik, Aylin; Yuce, Aslihan] Turgut Ozal Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
C3 Turgut Ozal University
RP Dervisogullan, MS (通讯作者)，Turgut Ozal Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
EM serdarderv@hotmail.com
RI dervişoğulları, mehmet serdar/G-7851-2015
OI dervişoğulları, mehmet serdar/0000-0003-2006-2906
CR Benowitz NL, 1997, PREV MED, V26, P412, DOI 10.1006/pmed.1997.0175
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784
   FIELDING JE, 1985, NEW ENGL J MED, V313, P491, DOI 10.1056/NEJM198508223130807
   FLUGEL C, 1994, INVEST OPHTH VIS SCI, V35, P592
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garhofer G, 2011, MICROVASC RES, V82, P351, DOI 10.1016/j.mvr.2011.07.001
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   HARA K, 1991, Folia Ophthalmologica Japonica, V42, P263
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   KOOL MJF, 1993, J AM COLL CARDIOL, V22, P1881, DOI 10.1016/0735-1097(93)90773-T
   KUBOTA T, 1993, BRIT J OPHTHALMOL, V77, P430, DOI 10.1136/bjo.77.7.430
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P3430, DOI 10.1167/iovs.10-6600
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Resch H, 2005, INVEST OPHTH VIS SCI, V46, P4275, DOI 10.1167/iovs.05-0417
   Schmetterer L, 1998, INVEST OPHTH VIS SCI, V39, P1210
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Steigerwalt RD, 2000, RETINA-J RET VIT DIS, V20, P394, DOI 10.1097/00006982-200007000-00013
   Tamaki Y, 1999, OPHTHALMOLOGY, V106, P564, DOI 10.1016/S0161-6420(99)90117-3
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Usui S, 2012, AM J OPHTHALMOL, V153, P10, DOI 10.1016/j.ajo.2011.05.037
   van den Berkmortel FWPJ, 2000, ATHEROSCLEROSIS, V150, P397, DOI 10.1016/S0021-9150(99)00391-3
   WALKER RE, 1975, EXP EYE RES, V20, P245, DOI 10.1016/0014-4835(75)90138-4
   WALKER RE, 1972, EXP EYE RES, V13, P14, DOI 10.1016/0014-4835(72)90120-0
   Wimpissinger B, 2004, BRIT J OPHTHALMOL, V88, P776, DOI 10.1136/bjo.2003.031773
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 37
TC 15
Z9 15
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2015
VL 34
IS 3
BP 217
EP 221
DI 10.3109/15569527.2014.950380
PG 5
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA CR4SU
UT WOS:000361329600008
PM 25198410
DA 2022-11-30
ER

PT J
AU Tan, GX
   Liu, DD
   Zhu, RF
   Pan, H
   Li, JY
   Pan, WS
AF Tan, Guoxin
   Liu, Dandan
   Zhu, Renfang
   Pan, Hao
   Li, Jiayang
   Pan, Weisan
TI A core-shell nanoplatform as a nonviral vector for targeted delivery of
   genes to the retina
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Gene delivery; Nonviral vectors; Nuclear localization signal; Retina;
   Angiogenesis
ID RGD PEPTIDE; CD44; NANOPARTICLES; NANOMEDICINES; LOCALIZATION;
   ANGIOGENESIS; CHEMOTHERAPY; RELEASE; SURFACE; SIRNA
AB Retinal diseases, including age-related macular degeneration (AMD), are a major cause of blindness. Efficient delivery of therapeutic genes to retinal cells to treat retinal disease is a formidable challenge. In this study, we developed a core-shell nanoplatform composed of a core and two external layers for targeted delivery of the gene to the retina. The inner core was composed of amino acid-functionalized dendrimers and a nuclear localization signal (NLS) for DNA complexation, nuclear transport and efficient transfection. The inner core was coated in a lipid bilayer that comprised pH-sensitive lipids as the inner shell layer. Hyaluronic acid (HA)-1,2-dioleoylphosphatidylethanolamine (DOPE) as the outermost shell layer was used for retinal cell targeting. This core-shell nanoplatform was developed so that the mobility in the vitreous body of these negatively charged carriers would not be affected by their surface charge, allowing diffusion into the retina, uptake into the retinal cells via CD44-mediated internalization, and finally transport into the nucleus by the NLS. The designed nanoparticles showed safety both in vitro and in vivo and inhibited the expression of VEGF under hypoxia-mimicking conditions. In vitro angiogenesis assays exhibited significant inhibitory effects on cell migration and tube formation. The in vivo assays indicated that this nanoplatform could be delivered to the retina. Taken together, this nanoplatform has the potential to transfer gene material into the retina for the treatment of retinal diseases, including AMD.
   Statement of significance
   It remains a challenge to develop an efficient nonviral vector for gene therapy, especially retinal gene therapy. Various barriers exist in gene delivery and the unique ocular environment, making gene delivery to the retina difficult. In this study, we designed a negatively charged core-shell nanoplatform (HD-NPPND) for the targeted delivery of gene to the retina. The developed nanoplatform possessed excellent transfection efficiency and safety both in vitro and in vivo. It efficiently delivered a gene to the retina. The results of this study suggested that this core-shell nanoplatform has the potential to deliver genes to the retina to treat retinal diseases, including age-related macular degeneration (AMD). (c) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Tan, Guoxin; Zhu, Renfang; Li, Jiayang; Pan, Weisan] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 103 Wenhua Rd, Shenyang 110016, Peoples R China.
   [Liu, Dandan] Liaoning Inst Sci & Technol, Sch Biomed & Chem Engn, Benxi 117004, Peoples R China.
   [Pan, Hao] Liaoning Univ, Coll Pharm, Shenyang 110036, Peoples R China.
C3 Shenyang Pharmaceutical University; Liaoning Institute of Science &
   Technology; Liaoning University
RP Pan, WS (通讯作者)，Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 103 Wenhua Rd, Shenyang 110016, Peoples R China.
EM pppwwwsss@163.com
CR Bai LC, 2020, ACS APPL MATER INTER, V12, P40121, DOI 10.1021/acsami.0c11971
   Bhattacharya M, 2020, J CONTROL RELEASE, V327, P584, DOI 10.1016/j.jconrel.2020.09.005
   Cai WT, 2020, BIOMATER SCI-UK, V8, P4481, DOI 10.1039/c9bm02086a
   Chen K, 2017, ACTA BIOMATER, V48, P215, DOI 10.1016/j.actbio.2016.11.004
   Cocco E, 2017, MOL CANCER THER, V16, P323, DOI 10.1158/1535-7163.MCT-16-0501
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Rosa JMR, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901182
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Gallego I, 2019, NANOMED-NANOTECHNOL, V17, P308, DOI 10.1016/j.nano.2018.12.018
   Han HJ, 2020, J MATER CHEM B, V8, P5143, DOI 10.1039/d0tb00874e
   Hatakeyama H, 2011, BIOMATERIALS, V32, P4306, DOI 10.1016/j.biomaterials.2011.02.045
   Hossen MN, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5379
   Ibuki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238940
   Jang SH, 2011, DRUG DEV IND PHARM, V37, P41, DOI 10.3109/03639045.2010.489563
   Kim K, 2019, COLLOID SURFACE B, V184, DOI 10.1016/j.colsurfb.2019.110497
   Kim WJ, 2005, J CONTROL RELEASE, V106, P224, DOI 10.1016/j.jconrel.2005.04.016
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Lai SS, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0498-7
   Li C, 2017, BIOMATER SCI-UK, V5, P77, DOI 10.1039/c6bm00449k
   Li H, 2013, BIOMATERIALS, V34, P7923, DOI 10.1016/j.biomaterials.2013.06.064
   Li TT, 2017, SCI REP-UK, V7, DOI 10.1038/srep45807
   Lindberg GCJ, 2019, ACTA BIOMATER, V85, P117, DOI 10.1016/j.actbio.2018.12.022
   Lipinski DM, 2013, PROG RETIN EYE RES, V32, P22, DOI 10.1016/j.preteyeres.2012.09.001
   Liu XL, 2010, INVEST OPHTH VIS SCI, V51, P3749, DOI 10.1167/iovs.09-4226
   Liu XX, 2015, NANOSCALE, V7, P3867, DOI 10.1039/c4nr04759a
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Martens TF, 2013, NANOMEDICINE-UK, V8, P1955, DOI 10.2217/nnm.12.202
   Mochimaru H, 2009, INVEST OPHTH VIS SCI, V50, P4410, DOI 10.1167/iovs.08-3044
   Oh EJ, 2011, BIOMATERIALS, V32, P3115, DOI 10.1016/j.biomaterials.2011.01.003
   Sanfilippo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093085
   Shinoe T, 2010, J NEUROCHEM, V115, P1633, DOI 10.1111/j.1471-4159.2010.07072.x
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Surace C, 2009, MOL PHARMACEUT, V6, P1062, DOI 10.1021/mp800215d
   Tan GX, 2021, INT J PHARMACEUT, V602, DOI 10.1016/j.ijpharm.2021.120641
   Tang MT, 2019, J CONTROL RELEASE, V305, P89, DOI 10.1016/j.jconrel.2019.05.018
   Vercauteren D, 2012, J CONTROL RELEASE, V161, P566, DOI 10.1016/j.jconrel.2012.05.020
   Wang F, 2014, BIOMATERIALS, V35, P9187, DOI 10.1016/j.biomaterials.2014.07.027
   Wang JJ, 2019, THERANOSTICS, V9, P3940, DOI 10.7150/thno.31647
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wang X, 2010, BIOMACROMOLECULES, V11, P245, DOI 10.1021/bm901091z
   Warriner LW, 2018, BIOMACROMOLECULES, V19, P4348, DOI 10.1021/acs.biomac.8b01248
   Wen YT, 2012, BIOMATERIALS, V33, P8111, DOI 10.1016/j.biomaterials.2012.07.032
   Yamada Y, 2015, BIOMATERIALS, V52, P189, DOI 10.1016/j.biomaterials.2015.02.027
   Yi WJ, 2014, ACTA BIOMATER, V10, P1412, DOI 10.1016/j.actbio.2013.12.010
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang XH, 2015, MOL THER, V23, P226, DOI 10.1038/mt.2014.199
NR 47
TC 4
Z9 4
U1 6
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT 15
PY 2021
VL 134
BP 605
EP 620
DI 10.1016/j.actbio.2021.07.053
EA OCT 2021
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA WK8IC
UT WOS:000709963900006
PM 34329781
DA 2022-11-30
ER

PT J
AU Hariprasad, SM
   Mieler, WF
   Grassi, M
   Green, JL
   Jager, RD
   Miller, L
AF Hariprasad, S. M.
   Mieler, W. F.
   Grassi, M.
   Green, J. L.
   Jager, R. D.
   Miller, L.
TI Vision-related quality of life in patients with diabetic macular oedema
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; FOCUS GROUPS; RETINOPATHY; TYPE-1;
   PHOTOCOAGULATION; DEGENERATION; PERSPECTIVES; NEI-VFQ-25; PEOPLE; CHARTS
AB Aims: The aim of this study was to determine the impact of diabetic macular oedema (DME) on the quality of life (QOL) in patients with type 2 diabetes mellitus.
   Methods: The study was a prospective, consecutive, non-comparative case series. An observational study evaluated the quality of vision and vision-specific QOL using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Mean VFQ-25 subscale scores in type 2 diabetic study patients were compared with mean VFQ-25 subscale score in groups of patients with type 1 diabetic retinopathy (T1DR) and varying degrees of age-related macular degeneration (ARMD), glaucoma and cataracts and in reference populations.
   Results: Thirty-three patients completed the NEI VFQ-25. The mean age of the study population was 64 years. When performing a comparison of those patients with DME versus those with isolated T1DR we found that for the general health subscale, the DME versus T1DR group means were 42 +/- 4.4 versus 61 +/- 1.0 respectively. The DME versus T1DR quality of vision categorical mean scores were 69 +/- 4.1 versus 93 +/- 3.9. The DME versus T1DR VR-QOL categorical mean scores were 62 +/- 5.0 versus 93 +/- 1.0. The DME group was significantly worse in each of these three categories compared with the T1DR group (p<0.01). An additional analysis was performed to examine the differences in VR-QOL in the DME group versus varying common ocular diseases, including age-related macular degeneration (ARMD), glaucoma, cataracts and disease-free reference groups. The mean values of VFQ-25 subscale in the DME group were significantly lower then the glaucoma group in ten of 12 subscales, the cataract group in 11 of 12 subscales, and the reference group in 12 of 12 subscales. However, the mean values of VFQ-25 subscale in the DME group were only significantly different from the ARMD group in three of 12 subscales.
   Conclusions: Type 2 diabetes patients with macular oedema experience a decreased VR-QOL compared with type 1 diabetic patients with diabetic retinopathy, glaucoma or cataracts. However, VR-QOL in type 2 diabetic patients with macular oedema was similar to those individuals with ARMD.
C1 [Hariprasad, S. M.; Mieler, W. F.; Grassi, M.; Green, J. L.; Jager, R. D.] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Miller, L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago
RP Hariprasad, SM (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland, Chicago, IL 60637 USA.
EM retina@uchicago.edu
CR Aiello LM, 2003, AM J OPHTHALMOL, V136, P122, DOI 10.1016/S0002-9394(03)00219-8
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   Cusick M, 2005, AM J OPHTHALMOL, V139, P1042, DOI 10.1016/j.ajo.2005.01.008
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733
   Lee JE, 2003, OPHTHALMIC EPIDEMIOL, V10, P177, DOI 10.1076/opep.10.3.177.15084
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Sharma Sanjay, 2005, Curr Opin Ophthalmol, V16, P155, DOI 10.1097/01.icu.0000161227.21797.3d
   Tranos PG, 2004, AM J OPHTHALMOL, V138, P995, DOI 10.1016/j.ajo.2004.07.049
   Tranos PG, 2004, CURR EYE RES, V29, P41, DOI 10.1080/02713680490513191
   U.M. Office, 2012, NAT MET LIBR ARCH FA
   Wu SY, 1998, DIABETES CARE, V21, P725, DOI 10.2337/diacare.21.5.725
NR 21
TC 81
Z9 83
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2008
VL 92
IS 1
BP 89
EP 92
DI 10.1136/bjo.2007.122416
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 247CM
UT WOS:000252054700021
PM 17584999
DA 2022-11-30
ER

PT J
AU Assi, L
   Chamseddine, F
   Ibrahim, P
   Sabbagh, H
   Rosman, L
   Congdon, N
   Evans, J
   Ramke, J
   Kuper, H
   Burton, MJ
   Ehrlich, JR
   Swenor, BK
AF Assi, Lama
   Chamseddine, Fatimah
   Ibrahim, Perla
   Sabbagh, Hadi
   Rosman, Lori
   Congdon, Nathan
   Evans, Jennifer
   Ramke, Jacqueline
   Kuper, Hannah
   Burton, Matthew J.
   Ehrlich, Joshua R.
   Swenor, Bonnielin K.
TI A Global Assessment of Eye Health and Quality of Life A Systematic
   Review of Systematic Reviews
SO JAMA OPHTHALMOLOGY
LA English
DT Review
AB IMPORTANCE More than 1 billion people worldwide have vision impairment or blindness from potentially preventable or correctable causes. Quality of life, an important measure of physical, emotional, and social well-being, appears to be negatively associated with vision impairment, and increasingly, ophthalmic interventions are being assessed for their association with quality of life.
   OBJECTIVE To examine the association between vision impairment or eye disease and quality of life, and the outcome of ophthalmic interventions on quality of life globally and across the life span, through an umbrella review or systematic review of systematic reviews.
   EVIDENCE REVIEW The electronic databases MEDLINE, Ovid, Embase, Cochrane Database of Systematic Reviews, Proquest Dissertations, and Theses Global were searched from inception through June 29, 2020, using a comprehensive search strategy. Systematic reviews addressing vision impairment, eye disease, or ophthalmic interventions and quantitatively or qualitatively assessing health-related, vision-related, or disease-specific quality of life were included. Article screening, quality appraisal, and data extraction were performed by 4 reviewers working independently and in duplicate. The Joanna Briggs Institute critical appraisal and data extraction forms for umbrella reviews were used.
   FINDINGS Nine systematic reviews evaluated the association between quality of life and vision impairment, age-related macular degeneration, glaucoma, diabetic retinopathy, or mendelian eye conditions (including retinitis pigmentosa). Of these, 5 were reviews of quantitative observational studies, 3 were reviews of qualitative studies, and 1 was a review of qualitative and quantitative studies. All found an association between vision impairment and lower quality of life. Sixty systematic reviews addressed at least 1 ophthalmic intervention in association with quality of life. Overall, 33 unique interventions were investigated, of which 25 were found to improve quality of life compared with baseline measurements or a group receiving no intervention. These interventions included timely cataract surgery, anti-vascular endothelial growth factor therapy for age-related macular degeneration, and macular edema.
   CONCLUSIONS AND RELEVANCE There is a consistent association between vision impairment, eye diseases, and reduced quality of life. These findings support pursuing ophthalmic interventions, such as timely cataract surgery and anti-vascular endothelial growth factor therapy, for common retinal diseases, where indicated, to improve quality of life for millions of people globally each year.
C1 [Assi, Lama; Swenor, Bonnielin K.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Wilmer 116, Baltimore, MD 21287 USA.
   [Chamseddine, Fatimah] Amer Univ Beirut, Fac Med, Clin Res Inst, Beirut, Lebanon.
   [Ibrahim, Perla; Sabbagh, Hadi] Amer Univ Beirut, Fac Med, Dept Ophthalmol, Beirut, Lebanon.
   [Rosman, Lori] Johns Hopkins Univ, Sch Med, Welch Med Lib, Baltimore, MD USA.
   [Congdon, Nathan] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Congdon, Nathan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   [Evans, Jennifer; Ramke, Jacqueline; Burton, Matthew J.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England.
   [Ramke, Jacqueline] Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.
   [Kuper, Hannah] London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London, England.
   [Burton, Matthew J.] Moorfields Eye Hosp, London, England.
   [Ehrlich, Joshua R.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Ehrlich, Joshua R.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
   [Swenor, Bonnielin K.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; American University of
   Beirut; American University of Beirut; Johns Hopkins University; Queens
   University Belfast; Sun Yat Sen University; University of London; London
   School of Hygiene & Tropical Medicine; University of Auckland;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan; Johns
   Hopkins University; Johns Hopkins Bloomberg School of Public Health
RP Swenor, BK (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St,Wilmer 116, Baltimore, MD 21287 USA.
EM bswenor@jhmi.edu
RI Swenor, Bonnie/ABH-1542-2021; Ramke, Jacqueline/I-8844-2019; Evans,
   Jennifer/F-4672-2012
OI Swenor, Bonnie/0000-0002-6044-0951; Ramke,
   Jacqueline/0000-0002-5764-1306; Burton, Matthew/0000-0003-1872-9169;
   Evans, Jennifer/0000-0002-6137-2030
FU National Institutes of Health [K01AG052640, K23EY027848]; Wellcome Trust
   [207472/Z/17/Z]; Queen Elizabeth Diamond Jubilee Trust; Moorfields Eye
   Charity [GR001061]; National Institute of Health Research Moorfields
   Biomedical Research Centre; Sightsavers; Fred Hollows Foundation; SEVA
   Foundation; British Council for the Prevention of Blindness; Christian
   Blind Mission
FX Dr Swenor is supported by a grant from the National Institutes of Health
   (K01AG052640). Dr Ehrlich is supported by a grant from the National
   Institutes of Health (K23EY027848). Dr Burton is supported by the
   Wellcome Trust (207472/Z/17/Z). The Lancet Global Health Commission on
   Global Eye Health is supported by the Queen Elizabeth Diamond Jubilee
   Trust, Moorfields Eye Charity (grant GR001061), National Institute of
   Health Research Moorfields Biomedical Research Centre, theWellcome
   Trust, Sightsavers, the Fred Hollows Foundation, the SEVA Foundation,
   the British Council for the Prevention of Blindness, and Christian Blind
   Mission.
CR [Anonymous], 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18680
   Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055
   Assi L, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037648
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brady CJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010469.pub2
   Braithwaite T, 2019, PATIENT-RELAT OUTCOM, V10, P9, DOI 10.2147/PROM.S162802
   Braithwaite T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub3
   Brito-Garcia N, 2017, EYE, V31, P273, DOI 10.1038/eye.2016.286
   Burr J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004399.pub3
   Burton M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004008.pub3
   Burton MJ, 2019, LANCET GLOB HEALTH, V7, pE1612, DOI 10.1016/S2214-109X(19)30450-4
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chi SC, 2020, BRIT J OPHTHALMOL, V104, P1500, DOI 10.1136/bjophthalmol-2019-315613
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Clarke EL, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001054.pub3
   Conner-Spady B, 2007, CAN J OPHTHALMOL, V42, P543, DOI 10.3129/canjoplithalmol.i07-094
   Cornish KS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009306.pub2
   Covidence Inc, COVID SYST REV SOFTW
   D'Amanda CS, 2020, SURV OPHTHALMOL, V65, P562, DOI 10.1016/j.survophthal.2020.02.002
   de Silva SR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003169.pub4
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Erekosima N, 2014, LARYNGOSCOPE, V124, P616, DOI 10.1002/lary.24295
   Evans JR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005023.pub3
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Ford JA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004120
   Garip G, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1169-z
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   GRADE, 2018, GRAD DEF
   Herretes S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005430.pub3
   Hodge W, 2007, CAN MED ASSOC J, V176, P1285, DOI 10.1503/cmaj.060962
   Ishikawa T, 2013, J CATARACT REFR SURG, V39, P1593, DOI 10.1016/j.jcrs.2013.08.033
   Jin SS, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1078-1
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P10, DOI 10.1111/aos.12758
   Kessel L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/912481
   Khandelwal SS, 2019, GRAEF ARCH CLIN EXP, V257, P863, DOI 10.1007/s00417-018-04218-6
   Khoo K, 2019, QUAL LIFE RES, V28, P2017, DOI 10.1007/s11136-019-02165-1
   Kim JM, 2013, PEDIATRICS, V131, P1155, DOI 10.1542/peds.2013-0343
   Lake JC, 2019, COCHRANE DB SYST REV, DOI 10.1002/14551858.CD012801.pub2
   Lawrence D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004242.pub5
   Lescrauwaet B, 2019, PATIENT-RELAT OUTCOM, V10, P101, DOI 10.2147/PROM.S153718
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Li TJ, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006460.pub3
   Lim BX., 2016, COCHRANE DB SYST REV, V11
   Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Low A, 2019, BRIT J OPHTHALMOL, V103, P442, DOI 10.1136/bjophthalmol-2018-312691
   McDonald M, 2016, OCUL SURF, V14, P144, DOI 10.1016/j.jtos.2015.11.002
   Mitry D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009510.pub2
   Neffendorf JE, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011874.pub2
   Nyman SR, 2010, BRIT J OPHTHALMOL, V94, P1427, DOI 10.1136/bjo.2009.164814
   Nyman SR, 2012, DISABIL REHABIL, V34, P971, DOI 10.3109/09638288.2011.626487
   Ollendorf DA, 2013, INT J TECHNOL ASSESS, V29, P392, DOI 10.1017/S0266462313000500
   Rajendram R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007114.pub2
   Rees G, 2010, EXPERT REV OPHTHALMO, V5, P385, DOI 10.1586/EOP.10.32
   Riaz Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001323.pub2
   Rodrigo GJ, 2011, CLIN EXP ALLERGY, V41, P160, DOI 10.1111/j.1365-2222.2010.03654.x
   Rolim DMC, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003919.pub2
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schakel W, 2019, OPHTHAL PHYSL OPT, V39, P399, DOI 10.1111/opo.12647
   Schuster AK, 2013, OPHTHALMOLOGY, V120, P2166, DOI 10.1016/j.ophtha.2013.04.011
   Siemieniuk R., WHAT IS GRADE BMJ BE
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Squires H, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21680
   Tseng YC, 2018, QUAL LIFE RES, V27, P1957, DOI 10.1007/s11136-018-1799-2
   Urruticoechea-Arana A, 2019, RHEUMATOL INT, V39, P47, DOI 10.1007/s00296-018-4193-z
   van Nispen RMA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006543.pub2
   Viani GA, 2012, ARQ BRAS OFTALMOL, V75, P324, DOI 10.1590/S0004-27492012000500006
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   VIRGILI G, 2018, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003303.PUB4
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Wang SY, 2017, EUR J OPHTHALMOL, V27, P387, DOI 10.5301/ejo.5000978
   Wang Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008019
   World Health Organization, 2019, WORLD REP VIS
   Xu ZQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186522
   Yang JJ, 2018, INT J OPHTHALMOL-CHI, V11, P484, DOI 10.18240/ijo.2018.03.20
   Zhou SW, 2014, CLIN EXP OPHTHALMOL, V42, P637, DOI 10.1111/ceo.12286
   Zhu Y, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011160.pub2
NR 82
TC 19
Z9 20
U1 3
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2021
VL 139
IS 5
BP 526
EP 541
DI 10.1001/jamaophthalmol.2021.0146
EA FEB 2021
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SF2VX
UT WOS:000617178000001
PM 33576772
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chew, EY
   SanGiovanni, JP
   Ferris, FL
   Wong, WT
   Agron, E
   Clemons, TE
   Sperduto, R
   Danis, R
   Chandra, SR
   Blodi, BA
   Domalpally, A
   Elman, MJ
   Antoszyk, AN
   Ruby, AJ
   Orth, D
   Bressler, SB
   Fish, GE
   Hubbard, GB
   Klein, ML
   Friberg, TR
   Rosenfeld, PJ
   Toth, CA
   Bernstein, P
AF Chew, Emily Y.
   SanGiovanni, John Paul
   Ferris, Frederick L.
   Wong, Wai T.
   Agron, Elvira
   Clemons, Traci E.
   Sperduto, Robert
   Danis, Ronald
   Chandra, Suresh R.
   Blodi, Barbara A.
   Domalpally, Amitha
   Elman, Michael J.
   Antoszyk, Andrew N.
   Ruby, Alan J.
   Orth, David
   Bressler, Susan B.
   Fish, Gary E.
   Hubbard, George B.
   Klein, Michael L.
   Friberg, Thomas R.
   Rosenfeld, Philip J.
   Toth, Cynthia A.
   Bernstein, Paul
TI Lutein/Zeaxanthin for the Treatment of Age-Related Cataract AREDS2
   Randomized Trial Report No. 4
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE; VISUAL IMPAIRMENT; LENS OPACITIES; EYE DISEASE;
   VITAMIN-E; CLINICAL-TRIAL; UNITED-STATES; RISK-FACTORS; ZEAXANTHIN;
   LUTEIN
AB IMPORTANCE Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020.
   OBJECTIVE To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery.
   DESIGN, SETTING, AND PATIENTS The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration.
   INTERVENTIONS Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration.
   MAIN OUTCOMES AND MEASURES Cataract surgery was documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery.
   RESULTS A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95% CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95% CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).
   CONCLUSIONS AND RELEVANCE Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.
C1 [SanGiovanni, John Paul; Ferris, Frederick L.; Wong, Wai T.; Agron, Elvira] NIH, NEI, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert] EMMES Corp, Rockville, MD USA.
   [Danis, Ronald; Chandra, Suresh R.; Blodi, Barbara A.; Domalpally, Amitha] Univ Wisconsin, Madison, WI USA.
   [Elman, Michael J.] Elman Retina Grp PA, Baltimore, MD USA.
   [Antoszyk, Andrew N.] Charlotte Eye Ear Nose & Throat Assoc, Charlotte, NC USA.
   [Ruby, Alan J.] Vision Res Fdn, Royal Oak, MI USA.
   [Orth, David] Ingalls Mem Hosp, Harvey, IL USA.
   [Bressler, Susan B.] Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Fish, Gary E.] Texas Retina Assoc, Dallas, TX USA.
   [Hubbard, George B.] Emory Univ, Ctr Eye, Atlanta, GA 30322 USA.
   [Klein, Michael L.] Devers Eye Inst, Portland, OR USA.
   [Friberg, Thomas R.] Univ Pittsburgh, Med Ctr Eye Ctr, Pittsburgh, PA USA.
   [Rosenfeld, Philip J.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Toth, Cynthia A.] Duke Univ, Durham, NC USA.
   [Bernstein, Paul] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine;
   Emory University; Devers Eye Institute; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; Bascom Palmer Eye
   Institute; Duke University; Utah System of Higher Education; University
   of Utah
RP Chew, EY (通讯作者)，NIH, NEI, Bldg 10,CRC Rm 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Toth, Cynthia/L-5534-2019; SanGiovanni, John Paul/AAU-3895-2020;
   Domalpally, Amitha/B-2367-2015; Wong, Wai/B-6118-2017
OI Toth, Cynthia/0000-0002-2324-0854; Wong, Wai/0000-0003-0681-4016; Elman,
   Michael/0000-0001-7726-9508; Domalpally, Amitha/0000-0002-8145-9619;
   Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute/National Institutes of Health; Department of
   Health and Human Services, Bethesda, MD [HHS-N-260-2005-00007-C,
   N01-EY-5-0007]; National Institutes of Health institute: Office of
   Dietary Supplements; National Institutes of Health institute: National
   Center for Complementary and Alternative Medicine; National Institutes
   of Health institute: National Institute on Aging; National Institutes of
   Health institute: National Heart, Lung and Blood Institute; National
   Institutes of Health institute: National Institute of Neurological
   Disorders and Stroke; NATIONAL EYE INSTITUTE [ZIEEY000487, ZIAEY000485,
   R01EY021532] Funding Source: NIH RePORTER
FX This study was supported by the intramural program funds and contracts
   from the National Eye Institute/National Institutes of Health, the
   Department of Health and Human Services, Bethesda, MD (contract No.
   HHS-N-260-2005-00007-C and ADB contract No. N01-EY-5-0007). Funds were
   contributed to these contracts by the following National Institutes of
   Health institutes: Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The study medications and raw
   materials were provided by Alcon, Bausch and Lomb, DSM, and Pfizer.
CR ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christen WG, 2004, OPHTHAL EPIDEMIOL, V11, P401, DOI 10.1080/09286580490515152
   Christen WG, 2003, ARCH OPHTHALMOL-CHIC, V121, P372, DOI 10.1001/archopht.121.3.372
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dorey CK, 2005, EXP EYE RES, V81, P464, DOI 10.1016/j.exer.2005.03.007
   Gritz DC, 2006, BRIT J OPHTHALMOL, V90, P847, DOI 10.1136/bjo.2005.088104
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Kuzniarz M, 2001, AM J OPHTHALMOL, V132, P19, DOI 10.1016/S0002-9394(01)00922-9
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 1998, OPHTHALMOLOGY, V105, P831, DOI 10.1016/S0161-6420(98)95021-7
   Lewis A, 2004, BRIT J OPHTHALMOL, V88, P1512, DOI 10.1136/bjo.2004.045484
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009
   Milton RC, 2006, OPHTHALMOLOGY, V113, P1264, DOI 10.1016/j.ophtha.2006.02.054
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   TAYLOR A, 1993, J AM COLL NUTR, V12, P138
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
NR 36
TC 90
Z9 92
U1 1
U2 28
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2013
VL 131
IS 7
BP 843
EP 850
DI 10.1001/jamaophthalmol.2013.4412
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206VW
UT WOS:000323553600004
PM 23645227
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Nanegrungsunk, O
   Gu, SZ
   Bressler, SB
   Du, WM
   Amer, F
   Moini, H
   Bressler, NM
AF Nanegrungsunk, Onnisa
   Gu, Sophie Z.
   Bressler, Susan B.
   DU, Weiming
   Amer, Fouad
   Moini, Hadi
   Bressler, Neil M.
TI Correlation of Change in Central Subfield Thickness and Change in Visual
   Acuity in Neovascular AMD: Post Hoc Analysis of VIEW 1 and 2
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: Determine correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor agents.
   DESIGN: A post hoc analysis of VIEW 1 and 2 randomized clinical trials.
   METHODS: This analysis included participants randomized to ranibizumab 0.5 mg every 4 weeks (Rq4), intravitreal aflibercept injection 2 mg every 4 weeks (2q4), and intravitreal aflibercept injection 2 mg every 8 weeks after 3 monthly doses (2q8) to week 52, followed by capped as-needed (at least every 12 weeks) dosing to week 96. Relationship between changes in CST and BCVA was determined using Pearson correlation coefficient.
   RESULTS: Of 1815 eyes, 595 were assigned to the Rq4, 613 to 2q4, and 607 to 2q8 arms. Correlations (95% confidence intervals [CI]) at weeks 12, 52, and 96 were -0.08 (95% CI, -0.17 to 0.00), -0.05 (95% CI, -0.14 to 0.04), and -0.15 (95% CI, -0.24 to -0.06) for Rq4; -0.13 (95% CI, -0.21 to -0.04), -0.06 (95% CI, -0.14 to 0.03) and -0.04 (95% CI, -0.13 to 0.05) for 2q4, and -0.04 (95% CI, -0.12 to 0.05), -0.01 (95% CI, -0.09 to 0.08), and -0.01 (95% CI, -0.10 to 0.09) for 2q8. Linear regression analysis adjusted for relevant baseline factors showed CST changes accounted for 11% of BCVA changes. Every 100 mu m decrease in CST was associated with a 0.3 letter decrease (P =.25) at week 52 and a 0.14 letter decrease (P =.69) at week 96.
   CONCLUSIONS: Weak or no correlation was found between changes in CST and BCVA with either agent or regimen, suggesting changes in CST should not be used as a surrogate for visual acuity out-comes in neovascular age-related macular degeneration. (c) 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
C1 [Nanegrungsunk, Onnisa; Bressler, Susan B.; Bressler, Neil M.] Johns Hopkins Univ, Dept Ophthalmol, Retina Div, Sch Med, Baltimore, MD USA.
   [Nanegrungsunk, Onnisa] Chiang Mai Univ, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Gu, Sophie Z.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [DU, Weiming; Amer, Fouad; Moini, Hadi] Regeneron Pharmaceut Inc, Tarrytown, NY USA.
   [Bressler, Neil M.] Johns Hopkins Univ Sch Med & Hosp, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
   [Nanegrungsunk, Onnisa] Univ Calif Los Angeles, Doheny Imaging Reading Ctr, David Geffen Sch Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Nanegrungsunk, Onnisa] Univ Calif Los Angeles, Doheny Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 Johns Hopkins University; Chiang Mai University; Johns Hopkins
   University; Regeneron; Johns Hopkins University; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Nanegrungsunk, O (通讯作者)，Univ Calif Los Angeles, Doheny Imaging Reading Ctr, David Geffen Sch Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Nanegrungsunk, O (通讯作者)，Univ Calif Los Angeles, Doheny Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM nmboffice@jhmi.edu
OI Gu, Zhuoying/0000-0001-6956-7134; Nanegrungsunk,
   Onnisa/0000-0001-9542-1323
FU Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA); Bayer
   HealthCare (Berlin, Germany); Regeneron Pharmaceuticals, Inc.,
   (Tarrytown, New York)
FX The VIEW 1 & 2 studies were funded by Regeneron Pharmaceuticals, Inc.
   (Tarrytown, New York, USA) and Bayer HealthCare (Berlin, Germany) . This
   project was funded by Regeneron Pharmaceuticals, Inc., (Tarrytown, New
   York) and by philanthropic grants awarded to the Johns Hopkins
   University School of Medicine (Principal investigator: Dr Neil Bressler)
   . Regeneron Pharmaceuticals, Inc employees participated in design of the
   study, data analysis, and preparation of the article.
CR Bressler NM, 2019, JAMA OPHTHALMOL, V137, P977, DOI 10.1001/jamaophthalmol.2019.1963
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2022
VL 238
BP 97
EP 102
DI 10.1016/j.ajo.2021.11.020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V0AN
UT WOS:000805763900011
PM 34848169
DA 2022-11-30
ER

PT J
AU Colijn, JM
   Liefers, B
   Joachim, N
   Verzijden, T
   Meester-Smoor, MA
   Biarnes, M
   Mones, J
   de Jong, PTVM
   Vingerling, JR
   Mitchell, P
   Sanchez, CI
   Wang, JJ
   Klaver, CCW
AF Colijn, Johanna M.
   Liefers, Bart
   Joachim, Nichole
   Verzijden, Timo
   Meester-Smoor, Magda A.
   Biarnes, Marc
   Mones, Jordi
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
   Mitchell, Paul
   Sanchez, Clara, I
   Wang, Jie J.
   Klaver, Caroline C. W.
CA EyeNED Reading Ctr EYE-RISK Consor
TI Enlargement of Geographic Atrophy From First Diagnosis to End of Life
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   NATURAL-HISTORY; VISUAL-ACUITY; PROGRESSION; SECONDARY; CLASSIFICATION;
   DISEASE; DESIGN
AB IMPORTANCE Treatments for geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), are currently under development. Understanding the natural course is needed for optimal trial design. Although enlargement rates of GA and visual acuity (VA) in the short term are known from clinical studies, knowledge of enlargement in the long term, life expectancy, and visual course is lacking.
   OBJECTIVE To determine long-term enlargement of GA.
   DESIGN, SETTING, AND PARTICIPANTS In this study, participant data were collected from 4 population-based cohort studies, with up to 25 years of follow-up and eye examinations at 5-year intervals: the Rotterdam Study cohorts 1, 2, and 3 and the Blue Mountains Eye Study. Data were collected from 1990 to 2015, and data were analyzed from January 2019 to November 2020.
   MAIN OUTCOMES AND MEASURES Area of GA was measured pixel by pixel using all available imaging. Area enlargement and enlargement of the square root-transformed area, time until GA reached the central fovea, and time until death were assessed, and best-corrected VA, smoking status, macular lesions according to the Three Continent AMD Consortium classification, a modified version of the Wisconsin age-related maculopathy grading system, and AMD genetic variants were covariates in Spearman, Pearson, or Mann-Whitney analyses.
   RESULTS Of 171 included patients, 106 (62.0%) were female, and the mean (SD) age at inclusion was 82.6 (7.1) years. A total of 147 of 242 eyes with GA (60.7%) were newly diagnosed in our study. The mean area of GA at first presentation was 3.74 mm(2) (95% CI, 3.11-4.67). Enlargement rate varied widely between persons (0.02 to 4.05 mm(2) per year), with a mean of 1.09 mm(2) per year (95% CI, 0.89-1.30). Stage of AMD in the other eye was correlated with GA enlargement (Spearman rho = 0.34; P = .01). Foveal involvement was already present in incident GA in 55 of 147 eyes (37.4%); 23 of 42 eyes (55%) developed this after a mean (range) period of 5.6 (3-12) years, and foveal involvement did not develop before death in 11 of 42 eyes (26%). After first diagnosis, 121 of 171 patients with GA (70.8%) died after a mean (SD) period of 6.4 (5.4) years. Visual function was visually impaired (less than 20/63) in 47 of 107 patients (43.9%) at last visit before death.
   CONCLUSIONS AND RELEVANCE In this study, enlargement of GA appeared to be highly variable in the general population. More than one-third of incident GA was foveal at first presentation; those with extrafoveal GA developed foveal GA after a mean of 5.6 years. Future intervention trials should focus on recruiting those patients who have a high chance of severe visual decline within their life expectancy.
C1 [Colijn, Johanna M.; Verzijden, Timo; Meester-Smoor, Magda A.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Colijn, Johanna M.; Verzijden, Timo; Meester-Smoor, Magda A.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Liefers, Bart] RadboudUMC, Dept Radiol & Nucl Med, Nijmegen, Netherlands.
   [Joachim, Nichole] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Biarnes, Marc; Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Biarnes, Marc; Mones, Jordi] Hosp Quiron Teknon, Inst Macula, Barcelona, Spain.
   [de Jong, Paulus T. V. M.] Leiden Univ, Amsterdam Univ, Netherlands Inst Neurosci, Dept Retinal Signal Proc,Med Ctr,KNAW,Dept Ophtha, Leiden, Netherlands.
   [Mitchell, Paul; Wang, Jie J.] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Sanchez, Clara, I] Univ Amsterdam, Fac Sci, Informat Inst, Amsterdam, Netherlands.
   [Sanchez, Clara, I] Univ Amsterdam, Dept Biomed Engn & Phys, Med Ctr, Amsterdam, Netherlands.
   [Wang, Jie J.] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore, Singapore.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Radboud University Nijmegen; University of Sydney; Westmead
   Institute for Medical Research; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University - Excl LUMC; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Sydney; Westmead Institute for Medical
   Research; University of Amsterdam; University of Amsterdam; National
   University of Singapore; Radboud University Nijmegen
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160
FU European Union Horizon 2020 research and innovation programme [634479];
   Erasmus Medical Center, Rotterdam; Erasmus University, Rotterdam;
   Netherlands Organization for the Health Research and Development
   (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry
   of Education, Culture and Science; Ministry for Health, Welfare and
   Sports; European Commission (DG XII); Municipality of Rotterdam;
   Oogfonds through UitZicht [2015-36]; Landelijke Stichting voor Blinden
   en Slechtzienden through UitZicht [2015-36]; Novartis Foundation through
   UitZicht [2015-36]; MaculaFonds through UitZicht [2015-36]; Automation
   in Medical Imaging (AMI) project, a collaborative project of the
   Fraunhofer-Gesellschaft; Radboud University; University Medical Center;
   Australian National Health and Medical Research Council [211069, 457349,
   512423]
FX This project has received funding from grant 634479 from the European
   Union Horizon 2020 research and innovation programme (Dr Klaver). The
   Rotterdam Study is funded by Erasmus Medical Center and Erasmus
   University, Rotterdam; Netherlands Organization for the Health Research
   and Development (ZonMw); the Research Institute for Diseases in the
   Elderly (RIDE); the Ministry of Education, Culture and Science; the
   Ministry for Health, Welfare and Sports; the European Commission (DG
   XII); and the Municipality of Rotterdam. Additionally, the ophthalmic
   research within the Rotterdam Study was supported by the following
   foundations: Oogfonds, Landelijke Stichting voor Blinden en
   Slechtzienden, Novartis Foundation, and MaculaFonds, which contributed
   through UitZicht (grants 2015-36). Other funding was obtained from the
   Automation in Medical Imaging (AMI) project, a collaborative project of
   the Fraunhofer-Gesellschaft and the Radboud University and University
   Medical Center. The study was also supported by grants 211069 and 457349
   (Dr Mitchell) and grant 512423 (DrWang) from the Australian National
   Health and Medical Research Council.
CR Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Holmen IC, 2019, OPHTHALMOL RETINA, V3, P724, DOI 10.1016/j.oret.2019.04.011
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
NR 34
TC 4
Z9 4
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2021
VL 139
IS 7
BP 743
EP 750
DI 10.1001/jamaophthalmol.2021.1407
EA MAY 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TN1OE
UT WOS:000652635200006
PM 34014262
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Xia, HM
   Krebs, MP
   Kaushal, S
   Scott, EW
AF Xia, Huiming
   Krebs, Mark P.
   Kaushal, Shalesh
   Scott, Edward W.
TI Enhanced retinal pigment epithelium regeneration after injury in MRL/MpJ
   mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE healer mice; regenerative medicine; sodium iodate; macular degeneration;
   MRL/MpJ; regeneration; retinal pigment epithelium
ID SODIUM IODATE; MRL MICE; GENE-EXPRESSION; MOUSE HEART; STEM-CELLS;
   MECHANISMS; DIFFERENTIATION; DEGENERATION; APOPTOSIS; DEFECTS
AB Regenerative medicine holds the promise of restoring cells and tissues that are destroyed in human disease, including degenerative eye disorders. However, development of this approach in the eye has been limited by a lack of animal models that show robust regeneration of ocular tissue. Here, we test whether MRL/MpJ mice, which exhibit enhanced wound healing, can efficiently regenerate the retinal pigment epithelium (RPE) after an injury that mimics the loss of this tissue in age-related macular degeneration. The RPE of MRL/MpJ and control AKR/J mice was injured by retro-orbital injection of sodium iodate at 20 mg/kg body weight, which titration studies indicated was optimal for highlighting strain differences in the response to injury. Five days after sodium iodate injection at this dose, electroretinography of both strains revealed equivalent retinal responses that were significantly reduced compared to untreated mice. At one and two months post-injection, retinal responses were restored in MRL/MpJ but not AKR/J mice. Bright field and fluorescence microscopy of eyecup cryosections indicated an initial central loss of RPE cells and RPE65 immunostaining in MRL/MpJ and AKR/J mice, with preservation of peripheral RPE. Phalloidin staining of posterior eye whole mounts confirmed this pattern of RPE loss, and revealed a transition region characterized by RPE cell shedding and restructuring in both strains, suggesting a similar initial response to injury. At one month post-injection, central RPE cells, RPE65 immunostaining and phalloidin staining were restored in MRL/MpJ but not AKR/J mice. BrdU incorporation was observed throughout the RPE of MRL/MpJ but not AKR/J mice after one month of administration following sodium iodate treatment, consistent with RPE proliferation. These findings provide evidence for a dramatic regeneration of the RPE after injury in MRL/MpJ mice that supports full recovery of retinal function, which has not been observed previously in mammalian eyes. This model should prove useful for understanding molecular mechanisms that underlie regeneration, and for identifying factors that promote RPE regeneration in age-related macular degeneration and related diseases. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Xia, Huiming; Krebs, Mark P.; Kaushal, Shalesh; Scott, Edward W.] Univ Florida, Dept Mol Genet & Microbiol, Program Stem Cell Biol & Regenerat Med, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida
RP Scott, EW (通讯作者)，Univ Florida, Dept Mol Genet & Microbiol, Program Stem Cell Biol & Regenerat Med, 1600 SW Archer Rd, Gainesville, FL 32610 USA.
EM escott@ufl.edu
RI Xia, Huiming/F-2713-2012
OI Krebs, Mark/0000-0001-9017-6066
FU National Institutes of Health [EY018158]; NATIONAL EYE INSTITUTE
   [P30EY021721, R01EY018158] Funding Source: NIH RePORTER
FX Grant support: This study is supported by National Institutes of Health
   grant EY018158 awarded to EWS.
CR Abdullah I, 2005, WOUND REPAIR REGEN, V13, P205, DOI 10.1111/j.1067-1927.2005.130212.x
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Anam K, 2009, LUPUS, V18, P318, DOI 10.1177/0961203308097479
   Bedelbaeva K, 2010, P NATL ACAD SCI USA, V107, P5845, DOI 10.1073/pnas.1000830107
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Caldwell RL, 2008, WOUND REPAIR REGEN, V16, P442, DOI 10.1111/j.1524-475X.2007.00351.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chadwick RB, 2007, WOUND REPAIR REGEN, V15, P275, DOI 10.1111/j.1524-475X.2007.00216.x
   Cimini M, 2008, CARDIOVASC PATHOL, V17, P32, DOI 10.1016/j.carpath.2007.06.006
   Clark LD, 1998, CLIN IMMUNOL IMMUNOP, V88, P35, DOI 10.1006/clin.1998.4519
   Costa RA, 2009, BRAZ J MED BIOL RES, V42, P1143, DOI 10.1590/S0100-879X2009005000042
   Davis TA, 2007, WOUND REPAIR REGEN, V15, P577, DOI 10.1111/j.1524-475X.2007.00266.x
   Eming SA, 2009, SEMIN CELL DEV BIOL, V20, P517, DOI 10.1016/j.semcdb.2009.04.009
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fitzgerald J, 2008, OSTEOARTHR CARTILAGE, V16, P1319, DOI 10.1016/j.joca.2008.03.014
   Florian P, 2002, J PHYSIOL-LONDON, V545, P485, DOI 10.1113/jphysiol.2002.031161
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Garcia-Fernandez B, 2009, INT J DEV BIOL, V53, P1549, DOI 10.1387/ijdb.072308bg
   Gourevitch DL, 2009, WOUND REPAIR REGEN, V17, P447, DOI 10.1111/j.1524-475X.2009.00492.x
   Grisel P, 2008, CARDIOVASC PATHOL, V17, P14, DOI 10.1016/j.carpath.2007.01.007
   Gurley KA, 2008, STEM CELLS ANIMAL MO
   Gurtner GC, 2007, ANNU REV MED, V58, P299, DOI 10.1146/annurev.med.58.082405.095329
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   Harris JR, 2009, STEM CELLS, V27, P457, DOI 10.1634/stemcells.2008-0836
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Heber-Katz E, 2009, ANN NY ACAD SCI, V1172, P110, DOI 10.1111/j.1749-6632.2009.04499.x
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kawakami A, 2010, DEV GROWTH DIFFER, V52, P77, DOI 10.1111/j.1440-169X.2009.01138.x
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   KORTE GE, 1995, EXP EYE RES, V61, P189, DOI 10.1016/S0014-4835(05)80039-9
   KORTE GE, 1994, INT REV CYTOL, V152, P223, DOI 10.1016/S0074-7696(08)62558-9
   Lee E., 2010, BRIT J OPHTHALMOLOGY
   Leferovich JM, 2001, P NATL ACAD SCI USA, V98, P9830, DOI 10.1073/pnas.181329398
   Li QH, 2001, INVEST OPHTH VIS SCI, V42, P2981
   Li XM, 2001, MAMM GENOME, V12, P52, DOI 10.1007/s003350010230
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   Nagai H, 1996, EXP EYE RES, V62, P55, DOI 10.1006/exer.1996.0007
   Naseem RH, 2007, PHYSIOL GENOMICS, V30, P44, DOI 10.1152/physiolgenomics.00070.2006
   Naviaux RK, 2009, MOL GENET METAB, V96, P133, DOI 10.1016/j.ymgme.2008.11.164
   Oh YS, 2004, CARDIOVASC PATHOL, V13, P203, DOI 10.1016/j.carpath.2004.03.610
   Redfern WS, 2011, J PHARMACOL TOXICOL, V63, P102, DOI 10.1016/j.vascn.2010.06.008
   Reines B, 2009, REJUV RES, V12, P45, DOI 10.1089/rej.2008.0792
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Robey TE, 2008, CARDIOVASC PATHOL, V17, P6, DOI 10.1016/j.carpath.2007.01.005
   Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5
   Seagle BLL, 2006, P NATL ACAD SCI USA, V103, P16644, DOI 10.1073/pnas.0605986103
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thevenaz P, 2007, MICROSC RES TECHNIQ, V70, P135, DOI 10.1002/jemt.20393
   Tolba RH, 2010, WOUND REPAIR REGEN, V18, P662, DOI 10.1111/j.1524-475X.2010.00631.x
   Tucker B, 2008, INVEST OPHTH VIS SCI, V49, P1686, DOI 10.1167/iovs.07-1058
   Ueno M, 2005, INVEST OPHTH VIS SCI, V46, P4097, DOI 10.1167/iovs.05-0548
   Uygun Basak E., 2009, Critical Reviews in Biomedical Engineering, V37, P355
   von Leithner PL, 2010, MOL VIS, V16, P570
   Vossmerbaeumer U, 2008, CLIN EXP OPHTHALMOL, V36, P358, DOI 10.1111/j.1442-9071.2008.01770.x
   Xu Y, 2008, NATURE, V453, P338, DOI 10.1038/nature07042
   Zins SR, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-25
NR 60
TC 29
Z9 31
U1 0
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2011
VL 93
IS 6
BP 862
EP 872
DI 10.1016/j.exer.2011.09.020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 859UZ
UT WOS:000297902600010
PM 21989111
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Luu, KT
   Seal, JR
   Attar, M
AF Luu, Kenneth T.
   Seal, Jennifer R.
   Attar, Mayssa
TI A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of
   Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ANKYRIN REPEAT PROTEIN; MACULAR DEGENERATION;
   OCULAR ANGIOGENESIS; PIGMENT EPITHELIUM; VEGF TRAP; RANIBIZUMAB;
   AFLIBERCEPT; BLINDNESS; BINDING
AB Abicipar pegol (abicipar) is a novel DARPin therapeutic and highly potent vascular endothelial growth factor (VEGF) inhibitor intended for the treatment of neovascular age-related macular degeneration (nAMD). Here we develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for abicipar to guide dosing regimens in the clinic. The model incorporated abiciparVEGF binding kinetics, VEGF expression levels, and VEGF turnover rates to describe the ocular and systemic PK data collected from the vitreous, aqueous humor (AH), choroid, retina, and serum of rabbits after a 1-mg abicipar intravitreal (IVT) dose. The model was translated to humans using human-specific mechanistic parameters and refitted to human serum and AH concentrations from patients with diabetic macular edema and nAMD. The model was then used to simulate 8-, 12- (quarterly), and 16-week dosing intervals in the clinic. Simulations of 2 mg abicipar IVT at 8-week or quarterly dosing in humans indicates minimum steady-state vitreal concentrations are maintained above both in vitro IC50 and in vivo human IC50 values. The model predicted virtually complete VEGF inhibition for the 8-week and quarterly dosing schedule during the 52-week treatment period. In the 16-week schedule, clinically significant VEGF inhibition was maintained during the 52-week period. The model quantitatively described abicipar-VEGF target engagement leading to rapid reduction of VEGF and a long duration of VEGF inhibition demonstrating the clinical feasibility of up to a 16-week dosing interval. Abicipar is predicted to reduce IVT dosing compared with other anti-VEGF therapies with the potential to lessen patient treatment burden.
   SIGNIFICANCE STATEMENT
   Current anti-VEGF treatments for neovascular age-related macular degeneration require frequent (monthly) intravitreal injections and monitoring, which increases patient burden. We developed a mechanistic pharmakinetic/pharmadynamic model to describe the interaction between abicipar (a novel VEGF inhibitor) and VEGF to evaluate the duration of action. The model demonstrates extended abicipar-VEGF target engagement leading to clinical feasibility of up to a 16-week dosing interval. Our model predicted that abicipar 8-week and quarterly dosing schedules maintain virtually complete VEGF inhibition during the 52-week period.
C1 [Luu, Kenneth T.; Seal, Jennifer R.; Attar, Mayssa] Allergan Plc, RD2-2B,2525 Dupont Dr, Irvine, CA 92612 USA.
C3 AbbVie; Allergan
RP Luu, KT (通讯作者)，Allergan Plc, RD2-2B,2525 Dupont Dr, Irvine, CA 92612 USA.
EM Ken.Luu@allergan.com
FU Allergan plc, Dublin, Ireland
FX This study was sponsored by Allergan plc, Dublin, Ireland. K.T.L., PhD,
   J.R.S., PhD, and M.A., PhD are full-time employees and stockholders of
   Allergan plc.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, AGE RELATED MACULAR
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Burgos R, 1997, DIABETOLOGIA, V40, P1107, DOI 10.1007/s001250050794
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chen YQ, 2012, J OCUL PHARMACOL TH, V28, P110, DOI 10.1089/jop.2011.0099
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Girach APS, 2014, EXPERT REV OPHTHALMO, V7, P311
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Luu KT, 2012, J PHARMACOL EXP THER, V341, P702, DOI 10.1124/jpet.112.191999
   Mager DE, 2003, J PHARMACOL EXP THER, V306, P262, DOI 10.1124/jpet.103.049502
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smithwick Elizabeth, 2017, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V16, P33, DOI 10.2174/1871523016666170502115816
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Struble C, 2014, COMPARISON OCULAR TI
   To Chi-ho, 2002, Clin Exp Optom, V85, P335
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   WU C-D, 1970, Ophthalmic Research, V1, P124
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zernii EY, 2016, CNS NEUROL DISORD-DR, V15, P267, DOI 10.2174/1871527315666151110124957
NR 43
TC 8
Z9 7
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAY 1
PY 2020
VL 373
IS 2
BP 184
EP 192
DI 10.1124/jpet.119.263178
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MN9JE
UT WOS:000551155200003
PM 32098861
OA hybrid
DA 2022-11-30
ER

PT J
AU Smith, RT
   Nagasaki, T
   Sparrow, JR
   Barbazetto, I
   Klaver, CCW
   Chan, JK
AF Smith, R. Theodore
   Nagasaki, Takayuki
   Sparrow, Janet R.
   Barbazetto, Irene
   Klaver, Caroline C. W.
   Chan, Jackie K.
TI A Method of Drusen Measurement Based on the Geometry of Fundus
   Reflectance
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
AB Background: The hallmarks of age-related macular degeneration, the leading cause of blindness in the developed world, are the subretinal deposits known as drusen. Drusen identification and measurement play a key role in clinical studies of this disease. Current manual methods of drusen measurement are laborious and subjective. Our purpose was to expedite clinical research with an accurate, reliable digital method.
   Methods: An interactive semi-automated procedure was developed to level the macular background reflectance for the purpose of morphometric analysis of drusen. 12 color fundus photographs of patients with age-related macular degeneration and drusen were analyzed. After digitizing the photographs, the underlying background pattern in the green channel was leveled by an algorithm based on the elliptically concentric geometry of the reflectance in the normal macula: the gray scale values of all structures within defined elliptical boundaries were raised sequentially until a uniform background was obtained. Segmentation of drusen and area measurements in the central and middle subfields (1000 mu m and 3000 mu m diameters) were performed by uniform thresholds. Two observers using this interactive semi-automated software measured each image digitally. The mean digital measurements were compared to independent stereo fundus gradings by two expert graders (stereo Grader 1 estimated the drusen percentage in each of the 24 regions as falling into one of four standard broad ranges; stereo Grader 2 estimated drusen percentages in 1% to 5% intervals).
   Results: The mean digital area measurements had a median standard deviation of 1.9%. The mean digital area measurements agreed with stereo Grader 1 in 22/24 cases. The 95% limits of agreement between the mean digital area measurements and the more precise stereo gradings of Grader 2 were -6.4 % to +6.8 % in the central subfield and -6.0 % to +4.5 % in the middle subfield. The mean absolute differences between the digital and stereo gradings 2 were 2.8 +/- 3.4% in the central subfield and 2.2 +/- 2.7% in the middle subfield.
   Conclusions: Semi-automated, supervised drusen measurements may be done reproducibly and accurately with adaptations of commercial software. This technique for macular image analysis has potential for use in clinical research.
C1 [Smith, R. Theodore; Nagasaki, Takayuki; Sparrow, Janet R.; Barbazetto, Irene; Chan, Jackie K.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Klaver, Caroline C. W.] IGT Afdeling Oogheelkunde, NL-3015 GD Rotterdam, Netherlands.
C3 Columbia University
RP Smith, RT (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
EM rts1@columbia.edu; tn4@columbia.edu; jrs88@columbia.edu;
   ib206@columbia.edu; carolineklaver@yahoo.com; jc804@columbia.edu
OI smith, theodore/0000-0002-1693-943X; Klaver,
   Caroline/0000-0002-2355-5258
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   [Anonymous], 1998, Ophthalmology, V105, P11
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BRESSLER SB, 1988, RETINA-J RET VIT DIS, V8, P102, DOI 10.1097/00006982-198808020-00004
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   GOLDBAUM MH, 1990, INVEST OPHTH VIS SCI, V31, P617
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KNIGHTON RW, 1989, INVEST OPHTH VIS SCI, V30, P2393
   LEISTRITZ L, 1994, P SOC PHOTO-OPT INS, V2298, P690, DOI 10.1117/12.186598
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   OGDEN TE, 1983, VISION RES, V23, P581, DOI 10.1016/0042-6989(83)90063-9
   OGDEN TE, 1984, INVEST OPHTH VIS SCI, V25, P19
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   RADIUS RL, 1980, ARCH OPHTHALMOL-CHIC, V98, P1625
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Russ JC, 2002, IMAGE PROCESSING HDB, P131
   Schweitzer D, 1998, LASERS LIGHT, V8, P143
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith RT, 2001, INVEST OPHTHALMOLO S, V42, P153
   Smith RT, 2002, INVEST OPHTHALMOL VI, V43
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 37
TC 19
Z9 19
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PY 2003
VL 2
AR 10
DI 10.1186/1475-925X-2-10
PG 13
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA VI5XS
UT WOS:000497962600010
PM 12740042
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bylsma, GW
   Le, A
   Mukesh, BN
   Taylor, HR
   McCarty, CA
AF Bylsma, GW
   Le, A
   Mukesh, BN
   Taylor, HR
   McCarty, CA
TI Utilization of eye care services by Victorians likely to benefit from
   eye care
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE diagnosis; epidemiology; eye disease; population; prevalence
AB Aim: To assess the utilization of eye care services by Australians most likely to benefit from eye assessment.
   Methods: The Melbourne Visual Impairment Project was a population-based study that collected demographic, health and vision-related information including use of eye care services. A standardized detailed ophthalmic examination was performed. Utilization of eye care services by those who might most benefit from eye care was assessed and compared to the general population. These participants include those with undiagnosed glaucoma, unoperated visually significant cataract, undercorrected refractive error, diabetes mellitus, age-related macular degeneration and visual acuity < 6/12. Sociodemographic characteristics were assessed for their influence on eye care utilization among these participants.
   Results: A total of 4744 urban and rural residents participated (86% of those eligible) and 4612 (83% of total eligible) of these had a complete data set for the use of eye care services and were included. There were 933 participants (20.2%) who did not report eye assessment in the previous 5 years, and 891 participants (19.3%) had one or more aforementioned conditions potentially benefiting from eye care. Of these, between 34.4% and 59.4% reported no examination in the previous year and between 9% and 25% reported no examination within the previous 5 years. These participants were more likely to seek eye care within the short term (1 year) if they had a family history of eye disease, otherwise a noticed change in vision was the main influence in the longer term (2-5 years). Male participants, younger participants and those whose main spoken language was not English were less likely to seek eye care in the longer term.
   Conclusions: In Victoria 19% of those >40 years of age have potentially unmanaged eye disease including glaucoma, unoperated visually significant cataract, undercorrected refractive error, age-related macular degeneration, diabetes mellitus or visual acuity < 6/12. A substantial proportion of these report no eye assessment in the previous 1, 2 or 5 years or ever before. Younger age, male sex and main language other than English make assessment less likely. Many may have these conditions despite having had a recent eye assessment.
C1 Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA.
   Univ Melbourne, Ctr Eye Res Australia, Parkville, Vic 3052, Australia.
C3 Marshfield Clinic; Centre for Eye Research Australia; University of
   Melbourne
RP Bylsma, GW (通讯作者)，35 Broomfield Ave, Alphington, Vic 3078, Australia.
EM guyandbron@optusnet.com.au
OI Taylor, Hugh/0000-0002-9437-784X; McCarty, Catherine/0000-0003-1089-0142
CR *AM AC OPHTH, 2000, COMPR AD MED EY EV P
   Evans C, 1999, PHARMACOECONOMICS, V15, P241, DOI 10.2165/00019053-199915030-00004
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P24, DOI 10.1136/bjo.86.1.24
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   McCarty CA, 2000, CLIN EXP OPHTHALMOL, V28, P77, DOI 10.1046/j.1442-9071.2000.00276.x
   McKay R, 2000, AUST NZ J PUBL HEAL, V24, P565, DOI 10.1111/j.1467-842X.2000.tb00518.x
   *NAT HLTH MED RES, 1997, MAN DIAB RET CLIN PR
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   *VISION 2020, 2002, RIGHT SIGHT AUSTR PR
   Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3
   WONG E, 2002, MELB OPHTH AL ANN SC
NR 11
TC 29
Z9 29
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2004
VL 32
IS 6
BP 573
EP 577
DI 10.1111/j.1442-9071.2004.00905.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 876HP
UT WOS:000225487700005
PM 15575826
DA 2022-11-30
ER

PT J
AU Singh, KK
   Dawson, WW
   Krawczak, M
   Schmidtke, J
AF Singh, Krishna K.
   Dawson, William W.
   Krawczak, Michael
   Schmidtke, Joerg
TI IMPG1 gene variation in rhesus macular drusen
SO VETERINARY OPHTHALMOLOGY
LA English
DT Article
DE drusen; IMPG1; Macaca mulatta; risk haplotype
ID MACAQUES; PRIMATE; MONKEYS; LOCUS; MODEL
AB Drusen is a hallmark of human age-related maculopathy. Rhesus macaques (Macaca mulatta) represent a natural model of age-related maculopathy with drusen. We have already mapped the macular drusen susceptibility locus in rhesus macaques to the homolog of human chromosome 6q14-15 and shown that a particular IMPG1 gene SNP haplotype was apparently associated with drusen formation in the rhesus macaques maintained by the Caribbean Primate Research Center (CPRC), Puerto Rico, USA. The aim of the present study was to verify this finding in the macaques kept at the German Primate Research Center (DPZ), Germany. The study group comprised 64 animals (34 affected, 30 unaffected). These monkeys were genotyped for all known variations in the IMPG1 gene and haplotype analysis was performed. A total absence of the previously identified risk haplotype of the IMPG1 gene, and a much lower drusen prevalence in comparison to the CPRC group, was observed in the DPZ samples. This prompted a re-analysis of the original disease association in the CPRC, which revealed that the implied risk haplotype was in fact a sequencing artifact. Taken together, the data highlight that additional factors, other than IMPG1 variation, must play a role in drusen pathogenesis in rhesus macaques.
C1 Inst Human Genet & Anthropol, Hannover, Germany.
   Univ Florida, FH Miller Hlth Sci Ctr, Gainesville, FL USA.
   Univ Kiel, Inst Med Informat & Stat, Kiel, Germany.
C3 State University System of Florida; University of Florida; University of
   Kiel
RP Schmidtke, J (通讯作者)，Inst Human Genet & Anthropol, Hannover, Germany.
EM schmidtke.joerg@mh-hannover.de
RI Krawczak, Michael/A-8964-2010
OI Krawczak, Michael/0000-0003-2603-1502
CR ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   KRAWCZAK M, 1988, HUM GENET, V80, P78, DOI 10.1007/BF00451461
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Rawlins RG., 1986, CAYO SANTIAGO MACAQU
   Singh KK, 2005, EXP EYE RES, V81, P401, DOI 10.1016/j.exer.2005.02.011
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
NR 9
TC 4
Z9 4
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1463-5216
J9 VET OPHTHALMOL
JI Vet. Ophthalmol.
PD SEP-OCT
PY 2007
VL 10
IS 5
BP 274
EP 277
DI 10.1111/j.1463-5224.2007.00549.x
PG 4
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 209YT
UT WOS:000249424600002
PM 17760704
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Niemeyer, M
   Geitzenauer, W
   Michels, S
AF Schmidt-Erfurth, U
   Niemeyer, M
   Geitzenauer, W
   Michels, S
TI Time course and morphology of vascular effects associated with
   photodynamic therapy
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; TRIAMCINOLONE ACETONIDE; HUMAN EYES; VERTEPORFIN;
   ANGIOGRAPHY; TOPOGRAPHY; DISEASE
AB Purpose: To evaluate the time course and morphologic features of verteporfin therapy-induced vascular effects using 3-dimensional topographic angiography (TAG) in patients with choroidal neovascularization (CNV).
   Design: Prospective observational case series.
   Participants: Fifty-three eyes of 53 patients with neovascular age-related macular degeneration and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy/Verteporfin in Photodynamic Therapy characteristics were treated with verteporfin therapy using standard parameters.
   Methods: Treatment effects were evaluated before and at 5 hours, 1 day, 1 week, and 3 months after treatment by serial confocal fluorescein angiography (FA) and indocyanine green angiography (ICGA). The axial distribution of fluorescence at each x-position and y-position within a tomographic scan of 32 images over a depth of 4 mm was analyzed, and a 3-dimensional profile was generated. Changes at the level of the CNV lesion and the collateral choroid were documented over time with respect to vascular closure, leakage resulting from vascular barrier breakdown, and alteration of physiologic perfusion.
   Main Outcome Measures: Three-dimensional imaging of exudation and nonperfusion.
   Results: At baseline, 3-dimensional FA and ICGA imaging demonstrated a well-defined prominent CNV complex. At 5 hours after verteporfin therapy, 3-dimensional FA identified an extensive increase in hyperfluorescent prominence as well as lesion extension in most verteporfin-treated eyes (65%), resulting from increased permeability and leakage due to a vascular barrier breakdown in the collateral choroid. Massive exudation throughout the entire light-exposed area was still noted in most eyes 1 day after treatment. At 1 week, the exudative response, seen in 3-dimensional imaging, had diminished substantially. Simultaneously, documented best by 3-dimensional ICGA, TAG demonstrated perfusion defects within the adjacent choroid, which started as early as 1 day after verteporfin therapy and persisted during extended follow-up. Three-dimensional angiography identified the morphologic features of hyperfluorescence and hypofluorescence more realistically than conventional angiography.
   Conclusions: Three-dimensional angiography demonstrates a characteristic sequence of changes in the vascular architecture of the CNV lesion and the collateral choroid after verteporfin therapy. Choroidal neovascularization occlusion is associated with immediate massive exudation and is followed by occlusive effects within the collateral choroid. Knowledge of the time course and mechanisms of phototoxic events should help to develop appropriate combination treatment strategies.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   Univ Schleswig Holstein, Dept Ophthalmol, Lubeck, Germany.
C3 Medical University of Vienna; University of Kiel; Schleswig Holstein
   University Hospital
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   AUGUSTIN A, IN PRESS AM J OPHTHA
   Birngruber R, 2000, GRAEF ARCH CLIN EXP, V238, P559, DOI 10.1007/s004179900059
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008-5472.CAN-03-3513
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   MALECAZE F, 1996, ARCH OPHTHALMOL-CHIC, V12, P1476
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   SAITO T, 1996, J JPN OPHTHALMOL SOC, V100, P617
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, OPHTHALMOLOGE, V96, P797, DOI 10.1007/s003470050499
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2001, INVEST OPHTH VIS SCI, V42, P2386
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Teschner S, 2003, OPHTHALMOLOGY, V110, P687, DOI 10.1016/S0161-6420(02)01972-3
NR 24
TC 68
Z9 74
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2005
VL 112
IS 12
BP 2061
EP 2069
DI 10.1016/j.ophtha.2005.09.007
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991MS
UT WOS:000233818700002
PM 16325705
DA 2022-11-30
ER

PT J
AU Yang, JM
   Chung, S
   Yun, K
   Kim, B
   So, S
   Kang, S
   Kang, E
   Lee, JY
AF Yang, Jee Myung
   Chung, Sunho
   Yun, KyungA
   Kim, Bora
   So, Seongjun
   Kang, Seoon
   Kang, Eunju
   Lee, Joo Yong
TI Long-term effects of human induced pluripotent stem cell-derived retinal
   cell transplantation in Pde6b knockout rats
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID SUBRETINAL IMPLANTATION; INTEGRATION; BARRIER; AGE; DEGENERATION;
   CAPACITY; SAFETY
AB Retinal degenerative disorders, including age-related macular degeneration and retinitis pigmentosa (RP), are characterized by the irreversible loss of photoreceptor cells and retinal pigment epithelial (RPE) cells; however, the long-term effect of implanting both human induced pluripotent stem cell (hiPSC)-derived RPE and photoreceptor for retinal regeneration has not yet been investigated. In this study, we evaluated the long-term effects of hiPSC-derived RPE and photoreceptor cell transplantation in Pde6b knockout rats to study RP; cells were injected into the subretinal space of the right eyes of rats before the appearance of signs of retinal degeneration at 2-3 weeks of age. Ten months after transplantation, we evaluated the cells using fundus photography, optical coherence tomography, and histological evaluation, and no abnormal cell proliferation was observed. A relatively large number of transplanted cells persisted during the first 4 months; subsequently, the number of these cells decreased gradually. Notably, immunohistochemical analysis revealed that the hiPSC-derived retinal cells showed characteristics of both RPE cells and photoreceptors of human origin after transplantation. Functional analysis of vision by scotopic electroretinogram revealed significant preservation of vision after transplantation. Our study suggests that the transplantation of hiPSC-derived retinal cells, including RPE cells and photoreceptors, has a potential therapeutic effect against irreversible retinal degenerative diseases.
   Retinal disease: Cell transplants offer hope Cells with the potential to regenerate retinal cells could become a useful treatment for serious eye diseases such as age-related macular degeneration and retinitis pigmentosa. The retina has only limited self-regenerating potential. Joo Yong Lee and colleagues at the University of Ulsan in Seoul, South Korea, studied the long-term effects of implanting cells derived from human stem cells into the eyes of rats that had been genetically modified to act as a model of retinal degenerative disease. The implanted cells have the features of the photoreceptor cells that detect light and those cells that generate a layer of the retina called the retinal pigment epithelium. A substantial population of the cells persisted for at least four months, significantly preserving the animals' vision. The results justify further exploration of the therapeutic possibilities.
C1 [Yang, Jee Myung; Chung, Sunho; Yun, KyungA; Kim, Bora; Lee, Joo Yong] Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [So, Seongjun; Kang, Seoon; Kang, Eunju] Univ Ulsan, Stem Cell Ctr, Asan Med Ctr, Asan Inst Life Sci,Coll Med, Seoul, South Korea.
   [Kang, Eunju] Univ Ulsan, Asan Med Ctr, Asan Inst Life Sci, Dept Convergence Med,Coll Med, Seoul, South Korea.
C3 University of Ulsan; University of Ulsan; Asan Medical Center;
   University of Ulsan; Asan Medical Center
RP Lee, JY (通讯作者)，Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM ophthalmo@amc.seoul.kr
OI Yang, Jee Myung/0000-0001-5729-2233
FU Asan Institute for Life Sciences [2019IP0484-1]; Asan Medical Center,
   Seoul, Republic of Korea
FX This work was supported by a grant from the Asan Institute for Life
   Sciences (2019IP0484-1), Asan Medical Center, Seoul, Republic of Korea.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Ikelle L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00743
   Jacobson SG, 2010, NEW ENGL J MED, V363, P1669, DOI 10.1056/NEJMcibr1007685
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Liu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0661-8
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   So S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233057
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   Yamanaka S, 2009, CELL, V137, P13, DOI 10.1016/j.cell.2009.03.034
   Yang JM, 2020, CIRC RES, V126, P767, DOI 10.1161/CIRCRESAHA.119.316476
   Yeo JH, 2019, INVEST OPHTH VIS SCI, V60, P1519, DOI 10.1167/iovs.18-25556
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhu J, 2017, CELL STEM CELL, V20, P374, DOI 10.1016/j.stem.2016.11.019
NR 34
TC 7
Z9 7
U1 2
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD APR
PY 2021
VL 53
IS 4
BP 631
EP 642
DI 10.1038/s12276-021-00588-w
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA RY2UO
UT WOS:000647772600013
PM 33828232
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Silva, R
   Arias, L
   Nunes, S
   Farinha, C
   Coimbra, R
   Marques, JP
   Cachulo, ML
   Figueira, J
   Barreto, P
   Madeira, MH
   Pires, I
   Sousa, JC
   Distefano, L
   Rosa, P
   Carneiro, A
   Vaz-Pereira, S
   Meireles, A
   Cabrera, F
   Bures, A
   Mendonca, L
   Fernandez-Vega-Sanz, A
   Barrao, S
   Koh, A
   Cheung, CMG
   Cunha-Vaz, JG
   Murta, J
AF Silva, Rufino
   Arias, Luis
   Nunes, Sandrina
   Farinha, Claudia
   Coimbra, Rita
   Marques, Joao P.
   Cachulo, Maria L.
   Figueira, Joao
   Barreto, Patricia
   Madeira, Maria H.
   Pires, Isabel
   Sousa, Joao C.
   Distefano, Laura
   Rosa, Paulo
   Carneiro, Angela
   Vaz-Pereira, Sara
   Meireles, Angelina
   Cabrera, Francisco
   Bures, Anniken
   Mendonca, Luis
   Fernandez-Vega-Sanz, Alvaro
   Barrao, Sandra
   Koh, Adrian
   Cheung, Chui Ming Gemmy
   Cunha-Vaz, Jose G.
   Murta, Joaquim
CA EVICRnet ATLANTIC Study Grp
TI Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for
   Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized
   Clinical Trial
SO OPHTHALMOLOGICA
LA English
DT Article
DE Aflibercept; Efficacy; Monotherapy; Photodynamic therapy; Polypoidal
   choroidal vasculopathy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB;
   COMBINATION; ASSOCIATION; DIAGNOSIS; EVEREST
AB Importance: Polypoidal choroidal vasculopathy (PCV) is far less common and studied in a Caucasian population than in an Asian population, and the optimal treatment approach remains to be confirmed. Methods: A 52-week, double-masked, sham-controlled, phase 4, investigator-initiated randomized clinical trial (RCT) in naive symptomatic Caucasian patients with PCV treated with aflibercept in a treat-and-extend regimen (T&E) (intravitreal aflibercept injection [IVAI] T&E). Patients were randomized at week 16 to receive IVAI T&E plus either sham photodynamic therapy (PDT) or standard fluence PDT with verteporfin. The main outcome measures were changes in best-corrected visual acuity (BCVA) from baseline to 52 weeks and polyp occlusion at week 52. Data are presented as median (interquartile range [IQR]) for BCVA, number of IVAI, and change in central retinal thickness (CRT). Results: Of the 50 patients included in the study, 48 patients completed the 52 weeks of follow-up. During this period, a significant median (IQR) BCVA gain of 6 [2-12] Early Treatment Diabetic Retinopathy Study letters was observed for all patients (p < 0.001), after 8 (7-9) injections, with a significant reduction of -93.0 [-154.0, -44.0] mu m in central macular thickness (p < 0.001). Using indocyanine green angiography, a complete occlusion of polypoidal lesions was documented in 72% of the cases. Still, no significant difference was detected between the sham PDT and the aflibercept PDT arms, at week 52, for BCVA change (6.5 [2-11] vs. 5 [2-13] letters (p = 0.98)), number of IVAIs (8.5 [7-9] vs. 8 [7-9] (p = 0.21)), change in CRT (-143 [-184; -47] vs. -89 [-123; -41.5] mu m [p = 0.23]), and rates of complete polyp occlusion: 77 versus 68% (p = 0.53) or presence of fluid: 68 versus 57% (p = 0.56). No serious ocular adverse events were registered in the 2 arms. Conclusions and Relevance: To our knowledge, this is the first RCT to compare aflibercept T&E monotherapy with aflibercept T&E plus verteporfin PDT in a Caucasian population with PCV. Aflibercept monotherapy in a T&E showed to be effective and safe with a significant median BCVA improvement of 6 letters and a complete occlusion of polypoidal lesions in near 3 quarters of the eyes, at 1 year. As only 22% of the eyes underwent PDT treatment, the benefit of combined treatment for PCV in Caucasian patients could not be definitively elucidated from this study. (C) 2021 The Author(s) Published by S. Karger AG, Basel
C1 [Silva, Rufino; Nunes, Sandrina; Farinha, Claudia; Coimbra, Rita; Marques, Joao P.; Cachulo, Maria L.; Figueira, Joao; Barreto, Patricia; Madeira, Maria H.; Pires, Isabel; Cunha-Vaz, Jose G.; Murta, Joaquim] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Silva, Rufino; Farinha, Claudia; Marques, Joao P.; Cachulo, Maria L.; Figueira, Joao; Pires, Isabel; Murta, Joaquim] Ctr Hosp & Univ Coimbra CHUC, Ophthalmol Dept, Coimbra, Portugal.
   [Silva, Rufino; Nunes, Sandrina; Farinha, Claudia; Marques, Joao P.; Cachulo, Maria L.; Figueira, Joao; Barreto, Patricia; Madeira, Maria H.; Cunha-Vaz, Jose G.; Murta, Joaquim] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
   [Silva, Rufino; Figueira, Joao; Cunha-Vaz, Jose G.] Espaco Med Coimbra, Coimbra, Portugal.
   [Arias, Luis] Bellvitge Univ Hosp, Barcelona, Spain.
   [Farinha, Claudia; Marques, Joao P.; Murta, Joaquim] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.
   [Barreto, Patricia] Polytech Porto, Dept Orthopt, Sch Hlth, Oporto, Portugal.
   [Sousa, Joao C.] Ctr Hosp Leiria, Leiria, Portugal.
   [Distefano, Laura] Vall dHebron Hosp, Barcelona, Spain.
   [Rosa, Paulo] Inst Retina Diabet Ocular Lisboa, Lisbon, Portugal.
   [Carneiro, Angela] Ctr Hosp Sao Joao EPE, Dept Ophthalmol, Oporto, Portugal.
   [Vaz-Pereira, Sara] Ctr Hosp Univ Lisboa Norte, EPE Hosp Santa Maria, Dept Ophthalmol, Lisbon, Portugal.
   [Vaz-Pereira, Sara] Univ Lisbon, Fac Med, Dept Ophthalmol, Lisbon, Portugal.
   [Meireles, Angelina] Hosp Santo Antonio, Ctr Hosp Porto, Oporto, Portugal.
   [Cabrera, Francisco] Hosp Insular Gran Canaria Las Palmas, Canarias, Spain.
   [Bures, Anniken] Inst Microcirugia Ocular, Barcelona, Spain.
   [Mendonca, Luis] Hosp Braga, Dept Ophthalmol, Braga, Portugal.
   [Fernandez-Vega-Sanz, Alvaro] Inst Oftalmol Fernandez Veja, Oviedo, Spain.
   [Barrao, Sandra] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Koh, Adrian] Eye & Retina Surg, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital; University of Barcelona; Universidade de Coimbra; Polytechnic
   Institute of Porto; Hospital Universitari Vall d'Hebron; Sao Joao
   Hospital; Universidade de Lisboa; Hospital Santa Maria; Universidade de
   Lisboa; Hospital de Braga; National University of Singapore; Singapore
   National Eye Center
RP Silva, R (通讯作者)，Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.; Silva, R (通讯作者)，Ctr Hosp & Univ Coimbra CHUC, Ophthalmol Dept, Coimbra, Portugal.; Silva, R (通讯作者)，Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.; Silva, R (通讯作者)，Espaco Med Coimbra, Coimbra, Portugal.
EM rutino.silva@oftalmologia.co.pt
RI ; Murta, Joaquim/V-5494-2017; Farinha, Claudia/R-1392-2017
OI Distefano, Laura N/0000-0003-2319-1324; Murta,
   Joaquim/0000-0001-8926-5176; Madeira, Maria Helena/0000-0001-6282-3553;
   Figueira, Joao P/0000-0002-3511-1515; Farinha,
   Claudia/0000-0003-4596-0913
FU Bayer
FX This investigator-initiated study was financially supported by Bayer.
   Role of the funder/sponsor: Bayer had no role in the design and conduct
   of the study, collection, management, analysis, and interpretation of
   the data.
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cunha-Vaz J., 2011, Clinical Investigation, V1, P375, DOI 10.4155/cli.11.13
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Jordan-Yu JM, 2021, BRIT J OPHTHALMOL, V105, P1716, DOI 10.1136/bjophthalmol-2020-317537
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liew G, 2021, EYE, V35, P1011, DOI 10.1038/s41433-020-0834-z
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Marques JP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015785
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   van Dijk EHC, 2021, GRAEF ARCH CLIN EXP, V259, P351, DOI 10.1007/s00417-020-04844-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 38
TC 1
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2022
VL 245
IS 1
BP 80
EP 90
DI 10.1159/000518235
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2P4NS
UT WOS:000819720600011
PM 34348351
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Gliem, M
   Hendig, D
   Finger, RP
   Holz, FG
   Charbellssa, P
AF Gliem, Martin
   Hendig, Doris
   Finger, Robert P.
   Holz, Frank G.
   Charbellssa, Peter
TI Reticular Pseudodrusen Associated With a Diseased Bruch Membrane in
   Pseudoxanthoma Elasticum
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; GEOGRAPHIC-ATROPHY; MORPHOMETRIC-ANALYSIS; PREVALENCE;
   EYES; ABCC6; PROGRESSION; PATHOLOGY
AB IMPORTANCE Reticular pseudodrusen (RPD) are frequently associated with age-related macular degeneration and considered to be an independent risk factor for disease progression, but the pathophysiologic mechanisms are only incompletely understood. Therefore, it may be helpful to identify the associations of RPD with other diseases that have defined pathophysiologic mechanisms.
   OBJECTIVE To describe the phenotype, prevalence, and topographic distribution of RPD in patients with pseudoxanthoma elasticum (PXE) and their association with a diseased Bruch membrane.
   DESIGN, SETTING, AND PARTICIPANTS In this single-center, prospective, cross-sectional case series, 57 consecutive patients with PXE from a university referral center whose diagnosis has been confirmed by genetic testing and/or skin biopsy were studied from March 1, 2013, through February 28, 2014.
   MAIN OUTCOMES AND MEASURES Phenotypic characteristics of RPDwere evaluated with multiple imaging techniques. The RPD were defined as irregular networks of round to oval lesions that appear hyporeflective on near-infrared reflectance, hypoautofluorescent on fundus autofluorescence, and as subretinal deposits on spectral-domain optical coherence tomographic images. The presence of RPD was judged based on characteristic findings in at least 2 of the 3 imaging modalities.
   RESULTS A total of 57 patients were examined, and 15 patients were excluded mainly because of large central atrophy or fibrosis. In the remaining 42 patients with PXE, RPD were detected in 22 patients (52%; 95% CI, 38%-67%). Prevalence of RPD was highest in the fifth decade at 67%(10/15; 95% CI, 42%-85%). The RPD were most frequently located within the superior quadrant and least frequently located within the central macula. The RPD were always located central to areas with peau d'orange and within an area of hypofluorescence on late-phase indocyanine green angiographic images.
   CONCLUSIONS AND RELEVANCE These data suggest that RPD have a high prevalence in eyes of patients with PXE. Although RPD in patients with PXE occur at a younger age, their distribution and phenotype appear to be similar to RPD associated with age-related macular degeneration. The association with diseased Bruch membrane in PXE suggests a pathogenetic role of Bruch membrane alterations for the development of RPD.
C1 [Gliem, Martin; Finger, Robert P.; Holz, Frank G.; Charbellssa, Peter] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Hendig, Doris] Ruhr Univ Bochum, Univ Hosp, Heart & Diabet Ctr North Rhine Westphalia, Inst Lab & Transfus Med, Bad Oeynhausen, Germany.
   [Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Bonn; Ruhr University Bochum; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Charbellssa, P (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM peter.issa@ukb.uni-bonn.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/E-8935-2018;
   Hendig, Doris/F-1112-2013
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Hendig, Doris/0000-0002-3660-6923; Finger,
   Robert P/0000-0003-4253-7597
FU ProRetina Deutschland, Aachen, Germany; BONFOR research program of the
   University of Bonn, Bonn, Germany [O-137.0018]; National Health and
   Medical Research Council Centre for Clinical Research Excellence,
   Canberra, Australia [529923]
FX This study was supported by ProRetina Deutschland, Aachen, Germany;
   grant O-137.0018 from the BONFOR research program of the University of
   Bonn, Bonn, Germany (Dr Gliem); and grant 529923 from the National
   Health and Medical Research Council Centre for Clinical Research
   Excellence, Canberra, Australia (Dr Finger). The Department of
   Ophthalmology, University of Bonn, receives imaging devices from
   Heidelberg Engineering. The Centre for Eye Research Australia receives
   operational infrastructure support from the Victorian government.
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bock J, 1938, Z AUGENHEILKD, V95, P1
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Chassaing N, 2005, J MED GENET, V42, P881, DOI 10.1136/jmg.2004.030171
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gliem M, 2014, AM J OPHTHALMOL, V158, P198, DOI 10.1016/j.ajo.2014.04.005
   Gliem Martin, 2013, Frontiers in Genetics, V4, P14, DOI 10.3389/fgene.2013.00014
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Issa PC, 2010, OPHTHALMOLOGY, V117, P1406, DOI 10.1016/j.ophtha.2009.11.008
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Le Saux Olivier, 2012, Frontiers in Genetics, V3, P289, DOI 10.3389/fgene.2012.00289
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schulz V, 2006, HUM MUTAT, V27, DOI 10.1002/humu.9444
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 47
TC 44
Z9 45
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2015
VL 133
IS 5
BP 581
EP 588
DI 10.1001/jamaophthalmol.2015.117
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK2NF
UT WOS:000356046700013
PM 25764262
DA 2022-11-30
ER

PT J
AU Al-Serafi, M
   Markowitz, SN
   Reyes, SV
AF Al-Serafi, Murad
   Markowitz, Samuel N.
   Reyes, Sophia V.
TI Scotoma displacement in the macular mapping test as a tool for
   identification of preferred retinal loci
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID LOW-VISION REHABILITATION; DEGENERATION; PERIMETRY; LOCATION
AB Objective: To clarify the efficacy of the macular mapping test (MMT) to identify eccentric fixation with preferred retinal loci (PRL).
   Design: Retrospective observational case series from archived data.
   Participants: Cases with age-related macular degeneration with low vision in both eyes and best corrected visual activity (BCVA) of 20/50 to 20/400 in the better eye.
   Methods: Identification of preferred retinal loci with the Nidek MP-1 microperimeter and correlation with scotoma displacement on perimetry records as recorded with the MMT.
   Results: We recruited data on 43 patients (12 males and 31 females), aged 57-96 years (mean 84.05 years +/- SD 8.00). Mean BCVA was 0.9 +/- 0.32 SD logMar units (20/160). PRL location matched the direction of scotoma displacement in 32 study subjects (74.41%, p < 0.002).
   Conclusions: Scotoma displacement recorded with the MMT offers reasonable indirect estimates on PRL location.
C1 [Al-Serafi, Murad; Markowitz, Samuel N.; Reyes, Sophia V.] Univ Toronto, Dept Ophthalmol & Vis Sci, Low Vis Serv, Univ Hlth Network Hosp, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
CR Aulhorn E, 1971, ZUS DTSCH OPHTH GES
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   ESTERMAN B, 1967, ARCH OPHTHALMOL-CHIC, V77, P780, DOI 10.1001/archopht.1967.00980020782012
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Haley MJ, 1987, FIELD ANAL PRIMER, P6
   Jarc-Vidmar M, 2006, EYE, V20, P688, DOI 10.1038/sj.eye.6701949
   MacKeben M, 2008, J VISUAL IMPAIR BLIN, V102, P649, DOI 10.1177/0145482X0810201009
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2011, INVEST OPHTH VIS SCI, V52, P1191, DOI 10.1167/iovs.11-7197
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   Markowitz SN, 2008, P 9 INT C LOW VIS MO
   MEHR HM, 1970, AMER J OPT ARCH AM A, V47, P605
   Otto J, 1969, Klin Monbl Augenheilkd, V154, P370
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Tratizettel-Klosinski S, 2003, VIS IMPAIRM RES, V59, P83
   Trauzettel-Klosinski S, 2003, GRAEF ARCH CLIN EXP, V241, P988, DOI 10.1007/s00417-003-0757-y
NR 19
TC 1
Z9 1
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2012
VL 47
IS 1
BP 62
EP 65
DI 10.1016/j.jcjo.2011.12.011
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 903DH
UT WOS:000301095700013
PM 22333854
DA 2022-11-30
ER

PT J
AU Boon, CJF
   van de Kar, NC
   Klevering, BJ
   Keunen, JEE
   Cremers, FPM
   Klaver, CCW
   Hoyng, CB
   Daha, MR
   den Hollandera, AI
AF Boon, Camiel J. F.
   van de Kar, Nicole C.
   Klevering, B. Jeroen
   Keunen, Jan E. E.
   Cremers, Frans P. M.
   Klaver, Caroline C. W.
   Hoyng, Carel B.
   Daha, Mohamed R.
   den Hollandera, Anneke I.
TI The spectrum of phenotypes caused by variants in the CFH gene
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE CFH; Complement; Membranoproliferative glomerulonephritis; Atypical
   hemolytic uremic syndrome; Age-related macular degeneration; Basal
   laminar drusen; Drusen; Genotype-phenotype correlation
ID COMPLEMENT-FACTOR-H; HEMOLYTIC-UREMIC-SYNDROME; C-REACTIVE-PROTEIN;
   GLOMERULONEPHRITIS TYPE-II; DENSE-DEPOSIT DISEASE; TRANSLATIONAL
   MINIREVIEW SERIES; RETINAL-PIGMENT EPITHELIUM; MEMBRANE COFACTOR
   PROTEIN; AGE-RELATED MACULOPATHY; SHORT CONSENSUS REPEAT
AB Complement factor H (CFH) is a complement inhibitor, which is present as a soluble protein and attached to cell surfaces throughout the human body. As such, CFH is a key player in complement homeostasis, inhibiting excessive activation of the complement cascade, with an emphasis on the alternative pathway. The significance of CFH is demonstrated by the broad range of phenotypes associated with specific CFH gene variants. This phenotypic spectrum includes renal phenotypes, such as membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome, as well as ocular phenotypes, such as basal laminar drusen and age-related macular degeneration. In addition, several overlapping phenotypes have been described in association with CFH gene variants. The phenotypic outcome of these CFH variants depends on their differential impact on plasma- and surface-bound CFH function. Consequently, distinct genotype-phenotype correlations may be observed. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Boon, Camiel J. F.; Klevering, B. Jeroen; Keunen, Jan E. E.; Hoyng, Carel B.; den Hollandera, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   [van de Kar, Nicole C.] Radboud Univ Nijmegen, Med Ctr, Dept Paediat Nephrol, NL-6500 HB Nijmegen, Netherlands.
   [Cremers, Frans P. M.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
   [Cremers, Frans P. M.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Daha, Mohamed R.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC
RP Boon, CJF (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 400, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM c.boon@ohk.umcn.nl
RI Hoyng, C.B./H-8050-2014; Klaver, Caroline C.W./A-2013-2016; Cremers,
   Frans/A-5625-2014; Boon, Camiel/P-7534-2014; van de Kar, Nicole
   CAJ/J-6402-2015; Keunen, J.E.E./H-8061-2014; Klevering,
   B.J./L-4434-2015; Hollander, Anneke den/N-4911-2014
OI Cremers, Frans/0000-0002-4954-5592; Boon, Camiel/0000-0002-6737-7932;
   van de Kar, Nicole CAJ/0000-0002-1990-1189; Klaver,
   Caroline/0000-0002-2355-5258
CR Abarrategui-Garrido C, 2008, AM J KIDNEY DIS, V52, P171, DOI 10.1053/j.ajkd.2008.01.026
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Alexander JJ, 2006, J AM SOC NEPHROL, V17, P1354, DOI 10.1681/ASN.2006020138
   ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Asanuma K, 2007, NEPHROLOGY, V12, pS15, DOI 10.1111/j.1440-1797.2007.00876.x
   Asanuma Katsuhiko, 2003, Clin Exp Nephrol, V7, P255, DOI 10.1007/s10157-003-0259-6
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BENNETT WM, 1989, AM J KIDNEY DIS, V13, P469, DOI 10.1016/S0272-6386(89)80004-6
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boyer O, 2008, AM J KIDNEY DIS, V51, P671, DOI 10.1053/j.ajkd.2007.11.032
   BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156
   BRANTLEY MA, 2008, EYE
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Braun MC, 2005, J AM SOC NEPHROL, V16, P2225, DOI 10.1681/ASN.2005020175
   Bresin E, 2006, CLIN J AM SOC NEPHRO, V1, P88, DOI 10.2215/CJN.00050505
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   CAUDWELL V, 1990, EUR J IMMUNOL, V20, P2643, DOI 10.1002/eji.1830201218
   Chadban SJ, 2005, LANCET, V365, P1797, DOI 10.1016/S0140-6736(05)66583-X
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cheong HI, 2004, PEDIATR NEPHROL, V19, P454, DOI 10.1007/s00467-003-1371-2
   Cho HY, 2007, PEDIATR NEPHROL, V22, P874, DOI 10.1007/s00467-007-0438-x
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   D'souza Y, 2008, BRIT J OPHTHALMOL, V92, P950, DOI 10.1136/bjo.2007.130138
   DAHA MR, 1979, J IMMUNOL, V122, P801
   DAHA MR, 1979, J IMMUNOL, V123, P755
   Daha MR, 2000, J NEPHROL, V13, pS89
   DAVIS TME, 1988, POSTGRAD MED J, V64, P871, DOI 10.1136/pgmj.64.757.871
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DIBELGIOJOSO GB, 1977, NEPHRON, V19, P250
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EISINGER AJ, 1972, Q J MED, V41, P343
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   ERDEI A, 1994, EUR J IMMUNOL, V24, P867, DOI 10.1002/eji.1830240414
   Esparza-Gordillo J, 2006, MOL IMMUNOL, V43, P1769, DOI 10.1016/j.molimm.2005.11.008
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Fakhouri F, 2008, BLOOD, V112, P4542, DOI 10.1182/blood-2008-03-144691
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8
   Fijen CAP, 1996, CLIN EXP IMMUNOL, V105, P511, DOI 10.1046/j.1365-2249.1996.d01-777.x
   Filler G, 2004, PEDIATR NEPHROL, V19, P908, DOI 10.1007/s00467-004-1526-9
   FISHELSON Z, 1987, MOL IMMUNOL, V24, P987, DOI 10.1016/0161-5890(87)90011-3
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   FRANCIS PJ, 2008, J MED GENET
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Garcia-de la Puente S, 2008, PEDIATR NEPHROL, V23, P929, DOI 10.1007/s00467-008-0754-9
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goodship THJ, 2006, KIDNEY INT, V70, P12, DOI 10.1038/sj.ki.5001612
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Herbert A, 2002, BIOCHEM SOC T, V30, P990, DOI 10.1042/bst0300990
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hye A, 2006, BRAIN, V129, P3042, DOI 10.1093/brain/awl279
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   JANSEN JH, 1995, VET REC, V137, P240, DOI 10.1136/vr.137.10.240
   Jansen JH, 1998, KIDNEY INT, V53, P331, DOI 10.1046/j.1523-1755.1998.00765.x
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jha V, 1998, RENAL FAILURE, V20, P845, DOI 10.3109/08860229809045182
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   JOUVIN MH, 1984, J IMMUNOL, V133, P3250
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   Jozsi M, 2001, IMMUNOL LETT, V77, P55, DOI 10.1016/S0165-2478(01)00194-8
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   JYLHAVA J, 2008, EXP GERONTOL
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kardys I, 2007, AM J CARDIOL, V100, P646, DOI 10.1016/j.amjcard.2007.03.079
   KASHTAN CE, 1990, CLIN NEPHROL, V33, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kavanagh D, 2005, J AM SOC NEPHROL, V16, P2150, DOI 10.1681/ASN.2005010103
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004
   Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim RY, 1997, AM J OPHTHALMOL, V123, P619, DOI 10.1016/S0002-9394(14)71074-8
   Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x
   Klaver CCW, 2008, LANCET, V372, P1788, DOI 10.1016/S0140-6736(08)61349-5
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN M, 1983, CLIN NEPHROL, V20, P163
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Larakeb A, 2007, PEDIATR NEPHROL, V22, P1967, DOI 10.1007/s00467-007-0540-0
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   LEE AY, 2008, BR J OPHTHALMOL
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   LEFUR I, 2008, NEUROBIOL AGING
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leys A, 1996, NEPHROL DIAL TRANSPL, V11, P211
   Leys A, 1991, Eur J Ophthalmol, V1, P17
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   LEYS A, 1990, GRAEF ARCH CLIN EXP, V228, P499, DOI 10.1007/BF00918479
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Licht C, 2005, AM J KIDNEY DIS, V45, P415, DOI 10.1053/j.ajkd.2004.10.018
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   MacLaren RE, 2006, CLIN EXP OPHTHALMOL, V34, P233, DOI 10.1111/j.1442-9071.2006.01191.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Matsumoto Yoko, 2007, Compr Ophthalmol Update, V8, P179
   MERI S, 1990, EUR J IMMUNOL, V20, P2555, DOI 10.1002/eji.1830201205
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Misra A, 2004, MEDICINE, V83, P18, DOI 10.1097/01.md.0000111061.69212.59
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   MOLD C, 1981, J IMMUNOL, V127, P2080
   MOLD C, 1984, J IMMUNOL, V133, P882
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nicaud V, 2007, J MOL MED-JMM, V85, P771, DOI 10.1007/s00109-007-0185-2
   NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277
   Noris M, 2008, CLIN EXP IMMUNOL, V151, P199, DOI 10.1111/j.1365-2249.2007.03552.x
   Noris M, 2005, J AM SOC NEPHROL, V16, P1035, DOI 10.1681/ASN.2004100861
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   OLLERT MW, 1995, J IMMUNOL, V155, P4955
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707
   Pai JK, 2007, EUR HEART J, V28, P1297, DOI 10.1093/eurheartj/ehm090
   Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702
   PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pickering MC, 2006, P NATL ACAD SCI USA, V103, P9649, DOI 10.1073/pnas.0601094103
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pickering MC, 2000, RHEUMATOLOGY, V39, P133, DOI 10.1093/rheumatology/39.2.133
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   Ren GH, 2003, KIDNEY INT, V64, P914, DOI 10.1046/j.1523-1755.2003.00188.x
   Renganathan K, 2008, ADV EXP MED BIOL, V613, P261, DOI 10.1007/978-0-387-74904-4_30
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Runza VL, 2008, IMMUNOBIOLOGY, V213, P297, DOI 10.1016/j.imbio.2007.10.009
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saland JM, 2006, AM J TRANSPLANT, V6, P1948, DOI 10.1111/j.1600-6143.2006.01375.x
   Sanchez-Corral P, 2000, IMMUNOGENETICS, V51, P366, DOI 10.1007/s002510050631
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt BZ, 1999, J BIOL CHEM, V274, P11782, DOI 10.1074/jbc.274.17.11782
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt S, 2000, MOL VIS, V6, P287
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SCHULZ TF, 1984, J IMMUNOL, V132, P392
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016
   Seitz B, 2007, TRANSPL P, V39, P2583, DOI 10.1016/j.transproceed.2007.08.021
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Shankland SJ, 2006, KIDNEY INT, V69, P2131, DOI 10.1038/sj.ki.5000410
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   SJOBERG AP, 2009, TRENDS IMMUNOL
   Sjowall C, 2007, BIOCHEM BIOPH RES CO, V352, P251, DOI 10.1016/j.bbrc.2006.11.013
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   SPITZER RE, 1992, CLIN IMMUNOL IMMUNOP, V64, P177, DOI 10.1016/0090-1229(92)90197-V
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strukova S, 2006, FRONT BIOSCI-LANDMRK, V11, P59, DOI 10.2741/1780
   Sunness JS, 1999, MOL VIS, V5
   Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   THORNER P, 1982, ARCH PATHOL LAB MED, V106, P628
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vaziri-Sani F, 2006, KIDNEY INT, V69, P981, DOI 10.1038/sj.ki.5000155
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Walker PD, 2007, MODERN PATHOL, V20, P605, DOI 10.1038/modpathol.3800773
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   West CD, 2001, AM J KIDNEY DIS, V37, P1120, DOI 10.1053/ajkd.2001.24511
   WEST CD, 1994, AM J KIDNEY DIS, V24, P956, DOI 10.1016/S0272-6386(12)81068-7
   Winkler BS, 1999, MOL VIS, V5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   WURZNER R, 1991, COMPLEMENT INFLAMMAT, V8, P328
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   ZHOU J, 2008, INVEST OPHTHALMOL VI
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 330
TC 66
Z9 68
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAY
PY 2009
VL 46
IS 8-9
BP 1573
EP 1594
DI 10.1016/j.molimm.2009.02.013
PG 22
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 447KM
UT WOS:000266190000002
PM 19297022
DA 2022-11-30
ER

PT J
AU Bernstein, PS
   Horn, RS
AF Bernstein, Paul S.
   Horn, Rachael Sue
TI Verteporfin photodynamic therapy involving the optic nerve for
   peripapillary choroidal neovascularization
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative macular degeneration; peripapillary choroidal
   neovascularization; photodynamic therapy; verteporfin
AB Background: To report the outcome of consecutive patients treated with verteporfin photodynamic therapy in which the treatment zone overlapped the optic nerve.
   Methods: Retrospective interventional case series with chart review of seven patients with peripapillary choroidal neovascularization secondary to age-related macular degeneration treated with standard-dose verteporfin photodynamic therapy.
   Results: The first of seven patients had excellent visual outcome with visual acuity measurement improved from 20/80 to 20/20 at 6 months post-treatment which remained stable for over 2 years. All remaining patients had improvement of visual acuity with resolution of peripapillary hemorrhage. Only two of the seven patients required more than one treatment with verteporfin photodynamic therapy.
   Conclusion: Peripapillary choroidal neovascular membranes can be successfully treated with standard-dose verteporfin photodynamic therapy, often with resolution of neovascularization with one treatment. There was no evidence of optic nerve damage from the intervention.
C1 [Bernstein, Paul S.; Horn, Rachael Sue] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Moran Eye Ctr, 65 Med Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hse.utah.edu
CR Bains HS, 2003, RETINA-J RET VIT DIS, V23, P469, DOI 10.1097/00006982-200308000-00004
   Blinder KJ, 2005, OPHTHAL SURG LAS IM, V36, P358, DOI 10.3928/1542-8877-20050901-03
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Kokame GT, 2005, RETINA-J RET VIT DIS, V25, P564, DOI 10.1097/00006982-200507000-00004
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P1256, DOI 10.1016/S0161-6420(02)01059-X
   *TAP STUD GROUP, 1999, ARCH OPHTHALMOL-CHIC, V17, P1329
NR 9
TC 16
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2008
VL 28
IS 1
BP 81
EP 84
DI 10.1097/IAE.0b013e31815e9351
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 251JT
UT WOS:000252370000010
PM 18185142
DA 2022-11-30
ER

PT J
AU Li, LH
   Lee, JCY
   Leung, HH
   Lam, WC
   Fu, ZJ
   Lo, ACY
AF Li, Long Hin
   Lee, Jetty Chung-Yung
   Leung, Ho Hang
   Lam, Wai Ching
   Fu, Zhongjie
   Lo, Amy Cheuk Yin
TI Lutein Supplementation for Eye Diseases
SO NUTRIENTS
LA English
DT Review
DE age-related macular degeneration; antioxidant; carotenoid; diabetic
   retinopathy; myopia; cataract; nutrition; retina; retinopathy of
   prematurity; xanthophyll
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED MACULOPATHY; OXYGEN-INDUCED
   RETINOPATHY; MACULAR PIGMENT; DIABETIC-RETINOPATHY; ZEAXANTHIN
   SUPPLEMENTATION; OXIDATIVE STRESS; TISSUE CONCENTRATIONS; DIETARY
   ANTIOXIDANTS; INVERSE RELATIONSHIP
AB Lutein is one of the few xanthophyll carotenoids that is found in high concentration in the macula of human retina. Asde novosynthesis of lutein within the human body is impossible, lutein can only be obtained from diet. It is a natural substance abundant in egg yolk and dark green leafy vegetables. Many basic and clinical studies have reported lutein's anti-oxidative and anti-inflammatory properties in the eye, suggesting its beneficial effects on protection and alleviation of ocular diseases such as age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, myopia, and cataract. Most importantly, lutein is categorized as Generally Regarded as Safe (GRAS), posing minimal side-effects upon long term consumption. In this review, we will discuss the chemical structure and properties of lutein as well as its application and safety as a nutritional supplement. Finally, the effects of lutein consumption on the aforementioned eye diseases will be reviewed.
C1 [Li, Long Hin; Lam, Wai Ching; Lo, Amy Cheuk Yin] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.
   [Lee, Jetty Chung-Yung; Leung, Ho Hang] Univ Hong Kong, Sch Biol Sci, Fac Sci, Hong Kong, Peoples R China.
   [Fu, Zhongjie] Harvard Med Sch, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA 02115 USA.
   [Fu, Zhongjie] Harvard Med Sch, Boston Childrens Hosp, Manton Ctr Orphan Dis, Boston, MA 02115 USA.
C3 University of Hong Kong; University of Hong Kong; Harvard University;
   Boston Children's Hospital; Harvard Medical School; Harvard University;
   Boston Children's Hospital; Harvard Medical School
RP Lo, ACY (通讯作者)，Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.; Fu, ZJ (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA 02115 USA.; Fu, ZJ (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Manton Ctr Orphan Dis, Boston, MA 02115 USA.
EM u3548400@connect.hku.hk; jettylee@hku.hk; lhhkoala@connect.hku.hk;
   waichlam@hku.hk; zhongjie.fu@childrens.harvard.edu; amylo@hku.hk
RI Lee, Jetty Chung-Yung/E-1475-2011; Lee, Jetty Chung-Yung/S-1443-2019;
   Lo, Amy C. Y./C-1195-2009
OI Lee, Jetty Chung-Yung/0000-0002-8175-7069; Lee, Jetty
   Chung-Yung/0000-0002-8175-7069; Lo, Amy C. Y./0000-0003-4239-6851; Li,
   Long Hin/0000-0002-7757-856X; FU, ZHONGJIE/0000-0002-8182-2983
FU Health and Medical Research Fund; Food and Health Bureau; Government of
   the Hong Kong Special Administrative Region [04150746, 05163526]; Boston
   Children's Hospital OFD/BTREC/CTREC Faculty Career Development Grant;
   Boston Children's Hospital Ophthalmology Foundation; Boston Children's
   Hospital Manton Center for Orphan Disease Research; Little Giraffe
   Foundation
FX A.C.Y.L. is supported by Health and Medical Research Fund, the Food and
   Health Bureau, The Government of the Hong Kong Special Administrative
   Region (04150746 and 05163526). Z.F. is supported by Boston Children's
   Hospital OFD/BTREC/CTREC Faculty Career Development Grant, Boston
   Children's Hospital Ophthalmology Foundation, Boston Children's Hospital
   Manton Center for Orphan Disease Research, and Little Giraffe
   Foundation.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnal E, 2009, CURR EYE RES, V34, P928, DOI 10.3109/02713680903205238
   Arunkumar R, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158617
   Asbell PA, 2005, LANCET, V365, P599
   Ates O, 2009, EUR J OPHTHALMOL, V19, P80, DOI 10.1177/112067210901900112
   Bashinsky Alice L, 2017, N C Med J, V78, P124, DOI 10.18043/ncm.78.2.124
   Benoudis L, 2016, J FR OPHTALMOL, V39, P615, DOI 10.1016/j.jfo.2016.04.001
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Bohn T, 2008, CURR NUTR FOOD SCI, V4, P240, DOI 10.2174/157340108786263685
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brazionis L, 2009, BRIT J NUTR, V101, P270, DOI 10.1017/S0007114508006545
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Choi RY, 2016, JAMA OPHTHALMOL, V134, P1445, DOI 10.1001/jamaophthalmol.2016.4117
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Cryotherapy for Retinopathy of Prematurity Cooperative Group, 1988, PEDIATRICS, V81, P697
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dagnelie G, 2000, Optometry, V71, P147
   Damgaard IB, 2018, OPEN OPHTHALMOL J, V12, P164, DOI 10.2174/1874364101812010164
   Dani Carlo, 2012, J Matern Fetal Neonatal Med, V25, P523, DOI 10.3109/14767058.2011.629252
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Duan XR, 2010, OPHTHALMOLOGY, V117, P1585, DOI 10.1016/j.ophtha.2009.12.036
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   EJ T., 1940, OPTICAL ELEMENTS REF
   FAGERHOLM P, 1994, ACTA OPHTHALMOL, V72, P229
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fernandez-Robredo P, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/213505
   Fernandez-Robredo P, 2009, CURR EYE RES, V34, P543, DOI 10.1080/02713680902963142
   Fierson WM, 2013, PEDIATRICS, V131, P189, DOI 10.1542/peds.2012-2996
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fu ZJ, 2017, CLIN EXP OPHTHALMOL, V45, P529, DOI 10.1111/ceo.12908
   Fung FKC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167828
   Gao SS, 2011, MOL VIS, V17, P3180
   GARCIA M, 2014, INVEST OPHTH VIS SCI, V55
   Genuth S, 2015, DIABETES, V64, P266, DOI 10.2337/db14-0215
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Graven SN, 2011, CLIN PERINATOL, V38, P671, DOI 10.1016/j.clp.2011.08.006
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gupta VB, 2014, INDIAN J OPHTHALMOL, V62, P103, DOI 10.4103/0301-4738.121141
   Hammond BR, 2014, EXP EYE RES, V129, P135, DOI 10.1016/j.exer.2014.09.005
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hof KHV, 2000, J NUTR, V130, P503
   Hu BJ, 2011, INT J OPHTHALMOL-CHI, V4, P303, DOI 10.3980/j.issn.2222-3959.2011.03.19
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Institute of Medicine Panel on Dietary A Related C, 2000, DIET REF INT VIT C V
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Karppi J, 2012, BRIT J NUTR, V108, P148, DOI 10.1017/S0007114511005332
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kowluru RA, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-8
   Krinsky NI, 2003, BIOCHEM BIOPH RES CO, V305, P754, DOI 10.1016/S0006-291X(03)00816-7
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2004, OXIDAT STRESS DIS, V13, P445
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125-007-0886-7
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li SY, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/426769
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Lim JC, 2020, CLIN EXP OPHTHALMOL, V48, P1031, DOI 10.1111/ceo.13801
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Manayi A, 2016, CRIT REV BIOTECHNOL, V36, P829, DOI 10.3109/07388551.2015.1049510
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Manzoni P, 2013, AM J PERINAT, V30, P25, DOI 10.1055/s-0032-1321494
   Maoka T, 2020, J NAT MED-TOKYO, V74, P1, DOI 10.1007/s11418-019-01364-x
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Moschos MM, 2017, EYE VISION, V4, DOI 10.1186/s40662-017-0088-4
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Mutlu FM, 2013, INT J OPHTHALMOL-CHI, V6, P228, DOI 10.3980/j.issn.2222-3959.2013.02.23
   Nagao A, 2011, BIOFACTORS, V37, P83, DOI 10.1002/biof.151
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Neelam K, 2017, BRIT J OPHTHALMOL, V101, P551, DOI 10.1136/bjophthalmol-2016-309814
   Nian S., 2019, PROTECTING AGING RET, DOI [10.5772/intechopen.82330, DOI 10.5772/INTECHOPEN.82330]
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PENN JS, 1994, INVEST OPHTH VIS SCI, V35, P3429
   Perrone S, 2010, NEONATOLOGY, V97, P36, DOI 10.1159/000227291
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Phelan D, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101133
   Qanungo S, 2000, MOL CELL BIOCHEM, V215, P11, DOI 10.1023/A:1026511420505
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Ranard KM, 2017, EUR J NUTR, V56, P537, DOI 10.1007/s00394-017-1580-2
   REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G
   Renard G, 2016, J FR OPHTALMOL, V39, P483, DOI 10.1016/j.jfo.2016.02.003
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Romagnoli C, 2010, EUR J CLIN NUTR, V64, P760, DOI 10.1038/ejcn.2010.62
   Romagnoli C, 2011, J MATERN-FETAL NEO M, V24, P147, DOI 10.3109/14767058.2011.607618
   Rubin LP, 2012, J PERINATOL, V32, P418, DOI 10.1038/jp.2011.87
   Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Sayo T, 2013, BIOSCI BIOTECH BIOCH, V77, P1282, DOI 10.1271/bbb.130124
   SCHAEFFER JL, 1988, POULTRY SCI, V67, P608, DOI 10.3382/ps.0670608
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stahl W, 2005, DEV OPHTHALMOL, V38, P70, DOI 10.1159/000082768
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanito M, 2012, JPN J OPHTHALMOL, V56, P488, DOI 10.1007/s10384-012-0157-0
   Thompson J, 2015, PRIMARY CARE, V42, P409, DOI 10.1016/j.pop.2015.05.012
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Tong NT, 2013, GRAEF ARCH CLIN EXP, V251, P1495, DOI 10.1007/s00417-012-2225-z
   TREVORRO.PD, 1970, BRIT MED J, V3, P33, DOI 10.1136/bmj.3.5713.33
   Tsang JKW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174321
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vishwanathan R, 2016, NUTR NEUROSCI, V19, P95, DOI 10.1179/1476830514Y.0000000141
   Viswanath K, 2003, Community Eye Health, V16, P21
   Walz JM, 2018, OPHTHALMOLOGE, V115, P476, DOI 10.1007/s00347-018-0701-5
   Wang ZH, 2014, INT J OPHTHALMOL-CHI, V7, P663, DOI 10.3980/j.issn.2222-3959.2014.04.14
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   Williams KM, 2017, JAMA OPHTHALMOL, V135, P47, DOI 10.1001/jamaophthalmol.2016.4752
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu L, 2013, WORLD J DIABETES, V4, P290, DOI 10.4239/wjd.v4.i6.290
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yoshizako H, 2016, ACTA OPHTHALMOL, V94, pE411, DOI 10.1111/aos.13106
   Yu HF, 2013, MOL NUTR FOOD RES, V57, P1158, DOI 10.1002/mnfr.201200642
   Zavrelova H, 2011, DIABETES CARE, V34, P867, DOI 10.2337/dc10-1741
   Zhang PC, 2017, ASIA PAC J CLIN NUTR, V26, P406, DOI 10.6133/apjcn.032016.13
   Zhang XR, 2013, GRAEF ARCH CLIN EXP, V251, P2285, DOI 10.1007/s00417-013-2303-x
   Zielinska MA, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080838
NR 163
TC 25
Z9 25
U1 15
U2 53
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2020
VL 12
IS 6
AR 1721
DI 10.3390/nu12061721
PG 27
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ML1RO
UT WOS:000549252200001
PM 32526861
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lombardo, M
   Serrao, S
   Devaney, N
   Parravano, M
   Lombardo, G
AF Lombardo, Marco
   Serrao, Sebastiano
   Devaney, Nicholas
   Parravano, Mariacristina
   Lombardo, Giuseppe
TI Adaptive Optics Technology for High-Resolution Retinal Imaging
SO SENSORS
LA English
DT Review
DE adaptive optical systems; optical sensors; biomedical imaging
   techniques; eye
ID WAVE-FRONT SENSOR; HIGHER-ORDER ABERRATIONS; NERVE-FIBER LAYER;
   PHOTORECEPTOR PACKING DENSITY; SCANNING LASER OPHTHALMOSCOPE; HUMAN CONE
   PHOTORECEPTORS; GENOME-WIDE ASSOCIATION; OF-INTENSITY EQUATION; MACULAR
   DEGENERATION; COHERENCE TOMOGRAPHY
AB Adaptive optics (AO) is a technology used to improve the performance of optical systems by reducing the effects of optical aberrations. The direct visualization of the photoreceptor cells, capillaries and nerve fiber bundles represents the major benefit of adding AO to retinal imaging. Adaptive optics is opening a new frontier for clinical research in ophthalmology, providing new information on the early pathological changes of the retinal microstructures in various retinal diseases. We have reviewed AO technology for retinal imaging, providing information on the core components of an AO retinal camera. The most commonly used wavefront sensing and correcting elements are discussed. Furthermore, we discuss current applications of AO imaging to a population of healthy adults and to the most frequent causes of blindness, including diabetic retinopathy, age-related macular degeneration and glaucoma. We conclude our work with a discussion on future clinical prospects for AO retinal imaging.
C1 [Lombardo, Marco; Serrao, Sebastiano; Parravano, Mariacristina] Fdn GB Bietti IRCCS, I-00198 Rome, Italy.
   [Devaney, Nicholas] Natl Univ Ireland, Sch Phys, Appl Opt Grp, Galway, Ireland.
   [Lombardo, Giuseppe] Univ Calabria, CNR IPCF Unit Support Cosenza, I-87036 Arcavacata Di Rende, Italy.
   [Lombardo, Giuseppe] Vision Engn, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Ollscoil na Gaillimhe-University of Galway; Consiglio
   Nazionale delle Ricerche (CNR); Istituto per i Processi Chimico-Fisici
   (IPCF-CNR); University of Calabria
RP Lombardo, M (通讯作者)，Fdn GB Bietti IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM mlombardo@visioeng.it; serrao@serraolaser.it;
   nicholas.devaney@nuigalway.ie; criparra@tin.it; giuseppe.lombardo@cnr.it
RI ; Lombardo, Giuseppe/B-2656-2012
OI Devaney, Nicholas/0000-0001-9317-1359; Lombardo,
   Marco/0000-0001-8842-7102; Lombardo, Giuseppe/0000-0002-9416-967X
CR Alencar LM, 2010, INVEST OPHTH VIS SCI, V51, P3531, DOI 10.1167/iovs.09-4350
   ALPERN M, 1983, J PHYSIOL-LONDON, V343, P577, DOI 10.1113/jphysiol.1983.sp014911
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Bifano T, 2002, P SOC PHOTO-OPT INS, V4825, P10, DOI 10.1117/12.457847
   Bonora S, 2012, OPT EXPRESS, V20, P5178, DOI 10.1364/OE.20.005178
   Bonora S, 2006, OPT EXPRESS, V14, P11935, DOI 10.1364/OE.14.011935
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   BROSTOW W, 1978, J COMPUT PHYS, V29, P81, DOI 10.1016/0021-9991(78)90110-9
   Burns SA, 1997, J OPT SOC AM A, V14, P2033, DOI 10.1364/JOSAA.14.002033
   Carroll J, 2004, P NATL ACAD SCI USA, V101, P8461, DOI 10.1073/pnas.0401440101
   Carroll J, 2008, VISION RES, V48, P2564, DOI 10.1016/j.visres.2008.04.006
   Castejon-Mochon JF, 2002, VISION RES, V42, P1611
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chamot SR, 2006, OPT EXPRESS, V14, P518, DOI 10.1364/OPEX.14.000518
   Chanteloup JC, 2005, APPL OPTICS, V44, P1559, DOI 10.1364/AO.44.001559
   Charman WN, 2003, OPHTHAL PHYSL OPT, V23, P479, DOI 10.1046/j.1475-1313.2003.00132.x
   Chen DC, 2007, J OPT SOC AM A, V24, P1305, DOI 10.1364/JOSAA.24.001305
   Chen YM, 2011, INVEST OPHTH VIS SCI, V52, P3281, DOI 10.1167/iovs.10-6538
   Cheng H, 2004, J VISION, V4, P272, DOI 10.1167/4.4.3
   Choi SS, 2005, J OPT SOC AM A, V22, P2598, DOI 10.1364/JOSAA.22.002598
   Choi SS, 2011, BRIT J OPHTHALMOL, V95, P131, DOI 10.1136/bjo.2010.183756
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Chui TYP, 2012, BIOMED OPT EXPRESS, V3, P2537, DOI 10.1364/BOE.3.002537
   Chui TYP, 2008, INVEST OPHTH VIS SCI, V49, P4679, DOI 10.1167/iovs.08-2135
   Chui TYP, 2008, J OPT SOC AM A, V25, P3021, DOI 10.1364/JOSAA.25.003021
   Coletta NJ, 2006, VISION RES, V46, P636, DOI 10.1016/j.visres.2005.05.025
   Cooper RF, 2011, BIOMED OPT EXPRESS, V2, P2577, DOI 10.1364/BOE.2.002577
   CUNHAVAZ JG, 1978, BRIT J OPHTHALMOL, V62, P351, DOI 10.1136/bjo.62.6.351
   CURCIO CA, 1992, VISUAL NEUROSCI, V9, P169, DOI 10.1017/S0952523800009639
   CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Devaney N, 2008, APPL OPTICS, V47, P6550, DOI 10.1364/AO.47.006550
   Diaz-Douton F, 2006, OPT LETT, V31, P2245, DOI 10.1364/OL.31.002245
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doble N, 2011, OPT LETT, V36, P31, DOI 10.1364/OL.36.000031
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   DREHER AW, 1989, APPL OPTICS, V28, P804, DOI 10.1364/AO.28.000804
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1757, DOI 10.1364/BOE.2.001757
   Duncan JL, 2007, INVEST OPHTH VIS SCI, V48, P3283, DOI 10.1167/iovs.06-1422
   Fernandez EJ, 2006, OPT EXPRESS, V14, P8900, DOI 10.1364/OE.14.008900
   Fernandez EJ, 2010, J OPT SOC AM A, V27, pA48, DOI 10.1364/JOSAA.27.000A48
   FIENUP JR, 1982, APPL OPTICS, V21, P2758, DOI 10.1364/AO.21.002758
   Fischer MD, 2010, INVEST OPHTH VIS SCI, V51, P5254, DOI 10.1167/iovs.09-5139
   Fletcher Erica L, 2005, Clin Exp Optom, V88, P132
   Garrioch R, 2012, OPTOMETRY VISION SCI, V89, P632, DOI 10.1097/OPX.0b013e3182540562
   Godara P, 2012, ADV EXP MED BIOL, V723, P451, DOI 10.1007/978-1-4614-0631-0_57
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Godara P, 2010, OPTOMETRY VISION SCI, V87, P930, DOI 10.1097/OPX.0b013e3181ff9a8b
   GONSALVES RA, 1982, OPT ENG, V21, P829, DOI 10.1117/12.7972989
   Griffin DW, 2001, OPT LETT, V26, P140, DOI 10.1364/OL.26.000140
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Guirao A, 2002, J OPT SOC AM A, V19, P1, DOI 10.1364/JOSAA.19.000001
   Gundlach A, 1997, OPT ENG, V36, P1488, DOI 10.1117/1.601351
   GUREYEV TE, 1995, J OPT SOC AM A, V12, P1932, DOI 10.1364/JOSAA.12.001932
   Gureyev TE, 1996, J OPT SOC AM A, V13, P1670, DOI 10.1364/JOSAA.13.001670
   Hammer DX, 2008, INVEST OPHTH VIS SCI, V49, P2061, DOI 10.1167/iovs.07-1228
   Hampson KM, 2008, J MOD OPTIC, V55, P3425, DOI 10.1080/09500340802541777
   Harbers G, 1996, APPL OPTICS, V35, P6162, DOI 10.1364/AO.35.006162
   Hardy JW., 1998, ADAPTIVE OPTICS ASTR
   He JC, 1999, J OPT SOC AM A, V16, P2363, DOI 10.1364/JOSAA.16.002363
   Hofer H, 2001, J OPT SOC AM A, V18, P497, DOI 10.1364/JOSAA.18.000497
   Horsley DA, 2005, PROC SPIE, V5688, P133, DOI 10.1117/12.591848
   Huang G, 2012, OPTOMETRY VISION SCI, V89, P593, DOI 10.1097/OPX.0b013e318253e081
   Iglesias I, 2002, OPT EXPRESS, V10, P419, DOI 10.1364/OE.10.000419
   Iqbal A, 2009, OPT EXPRESS, V17, P18957, DOI 10.1364/OE.17.018957
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   Jonnal RS, 2010, OPT EXPRESS, V18, P5257, DOI 10.1364/OE.18.005257
   Karp JH, 2008, APPL OPTICS, V47, P6666, DOI 10.1364/AO.47.006666
   KERN TS, 1995, EXP EYE RES, V60, P545, DOI 10.1016/S0014-4835(05)80069-7
   Kim YJ, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2342076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Kocaoglu OP, 2011, VISION RES, V51, P1835, DOI 10.1016/j.visres.2011.06.013
   Kocaoglu OP, 2011, BIOMED OPT EXPRESS, V2, P748, DOI 10.1364/BOE.2.000748
   Kong NN, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.2.026001
   Kotecha A, 2012, BRIT J OPHTHALMOL, V96, P816, DOI 10.1136/bjophthalmol-2012-301499
   Kuroda T, 2002, J CATARACT REFR SURG, V28, P438, DOI 10.1016/S0886-3350(01)01176-2
   Kylstra JA, 1999, OPHTHALMOLOGY, V106, P2068, DOI 10.1016/S0161-6420(99)90485-2
   Leibbrandt GWR, 1996, APPL OPTICS, V35, P6151, DOI 10.1364/AO.35.006151
   Li KY, 2007, J OPT SOC AM A, V24, P1358, DOI 10.1364/JOSAA.24.001358
   Li KY, 2006, OPT EXPRESS, V14, P12552, DOI 10.1364/OE.14.012552
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   LIANG JZ, 1994, J OPT SOC AM A, V11, P1949, DOI 10.1364/JOSAA.11.001949
   Lieth E, 2000, CLIN EXP OPHTHALMOL, V28, P3, DOI 10.1046/j.1442-9071.2000.00222.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TC, 2012, MED ENG PHYS, V34, P129, DOI 10.1016/j.medengphy.2011.07.030
   Lombardo M., 2013, RETINA IN PRESS
   Lombardo M, 2012, OPHTHALMOLOGY, V119, P1498, DOI 10.1016/j.ophtha.2012.03.019
   Lombardo M, 2012, J CATARACT REFR SURG, V38, P1147, DOI 10.1016/j.jcrs.2012.02.033
   Lombardo M, 2010, J CATARACT REFR SURG, V36, P313, DOI 10.1016/j.jcrs.2009.09.026
   Lombardo M, 2009, CLIN EXP OPTOM, V92, P176, DOI 10.1111/j.1444-0938.2009.00356.x
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mansouri K, 2011, EYE, V25, P269, DOI 10.1038/eye.2010.202
   Marcos S, 1997, VISION RES, V37, P1909, DOI 10.1016/S0042-6989(96)00295-7
   Marsack J, 2002, BIOMED SCI INSTRUM, V38, P471
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Merino D, 2011, BIOMED OPT EXPRESS, V2, P2189, DOI 10.1364/BOE.2.002189
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   Miller JM, 2002, J REFRACT SURG, V18, pS579
   Moore J, 1999, J ANAT, V194, P89, DOI 10.1046/j.1469-7580.1999.19410089.x
   NAKANO Y, 1984, APPL OPTICS, V23, P2296, DOI 10.1364/AO.23.002296
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Odlund E, 2010, APPL OPTICS, V49, pG120, DOI 10.1364/AO.49.00G120
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Pallikaris A, 2003, INVEST OPHTH VIS SCI, V44, P4580, DOI 10.1167/iovs.03-0094
   Parravano M., 2012, INVEST OPHTH VIS SCI, V53, P5657
   Pfund J., 2000, OPT LETT, V39, P561
   Pircher M, 2011, BIOMED OPT EXPRESS, V2, P100, DOI 10.1364/BOE.2.000100
   Platt BC, 2001, J REFRACT SURG, V17, pS573
   Popovic Z, 2011, INVEST OPHTH VIS SCI, V52, P2649, DOI 10.1167/iovs.10-6054
   Porter J, 2001, J OPT SOC AM A, V18, P1793, DOI 10.1364/JOSAA.18.001793
   Prieto PM, 2004, OPT EXPRESS, V12, P4059, DOI 10.1364/OPEX.12.004059
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   QUIGLEY HA, 1993, OPHTHALMOLOGY, V100, P1800
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ragazzoni R, 1996, J MOD OPTIC, V43, P289, DOI 10.1080/095003496156165
   Ragazzoni R, 1999, ASTRON ASTROPHYS, V350, pL23
   Rativa D, 2011, BIOMED OPT EXPRESS, V2, P1423, DOI 10.1364/BOE.2.001423
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rha J, 2006, OPT EXPRESS, V14, P4552, DOI 10.1364/OE.14.004552
   Rha J, 2010, ADV EXP MED BIOL, V664, P309, DOI 10.1007/978-1-4419-1399-9_35
   Rha J, 2009, OPT LETT, V34, P3782, DOI 10.1364/OL.34.003782
   RODDIER F, 1988, APPL OPTICS, V27, P1223, DOI 10.1364/AO.27.001223
   RODIECK RW, 1991, VISUAL NEUROSCI, V6, P95, DOI 10.1017/S095252380001049X
   Roorda A., 2002, J VIS, V35, P607
   Rossi EA, 2010, NAT NEUROSCI, V13, P156, DOI 10.1038/nn.2465
   Sakamoto A, 2010, INVEST OPHTH VIS SCI, V51, P5062, DOI 10.1167/iovs.09-4954
   Salama NH, 1999, OPT LASER TECHNOL, V31, P269, DOI 10.1016/S0030-3992(99)00053-5
   Salmon TO, 2006, J CATARACT REFR SURG, V32, P2064, DOI 10.1016/j.jcrs.2006.07.022
   Schmoll T, 2011, BIOMED OPT EXPRESS, V2, P1159, DOI 10.1364/BOE2.001159
   Scully Tony, 2012, Nature, V485, pS2
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sekine R, 2006, OPT REV, V13, P207, DOI 10.1007/s10043-006-0207-2
   Seyedahmadi BJ, 2010, SEMIN OPHTHALMOL, V25, P186, DOI 10.3109/08820538.2010.518483
   Siegel C, 2001, OPT COMMUN, V194, P265, DOI 10.1016/S0030-4018(01)01288-3
   Sjostrand J, 1999, VISION RES, V39, P2987, DOI 10.1016/S0042-6989(99)00030-9
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Song HX, 2011, INVEST OPHTH VIS SCI, V52, P7376, DOI 10.1167/iovs.11-7199
   Takayama K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033158
   Tam J, 2012, INVEST OPHTH VIS SCI, V52, P9257
   Tam J, 2012, OPTOMETRY VISION SCI, V89, pE692, DOI 10.1097/OPX.0b013e3182548b07
   Tam J, 2011, BIOMED OPT EXPRESS, V2, P781, DOI 10.1364/BOE.2.000781
   Tam J, 2010, INVEST OPHTH VIS SCI, V51, P1691, DOI 10.1167/iovs.09-4483
   TEAGUE MR, 1983, J OPT SOC AM, V73, P1434, DOI 10.1364/JOSA.73.001434
   Thibos LN, 2002, J OPT SOC AM A, V19, P2329, DOI 10.1364/JOSAA.19.002329
   Thibos LN, 2002, OPHTHAL PHYSL OPT, V22, P427, DOI 10.1046/j.1475-1313.2002.00059.x
   Thibos LN, 2000, J REFRACT SURG, V16, pS540
   Uji A, 2012, INVEST OPHTH VIS SCI, V53, P171, DOI 10.1167/iovs.11-8192
   van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143
   VDOVIN G, 1995, APPL OPTICS, V34, P2968, DOI 10.1364/AO.34.002968
   Vdovin G, 2009, OPT LETT, V34, P524, DOI 10.1364/OL.34.000524
   Verma A, 2009, EYE, V23, P1824, DOI 10.1038/eye.2009.184
   Wang Q, 2011, INVEST OPHTH VIS SCI, V52, P6292, DOI 10.1167/iovs.10-6424
   Wang Y, 2003, J REFRACT SURG, V19, pS270
   Warden L, 2008, J REFRACT SURG, V24, P188, DOI 10.3928/1081597X-20080201-10
   Williams D, 2000, J REFRACT SURG, V16, pS554
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
   Wojtas DH, 2008, J OPT SOC AM A, V25, P1181, DOI 10.1364/JOSAA.25.001181
   Xue B, 2007, J OPT SOC AM A, V24, P1364, DOI 10.1364/JOSAA.24.001364
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zawadzki RJ, 2011, BIOMED OPT EXPRESS, V2, P1674, DOI 10.1364/BOE.2.001674
   Zhong ZY, 2008, OPT EXPRESS, V16, P12746, DOI 10.1364/OE.16.012746
NR 170
TC 76
Z9 78
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1424-8220
J9 SENSORS-BASEL
JI Sensors
PD JAN
PY 2013
VL 13
IS 1
BP 334
EP 366
DI 10.3390/s130100334
PG 33
WC Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments
   & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Instruments & Instrumentation
GA 077JV
UT WOS:000314024800019
PM 23271600
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Alvarez, Y
   Astudillo, O
   Jensen, L
   Reynolds, AL
   Waghorne, N
   Brazil, DP
   Cao, YH
   O'Connor, JJ
   Kennedy, BN
AF Alvarez, Yolanda
   Astudillo, Olaya
   Jensen, Lasse
   Reynolds, Alison L.
   Waghorne, Nora
   Brazil, Derek P.
   Cao, Yihai
   O'Connor, John J.
   Kennedy, Breandan N.
TI Selective Inhibition of Retinal Angiogenesis by Targeting PI3 Kinase
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; 3-KINASE INHIBITOR; MODEL; VEGF;
   SUPPRESSION; RETINOPATHY; MECHANISMS; ZEBRAFISH; ANTITUMOR; THERAPY
AB Ocular neovascularisation is a pathological hallmark of some forms of debilitating blindness including diabetic retinopathy, age related macular degeneration and retinopathy of prematurity. Current therapies for delaying unwanted ocular angiogenesis include laser surgery or molecular inhibition of the pro-angiogenic factor VEGF. However, targeting of angiogenic pathways other than, or in combination to VEGF, may lead to more effective and safer inhibitors of intraocular angiogenesis. In a small chemical screen using zebrafish, we identify LY294002 as an effective and selective inhibitor of both developmental and ectopic hyaloid angiogenesis in the eye. LY294002, a PI3 kinase inhibitor, exerts its anti-angiogenic effect in a dose-dependent manner, without perturbing existing vessels. Significantly, LY294002 delivered by intraocular injection, significantly inhibits ocular angiogenesis without systemic side-effects and without diminishing visual function. Thus, targeting of PI3 kinase pathways has the potential to effectively and safely treat neovascularisation in eye disease.
RP Alvarez, Y (通讯作者)，Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol, Dublin 2, Ireland.
EM yolanda.alvarez@ucd.ie; brendan.kennedy@ucd.ie
RI kennedy, Breandan/H-5643-2019
OI kennedy, Breandan/0000-0001-7991-4689; Brazil,
   Derek/0000-0003-1375-1076; Jensen, Lasse/0000-0003-2338-357X; O'Connor,
   John/0000-0001-8229-8602; Reynolds, Alison/0000-0002-3147-0094
CR Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bayliss PE, 2006, NAT CHEM BIOL, V2, P265, DOI 10.1038/nchembio778
   Billottet C, 2009, CANCER RES, V69, P1027, DOI 10.1158/0008-5472.CAN-08-2608
   Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8
   Brockerhoff SE, 2006, NAT PROTOC, V1, P2448, DOI 10.1038/nprot.2006.255
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   Cao Y, 2008, ADV CANCER RES, V100, P113, DOI 10.1016/S0065-230X(08)00004-3
   Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FLEISCH VJ, 2008, MEASUREMENTS LARVAL, DOI DOI 10.1103/PDB.PROT4973
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669
   Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489
   Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892
   HAYAT M, 1987, PRINCIPLES TECHNIQUE
   Hernandez C, 2007, EXPERT OPIN INV DRUG, V16, P1209, DOI 10.1517/13543784.16.8.1209
   Ihle NT, 2009, MOL CANCER THER, V8, P1, DOI 10.1158/1535-7163.MCT-08-0801
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia SD, 2009, CURR OPIN CELL BIOL, V21, P199, DOI 10.1016/j.ceb.2008.12.007
   Kitambi SS, 2009, MECH DEVELOP, V126, P464, DOI 10.1016/j.mod.2009.01.002
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Peterson RT, 2000, P NATL ACAD SCI USA, V97, P12965, DOI 10.1073/pnas.97.24.12965
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Westerfield M., 1993, GUIDE LAB USE ZEBRAF
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Yoo SA, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/129873
   Yu WZ, 2008, OPHTHALMIC RES, V40, P19, DOI 10.1159/000111154
   Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606
NR 41
TC 58
Z9 66
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 17
PY 2009
VL 4
IS 11
AR e7867
DI 10.1371/journal.pone.0007867
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 520OG
UT WOS:000271854200014
PM 19924235
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Johnson, EJ
AF Johnson, EJ
TI A biological role of lutein
SO FOOD REVIEWS INTERNATIONAL
LA English
DT Review
DE lutein; zeaxanthin; carotenoids; beta-carotene; spinach; age-related
   macular degeneration
ID SUPPLEMENTAL BETA-CAROTENE; MACULAR PIGMENT; ALPHA-TOCOPHEROL; PLASMA
   CAROTENOIDS; VITAMIN-A; ZEAXANTHIN CONCENTRATIONS; CATARACT-EXTRACTION;
   SERUM CAROTENOIDS; VEGETABLE INTAKE; NATIONAL-HEALTH
AB Lutein, a non-provitamin A carotenoid, is found in dark green, leafy vegetables. Lutein, being fat soluble, follows the same intestinal absorption path as dietary fat and is affected by the same factors that influence fat absorption. Unlike beta-carotene, another major carotenoid in diet and tissue, the bioavailability of lutein appears to be less influenced by food processing. Lutein has been strongly implicated as being protective against eye diseases, age-related macular degeneration, and cataracts. In the eye, lutein may act as a blue light filter to protect the underlying tissues from phototoxic damage. The mechanism by which lutein is involved in the prevention of eye diseases may also involve its role as an antioxidant. Dietary surveys indicate that average intakes of lutein in the United States may be below levels that are associated with disease prevention. Therefore, increased intakes of food sources rich in lutein may be warranted.
C1 Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, USDA, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Johnson, EJ (通讯作者)，Tufts Univ, Jean Mayer Human Nutr Res Ctr Aging, USDA, 711 Washington St, Boston, MA 02111 USA.
EM elizabeth.johnson@tufts.edu
CR Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   BEECHER GR, 1984, J NATL CANCER I, V73, P1397
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   BROWN PK, 1963, NATURE, V200, P37, DOI 10.1038/200037a0
   CAMPBELL DR, 1994, CANCER EPIDEM BIOMAR, V3, P493
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Dagnelie G, 2000, Optometry, V71, P147
   DOLIN PJ, 1994, DOC OPHTHALMOL, V88, P327
   Drewnowski A, 1997, AM J CLIN NUTR, V65, P1796, DOI 10.1093/ajcn/65.6.1796
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   Food and Nutrition Board, 2000, DIET REF INT VIT C V
   Gabrielska J, 1996, BBA-BIOMEMBRANES, V1285, P167, DOI 10.1016/S0005-2736(96)00152-6
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAN WT, 1989, LASER APPL MED BIOL, P191
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANKINSON SE, 1999, BMJ-BRIT MED J, V305, P335
   HOF KHV, 1999, AM J CLIN NUTR, V7, P261
   Holden Joanne M., 1999, Journal of Food Composition and Analysis, V12, P169, DOI 10.1006/jfca.1999.0827
   JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022
   JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S
   Johnson EJ, 1997, J NUTR, V127, P1993, DOI 10.1093/jn/127.10.1993
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 1997, J NUTR, V127, P1833, DOI 10.1093/jn/127.9.1833
   Johson EJ, 1996, J AM COLL NUTR, V15, P620, DOI 10.1080/07315724.1996.10718639
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P205
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LI R, 2000, AM J PUB HLTH, V90
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MARTINI MC, 1995, CANCER EPIDEM BIOMAR, V4, P491
   Mayne ST, 1998, AM J CLIN NUTR, V68, P642, DOI 10.1093/ajcn/68.3.642
   MICOZZI MS, 1990, JNCI-J NATL CANCER I, V82, P282, DOI 10.1093/jnci/82.4.282
   Mohamedshah FY, 1999, FASEB J, V13, pA554
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   Nierenberg DW, 1997, AM J CLIN NUTR, V66, P315, DOI 10.1093/ajcn/66.2.315
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   OLSON JA, 1989, J NUTR, V119, P94, DOI 10.1093/jn/119.1.94
   OMENN GS, N ENG J MED
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Polsinelli ML, 1998, J AM DIET ASSOC, V98, P194, DOI 10.1016/S0002-8223(98)00048-0
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer S, 1999, J Am Optom Assoc, V70, P24
   SCHALCH W, 1994, ADV EXP MED BIOL, V366, P335
   SCHMITZ HH, 1993, METHOD ENZYMOL, V214, P102
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   SUBAR AF, 1995, AM J HEALTH PROMOT, V9, P352, DOI 10.4278/0890-1171-9.5.352
   Surai PF, 2000, EUR J CLIN NUTR, V54, P298, DOI 10.1038/sj.ejcn.1600939
   TEE ES, 1992, CRIT REV FOOD SCI, V31, P103, DOI 10.1080/10408399209527563
   Tucker KL, 1999, J NUTR, V129, P438, DOI 10.1093/jn/129.2.438
   van den Berg H, 1998, AM J CLIN NUTR, V68, P82, DOI 10.1093/ajcn/68.1.82
   VandenLangenberg GM, 1996, J AM DIET ASSOC, V96, P1271, DOI 10.1016/S0002-8223(96)00332-X
   VILE GF, 1988, FEBS LETT, V238, P353, DOI 10.1016/0014-5793(88)80511-8
   WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936
   Yeum K J, 1999, Asia Pac J Clin Nutr, V8, P4, DOI 10.1046/j.1440-6047.1999.00035.x
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
NR 79
TC 39
Z9 43
U1 3
U2 31
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 8755-9129
EI 1525-6103
J9 FOOD REV INT
JI Food Rev. Int.
PY 2004
VL 20
IS 1
BP 1
EP 16
DI 10.1081/FRI-120028826
PG 16
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 810EI
UT WOS:000220687200001
DA 2022-11-30
ER

PT J
AU Li, BH
   Ning, BB
   Yang, F
   Guo, CW
AF Li, Baohua
   Ning, Bobiao
   Yang, Fan
   Guo, Chengwei
TI Nerve Growth Factor Promotes Retinal Neurovascular Unit Repair: A Review
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Nerve growth factor; retinal neurovascular unit; coupling mechanism;
   retinal degenerative diseases
ID OPTIC-NERVE; FACTOR NGF; MACULAR DEGENERATION; OXIDATIVE STRESS;
   GANGLION-CELLS; GLIAL-CELLS; AGE; PRONGF; P75(NTR); SURVIVAL
AB Purpose: The purpose of this paper is to investigate how the imbalance of neurogenic factor (NGF) and its precursor (pro-NGF) mediates structural and functional impairment of retinal neurovascular unit (RNVU) that plays a role in retinal degenerative diseases. Methods: A literature search of electronic databases was performed. Results: The pro-apoptotic effect of pro-NGF and the pro-growth effect of NGF are essential for the pathological and physiological activities of RNVU. Studies show that NGF-based treatment of retinal degenerative diseases, including glaucoma, age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy, has achieved remarkable efficacy. Conclusions: RNVU plays a complex and multifaceted role in retinal degenerative diseases. The exploration of the differential signaling expression of proNGF-NGF homeostasis under physiological and pathological conditions, and the corresponding pathological processes induced by its regulation, has prompted us to focus on earlier retinal neuroprotective therapeutic strategies to prevent retinal degenerative diseases.
C1 [Li, Baohua; Yang, Fan; Guo, Chengwei] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan 250355, Shandong, Peoples R China.
   [Ning, Bobiao] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Guo, CW (通讯作者)，Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan 250355, Shandong, Peoples R China.
EM guocw12009@163.com
CR Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149
   Ahmad I, 2014, GLIA, V62, P1699, DOI 10.1002/glia.22709
   Al-Gayyar MMH, 2011, DIABETOLOGIA, V54, P669, DOI 10.1007/s00125-010-1994-3
   Al-Gayyar MMH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054692
   Ali TK, 2011, DIABETOLOGIA, V54, P657, DOI 10.1007/s00125-010-1935-1
   Aloe L, 2001, Arch Physiol Biochem, V109, P354, DOI 10.1076/apab.109.3.354.9339
   Aloe L, 2021, INT J OPHTHALMOL-CHI, V14, P209, DOI 10.18240/ijo.2021.02.05
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AnandBabu K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216899
   Asakawa K, 2016, NEURO-OPHTHALMOLOGY, V40, P286, DOI 10.1080/01658107.2016.1229339
   Aung MH, 2014, J NEUROSCI, V34, P726, DOI 10.1523/JNEUROSCI.3483-13.2014
   Balzamino BO, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212732
   Barcelona PF, 2016, J NEUROSCI, V36, P8826, DOI 10.1523/JNEUROSCI.4278-15.2016
   Beltramo E, 2013, CURR MED CHEM, V20, P3218, DOI 10.2174/09298673113209990022
   Beykin Gala, 2022, Am J Ophthalmol, V234, P223, DOI 10.1016/j.ajo.2021.11.002
   Bilimoria PM, 2015, BRAIN RES, V1617, P7, DOI 10.1016/j.brainres.2014.11.032
   BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bradshaw RA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061143
   Bringmann Andreas, 2013, Front Endocrinol (Lausanne), V4, P48, DOI 10.3389/fendo.2013.00048
   Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005
   Calkins DJ, 2012, PROG RETIN EYE RES, V31, P702, DOI 10.1016/j.preteyeres.2012.07.001
   CARMIGNOTO G, 1989, J NEUROSCI, V9, P1263
   Cattaneo A, 2019, PHARMACOL RES, V139, P17, DOI 10.1016/j.phrs.2018.10.028
   Cecilia OM, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8562408
   CHAKRABARTI S, 1990, BRAIN RES, V523, P11, DOI 10.1016/0006-8993(90)91630-Y
   Chan G, 2012, INVEST OPHTH VIS SCI, V53, P5502, DOI 10.1167/iovs.12-10265
   Ciavarella C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234145
   Cowan WM, 2001, ANNU REV NEUROSCI, V24, P551, DOI 10.1146/annurev.neuro.24.1.551
   Dai WL, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00556-3
   Di Marco S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050678
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Elshaer SL, 2019, DIABETOLOGIA, V62, P1488, DOI 10.1007/s00125-019-4885-2
   Elsherbiny NM, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01089
   Fahnestock M, 2004, PROG BRAIN RES, V146, P101, DOI 10.1016/S0079-6123(03)46007-X
   Fahnestock M, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00129
   Falsini B, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0750-3
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fudalej E, 2021, OPHTHALMIC RES, V64, P345, DOI 10.1159/000514441
   Galassi F, 2003, ARCH OPHTHALMOL-CHIC, V121, P1711, DOI 10.1001/archopht.121.12.1711
   Garcia TB, 2017, CYTOKINE GROWTH F R, V34, P43, DOI 10.1016/j.cytogfr.2016.11.005
   Gardner TW, 2017, GRAEF ARCH CLIN EXP, V255, P1, DOI 10.1007/s00417-016-3548-y
   Gudasheva TA, 2020, DOKL BIOCHEM BIOPHYS, V494, P244, DOI 10.1134/S1607672920050075
   Guo L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60427-2
   Hammes HP, 2018, DIABETOLOGIA, V61, P29, DOI 10.1007/s00125-017-4435-8
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   Hill D, 2021, EXPERT OPIN INV DRUG, V30, P571, DOI 10.1080/13543784.2021.1896701
   Hill J, 2014, J NEUROIMMUNE PHARM, V9, P591, DOI 10.1007/s11481-014-9557-x
   Hou Y, 2017, ONCOTARGET, V8, P105692, DOI 10.18632/oncotarget.22389
   Hudson N, 2020, NEURAL REGEN RES, V15, P1656, DOI 10.4103/1673-5374.276332
   Ishitsuka K, 2012, MICROVASC RES, V83, P352, DOI 10.1016/j.mvr.2012.02.009
   Ji ZY, 2021, DIABET METAB SYND OB, V14, P719, DOI 10.2147/DMSO.S288482
   Jian Q, 2015, EXP EYE RES, V132, P34, DOI 10.1016/j.exer.2015.01.008
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Kawasaki R, 2013, OPHTHALMOLOGY, V120, P84, DOI 10.1016/j.ophtha.2012.07.007
   Ke Y, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/6084496
   Ki YW, 2013, TOXICOL LETT, V218, P235, DOI 10.1016/j.toxlet.2013.02.003
   Kim SJ, 2016, CURR EYE RES, V41, P249, DOI 10.3109/02713683.2015.1006372
   Kinuthia UM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564077
   Kowianski P, 2013, NEUROSCI RES, V75, P171, DOI 10.1016/j.neures.2013.01.014
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863
   Lambiase A, 1996, GRAEF ARCH CLIN EXP, V234, pS96, DOI 10.1007/BF02343055
   Lambiase A, 2009, P NATL ACAD SCI USA, V106, P13469, DOI 10.1073/pnas.0906678106
   LEVIMONTALCINI R, 1951, J EXP ZOOL, V116, P321, DOI 10.1002/jez.1401160206
   Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445
   Liu HJ, 2019, MOL MED REP, V19, P5321, DOI 10.3892/mmr.2019.10206
   Lu B, 2013, VISUAL NEUROSCI, V30, P77, DOI 10.1017/S0952523813000011
   Luo D, 2018, MOL NEUROBIOL, V55, P2258, DOI 10.1007/s12035-017-0486-6
   Luo MX, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204264
   Manti S, 2017, VITAM HORM, V104, P313, DOI 10.1016/bs.vh.2016.10.010
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Meng CR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763092
   Mesentier-Louro LA, 2019, MOL NEUROBIOL, V56, P1056, DOI 10.1007/s12035-018-1154-1
   Minnone G, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2017-000441
   Minnone G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051028
   Mohamed Riyaz, 2017, J Diabetes Metab Disord Control, V4, DOI 10.15406/jdmdc.2017.04.00129
   Mohamed Riyaz, 2015, J Clin Exp Ophthalmol, V6
   Moosavi F, 2016, DRUG DES DEV THER, V10, P23, DOI 10.2147/DDDT.S96936
   Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250
   Mysona BA, 2013, DIABETOLOGIA, V56, P2329, DOI 10.1007/s00125-013-2998-6
   Newman A, 2018, CLIN EXP OPHTHALMOL, V46, P531, DOI 10.1111/ceo.13119
   Ng DSK, 2016, CLIN EXP OPHTHALMOL, V44, P243, DOI 10.1111/ceo.12724
   Nguyen NM, 2019, J SEX MED, V16, P351, DOI 10.1016/j.jsxm.2019.01.013
   Nian S, 2021, EYE VISION, V8, DOI 10.1186/s40662-021-00239-1
   Noonan JE, 2015, CLIN EXP OPHTHALMOL, V43, P673, DOI 10.1111/ceo.12530
   Oddone F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168565
   Osman AM, 2019, NEUROSCIENCE, V405, P92, DOI 10.1016/j.neuroscience.2017.10.034
   Pallottini V, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102232
   Platon-Corchado M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.306
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460
   Reed MJ, 2019, TISSUE BARRIERS, V7, DOI 10.1080/21688370.2019.1651157
   Retamales-Ortega R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030507
   Rocco ML, 2021, ADV EXP MED BIOL, V1331, P255, DOI 10.1007/978-3-030-74046-7_17
   Rocco ML, 2017, GRAEF ARCH CLIN EXP, V255, P567, DOI 10.1007/s00417-016-3567-8
   Rocco ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124810
   Rosso P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810014
   Rush RA, 1997, CLIN EXP PHARMACOL P, V24, P549, DOI 10.1111/j.1440-1681.1997.tb02089.x
   Sacchetti M, 2019, CURR OPIN ALLERGY CL, V19, P510, DOI 10.1097/ACI.0000000000000555
   Sacchetti M, 2017, CURR EYE RES, V42, P1064, DOI 10.1080/02713683.2017.1279634
   Sahin K, 2019, BIOCHEM BIOPH RES CO, V516, P163, DOI 10.1016/j.bbrc.2019.06.032
   Saleh Irsan, 2019, Open Access Maced J Med Sci, V7, P3921, DOI 10.3889/oamjms.2019.759
   Schuster AK, 2020, DTSCH ARZTEBL INT, V117, P225, DOI 10.3238/arztebl.2020.0225
   Shen LL, 2018, MOL PSYCHIATR, V23, P1813, DOI 10.1038/s41380-018-0071-z
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Sinclair SH, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00843
   Sorrentino FS, 2016, LIFE SCI, V162, P54, DOI 10.1016/j.lfs.2016.08.001
   Syc-Mazurek SB, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.002
   Tawfik A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081119
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Tessarollo L, 1998, CYTOKINE GROWTH F R, V9, P125, DOI 10.1016/S1359-6101(98)00003-3
   Tirassa P, 2018, METHODS MOL BIOL, V1727, P19, DOI 10.1007/978-1-4939-7571-6_2
   Troullinaki M, 2019, J CELL MOL MED, V23, P2362, DOI 10.1111/jcmm.14002
   TURNER JE, 1979, BRAIN RES, V171, P197, DOI 10.1016/0006-8993(79)90327-5
   Usui Yoshihiko, 2020, JMA J, V3, P201, DOI 10.31662/jmaj.2020-0022
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Volgyi B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112483
   von Bartheld CS, 1998, HISTOL HISTOPATHOL, V13, P437, DOI 10.14670/HH-13.437
   Wang HT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/759473
   Wang LF, 2018, EXP THER MED, V15, P300, DOI 10.3892/etm.2017.5386
   Wang QC, 2020, INT OPHTHALMOL, V40, P3501, DOI 10.1007/s10792-020-01537-8
   Wang SB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588050
   Wareham LK, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00452
   Wei X, 2019, J NEUROSCI RES, V97, P70, DOI 10.1002/jnr.24256
   Wei Y, 2012, CHINESE MED J-PEKING, V125, P3875, DOI 10.3760/cma.j.issn.0366-6999.2012.21.024
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wong HLX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09744-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Q, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2429843
   Wyganowska-Swiatkowska M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010248
   Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P596, DOI 10.1073/pnas.93.2.596
   Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713
   Yang ST, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110818
   YIP HK, 1982, BRAIN RES, V238, P329, DOI 10.1016/0006-8993(82)90108-1
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Zhou YX, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00581
   Zhu MC, 2017, MED HYPOTHESES, V108, P151, DOI 10.1016/j.mehy.2017.09.003
NR 143
TC 0
Z9 0
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG 3
PY 2022
VL 47
IS 8
BP 1095
EP 1105
DI 10.1080/02713683.2022.2055084
EA APR 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3K0JE
UT WOS:000789778500001
PM 35499266
OA hybrid
DA 2022-11-30
ER

PT J
AU Damdimopoulou, P
   Rodin, S
   Stenfelt, S
   Antonsson, L
   Tryggvason, K
   Hovatta, O
AF Damdimopoulou, Pauliina
   Rodin, Sergey
   Stenfelt, Sonya
   Antonsson, Liselotte
   Tryggvason, Karl
   Hovatta, Outi
TI Human embryonic stem cells
SO BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
LA English
DT Article
DE embryonic stem cell; pluripotency; regenerative medicine; age-related
   macular degeneration; spinal cord injury
ID SERUM REPLACEMENT MEDIUM; FEEDER CELLS; SELF-RENEWAL; XENO-FREE;
   IN-VITRO; GROWTH; LINES; SAFETY; FIBROBLASTS; LAMININ-511
AB The establishment of permanent human embryonic stem cell lines (hESCs) was first reported in 1998. Due to their pluripotent nature and ability to differentiate to all cell types in the body, they have been considered as a cell source for regenerative medicine. Since then, intensive studies have been carried out regarding factors regulating pluripotency and differentiation. hESCs are obtained from supernumerary human IVF (in vitro fertilization) embryos that cannot be used for the couple's infertility treatment. Today, we can establish and expand these cells in animal substance-free conditions, even from single cells biopsied from eight-cell stage embryos. There are satisfactory tests for the demonstration of genetic stability, absence of tumorigenic mutations, functionality, and safety of hESCs. Clinical trials are ongoing for age-related macular degeneration (AMD) and spinal cord injury (SCI). This review focuses on the present state of these techniques. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Damdimopoulou, Pauliina; Stenfelt, Sonya; Antonsson, Liselotte; Hovatta, Outi] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Rodin, Sergey; Tryggvason, Karl] Karolinska Inst, Dept Biochem & Biophys, Stockholm, Sweden.
   [Tryggvason, Karl] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders Program, Singapore, Singapore.
C3 Karolinska Institutet; Karolinska Institutet; National University of
   Singapore
RP Hovatta, O (通讯作者)，K57 Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Clin Sci Intervent & Technol, SE-14186 Stockholm, Sweden.
EM Pauliina.Damdimopoulou@ki.se; Sergey.Rodin@ki.se; Sonya.Stenfelt@ki.se;
   Liselotte.Antonsson@ki.se; Karl.tryggvason@ki.se; Outi.Hovatta@ki.se
OI Rodin, Sergey/0000-0002-6954-1986
CR Akopian V, 2010, IN VITRO CELL DEV-AN, V46, P247, DOI 10.1007/s11626-010-9297-z
   Alici E, 2010, CURR GENE THER, V10, P508, DOI 10.2174/156652310793797757
   Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015
   Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193
   Cerdan C, 2007, CURR PROTOC STEM CEL
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576
   Cooke MJ, 2006, STEM CELLS DEV, V15, P254, DOI 10.1089/scd.2006.15.254
   Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152
   Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200
   Domogatskaya A, 2008, STEM CELLS, V26, P2800, DOI 10.1634/stemcells.2007-0389
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   Gafni O, 2013, NATURE, V504, P282, DOI 10.1038/nature12745
   Gertow K, 2007, CURR PROTOC STEM CEL
   Gropp M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045532
   Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002
   Hovatta O, 2003, HUM REPROD, V18, P1404, DOI 10.1093/humrep/deg290
   Hovatta O, 2010, STEM CELLS, V28, P1005, DOI 10.1002/stem.436
   Inzunza J, 2005, STEM CELLS, V23, P544, DOI 10.1634/stemcells.2004-0201
   James D, 2006, DEV BIOL, V295, P90, DOI 10.1016/j.ydbio.2006.03.026
   Klaffky E, 2001, DEV BIOL, V239, P161, DOI 10.1006/dbio.2001.0404
   Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004
   Koivisto H, 2004, REPROD BIOMED ONLINE, V9, P330, DOI 10.1016/S1472-6483(10)62150-5
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Murdoch A, 2012, STEM CELL REV REP, V8, P91, DOI 10.1007/s12015-011-9288-9
   Narva E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615
   Piltti KM, 2013, STEM CELL TRANSL MED, V2, P961, DOI 10.5966/sctm.2013-0064
   Prokhorova TA, 2009, STEM CELLS DEV, V18, P47, DOI 10.1089/scd.2007.0266
   Rodin S, 2014, NAT PROTOC, V9, P2354, DOI 10.1038/nprot.2014.159
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Rodin S, 2010, NAT BIOTECHNOL, V28, P611, DOI 10.1038/nbt.1620
   Rony IK, 2015, CELL PROLIFERAT, V48, P140, DOI 10.1111/cpr.12162
   Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SEIGER A, 1989, Fetal Therapy, V4, P104
   Strom S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015329
   Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Unger C, 2008, HUM MOL GENET, V17, pR48, DOI 10.1093/hmg/ddn079
   Wesselschmidt RL, 2011, METHODS MOL BIOL, V767, P231, DOI 10.1007/978-1-61779-201-4_17
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 43
TC 19
Z9 20
U1 0
U2 27
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6934
EI 1532-1932
J9 BEST PRACT RES CL OB
JI Best Pract. Res. Clin. Obstet. Gynaecol.
PD FEB
PY 2016
VL 31
BP 2
EP 12
DI 10.1016/j.bpobgyn.2015.08.010
PG 11
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA DF7PF
UT WOS:000371549300002
PM 26602389
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Eter, N
AF Clemens, Christoph R.
   Eter, Nicole
TI Retinal Pigment Epithelium Tears: Risk Factors, Mechanism and
   Therapeutic Monitoring
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Retinal pigment epithelium; Retinal
   pigment epithelial detachment; Retinal pigment epithelium tear;
   Intravitreal injection; Spectral-domain optical coherence tomography
ID GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; INTRAVITREAL BEVACIZUMAB;
   MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; FUNDUS
   AUTOFLUORESCENCE; RPE TEARS; RANIBIZUMAB; INJECTION; DETACHMENT
AB Tears of the retinal pigment epithelium (RPE) are most commonly associated with vascularised RPE detachment due to age-related macular degeneration (AMD), and they usually involve a deleterious loss in visual acuity. Recent studies suggest an increase in RPE tear incidences since the introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies as well as a temporal association between the tear event and the intravitreal injection. As the number of AMD patients and the number of administered anti-VEGF injections increase, both the challenge of RPE tear prevention and the treatment after RPE tear formation have become more important. At the same time, the evolution of retinal imaging has significantly contributed to a better understanding of RPE tear development in recent years. This review summarises the current knowledge on RPE tear development, predictive factors, and treatment strategies before and after RPE tear formation. (C) 2015 S. Karger AG, Basel
C1 [Clemens, Christoph R.; Eter, Nicole] Univ Munster, Med Ctr, Dept Ophthalmol, DE-48149 Munster, Germany.
C3 University of Munster
RP Clemens, CR (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, DE-48149 Munster, Germany.
EM Christoph.Clemens@ukmuenster.de
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Bartels S, 2014, OPHTHALMOLOGE, V111, P460, DOI 10.1007/s00347-013-2883-1
   Bertelmann T, 2014, OPHTHALMOLOGE, V111, P775, DOI 10.1007/s00347-013-2954-3
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Caramoy A, 2010, BR J OPHTHALMOL, V96, P1211
   Caramoy A, 2012, ACTA OPHTHALMOL, V90, pE328, DOI 10.1111/j.1755-3768.2011.02284.x
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Clemens CR, 2015, ACTA OPHTHALMOL
   Clemens CR, 2015, MONTHLY TREATMENT RA
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Guber J, 2013, BRIT J OPHTHALMOL, V97, P1486, DOI 10.1136/bjophthalmol-2013-303978
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   IE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443, DOI 10.1001/archopht.1992.01080220105030
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 55
TC 32
Z9 35
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 235
IS 1
BP 1
EP 9
DI 10.1159/000439445
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0FS
UT WOS:000368184600001
PM 26489018
OA Bronze
DA 2022-11-30
ER

PT J
AU Tucker, BA
   Mullins, RF
   Stone, EM
AF Tucker, Budd A.
   Mullins, Robert F.
   Stone, Edwin M.
TI Stem cells for investigation and treatment of inherited retinal disease
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID LEBER CONGENITAL AMAUROSIS; THERAPY RESTORES VISION; GENE-THERAPY; MOUSE
   MODEL; PROGENITOR CELLS; RETINITIS-PIGMENTOSA; MOLECULAR
   CHARACTERIZATION; PHOTORECEPTOR PRECURSORS; FUNCTIONAL EXPRESSION;
   ADENOASSOCIATED VIRUS
AB Vision is the most important human sense. It facilitates every major activity of daily living ranging from basic communication, mobility and independence to an appreciation of art and nature. Heritable diseases of the retina, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world, collectively affecting as many as one-third of all people over the age of 75, to some degree. For decades, scientists have dreamed of preventing vision loss or of restoring the vision of patients affected with retinal degeneration through some type of drug, gene or cell-based transplantation approach. In this review, we will discuss the current literature pertaining to retinal transplantation. We will focus on the use of induced pluripotent stem cells for interrogation of disease pathophysiology, analysis of drug and gene therapeutics and as a source of autologous cells for cell replacement.
C1 [Tucker, Budd A.; Mullins, Robert F.; Stone, Edwin M.] Univ Iowa, Carver Coll Med, Stephen A Wynn Inst Vis Res, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Stone, EM (通讯作者)，Univ Iowa, Carver Coll Med, Dept Ophthalmol, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM edwin-stone@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Tucker, Budd/0000-0003-2178-1742; Mullins, Robert/0000-0002-5006-0891;
   Stone, Edwin M./0000-0003-3343-4414
FU NIH - Directors New Innovator Award [DP2OD00748301, EY016822]; HHMI;
   Stephen A. Wynn Foundation; Grousbeck Family Foundation; Foundation
   Fighting Blindness; Hansjoerg E. J. W. Kolder, MD, PhD, Professorship in
   Best Disease Research; Elmer and Sylvia Sramek Charitable Foundation;
   NATIONAL EYE INSTITUTE [R01EY016822] Funding Source: NIH RePORTER;
   OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD007483]
   Funding Source: NIH RePORTER
FX NIH - Directors New Innovator Award DP2OD00748301 and EY016822; HHMI;
   Stephen A. Wynn Foundation; Grousbeck Family Foundation; Foundation
   Fighting Blindness; Hansjoerg E. J. W. Kolder, MD, PhD, Professorship in
   Best Disease Research; The Elmer and Sylvia Sramek Charitable
   Foundation. Funding to pay the Open Access publication charges for this
   article was provided by the HHMI.
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Boye SL, 2013, HUM GENE THER, V24, P189, DOI 10.1089/hum.2012.193
   CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Dai X., 2014, INVEST OPHTH VIS SCI, DOI [10.1167/ioversus13-13654, DOI 10.1167/IOVERSUS13-13654]
   Egawa N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004052
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gorbatyuk MS, 2012, ADV EXP MED BIOL, V723, P191, DOI 10.1007/978-1-4614-0631-0_26
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inoue H, 2011, CLIN PHARMACOL THER, V89, P655, DOI 10.1038/clpt.2011.38
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Koch S, 2012, HUM MOL GENET, V21, P4486, DOI 10.1093/hmg/dds290
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Li X, 2011, INVEST OPHTH VIS SCI, V52, P7, DOI 10.1167/iovs.10-6138
   LINDAHL T, 1993, COLD SPRING HARB SYM, V58, P619, DOI 10.1101/SQB.1993.058.01.068
   Liu Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043251
   Lopes VS, 2013, GENE THER, V20, P824, DOI 10.1038/gt.2013.3
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maclaren R. E., 2014, LANCET, DOI [10.1016/S0140-6736(13)62117-0, DOI 10.1016/S0140-6736(13)62117-0.]
   Maeder ML, 2013, NAT METHODS, V10, P977, DOI [10.1038/nmeth.2598, 10.1038/NMETH.2598]
   Mali P, 2013, NAT BIOTECHNOL, V31, P833, DOI 10.1038/nbt.2675
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Michalakis S, 2012, ADV EXP MED BIOL, V723, P183, DOI 10.1007/978-1-4614-0631-0_25
   Mihelec M, 2011, HUM GENE THER, V22, P1179, DOI 10.1089/hum.2011.069
   Mowat FM, 2013, GENE THER, V20, P545, DOI 10.1038/gt.2012.63
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Mullins RF, 2012, INVEST OPHTH VIS SCI, V53, P1883, DOI 10.1167/iovs.12-9477
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Niederkorn Jerry Y, 2007, Chem Immunol Allergy, V92, P27, DOI 10.1159/000099251
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Seo S, 2013, INVEST OPHTH VIS SCI, V54, P6118, DOI 10.1167/iovs.13-11673
   Simons DL, 2011, P NATL ACAD SCI USA, V108, P6276, DOI 10.1073/pnas.1019222108
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tolmachova T, 2013, J MOL MED, V91, P825, DOI 10.1007/s00109-013-1006-4
   Tolmachova T, 2012, J GENE MED, V14, P158, DOI 10.1002/jgm.1652
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yahata N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025788
   Young M. J., 2014, TISSUE ENG PART A, DOI [10.1089/ten.TEA.2013.0361, DOI 10.1089/TEN.TEA.2013.0361.]
   Yu H, 2012, P NATL ACAD SCI USA, V109, pE1238, DOI 10.1073/pnas.1119577109
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
NR 66
TC 48
Z9 48
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 15
PY 2014
VL 23
SI 1
BP R9
EP R16
DI 10.1093/hmg/ddu124
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CB7RS
UT WOS:000349825700002
PM 24647603
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Chong, EWT
   Sinclair, AJ
   Guymer, RH
AF Chong, Elaine W-T
   Sinclair, Andrew J.
   Guymer, Robyn H.
TI Facts on fats
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; fatty acid; omega 3 fatty acid; omega
   6 fatty acid; trans-unsaturated fat
ID CORONARY-HEART-DISEASE; DIETARY-FAT; FISH CONSUMPTION; MACULAR
   DEGENERATION; ACIDS; RISK; LIPIDS; METAANALYSIS; CHOLESTEROL; MARGARINES
AB Cardiovascular disease and age-related macular degeneration (AMD) may share common risk factors in their causal pathways. Decades of research from the cardiovascular sciences on fats have led investigators to focus on specific types of fats rather than total fat as a whole. They have established that saturated and trans-unsaturated fats (trans fats) are damaging to cardiovascular health while polyunsaturated fats, particularly the marine omega 3 fatty acids appear protective. This has led to a number of studies investigating the associations of fat and AMD. Though the causal relationship between fats and AMD remain unproven, some studies suggest that an association may be present. To be able to understand and interpret the study results and their implications, an understanding of the fats in the diet is important. This review aims to give an overview of fatty acids, particularly the trans-unsaturated fatty acids, and the relevant food groups.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Deakin Univ, Sch Exercise & Nutr Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Deakin
   University
RP Chong, EWT (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 3002, Australia.
EM e.chong2@pgrad.unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR AKOH CC, 2005, HEALTHFUL LIPIDS, P593
   Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84
   BEAREROGERS JL, 1985, CAN J PUBLIC HEALTH, V76, P276
   Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112
   Clifton PM, 2004, J NUTR, V134, P1848
   Clifton PM, 2004, J NUTR, V134, P874, DOI 10.1093/jn/134.4.874
   *DEP HLTH, 2003, REG AM FOOD DRUG 11
   *DEP HLTH AG AUSTR, 2004, NUTR REF VAL AUSTR N, P285
   Din JN, 2004, BMJ-BRIT MED J, V328, P30, DOI 10.1136/bmj.328.7430.30
   Dreher ML, 1996, NUTR REV, V54, P241, DOI 10.1111/j.1753-4887.1996.tb03941.x
   Dubnov G, 2003, WORLD REV NUTR DIET, V92, P81
   EASTWOOD M, 1997, PRINCIPLES HUMAN NUT
   Feldman EB, 2002, J NUTR, V132, p1062S, DOI 10.1093/jn/132.5.1062S
   Feldman EB, 1996, AM J CLIN NUTR, V63, P663
   Gebauer S., 2005, HEALTHFUL LIPIDS, P221
   GOLDSTEIN JL, 1984, CLIN RES, V32, P412
   GURR MI, 1984, ROLE FATS FOOD NUTR
   He K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B
   He K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   HILDEBRAND D, 2005, HEALTHFUL LIPIDS, P526
   Howell WH, 1997, AM J CLIN NUTR, V65, P1747, DOI 10.1093/ajcn/65.6.1747
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Hu FB, 2001, J AM COLL NUTR, V20, P5, DOI 10.1080/07315724.2001.10719008
   INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q
   Innis SM, 1999, J AM COLL NUTR, V18, P255, DOI 10.1080/07315724.1999.10718860
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Karupaiah T., 2005, HLTH LIPIDS, P171
   KEYS A, 1970, CIRCULATION, V41, P1162
   Kris-Etherton PM, 1999, AM J CLIN NUTR, V70, p504S, DOI 10.1093/ajcn/70.3.504s
   Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0
   Larsson SC, 2004, AM J CLIN NUTR, V79, P935
   Mansour M P, 1993, Asia Pac J Clin Nutr, V2, P155
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mozaffarian D, 2003, CIRCULATION, V107, P1372, DOI 10.1161/01.CIR.0000055315.79177.16
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   Nicklas TA, 2004, NUTR REV, V62, P132, DOI [10.1301/nr.2004.apr.132-141, 10.1301/nr.2004.apr.132&ndash;141]
   NOAKES M, 1994, FOOD AUST, V46, P124
   OHTANI H, 1990, J LIPID RES, V31, P1413
   Potts A M, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P1058
   Ratnayake W. M. N., 2005, HEALTHFUL LIPIDS, P1
   Ratnayake WMN, 1998, J AM OIL CHEM SOC, V75, P1587, DOI 10.1007/s11746-998-0098-4
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sinclair A. J., 1998, Australian Journal of Nutrition and Dietetics, V55, P116
   SINCLAIR AJ, 1994, LIPIDS, V29, P337, DOI 10.1007/BF02537187
   SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   STENDER S, 2003, PUBLICATION DANISH N, V34
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722
   WILLS RBH, 1982, FOOD TECHNOL AUST, V34, P240
   WOOLLETT LA, 1992, J LIPID RES, V33, P77
   Zock PL, 1996, CURR OPIN LIPIDOL, V7, P34, DOI 10.1097/00041433-199602000-00008
NR 58
TC 23
Z9 24
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2006
VL 34
IS 5
BP 464
EP 471
DI 10.1111/j.1442-9071.2006.01250.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 061PA
UT WOS:000238883400015
PM 16872345
DA 2022-11-30
ER

PT J
AU Voigt, AP
   Whitmore, SS
   Mulfaul, K
   Chirco, KR
   Giacalone, JC
   Flamme-Wiese, MJ
   Stockman, A
   Stone, EM
   Tucker, BA
   Scheetz, TE
   Mullins, RF
AF Voigt, Andrew P.
   Whitmore, S. Scott
   Mulfaul, Kelly
   Chirco, Kathleen R.
   Giacalone, Joseph C.
   Flamme-Wiese, Miles J.
   Stockman, Adam
   Stone, Edwin M.
   Tucker, Budd A.
   Scheetz, Todd E.
   Mullins, Robert F.
TI Bulk and single-cell gene expression analyses reveal aging human
   choriocapillaris has pro-inflammatory phenotype
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Single-cell; Choroid; Choriocapillaris; Pericytes; Infant; Age-related
   macular degeneration
ID ENDOTHELIAL-CELLS; NUCLEAR RECEPTORS; HUMAN RETINA; TRANSCRIPTION;
   MACULA; PATHOGENESIS; SIGNATURE; ADHESION; ROLES
AB The human choroidal vasculature is subject to age-related structural and gene expression changes implicated in age-related macular degeneration (AMD). In this study, we performed both bulk and single-cell RNA sequencing on infant (n = 4 for bulk experiments, n = 2 for single-cell experiments) and adult (n = 13 for bulk experiments, n = 6 for single-cell experiments) human donors to characterize how choroidal gene expression changes with age. Differential expression analysis revealed that aged choroidal samples were enriched in genes encoding proinflammatory transcription factors and leukocyte transendothelial cell migration adhesion proteins. Such genes were observed to be differentially expressed specifically within choroidal endothelial cells at the single-cell level. Immunohistochemistry experiments support transcriptional findings that CD34 is elevated in infant choriocapillaris endothelial cells while ICAM-1 is enriched in adults. These results suggest several potential drivers of the pro-inflammatory vascular phenotype observed with advancing age.
C1 [Voigt, Andrew P.; Whitmore, S. Scott; Mulfaul, Kelly; Chirco, Kathleen R.; Giacalone, Joseph C.; Flamme-Wiese, Miles J.; Stockman, Adam; Stone, Edwin M.; Tucker, Budd A.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA 52242 USA.
   [Voigt, Andrew P.; Whitmore, S. Scott; Mulfaul, Kelly; Chirco, Kathleen R.; Giacalone, Joseph C.; Flamme-Wiese, Miles J.; Stone, Edwin M.; Tucker, Budd A.; Scheetz, Todd E.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
   [Stockman, Adam] Iowa Lions Eye Bank, Coralville, IA 52241 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Tucker, Budd/0000-0003-2178-1742; Whitmore, S.
   Scott/0000-0003-0161-9625; Scheetz, Todd/0000-0002-1965-5811; Giacalone,
   Joseph/0000-0003-4404-9749; Mullins, Robert/0000-0002-5006-0891; Stone,
   Edwin M./0000-0003-3343-4414; Voigt, Andrew/0000-0001-8107-8317
FU NIH [T32 GM007337, EY024605, P30 EY025580]; Research to Prevent
   Blindness; Elmer and Sylvia Sramek Charitable Trust; Martin Carver Chair
   in Ocular Cell Biology
FX These studies were funded by NIH grants T32 GM007337, EY024605, and P30
   EY025580 with additional support from the Research to Prevent Blindness,
   the Elmer and Sylvia Sramek Charitable Trust, and the Martin Carver
   Chair in Ocular Cell Biology.
CR Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Chasseigneaux S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30739-5
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chirco KR, 2018, EYE, V32, P1740, DOI 10.1038/s41433-018-0170-8
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Choudhary M, 2016, J BIOMOL SCREEN, V21, P1007, DOI 10.1177/1087057116659856
   Cui XF, 2015, SCI REP-UK, V5, DOI 10.1038/srep16193
   Das JK, 2015, MICROVASC RES, V98, P126, DOI 10.1016/j.mvr.2015.01.006
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giacalone JC, 2019, MICROVASC RES, V123, P50, DOI 10.1016/j.mvr.2018.12.002
   He XJ, 2020, NAT METAB, V2, P293, DOI 10.1038/s42255-020-0196-7
   Hu YQ, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000365
   Ito Y, 2013, CURR PHARM BIOTECHNO, V14, P400, DOI 10.2174/1389201011314040003
   Jia J, 2016, MICROVASC RES, V105, P103, DOI 10.1016/j.mvr.2016.02.004
   Kallestad L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51379-3
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kitagawa M, 2013, MECH DEVELOP, V130, P458, DOI 10.1016/j.mod.2013.07.001
   Lehmann GL, 2020, J EXP MED, V217, DOI 10.1084/jem.20190730
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Lun ATL, 2017, BIOSTATISTICS, V18, P451, DOI 10.1093/biostatistics/kxw055
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mullins RF, 2006, MOL VIS, V12, P224
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nork TM, 2006, ARCH OPHTHALMOL-CHIC, V124, P860, DOI 10.1001/archopht.124.6.860
   Paneni F, 2013, CIRCULATION, V127, P1229, DOI 10.1161/CIRCULATIONAHA.112.000826
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rohlenova K, 2020, CELL METAB, V31, P862, DOI 10.1016/j.cmet.2020.03.009
   SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Songstad AE, 2017, STEM CELL TRANSL MED, V6, P1533, DOI 10.1002/sctm.16-0399
   Steen R, 1998, LEUKEMIA LYMPHOMA, V30, P23, DOI 10.3109/10428199809050926
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   van Soest SS, 2007, MOL VIS, V13, P1608
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   You B, 2009, CIRC RES, V104, P742, DOI 10.1161/CIRCRESAHA.108.192286
   Zhao Y, 2010, CIRC RES, V107, P501, DOI 10.1161/CIRCRESAHA.110.222083
NR 60
TC 19
Z9 18
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD SEP
PY 2020
VL 131
AR 104031
DI 10.1016/j.mvr.2020.104031
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA MV5MB
UT WOS:000556400800015
PM 32531351
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yu, C
   Roubeix, C
   Sennlaub, F
   Saban, DR
AF Yu, Chen
   Roubeix, Christophe
   Sennlaub, Florian
   Saban, Daniel R.
TI Microglia versus Monocytes: Distinct Roles in Degenerative Diseases of
   the Retina
SO TRENDS IN NEUROSCIENCES
LA English
DT Review
ID FATE MAPPING REVEALS; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; PHOTORECEPTOR DEGENERATION; CHEMOATTRACTANT
   PROTEIN-1; SUBRETINAL INFLAMMATION; PIGMENT EPITHELIUM; LANGERHANS
   CELLS; APOPTOTIC CELLS; POOLED ANALYSIS
AB Unlike in the healthy mammalian retina, macrophages in retinal degenerative states are not solely comprised of microglia but may include monocyte-derived recruits. Recent studies have applied transgenics, lineage-tracing, and transcriptomics to help decipher the distinct roles of these two cell types in the disease settings of inherited retinal degenerations and age-related macular degeneration. Literature discussed here focuses on the ectopic presence of both macrophage types in the extracellular site surrounding the outer aspect of photoreceptor cells (i.e., the subretinal space), which is crucially involved in the pathobiology. From these studies we propose a working model in which perturbed photoreceptor states cause microglial dominant migration to the subretinal space as a protective response, whereas the abundant presence of monocyte-derived cells there instead drives and accelerates pathology. The latter, we propose, is underpinned by specific genetic and nongenetic determinants that lead to a maladaptive macrophage state.
C1 [Yu, Chen; Saban, Daniel R.] Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
   [Roubeix, Christophe; Sennlaub, Florian] Sorbonne Univ, INSERM, CNRS, Inst Vis, F-75012 Paris, France.
   [Saban, Daniel R.] Duke Univ, Dept Immunol, Durham, NC 27710 USA.
C3 Duke University; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Duke University
RP Saban, DR (通讯作者)，Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.; Sennlaub, F (通讯作者)，Sorbonne Univ, INSERM, CNRS, Inst Vis, F-75012 Paris, France.; Saban, DR (通讯作者)，Duke Univ, Dept Immunol, Durham, NC 27710 USA.
EM florian.sennlaub@inserm.fr; daniel.saban@duke.edu
RI Yu, Chen/GPG-1530-2022; Sennlaub, Florian/F-2756-2017
OI Yu, Chen/0000-0001-9651-9875; Sennlaub, Florian/0000-0003-4412-1341
FU NIH [R01EY021798, P30EY005722]; Bright Focus MDR; Research to Prevent
   Blindness; ANR (Programme d'Investissements d'Avenir) [ANR-10-LABX-65,
   ANR-11-IDEX-0004-02]; BrightFocus Foundation [M2018096]; AVIESAN-UNADEV
   Maladies de la Vision 2018-2019 [UU159-00-C18/1616, UU11300-C17/2086];
   ANR MACLEAR [ANR-15-CE14-0015-01]
FX This work was supported by grants from NIH R01EY021798, NIH P30EY005722,
   Bright Focus MDR, Research to Prevent Blindness (Unrestricted) for
   Saban. For Sennlaub, INSERM, ANR MACLEAR (ANR-15-CE14-0015-01), LABEX
   LIFESENSES [ANR-10-LABX-65] supported by the ANR (Programme
   d'Investissements d'Avenir [ANR-11-IDEX-0004-02]), BrightFocus
   Foundation grant (M2018096), AVIESAN-UNADEV Maladies de la Vision
   2018-2019 (N degrees UU159-00-C18/1616, N degrees UU11300-C17/2086),
   Carnot, and a generous donation by Doris and Michael Bunte.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887
   Anderson SR, 2019, CELL REP, V27, P2002, DOI 10.1016/j.celrep.2019.04.062
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dando SJ, 2019, GLIA, V67, P935, DOI 10.1002/glia.23581
   Deczkowska A, 2018, NAT NEUROSCI, V21, P779, DOI 10.1038/s41593-018-0145-x
   Dransfield I, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.18
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Duncan JL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.6
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   ESSNER E, 1979, INVEST OPHTH VIS SCI, V18, P11
   Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Feng CY, 2017, MOL VIS, V23, P765
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423
   Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Greter M, 2012, IMMUNITY, V37, P1050, DOI 10.1016/j.immuni.2012.11.001
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hammond TR, 2019, IMMUNITY, V50, P253, DOI 10.1016/j.immuni.2018.11.004
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200
   Heng JS, 2019, P NATL ACAD SCI USA, V116, P26734, DOI 10.1073/pnas.1915571116
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Karlen SJ, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1365-4
   Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Kohno H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0408-3
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lapenna A, 2018, NAT REV IMMUNOL, V18, P689, DOI 10.1038/s41577-018-0056-9
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Liu ZY, 2019, CELL, V178, P1509, DOI 10.1016/j.cell.2019.08.009
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   McPherson SW, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1546-9
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Morshedian A, 2019, NEURON, V102, P1172, DOI 10.1016/j.neuron.2019.04.004
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Norris GT, 2018, J EXP MED, V215, P1789, DOI 10.1084/jem.20172244
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   O'Koren EG, 2019, IMMUNITY, V50, P723, DOI 10.1016/j.immuni.2019.02.007
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989
   Prokop S, 2015, J EXP MED, V212, P1811, DOI 10.1084/jem.20150479
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Reed-Geaghan EG, 2020, J EXP MED, V217, DOI 10.1084/jem.20191374
   Reyes NJ, 2017, NAT REV IMMUNOL, V17, P322, DOI 10.1038/nri.2017.13
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Ronning KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41141-0
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Sakami S, 2011, J BIOL CHEM, V286, P10551, DOI 10.1074/jbc.M110.209759
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Silverman SM, 2019, J EXP MED, V216, P1925, DOI 10.1084/jem.20190009
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Sim DA, 2015, DIS MODEL MECH, V8, P1479, DOI 10.1242/dmm.019018
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spencer WJ, 2019, P NATL ACAD SCI USA, V116, P13087, DOI 10.1073/pnas.1906421116
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sullivan PM, 2011, NEUROBIOL AGING, V32, P791, DOI 10.1016/j.neurobiolaging.2009.05.011
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Todd L, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1505-5
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Van Hove H, 2019, NAT NEUROSCI, V22, P1021, DOI 10.1038/s41593-019-0393-4
   Varvel NH, 2015, J EXP MED, V212, P1803, DOI 10.1084/jem.20150478
   Wang X, 2017, J NEUROSCI, V37, P3294, DOI 10.1523/JNEUROSCI.2717-16.2017
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wang YM, 2012, NAT IMMUNOL, V13, P753, DOI 10.1038/ni.2360
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Yu C, 2019, J CELL SCI, V132, DOI 10.1242/jcs.232439
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zabel MK, 2013, AGEING RES REV, V12, P749, DOI 10.1016/j.arr.2013.02.001
   Zhang R, 2015, INVEST OPHTH VIS SCI, V56, P5590, DOI 10.1167/iovs.15-16830
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zoller T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06224-y
NR 133
TC 40
Z9 40
U1 3
U2 10
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0166-2236
EI 1878-108X
J9 TRENDS NEUROSCI
JI Trends Neurosci.
PD JUN
PY 2020
VL 43
IS 6
BP 433
EP 449
DI 10.1016/j.tins.2020.03.012
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA LT0DR
UT WOS:000536748200010
PM 32459994
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Cheng, L
   Yu, HH
   Yan, NH
   Lai, KB
   Xiang, MQ
AF Cheng, Lin
   Yu, Honghua
   Yan, Naihong
   Lai, Kunbei
   Xiang, Mengqing
TI Hypoxia-Inducible Factor-1 alpha Target Genes Contribute to Retinal
   Neuroprotection
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Article
DE HIF-1 alpha; hypoxia preconditioning; retina; neuroprotection; retinal
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS;
   ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; PROLIFERATIVE
   DIABETIC-RETINOPATHY; HEME OXYGENASE-1 EXPRESSION; MESSENGER-RNA
   EXPRESSION; NERVE-FIBER LAYER; GANGLION-CELLS; ERYTHROPOIETIN PROTECTS
AB Hypoxia-inducible factor (HIF) is a transcription factor that facilitates cellular adaptation to hypoxia and ischemia. Long-standing evidence suggests that one isotype of HIF, HIF-1 alpha, is involved in the pathogenesis of various solid tumors and cardiac diseases. However, the role of HIF-1 alpha in retina remains poorly understood. HIF-1 alpha has been recognized as neuroprotective in cerebral ischemia in the past two decades. Additionally, an increasing number of studies has shown that HIF-1 alpha and its target genes contribute to retinal neuroprotection. This review will focus on recent advances in the studies of HIF-1 alpha and its target genes that contribute to retinal neuroprotection. A thorough understanding of the function of HIF-1 alpha and its target genes may lead to identification of novel therapeutic targets for treating degenerative retinal diseases including glaucoma, age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.
C1 [Cheng, Lin; Yu, Honghua; Lai, Kunbei; Xiang, Mengqing] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
   [Yu, Honghua] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Yan, Naihong] Sichuan Univ, Dept Ophthalmol & Ophthalm Labs, Steate Key Lab Biotherapy, Chengdu, Peoples R China.
   [Yan, Naihong] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China.
   [Xiang, Mengqing] Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08901 USA.
   [Xiang, Mengqing] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08901 USA.
C3 Sun Yat Sen University; Southern Theater Command General Hospital;
   Sichuan University; Sichuan University; Rutgers State University New
   Brunswick; Rutgers State University Medical Center; Rutgers State
   University New Brunswick; Rutgers State University Medical Center
RP Cheng, L; Xiang, MQ (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.; Xiang, MQ (通讯作者)，Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08901 USA.; Xiang, MQ (通讯作者)，Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08901 USA.
EM kjade.cheng@gmail.com; xiangmq3@mail.sysu.edu.cn
OI Yu, Honghua/0000-0002-0782-346X; Cheng, Lin/0000-0002-4960-8186
FU Fundamental Research Funds of the State Key Laboratory of Ophthalmology
   in Sun Yat-sen University; National Basic Research Program (973 Program)
   of China [2015CB964600]; National Natural Science Foundation of China
   [81670862, 81603200]; New Jersey Health Foundation; China Postdoctoral
   Science Foundation [2015M580758]; Natural Science Foundation of
   Guangdong Province [2016A030310201]
FX We thank Dr. Sumit Bhattacharya at Department of Neurosciences,
   University of Toledo for language editing. This work was supported in
   part by the Fundamental Research Funds of the State Key Laboratory of
   Ophthalmology in Sun Yat-sen University, National Basic Research Program
   (973 Program) of China (2015CB964600), National Natural Science
   Foundation of China (81670862, 81603200), New Jersey Health Foundation,
   China Postdoctoral Science Foundation (2015M580758), and Natural Science
   Foundation of Guangdong Province (2016A030310201).
CR Abu El-Asrar AM, 2004, EYE, V18, P306, DOI 10.1038/sj.eye.6700642
   Ando H, 2013, BIOCHEM BIOPH RES CO, V433, P139, DOI 10.1016/j.bbrc.2013.02.044
   Arai-Gaun S, 2004, INVEST OPHTH VIS SCI, V45, P4226, DOI 10.1167/iovs.04-0450
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Augstein A, 2011, CELL MOL LIFE SCI, V68, P2627, DOI 10.1007/s00018-010-0575-4
   Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031
   Becerra SP, 2002, NEW ENGL J MED, V347, P1968, DOI 10.1056/NEJMcibr022629
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Blom J, 2012, MOL VIS, V18, P1339
   Bocker-Meffert S, 2002, INVEST OPHTH VIS SCI, V43, P2021
   Busch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102013
   Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898
   Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   Chao HM, 2013, J OCUL PHARMACOL TH, V29, P539, DOI 10.1089/jop.2012.0179
   Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]
   Chen ZG, 2014, MOL VIS, V20, P259
   Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   Colella P, 2011, HUM MOL GENET, V20, P2251, DOI 10.1093/hmg/ddr115
   Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Cuevas P, 1998, NEUROSCI LETT, V255, P1, DOI 10.1016/S0304-3940(98)00672-7
   Cukiernik M, 2003, CURR EYE RES, V27, P301, DOI 10.1076/ceyr.27.5.301.17227
   daSilva JL, 1997, CURR EYE RES, V16, P380, DOI 10.1076/ceyr.16.4.380.10695
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Dogan A, 1997, J CEREBR BLOOD F MET, V17, P19, DOI 10.1097/00004647-199701000-00004
   Eckardt KU, 2005, EUR J CLIN INVEST, V35, P13, DOI 10.1111/j.1365-2362.2005.01525.x
   Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029
   Emerich DF, 2010, CELL TRANSPLANT, V19, P1063, DOI 10.3727/096368910X498278
   Erbayraktar Serhat, 2003, Curr Hematol Rep, V2, P465
   Evereklioglu C, 2002, JPN J OPHTHALMOL, V46, P203, DOI 10.1016/S0021-5155(01)00501-9
   Fan JW, 2012, INVEST OPHTH VIS SCI, V53, P6541, DOI 10.1167/iovs.11-9241
   Fernandes R, 2011, AM J PHYSIOL-CELL PH, V300, pC927, DOI 10.1152/ajpcell.00140.2010
   Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006
   Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fulton AB, 2009, DOC OPHTHALMOL, V118, P55, DOI 10.1007/s10633-008-9127-8
   GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135
   Garcia-Ramirez M, 2008, DIABETES CARE, V31, P1189, DOI 10.2337/dc07-2075
   Gassmann M, 2003, ADV EXP MED BIOL, V543, P323
   Gawad AE, 2009, EYE, V23, P2245, DOI 10.1038/eye.2008.398
   Geraldes P, 2008, J BIOL CHEM, V283, P34327, DOI 10.1074/jbc.M807036200
   Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927
   GLAZIER SS, 1994, J CEREBR BLOOD F MET, V14, P545, DOI 10.1038/jcbfm.1994.68
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Grimm C, 2012, HIGH ALT MED BIOL, V13, P169, DOI 10.1089/ham.2012.1031
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7
   Hanaoka M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050566
   Harten SK, 2010, ANTIOXID REDOX SIGN, V12, P459, DOI 10.1089/ars.2009.2870
   He MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084800
   He MH, 2013, INVEST OPHTH VIS SCI, V54, P4092, DOI 10.1167/iovs.13-12004
   Hegazy KA, 2000, NEUROREPORT, V11, P1185, DOI 10.1097/00001756-200004270-00008
   Heikkila M, 2011, CELL MOL LIFE SCI, V68, P3885, DOI 10.1007/s00018-011-0679-5
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hernandez C, 2012, CURR DIABETES REP, V12, P329, DOI 10.1007/s11892-012-0284-5
   Himori N, 2014, J NEUROSCI RES, V92, P1134, DOI 10.1002/jnr.23398
   Hines-Beard J, 2013, CURR GENE THER, V13, P275
   Hosoya K, 2008, NEUROCHEM INT, V52, P1351, DOI 10.1016/j.neuint.2008.02.001
   Iesato Y, 2013, AM J PATHOL, V182, P2380, DOI 10.1016/j.ajpath.2013.02.015
   Igarashi K, 2014, PEPTIDES, V62, P21, DOI 10.1016/j.peptides.2014.08.013
   Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1
   Ito S, 2003, OPHTHALMOLOGICA, V217, P53, DOI 10.1159/000068244
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399
   KATZ B, 1989, ANN NEUROL, V26, P221, DOI 10.1002/ana.410260207
   Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000
   Kikuchi G, 2005, BIOCHEM BIOPH RES CO, V338, P558, DOI 10.1016/j.bbrc.2005.08.020
   Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje
   Kilic U, 2004, NEURODEGENER DIS, V1, P44, DOI 10.1159/000076669
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kim KJ, 2012, INVEST OPHTH VIS SCI, V53, P6456, DOI 10.1167/iovs.12-9658
   KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I
   Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000
   Koskela A, 2014, MOL VIS, V20, P760
   Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lee D, 2014, APOPTOSIS, V19, P603, DOI 10.1007/s10495-013-0956-x
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Lopez J, 2002, INT REV CYTOL, V221, P1
   Lu LL, 2013, J CELL PHYSIOL, V228, P251, DOI 10.1002/jcp.24133
   Maenhaut N, 2007, MICROCIRCULATION, V14, P39, DOI 10.1080/10739680601072131
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mitsuhashi J, 2013, EXP EYE RES, V106, P64, DOI 10.1016/j.exer.2012.11.001
   Miyashita K, 2006, ENDOCRINOLOGY, V147, P1642, DOI 10.1210/en.2005-1038
   Montuenga LM, 1997, ENDOCRINOLOGY, V138, P440, DOI 10.1210/en.138.1.440
   Moravski CJ, 2003, AM J PATHOL, V162, P151, DOI 10.1016/S0002-9440(10)63806-0
   Morse D, 2005, AM J RESP CRIT CARE, V172, P660, DOI 10.1164/rccm.200404-465SO
   Mowat FM, 2012, AM J PATHOL, V180, P1726, DOI 10.1016/j.ajpath.2011.12.033
   Nagpal Manish, 2007, Indian Journal of Ophthalmology, V55, P437
   NIHIRA M, 1995, INVEST OPHTH VIS SCI, V36, P1259
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Peng PH, 2011, CURR EYE RES, V36, P238, DOI 10.3109/02713683.2010.539760
   Peng PH, 2008, CLIN SCI, V115, P335, DOI 10.1042/CS20070384
   Ponnaluri VKC, 2011, BIOCHEM BIOPH RES CO, V415, P373, DOI 10.1016/j.bbrc.2011.10.075
   Puchowicz MA, 2004, J CEREBR BLOOD F MET, V24, P449, DOI 10.1097/00004647-200404000-00010
   Rappoport D, 2013, INVEST OPHTH VIS SCI, V54, P8160, DOI 10.1167/iovs.13-12771
   Ray D, 2004, DIABETES, V53, P861, DOI 10.2337/diabetes.53.3.861
   Ren H, 2011, INVEST OPHTH VIS SCI, V52, P3112, DOI 10.1167/iovs.10-5605
   Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakamoto K, 2006, EXP EYE RES, V82, P512, DOI 10.1016/j.exer.2005.08.011
   Satarug S, 2008, BIOCHEM BIOPH RES CO, V377, P878, DOI 10.1016/j.bbrc.2008.10.094
   Schubert D, 2005, AGEING RES REV, V4, P240, DOI 10.1016/j.arr.2005.02.003
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semeran K, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/274726
   Shaw SG, 2006, EXP BIOL MED, V231, P1101
   Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544
   Shen WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104759
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111
   ShyongAb MP, 2008, VISION RES, V48, P2394, DOI 10.1016/j.visres.2008.07.017
   Sierra A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106048
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005
   Sullivan TA, 2011, HUM GENE THER, V22, P1191, DOI 10.1089/hum.2011.052
   Sun MH, 2007, INVEST OPHTH VIS SCI, V48, P5699, DOI 10.1167/iovs.07-0340
   Sun MH, 2010, INVEST OPHTH VIS SCI, V51, P4798, DOI 10.1167/iovs.09-4086
   Suzuki M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-176
   Takahashi K, 2001, TOHOKU J EXP MED, V193, P79, DOI 10.1620/tjem.193.79
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Toft-Kehler AK, 2014, NEUROCHEM RES, V39, P941, DOI 10.1007/s11064-014-1289-z
   Udono T, 2000, INVEST OPHTH VIS SCI, V41, P1962
   Udono T, 2002, PEPTIDES, V23, P1865, DOI 10.1016/S0196-9781(02)00145-6
   Udono T, 2001, INVEST OPHTH VIS SCI, V42, P1080
   Udono-Fujimori R, 2003, REGUL PEPTIDES, V112, P95, DOI 10.1016/S0167-0115(03)00027-2
   Ulyanova T, 2001, INVEST OPHTH VIS SCI, V42, P1370
   Valter K, 2005, INVEST OPHTH VIS SCI, V46, P1748, DOI 10.1167/iovs.04-0657
   Varga B, 2013, J MOL NEUROSCI, V50, P558, DOI 10.1007/s12031-013-9998-3
   Vingolo EM, 2005, CLIN BIOCHEM, V38, P735, DOI 10.1016/j.clinbiochem.2005.04.007
   Wang Q, 2011, CELL PHYSIOL BIOCHEM, V27, P769, DOI 10.1159/000330085
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Weng Yan, 2006, Fen Zi Xi Bao Sheng Wu Xue Bao, V39, P373
   Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87
   Willmann G, 2013, JAMA-J AM MED ASSOC, V309, P2210, DOI 10.1001/jama.2013.5550
   Xia CF, 2006, EXP NEUROL, V197, P521, DOI 10.1016/j.expneurol.2005.10.027
   Xia CF, 2004, HUM GENE THER, V15, P1243, DOI 10.1089/hum.2004.15.1243
   Xie Z, 2012, EYE, V26, P144, DOI 10.1038/eye.2011.254
   Xie ZG, 2012, CURR EYE RES, V37, P138, DOI 10.3109/02713683.2011.647225
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Yi X, 2010, SCIENCE, V329, P75, DOI 10.1126/science.1190371
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
   Yuda K, 2012, AM J PATHOL, V181, P1464, DOI 10.1016/j.ajpath.2012.06.028
   Zhang H, 2014, PEPTIDES, V52, P44, DOI 10.1016/j.peptides.2013.11.025
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
   Zhang XX, 2014, VISUAL NEUROSCI, V31, P245, DOI 10.1017/S0952523814000121
   Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510
   Zhong YS, 2008, J OCUL PHARMACOL TH, V24, P453, DOI 10.1089/jop.2008.0021
   Zhu YL, 2007, INVEST OPHTH VIS SCI, V48, P1735, DOI 10.1167/iovs.06-1037
   Zhu YL, 2013, MOL VIS, V19, P2360
   Zhu YL, 2008, J OCUL PHARMACOL TH, V24, P527, DOI 10.1089/jop.2008.0082
   Zhu YL, 2006, EXP EYE RES, V82, P153, DOI 10.1016/j.exer.2005.06.005
NR 166
TC 39
Z9 41
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD FEB 27
PY 2017
VL 11
AR 20
DI 10.3389/fncel.2017.00020
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EL8SP
UT WOS:000394890500001
PM 28289375
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jo, DH
   Kim, S
   Kim, D
   Kim, JH
   Jon, S
   Kim, JH
AF Jo, Dong Hyun
   Kim, Sunghyun
   Kim, Daejin
   Kim, Jin Hyoung
   Jon, Sangyong
   Kim, Jeong Hun
TI VEGF-binding aptides and the inhibition of choroidal and retinal
   neovascularization
SO BIOMATERIALS
LA English
DT Article
DE Pathological angiogenesis; Vascular endothelial growth factor; Choroidal
   neovascularization; Retinal neovascularization; Age-related macular
   degeneration; Diabetic retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; OXYGEN-INDUCED RETINOPATHY; LARGE GENE LISTS;
   MACULAR DEGENERATION; VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY;
   BEVACIZUMAB; ANGIOGENESIS; RANIBIZUMAB; AFLIBERCEPT
AB Age-related macular degeneration and diabetic retinopathy are leading causes of blindness. Vascular endothelial growth factor (VEGF) is known to be the main factor that induces pathological angiogenesis in these diseases. In this study, we investigate the therapeutic potential and safety profiles of high-affinity peptides targeting VEGF which are identified using an 'aptide' technology. We show that two VEGF-binding aptides, APT(VEGF1) and APT(VEGF2), demonstrate high binding affinity and specificity to VEGF. Furthermore, they suppress VEGF-induced activation of VEGF receptor-2, in vitro angiogenesis, and in vivo pathological choroidal and retinal neovascularization. Despite potent anti-angiogenic effects, both VEGF-binding aptides do not induce any definite toxicity at the level of cellular viability, histological integrity, and gene expression. Our data show the therapeutic potential of VEGF-binding peptides for the treatment of choroidal and retinal neovascularization. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Fight Against Agiogenesis Related Blindness FARB, Clin Res Inst, Seoul 110744, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea.
   [Kim, Sunghyun; Kim, Daejin; Jon, Sangyong] Korea Adv Inst Sci & Technol KAIST, Dept Biol Sci, KAIST Inst BioCentury, Taejon 305701, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Korea Advanced Institute of Science &
   Technology (KAIST); Seoul National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Fight Against Agiogenesis Related Blindness FARB, Clin Res Inst, Seoul 110744, South Korea.
EM steph25@snu.ac.kr; syjon@kaist.ac.kr
RI Jon, Sangyong/C-3725-2012; Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU National Research Foundation of Korea; Korean Government
   [NRF-2012-M2A2A7047948, NRF-2012-K1A1A2048701, 2009-0090895,
   2012-0009544, 2012-0006019]; Seoul National University [800-20130338]
FX This study was supported by grants from the National Research Foundation
   of Korea funded by the Korean Government (NRF-2012-M2A2A7047948 and
   NRF-2012-K1A1A2048701 to S.J.; 2009-0090895, 2012-0009544, and
   2012-0006019 to Je.H.K.) and Seoul National University Research Grant
   (800-20130338) to Je.H.K.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cochran AG, 2001, P NATL ACAD SCI USA, V98, P5578, DOI 10.1073/pnas.091100898
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heo JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033456
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jo Dong Hyun, 2012, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V12, P110
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720
   Kim JH, 2007, INT J ONCOL, V31, P585
   Kim JH, 2008, NEUROTOXICOLOGY, V29, P1131, DOI 10.1016/j.neuro.2008.06.006
   Kim S, 2007, J BIOTECHNOL, V128, P638, DOI 10.1016/j.jbiotec.2006.11.027
   Kim S, 2012, ANGEW CHEM INT EDIT, V51, P1890, DOI 10.1002/anie.201107894
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   Nestor JJ, 2009, CURR MED CHEM, V16, P4399, DOI 10.2174/092986709789712907
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   PARK JM, 2013, J MATER CHEM B, V135, P1
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saw PE, 2013, J MATER CHEM B, V1, P4723, DOI 10.1039/c3tb20815j
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
NR 37
TC 17
Z9 19
U1 1
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2014
VL 35
IS 9
BP 3052
EP 3059
DI 10.1016/j.biomaterials.2013.12.031
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA AC0MH
UT WOS:000332188900049
PM 24388818
DA 2022-11-30
ER

PT J
AU Ferrara, N
   Hillan, KJ
   Novotny, W
AF Ferrara, N
   Hillan, KJ
   Novotny, W
TI Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for
   cancer therapy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Review
DE VEGF; endothelium; angiogenesis; chemotherapy; tumor; monoclonal
   antibodies
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; RECEPTOR
   TYROSINE KINASES; TUMOR ANGIOGENESIS; IN-VIVO; NEUTRALIZING ANTIBODY;
   COMPLETE INHIBITION; COLORECTAL-CANCER; BLOOD-VESSELS; FACTOR FAMILY
AB Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in vivo. The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2) are high affinity VEGF receptors. VEGF plays an essential role in developmental angiogenesis and is important also for reproductive and bone angiogenesis. Substantial evidence also implicates VEGF as a mediator of pathological angiogenesis. Anti-VEGF monoclonal antibodies and other VEGF inhibitors block the growth of several tumor cell lines in nude mice. Clinical trials with VEGF inhibitors in a variety of malignancies are ongoing. Recently, a humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration. (c) 2005 Elsevier Inc. All rights reserved.
C1 Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Dev Sci, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Clin Oncol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR ASANO M, 1995, CANCER RES, V55, P5296
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Borgstrom P, 1998, PROSTATE, V35, P1
   Borgstrom P, 1996, CANCER RES, V56, P4032
   Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020
   Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158
   CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
   DEVORE R, 2000, 36 ASCO ANN M NEW OR
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   EHRMANN RL, 1968, J NATL CANCER I, V41, P1329
   Ellis LM, 1998, EUR J CANCER, V34, P337, DOI 10.1016/S0959-8049(97)10068-5
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 2005, CANCER RES, V65, P671
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111
   GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Kozin SV, 2001, CANCER RES, V61, P39
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   Lee CG, 2000, CANCER RES, V60, P5565
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lin YS, 1999, J PHARMACOL EXP THER, V288, P371
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Melnyk O, 1996, CANCER RES, V56, P921
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Miller KD, 2002, BREAST CANCER RES TR, V76, pS37
   Mole DR, 2001, IUBMB LIFE, V52, P43
   Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609
   Oku T, 1998, CANCER RES, V58, P4185
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Pham CD, 1998, CANCER INVEST, V16, P225, DOI 10.3109/07357909809039771
   Presta LG, 1997, CANCER RES, V57, P4593
   Prewett M, 1999, CANCER RES, V59, P5209
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Saltz LB, 2001, ONCOLOGIST, V6, P81, DOI 10.1634/theoncologist.6-1-81
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shi YP, 1999, BIOCHEM BIOPH RES CO, V254, P480, DOI 10.1006/bbrc.1998.9966
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Sowter HM, 1997, LAB INVEST, V77, P607
   Strawn LM, 1996, CANCER RES, V56, P3540
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tomisawa M, 1999, EUR J CANCER, V35, P133, DOI 10.1016/S0959-8049(98)00278-0
   Volm M, 1997, INT J CANCER, V74, P64, DOI 10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857
   Wedge SR, 2000, CANCER RES, V60, P970
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Wood JM, 2000, CANCER RES, V60, P2178
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yoshiji H, 1996, CANCER RES, V56, P2013
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Zhang XB, 2001, CANCER RES, V61, P6050
NR 96
TC 700
Z9 787
U1 0
U2 110
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2005
VL 333
IS 2
BP 328
EP 335
DI 10.1016/j.bbrc.2005.05.132
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 944HU
UT WOS:000230418700006
PM 15961063
DA 2022-11-30
ER

PT J
AU Ricklin, D
   Lambris, JD
AF Ricklin, Daniel
   Lambris, John D.
TI Complement in Immune and Inflammatory Disorders: Therapeutic
   Interventions
SO JOURNAL OF IMMUNOLOGY
LA English
DT Review
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; COBRA VENOM FACTOR; ALTERNATIVE
   PATHWAY; MONOCLONAL-ANTIBODY; MOUSE MODEL; C5A BLOCKADE; INHIBITOR;
   RECEPTOR; ACTIVATION; C3
AB With the awareness that immune-inflammatory crosstalk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. Although prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, in this review we discuss complement-directed therapeutic concepts and highlight promising candidate molecules. The Journal of Immunology, 2013, 190: 3839-3847.
C1 [Ricklin, Daniel; Lambris, John D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Ricklin, D (通讯作者)，Univ Penn, 401 Stellar Chance, Philadelphia, PA 19104 USA.
EM ricklin@upenn.edu; lambris@upenn.edu
RI Lambris, John/Q-5633-2018
OI Lambris, John/0000-0002-9370-5776
FU National Institutes of Health [AI003040, AI068730, AI072106, AI097805,
   EY020633, GM097747, DE021685]; NATIONAL EYE INSTITUTE [R01EY020633]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [P01AI068730, R01AI030040, R01AI072106, R21AI097805]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &
   CRANIOFACIAL RESEARCH [R01DE021685] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097747] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants
   AI003040, AI068730, AI072106, AI097805, EY020633, GM097747, and
   DE021685.
CR Alfinito F, 2012, IMMUNOBIOLOGY, V217, P698, DOI 10.1016/j.imbio.2011.11.009
   Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208
   Barratt-Due A, 2012, IMMUNOBIOLOGY, V217, P1047, DOI 10.1016/j.imbio.2012.07.019
   Barratt-Due A, 2011, J IMMUNOL, V187, P4913, DOI 10.4049/jimmunol.1101000
   Bestebroer J, 2010, CELL MICROBIOL, V12, P1506, DOI 10.1111/j.1462-5822.2010.01486.x
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Breivik T, 2011, J PERIODONTAL RES, V46, P643, DOI 10.1111/j.1600-0765.2011.01383.x
   Brekke OL, 2013, ADV EXP MED BIOL, V735, P123, DOI 10.1007/978-1-4614-4118-2_8
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chen S, 2011, AM J TRANSPLANT, V11, P2057, DOI 10.1111/j.1600-6143.2011.03646.x
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Cousins SW, 2010, INVEST OPHTH VIS SCI, V51
   Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512
   Drews J, 2004, NAT REV DRUG DISCOV, V3, P797, DOI 10.1038/nrd1498
   Duvall MR, 2010, IMMUNOBIOLOGY, V215, P395, DOI 10.1016/j.imbio.2009.05.010
   Ferraresso M, 2008, TRANSPLANTATION, V86, P1445, DOI 10.1097/TP.0b013e31818a68e2
   Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005
   FREI Y, 1987, MOL CELL PROBE, V1, P141, DOI 10.1016/0890-8508(87)90022-3
   Fridkis-Hareli M, 2011, BLOOD, V118, P4705, DOI 10.1182/blood-2011-06-359646
   Fritzinger DC, 2010, ADV EXP MED BIOL, V703, P151, DOI 10.1007/978-1-4419-5635-4_11
   Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Heja D, 2012, J BIOL CHEM, V287, P20290, DOI 10.1074/jbc.M112.354332
   Hepburn NJ, 2007, J BIOL CHEM, V282, P8292, DOI 10.1074/jbc.M609858200
   Hill A, 2005, BLOOD, V106, P2559, DOI 10.1182/blood-2005-02-0564
   Holers M, 2012, IMMUNOBIOLOGY, V217, P1210, DOI 10.1016/j.imbio.2012.08.232
   Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9
   Hussell T, 2012, EXPERT REV ANTI-INFE, V10, P249, DOI [10.1586/eri.12.12, 10.1586/ERI.12.12]
   Jain U, 2013, BRIT J PHARMACOL, V168, P488, DOI 10.1111/j.1476-5381.2012.02183.x
   Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   Kimura Y, 2010, J CLIN INVEST, V120, P3545, DOI 10.1172/JCI41782
   Koehl J, 2006, CURR OPIN MOL THER, V8, P529
   Koulmanda M., 2012, 14 INT COMPL WORKSH
   Kourtzelis I, 2010, BLOOD, V116, P631, DOI 10.1182/blood-2010-01-264051
   Lachmann PJ, 2009, SCAND J IMMUNOL, V69, P471, DOI 10.1111/j.1365-3083.2009.02258.x
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Li Jennifer S, 2006, Expert Rev Cardiovasc Ther, V4, P649, DOI 10.1586/14779072.4.5.649
   Lim J, 2013, FASEB J, V27, P822, DOI 10.1096/fj.12-220582
   Lindorfer MA, 2010, BLOOD, V115, P2283, DOI 10.1182/blood-2009-09-244285
   Lu FX, 2013, CARDIOVASC PATHOL, V22, P75, DOI 10.1016/j.carpath.2012.05.003
   Macor P, 2012, ARTHRITIS RHEUM-US, V64, P2559, DOI 10.1002/art.34430
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Mathieu MC, 2005, IMMUNOL LETT, V100, P139, DOI 10.1016/j.imlet.2005.03.003
   Morgan EL, 2009, VACCINE, V28, P463, DOI 10.1016/j.vaccine.2009.10.029
   Nilsson PH, 2013, BIOMATERIALS, V34, P985, DOI 10.1016/j.biomaterials.2012.10.040
   Okada N., 2012, CLIN EXP PHARMACOL P, V2
   Orth-Holler D, 2011, EMBO MOL MED, V3, P617, DOI 10.1002/emmm.201100169
   Pavlov VI, 2012, CIRCULATION, V126, P2227, DOI 10.1161/CIRCULATIONAHA.112.123968
   Qu H., 2012, IMMUNOBIOLO IN PRESS
   Qu H, 2009, MOL IMMUNOL, V47, P185, DOI 10.1016/j.molimm.2009.08.032
   Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x
   Ricklin D, 2013, ADV EXP MED BIOL, V735, P1, DOI 10.1007/978-1-4614-4118-2_1
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Ricklin D, 2012, IMMUNOBIOLOGY, V217, P1057, DOI 10.1016/j.imbio.2012.07.016
   Ricklin D, 2012, NAT MED, V18, P1340, DOI 10.1038/nm.2916
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   Rioux P, 2001, Curr Opin Investig Drugs, V2, P364
   Risitano AM, 2012, IMMUNOBIOLOGY, V217, P1080, DOI 10.1016/j.imbio.2012.07.014
   Risitano AM, 2012, BLOOD, V119, P6307, DOI 10.1182/blood-2011-12-398792
   Roth A, 2011, INT J HEMATOL, V93, P704, DOI 10.1007/s12185-011-0867-y
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Sacks S, 2013, ADV EXP MED BIOL, V735, P247, DOI 10.1007/978-1-4614-4118-2_17
   Schmidt CQ, 2012, IMMUNOBIOLOGY, V217, P1197, DOI 10.1016/j.imbio.2012.08.195
   Schmidtko J, 2013, AM J KIDNEY DIS, V61, P289, DOI 10.1053/j.ajkd.2012.07.028
   Schwaeble W. J., 2012, U.S. Patent Application, Patent No. 13441827
   Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108
   Sheen TR, 2011, VACCINE, V30, P9, DOI 10.1016/j.vaccine.2011.10.054
   Silasi-Mansat R, 2010, BLOOD, V116, P1002, DOI 10.1182/blood-2010-02-269746
   Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001
   Smith PK, 2011, J THORAC CARDIOV SUR, V142, P89, DOI 10.1016/j.jtcvs.2010.08.035
   Smith RAG, 2002, BIOCHEM SOC T, V30, P1037, DOI 10.1042/bst0301037
   Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374
   Subasinghe NL, 2012, BIOORG MED CHEM LETT, V22, P5303, DOI 10.1016/j.bmcl.2012.06.030
   Subasinghe NL, 2006, BIOORG MED CHEM LETT, V16, P2200, DOI 10.1016/j.bmcl.2006.01.036
   Testa L, 2008, J THORAC CARDIOV SUR, V136, P884, DOI 10.1016/j.jtcvs.2007.12.062
   Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043
   Tillou X, 2010, KIDNEY INT, V78, P152, DOI 10.1038/ki.2010.75
   Tokodai K, 2010, TRANSPLANTATION, V90, P1358, DOI 10.1097/TP.0b013e3181ffb9f5
   van der Pals J, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-45
   Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222
   Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319
   Vogel CW, 2010, TOXICON, V56, P1198, DOI 10.1016/j.toxicon.2010.04.007
   von Kockritz-Blickwede M, 2010, J INNATE IMMUN, V2, P87, DOI 10.1159/000247157
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955
   Woodruff TM, 2011, MOL IMMUNOL, V48, P1631, DOI 10.1016/j.molimm.2011.04.014
   Wu YQ, 2011, J IMMUNOL, V186, P4269, DOI 10.4049/jimmunol.1003802
   Zeerleder S, 2011, SEMIN THROMB HEMOST, V37, P362, DOI 10.1055/s-0031-1276585
   Zhou HF, 2012, P NATL ACAD SCI USA, V109, pE415, DOI 10.1073/pnas.1119000109
NR 91
TC 167
Z9 184
U1 0
U2 44
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2013
VL 190
IS 8
BP 3839
EP 3847
DI 10.4049/jimmunol.1203200
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 121WC
UT WOS:000317274500002
PM 23564578
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Detorakis, ET
   Pallikaris, IG
AF Detorakis, Efstathios T.
   Pallikaris, Ioannis G.
TI Ocular rigidity: biomechanical role, in vivo measurements and clinical
   significance
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE axial length measurement; ocular rigidity measurement; glaucoma
ID OPTIC-NERVE HEAD; GOLDMANN APPLANATION TONOMETRY; DYNAMIC CONTOUR
   TONOMETRY; INTRAOCULAR-PRESSURE; BLOOD-FLOW; MACULAR DEGENERATION;
   CORNEAL THICKNESS; SCLERAL RIGIDITY; AXIAL LENGTH; RESPONSE ANALYZER
AB Ocular rigidity (OR) refers to the relationship between pressure and volume changes in the eyeball. Since the description of the differential tonometry method for the calculation of an OR coefficient by Friedenwald, several other methodologies have been proposed to measure OR, including the anterior chamber manometry, axial length (AL) changes, measurement of pulse amplitude and fundus pulse, ultrasound elastography and evaluation of corneal hysteresis. However, most of these methodologies suffer from deficiencies, such as invasive nature, poor accuracy or reproducibility or technical complexity. Nevertheless, it is possible that OR affects the pathogenesis and clinical course of a variety of ocular conditions, including glaucoma, age-related macular degeneration, presbyopia, corneal changes following refractive surgery as well as the accuracy of IOP measurements by many tonometers. Thus, the future development of non-invasive and easy-to-use methodologies for the accurate measurement of OR in the every-day practice would be clinically important.
C1 [Detorakis, Efstathios T.] Univ Hosp Heraklion, Dept Ophthalmol, Iraklion 71110, Crete, Greece.
   Inst Vis & Opt IVO, Iraklion, Crete, Greece.
C3 University Hospital of Heraklion
RP Detorakis, ET (通讯作者)，Univ Hosp Heraklion, Dept Ophthalmol, Iraklion 71110, Crete, Greece.
EM detorakis@hotmail.com
RI Detorakis, Efstathios/AAN-4700-2021
CR ABDALLA MI, 1970, BRIT J OPHTHALMOL, V54, P122, DOI 10.1136/bjo.54.2.122
   Agrawal K K, 1991, Indian J Ophthalmol, V39, P85
   Croft Mary Ann, 2006, Ophthalmol Clin North Am, V19, P13
   Cronemberger S, 2009, ARQ BRAS OFTALMOL, V72, P439, DOI 10.1590/S0004-27492009000400003
   Dallinger S, 1998, STROKE, V29, P997, DOI 10.1161/01.STR.29.5.997
   Dastiridou AI, 2009, INVEST OPHTH VIS SCI, V50, P5718, DOI 10.1167/iovs.09-3760
   Detorakis ET, 2010, J GLAUCOMA, V19, P194, DOI 10.1097/IJG.0b013e3181aae954
   Detorakis ET, 2010, OPHTHAL SURG LAS IM, V41, P135, DOI 10.3928/15428877-20091230-24
   DRANCE SM, 1960, ARCH OPHTHALMOL-CHIC, V63, P668
   Ebneter A, 2009, EYE, V23, P606, DOI 10.1038/eye.2008.47
   EHLERS N, 1975, ACTA OPHTHALMOL, V53, P34
   Eisenlohr J E, 1962, Br J Ophthalmol, V46, P536, DOI 10.1136/bjo.46.9.536
   EISENLOHR JE, 1962, INVEST OPHTH VISUAL, V1, P63
   Ethier CR, 2006, CAN J OPHTHALMOL, V41, P9, DOI 10.1016/S0008-4182(06)80060-8
   Francis BA, 2007, OPHTHALMOLOGY, V114, P20, DOI 10.1016/j.ophtha.2006.06.047
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   FRIEDENWALD J S, 1957, Trans Am Acad Ophthalmol Otolaryngol, V61, P108
   FRIEDENWALD J S, 1949, Trans Am Acad Ophthalmol Otolaryngol, V53, P262
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   GAASTERLAND D, 1978, EXP EYE RES, V26, P651, DOI 10.1016/0014-4835(78)90099-4
   GILMARTIN B, 1995, OPHTHAL PHYSL OPT, V15, P431, DOI 10.1016/0275-5408(95)00095-U
   Glass DH, 2008, INVEST OPHTH VIS SCI, V49, P3919, DOI 10.1167/iovs.07-1321
   GOLDMANN H, 1957, Ophthalmologica, V133, P330
   Goldmann H, 1956, GLAUCOMA, P167
   Grammenandi E, 2010, CLIN EXP OPHTHALMOL, V38, P444, DOI 10.1111/j.1442-9071.2010.02275.x
   Gupta Vinod Kumar, 2006, MedGenMed, V8, P63
   Heron G, 1999, INVEST OPHTH VIS SCI, V40, P2872
   Hommer A, 2008, INVEST OPHTH VIS SCI, V49, P4046, DOI 10.1167/iovs.07-1342
   Kniestedt C, 2008, SURV OPHTHALMOL, V53, P568, DOI 10.1016/j.survophthal.2008.08.024
   Konofagou EE, 2001, ULTRASOUND MED BIOL, V27, P1387, DOI 10.1016/S0301-5629(01)00433-1
   Kotecha A, 2006, INVEST OPHTH VIS SCI, V47, P5337, DOI 10.1167/iovs.06-0557
   Kymionis GD, 2008, J REFRACT SURG, V24, P173, DOI 10.3928/1081597X-20080201-08
   Lam AKC, 2003, OPTOMETRY VISION SCI, V80, P305, DOI 10.1097/00006324-200304000-00008
   LEIGHTON DA, 1973, BRIT J OPHTHALMOL, V57, P499, DOI 10.1136/bjo.57.7.499
   Mangouritsas G, 2011, CLIN OPHTHALMOL, V5, P1071, DOI 10.2147/OPTH.S23086
   MARK HH, 1973, AM J OPHTHALMOL, V76, P223, DOI 10.1016/0002-9394(73)90164-5
   Mark HH, 2002, J CATARACT REFR SURG, V28, P504, DOI 10.1016/S0886-3350(01)01091-4
   Nguyen CTO, 2007, INVEST OPHTH VIS SCI, V48, P756, DOI 10.1167/iovs.06-0585
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Pavlin CJ, 1998, AM J OPHTHALMOL, V126, P719, DOI 10.1016/S0002-9394(98)00143-3
   Pierscionek K, 2007, BRIT J OPHTHALMOL, V91, P801, DOI 10.1136/bjo.2006.110221
   Pitchon EM, 2006, AM J OPHTHALMOL, V142, P706, DOI 10.1016/j.ajo.2006.06.010
   Pulido J, 2006, AM J OPHTHALMOL, V141, P731, DOI 10.1016/j.ajo.2005.12.021
   Punjabi OS, 2006, CLIN EXP OPHTHALMOL, V34, P837, DOI 10.1111/j.1442-9071.2006.01389.x
   Ravalico G, 1996, INVEST OPHTH VIS SCI, V37, P2645
   Riva I, 2012, EUR J OPHTHALMOL, V22, P55, DOI 10.5301/ejo.5000067
   Roberts MD, 2010, INVEST OPHTH VIS SCI, V51, P5675, DOI 10.1167/iovs.10-5411
   Sáenz-Francés F., 2011, Arch Soc Esp Oftalmol, V86, P287, DOI 10.1016/j.oftal.2011.04.012
   Sarvazyan A, 2011, CURR MED IMAGING, V7, P255, DOI 10.2174/157340511798038684
   Senthil S, 2010, INDIAN J OPHTHALMOL, V58, P333, DOI 10.4103/0301-4738.64133
   Shah S, 2007, INVEST OPHTH VIS SCI, V48, P3026, DOI 10.1167/iovs.04-0694
   Sigal IA, 2009, EXP EYE RES, V88, P799, DOI 10.1016/j.exer.2009.02.003
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   TOMLINSON A, 1970, BRIT J OPHTHALMOL, V54, P548, DOI 10.1136/bjo.54.8.548
NR 56
TC 30
Z9 32
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2013
VL 41
IS 1
BP 73
EP 81
DI 10.1111/j.1442-9071.2012.02809.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 079OV
UT WOS:000314181000012
PM 22594543
DA 2022-11-30
ER

PT J
AU Prokofyeva, E
   Zrenner, E
AF Prokofyeva, Elena
   Zrenner, Eberhart
TI Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A
   Literature Review
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Diabetic retinopathy; European data;
   Epidemiology; Glaucoma; High intraocular pressure; Incidence; Ocular
   hypertension; Hypertension; Prevalence
ID OPEN-ANGLE GLAUCOMA; AGE-RELATED MACULOPATHY; VISUAL IMPAIRMENT; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; OCULAR HYPERTENSION; RISK-FACTORS;
   COST-EFFECTIVENESS; VASCULAR-DISEASE; LASER PHOTOCOAGULATION
AB The objective of this work was to study the epidemiology of major eye diseases leading to blindness in Europe through a systematic literature review. The literature search was performed using the Medline database (PubMed), with MeSH and free text search terms. Inclusion criteria for the studies were: (a) performed on a healthy population of Caucasian origin aged between 50 and 75 years; (b) diagnosed by ophthalmological examination in accordance with the International Classification of Diseases 10; (c) contained a detailed description of the sampling and diagnostic procedures and data resources; (d) sample size >500, and (e) published between 1990 and 2008. The results of 57 studies on the prevalence and incidence of age-related macular degeneration, diabetic retinopathy and glaucoma are reported, providing an up-to-date and comprehensive overview of these diseases in Europe from an epidemiological perspective. Copyright (C) 2011 S. Karger AG, Basel
C1 [Prokofyeva, Elena; Zrenner, Eberhart] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, DE-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Prokofyeva, E (通讯作者)，Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Frondsberstr 23, DE-72076 Tubingen, Germany.
EM elena.prokofyeva@biomed-engineering.de
FU Tistou and Charlotte Kerstan Foundation [EVI-GENORET
   LSHG-CT-2005-512036]
FX This work was supported by a stipend from the Tistou and Charlotte
   Kerstan Foundation Vision 2000, EU grant EVI-GENORET
   LSHG-CT-2005-512036. The funding sources for this study had no influence
   on the study design, the manner in which data were collected, analysed,
   and interpreted, the writing of the report, or the decision to submit
   the paper for publication.
CR Acosta R., 2006, Arch Soc Esp Oftalmol, V81, P509
   Alabyeva GU, 2008, CLIN OPHTHALMOLOGY G, P97
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 2007, MORB POP ARKH OBL 20, P19
   [Anonymous], 2009, AL CART RES LAB
   Anton A, 2004, J GLAUCOMA, V13, P371
   Ariturk N, 1996, ACTA OPHTHALMOL SCAN, V74, P411
   Astachov US, 2008, CLIN OPHTHALMOLOGY G, P164
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bannikova R V, 2002, Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med, P35
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blum M, 2007, OPHTHALMOLOGE, V104, P499, DOI 10.1007/s00347-007-1522-0
   Bourne RRA, 2006, BRIT J OPHTHALMOL, V90, P253, DOI 10.1136/bjo.2005.083527
   Brainerd EL, 2000, SCIENCE, V290, P52, DOI 10.1126/science.290.5489.52
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Busbee BG, 2003, RETINA, V23, P443
   Cedrone C, 1997, Ophthalmic Epidemiol, V4, P59
   Cohen D, 2000, J FR OPHTALMOL, V23, P437
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Davies R, 1996, BRIT J OPHTHALMOL, V80, P945, DOI 10.1136/bjo.80.11.945
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DRANCE SM, 1971, CAN J OPHTHALMOLOGY, V6, P9
   European Glaucoma Society, 2020, TERM GUID GLAUC
   FERNANDEZVIGO J, 1993, ACTA OPHTHALMOL, V71, P22
   Friedman DS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1625, DOI 10.1001/archopht.124.11.1625
   FUKUDA M, 1994, DIABETES RES CLIN PR, V24, pS171, DOI 10.1016/0168-8227(94)90246-1
   Giuffre G, 2004, GRAEF ARCH CLIN EXP, V242, P535, DOI 10.1007/s00417-004-0880-4
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gray SF, 2000, BRIT J OPHTHALMOL, V84, P456, DOI 10.1136/bjo.84.5.456
   Gruener F, 2001, THESIS MARBURG
   Gupta N, 1997, Curr Opin Ophthalmol, V8, P38, DOI 10.1097/00055735-199704000-00007
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Hesse L, 2001, OPHTHALMOLOGE, V98, P1065, DOI 10.1007/s003470170026
   Hirskyj P, 2007, NURS ETHICS, V14, P72, DOI 10.1177/0969733007071360
   Hitzl W, 2007, KLIN MONATSBL AUGENH, V224, P115, DOI 10.1055/s-2007-962959
   Hitzl W, 2006, EUR J OPHTHALMOL, V16, P92, DOI 10.1177/112067210601600115
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Horle S, 2002, KLIN MONATSBL AUGENH, V219, P777, DOI 10.1055/s-2002-36318
   HUANG TC, 1989, AM J OPHTHALMOL, V107, P151, DOI 10.1016/0002-9394(89)90214-6
   Idil A, 2004, EUR J OPHTHALMOL, V14, P298, DOI 10.1177/112067210401400404
   Infeld DA, 1998, POSTGRAD MED J, V74, P129, DOI 10.1136/pgmj.74.869.129
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Johnson LN, 2002, J NATL MED ASSOC, V94, P908
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keen H, 2001, DIABETOLOGIA, V44, pS22, DOI 10.1007/PL00002935
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Koleva D, 2007, OPHTHALMOLOGICA, V221, P340, DOI 10.1159/000104765
   Krieglstein G. K., 1993, Ophthalmologe, V90, P554
   Kristinsson JK, 1997, ACTA OPHTHALMOL SC S, P1
   Kroese M, 2002, BRIT J OPHTHALMOL, V86, P978, DOI 10.1136/bjo.86.9.978
   Krumpaszky H. G., 1996, Ophthalmologica, V210, P1
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   Lee Brian L, 2003, Curr Opin Ophthalmol, V14, P74, DOI 10.1097/00055735-200304000-00003
   Lee ET, 2001, DIABETOLOGIA, V44, pS78, DOI 10.1007/PL00002943
   Lopez MI, 2002, OPHTHAL EPIDEMIOL, V9, P205, DOI 10.1076/opep.9.3.205.1516
   Michelson G, 2001, CURR OPIN OPHTHALMOL, V12, P105, DOI 10.1097/00055735-200104000-00005
   Miki E, 2001, DIABETOLOGIA, V44, pS31, DOI 10.1007/PL00002937
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Moshetova LK, 2008, CLIN OPHTHALMOLOGY G, P139
   Muchamedova AS, 2007, VESTN OFTALMOL, V123, P43
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Esteban JJN, 2007, EUR J OPHTHALMOL, V17, P29, DOI 10.1177/112067210701700105
   Nesterov AP, 2002, EYE DIS, P353
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Orme M, 2006, PHARMACOECONOMICS, V24, P743, DOI 10.2165/00019053-200624080-00002
   Owen CG, 2006, BRIT J OPHTHALMOL, V90, P861, DOI 10.1136/bjo.2005.088666
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Santos Bueso E, 2005, Arch Soc Esp Oftalmol, V80, P187
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P446, DOI 10.1136/bjo.87.4.446
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmier JK, 2007, PHARMACOECONOMICS, V25, P287, DOI 10.2165/00019053-200725040-00003
   [Шуршуков Ю.Ю. Shurshukov Yu. Yu.], 2007, [Здравоохранение Российской Федерации, Zdravookhranenie Rossiiskoi Federatsii], P53
   Simmons D, 2007, DIABETIC MED, V24, P1093, DOI 10.1111/j.1464-5491.2007.02227.x
   Skenduli-Bala E, 2005, ARCH OPHTHALMOL-CHIC, V123, P233, DOI 10.1001/archopht.123.2.233
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SPARROW JM, 1993, EYE, V7, P158, DOI 10.1038/eye.1993.34
   Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119
   Teruel Maicas C, 2005, ARCH SOC ESP OFTALMO, V80, P85
   THYLEFORS B, 1994, B WORLD HEALTH ORGAN, V72, P323
   Topouzis F, 2007, AM J OPHTHALMOL, V144, P511, DOI 10.1016/j.ajo.2007.06.029
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Traverso CE, 2005, BRIT J OPHTHALMOL, V89, P1245, DOI 10.1136/bjo.2005.067355
   Tuck M W, 1998, Ophthalmic Epidemiol, V5, P173, DOI 10.1076/opep.5.4.173.4192
   Tuck MW, 2003, OPHTHAL PHYSL OPT, V23, P175, DOI 10.1046/j.1475-1313.2003.00104.x
   Tuulonen A, 2003, ACTA OPHTHALMOL SCAN, V81, P3, DOI 10.1034/j.1600-0420.2003.00021.x
   Ulbig MW, 1996, MANAGMENT DIABETIC R
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Varma R, 2004, OPHTHALMOLOGY, V111, P1449, DOI 10.1016/j.ophtha.2004.01.024
   Varma R, 2004, OPHTHALMOLOGY, V111, P1298, DOI 10.1016/j.ophtha.2004.03.002
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Villain M, 2006, J FR OPHTALMOL, V29, P520, DOI 10.1016/S0181-5512(06)73805-0
   Vorob'eva M V, 2006, Vestn Oftalmol, V122, P50
   Waked N, 2007, J FR OPHTALMOL, V30, P497, DOI 10.1016/S0181-5512(07)89630-6
   Weih LM, 2001, OPHTHALMOLOGY, V108, P1966, DOI 10.1016/S0161-6420(01)00799-0
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   West S, 2001, B WORLD HEALTH ORGAN, V79, P244
NR 112
TC 131
Z9 140
U1 0
U2 17
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2012
VL 47
IS 4
BP 171
EP 188
DI 10.1159/000329603
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 936VE
UT WOS:000303617300001
PM 22123077
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Nagaraj, R
   Bijukumar, DR
   Mathew, B
   Scott, EA
   Mathew, MT
AF Nagaraj, Rajini
   Bijukumar, Divya Rani
   Mathew, Benjamin
   Scott, Evan A.
   Mathew, Mathew T.
TI A review on recent advancements in ophthalmology devices: Currently in
   market and under clinical trials
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Review
DE Ophthalmic implants; Ocular drug delivery; Ophthalmic devices; Ocular
   diseases; Electronic retinal implants; Nanoparticle drug delivery
   systems
ID DRUG-DELIVERY SYSTEMS; MULTIFOCAL INTRAOCULAR LENSES; SUSTAINED OCULAR
   DELIVERY; RETINAL IMAGE QUALITY; FLUOCINOLONE ACETONIDE; GLOBAL
   PREVALENCE; PATIENT SELECTION; IMPLANT; NANOPARTICLES; GLAUCOMA
AB The complex anatomical features of the eye and the presence of different ocular barriers has led to complications in the development of an effective treatment strategy for posterior segment diseases like diabetic retinopathy, age-related macular degeneration, retinal pigmentosa, etc., thus demanding the need for novel and innovative approaches. There are various treatment options available in the market which includes the new implants and drug delivery systems apart from the therapeutic agents which are benefiting the patients with modern improvements, enhanced formulations, targeted and long-term delivery. But they all still have numerous drawbacks which need to be addressed. This review article discusses and highlights the recent developments made in the ophthalmology which are in the market currently and under clinical trial. This review also suggests a possible alternative system that can be an effective and practical option for the treatment of posterior segment ophthalmic diseases.
C1 [Nagaraj, Rajini; Bijukumar, Divya Rani; Mathew, Mathew T.] Univ Illinois, Coll Med Rockford, Dept Biomed Sci, Regenerat Med & Disabil Res Lab, Rockford, IL 61107 USA.
   [Mathew, Benjamin] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Scott, Evan A.] Northwestern Univ, Dept Biomed Sci, Evanston, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Rockford; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   Northwestern University
RP Mathew, MT (通讯作者)，Univ Illinois, Dept Biomed Sci, Coll Med Rockford UICOMR, 1601 Parkview Ave, Rockford, IL 61107 USA.
EM mtmathew@uic.edu
RI Scott, Evan/K-1963-2014
FU Blazer Foundation; MBT program at the Department of Biomedical Science
FX The authors acknowledge the Blazer Foundation for supporting the
   Regenerative Medicine and Disability (RMDR) Lab at the Department of
   Biomedical Sciences, University of Illinois College of Medicine at
   Rockford. The financial support from the MBT program at the Department
   of Biomedical Science is also acknowledged.
CR Aldave AJ, 2009, OPHTHALMOLOGY, V116, P640, DOI 10.1016/j.ophtha.2008.12.058
   Alhalafi Ali Mohammed, 2017, Oman J Ophthalmol, V10, P3, DOI 10.4103/0974-620X.200692
   Alio JL, 2005, J CATARACT REFR SURG, V31, P1557, DOI 10.1016/j.jcrs.2005.01.026
   Almeida H, 2014, J PHARM PHARM SCI, V17, P278, DOI 10.18433/J3DP43
   Ament JD, 2009, CORNEA, V28, P808, DOI 10.1097/ICO.0b013e31819670ac
   [Anonymous], STUD MK0140 DIAB PAT
   [Anonymous], LAT GLOB BLINDN 6 PR
   [Anonymous], 2010, AM ACAD OPHTHALMOL
   Ashton P., 2015, ONDRUG DELIV, V54, P18
   Atchison D.A., 2000, OPTICS HUMAN EYE
   Barisic A, 2008, COLLEGIUM ANTROPOL, V32, P27
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   Braga-Mele R, 2014, J CATARACT REFR SURG, V40, P313, DOI 10.1016/j.jcrs.2013.12.011
   Brandt JD, 2016, OPHTHALMOLOGY, V123, P1685, DOI 10.1016/j.ophtha.2016.04.026
   Bu HZ, 2007, CURR DRUG METAB, V8, P91, DOI 10.2174/138920007779815977
   Buckhurst P.J., 2010, EUR OPHTHALMIC REV, V4, P82, DOI [10.17925/EOR.2010.04.01.82, DOI 10.17925/EOR.2010.04.01.82]
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1393, DOI 10.1016/j.ophtha.2009.11.024
   Chaerkady R, 2013, J PROTEOMICS, V87, P122, DOI 10.1016/j.jprot.2013.05.023
   Chew HF, 2009, CORNEA, V28, P989, DOI 10.1097/ICO.0b013e3181a186dc
   Davidson AE, 2014, EYE, V28, P189, DOI 10.1038/eye.2013.278
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Dua HS, 2013, OPHTHALMOLOGY, V120, P1778, DOI 10.1016/j.ophtha.2013.01.018
   Edwards TL, 2018, OPHTHALMOLOGY, V125, P432, DOI 10.1016/j.ophtha.2017.09.019
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Eppig T, 2009, J CATARACT REFR SURG, V35, P1091, DOI 10.1016/j.jcrs.2009.01.034
   Falabella P., 2017, ARGUS 2 RETINAL PROS, P49, DOI [10.1007/978-3-319-41876-6_5, DOI 10.1007/978-3-319-41876-6_5]
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fea AM, 2017, CLIN EXP OPHTHALMOL, V45, P120, DOI 10.1111/ceo.12805
   Finn AP, 2018, CLIN OPHTHALMOL, V12, P1089, DOI 10.2147/OPTH.S137525
   Fournie P, 2013, J FR OPHTALMOL, V36, P618, DOI 10.1016/j.jfo.2013.05.004
   Franca JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095461
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504-613PP
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gordon-Shaag A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/795738
   Greco A, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.038
   Guirao A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1143
   Gupta VB, 2014, INDIAN J OPHTHALMOL, V62, P103, DOI 10.4103/0301-4738.121141
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Halasz K, 2019, CURR DRUG DELIV, V16, P153, DOI 10.2174/1567201815666181017095708
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hodges RR, 2013, EXP EYE RES, V117, P62, DOI 10.1016/j.exer.2013.07.027
   Huang H, 2018, ADV DRUG DELIVER REV, V126, P96, DOI 10.1016/j.addr.2017.09.008
   Icon Bioscience Inc, VER DRUG DEL TECHN
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Janagam DR, 2017, ADV DRUG DELIVER REV, V122, P31, DOI 10.1016/j.addr.2017.04.001
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Karabin NB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03001-9
   Kaur M, 2017, INDIAN J OPHTHALMOL, V65, P1301, DOI 10.4103/ijo.IJO_810_17
   Kitiratschky VBD, 2015, GRAEF ARCH CLIN EXP, V253, P381, DOI 10.1007/s00417-014-2797-x
   Klamann MKJ, 2015, GRAEF ARCH CLIN EXP, V253, P941, DOI 10.1007/s00417-015-3014-2
   Kolb H., 1995, WEBVISION ORG RETINA
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kothamasu P, 2012, BIOIMPACTS, V2, P71, DOI 10.5681/bi.2012.011
   Kuno N., OCULAR DRUG DELIVERY
   Kymionis GD, 2007, AM J OPHTHALMOL, V143, P236, DOI 10.1016/j.ajo.2006.10.041
   Lavik E, 2011, EYE, V25, P578, DOI 10.1038/eye.2011.82
   Le K, 2014, CLIN OPHTHALMOL, V8, P1937, DOI 10.2147/OPTH.S45920
   Leyland M, 2003, OPHTHALMOLOGY, V110, P1789, DOI 10.1016/S0161-6420(03)00722-X
   LIM JI, 2010, INVEST OPHTH VIS SCI, V51
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Lp J., 2016, J BIOEQUIV BIOAVAILA, V9, P320, DOI DOI 10.4172/JBB.1000318
   Malgorzata K, 2014, CHEMIK, V68, P141
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Mantravadi AV, 2015, PRIMARY CARE, V42, P437, DOI 10.1016/j.pop.2015.05.008
   Mason ECM, 2017, HANDBOOK OF STRENGTHS-BASED CLINICAL PRACTICES: FINDING COMMON FACTORS, P85
   Mathebula SD, 2012, AFR VIS EYE HEALTH J, V71, P178
   McGwin G, 2010, CURR EYE RES, V35, P451, DOI 10.3109/02713681003664931
   Mehta H, 2015, THER ADV CHRONIC DIS, V6, P234, DOI 10.1177/2040622315590319
   Melnikova I, 2005, NAT REV DRUG DISCOV, V4, P711, DOI 10.1038/nrd1827
   Moshirfar Majid, 2010, J Ophthalmic Vis Res, V5, P215
   Nagaich U, 2014, J ADV PHARM TECHNOL, V5, P151, DOI 10.4103/2231-4040.143022
   Nichamin LD, 2009, MIDDLE EAST AFR J OP, V16, P138, DOI 10.4103/0974-9233.56227
   Occhiutto Marcelo L, 2012, Pharmaceutics, V4, P252, DOI 10.3390/pharmaceutics4020252
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Peptu CA, 2015, CURR PHARM DESIGN, V21, P6055, DOI 10.2174/1381612821666151027151847
   Pfeiffer N, 2015, OPHTHALMOLOGY, V122, P1283, DOI 10.1016/j.ophtha.2015.03.031
   Potvin R, 2016, CLIN OPHTHALMOL, V10, P1829, DOI 10.2147/OPTH.S114118
   Prokosch-Willing V, 2017, J GLAUCOMA, V26, pE261, DOI 10.1097/IJG.0000000000000795
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   Resende AF, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2731856
   Rizzo JF, 2011, J NEURO-OPHTHALMOL, V31, P160, DOI 10.1097/WNO.0b013e31821eb79e
   Rubio R.G., 2014, RETINA TODAY, P78
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Salerno Liberdade C, 2017, Taiwan J Ophthalmol, V7, P179, DOI 10.4103/tjo.tjo_19_17
   Schmit-Eilenberger VK, 2015, CLIN OPHTHALMOL, V9, P801, DOI 10.2147/OPTH.S79785
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   Shareef S., 2014, SURG INNOVATIONS GLA, P171
   Shepherd RK, 2013, TRENDS BIOTECHNOL, V31, P562, DOI 10.1016/j.tibtech.2013.07.001
   Shetty R, 2008, CORNEA, V27, P1022, DOI 10.1097/ICO.0b013e318172fc54
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Singh A, 2010, INT J PHARM SCI REV, V5, P84
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Snell R.S., 2013, CLIN ANATOMY EYE
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   Sugar J, 2012, CORNEA, V31, P716, DOI 10.1097/ICO.0b013e31823f8c72
   Swider G., 2006, INVEST OPHTH VIS SCI, V47, P3187
   Synek S, 2013, COLLEGIUM ANTROPOL, V37, P217
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tian J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37676
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230-973X.96920
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vaishya RD, 2014, WIRES NANOMED NANOBI, V6, P422, DOI 10.1002/wnan.1272
   VERA VI, 2014, SURG INNOVATIONS GLA, P189
   Vinod K, 2017, CURR OPIN OPHTHALMOL, V28, P187, DOI 10.1097/ICU.0000000000000336
   Visser N, 2013, J CATARACT REFR SURG, V39, P624, DOI 10.1016/j.jcrs.2013.02.020
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Weng YH, 2017, ACTA PHARM SIN B, V7, P281, DOI 10.1016/j.apsb.2016.09.001
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Witting M, 2015, BIOTECHNOL ADV, V33, P1355, DOI 10.1016/j.biotechadv.2015.01.010
   Wong FSY, 2017, NEURAL REGEN RES, V12, P576, DOI 10.4103/1673-5374.205093
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yasukawa Tsutomu, 2006, Expert Opin Drug Deliv, V3, P261, DOI 10.1517/17425247.3.2.261
   Yorston David, 2014, Community Eye Health, V27, P44
NR 125
TC 6
Z9 6
U1 1
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD AUG
PY 2019
VL 52
BP 334
EP 345
DI 10.1016/j.jddst.2019.04.038
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IM0WE
UT WOS:000477709600035
DA 2022-11-30
ER

PT J
AU Gowda, V
   Foulke-Abel, J
   Agbo, H
   Bench, BJ
   Chae, J
   Russell, WK
   Watanabe, CMH
AF Gowda, Vishruth
   Foulke-Abel, Jennifer
   Agbo, Hillary
   Bench, Bennie J.
   Chae, Jooyeon
   Russell, William K.
   Watanabe, Coran M. H.
TI Lipofuscin Formation Catalyzed by the Milk Protein beta-Lactoglobulin:
   Lysine Residues in Cycloretinal Synthesis
SO BIOCHEMISTRY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; ESCHERICHIA-COLI;
   BINDING-SITE; BOVINE; EXPRESSION; LIPOCALIN
AB Lipofuscins are toxic autofluorescent by-products of the visual cycle. The accumulation of lipofuscins such as cycloretinal in the retina is thought to play a role in the progression of age-related macular degeneration (AMD). Intriguingly, the milk protein beta-lactoglobulin (BLG) can promote the cyclodimerization of all-trans-retinal to cycloretinal both in vitro and in vivo. Here, site-directed mutagenesis of BLG and mass spectrometric analysis with substrate analogues demonstrate that lysine residues play a key role in catalysis. It is also shown that catalytic activity necessitates the presence of a physical binding site and cannot be mediated by a peptide chain. These studies provide insight into the mechanism of the cyclodimerization process and provide a model system for biocatalysis and biosynthesis of cycloretinal in vivo. In the long term, these studies may pave the way for drug development and inhibitor design as an early treatment regimen for AMD.
C1 [Gowda, Vishruth; Foulke-Abel, Jennifer; Agbo, Hillary; Bench, Bennie J.; Chae, Jooyeon; Russell, William K.; Watanabe, Coran M. H.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station
RP Watanabe, CMH (通讯作者)，Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
EM watanabe@chem.tamu.edu
FU National Science Foundation [CHE-1608580]; Welch Foundation [A-1828]
FX The authors are grateful to the National Science Foundation
   (CHE-1608580) and the Welch Foundation (A-1828).
CR Ariyaratne KANS, 2002, INT DAIRY J, V12, P311, DOI 10.1016/S0958-6946(02)00027-4
   BATT CA, 1990, AGR BIOL CHEM TOKYO, V54, P949, DOI 10.1080/00021369.1990.10870080
   Bench BJ, 2008, BIOORGAN MED CHEM, V16, P7573, DOI 10.1016/j.bmc.2008.07.030
   Bench BJ, 2006, J ORG CHEM, V71, P9458, DOI 10.1021/jo061763t
   Bench BJ, 2011, MOL BIOSYST, V7, P162, DOI 10.1039/c0mb00186d
   Chatel JM, 1999, PROTEIN EXPRES PURIF, V16, P70, DOI 10.1006/prep.1999.1055
   CHO YJ, 1994, J BIOL CHEM, V269, P11102
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Invernizzi G, 2004, J BIOTECHNOL, V109, P169, DOI 10.1016/j.jbiotec.2003.10.034
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   LOVEGROVE JA, 1993, GUT, V34, P203, DOI 10.1136/gut.34.2.203
   Narayan ARH, 2015, NAT CHEM, V7, P653, DOI [10.1038/NCHEM.2285, 10.1038/nchem.2285]
   Ponniah K, 2010, PROTEIN EXPRES PURIF, V70, P283, DOI 10.1016/j.pep.2009.12.006
   Rogers TA, 2010, CHEM ENG SCI, V65, P2118, DOI 10.1016/j.ces.2009.12.005
   Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Yang MC, 2008, PROTEINS, V71, P1197, DOI 10.1002/prot.21811
NR 21
TC 5
Z9 5
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 31
PY 2017
VL 56
IS 43
BP 5715
EP 5719
DI 10.1021/acs.biochem.7b00709
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FL6VD
UT WOS:000414383400002
PM 28960961
DA 2022-11-30
ER

PT J
AU Stewart, MW
AF Stewart, Michael W.
TI Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of
   ophthalmic drugs that bind VEGF
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE aflibercept; bevacizumab; pegaptanib; pharmacokinetics; ranibizumab;
   VEGF
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; INTRAVITREAL
   BEVACIZUMAB AVASTIN; DIFFERENT OCULAR CELLS; COHERENCE TOMOGRAPHY
   FINDINGS; RETINAL-PIGMENT EPITHELIUM; IN-VITRO; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB LUCENTIS; VITRECTOMIZED EYES
AB Drugs that prevent the binding of VEGF to its trans-membrane cognate receptors have revolutionized the treatment of the most important chorioretinal vascular disorders: exudative age-related macular degeneration, diabetic macular edema, and retinal vein occlusions. Pegaptanib, which binds to VEGF(165) and longerisoforms, ranibizumab and bevacizumab, which bind all VEGF-A isoforms, and aflibercept, which binds VEGF-A, VEGF-B, and placental growth factor, all bind VEGF(165) with high affinity. The drugs have relatively long half-lives (7 to 10 days) after intravitreal depot injections and clinical durations of action that usually exceed 4 weeks. Plasma VEGF concentrations decrease after intravitreal injections of bevacizumab and aflibercept because their systemic half-lives are extended by their Fc fragments. Extensive in vitro and in vivo testing shows that the drugs prevent VEGF-mediated activation of endothelial cells while exhibiting little evidence of toxicity. Further anti-VEGF drug development is on-going.
C1 Mayo Clin & Mayo Grad Sch Med, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic
RP Stewart, MW (通讯作者)，Mayo Clin & Mayo Grad Sch Med, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM stewart.michael@mayo.edu
CR Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akar EE, 2013, INT J OPHTHALMOL-CHI, V6, P136, DOI 10.3980/j.issn.2222-3959.2013.02.05
   Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Ammar DA, 2013, RETINA-J RET VIT DIS, V33, P1056, DOI 10.1097/IAE.0b013e31827b646d
   Avci B, 2009, INVEST OPHTH VIS SCI, V50, P3438, DOI 10.1167/iovs.08-2871
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Axer-Siegel R, 2009, CURR EYE RES, V34, P660, DOI 10.1080/02713680903007154
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Barzelay A, 2010, CURR EYE RES, V35, P835, DOI 10.3109/02713683.2010.489727
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Brar VS, 2009, J OCUL PHARMACOL TH, V25, P507, DOI 10.1089/jop.2009.0028
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chen E, 2010, CURR MED RES OPIN, V26, P1587, DOI 10.1185/03007995.2010.482503
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Christoforidis JB, 2011, INVEST OPHTH VIS SCI, V52, P5899, DOI 10.1167/iovs.10-6862
   Cortez RT, 2010, ARCH OPHTHALMOL-CHIC, V128, P884, DOI 10.1001/archophthalmol.2010.139
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Criswell MH, 2008, ARCH OPHTHALMOL-CHIC, V126, P946, DOI 10.1001/archopht.126.7.946
   CSAKY KG, 2007, INVEST OPHTHALMOL VI, V48
   Cursiefen C, 2004, INVEST OPHTH VIS SCI, V45, P2666, DOI 10.1167/iovs.03-1380
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dastjerdi MH, 2011, INVEST OPHTH VIS SCI, V52, P8718, DOI 10.1167/iovs.11-7871
   Deissler H, 2008, BRIT J OPHTHALMOL, V92, P839, DOI 10.1136/bjo.2007.135640
   Deissler HL, 2013, EXP EYE RES, V115, P162, DOI 10.1016/j.exer.2013.07.018
   Deissler HL, 2013, GRAEF ARCH CLIN EXP, V251, P2345, DOI 10.1007/s00417-013-2393-5
   Deissler HL, 2012, BRIT J OPHTHALMOL, V96, P1023, DOI 10.1136/bjophthalmol-2012-301677
   Deissler HL, 2011, BRIT J OPHTHALMOL, V95, P1151, DOI 10.1136/bjo.2010.192229
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Dib E, 2008, INVEST OPHTH VIS SCI, V49, P1097, DOI 10.1167/iovs.07-1225
   Dursun A, 2012, INT J OPHTHALMOL-CHI, V5, P448, DOI 10.3980/j.issn.2222-3959.2012.04.08
   Ehlken C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1226, DOI 10.1001/archophthalmol.2012.112
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Foy JWD, 2007, J OCUL PHARMACOL TH, V23, P452, DOI 10.1089/jop.2006.0149
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Furfine E, INVEST OPHTHALMOL VI, V47, P1430
   Fusco MA, 2012, CLINICS, V67, P61, DOI 10.6061/clinics/2012(01)10
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hosny MH, 2009, J OCUL PHARMACOL TH, V25, P513, DOI 10.1089/jop.2009.0056
   Iandiev I, 2011, GRAEF ARCH CLIN EXP, V249, P1821, DOI 10.1007/s00417-011-1773-y
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jeon S, 2012, CYTOKINE, V60, P535, DOI 10.1016/j.cyto.2012.07.005
   Johnsen-Soriano S, 2011, EUR J OPHTHALMOL, V21, P427, DOI 10.5301/EJO.2010.5842
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Khaliq A, 1998, LAB INVEST, V78, P109
   Kim H, 2009, MOL VIS, V15
   Kim MJ, 2010, J OCUL PHARMACOL TH, V26, P49, DOI 10.1089/jop.2009.0022
   Kim TI, 2009, INVEST OPHTH VIS SCI, V50, P4653, DOI 10.1167/iovs.08-2805
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Ko BY, 2013, CORNEA, V32, P689, DOI 10.1097/ICO.0b013e3182801645
   Koss MJ, 2012, ACTA OPHTHALMOL, V90, pe98, DOI 10.1111/j.1755-3768.2011.02292.x
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kuo CN, 2012, MOL MED REP, V6, P701, DOI 10.3892/mmr.2012.986
   Lee SS, 2013, INVEST OPHTH VIS SCI, V51, P2135
   Li E, 2012, J OCUL PHARMACOL TH, V28, P219, DOI 10.1089/jop.2011.0148
   Lopez-Guajardo L, 2008, EYE, V22, P430, DOI 10.1038/sj.eye.6703054
   Lorenz K, 2010, GRAEF ARCH CLIN EXP, V248, P1573, DOI 10.1007/s00417-010-1490-y
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Luke M, 2010, CURR EYE RES, V35, P248, DOI 10.3109/02713680903503504
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Lutty GA, 2011, INVEST OPHTH VIS SCI, V52, P4039, DOI 10.1167/iovs.10-6798
   Ma J, 2010, CLIN EXP OPHTHALMOL, V38, P875, DOI 10.1111/j.1442-9071.2010.02370.x
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Matsuyama K, 2009, JPN J OPHTHALMOL, V53, P243, DOI 10.1007/s10384-008-0645-4
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Myers AC, 2012, CURR EYE RES, V37, P399, DOI 10.3109/02713683.2011.611609
   Niers TMH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019873
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peng SM, 2010, INVEST OPHTH VIS SCI, V51, P3216, DOI 10.1167/iovs.09-4162
   Peters S, 2007, BRIT J OPHTHALMOL, V91, P827, DOI 10.1136/bjo.2006.109702
   Presta LG, 1997, CANCER RES, V57, P4593
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Roh MI, 2009, OPHTHALMOLOGY, V116, P80, DOI 10.1016/j.ophtha.2008.09.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Rusovici R, 2013, CLIN OPHTHALMOL, V7, P321, DOI 10.2147/OPTH.S41556
   Rusovici R, 2011, MOL VIS, V17, P3339
   Saati S, 2010, GRAEF ARCH CLIN EXP, V248, P457, DOI 10.1007/s00417-009-1153-z
   Saeed MU, 2011, SEMIN OPHTHALMOL, V26, P357, DOI 10.3109/08820538.2011.588648
   Saeed MU, 2011, SEMIN OPHTHALMOL, V26, P61, DOI 10.3109/08820538.2011.559518
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Sawada O, 2008, GRAEF ARCH CLIN EXP, V246, P1379, DOI 10.1007/s00417-008-0874-8
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Schnichels S, 2013, BRIT J OPHTHALMOL, V97, P917, DOI 10.1136/bjophthalmol-2013-303130
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sharma RK, 2009, ACTA OPHTHALMOL, V87, P618, DOI 10.1111/j.1755-3768.2008.01410.x
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Sohn HJ, 2013, ACTA OPHTHALMOL
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Stewart EA, 2011, EXP EYE RES, V93, P761, DOI 10.1016/j.exer.2011.09.010
   Stewart MW, 2013, CLIN MED INSIGHTS-TH, V5, P81, DOI 10.4137/CMT.S8921
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Suzuki Y, 2014, RETINA-J RET VIT DIS, V34, P165, DOI 10.1097/IAE.0b013e3182979df6
   Thaler S, 2010, ACTA OPHTHALMOL, V88, pE170, DOI 10.1111/j.1755-3768.2010.01927.x
   Tojo N, 2010, ACTA OPHTHALMOL, V88, pe66, DOI 10.1111/j.1755-3768.2010.01879.x
   TOLENTINO MJ, 1996, OPHTHALMOLOGY, V114, P964
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004
   Veurink M, 2013, PHARM RES-DORDR, V30, P1176, DOI 10.1007/s11095-012-0955-6
   Wang X, 2013, GRAEFES ARCH CLIN EX
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Xu WQ, 2010, CAN J OPHTHALMOL, V45, P386, DOI 10.3129/i10-024
   Xu Y, 2012, INVEST OPHTH VIS SCI, V53, P5221, DOI 10.1167/iovs.12-9702
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zayit-Soudry S, 2011, RETINA-J RET VIT DIS, V31, P1885, DOI 10.1097/IAE.0b013e31821a88e2
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 146
TC 66
Z9 71
U1 1
U2 24
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD MAR
PY 2014
VL 7
IS 2
BP 167
EP 180
DI 10.1586/17512433.2014.884458
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CB9YA
UT WOS:000349989200009
PM 24483136
DA 2022-11-30
ER

PT J
AU Chen, CR
   Hong, SE
   Wang, YC
   Hsu, SL
   Hsiang, D
   Chang, CMJ
AF Chen, Chao-Rui
   Hong, Siang-En
   Wang, Yuan-Chuen
   Hsu, Shih-Lan
   Hsiang, Daina
   Chang, Chieh-Ming J.
TI Preparation of highly pure zeaxanthin particles from sea
   water-cultivated microalgae using supercritical anti-solvent
   recrystallization
SO BIORESOURCE TECHNOLOGY
LA English
DT Article
DE Supercritical anti-solvent; Column partition chromatography; Microalgae;
   Nannochloropsis oculata; Zeaxanthin
ID PRECIPITATION; PURIFICATION; PROPOLIS
AB Xanthophylls, including zeaxanthin, are considered dietary supplements with a potentially positive impact on age-related macular degeneration. Using pilot-scale column fractionation coupled with supercritical anti-solvent (SAS) recrystallization, highly pure zeaxanthin particulates were prepared from ultrasonic extracts of the microalgae, Nannochloropsis oculata, grown in sea water. Column partition chromatography increased the concentration of zeaxanthin from 36.2 mg/g of the ultrasonic extracts to 425.6 mg/g of the collected column fractions. A response surface methodology was systematically designed for the SAS process by changing feed concentration, CO2 flow rate and anti-solvent pressure. Zeaxanthin-rich particles with a purity of 84.2% and a recovery of 85.3% were produced using supercritical anti-solvent recrystallization from the column eluate at a feed concentration of 1.5 mg/mL, CO2 flow rate of 48.6 g/min and pressure of 135 bar. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Chen, Chao-Rui; Hong, Siang-En; Chang, Chieh-Ming J.] Natl Chung Hsing Univ, Dept Chem Engn, Taichung 40227, Taiwan.
   [Chen, Chao-Rui] Inst Nucl Energy Res, Div Chem Engn, Tao Yuan 32546, Taiwan.
   [Wang, Yuan-Chuen] Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, Taichung 40227, Taiwan.
   [Hsu, Shih-Lan] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung 40705, Taiwan.
   [Hsiang, Daina] Nanya Inst Technol, Dept Informat Management, Tao Yuan 32091, Taiwan.
C3 National Chung Hsing University; Institute of Nuclear Energy Research -
   Taiwan; National Chung Hsing University; Taichung Veterans General
   Hospital
RP Chang, CMJ (通讯作者)，Natl Chung Hsing Univ, Dept Chem Engn, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.
EM cmchang@dragon.nchu.edu.tw
FU National Science Council of the Republic of China, Taiwan
   [NSC98-2221-E005-053-MY3]; Ministry of Education, Taiwan, ROC under the
   ATU
FX The authors would like to thank the National Science Council of the
   Republic of China, Taiwan for financially supporting this research
   (NSC98-2221-E005-053-MY3). This work is also supported in part by the
   Ministry of Education, Taiwan, ROC under the ATU plan.
CR Andersen R. A., 2005, ALGAL CULTURING TECH, P507
   Catchpole OJ, 2004, J SUPERCRIT FLUID, V29, P97, DOI 10.1016/S0896-8446(03)00033-0
   Chang LP, 2011, J SUPERCRIT FLUID, V57, P155, DOI 10.1016/j.supflu.2011.02.008
   Chen CR, 2009, J SUPERCRIT FLUID, V50, P176, DOI 10.1016/j.supflu.2009.06.001
   Chen F, 2005, J CHROMATOGR A, V1064, P183, DOI 10.1016/j.chroma.2004.12.065
   Hong HL, 2009, POWDER TECHNOL, V191, P294, DOI 10.1016/j.powtec.2008.10.022
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Liau BC, 2011, SEP PURIF TECHNOL, V78, P1, DOI 10.1016/j.seppur.2011.01.008
   Lubian LM, 2000, J APPL PHYCOL, V12, P249, DOI 10.1023/A:1008170915932
   Miguel F, 2006, J SUPERCRIT FLUID, V36, P225, DOI 10.1016/j.supflu.2005.06.009
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Shen CT, 2011, J SUPERCRIT FLUID, V55, P955, DOI 10.1016/j.supflu.2010.10.003
NR 13
TC 8
Z9 8
U1 3
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD JAN
PY 2012
VL 104
BP 828
EP 831
DI 10.1016/j.biortech.2011.11.083
PG 4
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 903XK
UT WOS:000301155800117
PM 22169217
DA 2022-11-30
ER

PT J
AU Chandrika, UG
   Basnayake, BMLB
   Athukorala, I
   Colombagama, PWNM
   Goonetilleke, A
AF Chandrika, Udumalagala Gamage
   Basnayake, Basnayake Mudiyanselage Lohitha Bandara
   Athukorala, Indika
   Colombagama, Pula Wahampurage Nilanka Madurangi
   Goonetilleke, Anil
TI Carotenoid Content and In Vitro Bioaccessibility of Lutein in Some Leafy
   Vegetables Popular in Sri Lanka
SO JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY
LA English
DT Article
DE beta-carotene; lutein; HPLC-DAD; green leafy vegetables; in vitro
   bioaccessibility
ID VITAMIN-A; CATARACT-EXTRACTION; MACULAR PIGMENT; BETA-CAROTENE;
   ZEAXANTHIN; SERUM; IDENTIFICATION; DIET; RISK
AB Lutein is one of the major carotenoids in green leafy vegetables (GLVs). which show a marked antioxidant activity. The study was carried out to identify and quantify the carotenoid content of selected Sri Lankan GLVs. RP-HPLC with photodiode array detection method was followed for the separation, identification and quantification of carotenoids. Among the vegetables analyzed. Ipomoea batatas leaves showed the highest beta-carotene content (743.9 +/- 35.0 mu g/g dry weight (DW)) while Syngonium angustatum leaves contained the highest amount of lutein (1.728.2 +/- 168.3 mu g/g DW). Percentage in vitro bioaccessibility of lutein from cooked GLVs ranged from 10.1 to 48.0% in stir-fried preparations of Centella asiatica and Cucurbita maxima, respectively. Hence these GLVs can be exploited as a rich source of beta-carotene and lutein to overcome vitamin A deficiency and age-related macular degeneration.
C1 [Chandrika, Udumalagala Gamage; Athukorala, Indika] Univ Sri Jayewardenepura, Dept Biochem, Fac Med Sci, Nugegoda, Sri Lanka.
   [Basnayake, Basnayake Mudiyanselage Lohitha Bandara; Goonetilleke, Anil] Univ Sri Jayewardenepura, Dept Pharmacol, Fac Med Sci, Nugegoda, Sri Lanka.
   [Colombagama, Pula Wahampurage Nilanka Madurangi] Univ Sri Jayewardenepura, Dept Food & Sci & Technol, Nugegoda, Sri Lanka.
C3 University Sri Jayewardenepura; University Sri Jayewardenepura;
   University Sri Jayewardenepura
RP Chandrika, UG (通讯作者)，Univ Sri Jayewardenepura, Dept Biochem, Fac Med Sci, Nugegoda, Sri Lanka.
EM udumalagala2002@yahoo.com
FU National Research Council [05-36]; International Foundation for Science
   [E/3655-1]
FX This research was supported by the National Research Council Grant 2005:
   No. 05-36 and International Foundation for Science (Research grant No:
   E/3655-1).
CR Brown L, 1999, AM J CLIN NUTR, V70, P517
   Chandrika UG, 2006, J SCI FOOD AGR, V86, P54, DOI 10.1002/jsfa.2307
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   LANDRUM JT, 2000, ARVO, V41, pS60
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   PADMAVATI K, 1992, J FOOD SCI TECH MYS, V29, P137
   Rodriguez-Amaya D.B., 1999, GUIDE CAROTENOID ANA
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Su Q, 2002, EUR J CLIN NUTR, V56, P1149, DOI 10.1038/sj.ejcn.1601472
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
NR 18
TC 20
Z9 20
U1 0
U2 14
PU CENTER ACADEMIC PUBL JAPAN
PI TOKYO
PA 2-4-16 YAYOI, BUNKYO-KU, TOKYO, 113-0032, JAPAN
SN 0301-4800
EI 1881-7742
J9 J NUTR SCI VITAMINOL
JI J. Nutr. Sci. Vitaminol.
PD JUN
PY 2010
VL 56
IS 3
BP 203
EP 207
DI 10.3177/jnsv.56.203
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 615JW
UT WOS:000279132200008
PM 20651462
OA gold
DA 2022-11-30
ER

PT J
AU Idelson, M
   Alper, R
   Obolensky, A
   Ben-Shushan, E
   Hemo, I
   Yachimovich-Cohen, N
   Khaner, H
   Smith, Y
   Wiser, O
   Gropp, M
   Cohen, MA
   Even-Ram, S
   Berman-Zaken, Y
   Matzrafi, L
   Rechavi, G
   Banin, E
   Reubinoff, B
AF Idelson, Maria
   Alper, Ruslana
   Obolensky, Alexey
   Ben-Shushan, Etti
   Hemo, Itzhak
   Yachimovich-Cohen, Nurit
   Khaner, Hanita
   Smith, Yoav
   Wiser, Ofer
   Gropp, Michal
   Cohen, Malkiel A.
   Even-Ram, Sharona
   Berman-Zaken, Yael
   Matzrafi, Limor
   Rechavi, Gideon
   Banin, Eyal
   Reubinoff, Benjamin
TI Directed Differentiation of Human Embryonic Stem Cells into Functional
   Retinal Pigment Epithelium Cells
SO CELL STEM CELL
LA English
DT Article
ID RCS RATS; PHOTORECEPTOR DEGENERATION; EYE DEVELOPMENT; VISUAL FUNCTION;
   NICOTINAMIDE; TRANSPLANTATION; PRESERVATION; CONTRIBUTES; INHIBITOR;
   LONGEVITY
AB Dysfunction and loss of retinal pigment epithelium (RPE) leads to degeneration of photoreceptors in age-related macular degeneration and subtypes of retinitis pigmentosa. Human embryonic stem cells (hESCs) may serve as an unlimited source of RPE cells for transplantation in these blinding conditions. Here we show the directed differentiation of hESCs toward an RPE fate under defined culture conditions. We demonstrate that nicotinamide promotes the differentiation of hESCs to neural and subsequently to RPE fate. In the presence of nicotinamide, factors from the TGF-beta superfamily, which presumably pattern RIDE development during embryogenesis, further direct RPE differentiation. The hESC-derived pigmented cells exhibit the morphology, marker expression, and function of authentic RPE and rescue retinal structure and function after transplantation to an animal model of retinal degeneration caused by RPE dysfunction. These results are an important step toward the future use of hESCs to replenish RPE in blinding diseases.
C1 [Idelson, Maria; Ben-Shushan, Etti; Yachimovich-Cohen, Nurit; Khaner, Hanita; Gropp, Michal; Cohen, Malkiel A.; Even-Ram, Sharona; Berman-Zaken, Yael; Reubinoff, Benjamin] Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, Hadassah Human Embryon Stem Cell Res Ctr, IL-91120 Jerusalem, Israel.
   [Idelson, Maria; Ben-Shushan, Etti; Yachimovich-Cohen, Nurit; Khaner, Hanita; Gropp, Michal; Cohen, Malkiel A.; Even-Ram, Sharona; Berman-Zaken, Yael; Reubinoff, Benjamin] Hadassah Hebrew Univ Med Ctr, Dept Gynecol, IL-91120 Jerusalem, Israel.
   [Smith, Yoav] Hadassah Hebrew Univ Med Ctr, Genom Data Anal Unit, IL-91120 Jerusalem, Israel.
   [Alper, Ruslana; Obolensky, Alexey; Hemo, Itzhak; Banin, Eyal] Hadassah Hebrew Univ Med Ctr, Ctr Retinal & Macular Degenerat, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Wiser, Ofer; Matzrafi, Limor] CellCure Neurosci Ltd, IL-91120 Jerusalem, Israel.
   [Rechavi, Gideon] Chaim Sheba Med Ctr, Pediat Hematooncol Dept, IL-52621 Tel Aviv, Israel.
   [Rechavi, Gideon] Chaim Sheba Med Ctr, Inst Hematol, IL-52621 Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem; Hebrew University of Jerusalem; Chaim Sheba
   Medical Center; Chaim Sheba Medical Center
RP Reubinoff, B (通讯作者)，Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, Hadassah Human Embryon Stem Cell Res Ctr, IL-91120 Jerusalem, Israel.
EM benjaminr@ekmd.huji.ac.il
RI Cohen, Malkiel/AAE-1115-2020
OI Cohen, Malkiel/0000-0002-4187-691X; Reubinoff,
   Benjamin/0000-0003-0353-1299; Even-Ram, Sharona/0000-0002-5540-3822
FU Hadassah Hebrew University Medical Center; Israel Science Foundation
   [989/07]; Chief Scientist Office of the Israel Ministry of Health
   [3000003274]; Israel Ministry of Science, Yedidut Research Grant; Sidney
   Swartz Chair in Human Embryonic Stem Cell Research; CellCure
   Neurosciences Ltd; CSO of CellCure Neurosciences
FX We gratefully acknowledge the following members of the Hadassah
   Embryonic Stem Cell Research Center: Talia Mordechai, Michal Aharonowiz,
   and Galit Tzur for technical support and Shelly Tannenbaum for editing
   the manuscript. We also gratefully acknowledge Vitali Shilo from
   CellCure Neurosciences Ltd. for helping with cell counting and Temima
   Schnitzer Perlman from The Goldyne Savad Institute of Gene Therapy for
   helping with the deposit of the microarray data. We thank Ruth Yaul from
   the Hadassah Center for Retinal and Macular Degeneration for excellent
   technical assistance and to Israel Barzel and Marina Schulman from the
   department of Ophthalmology for their help in fundus imaging in vivo. We
   thank Michal Lotern (Sharett Institute of Oncology, Hadassah University
   Hospital) for her kind gift of human melanoma cell line M51 and WiCell
   Research Institute (Madison, WI) for providing H7 hESCs. Many thanks to
   John C. Saari (University of Washington, Seattle, WA) for providing the
   CRALBP antibody, to Micha Spira (Faculty of Science, Hebrew University,
   Jerusalem) for providing the green fluorescent beads, and to Naomi
   Feinstein and Hava Glickstein from The Department of Electron Microscopy
   (Hebrew University, Jerusalem) for their help in obtaining electron
   microscopy images. This research was supported in part by a grant to
   Hadassah Hebrew University Medical Center by the Israel Science
   Foundation (grant No. 989/07), the Chief Scientist Office of the Israel
   Ministry of Health (grant No. 3000003274), the Israel Ministry of
   Science, Yedidut Research Grant, and the Sidney Swartz Chair in Human
   Embryonic Stem Cell Research. N.Y.-C., H.K., M.G., and Y.B.-Z. are
   partially supported by a grant from CellCure Neurosciences Ltd. O.W. and
   L.M. are employees of CellCure Neurosciences, and B.R. is a founder,
   shareholder, and CSO of CellCure Neurosciences.
CR Aoki H, 2006, EXP EYE RES, V82, P265, DOI 10.1016/j.exer.2005.06.021
   Ben-Dor I, 2006, MOL THER, V14, P255, DOI 10.1016/j.ymthe.2006.02.010
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P271, DOI 10.2174/156720205774322584
   Cimadamore F, 2009, STEM CELLS, V27, P1772, DOI 10.1002/stem.107
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Gropp M, 2003, MOL THER, V7, P281, DOI 10.1016/S1525-0016(02)00047-3
   Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058
   Lin N, 1996, CURR EYE RES, V15, P1069, DOI 10.3109/02713689609017657
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   OTONKOSKI T, 1993, J CLIN INVEST, V92, P1459, DOI 10.1172/JCI116723
   Pankratz MT, 2007, STEM CELLS, V25, P1511, DOI 10.1634/stemcells.2006-0707
   Paquet-Durand F, 2007, J NEUROSCI, V27, P10311, DOI 10.1523/JNEUROSCI.1514-07.2007
   Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Shen CC, 2004, J BIOMED SCI, V11, P472, DOI [10.1159/000077897, 10.1007/BF02256096]
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Taylor RA, 2006, NAT METHODS, V3, P179, DOI 10.1038/nmeth855
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
NR 35
TC 334
Z9 378
U1 1
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD OCT 2
PY 2009
VL 5
IS 4
BP 396
EP 408
DI 10.1016/j.stem.2009.07.002
PG 13
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 514NP
UT WOS:000271401900011
PM 19796620
OA Bronze
DA 2022-11-30
ER

PT J
AU Nishimura, Y
   Hara, H
AF Nishimura, Yuhei
   Hara, Hideaki
TI Integrated Approaches to Drug Discovery for Oxidative Stress-Related
   Retinal Diseases
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID RENIN-ANGIOTENSIN SYSTEM; GENOME-WIDE ASSOCIATION; MACULAR DEGENERATION;
   SUSCEPTIBILITY LOCI; NEURAL RETINA; MOUSE MODEL; CELL-DEATH; RECEPTOR 4;
   ZEBRAFISH; PROTEIN
AB Excessive oxidative stress induces dysregulation of functional networks in the retina, resulting in retinal diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Although various therapies have been developed to reduce oxidative stress in retinal diseases, most have failed to show efficacy in clinical trials. This may be due to oversimplification of target selection for such a complex network as oxidative stress. Recent advances in high-throughput technologies have facilitated the collection of multilevel omics data, which has driven growth in public databases and in the development of bioinformatics tools. Integration of the knowledge gained from omics databases can be used to generate disease-related biological networks and to identify potential therapeutic targets within the networks. Here, we provide an overview of integrative approaches in the drug discovery process and provide simple examples of how the approaches can be exploited to identify oxidative stress-related targets for retinal diseases.
C1 [Nishimura, Yuhei] Mie Univ, Dept Mol & Cellular Pharmacol, Pharmacogen & Pharmacoinformat, Grad Sch Med, Tsu, Mie 5148507, Japan.
   [Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan.
C3 Mie University; Gifu Pharmaceutical University
RP Nishimura, Y (通讯作者)，Mie Univ, Dept Mol & Cellular Pharmacol, Pharmacogen & Pharmacoinformat, Grad Sch Med, Tsu, Mie 5148507, Japan.
EM yuhei@doc.medic.mie-u.ac.jp
OI Hara, Hideaki/0000-0003-2046-9001; Nishimura, Yuhei/0000-0003-1901-8799
FU Japan Society for the Promotion of Science KAKENHI [16K08547];
   Long-Range Research Initiative of the Japan Chemical Industrial
   Association [13-PT01-01]; Okasan-Kato Foundation
FX This work was supported in part by the Japan Society for the Promotion
   of Science KAKENHI (16K08547), the Long-Range Research Initiative of the
   Japan Chemical Industrial Association (13-PT01-01), and Okasan-Kato
   Foundation.
CR Abu-Amero K, 2015, INT J MOL SCI, V16, P28886, DOI 10.3390/ijms161226135
   Akane M, 2011, NEUROSCI LETT, V488, P87, DOI 10.1016/j.neulet.2010.11.008
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   [Anonymous], ANAL BIOANAL CHEM
   Bai N, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-22
   Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367
   Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482
   Bajorath J., 2015, F1000RESEARCH, V4
   Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Chen B, 2016, CLIN PHARMACOL THER, V99, P285, DOI 10.1002/cpt.318
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Chen Y, 2016, ANNU REV PHARMACOL, V56, P273, DOI 10.1146/annurev-pharmtox-010715-103033
   Chhetri J, 2014, EYE, V28, P367, DOI 10.1038/eye.2014.19
   Choi S. H., 2016, BIOCH BIOPHYS ACTA
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   de Moraes G., 2016, CLIN EXPT OPHTHALMOL
   Dehairs Jonas, 2015, Drug Discov Today Technol, V13, P33, DOI 10.1016/j.ddtec.2015.03.002
   DelVCanoandP M., 2008, PPAR RES, V2008
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Donegan RK, 2016, J MED CHEM, V59, P788, DOI 10.1021/acs.jmedchem.5b00828
   Dopazo J, 2014, DRUG DISCOV TODAY, V19, P126, DOI 10.1016/j.drudis.2013.06.003
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Falk MJ, 2011, EMBO MOL MED, V3, P410, DOI 10.1002/emmm.201100149
   Favari E, 2004, ARTERIOSCL THROM VAS, V24, P2345, DOI 10.1161/01.ATV.0000148706.15947.8a
   Fillet Marianne, 2015, Drug Discov Today Technol, V13, P19, DOI 10.1016/j.ddtec.2015.01.006
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Giese MJ, 2014, PHARMACOL THERAPEUT, V142, P11, DOI 10.1016/j.pharmthera.2013.11.002
   Gower NJD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0188-2
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Gupta V, 2014, BBA-MOL BASIS DIS, V1842, P1567, DOI 10.1016/j.bbadis.2014.05.026
   Harada T, 2007, J CLIN INVEST, V117, P1763, DOI 10.1172/JCI30178
   Hasegawa T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31184
   Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786
   Hernandez C, 2016, J DIABETES RES, V2016, DOI DOI 10.1155/2016/9508541
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Hirota R, 2012, INVEST OPHTH VIS SCI, V53, P1467, DOI 10.1167/iovs.11-9006
   Hong S, 2014, MOL VIS, V20, P1456
   Hsieh HL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/484613
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Ito Y, 2012, MOL VIS, V18, P2647
   Jones BW, 2011, J COMP NEUROL, V519, P2713, DOI 10.1002/cne.22703
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kawase R, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00126
   Khor CC, 2016, NAT GENET, V48, P556, DOI 10.1038/ng.3540
   Knickelbein JE, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0786-7
   Kowluru R. A., 2015, BIOCHIM BIOPHYS ACTA, V1852, P2474
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   de la Camara CMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074223
   Mastropasqua R, 2015, PROG BRAIN RES, V221, P213, DOI 10.1016/bs.pbr.2015.05.007
   Matsubara H, 2013, INVEST OPHTH VIS SCI, V54
   Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601
   Mukhopadhyay S, 2010, ARTIF INTELL MED, V49, P145, DOI 10.1016/j.artmed.2010.03.002
   NAITO M, 1995, NEUROSCI LETT, V186, P211, DOI 10.1016/0304-3940(95)11321-M
   Nakagami Y., 2015, CURR EYE RES, P1
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nakao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032472
   Namekata K, 2013, CELL DEATH DIFFER, V20, P1250, DOI 10.1038/cdd.2013.91
   Nishimura Y, 2016, CONGENIT ANOM, V56, P18, DOI 10.1111/cga.12142
   Nishimura Y, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00257
   Nishimura Y, 2015, CONGENIT ANOM, V55, P1, DOI 10.1111/cga.12079
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Patrias K., 2007, CITING MED NLM STYLE
   Peri F, 2014, J MED CHEM, V57, P3612, DOI 10.1021/jm401006s
   Phipps JA, 2012, CLIN EXP OPTOM, V95, P282, DOI 10.1111/j.1444-0938.2012.00747.x
   Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Richardson R., 2016, EYE
   Saito Y, 2016, J PHARMACOL SCI, V131, P215, DOI 10.1016/j.jphs.2016.05.009
   Salt TE, 2014, NEUROTOX RES, V26, P440, DOI 10.1007/s12640-014-9488-6
   Sasagawa S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00162
   Sasagawa S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00142
   Sasagawa S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00057
   Segura-Cabrera A, 2015, MOL BIOSYST, V11, P2850, DOI 10.1039/c5mb00444f
   Semba K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.296
   Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323
   Shah AN, 2015, NAT METHODS, V12, P535, DOI 10.1038/nmeth.3360
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235
   Shimazawa M, 2015, CURR NEUROVASC RES, V12, P128, DOI 10.2174/1567202612666150311105814
   Shimazawa M, 2013, EXP EYE RES, V111, P1, DOI 10.1016/j.exer.2013.03.010
   Shimazawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030526
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Sur A, 2014, P NATL ACAD SCI USA, V111, P16754, DOI 10.1073/pnas.1419576111
   Suzuki Y, 2012, SCI REP-UK, V2, DOI 10.1038/srep00896
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P6729, DOI 10.1167/iovs.11-9378
   Tsuruma K, 2011, MOL VIS, V17, P3556
   Vailaya A, 2005, BIOINFORMATICS, V21, P430, DOI 10.1093/bioinformatics/bti187
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Wilkinson-Berka JL, 2012, PEPTIDES, V36, P142, DOI 10.1016/j.peptides.2012.04.008
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
   Zhu WH, 2000, LAB INVEST, V80, P545, DOI 10.1038/labinvest.3780060
NR 105
TC 8
Z9 10
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 2370252
DI 10.1155/2016/2370252
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EF8FE
UT WOS:000390563500001
PM 28053689
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Yang, TT
   Justus, S
   Li, Y
   Tsang, SH
AF Yang, Tingting
   Justus, Sally
   Li, Yao
   Tsang, Stephen H.
TI BEST1: the Best Target for Gene and Cell Therapies
SO MOLECULAR THERAPY
LA English
DT Article
ID AUTOSOMAL RECESSIVE BESTROPHINOPATHY; LEBERS CONGENITAL AMAUROSIS;
   MACULAR DEGENERATION; MUTATION; DISEASE; PATIENT; INSIGHTS; CHANNEL
AB A retinal pigmented epithelial (RPE) disorder, bestrophinopathy has recently been proven to be amenable to gene and cell-based therapies in preclinical models. RPE disorders and allied retinal degenerations exhibit significant genetic heterogeneity, and diverse mutations can result in similar disease phenotypes. Several RPE disorders have recently become targets for gene therapies in humans. The year 2011 brought a new advance in cell-based therapies, with the Food and Drug Administration approving clinical trials using embryonic stem cells for an RPE disorder known as age-related macular degeneration. Recent studies on induced pluripotent stem (iPS)-RPE generation indicate strong potential for developing patient-specific disease models in vitro, which could eventually enable personalized treatment. This mini-review will briefly highlight the suitability of the retina for gene and cell therapies, the pathophysiology of bestrophinopathy, and the research and treatment opportunities afforded by stem cell and genetic therapies.
C1 [Yang, Tingting] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.
   [Justus, Sally; Li, Yao; Tsang, Stephen H.] Columbia Univ, Barbara & Donald Jonas Stem Cell & Regenerat Med, Inst Human Nutr, Coll Phys & Surg, New York, NY 10032 USA.
   [Justus, Sally; Li, Yao; Tsang, Stephen H.] Columbia Univ, Bernard & Shirlee Brown Glaucoma Lab, Inst Human Nutr, Dept Pathol & Cell Biol,Coll Phys & Surg, New York, NY 10032 USA.
   [Li, Yao; Tsang, Stephen H.] Columbia Univ, Med Ctr, Irving Inst Clin & Translat Res, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP Tsang, SH (通讯作者)，Columbia Univ, Barbara & Donald Jonas Stem Cell & Regenerat Med, Inst Human Nutr, Coll Phys & Surg, 635 West 165th St,Box 112, New York, NY 10032 USA.
EM sht2@cumc.columbia.edu
FU NIH [R01EY018213, R01EY024698, R21AG050437]; Research to Prevent
   Blindness Physician-Scientist Award; New York State [C029572];
   Foundation Fighting Blindness New York Regional Research Center
   [C-NY05-0705-0312]; NATIONAL EYE INSTITUTE [R01EY018213, R00EY025290,
   K99EY025290, R01EY024698] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R21AG050437] Funding Source: NIH RePORTER
FX The Barbara & Donald Jonas Stem Cell & Regenerative Medicine Laboratory
   is supported by NIH R01EY018213, R01EY024698, and R21AG050437; the
   Research to Prevent Blindness Physician-Scientist Award; New York State
   (C029572); and the Foundation Fighting Blindness New York Regional
   Research Center Grant (C-NY05-0705-0312). Additionally, the authors
   would like to extend their gratitude and appreciation to our patients
   and especially to Lawrence Chan for reviewing this manuscript as well as
   serving as our leading research adviser for our macular degeneration
   program. The authors declare no conflict of interest.
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barnard AR, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017293
   Boon CJF, 2013, OPHTHALMOLOGY, V120, P809, DOI 10.1016/j.ophtha.2012.09.057
   Burgess R, 2008, AM J HUM GENET, V82, P19, DOI 10.1016/j.ajhg.2007.08.004
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Davidson AE, 2010, MOL VIS, V16, P2916
   Dickson VK, 2014, NATURE, V516, P213, DOI 10.1038/nature13913
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AT, 2015, RETINA-J RET VIT DIS, V35, P773, DOI 10.1097/IAE.0000000000000387
   Guziewicz KE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075666
   Hartzell HC, 2008, PHYSIOL REV, V88, P639, DOI 10.1152/physrev.00022.2007
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Johnson AA, 2015, INVEST OPHTH VIS SCI, V56, P4619, DOI 10.1167/iovs.15-16910
   Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Lin Michael K, 2015, Taiwan J Ophthalmol, V5, P105, DOI 10.1016/j.tjo.2015.06.002
   MacDonald IM, 1993, GENEREVIEWS
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein AD, 2009, PROG RETIN EYE RES, V28, P206, DOI 10.1016/j.preteyeres.2009.04.004
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   North V, 2014, DEV OPHTHALMOL, V53, P44, DOI 10.1159/000357293
   Rosenberg EA, 2008, AM FAM PHYSICIAN, V77, P1431
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
   Xiao QH, 2010, PFLUG ARCH EUR J PHY, V460, P559, DOI 10.1007/s00424-010-0821-5
   Yang TT, 2014, SCIENCE, V346, P355, DOI 10.1126/science.1259723
NR 32
TC 32
Z9 32
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD DEC
PY 2015
VL 23
IS 12
BP 1805
EP 1809
DI 10.1038/mt.2015.177
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA CZ3IH
UT WOS:000366997200004
PM 26388462
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Sanfilippo, PG
   Kearns, LS
   Wright, P
   Mackey, DA
   Hewitt, AW
AF Sanfilippo, Paul G.
   Kearns, Lisa S.
   Wright, Philip
   Mackey, David A.
   Hewitt, Alex W.
TI Current landscape of direct-to-consumer genetic testing and its role in
   ophthalmology: a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE eye disease; direct-to-consumer; DTC; genetic testing; ophthalmology
ID CHALLENGES
AB The sequencing of the human genome has seen the emergence of the direct-to-consumer (DTC) genetic-testing market, which allows individuals to obtain information about their genetic profile and its many health and lifestyle implications. Genetics play an important role in the development of many eye diseases, however, little information is available describing the influence of the DTC industry in ophthalmology. In this review, we examined DTC companies providing genetic test products for eye disease. Of all eye conditions, the majority of DTC companies provided susceptibility testing or risk assessment for age-related macular degeneration (AMD). For the 15 companies noted to offer products, we found considerable variation in the cost, scope and clarity of informational content of DTC genetic testing for ophthalmic conditions. The clinical utility of these tests remains in question, and the American Academy of Ophthalmology recommendations against routine testing for many conditions probably still apply.
C1 [Sanfilippo, Paul G.; Kearns, Lisa S.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wright, Philip; Mackey, David A.; Hewitt, Alex W.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Res Inst Tasmania, Sch Med, Hobart, Tas, Australia.
   [Wright, Philip] Univ Nottingham, Sch Med, Queens Med Ctr, Nottingham, England.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Lions Eye Institute; University of Western
   Australia; University of Tasmania; Menzies Institute for Medical
   Research; University of Nottingham
RP Sanfilippo, PG (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM prseye@gmail.com
RI Hewitt, Alex W/D-1936-2013; Mackey, David A/H-5340-2014
OI Hewitt, Alex W/0000-0002-5123-5999; Mackey, David A/0000-0001-7914-4709;
   Sanfilippo, Paul/0000-0002-1778-9154; Kearns, Lisa/0000-0001-9432-4054
FU Australian National Health and Medical Research Council (NHMRC) Centres
   of Research Excellence Grant [1023911]; BrightFocus Foundation;
   Ophthalmic Research Institute of Australia
FX CERA receives Operational Infrastructure Support from the Victorian
   Government. Funding support provided by an Australian National Health
   and Medical Research Council (NHMRC) Centres of Research Excellence
   Grant No. 1023911 (2012-2016) as well as from the BrightFocus
   Foundation, and the Ophthalmic Research Institute of Australia.
CR [Anonymous], 2010, LANCET, V376, P488, DOI 10.1016/S0140-6736(10)61234-2
   [Anonymous], 2003, HUMAN GENOME EPIDEMI
   Berg C, 2008, J BUS ETHICS, V77, P17, DOI 10.1007/s10551-006-9298-8
   Bloss CS, 2011, NEW ENGL J MED, V364, P524, DOI 10.1056/NEJMoa1011893
   Dandara C, 2013, SAMJ, S. Afr. med. j., V103, P510, DOI 10.7196/samj.7049
   Duncan RE, 2005, GENET MED, V7, P390, DOI 10.1097/01.GIM.0000170775.390921.44
   Francke U, 2013, PEERJ, V1, DOI 10.7717/peerj.8
   Gunning R, 1952, TECHNIQUE CLEAR WRIT
   GUTHRIE R, 1963, PEDIATRICS, V32, P338
   Hall MA, 2005, GENET MED, V7, P311, DOI 10.1097/01.GIM.0000162874.58370.C0
   Harris A, 2013, J GENET COUNS, V22, P277, DOI 10.1007/s10897-012-9548-0
   Hawkins AK, 2012, J GENET COUNS, V21, P367, DOI 10.1007/s10897-012-9488-8
   Janssens ACJW, 2008, HUM MOL GENET, V17, pR166, DOI 10.1093/hmg/ddn250
   Lachance CR, 2010, GENET MED, V12, P304, DOI 10.1097/GIM.0b013e3181dbd8b2
   Ledley F, 2002, NAT BIOTECHNOL, V20, P767, DOI 10.1038/nbt0802-767
   Li XM, 2008, CURR GENOMICS, V9, P466, DOI 10.2174/138920208786241199
   Matloff E, 2008, AM J BIOETHICS, V8, P5, DOI 10.1080/15265160802248179
   Ng PC, 2009, NATURE, V461, P724, DOI 10.1038/461724a
   Sheridan C, 2014, NAT BIOTECHNOL, V32, P111, DOI [10.1038/nbt0214-115a, 10.1038/nbt0214-111]
   Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
NR 21
TC 7
Z9 7
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 43
IS 6
BP 578
EP 590
DI 10.1111/ceo.12508
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN8XC
UT WOS:000358728000012
PM 25676199
OA Bronze
DA 2022-11-30
ER

PT J
AU Oka, C
   Saleh, R
   Bessho, Y
   Reza, HM
AF Oka, Chio
   Saleh, Razwa
   Bessho, Yasumasa
   Reza, Hasan Mahmud
TI Interplay between HTRA1 and classical signalling pathways in
   organogenesis and diseases
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Review
DE HTRA1; TGF-beta; WNT; NOTCH; Preeclampsia; HTRA inhibitors
ID HIGH-TEMPERATURE REQUIREMENT; SERINE-PROTEASE HTRA1; TGF-BETA; MACULAR
   DEGENERATION; PLACENTAL DEVELOPMENT; STRUCTURAL INSIGHTS;
   FUNCTIONAL-ANALYSIS; OVARIAN-CANCER; GENE; SUSCEPTIBILITY
AB The high temperature requirement factor Al (HTRA1) is a serine protease which modulates an array of signalling pathways driving basal biological processes. HTRA1 plays a significant role in cell proliferation, migration and fate determination, in addition to controlling protein aggregates through refolding, translocation or degradation. The mutation of HTRA1 has been implicated in a plethora of disorders and this has also led to its growing interest as drug therapy target. This review details the involvement of HTRA1 in certain signalling pathways, namely the transforming growth factor beta (TGF-beta), canonical Wingless/Integrated (WNT) and NOTCH signalling pathways during organogenesis and various disease pathogenesis such as preeclampsia, age-related macular degeneration (AMD), small vessel disease and cancer. We have also explored possible avenues of exploiting the serine proteases for therapeutic management of these disorders. (C) 2021 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
C1 [Oka, Chio] Nara Inst Sci & Technol, Div Biol Sci, Funct Genom & Med, 8916-5 Takayama, Ikoma, Nara 6300192, Japan.
   [Saleh, Razwa; Reza, Hasan Mahmud] North South Univ, Dept Pharmaceut Sci, Dhaka 1229, Bangladesh.
   [Bessho, Yasumasa] Nara Inst Sci & Technol, Div Biol Sci, Gene Regulat Res, 8916-5 Takayama, Ikoma, Nara 6300192, Japan.
C3 Nara Institute of Science & Technology; North South University (NSU);
   Nara Institute of Science & Technology
RP Reza, HM (通讯作者)，North South Univ, Dept Pharmaceut Sci, Sch Hlth & Life Sci, Dhaka 1229, Bangladesh.
EM hasan.reza@northsouth.edu
RI Reza, Hasan Mahmud/AFL-0151-2022
OI Reza, Hasan Mahmud/0000-0003-3287-942X
CR Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034
   Attisano L, 2004, CANCER METAST REV, V23, P53, DOI 10.1023/A:1025811012690
   Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5-17
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Bejugam PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055416
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Cheng H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20187718, 10.1590/1414-431x20187718]
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dynon K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045956
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Filliat G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181600
   Folgueira MAAK, 2005, CLIN CANCER RES, V11, P7434
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fu YB, 2014, INVEST OPHTH VIS SCI, V55, P6524, DOI 10.1167/iovs.14-15670
   FUKUTAKE T, 1995, EUR NEUROL, V35, P69, DOI 10.1159/000117096
   Glaza P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131142
   Globus O, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18203-2
   Graham JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074094
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grigsby PL, 2016, SEMIN REPROD MED, V34, P11, DOI 10.1055/s-0035-1570031
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hasan MZ, 2015, DEV BIOL, V397, P89, DOI 10.1016/j.ydbio.2014.10.015
   Henrique D, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172148
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Ikawati M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196628
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kim YH, 2012, J BIOL CHEM, V287, P38957, DOI 10.1074/jbc.M112.357863
   Klose R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54807-6
   Klose R, 2018, ONCOGENE, V37, P4260, DOI 10.1038/s41388-018-0258-4
   Kocher S, 2017, ANGEW CHEM INT EDIT, V56, P8555, DOI 10.1002/anie.201701771
   Kummari R, 2019, BIOCHEM J, V476, P1445, DOI 10.1042/BCJ20190224
   Larkin DJ, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00121
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795
   Li Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04867-3
   Li Y, 2011, J CLIN ENDOCR METAB, V96, P403, DOI 10.1210/jc.2010-1405
   Liao SM, 2017, MOL VIS, V23, P318
   Lin M.K., 2018, PROCESSES EXTRACELLU, DOI [10.1111/acel.12710, DOI 10.1111/ACEL.12710]
   Liu CH, 2018, MOL MED REP, V18, P2937, DOI 10.3892/mmr.2018.9289
   Liu J, 2015, INVEST OPHTH VIS SCI, V56, P1387, DOI 10.1167/iovs.14-15914
   Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409
   Moisoi N, 2009, CELL DEATH DIFFER, V16, P449, DOI 10.1038/cdd.2008.166
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Ng T.K., 2016, SCI REP-UK, V6, P1
   Nguyen C., 2017, CHARACTERIZING FUNCT
   Nie GY, 2006, BIOL REPROD, V74, P366, DOI 10.1095/biolreprod.105.047324
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Onodera O., 2019, HTRA1 DISORDER
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Pan Y., J BIOL CHEM, V296
   Pelullo M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00711
   Perna AM, 2014, CHEM SCI, V5, P3583, DOI 10.1039/c4sc01443j
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570
   Runyon ST, 2007, PROTEIN SCI, V16, P2454, DOI 10.1110/ps.073049407
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Soncin F, 2015, CELL MOL LIFE SCI, V72, P1291, DOI 10.1007/s00018-014-1794-x
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Tang YF, 2010, J BIOL CHEM, V285, P17556, DOI 10.1074/jbc.M109.076414
   Tikka S, 2014, BRAIN PATHOL, V24, P525, DOI 10.1111/bpa.12181
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Vande Walle L, 2008, CELL DEATH DIFFER, V15, P453, DOI 10.1038/sj.cdd.4402291
   Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z
   Wang LJ, 2012, MOL CELL BIOL, V32, P3707, DOI 10.1128/MCB.00223-12
   Wang Y., 2018, HTRA3 ISOFORM SPECIF, P27, DOI [10.1177/1087057116682425, DOI 10.1177/1087057116682425]
   Wang Y, 2018, SLAS DISCOV, V23, P1092, DOI 10.1177/1087057116682425
   Wenta T, 2019, FEBS J, V286, P4579, DOI 10.1111/febs.14977
   Woods L, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00570
   Wu XW, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431x20176632, 10.1590/1414-431X20176632]
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zellner A, 2018, ACTA NEUROPATHOL, V136, P111, DOI 10.1007/s00401-018-1853-8
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zong L, 2013, ARCH MED SCI, V9, P690, DOI 10.5114/aoms.2013.34989
   Zurawa-Janicka D, 2017, ARCH BIOCHEM BIOPHYS, V621, P6, DOI 10.1016/j.abb.2017.04.004
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 86
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-562X
EI 2213-7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD APR
PY 2022
VL 29
IS 4
BP 1919
EP 1927
DI 10.1016/j.sjbs.2021.11.056
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 1L0LF
UT WOS:000798983400001
PM 35531175
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, C
   Wang, CG
   Zhou, XB
   Xu, LX
   Chen, H
   Qian, K
   Jia, B
   Su, GF
   Fu, JL
AF Chen, Chen
   Wang, Chenguang
   Zhou, Xuebin
   Xu, Lingxian
   Chen, Han
   Qian, Kun
   Jia, Bo
   Su, Guanfang
   Fu, Jinling
TI Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative
   diseases
SO PROSTAGLANDINS & OTHER LIPID MEDIATORS
LA English
DT Review
DE NSAIDs; Retinal neurodegenerative diseases; Age-related macular
   degeneration; Diabetic retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; INDUCED OCULAR INFLAMMATION; PROSTAGLANDIN
   E-2 LEVELS; DIABETIC MACULAR EDEMA; CHOROIDAL NEOVASCULARIZATION;
   INTRAOCULAR-PRESSURE; INTRAVITREAL DICLOFENAC; BROMFENAC 0.09-PERCENT;
   KETOROLAC TROMETHAMINE; TOPICAL NEPAFENAC
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common prescription drugs for inflammation, and topical NSAIDs are often used in ophthalmology to reduce pain, photophobia, inflammation, and edema. In recent years, many published reports have found that NSAIDs play an important role in the treatment of retinal neurodegenerative diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, pathological myopia, and retinitis pigmentosa (RP). The aim of the current review is to provide an overview of the role of various NSAIDs in the treatment of retinal neurodegenerative diseases and the corresponding mechanisms of action. This review highlighted that the topical application of NSAIDs for the treatment of retinal degenerative diseases has been studied to a remarkable extent and that its beneficial effects in many diseases have been proven. In the future, prospective studies with large study populations are required to extend these effects to clinical settings.
C1 [Chen, Chen; Wang, Chenguang; Zhou, Xuebin; Xu, Lingxian; Chen, Han; Qian, Kun; Jia, Bo; Su, Guanfang; Fu, Jinling] Jilin Univ, Hosp 2, Dept Ophthalmol, 4026 Yatai St, Changchun, Jilin 130022, Peoples R China.
C3 Jilin University
RP Fu, JL (通讯作者)，Jilin Univ, Hosp 2, Dept Ophthalmol, 4026 Yatai St, Changchun, Jilin 130022, Peoples R China.
EM chenchen18@mails.jlu.edu.cn; wangchenguang1977@163.com;
   429218113@qq.com; 1184008374@qq.com; chenhan@jlu.edu.cn;
   qk18737816982@163.com; jiabo1997@163.com; sugf2012@163.com;
   fujinling1981@163.com
OI Su, Guanfang/0000-0003-4820-6537
FU National Natural Science Foundation [81970836]; International
   Cooperation Project of Science and Technology Department of Jilin
   Province [20190701044GH]; Training Program for Outstanding Young
   Teachers of Jilin University [419080520313]; Natural Science Foundation
   Project of Science and Technology Department of Jilin Province
   [20200201360JC]
FX This work was supported by the National Natural Science Foundation
   (81970836), the International Cooperation Project of Science and
   Technology Department of Jilin Province (20190701044GH), the Training
   Program for Outstanding Young Teachers of Jilin University
   (419080520313), and the Natural Science Foundation Project of Science
   and Technology Department of Jilin Province (20200201360JC).
CR Abu El-Asrar AM, 2008, BRIT J OPHTHALMOL, V92, P1534, DOI 10.1136/bjo.2008.142182
   Achiron A, 2016, J OCUL PHARMACOL TH, V32, P601, DOI 10.1089/jop.2016.0057
   Reis ADA, 2010, ARQ BRAS OFTALMOL, V73, P338, DOI 10.1590/S0004-27492010000400007
   Ahn SJ, 2016, RETINA-J RET VIT DIS, V36, P2140, DOI 10.1097/IAE.0000000000001043
   Ahuja M, 2008, AAPS J, V10, P229, DOI 10.1208/s12248-008-9024-9
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Baklayan GA, 2008, J OCUL PHARMACOL TH, V24, P392, DOI 10.1089/jop.2007.0082
   Baranano DE, 2009, BRIT J OPHTHALMOL, V93, P1387, DOI 10.1136/bjo.2009.157297
   Bucci FA, 2011, ADV THER, V28, P1089, DOI 10.1007/s12325-011-0080-7
   Bucci FA, 2009, ADV THER, V26, P645, DOI 10.1007/s12325-009-0042-5
   Callanan D, 2008, CLIN OPHTHALMOL, V2, P689
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Castro MR, 2004, EXP EYE RES, V79, P275, DOI 10.1016/j.exer.2004.04.008
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1249, DOI 10.2147/OPTH.S14092
   Chen YY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1284-x
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Chiba T, 2006, BRIT J OPHTHALMOL, V90, P314, DOI 10.1136/bjo.2005.080895
   Costagliola C, 2008, CURR EYE RES, V33, P477, DOI 10.1080/02713680802100845
   Curtin B J, 1988, Acta Ophthalmol Suppl, V185, P111
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Ducloyer JB, 2020, M S-MED SCI, V36, P607, DOI 10.1051/medsci/2020095
   El-Asrar Ahmed M Abu, 2011, Mol Vis, V17, P1829
   Elbendary AM, 2011, RETINA-J RET VIT DIS, V31, P2058, DOI 10.1097/IAE.0b013e31822a042a
   Flach Allan Joseph, 2002, International Ophthalmology Clinics, V42, P1
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Friedman SM, 2015, RETINA-J RET VIT DIS, V35, P944, DOI 10.1097/IAE.0000000000000403
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gan TJ, 2010, CURR MED RES OPIN, V26, P1715, DOI 10.1185/03007995.2010.486301
   Giannaccare G, 2018, CURR EYE RES, V43, P1445, DOI 10.1080/02713683.2018.1501489
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hariprasad SM, 2007, J OCUL PHARMACOL TH, V23, P585, DOI 10.1089/jop.2007.0062
   Hattori Y, 2007, CURR MED RES OPIN, V23, P1913, DOI 10.1185/030079907X218770
   Heier JS, 2009, RETINA-J RET VIT DIS, V29, P1310, DOI 10.1097/IAE.0b013e3181b094e6
   Isawi H, 2007, J CATARACT REFR SURG, V33, P1644, DOI 10.1016/j.jcrs.2007.04.041
   Johnson EIM, 1999, CURR EYE RES, V18, P79, DOI 10.1076/ceyr.18.2.79.5386
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Kern TS, 2007, DIABETES, V56, P373, DOI 10.2337/db05-1621
   Kida T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096481
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Kocak Nilufer, 2010, Ann Ophthalmol (Skokie), V42 Spec No, P10
   KOTHARI HV, 1987, BIOCHIM BIOPHYS ACTA, V921, P502, DOI 10.1016/0005-2760(87)90078-6
   Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com
   Li QH, 2010, INVEST OPHTH VIS SCI, V51, P5240, DOI 10.1167/iovs.09-5147
   Li SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184998
   Libondi T, 2010, ACTA OPHTHALMOL, V88, pe32, DOI 10.1111/j.1755-3768.2008.01491.x
   Lin FL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41086
   Lindstrom R, 2006, CURR MED RES OPIN, V22, P397, DOI 10.1185/030079906X89775
   Long Q, 2013, OPTOMETRY VISION SCI, V90, P501, DOI 10.1097/OPX.0b013e31828daa6e
   Maldonado RM, 2011, CURR EYE RES, V36, P768, DOI 10.3109/02713683.2011.585734
   Massengill MT, 2018, ADV EXP MED BIOL, V1074, P185, DOI 10.1007/978-3-319-75402-4_23
   Masuda I, 2010, EUR J OPHTHALMOL, V20, P454, DOI 10.1177/112067211002000230
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Meleth AD, 2005, INVEST OPHTH VIS SCI, V46, P4295, DOI 10.1167/iovs.04-1057
   Messerschmidt L, 2019, MOL VIS, V25, P329
   Miao H, 2012, MOL VIS, V18, P574
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Mohamed-Noriega K, 2016, CASE REP OPHTHAL, V7, P119, DOI 10.1159/000444437
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Nagasaka Y, 2018, OPHTHALMOL RETINA, V2, P726, DOI 10.1016/j.oret.2017.07.020
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Ozyol P, 2016, J GLAUCOMA, V25, pE145, DOI 10.1097/IJG.0000000000000204
   Panahi Y, 2018, INT OPHTHALMOL, V38, P99, DOI 10.1007/s10792-016-0428-8
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pinna A, 2017, EUR J OPHTHALMOL, V27, P326, DOI 10.5301/ejo.5000888
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Rezaei KA, 2011, INVEST OPHTH VIS SCI, V52, P701, DOI 10.1167/iovs.10-6319
   Rigas B, 2020, SURV OPHTHALMOL, V65, P1, DOI 10.1016/j.survophthal.2019.07.001
   Rovere G, 2016, INVEST OPHTH VIS SCI, V57, P6098, DOI 10.1167/iovs.16-20425
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   Sahoo S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010009.pub2
   Schalnus R, 2003, OPHTHALMOLOGICA, V217, P89, DOI 10.1159/000068563
   Schoenberger SD, 2014, JAMA OPHTHALMOL, V132, P150, DOI 10.1001/jamaophthalmol.2013.5692
   Schoenberger SD, 2012, INVEST OPHTH VIS SCI, V53, P5906, DOI 10.1167/iovs.12-10410
   Semeraro F, 2015, EXPERT OPIN DRUG DEL, V12, P1767, DOI 10.1517/17425247.2015.1068756
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Sheppard JD, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S86971
   Simon MV, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000972
   SMALL RE, 1989, CLIN PHARMACY, V8, P545
   Soheilian M, 2015, INT OPHTHALMOL, V35, P421, DOI 10.1007/s10792-014-9967-z
   Soheilian M, 2010, RETINA-J RET VIT DIS, V30, P509, DOI 10.1097/IAE.0b013e3181bdfa43
   Sorkhabi R, 2011, J GLAUCOMA, V20, P240, DOI 10.1097/IJG.0b013e3181e07933
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Tofflemire K, 2017, VET OPHTHALMOL, V20, P398, DOI 10.1111/vop.12439
   Toris CB, 2008, SURV OPHTHALMOL, V53, pS107, DOI 10.1016/j.survophthal.2008.08.010
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Turan-Vural E, 2012, OPHTHALMOLOGICA, V227, P205, DOI 10.1159/000333822
   Ueta M, 2012, CORNEA, V31, P1294, DOI 10.1097/ICO.0b013e318242fd7c
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Unlu N, 2010, CAN J OPHTHALMOL, V45, P610, DOI 10.3129/i10-048
   Walters T, 2007, J CATARACT REFR SURG, V33, P1539, DOI 10.1016/j.jcrs.2007.05.015
   Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471
   Williams PA, 2017, EXP EYE RES, V157, P20, DOI 10.1016/j.exer.2017.02.014
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wygledowska-Promienska D, 2015, MED SCI MONITOR, V21, P3906, DOI 10.12659/MSM.895977
   Wygledowska-Promienska D, 2014, MED SCI MONITOR, V20, P1168, DOI 10.12659/MSM.890671
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yamagishi-Kimura R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29273-1
   Yamamoto Y, 2015, RETINA-J RET VIT DIS, V35, P344, DOI 10.1097/IAE.0000000000000311
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 114
TC 0
Z9 0
U1 5
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098-8823
EI 2212-196X
J9 PROSTAG OTH LIPID M
JI Prostaglandins Other Lipid Mediat.
PD OCT
PY 2021
VL 156
AR 106578
DI 10.1016/j.prostaglins.2021.106578
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WB4TQ
UT WOS:000703566400009
PM 34245897
DA 2022-11-30
ER

PT J
AU Munk, M
   Dysli, C
AF Munk, Marion
   Dysli, Chantal
TI Modern Imaging Techniques for Visualising Choroidal Morphology and
   Function
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE choroid; choriocapillaris; ocular imaging; choroidopathy; chorioretinal
   pathology
ID LESIONS; OCT
AB The choroid is directly adjacent to the retina and consists of a dense vascular network that supplies the outer retina. Pathologies in the choroid can lead to changes in the retinal pigment epithelium (RPE) and photoreceptors. Thus, the choroid plays a crucial role in the development of retinal diseases such as age-related macular degeneration (AMD), central serous chorioretinopathy (CSCR), pathologic myopia, and inflammatory diseases such as Vogt-Koyanagi-Harada syndrome (VKH). Basic knowledge of the structure and physiology of the choroid, as well as diagnostic options for visualizing choroidal changes, provides a better understanding of the physiology and pathology of choroidal processes. This review provides an overview of the anatomy and function of the choroid, and describes the diagnostic techniques currently available to characterize and visualize the choroid. It also includes an overview of various retinal conditions, which are associated with choroidal changes.
C1 [Munk, Marion; Dysli, Chantal] Univ Bern, Univ Klin Augenheilkunde, Inselspital, Freiburgstr 4, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Munk, M (通讯作者)，Univ Bern, Univ Klin Augenheilkunde, Inselspital, Freiburgstr 4, CH-3010 Bern, Switzerland.
EM marion.munk@insel.ch
CR Alm A, 2009, EXP EYE RES, V88, P760, DOI 10.1016/j.exer.2008.12.012
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Chee SP, 2017, OCUL IMMUNOL INFLAMM, V25, P528, DOI 10.3109/09273948.2016.1151896
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Gaucher D, 2008, AM J OPHTHALMOL, V145, P289, DOI 10.1016/j.ajo.2007.09.029
   Giocanti-Auregan A, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20855
   GODEL V, 1989, ANN OPHTHALMOL, V21, P49
   Invernizzi A, 2020, ASIA-PAC J OPHTHALMO, V9, P335, DOI 10.1097/APO.0000000000000307
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Mrejen Sarah, 2012, Int Ophthalmol Clin, V52, P67, DOI 10.1097/IIO.0b013e318265f676
   Munk MR, 2016, CURR EYE RES, V41, P97, DOI 10.3109/02713683.2014.1002047
   Munk MR, 2013, RETINA-J RET VIT DIS, V33, P1673, DOI 10.1097/IAE.0b013e318285cc52
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pichi F, 2018, INDIAN J OPHTHALMOL, V66, P1716, DOI 10.4103/ijo.IJO_893_18
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Romdhane K, 2019, KLIN MONATSBL AUGENH, V236, P536, DOI 10.1055/a-0834-6118
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarfare S, 2020, EXP EYE RES, V195, DOI 10.1016/j.exer.2020.108039
   Shah KH, 2005, SURV OPHTHALMOL, V50, P519, DOI 10.1016/j.survophthal.2005.08.004
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   SOUBRANE G, 1990, AM J OPHTHALMOL, V109, P204, DOI 10.1016/S0002-9394(14)75988-4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
NR 26
TC 2
Z9 2
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD SEP
PY 2021
VL 238
IS 9
BP 951
EP 960
DI 10.1055/a-1562-8731
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YR5SL
UT WOS:000750054500006
PM 34492711
DA 2022-11-30
ER

PT J
AU Edwards, DA
   Emerick, B
   Kondic, AG
   Kiradjiev, K
   Raymond, C
   Zyskin, M
AF Edwards, David A.
   Emerick, Brooks
   Kondic, Anna Georgieva
   Kiradjiev, Kristian
   Raymond, Christopher
   Zyskin, Maxim
TI Mathematical models for the effect of anti-vascular endothelial growth
   factor on visual acuity
SO JOURNAL OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Pharmacokinetics; Pharmacodynamics; Analytical solutions; Macular
   degeneration; Diffusion equation; Discrete modeling
ID ANTI-VEGF DRUGS; INTRAVITREAL; RETINA; PHARMACOKINETICS
AB The standard of care treatment for neovascular age-related macular degeneration, delivered as ocular injection, is based on anti-vascular endothelial growth factor (anti-VEGF). The course of treatment may need to be modified quickly for certain patients based on their response. Models that track both the concentration and the response to an anti-VEGF treatment are presented. The specific focus is to assess the existence of analytical solutions for the different types of models. Both an ODE-based model and a map-based model illustrate the dependence of the solution on various biological parameters and allow the measurement of patient-specific parameters from experimental data. A PDE-based model incorporates diffusive effects. The results are consistent with observed values, and could provide a framework for practitioners to understand the effect of the therapy on the progression of the disease in both responsive and non-responsive patients.
C1 [Edwards, David A.; Raymond, Christopher] Univ Delaware, Dept Math Sci, Newark, DE 19716 USA.
   [Emerick, Brooks] Kutztown State Univ, Dept Math, Kutztown, PA 19530 USA.
   [Kondic, Anna Georgieva] Certara, Princeton, NJ 08540 USA.
   [Kiradjiev, Kristian] Univ Oxford, Math Inst, Oxford OX2 6GG, England.
   [Zyskin, Maxim] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England.
C3 University of Delaware; Pennsylvania State System of Higher Education
   (PASSHE); Kutztown University - Pennsylvania; University of Oxford;
   University of Oxford
RP Edwards, DA (通讯作者)，Univ Delaware, Dept Math Sci, Newark, DE 19716 USA.
EM dedwards@udel.edu
OI Kiradjiev, Kristian/0000-0002-4716-0330
FU National Science Foundation [DMS-1261592]; EPSRC Centre For Doctoral
   Training in Industrially Focused Mathematical Modelling [EP/L015803/1];
   EPSRC [EP/S003053/1] Funding Source: UKRI
FX The authors would like to thank the reviewers for their helpful
   comments. The authors would like to thank Novartis (makers of two of the
   most successful anti-VEGF medicines) for (1) their interest in further
   developing models from first principles that can guide real world
   practices and for (2) sharing a small representative sample of BCVA and
   CSFT data that could guide the thinking expressed in this paper. The
   work in this manuscript arose out of the 2019 Mathematical Problems in
   Industry workshop, supported in part by National Science Foundation
   Grant DMS-1261592. Dr. Kiradjiev was partially supported by the EPSRC
   Centre For Doctoral Training in Industrially Focused Mathematical
   Modelling (EP/L015803/1).
CR Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   Bekerman I, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/503645
   Bell W, 1968, DOVER BOOKS MATH
   Bergmanson JPG, 2017, CLIN EXP OPTOM, V100, P522, DOI 10.1111/cxo.12583
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Frenkel REP, 2010, CLIN OPHTHALMOL, V4, P1279, DOI 10.2147/OPTH.S12846
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Harding I.C., 2014, WIKIJ MED, V1, P153, DOI [10.15347/wjm/2014.010, DOI 10.15347/WJM/2014.010]
   Hoyle D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189053
   Hutton-Smith LA, 2017, MOL PHARMACEUT, V14, P2690, DOI 10.1021/acs.molpharmaceut.7b00164
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   Kotha S, 2014, MATH BIOSCI, V253, P11, DOI 10.1016/j.mbs.2014.03.014
   Martinez-Canada P, 2016, INT J NEURAL SYST, V26, DOI 10.1142/S0129065716500301
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Rattanakijsuntorn K, 2018, IOP CONF SER-MAT SCI, V297, DOI 10.1088/1757-899X/297/1/012024
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Zhang Y, 2018, INVEST OPHTH VIS SCI, V59, P5266, DOI 10.1167/iovs.17-23632
NR 23
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0303-6812
EI 1432-1416
J9 J MATH BIOL
JI J. Math. Biol.
PD DEC
PY 2020
VL 81
IS 6-7
BP 1397
EP 1428
DI 10.1007/s00285-020-01544-4
EA SEP 2020
PG 32
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA PA2MC
UT WOS:000572327900001
PM 32968840
DA 2022-11-30
ER

PT J
AU Kermany, DS
   Goldbaum, M
   Cai, WJ
   Valentim, CCS
   Liang, HY
   Baxter, SL
   McKeown, A
   Yang, G
   Wu, XK
   Yan, FB
   Dong, J
   Prasadha, MK
   Pei, J
   Ting, M
   Zhu, J
   Li, C
   Hewett, S
   Dong, JS
   Ziyar, I
   Shi, A
   Zhang, RZ
   Zheng, LH
   Hou, R
   Shi, W
   Fu, X
   Duan, YO
   Huu, VAN
   Wen, C
   Zhang, ED
   Zhang, CL
   Li, OL
   Wang, XB
   Singer, MA
   Sun, XD
   Xu, J
   Tafreshi, A
   Lewis, MA
   Xia, HM
   Zhang, K
AF Kermany, Daniel S.
   Goldbaum, Michael
   Cai, Wenjia
   Valentim, Carolina C. S.
   Liang, Huiying
   Baxter, Sally L.
   McKeown, Alex
   Yang, Ge
   Wu, Xiaokang
   Yan, Fangbing
   Dong, Justin
   Prasadha, Made K.
   Pei, Jacqueline
   Ting, Magdalena
   Zhu, Jie
   Li, Christina
   Hewett, Sierra
   Dong, Jason
   Ziyar, Ian
   Shi, Alexander
   Zhang, Runze
   Zheng, Lianghong
   Hou, Rui
   Shi, William
   Fu, Xin
   Duan, Yaou
   Huu, Viet A. N.
   Wen, Cindy
   Zhang, Edward D.
   Zhang, Charlotte L.
   Li, Oulan
   Wang, Xiaobo
   Singer, Michael A.
   Sun, Xiaodong
   Xu, Jie
   Tafreshi, Ali
   Lewis, M. Anthony
   Xia, Huimin
   Zhang, Kang
TI Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep
   Learning
SO CELL
LA English
DT Article
ID MACULAR DEGENERATION; RETINAL IMAGES; BLOOD-VESSELS; PREVALENCE
AB The implementation of clinical-decision support algorithms for medical imaging faces challenges with reliability and interpretability. Here, we establish a diagnostic tool based on a deep-learning framework for the screening of patients with common treatable blinding retinal diseases. Our framework utilizes transfer learning, which trains a neural network with a fraction of the data of conventional approaches. Applying this approach to a dataset of optical coherence tomography images, we demonstrate performance comparable to that of human experts in classifying age-related macular degeneration and diabetic macular edema. We also provide a more transparent and interpretable diagnosis by highlighting the regions recognized by the neural network. We further demonstrate the general applicability of our AI system for diagnosis of pediatric pneumonia using chest X-ray images. This tool may ultimately aid in expediting the diagnosis and referral of these treatable conditions, thereby facilitating earlier treatment, resulting in improved clinical outcomes.
C1 [Kermany, Daniel S.; Liang, Huiying; Dong, Justin; Pei, Jacqueline; Zhu, Jie; Hewett, Sierra; Dong, Jason; Fu, Xin; Huu, Viet A. N.; Zhang, Edward D.; Zhang, Charlotte L.; Li, Oulan; Xia, Huimin; Zhang, Kang] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou 510005, Guangdong, Peoples R China.
   [Kermany, Daniel S.; Goldbaum, Michael; Cai, Wenjia; Valentim, Carolina C. S.; Baxter, Sally L.; Yang, Ge; Prasadha, Made K.; Pei, Jacqueline; Ting, Magdalena; Li, Christina; Hewett, Sierra; Ziyar, Ian; Shi, Alexander; Zhang, Runze; Shi, William; Fu, Xin; Duan, Yaou; Huu, Viet A. N.; Wen, Cindy; Zhang, Edward D.; Zhang, Charlotte L.; Li, Oulan; Zhang, Kang] Univ Calif San Diego, Shiley Eye Inst, Inst Engn Med, Inst Genom Med, La Jolla, CA 92093 USA.
   [McKeown, Alex; Tafreshi, Ali] Heidelberg Engn, Heidelberg, Germany.
   [Wu, Xiaokang; Yan, Fangbing; Zhang, Kang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, Natl Clin Res Ctr Senile Dis,State Key Lab Biothe, Chengdu, Sichuan, Peoples R China.
   [Zhu, Jie; Hou, Rui] Guangzhou KangRui Biol Pharmaceut Technol Co, Guangzhou 510005, Guangdong, Peoples R China.
   [Zheng, Lianghong] YouHealth Al, Guangzhou 510005, Guangdong, Peoples R China.
   [Wang, Xiaobo] Beihai Hosp, Dalian 116021, Peoples R China.
   [Singer, Michael A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Ocular Fundus Dis, Shanghai 200080, Peoples R China.
   [Xu, Jie] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Lewis, M. Anthony] Qualcomm, San Diego, CA 92121 USA.
   [Zhang, Kang] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510005, Guangdong, Peoples R China.
   [Zhang, Kang] Vet Adm Healthcare Syst, San Diego, CA 92037 USA.
C3 Guangzhou Medical University; University of California System;
   University of California San Diego; Sichuan University; University of
   Texas System; University of Texas Health San Antonio; Shanghai Jiao Tong
   University; Capital Medical University; Qualcomm; Guangzhou Regenerative
   Medicine & Health Guangdong Laboratory (Bioisland Laboratory)
RP Zhang, K (通讯作者)，Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou 510005, Guangdong, Peoples R China.; Zhang, K (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Inst Engn Med, Inst Genom Med, La Jolla, CA 92093 USA.; Zhang, K (通讯作者)，Sichuan Univ, West China Hosp, Mol Med Res Ctr, Natl Clin Res Ctr Senile Dis,State Key Lab Biothe, Chengdu, Sichuan, Peoples R China.; Zhang, K (通讯作者)，Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510005, Guangdong, Peoples R China.; Zhang, K (通讯作者)，Vet Adm Healthcare Syst, San Diego, CA 92037 USA.
EM kang.zhang@gmail.com
RI xu, jie/GQR-1913-2022; Goldbaum, Michael/AAG-4258-2020; Xu,
   Jie/AIE-0524-2022; Zhu, Jie/AAD-1330-2022; Cai, Wenjia/AAE-4402-2020;
   Zhang, Kang/Y-2740-2019
OI xu, jie/0000-0002-2039-7055; Goldbaum, Michael/0000-0002-7721-2736; Zhu,
   Jie/0000-0001-6862-9022; Cai, Wenjia/0000-0003-2398-1449; Zhang,
   Kang/0000-0002-4549-1697; Hewett, Sierra/0000-0002-9997-0730; Shi,
   William/0000-0001-5452-2902; Ting, Magdalene Yin
   Lin/0000-0002-8108-2903; Baxter, Sally/0000-0002-5271-7690; Wu,
   Xiaokang/0000-0003-1020-6232; Liang, Huiying/0000-0002-9987-8002;
   McKeown, Alex/0000-0002-5075-3532; Carvalho Soares Valentim,
   Carolina/0000-0003-4203-6856
FU National Key Research and Development Program of China [2017YFC1104600];
   National Natural Science Foundation of China [81771629, 81700882];
   Guangzhou Women and Children's Medical Center; Richard Annesser Fund;
   Michael Martin Fund; Dick and Carol Hertzberg Fund; Guangzhou
   Regenerative Medicine and Health Guangdong Laboratory
FX This study was funded by the National Key Research and Development
   Program of China (2017YFC1104600), National Natural Science Foundation
   of China (81771629 and 81700882), Guangzhou Women and Children's Medical
   Center, Guangzhou Regenerative Medicine and Health Guangdong Laboratory,
   the Richard Annesser Fund, the Michael Martin Fund, and the Dick and
   Carol Hertzberg Fund.
CR Adegbola RA, 2012, CLIN INFECT DIS, V54, pS89, DOI 10.1093/cid/cir1051
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Donahue J., 2013, ARXIV13101531
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Goldbaum M, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL III, P695, DOI 10.1109/ICIP.1996.560760
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Mcluckie A., 2009, RESP DIS ITS MANAGEM, V57
   Razavian AS, 2014, IEEE COMPUT SOC CONF, P512, DOI 10.1109/CVPRW.2014.131
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Swanson EA, 2017, BIOMED OPT EXPRESS, V8, P1638, DOI 10.1364/BOE.8.001638
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Varma R, 2014, JAMA OPHTHALMOL, V132, P1334, DOI 10.1001/jamaophthalmol.2014.2854
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YOSINSKI J, 2014, ADV NEURAL INFORM PR, P3320, DOI DOI 10.1109/IJCNN.2016.7727519
NR 19
TC 1455
Z9 1498
U1 107
U2 671
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD FEB 22
PY 2018
VL 172
IS 5
BP 1122
EP +
DI 10.1016/j.cell.2018.02.010
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FX2ZG
UT WOS:000425937100020
PM 29474911
OA Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Tochitsky, I
   Polosukhina, A
   Degtyar, VE
   Gallerani, N
   Smith, CM
   Friedman, A
   Van Gelder, RN
   Trauner, D
   Kaufer, D
   Kramer, RH
AF Tochitsky, Ivan
   Polosukhina, Aleksandra
   Degtyar, Vadim E.
   Gallerani, Nicholas
   Smith, Caleb M.
   Friedman, Aaron
   Van Gelder, Russell N.
   Trauner, Dirk
   Kaufer, Daniela
   Kramer, Richard H.
TI Restoring Visual Function to Blind Mice with a Photoswitch that Exploits
   Electrophysiological Remodeling of Retinal Ganglion Cells
SO NEURON
LA English
DT Article
ID RETINITIS-PIGMENTOSA; HCN CHANNELS; PHOTORECEPTORS RESTORES; MACULAR
   DEGENERATION; VISIBLE-LIGHT; BIPOLAR CELLS; MOUSE; RESPONSES; ADULT;
   EXCITABILITY
AB Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are blinding diseases caused by the degeneration of rods and cones, leaving the remainder of the visual system unable to respond to light. Here, we report a chemical photoswitch named DENAQ that restores retinal responses to white light of intensity similar to ordinary daylight. A single intraocular injection of DENAQ photosensitizes the blind retina for days, restoring electrophysiological and behavioral responses with no toxicity. Experiments on mouse strains with functional, nonfunctional, or degenerated rods and cones show that DENAQ is effective only in retinas with degenerated photoreceptors. DENAQ confers light sensitivity on a hyperpolarization-activated inward current that is enhanced in degenerated retina, enabling optical control of retinal ganglion cell firing. The acceptable light sensitivity, favorable spectral sensitivity, and selective targeting to diseased tissue make DENAQ a prime drug candidate for vision restoration in patients with end-stage RP and AMD.
C1 [Tochitsky, Ivan; Degtyar, Vadim E.; Gallerani, Nicholas; Smith, Caleb M.; Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   [Polosukhina, Aleksandra; Kramer, Richard H.] Univ Calif Berkeley, Vis Sci Grad Grp, Berkeley, CA 94720 USA.
   [Friedman, Aaron; Kaufer, Daniela] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.
   [Van Gelder, Russell N.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Van Gelder, Russell N.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Van Gelder, Russell N.] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.
   [Trauner, Dirk] Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany.
   [Kaufer, Daniela; Kramer, Richard H.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley;
   University of California System; University of California Berkeley;
   University of California System; University of California Berkeley;
   University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle; University of
   Washington; University of Washington Seattle; University of Munich;
   University of California System; University of California Berkeley
RP Kramer, RH (通讯作者)，Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
EM rhkramer@berkeley.edu
RI Van Gelder, Russell/ABB-4225-2021
OI Van Gelder, Russell/0000-0001-5368-3659; Gallerani,
   Nicholas/0000-0002-7564-3524; Tochitsky, Ivan/0000-0003-0650-9193
FU National Eye Institute [R01 EY018957, P30 EY003176, PN2 EY018241];
   European Science Foundation [268795]; NATIONAL EYE INSTITUTE
   [R01EY018957, PN2EY018241, P30EY003176, R21EY016249, R01EY024334]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [T32GM007232, T32GM066698] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH088484] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
   [U01NS090527] Funding Source: NIH RePORTER
FX We thank Lars Holzhausen, Jeffrey Litt, Elizabeth Epstein, Amy Choi, and
   Natasha Slepak for help with experiments; Florian Huber for chemical
   synthesis; and Nace Golding for insightful comments. This work was
   supported by grants to R. H. K. from the National Eye Institute (R01
   EY018957, P30 EY003176, and PN2 EY018241) and to D. T. from the European
   Science Foundation (268795). R. H. K. and D. T. are SAB members and
   consultants of Photoswitch Bioscience, Inc., which is developing
   commercial uses for chemical photoswitches.
CR Amendola T, 2003, NEUROSCI LETT, V345, P37, DOI 10.1016/S0304-3940(03)00491-9
   Artigas JM, 2012, INVEST OPHTH VIS SCI, V53, P4076, DOI 10.1167/iovs.12-9471
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Caporale N, 2011, MOL THER, V19, P1212, DOI 10.1038/mt.2011.103
   Chow BY, 2010, NATURE, V463, P98, DOI 10.1038/nature08652
   FISCHER E, 1955, J CHEM PHYS, V23, P1367, DOI 10.1063/1.1742302
   Fortin DL, 2008, NAT METHODS, V5, P331, DOI [10.1038/NMETH.1187, 10.1038/nmeth.1187]
   Garcia-Amoros J, 2012, ANGEW CHEM INT EDIT, V51, P12820, DOI 10.1002/anie.201207602
   Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kitamura E, 2006, INVEST OPHTH VIS SCI, V47, P1293, DOI 10.1167/iovs.05-1164
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lee SC, 2007, J NEUROPHYSIOL, V97, P3790, DOI 10.1152/jn.01241.2006
   Lewis AS, 2011, MOL CELL NEUROSCI, V46, P357, DOI 10.1016/j.mcn.2010.11.007
   Li YK, 2012, NEUROPSYCHOPHARMACOL, V37, P1867, DOI 10.1038/npp.2012.34
   Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808
   London NJS, 2011, ADV THER, V28, P351, DOI 10.1007/s12325-011-0019-z
   Loo DT, 2011, METHODS MOL BIOL, V682, P3, DOI 10.1007/978-1-60327-409-8_1
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Mourot A, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00005
   Mourot A, 2011, ACS CHEM NEUROSCI, V2, P536, DOI 10.1021/cn200037p
   Muller F, 2003, EUR J NEUROSCI, V17, P2084, DOI 10.1046/j.1460-9568.2003.02634.x
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Petersen-Jones S, 2005, J SMALL ANIM PRACT, V46, P371, DOI 10.1111/j.1748-5827.2005.tb00333.x
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Postea O, 2011, NAT REV DRUG DISCOV, V10, P903, DOI 10.1038/nrd3576
   Ren L, 2010, DEV NEUROBIOL, V70, P397, DOI 10.1002/dneu.20777
   Roderick TH, 1997, GENOMICS, V42, P393, DOI 10.1006/geno.1997.4717
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Santoro B, 2009, NEURON, V62, P802, DOI 10.1016/j.neuron.2009.05.009
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010
   Stacey PC, 2010, INT J AUDIOL, V49, P347, DOI 10.3109/14992020903397838
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stradleigh TW, 2011, J COMP NEUROL, V519, P2546, DOI 10.1002/cne.22638
   Thyagarajan S, 2010, J NEUROSCI, V30, P8745, DOI 10.1523/JNEUROSCI.4417-09.2010
   Weiland JD, 2011, OPHTHALMOLOGY, V118, P2227, DOI 10.1016/j.ophtha.2011.08.042
   Wong KY, 2007, J PHYSIOL-LONDON, V582, P279, DOI 10.1113/jphysiol.2007.133751
   Wu X, 2012, CHANNELS, V6, P438, DOI 10.4161/chan.22209
NR 47
TC 120
Z9 125
U1 1
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD FEB 19
PY 2014
VL 81
IS 4
BP 800
EP 813
DI 10.1016/j.neuron.2014.01.003
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AB0EK
UT WOS:000331464400011
PM 24559673
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Shirley, M
AF Shirley, Matt
TI Faricimab: First Approval
SO DRUGS
LA English
DT Article
ID DIABETIC MACULAR EDEMA; OUTCOMES
AB Faricimab (faricimab-svoa; Vabysmo (TM)) is a bispecific antibody that binds to and inhibits both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered by intravitreal injection, faricimab is being developed by Roche/Genentech for use in the treatment of retinal vascular diseases. In January 2022 faricimab received its first approvals, in the USA, for use in the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular edema (DME). Faricimab has also recently been approved in Japan, and is currently under regulatory review in the EU, for use in nAMD and DME. Phase III clinical development of faricimab for use in the treatment of nAMD, DME, and macular edema due to retinal vein occlusion is continuing in multiple other countries worldwide. This article summarizes the milestones in the development of faricimab leading to these first approvals for nAMD and DME in the USA.
C1 [Shirley, Matt] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
RP Shirley, M (通讯作者)，Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
EM dru@adis.com
CR Adamis AP, 2020, EYE, V34, P1966, DOI 10.1038/s41433-020-0895-z
   Baumal CR, 2020, AM J MANAG CARE, V26, pS103, DOI 10.37765/ajmc.2020.43435
   Canonica J, 2021, INVEST OPHTH VIS SCI, V62
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chugai Pharmaceutical Co, 2022, CHUG OBT REG APPR VA
   Ciulla TA, 2021, BRIT J OPHTHALMOL, V105, P216, DOI 10.1136/bjophthalmol-2020-315933
   European Medicines Agency, 2021, COMM MED PROD HUM US
   Glassman AR, 2020, OPHTHALMOLOGY, V127, P1201, DOI 10.1016/j.ophtha.2020.03.021
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Khanani AM, 2021, CLIN OPHTHALMOL, V15, P3747, DOI 10.2147/OPTH.S231801
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Linder M, 2021, INVEST OPHTH VIS SCI, V62
   Roche, 2021, FDA ACC APPL ROCH FA
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   US FDA, 2022, VABYSMO TRADE FARICI
   US FDA, 2022, BLA APPR VAB
   Wykoff CC, 2022, LANCET, V399, P741, DOI 10.1016/S0140-6736(22)00018-6
NR 19
TC 5
Z9 5
U1 5
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD MAY
PY 2022
VL 82
IS 7
BP 825
EP 830
DI 10.1007/s40265-022-01713-3
EA APR 2022
PG 6
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 1N3NS
UT WOS:000787649100001
PM 35474059
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Li, MJ
   Xu, ZJ
   Zhang, L
   Cui, MY
   Zhu, MH
   Guo, Y
   Sun, R
   Han, JF
   Song, E
   He, Y
   Su, YY
AF Li, Manjing
   Xu, Zhaojian
   Zhang, Lu
   Cui, Mingyue
   Zhu, Manhui
   Guo, Yang
   Sun, Rong
   Han, Junfei
   Song, E.
   He, Yao
   Su, Yuanyuan
TI Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid
   Cell-Membrane-Cloaked Biomimetic Nanoparticles
SO ACS NANO
LA English
DT Article
DE antiangiogenic; choroidal neovascularization; cell-membrane-cloaked
   nanoparticles; intravenous injection; targeted therapy
ID ANGIOGENESIS; CD47; VEGF; DISCOVERY
AB Choroidal neovascularization (CNV) is the leading cause of vision loss in many blinding diseases, but current antiangiogenic therapies with invasively intravitreal injection suffer from poor patient compliance and a rate of devastating ocular complications. Here, we develop an alternative antiangiogenic agent based on hybrid cell-membrane-cloaked nanoparticles for noninvasively targeted treatment of CNV. The retinal endotheliocyte membrane coating provides as-fabricated nanoagents with homotypic targeting capability and binding ability to the vascular endothelial growth factor. The fusion of red blood cell membranes protects the hybrid membrane-coated nanoparticles from phagocytosis by macrophages. In a laser-induced wet age-related macular degeneration mouse model, a significantly enhanced accumulation is observed in CNV regions after intravenous delivery of the hybrid membrane-coated nanoparticles. Moreover, an excellent therapeutic efficacy is achieved in reducing the leakage and area of CNV. Overall, the biomimetic antiangiogenic nanoagents provide an effective approach for noninvasive treatment of CNV.
C1 [Li, Manjing; Xu, Zhaojian; Zhang, Lu; Cui, Mingyue; Sun, Rong; Han, Junfei; He, Yao] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Lab Nanoscale Biochem Anal, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.
   [Zhu, Manhui; Guo, Yang; Song, E.] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou 215123, Peoples R China.
   [Su, Yuanyuan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.
C3 Soochow University - China; Soochow University - China; Sun Yat Sen
   University
RP He, Y (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Lab Nanoscale Biochem Anal, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.; Su, YY (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.
EM yaohe@suda.edu.cn; suyy36@mail.sysu.edu.cn
FU National Natural Science Foundation of China [21825402, 31400860,
   21575096, 21605109]; Natural Science Foundation of Jiangsu Province of
   China [BK20191417, BK20170061]; Program for Jiangsu Specially-Appointed
   Professors; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD)
FX We appreciate financial support from National Natural Science Foundation
   of China (Nos. 21825402, 31400860, 21575096, and 21605109), Natural
   Science Foundation of Jiangsu Province of China (Nos. BK20191417 and
   BK20170061), and the Program for Jiangsu Specially-Appointed Professors
   to Prof. Yao He, a project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD).
CR Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chen Z, 2016, ACS NANO, V10, P10049, DOI 10.1021/acsnano.6b04695
   Cibecchini G, 2020, ACS APPL MATER INTER, V12, P22507, DOI 10.1021/acsami.0c03404
   Dehaini D, 2017, ADV MATER, V29, DOI 10.1002/adma.201606209
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Giampietro C, 2012, BLOOD, V119, P2159, DOI 10.1182/blood-2011-09-381012
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110
   Han X, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw6870
   Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176
   Hu CMJ, 2015, NATURE, V526, P118, DOI 10.1038/nature15373
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/nnano.2013.54, 10.1038/NNANO.2013.54]
   Hu QY, 2015, ADV MATER, V27, P7043, DOI 10.1002/adma.201503323
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931
   Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Peng F, 2019, NAT NANOTECHNOL, V14, P279, DOI 10.1038/s41565-018-0356-z
   Piao JG, 2014, ACS NANO, V8, P10414, DOI 10.1021/nn503779d
   Rama N, 2015, NAT MED, V21, P483, DOI 10.1038/nm.3849
   Rao L, 2020, P NATL ACAD SCI USA, V117, P27141, DOI 10.1073/pnas.2014352117
   Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18626-y
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Setyawati MI, 2017, ACS NANO, V11, P5020, DOI 10.1021/acsnano.7b01744
   Setyawati MI, 2017, ACS APPL MATER INTER, V9, P6690, DOI 10.1021/acsami.6b12524
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Sun HP, 2016, ADV MATER, V28, P9581, DOI 10.1002/adma.201602173
   Tee JK, 2019, CHEM SOC REV, V48, P5381, DOI 10.1039/c9cs00309f
   Thamphiwatana S, 2017, P NATL ACAD SCI USA, V114, P11488, DOI 10.1073/pnas.1714267114
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Wang DD, 2018, ACS NANO, V12, P5241, DOI 10.1021/acsnano.7b08355
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang QZ, 2020, NANO LETT, V20, P5570, DOI 10.1021/acs.nanolett.0c02278
   Zhang QZ, 2018, NAT NANOTECHNOL, V13, P1182, DOI 10.1038/s41565-018-0254-4
NR 44
TC 19
Z9 19
U1 15
U2 93
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN 22
PY 2021
VL 15
IS 6
BP 9808
EP 9819
DI 10.1021/acsnano.1c00680
EA MAY 2021
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA SY2UZ
UT WOS:000665748900051
PM 34037377
DA 2022-11-30
ER

PT J
AU Marsh, J
   Pidaparti, RM
AF Marsh, Jonathan
   Pidaparti, Ramana M.
TI Design Optimization of an Implantable Device Concept for Passive Ocular
   Drug Delivery
SO JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
LA English
DT Article
DE ocular drug delivery device; micro/nanotubes; CFD analysis; optimization
AB This paper presents an implantable device concept with applications for treating ocular diseases such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa. The design of a biodegradable drug delivery device concept consisting of a polydimethylsiloxane (PDMS) shell with a fluid reservoir and micro/nano-fluidic tubes that allow the drug to be stored and delivered at a specified rate is discussed. Computational fluid dynamics simulations were conducted through various tube configurations in order to obtain the drug diffusion characteristics. The results from the simulation studies revealed information related to drug transport under varying design parameters. The design simulations were conducted with a desired rate. Based on results from several simulations, an optimization study was conducted to achieve the required dosage for about 2 years. The results obtained from the optimization study shows that the device concept can be extended for different drugs to treat ocular diseases.
C1 [Marsh, Jonathan] Virginia Commonwealth Univ, Dept Mech & Nucl Engn, Richmond, VA 23284 USA.
   [Pidaparti, Ramana M.] Univ Georgia, Coll Engn, Athens, GA 30602 USA.
C3 Virginia Commonwealth University; University System of Georgia;
   University of Georgia
RP Marsh, J (通讯作者)，Virginia Commonwealth Univ, Dept Mech & Nucl Engn, Med Coll Virginia Campus, Richmond, VA 23284 USA.
FU US National Science Foundation [NSF-ECCS-1058067]
FX The authors thank the US National Science Foundation for supporting this
   research through Grant NSF-ECCS-1058067.
CR Arora J.S., 2012, INTRO OPTIMUM DESIGN, V3rd ed.
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Khanafer K, 2009, BIOMED MICRODEVICES, V11, P503, DOI 10.1007/s10544-008-9256-6
   LEE JH, 2012, J DRUG DELIV, V2012
   Li TL, 1997, J CONTROL RELEASE, V48, P57, DOI 10.1016/S0168-3659(97)00033-3
   Lo R, 2009, BIOMED MICRODEVICES, V11, P959, DOI 10.1007/s10544-009-9313-9
   Molokhia SA, 2010, VISION RES, V50, P680, DOI 10.1016/j.visres.2009.10.013
   Staples M, 2006, PHARM RES-DORDR, V23, P847, DOI 10.1007/s11095-006-9906-4
   Swanson S. D., 2006, P 14 SCI M INT SOC M
   Thrimawithana TR, 2011, DRUG DELIV LETT, V1, P40
NR 12
TC 5
Z9 5
U1 0
U2 13
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1932-6181
EI 1932-619X
J9 J MED DEVICES
JI J. Med. Devices
PD JUN
PY 2014
VL 8
IS 2
AR 021005
DI 10.1115/1.4026451
PG 6
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA AH3SO
UT WOS:000336045900058
DA 2022-11-30
ER

PT J
AU Landau, IME
   Steen, B
   Seregard, S
AF Landau, IME
   Steen, B
   Seregard, S
TI Photodynamic therapy for circumscribed choroidal haemangioma
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE choroidal haemangioma; photodynamic therapy; treatment; visual acuity;
   echography
ID TRANSPUPILLARY THERMOTHERAPY; PHOTOCOAGULATION
AB Purpose: To assess the efficacy of photodynamic therapy (PDT) as a new treatment for circumscribed choroidal haemangioma (CCH).
   Methods: Eight patients with CCH were treated with PDT using a protocol similar to that used in the standard treatment of neovascular age-related macular degeneration.
   Results: Visual acuity improved in six of eight eyes, remained unchanged in one eye and deteriorated in one eye after 3-15 months (median 7 months) follow-up. Pre-treatment metamorphopsia disappeared in all but two cases. The thickness of the CCH measured with standardized echography showed marked regression within 1 month after PDT. In six eyes there was no remaining protrusion after PDT and one lesion was barely detectable. One patient experienced a transient choroidal effusion and perifoveal haemorrhage.
   Conclusion: Photodynamic therapy is a promising new treatment for CCH as it restores visual function in most cases without causing apparent ocular or systemic side-effects.
C1 Karolinska Inst, St Eriks Eye Hosp, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Landau, IME (通讯作者)，Karolinska Inst, St Eriks Eye Hosp, Polhernsgatan 50, SE-11282 Stockholm, Sweden.
EM irene.landau@sankterik.se
CR ANAND R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1338, DOI 10.1001/archopht.1989.01070020408045
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Garcia-Arumi J, 2000, OPHTHALMOLOGY, V107, P351, DOI 10.1016/S0161-6420(99)00046-9
   HUMPHREY WT, 1979, ANN OPHTHALMOL, V11, P100
   Kamal A, 2000, EYE, V14, P701, DOI 10.1038/eye.2000.187
   Lee V, 1998, EYE, V12, P925, DOI 10.1038/eye.1998.240
   Madreperla SA, 1997, OPHTHALMOLOGY, V104, P1773, DOI 10.1016/S0161-6420(97)30027-X
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Othmane IS, 1999, ARCH OPHTHALMOL-CHIC, V117, P136
   Ritland JS, 2001, ACTA OPHTHALMOL SCAN, V79, P184, DOI 10.1034/j.1600-0420.2001.079002184.x
   SANBORN GE, 1982, OPHTHALMOLOGY, V89, P1374
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   SHIELDS JA, 1994, RETINA-J RET VIT DIS, V14, P310, DOI 10.1097/00006982-199414040-00004
   Zografos L, 1996, AM J OPHTHALMOL, V121, P190, DOI 10.1016/S0002-9394(14)70584-7
NR 15
TC 49
Z9 56
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD OCT
PY 2002
VL 80
IS 5
BP 531
EP 536
DI 10.1034/j.1600-0420.2002.800513.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 605HY
UT WOS:000178673400013
PM 12390166
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, M
   Luo, C
   Zhao, JW
   Devarajan, G
   Xu, HP
AF Chen, Mei
   Luo, Chang
   Zhao, Jiawu
   Devarajan, Gayathri
   Xu, Heping
TI Immune regulation in the aging retina
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Retinal degeneration; Inflammation; Blood-retina barrier; Microglia;
   Complement; Aging
ID PIGMENT EPITHELIAL-CELLS; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS;
   HEAT-SHOCK PROTEINS; COMPLEMENT FACTOR-H; MACULAR DEGENERATION; SERUM
   AUTOANTIBODIES; UP-REGULATION; CANNABINOID RECEPTOR;
   DIABETIC-RETINOPATHY; CHRONIC INFLAMMATION
AB The retina is an immune privileged tissue, which is protected from external and internal insults by its blood retina barriers and immune suppressive microenvironment. Apart from the avoidance and tolerance strategies, the retina is also protected by its own defense system, i.e., microglia and the complement system. The immune privilege and defense mechanisms work together to maintain retinal homeostasis. During aging, the retina is at an increased risk of developing various degenerative diseases such as age-related macular degeneration, diabetic retinopathy, and glaucomatous retinopathy. Previously, we have shown that aging induces a para-inflammatory response in the retina. In this review, we explore the impact of aging on retinal immune regulation and the connection between homeostatic control of retinal immune privilege and para-inflammation under aging conditions and present a view that may explain why aging puts the retina at risk of developing degenerative diseases.
C1 [Chen, Mei; Luo, Chang; Zhao, Jiawu; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Luo, Chang; Xu, Heping] Cent S Univ, Aier Eye Inst, Aier Sch Ophthalmol, Changsha, Hunan, Peoples R China.
   [Devarajan, Gayathri] Univ Aberdeen, Sch Med, Infect & Immun, Aberdeen, Scotland.
C3 Queens University Belfast; Central South University; University of
   Aberdeen
RP Xu, HP (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X
FU Fight for Sight [1361/1362, 1425/1426, 1574/1574, 5057/5058]; Dunhill
   Medical Trust [R188/0211]; National Eye Research Centre [SCIAD 061]
FX The work was funded by Fight for Sight (1361/1362; 1425/1426; 1574/1574;
   5057/5058), Dunhill Medical Trust (R188/0211), and National Eye Research
   Centre (SCIAD 061). The authors would like to thank Kevin Harkin for
   helping with English expression.
CR Ahn BY, 2006, PROTEOMICS, V6, P1200, DOI 10.1002/pmic.200500457
   Anand-Apte B, 2010, ENCY EYE, P9
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Banerjee D, 2004, OCUL IMMUNOL INFLAMM, V12, P115, DOI 10.1080/09273940490895326
   Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142
   Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859
   Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8
   Battista Natalia, 2006, Ital J Biochem, V55, P283
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Cardona SM, 2015, ASN NEURO, V7, DOI 10.1177/1759091415608204
   Caspi RR, 2006, IMMUNOL REV, V213, P23, DOI 10.1111/j.1600-065X.2006.00439.x
   CASPI RR, 1986, J IMMUNOL, V136, P928
   CHAN CC, 1985, CELL IMMUNOL, V96, P430, DOI 10.1016/0008-8749(85)90373-9
   Chen H., 2018, NAT COMMUN, V9
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Chinnery HR, 2015, INVEST OPHTH VIS SCI, V56, P7377, DOI 10.1167/iovs.15-17587
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Copland DA, 2007, AM J PATHOL, V171, P580, DOI 10.2353/ajpath.2007.070272
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   De Simone R, 2007, J NEUROIMMUNOL, V190, P53, DOI 10.1016/j.jneuroim.2007.07.020
   Deczkowska A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00769-0
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Egan RM, 1996, J IMMUNOL, V157, P2262
   Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x
   Ferguson Thomas A, 2007, Chem Immunol Allergy, V92, P140, DOI 10.1159/000099265
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Galatro TF, 2017, NAT NEUROSCI, V20, P1162, DOI 10.1038/nn.4597
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Goto M, 2008, BIOSCI TRENDS, V2, P218
   Grabert K, 2016, NAT NEUROSCI, V19, P504, DOI 10.1038/nn.4222
   Gregerson DS, 1998, OCUL IMMUNOL INFLAMM, V6, P257, DOI 10.1076/ocii.6.4.257.4029
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta RK, 2013, BIOGERONTOLOGY, V14, P531, DOI 10.1007/s10522-013-9459-y
   Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896
   Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013
   He JQ, 2008, MOL IMMUNOL, V45, P4041, DOI 10.1016/j.molimm.2008.07.011
   Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665
   Hernangomez M, 2014, CURR PHARM DESIGN, V20, P4707
   Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021
   Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Hughes S, 2006, NEUROBIOL AGING, V27, P1838, DOI 10.1016/j.neurobiolaging.2005.10.021
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kaestel CG, 2005, CURR EYE RES, V30, P375, DOI 10.1080/02713680590934120
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Krishnan G, 2012, GLIA, V60, P1629, DOI 10.1002/glia.22380
   Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Lin JB, 2018, EBIOMEDICINE, V32, P9, DOI 10.1016/j.ebiom.2018.05.035
   Lopez EM, 2011, SYNAPSE, V65, P388, DOI 10.1002/syn.20856
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Lucas K, 2012, J IMMUNOL, V189, P1237, DOI 10.4049/jimmunol.1103264
   Ludwig A, 2008, J NEUROIMMUNOL, V198, P92, DOI 10.1016/j.jneuroim.2008.04.024
   Lueck K, 2012, INVEST OPHTH VIS SCI, V53, P1406, DOI 10.1167/iovs.11-8889
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001
   Luo C., 2018, AGING ALBANY NY
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2011, MOL VIS, V17, P1588
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Mansour H, 2008, AGING CELL, V7, P526, DOI 10.1111/j.1474-9726.2008.00402.x
   Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002
   Mecca C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010318
   Mecha M, 2016, PHARMACOL THERAPEUT, V166, P40, DOI 10.1016/j.pharmthera.2016.06.011
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313
   Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1
   MOCHIZUKI M, 1985, INVEST OPHTH VIS SCI, V26, P1
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200
   Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250
   Nag TC, 2011, ANN ANAT, V193, P205, DOI 10.1016/j.aanat.2011.02.004
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139
   Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286
   Painter MM, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0040-9
   Pascual AC, 2014, EXP GERONTOL, V60, P92, DOI 10.1016/j.exger.2014.10.011
   Pascual AC, 2014, EXP GERONTOL, V55, P134, DOI 10.1016/j.exger.2014.04.008
   Pascual AC, 2013, BIOFACTORS, V39, P209, DOI 10.1002/biof.1055
   Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454
   Pettersen RD, 2000, APOPTOSIS, V5, P299, DOI 10.1023/A:1009612821625
   Piccio L, 2007, EUR J IMMUNOL, V37, P1290, DOI 10.1002/eji.200636837
   Poliani PL, 2015, J CLIN INVEST, V125, P2161, DOI 10.1172/JCI77983
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   Qiao H, 2009, AM J PATHOL, V174, P414, DOI 10.2353/ajpath.2009.080766
   Rajapakse D, 2017, AGING-US, V9, P2051, DOI 10.18632/aging.101299
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Remmerie A, 2018, CELL IMMUNOL, V330, P27, DOI 10.1016/j.cellimm.2018.01.020
   ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0
   Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325
   Sarfati M, 2008, CURR DRUG TARGETS, V9, P842, DOI 10.2174/138945008785909310
   Schwitzer T, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2916732
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Straiker A, 1999, P NATL ACAD SCI USA, V96, P14565, DOI 10.1073/pnas.96.25.14565
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   STREILEIN JW, 1995, EYE, V9, P236, DOI 10.1038/eye.1995.46
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Takizawa F, 1996, FEBS LETT, V397, P269, DOI 10.1016/S0014-5793(96)01197-0
   Tezel G, 2004, BRAIN RES BULL, V62, P473, DOI 10.1016/S0361-9230(03)00074-1
   Tezel G, 1999, ARCH OPHTHALMOL-CHIC, V117, P917
   Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520
   Vagaja NN, 2012, INVEST OPHTH VIS SCI, V53, P1445, DOI 10.1167/iovs.11-8601
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang YK, 2018, NEUROBIOL AGING, V71, P223, DOI 10.1016/j.neurobiolaging.2018.07.024
   Wax MB, 2001, J GLAUCOMA, V10, pS22, DOI 10.1097/00061198-200110001-00009
   Wax MB, 2001, OPHTHALMOLOGY, V108, P296, DOI 10.1016/S0161-6420(00)00525-X
   Wei Y, 2009, MOL VIS, V15, P1243
   Welge-Lussen U, 1999, INVEST OPHTH VIS SCI, V40, P3209
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202
   Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6
   Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x
   Xie X, 2017, J NEUROCHEM, V141, P222, DOI 10.1111/jnc.13972
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, J LEUKOCYTE BIOL, V82, P532, DOI 10.1189/jlb.0307159
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yazulla S, 2008, PROG RETIN EYE RES, V27, P501, DOI 10.1016/j.preteyeres.2008.07.002
   Yeh FL, 2017, TRENDS MOL MED, V23, P512, DOI 10.1016/j.molmed.2017.03.008
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zhang HY, 2015, BRAIN RES, V1623, P74, DOI 10.1016/j.brainres.2015.03.012
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V
   2007, MICROCIRCULATION, V14, P63, DOI DOI 10.1080/10739680601073451
   2007, J CLIN INVEST, V117, P2920, DOI DOI 10.1172/JCI31692
   2007, EXP PHYSIOL, V92, P635, DOI DOI 10.1113/EXPPHYSIOL.2006.036376
NR 162
TC 73
Z9 76
U1 5
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2019
VL 69
BP 159
EP 172
DI 10.1016/j.preteyeres.2018.10.003
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW1OL
UT WOS:000466452100007
PM 30352305
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thorel, J
   Civade, E
   Quintyn, JC
   Cestac, P
   Montastruc, JL
   Bagheri, H
AF Thorel, J.
   Civade, E.
   Quintyn, J. C.
   Cestac, P.
   Montastruc, J. -L.
   Bagheri, H.
TI Ischaemic stroke after exposure to aflibercept: interaction with vitamin
   K antagonist and/or direct pharmacodynamic effect?
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE anti-vascular endothelial growth factor agents; drug interactions;
   thrombosis
ID MACULAR DEGENERATION; VEGF; INHIBITION; THROMBOSIS; DRUGS
AB What is known and objectiveVascular endothelial growth factor (VEGF) proteins are involved in the regulation of vascular endothelium, and their inhibition led to the development of a number of drugs used for malignancies or exudative neo-vascular age-related macular degeneration (AMD).
   Case summaryWe report a case of ischemic stroke in an 87-year-old woman having received intravitreal aflibercept, a new anti-VEGF for AMD. She had been treated with ranibizumab since 2007. In 2013, ranibizumab was replaced with aflibercept, followed by a decrease in the International Normalized Ratio, complicated by a stroke a few days later. The rechallenge was positive.
   What is new and conclusionA potential time-dependent interaction between aflibercept and VKA antagonist and/or a direct effect of aflibercept may have contributed to the occurrence of the ischaemic stroke. Currently available data suggest some pharmacokinetic and pharmacodynamic effects of aflibercept by explaining its pro-thrombotic profile.
C1 [Thorel, J.; Civade, E.; Cestac, P.] Toulouse Univ Hosp, Dept Pharm, Toulouse, France.
   [Quintyn, J. C.] Toulouse Univ Hosp, Dept Ophthalmol, Toulouse, France.
   [Cestac, P.] Univ Toulouse 3, Fac Pharmaceut Sci, F-31062 Toulouse, France.
   [Montastruc, J. -L.; Bagheri, H.] Univ Toulouse, Serv Pharmacol Med & Clin, Ctr Midipyrenees PharmacoVigilance Pharmacoepidem, CHU Toulouse,INSERM U1027,Fac Med, F-31000 Toulouse, France.
C3 CHU de Toulouse; CHU de Toulouse; Universite de Toulouse; Universite
   Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte;
   Universite de Toulouse
RP Bagheri, H (通讯作者)，Univ Toulouse, Serv Pharmacol Med & Clin, Ctr Midipyrenees PharmacoVigilance Pharmacoepidem, CHU Toulouse,INSERM U1027,Fac Med, 37 Allees Jules Guesdes, F-31000 Toulouse, France.
EM haleh.bagheri@univ-tlse3.fr
CR [Anonymous], EMA5606262013 EYL
   [Anonymous], 2007, SYNTH AV COM TRANSP
   [Anonymous], 2013, SYNTH AV COM TRANSP
   [Anonymous], EMA1256372014 LUC
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bair SM, 2013, TRENDS CARDIOVAS MED, V23, P104, DOI 10.1016/j.tcm.2012.09.008
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Bergmeier W, 2006, P NATL ACAD SCI USA, V103, P16900, DOI 10.1073/pnas.0608207103
   Cines DB, 1998, BLOOD, V91, P3527
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Hathcock JJ, 2006, ARTERIOSCL THROM VAS, V26, P1729, DOI 10.1161/01.ATV.0000229658.76797.30
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horn JR, 2007, ANN PHARMACOTHER, V41, P674, DOI 10.1345/aph.1H423
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Takashi U., 2014, OPHTHALMOLOGY, V121, pe5
   Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
NR 20
TC 4
Z9 4
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD AUG
PY 2015
VL 40
IS 4
BP 477
EP 479
DI 10.1111/jcpt.12278
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CM5QH
UT WOS:000357742800020
PM 25930164
DA 2022-11-30
ER

PT J
AU Wong, CW
   Wong, TY
   Cheng, CY
   Sabanayagam, C
AF Wong, Chee Wai
   Wong, Tien Yin
   Cheng, Ching-Yu
   Sabanayagam, Charumathi
TI Kidney and eye diseases: common risk factors, etiological mechanisms,
   and pathways
SO KIDNEY INTERNATIONAL
LA English
DT Review
DE age-related macular degeneration; cataract; chronic kidney disease;
   diabetic retinopathy; retinal microvascular parameters
ID COMPLEMENT FACTOR-H; RETINAL MICROVASCULAR ABNORMALITIES; AGE-RELATED
   MACULOPATHY; STAGE RENAL-DISEASE; OPEN-ANGLE GLAUCOMA; PIGMENT
   EPITHELIAL DETACHMENTS; TYPE-2 DIABETES-MELLITUS; GLYCATION
   END-PRODUCTS; SERUM CYSTATIN C; MACULAR DEGENERATION
AB Chronic kidney disease is an emerging health problem worldwide. The eye shares striking structural, developmental, and genetic pathways with the kidney, suggesting that kidney disease and ocular disease may be closely linked. A growing number of studies have found associations of chronic kidney disease with age-related macular degeneration, diabetic retinopathy, glaucoma, and cataract. In addition, retinal microvascular parameters have been shown to be predictive of chronic kidney disease. Chronic kidney disease shares common vascular risk factors including diabetes, hypertension, smoking, and obesity, and pathogenetic mechanisms including inflammation, oxidative stress, endothelial dysfunction, and microvascular dysfunction, with ocular diseases supporting the 'Common Soil Hypothesis.' In this review, we present major epidemiological evidence for these associations and explore underlying pathogenic mechanisms and common risk factors for kidney and ocular disease. Understanding the link between kidney and ocular disease can lead to the development of new treatment and screening strategies for both diseases.
C1 [Wong, Chee Wai; Wong, Tien Yin; Cheng, Ching-Yu; Sabanayagam, Charumathi] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin; Cheng, Ching-Yu; Sabanayagam, Charumathi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Sabanayagam, Charumathi] Duke NUS Grad Med Sch, Off Clin Sci, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore
RP Sabanayagam, C (通讯作者)，Singapore Eye Res Inst, 11 Third Hosp Ave,06-13,SNEC Bldg, Singapore 168751, Singapore.
EM charumathi.sabanayagam@seri.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Sabanayagam, Charumathi/C-1294-2011; Wong,
   Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Sabanayagam,
   Charumathi/0000-0002-4042-4719; Wong, Tien Yin/0000-0002-8448-1264
FU National Medical Research Council [0796/2003, 0863/2004, CSI/0002/2005];
   Biomedical Research Council [501/1/25-5]; Singapore Ministry of Health's
   National Medical Research Council under its Talent Development Scheme
   [NMRC/TA/0008/2012]; Duke-NUS/SingHealth Academic Medicine Research
   Institute
FX This study was supported by the National Medical Research Council grants
   0796/2003, 0863/2004, and CSI/0002/2005, Biomedical Research Council
   grant 501/1/25-5, and Singapore Ministry of Health's National Medical
   Research Council under its Talent Development Scheme NMRC/TA/0008/2012
   (to CS). The authors also appreciate the support of Duke-NUS/SingHealth
   Academic Medicine Research Institute and the medical editing assistance
   of Taara Madhavan (Associate, Clinical Sciences, Duke-NUS Graduate
   Medical School).
CR Alebiosu CO, 2005, ETHNIC DIS, V15, P418
   Amann K, 2000, J AM SOC NEPHROL, V11, P1702, DOI 10.1681/ASN.V1191702
   Barri Yousri M, 2006, Curr Cardiol Rep, V8, P411, DOI 10.1007/s11886-006-0098-7
   Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080
   BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
   BERLYNE GM, 1972, LANCET, V1, P509
   Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508
   Bis JC, 2011, NAT GENET, V43, P940, DOI 10.1038/ng.920
   Boger CA, 2011, J AM SOC NEPHROL, V22, P555, DOI 10.1681/ASN.2010060598
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   Bostom AG, 1996, ATHEROSCLEROSIS, V125, P91, DOI 10.1016/0021-9150(96)05865-0
   Brancati FL, 1997, JAMA-J AM MED ASSOC, V278, P2069, DOI 10.1001/jama.278.23.2069
   Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26
   Busch M, 2010, EUR J CLIN INVEST, V40, P742, DOI 10.1111/j.1365-2362.2010.02317.x
   Canellos Harriette Moutopoulos, 2005, Optometry, V76, P181
   Canning P, 2007, EXP DIABETES RES, DOI 10.1155/2007/51837
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   CHAVERS BM, 1994, DIABETES, V43, P441, DOI 10.2337/diabetes.43.3.441
   Chen YH, 2012, DIABETES CARE, V35, P803, DOI 10.2337/dc11-1955
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237
   Cook C, 2012, CAN J OPHTHALMOL, V47, P223, DOI 10.1016/j.jcjo.2012.02.003
   Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038
   Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613
   CRUICKSHANKS KJ, 1993, OPHTHALMOLOGY, V100, P862
   Cumurcu T, 2007, J GLAUCOMA, V16, P645, DOI 10.1097/IJG.0b013e31804a5eb3
   de Jong PE, 2002, INT J OBESITY, V26, pS21, DOI 10.1038/sj.ijo.0802213
   DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568
   Deva R, 2011, CLIN J AM SOC NEPHRO, V6, P1866, DOI 10.2215/CJN.10321110
   Devalliere J, 2012, FASEB J, V26, P2592, DOI 10.1096/fj.11-193383
   Edwards MS, 2005, AM J KIDNEY DIS, V46, P214, DOI 10.1053/j.ajkd.2005.05.005
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Evans T, 2000, DIABETES, V49, P662, DOI 10.2337/diabetes.49.4.662
   Fornage M, 2011, ANN NEUROL, V69, P928, DOI 10.1002/ana.22403
   Foster MC, 2008, AM J KIDNEY DIS, V52, P39, DOI 10.1053/j.ajkd.2008.03.003
   Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P844, DOI 10.1001/jama.291.7.844
   Franke S, 2003, J CATARACT REFR SURG, V29, P998, DOI 10.1016/S0886-3350(02)01841-2
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gao BX, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-62
   GASS JDM, 1992, GRAEF ARCH CLIN EXP, V230, P454
   Gerhardinger C, 2009, DIABETES, V58, P1659, DOI 10.2337/db08-1008
   Girach A, 2006, J DIABETES COMPLICAT, V20, P228, DOI 10.1016/j.jdiacomp.2006.03.001
   Grunwald JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1136, DOI 10.1001/archophthalmol.2012.1800
   Grunwald JE, 2010, CLIN J AM SOC NEPHRO, V5, P867, DOI 10.2215/CJN.08271109
   Hallan SI, 2006, J AM SOC NEPHROL, V17, P2275, DOI 10.1681/ASN.2005121273
   Haroun MK, 2003, J AM SOC NEPHROL, V14, P2934, DOI 10.1097/01.ASN.0000095249.99803.85
   He R, 2013, EUR J EPIDEMIOL, V28, P775, DOI 10.1007/s10654-013-9839-2
   Hu MC, 2010, J NEPHROL, V23, pS136
   Huynh SC, 2005, OPHTHALMOLOGY, V112, P293, DOI 10.1016/j.ophtha.2004.09.014
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001184
   Ikram MK, 2004, INVEST OPHTH VIS SCI, V45, P2129, DOI 10.1167/iovs.03-1390
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Iseki K, 2007, HYPERTENS RES, V30, P55, DOI 10.1291/hypres.30.55
   Islam FMA, 2009, EYE, V23, P1719, DOI 10.1038/eye.2008.362
   Izzedine H, 2003, J AM SOC NEPHROL, V14, P516, DOI 10.1097/01.ASN.0000051705.97966.AD
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   KLAASSENBROEKEMA N, 1993, BRIT J OPHTHALMOL, V77, P569, DOI 10.1136/bjo.77.9.569
   Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103
   Klein BEK, 2008, ARCH OPHTHALMOL-CHIC, V126, P1724, DOI 10.1001/archophthalmol.2008.502
   Klein BEK, 1998, CURR EYE RES, V17, P720, DOI 10.1076/ceyr.17.7.720.5160
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Klein R, 2006, ARCH OPHTHALMOL-CHIC, V124, P87, DOI 10.1001/archopht.124.1.87
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P2118, DOI 10.1016/S0161-6420(03)00863-7
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P1884, DOI 10.1016/j.ophtha.2007.02.023
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kottgen A, 2010, NAT GENET, V42, P376, DOI 10.1038/ng.568
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Levy J, 2005, EYE, V19, P1249, DOI 10.1038/sj.eye.6701755
   Liew G, 2012, KIDNEY BLOOD PRESS R, V35, P589, DOI 10.1159/000339173
   Liew G, 2008, ARCH OPHTHALMOL-CHIC, V126, P1404, DOI 10.1001/archopht.126.10.1404
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Liew G, 2011, EUR HEART J, V32, P422, DOI 10.1093/eurheartj/ehq431
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu CT, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002264
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   Menon V, 2007, ANN INTERN MED, V147, P19, DOI 10.7326/0003-4819-147-1-200707030-00004
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell GF, 2012, CIRC-CARDIOVASC GENE, V5, P81, DOI 10.1161/CIRCGENETICS.111.959817
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Mitchell P, 2004, J GLAUCOMA, V13, P319, DOI 10.1097/00061198-200408000-00010
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Mottl AK, 2012, DIABETES RES CLIN PR, V98, P487, DOI 10.1016/j.diabres.2012.09.041
   Myers CE, 2012, OPHTHALMOLOGY, V119, P2563, DOI 10.1016/j.ophtha.2012.06.038
   Nagaraj RH, 2012, AMINO ACIDS, V42, P1205, DOI 10.1007/s00726-010-0778-x
   Nassiri N, 2012, MOL VIS, V18, P1991
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Nongpiur ME, 2010, OPHTHALMOLOGY, V117, P477, DOI 10.1016/j.ophtha.2009.07.029
   Ohguro N, 1999, AM J OPHTHALMOL, V128, P234, DOI 10.1016/S0002-9394(99)00086-0
   Ooi QL, 2011, CLIN J AM SOC NEPHRO, V6, P1872, DOI 10.2215/CJN.10291110
   Ortwerth BJ, 2003, INVEST OPHTH VIS SCI, V44, P3094, DOI 10.1167/iovs.02-0857
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156
   Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8
   Payne JF, 2012, ENDOCR PRACT, V18, P185, DOI 10.4158/EP11147.OR
   Penno G, 2012, DIABETES CARE, V35, P2317, DOI 10.2337/dc12-0628
   Rani PK, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-9
   Reitsamer HA, 2003, INVEST OPHTH VIS SCI, V44, P3967, DOI 10.1167/iovs.03-0088
   Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743
   Sabanayagam C, 2011, AM J KIDNEY DIS, V57, P682, DOI 10.1053/j.ajkd.2010.11.025
   Sabanayagam C, 2009, J HYPERTENS, V27, P2209, DOI 10.1097/HJH.0b013e328330141d
   Sabanayagam C, 2009, AM J EPIDEMIOL, V169, P625, DOI 10.1093/aje/kwn367
   Schiffrin EL, 2007, CIRCULATION, V116, P85, DOI 10.1161/CIRCULATIONAHA.106.678342
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shen F, 2001, Yan Ke Xue Bao, V17, P209
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Sng CCA, 2010, NEPHROL DIAL TRANSPL, V25, P2252, DOI 10.1093/ndt/gfq007
   Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725
   Stefoni S, 2002, KIDNEY INT, V61, P324, DOI 10.1046/j.1523-1755.2002.00119.x
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Su DHW, 2009, AM J OPHTHALMOL, V147, P709, DOI 10.1016/j.ajo.2008.10.013
   Sun C, 2008, INVEST OPHTH VIS SCI, V49, P1784, DOI 10.1167/iovs.07-1450
   Tacer KF, 2010, MOL ENDOCRINOL, V24, P2050, DOI 10.1210/me.2010-0142
   Takaki S, 2002, J EXP MED, V195, P151, DOI 10.1084/jem.20011170
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085
   Tornig J, 1996, J AM SOC NEPHROL, V7, P667
   Troiano P, 1998, NEPHROL DIAL TRANSPL, V13, P2135, DOI 10.1093/ndt/13.8.2135
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   US Renal Data System, 2005, US REN DAT SYST USRD
   Vaajanen A, 2011, BASIC CLIN PHARMACOL, V109, P217, DOI 10.1111/j.1742-7843.2011.00729.x
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leiden HA, 2002, DIABETES CARE, V25, P1320, DOI 10.2337/diacare.25.8.1320
   Wang TJ, 2012, OPHTHAL EPIDEMIOL, V19, P137, DOI 10.3109/09286586.2012.680531
   Wang ZY, 2010, CURR EYE RES, V35, P680, DOI 10.3109/02713681003778780
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI 10.1038/sj.ijo.0802158
   Wilkinson-Berka JL, 2012, PEPTIDES, V36, P142, DOI 10.1016/j.peptides.2012.04.008
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, INVEST OPHTH VIS SCI, V45, P2949, DOI 10.1167/iovs.04-0069
   Wong TY, 2004, J AM SOC NEPHROL, V15, P2469, DOI 10.1097/01.ASN.0000136133.28194.E4
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Xu X, 2003, GRAEF ARCH CLIN EXP, V241, P56, DOI 10.1007/s00417-002-0575-7
   Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625
   Yang HW, 2009, INVEST OPHTH VIS SCI, V50, P5800, DOI 10.1167/iovs.09-3678
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yau JWY, 2011, AM J KIDNEY DIS, V58, P39, DOI 10.1053/j.ajkd.2011.02.382
   Yokota H, 2007, AM J OPHTHALMOL, V143, P531, DOI 10.1016/j.ajo.2006.10.046
   Yokota H, 2011, J RENIN-ANGIO-ALDO S, V12, P290, DOI 10.1177/1470320310391327
   ZANDER E, 1992, EXP CLIN ENDOCRINOL, V99, P102, DOI 10.1055/s-0029-1211146
   Zepeda-Orozco D, 2012, PEDIATR NEPHROL, V27, P2205, DOI 10.1007/s00467-012-2199-4
   Zhang LX, 2008, AM J KIDNEY DIS, V51, P373, DOI 10.1053/j.ajkd.2007.11.009
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 160
TC 108
Z9 111
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2014
VL 85
IS 6
BP 1290
EP 1302
DI 10.1038/ki.2013.491
PG 13
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA AI4FG
UT WOS:000336820500011
PM 24336029
OA Bronze
DA 2022-11-30
ER

PT J
AU Fledelius, HC
   Rosenberg, T
AF Fledelius, Hans C.
   Rosenberg, Thomas
TI Bilateral symmetric autosomal dominant sector chorioretinopathy with
   late maculopathy: a review based on a case with 48 years follow-up
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Adaptometry; Bilateral symmetric sector chorioretinopathy; Long-term
   follow-up; Macular degeneration; Ocular electrophysiology; Retinal
   pigmentary dystrophy; Visual field defect
ID RETINITIS-PIGMENTOSA; RHODOPSIN GENE; MUTATION
AB PURPOSE. To describe the long-term course of bilateral symmetric autosomal dominant sector chorioretinopathy in a 79-year-old man who was diagnosed at age 31.
   METHODS. Ophthalmic examinations including fundus photography, fluorescein and indocyanine angiography, adaptometry, and ocular electrophysiology were performed at intervals from 1962 to 2010.
   RESULTS AND CONCLUSIONS. The patient experienced no visual symptoms during his entire working life, but acquired an exudative maculopathy in his left eye at age 67. Two years later, a central subretinal neovascular membrane affected the right eye. The latter responded only temporarily to photodynamic therapy (Visudyne), and from age 71 he had best-corrected visual acuities <0.1 in both eyes, with eccentric fixation. We are not aware of any report on late macular involvement in this disorder Whether the maculopathy should be considered a late manifestation of the sector chorioretinopathy or a coincidental occurrence of age-related macular degeneration remains unsettled.
C1 [Fledelius, Hans C.] Rigshosp, Univ Eye Dept, DK-2100 Copenhagen O, Denmark.
   [Rosenberg, Thomas] Kennedy Ctr, Natl Eye Clin, Gordon Norrie Ctr Genet Eye Dis, Glostrup, Denmark.
C3 Rigshospitalet
RP Fledelius, HC (通讯作者)，Rigshosp, Eye Dept E 2061, 9 Blegdamsvej, DK-2100 Copenhagen O, Denmark.
EM rh03217@rh.dk
CR ALMAGHTHEH M, 1993, HUM MUTAT, V2, P249, DOI 10.1002/humu.1380020403
   Bietti G., 1937, BOLL OCUL, V16, P1159
   FISHMAN GA, 1978, ARCH OPHTHALMOL-CHIC, V96, P822, DOI 10.1001/archopht.1978.03910050428005
   FISHMAN GA, 1985, ARCH OPHTHALMOL-CHIC, V103, P366, DOI 10.1001/archopht.1985.01050030062023
   FISHMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P646, DOI 10.1001/archopht.1992.01080170068026
   FLEDELIUS H, 1970, Acta Ophthalmologica, V48, P14
   Grover S, 1999, OPHTHALMOLOGY, V106, P1780, DOI 10.1016/S0161-6420(99)90342-1
   Haase W, 1965, Klin Monbl Augenheilkd, V147, P365
   HAIM M, 1992, ACTA OPHTHALMOL, V70, P165
   Haim M, 2002, ACTA OPHTHALMOL S233, V80
   HECKENLIVELY JR, 1991, ARCH OPHTHALMOL-CHIC, V109, P84, DOI 10.1001/archopht.1991.01080010086038
   HENNING V, 1981, ACTA OPHTHALMOL, V59, P909
   KUPER J, 1960, KLIN MBL AUGENHEILK, V136, P97
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P143
   MASSOF RW, 1979, ARCH OPHTHALMOL-CHIC, V97, P1899
   MOORE AT, 1992, BRIT J OPHTHALMOL, V76, P465, DOI 10.1136/bjo.76.8.465
   STONE EM, 1991, OPHTHALMOLOGY, V98, P1806
   SULLIVAN LJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1512, DOI 10.1001/archopht.1993.01090110078029
NR 18
TC 1
Z9 1
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2012
VL 22
IS 2
BP 280
EP 283
DI 10.5301/ejo.5000014
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 952IW
UT WOS:000304787200022
PM 21688253
DA 2022-11-30
ER

PT J
AU Rowland, TJ
   Buchholz, DE
   Clegg, DO
AF Rowland, Teisha J.
   Buchholz, David E.
   Clegg, Dennis O.
TI Pluripotent human stem cells for the treatment of retinal disease
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; VISUAL FUNCTION; EXTRACELLULAR-MATRIX; CONE
   PHOTORECEPTORS; AMNIOTIC MEMBRANE; BRUCHS MEMBRANE; DIFFERENTIATION;
   TRANSPLANTATION; RPE; GENERATION
AB Despite advancements made in our understanding of ocular biology, therapeutic options for many debilitating retinal diseases remain limited. Stem cell-based therapies are a potential avenue for treatment of retinal disease, and this mini-review will focus on current research in this area. Cellular therapies to replace retinal pigmented epithelium (RPE) and/or photoreceptors to treat age-related macular degeneration (AMD), Stargardt's macular dystrophy, and retinitis pigmentosa are currently being developed. Over the past decade, significant advancements have been made using different types of human stem cells with varying capacities to differentiate into these target retinal cell types. We review and evaluate pluripotent stem cells, both human embryonic stem cells and human induced pluripotent stem cells, as well as protocols for differentiation of ocular cells, and culture and transplant techniques that might be used to deliver cells to patients. J. Cell. Physiol. 227: 457466, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Rowland, Teisha J.; Buchholz, David E.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Rowland, Teisha J.; Buchholz, David E.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Rowland, Teisha J.; Buchholz, David E.; Clegg, Dennis O.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
   [Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM clegg@lifesci.ucsb.edu
OI Rowland, Teisha/0000-0001-5038-6763
FU California Institute for Regenerative Medicine (CIRM) [TG2-01151,
   T3-00009]
FX We thank Andrew James Bonham and Lisa R. Conti, University of
   California, Santa Barbara, for a critical reading of the manuscript.
   Teisha J. Rowland and David E. Buchholz were supported by California
   Institute for Regenerative Medicine (CIRM) Training Awards TG2-01151 and
   T3-00009, respectively.
CR Anghileri E, 2008, STEM CELLS DEV, V17, P909, DOI 10.1089/scd.2007.0197
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Bovolenta P, 2009, NAT NEUROSCI, V12, P5, DOI 10.1038/nn0109-5
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dhar S, 2007, TISSUE ENG, V13, P2625, DOI 10.1089/ten.2007.0017
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dutt K, 2009, TISSUE ENG PT A, V15, P1401, DOI 10.1089/ten.tea.2007.0358
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Enzmann V, 2003, INVEST OPHTH VIS SCI, V44, P5417, DOI 10.1167/iovs.03-0468
   Feng Q, 2010, STEM CELLS, V28, P704, DOI 10.1002/stem.321
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Ho TC, 1996, CURR EYE RES, V15, P991, DOI 10.3109/02713689609017645
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Huang JC, 1998, CURR EYE RES, V17, P573, DOI 10.1076/ceyr.17.6.573.5184
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Idelson M, 2010, HUM GENE THER, V21, P649
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Jomary C, 2010, INVEST OPHTH VIS SCI, V51, P1181, DOI 10.1167/iovs.09-4385
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2011, INVEST OPHTHALMOL VI
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lim JM, 2004, INVEST OPHTH VIS SCI, V45, P4210, DOI 10.1167/iovs.03-1036
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Narsinh KH, 2011, NAT PROTOC, V6, P78, DOI 10.1038/nprot.2010.173
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Sodha S, 2011, J BIOMAT SCI-POLYM E, V22, P443, DOI 10.1163/092050610X487738
   Solanki A, 2010, CHEMBIOCHEM, V11, P755, DOI 10.1002/cbic.201000032
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03-1100fje
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Stone EM, 2009, CURR OPIN GENET DEV, V19, P283, DOI 10.1016/j.gde.2009.03.006
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suon S, 2004, STEM CELLS DEV, V13, P625, DOI 10.1089/scd.2004.13.625
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson HA, 2010, J BIOMED MATER RES A, V95A, P1233, DOI 10.1002/jbm.a.32940
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vossmerbaeumer U, 2009, CYTOTHERAPY, V11, P177, DOI 10.1080/14653240802714819
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017557
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853
NR 96
TC 69
Z9 72
U1 2
U2 56
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2012
VL 227
IS 2
BP 457
EP 466
DI 10.1002/jcp.22814
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 862LQ
UT WOS:000298092800008
PM 21520078
DA 2022-11-30
ER

PT J
AU Jain, P
   Anantharaman, G
   Gopalakrishnan, M
   Goyal, A
AF Jain, Prashant
   Anantharaman, Giridhar
   Gopalakrishnan, Mahesh
   Goyal, Anubhav
TI Long-term efficacy and safety of verteporfin photodynamic therapy in
   combination with anti-vascular endothelial growth factor for polypoidal
   choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Long-term efficacy; photodynamic therapy; polypoidal choroidal
   vasculopathy
ID INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; RANIBIZUMAB; INJECTIONS;
   FEATURES; OUTCOMES; CHINESE
AB Purpose: The aim of the study was to analyze the outcomes of photodynamic therapy (PDT) with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for patients with polypoidal choroidal vasculopathy (PCV) having visual acuity (VA) better than 20/60 in a real-world scenario in India. Methods: Retrospective review of 42 eyes of 40 patients (mean age 64.3 years) with best-corrected VA(BCVA) 20/60 or better and mean follow-up of 40 months (median 38 months; range 12-71 months) treated with PDT and anti-VEGF or triamcinolone for indocyanine green angiography (lCGA)-proven subfovcal PCV. Results: Mean BCVA improved from 0.22 logMAR at baseline to 0.15 at last visit (P < 0.001). On ICGA, polyp was observed in 42 eyes (100%) and branching vascular network (BVN) in 37 eyes (88.1%). Polyp regressed in 33 (78.6%) of 42 eyes and BVN in 26 (70.3%) of 37 eyes after combined therapy at 3 months. Mean greatest linear diameter reduced significantly (P < 0.001) from 7.22 mm to 4.11 mm. Standard-fluence PDT was performed in 35 eyes and reduced-fluence in 7 eyes. The mean number of PDT was 1.17 with mean number of injections being 6.38 at the end of follow-up. In five eyes, more than one PDT was administered. Of 42 eyes, 40 showed complete resolution of serous macular detachment (SMD) after the combined therapy at 3 months; 17 (42.5%) of the 40 eyes showed no recurrence of fluid on spectral domain optical coherence tomography till the last visit with a mean follow-up of 27 months. On long-term follow-up, SMD reoccurred in 23 eyes with a mean follow-up period of 9.64 +/- 5.24 months. Of 38 eyes having a double-layer sign (DLS) on optical coherence tomography at baseline, 37 eyes were having regression of the DLS, that is, it either reduced or resolved at the final visit. At the final visit, 66.7% (P < 0.001) eves were having fluid-free retina. No complication of subretinal hemorrhage was noted. Of the 42 eyes, only one eye had BCVA worse than 20/60 on the final visit. Conclusion: To the best of our knowledge, this is the first study to look into the long-term effect of combined PDT with anti-VEGF in PCV in eyes having good VA. Long-term effect of combined PDT appears to be a safe and effective treatment for PCV in eyes having good VA with better outcomes in real-world setting. This study further strengthens the superiority of the combined treatment modality for treatment of subfoveal PCV with no or minimal risk of complication on long-term follow-up.
C1 [Jain, Prashant; Anantharaman, Giridhar; Gopalakrishnan, Mahesh; Goyal, Anubhav] Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
RP Anantharaman, G (通讯作者)，Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
EM giridhareye@gmail.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Miki A, 2013, JPN J OPHTHALMOL, V57, P301, DOI 10.1007/s10384-013-0237-9
   Mukai R, 2010, OPHTHALMOLOGICA, V224, P267, DOI 10.1159/000287348
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rishi P, 2017, INDIAN J OPHTHALMOL, V65, P712, DOI 10.4103/ijo.IJO_174_17
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sen P, 2016, INDIAN J OPHTHALMOL, V64, P908, DOI 10.4103/0301-4738.198856
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang W, 2014, PLOS ONE, V9
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 40
TC 6
Z9 6
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD AUG
PY 2018
VL 66
IS 8
BP 1119
EP 1127
DI 10.4103/ijo.IJO_1222_17
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO3VE
UT WOS:000439924900015
PM 30038155
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shah, N
   Ishii, M
   Brandon, C
   Ablonczy, Z
   Cai, JW
   Liu, YT
   Chou, CJ
   Rohrer, B
AF Shah, Navjot
   Ishii, Masakii
   Brandon, Carlene
   Ablonczy, Zsolt
   Cai, Jingwen
   Liu, Yutao
   Chou, C. James
   Rohrer, Barbel
TI Extracellular vesicle-mediated long-range communication in stressed
   retinal pigment epithelial cell monolayers
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Retinal pigment epithelium; Extracellular vesicles; Exosomes; Tight
   junctions; HDAC6; Age-related macular degeneration
ID MACULAR DEGENERATION; OXIDATIVE STRESS; EXOSOME SECRETION; CURRENT
   PERSPECTIVES; IN-VIVO; RPE; MICROVESICLES; DEACETYLASE; INHIBITION;
   MICROTUBULES
AB Retinal pigment epithelium (RPE) alterations in age-related macular degeneration occur in patches, potentially involving long-distance communication between damaged and healthy areas. Communication along the epithelium might be mediated by extracellular vesicles (EVs). To test this hypothesis, EVs were collected from supernatants of polarized ARPE-19 and primary porcine RPE monolayers for functional and biochemical assays. EVs from oxidatively stressed donor cells reduced barrier function in recipient RPE monolayers when compared to control EVs. The effect on barrier function was dependent on EV uptake, which occurred rapidly with EVs from oxidatively stressed donor cells. Mass spectrometry-based proteomic analysis of EVs identified HDAC6, which is known to reduce tight junction stability. Activity assays confirmed the presence of HDAC6 in EVs, and EV transfer assays using HDAC6 inhibitors confirmed its effect in monolayers. These findings demonstrate that EVs can communicate stress messages to healthy RPE cells, potentially contributing to RPE dysfunction.
C1 [Shah, Navjot; Ishii, Masakii; Brandon, Carlene; Ablonczy, Zsolt; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Shah, Navjot; Ishii, Masakii; Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
   [Cai, Jingwen; Liu, Yutao] Augusta Univ, Cellular Biol & Anat, Augusta, GA 30912 USA.
   [Chou, C. James] Med Univ South Carolina, Dept Drug Discovery, Charleston, SC 29425 USA.
   [Rohrer, Barbel] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center;
   University System of Georgia; Augusta University; Medical University of
   South Carolina; Medical University of South Carolina
RP Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
OI Ishii, Masaaki/0000-0002-0775-5401
FU National Institutes of Health (NIH) [R01EY019320]; Department of
   Veterans Affairs [RX000444, BX003050]; South Carolina SmartState
   Endowment [MUCR 2236010 8B571 9923 88]; BrightFocus Foundation
   [G2016023]; Glaucoma Foundation; Glaucoma Research Foundation; Startup
   Fund from the Medical College of Georgia; NATIONAL EYE INSTITUTE
   [R01EY019320, R01EY024581, R21EY028671] Funding Source: NIH RePORTER;
   Veterans Affairs [I01RX000444, I01BX003050] Funding Source: NIH RePORTER
FX Funding for this project was provided in part by the National Institutes
   of Health (NIH) (R01EY019320) (BR), the Department of Veterans Affairs
   (RX000444, BX003050) (BR), the South Carolina SmartState Endowment (MUCR
   2236010 8B571 9923 88) (BR), the BrightFocus Foundation (G2016023) (YL),
   The Glaucoma Foundation (YL), the Glaucoma Research Foundation (YL), and
   the Startup Fund from the Medical College of Georgia (YL).
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andreu Z, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442
   Asthana J, 2013, J BIOL CHEM, V288, P22516, DOI 10.1074/jbc.M113.489328
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007
   Berditchevski F, 2007, TRAFFIC, V8, P89, DOI 10.1111/j.1600-0854.2006.00515.x
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Bordin M, 2004, MOL CANCER RES, V2, P692
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Camussi G, 2011, AM J CANCER RES, V1, P98
   Cayo MA, 2017, CELL STEM CELL, V20, P478, DOI 10.1016/j.stem.2017.01.011
   Chistiakov DA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00365
   Chou DHC, 2012, CHEM BIOL, V19, P669, DOI 10.1016/j.chembiol.2012.05.010
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   Davidson JO, 2013, CURR DRUG TARGETS, V14, P36
   Desjardins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162596
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Gangalum RK, 2016, J BIOL CHEM, V291, P12930, DOI 10.1074/jbc.M115.698530
   Garcia NA, 2016, CARDIOVASC RES, V109, P397, DOI 10.1093/cvr/cvv260
   Guescini M, 2010, J NEURAL TRANSM, V117, P1, DOI 10.1007/s00702-009-0288-8
   Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Hall EJ, 2003, HEALTH PHYS, V85, P31, DOI 10.1097/00004032-200307000-00008
   Harding CV, 2013, J CELL BIOL, V200, P367, DOI 10.1083/jcb.201212113
   Hedhli N, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/406273
   Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628
   Hoang QV, 2010, MOL VIS, V16, P1343
   Hsu C, 2010, J CELL BIOL, V189, P223, DOI 10.1083/jcb.200911018
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Ibrahim A, 2016, ANNU REV PHYSIOL, V78, P67, DOI 10.1146/annurev-physiol-021115-104929
   Imjeti NS, 2017, P NATL ACAD SCI USA, V114, P12495, DOI 10.1073/pnas.1713433114
   Inks ES, 2012, ACS CHEM BIOL, V7, P330, DOI 10.1021/cb200134p
   Ishii M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.71
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kunchithapautham K, 2012, ADV EXP MED BIOL, V723, P23, DOI 10.1007/978-1-4614-0631-0_4
   Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204
   McKelvey KJ, 2015, J CIRC BIOMARK, V4, P7, DOI [DOI 10.5772/61186, 10.5772/61186]
   Meckes DG, 2015, J VIROL, V89, P5200, DOI 10.1128/JVI.02470-14
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moldovan Leni, 2013, Methods Mol Biol, V1024, P129, DOI 10.1007/978-1-62703-453-1_10
   Obert E, 2017, J MOL MED, V95, P535, DOI 10.1007/s00109-017-1506-8
   Rajapakse D, 2017, EXP CELL RES, V361, P333, DOI 10.1016/j.yexcr.2017.10.036
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Ratajczak MZ, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0087-4
   Rider MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep23978
   Rohlena J, 2009, CARDIOVASC RES, V81, P187, DOI 10.1093/cvr/cvn256
   Roseblade A, 2013, J PHARM PHARM SCI, V16, P238, DOI 10.18433/J3989X
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Soragni E, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00044
   Soria FN, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00026
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Stewart A., 2016, MATTERS ZURICH
   Stewart MW, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0510-4
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15
   Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0
   Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985
   Voloboueva LA, 2007, FASEB J, V21, P4077, DOI 10.1096/fj.07-8396com
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00300
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Xiao TT, 2017, TRANSL NEURODEGENER, V6, DOI [10.1186/s40035-017-0081-9, 10.1186/s40035-017-0072-x]
   Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yano T, 2013, J CELL BIOL, V203, P605, DOI 10.1083/jcb.201304194
   Yu JY, 2016, AM J PHYSIOL-LUNG C, V311, pL39, DOI 10.1152/ajplung.00051.2016
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
   Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115
NR 85
TC 32
Z9 32
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD AUG
PY 2018
VL 1864
IS 8
BP 2610
EP 2622
DI 10.1016/j.bbadis.2018.04.016
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA GJ1TB
UT WOS:000435049600010
PM 29684588
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Zhu, YX
   Yao, J
   Liu, C
   Hu, HT
   Li, XM
   Ge, HM
   Zhou, YF
   Shan, K
   Jiang, Q
   Yan, B
AF Zhu, Yun-Xi
   Yao, Jin
   Liu, Chang
   Hu, Hai-Tao
   Li, Xiu-Miao
   Ge, Hui-Min
   Zhou, Yun-Fan
   Shan, Kun
   Jiang, Qin
   Yan, Biao
TI Long non-coding RNA MEG3 silencing protects against light-induced
   retinal degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Long non-coding RNA; Light insult; Retinal degeneration; Protein decoy
ID OXIDATIVE STRESS; MICROVASCULAR DYSFUNCTION; MOLECULAR-MECHANISMS;
   DOCOSAHEXAENOIC ACID; CELL-PROLIFERATION; TUMOR-SUPPRESSOR;
   GENE-EXPRESSION; IN-VITRO; APOPTOSIS; P53
AB Excessive light exposure leads to retinal degeneration and accelerates the progression and severity of several ocular diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa. Long non-coding RNAs (LncRNAs) have emerged as important regulators of photoreceptor development and ocular diseases. In this study, we investigated the role of IncRNA-MEG3 in light-induced retinal degeneration. MEG3 expression was significantly up-regulated after light insult in vivo and in vitro. MEG3 silencing protected against light-induced retinal degeneration in vivo and light-induced photoreceptor cell apoptosis in vitro. Mechanistically, MEG3 regulated retinal photoreceptor cell function by acting as p53 decoy. MEG3 silencing decreased caspase 3/7 activity, up-regulated anti-apoptotic protein (Bcl-2) expression, and down-regulated pro-apoptotic protein (Bax) expression. Taken together, this study provides a promising method of MEG3 silencing for treating light-induced retinal degeneration. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Zhu, Yun-Xi; Yao, Jin; Hu, Hai-Tao; Li, Xiu-Miao; Jiang, Qin] Nanjing Med Univ, Eye Hosp, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Yun-Xi; Yao, Jin; Liu, Chang; Hu, Hai-Tao; Ge, Hui-Min; Zhou, Yun-Fan; Jiang, Qin] Nanjing Med Univ, Sch Clin Med 4, Nanjing, Jiangsu, Peoples R China.
   [Liu, Chang; Shan, Kun; Yan, Biao] Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China.
   [Yan, Biao] Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
C3 Nanjing Medical University; Fudan University
RP Yan, B (通讯作者)，Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Eye Inst, Shanghai, Peoples R China.; Jiang, Q (通讯作者)，Nanjing Med Univ, 138 Hanzhong Rd, Nanjing 200090, Jiangsu, Peoples R China.
EM jqin710@vip.sina.com; biao.yan@fdeent.org
FU National Natural Science Foundation of China [81570859, 81670878];
   Medical Science and Technology Development Project Fund of Nanjing
   [YKK15241, YKK16270]; Natural Science Foundation of Jiangsu Province
   [SB2016022104]; Innovation Team Project Fund of Jiangsu Province
   [CXTDB2017010]
FX This work was generously supported by the grants from the National
   Natural Science Foundation of China (Grant No. 81570859 to Q.J. and
   Grant No. 81670878 to J.Y.), grants from the Medical Science and
   Technology Development Project Fund of Nanjing (Grant No. YKK15241 to
   J.Y. and Grant No. YKK16270 to XM.L.), Grants from the Natural Science
   Foundation of Jiangsu Province (SB2016022104 to J.Y.), and Grants from
   the Innovation Team Project Fund of Jiangsu Province (Grant No.
   CXTDB2017010 to Q.J.).
CR Arakawa H, 2005, CELL DEATH DIFFER, V12, P1057, DOI 10.1038/sj.cdd.4401601
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Casson RJ, 2003, INVEST OPHTH VIS SCI, V44, P1348, DOI 10.1167/iovs.02-0368
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   [高亚莉 Gao Yali], 2016, [肿瘤, Tumor], V36, P294
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Lakhotia S.C., 2017, BIORXIV
   Li XM, 2014, NEUROL SCI, V35, P847, DOI 10.1007/s10072-013-1610-7
   Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461
   Meola N, 2012, RNA, V18, P111, DOI 10.1261/rna.029454.111
   MIYASHITA T, 1994, ONCOGENE, V9, P1799
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Qin R, 2013, NEOPLASMA, V60, P486, DOI 10.4149/neo_2013_063
   Qiu GZ, 2016, BIOCHEM BIOPH RES CO, V471, P135, DOI 10.1016/j.bbrc.2016.01.164
   Qu CS, 2013, GENE EXPR PATTERNS, V13, P51, DOI 10.1016/j.gep.2012.11.003
   Rapicavoli NA, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-49
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Ueki Y, 2009, P NATL ACAD SCI USA, V106, P21389, DOI 10.1073/pnas.0906156106
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang PJ, 2012, J CELL BIOCHEM, V113, P1868, DOI 10.1002/jcb.24055
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Yan Biao, 2014, Epigenomics, V6, P375, DOI 10.2217/epi.14.29
   Yan B, 2012, DNA CELL BIOL, V31, pS34, DOI 10.1089/dna.2011.1544
   Yan HL, 2016, NEUROSCIENCE, V337, P191, DOI 10.1016/j.neuroscience.2016.09.017
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
   Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200
   Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008
NR 33
TC 20
Z9 20
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 19
PY 2018
VL 496
IS 4
BP 1236
EP 1242
DI 10.1016/j.bbrc.2018.01.177
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FX8IT
UT WOS:000426336400034
PM 29409883
DA 2022-11-30
ER

PT J
AU Andriessen, EMMA
   Wilson, AM
   Mawambo, G
   Dejda, A
   Miloudi, K
   Sennlaub, F
   Sapieha, P
AF Andriessen, Elisabeth M. M. A.
   Wilson, Ariel M.
   Mawambo, Gaelle
   Dejda, Agnieszka
   Miloudi, Khalil
   Sennlaub, Florian
   Sapieha, Przemyslaw
TI Gut microbiota influences pathological angiogenesis in obesity-driven
   choroidal neovascularization
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; angiogenesis; gut microbiota;
   inflammaging; obesity
ID INCREASED INTESTINAL PERMEABILITY; COMPLEMENT FACTOR-H; MACULAR
   DEGENERATION; METABOLIC ENDOTOXEMIA; CHRONIC INFLAMMATION;
   CARDIOVASCULAR RISK; COMMON VARIANTS; UNITED-STATES; IMMUNE-SYSTEM; MICE
AB Age-related macular degeneration in its neovascular form (NV AMD) is the leading cause of vision loss among adults above the age of 60. Epidemiological data suggest that in men, overall abdominal obesity is the second most important environmental risk factor after smoking for progression to late-stage NV AMD. To date, the mechanisms that underscore this observation remain ill-defined. Given the impact of high-fat diets on gut microbiota, we investigated whether commensal microbes influence the evolution of AMD. Using mouse models of NV AMD, microbiotal transplants, and other paradigms that modify the gut microbiome, we uncoupled weight gain from confounding factors and demonstrate that high-fat diets exacerbate choroidal neovascularization (CNV) by altering gut microbiota. Gut dysbiosis leads to heightened intestinal permeability and chronic low-grade inflammation characteristic of inflammaging with elevated production of IL-6, IL-1,TNF-, and VEGF-A that ultimately aggravate pathological angiogenesis.
C1 [Andriessen, Elisabeth M. M. A.; Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biomed Sci, Res Ctr, Montreal, PQ, Canada.
   [Wilson, Ariel M.; Sapieha, Przemyslaw] Ecole Polytech Montreal, Dept Engn Phys, Laser Proc & Plasmon Lab, Montreal, PQ, Canada.
   [Mawambo, Gaelle; Dejda, Agnieszka; Sapieha, Przemyslaw] Univ Montreal, Dept Biochem, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.
   [Dejda, Agnieszka; Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.
   [Miloudi, Khalil; Sapieha, Przemyslaw] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada.
   [Sennlaub, Florian] Univ Pierre & Marie Curie Paris 06, Sorbonne Univ, Inst Vis,CNRS,Unite Mixte Rech, INSERM,U968,Unite Mixte Rech S 968, Paris, France.
C3 Universite de Montreal; Universite de Montreal; Polytechnique Montreal;
   Universite de Montreal; Universite de Montreal; McGill University;
   Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite
RP Sapieha, P (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biomed Sci, Res Ctr, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，Ecole Polytech Montreal, Dept Engn Phys, Laser Proc & Plasmon Lab, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，Univ Montreal, Dept Biochem, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada.
EM mike.sapieha@umontreal.ca
RI Andriessen, Elisabeth MMA/J-4373-2019; Sennlaub, Florian/F-2756-2017
OI Sennlaub, Florian/0000-0003-4412-1341; Sapieha,
   Przemyslaw/0000-0002-9171-2825
FU Reseau en Recherche en Sante de la Vision; Faculte des Etudes
   Superieures de l'UdM; Wolfe Professorship in Translational Vision
   Research; Canada Research Chair in Retinal Cell Biology; Alcon Research
   Institute; Foundation Fighting Blindness Canada (FFB); Canadian
   Institutes of Health Research [324573]; Canadian Diabetes Association
   [OG-3-11-3329-PS]; Natural Sciences and Engineering Research Council of
   Canada [418637]; Fondation de l'Avenir, Paris, France [AP-RMA-2015-010]
FX E.A. holds scholarships from the Reseau en Recherche en Sante de la
   Vision and the Faculte des Etudes Superieures de l'UdM. P.S. holds The
   Wolfe Professorship in Translational Vision Research and the Canada
   Research Chair in Retinal Cell Biology and the Alcon Research Institute
   Young Investigator Award. This work was supported by grants to P.S. from
   The Foundation Fighting Blindness Canada (FFB), the Canadian Institutes
   of Health Research (324573), the Canadian Diabetes Association
   (OG-3-11-3329-PS), and The Natural Sciences and Engineering Research
   Council of Canada (418637) and the Fondation de l'Avenir, Paris, France,
   Etude noAP-RMA-2015-010 to FS.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amar J, 2008, AM J CLIN NUTR, V87, P1219, DOI 10.1093/ajcn/87.5.1219
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816
   Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006
   Caesar R, 2015, CELL METAB, V22, P658, DOI 10.1016/j.cmet.2015.07.026
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Cerf-Bensussan N, 2010, NAT REV IMMUNOL, V10, P735, DOI 10.1038/nri2850
   Chassaing B, 2014, TOXICOL PATHOL, V42, P49, DOI 10.1177/0192623313508481
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   DiBaise JK, 2012, AM J GASTROENTEROL S, V1, P22, DOI [DOI 10.1038/AJGSUP.2012.5, 10.1038/ajgsup.2012.5]
   Dorrestein PC, 2014, IMMUNITY, V40, P824, DOI 10.1016/j.immuni.2014.05.015
   Ellekilde M, 2014, SCI REP-UK, V4, DOI 10.1038/srep05922
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Evans CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092193
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gerova VA, 2011, WORLD J GASTROENTERO, V17, P2211, DOI [10.3748/wjg.v17.i17.2211, 10.3748/wjg.v17.i17.]
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Manco M, 2010, ENDOCR REV, V31, P817, DOI 10.1210/er.2009-0030
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mehal WZ, 2013, NAT REV GASTRO HEPAT, V10, P637, DOI 10.1038/nrgastro.2013.146
   Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723
   Neves AL, 2013, J MOL ENDOCRINOL, V51, pR51, DOI 10.1530/JME-13-0079
   O'Toole PW, 2015, SCIENCE, V350, P1214, DOI 10.1126/science.aac8469
   Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627
   Prinz M, 2014, ACTA NEUROPATHOL, V128, P319, DOI 10.1007/s00401-014-1267-1
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   Tremblay S, 2013, INVEST OPHTH VIS SCI, V54, P8125, DOI 10.1167/iovs.13-12496
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu N, 2013, MICROB ECOL, V66, P462, DOI 10.1007/s00248-013-0245-9
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 68
TC 77
Z9 81
U1 3
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD DEC
PY 2016
VL 8
IS 12
BP 1366
EP 1379
DI 10.15252/emmm.201606531
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EE0XN
UT WOS:000389303100003
PM 27861126
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Saeed, AM
   Duffort, S
   Ivanov, D
   Wang, H
   Laird, JM
   Salomon, RG
   Cruz-Guilloty, F
   Perez, VL
AF Saeed, Ali M.
   Duffort, Stephanie
   Ivanov, Dmitry
   Wang, Hua
   Laird, James M.
   Salomon, Robert G.
   Cruz-Guilloty, Fernando
   Perez, Victor L.
TI The Oxidative Stress Product Carboxyethylpyrrole Potentiates TLR2/TLR1
   Inflammatory Signaling in Macrophages
SO PLOS ONE
LA English
DT Article
ID CHLAMYDIA-PNEUMONIAE INFECTION; LOW-DENSITY-LIPOPROTEIN; TOLL-LIKE
   RECEPTORS; MACULAR DEGENERATION; PATTERN-RECOGNITION;
   TOLL-LIKE-RECEPTOR-2; ATHEROSCLEROSIS; IDENTIFICATION; EPITOPES; LIGANDS
AB Oxidative stress is key in the pathogenesis of several diseases including age-related macular degeneration (AMD), atherosclerosis, diabetes, and Alzheimer's disease. It has previously been established that a lipid peroxidation product, carboxyethylpyrrole (CEP), accumulates in the retinas of AMD patients. Retinal infiltrating macrophages also accumulate in the retinas of both AMD patients and in a murine model of AMD. We therefore investigated the ability of CEP-adducts to activate innate immune signaling in murine bone-marrow derived macrophages (BMDMs). We found that CEP specifically synergizes with low-dose TLR2-agonists (but not agonists for other TLRs) to induce production of inflammatory cytokines. Moreover, CEP selectively augments TLR2/TLR1-signaling instead of TLR2/TLR6-signaling. These studies uncover a novel synergistic inflammatory relationship between an endogenously produced oxidation molecule and a pathogen-derived product, which may have implications in the AMD disease process and other oxidative stress-driven pathologies.
C1 [Saeed, Ali M.] Univ Miami, Miller Sch Med, Sheila & David Fuente Program Canc Biol, Miami, FL 33136 USA.
   [Duffort, Stephanie; Ivanov, Dmitry; Cruz-Guilloty, Fernando; Perez, Victor L.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Wang, Hua; Laird, James M.; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Cruz-Guilloty, Fernando; Perez, Victor L.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
C3 University of Miami; Bascom Palmer Eye Institute; University of Miami;
   Case Western Reserve University; University of Miami
RP Cruz-Guilloty, F (通讯作者)，Immucor Inc, Norcross, GA 30071 USA.
EM Fcruzguilloty@gmail.com; Vperez4@med.miami.edu
RI Perez, Victor L./AAY-8633-2020; Wang, Hua/N-9400-2015
OI Wang, Hua/0000-0002-2109-5497; Ivanov, Dmitry/0000-0002-5573-4402;
   Salomon, Robert/0000-0001-9456-3557
FU Edward N. & Della L. Thome Memorial Foundation Bank of America N.A.
   Trustee Award Program in Macular Degeneration Research; NIH [P30EY14801,
   R01-GM21249]; Research to Prevent Blindness; Sheila and David Fuente
   Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer
   Center; Howard Hughes Medical Institute Fellowship of the Life Sciences
   Research Foundation; NATIONAL EYE INSTITUTE [P30EY014801, R01EY016813]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM021249] Funding Source: NIH RePORTER
FX This work was supported by The Edward N. & Della L. Thome Memorial
   Foundation Bank of America N.A. Trustee Award Program in Macular
   Degeneration Research (VLP), NIH P30EY14801 (Center Grant), Research to
   Prevent Blindness (Unrestricted Grant to the Bascom Palmer Eye
   Institute), NIH R01-GM21249 (RGS). AMS acknowledges partial support and
   assistance from the Sheila and David Fuente Graduate Program in Cancer
   Biology, Sylvester Comprehensive Cancer Center. FCG was supported by a
   Howard Hughes Medical Institute Fellowship of the Life Sciences Research
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bagchi A, 2007, J IMMUNOL, V178, P1164, DOI 10.4049/jimmunol.178.2.1164
   Beckett EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039460
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cheng K, 2012, ANGEW CHEM INT EDIT, V51, P12246, DOI 10.1002/anie.201204910
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004
   Doyle SL, 2012, NAT MED
   Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158
   Evans T. A., 2008, AM J BIOCH BIOTECHNO, V4, P61, DOI DOI 10.3844/AJBBSP.2008.61.72
   Forner L, 2006, J CLIN PERIODONTOL, V33, P401, DOI 10.1111/j.1600-051X.2006.00924.x
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gibson FC, 2006, J DENT RES, V85, P106, DOI 10.1177/154405910608500202
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hayashi C, 2010, J INNATE IMMUN, V2, P334, DOI 10.1159/000314686
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jimenez-Dalmaroni MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007411
   Kadl A, 2010, CIRC RES, V107, P737, DOI 10.1161/CIRCRESAHA.109.215715
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724
   Laman JD, 2002, AM J CARDIOL, V90, P119, DOI 10.1016/S0002-9149(02)02432-3
   Lappin DF, 2011, J CLIN PERIODONTOL, V38, P318, DOI 10.1111/j.1600-051X.2011.01702.x
   Lin TA, 2010, J INFECT DIS, V202, P624, DOI 10.1086/654929
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Maharaj B, 2012, CARDIOVASC J AFR, V23, P340, DOI 10.5830/CVJA-2012-016
   McLaughlin RW, 2002, J CLIN MICROBIOL, V40, P4771, DOI 10.1128/JCM.40.12.4771-4775.2002
   Miller YI, 2005, ARTERIOSCL THROM VAS, V25, P1213, DOI 10.1161/01.ATV.0000159891.73193.31
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Monaco C, 2009, CIRCULATION, V120, P2462, DOI 10.1161/CIRCULATIONAHA.109.851881
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Nikkari S, 2001, J CLIN MICROBIOL, V39, P1956, DOI 10.1128/JCM.39.5.1956-1959.2001
   Nilsen NJ, 2008, J LEUKOCYTE BIOL, V84, P280, DOI 10.1189/jlb.0907656
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Panigrahi S, 2013, CIRC RES, V112, P103, DOI 10.1161/CIRCRESAHA.112.274241
   Prebeck S, 2001, J IMMUNOL, V167, P3316, DOI 10.4049/jimmunol.167.6.3316
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Schumann RR, 2007, EUR J IMMUNOL, V37, P2059, DOI 10.1002/eji.200737604
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9
   Wiesner P, 2010, CIRC RES, V107, P56, DOI 10.1161/CIRCRESAHA.110.218420
   Yang X, 2005, ARTERIOSCL THROM VAS, V25, P2308, DOI 10.1161/01.ATV.0000187468.00675.a3
   Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105
NR 59
TC 24
Z9 24
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2014
VL 9
IS 9
AR e106421
DI 10.1371/journal.pone.0106421
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AO3TB
UT WOS:000341257700069
PM 25184331
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ivanoff, SD
   Sonn, U
   Svensson, E
AF Ivanoff, SD
   Sonn, U
   Svensson, E
TI A health education program for elderly persons with visual impairments
   and perceived security in the performance of daily occupations: A
   randomized study
SO AMERICAN JOURNAL OF OCCUPATIONAL THERAPY
LA English
DT Article
DE aging; evaluation process, occupational therapy; macular degeneration
ID ORDERED CATEGORICAL-DATA; OLDER ADULTS; POPULATION
AB OBJECTIVE. The purpose of this randomized, longitudinal study was to investigate the impact of a health education program on perceived security in the performance of daily occupations 4 months after the intervention period.
   METHOD. Two groups of persons with age-related macular degeneration were compared: Those who had followed a newly developed health education program that was based on occupation and those who took part in a standard individual intervention program.
   RESULTS. Significant differences in the level of perceived security between the groups were found for 13 of 28 occupations. Participants in the health education group maintained or improved their level of perceived security in 22 daily occupations, whereas those in the individual intervention group declined to a lower level in 17 daily occupations.
   CONCLUSION. This study provides support for the effectiveness of the health education program to enhance security and hinder a progressive decline in perceived security in daily occupations.
C1 Univ Gothenburg, Inst Occupat Therapy & Physiotherapy, Dept Ophthalmol, Gothenburg, Sweden.
   Univ Gothenburg, Inst Occupat Therapy & Physiotherapy, Dept Geriat Med, Gothenburg, Sweden.
   Orebro Univ, Dept Stat, Orebro, Sweden.
C3 University of Gothenburg; University of Gothenburg; Orebro University
RP Ivanoff, SD (通讯作者)，Univ Gothenburg, Inst Occupat Therapy & Physiotherapy, Dept Ophthalmol, Gothenburg, Sweden.
EM sydi@fhs.gu.se
RI Dahlin-Ivanoff, Synneve/U-9819-2018; Svensson, Elisabeth/X-4198-2019
OI Svensson, Elisabeth/0000-0001-7210-1925
CR Altman DG, 1991, PRACTICAL STAT MED R
   Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188
   CARTER WB, 1989, PATIENT EDUC COUNS, V13, P117, DOI 10.1016/0738-3991(89)90055-4
   CASERTA MS, 1995, J COMMUN HEALTH, V20, P283, DOI 10.1007/BF02260411
   Clark F, 1996, AM J OCCUP THER, V50, P99, DOI 10.5014/ajot.50.2.99
   CRIMMINS EM, 1993, J ING HLTH, V0005
   DAHLIN IS, 2001, DISABIL REHABIL, V23, P69
   DAHLIN IS, 1996, DISABIL REHABIL, V18, P515
   DAHLIN IS, 2000, THESIS GOTEBORG U GO
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520
   Jackson J, 1998, AM J OCCUP THER, V52, P326, DOI 10.5014/ajot.52.5.326
   JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Law M, 1995, Can J Occup Ther, V62, P250
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MINKLER M, 1988, GERIATR HLTH PROMOT, V3, P277
   Rebeiro K L, 1999, Can J Occup Ther, V66, P176
   ROTER DL, 1977, HEALTH EDUC QUART, V5, P281, DOI 10.1177/109019817700500402
   Sonn U, 1997, SCAND J REHABIL MED, V29, P233
   Sonntag SK, 1996, J COMMONW COMP POLIT, V34, P1
   STRECHER VJ, 1986, HEALTH EDUC QUART, V13, P73, DOI 10.1177/109019818601300108
   Svensson E, 1998, STAT MED, V17, P2923, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2923::AID-SIM104>3.0.CO;2-#
   SVENSSON E, 1993, THESIS ALMQV WIKS IN
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   Vinding T, 1995, ACTA OPHTHALMOL SCAN, V73, P3
NR 27
TC 42
Z9 42
U1 0
U2 10
PU AMER OCCUPATIONAL THERAPY ASSOC, INC
PI BETHESDA
PA 4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA
SN 0272-9490
EI 1943-7676
J9 AM J OCCUP THER
JI Am. J. Occup. Ther.
PD MAY-JUN
PY 2002
VL 56
IS 3
BP 322
EP 330
DI 10.5014/ajot.56.3.322
PG 9
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 558KP
UT WOS:000175965400009
PM 12058521
DA 2022-11-30
ER

PT J
AU Elmasry, K
   Habib, S
   Moustafa, M
   Al-Shabrawey, M
AF Elmasry, Khaled
   Habib, Samar
   Moustafa, Mohamed
   Al-Shabrawey, Mohamed
TI Bone Morphogenetic Proteins and Diabetic Retinopathy
SO BIOMOLECULES
LA English
DT Review
DE bone morphognetic proteins; BMP2; BMP4; diabetic retinopathy;
   age-related macular degeneration
AB Bone morphogenetic proteins (BMPs) play an important role in bone formation and repair. Recent studies underscored their essential role in the normal development of several organs and vascular homeostasis in health and diseases. Elevated levels of BMPs have been linked to the development of cardiovascular complications of diabetes mellitus. However, their particular role in the pathogenesis of microvascular dysfunction associated with diabetic retinopathy (DR) is still under-investigated. Accumulated evidence from our and others' studies suggests the involvement of BMP signaling in retinal inflammation, hyperpermeability and pathological neovascularization in DR and age-related macular degeneration (AMD). Therefore, targeting BMP signaling in diabetes is proposed as a potential therapeutic strategy to halt the development of microvascular dysfunction in retinal diseases, particularly in DR. The goal of this review article is to discuss the biological functions of BMPs, their underlying mechanisms and their potential role in the pathogenesis of DR in particular.
C1 [Elmasry, Khaled; Al-Shabrawey, Mohamed] Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   [Elmasry, Khaled; Moustafa, Mohamed; Al-Shabrawey, Mohamed] Augusta Univ, Culver Vis Discovery Inst, Augusta, GA 30912 USA.
   [Elmasry, Khaled] Mansoura Univ, Mansoura Fac Med, Dept Anat, Dakahlia Governorate 35516, Egypt.
   [Habib, Samar] Mansoura Univ, Mansoura Fac Med, Dept Med Parasitol, Dakahlia Governorate 35516, Egypt.
   [Habib, Samar] Augusta Univ, Dept Obstet & Gynecol, Med Coll Georgia, Augusta, GA 30912 USA.
   [Moustafa, Mohamed; Al-Shabrawey, Mohamed] Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Egyptian Knowledge Bank (EKB); Mansoura
   University; Egyptian Knowledge Bank (EKB); Mansoura University;
   University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP Al-Shabrawey, M (通讯作者)，Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Culver Vis Discovery Inst, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA.
EM elmasryanatomy@gmail.com; parasitologist2012@gmail.com;
   mmoustafa@augusta.edu; malshabrawey@augusta.edu
OI Habib, Samar/0000-0002-0690-8277
FU National Eye Institute [R01EY030054]
FX R01EY030054 from the National Eye Institute to (Mohamed Al-Shabrawey).
CR Akeel S, 2012, ARCH ORAL BIOL, V57, P445, DOI 10.1016/j.archoralbio.2011.10.002
   Akla N, 2018, ARTERIOSCL THROM VAS, V38, P1821, DOI 10.1161/ATVBAHA.118.310733
   Al-Shabrawey M, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.568795
   Alsina-Sanchis E, 2018, ARTERIOSCL THROM VAS, V38, P1216, DOI 10.1161/ATVBAHA.118.310760
   Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584
   Benn A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030488
   Benn A, 2017, FASEB J, V31, P4720, DOI 10.1096/fj.201700193RR
   Bostrom KI, 2011, CIRC RES, V108, P446, DOI 10.1161/CIRCRESAHA.110.236596
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Callanan DG, 2013, OPHTHALMOLOGY, V120, P1843, DOI 10.1016/j.ophtha.2013.02.018
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Cau E, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.2006250
   Chang CB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021923
   Chattopadhyay T, 2017, BIOFACTORS, V43, P195, DOI 10.1002/biof.1334
   David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124
   de Vinuesa AG, 2016, CYTOKINE GROWTH F R, V27, P65, DOI 10.1016/j.cytogfr.2015.12.005
   Delot EC, 2003, DEVELOPMENT, V130, P209, DOI 10.1242/dev.00181
   DeRubertis FR, 2004, DIABETES, V53, P762, DOI 10.2337/diabetes.53.3.762
   Derwall M, 2012, ARTERIOSCL THROM VAS, V32, P613, DOI 10.1161/ATVBAHA.111.242594
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Dyer L, 2014, DEV BIOL, V386, P385, DOI 10.1016/j.ydbio.2013.12.019
   Dyer LA, 2014, TRENDS ENDOCRIN MET, V25, P472, DOI 10.1016/j.tem.2014.05.003
   Esser JS, 2015, ARTERIOSCL THROM VAS, V35, P358, DOI 10.1161/ATVBAHA.114.304345
   Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Goto K, 2007, J BIOL CHEM, V282, P20603, DOI 10.1074/jbc.M702100200
   Guo L, 2014, DIABETES TECHNOL THE, V16, P224, DOI 10.1089/dia.2013.0181
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Hanna A, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00140
   Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023
   Harris RE, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-229881
   Helbing T, 2017, INFLAMMATION, V40, P1862, DOI 10.1007/s10753-017-0627-0
   Helbing T, 2017, INFLAMMATION, V40, P442, DOI 10.1007/s10753-016-0490-4
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Horbelt D, 2012, INT J BIOCHEM CELL B, V44, P469, DOI 10.1016/j.biocel.2011.12.013
   Huan CJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14910
   Hussein KA, 2014, EXP EYE RES, V125, P79, DOI 10.1016/j.exer.2014.05.012
   Ibrahim AS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072293
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064
   Khalaf M, 2013, EUR J ENDOCRINOL, V168, P437, DOI 10.1530/EJE-12-0891
   Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200
   Koga M, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-32
   Lee HW, 2017, ARTERIOSCL THROM VAS, V37, P657, DOI 10.1161/ATVBAHA.116.308422
   Li ZT, 2014, EUR J IMMUNOL, V44, P3283, DOI 10.1002/eji.201344287
   Liu L, 2019, ADV EXP MED BIOL, V1141, P467, DOI 10.1007/978-981-13-7647-4_10
   Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Moganti K, 2017, IMMUNOBIOLOGY, V222, P952, DOI 10.1016/j.imbio.2016.07.006
   Moreno-Miralles I, 2011, ARTERIOSCL THROM VAS, V31, P2216, DOI 10.1161/ATVBAHA.111.230235
   Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Ola R, 2018, CIRCULATION, V138, P2379, DOI 10.1161/CIRCULATIONAHA.118.033842
   Paine SK, 2012, MOL VIS, V18, P2749
   Pandit T, 2015, DEVELOPMENT, V142, P1850, DOI 10.1242/dev.123653
   Pardali E, 2018, J CELL MOL MED, V22, P5429, DOI 10.1111/jcmm.13814
   Pauk M, 2019, ACTA DIABETOL, V56, P365, DOI 10.1007/s00592-018-1265-1
   Perera N, 2020, ACS PHARMACOL TRANSL, V3, P11, DOI 10.1021/acsptsci.9b00064
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Romero-Aroca P, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/2156273
   ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Sedlmeier G, 2017, BIOCHEM SOC T, V45, P173, DOI 10.1042/BST20160263
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Steinfeld J, 2017, BIOL OPEN, V6, P979, DOI 10.1242/bio.018739
   ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9
   Todd L, 2017, GLIA, V65, P1640, DOI 10.1002/glia.23185
   Torres-Castro I, 2016, IMMUNOL LETT, V176, P81, DOI 10.1016/j.imlet.2016.06.001
   Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wyliea LA, 2018, DEV BIOL, V442, P199, DOI 10.1016/j.ydbio.2018.07.027
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Yan XH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.44
   Yao HP, 2016, SCI REP-UK, V6, DOI 10.1038/srep32182
   Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071
   Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200
   Zhang M, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0214-3
   Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129
   Zhao Q, 2012, INT J OPHTHALMOL-CHI, V5, P119, DOI 10.3980/j.issn.2222-3959.2012.02.01
NR 85
TC 3
Z9 3
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD APR
PY 2021
VL 11
IS 4
AR 593
DI 10.3390/biom11040593
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA RR0HI
UT WOS:000642789900001
PM 33919531
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Graham, BC
   Pulido, JS
   Winters, JL
AF Graham, Brendan C.
   Pulido, Jose S.
   Winters, Jeffrey L.
TI Seeing is believing: A review of apheresis therapy in the treatment of
   ophthalmologic disease
SO JOURNAL OF CLINICAL APHERESIS
LA English
DT Review
DE plasma exchange; plasmapheresis; apheresis; ophthalmologic disease;
   occular disease
ID UVEAL MELANOCYTIC PROLIFERATION; CANCER-ASSOCIATED RETINOPATHY; MEMBRANE
   DIFFERENTIAL FILTRATION; MACULAR DEGENERATION; PLASMA-EXCHANGE; ATOPIC
   KERATOCONJUNCTIVITIS; PARANEOPLASTIC RETINOPATHY; SYMPATHETIC
   OPHTHALMIA; GRAVES OPHTHALMOPATHY; AUTOIMMUNE RETINOPATHIES
AB Apheresis procedures have a role in treatment of disparate diseases involving many different organ systems. Often the disease processes where apheresis plays a role in treatment are considered orphan diseasesrelatively rare disease processes that lack specific pharmaceutical agents or established treatment protocols. Many of these disease processes can affect the eye with devastating results for the eyesight of these patients. The unique ability of apheresis to affect disease by modifying blood plasma and modulating disease-causing agents therein renders apheresis procedures valuable tools in the treatment of certain ophthalmologic diseases. This review comprehensively evaluates the role of apheresis in the treatment of ophthalmologic diseases of the eye and surrounding orbit including age-related macular degeneration, bilateral diffuse uveal melanocytic proliferation, paraneoplastic retinopathy, atopic keratoconjunctivitis, sympathetic ophthalmia, and endocrine-associated ophthalmopathy. Apheresis procedure parameters are provided for the apheresis practitioner based on review of the relevant literature.
C1 [Graham, Brendan C.; Winters, Jeffrey L.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Pulido, Jose S.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Winters, JL (通讯作者)，Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
EM winters.jeffrey@mayo.edu
RI Winters, Jeffrey Lawrence/A-2000-2013
OI Winters, Jeffrey Lawrence/0000-0001-8654-3732
CR Adamus G, 1998, ARCH OPHTHALMOL-CHIC, V116, P251
   Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5
   Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002
   ALBERT DM, 1989, SURV OPHTHALMOL, V34, P1, DOI 10.1016/0039-6257(89)90125-2
   ASWAD MI, 1988, OPHTHALMOLOGY, V95, P444
   BAHN RS, 1993, NEW ENGL J MED, V329, P1468
   BARR CC, 1982, ARCH OPHTHALMOL-CHIC, V100, P249, DOI 10.1001/archopht.1982.01030030251003
   Bartalena L, 2000, ENDOCR REV, V21, P168, DOI 10.1210/er.21.2.168
   Berlin G, 1990, J Clin Apher, V5, P192, DOI 10.1002/jca.2920050405
   Bhatti MT, 2014, J NEURO-OPHTHALMOL, V34, P186, DOI 10.1097/WNO.0000000000000128
   Boeck K, 1997, BRIT J DERMATOL, V137, P457, DOI 10.1111/j.1365-2133.1997.tb03759.x
   BRUNNER R, 1991, Acta Medica Austriaca, V18, P63
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Brunner R, 1995, INT J ARTIF ORGANS, V18, P794, DOI 10.1177/039139889501801208
   Cap J, 2010, J CLIN APHERESIS, V25, P209, DOI 10.1002/jca.20244
   CHAN CC, 1995, ARCH OPHTHALMOL-CHIC, V113, P597, DOI 10.1001/archopht.1995.01100050065032
   Chan JW, 2003, SURV OPHTHALMOL, V48, P12, DOI 10.1016/S0039-6257(02)00416-2
   Chang GC, 2011, SEMIN OPHTHALMOL, V26, P316, DOI 10.3109/08820538.2011.588658
   Charlin J F, 1987, Ophtalmologie, V1, P305
   CHENTSOVA OB, 1991, VESTN OFTALMOL, P38
   Crews J, 2015, OSLI RETINA, V46, P658, DOI 10.3928/23258160-20150610-10
   DANDONA P, 1979, BRIT MED J, V2, P667, DOI 10.1136/bmj.2.6191.667-c
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhingra A, 2011, J NEUROSCI, V31, P3962, DOI 10.1523/JNEUROSCI.6007-10.2011
   Espandar L, 2007, J NEURO-ONCOL, V83, P295, DOI 10.1007/s11060-006-9326-7
   Ferreyra HA, 2009, ARCH OPHTHALMOL-CHIC, V127, P390, DOI 10.1001/archophthalmol.2009.24
   FILIPIC M, 1986, AUST NZ J OPHTHALMOL, V14, P293, DOI 10.1111/j.1442-9071.1986.tb00463.x
   Finger RP, 2010, THER APHER DIAL, V14, P607, DOI 10.1111/j.1744-9987.2010.00879.x
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P569, DOI 10.1097/IAE.0b013e3181a2f3fa
   FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992
   FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190
   Freidlin J, 2006, OPHTHAL PLAST RECONS, V22, P133, DOI 10.1097/01.iop.0000203495.67894.c7
   GASS JDM, 1991, BRIT J OPHTHALMOL, V75, P693, DOI 10.1136/bjo.75.11.693
   GASS JDM, 1990, ARCH OPHTHALMOL-CHIC, V108, P527, DOI 10.1001/archopht.1990.01070060075053
   Gittinger JW, 1999, AM J OPHTHALMOL, V127, P612, DOI 10.1016/S0002-9394(98)00431-0
   GLINOER D, 1986, ACTA ENDOCRINOL-COP, V111, P30, DOI 10.1530/acta.0.1110030
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P471
   Haddox CL, 2017, ANN ONCOL, V28, P673, DOI 10.1093/annonc/mdw655
   Hingorani M, 1998, OPHTHALMOLOGY, V105, P1715, DOI 10.1016/S0161-6420(98)99043-1
   Jaben EA, 2011, J CLIN APHERESIS, V26, P356, DOI 10.1002/jca.20310
   Jansen JCG, 2015, BRIT J OPHTHALMOL, V99, P943, DOI 10.1136/bjophthalmol-2014-305893
   JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12
   KADEN R, 1977, KLIN MONATSBL AUGENH, V170, P154
   Katsuta H, 2002, AM J OPHTHALMOL, V134, P383, DOI 10.1016/S0002-9394(02)01598-2
   Keegan M, 2005, LANCET, V366, P579, DOI 10.1016/S0140-6736(05)67102-4
   KELLY W, 1983, CLIN ENDOCRINOL, V18, P485, DOI 10.1111/j.1365-2265.1983.tb02878.x
   Keltner JL, 2001, J NEURO-OPHTHALMOL, V21, P173, DOI 10.1097/00041327-200109000-00004
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel R, 2010, THER APHER DIAL, V14, P276, DOI 10.1111/j.1744-9987.2010.00807.x
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Lardenet F, 1983, Bull Soc Ophtalmol Fr, V83, P239
   Liu CY, 2014, RETINA-J RET VIT DIS, V34, P1261, DOI 10.1097/IAE.0000000000000242
   Liu YN, 2015, OCUL IMMUNOL INFLAMM, V23, P405, DOI 10.3109/09273948.2014.884599
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Machemer R, 1966, Klin Monbl Augenheilkd, V148, P641
   Merle H, 2012, ARCH OPHTHALMOL-CHIC, V130, P858, DOI 10.1001/archophthalmol.2012.1126
   Mets RB, 2011, ARCH OPHTHALMOL-CHIC, V129, P1235, DOI 10.1001/archophthalmol.2011.277
   Miles SL, 2012, RETINA-J RET VIT DIS, V32, P1959, DOI 10.1097/IAE.0b013e3182618bab
   Mittal R, 2016, OCUL ONCOL PATHOL, V2, P94, DOI 10.1159/000440766
   Miyazaki D, 2008, OPHTHALMOLOGY, V115, P988, DOI 10.1016/j.ophtha.2007.07.025
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   MULLANEY J, 1984, BRIT J OPHTHALMOL, V68, P261, DOI 10.1136/bjo.68.4.261
   Murphy MA, 1997, J NEURO-OPHTHALMOL, V17, P77
   O'Neal KD, 2003, SURV OPHTHALMOL, V48, P613, DOI 10.1016/j.survophthal.2003.08.005
   Pefkianaki M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1020-8
   Power WJ, 1998, OPHTHALMOLOGY, V105, P637, DOI 10.1016/S0161-6420(98)94017-9
   PRAUSE JU, 1984, OPHTHALMOLOGICA, V189, P221, DOI 10.1159/000309413
   Pulido JS, 2013, EYE, V27, P1058, DOI 10.1038/eye.2013.131
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Ritland JS, 2000, ACTA OPHTHALMOL SCAN, V78, P366, DOI 10.1034/j.1600-0420.2000.078003366.x
   ROHRBACH JM, 1990, AM J OPHTHALMOL, V110, P49, DOI 10.1016/S0002-9394(14)76937-5
   Rossi M, 2009, THER APHER DIAL, V13, P540, DOI 10.1111/j.1744-9987.2009.00705.x
   RUSH JA, 1993, AM J OPHTHALMOL, V115, P390, DOI 10.1016/S0002-9394(14)73594-9
   RYLL DL, 1980, OPHTHALMOLOGY, V87, P1181
   SAWERS JSA, 1981, J CLIN LAB IMMUNOL, V6, P245
   SAWYER RA, 1976, AM J OPHTHALMOL, V81, P606, DOI 10.1016/0002-9394(76)90125-2
   Schelvergem Kristof V, 2015, Retin Cases Brief Rep, V9, P106, DOI 10.1097/ICB.0000000000000104
   Schwartz J, 2016, J CLIN APHERESIS, V31, P149, DOI 10.1002/jca.21470
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   THIRKILL CE, 1989, NEW ENGL J MED, V321, P1589, DOI 10.1056/NEJM198912073212307
   TSUKAHARA S, 1986, BRIT J OPHTHALMOL, V70, P33, DOI 10.1136/bjo.70.1.33
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Weleber RG, 2005, AM J OPHTHALMOL, V139, P780, DOI 10.1016/j.ajo.2004.12.104
   Winters JL, 2013, THERAPEUTIC APHERESI
   Yeh JH, 2008, THER APHER DIAL, V12, P500, DOI 10.1111/j.1744-9987.2008.00641.x
NR 89
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0733-2459
EI 1098-1101
J9 J CLIN APHERESIS
JI J. Clin. Apheresis
PD JUN
PY 2018
VL 33
IS 3
BP 380
EP 392
DI 10.1002/jca.21607
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA GQ1YA
UT WOS:000441439100022
PM 29150864
DA 2022-11-30
ER

PT J
AU Huang, XG
   Zhou, GH
   Wu, WY
   Duan, YJ
   Ma, GE
   Song, JY
   Xiao, R
   Vandenberghe, L
   Zhang, F
   D'Amore, PA
   Lei, HT
AF Huang, Xionggao
   Zhou, Guohong
   Wu, Wenyi
   Duan, Yajian
   Ma, Gaoen
   Song, Jingyuan
   Xiao, Ru
   Vandenberghe, Luk
   Zhang, Feng
   D'Amore, Patricia A.
   Lei, Hetian
TI Genome editing abrogates angiogenesis in vivo
SO NATURE COMMUNICATIONS
LA English
DT Article
ID LEBERS CONGENITAL AMAUROSIS; GENE-THERAPY; PATHOLOGICAL ANGIOGENESIS;
   MACULAR DEGENERATION; CELLS; RECEPTOR; MOUSE; MODEL; CARCINOGENESIS;
   IDENTIFICATION
AB Angiogenesis, in which vascular endothelial growth factor receptor (VEGFR) 2 plays an essential role, is associated with a variety of human diseases including proliferative diabetic retinopathy and wet age-related macular degeneration. Here we report that a system of adeno-associated virus (AAV)-mediated clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease (Cas) 9 from Streptococcus pyogenes (SpCas9) is used to deplete VEGFR2 in vascular endothelial cells (ECs), whereby the expression of SpCas9 is driven by an endothelial-specific promoter of intercellular adhesion molecule 2. We further show that recombinant AAV serotype 1 (rAAV1) transduces ECs of pathologic vessels, and that editing of genomic VEGFR2 locus using rAAV1-mediated CRISPR/Cas9 abrogates angiogenesis in the mouse models of oxygen-induced retinopathy and laser-induced choroid neovascularization. This work establishes a strong foundation for genome editing as a strategy to treat angiogenesis-associated diseases.
C1 [Huang, Xionggao; Zhou, Guohong; Wu, Wenyi; Duan, Yajian; Ma, Gaoen; Song, Jingyuan; Xiao, Ru; Vandenberghe, Luk; D'Amore, Patricia A.; Lei, Hetian] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Huang, Xionggao; Zhou, Guohong; Wu, Wenyi; Duan, Yajian; Ma, Gaoen; Song, Jingyuan; Xiao, Ru; Vandenberghe, Luk; D'Amore, Patricia A.; Lei, Hetian] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
   [Huang, Xionggao] Hainan Eye Hosp, Haikou 570311, Hainan, Peoples R China.
   [Zhou, Guohong; Duan, Yajian] Shanxi Eye Hosp, Taiyuan 030002, Shanxi, Peoples R China.
   [Wu, Wenyi] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410013, Hunan, Peoples R China.
   [Song, Jingyuan] Chinese Acad Med Sci, Inst Med Plant Dev, Beijing 100193, Peoples R China.
   [Song, Jingyuan] Peking Union Med Coll, Beijing 100193, Peoples R China.
   [Zhang, Feng] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA 02142 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Schepens Eye Research Institute; Harvard University; Harvard
   Medical School; Shanxi Medical University; Central South University;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Medicinal Plant Development - CAMS; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute
RP Lei, HT (通讯作者)，Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA 02114 USA.; Lei, HT (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
EM hetian_lei@meei.harvard.edu
RI Vandenberghe, Luk H./J-6395-2014; Macrae, Rhiannon/AAX-1536-2020;
   VANDENBERGHE, LUC H./ABH-1765-2020; D'Amore, Patricia/G-5660-2017
OI Vandenberghe, Luk H./0000-0002-3508-4924; VANDENBERGHE, LUC
   H./0000-0002-3508-4924; D'Amore, Patricia/0000-0001-9652-8974
FU National Institutes of Health, National Eye Institute [R01 EY012509,
   P30EY003790]; NATIONAL EYE INSTITUTE [R01EY012509, P30EY003790] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health, National Eye
   Institute Grants R01 EY012509 (to H.L.) and Core Grant P30EY003790.
CR Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chitranshi N, 2015, INT J MOL SCI, V16, P21087, DOI 10.3390/ijms160921087
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Cox DBT, 2015, NAT MED, V21, P121, DOI 10.1038/nm.3793
   Dai C, 2004, J VIROL, V78, P6209, DOI 10.1128/JVI.78.12.6209-6221.2004
   Deyle DR, 2009, CURR OPIN MOL THER, V11, P442
   Duan YJ, 2016, J BIOL CHEM, V291, P16339, DOI 10.1074/jbc.M116.729467
   Ellis BL, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-74
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Fraser-Bell S, 2008, CURR OPIN OPHTHALMOL, V19, P185, DOI 10.1097/ICU.0b013e3282fb7c45
   Gaudet D, 2013, GENE THER, V20, P361, DOI 10.1038/gt.2012.43
   Gaudet D, 2012, CURR OPIN LIPIDOL, V23, P310, DOI 10.1097/MOL.0b013e3283555a7e
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Huang XG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20537
   Jessup M, 2011, CIRCULATION, V124, P304, DOI 10.1161/CIRCULATIONAHA.111.022889
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kawamoto A, 2001, CIRCULATION, V103, P634
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lei HT, 2015, MOL CELL BIOL, V35, P1673, DOI 10.1128/MCB.01248-14
   Lei HT, 2004, CIRC RES, V94, P902, DOI 10.1161/01.RES.0000124979.46214.E3
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Pillay S, 2016, NATURE, V530, P108, DOI 10.1038/nature16465
   Ruan GX, 2012, EMBO J, V31, P1692, DOI 10.1038/emboj.2012.21
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Swiech L, 2015, NAT BIOTECHNOL, V33, P102, DOI 10.1038/nbt.3055
   Tabebordbar M, 2016, SCIENCE, V351, P407, DOI 10.1126/science.aad5177
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   Zhang F, 2015, HUM GENE THER, V26, P409, DOI 10.1089/hum.2015.29002.fzh
NR 40
TC 78
Z9 85
U1 0
U2 36
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 24
PY 2017
VL 8
AR 112
DI 10.1038/s41467-017-00140-3
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FB5BO
UT WOS:000406156600011
PM 28740073
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, KA
   Kang, SW
   Ahn, HR
   Song, Y
   Yang, SJ
   Jung, SH
AF Kim, Kyung-A
   Kang, Suk Woo
   Ahn, Hong Ryul
   Song, Youngwoo
   Yang, Sung Jae
   Jung, Sang Hoon
TI Leaves of Persimmon (Diospyros kaki Thunb.) Ameliorate
   N-Methyl-N-nitrosourea (MNU)-Induced Retinal Degeneration in Mice
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Diospyros kaki; N-methyl-N-nitrosourea; persimmon; photoreceptor;
   retinal degeneration
ID CONE CELL-DEATH; PHOTORECEPTOR DEGENERATION; SMALL-INTESTINE; MULLER
   CELLS; NESTIN; EXPRESSION; ANTIOXIDANTS; GLYCOSIDES; QUERCETIN; CATARACT
AB The purpose of the study was to investigate the protective effects of the ethanol extract of Diospyros kaki (EEDK) persimmon leaves to study N-methyl-N-nitrosourea (MNU)-induced retinal degeneration in mice. EEDK was orally administered after MNU injection. Retinal layer thicknesses were significantly increased in the EEDK-treated group compared with the MNU-treated group. The outer nuclear layer was preserved in the retinas of EEDK-treated mice. Moreover, EEDK treatment reduced the MNU-dependent up-regulation of glial fibrillary acidic protein (GFAP) and nestin expression in Muller and astrocyte cells. EEDK treatment also inhibited MNU-dependent down-regulation of rhodopsin expression. Quercetin exposure significantly attenuated the negative effects of H2O2 in R28 cells, suggesting that quercetin can act in an antioxidative capacity. Thus, EEDK may be considered as an agent for treating or preventing degenerative retinal diseases, such as retinitis pigmentosa and age-related macular degeneration.
C1 [Kim, Kyung-A; Kang, Suk Woo; Ahn, Hong Ryul; Song, Youngwoo; Jung, Sang Hoon] Korea Inst Sci & Technol, Nat Prod Res Ctr, Kangnung, South Korea.
   [Yang, Sung Jae] Univ Ulsan, Gangneung Man Hosp, Dept Ophthalmol, Kangnung, South Korea.
   [Kim, Kyung-A; Jung, Sang Hoon] Univ Sci & Technol, Dept Biol Chem, Daejeon, South Korea.
C3 Korea Institute of Science & Technology (KIST); University of Ulsan;
   University of Science & Technology (UST)
RP Jung, SH (通讯作者)，Korea Inst Sci & Technol, Nat Prod Res Ctr, Kangnung, South Korea.
EM shjung507@gmail.com
RI Kang, SW/GYJ-4352-2022
OI Kang, SW/0000-0002-5678-6394
FU Korea Institute of Science and Technology (KIST), Republic of Korea
   [2Z04381]
FX This work was financially supported by an intramural grant (2Z04381)
   from the Korea Institute of Science and Technology (KIST), Republic of
   Korea.
CR Ahn HS, 2002, NUTR RES, V22, P1265, DOI 10.1016/S0271-5317(02)00429-3
   Anderson B Jr, 1968, Trans Am Ophthalmol Soc, V66, P423
   Bei WJ, 2009, J ETHNOPHARMACOL, V126, P134, DOI 10.1016/j.jep.2009.07.034
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Danulescu R, 2012, MED-SURG J, V116, P1136
   Day AJ, 2000, FEBS LETT, V468, P166, DOI 10.1016/S0014-5793(00)01211-4
   Day AJ, 1998, FEBS LETT, V436, P71, DOI 10.1016/S0014-5793(98)01101-6
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Ioku K, 1998, BIOSCI BIOTECH BIOCH, V62, P1428, DOI 10.1271/bbb.62.1428
   Izuchi R, 2009, BIOSCI BIOTECH BIOCH, V73, P2793, DOI 10.1271/bbb.90616
   Jeong E, 2011, ANAT CELL BIOL, V44, P314, DOI 10.5115/acb.2011.44.4.314
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katsube T, 2004, J AGR FOOD CHEM, V52, P2391, DOI 10.1021/jf035372g
   Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925
   Kawakami K, 2011, PHYTOCHEM ANALYSIS, V22, P403, DOI 10.1002/pca.1295
   Kiang AS, 2014, ADV EXP MED BIOL, V801, P783, DOI 10.1007/978-1-4614-3209-8_98
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kohno H, 2006, GRAEF ARCH CLIN EXP, V244, P90, DOI 10.1007/s00417-005-0030-7
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Ozen A, 2004, FOOD CHEM, V85, P431, DOI 10.1016/j.foodchem.2003.07.022
   Prater MR, 2006, PLACENTA, V27, P502, DOI 10.1016/j.placenta.2005.04.003
   Rosch S, 2014, INVEST OPHTH VIS SCI, V55, P1711, DOI 10.1167/iovs.13-13242
   Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031
   Tsubura A, 2011, IN VIVO, V25, P11
   Usui S, 2011, FREE RADICAL BIO MED, V51, P1347, DOI 10.1016/j.freeradbiomed.2011.06.010
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   Valamanesh F, 2013, EXP EYE RES, V110, P26, DOI 10.1016/j.exer.2013.01.013
   Wan J, 2008, VISION RES, V48, P223, DOI 10.1016/j.visres.2007.11.002
   Xue LP, 2010, CAN J NEUROL SCI, V37, P643, DOI 10.1017/S0317167100010830
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zulliger R, 2011, GRAEF ARCH CLIN EXP, V249, P859, DOI 10.1007/s00417-010-1584-6
NR 37
TC 18
Z9 20
U1 1
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD SEP 9
PY 2015
VL 63
IS 35
BP 7750
EP 7759
DI 10.1021/acs.jafc.5b02578
PG 10
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA CR3RZ
UT WOS:000361252100021
PM 26260943
DA 2022-11-30
ER

PT J
AU Zhang, TQ
   Song, ZJ
   Wang, XG
   Zheng, HM
   Jia, FC
   Wu, JH
   Jia, FC
   Wu, JH
   Li, GL
   Hu, QM
AF Zhang, Tianqiao
   Song, Zhangjun
   Wang, Xiaogang
   Zheng, Huimin
   Jia, Fucang
   Wu, Jianhuang
   Jia, Fucang
   Wu, Jianhuang
   Li, Guanglin
   Hu, Qingmao
TI Fast retinal layer segmentation of spectral domain optical coherence
   tomography images
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE spectral domain optical coherence tomography; Kalman filtering; active
   contour; curve smoothing; macular layer boundary; segmentation; fast
   algorithm
ID MACULAR OCT IMAGES; AUTOMATIC SEGMENTATION; MULTIPLE-SCLEROSIS;
   THICKNESS; DIFFERENTIATION; BOUNDARIES; PATHOLOGY
AB An approach to segment macular layer thicknesses from spectral domain optical coherence tomography has been proposed. The main contribution is to decrease computational costs while maintaining high accuracy via exploring Kalman filtering, customized active contour, and curve smoothing. Validation on 21 normal volumes shows that 8 layer boundaries could be segmented within 5.8 s with an average layer boundary error <2.35 mu m. It has been compared with state-of-the-art methods for both normal and age-related macular degeneration cases to yield similar or significantly better accuracy and is 37 times faster. The proposed method could be a potential tool to clinically quantify the retinal layer boundaries. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.
C1 [Zhang, Tianqiao; Song, Zhangjun; Zheng, Huimin; Jia, Fucang; Wu, Jianhuang; Jia, Fucang; Wu, Jianhuang; Li, Guanglin; Hu, Qingmao] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.
   [Zhang, Tianqiao] Univ Chinese Acad Sci, Shenzhen Coll Adv Technol, Shenzhen 518055, Peoples R China.
   [Wang, Xiaogang] Shanxi Eye Hosp, Taiyuan 030002, Peoples R China.
   [Li, Guanglin; Hu, Qingmao] Key Lab Human Machine Intelligence Synergy Syst, Shenzhen 518055, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Shanxi Medical University
RP Hu, QM (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, 1068 Xueyuan Blvd, Shenzhen 518055, Peoples R China.
EM qm.hu@siat.ac.cn
RI , Tianqiao/F-1792-2015
OI , Tianqiao/0000-0003-2982-2916; Li, Guanglin/0000-0001-9016-2617
FU Key Joint Program of National Natural Science Foundation and Guangdong
   Province of China [U1201257]; Shenzhen Key Technical Development Grant
   [CXZZ20140610151856719]; Introduced Innovative R&D Teams of Guangdong
   Province of China [201001D0104648280, 2011S013]
FX We would like to thank Dr. Stephanie J. Chiu for providing the datasets
   introduced in Ref. 23 (normal) and Ref. 26 (pathological). The work is
   supported by Key Joint Program of National Natural Science Foundation
   and Guangdong Province of China U1201257, Shenzhen Key Technical
   Development Grant (No. CXZZ20140610151856719), and Introduced Innovative
   R&D Teams of Guangdong Province of China "Robot and Intelligent
   Information Technology" (Grant No. 201001D0104648280), and "Technologies
   for Image-guided Bio-simulation Radiotherapy Machinery" (Grant No.
   2011S013).
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Bagci AM, 2008, AM J OPHTHALMOL, V146, P679, DOI 10.1016/j.ajo.2008.06.010
   Boyer KL, 2006, IEEE T MED IMAGING, V25, P553, DOI 10.1109/TMI.2006.871417
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fabritius T, 2009, OPT EXPRESS, V17, P15659, DOI 10.1364/OE.17.015659
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Frohman EM, 2008, NAT CLIN PRACT NEURO, V4, P664, DOI 10.1038/ncpneuro0950
   Fujimoto JG, 2009, OPT EXPRESS, V17, P3978, DOI 10.1364/OE.17.003978
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   GORRY PA, 1990, ANAL CHEM, V62, P570, DOI 10.1021/ac00205a007
   Greenfield DS, 2003, ARCH OPHTHALMOL-CHIC, V121, P41
   Guedes V, 2003, OPHTHALMOLOGY, V110, P177, DOI 10.1016/S0161-6420(02)01564-6
   Hajee ME, 2009, ARCH OPHTHALMOL-CHIC, V127, P737, DOI 10.1001/archophthalmol.2009.106
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Jacob M, 2004, IEEE T IMAGE PROCESS, V13, P1231, DOI 10.1109/TIP.2004.832919
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalman RE., 1960, T ASME J BASIC ENG, V82, P35, DOI DOI 10.1115/1.3662552
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   Kirbas S, 2013, J NEURO-OPHTHALMOL, V33, P58, DOI 10.1097/WNO.0b013e318267fd5f
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   LAM KM, 1994, ELECTRON LETT, V30, P21, DOI 10.1049/el:19940040
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Saidha S, 2012, LANCET NEUROL, V11, P963, DOI 10.1016/S1474-4422(12)70213-2
   Saidha S, 2011, BRAIN, V134, P518, DOI 10.1093/brain/awq346
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   Shahidi M, 2005, AM J OPHTHALMOL, V139, P1056, DOI 10.1016/j.ajo.2005.01.012
   Somfai GM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-295
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   WILLIAMS DJ, 1992, CVGIP-IMAG UNDERSTAN, V55, P14, DOI 10.1016/1049-9660(92)90003-L
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yazdanpanah A, 2011, IEEE T MED IMAGING, V30, P484, DOI 10.1109/TMI.2010.2087390
NR 51
TC 5
Z9 6
U1 0
U2 11
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD SEP
PY 2015
VL 20
IS 9
AR 096014
DI 10.1117/1.JBO.20.9.096014
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA CW6SO
UT WOS:000365128100032
PM 26385655
OA hybrid
DA 2022-11-30
ER

PT J
AU Weissbrodt, D
   Mueller, R
   Perrin, J
   Backhaus, J
   Jonas, JB
AF Weissbrodt, David
   Mueller, Ralf
   Perrin, Jessica
   Backhaus, Juergen
   Jonas, Jost B.
TI Infrared spectroscopic examination of aqueous humor
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID RAMAN-SPECTROSCOPY
AB Objective: The aim of this study was to report on a new technique for examining aqueous humor.
   Participants: Aqueous humor samples obtained from 198 patients (cataract: n = 66 eyes; age-related macular degeneration [AMD]: n = 66; diabetic macular edema: n = 66) were in vitro examined by mid infrared spectroscopy. After training and validating the technique, 66 samples were taken for the final independent prediction.
   Results: In computerized analysis of the spectrometric data, 22 (100%) cataract eyes were diagnosed as the cataract group, 17 (77%) diabetic macular edema eyes were diagnosed as the diabetic macular edema group, and 14 (64%) eyes with AMD were diagnosed as the AMD group. Mid infrared spectrometry could statistically significantly (P = 0.004) differentiate between the 3 study groups.
   Conclusions: Mid infrared spectroscopic examination of aqueous humor may be able to differentiate eyes with cataract, AMD, or diabetic macular edema.
C1 Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
   Mannheim Univ Appl Sci, Inst Instrumental Anal, Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI Weissbrodt, David Gregory/A-2101-2017
OI Weissbrodt, David Gregory/0000-0002-6313-1652
CR Barton F., 2002, SPECTROSCOPY EUROPE, V14, P12
   Liu KZ, 2002, CLIN CHEM, V48, P499
   Liu KZ, 2001, APOPTOSIS, V6, P269, DOI 10.1023/A:1011383408381
   McIntosh LM, 1999, J INVEST DERMATOL, V112, P951, DOI 10.1046/j.1523-1747.1999.00612.x
   Molckovsky A, 2003, GASTROINTEST ENDOSC, V57, P396, DOI 10.1067/mge.2003.105
   Schrader B, 1996, FRESEN J ANAL CHEM, V355, P233
   Silveira L, 2003, J CLIN LASER MED SUR, V21, P203, DOI 10.1089/104454703768247774
   Sowa MG, 2001, BURNS, V27, P241, DOI 10.1016/S0305-4179(00)00111-X
   Weissbrodt D, 2005, AM J OPHTHALMOL, V140, P307, DOI 10.1016/j.ajo.2005.01.043
NR 9
TC 1
Z9 1
U1 2
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2007
VL 23
IS 1
BP 54
EP 56
DI 10.1089/jop.2006.0051
PG 3
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 146DK
UT WOS:000244914500008
PM 17341151
DA 2022-11-30
ER

PT J
AU Baek, A
   Son, S
   Baek, YM
   Kim, DE
AF Baek, Ahruem
   Son, Sumin
   Baek, Yu Mi
   Kim, Dong-Eun
TI KRT8 (keratin 8) attenuates necrotic cell death by facilitating
   mitochondrial fission-mediated mitophagy through interaction with PLEC
   (plectin)
SO AUTOPHAGY
LA English
DT Article
DE Age-related macular degeneration (AMD); autophagy; keratin 8 (KRT8);
   mitochondrial fission; mitophagy; necrosis; Plectin (PLEC)
AB Dysregulation of mitochondrial homeostasis and accumulation of damaged mitochondria cause degenerative diseases such as age-related macular degeneration (AMD). We studied the effects of the intermediate cytofilament KRT8 (keratin 8) on mitochondrial homeostasis in relation to the morphology and function of mitochondria in retinal pigment epithelial cells under oxidative stress. When the mitochondria were damaged owing to oxidative stress, the damaged mitochondria were readily disposed of via mitophagy following mitochondrial fission. During this process, KRT8 was found to physically interact with the mitochondria through PLEC (plectin) and facilitate the mitochondrial fission-mediated mitophagy. However, the association between PLEC-anchoring mitochondria and KRT8 was dwindled by KRT8 phosphorylation under oxidative stress. The efficient KRT8-facilitated mitophagy flux suppressed the accumulation of damaged mitochondria and consequently diminished necrotic cell death under oxidative stress. Thus, by facilitating mitophagy, KRT8 protects RPE cells against necrotic cell death due to oxidative stress.
C1 [Baek, Ahruem; Son, Sumin; Baek, Yu Mi; Kim, Dong-Eun] Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea.
C3 Konkuk University
RP Kim, DE (通讯作者)，Konkuk Univ, Dept Biosci & Biotechnol, Seoul, South Korea.
EM kimde@konkuk.ac.kr
OI Son, Sumin/0000-0002-0160-5226; Baek, Yu Mi/0000-0002-3043-1237
FU Konkuk University; National Research Foundation of Korea
   [2017R1E1A1A01074656]
FX This work was supported by the Konkuk University [2019]; National
   Research Foundation of Korea [2020R1I1A1A01067670]; National Research
   Foundation of Korea [2017R1E1A1A01074656].
CR Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Burman JL, 2017, J CELL BIOL, V216, P3231, DOI 10.1083/jcb.201612106
   Castanon MJ, 2013, HISTOCHEM CELL BIOL, V140, P33, DOI 10.1007/s00418-013-1102-0
   Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200
   CHAPPELL JB, 1965, BIOCHEM J, V95, P378, DOI 10.1042/bj0950378
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Chen YW, 2012, ARCH TOXICOL, V86, P1547, DOI 10.1007/s00204-012-0873-8
   Chinta SJ, 2008, NEUROMOL MED, V10, P333, DOI 10.1007/s12017-008-8047-9
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Duan S, 2009, CELL DEATH DIFFER, V16, P826, DOI 10.1038/cdd.2009.12
   Eisner V, 2018, NAT CELL BIOL, V20, P755, DOI 10.1038/s41556-018-0133-0
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galloway CA, 2012, DIABETES, V61, P2093, DOI 10.2337/db11-1640
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gottlieb RA, 2016, CELL CALCIUM, V60, P88, DOI 10.1016/j.ceca.2016.04.006
   HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1
   Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hernandez G, 2013, AUTOPHAGY, V9, P1852, DOI 10.4161/auto.26501
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Karlsson M, 2013, EXP EYE RES, V116, P359, DOI 10.1016/j.exer.2013.10.014
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Leidal AM, 2018, NAT CELL BIOL, V20, P1338, DOI 10.1038/s41556-018-0235-8
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mao K, 2013, AUTOPHAGY, V9, P1900, DOI 10.4161/auto.25804
   Matveeva EA, 2015, BIOL OPEN, V4, P1290, DOI 10.1242/bio.011874
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Natsuga K, 2010, HUM MUTAT, V31, pE1687, DOI 10.1002/humu.21330
   Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2
   Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788
   Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257
   Pendergrass W, 2004, CYTOM PART A, V61A, P162, DOI 10.1002/cyto.a.20033
   Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308
   Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412
   Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450
   Sripathi SR, 2016, PROTEIN J, V35, P179, DOI 10.1007/s10930-016-9659-9
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tao GZ, 2009, J CELL SCI, V122, P3851, DOI 10.1242/jcs.051862
   Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972
   Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094
   Terman Alexei, 2005, Heart Lung Circ, V14, P107, DOI 10.1016/j.hlc.2004.12.023
   Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Wiche Gerhard, 2011, Bioarchitecture, V1, P14
   Winter L, 2008, J CELL BIOL, V181, P903, DOI 10.1083/jcb.200710151
   Winter L, 2015, HUM MOL GENET, V24, P4530, DOI 10.1093/hmg/ddv184
   Yamada T, 2018, CELL METAB, V28, P588, DOI 10.1016/j.cmet.2018.06.014
   Yoo SM, 2020, FASEB J, V34, P2944, DOI 10.1096/fj.201901735R
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang CS, 2016, CELL METAB, V23, P399, DOI 10.1016/j.cmet.2016.02.017
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 70
TC 2
Z9 2
U1 1
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD DEC 2
PY 2021
VL 17
IS 12
BP 3939
EP 3956
DI 10.1080/15548627.2021.1897962
EA MAR 2021
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XU9DW
UT WOS:000635021200001
PM 33783309
OA Green Published
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Flamme-Wiese, MJ
   Wiley, JS
   Potempa, LA
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Chirco, Kathleen R.
   Flamme-Wiese, Miles J.
   Wiley, Jill S.
   Potempa, Lawrence A.
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Evaluation of serum and ocular levels of membrane attack complex and
   C-reactive protein in CFH-genotyped human donors
SO EYE
LA English
DT Article
ID MACULAR DEGENERATION; FACTOR-H
AB Background: There is a considerable body of evidence demonstrating a link between the membrane attack complex (MAC) and age-related macular degeneration (AMD), and between C-reactive protein (CRP) and AMD. Both the MAC and the monomeric form of CRP (mCRP) accumulate within the choriocapillaris in AMD. However, the precise contribution of these species to AMD pathophysiology has not been fully elucidated.
   Methods: We sought to directly assess CRP and MAC levels between human serum and ocular tissues from the same CFH Y402H genotyped donors using ELISA of serum and RPE/choroid proteins.
   Results: The Y402H polymorphism was associated with significantly increased MAC in RPE/choroid samples, but not in the serum, in a previously unstudied cohort. While MAC levels in the choroid were independent of circulating levels, choroidal CRP was correlated to serum levels.
   Conclusions: These data provide further evidence for local activation of complement within the choriocapillaris in AMD.
C1 [Chirco, Kathleen R.; Flamme-Wiese, Miles J.; Wiley, Jill S.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
   [Chirco, Kathleen R.; Flamme-Wiese, Miles J.; Wiley, Jill S.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.; Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Tucker, Budd/0000-0003-2178-1742;
   Stone, Edwin M./0000-0003-3343-4414
FU NIH [EY024605, P30 EY025580]; Elmer and Sylvia Sramek Charitable
   Foundation; NATIONAL EYE INSTITUTE [R01EY026087, R01EY024605,
   P30EY025580] Funding Source: NIH RePORTER
FX We wish to thank the Iowa Lions Eye Bank as well as the donors and their
   families for their essential contributions to this research. This work
   was supported in part by NIH grants EY024605 and P30 EY025580, and the
   Elmer and Sylvia Sramek Charitable Foundation.
CR Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
NR 5
TC 12
Z9 12
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2018
VL 32
IS 11
BP 1740
EP 1742
DI 10.1038/s41433-018-0170-8
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ6QB
UT WOS:000449564900009
PM 30013157
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Whitmore, SS
   Sohn, EH
   Chirco, KR
   Drack, AV
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Whitmore, S. Scott
   Sohn, Elliott H.
   Chirco, Kathleen R.
   Drack, Arlene V.
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Complement activation and choriocapillaris loss in early AMD:
   Implications for pathophysiology and therapy
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidmacula; Complement system;
   Endothelial cells; Choriocapillaris; Pathophysiology
ID C-REACTIVE PROTEIN; AGE-RELATED MACULOPATHY; RETINAL-PIGMENT EPITHELIUM;
   OPTICAL COHERENCE TOMOGRAPHY; MEMBRANE ATTACK COMPLEX; FACTOR-H
   POLYMORPHISM; CHOROIDAL BLOOD-FLOW; SUBRETINAL DRUSENOID DEPOSITS;
   POLYUNSATURATED FATTY-ACIDS; HTRA1 PROMOTER POLYMORPHISM
AB Age-related macular degeneration (AMD) is a common and devastating disease that can result in severe visual dysfunction. Over the last decade, great progress has been made in identifying genetic variants that contribute to AMD, many of which lie in genes involved in the complement cascade. In this review we discuss the significance of complement activation in AMD, particularly with respect to the formation of the membrane attack complex in the aging choriocapillaris. We review the clinical, histological and biochemical data that indicate that vascular loss in the choroid occurs very early in the pathogenesis of AMD, and discuss the potential impact of vascular dropout on the retinal pigment epithelium, Bruch's membrane and the photoreceptor cells. Finally, we present a hypothesis for the pathogenesis of early AMD and consider the implications of this model on the development of new therapies. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Whitmore, S. Scott; Sohn, Elliott H.; Chirco, Kathleen R.; Drack, Arlene V.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, Iowa City, IA 52242 USA.
   [Whitmore, S. Scott; Sohn, Elliott H.; Chirco, Kathleen R.; Drack, Arlene V.; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, 4130 MERF,375 Newton Rd, Iowa City, IA 52242 USA.
RI Mullins, Robert F/I-6717-2013
OI Tucker, Budd/0000-0003-2178-1742; Sohn, Elliott/0000-0002-3778-9362;
   Stone, Edwin M./0000-0003-3343-4414; Whitmore, S.
   Scott/0000-0003-0161-9625; Drack, Arlene/0000-0002-8195-8426; Mullins,
   Robert/0000-0002-5006-0891; Boldt, H. Culver/0000-0002-7292-2093
FU National Eye Institute [EY-016822, EY-024605]; National Institutes of
   Health grant [1DP2OD007483]; Elmer and Sylvia Sramek Charitable
   Foundation; Martin and Ruth Carver Chair in Ocular Cell Biology;
   NATIONAL EYE INSTITUTE [R01EY024605, R01EY016822] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629]
   Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL
   INSTITUTES OF HEALTH [DP2OD007483] Funding Source: NIH RePORTER
FX Supported in part by the National Eye Institute grants EY-016822 (EMS)
   and EY-024605 (RFM/BAT), the National Institutes of Health grant
   1DP2OD007483 (BAT), the Elmer and Sylvia Sramek Charitable Foundation,
   and the Martin and Ruth Carver Chair in Ocular Cell Biology.
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Allende A, 2006, BRIT J OPHTHALMOL, V90, P1046, DOI 10.1136/bjo.2006.092080
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   AMES A, 1992, CAN J PHYSIOL PHARM, V70, pS158, DOI 10.1139/y92-257
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Arora KS, 2012, INVEST OPHTH VIS SCI, V53, P6393, DOI 10.1167/iovs.12-10224
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biesemeier A., 2014, NEUROBIOL A IN PRESS, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Birke MT, 2014, GENE THER, V21, P507, DOI 10.1038/gt.2014.24
   Birol G, 2007, AM J PHYSIOL-HEART C, V293, pH1696, DOI 10.1152/ajpheart.00221.2007
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROOKS GA, 1971, AM J PHYSIOL, V220, P1053, DOI 10.1152/ajplegacy.1971.220.4.1053
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, P128, DOI 10.1136/bjophthalmol-2011-300572
   BRUNETTE JR, 1986, DOC OPHTHALMOL, V63, P359
   BURNS MS, 1992, CURR EYE RES, V11, P863, DOI 10.3109/02713689209033484
   Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew E.Y., 2014, OPHTHALMOLOGY
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clow LA, 2004, J EXP BIOL, V207, P2147, DOI 10.1242/jeb.01001
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Degn SE, 2007, IMMUNOBIOLOGY, V212, P301, DOI 10.1016/j.imbio.2006.12.004
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Ducruet AF, 2009, EXP NEUROL, V219, P398, DOI 10.1016/j.expneurol.2009.07.018
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Eklund CM, 2009, ADV CLIN CHEM, V48, P111, DOI 10.1016/S0065-2423(09)48005-3
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Filep JG, 2009, CIRC RES, V105, P109, DOI 10.1161/CIRCRESAHA.109.202010
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fitzgerald MEC, 2005, EXP EYE RES, V81, P478, DOI 10.1016/j.exer.2005.03.008
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Flyvbjerg A, 2010, NAT REV ENDOCRINOL, V6, P94, DOI 10.1038/nrendo.2009.266
   FOLK JC, 1985, OPHTHALMOLOGY, V92, P594
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Forooghian F, 2010, RETINA-J RET VIT DIS, V30, P63, DOI 10.1097/IAE.0b013e3181bd2c5a
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon WC, 2013, CURR EYE RES, V38, P995, DOI 10.3109/02713683.2013.827211
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta OP, 2007, CURR OPIN OPHTHALMOL, V18, P201, DOI 10.1097/ICU.0b013e32810c8df4
   Guymer RH, 2004, INVEST OPHTH VIS SCI, V45, P1660, DOI 10.1167/iovs.03-0913
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hogan M., 1971, ATLAS TXB, V1st
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kay CN, 2012, ARCH OPHTHALMOL-CHIC, V130, P357, DOI 10.1001/archophthalmol.2011.363
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kubista KE, 2011, MOL VIS, V17, P2080
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Langford-Smith A., 2013, J INNATE IMMUN
   Lau JCM, 2012, EXP EYE RES, V102, P50, DOI 10.1016/j.exer.2012.07.004
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Li CY, 2010, BRAIN RES, V1358, P123, DOI 10.1016/j.brainres.2010.08.065
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Liu AH, 2013, J CHROMATOGR A, V1307, P191, DOI 10.1016/j.chroma.2013.07.103
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lozanoska-Ochser B, 2009, CLIN EXP IMMUNOL, V157, P119, DOI 10.1111/j.1365-2249.2009.03940.x
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Lutty GA, 2005, VISION RES, V45, P3504, DOI 10.1016/j.visres.2005.08.022
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MANCINI MA, 1986, INVEST OPHTH VIS SCI, V27, P336
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mao M, 2009, MAMM GENOME, V20, P462, DOI 10.1007/s00335-009-9210-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   May CA, 2004, INVEST OPHTH VIS SCI, V45, P361, DOI 10.1167/iovs.03-0624
   May CA, 2005, CURR EYE RES, V30, P667, DOI 10.1080/02713680590968231
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Melillo D, 2006, J IMMUNOL, V177, P4132, DOI 10.4049/jimmunol.177.6.4132
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins R.F., 2012, RECENT ADV BASIC RES, P49
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nielsen JS, 2008, J CELL SCI, V121, P3683, DOI 10.1242/jcs.037507
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nonaka M, 2004, MOL IMMUNOL, V40, P897, DOI 10.1016/j.molimm.2003.10.009
   Nonaka M, 2006, IMMUNOGENETICS, V58, P701, DOI 10.1007/s00251-006-0142-1
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Otsuji T, 2002, EXP EYE RES, V75, P201, DOI 10.1006/exer.2002.2020
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Parham P, 2012, PLACENTA, V33, pS71, DOI 10.1016/j.placenta.2011.11.020
   PARVER L M, 1991, Eye (London), V5, P181
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pavlov N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/781632
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pinto MR, 2007, ADV EXP MED BIOL, V598, P372
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P9195, DOI 10.1167/iovs.10-6793
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P2976, DOI 10.1167/iovs.10-6232
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rifai N, 2001, CLIN CHEM, V47, P403
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rus H, 2006, AUTOIMMUNITY, V39, P395, DOI 10.1080/08916930600739605
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1979, P 13 INT C KYOT, P228
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schrodl F, 2006, INVEST OPHTH VIS SCI, V47, P3225, DOI 10.1167/iovs.05-1279
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sekine H, 2013, ADV EXP MED BIOL, V735, P41, DOI 10.1007/978-1-4614-4118-2_3
   Sekiyama E, 2012, FASEB J, V26, P567, DOI 10.1096/fj.11-184127
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Slakter J S, 1995, Curr Opin Ophthalmol, V6, P25
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sohn E., 2013, RETINA-J RET VIT DIS, V5th ed, P852
   Sohn E.H., 2014, INVESTIG OPHTHALMOL
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Staurenghi G, 2002, AM J OPHTHALMOL, V133, P801, DOI 10.1016/S0002-9394(02)01436-8
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stewart EA, 2011, EXP EYE RES, V93, P761, DOI 10.1016/j.exer.2011.09.010
   Stitt AW, 2011, PROG RETIN EYE RES, V30, P149, DOI 10.1016/j.preteyeres.2011.02.001
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   SUGITA A, 1982, JPN J OPHTHALMOL, V26, P47
   Takano T, 2013, SEMIN NEPHROL, V33, P586, DOI 10.1016/j.semnephrol.2013.08.009
   Taubes G, 2002, SCIENCE, V296, P242, DOI 10.1126/science.296.5566.242
   Thompson BR, 2010, MOL CELL ENDOCRINOL, V318, P24, DOI 10.1016/j.mce.2009.08.015
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561
   TILTON RG, 1985, INVEST OPHTH VIS SCI, V26, P68
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tucker BA, 2014, HUM MOL GENET, V23, pR9, DOI 10.1093/hmg/ddu124
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tymms Martin J, 1999, Clin Exp Optom, V82, P124
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wallis R, 2010, IMMUNOBIOLOGY, V215, P1, DOI 10.1016/j.imbio.2009.08.006
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2012, EXP EYE RES, V94, P187, DOI 10.1016/j.exer.2011.11.005
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JC, 2012, CIRC RES, V111, P245, DOI 10.1161/CIRCRESAHA.111.261388
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wang MY, 2011, FASEB J, V25, P3186, DOI 10.1096/fj.11-182741
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   Wang SF, 2007, INVEST OPHTH VIS SCI, V48, P1335, DOI 10.1167/iovs.06-0842
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   YU Y, 2014, HUM MOL GENET
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   ZALMAN LS, 1990, MOL IMMUNOL, V27, P533, DOI 10.1016/0161-5890(90)90072-8
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeng FX, 2013, GRAEF ARCH CLIN EXP, V251, P2539, DOI 10.1007/s00417-013-2442-0
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 342
TC 135
Z9 137
U1 0
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2015
VL 45
BP 1
EP 29
DI 10.1016/j.preteyeres.2014.11.005
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD1LL
UT WOS:000350836300001
PM 25486088
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rosner, B
   Qiu, WL
   Lee, MLT
AF Rosner, Bernard
   Qiu, Weiliang
   Lee, Mei-Ling T.
TI Assessing discrimination of risk prediction rules in a clustered data
   setting
SO LIFETIME DATA ANALYSIS
LA English
DT Article
DE Risk prediction; ROC curves; Clustered data; GEE
ID OPERATING CHARACTERISTIC CURVES; RANK-SUM TEST; ROC CURVE; MODELS; AREA
AB The AUC (area under ROC curve) is a commonly used metric to assess discrimination of risk prediction rules; however, standard errors of AUC are usually based on the Mann-Whitney U test that assumes independence of sampling units. For ophthalmologic applications, it is desirable to assess risk prediction rules based on eye-specific outcome variables which are generally highly, but not perfectly correlated in fellow eyes [e.g. progression of individual eyes to age-related macular degeneration (AMD)]. In this article, we use the extended Mann-Whitney U test (Rosner and Glynn, Biometrics 65:188-197, 2009) for the case where subunits within a cluster may have different progression status and assess discrimination of different prediction rules in this setting. Both data analyses based on progression of AMD and simulation studies show reasonable accuracy of this extended Mann-Whitney U test to assess discrimination of eye-specific risk prediction rules.
C1 [Rosner, Bernard; Qiu, Weiliang] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
   [Lee, Mei-Ling T.] Univ Maryland, Dept Epidemiol & Biostat, College Pk, MD 20742 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   University System of Maryland; University of Maryland College Park
RP Rosner, B (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM stbar@channing.harvard.edu
OI Qiu, Weiliang/0000-0002-9155-6957
FU National Institutes of Health from the National Eye Institute [EY12269];
   NATIONAL EYE INSTITUTE [R01EY012269, R01EY022445] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health Grant
   EY12269 from the National Eye Institute.
CR HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   HODGES JL, 1956, ANN MATH STAT, V27, P324, DOI 10.1214/aoms/1177728261
   Kendall M.G., 1969, ADV THEORY STAT
   Li G, 2008, J AM STAT ASSOC, V103, P705, DOI 10.1198/016214508000000364
   National Eye Institute, 2011, AG REL MAC DEG
   Obuchowski NA, 1997, STAT MED, V16, P1529, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1529::AID-SIM565>3.0.CO;2-H
   Obuchowski NA, 2003, RADIOLOGY, V229, P3, DOI 10.1148/radiol.2291010898
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   Rosner B, 2009, BIOMETRICS, V65, P188, DOI 10.1111/j.1541-0420.2008.01062.x
   Rosner B, 2006, BIOMETRICS, V62, P1251, DOI 10.1111/j.1541-0420.2006.00582.x
   Rubin D.B., 1987, MULTIPLE IMPUTATION, P1
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Toledano AY, 1999, BIOMETRICS, V55, P488, DOI 10.1111/j.0006-341X.1999.00488.x
   Zou KH, 2007, CIRCULATION, V115, P654, DOI 10.1161/CIRCULATIONAHA.105.594929
NR 14
TC 2
Z9 2
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-7870
J9 LIFETIME DATA ANAL
JI Lifetime Data Anal.
PD APR
PY 2013
VL 19
IS 2
SI SI
BP 242
EP 256
DI 10.1007/s10985-012-9240-6
PG 15
WC Mathematics, Interdisciplinary Applications; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA 131FR
UT WOS:000317978600006
PM 23263872
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Eljarrat-Binstock, E
   Pe'er, J
   Domb, AJ
AF Eljarrat-Binstock, Esther
   Pe'er, Jacob
   Domb, Abraham J.
TI New Techniques for Drug Delivery to the Posterior Eye Segment
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE drug delivery; Iontophoresis; ocular; posterior segment
ID COULOMB-CONTROLLED IONTOPHORESIS; CORNEAL GRAFT-REJECTION; ANTI-VEGF
   APTAMER; TRANSSCLERAL IONTOPHORESIS; RABBIT EYE; OCULAR DELIVERY;
   TRANSCORNEAL IONTOPHORESIS; INTRAVITREAL DELIVERY; TRANSDERMAL DELIVERY;
   IN-VITRO
AB Ocular drug delivery has become an increasingly important field of research especially when treating posterior segment diseases of the eye, such as age-related macular degeneration, diabetic retinopathy, posterior uveitis and retinitis. These diseases are the leading causes of vision loss in developed countries which require repeated long-term administration of therapeutic agents. New drugs for the medication of the posterior ocular segment have emerged, but most drugs are delivered by repeated intravitreal injections associated with ocular complications. Advances in ocular drug delivery system research are expected to provide new tools for the treatment of the posterior segment diseases, providing improved drug penetration, prolonged action, higher efficacy, improved safety and less invasive administration, resulting in higher patient compliance. This review provides an insight into the recent progress and trends in ocular drug delivery systems for treating posterior eye segment diseases, with an emphasis on transscleral iontophoresis.
C1 [Eljarrat-Binstock, Esther; Domb, Abraham J.] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel.
   [Pe'er, Jacob] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Domb, AJ (通讯作者)，Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel.
EM avid@ekmd.huji.ac.il
OI Domb, Abraham J./0000-0002-2241-7726
CR Ali Y, 2006, ADV DRUG DELIVER REV, V58, P1258, DOI 10.1016/j.addr.2006.07.022
   ALONSO MJ, 1989, C INT TECHN PHARM 5, V1, P77
   Alvarez-Figueroa MJ, 2001, INT J PHARM, V215, P57, DOI 10.1016/S0378-5173(00)00674-8
   Andrieu-Soler C, 2006, MOL VIS, V12, P1098
   Asahara T, 2001, JPN J OPHTHALMOL, V45, P31, DOI 10.1016/S0021-5155(00)00291-4
   Baeyens V, 1997, ADV DRUG DELIVER REV, V28, P335, DOI 10.1016/S0169-409X(97)00088-4
   BANGA AK, 1993, PHARMACEUT RES, V10, P697, DOI 10.1023/A:1018955631835
   BAPATLA KM, 2006, PHARM DOSAGE FORMS D, P357
   BARZA M, 1986, OPHTHALMOLOGY, V93, P133
   BARZA M, 1987, INVEST OPHTH VIS SCI, V28, P1033
   BARZA M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1418
   Behar-Cohen FF, 2002, EXP EYE RES, V74, P51, DOI 10.1006/exer.2001.1098
   Behar-Cohen FF, 2002, INVEST OPHTH VIS SCI, V43, pU504
   BeharCohen FF, 1997, EXP EYE RES, V65, P533, DOI 10.1006/exer.1997.0364
   Bejjani R, 2005, MOL VIS, V11, P124
   Bejjani RA, 2005, CHIMIA, V59, P344, DOI 10.2533/000942905777676281
   Berdugo M, 2003, ANTISENSE NUCLEIC A, V13, P107, DOI 10.1089/108729003321629647
   Binstock EE, 2007, NANOPARTICLES PHARM, P367
   Bochot A, 2002, INVEST OPHTH VIS SCI, V43, P253
   Bochot A, 2000, PROG RETIN EYE RES, V19, P131, DOI 10.1016/S1350-9462(99)00014-2
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BRIDGER MWM, 1982, J MED ENG TECHNOL, V6, P62, DOI 10.3109/03091908209040983
   Bucolo C, 2004, J PHARM PHARMACOL, V56, P841, DOI 10.1211/0022357023835
   Burstein N L, 1985, J Ocul Pharmacol, V1, P363, DOI 10.1089/jop.1985.1.363
   Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012
   Calvo P, 1996, J PHARM PHARMACOL, V48, P1147, DOI 10.1111/j.2042-7158.1996.tb03911.x
   Calvo P, 1996, J PHARM SCI, V85, P530, DOI 10.1021/js950474+
   Calvo P, 1996, PHARMACEUT RES, V13, P311, DOI 10.1023/A:1016015803611
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   CARTER EP, 1984, ARCH DIS CHILD, V59, P919, DOI 10.1136/adc.59.10.919
   Chapon P, 1999, INVEST OPHTH VIS SCI, V40, pS189
   CHASTAIN JE, 2003, OPHTHALMIC DRUG DELI, P59
   Chauvaud D, 2000, INVEST OPHTH VIS SCI, V41, pS79
   Cheng LY, 2000, INVEST OPHTH VIS SCI, V41, P1523
   CHOI TB, 1988, J OCUL PHARMACOL, V4, P153, DOI 10.1089/jop.1988.4.153
   Conway Barbara R, 2008, Recent Pat Drug Deliv Formul, V2, P1, DOI 10.2174/187221108783331410
   Cook G. P., 2006, INVEST OPHTHALMOL VI, V47
   Davies NM, 2000, CLIN EXP PHARMACOL P, V27, P558, DOI 10.1046/j.1440-1681.2000.03288.x
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   DeCou JM, 1999, J PEDIATR SURG, V34, P946, DOI 10.1016/S0022-3468(99)90765-0
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   DIEPOLD R, 1989, GRAEF ARCH CLIN EXP, V227, P188, DOI 10.1007/BF02169795
   Ding SL, 1998, PHARM SCI TECHNOL TO, V1, P328, DOI 10.1016/S1461-5347(98)00087-X
   Dos Santos ALG, 2005, CURR PHARM BIOTECHNO, V6, P7
   Eljarrat-Binstock E, 2005, J CONTROL RELEASE, V106, P386, DOI 10.1016/j.jconrel.2005.05.020
   Eljarrat-Binstock E, 2004, J BIOMAT SCI-POLYM E, V15, P397, DOI 10.1163/156856204323005271
   Eljarrat-Binstock E, 2004, INVEST OPHTH VIS SCI, V45, P2543, DOI 10.1167/iovs.03-1294
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Eljarrat-Binstock E, 2008, J OCUL PHARMACOL TH, V24, P344, DOI 10.1089/jop.2007.0097
   Eljarrat-Binstock E, 2008, J CONTROL RELEASE, V126, P156, DOI 10.1016/j.jconrel.2007.11.016
   Eljarrat-Binstock E, 2008, CURR EYE RES, V33, P269, DOI 10.1080/02713680701871140
   Eljarrat-Binstock E, 2007, CURR EYE RES, V32, P639, DOI 10.1080/02713680701528674
   ELJARRATBINSTOC.E, 2006, ENHANCEMENT DRUG DEL
   ELLIS PP, 1985, OCULAR THERAPEUTICS, P3
   ERLANGER G, 1954, OPHTHALMOLOGICA, V128, P232, DOI 10.1159/000302420
   Fang JY, 1999, INT J PHARM, V180, P137, DOI 10.1016/S0378-5173(98)00287-7
   Fang JY, 2002, J PHARM PHARMACOL, V54, P1329, DOI 10.1211/002235702760345392
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Fischer G. A., 2002, DRUG DELIV TECH, V2, P50
   FITZGERALD P, 1987, J PHARM PHARMACOL, V39, P487, DOI 10.1111/j.2042-7158.1987.tb03428.x
   Frucht-Pery J, 1999, J OCUL PHARMACOL TH, V15, P251, DOI 10.1089/jop.1999.15.251
   Frucht-Pery J, 2004, EXP EYE RES, V78, P745, DOI 10.1016/S0014-4835(03)00215-X
   GANGAROSA LP, 1986, J INFECT DIS, V154, P930, DOI 10.1093/infdis/154.6.930
   GROSSMAN R, 1989, OPHTHALMOLOGY, V96, P724, DOI 10.1016/S0161-6420(89)32832-6
   GROSSMAN RE, 1990, INVEST OPHTH VIS SCI, V31, P909
   Guidetti B., 2008, Current Drug Delivery, V5, P7, DOI 10.2174/156720108783331050
   GURNY R, 1985, Journal of Controlled Release, V2, P353, DOI 10.1016/0168-3659(85)90057-4
   Halhal M, 2004, EXP EYE RES, V78, P751, DOI 10.1016/j.exer.2003.10.017
   Halhal M, 2003, J FR OPHTALMOL, V26, P391
   Hastings M. S., 2004, DRUG DELIVERY TECH, V4, P53
   Hayden BC, 2004, INVEST OPHTH VIS SCI, V45, P3644, DOI 10.1167/iovs.04-0228
   Heller J, 2005, ADV DRUG DELIVER REV, V57, P2053, DOI 10.1016/j.addr.2005.09.007
   HIGUCHI JW, 2007, INVEST OPHTHALMOL VI, V48
   HIGUCHI W, 2006, INVEST OPHTHALMOL VI, V47
   HILL JM, 1978, INVEST OPHTH VIS SCI, V17, P473
   HOBDEN JA, 1989, CURR EYE RES, V8, P1163, DOI 10.3109/02713688909000041
   HOBDEN JA, 1990, INVEST OPHTH VIS SCI, V31, P1940
   Horwath-Winter J, 2005, BRIT J OPHTHALMOL, V89, P40, DOI 10.1136/bjo.2004.048314
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   HUGHES L, 1984, Archives of Ophthalmology, V102, P1825
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jarrat-Binstock E, 2007, POLYM ADVAN TECHNOL, V18, P720, DOI 10.1002/pat.948
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   KASTING GB, 1992, ADV DRUG DELIVER REV, V9, P177, DOI 10.1016/0169-409X(92)90023-J
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kishida A., 2001, POLYM BIOMATERIALS, P133
   KONDO M, 1989, INVEST OPHTH VIS SCI, V30, P583
   Kothuri M.K., 2003, OPHTHALMIC DRUG DELI, P437
   Kralinger MT, 2003, OPHTHALMIC RES, V35, P102, DOI 10.1159/000069129
   KRAUSER JT, 1986, J PROSTHET DENT, V56, P307, DOI 10.1016/0022-3913(86)90009-0
   Kreuter J., 1990, BIOADHESIVE DRUG DEL, P203
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   LAM TT, 1989, ARCH OPHTHALMOL-CHIC, V107, P1368, DOI 10.1001/archopht.1989.01070020438050
   LAM TT, 1994, J OCUL PHARMACOL, V10, P571, DOI 10.1089/jop.1994.10.571
   LAM TT, 1991, GRAEF ARCH CLIN EXP, V229, P389, DOI 10.1007/BF00170699
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   LeBourlais CA, 1997, J MICROENCAPSUL, V14, P457, DOI 10.3109/02652049709033830
   Lee TWY, 2001, J OCUL PHARMACOL TH, V17, P565, DOI 10.1089/10807680152729257
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   LOSA C, 1991, J PHARM PHARMACOL, V43, P548, DOI 10.1111/j.2042-7158.1991.tb03534.x
   Mainardes RM, 2005, CURR DRUG TARGETS, V6, P363, DOI 10.2174/1389450053765914
   Marchal-Heussler L., 1992, STP PHARMA SCI, V2, P98
   Merodio M, 2002, BIOMATERIALS, V23, P1587, DOI 10.1016/S0142-9612(01)00284-8
   Mitra, 1993, OPHTHALMIC DRUG DELI, P29
   Mitra AK., 2005, ADV ORGAN BIOL, V10, P307
   Molokhia S, 2008, J PHARM SCI-US, V97, P831, DOI 10.1002/jps.21003
   Moppett IK, 2004, EUR J ANAESTH, V21, P210, DOI 10.1017/S0265021504003084
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Myles ME, 2003, OPHTHALMIC DRUG DELI, P365
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Paasonen L, 2007, J CONTROL RELEASE, V122, P86, DOI 10.1016/j.jconrel.2007.06.009
   PAPANGKORN K, 2007, INVEST OPHTHALMOL VI, V48
   Parkinson TM, 2000, INVEST OPHTH VIS SCI, V41, pS772
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   PEYMAN GA, 1992, INT OPHTHALMOL, V16, P109, DOI 10.1007/BF00918942
   Pignatello R, 2002, EUR J PHARM SCI, V16, P53, DOI 10.1016/S0928-0987(02)00057-X
   Pikal MJ, 2001, ADV DRUG DELIVER REV, V46, P281, DOI 10.1016/S0169-409X(00)00138-1
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Pitkanen Leena, 2004, AAPS J, V6, pe25
   Rabinovich-Guilatt L, 2004, J DRUG TARGET, V12, P623, DOI 10.1080/10611860400015910
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   RIGANO W, 1992, Journal of Burn Care and Rehabilitation, V13, P407, DOI 10.1097/00004630-199207000-00004
   ROOTMAN DS, 1988, INVEST OPHTH VIS SCI, V29, P1397
   ROOTMAN DS, 1988, ARCH OPHTHALMOL-CHIC, V106, P262
   Ruiz-Moreno JM, 2006, ACTA OPHTHALMOL SCAN, V84, P743, DOI 10.1111/j.1600-0420.2006.00691.x
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   SARRAF D, 1993, AM J OPHTHALMOL, V115, P748, DOI 10.1016/S0002-9394(14)73642-6
   Sasaki H, 1999, CRIT REV THER DRUG, V16, P85
   SCHOENWALD RD, 1990, CLIN PHARMACOKINET, V18, P255, DOI 10.2165/00003088-199018040-00001
   Souied EH, 2008, EXP EYE RES, V87, P168, DOI 10.1016/j.exer.2008.04.009
   Sultana Yasmin, 2006, Current Drug Delivery, V3, P207, DOI 10.2174/156720106776359186
   TUITUPOU AL, 2007, INVEST OPHTHALMOL VI, V48
   Vandervoort J, 2004, EUR J PHARM BIOPHARM, V57, P251, DOI 10.1016/s0939-6411(03)00187-5
   Voigt M, 2002, BIOCHEM BIOPH RES CO, V295, P336, DOI 10.1016/S0006-291X(02)00656-3
   Voigt M, 2002, INVEST OPHTH VIS SCI, V43, P3299
   Vollmer DL, 2002, J OCUL PHARMACOL TH, V18, P549, DOI 10.1089/108076802321021090
   Weijtens O, 2002, OPHTHALMOLOGY, V109, P1887, DOI 10.1016/S0161-6420(02)01176-4
   Weijtens O, 1999, AM J OPHTHALMOL, V128, P192, DOI 10.1016/S0002-9394(99)00129-4
   Wirtz R., 1908, KLIN MONATSBL AUGENH, V46, P543
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yoshizumi MO, 1996, AM J OPHTHALMOL, V122, P86, DOI 10.1016/S0002-9394(14)71967-1
   YOSHIZUMI MO, 1991, J OCUL PHARMACOL, V7, P163, DOI 10.1089/jop.1991.7.163
   YOSHIZUMI MO, 1995, J OCUL PHARMACOL TH, V11, P183, DOI 10.1089/jop.1995.11.183
   Zempsky WT, 2004, CLIN THER, V26, P1110, DOI 10.1016/S0149-2918(04)90183-X
   ZIMMER AK, 1995, J CONTROL RELEASE, V33, P31, DOI 10.1016/0168-3659(94)00059-4
NR 153
TC 103
Z9 107
U1 0
U2 57
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD APR
PY 2010
VL 27
IS 4
BP 530
EP 543
DI 10.1007/s11095-009-0042-9
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 568WN
UT WOS:000275556000003
PM 20155388
DA 2022-11-30
ER

PT J
AU Hussain, AA
   Rowe, L
   Marshall, J
AF Hussain, AA
   Rowe, L
   Marshall, J
TI Age-related alterations in the diffusional transport of amino acids
   across the human Bruch's-choroid complex
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; TAURINE DEFICIENCY; MEMBRANE; DEGENERATION;
   PERMEABILITY; METABOLISM; SITE; GABA
AB Photoreceptor maintenance is dependent on effective delivery of nutrients from the choroidal circulation by way of the acellular Bruch's membrane and the retinal pigment epithelium. Aging of Bruch's membrane is associated with thickening, increased cross linking of fibers, and deposition of debris culminating in reduced porosity. The present study has investigated the effects of aging on the diffusional transport of eight amino acids across Bruch's membrane in 19 human donors. Diffusion studies were carried out in Ussing chambers, and the amount of time-dependent transfer of amino acids across the preparation was quantified by reverse-phase high-performance liquid chromatography. Diffusion rates for all amino acids showed a significant linear decline with aging of donor. The importance of this reduction in delivery of amino acids is discussed with reference to both normal physiology and age-related macular degeneration. (C) 2002 Optical Society of America.
C1 Kings Coll London, Guys Kings & St Thomas Hosp Med & Dent Sch, Dept Ophthalmol, London, England.
C3 University of London; King's College London
RP Hussain, AA (通讯作者)，St Thomas Hosp, Rayne Inst, GKT Med & Dent Sch, Dept Ophthalmol, Lambeth Palace Rd, London SE1 7EH, England.
EM alyhussain@aol.com
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   ALDER VA, 1983, INVEST OPHTH VIS SCI, V24, P30
   Antcliff RJ, 1999, INVEST OPHTH VIS SCI, V40, pS973
   Bean C P, 1972, Membranes, V1, P1
   BECK RE, 1972, BIOCHIM BIOPHYS ACTA, V255, P273, DOI 10.1016/0005-2736(72)90028-4
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BURNS MS, 1986, PROG RETIN RES, V5, P253
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   CUNHAVAZ JG, 1966, BRIT J OPHTHALMOL, V50, P441, DOI 10.1136/bjo.50.8.441
   CURRY FE, 1980, MICROVASC RES, V20, P96, DOI 10.1016/0026-2862(80)90024-2
   FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HAYES KC, 1975, SCIENCE, V188, P949, DOI 10.1126/science.1138364
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HUSSAIN AA, 1990, THESIS U LONDON LOND, P75
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kundaiker S, 1996, J PHYSIOL-LONDON, V492, P505, DOI 10.1113/jphysiol.1996.sp021325
   Landis EM., 1963, HDB PHYSIOLOGY     2, V2, P961
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MCMENAMY RH, 1957, J CLIN INVEST, V36, P1672, DOI 10.1172/JCI103568
   MICHEL CC, 1978, ARCH INT PHYSIOL BIO, V86, P657, DOI 10.3109/13813457809055934
   MICHEL CC, 1980, J PHYSIOL-LONDON, V309, P341, DOI 10.1113/jphysiol.1980.sp013512
   MILLER S, 1976, EXP EYE RES, V23, P177, DOI 10.1016/0014-4835(76)90201-3
   MIYAMOTO Y, 1994, INVEST OPHTH VIS SCI, V35, P3589
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   NEAL MJ, 1989, BRIT J PHARMACOL, V98, P105, DOI 10.1111/j.1476-5381.1989.tb16869.x
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAPPENHEIMER JR, 1953, PHYSIOL REV, V33, P387, DOI 10.1152/physrev.1953.33.3.387
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAUTLER EL, 1986, EXP EYE RES, V43, P207, DOI 10.1016/S0014-4835(86)80088-4
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RENKIN EM, 1954, J GEN PHYSIOL, V38, P225
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHMIDT SY, 1977, INVEST OPHTH VIS SCI, V16, P673
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SIVAKAMI S, 1992, BIOCHEM J, V283, P391, DOI 10.1042/bj2830391
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307
   To CH, 1998, COMP BIOCHEM PHYS A, V121, P441, DOI 10.1016/S1095-6433(98)10156-3
   TSUBOI S, 1988, INVEST OPHTH VIS SCI, V29, P1652
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Waagepetersen HS, 1999, J NEUROSCI RES, V57, P342, DOI 10.1002/(SICI)1097-4547(19990801)57:3<342::AID-JNR6>3.0.CO;2-X
   WENDT RP, 1979, J MEMBRANE SCI, V5, P23, DOI 10.1016/S0376-7388(00)80436-6
   WESTERGAARD N, 1995, DEV NEUROSCI-BASEL, V17, P203, DOI 10.1159/000111288
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 48
TC 53
Z9 55
U1 0
U2 1
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD JAN
PY 2002
VL 19
IS 1
BP 166
EP 172
DI 10.1364/JOSAA.19.000166
PG 7
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 505TA
UT WOS:000172930600024
PM 11778720
DA 2022-11-30
ER

PT J
AU Courtaut, F
   Scagliarini, A
   Aires, V
   Cornebise, C
   de Barros, JPP
   Olmiere, C
   Delmas, D
AF Courtaut, Flavie
   Scagliarini, Alessandra
   Aires, Virginie
   Cornebise, Clarisse
   de Barros, Jean-Paul Pais
   Olmiere, Celine
   Delmas, Dominique
TI VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A
   Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an
   Omega-3/Polyphenol Combination
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; angiogenesis; ocular diseases; VEGF; VEGF-receptor; omega-3 fatty
   acids; resveratrol
ID ENDOTHELIAL GROWTH-FACTOR; OCULAR NEOVASCULARIZATION; MACULAR
   DEGENERATION; SIGNAL-TRANSDUCTION; TUMOR-GROWTH; C-JUN; RESVERATROL;
   CAVEOLIN-1; PHOSPHORYLATION; ANGIOGENESIS
AB Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 retinal cells, a disruption of the VEGF receptors (VEGF-R)/caveolin-1 (Cav-1)/protein kinases pathway could be a target for counteracting VEGF secretion. We highlight that Resvega(R), a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation. Moreover, DNA ChIP analysis reveals that this combination prevents the interaction between AP-1 and vegf-a and vegf-r2 gene promoters. By these pathways, Resvega could present a potential interest as nutritional complementation against AMD.
C1 [Courtaut, Flavie; Scagliarini, Alessandra; Aires, Virginie; Cornebise, Clarisse; de Barros, Jean-Paul Pais; Delmas, Dominique] Univ Bourgogne Franche Comte, F-21000 Dijon, France.
   [Courtaut, Flavie; Scagliarini, Alessandra; Aires, Virginie; Cornebise, Clarisse; de Barros, Jean-Paul Pais; Delmas, Dominique] INSERM Res Ctr U1231, Bioact Mol & Hlth Res Grp, Canc & Adapt Immune Response Team, F-21000 Dijon, France.
   [de Barros, Jean-Paul Pais] Lipid Analyt Platform, F-21000 Dijon, France.
   [Olmiere, Celine] Labs Thea, 12 Rue Louis Bleriot, F-63000 Clermont Ferrand, France.
   [Delmas, Dominique] Ctr Anticancereux Georges Francois Leclerc Ctr, F-21000 Dijon, France.
C3 Institut Agro; AgroSup Dijon; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bourgogne; Institut Agro;
   AgroSup Dijon; Universite de Bourgogne
RP Delmas, D (通讯作者)，Univ Bourgogne Franche Comte, F-21000 Dijon, France.; Delmas, D (通讯作者)，INSERM Res Ctr U1231, Bioact Mol & Hlth Res Grp, Canc & Adapt Immune Response Team, F-21000 Dijon, France.; Delmas, D (通讯作者)，Ctr Anticancereux Georges Francois Leclerc Ctr, F-21000 Dijon, France.
EM flavie.courtaut@gmail.com; alescaglia@gmail.com;
   virginie.aires02@u-bourgogne.fr; clarisse.cornebise@gmail.com;
   jppais@u-bourgogne.fr; celine.olmiere@theaopeninnovation.com;
   dominique.delmas@u-bourgogne.fr
OI CORNEBISE, Clarisse/0000-0003-0038-3809; PAIS DE BARROS,
   Jean-Paul/0000-0002-5124-2283; Delmas, Dominique/0000-0002-8911-8499
FU ANRT [2016/0003]; French Government grant [ANR-11-LABX-0021]; Conseil
   Regional Bourgogne, Franche-Comte (PARI grant); FEDER (European Funding
   for Regional Economic Development)
FX This work was supported by grants from the ANRT No 2016/0003, by a
   French Government grant managed by the French National Research Agency
   under the program "Investissements d'Avenir", reference
   ANR-11-LABX-0021, the Conseil Regional Bourgogne, Franche-Comte (PARI
   grant) and the FEDER (European Funding for Regional Economic
   Development).
CR Abhinand CS, 2016, J CELL COMMUN SIGNAL, V10, P347, DOI 10.1007/s12079-016-0352-8
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Bhattarai N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010067
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Blondelle J, 2017, METHODS MOL BIOL, V1668, P39, DOI 10.1007/978-1-4939-7283-8_4
   Caliceti C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/857504
   Cao YH, 2002, J NUTR BIOCHEM, V13, P380, DOI 10.1016/S0955-2863(02)00204-8
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098
   Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331
   Delmas D, 2011, CURR MED CHEM, V18, P1100, DOI 10.2174/092986711795029708
   Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Ghiringhelli F, 2012, ANTI-CANCER AGENT ME, V12, P852, DOI 10.2174/187152012802650048
   Gu XW, 2014, ADV EXP MED BIOL, V801, P15, DOI 10.1007/978-1-4614-3209-8_3
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   Jia J, 2016, MICROVASC RES, V105, P103, DOI 10.1016/j.mvr.2016.02.004
   Jiang YD, 2017, P NATL ACAD SCI USA, V114, P10737, DOI 10.1073/pnas.1706394114
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kimura Y, 2001, J NUTR, V131, P1844, DOI 10.1093/jn/131.6.1844
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Limagne E, 2017, CELL REP, V19, P746, DOI 10.1016/j.celrep.2017.04.004
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Matsumoto T, 2006, J ATHEROSCLER THROMB, V13, P130, DOI 10.5551/jat.13.130
   Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mora RC, 2006, AM J PHYSIOL-CELL PH, V290, pC832, DOI 10.1152/ajpcell.00405.2005
   Morais C, 2012, AM J PATHOL, V180, P1702, DOI 10.1016/j.ajpath.2011.12.018
   Olmiere C, 2013, ACTA OPHTHALMOL, V91, DOI 10.1111/j.1755-3768.2013.F015.x
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Seong H, 2015, MOL MED REP, V12, P1479, DOI 10.3892/mmr.2015.3518
   SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0
   Song M, 2018, BMC SYST BIOL, V12, DOI 10.1186/s12918-018-0668-5
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tahir AA, 2009, CANCER BIOL THER, V8, P2286
   Wu HY, 2018, CLIN EXP PHARMACOL P, V45, P1265, DOI 10.1111/1440-1681.13017
   Yu HB, 2010, HEPATO-GASTROENTEROL, V57, P1241
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
NR 51
TC 4
Z9 4
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 12
AR 6590
DI 10.3390/ijms22126590
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SY8WF
UT WOS:000666160600001
PM 34205419
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Agrawal, R
   Balne, PK
   Tun, SBB
   Wey, YS
   Khandelwal, N
   Barathi, VA
AF Agrawal, Rupesh
   Balne, Praveen Kumar
   Tun, Sai Bo Bo
   Wey, Yeo Sia
   Khandelwal, Neha
   Barathi, Veluchamy A.
TI Fluorescent Dye Labeling of Erythrocytes and Leukocytes for Studying the
   Flow Dynamics in Mouse Retinal Circulation
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 125; Indocyanine green; sodium fluorescein;
   erythrocytes; leukocytes; blood flow dynamics; fluorescently labeled
   blood cells
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW;
   IN-VIVO; LYMPHOCYTE MIGRATION; RHODAMINE ISOTHIOCYANATE; CHOROIDAL
   CIRCULATION; POTENTIAL APPLICATION; DIABETIC-RETINOPATHY; CELLULAR
   FUNCTION
AB The retinal and choroidal blood flow dynamics may provide insight into the pathophysiology and sequelae of various ocular diseases, such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD) and other ocular inflammatory conditions. It may also help to monitor the therapeutic responses in the eye. The proper labeling of the blood cells, coupled with live-cell imaging of the labeled cells, allows for the investigation of the flow dynamics in the retinal and choroidal circulation. Here, we describe the standardized protocols of 1.5% indocyanine green (ICG) and 1% sodium fluorescein labeling of mice erythrocytes and leukocytes, respectively. Scanning laser ophthalmoscopy (SLO) was applied to visualize the labeled cells in the retinal circulation of C57BL/6J mice (wild type). Both methods demonstrated distinct fluorescently labeled cells in the mouse retinal circulation. These labeling methods can have wider applications in various ocular disease models.
C1 [Agrawal, Rupesh; Khandelwal, Neha] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Agrawal, Rupesh; Balne, Praveen Kumar; Tun, Sai Bo Bo; Wey, Yeo Sia; Barathi, Veluchamy A.] Singapore Natl Eye Ctr, SERI, Singapore, Singapore.
   [Agrawal, Rupesh] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore.
   [Barathi, Veluchamy A.] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Barathi, Veluchamy A.] DUKE NUS Grad Med Sch, Ophthalmol Acad Clin Res Program, Singapore, Singapore.
C3 Tan Tock Seng Hospital; Singapore National Eye Center; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; National University of
   Singapore; National University of Singapore
RP Agrawal, R (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.; Agrawal, R; Barathi, VA (通讯作者)，Singapore Natl Eye Ctr, SERI, Singapore, Singapore.; Agrawal, R (通讯作者)，Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore.; Barathi, VA (通讯作者)，Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.; Barathi, VA (通讯作者)，DUKE NUS Grad Med Sch, Ophthalmol Acad Clin Res Program, Singapore, Singapore.
EM rupesh_agrawal@ttsh.com.sg; amutha.b.veluchamy@seri.com.sg
RI Tun, Sai Bo Bo/GRF-2470-2022; TUN, SAI BO BO/O-1085-2018; Balne, Praveen
   Kumar/X-7075-2019
OI TUN, SAI BO BO/0000-0002-2013-8379; Balne, Praveen
   Kumar/0000-0001-8365-9991
FU National Medical Research Council (NMRC), Singapore
FX The research project was funded under New Investigator grant from the
   National Medical Research Council (NMRC), Singapore. The team will like
   to acknowledge the research training provided to Dr Agrawal at Institute
   of Ophthalmology (IoO), University College London (UCL) under National
   Medical Research Council (NMRC) Overseas Research Training Fellowship
   from November 2012 till October 2014 under mentorship of Prof. David
   Shima. Dr. Agrawal acquired the concept and skills for labelling the
   cells and live imaging in Dr. Shima's lab. The team will hence like to
   acknowledge supervision and guidance during the training fellowship from
   Prof. David Shima, Pro. f Kenith Meissner, Dr. Peter Lundh and Dr. Daiju
   Iwata.
CR Albertine KH, 1996, J LEUKOCYTE BIOL, V59, P631, DOI 10.1002/jlb.59.5.631
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Beem E, 2013, J FLUORESC, V23, P975, DOI 10.1007/s10895-013-1224-8
   BRENAN M, 1984, J IMMUNOL METHODS, V74, P31, DOI 10.1016/0022-1759(84)90364-8
   BUTCHER EC, 1980, J IMMUNOL METHODS, V37, P109, DOI 10.1016/0022-1759(80)90196-9
   BUTCHER EC, 1980, J IMMUNOL METHODS, V37, P97, DOI 10.1016/0022-1759(80)90195-7
   Chiba K, 1998, J IMMUNOL, V160, P5037
   Clermont AC, 1997, AM J OPHTHALMOL, V124, P433, DOI 10.1016/S0002-9394(14)70860-8
   DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0
   FILLACIER K, 1995, CURR EYE RES, V14, P579, DOI 10.3109/02713689508998405
   Ford W. L., 1978, HDB EXPT IMMUNOLOGY, V3
   Nguyen HT, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0105-y
   Horan P K, 1990, Methods Cell Biol, V33, P469
   Hossain P, 1998, INVEST OPHTH VIS SCI, V39, P1879
   Johnsson C, 1997, SCAND J IMMUNOL, V45, P511, DOI 10.1046/j.1365-3083.1997.d01-430.x
   KHALAF AN, 1993, J IMMUNOL METHODS, V165, P121, DOI 10.1016/0022-1759(93)90113-L
   Khoobehi B, 1999, OPHTHALMIC SURG LAS, V30, P140
   KHOOBEHI B, 1994, OPHTHALMOLOGY, V101, P1716
   Kim J, 1997, OPHTHALMIC RES, V29, P374, DOI 10.1159/000268038
   Kornfield TE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0005-15.2015
   Kornfield TE, 2014, J NEUROSCI, V34, P11504, DOI 10.1523/JNEUROSCI.1971-14.2014
   LeGargasson JF, 1997, GRAEF ARCH CLIN EXP, V235, P56, DOI 10.1007/BF01007838
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4
   MANIVANNAN A, 1993, PHYSIOL MEAS, V14, P43, DOI 10.1088/0967-3334/14/1/006
   Matsuda N., INVEST OPHTHALMOL VI, V37, P2228
   MOLNAR J, 1993, ANTICANCER RES, V13, P263
   Nakano Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159650
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okanouchi T, 2003, JPN J OPHTHALMOL, V47, P572, DOI 10.1016/S0021-5155(03)00147-3
   Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x
   RANNIE GH, 1977, CLIN EXP IMMUNOL, V29, P509
   SAMLOWSKI WE, 1991, J IMMUNOL METHODS, V144, P101, DOI 10.1016/0022-1759(91)90236-9
   Schumann J, 2000, AM J OPHTHALMOL, V129, P728, DOI 10.1016/S0002-9394(99)00481-X
   Sharp PF, 2004, PHYS MED BIOL, V49, P1085, DOI 10.1088/0031-9155/49/7/001
   SLEZAK SE, 1989, BLOOD, V74, P2172
   Srinivas S, 2015, INVEST OPHTH VIS SCI, V56, P1569, DOI 10.1167/iovs.14-15038
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   TEARE GF, 1991, CELL IMMUNOL, V134, P157, DOI 10.1016/0008-8749(91)90339-D
   Turksever C, 2015, ACTA OPHTHALMOL, V93, pE439, DOI 10.1111/aos.12598
   UNTHANK JL, 1993, MICROVASC RES, V45, P193, DOI 10.1006/mvre.1993.1018
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   Wang YM, 2009, OPT EXPRESS, V17, P4061, DOI 10.1364/OE.17.004061
   WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M
   Yang Y, 1997, GRAEF ARCH CLIN EXP, V235, P27, DOI 10.1007/BF01007834
   Yang YS, 1997, OPHTHALMOLOGY, V104, P1670, DOI 10.1016/S0161-6420(97)30080-3
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x
NR 47
TC 5
Z9 5
U1 1
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2017
IS 125
AR e55495
DI 10.3791/55495
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD3TS
UT WOS:000407455900014
PM 28715402
OA Green Published
DA 2022-11-30
ER

PT J
AU Peng, YQ
   Tang, LS
   Zhou, YD
AF Peng, Yingqian
   Tang, Luosheng
   Zhou, Yedi
TI Subretinal Injection: A Review on the Novel Route of Therapeutic
   Delivery for Vitreoretinal Diseases
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Subretinal injection; Drug delivery; Intravitreal injection;
   Vitreoretinal disease
ID RETINAL-PIGMENT EPITHELIUM; LEBER CONGENITAL AMAUROSIS; ENDOTHELIAL
   GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; ANTI-VEGF AGENTS; GENE-THERAPY;
   ADENOASSOCIATED VIRUS; CHOROIDAL NEOVASCULARIZATION; PROGENITOR CELLS;
   MACULAR DEGENERATION
AB Compared to intravitreal injection, subretinal injection has more direct effects on the targeting cells in the subretinal space, which provides a new therapeutic method for vitreoretinal diseases, especially when gene therapy and/or cell therapy is involved. To date, subretinal delivery has been widely applied by scientists and clinicians as a more precise and efficient route of ocular drug delivery for gene therapies and cell therapies including stem cells in many degenerative vitreoretinal diseases, such as retinitis pigmentosa, age-related macular degeneration, and Leber's congenital amaurosis. However, clinicians should be aware of adverse events and possible complications when performing subretinal delivery. In the present review, the subretinal injection used in vitreoretinal diseases for basic research and clinical trials is summarized and described. Different methods of subretinal delivery, as well as its benefits and challenges, are also briefly introduced. (C) 2017 S. Karger AG, Basel
C1 [Peng, Yingqian; Tang, Luosheng; Zhou, Yedi] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Zhou, YD (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM zhouyedi@csu.edu.cn
OI Zhou, Yedi/0000-0002-8948-1108; Peng, Yingqian/0000-0003-4778-0713
FU National Natural Science Foundation of China [81371036]
FX This review article was supported in part by the National Natural
   Science Foundation of China (No. 81371036)
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Amado D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000659
   Amirpour N, 2012, STEM CELLS DEV, V21, P42, DOI 10.1089/scd.2011.0073
   Annear MJ, 2013, HUM GENE THER, V24, P883, DOI 10.1089/hum.2013.146
   Ausayakhun Somsanguan, 2005, Journal of the Medical Association of Thailand, V88, pS15
   Bainbridge JWB, 2006, GENE THER, V13, P1191, DOI 10.1038/sj.gt.3302812
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Barker SE, 2009, J GENE MED, V11, P486, DOI 10.1002/jgm.1327
   Bek T, 2016, INVEST OPHTH VIS SCI, V57, P5429, DOI 10.1167/iovs.16-20305
   Bindewald A, 2004, OPHTHALMOLOGE, V101, P886, DOI 10.1007/s00347-004-1077-2
   Bloquel C, 2006, ADV DRUG DELIVER REV, V58, P1224, DOI 10.1016/j.addr.2006.07.023
   Bollinger KE, 2009, CURR OPIN OPHTHALMOL, V20, P99, DOI 10.1097/ICU.0b013e32831d7f3a
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chatziralli I, 2015, EXPERT OPIN BIOL TH, V15, DOI 10.1517/14712598.2015.1086744
   Chen SN, 2015, RETINA-J RET VIT DIS, V35, P667, DOI 10.1097/IAE.0000000000000380
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   Conlon TJ, 2013, HUM GENE THER CL DEV, V24, P23, DOI 10.1089/humc.2013.037
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dai XF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156542
   Day TP, 2014, ADV EXP MED BIOL, V801, P687, DOI 10.1007/978-1-4614-3209-8_86
   De Silva S, 2016, GENE THER, V23, P767, DOI 10.1038/gt.2016.54
   Ehlers JP, 2015, OSLI RETINA, V46, P327, DOI 10.3928/23258160-20150323-05
   Emre E, 2015, CYTOTHERAPY, V17, P543, DOI 10.1016/j.jcyt.2014.12.005
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fernandes RAB, 2016, OSLI RETINA, V47, P342, DOI 10.3928/23258160-20160324-07
   Fitzgerald JT, 2015, CLIN EXP OPHTHALMOL, V43, P234, DOI 10.1111/ceo.12433
   Flachsbarth K, 2014, INVEST OPHTH VIS SCI, V55, P7029, DOI 10.1167/iovs.14-15266
   Francis PJ, 2009, INVEST OPHTH VIS SCI, V50, P3425, DOI 10.1167/iovs.08-2908
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Georgiadis A, 2016, GENE THER, V23, P857, DOI 10.1038/gt.2016.66
   Gerding H, 2007, J NEURAL ENG, V4, pS30, DOI 10.1088/1741-2560/4/1/S05
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Giocanti-Auregan A, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0317-y
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Gunther J, 2009, CURR DIABETES REP, V9, P272, DOI 10.1007/s11892-009-0042-5
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang Qian, 2006, Zhonghua Yan Ke Za Zhi, V42, P127
   Huang R, 2014, MOL VIS, V20, P1271
   Hwang DJ, 2012, J KOREAN MED SCI, V27, P1580, DOI 10.3346/jkms.2012.27.12.1580
   Ikeda Y, 2009, HUM GENE THER, V20, P573, DOI 10.1089/hum.2009.009
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Johnson CJ, 2008, MOL VIS, V14, P2211
   Jonas JB, 2008, EUR J OPHTHALMOL, V18, P834, DOI 10.1177/112067210801800531
   Jones MK, 2016, MOL VIS, V22, P472
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanchanaranya Navapol, 2015, Journal of the Medical Association of Thailand, V98, P489
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Kolstad KD, 2010, HUM GENE THER, V21, P571, DOI 10.1089/hum.2009.194
   Komaromy AM, 2006, CELL TRANSPLANT, V15, P511, DOI 10.3727/000000006783981701
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kuhicka-Trzaska Agnieszka, 2015, Klin Oczna, V117, P35
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lambert NG, 2016, EXP EYE RES, V145, P248, DOI 10.1016/j.exer.2016.01.009
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Li FL, 2015, EXP EYE RES, V136, P78, DOI 10.1016/j.exer.2015.05.004
   Li QH, 2008, MOL VIS, V14, P1760
   Li WS, 2009, MOL VIS, V15, P267
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Logan Sarah A, 2016, Int Ophthalmol Clin, V56, P127, DOI 10.1097/IIO.0000000000000132
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Maia M, 2004, RETINA-J RET VIT DIS, V24, P80, DOI 10.1097/00006982-200402000-00012
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Muhlfriedel Regine, 2013, Methods Mol Biol, V935, P343, DOI 10.1007/978-1-62703-080-9_24
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nickerson John M, 2012, Methods Mol Biol, V884, P53, DOI 10.1007/978-1-61779-848-1_4
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Parikh S, 2016, JOVE-J VIS EXP, DOI 10.3791/54808
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Peng YT, 2014, CURR STEM CELL RES T, V9, P124, DOI 10.2174/1574888X09666131219115125
   PFEFFER B, 1983, J CELL PHYSIOL, V117, P333, DOI 10.1002/jcp.1041170308
   Qi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136523
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seo S, 2013, INVEST OPHTH VIS SCI, V54, P6118, DOI 10.1167/iovs.13-11673
   Shao JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048127
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Smith AJ, 2012, GENE THER, V19, P154, DOI 10.1038/gt.2011.161
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stout JT, 2011, HUM GENE THER, V22, P531, DOI 10.1089/hum.2011.060
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Tian LC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019542
   Timmers A, 2001, MOL VIS, V7, P131
   Tracy CJ, 2016, EXP EYE RES, V152, P77, DOI 10.1016/j.exer.2016.09.003
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Vujosevic S, 2017, ACTA OPHTHALMOL, V95, P464, DOI 10.1111/aos.13294
   Watanabe S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054146
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Wert KJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4286
   Wert KJ, 2013, HUM MOL GENET, V22, P558, DOI 10.1093/hmg/dds466
   Wojciechowski AB, 2002, STEM CELLS, V20, P163, DOI 10.1634/stemcells.20-2-163
   Wu LD, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-15
   Xu H, 2014, INVEST OPHTH VIS SCI, V55, P1519, DOI 10.1167/iovs.13-13155
   Yan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045659
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yavuz B, 2017, HANDB EXP PHARMACOL, V242, P57, DOI 10.1007/164_2016_84
NR 113
TC 75
Z9 78
U1 3
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 4
BP 217
EP 226
DI 10.1159/000479157
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL1FD
UT WOS:000413959100005
PM 28858866
OA Bronze
DA 2022-11-30
ER

PT J
AU Chung, YG
   Matoba, S
   Liu, YT
   Eum, JH
   Lu, FL
   Jiang, W
   Lee, JE
   Sepilian, V
   Cha, KY
   Lee, DR
   Zhang, Y
AF Chung, Young Gie
   Matoba, Shogo
   Liu, Yuting
   Eum, Jin Hee
   Lu, Falong
   Jiang, Wei
   Lee, Jeoung Eun
   Sepilian, Vicken
   Cha, Kwang Yul
   Lee, Dong Ryul
   Zhang, Yi
TI Histone Demethylase Expression Enhances Human Somatic Cell Nuclear
   Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells
SO CELL STEM CELL
LA English
DT Article
ID IMPLANTATION; PREGNANCY; EMBRYOS; RATES
AB The extremely low efficiency of human embryonic stem cell (hESC) derivation using somatic cell nuclear transfer (SCNT) limits its potential application. Blastocyst formation from human SCNT embryos occurs at a low rate and with only some oocyte donors. We previously showed in mice that reduction of histone H3 lysine 9 trimethylation (H3K9me3) through ectopic expression of the H3K9me3 demethylase Kdm4d greatly improves SCNT embryo development. Here we show that overexpression of a related H3K9me3 demethylase KDM4A improves human SCNT, and that, as in mice, H3K9me3 in the human somatic cell genome is an SCNT reprogramming barrier. Overexpression of KDM4A significantly improves the blastocyst formation rate in human SCNT embryos by facilitating transcriptional reprogramming, allowing efficient derivation of SCNT-derived ESCs using adult Age-related Macular Degeneration (AMD) patient somatic nuclei donors. This conserved mechanistic insight has potential applications for improving SCNT in a variety of contexts, including regenerative medicine.
C1 [Chung, Young Gie; Sepilian, Vicken; Lee, Dong Ryul] CHA Hlth Syst, Res Inst Stem Cell Res, Los Angeles, CA 90036 USA.
   [Chung, Young Gie; Eum, Jin Hee; Lee, Jeoung Eun; Cha, Kwang Yul; Lee, Dong Ryul] CHA Univ, CHA Stem Cell Inst, Seoul 135081, South Korea.
   [Matoba, Shogo; Liu, Yuting; Lu, Falong; Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
   [Matoba, Shogo; Liu, Yuting; Lu, Falong; Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Matoba, Shogo; Liu, Yuting; Lu, Falong; Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
   [Zhang, Yi] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02115 USA.
C3 Pochon Cha University; Harvard University; Harvard Medical School;
   Howard Hughes Medical Institute; Harvard University; Boston Children's
   Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard
   Medical School; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School
RP Lee, DR (通讯作者)，CHA Hlth Syst, Res Inst Stem Cell Res, Los Angeles, CA 90036 USA.
EM drleedr@cha.ac.kr; yzhang@genetics.med.harvard.edu
RI Chung, Young Gie/AAC-8149-2020; Lu, Falong/Q-3013-2016; Jiang,
   Wei/J-7993-2012; MATOBA, Shogo/D-9995-2016
OI Jiang, Wei/0000-0002-6463-7356; MATOBA, Shogo/0000-0003-0474-232X; Lu,
   Falong/0000-0002-8321-4818
FU HHMI; Bio & Medical Technology Development Program of NRF and MSIP of
   Republic of Korea [2012M3A9C6049723, 2015M3A9C6028961]; Cha Medical
   Foundation in Republic of Korea; Japan Society for the Promotion of
   Science (JSPS); Juvenile Diabetes Research Foundation [3-2012-293]
FX We thank Dr. Luis Tuesta for critical reading of the manuscript; Drs.
   Sungwook Hong and Yumie Lee for oocyte preparations and donor
   recruitments, respectively; and Dr. Young Ho Choi for technical help in
   SCNT. This project is supported by HHMI (to Y.Z.) and the Bio & Medical
   Technology Development Program (2012M3A9C6049723 and 2015M3A9C6028961)
   of NRF and MSIP of Republic of Korea (to D.R.L). This project is also
   partially supported by Cha Medical Foundation in Republic of Korea (to
   D.R.L). S.M. is supported by a postdoctoral fellowship from the Japan
   Society for the Promotion of Science (JSPS). W.J. is supported by a
   Juvenile Diabetes Research Foundation postdoctoral fellowship
   (3-2012-293). Y.Z. is an Investigator of the Howard Hughes Medical
   Institute.
CR Chung YG, 2014, CELL STEM CELL, V14, P777, DOI 10.1016/j.stem.2014.03.015
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   French AJ, 2008, STEM CELLS, V26, P485, DOI 10.1634/stemcells.2007-0252
   GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622
   Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Krishnan S, 2013, STRUCTURE, V21, P98, DOI 10.1016/j.str.2012.10.018
   Ma H, 2015, NATURE, V524, P234, DOI 10.1038/nature14546
   Matoba S, 2014, CELL, V159, P884, DOI 10.1016/j.cell.2014.09.055
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Niakan KK, 2012, DEVELOPMENT, V139, P829, DOI 10.1242/dev.060426
   Noggle S, 2011, NATURE, V478, P70, DOI 10.1038/nature10397
   Rodriguez-Osorio N, 2012, THERIOGENOLOGY, V78, P1869, DOI 10.1016/j.theriogenology.2012.05.030
   Shapiro BS, 2002, FERTIL STERIL, V77, P1296, DOI 10.1016/S0015-0282(02)03086-8
   Simerly C, 2003, SCIENCE, V300, P297, DOI 10.1126/science.1082091
   Stone BA, 2014, FERTIL STERIL, V102, P1055, DOI 10.1016/j.fertnstert.2014.06.049
   Tachibana M, 2013, CELL, V153, P1228, DOI 10.1016/j.cell.2013.05.006
   Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399
   Wang L, 2013, CELL STEM CELL, V13, P676, DOI 10.1016/j.stem.2013.10.008
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Xue ZG, 2013, NATURE, V500, P593, DOI 10.1038/nature12364
   Yamada M, 2014, NATURE, V510, P533, DOI 10.1038/nature13287
   Yamada M, 2010, HUM MOL GENET, V19, P480, DOI 10.1093/hmg/ddp512
   Yang XZ, 2007, NAT GENET, V39, P295, DOI 10.1038/ng1973
NR 24
TC 120
Z9 133
U1 2
U2 39
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 3
PY 2015
VL 17
IS 6
BP 758
EP 766
DI 10.1016/j.stem.2015.10.001
PG 9
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CY1AS
UT WOS:000366139100016
PM 26526725
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Bisti, S
   Maccarone, R
   Falsini, B
AF Bisti, Silvia
   Maccarone, Rita
   Falsini, Benedetto
TI Saffron and retina: Neuroprotection and pharmacokinetics
SO VISUAL NEUROSCIENCE
LA English
DT Review
DE Age-related macular degeneration; Focal electroretinogram;
   Neuroprotection; Photoreceptors; Saffron
ID AGE-RELATED MACULOPATHY; CROCUS-SATIVUS L.; MACULAR DEGENERATION;
   OXIDATIVE STRESS; DAMAGING LIGHT; IN-VITRO; CROCETIN; SUPPLEMENTATION;
   SENSITIVITY; PHOTORECEPTORS
AB Age-related macular degeneration (AMD) is a retinal neurodegenerative disease whose development and progression are the results of a complex interaction between genetic and environmental risk factors. Both oxidative stress and chronic inflammation play a significant role in the pathogenesis of AMD. Experimental studies in rats with light-induced photoreceptors degeneration demonstrated that saffron may protect photoreceptor from retinal stress, preserving both morphology and function and probably acting as a regulator of programmed cell death, in addition to its antioxidant and anti-inflammatory properties. Recently, a randomized clinical trial showed that in patients with early AMD, dietary supplementation with saffron was able to improve significantly the retinal flicker sensitivity suggesting neuroprotective effect of the compound. Here, we examine the progress of saffron dietary supplementation both in animal model and AMD patients, and discuss the potential and safety for using dietary saffron to treat retinal degeneration.
C1 [Bisti, Silvia; Maccarone, Rita] Univ Aquila, DISCAB, I-67100 Laquila, Italy.
   [Falsini, Benedetto] Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, Rome, Italy.
C3 University of L'Aquila; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli
RP Bisti, S (通讯作者)，Univ Aquila, DISCAB, I-67100 Laquila, Italy.
EM silvia.bisti@univaq.it
RI Falsini, Benedetto/V-1070-2019; Falsini, Benedetto/AAC-5907-2022
OI Falsini, Benedetto/0000-0002-1694-1062; Falsini,
   Benedetto/0000-0002-3569-4968; MACCARONE, Rita/0000-0003-0648-3771
FU MIUR-PRIN; Hortus Novus s.r.l.
FX We wish to thank Dr. Maria Maggi for performing the chemical analysis.
   Supported by a MIUR-PRIN (2010-2011) research grant to SB and Hortus
   Novus s.r.l.
CR Abdullaev FI, 2003, TOXICOL IN VITRO, V17, P731, DOI 10.1016/S0887-2333(03)00098-5
   Akhondzadeh S, 2005, PHYTOTHER RES, V19, P148, DOI 10.1002/ptr.1647
   Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x
   Akhondzadeh S, 2010, PSYCHOPHARMACOLOGY, V207, P637, DOI 10.1007/s00213-009-1706-1
   Amin A, 2011, HEPATOLOGY, V54, P857, DOI 10.1002/hep.24433
   Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355
   Ayatollahi H, 2014, PHYTOTHER RES, V28, P539, DOI 10.1002/ptr.5021
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bowers F, 2001, INVEST OPHTH VIS SCI, V42, P804
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Di Marco F, 2013, AM J NEURODEGENER DI, V2, P208
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074
   Garcia-Olmo DC, 1999, NUTR CANCER, V35, P120, DOI 10.1207/S15327914NC352_4
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hosseinzadeh H, 2012, PHYTOTHER RES, V26, P381, DOI 10.1002/ptr.3566
   Iarossi G, 2003, INVEST OPHTH VIS SCI, V44, P866, DOI 10.1167/iovs.01-1256
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kanakis CD, 2007, J AGR FOOD CHEM, V55, P970, DOI 10.1021/jf062638l
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Natoli R, 2010, MOL VIS, V16, P1801
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Purushothuman S, 2013, J PARKINSON DIS, V3, P77, DOI 10.3233/JPD-130173
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Stone J, 2005, MACULAR DEGENERATION, P149, DOI 10.1007/3-540-26977-0_9
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Umigai N, 2011, PHYTOMEDICINE, V18, P575, DOI 10.1016/j.phymed.2010.10.019
   Xi L, 2007, PHYTOMEDICINE, V14, P633, DOI 10.1016/j.phymed.2006.11.028
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
NR 42
TC 36
Z9 37
U1 0
U2 39
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD SEP
PY 2014
VL 31
IS 4-5
SI SI
BP 355
EP 361
DI 10.1017/S0952523814000108
PG 7
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA AP5NQ
UT WOS:000342126300007
PM 24819927
DA 2022-11-30
ER

PT J
AU Zhang, H
   Zhang, XM
   Li, XR
AF Zhang, Hui
   Zhang, Xiaomin
   Li, Xiaorong
TI Intraocular Exosomes in Eye Diseases
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Exosomes; aqueous humor; vitreous humor; glaucoma; age-related macular
   degeneration; extracellular vesicles
ID TRABECULAR MESHWORK CELLS; AQUEOUS-HUMOR; MACULAR DEGENERATION;
   MESENCHYMAL TRANSITION; EXTRACELLULAR VESICLES; COMPLEMENT PATHWAY;
   PROTEOMIC ANALYSIS; MYOCILIN; BIOMARKERS; OUTFLOW
AB Exosomes, nanosized extracellular vesicles with a size of 30-150nm, contain many biological materials, such as messenger RNA (mRNA), microRNA (miRNA), proteins, and transcription factors. It has been identified in all biological fluids and recognized as an important part of intercellular communication. While the role of exosomes in cancer has been studied in-depth, our understanding of their relevance for ocular tissues has just begun to evolve. Intraocular fluids, including aqueous humor and vitreous humor, play a role in nourishing eye tissues and in expelling metabolites. In the pathological state, intraocular exosomes can mediate pathological processes such as ECM remodeling, retinal inflammation, and blood-retinal barrier dysfunction. Herein, we reviewed the latest advances of intraocular exosomes in the research of several eye diseases, including glaucoma, age-related macular degeneration, myopia, and ocular tumors, and discuss how intraocular exosomes contribute to the pathogenesis and progression of multiple eye diseases.
C1 [Zhang, Hui; Zhang, Xiaomin; Li, Xiaorong] Tianjin Med Univ, Natl Clin Res Ctr Ocular Dis, Tianjin Key Lab Retinal Funct & Dis, Eye Inst,Tianjin Branch,Eye Hosp, Tianjin, Peoples R China.
   [Zhang, Hui; Zhang, Xiaomin; Li, Xiaorong] Tianjin Med Univ, Sch Optometry, Eye Hosp, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Zhang, XM (通讯作者)，Tianjin Med Univ, Eye Hosp, 251 Fukang Rd, Tianjin 300384, Peoples R China.
EM xzhang08@tmu.edu.cn
OI Zhang, Xiaomin/0000-0003-4898-4152
CR Abu El-Asrar AM, 2020, EYE, V34, P1614, DOI 10.1038/s41433-019-0693-7
   Agarwal P, 2018, EXPERT OPIN THER TAR, V22, P629, DOI 10.1080/14728222.2018.1486822
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ashok A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.24
   Balaj L, 2015, SCI REP-UK, V5, DOI 10.1038/srep10266
   Barathi VA, 2013, DIS MODEL MECH, V6, P1146, DOI 10.1242/dmm.010967
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Breda JB, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108268
   Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5
   Carreon T, 2017, PROG RETIN EYE RES, V57, P108, DOI 10.1016/j.preteyeres.2016.12.004
   Chang M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199438
   Chen CF, 2019, TOHOKU J EXP MED, V249, P213, DOI 10.1620/tjem.249.213
   Cho HY, 2020, CLIN EXP OPHTHALMOL, V48, P624, DOI 10.1111/ceo.13750
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Dismuke WM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165326
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Elliott RO, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010122
   Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x
   Fautsch MP, 2000, INVEST OPHTH VIS SCI, V41, P4163
   Fingert JH, 2019, JAMA OPHTHALMOL, V137, P35, DOI 10.1001/jamaophthalmol.2018.4470
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galardi A, 2020, CANCERS, V12, DOI 10.3390/cancers12061555
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Garcia-Contreras M, 2017, EUR REV MED PHARMACO, V21, P2940
   Genschmer KR, 2019, CELL, V176, P113, DOI 10.1016/j.cell.2018.12.002
   Guo SW, 2019, ACS NANO, V13, P10015, DOI 10.1021/acsnano.9b01892
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Han KY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40548
   Hardy KM, 2005, J BIOL CHEM, V280, P28917, DOI 10.1074/jbc.M504803200
   Hoffman EA, 2009, INVEST OPHTH VIS SCI, V50, P1313, DOI 10.1167/iovs.08-2326
   Honjo M, 2018, INVEST OPHTH VIS SCI, V59, P21, DOI 10.1167/iovs.17-22807
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Kagemann L, 2011, EXP EYE RES, V93, P308, DOI 10.1016/j.exer.2011.03.019
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kang YT, 2020, ADV SCI, V7, DOI 10.1002/advs.202001581
   Kang YT, 2019, SMALL, V15, DOI 10.1002/smll.201903600
   Kasetti RB, 2016, INVEST OPHTH VIS SCI, V57, P6058, DOI 10.1167/iovs.16-19610
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kiss Szilard, 2008, Int Ophthalmol Clin, V48, P135, DOI 10.1097/IIO.0b013e3181693670
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lerner N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176105
   Lerner N, 2020, J CELL MOL MED, V24, P4646, DOI 10.1111/jcmm.15129
   Lerner N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171153
   Li K, 2018, METHODS MOL BIOL, V1740, P69, DOI 10.1007/978-1-4939-7652-2_7
   Li WH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0706-8
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu F, 2017, ACS NANO, V11, P10712, DOI 10.1021/acsnano.7b04878
   Liu P, 2018, P NATL ACAD SCI USA, V115, P9032, DOI 10.1073/pnas.1807982115
   Lo TW, 2020, LAB CHIP, V20, P1762, DOI 10.1039/c9lc01190k
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Ma ZX, 2022, OCUL IMMUNOL INFLAMM, V30, P630, DOI 10.1080/09273948.2020.1828488
   Makler A, 2020, EXPERT REV MOL DIAGN, V20, P387, DOI 10.1080/14737159.2020.1731308
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9
   McBrien NA, 2013, EXP EYE RES, V114, P128, DOI 10.1016/j.exer.2013.01.014
   Mead B, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100849
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Moazzeni H, 2019, HUM MOL GENET, V28, P3637, DOI 10.1093/hmg/ddz222
   Navajas R, 2019, METHODS MOL BIOL, V1959, P39, DOI 10.1007/978-1-4939-9164-8_3
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Perkumas KM, 2007, EXP EYE RES, V84, P209, DOI 10.1016/j.exer.2006.09.020
   Qiu YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1331, DOI 10.1159/000354531
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Sekhar A, 2018, ELIFE, V7, DOI 10.7554/eLife.32764
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shi M, 2014, ACTA NEUROPATHOL, V128, P639, DOI 10.1007/s00401-014-1314-y
   Sidhom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186466
   Stamer WD, 2011, J PROTEOMICS, V74, P796, DOI 10.1016/j.jprot.2011.02.024
   Sundararajan V, 2018, CELL ONCOL, V41, P223, DOI 10.1007/s13402-018-0378-4
   Tabak S, 2018, J CELL MOL MED, V22, P1992, DOI 10.1111/jcmm.13505
   Takahashi E, 2014, EXP EYE RES, V118, P72, DOI 10.1016/j.exer.2013.11.014
   Tamm ER, 2002, PROG RETIN EYE RES, V21, P395, DOI 10.1016/S1350-9462(02)00010-1
   Tamm ER, 2015, PROG MOL BIOL TRANSL, V134, P301, DOI 10.1016/bs.pmbts.2015.06.007
   Tanaka Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05089
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Tian Y, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1697028
   Villarroya-Beltri C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13588
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wecker T, 2016, INVEST OPHTH VIS SCI, V57, P1706, DOI 10.1167/iovs.15-17828
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wierenga APA, 2019, INVEST OPHTH VIS SCI, V60, P4740, DOI 10.1167/iovs.19-28309
   Wu HM, 2020, ONCOL REP, V43, P240, DOI 10.3892/or.2019.7401
   Xiao DY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046874
   Xie LL, 2019, AM J PATHOL, V189, P739, DOI 10.1016/j.ajpath.2018.12.011
   Xu L, 2019, CURR MOL MED, V19, P387, DOI 10.2174/1566524019666190429144310
   Xu Qing, 2015, Zhonghua Yan Ke Za Zhi, V51, P295
   Xu R, 2016, J CLIN INVEST, V126, P1152, DOI 10.1172/JCI81129
   Yang DB, 2020, THERANOSTICS, V10, P3684, DOI 10.7150/thno.41580
   Yang HJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107792
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yuan Y, 2013, INVEST OPHTH VIS SCI, V54, P6502, DOI 10.1167/iovs.13-12447
   Zhang XY, 2005, INVEST OPHTH VIS SCI, V46, P4607, DOI 10.1167/iovs.05-0571
   Zhao YJ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.6
NR 98
TC 0
Z9 0
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2022
VL 22
IS 6
BP 540
EP 548
DI 10.2174/1566524021666210901122948
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 2U8SS
UT WOS:000823425200007
PM 34488586
DA 2022-11-30
ER

PT J
AU Skerka, C
   Pradel, G
   Halder, LD
   Zipfel, PF
   Zipfel, SLH
   Strauss, O
AF Skerka, Christine
   Pradel, Gabriele
   Halder, Luke D.
   Zipfel, Peter F.
   Zipfel, Svante L. H.
   Strauss, Olaf
TI Factor H-related protein 1: a complement regulatory protein and guardian
   of necrotic-type surfaces
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE complement; factor H&#8208; related protein 1; inflammation
ID HEMOLYTIC-UREMIC SYNDROME; GENOME-WIDE ASSOCIATION; MACULAR
   DEGENERATION; BINDING-PROTEIN; ACTIVATION; DISEASES; MOUSE; CFHR1;
   LIPOPROTEIN; INSIGHTS
AB Factor H-related protein 1 (FHR-1) is a member of the factor H protein family, which is involved in regulating innate immune complement reactions. Genetic modification of the encoding gene, CFHR1 on human chromosome 1, is involved in diseases such as age-related macular degeneration, C3 glomerulopathy and atypical haemolytic uraemic syndrome, indicating an important role for FHR-1 in human health. Recent research data demonstrate that FHR-1 levels increase in IgA nephropathy and anti-neutrophilic cytoplasmic autoantibodies (ANCA) vasculitis and that FHR-1 induces strong inflammation in monocytes on necrotic-type surfaces, suggesting a complement-independent role. These new results increase our knowledge about the role of this complement protein in pathology and provide a new therapeutic target, particularly in the context of inflammatory diseases induced by necrosis. This review summarizes current knowledge about FHR-1 and discusses its role in complement reactions and inflammation.
C1 [Skerka, Christine; Halder, Luke D.; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Hans Knoll Inst, Dept Infect Biol, Jena, Germany.
   [Pradel, Gabriele] Rhein Westfal TH Aachen, Div Cellular & Appl Infect Biol, Aachen, Germany.
   [Zipfel, Svante L. H.] Univ Med Ctr Hamburg Eppendorf, Univ Heart Ctr, Dept Cardiovasc Surg, Hamburg, Germany.
   [Strauss, Olaf] Charite, Expt Ophthalmol, Campus Virchow Clin, Berlin, Germany.
C3 Hans Knoll Institute (HKI); RWTH Aachen University; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin
RP Skerka, C (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11a, D-07745 Jena, Germany.
EM christine.skerka@hki-jena.de
OI Halder, Luke Donald/0000-0002-8155-1458; Strauss,
   Olaf/0000-0002-6272-8596
FU Deutsche Forschungsgemeinschaft [PR 905/12-1, SFB 1192/B6, SK 46/4-1,
   PFZ SFB1192]; Kidneeds
FX Deutsche Forschungsgemeinschaft, Grant/Award Numbers: PR 905/12-1, SFB
   1192/B6, SK 46/4-1, PFZ SFB1192; Kidneeds
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS21, DOI 10.1111/bph.14748
   Alic L, 2020, P NATL ACAD SCI USA, V117, P9942, DOI 10.1073/pnas.1913970117
   Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Barbour TD, 2016, NEPHROL DIAL TRANSPL, V31, P717, DOI 10.1093/ndt/gfu317
   Bhasym A, 2019, BLOOD CELL MOL DIS, V79, DOI 10.1016/j.bcmd.2019.102349
   Bhasym A, 2019, J CLIN IMMUNOL, V39, P336, DOI 10.1007/s10875-019-00619-2
   Binder CJ, 2016, NAT REV IMMUNOL, V16, P485, DOI 10.1038/nri.2016.63
   Chen Q, 2016, J AM SOC NEPHROL, V27, P1413, DOI 10.1681/ASN.2015020212
   Chen XM, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23297
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Foley JH, 2016, EBIOMEDICINE, V5, P175, DOI 10.1016/j.ebiom.2016.02.011
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Granoff DM, 2013, CLIN VACCINE IMMUNOL, V20, P1099, DOI 10.1128/CVI.00260-13
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858
   Hamann J, 2015, PHARMACOL REV, V67, P338, DOI 10.1124/pr.114.009647
   Hannan JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166200
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 2006, IMMUNOGENETICS, V58, P883, DOI 10.1007/s00251-006-0153-y
   Holmes LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060352
   Irmscher S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10766-0
   Irmscher S, 2018, J INNATE IMMUN, V10, P94, DOI 10.1159/000484257
   Jiang Q, 2019, TRANSPL IMMUNOL, V53, P7, DOI 10.1016/j.trim.2018.11.005
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2019, SEMIN CELL DEV BIOL, V85, P122, DOI 10.1016/j.semcdb.2017.12.018
   Jozsi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00571
   Keshari RS, 2017, BLOOD, V130, P2678, DOI 10.1182/blood-2017-06-788216
   Kiryluk K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002765
   Kraiczy P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00385
   Li XR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01123
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Medjeral-Thomas N, 2016, IMMUNOL REV, V274, P191, DOI 10.1111/imr.12477
   Medjeral-Thomas NR, 2017, KIDNEY INT, V92, P942, DOI 10.1016/j.kint.2017.03.043
   Mehta G, 2014, MOL IMMUNOL, V62, P235, DOI 10.1016/j.molimm.2014.06.028
   Michelfelder S, 2018, J AM SOC NEPHROL, V29, P1141, DOI 10.1681/ASN.2017070738
   Morgan HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032187
   Noris M, 2012, NAT REV NEPHROL, V8, P622, DOI 10.1038/nrneph.2012.195
   Obermayer G, 2018, J THROMB HAEMOST, V16, P418, DOI 10.1111/jth.13925
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   Park CT, 2000, BLOOD, V95, P198, DOI 10.1182/blood.V95.1.198.001k31_198_204
   Pouw RB, 2015, MOL IMMUNOL, V67, P12, DOI 10.1016/j.molimm.2015.03.011
   Reiss T, 2018, J IMMUNOL, V201, P3497, DOI 10.4049/jimmunol.1800662
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Shi KB, 2016, J IMMUNOL, V197, P3471, DOI 10.4049/jimmunol.1600135
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   Skerka C, 2008, VACCINE, V26, pI9, DOI 10.1016/j.vaccine.2008.11.021
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Susukida R, 2007, ELECTROPHORESIS, V28, P309, DOI 10.1002/elps.200600287
   Tajbakhsh A, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106134
   Thurman JM, 2017, KIDNEY INT, V92, P790, DOI 10.1016/j.kint.2017.05.025
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Tortajada A, 2017, KIDNEY INT, V92, P953, DOI 10.1016/j.kint.2017.03.041
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   van Beek AE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01727
   Zhang P, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600237
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
   Zindel J, 2020, ANNU REV PATHOL-MECH, V15, P493, DOI 10.1146/annurev-pathmechdis-012419-032847
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2020, J AM SOC NEPHROL, V31, P241, DOI 10.1681/ASN.2019050515
   Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012
   Zipfel PF, 2013, MOL IMMUNOL, V56, P152, DOI 10.1016/j.molimm.2013.05.222
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015
NR 68
TC 11
Z9 11
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUL
PY 2021
VL 178
IS 14
BP 2823
EP 2831
DI 10.1111/bph.15290
EA DEC 2020
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SW1VX
UT WOS:000601072800001
PM 33085794
OA hybrid
DA 2022-11-30
ER

PT J
AU Zuber, V
   Colijn, JM
   Klaver, C
   Burgess, S
AF Zuber, Verena
   Colijn, Johanna Maria
   Klaver, Caroline
   Burgess, Stephen
TI Selecting likely causal risk factors from high-throughput experiments
   using multivariable Mendelian randomization
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MACULAR DEGENERATION; GENETIC-VARIANTS; AGE; INSTRUMENTS; METAANALYSIS;
   ASSOCIATION; PLEIOTROPY; ATLAS
AB Modern high-throughput experiments provide a rich resource to investigate causal determinants of disease risk. Mendelian randomization (MR) is the use of genetic variants as instrumental variables to infer the causal effect of a specific risk factor on an outcome. Multivariable MR is an extension of the standard MR framework to consider multiple potential risk factors in a single model. However, current implementations of multivariable MR use standard linear regression and hence perform poorly with many risk factors. Here, we propose a two-sample multivariable MR approach based on Bayesian model averaging (MR-BMA) that scales to high-throughput experiments. In a realistic simulation study, we show that MR-BMA can detect true causal risk factors even when the candidate risk factors are highly correlated. We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to prioritise likely causal biomarkers for age-related macular degeneration.
C1 [Zuber, Verena; Burgess, Stephen] Univ Cambridge, Sch Clin Med, MRC Biostat Unit, Cambridge, England.
   [Zuber, Verena] Imperial Coll London, Dept Epidemiol & Biostat, London, England.
   [Colijn, Johanna Maria; Klaver, Caroline] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Colijn, Johanna Maria; Klaver, Caroline] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Klaver, Caroline] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Burgess, Stephen] Univ Cambridge, Sch Clin Med, MRC BHF Cardiovasc Epidemiol Unit, Cambridge, England.
C3 MRC Biostatistics Unit; University of Cambridge; Imperial College
   London; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Radboud University Nijmegen; University of
   Cambridge
RP Burgess, S (通讯作者)，Univ Cambridge, Sch Clin Med, MRC Biostat Unit, Cambridge, England.; Burgess, S (通讯作者)，Univ Cambridge, Sch Clin Med, MRC BHF Cardiovasc Epidemiol Unit, Cambridge, England.
EM sb452@medschl.cam.ac.uk
OI Zuber, Verena/0000-0001-9827-1877; Burgess, Stephen/0000-0001-5365-8760
FU UK Medical Research Council [MC_UU_00002/7]; Sir Henry Dale Fellowship -
   Wellcome Trust [204623/Z/16/Z]; Sir Henry Dale Fellowship - Royal
   Society [204623/Z/16/Z]
FX This work was supported by the UK Medical Research Council
   (MC_UU_00002/7). S.B. and V.Z. are supported by Sir Henry Dale
   Fellowship jointly funded by the Wellcome Trust and the Royal Society
   (Grant Number 204623/Z/16/Z). This study would not have been possible
   without the access to publicly available summary data. We would like to
   thank the International AMD Genetics consortium
   (http://amdgenetics.org/), the authors of the blood trait GWAS as
   curated by the GWAS catalog (https://www.ebi.ac.uk/gwas/), and the
   authors of the NMR-GWAS (http://www.computationalmedicine.fi/data).
CR Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042
   Biffi C, 2018, BIOINFORMATICS, V34, P97, DOI [10.1093/bioinformatics/btx552, 10.5281/zenodo.834610]
   Bowden J, 2019, INT J EPIDEMIOL, V48, P728, DOI 10.1093/ije/dyy258
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S, 2018, INT J EPIDEMIOL, V47, P1242, DOI 10.1093/ije/dyy080
   Burgess S, 2018, ANNU REV GENOM HUM G, V19, P303, DOI 10.1146/annurev-genom-083117-021731
   Burgess S, 2017, GENETICS, V207, P481, DOI 10.1534/genetics.117.300191
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Burgess S, 2015, AM J EPIDEMIOL, V181, P251, DOI 10.1093/aje/kwu283
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   COOK RD, 1977, TECHNOMETRICS, V19, P15, DOI 10.2307/1268249
   COOK RD, 1979, J AM STAT ASSOC, V74, P169, DOI 10.2307/2286747
   Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hans C, 2007, J AM STAT ASSOC, V102, P507, DOI 10.1198/016214507000000121
   Hartwig FP, 2017, INT J EPIDEMIOL, V46, P1985, DOI 10.1093/ije/dyx102
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Lee JD, 2016, ANN STAT, V44, P907, DOI 10.1214/15-AOS1371
   Maddala GS., 1992, INTRO ECONOMETRICS
   Mahajan A, 2018, NAT GENET, V50, P559, DOI 10.1038/s41588-018-0084-1
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Pierce BL, 2013, AM J EPIDEMIOL, V178, P1177, DOI 10.1093/aje/kwt084
   Rees JMB, 2017, STAT MED, V36, P4705, DOI 10.1002/sim.7492
   Sanderson E, 2019, INT J EPIDEMIOL, V48, P713, DOI 10.1093/ije/dyy262
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Servin B, 2007, PLOS GENET, V3, P1296, DOI 10.1371/journal.pgen.0030114
   Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Solovieff N, 2013, NAT REV GENET, V14, P483, DOI 10.1038/nrg3461
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Taylor J, 2015, P NATL ACAD SCI USA, V112, P7629, DOI 10.1073/pnas.1507583112
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
NR 44
TC 42
Z9 42
U1 2
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 7
PY 2020
VL 11
IS 1
AR 29
DI 10.1038/s41467-019-13870-3
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KJ3KH
UT WOS:000511956100011
PM 31911605
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ding, SLS
   Leow, SN
   Munisvaradass, R
   Koh, EH
   Bastion, MLC
   Then, KY
   Kumar, S
   Mok, PL
AF Ding, S. L. Shirley
   Leow, S. N.
   Munisvaradass, R.
   Koh, E. H.
   Bastion, M. L. C.
   Then, K. Y.
   Kumar, S.
   Mok, P. L.
TI Revisiting the role of erythropoietin for treatment of ocular disorders
SO EYE
LA English
DT Review
ID MESENCHYMAL STEM-CELLS; RETINAL GANGLION-CELLS; MARROW STROMAL CELLS;
   CARBAMYLATED-ERYTHROPOIETIN; GROWTH-FACTORS; INTRAVITREAL
   ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; DIRECTED DIFFERENTIATION;
   EXPERIMENTAL-MODEL; DARBEPOETIN-ALPHA
AB Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.
C1 [Ding, S. L. Shirley; Munisvaradass, R.; Koh, E. H.; Kumar, S.; Mok, P. L.] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Upm Serdang 43400, Selangor, Malaysia.
   [Leow, S. N.] Hosp Sultanah Aminah, Dept Ophthalmol, Johor Baharu, Malaysia.
   [Bastion, M. L. C.; Then, K. Y.] Univ Kebangsaan Malaysia, Med Ctr, Dept Ophthalmol, Kuala Lumpur, Malaysia.
   [Kumar, S.] Univ Putra Malaysia, Dept Med Microbiol & Parasitol, Upm Serdang, Selangor, Malaysia.
   [Mok, P. L.] Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Upm Serdang, Selangor, Malaysia.
C3 Universiti Putra Malaysia; Universiti Kebangsaan Malaysia; Universiti
   Putra Malaysia; Universiti Putra Malaysia
RP Ding, SLS (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Upm Serdang 43400, Selangor, Malaysia.
EM rachelmok2005@gmail.com
RI Koh, Avin Ee-Hwan/P-6519-2017; Bastion, Mae-Lynn/ABE-1237-2020; Mok,
   Pooi Ling/AAJ-7480-2021; Kumar S, Suresh/J-2423-2017
OI Koh, Avin Ee-Hwan/0000-0002-6519-0939; Bastion,
   Mae-Lynn/0000-0002-6856-8052; Kumar S, Suresh/0000-0002-0505-7554
FU Fundamental Research Grants Scheme (FRGS), Ministry of Educations,
   Malaysia [5524401]; Putra Grant, Universiti Putra Malaysia, Malaysia
   [9436300]
FX This research was completely supported by the Fundamental Research
   Grants Scheme (FRGS), Ministry of Educations, Malaysia, under the grant
   number 5524401. This work was also supported by the Putra Grant,
   Universiti Putra Malaysia, Malaysia (9436300).
CR Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Auricchio A, 2002, MOL THER, V6, P238, DOI 10.1006/mthe.2002.0660
   BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3
   Boesch S, 2014, MOVEMENT DISORD, V29, P935, DOI 10.1002/mds.25836
   Bohl D, 2000, J AM SOC NEPHROL, V11, pS159
   Bond WS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00523
   Borhani-Haghighi A, 2012, NEUROSCIENCES, V17, P151
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526
   Brown MS, 2006, J AAPOS, V10, P143, DOI 10.1016/j.jaapos.2005.09.005
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Busch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102013
   Caprara C, 2014, MOL VIS, V20, P307
   Carelli S, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/453179
   Castanheira P, 2008, ARQ BRAS OFTALMOL, V71, P644, DOI 10.1590/S0004-27492008000500007
   Cersosimo RJ, 2006, ANN PHARMACOTHER, V40, P58, DOI 10.1345/aph.1G042
   Chang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055291
   Chateauvieux S, 2011, BIOCHEM PHARMACOL, V82, P1291, DOI 10.1016/j.bcp.2011.06.045
   Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]
   Chong DY, 2008, INVEST OPHTH VIS SCI, V49, P3193, DOI 10.1167/iovs.07-1641
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   Colella Pasqualina, 2013, Methods Mol Biol, V982, P237, DOI 10.1007/978-1-62703-308-4_16
   Colella P, 2011, HUM MOL GENET, V20, P2251, DOI 10.1093/hmg/ddr115
   Daga A, 2002, GENE THER, V9, P915, DOI 10.1038/sj.gt.3301727
   Danielyan L, 2009, CELL DEATH DIFFER, V16, P1599, DOI 10.1038/cdd.2009.95
   de Iongh RU, 2006, FRONT BIOSCI-LANDMRK, V11, P2442, DOI 10.2741/1982
   Eliopoulos N, 2011, MOL THER, V19, P2072, DOI 10.1038/mt.2011.162
   Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100
   Garcia-Ramirez M, 2008, DIABETES CARE, V31, P1189, DOI 10.2337/dc07-2075
   Gholamhossein Yaghoobi, 2014, Korean J Ophthalmol, V28, P373, DOI 10.3341/kjo.2014.28.5.373
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hernandez C, 2012, ENDOCRINE, V41, P220, DOI 10.1007/s12020-011-9579-6
   Hines-Beard J, 2013, CURR GENE THER, V13, P275
   Hou HY, 2010, MOL THER, V18, P1837, DOI 10.1038/mt.2010.144
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Jiang YF, 2014, INT J MOL SCI, V15, P9372, DOI 10.3390/ijms15069372
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399
   Kase S, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.119404
   Kashkouli MB, 2011, GRAEF ARCH CLIN EXP, V249, P731, DOI 10.1007/s00417-010-1534-3
   Kaspar AA, 2013, DRUG DISCOV TODAY, V18, P807, DOI 10.1016/j.drudis.2013.05.011
   Katsura Y, 2005, DIABETES CARE, V28, P2252, DOI 10.2337/diacare.28.9.2252
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kilic U, 2004, FASEB J, V18, P249, DOI 10.1096/fj.04-2493fje
   Kim Mi-Hwa, 2010, Mol Biol (Mosk), V44, P656
   King CE, 2007, EXP NEUROL, V205, P48, DOI 10.1016/j.expneurol.2007.01.017
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009
   Kristiansen OP, 2005, DIABETES, V54, pS114, DOI 10.2337/diabetes.54.suppl_2.S114
   Lagreze WA, 2009, BRIT J OPHTHALMOL, V93, P1667, DOI 10.1136/bjo.2008.156794
   Lai NM, 2010, EDUC HEALTH, V23, P151
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lapchak PA, 2008, BRAIN RES, V1238, P208, DOI 10.1016/j.brainres.2008.08.017
   LeBlanc RA, 1999, J VIROL, V73, P8145, DOI 10.1128/JVI.73.10.8145-8151.1999
   Leibinger M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.126
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li WY, 2010, OPHTHAL SURG LAS IM, V41, P18, DOI 10.3928/15428877-20091230-03
   Liu NM, 2013, EXP CELL RES, V319, P2019, DOI 10.1016/j.yexcr.2013.04.008
   Liu XJ, 2015, GRAEF ARCH CLIN EXP, V253, P1263, DOI 10.1007/s00417-015-2969-3
   Livny E, 2013, OPHTHALMIC RES, V50, P129, DOI 10.1159/000351627
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Luo WT, 2015, OPHTHALMIC RES, V53, P74, DOI 10.1159/000369885
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026
   Mead B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109305
   Mead B, 2013, INVEST OPHTH VIS SCI, V54, P7544, DOI 10.1167/iovs.13-13045
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Modarres M, 2011, BRIT J OPHTHALMOL, V95, P992, DOI 10.1136/bjo.2010.191627
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Mok PL, 2012, TISSUE CELL, V44, P249, DOI 10.1016/j.tice.2012.04.002
   Mok PL, 2012, CYTOTECHNOLOGY, V64, P203, DOI 10.1007/s10616-011-9413-2
   Mok PL, 2008, CYTOTHERAPY, V10, P116, DOI 10.1080/14653240701816996
   Mok PL, 2013, MALAYS J PATHOL, V35, P17
   MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589
   Nakano M, 2007, CIRC RES, V100, P662, DOI 10.1161/01.RES.0000260179.43672.fe
   Omoto M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15413
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Ostrvica Edin, 2010, Med Arh, V64, P4
   Pagonopoulou O, 2008, IN VIVO, V22, P587
   Pakravan M, 2012, J NEURO-OPHTHALMOL, V32, P325, DOI 10.1097/WNO.0b013e318262a7c2
   Patel S, 2008, PEDIATR RES, V63, P394, DOI 10.1203/PDR.0b013e318165b8d1
   Patton J, 2004, ONCOLOGIST, V9, P451, DOI 10.1634/theoncologist.9-4-451
   Philbin MK, 1998, PEDIATR RES, V43, P40
   Provatopoulou ST, 2011, HIPPOKRATIA, V15, P109
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008
   Ramirez R, 2009, J MOL CELL CARDIOL, V47, P781, DOI 10.1016/j.yjmcc.2009.09.005
   Resende AP, 2013, GRAEF ARCH CLIN EXP, V251, P2051, DOI 10.1007/s00417-013-2367-7
   Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Romagnoli C, 2011, EARLY HUM DEV, V87, pS39, DOI 10.1016/j.earlhumdev.2011.01.027
   Sattler MB, 2004, CELL DEATH DIFFER, V11, pS181, DOI 10.1038/sj.cdd.4401504
   Sautina L, 2010, BLOOD, V115, P896, DOI 10.1182/blood-2009-04-216432
   Savino C, 2006, J NEUROIMMUNOL, V172, P27, DOI 10.1016/j.jneuroim.2005.10.016
   Shah N, 2010, AM J PERINAT, V27, P67, DOI 10.1055/s-0029-1224872
   Shah Shaival S, 2009, BMC Res Notes, V2, P234, DOI 10.1186/1756-0500-2-234
   Sharples EJ, 2006, CURR OPIN PHARMACOL, V6, P184, DOI 10.1016/j.coph.2006.01.003
   Shayegannejad V, 2015, GRAEF ARCH CLIN EXP, V253, P797, DOI 10.1007/s00417-014-2925-7
   Shen WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104759
   Sinclair SH, 2014, INVEST OPHTH VIS SCI, V55
   Song BJ, 2008, CURR EYE RES, V33, P750, DOI 10.1080/02713680802366602
   Su KH, 2011, J CELL PHYSIOL, V226, P3330, DOI 10.1002/jcp.22678
   Suhs KW, 2012, ANN NEUROL, V72, P199, DOI 10.1002/ana.23573
   Szabo A, 2008, INVEST OPHTHALMOL, V49, P5896
   Tao YX, 2010, INDIAN J EXP BIOL, V48, P444
   Tomita H, 2013, GENE THER, V127, P1, DOI DOI 10.5772/52987
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   Torup L, 2006, ERYTHROPOIETIN AND THE NERVOUS SYSTEM: NOVEL THERAPEUTIC OPTIONS FOR NEUROPROTECTION, P211, DOI 10.1007/978-0-387-30011-5_13
   Tsai JC, 2007, J GLAUCOMA, V16, P567, DOI 10.1097/IJG.0b013e318156a556
   Tsai James C, 2008, Trans Am Ophthalmol Soc, V106, P459
   Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Vossmerbaeumer U, 2009, CYTOTHERAPY, V11, P177, DOI 10.1080/14653240802714819
   Wang XY, 2004, J NEUROCHEM, V91, P900, DOI 10.1111/j.1471-4159.2004.02769.x
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Wei X, 2014, INFECT IMMUN, V82, P165, DOI 10.1128/IAI.00929-13
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu L, 2008, INVEST OPHTH VIS SCI, V49, P3078
   Xie Z, 2012, EYE, V26, P144, DOI 10.1038/eye.2011.254
   Xie ZG, 2007, CURR EYE RES, V32, P757, DOI 10.1080/02713680701531074
   Yamasaki M, 2005, BRAIN RES, V1050, P15, DOI 10.1016/j.brainres.2005.05.037
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang ZH, 2014, AM J PATHOL, V184, P1230, DOI 10.1016/j.ajpath.2013.12.023
   Zhang H, 2013, AFRICAN J BIOTECHNOL, V10, P3695
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
   Zhang YY, 2014, INT J MOL SCI, V15, P10296, DOI 10.3390/ijms150610296
   Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757
   Zhong YS, 2008, J OCUL PHARMACOL TH, V24, P453, DOI 10.1089/jop.2008.0021
   Zhu Hui-feng, 2011, Chinese Pharmacological Bulletin, V27, P451, DOI 10.3969/j.issn.1001-1978.2011.04.003
NR 141
TC 37
Z9 37
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2016
VL 30
IS 10
BP 1293
EP 1309
DI 10.1038/eye.2016.94
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ7FH
UT WOS:000386029800002
PM 27285322
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Montalvo, V
   Chan, CC
   Gery, I
   Campos, MM
   Wawrousek, EF
   Bush, RA
   Lambris, JD
AF Montalvo, Vanessa
   Chan, Chi-Chao
   Gery, Igal
   Campos, Maria M.
   Wawrousek, Eric F.
   Bush, Ronald A.
   Lambris, John D.
TI Complement deposits on ocular tissues adjacent to sites of inflammation
SO CURRENT EYE RESEARCH
LA English
DT Article
DE complement; cornea; experimental autoimmune uveitis; inflammation; lens
   capsule; light damage; transgenic mice
ID FACTOR-H POLYMORPHISM; GENES
AB Purpose: The complement system plays important roles in a variety of chronic ocular diseases such as age-related macular degeneration. Here we examined the deposition of complement components in mouse eyes damaged by various mechanisms. Methods: Mouse eyes were damaged by light or by three models of inflammation, i.e., local transgenic expression of cytokines, interleukin-1 or -7, or by induction of experimental autoimmune uveitis. Eye tissues obtained from each model were immunostained with antibodies against complement components C1q, C3, and C4. Results: No complement deposition was seen in light damaged eyes, while in inflamed eyes we found complement deposition at sites of tissue damage and cellular infiltration. In addition to affected tissues, intense immunoreactivity against complement was unexpectedly observed in corneal tissues and lens capsule, despite lack of inflammation in these tissues. Conclusion: Our observations suggest that ocular tissues adjacent to inflammatory sites undergo changes that facilitate complement deposition.
C1 NIH, NEI, Immunol Lab, Bethesda, MD 20892 USA.
   NIH, NEI, Biol Imaging Core, Bethesda, MD 20892 USA.
   NIH, NEI, Mol & Dev Biol Lab, Bethesda, MD 20892 USA.
   NIH, Natl Inst Deafness & Other Commun Disorders, Sect Translat Res Retina & Macular Degenerat, Bethesda, MD 20892 USA.
   Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH
   National Institute on Deafness & Other Communication Disorders (NIDCD);
   University of Pennsylvania
RP Gery, I (通讯作者)，NIH, NEI, Immunol Lab, Bldg 10,Room 10N208,Ctr Dr, Bethesda, MD 20892 USA.
EM geryi@nei.nih.gov
RI Lambris, John/Q-5633-2018; Wawrousek, Eric/A-4547-2008
OI Lambris, John/0000-0002-9370-5776; Reddin, Vanessa/0000-0002-4027-6322
FU Intramural NIH HHS Funding Source: Medline; NATIONAL EYE INSTITUTE
   [ZICEY000458, Z01EY000461, ZICEY000461, Z01EY000458, Z01EY000441]
   Funding Source: NIH RePORTER
CR Adamus Grazyna, 2002, Int Rev Immunol, V21, P209, DOI 10.1080/08830180212068
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KORF HW, 1986, SCIENCE, V231, P735, DOI 10.1126/science.3454660
   Lai JC, 1998, INVEST OPHTH VIS SCI, V39, P2049
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Takase H, 2005, J NEUROIMMUNOL, V168, P118, DOI 10.1016/j.jneuroim.2005.07.021
   Takase H, 2006, J LEUKOCYTE BIOL, V80, P538, DOI 10.1189/jlb.1205719
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Zhang C, 2005, MOL VIS, V11, P887
   Zhang MF, 2000, J NEUROIMMUNOL, V103, P189, DOI 10.1016/S0165-5728(99)00239-8
NR 19
TC 11
Z9 13
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV
PY 2007
VL 32
IS 11
BP 917
EP 922
DI 10.1080/02713680701656343
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239GJ
UT WOS:000251506500001
PM 18027167
DA 2022-11-30
ER

PT J
AU Giacalone, JC
   Wiley, LA
   Burnight, ER
   Songstad, AE
   Mullins, RF
   Stone, EM
   Tucker, BA
AF Giacalone, Joseph C.
   Wiley, Luke A.
   Burnight, Erin R.
   Songstad, Allison E.
   Mullins, Robert F.
   Stone, Edwin M.
   Tucker, Budd A.
TI Concise Review: Patient-Specific Stem Cells to Interrogate Inherited Eye
   Disease
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Review
DE Induced pluripotent stem cells; Eye diseases; Hereditary; Retinal
   degeneration/genetics; Humans; Eye/pathology
ID LEBER CONGENITAL AMAUROSIS; RETINAL-PIGMENT EPITHELIUM; OPEN-ANGLE
   GLAUCOMA; NUCLEOTIDE-EXCHANGE FACTOR; VESICLE-LIKE STRUCTURES; MACULAR
   DEGENERATION; RETINITIS-PIGMENTOSA; GENE-THERAPY; RPE65 MUTATIONS;
   VISUAL FUNCTION
AB Whether we are driving to work or spending time with loved ones, we depend on our sense of vision to interact with the world around us. Therefore, it is understandable why blindness for many is feared above death itself. Heritable diseases of the retina, such as glaucoma, age related macular degeneration, and retinitis pigmentosa, are major causes of blindness worldwide. The recent success of gene augmentation trials for the treatment of RPE65-associated Leber congenital amaurosis has underscored the need for model systems that accurately recapitulate disease. With the advent of patient-specific induced pluripotent stem cells (iPSCs), researchers are now able to obtain disease-specific cell types that would otherwise be unavailable for molecular analysis. In the present review, we discuss how the iPSC technology is being used to confirm the pathogenesis of novel genetic variants, interrogate the pathophysiology of disease, and accelerate the development of patient-centered treatments.
C1 [Giacalone, Joseph C.; Wiley, Luke A.; Burnight, Erin R.; Songstad, Allison E.; Mullins, Robert F.; Stone, Edwin M.; Tucker, Budd A.] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Carver Coll Med, 375 Newton Rd, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Tucker, BA (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Carver Coll Med, 375 Newton Rd, Iowa City, IA 52242 USA.
EM budd-tucker@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Stone, Edwin M./0000-0003-3343-4414; Wiley, Luke/0000-0003-0136-2364;
   Mullins, Robert/0000-0002-5006-0891; Giacalone,
   Joseph/0000-0003-4404-9749; Tucker, Budd/0000-0003-2178-1742
FU NIH Directors New Innovator Award [1-DP2-OD007483-01]; NEI [EY024605];
   NIH [F32 EY022834]; Howard Hughes Medical Institute; Foundation Fighting
   Blindness; Stephen A. Wynn Foundation; NATIONAL EYE INSTITUTE
   [F32EY022834, R01EY024605] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
   [DP2OD007483] Funding Source: NIH RePORTER
FX The present study was supported by the NIH Directors New Innovator Award
   (Grant 1-DP2-OD007483-01); NEI Grant EY024605; NIH Grant F32 EY022834,
   the Howard Hughes Medical Institute; the Foundation Fighting Blindness;
   the Stephen A. Wynn Foundation; and NIH Grant F32 EY022834.
CR Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Baker SA, 2013, CURR TOP MEMBR, V72, P231, DOI 10.1016/B978-0-12-417027-8.00007-6
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Burnight ER, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017434
   Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638
   Chen P, 2015, EXP THER MED, V9, P351, DOI 10.3892/etm.2014.2103
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Croze RH, 2014, DEV OPHTHALMOL, V53, P81, DOI 10.1159/000357361
   DelMonte DW, 2011, J CATARACT REFR SURG, V37, P588, DOI 10.1016/j.jcrs.2010.12.037
   Ding QJ, 2014, INVEST OPHTH VIS SCI, V55, P7065, DOI 10.1167/iovs.14-14800
   Drivas TG, 2013, J CLIN INVEST, V123, P4525, DOI 10.1172/JCI69448
   Du YQ, 2012, INVEST OPHTH VIS SCI, V53, P1566, DOI 10.1167/iovs.11-9134
   Eiraku M, 2012, NAT PROTOC, V7, P69, DOI 10.1038/nprot.2011.429
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Fingert JH, 2011, HUM MOL GENET, V20, P2482, DOI 10.1093/hmg/ddr123
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu Y., 2015, WEBVISION ORG RETINA
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hayashi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045435
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Huopaniemi L, 1997, AM J HUM GENET, V60, P1139
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Libby RT, 2005, ANNU REV GENOM HUM G, V6, P15, DOI 10.1146/annurev.genom.6.080604.162209
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Lovicu FJ, 2011, PHILOS T R SOC B, V366, P1204, DOI 10.1098/rstb.2010.0339
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   MOSES RA, 1977, SURV OPHTHALMOL, V22, P88, DOI 10.1016/0039-6257(77)90088-1
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769
   Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Purves D, 2001, NEUROSCIENCE
   Purves D, 2001, NEUROSCIENCE RETINA
   Qiu XD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032612
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ran X, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau047
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035
   Sahly I, 2012, J CELL BIOL, V199, P381, DOI 10.1083/jcb.201202012
   Sareen D, 2014, STEM CELL TRANSL MED, V3, P1002, DOI 10.5966/sctm.2014-0076
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Schwarz N, 2015, HUM MOL GENET, V24, P972, DOI 10.1093/hmg/ddu509
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sheffield VC, 2011, NEW ENGL J MED, V364, P1932, DOI 10.1056/NEJMra1012354
   Shi YR, 2015, INVEST OPHTH VIS SCI, V56, P799, DOI 10.1167/iovs.14-16028
   Shortt AJ, 2007, STEM CELLS, V25, P1402, DOI 10.1634/stemcells.2006-0580
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Soldner F, 2012, SCIENCE, V338, P1155, DOI 10.1126/science.1227682
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tamm ER, 2007, SURV OPHTHALMOL, V52, pS101, DOI 10.1016/j.survophthal.2007.08.002
   Tucker BA, 2015, TRANSL RES
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Wiley LA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017160
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
   Wiley LA, 2011, DIS MODEL MECH, V4, P484, DOI 10.1242/dmm.006593
   Wiley LA, 2010, MOL VIS, V16, P1253
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 100
TC 13
Z9 13
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD FEB
PY 2016
VL 5
IS 2
BP 132
EP 140
DI 10.5966/sctm.2015-0206
PG 9
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DE8VI
UT WOS:000370914400002
PM 26683869
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pickering, MC
   Cook, HT
AF Pickering, M. C.
   Cook, H. T.
TI Translational Mini-Review Series on Complement Factor H: Renal diseases
   associated with complement factor H: novel insights from humans and
   animals
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Review
DE complement; factor H; glomerulonephritis; thrombosis
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULONEPHRITIS TYPE-II; DENSE DEPOSIT
   DISEASE; HOMOZYGOUS FACTOR-H; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   ALTERNATIVE PATHWAY; NEPHRITIC FACTOR; MOLECULAR-BASIS; SURFACE
   RECOGNITION; GENE-EXPRESSION
AB Factor H is the major regulatory protein of the alternative pathway of complement activation. Abnormalities in factor H have been associated with renal disease, namely glomerulonephritis with C3 deposition including membranoproliferative glomerulonephritis (MPGN) and the atypical haemolytic uraemic syndrome (aHUS). Furthermore, a common factor H polymorphism has been identified as a risk factor for the development of age-related macular degeneration. These associations suggest that alternative pathway dysregulation is a common feature in the pathogenesis of these conditions. However, with respect to factor H-associated renal disease, it is now clear that distinct molecular defects in the protein underlie the pathogenesis of glomerulonephritis and HUS. In this paper we review the associations between human factor H dysfunction and renal disease and explore how observations in both spontaneous and engineered animal models of factor H dysfunction have contributed to our understanding of the pathogenesis of factor H-related renal disease.
C1 [Pickering, M. C.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Mol Genet & Rehumatol Sect, London W12 0NN, England.
   [Cook, H. T.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Histopathol, London W12 0NN, England.
C3 Imperial College London; Imperial College London
RP Pickering, MC (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Fac Med, Mol Genet & Rehumatol Sect, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM matthew.pickering@imperial.ac.uk
OI Pickering, Matthew/0000-0002-1153-0192
CR Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Amadei N, 2001, SCAND J IMMUNOL, V53, P615, DOI 10.1046/j.1365-3083.2001.00931.x
   Andresdottir MB, 1999, NEPHROL DIAL TRANSPL, V14, P1723, DOI 10.1093/ndt/14.7.1723
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   BERGER J, 1962, J Urol Nephrol (Paris), V68, P116
   Bircan Z, 2004, NEPHROL DIAL TRANSPL, V19, P727, DOI 10.1093/ndt/gfg605
   BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156
   Braun MC, 2005, J AM SOC NEPHROL, V16, P2225, DOI 10.1681/ASN.2005020175
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   CAMERON JS, 1983, AM J MED, V74, P175, DOI 10.1016/0002-9343(83)90606-X
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Cheng ZZ, 2006, MOL IMMUNOL, V43, P972, DOI 10.1016/j.molimm.2005.05.011
   Cho HY, 2007, PEDIATR NEPHROL, V22, P874, DOI 10.1007/s00467-007-0438-x
   CONRAD DH, 1978, J EXP MED, V147, P1792, DOI 10.1084/jem.147.6.1792
   DAHA MR, 1976, J IMMUNOL, V116, P1
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Donne RL, 2002, AM J KIDNEY DIS, V40, DOI 10.1053/ajkd.2002.36938
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   DROZ D, 1977, NEPHRON, V19, P1, DOI 10.1159/000180859
   DROZ D, 1979, KIDNEY INT, V15, P386, DOI 10.1038/ki.1979.50
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2006, MOL IMMUNOL, V43, P1769, DOI 10.1016/j.molimm.2005.11.008
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   FALK RJ, 1987, AM J KIDNEY DIS, V9, P121, DOI 10.1016/S0272-6386(87)80089-6
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fijen CAP, 1996, CLIN EXP IMMUNOL, V105, P511, DOI 10.1046/j.1365-2249.1996.d01-777.x
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   GALLE P, 1971, TRANSPLANT P, V3, P368
   Genel F, 2005, SCAND J INFECT DIS, V37, P615, DOI 10.1080/00365540510034536
   GEWURZ AT, 1983, CLIN EXP IMMUNOL, V54, P253
   GORDON DL, 1995, J IMMUNOL, V155, P348
   HABIB R, 1975, KIDNEY INT, V7, P204, DOI 10.1038/ki.1975.32
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARRISON RA, 1980, MOL IMMUNOL, V17, P9, DOI 10.1016/0161-5890(80)90119-4
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   Hogasen K, 1997, VET REC, V140, P392, DOI 10.1136/vr.140.15.392
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   JANSEN JH, 1995, VET REC, V137, P240, DOI 10.1136/vr.137.10.240
   JANSEN JH, 1993, AM J PATHOL, V143, P1356
   Jansen JH, 1998, KIDNEY INT, V53, P331, DOI 10.1046/j.1523-1755.1998.00765.x
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Jozsi M, 2007, MOL IMMUNOL, V44, P3924, DOI 10.1016/j.molimm.2007.06.040
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   KIM Y, 1979, LAB INVEST, V40, P474
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   LEIBOWITCH J, 1979, KIDNEY INT, V15, P396, DOI 10.1038/ki.1979.51
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   LINSHAW MA, 1987, AM J NEPHROL, V7, P470, DOI 10.1159/000167525
   LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MARDER HK, 1983, KIDNEY INT, V23, P749, DOI 10.1038/ki.1983.89
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106
   Naked GM, 2000, CLIN IMMUNOL, V96, P162, DOI 10.1006/clim.2000.4878
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   NIELSEN HE, 1989, SCAND J IMMUNOL, V30, P711, DOI 10.1111/j.1365-3083.1989.tb02480.x
   NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   Ohali M, 1998, PEDIATR NEPHROL, V12, P619, DOI 10.1007/s004670050515
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   PANGBURN MK, 1980, J IMMUNOL, V124, P977
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1
   Pickering MC, 2006, P NATL ACAD SCI USA, V103, P9649, DOI 10.1073/pnas.0601094103
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   RENNKE HG, 1995, KIDNEY INT, V47, P643, DOI 10.1038/ki.1995.82
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Rose KL, 2007, MOL IMMUNOL, V44, P3924, DOI 10.1016/j.molimm.2007.06.041
   Rougier N, 1998, J AM SOC NEPHROL, V9, P2318
   SACKS S, 1993, CLIN EXP IMMUNOL, V93, P411, DOI 10.1111/j.1365-2249.1993.tb08193.x
   SACKS SH, 1993, IMMUNOLOGY, V79, P348
   Sadallah S, 1999, AM J KIDNEY DIS, V33, P1153, DOI 10.1016/S0272-6386(99)70155-1
   Sanchez-Corral P, 2000, IMMUNOGENETICS, V51, P366, DOI 10.1007/s002510050631
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   SCHENA FP, 1982, CLIN NEPHROL, V18, P240
   Schmidt BZ, 1999, J BIOL CHEM, V274, P11782, DOI 10.1074/jbc.274.17.11782
   SCHWAEBLE W, 1991, EUR J BIOCHEM, V198, P399, DOI 10.1111/j.1432-1033.1991.tb16028.x
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIBLEY RK, 1984, KIDNEY INT, V25, P660, DOI 10.1038/ki.1984.71
   SIMPSON IJ, 1978, KIDNEY INT, V13, P467, DOI 10.1038/ki.1978.69
   SISSONS JGP, 1976, NEW ENGL J MED, V294, P461, DOI 10.1056/NEJM197602262940902
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   SPITZER RE, 1969, SCIENCE, V164, P436, DOI 10.1126/science.164.3878.436
   STRIFE CF, 1977, CLIN NEPHROL, V7, P65
   THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110
   VANDENDOBBELSTEEN MEA, 1994, CLIN EXP IMMUNOL, V95, P173
   Vargas R, 1976, Clin Nephrol, V5, P73
   Vaziri-Sani F, 2006, KIDNEY INT, V69, P981, DOI 10.1038/sj.ki.5000155
   VERROUST PJ, 1974, KIDNEY INT, V6, P157, DOI 10.1038/ki.1974.94
   VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956
   VYSE TJ, 1994, Q J MED, V87, P385
   Walker PD, 2007, MODERN PATHOL, V20, P605, DOI 10.1038/modpathol.3800773
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   West CD, 2001, AM J KIDNEY DIS, V37, P1120, DOI 10.1053/ajkd.2001.24511
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 110
TC 129
Z9 139
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD FEB 8
PY 2008
VL 151
IS 2
BP 210
EP 230
DI 10.1111/j.1365-2249.2007.03574.x
PG 21
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 249CU
UT WOS:000252205300002
PM 18190458
OA Green Published
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UH
   Rensch, F
   Von Baltz, S
   Schlichtenbrede, F
AF Jonas, Jost B.
   Spandau, Ulrich H.
   Rensch, Florian
   Von Baltz, Stefan
   Schlichtenbrede, Frank
TI Infectious and noninfectious endophthalmitis after intravitreal
   bevacizumab
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID COHERENCE TOMOGRAPHY FINDINGS; MACULAR EDEMA; INJECTION; AVASTIN(R)
AB Aims: The aim of this study was to evaluate the rate of infectious and noninfectious endophthalmitis after an intravitreal injection of bevacizumab. Methods: This clinical interventional case-series study included 1218 intravitreal injections of 1.5 mg of bevacizumab consecutively performed for 684 eyes with exudative age-related macular degeneration. Among the injections were 534 reinjections. Follow-up after each injection was at least 4 weeks. Results: One (1) eye developed an infectious endophthalmitis 3 days after a second injection. In none of the other eyes, were signs of an infectious or noninfectious endophthalmitis observed with the cellular infiltration or amorphous opacification of the vitreous as marked by the Tyndall phenomenon in the anterior chamber, retinal infiltration, or pain. Conclusions: The rate of infectious endophthalmitis after an intravitreal injection of 1.5 mg bevacizumab may be approximately 1:1000, similar to injections of other drugs available thus far.
C1 Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.jonas@augen.ma.uni-heidelberg.de
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 7
TC 54
Z9 58
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2007
VL 23
IS 3
BP 240
EP 242
DI 10.1089/jop.2006.0146
PG 3
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 181RS
UT WOS:000247454400005
PM 17593007
DA 2022-11-30
ER

PT J
AU Gu, JY
   Qiu, ZX
   Li, LL
   Qin, B
   Zhou, YM
   Liu, Y
   Liu, XJ
   Zhu, MH
   Sang, AM
AF Gu, Jiayi
   Qiu, Zhaoxian
   Li, Lele
   Qin, Bai
   Zhou, Yamei
   Liu, Yu
   Liu, Xiaojuan
   Zhu, Manhui
   Sang, Aimin
TI Geniposide alleviates choroidal neovascularization by downregulating
   HB-EGF release from RPE cells by downregulating the miR-145-5p/ NF-KB
   axis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Wet age-related macular degeneration (AMD); Choroidal neovascularization
   (CNV); Retinal pigment epithelium (RPE); Geniposide (GEN)
ID CEREBRAL CAVERNOUS MALFORMATIONS; UP-REGULATION; GROWTH; ANGIOGENESIS;
   CANCER; MECHANISMS; EXPRESSION; INHIBITION; MANAGEMENT; PROGRESS
AB Age-related macular degeneration (AMD), mainly wet AMD, is the major reason for nonreversible vision loss worldwide. Choroidal neovascularization (CNV) is a characteristic pathological manifestation of wet AMD. Stress or injury to the retinal pigment epithelium (RPE) induces proangiogenic factors that drive CNV. An iridoid glycoside extracted from the fruit of gardenia, geniposide (GEN) plays an antiangiogenic role. In this study, GEN inhibited the transcription and expression of heparin-binding epidermal growth factor (HB-EGF), a proangiogenic factor, in hypoxic RPE cells and a mouse laser-induced CNV model. Inhibition of glucagon-like peptide-1 receptor (GLP-1R), a GEN receptor blocker, eliminated the protective effect of GEN. Additionally, GEN decreased the transcription and expression of HB-EGF in hypoxia-exposed RPE cells by downregulating the miR-145-5p/ NF-KB axis. Therefore, our research provides a promising novel strategy for wet AMD therapy.
C1 [Gu, Jiayi; Qiu, Zhaoxian; Qin, Bai; Liu, Yu; Sang, Aimin] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China.
   [Li, Lele] Nantong Univ, Dept Ophthalmol, Affiliated Hosp 2, Nantong 226001, Jiangsu, Peoples R China.
   [Zhou, Yamei; Liu, Xiaojuan] Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong, Peoples R China.
   [Zhu, Manhui] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University; Nantong University; Soochow
   University - China
RP Sang, AM (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong, Jiangsu, Peoples R China.; Liu, XJ (通讯作者)，Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong, Peoples R China.; Zhu, MH (通讯作者)，Soochow Univ, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
EM lxj@ntu.edu.cn; zhumanhuieye@126.com; sangam@ntu.edu.cn
RI 顾, 佳怡/AAE-6622-2022
OI Liu, Xiao-Juan/0000-0001-7577-2943; Qiu, Zhaoxian/0000-0003-0097-5687;
   gu, jiayi/0000-0003-4024-9305
FU Graduate Technology Innovation Program of Jiangsu Province [SJCX20_1170,
   SJCX20_1169]; Nantong Citizen Life Science and Technology Project
   [MS12020031]; major project of Nantong city [MS22018009]
FX The study was partially supported by the Graduate Technology Innovation
   Program of Jiangsu Province (SJCX20_1170 and SJCX20_1169), the Nantong
   Citizen Life Science and Technology Project (MS12020031) and the major
   project of Nantong city (No. MS22018009).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Chen J, 2015, J PHARMACEUT BIOMED, V108, P122, DOI 10.1016/j.jpba.2015.01.044
   Chen Y, 2019, BIOL OPEN, V8, DOI 10.1242/bio.044800
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Donato L, ANTIOXIDANTS-BASEL, V9
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9
   Donato L., 2020, INT J MOL SCI, V22
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fu C, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106547
   Giridharan S, 2018, J INFLAMM RES, V11, P407, DOI 10.2147/JIR.S140188
   Goitre L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08373-4
   Gunawardhana N, 2018, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00541
   Habtemariam S, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020039
   Hebsgaard JB, 2018, DIABETES OBES METAB, V20, P2304, DOI 10.1111/dom.13339
   Heo J, 2018, J CELL BIOCHEM, V119, P5297, DOI 10.1002/jcb.26639
   Hollborn M, 2005, MOL VIS, V11, P397
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Hollborn M, 2009, INVEST OPHTH VIS SCI, V50, P4452, DOI 10.1167/iovs.08-3194
   Inoue Y, 2018, ARTERIOSCL THROM VAS, V38, P174, DOI 10.1161/ATVBAHA.117.310337
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin CH, 2019, J CELL BIOCHEM, V120, P11115, DOI 10.1002/jcb.28388
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kim DI, 2015, INT J BIOCHEM CELL B, V59, P41, DOI 10.1016/j.biocel.2014.11.018
   Kir D, 2018, ANGIOGENESIS, V21, P699, DOI 10.1007/s10456-018-9632-7
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Kushwaha R, 2019, J NEUROCHEM, V149, P679, DOI 10.1111/jnc.14610
   Lawson J, 2017, ONCOTARGET, V8, P83913, DOI 10.18632/oncotarget.19996
   Lennikov A, 2018, ANGIOGENESIS, V21, P267, DOI 10.1007/s10456-018-9594-9
   Li N, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101215
   Li N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7480512
   Liang SW, 2017, CANCER LETT, V386, P12, DOI 10.1016/j.canlet.2016.11.003
   Liu WZ, 2015, REV NEUROSCIENCE, V26, P371, DOI 10.1515/revneuro-2015-0005
   Ma SL, 2019, ARTIF CELL NANOMED B, V47, P2875, DOI 10.1080/21691401.2019.1626406
   Maachi H, 2020, DIABETES, V69, P369, DOI 10.2337/db19-0643
   Mei LL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091833
   Mu HQ, 2020, CLIN TRANSL ONCOL, V22, P111, DOI 10.1007/s12094-019-02217-5
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Peng W, 2020, BRAIN RES BULL, V160, P74, DOI 10.1016/j.brainresbull.2020.04.003
   Puddu A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/975032
   Rinaldi C, 2017, J NEUROL SCI, V380, P31, DOI 10.1016/j.jns.2017.06.043
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Scimone C., 2020, ANTIOXIDANTS-BASEL, V9
   Scimone C, 2020, ANTIOXIDANTS-BASEL
   Scimone C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00953
   Scimone C, 2016, BMC MED GENET, V17, DOI 10.1186/s12881-016-0332-0
   Scuderi R, 2008, CLIN TER, V159, P111
   Shim JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep26794
   Song P, 2020, FREE RADICAL BIO MED, V152, P186, DOI 10.1016/j.freeradbiomed.2020.02.011
   Sun MH, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117988
   Taylor HR, 2019, ASIA-PAC J OPHTHALMO, V8, P424, DOI 10.1097/APO.0000000000000264
   Taylor SR, 2014, SEMIN CELL DEV BIOL, V28, P22, DOI 10.1016/j.semcdb.2014.03.004
   Thuringer D, 2016, ONCOTARGET, V7, P28160, DOI 10.18632/oncotarget.8583
   Tiwari A, 2018, CURR CANCER DRUG TAR, V18, P266, DOI 10.2174/1568009617666170630142725
   Tsai Y.M., 2020, INT J MOL SCI, V21
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Yde P, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-115
   Yin F, 2010, BIOL PHARM BULL, V33, P1841, DOI 10.1248/bpb.33.1841
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Zhang C, 2020, BRIT J PHARMACOL, V177, P3240, DOI 10.1111/bph.15046
   Zhang ZQ, 2018, CANCER MED-US, V7, P5611, DOI 10.1002/cam4.1783
   Zhou YX, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/4925682
   Zhu CC, 2018, BBA-MOL BASIS DIS, V1864, P387, DOI 10.1016/j.bbadis.2017.10.033
NR 67
TC 3
Z9 3
U1 2
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2021
VL 208
AR 108624
DI 10.1016/j.exer.2021.108624
EA MAY 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SV3WE
UT WOS:000663751900005
PM 34022175
DA 2022-11-30
ER

PT J
AU Zhang, S
   Gu, HW
   Hu, N
AF Zhang, Su
   Gu, Hongwei
   Hu, Nan
TI Role of Peroxisome Proliferator-Activated Receptor gamma in Ocular
   Diseases
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE
   PRODUCTION; PPAR-GAMMA; INSULIN SENSITIZER; OXIDATIVE STRESS;
   15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CORNEAL NEOVASCULARIZATION;
   PROMOTES NEUROPROTECTION; THERAPEUTIC TARGET
AB Peroxisome proliferator-activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that plays an important role in the control of a variety of physiological processes. The last decade has witnessed an increasing interest for the role played by the agonists of PPAR gamma in antiangiogenesis, antifibrosis, anti-inflammation effects and in controlling oxidative stress response in various organs. As the pathologic mechanisms of major blinding diseases, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), keratitis, and optic neuropathy, often involve neoangiogenesis and inflammation- and oxidative stress-mediated cell death, evidences are accumulating on the potential benefits of PPAR gamma to improve or prevent these vision threatening eye diseases. In this paper we describe what is known about the role of PPAR gamma in the ocular pathophysiological processes and PPAR gamma agonists as novel adjuvants in the treatment of eye diseases.
C1 [Zhang, Su; Gu, Hongwei; Hu, Nan] Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University
RP Hu, N (通讯作者)，Nantong Univ, Dept Ophthalmol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.
EM hunaneye@hotmail.com
CR Abdelrahman M, 2005, CARDIOVASC RES, V65, P772, DOI 10.1016/j.cardiores.2004.12.008
   Asgary Seddighe, 2002, Journal of Herbal Pharmacotherapy, V2, P47, DOI 10.1080/J157v02n02_05
   Azar Dimitri T, 2006, Trans Am Ophthalmol Soc, V104, P264
   Azar S, 2013, CAN J OPHTHALMOL, V48, P312, DOI 10.1016/j.jcjo.2013.04.003
   Baba T, 2001, DIABETES CARE, V24, P953, DOI 10.2337/diacare.24.5.953
   Balasubramanyam M, 2003, J BIOSCIENCES, V28, P715, DOI 10.1007/BF02708432
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9
   Beauregard C, 2003, J OCUL PHARMACOL TH, V19, P579, DOI 10.1089/108076803322660495
   Bhatia B, 2012, ACTA NEUROPATHOL, V123, P587, DOI 10.1007/s00401-012-0968-6
   Bishop-Bailey D, 2011, BIOCHEM SOC T, V39, P1601, DOI 10.1042/BST20110643
   Bishop-Bailey D, 2009, PHARMACOL THERAPEUT, V124, P141, DOI 10.1016/j.pharmthera.2009.06.011
   Bloise W, 2011, ARQ BRAS ENDOCRINOL, V55, P692, DOI 10.1590/S0004-27302011000900004
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calkin AC, 2005, ARTERIOSCL THROM VAS, V25, P1903, DOI 10.1161/01.ATV.0000177813.99577.6b
   Cariou B, 2012, TRENDS ENDOCRIN MET, V23, P205, DOI 10.1016/j.tem.2012.03.001
   Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046
   CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302
   Chen YH, 2014, MOL MED REP, V9, P2015, DOI 10.3892/mmr.2014.2041
   Choi JM, 2012, MOL CELLS, V33, P217, DOI 10.1007/s10059-012-2297-y
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388
   Colucciello M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1273, DOI 10.1001/archopht.123.9.1273
   da Silva FMC, 2013, BIOORG MED CHEM LETT, V23, P5795, DOI 10.1016/j.bmcl.2013.09.010
   Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145
   Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913
   Emoto M, 2001, DIABETES, V50, P1166, DOI 10.2337/diabetes.50.5.1166
   Engle SK, 2010, TOXICOL SCI, V114, P183, DOI 10.1093/toxsci/kfp311
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Escribano L, 2009, BIOCHEM BIOPH RES CO, V379, P406, DOI 10.1016/j.bbrc.2008.12.071
   Esposito E, 2011, EXPERT OPIN THER TAR, V15, P943, DOI 10.1517/14728222.2011.581231
   Fan F, 2012, GRAEF ARCH CLIN EXP, V250, P1213, DOI 10.1007/s00417-011-1903-6
   Fong DS, 2009, AM J OPHTHALMOL, V147, P583, DOI 10.1016/j.ajo.2008.10.016
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Gelman L, 2007, BBA-MOL CELL BIOL L, V1771, P1094, DOI 10.1016/j.bbalip.2007.03.004
   Giaginis C, 2007, EXPERT OPIN INV DRUG, V16, P1561, DOI 10.1517/13543784.16.10.1561
   Giaginis C, 2009, PHARMACOL RES, V60, P160, DOI 10.1016/j.phrs.2009.02.005
   Guo NX, 2011, J BIOL CHEM, V286, P18856, DOI 10.1074/jbc.M110.179317
   Hatanaka H, 2012, INVEST OPHTH VIS SCI, V53, P6955, DOI 10.1167/iovs.12-10488
   Herm RJ, 2008, NEW ENGL J MED, V359, P1735
   Herwig MC, 2013, EXP EYE RES, V107, P52, DOI 10.1016/j.exer.2012.11.012
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Higuchi A, 2010, ARTERIOSCL THROM VAS, V30, P46, DOI 10.1161/ATVBAHA.109.198465
   Houseknecht KL, 2002, DOMEST ANIM ENDOCRIN, V22, P1, DOI 10.1016/S0739-7240(01)00117-5
   Huxlin KR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070785
   HYVONEN T, 1990, J BIOCHEM-TOKYO, V107, P817, DOI 10.1093/oxfordjournals.jbchem.a123131
   Idris I, 2012, ARCH INTERN MED, V172, P1005, DOI 10.1001/archinternmed.2012.1938
   Jester JV, 2012, OCUL SURF, V10, P224, DOI 10.1016/j.jtos.2012.07.001
   Ji S, 2009, EXP NEUROL, V216, P321, DOI 10.1016/j.expneurol.2008.12.007
   Jiang YD, 2014, J BIOL CHEM, V289, P26395, DOI 10.1074/jbc.M114.583880
   Kaur J, 2010, EUR J CANCER PREV, V19, P319, DOI 10.1097/CEJ.0b013e32833ad385
   Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007
   Kim J, 2005, EXP EYE RES, V81, P65, DOI 10.1016/j.exer.2005.01.010
   KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393
   Knapp P, 2012, PPAR RES, V2012, DOI 10.1155/2012/471524
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kumar S, 2004, J CLIN ENDOCR METAB, V89, P930, DOI 10.1210/jc.2003-031427
   Kung J, 2012, EXPERT OPIN DRUG SAF, V11, P565, DOI 10.1517/14740338.2012.691963
   Kuriyan AE, 2012, EXP EYE RES, V94, P136, DOI 10.1016/j.exer.2011.11.018
   Lea MA, 2004, ANTICANCER RES, V24, P2765
   Lee C, 2008, J CUTAN PATHOL, V35, P989, DOI 10.1111/j.1600-0560.2007.00939.x
   Lee CH, 2002, TRENDS ENDOCRIN MET, V13, P331, DOI 10.1016/S1043-2760(02)00668-9
   Lee CH, 2011, J NEUROL SCI, V300, P120, DOI 10.1016/j.jns.2010.09.005
   Lehmann GM, 2008, PPAR RES, V2008, DOI 10.1155/2008/895901
   Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335
   Li PY, 2011, CURR EYE RES, V36, P673, DOI 10.3109/02713683.2011.572220
   Li YC, 2011, NEUROL SCI, V32, P1095, DOI 10.1007/s10072-011-0711-4
   Liang XC, 2002, PHYTOMEDICINE, V9, P377, DOI 10.1078/09447110260571599
   Liu JL, 2012, CHINESE MED J-PEKING, V125, P3719, DOI 10.3760/cma.j.issn.0366-6999.2012.20.022
   Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0
   Meyer S, 2010, PPAR RES, V2010, DOI 10.1155/2010/848645
   Mimura LY, 2003, THYROID, V13, P845, DOI 10.1089/105072503322401032
   Misra P, 2003, J PHARMACOL EXP THER, V306, P763, DOI 10.1124/jpet.103.049791
   Motomura K, 2009, J AGR FOOD CHEM, V57, P7666, DOI 10.1021/jf9007168
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841
   Muranaka K, 2006, INVEST OPHTH VIS SCI, V47, P4547, DOI 10.1167/iovs.05-1432
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709
   Musser A W, 1975, CRC Crit Rev Clin Lab Sci, V6, P47, DOI 10.3109/10408367509151564
   Niemeyer NV, 2002, PHARMACOTHERAPY, V22, P924, DOI 10.1592/phco.22.11.924.33626
   Nien CJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P462, DOI 10.1001/archophthalmol.2011.69
   Nien CJ, 2009, EXP EYE RES, V89, P1021, DOI 10.1016/j.exer.2009.08.013
   Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931
   Okunuki Y, 2013, EXP EYE RES, V116, P291, DOI 10.1016/j.exer.2013.09.017
   Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4
   Pan HW, 2011, MOL BIOL REP, V38, P4501, DOI 10.1007/s11033-010-0581-5
   Pan HW, 2009, MOL VIS, V15, P2279
   Panigrahy D, 2005, CANCER BIOL THER, V4, P687, DOI 10.4161/cbt.4.7.2014
   Pereira MP, 2005, J NEUROPATH EXP NEUR, V64, P797, DOI 10.1097/01.jnen.0000178852.83680.3c
   Polvani S, 2012, PPAR RES, V2012, DOI 10.1155/2012/641087
   Poulsen LL, 2012, SEMIN CELL DEV BIOL, V23, P631, DOI 10.1016/j.semcdb.2012.01.003
   Qi L, 2010, INT J CLIN EXP MED, V3, P283
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Racke MK, 2006, J NUTR, V136, P700, DOI 10.1093/jn/136.3.700
   Ramkalawan H, 2012, INFLAMMATION, V35, P1338, DOI 10.1007/s10753-012-9447-4
   Ren YS, 2009, VASC PHARMACOL, V51, P169, DOI 10.1016/j.vph.2009.06.004
   Richard CL, 2007, INT J ONCOL, V30, P1215
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rival Y, 2004, J PHARMACOL EXP THER, V311, P467, DOI 10.1124/jpet.104.068254
   Rodrigues GA, 2011, INVEST OPHTH VIS SCI, V52, P890, DOI 10.1167/iovs.10-5715
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Rousseaux C, 2005, J EXP MED, V201, P1205, DOI 10.1084/jem.20041948
   Saika S, 2007, AM J PHYSIOL-CELL PH, V293, pC75, DOI 10.1152/ajpcell.00332.2006
   Sakamoto J, 2004, EUR J PHARMACOL, V495, P17, DOI 10.1016/j.ejphar.2004.05.020
   Sarayba MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/j.exer.2004.10.009
   Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102
   Shen LQ, 2008, ARCH OPHTHALMOL-CHIC, V126, P793, DOI 10.1001/archopht.126.6.793
   Sheu SH, 2005, BIOCHEMISTRY-US, V44, P1193, DOI 10.1021/bi048032c
   Shibata T, 1999, EUR J PHARMACOL, V364, P211, DOI 10.1016/S0014-2999(98)00832-2
   Sime PJ, 2008, J INVEST MED, V56, P534, DOI 10.2310/JIM.0b013e31816464e9
   Sokolowska Milena, 2005, Postepy Hig Med Dosw (Online), V59, P472
   Song MK, 2012, BRIT J PHARMACOL, V165, P4, DOI 10.1111/j.1476-5381.2011.01411.x
   Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460
   Starkey K, 2003, J CLIN ENDOCR METAB, V88, P55, DOI 10.1210/jc.2002-020987
   Strauss O., 1995, RETINAL PIGMENT EPIT
   Szatmari I, 2006, ANN NY ACAD SCI, V1088, P207, DOI 10.1196/annals.1366.013
   Szeles L, 2007, BBA-MOL CELL BIOL L, V1771, P1014, DOI 10.1016/j.bbalip.2007.02.005
   Tarbett Aaron K, 2011, J Diabetes Sci Technol, V5, P945
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Uchiyama M, 2013, MOL VIS, V19, P2135
   Ulivieri C, 2007, MINI-REV MED CHEM, V7, P877, DOI 10.2174/138955707781662618
   Usui T, 2008, INVEST OPHTH VIS SCI, V49, P4370, DOI 10.1167/iovs.07-0964
   van Neerven S, 2007, PPAR RES, V2007, DOI 10.1155/2007/29275
   Vanden Heuvel JP, 2012, PROG MOL BIOL TRANSL, V108, P75, DOI 10.1016/B978-0-12-398397-8.00004-6
   Walczak R, 2002, J LIPID RES, V43, P177
   Wang HY, 2008, HEPATOB PANCREAT DIS, V7, P179
   Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200
   Wang TT, 2006, CRIT REV ONCOL HEMAT, V58, P1, DOI 10.1016/j.critrevonc.2005.08.011
   Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116
   Yamanaka O, 2009, INVEST OPHTH VIS SCI, V50, P187, DOI 10.1167/iovs.08-2282
   Yang XX, 2011, INT J OPHTHALMOL-CHI, V4, P143, DOI 10.3980/j.issn.2222-3959.2011.02.06
   Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074
   Young PW, 1998, J PHARMACOL EXP THER, V284, P751
   Zang CB, 2006, CELL CYCLE, V5, P2237, DOI 10.4161/cc.5.19.3259
   Zhang X, 2002, INT IMMUNOPHARMACOL, V2, P1029, DOI 10.1016/S1567-5769(02)00057-7
   Zhang XY, 2013, INVEST OPHTH VIS SCI, V54, P3912, DOI 10.1167/iovs.13-11614
   Zhao PQ, 2013, EXP EYE RES, V107, P65, DOI 10.1016/j.exer.2012.11.014
   Zhao Y, 2006, FASEB J, V20, P1162, DOI 10.1096/fj.05-5007com
   Zheng Z, 2010, DIABETES, V59, P2315, DOI 10.2337/db10-0638
   Zhou YJ, 2007, LAB INVEST, V87, P488, DOI 10.1038/labinvest.3700532
   Zhu JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068935
   ZHU YJ, 1993, J BIOL CHEM, V268, P26817
   Zingarelli B, 2005, SHOCK, V23, P393, DOI 10.1097/01.shk.0000160521.91363.88
   Zuckerman SH, 2002, LIPIDS, V37, P487, DOI 10.1007/s11745-002-0922-2
NR 150
TC 109
Z9 111
U1 1
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 275435
DI 10.1155/2015/275435
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK5PO
UT WOS:000356278200001
PM 26146566
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sun, YN
   Liu, B
   Wang, JJ
   Li, XM
   Zhu, JY
   Liu, C
   Yao, J
   Zhong, YL
   Jiang, Q
   Yan, B
AF Sun, Ya-Nan
   Liu, Ban
   Wang, Jia-Jian
   Li, Xiu-Miao
   Zhu, Jun-Ya
   Liu, Chang
   Yao, Jin
   Zhong, Yu-ling
   Jiang, Qin
   Yan, Biao
TI Identification of aberrantly expressed circular RNAs in
   hyperlipidemia-induced retinal vascular dysfunction in mice
SO GENOMICS
LA English
DT Article
DE Circular RNAs; Hyperlipidemia; GO analysis; KEGG pathway analysis
AB Hyperlipidemia-induced retinal vascular dysfunction is a complex pathological process. circRNAs are important regulators of biological processes and disease progression. However, the expression pattern of circRNAs in hyperlipidemia-induced retinal vascular dysfunction remains unclear. Herein, we used a murine model of hyperlipidemia and identified 317 differentially expressed circRNAs between hyperlipidemic retinas and normolipidemic retinas by circRNA microarrays. GO analysis indicated that the host genes of dysregulated circRNAs were targeted to cell differentiation (ontology: biological process), cytoplasm (ontology: cellular component), and protein binding (ontology: molecular function). Pathway analysis revealed that circRNAs-mediated network was mostly enriched in focal adhesion signaling. Notably, circLDB1 was significantly up-regulated in the serum of coronary artery disease patients and aqueous humor of age-related macular degeneration patients. circLDB1 regulated endothelial cell viability, proliferation, and apoptosis in vitro. Thus, circRNAs are the promising targets for the prediction and diagnosis of hyperlipidemia-induced vascular diseases.
C1 [Sun, Ya-Nan; Wang, Jia-Jian; Yan, Biao] Fudan Univ, Eye Inst, Eye & ENT Hosp, Shanghai 200031, Peoples R China.
   [Sun, Ya-Nan; Wang, Jia-Jian; Yan, Biao] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai 200031, Peoples R China.
   [Liu, Ban] Tongji Univ, Dept Cardiol, Shanghai Tenth Peoples Hosp, Sch Med, Shanghai, Peoples R China.
   [Li, Xiu-Miao; Zhu, Jun-Ya; Liu, Chang; Yao, Jin; Zhong, Yu-ling; Jiang, Qin] Nanjing Med Univ, Fourth Sch Clin Med, Nanjing, Peoples R China.
   [Li, Xiu-Miao; Zhu, Jun-Ya; Jiang, Qin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China.
   [Yan, Biao] Fudan Univ, NHC Key Lab Myopia, Key Lab Myopia, Chinese Acad Med Sci, Shanghai 200031, Peoples R China.
   [Yan, Biao] Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
C3 Fudan University; Fudan University; Tongji University; Nanjing Medical
   University; Nanjing Medical University; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Fudan University
RP Jiang, Q (通讯作者)，Nanjing Med Univ, Fourth Sch Clin Med, Nanjing, Peoples R China.; Jiang, Q (通讯作者)，Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China.; Yan, B (通讯作者)，Fudan Univ, 83 Fen Yang Rd, Shanghai 200030, Peoples R China.
EM jqin710@vip.sina.com; biao.yan@fdeent.org
FU National Natural Science Foundation of China [81770945, 81970809,
   81800858, 81470594, 81570859]; Medical Science and Technology
   Development Project Fund of Nanjing [ZKX1705, YKK19158]; Innovation Team
   Project Fund of Jiangsu Province [CXTDB2017010]; Science and Technology
   Development Plan Project Fund of Nanjing [201716007]
FX This work was generously supported by the grants from the National
   Natural Science Foundation of China (Grant No. 81770945, 81970809,
   81800858, 81470594, and 81570859), grants from the Medical Science and
   Technology Development Project Fund of Nanjing (Grant No ZKX1705 and
   YKK19158), grants from Innovation Team Project Fund of Jiangsu Province
   (No. CXTDB2017010), and the Science and Technology Development Plan
   Project Fund of Nanjing (Grant No 201716007).
CR Ansar S, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-61
   Arnaiz E, 2019, SEMIN CANCER BIOL, V58, P90, DOI 10.1016/j.semcancer.2018.12.002
   Baumer Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01186-z
   Cheng HS, 2013, EMBO MOL MED, V5, P1017, DOI 10.1002/emmm.201202318
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Eelen G, 2015, CIRC RES, V116, P1231, DOI 10.1161/CIRCRESAHA.116.302855
   Fiedler J, 2018, CARDIOVASC RES, V114, P1281, DOI 10.1093/cvr/cvy121
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Floris G, 2017, MOL NEUROBIOL, V54, P5156, DOI 10.1007/s12035-016-0055-4
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Huang QH, 2013, ARTERIOSCL THROM VAS, V33, P795, DOI 10.1161/ATVBAHA.113.301220
   Jaulim A, 2013, RETINA-J RET VIT DIS, V33, P901, DOI 10.1097/IAE.0b013e3182870c15
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Karali M, 2019, HUM GENET, V138, P957, DOI 10.1007/s00439-018-1931-y
   Kawakami A, 2008, CIRCULATION, V118, P731, DOI 10.1161/CIRCULATIONAHA.108.784785
   KEANE WF, 1988, AM J CLIN NUTR, V47, P157, DOI 10.1093/ajcn/47.1.157
   Khera AV, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2016.160
   Kim S, 2018, J BIOL CHEM, V293, P18989, DOI 10.1074/jbc.RA118.005197
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kowluru RA, 2016, METABOLISM, V65, P1570, DOI 10.1016/j.metabol.2016.07.012
   Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7
   Last AR, 2011, AM FAM PHYSICIAN, V84, P551
   Leung H, 2005, EYE, V19, P861, DOI 10.1038/sj.eye.6701668
   Li T, 2015, AM J PHYSIOL-ENDOC M, V308, pE257, DOI 10.1152/ajpendo.00348.2014
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li XY, 2016, ARTERIOSCL THROM VAS, V36, P1090, DOI 10.1161/ATVBAHA.115.306964
   Liu AJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12550
   Luchetti F, 2017, REDOX BIOL, V13, P581, DOI 10.1016/j.redox.2017.07.014
   Malakar AK, 2019, J CELL PHYSIOL, V234, P16812, DOI 10.1002/jcp.28350
   Nelson RH, 2013, PRIMARY CARE, V40, P195, DOI 10.1016/j.pop.2012.11.003
   Owens AP, 2014, TRENDS CARDIOVAS MED, V24, P95, DOI 10.1016/j.tcm.2013.07.003
   Pan XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13011
   Panda AC, 2018, ADV EXP MED BIOL, V1087, P67, DOI 10.1007/978-981-13-1426-1_6
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003
   Salzman J, 2016, TRENDS GENET, V32, P309, DOI 10.1016/j.tig.2016.03.002
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Shan K, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.145
   Sharma Y, 2017, EUR J NUTR, V56, P2013, DOI 10.1007/s00394-017-1406-2
   Stepien E, 2018, ACTA PHARMACOL SIN, V39, P1085, DOI 10.1038/aps.2018.35
   Tietge UJF, 2014, CURR OPIN LIPIDOL, V25, P94, DOI 10.1097/MOL.0000000000000051
   Tsai FJ, 2018, J ETHNOPHARMACOL, V219, P71, DOI 10.1016/j.jep.2018.03.006
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang W., 2019, BIOMED RES INT, V2019
   WHATLEY RE, 1990, PROG LIPID RES, V29, P45, DOI 10.1016/0163-7827(90)90005-6
   Xie KL, 2020, AM J PHYSIOL-CELL PH, V319, pC579, DOI 10.1152/ajpcell.00001.2020
   Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115
   Zhao ZJ, 2017, RNA BIOL, V14, P514, DOI 10.1080/15476286.2015.1122162
   Zhou Y, 2016, AM J PHYSIOL-CELL PH, V310, pC305, DOI 10.1152/ajpcell.00230.2015
NR 51
TC 1
Z9 1
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD JAN
PY 2021
VL 113
IS 1
BP 593
EP 600
DI 10.1016/j.ygeno.2020.09.055
EA JAN 2021
PN 2
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA QB0SM
UT WOS:000613852700009
PM 32991963
OA Bronze
DA 2022-11-30
ER

PT J
AU Martin, M
   Leffler, J
   Smolag, KI
   Mytych, J
   Bjork, A
   Chaves, LD
   Alexander, JJ
   Quigg, RJ
   Blom, AM
AF Martin, M.
   Leffler, J.
   Smolag, K. I.
   Mytych, J.
   Bjork, A.
   Chaves, L. D.
   Alexander, J. J.
   Quigg, R. J.
   Blom, A. M.
TI Factor H uptake regulates intracellular C3 activation during apoptosis
   and decreases the inflammatory potential of nucleosomes
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID COMPLEMENT-FACTOR-H; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MACULAR DEGENERATION;
   AGE; CELLS; DISEASE; SERUM; MICE; EYE; AUTOIMMUNITY
AB Factor H (FH) binds apoptotic cells to limit the inflammatory potential of complement. Here we report that FH is actively internalized by apoptotic cells to enhance cathepsin L-mediated cleavage of endogenously expressed C3, which results in increased surface opsonization with iC3b. In addition, internalized FH forms complexes with nucleosomes, facilitates their phagocytosis by monocytes and induces an anti-inflammatory biased cytokine profile. A similar cytokine response was noted for apoptotic cells coated with FH, confirming that FH diminishes the immunogenic and inflammatory potential of autoantigens. These findings were supported by in vivo observations from CFH-/- MRL-lpr mice, which exhibited higher levels of circulating nucleosomes and necrotic cells than their CFH+/+ littermates. This unconventional function of FH broadens the established view of apoptotic cell clearance and appears particularly important considering the strong associations with genetic FH alterations and diseases such as systemic lupus erythematosus and age-related macular degeneration.
C1 [Martin, M.; Leffler, J.; Smolag, K. I.; Mytych, J.; Bjork, A.; Blom, A. M.] Lund Univ, Sect Med Prot Chem, Dept Translat Med Malmo, Inga Marie Nilssons Gata 53, S-20502 Malmo, Sweden.
   [Chaves, L. D.; Alexander, J. J.; Quigg, R. J.] Univ Buffalo, Nephrol Sect, Dept Med, Buffalo, NY USA.
C3 Lund University; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo
RP Blom, AM (通讯作者)，Lund Univ, Sect Med Prot Chem, Dept Translat Med Malmo, Inga Marie Nilssons Gata 53, S-20502 Malmo, Sweden.
EM anna.blom@med.lu.se
RI Blom, Anna/B-9607-2009; Mytych, Jennifer/AAK-5961-2020; Leffler,
   Jonatan/A-8748-2018; Blom, Anna/AFS-7369-2022; Leffler,
   Jonatan/D-4630-2011; Alexander, Jessy/ABA-7664-2020
OI Blom, Anna/0000-0002-1348-1734; Mytych, Jennifer/0000-0002-1265-973X;
   Leffler, Jonatan/0000-0001-5674-8462; Leffler,
   Jonatan/0000-0001-5674-8462; Smolag-Klosowska,
   Karolina/0000-0001-6940-7130; Martin, Myriam/0000-0003-1526-8678
FU Swedish Research Council [K2012-66X-14928-09-5]; Cancerfonden; Skane
   University Hospital; Foundation of Osterlund; Foundation of Crafoord;
   Foundation of Greta and Johan Kock; Foundation of Lars Hiertas Minne;
   Foundation of Tore Nilsson; Foundation of King Gustav V's 80th
   Anniversary; Foundation of Knut and Alice Wallenberg; Foundation of
   Inga-Britt; Foundation of Arne Lundberg
FX We thank Dr. Ben King, Lund University, for language revision of the
   manuscript and Dr. Christiane Desel, University of Oxford, for
   discussion of our cytokine data. Jennifer Mytych and Karolina I. Smolag
   are students of Biotechnology at University of Rzeszow, Poland. This
   study was supported by the Swedish Research Council
   (K2012-66X-14928-09-5), Cancerfonden, Foundations of Osterlund,
   Crafoord, Greta and Johan Kock, Lars Hiertas Minne, Tore Nilsson, King
   Gustav V's 80th Anniversary, Knut and Alice Wallenberg, Inga-Britt and
   Arne Lundberg and grants for clinical research (ALF and from the Skane
   University Hospital).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ao W, 2011, RHEUMATOL INT, V31, P865, DOI 10.1007/s00296-010-1379-4
   Bao LH, 2002, J IMMUNOL, V168, P3601, DOI 10.4049/jimmunol.168.7.3601
   Bao LH, 2011, J AM SOC NEPHROL, V22, P285, DOI 10.1681/ASN.2010060647
   Botto M, 2002, IMMUNOBIOLOGY, V205, P395, DOI 10.1078/0171-2985-00141
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Jonsen A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3539
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kolev M, 2014, NAT REV IMMUNOL, V14, P811, DOI 10.1038/nri3761
   Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313
   Munoz LE, 2010, NAT REV RHEUMATOL, V6, P280, DOI 10.1038/nrrheum.2010.46
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pillai S, 2012, ANNU REV IMMUNOL, V30, P357, DOI 10.1146/annurev-immunol-020711-075018
   Radic M, 2011, AUTOIMMUNITY, V44, P349, DOI 10.3109/08916934.2010.536794
   Repnik U, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008755
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Stephan F, 2014, ARTHRITIS RHEUMATOL, V66, P686, DOI 10.1002/art.38265
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Williams RC, 2001, J RHEUMATOL, V28, P81
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
NR 33
TC 64
Z9 66
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD MAY
PY 2016
VL 23
IS 5
BP 903
EP 911
DI 10.1038/cdd.2015.164
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DJ3SW
UT WOS:000374127500015
PM 26768663
OA Green Accepted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kamao, H
   Mandai, M
   Okamoto, S
   Sakai, N
   Suga, A
   Sugita, S
   Kiryu, J
   Takahashi, M
AF Kamao, Hiroyuki
   Mandai, Michiko
   Okamoto, Satoshi
   Sakai, Noriko
   Suga, Akiko
   Sugita, Sunao
   Kiryu, Junichi
   Takahashi, Masayo
TI Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal
   Pigment Epithelium Cell Sheets Aiming for Clinical Application
SO STEM CELL REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; RCS RAT; GENERATION; DYSTROPHY; TRANSPLANTATION;
   MUTATIONS; MOUSE; GENE; IDENTIFICATION; INDUCTION
AB Age-related macular degeneration (AMD) causes severe visual impairment due in part to age-dependent impairment of retinal pigment epithelium (RPE). It has been suggested that autologous human induced pluripotent stem cells (hiPSCs) may represent a useful cell source for the generation of graft RPE. We generated hiPSC-derived RPE (hiPSC-RPE) cell sheets optimized to meet clinical use requirements, including quality, quantity, consistency, and safety. These cell sheets are generated as a monolayer of cells without any artificial scaffolds, express typical RPE markers, form tight junctions that exhibit polarized secretion of growth factors, and show phagocytotic ability and gene-expression patterns similar to those of native RPE. Additionally, upon transplantation, autologous nonhuman primate iPSC-RPE cell sheets showed no immune rejection or tumor formation. These results suggest that autologous hiPSC-RPE cell sheets may serve as a useful form of graft for use in tissue replacement therapy for AMD.
C1 [Kamao, Hiroyuki; Mandai, Michiko; Okamoto, Satoshi; Sakai, Noriko; Suga, Akiko; Sugita, Sunao; Takahashi, Masayo] RIKEN, Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
   [Kamao, Hiroyuki; Kiryu, Junichi] Kawasaki Med Sch, Dept Ophthalmol, Kurashiki, Okayama 7010114, Japan.
C3 RIKEN; Kawasaki Medical School
RP Takahashi, M (通讯作者)，RIKEN, Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
EM mretina@cdb.riken.jp
RI Okamoto, Satoshi/F-7309-2013
OI Okamoto, Satoshi/0000-0003-4071-9696; Kamao,
   Hiroyuki/0000-0002-2194-7063; Suga, Akiko/0000-0001-6609-2647
FU Project for Realization of Regenerative Medicine, MEXT
FX We thank Y. Kurimoto and Y. Hirami for providing skin samples from
   patients with RP; T. Kasukawa for analyzing the gene expression of
   hiPSC-RPE; T. Yasukawa for valuable comments on this work; C. Yamada, K.
   Iseki, Y. Wataoka, and K. Sadamoto for excellent technical assistance;
   and members of the Takahashi laboratory for discussions. This study was
   supported by a grant from the Project for Realization of Regenerative
   Medicine, MEXT.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Harimoto M, 2002, J BIOMED MATER RES, V62, P464, DOI 10.1002/jbm.10228
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Mason C, 2009, REGEN MED, V4, P153, DOI 10.2217/17460751.4.2.153
   Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198
   Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shimizu T, 2001, TISSUE ENG, V7, P141, DOI 10.1089/107632701300062732
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 38
TC 411
Z9 432
U1 4
U2 152
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD FEB 11
PY 2014
VL 2
IS 2
BP 205
EP 218
DI 10.1016/j.stemcr.2013.12.007
PG 14
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AI1XD
UT WOS:000336647600010
PM 24527394
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Han, HT
   Yang, YH
   Wu, ZP
   Liu, B
   Dong, LJ
   Deng, HW
   Tian, JK
   Lei, HT
AF Han, Haote
   Yang, Yanhui
   Wu, Zhipan
   Liu, Bing
   Dong, Lijun
   Deng, Hongwei
   Tian, Jingkui
   Lei, Hetian
TI Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary
   human retinal microvascular endothelial cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Capilliposide B; Proliferative diabetic retinopathy; VEGF; VEGFR2; Akt;
   Erk; Migration; Proliferation; Tube formation
ID GROWTH-FACTOR; ORF VIRUS; SAPONINS; PROTEIN; PHOSPHORYLATION;
   BEVACIZUMAB; RECEPTOR-2; ACTIVATION; EXPRESSION; AKT/PKB
AB Abnormal angiogenesis is associated with intraocular diseases such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, and current therapies for these eye diseases are not satisfactory. The purpose of this study was to determine whether capilliposide B (CPS-B), a novel oleanane triterpenoid saponin derived from Lysimachia capillipes Hemsl, can inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis signaling events and cellular responses in primary human retinal microvascular endothelial cells (HRECs). Our study revealed that the capilliposide B IC50 for HRECs was 8.5 mu M at 72 h and that 1 mu M capilliposide B specifically inhibited VEGF-induced activation of VEGFR2 and its downstream signaling enzymes Akt and Erk. In addition, we discovered that this chemical effectively blocked VEGF-stimulated proliferation, migration and tube formation of the HRECs, suggesting that capilliposide B is a promising prophylactic for angiogenesis-associated diseases such as proliferative diabetic retinopathy.
C1 [Han, Haote; Wu, Zhipan; Tian, Jingkui] Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Hangzhou 310027, Peoples R China.
   [Han, Haote; Wu, Zhipan; Tian, Jingkui] Zhejiang Univ, Zhejiang Malaysia Joint Res Ctr Tradit Med, Hangzhou 310027, Peoples R China.
   [Han, Haote; Liu, Bing] Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA USA.
   [Han, Haote; Liu, Bing] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Yang, Yanhui] Ningxia Med Univ, Sch Basic Med Sci, Yinchuan, Ningxia, Peoples R China.
   [Liu, Bing] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou 510005, Peoples R China.
   [Dong, Lijun; Deng, Hongwei; Lei, Hetian] Jinan Univ, Shenzhen Eye Hosp, Shenzhen Eye Inst, Shenzhen, Guangdong, Peoples R China.
C3 Zhejiang University; Zhejiang University; Harvard University;
   Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute;
   Harvard University; Harvard Medical School; Ningxia Medical University;
   Guangzhou Medical University; Jinan University
RP Deng, HW; Lei, HT (通讯作者)，Shenzhen Eye Hosp, 18 Zetian Rd, Shenzhen, Guangdong, Peoples R China.; Tian, JK (通讯作者)，Zhejiang Univ, 148 Tianmushan Rd, Hangzhou, Zhejiang, Peoples R China.
EM dhw@126.com; tjk@zju.edu.cn; leihetian18@hotmail.com
RI Dong, lijun/GXF-7835-2022; Deng, Hongwei/GVP-3581-2022
OI deng, hong wei/0000-0001-8453-8737
FU China Scholarship Council [201806320148]; National Science and
   Technology Major Project of China [2019ZX09301108]; Sanming Project of
   Medicine in Shenzhen [SZSM201812090]; National Natural Science
   Foundation of China [82070989]
FX This research was supported by China Scholarship Council (201806320148)
   to H.H, by the National Science and Technology Major Project of China
   (2019ZX09301108) to J.T, by Sanming Project of Medicine in Shenzhen
   (SZSM201812090) to H.D, and by National Natural Science Foundation of
   China (82070989) to H.L.
CR Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012
   Caceres PS, 2014, J BIOL CHEM, V289, P23951, DOI 10.1074/jbc.M114.589333
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307
   Chen N, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107716
   De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590
   DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665
   Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892
   Haddad G, 2014, BLOOD, V124, P2142, DOI 10.1182/blood-2014-02-557975
   Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Huang XG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20537
   Im E, 2007, J BIOL CHEM, V282, P29122, DOI 10.1074/jbc.M702637200
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   Kevin ZEN, 2017, HSU CHING HSUAN ALLG, V15, P542
   Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200
   Liang B, 2006, CARBOHYD RES, V341, P2444, DOI 10.1016/j.carres.2006.06.020
   Lien JC, 2019, BRIT J PHARMACOL, V176, P4034, DOI 10.1111/bph.14813
   Liu J, 2010, J IMMUNOL, V185, P1215, DOI 10.4049/jimmunol.0903660
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   Ma GE, 2016, INVEST OPHTH VIS SCI, V57, P3935, DOI 10.1167/iovs.16-19405
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Meadows KL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006577
   Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   National Society to Prevent Blindness, 1980, VIS PROBL US DAT AN
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Simo R, 2003, CLIN SCI, V104, P223, DOI 10.1042/CS20020278
   Summers J, 2010, ONCOLOGIST, V15, P104, DOI 10.1634/theoncologist.2009-0250
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Tian JK, 2006, J ASIAN NAT PROD RES, V8, P439, DOI 10.1080/10286020500173259
   Tian JK, 2006, CHEM PHARM BULL, V54, P567, DOI 10.1248/cpb.54.567
   Timar Jozsef, 2001, Pathology and Oncology Research, V7, P85
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wen Y., 2017, CJPMP, V24, P1004
   Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071
   Wu WY, 2020, DIABETES, V69, P736, DOI 10.2337/db19-0713
   Wu WY, 2017, INVEST OPHTH VIS SCI, V58, P6082, DOI 10.1167/iovs.17-21902
   Xu F., 2018, INT EYE SCI, V2, P309
   Zhang J, 2018, BBA-MOL BASIS DIS, V1864, P2369, DOI 10.1016/j.bbadis.2017.11.017
   ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E
NR 52
TC 4
Z9 5
U1 2
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2021
VL 133
AR 110999
DI 10.1016/j.biopha.2020.110999
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA PN6QU
UT WOS:000604602300005
PM 33227710
OA gold
DA 2022-11-30
ER

PT J
AU Zhang, QX
   Lu, RW
   Wang, BQ
   Messinger, JD
   Curcio, CA
   Yao, XC
AF Zhang, Qiuxiang
   Lu, Rongwen
   Wang, Benquan
   Messinger, Jeffrey D.
   Curcio, Christine A.
   Yao, Xincheng
TI Functional Optical Coherence Tomography Enables In Vivo Physiological
   Assessment of Retinal Rod and Cone Photoreceptors
SO Scientific Reports
LA English
DT Article
ID MEDIATED DARK-ADAPTATION; STIMULUS-INDUCED CHANGES; AGE-RELATED
   MACULOPATHY; ULTRAHIGH-RESOLUTION; MACULAR DEGENERATION; SCATTERING
   CHANGES; OUTER SEGMENTS; HIGH-SPEED; INTRINSIC SIGNALS; LIGHT-SCATTERING
AB Transient intrinsic optical signal (IOS) changes have been observed in retinal photoreceptors, suggesting a unique biomarker for eye disease detection. However, clinical deployment of IOS imaging is challenging due to unclear IOS sources and limited signal-to-noise ratios (SNRs). Here, by developing high spatiotemporal resolution optical coherence tomography (OCT) and applying an adaptive algorithm for IOS processing, we were able to record robust IOSs from single-pass measurements. Transient IOSs, which might reflect an early stage of light phototransduction, are consistently observed in the photoreceptor outer segment almost immediately (<4 ms) after retinal stimulation. Comparative studies of dark-and light-adapted retinas have demonstrated the feasibility of functional OCT mapping of rod and cone photoreceptors, promising a new method for early disease detection and improved treatment of diseases such as age-related macular degeneration (AMD) and other eye diseases that can cause photoreceptor damage.
C1 [Zhang, Qiuxiang; Lu, Rongwen; Wang, Benquan; Yao, Xincheng] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
   [Messinger, Jeffrey D.; Curcio, Christine A.; Yao, Xincheng] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Yao, Xincheng] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Yao, XC (通讯作者)，Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
EM xcy@uic.edu
RI Lu, Rongwen/B-4261-2015; Yao, Xincheng/ABA-1526-2020; Lu,
   Rongwen/J-6169-2015; Wang, Benquan/J-3895-2019
OI Lu, Rongwen/0000-0002-1167-6001; Wang, Benquan/0000-0002-7372-366X
FU Carmichael Scholarship; NSF EPSCoR Grant [1158862]; NSF [CBET-1055889];
   NIH [R01 EY023522, R01 EY024628, R01 EY06109]; vision sciences core
   grant [NIH P30 EY03039]; Div Of Chem, Bioeng, Env, & Transp Sys
   [1534687] Funding Source: National Science Foundation; NATIONAL EYE
   INSTITUTE [P30EY003039, R01EY023522, R01EY006109, R01EY024628] Funding
   Source: NIH RePORTER
FX Q.X.Z. is supported by Carmichael Scholarship. R.W.L. and B.Q.W. are
   supported by NSF EPSCoR Grant Number 1158862. X.C.Y. is supported by NSF
   CBET-1055889, NIH R01 EY023522 and NIH R01 EY024628. C.A.C. and J.D.M.
   are supported by NIH R01 EY06109 and institutional support from the
   Eyesight Foundation of Alabama and Research to Prevent Blindness, Inc.
   The authors wish to thank technical support of Mr. Jerry Millican at UAB
   VSRC machine shop which supported by vision sciences core grant NIH P30
   EY03039.
CR Abramoff MD, 2006, INVEST OPHTH VIS SCI, V47, P715, DOI 10.1167/iovs.05-0008
   Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229
   Ball SL, 2000, INVEST OPHTH VIS SCI, V41, P610
   Binns A, 2006, OPHTHAL PHYSL OPT, V26, P71, DOI 10.1111/j.1475-1313.2005.00355.x
   Binns A, 2005, OPHTHAL PHYSL OPT, V25, P492, DOI 10.1111/j.1475-1313.2005.00338.x
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   Cakir Y, 2005, PHARMACOL REP, V57, P467
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   FISH GE, 1989, OPHTHALMOLOGY, V96, P109
   Grieve K, 2008, INVEST OPHTH VIS SCI, V49, P713, DOI 10.1167/iovs.07-0837
   HOFMANN KP, 1976, BIOPHYS STRUCT MECH, V2, P61, DOI 10.1007/BF00535653
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Inomata K, 2008, INVEST OPHTH VIS SCI, V49, P2193, DOI 10.1167/iovs.07-0727
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873
   Latecki LJ, 2000, IEEE T PATTERN ANAL, V22, P1185, DOI 10.1109/34.879802
   Li YC, 2010, OPT LETT, V35, P1810, DOI 10.1364/OL.35.001810
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Lu RW, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.10.106013
   Moayed AA, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.1.016011
   Moayed AA, 2011, OPT LETT, V36, P4575, DOI 10.1364/OL.36.004575
   NILSSON SEG, 1964, J ULTRA MOL STRUCT R, V10, P390, DOI 10.1016/S0022-5320(64)80018-6
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Rha J, 2009, OPT LETT, V34, P3782, DOI 10.1364/OL.34.003782
   Schallek J, 2009, INVEST OPHTH VIS SCI, V50, P4865, DOI 10.1167/iovs.08-3290
   Schallek JB, 2012, INVEST OPHTH VIS SCI, V53, P1971, DOI 10.1167/iovs.11-8299
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   Srinivasan VJ, 2006, OPT LETT, V31, P2308, DOI 10.1364/OL.31.002308
   Srinivasan VJ, 2009, OPT EXPRESS, V17, P3861, DOI 10.1364/OE.17.003861
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki W, 2013, INVEST OPHTH VIS SCI, V54, P6345, DOI 10.1167/iovs.13-12381
   Ts'o D, 2009, JPN J OPHTHALMOL, V53, P334, DOI 10.1007/s10384-009-0687-2
   Tsunoda K, 2009, JPN J OPHTHALMOL, V53, P297, DOI 10.1007/s10384-009-0686-3
   VAEGAN, 1984, AUST J OPHTHALMOL, V12, P359
   Wang BQ, 2014, OPT LETT, V39, P6923, DOI 10.1364/OL.39.006923
   Wang BQ, 2013, OPT LETT, V38, P4526, DOI 10.1364/OL.38.004526
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Yao XC, 2005, APPL OPTICS, V44, P2019, DOI 10.1364/AO.44.002019
   Yao XC, 2008, OPT EXPRESS, V16, P12446, DOI 10.1364/OE.16.012446
   Yao XC, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2393155
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
   Zhang QX, 2012, INVEST OPHTH VIS SCI, V53, P8139, DOI 10.1167/iovs.12-10732
   Zhang QX, 2011, OPT LETT, V36, P4692, DOI 10.1364/OL.36.004692
NR 48
TC 35
Z9 36
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 22
PY 2015
VL 5
AR 9595
DI 10.1038/srep09595
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CG4UQ
UT WOS:000353283000002
PM 25901915
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Menard, C
   Wilson, AM
   Dejda, A
   Miloudi, K
   Binet, F
   Crespo-Garcia, S
   Parinot, C
   Pilon, F
   Juneau, R
   Andriessen, EMMA
   Mawambo, G
   SanGiovanni, JP
   De Guire, V
   Sapieha, P
AF Menard, Catherine
   Wilson, Ariel M.
   Dejda, Agnieszka
   Miloudi, Khalil
   Binet, Francois
   Crespo-Garcia, Sergio
   Parinot, Celia
   Pilon, Frederique
   Juneau, Rachel
   Andriessen, Elisabeth M. M. A.
   Mawambo, Gaelle
   SanGiovanni, John Paul
   De Guire, Vincent
   Sapieha, Przemyslaw
TI miR-106b suppresses pathological retinal angiogenesis
SO AGING-US
LA English
DT Article
DE age related macular degeneration; miR-106b; PERK; choroidal
   neovascularization; angiogenesis
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; ER STRESS; RANIBIZUMAB;
   RETINOPATHY; PREVALENCE; MICRORNAS; OUTCOMES; CLUSTER; MEMBERS
AB MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. We recently demonstrated that levels of miR-106b were significantly decreased in the vitreous and plasma of patients with neovascular age-related macular degeneration (AMD). Here we show that expression of the miR-106b-25 cluster is negatively regulated by the unfolded protein response pathway of protein kinase RNA-like ER kinase (PERK) in a mouse model of neovascular AMD. A reduction in levels of miR-106b triggers vascular growth both in vivo and in vitro by inducing production of pro-angiogenic factors. We demonstrate that therapeutic delivery of miR-106b to the retina with lentiviral vectors protects against aberrant retinal angiogenesis in two distinct mouse models of pathological retinal neovascularization. Results from this study suggest that miRNAs such as miR-106b have the potential to be used as multitarget therapeutics for conditions characterized by pathological retinal angiogenesis.
C1 [Menard, Catherine; Wilson, Ariel M.; Mawambo, Gaelle; De Guire, Vincent; Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Dept Biochem, Montreal, PQ H1T 2M4, Canada.
   [Dejda, Agnieszka; Binet, Francois; Crespo-Garcia, Sergio; Parinot, Celia; Pilon, Frederique; Juneau, Rachel; Andriessen, Elisabeth M. M. A.; Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Dept Ophthalmol, Montreal, PQ H1T 2M4, Canada.
   [Miloudi, Khalil; Sapieha, Przemyslaw] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ H3A 2B4, Canada.
   [SanGiovanni, John Paul] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85719 USA.
C3 Universite de Montreal; Universite de Montreal; McGill University;
   University of Arizona
RP De Guire, V; Sapieha, P (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Dept Biochem, Montreal, PQ H1T 2M4, Canada.; Sapieha, P (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Dept Ophthalmol, Montreal, PQ H1T 2M4, Canada.; Sapieha, P (通讯作者)，McGill Univ, Dept Neurol Neurosurg, Montreal, PQ H3A 2B4, Canada.
EM vdeguire.hmr@ssss.gouv.qc.ca; mike.sapieha@umontreal.ca
RI Crespo-Garcia, Sergio/H-7643-2019
OI Crespo-Garcia, Sergio/0000-0002-8640-9135
FU Foundation Fighting Blindness Canada; Canadian Diabetes Association
   [DI-3-18-5444-PS]; Canadian Institutes of Health Research (Foundation
   grant) [353770]; Canadian the Heart and Stroke Foundation Canada
   [G-16-00014658]; Natural Sciences and Engineering Research Council of
   Canada [418637]
FX This work was supported by operating grants from The Foundation Fighting
   Blindness Canada, the Canadian Diabetes Association (DI-3-18-5444-PS),
   the Canadian Institutes of Health Research (Foundation grant #353770 to
   P.S), the Canadian the Heart and Stroke Foundation Canada (G-16-00014658
   to P.S.), and Natural Sciences and Engineering Research Council of
   Canada (418637 to P.S.). P.S. holds the Wolfe Professorship in
   Translational Research and a Canada Research Chair in Retinal Cell
   Biology. We also thank the Fonds de Recherche en Ophtalmologie de
   l'Universite de Montreal (FROUM) and the RRSV.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010
   Binet F, 2013, CELL METAB, V17, P353, DOI 10.1016/j.cmet.2013.02.003
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Desjarlais M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218282
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Ertekin S, 2014, MOL VIS, V20, P1057
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74
   Hanna J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00478
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Huang Y, 2011, J PHYSIOL BIOCHEM, V67, P129, DOI 10.1007/s13105-010-0050-6
   Jacob J, 2017, INT J OPHTHALMOL-CHI, V10, P81, DOI 10.18240/ijo.2017.01.14
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Maimaiti A, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0216-5
   McMahon M, 2017, AM J PHYSIOL-CELL PH, V313, pC243, DOI 10.1152/ajpcell.00293.2016
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Xu GL, 2016, MOL ENDOCRINOL, V30, P917, DOI 10.1210/me.2016-1056
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
NR 51
TC 2
Z9 2
U1 0
U2 1
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD DEC 31
PY 2020
VL 12
IS 24
BP 24836
EP 24852
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA PP1DH
UT WOS:000605608700025
PM 33361521
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Clare, AJ
   Copland, DA
   Nicholson, LB
   Liu, J
   Neal, CR
   Moss, S
   Dick, AD
   Theodoropoulou, S
AF Clare, Alison J.
   Copland, David A.
   Nicholson, Lindsay B.
   Liu, Jian
   Neal, Chris R.
   Moss, Stephen
   Dick, Andrew D.
   Theodoropoulou, Sofia
TI Treatment with interleukin-33 is non-toxic and protects retinal pigment
   epithelium in an ageing model of outer retinal degeneration
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; complement factor H; IL-33; retinal
   pigment epithelium
ID IMMUNE-RESPONSE; INFLAMMATION
AB The leading cause of central vision loss, age-related macular degeneration (AMD), is a degenerative disorder characterized by atrophy of retinal pigment epithelium (RPE) and photoreceptors. For 15% of cases, neovascularization occurs, leading to acute vision loss if left untreated. For the remaining patients, there are currently no treatment options and preventing progressive RPE atrophy remains the main therapeutic goal. Previously, we have shown treatment with interleukin-33 can reduce choroidal neovascularization and attenuate tissue remodelling. Here, we investigate IL-33 delivery in aged, high-fat diet (HFD) fed mice on a wildtype and complement factor H heterozygous knockout background. We characterize the non-toxic effect following intravitreal injection of IL-33 and further demonstrate protective effects against RPE cell death with evidence of maintaining metabolic retinal homeostasis of Cfh+/-similar to HFD mice. Our results further support the potential utility of IL-33 to prevent AMD progression.
C1 [Clare, Alison J.; Copland, David A.; Nicholson, Lindsay B.; Liu, Jian; Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Translat Hlth Sci, Bristol, Avon, England.
   [Nicholson, Lindsay B.; Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Neal, Chris R.] Univ Bristol, Wolfson Bioimaging Facil, Bristol, Avon, England.
   [Moss, Stephen; Dick, Andrew D.] UCL Inst Ophthalmol, London, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Theodoropoulou, Sofia] Cheltenham Gen Hosp, Dept Ophthalmol, Cheltenham, Glos, England.
C3 University of Bristol; University of Bristol; University of Bristol;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General
   Hospital
RP Clare, AJ (通讯作者)，Univ Bristol, Acad Unit Ophthalmol, Translat Hlth Sci, Bristol, Avon, England.
EM alison.clare@bristol.ac.uk
OI Dick, Andrew/0000-0002-0742-3159; Clare, Alison/0000-0003-0048-8838
FU National Eye Research Centre; Bayer
FX National Eye Research Centre; Bayer
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Scott L, 2019, THESIS
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
NR 15
TC 3
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 22
BP 13546
EP 13550
DI 10.1111/jcmm.16000
EA OCT 2020
PG 5
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA OY0OR
UT WOS:000579562100001
PM 33079455
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tisi, A
   Passacantando, M
   Lozzi, L
   Riccitelli, S
   Bisti, S
   Maccarone, R
AF Tisi, A.
   Passacantando, M.
   Lozzi, L.
   Riccitelli, S.
   Bisti, S.
   Maccarone, R.
TI Retinal long term neuroprotection by Cerium Oxide nanoparticles after an
   acute damage induced by high intensity light exposure
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Nanoceria; Retina; Neuroprotection; Macular degeneration
ID MECHANISMS; DEGENERATION
AB Cerium Oxide nanoparticles are antioxidant agents with autoregenerative radical scavenging activities, effective in preventing degeneration of photoreceptors of an albino rat when intravitreally injected prior to exposure to high intensity light. In this study, we performed a post injury administration of nanoceria and a long term analysis of their neuroprotective properties in order to better simulate the therapeutic treatment as it is carried out on patients with age related macular degeneration, and while photoreceptor degeneration is ongoing. We also injected nanoceria labelled with fluorescein isothiocianate in order to analyze their persistence after a single administration in a damaged retina and to investigate how long they both maintain their neuroprotective properties and where they localize in the retina. We demonstrated that after a single intravitreal injection, nanoceria remained in the retina for a long time and retained their neuroprotective properties. All these data form excellent bases for future clinical applications.
C1 [Tisi, A.; Riccitelli, S.; Bisti, S.; Maccarone, R.] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
   [Passacantando, M.; Lozzi, L.] Univ Aquila, Dept Phys & Chem Sci, Via Vetoio,Coppito 1, I-67100 Laquila, Italy.
   [Bisti, S.] Interuniv Consortium, INBB, Rome, Italy.
C3 University of L'Aquila; University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
EM annamaria.tisi@graduate.univaq.it;
   maurizio.passacantando@aquila.infn.it; luca.lozzi@univaq.it;
   serenariccitelli@libero.it; silvia.bisti@univaq.it;
   rita.maccarone@univaq.it
RI Nanozymes, Nanozymes/D-8197-2019
OI MACCARONE, Rita/0000-0003-0648-3771; Tisi,
   Annamaria/0000-0002-8592-2412; Riccitelli, Serena/0000-0003-4369-4586
CR Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Fern L., 2014, PROGR RETINAL EYE RE, V43, DOI [10.1016/j.preteyeres.2014.07.001, DOI 10.1016/J.PRETEYERES.2014.07.001]
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Flynn E., 2014, FUNDUS AUTOFLUORESCE, P2, DOI [10.1167/iovs.14-14136, DOI 10.1167/IOVS.14-14136]
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kim EM, 2017, NUCL MED MOLEC IMAG, V51, P106, DOI 10.1007/s13139-016-0435-8
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Marc RE, 2008, MOL VIS, V14, P782
   Mazzanti ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021607
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Passacantando M, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1785-0
   Portioli C., 2013, NANOSCI NANOTECHNOL, V5, DOI [10.1166/rm1.2013.1715, DOI 10.1166/RM1.2013.1715]
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Walkey C, 2015, ENVIRON SCI-NANO, V2, P33, DOI 10.1039/c4en00138a
   Wong LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121977
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022
   2012, MOL VIS, V18, P675
NR 23
TC 21
Z9 21
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2019
VL 182
BP 30
EP 38
DI 10.1016/j.exer.2019.03.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY6RV
UT WOS:000468258300004
PM 30867118
DA 2022-11-30
ER

PT J
AU Winiarczyk, M
   Biela, K
   Michalak, K
   Winiarczyk, D
   Mackiewicz, J
AF Winiarczyk, Mateusz
   Biela, Katarzyna
   Michalak, Katarzyna
   Winiarczyk, Dagmara
   Mackiewicz, Jerzy
TI Changes in Tear Proteomic Profile in Ocular Diseases
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Review
DE biomarkers; proteomic; MALDI; tear film; ocular biomarker; glaucoma;
   AMD; cataract; diagnostic
ID PRIMARY OPEN-ANGLE; DIABETIC-RETINOPATHY; AQUEOUS-HUMOR; PROTEIN
   EXPRESSION; NUCLEAR CATARACTS; FILM PROTEOME; COLLECTION; KERATOCONUS;
   CYTOKINES; GLAUCOMA
AB The search for proteomic biomarkers in ocular disease is one of the most important research directions in recent years. Reliable biomarkers can be an immense adjuvant for both diagnostic and therapeutic approaches. There is no more readily available ocular tissue for proteomic analysis than tear film, which makes an interesting target for the biomarker search. Tear film is a complex fluid consisting of a superficial lipid layer, which covers the aqueous-mucous layer. Its complexity makes it a perfect candidate for all the "omics" approaches. Glaucoma, cataract, age-related macular degeneration, and other diseases are commonly thought to have a multifactorial background. Currently, no reliable non-invasive tests are available that would help physicians with screening and further patient management. The aim of the study is to present modern methods of measuring biomarkers in tears, with particular emphasis on spectrometric methods, and to discuss their diagnostic and therapeutic usefulness.
C1 [Winiarczyk, Mateusz; Biela, Katarzyna; Mackiewicz, Jerzy] Med Univ Lublin, Dept Vitreoretinal Surg, PL-20059 Lublin, Poland.
   [Biela, Katarzyna] Prov Hosp Zamosc, Dept Ophthalmol, PL-22400 Zamosc, Poland.
   [Michalak, Katarzyna] Univ Life Sci Lublin, Dept Epizootiol, PL-20400 Lublin, Poland.
   [Winiarczyk, Dagmara] Univ Life Sci Lublin, Dept Internal Dis Small Anim, PL-20400 Lublin, Poland.
C3 Medical University of Lublin; University of Life Sciences in Lublin;
   University of Life Sciences in Lublin
RP Winiarczyk, M (通讯作者)，Med Univ Lublin, Dept Vitreoretinal Surg, PL-20059 Lublin, Poland.
EM mateuszwiniarczyk@umlub.pl
OI Winiarczyk, Mateusz/0000-0001-9704-3848
FU National Science Centre, Poland [2017/25/N/NZ5/01875]
FX This research was funded by the National Science Centre, Poland, grant
   number 2017/25/N/NZ5/01875.
CR Ablamowicz AF, 2017, MOL VIS, V23, P529
   Acera A, 2011, EYE, V25, P1225, DOI 10.1038/eye.2011.105
   Aghamollaei H, 2020, J PROTEOMICS, V225, DOI 10.1016/j.jprot.2020.103881
   Agnifili L, 2015, PROG BRAIN RES, V221, P1, DOI 10.1016/bs.pbr.2015.05.006
   Aluru SV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051979
   Amil-Bangsa NH, 2019, OPTOMETRY VISION SCI, V96, P934, DOI 10.1097/OPX.0000000000001456
   Ang WJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221481
   [Anonymous], J OPHTHALMOL
   Aqrawi LA, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1228-x
   Bachhuber F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89514-8
   Barmada A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.23
   Burgos-Blasco B, 2020, ACTA OPHTHALMOL, V98, pE768, DOI 10.1111/aos.14374
   Costagliola C, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/629529
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Cristina Kenney M, 2003, Cont Lens Anterior Eye, V26, P139
   Csosz E, 2019, FEBS OPEN BIO, V9, P1020, DOI 10.1002/2211-5463.12637
   Csosz E, 2017, J PROTEOMICS, V150, P351, DOI 10.1016/j.jprot.2016.06.034
   Demirdogen BC, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107837
   Di Girolamo N, 2004, PROG RETIN EYE RES, V23, P195, DOI 10.1016/j.preteyeres.2004.02.002
   Dumortier G, 2004, OPHTHALMIC RES, V36, P183, DOI 10.1159/000078776
   Esmaeelpour M, 2008, OPHTHAL PHYSL OPT, V28, P577, DOI 10.1111/j.1475-1313.2008.00603.x
   Farias E, 2013, PESQUI VET BRASIL, V33, P261, DOI 10.1590/S0100-736X2013000200021
   Ferrari G, 2020, OCUL SURF, V18, P363, DOI 10.1016/j.jtos.2020.03.006
   Fung ET, 2000, CURR OPIN MOL THER, V2, P643
   Gomes JAP, 2015, CORNEA, V34, P359, DOI 10.1097/ICO.0000000000000408
   Green-Church KB, 2010, INVEST OPHTH VIS SCI, V51
   Green-Church KB, 2008, MOL VIS, V14, P456
   Grus FH, 2005, INVEST OPHTH VIS SCI, V46, P863, DOI 10.1167/iovs.04-0448
   Guyette N, 2013, INVEST OPHTH VIS SCI, V54, P3729, DOI 10.1167/iovs.12-11431
   Hagan S, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0065-3
   Huang Z, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200702
   Ihnatko R, 2013, J PROTEOMICS, V94, P78, DOI 10.1016/j.jprot.2013.09.003
   JANSSEN PT, 1986, SCAND J RHEUMATOL, P224
   Ji YH, 2015, CLIN BIOCHEM, V48, P1304, DOI 10.1016/j.clinbiochem.2015.08.006
   Johnson ME, 2004, PROG RETIN EYE RES, V23, P449, DOI 10.1016/j.preteyeres.2004.04.003
   Jones DT, 1997, CORNEA, V16, P450
   Jones G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042307
   Jun AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016437
   Jun JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235408
   KIJLSTRA A, 1983, BRIT J OPHTHALMOL, V67, P199, DOI 10.1136/bjo.67.3.199
   Kim HJ, 2012, CLIN BIOCHEM, V45, P60, DOI 10.1016/j.clinbiochem.2011.10.006
   Kim Won Soo, 2016, Korean J Ophthalmol, V30, P163, DOI 10.3341/kjo.2016.30.3.163
   Krajcikova K, 2022, TAIWAN J OPHTHALMOL, V12, P88, DOI 10.4103/tjo.tjo_14_21
   Kreps EO, 2021, CONTACT LENS ANTERIO, V44, DOI 10.1016/j.clae.2020.05.002
   Kuo MT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081932
   Lam SM, 2014, J LIPID RES, V55, P289, DOI 10.1194/jlr.M044826
   Lee SH, 2018, CORNEA, V37, P1163, DOI 10.1097/ICO.0000000000001603
   Lema I, 2005, OPHTHALMOLOGY, V112, P654, DOI 10.1016/j.ophtha.2004.11.050
   Liu JF, 2010, MOL VIS, V16, P2931
   Malozhen S A, 2017, Vestn Oftalmol, V133, P76, DOI 10.17116/oftalma2017133576-83
   Malvitte L, 2007, BRIT J OPHTHALMOL, V91, P29, DOI 10.1136/bjo.2006.101485
   Markoulli M, 2011, CURR EYE RES, V36, P198, DOI 10.3109/02713683.2010.542867
   Mastropasqua R, 2019, CURR MED CHEM, V26, P4225, DOI 10.2174/0929867325666181009153212
   Messmer EM, 2015, DTSCH ARZTEBL INT, V112, P71, DOI 10.3238/arztebl.2015.0071
   Micera A, 2018, INVEST OPHTH VIS SCI, V59, P2024, DOI 10.1167/iovs.17-23358
   Micera A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9672082
   Nattinen J, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.16
   Nichols KK, 2004, CORNEA, V23, P762, DOI 10.1097/01.ico.0000133997.07144.9e
   Pannebaker C, 2010, MOL VIS, V16, P1949
   Park KS, 2008, AM J OPHTHALMOL, V145, P432, DOI 10.1016/j.ajo.2007.11.011
   Perumal N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29629
   Pieragostino D, 2012, MOL BIOSYST, V8, P1017, DOI 10.1039/c1mb05357d
   Posa A, 2013, ANN ANAT, V195, P137, DOI 10.1016/j.aanat.2012.10.001
   Powell DR, 2010, OPTOMETRY VISION SCI, V87, P854, DOI 10.1097/OPX.0b013e3181f6fb71
   Quah JHM, 2014, OPTOMETRY VISION SCI, V91, P452, DOI 10.1097/OPX.0000000000000188
   Rabilloud T, 1996, ELECTROPHORESIS, V17, P813, DOI 10.1002/elps.1150170503
   Reddy S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201740
   Rentka A, 2017, ANN CLIN BIOCHEM, V54, P521, DOI 10.1177/0004563217695843
   Rouen Patricia A, 2018, Home Healthc Now, V36, P74, DOI 10.1097/NHH.0000000000000652
   Sahay P, 2017, INVEST OPHTH VIS SCI, V58, pBIO106, DOI 10.1167/iovs.17-21723
   Sebbag L, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1390-7
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   STUCHELL RN, 1984, INVEST OPHTH VIS SCI, V25, P374
   Su S, 2011, INVEST OPHTH VIS SCI, V52, P4182, DOI 10.1167/iovs.10-7094
   Torok Z, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/623619
   Tur VM, 2017, SURV OPHTHALMOL, V62, P770, DOI 10.1016/j.survophthal.2017.06.009
   Versura P, 2010, EYE, V24, P1396, DOI 10.1038/eye.2010.7
   Wanzeler ACV, 2019, ARQ BRAS OFTALMOL, V82, P528, DOI 10.5935/0004-2749.20190103
   Wang JY, 2020, LAB CHIP, V20, P356, DOI 10.1039/c9lc00975b
   Willcox MDP, 2017, OCUL SURF, V15, P366, DOI 10.1016/j.jtos.2017.03.006
   Winiarczyk D, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10122416
   Winiarczyk M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10143060
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Wong TNT, 2011, INVEST OPHTH VIS SCI, V52, P7385, DOI 10.1167/iovs.10-6532
   Xiang MH, 2017, MOL MED REP, V15, P3111, DOI 10.3892/mmr.2017.6345
   Yang Q, 2017, CURR MOL MED, V17, P249, DOI 10.2174/1566524017666171101164244
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Zhou HY, 2015, PROTEOM CLIN APPL, V9, P776, DOI 10.1002/prca.201400061
   Zhou L, 2013, PROTEOMICS, V13, P2469, DOI 10.1002/pmic.201200230
   Zhou L, 2009, J PROTEOME RES, V8, P4889, DOI 10.1021/pr900686s
   Zhou L, 2009, INVEST OPHTH VIS SCI, V50, P2077, DOI 10.1167/iovs.08-2604
NR 91
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2022
VL 19
IS 20
AR 13341
DI 10.3390/ijerph192013341
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 5S5NB
UT WOS:000875235400001
PM 36293921
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Camacho, ET
   Lenhart, S
   Melara, LA
   Villalobos, MC
   Wirkus, S
AF Camacho, Erika T.
   Lenhart, Suzanne
   Melara, Luis A.
   Villalobos, M. Cristina
   Wirkus, Stephen
TI Optimal control with MANF treatment of photoreceptor degeneration
SO MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA
LA English
DT Article
DE optimal control; mesencephalic astrocyte-derived neurotrophic factor;
   photoreceptor degeneration; apoptosis; model of ordinary differential
   equations
ID RETINITIS-PIGMENTOSA; CELL-DEATH; RETINAL DEGENERATION;
   MATHEMATICAL-MODEL; CONE SURVIVAL; MOUSE MODEL; ROD; EPITHELIUM; VISION;
   APOPTOSIS
AB People afflicted with diseases such as retinitis pigmentosa and age-related macular degeneration experience a decline in vision due to photoreceptor degeneration, which is currently unstoppable and irreversible. Currently there is no cure for diseases linked to photoreceptor degeneration. Recent experimental work showed that mesencephalic astrocyte-derived neurotrophic factor (MANF) can reduce neuron death and, in particular, photoreceptor death by reducing the number of cells that undergo apoptosis. In this work, we build on an existing system of ordinary differential equations that represent photoreceptor interactions and incorporate MANF treatment for three experimental mouse models having undergone varying degrees of photoreceptor degeneration. Using MANF treatment levels as controls, we investigate optimal control results in the three mouse models. In addition, our numerical solutions match the experimentally observed surviving percentage of photoreceptors and our uncertainty and sensitivity analysis identifies significant parameters in the math model both with and without MANF treatment.
C1 [Camacho, Erika T.; Wirkus, Stephen] Arizona State Univ, Sch Math & Nat Sci, Phoenix, AZ 85306 USA.
   [Lenhart, Suzanne] Univ Tennessee, Dept Math, Knoxville, TN 37996 USA.
   [Melara, Luis A.] Shippensburg Univ, Dept Math, Shippensburg, PA 17257 USA.
   [Villalobos, M. Cristina] Univ Texas Rio Grande Valley, Sch Math & Stat Sci, Edinburg, TX 78539 USA.
C3 Arizona State University; Arizona State University-Downtown Phoenix;
   University of Tennessee System; University of Tennessee Knoxville;
   Pennsylvania State System of Higher Education (PASSHE); Shippensburg
   University of Pennsylvania; University of Texas System; University of
   Texas Rio Grande Valley
RP Camacho, ET (通讯作者)，Arizona State Univ, Sch Math & Nat Sci, Phoenix, AZ 85306 USA.
EM erika.camacho@asu.edu
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Besharse J., 2011, RETINA ITS DISORDERS
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Camacho ET, 2014, B MATH BIOL, V76, P292, DOI 10.1007/s11538-013-9919-1
   Camacho ET, 2016, J THEOR BIOL, V408, P75, DOI 10.1016/j.jtbi.2016.08.001
   Camacho ET, 2016, B MATH BIOL, V78, P1394, DOI 10.1007/s11538-016-0185-x
   Camacho ET, 2016, COMMUN NONLINEAR SCI, V38, P267, DOI 10.1016/j.cnsns.2016.02.030
   Camacho ET, 2013, J THEOR BIOL, V317, P105, DOI 10.1016/j.jtbi.2012.09.034
   Camacho ET, 2010, J THEOR BIOL, V267, P638, DOI 10.1016/j.jtbi.2010.09.006
   Chalmel F, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-74
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   GUERIN CJ, 1993, INVEST OPHTH VIS SCI, V34, P175
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hendrickson A, 2008, EXP EYE RES, V87, P415, DOI 10.1016/j.exer.2008.07.016
   Jonnal RS, 2010, OPT EXPRESS, V18, P5257, DOI 10.1364/OE.18.005257
   Keener J., 2008, MATH PHYSL 2 SYSTEMS
   Kernan F. A. G., 2007, OPHTHALMOLOGY RES RE
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lenhart S., 2007, OPTIMAL CONTROL APPL, V1, DOI [10.1201/9781420011418, DOI 10.1201/9781420011418]
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Lindholm P, 2010, DEV NEUROBIOL, V70, P360, DOI 10.1002/dneu.20760
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Malanson KM, 2009, PROG MOL BIOL TRANSL, V88, P1, DOI 10.1016/S1877-1173(09)88001-0
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Matsumoto H, 2014, INVEST OPHTH VIS SCI, V55, P4165, DOI 10.1167/iovs.14-14238
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109
   Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646
   Oyster CW., 1999, HUMAN EYE STRUCTURE
   Pallikaris A, 2003, INVEST OPHTH VIS SCI, V44, P4580, DOI 10.1167/iovs.03-0094
   Petrova PS, 2004, PROG BRAIN RES, V146, P167, DOI 10.1016/S0079-6123(03)46012-3
   Phelan JK, 2000, MOL VIS, V6, P116
   Pizzarello L, 2004, ARCH OPHTHALMOL-CHIC, V122, P615, DOI 10.1001/archopht.122.4.615
   Pontryagin L.S., 2018, MATH THEORY OPTIMAL
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Sahel Jose-Alain, 2005, Retina, V25, pS38, DOI 10.1097/00006982-200512001-00015
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Wong F, 1997, PROG RETIN EYE RES, V16, P353, DOI 10.1016/S1350-9462(96)00032-8
   World Health Organization Vision Impairment and Blindness, 2017, VIS IMP BLINDN
   World Health Organization Vision Media Center, 2018, BLINDN VIS 2020 GLOB
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
NR 56
TC 4
Z9 4
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1477-8599
EI 1477-8602
J9 MATH MED BIOL
JI Math. Med. Biol.
PD MAR
PY 2020
VL 37
IS 1
BP 1
EP 21
DI 10.1093/imammb/dqz003
PG 21
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA LS5VS
UT WOS:000536452100001
PM 30810166
OA Green Published
DA 2022-11-30
ER

PT J
AU Molins, B
   Fuentes-Prior, P
   Adan, A
   Anton, R
   Arostegui, JI
   Yague, J
   Dick, AD
AF Molins, Blanca
   Fuentes-Prior, Pablo
   Adan, Alfredo
   Anton, Rosa
   Arostegui, Juan I.
   Yaguee, Jordi
   Dick, Andrew D.
TI Complement factor H binding of monomeric C-reactive protein
   downregulates proinflammatory activity and is impaired with at risk
   polymorphic CFH variants
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN ENDOTHELIAL-CELLS; MACULAR DEGENERATION; PENTAMERIC SYMMETRY;
   ACTIVATED PLATELETS; HUMAN NEUTROPHILS; INFLAMMATION; EXPRESSION;
   DISEASE; DRUSEN; SECRETION
AB Inflammation and immune-mediated processes are pivotal to the pathogenic progression of age-related macular degeneration (AMD). Although plasma levels of C-reactive protein (CRP) have been shown to be associated with an increased risk for AMD, the pathophysiological importance of the prototypical acute-phase reactant in the etiology of the disease is unknown, and data regarding the exact role of CRP in ocular inflammation are limited. In this study, we provide mechanistic insight into how CRP contributes to the development of AMD. In particular, we show that monomeric CRP (mCRP) but not the pentameric form (pCRP) upregulates IL-8 and CCL2 levels in retinal pigment epithelial cells. Further, we show that complement factor H (FH) binds mCRP to dampen its proinflammatory activity. FH from AMD patients carrying the "risk" His402 polymorphism displays impaired binding to mCRP, and therefore proinflammatory effects of mCRP remain unrestrained.
C1 [Molins, Blanca; Adan, Alfredo] Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi I Sunyer IDIBAPS, Barcelona 08028, Spain.
   [Fuentes-Prior, Pablo; Anton, Rosa] Biomed Res Inst St Pau IIB St Pau, Mol Bases Dis, Barcelona 08025, Spain.
   [Fuentes-Prior, Pablo] Univ Autonoma Barcelona, Bellaterra 08193, Cerdanyola Del, Spain.
   [Arostegui, Juan I.; Yaguee, Jordi] Hosp Clin Barcelona, IDIBAPS, Dept Immunol CDB, Barcelona 08028, Spain.
   [Dick, Andrew D.] Univ Bristol, Sch Clin Sci, Acad Unit Ophthalmol, Bristol BS8 1TH, Avon, England.
   [Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TH, Avon, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, City Rd, London EC1V 2PD, England.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London EC1V 2PD, England.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   Autonomous University of Barcelona; University of Barcelona; Hospital
   Clinic de Barcelona; IDIBAPS; University of Bristol; University of
   Bristol; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London
RP Molins, B (通讯作者)，Hosp Clin Barcelona, Inst Invest Biomed Agusti Pi I Sunyer IDIBAPS, Barcelona 08028, Spain.
EM bmolins@clinic.ub.es
RI Antón, Rosa/AAO-1350-2021
OI Antón, Rosa/0000-0003-4261-4150; Yague Ribes, Jordi/0000-0002-1935-4488;
   Arostegui, Juan Ignacio/0000-0003-4757-504X; Dick,
   Andrew/0000-0002-0742-3159; YAGUE, JORDI/0000-0001-8210-1929;
   Fuentes-Prior, Pablo/0000-0002-6618-3204
FU Ministry of Science and Innovation of Spain, "Instituto de Salud Carlos
   III", "Fondo de Investigacion Sanitaria" [RD12/0034]
FX This work was supported by the Ministry of Science and Innovation of
   Spain, "Instituto de Salud Carlos III", "Fondo de Investigacion
   Sanitaria" (RD12/0034).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Brandstatter H, 2012, VOX SANG, V103, P201, DOI 10.1111/j.1423-0410.2012.01610.x
   Ciubotaru I, 2005, EXP BIOL MED, V230, P762, DOI 10.1177/153537020523001010
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Devaraj S, 2004, J MOL CELL CARDIOL, V36, P405, DOI 10.1016/j.yjmcc.2003.12.005
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Khreiss T, 2004, CIRCULATION, V110, P2713, DOI 10.1161/01.CIR.0000146846.00816.DD
   Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Molins B, 2008, ARTERIOSCL THROM VAS, V28, P2239, DOI 10.1161/ATVBAHA.108.174359
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Singh U, 2006, ARTERIOSCL THROM VAS, V26, P2469, DOI 10.1161/01.ATV.0000241572.05292.fb
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Slevin M, 2010, BRAIN PATHOL, V20, P151, DOI 10.1111/j.1750-3639.2008.00256.x
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vilahur G, 2009, J THROMB HAEMOST, V7, P485, DOI 10.1111/j.1538-7836.2008.03244.x
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 56
TC 40
Z9 41
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 10
PY 2016
VL 6
AR 22889
DI 10.1038/srep22889
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG0DC
UT WOS:000371731600001
PM 26961257
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU van der Giet, M
   Henkel, C
   Schuchardt, M
   Tolle, M
AF van der Giet, Markus
   Henkel, Cornelia
   Schuchardt, Mirjam
   Toelle, Markus
TI Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic
   Effects
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Angiogenesis; anti-VEGF therapy; eye disease; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SUPPRESSES
   CHOROIDAL NEOVASCULARIZATION; SUNITINIB MALATE SU11248; MACULAR EDEMA
   SECONDARY; DIABETIC-RETINOPATHY; INTRAVITREAL INJECTION; TRAP-EYE;
   OCULAR NEOVASCULARIZATION; CLINICAL-TRIALS
AB Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, local anti-VEGF therapy was developed and established to treat proliferative diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. For systemic administration of anti-VEGF drugs, serious side effects including hypertension or renal disorders have been observed. Evidence suggests that systemic effects might occur or develop in long-term treatment, despite limited resorption and minimal local side effects. Here, only limited data from clinical studies are available. The VEGF system is delicately balanced, and changes might result in deleterious effects.
   This review provides a brief overview of the VEGF-system, and summarizes its relevance in proliferative eye diseases. The anti-VEGF drugs locally used to treat different disease conditions are discussed with their local and systemic side effects.
C1 [van der Giet, Markus; Henkel, Cornelia; Schuchardt, Mirjam; Toelle, Markus] Charite Univ Klinikum Berlin, Dept Nephrol & Transplantat, Berlin, Germany.
RP van der Giet, M (通讯作者)，Charite Campus Benjamin Franklin, Med Klin SP Nephrol, Hindenburgdamm 30, D-12203 Berlin, Germany.
EM Markus.vanderGiet@charite.de
RI Schuchardt, Mirjam/AAS-3704-2021; Tölle, Markus/GPP-7157-2022
OI Schuchardt, Mirjam/0000-0001-7388-9611; van der Giet,
   Markus/0000-0003-3590-5451
FU Peter and Traudl Engelhorn Stiftung
FX A scholarship of the Peter and Traudl Engelhorn Stiftung supported the
   work of M.S. We thank Dr. med. Christina Kerckhoff (ophthalmologist) for
   critical review of the manuscript.
CR Abcouwer S. F., 2013, J CLIN CELLULAR I S1
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   ARCHER DB, 1993, EYE, V7, P1, DOI 10.1038/eye.1993.3
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bello CL, 2006, ANTI-CANCER DRUG, V17, P353, DOI 10.1097/00001813-200603000-00015
   Bingaman DP, 2005, INVEST OPHTHALMOL, V46, P464
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bry M, 2010, CIRCULATION, V122, P1725, DOI 10.1161/CIRCULATIONAHA.110.957332
   Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2013, OPHTHALMOLOGY, V120, P795, DOI 10.1016/j.ophtha.2012.09.032
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Carmeliet P, 2013, CELL MOL LIFE SCI, V70, P1763, DOI 10.1007/s00018-013-1283-7
   Costa PZ, 2013, LIFE SCI, V92, P1037, DOI 10.1016/j.lfs.2013.04.001
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Davidovic SP, 2012, EUR J OPHTHALMOL, V22, P792, DOI 10.5301/ejo.5000118
   Deng YL, 2013, XENOBIOTICA, V43, P443, DOI 10.3109/00498254.2012.734642
   Dewerchin M, 2012, COLD SPRING HARBOR P, P2
   Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2012, ARVO
   Genentech, 2013, AV PRESCR INF
   Giacca M, 2012, GENE THER, V19, P622, DOI 10.1038/gt.2012.17
   Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Herbert SP, 2009, SCIENCE, V326, P294, DOI 10.1126/science.1178577
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   Houk BE, 2009, CLIN CANCER RES, V15, P2497, DOI 10.1158/1078-0432.CCR-08-1893
   Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kim H, 2009, MOL VIS, V15
   Kim HW, 2011, NEPHROL DIAL TRANSPL, V26, P1173, DOI 10.1093/ndt/gfq610
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Kinose F, 2005, MOL VIS, V11, P366
   Koga K, 2003, J CLIN ENDOCR METAB, V88, P2348, DOI 10.1210/jc.2002-021942
   Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lanahan AA, 2010, DEV CELL, V18, P713, DOI 10.1016/j.devcel.2010.02.016
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Marrony S, 2003, BONE, V33, P426, DOI 10.1016/S8756-3282(03)00195-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404
   Novartis Pharma AG., 2013, LUC PRESCR INF
   Nuzzi R, 2013, SEMINARS OPHTHALMOL
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Pavlakovic H, 2010, ANN NY ACAD SCI, V1207, pE7, DOI 10.1111/j.1749-6632.2010.05714.x
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   PETRELLA RJ, 2012, J OPHTHALMOL, DOI DOI 10.1155/2012/159167
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryberg M, 2013, SEMIN ONCOL, V40, P168, DOI 10.1053/j.seminoncol.2013.01.002
   Salam A, 2011, ACTA OPHTHALMOL, V89, P405, DOI 10.1111/j.1755-3768.2010.02079.x
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Senthil D, 2003, KIDNEY INT, V64, P468, DOI 10.1046/j.1523-1755.2003.00135.x
   Shahsuvaryan ML, 2012, INT J OPHTHALMOL-CHI, V5, P759, DOI 10.3980/j.issn.2222-3959.2012.06.20
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   Sison K, 2010, J AM SOC NEPHROL, V21, P1691, DOI 10.1681/ASN.2010030295
   Sivaskandarajah GA, 2012, DIABETES, V61, P2958, DOI 10.2337/db11-1655
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Sung SH, 2006, J AM SOC NEPHROL, V17, P3093, DOI 10.1681/ASN.2006010064
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045
   Testa U, 2008, J CARDIOVASC MED, V9, P1190, DOI 10.2459/JCM.0b013e3283117d37
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tvorogov D, 2010, CANCER CELL, V18, P630, DOI 10.1016/j.ccr.2010.11.001
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
   Wang FE, 2007, EXP EYE RES, V84, P922, DOI 10.1016/j.exer.2007.01.022
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wood JM, 2000, CANCER RES, V60, P2178
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 127
TC 15
Z9 18
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 24
BP 3548
EP 3556
DI 10.2174/1381612821666150225120314
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CO8PA
UT WOS:000359431100014
PM 25714990
DA 2022-11-30
ER

PT J
AU Lo, MT
   Lee, WC
AF Lo, Min-Tzu
   Lee, Wen-Chung
TI Detecting a Weak Association by Testing its Multiple Perturbations: a
   Data Mining Approach
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENE-GENE; RISK; MUTATIONS; BIOBANK; DISEASE; SNPS
AB Many risk factors/interventions in epidemiologic/biomedical studies are of minuscule effects. To detect such weak associations, one needs a study with a very large sample size (the number of subjects, n). The n of a study can be increased but unfortunately only to an extent. Here, we propose a novel method which hinges on increasing sample size in a different direction-the total number of variables (p). We construct a p-based `multiple perturbation test', and conduct power calculations and computer simulations to show that it can achieve a very high power to detect weak associations when p can be made very large. As a demonstration, we apply the method to analyze a genome-wide association study on age-related macular degeneration and identify two novel genetic variants that are significantly associated with the disease. The p-based method may set a stage for a new paradigm of statistical tests.
C1 [Lee, Wen-Chung] Natl Taiwan Univ, Coll Publ Hlth, Res Ctr Genes Environm & Human Hlth, Taipei 10764, Taiwan.
   Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan.
C3 National Taiwan University; National Taiwan University
RP Lee, WC (通讯作者)，Natl Taiwan Univ, Coll Publ Hlth, Res Ctr Genes Environm & Human Hlth, Taipei 10764, Taiwan.
EM wenchung@ntu.edu.tw
OI Lee, Wen-Chung/0000-0003-3171-7672
FU Ministry of Science and Technology, Taiwan [NSC 102-2628-B-002-036-MY3];
   National Taiwan University, Taiwan [NTU-CESRP-102R7622-8]
FX This paper is partly supported by grants from Ministry of Science and
   Technology, Taiwan (NSC 102-2628-B-002-036-MY3) and National Taiwan
   University, Taiwan (NTU-CESRP-102R7622-8). No additional external
   funding received for this study. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Buzkova P, 2011, ANN HUM GENET, V75, P36, DOI 10.1111/j.1469-1809.2010.00572.x
   Chapman K, 2011, GENET EPIDEMIOL, V35, P781, DOI 10.1002/gepi.20627
   Chatterjee N, 2006, AM J HUM GENET, V79, P1002, DOI 10.1086/509704
   Chen ZM, 2011, INT J EPIDEMIOL, V40, P1652, DOI 10.1093/ije/dyr120
   Duarri A, 2012, ANN NEUROL, V72, P870, DOI 10.1002/ana.23700
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gauderman WJ, 2007, GENET EPIDEMIOL, V31, P383, DOI 10.1002/gepi.20219
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grontved A, 2011, JAMA-J AM MED ASSOC, V305, P2448, DOI 10.1001/jama.2011.812
   HEMILA H, 2013, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000980.PUB4
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Ioannidis JPA, 2006, AM J EPIDEMIOL, V164, P609, DOI 10.1093/aje/kwj259
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee YC, 2012, ANN NEUROL, V72, P859, DOI 10.1002/ana.23701
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ollier W, 2005, PHARMACOGENOMICS, V6, P639, DOI 10.2217/14622416.6.6.639
   Pan W, 2010, HUM HERED, V69, P131, DOI 10.1159/000264450
   Pan W, 2009, GENET EPIDEMIOL, V33, P497, DOI 10.1002/gepi.20402
   Siontis GCM, 2011, INT J EPIDEMIOL, V40, P1292, DOI 10.1093/ije/dyr099
   Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335
   Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Tsaur ML, 1997, FEBS LETT, V400, P215, DOI 10.1016/S0014-5793(96)01388-9
   Wang T, 2009, GENET EPIDEMIOL, V33, P6, DOI 10.1002/gepi.20351
NR 30
TC 2
Z9 2
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 28
PY 2014
VL 4
AR 5081
DI 10.1038/srep05081
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AH8YV
UT WOS:000336425000001
PM 24866319
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Swoboda, JG
   Elliott, J
   Deshmukh, V
   de Lichtervelde, L
   Shen, WJ
   Tremblay, MS
   Peters, EC
   Cho, CY
   Lu, B
   Girman, S
   Wang, SM
   Schultz, PG
AF Swoboda, Jonathan G.
   Elliott, Jimmy
   Deshmukh, Vishal
   de Lichtervelde, Lorenzo
   Shen, Weijun
   Tremblay, Matthew S.
   Peters, Eric C.
   Cho, Charles Y.
   Lu, Bin
   Girman, Sergej
   Wang, Shaomei
   Schultz, Peter G.
TI Small Molecule Mediated Proliferation of Primary Retinal Pigment
   Epithelial Cells
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; MACULAR DEGENERATION; VISUAL FUNCTION; IN-VITRO;
   RCS RATS; RPE; TRANSPLANTATION; CULTURE; SURVIVAL; THERAPY
AB Retinal pigment epithelial (RPE) cells form a monolayer adjacent to the retina and play a critical role in the visual light cycle. Degeneration of RPE cells results in retinal disorders such as age-related macular degeneration. Cell transplant strategies have potential therapeutic value for such disorders; however, risks associated with an inadequate supply of donor cells limit their therapeutic success. The identification of factors that proliferate RPE cells ex vivo could provide a renewable source of cells for transplantation. Here, we report that a small molecule (WS3) can reversibly proliferate primary RPE cells isolated from fetal and adult human donors. Following withdrawal of WS3, RPE cells differentiate into a functional monolayer, as exhibited by their expression of mature RPE genes and phagocytosis of photoreceptor outer segments. Furthermore, chemically expanded RPE cells preserve vision when transplanted into dystrophic Royal College of Surgeons (RCS) rats, a well-established model of retinal degeneration.
C1 [Swoboda, Jonathan G.; Deshmukh, Vishal; de Lichtervelde, Lorenzo; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Swoboda, Jonathan G.; Deshmukh, Vishal; de Lichtervelde, Lorenzo; Schultz, Peter G.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Elliott, Jimmy; Peters, Eric C.; Cho, Charles Y.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
   [Shen, Weijun; Tremblay, Matthew S.] Calif Inst Biomed Res, La Jolla, CA 92037 USA.
   [Lu, Bin; Girman, Sergej; Wang, Shaomei] Cedars Sinai Med Ctr, Regenerat Med Inst, Los Angeles, CA 90048 USA.
C3 Scripps Research Institute; Scripps Research Institute; Novartis; Cedars
   Sinai Medical Center
RP Wang, SM (通讯作者)，Cedars Sinai Med Ctr, Regenerat Med Inst, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.
EM shaomei.wang@cshs.org; schultz@scripps.edu
RI Peters, Eric/W-2739-2019
OI Shen, Weijun/0000-0001-8388-729X
FU Juvenile Diabetes Research Foundation; Hear See Hope Foundation; Lincy
   Foundation, Foundation for Fighting Blindness, Regenerative Medicine
   Institute at CSMC; National Institutes of Health [R01EY020488-01];
   Skaggs Institute for Chemical Biology; NATIONAL EYE INSTITUTE
   [R01EY020488] Funding Source: NIH RePORTER
FX This work was supported by the Juvenile Diabetes Research Foundation (to
   J.G.S.); Hear See Hope Foundation (to B.L.); Lincy Foundation,
   Foundation for Fighting Blindness, Regenerative Medicine Institute at
   CSMC and National Institutes of Health R01EY020488-01 (to S.W.); and
   funds from the Skaggs Institute for Chemical Biology (to P.G.S.). This
   is manuscript number 21945 of The Scripps Research Institute.
CR Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Baehr W, 2009, VISION RES, V49, P2636, DOI 10.1016/j.visres.2009.04.008
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Corselli M, 2008, EXP HEMATOL, V36, P340, DOI 10.1016/j.exphem.2007.10.008
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023
   Ishida M, 1998, CURR EYE RES, V17, P392, DOI 10.1080/02713689808951220
   Kim KS, 1998, CURR EYE RES, V17, P962, DOI 10.1076/ceyr.17.10.962.5243
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   LaVail M M, 2001, Prog Brain Res, V131, P617
   Lee E, 2011, BRIT J OPHTHALMOL, V95, P445, DOI 10.1136/bjo.2009.171918
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shen W, 2013, J AM CHEM SOC, V135, P1669, DOI 10.1021/ja309304m
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Uebersax ED, 2000, EXP EYE RES, V70, P381, DOI 10.1006/exer.1999.0802
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
NR 31
TC 9
Z9 9
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JUL
PY 2013
VL 8
IS 7
BP 1407
EP 1411
DI 10.1021/cb4001712
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 188RA
UT WOS:000322210100007
PM 23621521
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Recalde, S
   Alaman, AS
   Robredo, PF
AF Garcia-Layana, Alfredo
   Recalde, Sergio
   Salinas Alaman, Angel
   Fernandez Robredo, Patricia
TI Effects of Lutein and Docosahexaenoic Acid Supplementation on Macular
   Pigment Optical Density in a Randomized Controlled Trial
SO NUTRIENTS
LA English
DT Article
DE lutein; docosahexaenoic acid; age-related macular degeneration; macular
   pigment density
ID DIETARY-FAT; AGE; DEGENERATION; LIPOPROTEINS; CAROTENOIDS; ZEAXANTHIN;
   METABOLISM; RETINA; SERUM; ASSOCIATION
AB We studied the macular pigment ocular density (MPOD) in patients with early age macular degeneration (AMD) before and 1 year after nutritional supplementation with lutein and docosahexaenoic acid (DHA). Forty-four patients with AMD were randomly divided into two groups that received placebo (n = 21) or a nutritional supplement (n = 23, 12 mg of lutein and 280 mg of DHA daily). Heterochromatic flicker photometry was used to determine the MPOD. At baseline, the MPOD in AMD patients with placebo was 0.286 +/- 0.017 meanwhile in AMD patients with supplementation it was 0.291 +/- 0.016. One year later, the mean MPOD had increased by 0.059 in the placebo group and by 0.162 in patients receiving lutein and DHA. This difference between groups was significant (p < 0.05). Lutein and DHA supplementation is effective in increasing the MPOD and may aid in prevention of age related macular degeneration.
C1 [Garcia-Layana, Alfredo; Recalde, Sergio; Salinas Alaman, Angel; Fernandez Robredo, Patricia] Univ Navarra Clin, Dept Ophthalmol, Pamplona 31080, Spain.
C3 University of Navarra
RP Garcia-Layana, A (通讯作者)，Univ Navarra Clin, Dept Ophthalmol, C Pio 12 36, Pamplona 31080, Spain.
EM aglayana@unav.es; srecalde@unav.es; asalinas@unav.es; pfrobredo@unav.es
RI Recalde, Sergio/D-1815-2017
OI Recalde, Sergio/0000-0002-9328-9725
FU Thea Laboratoires' Grant; RETICS from ISCIII, Ministerio de Ciencia e
   Innovacion, Spain [RD07/0062]
FX Authors want to thank to all patients that collaborated in the present
   project. Funding: "The present work was partially funded by a Thea
   Laboratoires' Grant and partially supported by RETICS (RD07/0062) from
   ISCIII, Ministerio de Ciencia e Innovacion, Spain".
CR Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Foulon T, 1999, SCAND J CLIN LAB INV, V59, P239, DOI 10.1080/00365519950185607
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Meagher K. A., 2012, BR J NUTR, V5, P1
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schalch W, 1992, EXS, V62, P280
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Thomas TR, 2004, METABOLISM, V53, P749, DOI 10.1016/j.metabol.2003.12.019
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
NR 30
TC 27
Z9 28
U1 1
U2 22
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2013
VL 5
IS 2
BP 543
EP 551
DI 10.3390/nu5020543
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 096JW
UT WOS:000315401100015
PM 23434908
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Steinle, JJ
   Cappocia, FC
   Jiang, YD
AF Steinle, Jena J.
   Cappocia, Frank C., Jr.
   Jiang, Youde
TI Beta-adrenergic receptor regulation of growth factor protein levels in
   human choroidal endothelial cells
SO GROWTH FACTORS
LA English
DT Article
DE Choroid; beta-adrenergic receptors; growth factors; macular degeneration
ID EPITHELIUM-DERIVED FACTOR; PIGMENT-EPITHELIUM; RAT RETINA; MACULAR
   DEGENERATION; FACTOR EXPRESSION; ANGIOGENESIS; ANGIOPOIETIN-1;
   SYMPATHECTOMY
AB Remodeling of the choroidal vasculature is a prominent factor in age-related macular degeneration. While many of the growth factors involved in this vascular remodeling are known, their regulation remains much less so. The hypothesis of the present study was that stimulation of human choroidal endothelial cells with the beta-adrenergic receptor agonist isoproterenol would lead to an increase in pigment epithelial derived factor (PEDF) and angiopoietin 1 (Ang1), markers of a stable vasculature. Protein levels of PEDF and Ang1 were significantly increased following stimulation with isoproterenol. However, isoproterenol also significantly increased protein levels of vascular endothelial cell growth factor, which is active during vasculature remodeling. These data suggest that beta-adrenergic receptor agonists are likely upstream of a number of growth factors implicated in ocular disease and have multiple effects on choroidal endothelial cells. Modulation of this signaling in the choroid may offer a new avenue for therapeutics.
C1 [Steinle, Jena J.; Jiang, Youde] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN 38163 USA.
   [Steinle, Jena J.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
   [Cappocia, Frank C., Jr.] So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; Southern Illinois University System; Southern Illinois
   University
RP Steinle, JJ (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Dept Ophthalmol, 930 Madison Ave,Suite 722A, Memphis, TN 38163 USA.
EM jjsteinle@utmem.edu
OI Steinle, Jena/0000-0002-7539-2892
FU Juvenile Diabetes Research Foundation [2-2006-114]; NIA [R01
   AG027827-01A1]; Research to Prevent Blindness; NATIONAL INSTITUTE ON
   AGING [R01AG027827] Funding Source: NIH RePORTER
FX Grant Support: Juvenile Diabetes Research Foundation 2-2006-114 (JJS)
   and NIA R01 AG027827-01A1 (JJS), Research to Prevent Blindness (JJS).
CR Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Folkman, 1984, BIOL ENDOTHELIAL CEL, DOI 10.1007/978-1-4613-2825-4_42
   Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X
   Lashbrook BL, 2005, AUTON NEUROSCI-BASIC, V121, P33, DOI 10.1016/j.autneu.2005.05.006
   Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nishishita T, 2004, J CELL BIOCHEM, V91, P584, DOI 10.1002/jcb.10718
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ortega Nathalie, 1999, Frontiers in Bioscience, V4, pD141, DOI 10.2741/Ortega
   Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51
   Silverman MD, 2001, INVEST OPHTH VIS SCI, V42, P2861
   Simons M, 2004, MOL CELL BIOCHEM, V264, P99, DOI 10.1023/B:MCBI.0000044379.25823.03
   Sivakumar B, 2004, JAMA-J AM MED ASSOC, V292, P972, DOI 10.1001/jama.292.8.972
   Smith CP, 2007, EXP EYE RES, V84, P75, DOI 10.1016/j.exer.2006.08.018
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Steinle JJ, 2006, EXP EYE RES, V83, P16, DOI 10.1016/j.exer.2005.11.006
   Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182
   Steinle JJ, 2002, BRIT J PHARMACOL, V136, P730, DOI 10.1038/sj.bjp.0704771
   Thurston G, 2005, DEVELOPMENT, V132, P3317, DOI 10.1242/dev.01888
   Wiley LA, 2006, INVEST OPHTH VIS SCI, V47, P439, DOI 10.1167/iovs.05-0656
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496
   Zamora DO, 2007, MOL VIS, V13, P2058
NR 29
TC 21
Z9 22
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0897-7194
J9 GROWTH FACTORS
JI Growth Factors
PY 2008
VL 26
IS 6
BP 325
EP 330
AR PII 905685419
DI 10.1080/08977190802442070
PG 6
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 378CB
UT WOS:000261297600003
PM 19021032
DA 2022-11-30
ER

PT J
AU Raftery, J
   Clegg, A
   Jones, J
   Tan, SC
   Lotery, A
AF Raftery, James
   Clegg, Andrew
   Jones, Jeremy
   Tan, Seng Chuen
   Lotery, Andrew
TI Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost
   effectiveness
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve 30k pound per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.
C1 Univ Southampton, Sch Med, Wessex Inst Hlth R&D, Southampton SO16 7PX, Hants, England.
   Univ Southampton, Southampton Gen Hosp, Southampton Eye Unit, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Raftery, J (通讯作者)，Univ Southampton, Sch Med, Wessex Inst Hlth R&D, Mailpoint 728, Southampton SO16 7PX, Hants, England.
EM raftery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   *DEP HLTH, 2005, NHS REF COST 2005
   FUNG AE, 2006, INVEST OPHTH VIS SCI, V47, P5251
   *GOV ACT DEP, 2005, UK INT LIF TABL 2002
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P144, DOI 10.3928/1542-8877-20060301-11
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   ZHOU S, 2006, INVEST OPHTH VIS SCI, V47, P2213
NR 18
TC 126
Z9 141
U1 0
U2 24
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1244
EP 1246
DI 10.1136/bjo.2007.116616
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202EN
UT WOS:000248884900039
PM 17431015
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nguyen, VP
   Li, YX
   Henry, J
   Zhang, W
   Wang, XD
   Paulus, YM
AF Van-Phuc Nguyen
   Li, Yanxiu
   Henry, Jessica
   Zhang, Wei
   Wang, Xueding
   Paulus, Yannis M.
TI Gold Nanorod Enhanced Photoacoustic Microscopy and Optical Coherence
   Tomography of Choroidal Neovascularization
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE photoacoustic microscopy; optical coherence tomography; choroidal
   neovascularization; contrast agents; multimodal molecular imaging; gold
   nanorods; photoacoustic ophthalmoscopy
ID MACULAR DEGENERATION; SELECTIVE DETECTION; NANOPARTICLES;
   MULTIWAVELENGTH; OPHTHALMOSCOPY; ANGIOGRAPHY; EYE
AB Visualization and evaluation of choroidal neo-vascularization (CNV) are major challenges to improve treatment outcomes for patients with age-related macular degeneration (AMD). Limitations of current imaging techniques include the limited penetration depth, spatial resolution, and sensitivity and difficulty visualizing CNV from the healthy microvasculature. In this study, a custom-built multimodal photoacoustic microscopy (PAM) and optical coherence tomography (OCT) system was developed to distinguish the margin of CNV in living rabbits with the assistance of functionalized gold nanorods conjugating with RGD ligands (GNR-RGD). Intravenous administration of GNRRGD into rabbits in a CNV model resulted in signal enhancements of 27.2-fold in PAM and 171.4% in OCT. This molecular imaging technique of contrast-enhanced PAM and OCT is a promising tool for the precise imaging of CNV as well as the evaluation of the pathophysiology in vivo without destruction of tissue.
C1 [Van-Phuc Nguyen; Li, Yanxiu; Henry, Jessica; Paulus, Yannis M.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   [Zhang, Wei; Wang, Xueding] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Paulus, YM (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.; Wang, XD (通讯作者)，Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48105 USA.
EM xdwang@umich.edu; ypaulus@med.umich.edu
FU National Eye Institute [1K08EY027458, P30 EY007003]; Fight for
   Sight-International Retinal Research Foundation [FFSGIA16002]; Research
   to Prevent Blindness; University of Michigan Department of Ophthalmology
   and Visual Sciences
FX This work was supported by the National Eye Institute (grant
   1K08EY027458 (Y.M.P.)) and Fight for Sight-International Retinal
   Research Foundation (grant FFSGIA16002 (Y.M.P.)). This work was also
   assisted by unrestricted departmental support from the Research to
   Prevent Blindness and the University of Michigan Department of
   Ophthalmology and Visual Sciences. A part of this research utilized the
   Core Center for Vision Research funded by the National Eye Institute
   (grant P30 EY007003). The authors thank Dr. Yuqing Chen and the Center
   for Advanced Models and Translational Sciences and Therapeutics
   (CAMTraST) at the University of Michigan Medical School for the generous
   donation of New Zealand rabbits; Dr. David Antonetti for the generous
   donation of BRECs and b.End3; Dr. Thomas David for assistance with
   immunohistochemistry; Dr. Wei Qian for assistance with DLS and FT-IR
   measurements; and Dr. Stephen Lentz, Dr. Qitao Zhang, and Dr. Xuwen Liu
   for helping with the confocal microscopy.
CR Akiyama Y, 2009, J CONTROL RELEASE, V139, P81, DOI 10.1016/j.jconrel.2009.06.006
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Beard P, 2011, INTERFACE FOCUS, V1, P602, DOI 10.1098/rsfs.2011.0028
   Chen YS, 2019, NAT NANOTECHNOL, V14, P465, DOI 10.1038/s41565-019-0392-3
   Chen YS, 2010, OPT EXPRESS, V18, P8867, DOI 10.1364/OE.18.008867
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   CRAANDIJK A, 1976, BRIT J OPHTHALMOL, V60, P377, DOI 10.1136/bjo.60.5.377
   de Oliveira T, 2019, ACTA OPHTHALMOL, V97, pE1006, DOI 10.1111/aos.14117
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Feenstra DJ, 2019, EXP EYE RES, V180, P122, DOI 10.1016/j.exer.2018.12.016
   Gordon AY, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.18
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   HUGHES A, 1972, VISION RES, V12, P123, DOI 10.1016/0042-6989(72)90143-5
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jathoul AP, 2015, NAT PHOTONICS, V9, P239, DOI [10.1038/NPHOTON.2015.22, 10.1038/nphoton.2015.22]
   Jeon S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04334-z
   Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967
   Jokerst JV, 2012, ACS NANO, V6, P10366, DOI 10.1021/nn304347g
   Jokerst JV, 2012, ACS NANO, V6, P5920, DOI 10.1021/nn302042y
   Lankveld DPK, 2011, NANOMEDICINE-UK, V6, P339, DOI 10.2217/NNM.10.122
   Lapierre-Landry M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10050-5
   Li L., 2018, INT SOC OPTICS PHOTO, P1049469
   Li Y, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107714
   Li ZB, 2016, ACS BIOMATER SCI ENG, V2, P789, DOI 10.1021/acsbiomaterials.5b00538
   Li ZM, 2010, MOL PHARMACEUT, V7, P94, DOI 10.1021/mp9001415
   Liba O, 2016, SCI REP-UK, V6, DOI 10.1038/srep23337
   Liu T, 2013, CURR EYE RES, V38, P1229, DOI 10.3109/02713683.2013.815219
   Liu WZ, 2016, PHOTOACOUSTICS, V4, P112, DOI 10.1016/j.pacs.2016.05.001
   Mallidi S, 2009, NANO LETT, V9, P2825, DOI 10.1021/nl802929u
   Murakawa S, 2019, GRAEF ARCH CLIN EXP, V257, P1119, DOI 10.1007/s00417-019-04275-5
   Nguyen V. P., NAT COMMUN, V12, P1
   Nguyen V. P., INT SOC OPTICS PHOTO, P1087104
   Nguyen VP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186508
   Nguyen VP, 2017, JPN J APPL PHYS, V56, DOI 10.7567/JJAP.56.07JF12
   Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017
   Pu KY, 2014, NAT NANOTECHNOL, V9, P233, DOI [10.1038/NNANO.2013.302, 10.1038/nnano.2013.302]
   Qian W, 2011, J PHYS CHEM C, V115, P23293, DOI 10.1021/jp2079567
   Querques G., 2016, OCT ANGIOGRAPHY RETI, V56, P101
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sauer L, 2019, INVEST OPHTH VIS SCI, V60, P3054, DOI 10.1167/iovs.19-26835
   Shen S, 2013, BIOMATERIALS, V34, P3150, DOI 10.1016/j.biomaterials.2013.01.051
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Song W, 2013, JOVE-J VIS EXP, DOI 10.3791/4390
   Tian C, 2018, JOVE-J VIS EXP, DOI 10.3791/57135
   Tian C, 2017, OPT EXPRESS, V25, P15947, DOI 10.1364/OE.25.015947
   Nguyen VP, 2021, J BIOPHOTONICS, V14, DOI 10.1002/jbio.202000458
   Nguyen V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47062-2
   Nguyen VP, 2018, J IMAGING, V4, DOI 10.3390/jimaging4120150
   Nguyen VP, 2018, J IMAGING, V4, DOI 10.3390/jimaging4120149
   Nguyen V, 2018, BIOMED OPT EXPRESS, V9, P5915, DOI 10.1364/BOE.9.005915
   Nguyen VP, 2020, ACS SENSORS, V5, P3070, DOI 10.1021/acssensors.0c00908
   VoDinh T, 2014, BIOMED PHOTONICS
   Wang LV, 2009, NAT PHOTONICS, V3, P503, DOI 10.1038/NPHOTON.2009.157
   Wang YW, 2004, NANO LETT, V4, P1689, DOI 10.1021/nl049126a
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wook Kang H, 2016, NOTHING EVER DIES VI
   Zhang W, 2020, PHOTOACOUSTICS, V20, DOI 10.1016/j.pacs.2020.100194
   Zhang W, 2018, LIGHT-SCI APPL, V7, DOI 10.1038/s41377-018-0093-y
   Zhang YM, 2014, NAT NANOTECHNOL, V9, P631, DOI [10.1038/NNANO.2014.130, 10.1038/nnano.2014.130]
NR 59
TC 7
Z9 7
U1 5
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
EI 1944-8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD SEP 1
PY 2021
VL 13
IS 34
BP 40214
EP 40228
DI 10.1021/acsami.1c03504
EA AUG 2021
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA UM0SJ
UT WOS:000693050200004
PM 34403578
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Molina-Martin, A
   Perez-Cambrodi, RJ
   Pinero, DP
AF Molina-Martin, Ainhoa
   Perez-Cambrodi, Rafael J.
   Pinero, David P.
TI Current Clinical Application of Microperimetry: A Review
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Amblyopia; eye fixation; microperimetry; nystagmus; retinal sensitivity;
   visual rehabilitation
ID DIABETIC MACULAR EDEMA; CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL
   COHERENCE TOMOGRAPHY; INTERNAL LIMITING MEMBRANE; BRILLIANT BLUE G;
   RETINAL SENSITIVITY; FUNDUS AUTOFLUORESCENCE; FIXATION STABILITY;
   STARGARDT DISEASE; VISUAL REHABILITATION
AB Microperimetry (MP) is a technology that allows the study of retinal sensitivity at different foveal and parafoveal areas as well as eye fixation. It is a technique of functional evaluation, providing a direct correlation between anatomical and functional outcomes. There are a great variety of studies which evaluate the repeatability or reliability of measurements obtained with this technology and also describe and explore different clinical applications. MP has been shown to be useful in the characterization of sensory and motor conditions, such as amblyopia or nystagmus. Concerning ocular pathology, several studies have confirmed the usefulness of MP for evaluating and analyzing different retinal pathological conditions, such as age-related macular degeneration or glaucoma, and for analyzing the effect of different medical or surgical treatments for these conditions. MP has also been shown to be useful for visual training or rehabilitation in some specific cases.
C1 [Molina-Martin, Ainhoa] Univ Valencia, Fundacio Lluis Alcanyis, Clin Optometr, Valencia, Spain.
   [Perez-Cambrodi, Rafael J.; Pinero, David P.] Vithas Medimar Int Hosp, Dept Ophthalmol OFTALMAR, Alicante, Spain.
   [Pinero, David P.] Univ Alicante, Dept Opt Pharmacol & Anat, Grp Opt & Visual Percept, Alicante, Spain.
C3 University of Valencia; Universitat d'Alacant
RP Pinero, DP (通讯作者)，Univ Alicante, Dept Opt Pharmacol & Anat, Crta San Vicente Raspeig S-N, Alicante 03016, Spain.
EM david.pinyero@ua.es
OI Molina-Martin, Ainhoa/0000-0003-4854-3592; Perez Cambrodi, Rafael
   Jose/0000-0002-7387-3035
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Almeida FPP, 2015, JAMA OPHTHALMOL, V133, P85, DOI 10.1001/jamaophthalmol.2014.3869
   Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Anastasakis A, 2011, EYE, V25, P245, DOI 10.1038/eye.2010.158
   Baba T, 2012, OPHTHALMOLOGY, V119, P2609, DOI 10.1016/j.ophtha.2012.06.048
   Battu R, 2015, EYE, V29, P895, DOI 10.1038/eye.2015.61
   Breukink MB, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0939-z
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Cennamo G, 2015, CAN J OPHTHALMOL, V50, P44, DOI 10.1016/j.jcjo.2014.08.005
   Chung HW, 2014, EYE, V28, P1223, DOI 10.1038/eye.2014.185
   Comyn O, 2014, AM J OPHTHALMOL, V157, P960, DOI 10.1016/j.ajo.2014.02.019
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Dickmann A, 2011, J AAPOS, V15, P338, DOI 10.1016/j.jaapos.2011.03.019
   Eandi CM, 2015, AM J OPHTHALMOL, V159, P652, DOI 10.1016/j.ajo.2014.12.023
   Felius J, 2011, INVEST OPHTH VIS SCI, V52, P8724, DOI 10.1167/iovs.11-7760
   Forte R, 2012, OPHTHALMIC RES, V48, P6, DOI 10.1159/000334618
   Forte R, 2011, J OCUL PHARMACOL TH, V27, P109, DOI 10.1089/jop.2010.0159
   Gella L, 2015, CAN J OPHTHALMOL, V50, P302, DOI 10.1016/j.jcjo.2014.12.008
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, pE105, DOI 10.1016/j.jcjo.2012.11.011
   Hatef E, 2011, AM J OPHTHALMOL, V152, P400, DOI 10.1016/j.ajo.2011.02.024
   Huang P, 2012, JPN J OPHTHALMOL, V56, P138, DOI 10.1007/s10384-011-0111-6
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Johnson David A, 2006, Trans Am Ophthalmol Soc, V104, P414
   Karacorlu Murat, 2010, International Ophthalmology, V30, P285, DOI 10.1007/s10792-009-9333-8
   Koinzer Stefan, 2012, Retin Cases Brief Rep, V6, P50, DOI 10.1097/ICB.0b013e3182051ed2
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Markowitz SN, 2010, CAN J OPHTHALMOL, V45, P58, DOI 10.3129/i09-244
   Martinez-Costa L, 2013, CAN J OPHTHALMOL, V48, P400, DOI 10.1016/j.jcjo.2013.03.018
   Mastropasqua R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145663
   Mayer WJ, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/297239
   Mettu PS, 2011, RETINA-J RET VIT DIS, V31, P1637, DOI 10.1097/IAE.0b013e31821800e0
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Molina A, 2013, CAN J OPHTHALMOL, V48, pE103, DOI 10.1016/j.jcjo.2013.07.017
   Molina-Martin A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/437271
   Molina-Martin A, 2016, CURR EYE RES, V41, P400, DOI 10.3109/02713683.2015.1020170
   Molina-Martin A, 2015, CAN J OPHTHALMOL, V50, P413, DOI 10.1016/j.jcjo.2015.07.012
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Ozdemir H, 2010, ACTA OPHTHALMOL, V88, pe222, DOI 10.1111/j.1755-3768.2010.01898.x
   Pal SS, 2011, INDIAN J OPHTHALMOL, V59, P498, DOI 10.4103/0301-4738.86324
   Parodi MB, 2015, BRIT J OPHTHALMOL, V99, P1354, DOI 10.1136/bjophthalmol-2014-306237
   Parravano M, 2013, BRIT J OPHTHALMOL, V97, P291, DOI 10.1136/bjophthalmol-2011-301219
   Pearce E, 2011, EYE, V25, P149, DOI 10.1038/eye.2010.167
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Raman Rajiv, 2015, J Ophthalmic Vis Res, V10, P160, DOI 10.4103/2008-322X.163771
   Rao HL, 2015, INVEST OPHTH VIS SCI, V56, P8063, DOI 10.1167/iovs.15-17922
   Ratra Vineet, 2012, Oman J Ophthalmol, V5, P97
   Reibaldi M, 2012, AM J OPHTHALMOL, V154, P974, DOI 10.1016/j.ajo.2012.06.008
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P953, DOI 10.1016/j.ajo.2010.12.007
   Ripandelli G, 2015, RETINA-J RET VIT DIS, V35, P498, DOI 10.1097/IAE.0000000000000330
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Salvatore S, 2011, CLIN OPHTHALMOL, V5, P1269, DOI 10.2147/OPTH.S23082
   Sato S, 2013, INVEST OPHTH VIS SCI, V54, P3046, DOI 10.1167/iovs.12-11173
   Seidensticker F, 2013, KLIN MONATSBL AUGENH, V230, P524, DOI 10.1055/s-0032-1327930
   Senturk F, 2011, AM J OPHTHALMOL, V151, P303, DOI 10.1016/j.ajo.2010.08.019
   Shpak AA, 2016, INT J OPHTHALMOL-CHI, V9, P253, DOI 10.18240/ijo.2016.02.13
   Shulman M, 2013, OPHTHAL SURG LAS IM, V44, P577, DOI 10.3928/23258160-20131105-07
   Smolek MK, 2013, CLIN OPHTHALMOL, V7, P1451, DOI 10.2147/OPTH.S46718
   Soliman W, 2012, ACTA OPHTHALMOL, V90, P248, DOI 10.1111/j.1755-3768.2010.01912.x
   Subash M, 2016, JAMA OPHTHALMOL, V134, P666, DOI 10.1001/jamaophthalmol.2016.0629
   Subramanian V, 2013, INVEST OPHTH VIS SCI, V54, P1998, DOI 10.1167/iovs.12-11054
   Sun ZC, 2012, GRAEF ARCH CLIN EXP, V250, P1587, DOI 10.1007/s00417-012-1997-5
   Tarita-Nistor L, 2013, OPHTHAL SURG LAS IM, V44, P46, DOI 10.3928/23258160-20121221-12
   Testa F, 2014, OPHTHALMOLOGY, V121, P2399, DOI 10.1016/j.ophtha.2014.06.032
   Ueda-Consolvo T, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/572942
   Verboschi F, 2013, FUNCT NEUROL, V28, P285, DOI 10.11138/FNeur/2013.28.4.285
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
NR 73
TC 25
Z9 27
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 5
BP 620
EP 628
DI 10.1080/08820538.2017.1375125
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM5CX
UT WOS:000438148800006
PM 28991503
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Blaum, BS
AF Blaum, Baerbel S.
TI The lectin self of complement factor H
SO CURRENT OPINION IN STRUCTURAL BIOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; SIALIC-ACID; STRUCTURAL BASIS; BINDING
   PROPERTIES; C3 CONVERTASE; PROTECTION; CELLS; SITE; GLYCOSAMINOGLYCAN;
   RECOGNITION
AB Complement, a part of the humoral innate immune system, is divided into three pathways. The classical and mannose-binding lectin pathways are triggered by specific recognition of foreign targets. Conversely, the alternative pathway (AP) is actively down-regulated on host tissue. Glycosaminoglycans (GAGs) and sialylated glycans mediate host recognition of the AP as self-associated molecular patterns (SAMPs) to the regulatory protein factor H (FH). This review summarizes the more recent years of research on SAMP recognition by FH from a structural biology point of view and discusses implications for two complement-associated conditions, age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). Taking into account crystal structures that elucidated FH binding to a bacterial evasion protein and to the thioester domain of C3b, the target of FH-mediated AP restriction, a novel atomistic model for the mechanism by which FH prevents AP activation on self surfaces is proposed.
C1 [Blaum, Baerbel S.] Univ Tubingen, Interfac Inst Biochem IFIB, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
RP Blaum, BS (通讯作者)，Univ Tubingen, Interfac Inst Biochem IFIB, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.
EM baerbel.blaum@uni-tuebingen.de
OI Blaum, Baerbel/0000-0003-4312-8912
FU German Research Foundation (DFG) [BL 1294/2-1]; University of Tubingen
   [2186-0-0]
FX This work was supported by the German Research Foundation (DFG, BL
   1294/2-1) and the University of Tubingen fortune program (2186-0-0).
CR Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m
   Bhattacharjee A, 2015, J BIOL CHEM, V290, P9500, DOI 10.1074/jbc.M114.630871
   Bhattacharjee A, 2013, J BIOL CHEM, V288, P18685, DOI 10.1074/jbc.M113.459040
   Blaum BS, 2016, GLYCOBIOLOGY, V26, P532, DOI 10.1093/glycob/cwv170
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Dane MJC, 2015, AM J PHYSIOL-RENAL, V308, pF956, DOI 10.1152/ajprenal.00532.2014
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Gulati S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005290
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Herbert AP, 2015, J IMMUNOL, V195, P4986, DOI 10.4049/jimmunol.1501388
   Hudson KL, 2015, J AM CHEM SOC, V137, P15152, DOI 10.1021/jacs.5b08424
   Hyvarinen S, 2016, BLOOD, V127, P2701, DOI 10.1182/blood-2015-11-680009
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Martin LT, 2002, J BIOL CHEM, V277, P32930, DOI 10.1074/jbc.M203362200
   Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MICHALEK MT, 1988, J IMMUNOL, V140, P1588
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Padler-Karavani V, 2008, GLYCOBIOLOGY, V18, P818, DOI 10.1093/glycob/cwn072
   PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Samraj AN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00033
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Seiradake E, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000277
   Springer SA, 2014, IMMUNOGENETICS, V66, P671, DOI 10.1007/s00251-014-0795-0
   Takemae N, 2010, J GEN VIROL, V91, P938, DOI 10.1099/vir.0.016691-0
   VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532
   Varki A, 2011, GLYCOBIOLOGY, V21, P1121, DOI 10.1093/glycob/cwr087
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Zhuravleva MA, 2008, J MOL BIOL, V375, P437, DOI 10.1016/j.jmb.2007.10.009
NR 49
TC 22
Z9 22
U1 0
U2 12
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-440X
EI 1879-033X
J9 CURR OPIN STRUC BIOL
JI Curr. Opin. Struct. Biol.
PD JUN
PY 2017
VL 44
BP 111
EP 118
DI 10.1016/j.sbi.2017.01.005
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FC3IF
UT WOS:000406731600014
PM 28189794
DA 2022-11-30
ER

PT J
AU Ahmed, F
   Fanning, K
   Netzel, M
   Turner, W
   Li, Y
   Schenk, PM
AF Ahmed, Faruq
   Fanning, Kent
   Netzel, Michael
   Turner, Warwick
   Li, Yan
   Schenk, Peer M.
TI Profiling of carotenoids and antioxidant capacity of microalgae from
   subtropical coastal and brackish waters
SO FOOD CHEMISTRY
LA English
DT Article
DE Carotenoids; Microalgae; Antioxidant capacity; ORAC; Total phenolics
ID OUTDOOR CULTIVATION; MURIELLOPSIS SP; EXTRACTION; LUTEIN; CHLORELLA;
   SPIRULINA; ACCUMULATION; OPTIMIZATION; FRACTIONS; ALGAE
AB Carotenoids are associated with various health benefits, such as prevention of age-related macular degeneration, cataract, certain cancers, rheumatoid arthritis, muscular dystrophy and cardiovascular problems. As microalgae contain considerable amounts of carotenoids, there is a need to find species with high carotenoid content. Out of hundreds of Australian isolates, 12 microalgal species were screened for carotenoid profiles, carotenoid productivity, and in vitro antioxidant capacity (total phenolic content (TPC) and ORAC). The top four carotenoid producers at 4.68-6.88 mg/g dry weight (DW) were Dunaliella salina, Tetraselmis suecica, Isochrysis galbana, and Pavlova salina. TPC was low, with D. salina possessing the highest TPC (1.54 mg Gallic Acid Equivalents/g DW) and ORAC (577 mu mol Trolox Equivalents/g DW). Results indicate that T. suecica, D. salina, P. salina and L galbana could be further developed for commercial carotenoid production. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ahmed, Faruq; Li, Yan; Schenk, Peer M.] Univ Queensland, Sch Agr & Food Sci, Algae Biotechnol Lab, Brisbane, Qld 4072, Australia.
   [Fanning, Kent; Turner, Warwick] DAFF, Coopers Plains, Qld 4108, Australia.
   [Netzel, Michael] Univ Queensland, Ctr Nutr & Food Sci, QAAFI, Brisbane, Qld 4072, Australia.
   [Li, Yan] James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia.
C3 University of Queensland; Queensland Department of Agriculture &
   Fisheries; University of Queensland; James Cook University
RP Schenk, PM (通讯作者)，Univ Queensland, Sch Agr & Food Sci, Algae Biotechnol Lab, Brisbane, Qld 4072, Australia.
EM p.schenk@uq.edu.au
RI Schenk, Peer/B-7879-2016; Netzel, Michael/M-4050-2013; Li,
   Yan/A-5532-2008
OI Schenk, Peer/0000-0003-4878-3799; Netzel, Michael/0000-0002-3136-3926;
   Li, Yan/0000-0002-9102-0917; Li, Yan/0000-0002-9742-0081
FU Australian Research Council, Australia
FX We wish to thank Ekaterina Nowak for maintaining the microalgal cultures
   and the Australian Research Council, Australia for financial support.
CR Blanco AM, 2007, APPL MICROBIOL BIOT, V73, P1259, DOI 10.1007/s00253-006-0598-9
   Borowitzka MA, 2013, J APPL PHYCOL, V25, P743, DOI 10.1007/s10811-013-9983-9
   Charles D. J., 2013, ANTIOXIDANT PROPERTI
   Connan S, 2011, AQUAT TOXICOL, V104, P1, DOI 10.1016/j.aquatox.2011.03.016
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   Del Campo JA, 2007, APPL MICROBIOL BIOT, V74, P1163, DOI 10.1007/s00253-007-0844-9
   Duan XJ, 2006, FOOD CHEM, V95, P37, DOI 10.1016/j.foodchem.2004.12.015
   Dugo P, 2008, J SEP SCI, V31, P2151, DOI 10.1002/jssc.200800073
   Fanning KJ, 2010, J SCI FOOD AGR, V90, P91, DOI 10.1002/jsfa.3787
   Fu W, 2012, ANAL BIOANAL CHEM, V404, P3145, DOI 10.1007/s00216-012-6434-4
   Guzman S, 2001, PHYTOTHER RES, V15, P224, DOI 10.1002/ptr.715
   Hajimahmoodi M, 2010, J APPL PHYCOL, V22, P43, DOI 10.1007/s10811-009-9424-y
   Herrero M, 2005, FOOD CHEM, V93, P417, DOI 10.1016/j.foodchem.2004.09.037
   Herrero M, 2006, J AGR FOOD CHEM, V54, P5597, DOI 10.1021/jf060546q
   Holeton C, 2009, J PLANKTON RES, V31, P661, DOI 10.1093/plankt/fbp016
   Hu CC, 2008, FOOD CHEM, V109, P439, DOI 10.1016/j.foodchem.2007.12.043
   Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c
   Huang DJ, 2002, J AGR FOOD CHEM, V50, P4437, DOI 10.1021/jf0201529
   Ibanez E, 2013, J SCI FOOD AGR, V93, P703, DOI 10.1002/jsfa.6023
   Jaime L, 2005, J SEP SCI, V28, P2111, DOI 10.1002/jssc.200500185
   Jin E, 2003, J MICROBIOL BIOTECHN, V13, P165
   Kepekci RA, 2012, J APPL PHYCOL, V24, P897, DOI 10.1007/s10811-011-9710-3
   Kim GN, 2009, FOOD CHEM, V117, P35, DOI 10.1016/j.foodchem.2009.03.072
   Kuda T, 2005, FOOD CHEM, V89, P617, DOI 10.1016/j.foodchem.2004.03.020
   Li HB, 2007, FOOD CHEM, V102, P771, DOI 10.1016/j.foodchem.2006.06.022
   Lim DKY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040751
   Lu QY, 2009, J AGR FOOD CHEM, V57, P10408, DOI 10.1021/jf901839h
   Maeda H, 2005, BIOCHEM BIOPH RES CO, V332, P392, DOI 10.1016/j.bbrc.2005.05.002
   Martins S, 2011, BIOTECHNOL ADV, V29, P365, DOI 10.1016/j.biotechadv.2011.01.008
   Mogedas B, 2009, J BIOSCI BIOENG, V108, P47, DOI 10.1016/j.jbiosc.2009.02.022
   Perez-Garcia O, 2011, WATER RES, V45, P11, DOI 10.1016/j.watres.2010.08.037
   Plaza M, 2010, J PHARMACEUT BIOMED, V51, P450, DOI 10.1016/j.jpba.2009.03.016
   Plaza M, 2009, J AGR FOOD CHEM, V57, P7159, DOI 10.1021/jf901070g
   Prior RL, 1998, J AGR FOOD CHEM, V46, P2686, DOI 10.1021/jf980145d
   Rao AR, 2006, J AGR FOOD CHEM, V54, P4593, DOI 10.1021/jf060799j
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schlesier K, 2002, FREE RADICAL RES, V36, P177, DOI 10.1080/10715760290006411
   Schubert N, 2006, J PHYCOL, V42, P1208, DOI 10.1111/j.1529-8817.2006.00274.x
   Shi XM, 2006, MOL NUTR FOOD RES, V50, P763, DOI 10.1002/mnfr.200600037
   SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144
   Stahl W, 2012, MOL NUTR FOOD RES, V56, P287, DOI 10.1002/mnfr.201100232
   Su L, 2007, FOOD CHEM, V100, P990, DOI 10.1016/j.foodchem.2005.10.058
   Wu LC, 2005, J AGR FOOD CHEM, V53, P4207, DOI 10.1021/jf0479517
NR 43
TC 95
Z9 100
U1 7
U2 282
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD DEC 15
PY 2014
VL 165
BP 300
EP 306
DI 10.1016/j.foodchem.2014.05.107
PG 7
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA AN0WB
UT WOS:000340303600039
PM 25038679
DA 2022-11-30
ER

PT J
AU Chou, WW
   Wang, YS
   Chen, KC
   Wu, JM
   Liang, CL
   Juo, SHH
AF Chou, Wen-Wen
   Wang, Yung-Song
   Chen, Ku-Chung
   Wu, Jing-Mei
   Liang, Chung-Ling
   Juo, Suh-Hang Hank
TI Tannic acid suppresses ultraviolet B-induced inflammatory signaling and
   complement factor B on human retinal pigment epithelial cells
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Ultraviolet; RPE; Interleukin-6; Complement factor B; Inflammation
ID UVB-MEDIATED INDUCTION; MACULAR DEGENERATION; HUMAN KERATINOCYTES;
   DNA-DAMAGE; IFN-GAMMA; INTERLEUKIN-6; EXPRESSION; STAT3; MICE;
   FIBROBLASTS
AB Ultraviolet B (UVB) radiation may cause the inflammation of retinal pigment epithelium (RPE) cells and play a role in development of age-related macular degeneration (AMD). The activation of the complement factor B (CFB) gene has been shown to be involved in formation of AMD. Here our results revealed that UVB induces IL-6/STAT3 signaling activation and the UVB-induced STAT3 is able to regulate the CFB expression in ARPE-19 cells. Tannic acid (TA) is a kind of water-soluble polyphenol and may have anti-inflammation effects. We also found that TA attenuates the UVB-induced IL-6 protein production, the STAT3 phosphorylation and the CFB expression. Taken together, these findings suggest UVB-induced inflammation of RPE can be mediated through the IL-6/STAT3/CFB pathway, and TA has a protected effect via the inhibition to the inflammatory response. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Chou, Wen-Wen; Wang, Yung-Song; Chen, Ku-Chung; Wu, Jing-Mei; Liang, Chung-Ling; Juo, Suh-Hang Hank] Kaohsiung Med Univ, Dept Med Genet, Coll Med, Kaohsiung 807, Taiwan.
   [Chou, Wen-Wen; Wang, Yung-Song; Chen, Ku-Chung; Wu, Jing-Mei; Juo, Suh-Hang Hank] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.
   [Liang, Chung-Ling] Bright Eyes Clin, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital
RP Liang, CL (通讯作者)，Kaohsiung Med Univ, Dept Med Genet, Coll Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM ling0228@gmail.com; hjuo@kmu.edu.tw
RI Juo, Suh-Hang/C-9545-2009
FU National Science Council, Taiwan [NSC95-3112B037-003]
FX This study was supported by National Science Council, Taiwan
   (NSC95-3112B037-003).
CR Afaq F, 2005, INT J CANCER, V113, P423, DOI 10.1002/ijc.20587
   Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq
   ANDLEY UP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1057, DOI 10.1111/j.1751-1097.1987.tb04893.x
   ANDOH A, 1993, J IMMUNOL, V151, P4239
   Balaiya S, 2010, CLIN OPHTHALMOL, V4, P33
   BARASH I, 1989, J BIOL REG HOMEOS AG, V3, P175
   Benko S, 2008, MOL VIS, V14, P1575
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Bito T, 2010, EXP DERMATOL, V19, P654, DOI 10.1111/j.1600-0625.2010.01084.x
   Boonstra A, 2001, J INVEST DERMATOL, V117, P141, DOI 10.1046/j.0022-202x.2001.01390.x
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Bradley D. T., 2011, EYE LOND
   Cavet ME, 2011, MOL VIS, V17, P533
   Chen X, 2003, CLIN CANCER RES, V9, P3115
   Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x
   Cooper KD, 2003, CUTIS, V72, P11
   Di Girolamo N, 2002, INVEST OPHTH VIS SCI, V43, P3430
   Di Girolamo N, 2006, INVEST OPHTH VIS SCI, V47, P2430, DOI 10.1167/iovs.05-1130
   Di Girolamo N, 2010, CURR PHARM DESIGN, V16, P1358, DOI 10.2174/138161210791033923
   Duthie MS, 1999, BRIT J DERMATOL, V140, P995
   Erdelyi K, 2005, MOL PHARMACOL, V68, P895, DOI 10.1124/mol.105.012518
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   GENSLER HL, 1994, NUTR CANCER, V22, P121, DOI 10.1080/01635589409514337
   Huang Y, 2001, EUR J IMMUNOL, V31, P3676, DOI 10.1002/1521-4141(200112)31:12<3676::AID-IMMU3676>3.0.CO;2-K
   Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jung MK, 2010, J INVEST DERMATOL, V130, P1459, DOI 10.1038/jid.2009.401
   KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605
   Liu X. C., 2011, INFLAMMATION
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lodovici M, 2009, TOXICOLOGY, V255, P1, DOI 10.1016/j.tox.2008.09.011
   McCarty CA, 2002, DEV OPHTHALMOL, V35, P21
   Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623
   Park HJ, 2006, EXP DERMATOL, V15, P589, DOI 10.1111/j.1600-0625.2006.00449.x
   Pasch MC, 2000, J INVEST DERMATOL, V114, P78, DOI 10.1046/j.1523-1747.2000.00841.x
   Patton WP, 1999, INVEST OPHTH VIS SCI, V40, P3268
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817
   Samardzija M, 2006, FASEB J, V20, P2411, DOI 10.1096/fj.06-5895fje
   SAVOLAINEN H, 1992, J APPL TOXICOL, V12, P191, DOI 10.1002/jat.2550120307
   Sherman CT, 2001, MOL ENDOCRINOL, V15, P441, DOI 10.1210/me.15.3.441
   Shibata A, 2010, J NUTR BIOCHEM, V21, P702, DOI 10.1016/j.jnutbio.2009.04.007
   Tokuda K, 2007, EXP EYE RES, V84, P537, DOI 10.1016/j.exer.2006.11.005
   Wu WC, 2010, MOL VIS, V16, P1864
   Xu JY, 2010, INVEST OPHTH VIS SCI, V51, P6665, DOI 10.1167/iovs.10-5698
   Zipplies JK, 2010, IMMUNOBIOLOGY, V215, P949, DOI 10.1016/j.imbio.2010.02.003
NR 48
TC 24
Z9 25
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2012
VL 273
IS 1
BP 79
EP 84
DI 10.1016/j.cellimm.2011.11.003
PG 6
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 886OC
UT WOS:000299862700011
PM 22169226
DA 2022-11-30
ER

PT J
AU Moreau, RA
   Johnston, DB
   Hicks, KB
AF Moreau, Robert A.
   Johnston, David B.
   Hicks, Kevin B.
TI A comparison of the levels of lutein and zeaxanthin in corn germ oil,
   corn fiber oil and corn kernel oil
SO JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY
LA English
DT Article
DE carotenoids; corn; maize; lutein; zeaxanthin; xanthophylls
ID SIMULTANEOUS QUANTIFICATION; EXTRACTION; CAROTENOIDS; TOCOPHEROL
AB All commercial corn oil is obtained by pressing corn germ and/or extracting the germ with hexane. In the current study, six types of corn oil were prepared by extracting corn germ, corn fiber and ground corn, each with hexane or with ethanol. The levels of lutein, zeaxanthin and other carotenoids were quantitatively analyzed in the six corn oils. The levels of lutein + zeaxanthin in the oil ranged from 2.3 mu g/g for hexane-extracted corn germ oil to 220.9 mu g/g for ethanol-extracted ground corn oil. These results indicate that a diet that includes 30 g (similar to 2 tbsp) per day of the unrefined corn oil obtained by extracting ground corn with ethanol would provide similar to 6 mg of lutein + zeaxanthin, the daily dosage that is currently considered to be necessary to slow the progression of age-related macular degeneration.
C1 USDA, ARS, ERRC, Crop Convers Sci & Engn Res Unit, Wyndmoor, PA 19038 USA.
   Eastern Reg Res Ctr, USDA, ARS, Wyndmoor, PA 19038 USA.
C3 United States Department of Agriculture (USDA); United States Department
   of Agriculture (USDA)
RP Moreau, RA (通讯作者)，USDA, ARS, ERRC, Crop Convers Sci & Engn Res Unit, 600 E Mermaid Lane, Wyndmoor, PA 19038 USA.
EM robert.moreau@ars.usda.gov
OI Moreau, Robert/0000-0002-8166-8322
CR BHOLE BM, 2005, J FOOD ENG, V69, P481
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hao ZG, 2005, J CHROMATOGR A, V1094, P83, DOI 10.1016/j.chroma.2005.07.097
   HOJILLAEVANGELISTA MP, 1992, CEREAL CHEM, V69, P643
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Kale A, 2007, IND CROP PROD, V26, P44, DOI 10.1016/j.indcrop.2007.01.006
   Kurilich AC, 1999, J LIQ CHROMATOGR R T, V22, P2925, DOI 10.1081/JLC-100102068
   Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1948, DOI 10.1021/jf981029d
   Kwiatkowski JR, 2002, J AM OIL CHEM SOC, V79, P825, DOI 10.1007/s11746-002-0565-8
   MILLER D, 1981, SIMULTANEOUS STAT IN
   Momany FA, 2006, J AGR FOOD CHEM, V54, P543, DOI 10.1021/jf058135h
   Moreau R. A., 2005, BAILEYS IND OIL FAT, V2, P149
   Moreau RA, 2005, J AM OIL CHEM SOC, V82, P809, DOI 10.1007/s11746-005-1148-4
   Moreau RA, 2003, J AM OIL CHEM SOC, V80, P1063, DOI 10.1007/s11746-003-0821-y
   Moreau RA, 1996, J AGR FOOD CHEM, V44, P2149, DOI 10.1021/jf950743h
   Moros EE, 2002, J AGR FOOD CHEM, V50, P5787, DOI 10.1021/jf020109l
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Panfili G, 2004, J AGR FOOD CHEM, V52, P6373, DOI 10.1021/jf0402025
   US Department of Agriculture, USDA NUTR DAT STAND
NR 20
TC 44
Z9 49
U1 2
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-021X
EI 1558-9331
J9 J AM OIL CHEM SOC
JI J. Am. Oil Chem. Soc.
PD NOV
PY 2007
VL 84
IS 11
BP 1039
EP 1044
DI 10.1007/s11746-007-1137-2
PG 6
WC Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology
GA 225TA
UT WOS:000250539200007
DA 2022-11-30
ER

PT J
AU Dou, XZ
   Nath, D
   Shin, H
   Nurmemmedov, E
   Bourne, PC
   Ma, JX
   Duerfeldt, AS
AF Dou, Xiaozheng
   Nath, Dinesh
   Shin, Henry
   Nurmemmedov, Elmar
   Bourne, Philip C.
   Ma, Jian-Xing
   Duerfeldt, Adam S.
TI Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious,
   Potent, and Isoform Selective PPAR alpha Agonists as Leads for Retinal
   Disorders
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PROLIFERATOR-ACTIVATED RECEPTOR; DIABETIC-RETINOPATHY; BIOLOGICAL
   EVALUATION; FENOFIBRATE; DISCOVERY; DESIGN; MECHANISMS; DOCKING
AB Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.
C1 [Dou, Xiaozheng; Nath, Dinesh; Duerfeldt, Adam S.] Univ Oklahoma, Inst Nat Prod Applicat & Res Technol, Norman, OK 73019 USA.
   [Dou, Xiaozheng; Nath, Dinesh; Bourne, Philip C.; Duerfeldt, Adam S.] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
   [Shin, Henry; Ma, Jian-Xing] Univ Oklahoma, Dept Physiol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
   [Nurmemmedov, Elmar] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA 90404 USA.
   [Nurmemmedov, Elmar] Providence St Johns Hlth Ctr, Pacific Neurosci Inst, Santa Monica, CA 90404 USA.
C3 University of Oklahoma System; University of Oklahoma - Norman;
   University of Oklahoma System; University of Oklahoma - Norman;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center; John Wayne Cancer Institute; John Wayne Cancer Institute
RP Duerfeldt, AS (通讯作者)，Univ Oklahoma, Inst Nat Prod Applicat & Res Technol, Norman, OK 73019 USA.; Duerfeldt, AS (通讯作者)，Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
EM adam.duerfeldt@ou.edu
RI Nath, Dinesh/ABA-6814-2021; Nath, Dinesh/AAX-6000-2020
OI Nath, Dinesh/0000-0003-0286-3144
FU University of Oklahoma Growth Fund; National Eye Institute of the
   National Institutes of Health [R21EY028279, R01EY019309, R01EY018659,
   R01EY012231]; Institutional Development Award (IDeA) from the National
   Institute of General Medical Sciences of the National Institutes of
   Health [P20GM103640]
FX Research reported in this publication was supported by the University of
   Oklahoma Growth Fund (A.S.D., H.S., J.-X.M.) and the National Eye
   Institute of the National Institutes of Health under award numbers
   R21EY028279 (A.S. D.), R01EY019309, R01EY018659, and R01EY012231
   (J.-X.M.). We acknowledge the use of the Protein Production Core (PPC)
   at the University of Oklahoma, Norman. PPC is supported by an
   Institutional Development Award (IDeA) from the National Institute of
   General Medical Sciences of the National Institutes of Health under
   grant number P20GM103640. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health. The authors are grateful to Cameron D.
   Siler and Will Drover for enlightening discussions and Eurofins for
   conducting the PK studies.
CR Babic I, 2018, FUTURE MED CHEM, V10, P1641, DOI 10.4155/fmc-2018-0139
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Bernardes A, 2013, J MOL BIOL, V425, P2878, DOI 10.1016/j.jmb.2013.05.010
   Cai X, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3789217
   Capelli D, 2016, SCI REP-UK, V6, DOI 10.1038/srep34792
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Dou XZ, 2018, BIOORG MED CHEM LETT, V28, P2717, DOI 10.1016/j.bmcl.2018.03.010
   Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fruchart JC, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-82
   Gangwal RP, 2015, BIOORG MED CHEM LETT, V25, P270, DOI 10.1016/j.bmcl.2014.11.052
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Li J, 2010, J MED CHEM, V53, P2854, DOI 10.1021/jm9016812
   Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0
   Mizuno CS, 2008, BIOORGAN MED CHEM, V16, P3800, DOI 10.1016/j.bmc.2008.01.051
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Nomura M, 2003, J MED CHEM, V46, P3581, DOI 10.1021/jm0205144
   Noonan JE, 2013, DIABETES, V62, P3968, DOI 10.2337/db13-0800
   Pearsall EA, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0451-x
   Pirat C, 2012, J MED CHEM, V55, P4027, DOI 10.1021/jm101360s
   Schonherr H, 2013, ANGEW CHEM INT EDIT, V52, P12256, DOI 10.1002/anie.201303207
   Sierra ML, 2007, J MED CHEM, V50, P685, DOI 10.1021/jm058056x
   Simo R, 2013, CURR MED CHEM, V20, P3258, DOI 10.2174/0929867311320260009
   Wei Shen Y. G., 2014, J CLIN EXP OPHTHALMO, V5
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
   Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198
   Zhang SX, 2005, AM J PATHOL, V166, P313, DOI 10.1016/S0002-9440(10)62255-9
   Zhao S, 2016, J NAT PROD, V79, P3127, DOI 10.1021/acs.jnatprod.6b00883
NR 31
TC 4
Z9 4
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 26
PY 2020
VL 63
IS 6
BP 2854
EP 2876
DI 10.1021/acs.jmedchem.9b01189
PG 23
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA LE0HA
UT WOS:000526404600009
PM 32096640
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vulpetti, A
   Randl, S
   Rudisser, S
   Ostermann, N
   Erbel, P
   Mac Sweeney, A
   Zoller, T
   Salem, B
   Gerhartz, B
   Cumin, F
   Hommel, U
   Dalvit, C
   Lorthiois, E
   Maibaum, J
AF Vulpetti, Anna
   Randl, Stefan
   Ruedisser, Simon
   Ostermann, Nils
   Erbel, Paul
   Mac Sweeney, Aengus
   Zoller, Thomas
   Salem, Bahaa
   Gerhartz, Bernd
   Cumin, Frederic
   Hommel, Ulrich
   Dalvit, Claudio
   Lorthiois, Edwige
   Maibaum, Juergen
TI Structure-Based Library Design and Fragment Screening for the
   Identification of Reversible Complement Factor D Protease Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SERINE-PROTEASE; LOCAL ENVIRONMENT; WATER SUPPRESSION; ACCURATE DOCKING;
   BINDING-SITES; NMR; DISCOVERY; FLUORINE; ACTIVATION; GENERATION
AB Chronic dysregulation of alternative complement pathway activation has been associated with diverse clinical disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea. Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymatic reaction of the amplification loop of the alternative pathway. In this article, we describe two hit finding approaches leading to the discovery of new chemical matter for this pivotal protease of the complement system: in silico active site mapping for hot spot identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries. The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different subpockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.
C1 [Vulpetti, Anna; Randl, Stefan; Ruedisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Juergen] Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, CH-4056 Basel, Switzerland.
   [Randl, Stefan] Evonik Japan Co Ltd, Shinjuku Ku, Shinjuku Monolith 12F 2-3-1, Tokyo 1630938, Japan.
   [Mac Sweeney, Aengus] Actel Pharmaceut Ltd, Drug Discovery Dept, CH-4123 Allschwil, Switzerland.
C3 Novartis; Actelion Pharmaceuticals Ltd
RP Vulpetti, A (通讯作者)，Novartis Pharma AG, Novartis Inst BioMed Res, Novartis Campus, CH-4056 Basel, Switzerland.
EM anna.vulpetti@novartis.com
OI Rudisser, Simon/0000-0002-1107-6196; Vulpetti, Anna/0000-0002-3114-8679
CR Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   Altmann E., 2014, [Preparation of indazolyl and other bicyclic heterocyclic compounds as complement alternative pathway modulators and uses for treating macular degeneration, diabetic retinopathy, and, W02014002051A2], Patent No. [WO2014002051A2, 2014, 2014002051, WO2014/002051 A2]
   [Anonymous], 2003, PYMOL MOL GRAPH SYST
   [Anonymous], 2006, PIP PIL
   [Anonymous], BOTH SITEMAP MOD HYD
   [Anonymous], 2006, MAESTR
   BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8
   Bolton SA, 2013, BIOORG MED CHEM LETT, V23, P5239, DOI 10.1016/j.bmcl.2013.06.028
   Brandt T, 2011, J MOL BIOL, V405, P1170, DOI 10.1016/j.jmb.2010.11.038
   Cheeseright TJ, 2008, J CHEM INF MODEL, V48, P2108, DOI 10.1021/ci800110p
   Cole LB, 1998, ACTA CRYSTALLOGR D, V54, P711, DOI 10.1107/S0907444997010457
   Dalvit C, 2000, J BIOMOL NMR, V18, P65, DOI 10.1023/A:1008354229396
   Dalvit C, 2002, COMB CHEM HIGH T SCR, V5, P605, DOI 10.2174/1386207023329923
   Dalvit C, 2007, PROG NUCL MAG RES SP, V51, P243, DOI 10.1016/j.pnmrs.2007.07.002
   Edfeldt FNB, 2011, DRUG DISCOV TODAY, V16, P284, DOI 10.1016/j.drudis.2011.02.002
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GHOSE AK, 1987, J CHEM INF COMP SCI, V27, P21, DOI 10.1021/ci00053a005
   Hajduk PJ, 2005, J MED CHEM, V48, P2518, DOI 10.1021/jm049131r
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047
   Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089
   Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804
   Johnson A, 1999, BBA-PROTEIN STRUCT M, V1435, P7, DOI 10.1016/S0167-4838(99)00202-2
   Jordan JB, 2012, J MED CHEM, V55, P678, DOI 10.1021/jm201441k
   KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588
   KAM CM, 1987, J BIOL CHEM, V262, P3444
   Kohrt JT, 2005, BIOORG MED CHEM LETT, V15, P4752, DOI 10.1016/j.bmcl.2005.07.059
   Kozakov D, 2015, J MED CHEM, V58, P9063, DOI 10.1021/acs.jmedchem.5b00586
   Kozakov D, 2015, NAT PROTOC, V10, P733, DOI 10.1038/nprot.2015.043
   Mahadevi AS, 2013, CHEM REV, V113, P2100, DOI 10.1021/cr300222d
   Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]
   MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296
   MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109
   Muller K, 2007, SCIENCE, V317, P1881, DOI 10.1126/science.1131943
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Ngan CH, 2012, BIOINFORMATICS, V28, P286, DOI 10.1093/bioinformatics/btr651
   Perot S, 2010, DRUG DISCOV TODAY, V15, P656, DOI 10.1016/j.drudis.2010.05.015
   PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855
   Politzer P, 2007, J MOL MODEL, V13, P305, DOI 10.1007/s00894-006-0154-7
   R Core Team, 2014, R LANG ENV STAT COMP
   Risitano AM, 2013, ADV EXP MED BIOL, V735, P155, DOI 10.1007/978-1-4614-4118-2_10
   Sanderson PEJ, 1999, MED RES REV, V19, P179, DOI 10.1002/(SICI)1098-1128(199903)19:2<179::AID-MED4>3.0.CO;2-5
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098
   Szalai AJ, 2000, J IMMUNOL, V164, P463, DOI 10.4049/jimmunol.164.1.463
   Taylor FR, 1999, BIOCHEMISTRY-US, V38, P2849, DOI 10.1021/bi982140f
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Vulpetti A, 2013, CHEMMEDCHEM, V8, P2057, DOI 10.1002/cmdc.201300351
   Vulpetti A, 2012, FUTURE MED CHEM, V4, P1971, DOI [10.4155/FMC.12.147, 10.4155/fmc.12.147]
   Vulpetti A, 2012, DRUG DISCOV TODAY, V17, P890, DOI 10.1016/j.drudis.2012.03.014
   Vulpetti A, 2010, PROTEINS, V78, P3281, DOI 10.1002/prot.22836
   Vulpetti A, 2009, J AM CHEM SOC, V131, P12949, DOI 10.1021/ja905207t
   Wendt MD, 2004, BIOORG MED CHEM LETT, V14, P3063, DOI 10.1016/j.bmcl.2004.04.030
NR 57
TC 19
Z9 19
U1 0
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 9
PY 2017
VL 60
IS 5
BP 1946
EP 1958
DI 10.1021/acs.jmedchem.6b01684
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA EN9BQ
UT WOS:000396296100022
PM 28157311
DA 2022-11-30
ER

PT J
AU Tian, B
   Maidana, DE
   Dib, B
   Miller, JB
   Bouzika, P
   Miller, JW
   Vavvas, DG
   Lin, HJ
AF Tian, Bo
   Maidana, Daniel E.
   Dib, Bernard
   Miller, John B.
   Bouzika, Peggy
   Miller, Joan W.
   Vavvas, Demetrios G.
   Lin, Haijiang
TI miR-17-3p Exacerbates Oxidative Damage in Human Retinal Pigment
   Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID MITOCHONDRIAL SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; DOWN-REGULATION;
   MOUSE MODEL; STRESS; THIOREDOXIN; ANTIOXIDANT; LIGHT; SOD2; PHAGOCYTOSIS
AB Oxidative stress has been shown to contribute to the development of age-related macular degeneration (AMD). MicroRNAs (miRNA) are small non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression. We showed miR-17-3p to be elevated in macular RPE cells from AMD patients and in ARPE-19 cells under oxidative stress. Transfection of miR-17-3p mimic in ARPE-19 induced cell death and exacerbated oxidative lethality that was alleviated by miR-17-3p inhibitor. The expression of antioxidant enzymes manganese superoxide dismutase (MnSOD) and thioredoxin reductase-2 (TrxR(2)) were suppressed by miR-17-3p mimic and reversed by miR-17-3p inhibitor. These results suggest miR-17-3p aggravates oxidative damage-induced cell death in human RPE cells, while miR-17-3p inhibitor acts as a potential protector against oxidative stress by regulating the expression of antioxidant enzymes.
C1 [Tian, Bo; Maidana, Daniel E.; Dib, Bernard; Miller, John B.; Bouzika, Peggy; Miller, Joan W.; Vavvas, Demetrios G.; Lin, Haijiang] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Retina Serv, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02115 USA.
   [Tian, Bo] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou, Henan, Peoples R China.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Zhengzhou University
RP Vavvas, DG; Lin, HJ (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear Infirm, Retina Serv, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02115 USA.
EM Demetrios_Vavvas@meei.harvard.edu; Haijiang_Lin@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Lin, Haijiang/0000-0003-2931-468X; Vavvas,
   Demetrios/0000-0002-8622-6478; Dib, Bernard/0000-0001-8973-9503
FU NEI [R21EY023079-01A1, EY014104]; Yeatts Family Foundation; Loefflers
   Family Fund; Macula Society Research Grant award; Physician Scientist
   Award; research to prevent blindness foundation; Bayer Healthcare Global
   Ophthalmology Award; NATIONAL EYE INSTITUTE [P30EY014104, R21EY023079,
   R01EY025362] Funding Source: NIH RePORTER
FX This work was supported by: NEI R21EY023079-01A1 (DGV); the Yeatts
   Family Foundation (DGV, JWM); the Loefflers Family Fund (DGV, JWM); the
   2013 Macula Society Research Grant award (DGV); a Physician Scientist
   Award (DGV), an unrestricted grant (JWM) from the research to prevent
   blindness foundation; NEI grant EY014104 (Meei Core Grant); and Bayer
   Healthcare Global Ophthalmology Award (DEM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; This work was supported by: NEI
   R21EY023079-01A1 (DGV); the Yeatts Family Foundation (DGV, JWM); the
   Loefflers Family Fund (DGV, JWM); the 2013 Macula Society Research Grant
   award (DGV); a Physician Scientist Award (DGV), an unrestricted grant
   (JWM) from the research to prevent blindness foundation; NEI grant
   EY014104 (Meei Core Grant); and Bayer Healthcare Global Ophthalmology
   Award (DEM). The authors would like to thank Kassandra Kosmidou for
   proofreading this manuscript.
CR AKEO K, 1988, CURR EYE RES, V7, P961, DOI 10.3109/02713688809015141
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Chen JA, 2011, NEURON, V69, P721, DOI 10.1016/j.neuron.2011.01.014
   Curti V, 2014, MOL NUTR FOOD RES, V58, P1776, DOI 10.1002/mnfr.201400007
   DELVECCHIO PJ, 1991, CURR EYE RES, V10, P919, DOI 10.3109/02713689109020327
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1047
   Du WW, 2015, J CELL SCI, V128, P293, DOI 10.1242/jcs.158360
   Flores Lisa C, 2012, Longev Healthspan, V1, P4, DOI 10.1186/2046-2395-1-4
   Fukui M, 2010, FREE RADICAL BIO MED, V48, P821, DOI 10.1016/j.freeradbiomed.2009.12.024
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200
   Guo L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/168358
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Halbeisen RE, 2008, CELL MOL LIFE SCI, V65, P798, DOI 10.1007/s00018-007-7447-6
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Jiang X, 2011, CELL BIOCHEM FUNCT, V29, P164, DOI 10.1002/cbf.1728
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005
   Kucera O, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752506
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu T, 2013, DNA CELL BIOL, V32, P685, DOI 10.1089/dna.2013.2032
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsuoka A, 2010, J CLIN ENDOCR METAB, V95, pE291, DOI 10.1210/jc.2010-0619
   Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Myers CR, 2009, TOXICOLOGY, V257, P95, DOI 10.1016/j.tox.2008.12.013
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427
   OLIVER PD, 1992, INVEST OPHTH VIS SCI, V33, P1909
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Raisch J, 2013, WORLD J GASTROENTERO, V19, P2985, DOI 10.3748/wjg.v19.i20.2985
   Satoh J, 2015, BIOMARK INSIGHTS, V10, P21, DOI [10.4137/BMI.S25132, 10.4137/BMIMI.S25132]
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Stanley BA, 2011, J BIOL CHEM, V286, P33669, DOI 10.1074/jbc.M111.284612
   Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270
   Sugano E, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/185825
   Sugano E, 2013, CELL STRUCT FUNCT, V38, P81, DOI 10.1247/csf.12025
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Thomas M, 2013, INT J MOL SCI, V14, P12273, DOI 10.3390/ijms140612273
   Tripanichkul W, 2007, BRAIN RES, V1164, P24, DOI 10.1016/j.brainres.2007.05.076
   Vandenbroucke K, 2008, MOL BIOL EVOL, V25, P507, DOI 10.1093/molbev/msm276
   Wang JCC, 2015, MOL VIS, V21, P264
   WANG M, 1995, RES COMMUN MOL PATH, V89, P291
   Weigel AL, 2003, FREE RADICAL BIO MED, V35, P465, DOI 10.1016/S0891-5849(03)00320-4
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Xu YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011004
   Yildirim SS, 2013, CELL BIOCHEM BIOPHYS, V67, P1397, DOI 10.1007/s12013-013-9672-y
   Yin RT, 2013, J VASC RES, V50, P157, DOI 10.1159/000345697
   Yokoyama T, 2006, EXP EYE RES, V83, P602, DOI 10.1016/j.exer.2006.02.016
NR 75
TC 21
Z9 22
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 9
PY 2016
VL 11
IS 8
AR e0160887
DI 10.1371/journal.pone.0160887
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DT3IK
UT WOS:000381374200073
PM 27505139
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Luo, L
   Uehara, H
   Zhang, XH
   Das, SK
   Olsen, T
   Holt, D
   Simonis, JM
   Jackman, K
   Singh, N
   Miya, TR
   Huang, W
   Ahmed, F
   Bastos-Carvalho, A
   Le, YZ
   Mamalis, C
   Chiodo, VA
   Hauswirth, WW
   Baffi, J
   Lacal, PM
   Orecchia, A
   Ferrara, N
   Gao, GP
   Young-hee, K
   Fu, YB
   Owen, L
   Albuquerque, R
   Baehr, WG
   Thomas, K
   Li, DY
   Chalam, KV
   Shibuya, M
   Grisanti, S
   Wilson, DJ
   Ambati, J
   Ambati, BK
AF Luo, Ling
   Uehara, Hironori
   Zhang, Xiaohui
   Das, Subrata K.
   Olsen, Thomas
   Holt, Derick
   Simonis, Jacquelyn M.
   Jackman, Kyle
   Singh, Nirbhai
   Miya, Tadashi R.
   Huang, Wei
   Ahmed, Faisal
   Bastos-Carvalho, Ana
   Le, Yun Zheng
   Mamalis, Christina
   Chiodo, Vince A.
   Hauswirth, William W.
   Baffi, Judit
   Lacal, Pedro M.
   Orecchia, Angela
   Ferrara, Napoleone
   Gao, Guangping
   Young-hee, Kim
   Fu, Yingbin
   Owen, Leah
   Albuquerque, Romulo
   Baehr, Wolfgang
   Thomas, Kirk
   Li, Dean Y.
   Chalam, Kakarla V.
   Shibuya, Masabumi
   Grisanti, Salvatore
   Wilson, David J.
   Ambati, Jayakrishna
   Ambati, Balamurali K.
TI Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
SO ELIFE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; LONG-TERM
   EVALUATION; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; TYROSINE
   KINASE; TRANSGENIC MICE; GENE-THERAPY; MOUSE MODEL; ANGIOGENESIS
AB Optimal phototransduction requires separation of the avascular photoreceptor layer from the adjacent vascularized inner retina and choroid. Breakdown of peri-photoreceptor vascular demarcation leads to retinal angiomatous proliferation or choroidal neovascularization, two variants of vascular invasion of the photoreceptor layer in age-related macular degeneration (AMD), the leading cause of irreversible blindness in industrialized nations. Here we show that sFLT-1, an endogenous inhibitor of vascular endothelial growth factor A (VEGF-A), is synthesized by photoreceptors and retinal pigment epithelium (RPE), and is decreased in human AMD. Suppression of sFLT-1 by antibodies, adeno-associated virus-mediated RNA interference, or Cre/lox-mediated gene ablation either in the photoreceptor layer or RPE frees VEGF-A and abolishes photoreceptor avascularity. These findings help explain the vascular zoning of the retina, which is critical for vision, and advance two transgenic murine models of AMD with spontaneous vascular invasion early in life.
C1 [Luo, Ling; Uehara, Hironori; Zhang, Xiaohui; Das, Subrata K.; Olsen, Thomas; Holt, Derick; Simonis, Jacquelyn M.; Jackman, Kyle; Singh, Nirbhai; Miya, Tadashi R.; Huang, Wei; Ahmed, Faisal; Mamalis, Christina; Fu, Yingbin; Owen, Leah; Baehr, Wolfgang; Ambati, Balamurali K.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84108 USA.
   [Luo, Ling] PLA, Hosp 306, Beijing, Peoples R China.
   [Bastos-Carvalho, Ana; Baffi, Judit; Young-hee, Kim; Albuquerque, Romulo; Ambati, Jayakrishna] Univ Kentucky, Lexington, KY 40506 USA.
   [Le, Yun Zheng] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
   [Le, Yun Zheng] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Oklahoma Diabet Ctr, Oklahoma City, OK USA.
   [Chiodo, Vince A.; Hauswirth, William W.] Univ Florida, Gainesville, FL USA.
   [Lacal, Pedro M.] IRCCS, IDI, Oncol Mol Lab, Rome, Italy.
   [Orecchia, Angela] IRCCS, Ist Dermopat Immacolata, Lab Mol & Cell Biol, Rome, Italy.
   [Ferrara, Napoleone] Genentech Inc, Pharmaceut Res, San Francisco, CA USA.
   [Gao, Guangping] Univ Massachusetts, Sch Med, Gene Therapy Ctr, Worcester, MA USA.
   [Gao, Guangping; Thomas, Kirk; Li, Dean Y.] Univ Utah, Dept Internal Med, Div Cardiol, Salt Lake City, UT 84112 USA.
   [Chalam, Kakarla V.] Univ Florida, Dept Ophthalmol, Jacksonville, FL USA.
   [Shibuya, Masabumi] Jobu Univ, Inst Physiol & Med, Takasaki, Gunma, Japan.
   [Grisanti, Salvatore] Univ Lubeck, Lubeck, Germany.
   [Wilson, David J.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
C3 Utah System of Higher Education; University of Utah; University of
   Kentucky; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; State University System of Florida; University
   of Florida; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS
   Istituto Dermopatico dell'Immacolata (IDI); Roche Holding; Genentech;
   University of Massachusetts System; University of Massachusetts
   Worcester; Utah System of Higher Education; University of Utah; State
   University System of Florida; University of Florida; University of
   Lubeck; Oregon Health & Science University
RP Luo, L (通讯作者)，Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84108 USA.
EM luoling1208@gmail.com; bambati@gmail.com
RI Chalam, kakarla/K-7507-2019; Lacal, Pedro M/A-1481-2013
OI Lacal, Pedro M/0000-0003-1166-4593; Ahmed, Faisal/0000-0003-1294-5274;
   hauswirth, william/0000-0002-3244-4947; DAS,
   SUBRATA/0000-0001-8608-3270; Chalam, K V/0000-0002-0004-9416; Chalam,
   kakarla/0000-0001-9325-8665; Owen, Leah/0000-0003-3802-3868; zhang,
   xiaohui/0000-0001-7216-4256
FU American Diabetes Association [ADA 1-10-BS-94]; VA Merit Award; Beckman
   Initiative for Macular Research [1003]; Doris Duke Charitable
   Foundation; Burroughs Wellcome Fund; Ellison Medical Foundation;
   National Eye Institute [NEI R01EY022238, NEI R01EY020672]; Fundacao
   Calouste Gulbenkian; Fundacao Champalimaud; Ministerio da Saude;
   Fundacao para a Ciencia e Tecnologia, Portugal; National Natural Science
   Foundation of China [81271016]; NATIONAL CANCER INSTITUTE [R01CA163970]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008123,
   R01EY022238, P30EY014800, R01EY020900, P30EY021721, R01EY020672] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL084516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [P20GM104934] Funding Source: NIH RePORTER
FX American Diabetes Association ADA 1-10-BS-94 Yun Zheng Ler VA Merit
   Award Balamurali K Ambatir Beckman Initiative for Macular Research Grant
   1003 Balamurali K Ambatir Doris Duke Charitable Foundation Jayakrishna
   Ambatir Burroughs Wellcome Fund Jayakrishna Ambatir Ellison Medical
   Foundation Jayakrishna Ambatir National Eye Institute NEI R01EY022238
   Jayakrishna Ambatir National Eye Institute NEI R01EY020672 Jayakrishna
   Ambatir Programme for Advanced Medical Education sponsored by Fundacao
   Calouste Gulbenkian, Fundacao Champalimaud, Ministerio da Saude, and
   Fundacao para a Ciencia e Tecnologia, Portugal Ana Bastos-Carvalhor
   National Natural Science Foundation of China 81271016 Ling Luo
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Ahmad S, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-15
   Ambati BK, 2007, BRIT J OPHTHALMOL, V91, P505, DOI 10.1136/bjo.2006.107417
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   [Anonymous], 2007, NATURE, V449, P378, DOI 10.1038/449378a
   Baldwin ME, 2004, P AM ASS CANC RES, V45
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jin J, 2012, CELL, V151, P384, DOI 10.1016/j.cell.2012.08.037
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kjellstrom S, 2007, INVEST OPHTH VIS SCI, V48, P3837, DOI 10.1167/iovs.07-0203
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097
   Line BR, 2005, J NUCL MED, V46, P1552
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Malik AK, 2006, BLOOD, V107, P550, DOI 10.1182/blood-2005-05-2047
   Meier ID, 2010, FASEB J, V24, P1714, DOI 10.1096/fj.09-140749
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Ruggeri M, 2009, OPT EXPRESS, V17, P4074, DOI 10.1364/OE.17.004074
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401
   Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665
   Schmucker C, 2004, VISION RES, V44, P1857, DOI 10.1016/j.visres.2004.03.011
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037773
   Sun T, 2001, J EXP MED, V193, P699, DOI 10.1084/jem.193.6.699
   Tatar O, 2009, BRIT J OPHTHALMOL, V93, P159, DOI 10.1136/bjo.2008.138594
   Yang LQ, 2013, TOXICOL LETT, V218, P187, DOI 10.1016/j.toxlet.2013.01.026
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zhao S, 2010, PLACENTA, V31, P512, DOI 10.1016/j.placenta.2010.03.014
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 59
TC 61
Z9 68
U1 0
U2 7
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUN 18
PY 2013
VL 2
AR e00324
DI 10.7554/eLife.00324
PG 22
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 274PR
UT WOS:000328619000001
PM 23795287
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jiang, ZC
   Wang, LY
   Wu, QX
   Shao, YL
   Shen, MX
   Jiang, WP
   Dai, CX
AF Jiang, Zhencun
   Wang, Lingyang
   Wu, Qixin
   Shao, Yilei
   Shen, Meixiao
   Jiang, Wenping
   Dai, Cuixia
TI Computer-aided diagnosis of retinopathy based on vision transformer
SO JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES
LA English
DT Article
DE Vision transformer; OCT; image classification; retinopathy;
   computer-aided diagnosis; model pruning
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC MACULAR EDEMA; DEGENERATION AMD;
   IMAGE; CLASSIFICATION; PATHOGENESIS; DISEASES
AB Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) are two common retinal diseases for elder people that may ultimately cause irreversible blindness. Timely and accurate diagnosis is essential for the treatment of these diseases. In recent years, computer-aided diagnosis (CAD) has been deeply investigated and effectively used for rapid and early diagnosis. In this paper, we proposed a method of CAD using vision transformer to analyze optical coherence tomography (OCT) images and to automatically discriminate AMD, DME, and normal eyes. A classification accuracy of 99.69% was achieved. After the model pruning, the recognition time reached 0.010 s and the classification accuracy did not drop. Compared with the Convolutional Neural Network (CNN) image classification models (VGG16, Resnet50, Densenet121, and EfficientNet), vision transformer after pruning exhibited better recognition ability. Results show that vision transformer is an improved alternative to diagnose retinal diseases more accurately.
C1 [Jiang, Zhencun; Wang, Lingyang; Wu, Qixin; Jiang, Wenping; Dai, Cuixia] Shanghai Inst Technol, 100 Haiquan Rd, Shanghai 201418, Peoples R China.
   [Shao, Yilei; Shen, Meixiao] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Xueyuan Rd 270, Wenzhou 325027, Zhejiang, Peoples R China.
C3 Shanghai Institute of Technology; Wenzhou Medical University
RP Jiang, WP; Dai, CX (通讯作者)，Shanghai Inst Technol, 100 Haiquan Rd, Shanghai 201418, Peoples R China.
EM jiangwenping@sit.edu.cn; sdadai7412@163.com
OI jiang, zhencun/0000-0002-6066-4875
FU Science and Technology innovation project of Shanghai Science and
   Technology Commission [19441905800]; Natural National Science Foundation
   of China [62175156, 81827807, 8210041176, 82101177, 61675134]; State Key
   Laboratory of Ophthalmology, Optometry and Visual Science, Wenzhou
   Medical University [K181002]; Key R&D Program Projects in Zhejiang
   Province [2019C03045]
FX This work was supported by the Science and Technology innovation project
   of Shanghai Science and Technology Commission (19441905800), the Natural
   National Science Foundation of China (62175156, 81827807, 8210041176,
   82101177, 61675134), the Project of State Key Laboratory of
   Ophthalmology, Optometry and Visual Science, Wenzhou Medical University
   (K181002), and the Key R&D Program Projects in Zhejiang Province
   (2019C03045).
CR Bazi Y, 2021, REMOTE SENS-BASEL, V13, DOI 10.3390/rs13030516
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Dosovitskiy A., 2020, ARXIV201011929
   Du FX, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S1793545821400125
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Ibrahim MR, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10144716
   Jiang ZC, 2021, COMPUT ELECTRON AGR, V186, DOI 10.1016/j.compag.2021.106184
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Li HK, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S1793545821300019
   Lin YP, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S1793545821400058
   Luo YM, 2021, BIOMED OPT EXPRESS, V12, P2684, DOI 10.1364/BOE.418364
   Luo YM, 2021, J BIOPHOTONICS, V14, DOI 10.1002/jbio.202100015
   Mousavi E, 2020, IET IMAGE PROCESS, V14, P1571, DOI 10.1049/iet-ipr.2018.6186
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Paszke A, 2019, ADV NEUR IN, V32
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Potapenko I., 2021, ACTA OPHTHALMOL
   Qin N, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S1793545821400071
   Saratxaga CL, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11073119
   Shih FY, 2020, INT J PATTERN RECOGN, V34, DOI 10.1142/S0218001420520023
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Tan MX, 2019, PR MACH LEARN RES, V97
   Thomas A, 2021, COMPUT METH PROG BIO, V209, DOI 10.1016/j.cmpb.2021.106294
   Wang YS, 2019, IEEE I CONF COMP VIS, P322, DOI 10.1109/ICCV.2019.00041
   Wang ZH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6974215
   Wen-Ping J., 2021, FIRE SCI TECHNOL, V40, P109
   Yu Y, 2021, J INNOV OPT HEAL SCI, V14, DOI 10.1142/S179354582140006X
   Zhang Q, 2020, DIABET METAB SYND OB, V13, P4787, DOI 10.2147/DMSO.S288419
   Zhen-Cun J, 2021, FIRE SCI TECHNOL, V40, P375
   Zhu M., 2021, ARXIV210408500
NR 35
TC 1
Z9 1
U1 15
U2 24
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 1793-5458
EI 1793-7205
J9 J INNOV OPT HEAL SCI
JI J. Innov. Opt. Health Sci.
PD MAR
PY 2022
VL 15
IS 02
AR 2250009
DI 10.1142/S1793545822500092
PG 9
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA ZO9KK
UT WOS:000766045800007
OA gold
DA 2022-11-30
ER

PT J
AU Xu, XY
   Lee, K
   Zhang, L
   Sonka, M
   Abramoff, MD
AF Xu, Xiayu
   Lee, Kyungmoo
   Zhang, Li
   Sonka, Milan
   Abramoff, Michael D.
TI Stratified Sampling Voxel Classification for Segmentation of
   Intraretinal and Subretinal Fluid in Longitudinal Clinical OCT Data
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Age-related macular degeneration; class imbalance; intraretinal fluid;
   stratified sampling; subretinal fluid
ID OPTICAL COHERENCE TOMOGRAPHY; RETINA; IMAGES; STRATEGIES
AB Automated three-dimensional retinal fluid (named symptomatic exudate-associated derangements, SEAD) segmentation in 3D OCT volumes is of high interest in the improved management of neovascular Age Related Macular Degeneration (AMD). SEAD segmentation plays an important role in the treatment of neovascular AMD, but accurate segmentation is challenging because of the large diversity of SEAD size, location, and shape. Here a novel voxel classification based approach using a layer-dependent stratified sampling strategy was developed to address the class imbalance problem in SEAD detection. The method was validated on a set of 30 longitudinal 3D OCT scans from 10 patients who underwent anti-VEGF treatment. Two retinal specialists manually delineated all intraretinal and subretinal fluid. Leave-one-patient-out evaluation resulted in a true positive rate and true negative rate of 96% and 0.16% respectively. This method showed promise for image guided therapy of neovascular AMD treatment.
C1 [Xu, Xiayu] Xi An Jiao Tong Univ, Dept Life Sci & Technol, Xian 710049, Peoples R China.
   [Xu, Xiayu; Lee, Kyungmoo; Zhang, Li] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Sonka, Milan] Univ Iowa, Dept Ophthalmol & Visual Sci, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Sonka, Milan] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Ophthalmol & Visual Sci, Dept Biomed Engn, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] VA Med Ctr, Iowa City, IA 52246 USA.
C3 Xi'an Jiaotong University; University of Iowa; University of Iowa;
   University of Iowa; University of Iowa; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care
   System
RP Abramoff, MD (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Dept Biomed Engn, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
EM xiayuxu@mail.xjtu.edu.cn; michael-abramoff@uiowa.edu
RI Abramoff, Michael D/A-5836-2009
OI Abramoff, Michael D/0000-0002-3490-0037
FU National Institutes of Health [R01 EY018853, R01 EY019112, R01 EY017451,
   R01 EY016822, R01 EB004640]; Department of Veterans Affairs, Veterans
   Health Administration, Office of Research and Development [I01
   CX000119]; Research to Prevent Blindness, New York, NY; National Natural
   Science Foundation of China [81401480]; NATIONAL EYE INSTITUTE
   [R01EY016822, R01EY017451, R01EY018853, R01EY019112] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB004640] Funding Source: NIH RePORTER; Veterans Affairs
   [I01CX000119] Funding Source: NIH RePORTER
FX This material is based upon work supported in part by the National
   Institutes of Health grants R01 EY018853, R01 EY019112, R01 EY017451,
   R01 EY016822, and R01 EB004640; the Department of Veterans Affairs,
   Veterans Health Administration, Office of Research and Development Grant
   I01 CX000119; Research to Prevent Blindness, New York, NY. X. Xu was
   also supported by the National Natural Science Foundation of China
   (81401480).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Answers Corp, 2013, 4 KINDS SAMPL TECHN
   Arya S, 1998, J ACM, V45, P891, DOI 10.1145/293347.293348
   Barandela R, 2003, PATTERN RECOGN, V36, P849, DOI 10.1016/S0031-3203(02)00257-1
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Christopher M, 2012, RETINA, V0, P1
   Drexler W., 2001, NEW TECHNOL, V7
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Garcia V., 2007, 2 C ESP INF, P289
   Gargesha M, 2008, OPT EXPRESS, V16, P12313, DOI 10.1364/OE.16.012313
   Goncalves R. P., 2007, 4 S INT AGR PREC
   Henderson JM, 1999, ANNU REV PSYCHOL, V50, P243, DOI 10.1146/annurev.psych.50.1.243
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016/j.ajo.2006.04.023
   Knollova I, 2005, J VEG SCI, V16, P479, DOI 10.1111/j.1654-1103.2005.tb02388.x
   Lee K. Y., 2009, THESIS U IOWA IOWA C
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Sharma U, 2008, OPT EXPRESS, V16, P19712, DOI 10.1364/OE.16.019712
   Stumpf A, 2014, IEEE T GEOSCI REMOTE, V52, P2492, DOI 10.1109/TGRS.2013.2262052
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   Tsiotsios C, 2013, PATTERN RECOGN, V46, P1369, DOI 10.1016/j.patcog.2012.11.012
   Udupa JK, 2006, COMPUT MED IMAG GRAP, V30, P75, DOI 10.1016/j.compmedimag.2005.12.001
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Yu YJ, 2002, IEEE T IMAGE PROCESS, V11, P1260, DOI 10.1109/TIP.2002.804279
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 30
TC 57
Z9 58
U1 5
U2 27
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD JUL
PY 2015
VL 34
IS 7
BP 1616
EP 1623
DI 10.1109/TMI.2015.2408632
PG 8
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA CM3VX
UT WOS:000357614300017
PM 25769146
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Xu, CF
   Wang, J
AF Xu, Cong-fei
   Wang, Jun
TI Delivery systems for siRNA drug development in cancer therapy
SO ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Review
DE RNA interference; Cancer therapy; Delivery systems; siRNA
ID IN-VIVO DELIVERY; INTERFERING RNA DELIVERY; SYNTHETIC LETHAL THERAPY;
   CELL LUNG-CARCINOMA; TARGETED DELIVERY; MAMMALIAN-CELLS; DENDRITIC
   CELLS; NUCLEIC-ACID; MICELLAR NANOPARTICLES; PLA NANOPARTICLES
AB Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten years ago, it has become a promising drug target for the treatment of multiple diseases, including cancer. There have already been some successful applications of siRNA drugs in the treatment of age-related macular degeneration and respiratory syncytial virus infection. However, significant barriers still exist on the road to clinical applications of siRNA drugs, including poor cellular uptake, instability under physiological conditions, off-target effects and possible immunogenicity. The successful application of siRNA for cancer therapy requires the development of clinically suitable, safe and effective drug delivery systems. Herein, we review the design criteria for siRNA delivery systems and potential siRNA drug delivery systems for cancer therapy, including chemical modifications, lipid-based nanovectors, polymer-mediated delivery systems, conjugate delivery systems, and others. (C) 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All rights reserved.
C1 [Wang, Jun] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; University of Science &
   Technology of China, CAS
RP Wang, J (通讯作者)，Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
EM jwang699@ustc.edu.cn
RI Wang, Jun/F-9033-2011; Xu, Cong-Fei/I-8653-2014
OI Wang, Jun/0000-0001-9957-9208; Xu, Cong-Fei/0000-0002-6291-5711
CR Aigner A, 2007, CURR OPIN MOL THER, V9, P345
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85
   Aleku M, 2008, CANCER RES, V68, P9788, DOI 10.1158/0008-5472.CAN-08-2428
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9
   Bao YJ, 2013, PHARM RES-DORDR, V30, P342, DOI 10.1007/s11095-012-0874-6
   Barquinero J, 2004, GENE THER, V11, pS3, DOI 10.1038/sj.gt.3302363
   Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   Bellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774
   Cesarone G, BIOCONJUG CHEM
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Dande P, 2006, J MED CHEM, V49, P1624, DOI 10.1021/jm050822c
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Deleavey GF, 2012, CHEM BIOL, V19, P937, DOI 10.1016/j.chembiol.2012.07.011
   Dominska M, 2010, J CELL SCI, V123, P1183, DOI 10.1242/jcs.066399
   El-Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gonzalez H, 1999, BIOCONJUGATE CHEM, V10, P1068, DOI 10.1021/bc990072j
   Goodman RP, 2005, SCIENCE, V310, P1661, DOI 10.1126/science.1120367
   Grayson ACR, 2006, PHARM RES-DORDR, V23, P1868, DOI 10.1007/s11095-006-9009-2
   Hall AHS, 2004, NUCLEIC ACIDS RES, V32, P5991, DOI 10.1093/nar/gkh936
   Hayes ME, 2006, BBA-BIOMEMBRANES, V1758, P429, DOI 10.1016/j.bbamem.2006.03.020
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   Jarad G, 2009, CURR OPIN NEPHROL HY, V18, P226, DOI 10.1097/MNH.0b013e3283296044
   Jeong JH, 2009, BIOCONJUGATE CHEM, V20, P5, DOI 10.1021/bc800278e
   Jilek S, 2005, ADV DRUG DELIVER REV, V57, P377, DOI 10.1016/j.addr.2004.09.010
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Khoury M, 2006, ARTHRITIS RHEUM, V54, P1867, DOI 10.1002/art.21876
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Larson SD, 2007, SURGERY, V142, P262, DOI 10.1016/j.surg.2007.03.011
   Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604
   Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]
   Lin SY, 2012, BIOMACROMOLECULES, V13, P664, DOI 10.1021/bm201746t
   Liu XQ, 2012, MOL PHARMACEUT, V9, P2863, DOI 10.1021/mp300193f
   Luu YK, 2003, J CONTROL RELEASE, V89, P341, DOI 10.1016/S0168-3659(03)00097-X
   Malek A, 2009, TOXICOL APPL PHARM, V236, P97, DOI 10.1016/j.taap.2009.01.014
   Mao CQ, 2014, MOL THER, V22, P964, DOI 10.1038/mt.2014.18
   Mao CQ, 2011, BIOMATERIALS, V32, P3124, DOI 10.1016/j.biomaterials.2011.01.006
   Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161
   Martina MS, 2007, BIOMATERIALS, V28, P4143, DOI 10.1016/j.biomaterials.2007.05.025
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Navarro G, 2012, NANOMEDICINE-UK, V7, P65, DOI [10.2217/NNM.11.93, 10.2217/nnm.11.93]
   Navarro G, 2011, DRUG DELIV TRANSL RE, V1, P25, DOI 10.1007/s13346-010-0004-0
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Philipp A, 2009, BIOCONJUGATE CHEM, V20, P2055, DOI 10.1021/bc9001536
   RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Schultz N, 2011, Silence, V2, P1
   Shen H, 2012, CANCER GENE THER, V19, P367, DOI 10.1038/cgt.2012.22
   Shen S, 2014, MOL PHARMACEUT, V11, P2612, DOI 10.1021/mp400714z
   Shim MS, 2012, ADV DRUG DELIVER REV, V64, P1046, DOI 10.1016/j.addr.2012.01.018
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Strumberg D, 2012, INT J CLIN PHARM TH, V50, P76, DOI 10.5414/CPP50076
   Sun TM, 2008, BIOMATERIALS, V29, P4348, DOI 10.1016/j.biomaterials.2008.07.036
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   Vaishnaw Akshay K, 2010, Silence, V1, P14, DOI 10.1186/1758-907X-1-14
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van de Water FM, 2006, DRUG METAB DISPOS, V34, P1393, DOI 10.1124/dmd.106.009555
   Vandenbroucke RE, 2008, J GENE MED, V10, P783, DOI 10.1002/jgm.1202
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Wang X, 2009, CANCER RES TREAT, V41, P1, DOI 10.4143/crt.2009.41.1.1
   Wartiovaara J, 2004, J CLIN INVEST, V114, P1475, DOI 10.1172/JCI200422562
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Woodrow KA, NAT MAT
   Wu SY, 2009, AAPS J, V11, P639, DOI 10.1208/s12248-009-9140-1
   Xia CF, 2007, PHARM RES, V24, P2309, DOI 10.1007/s11095-007-9460-8
   Yang XZ, 2011, J CONTROL RELEASE, V156, P203, DOI 10.1016/j.jconrel.2011.07.035
   Yu B, 2009, AAPS J, V11, P195, DOI 10.1208/s12248-009-9096-1
   Zuhorn IS, 2002, BIOPHYS J, V83, P2096, DOI 10.1016/S0006-3495(02)73970-2
NR 99
TC 166
Z9 183
U1 21
U2 119
PU SHENYANG PHARMACEUTICAL UNIV
PI SHENYANG
PA SHENYANG PHARMACEUTICAL UNIV, NO 103, WENHUA RD, SHENYANG, 110016,
   PEOPLES R CHINA
SN 1818-0876
J9 ASIAN J PHARM SCI
JI Asian J. Pharm. Sci.
PD FEB
PY 2015
VL 10
IS 1
BP 1
EP 12
DI 10.1016/j.ajps.2014.08.011
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CY7GH
UT WOS:000366576100001
OA gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Fang, LY
   Li, ST
   Nie, Q
   Izatt, JA
   Toth, CA
   Farsiu, S
AF Fang, Leyuan
   Li, Shutao
   Nie, Qing
   Izatt, Joseph A.
   Toth, Cynthia A.
   Farsiu, Sina
TI Sparsity based denoising of spectral domain optical coherence tomography
   images
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID AUTOMATIC SEGMENTATION; KERNEL REGRESSION; NOISE-REDUCTION; SD-OCT;
   SPECKLE; REPRESENTATIONS; RECONSTRUCTION; DICTIONARIES; ACQUISITION;
   ALGORITHM
AB In this paper, we make contact with the field of compressive sensing and present a development and generalization of tools and results for reconstructing irregularly sampled tomographic data. In particular, we focus on denoising Spectral-Domain Optical Coherence Tomography (SDOCT) volumetric data. We take advantage of customized scanning patterns, in which, a selected number of B-scans are imaged at higher signal-to-noise ratio (SNR). We learn a sparse representation dictionary for each of these high-SNR images, and utilize such dictionaries to denoise the low-SNR B-scans. We name this method multiscale sparsity based tomographic denoising (MSBTD). We show the qualitative and quantitative superiority of the MSBTD algorithm compared to popular denoising algorithms on images from normal and age-related macular degeneration eyes of a multi-center clinical trial. We have made the corresponding data set and software freely available online. (c) 2012 Optical Society of America
C1 [Fang, Leyuan; Li, Shutao] Hunan Univ, Coll Elect & Informat Engn, Changsha 410082, Hunan, Peoples R China.
   [Fang, Leyuan; Nie, Qing; Izatt, Joseph A.; Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Izatt, Joseph A.; Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Nie, Qing] Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
C3 Hunan University; Duke University; Duke University; Beijing Institute of
   Technology
RP Fang, LY (通讯作者)，Hunan Univ, Coll Elect & Informat Engn, Changsha 410082, Hunan, Peoples R China.
EM leyuan.fang@duke.edu
RI Izatt, Joseph/C-9067-2014; Toth, Cynthia/L-5534-2019; toth, cynthia
   a/F-5614-2011
OI Izatt, Joseph/0000-0003-1993-2249; Toth, Cynthia/0000-0002-2324-0854;
   Farsiu, Sina/0000-0003-4872-2902
FU American Health Assistance Foundation; NIH [1R21EY021321-01A1]; National
   Natural Science Foundation of China [61172161]; Chinese Ministry of
   Education; Hunan University; NATIONAL EYE INSTITUTE [R21EY021321,
   P30EY005722] Funding Source: NIH RePORTER
FX This work was supported in part by a grant from the American Health
   Assistance Foundation, grants from the NIH 1R21EY021321-01A1, by
   Research to Prevent Blindness 2011 Duke's Unrestricted Grant award, by a
   grant from the National Natural Science Foundation of China (61172161),
   by the Scholarship Award for Excellent Doctoral Student granted by the
   Chinese Ministry of Education, and by the Fundamental Research Funds for
   the Central Universities, Hunan University. We thank the A2A Ancillary
   SDOCT Study sites for sharing this deidentified data.
CR Adler DC, 2004, OPT LETT, V29, P2878, DOI 10.1364/OL.29.002878
   Aharon M, 2006, IEEE T SIGNAL PROCES, V54, P4311, DOI 10.1109/TSP.2006.881199
   [Anonymous], 2008, AGE RELATED EYE DIS
   Bao P, 2003, IEEE T MED IMAGING, V22, P1089, DOI 10.1109/TMI.2003.816958
   Bruckstein AM, 2009, SIAM REV, V51, P34, DOI 10.1137/060657704
   Buades A, 2005, MULTISCALE MODEL SIM, V4, P490, DOI 10.1137/040616024
   Candes EJ, 2006, IEEE T INFORM THEORY, V52, P489, DOI 10.1109/TIT.2005.862083
   Chang SG, 2000, IEEE T IMAGE PROCESS, V9, P1532, DOI 10.1109/83.862633
   Chatterjee P, 2011, IEEE T IMAGE PROCESS, V20, P1221, DOI 10.1109/TIP.2010.2092440
   Chatterjee P, 2009, IEEE T IMAGE PROCESS, V18, P1438, DOI 10.1109/TIP.2009.2018575
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Chong GT, 2009, ARCH OPHTHALMOL-CHIC, V127, P37, DOI 10.1001/archophthalmol.2008.550
   Cincotti G, 2001, IEEE T MED IMAGING, V20, P764, DOI 10.1109/42.938244
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Daubechies I, 2004, COMMUN PUR APPL MATH, V57, P1413, DOI 10.1002/cpa.20042
   Daubechies I, 2010, COMMUN PUR APPL MATH, V63, P1, DOI 10.1002/cpa.20303
   Dong WS, 2011, IEEE I CONF COMP VIS, P1259, DOI 10.1109/ICCV.2011.6126377
   Dong WS, 2011, PROC CVPR IEEE, P457, DOI 10.1109/CVPR.2011.5995478
   Dong Weisheng, 2011, IEEE Trans Image Process, V20, P1838, DOI 10.1109/TIP.2011.2108306
   Dong Weisheng, SPARSITY BASED IMAGE
   Donoho DL, 2006, IEEE T INFORM THEORY, V52, P1289, DOI 10.1109/TIT.2006.871582
   Elad M, 2006, IEEE T IMAGE PROCESS, V15, P3736, DOI 10.1109/TIP.2006.881969
   Estrada R, 2011, BIOMED OPT EXPRESS, V2, P2871, DOI 10.1364/BOE.2.002871
   Farsiu S, 2006, PROC SPIE, V6077, DOI 10.1117/12.644391
   Farsiu S., 2006, P SOC PHOTO-OPT INS, V6077
   Farsiu S, 2007, APPL OPTICS, V46, P5805, DOI 10.1364/AO.46.005805
   Foi A, 2011, I S BIOMED IMAGING, P1809, DOI 10.1109/ISBI.2011.5872758
   Gargesha M, 2008, OPT EXPRESS, V16, P12313, DOI 10.1364/OE.16.012313
   Healy D, 2008, IEEE SIGNAL PROC MAG, V25, P67, DOI 10.1109/MSP.2007.914996
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ji SH, 2008, IEEE T SIGNAL PROCES, V56, P2346, DOI 10.1109/TSP.2007.914345
   Jian ZP, 2010, OPT EXPRESS, V18, P1024, DOI 10.1364/OE.18.001024
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Karamata B, 2005, J OPT SOC AM A, V22, P593, DOI 10.1364/JOSAA.22.000593
   Lebed E, 2010, OPT EXPRESS, V18, P21003, DOI 10.1364/OE.18.021003
   Li ST, 2012, IEEE T BIO-MED ENG, V59, P417, DOI 10.1109/TBME.2011.2173935
   Li ST, 2012, IEEE T INSTRUM MEAS, V61, P26, DOI 10.1109/TIM.2011.2157547
   Liu XA, 2010, OPT EXPRESS, V18, P22010, DOI 10.1364/OE.18.022010
   Luisier F, 2007, IEEE T IMAGE PROCESS, V16, P593, DOI 10.1109/TIP.2007.891064
   Mairal J, 2008, MULTISCALE MODEL SIM, V7, P214, DOI 10.1137/070697653
   Mairal J, 2008, IEEE T IMAGE PROCESS, V17, P53, DOI 10.1109/TIP.2007.911828
   Mayer MA, 2012, BIOMED OPT EXPRESS, V3, P572, DOI 10.1364/BOE.3.000572
   Mohan N., 2010, P SOC PHOTO-OPT INS, V7570
   Mohan N, 2010, PROC SPIE, V7570, DOI 10.1117/12.844217
   Neifeld MA, 2007, APPL OPTICS, V46, P5293, DOI 10.1364/AO.46.005293
   Ophir B, 2011, IEEE J-STSP, V5, P1014, DOI 10.1109/JSTSP.2011.2155032
   PATI YC, 1993, CONFERENCE RECORD OF THE TWENTY-SEVENTH ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS & COMPUTERS, VOLS 1 AND 2, P40, DOI 10.1109/ACSSC.1993.342465
   Portilla J, 2001, 2001 INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, VOL II, PROCEEDINGS, P37, DOI 10.1109/ICIP.2001.958418
   Robinson F. S., 2010, SUPER RESOLUTION IMA, P383
   Robinson MD, 2010, IEEE T IMAGE PROCESS, V19, P2669, DOI 10.1109/TIP.2010.2050107
   Rubinstein R, 2010, IEEE T SIGNAL PROCES, V58, P1553, DOI 10.1109/TSP.2009.2036477
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Scott AW, 2009, AM J OPHTHALMOL, V147, P364, DOI 10.1016/j.ajo.2008.08.010
   Takeda H, 2006, IEEE IMAGE PROC, P1257, DOI 10.1109/ICIP.2006.312573
   Takeda H, 2007, IEEE T IMAGE PROCESS, V16, P349, DOI 10.1109/TIP.2006.888330
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Willett RM, 2011, OPT ENG, V50, DOI 10.1117/1.3596602
   Wong A, 2010, OPT EXPRESS, V18, P8338, DOI 10.1364/OE.18.008338
   Wright SJ, 2009, IEEE T SIGNAL PROCES, V57, P2479, DOI 10.1109/TSP.2009.2016892
   Young M, 2011, BIOMED OPT EXPRESS, V2, P2690, DOI 10.1364/BOE.2.002690
NR 62
TC 170
Z9 177
U1 3
U2 48
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAY 1
PY 2012
VL 3
IS 5
BP 927
EP 942
DI 10.1364/BOE.3.000927
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 935RH
UT WOS:000303537400010
PM 22567586
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xu, JW
   Tu, YY
   Wang, Y
   Xu, X
   Sun, XD
   Xie, LQ
   Zhao, QL
   Guo, Y
   Gu, YH
   Du, JX
   Du, S
   Zhu, MH
   Song, E
AF Xu, Jiaowen
   Tu, Yuanyuan
   Wang, Ying
   Xu, Xun
   Sun, Xiaodong
   Xie, Laiqing
   Zhao, Qingliang
   Guo, Yang
   Gu, Yonghui
   Du, Jingxia
   Du, Shu
   Zhu, Manhui
   Song, E.
TI Prodrug of epigallocatechin-3-gallate alleviates choroidal
   neovascularization via down-regulating HIF-1 alpha/VEGF/VEGFR2 pathway
   and M1 type macrophage/microglia polarization
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Prodrug of epigallocatechin-3-gallate (pro-EGCG); Age-related macular
   degeneration (AMD); Choroidal neovascularization (CNV); HIF-1
   alpha/VEGF/VEGFR2 pathway; M1-type macrophages/microglia
ID OCULAR NEOVASCULARIZATION; OXIDATIVE STRESS; PRO-EGCG; EXPRESSION; VEGF;
   GROWTH; ANGIOGENESIS; ACTIVATION; INTERLEUKIN-6; INFLAMMATION
AB Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly and is attributed to choroidal neovascularization (CNV), which is a feature of wet AMD. The hypoxia-inducible factor-1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway contributes to the pathogenesis of CNV. M1-type macrophages/microglia secrete interleukin-6 (IL-6) and tumor necrosis factor a (TNF-alpha), facilitating the development of CNV. Epigallocatechin-3-gallate (EGCG) is a kind of polyphenol in green tea that exerts anti-inflammatory and antiangiogenic effects. In this study, a prodrug of EGCG (pro-EGCG) alleviated mouse laser-induced CNV leakage and reduced CNV area by down-regulating HIF-1 alpha/VEGF/VEGFR2 pathway; M1-type macrophage/microglia polarization; as well as endothelial cell viability, proliferation, migration and tube formation, indicating a novel potential therapy for AMD.
C1 [Xu, Jiaowen; Xie, Laiqing; Guo, Yang; Du, Jingxia] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China.
   [Tu, Yuanyuan; Wang, Ying; Zhao, Qingliang; Du, Shu; Zhu, Manhui; Song, E.] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
   [Wang, Ying; Gu, Yonghui] Nanjing Med Univ, Suzhou Municipal Hosp, Dept Ophthalmol, Affiliated Suzhou Hosp, Suzhou, Jiangsu, Peoples R China.
   [Xu, Xun; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Xu, Xun; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Soochow University - China; Soochow University - China; Nanjing Medical
   University; Shanghai Jiao Tong University
RP Zhu, MH; Song, E (通讯作者)，Soochow Univ, Lixiang Eye Hosp, Suzhou, Jiangsu, Peoples R China.
EM zhumanhui@suda.edu.cn; songe@suda.edu.cn
RI 涂, 园园/AGE-3991-2022
FU Jiangsu Distinguished Medical Experts Program [2016]; Gusu Health
   Leading Talent Plan [025]; Suzhou Science and Technology Bureau
   [SYS2018004, SYS2018005]; Suzhou Commission of Health and Family
   Planning [KJXW2018076]
FX The study was supported by the Jiangsu Distinguished Medical Experts
   Program (No. 2016), the Gusu Health Leading Talent Plan (Grant No. 025),
   the Suzhou Science and Technology Bureau (Nos. SYS2018004 and
   SYS2018005) and the Suzhou Commission of Health and Family Planning (No.
   KJXW2018076).
CR Amadio M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8476164
   Bashir S, 2016, INFLAMM RES, V65, P1, DOI 10.1007/s00011-015-0874-1
   Chu KO, 2015, J NUTR BIOCHEM, V26, P1357, DOI 10.1016/j.jnutbio.2015.07.001
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ghasemi H, 2018, OCUL IMMUNOL INFLAMM, V26, P37, DOI 10.1080/09273948.2016.1277247
   He L, 2013, CANCER CHEMOTH PHARM, V71, P713, DOI 10.1007/s00280-012-2063-z
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jantan I, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00655
   Jiang YD, 2017, P NATL ACAD SCI USA, V114, P10737, DOI 10.1073/pnas.1706394114
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Kleiner J, 2018, MOL VIS, V24, P647
   Kumar R, 2019, BIOGERONTOLOGY, V20, P171, DOI 10.1007/s10522-018-9785-1
   Lam WH, 2004, BIOORGAN MED CHEM, V12, P5587, DOI 10.1016/j.bmc.2004.08.002
   Li F, 2018, EXPERT OPIN DRUG DIS, V13, P643, DOI 10.1080/17460441.2018.1465923
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821
   Luo HQ, 2014, J BUON, V19, P435
   Mi YS, 2018, FOOD FUNCT, V9, P1510, DOI 10.1039/c7fo01554b
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Niu YC, 2013, AGING CELL, V12, P1041, DOI 10.1111/acel.12133
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Reich S, 2003, MOL VIS, V9, P210
   Sasore T, 2014, ADV EXP MED BIOL, V801, P805, DOI 10.1007/978-1-4614-3209-8_101
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Vadlapatla RK, 2014, EYE, V28, P93, DOI 10.1038/eye.2013.240
   Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4
   Wang JZ, 2018, CANCER LETT, V412, P10, DOI 10.1016/j.canlet.2017.09.054
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Yang HJ, 2010, CANCER LETT, V292, P48, DOI 10.1016/j.canlet.2009.11.006
   Yang ZH, 2014, AM J PATHOL, V184, P1230, DOI 10.1016/j.ajpath.2013.12.023
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Zhang Q, 2019, CYTOKINE, V113, P238, DOI 10.1016/j.cyto.2018.07.011
   Zhou W, 2019, NEUROREPORT, V30, P60, DOI 10.1097/WNR.0000000000001149
NR 40
TC 17
Z9 20
U1 3
U2 18
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2020
VL 121
AR 109606
DI 10.1016/j.biopha.2019.109606
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JT1GJ
UT WOS:000500746200068
PM 31743875
OA gold
DA 2022-11-30
ER

PT J
AU Choudhary, M
   Malek, G
AF Choudhary, Mayur
   Malek, Goldis
TI Rethinking Nuclear Receptors as Potential Therapeutic Targets for
   Retinal Diseases
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Review
DE nuclear receptors; retinal diseases; age-related macular degeneration;
   diabetic retinopathy; retinitis pigmentosa
ID DIABETIC MACULAR EDEMA; BASAL LINEAR DEPOSIT; PPAR-GAMMA LIGANDS; LIVER
   X RECEPTORS; NF-KAPPA-B; LIPID-METABOLISM; PHOTORECEPTOR DEVELOPMENT;
   RETINITIS-PIGMENTOSA; INDUCED CYTOTOXICITY; OXIDATIVE STRESS
AB Collectively, retinal diseases, including age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy, result in severe vision impairment worldwide. The absence and/or limited availability of successful drug therapies for these blinding disorders necessitates further understanding their pathobiology and identifying new targetable signaling pathways. Nuclear receptors are transcription regulators of many key aspects of human physiology, as well as pathophysiology, with reported roles in development, aging, and disease. Some of the pathways regulated by nuclear receptors include, but are not limited to, angiogenesis, inflammation, and lipid metabolic dysregulation, mechanisms also important in the initiation and development of several retinal diseases. Herein, we present an overview of the biology of three diseases affecting the posterior eye, summarize a growing body of evidence that suggests direct or indirect involvement of nuclear receptors in disease progression, and discuss the therapeutic potential of targeting nuclear receptors for treatment.
C1 [Choudhary, Mayur; Malek, Goldis] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
EM gmalek@duke.edu
RI Choudhary, Mayur/AAU-3497-2021
OI Choudhary, Mayur/0000-0001-8056-011X; Malek, Goldis/0000-0003-0026-2388
FU National Eye Institute [NEI EY02868]; Brightfocus Foundation for Macular
   Degeneration Research; Edward N. & Della L. Thome Memorial Foundation
   AMD Research Award; NEI [NEI P30 EY005722]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [R01EY020868, P30EY005722] Funding
   Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: Goldis Malek
   is the recipient of funding from the National Eye Institute (NEI
   EY02868), the Brightfocus Foundation for Macular Degeneration Research,
   and the Edward N. & Della L. Thome Memorial Foundation AMD Research
   Award. Additional funds come from an unrestricted Research to Prevent
   Blindness award and NEI core grant (NEI P30 EY005722) to the Department
   of Ophthalmology at Duke University.
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ammann F, 1965, J Neurol Sci, V2, P183, DOI 10.1016/0022-510X(65)90079-1
   Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060
   Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758
   Baranowski M, 2008, J PHYSIOL PHARMACOL, V59, P31
   Baumgartner WA, 2000, MED HYPOTHESES, V54, P814, DOI 10.1054/mehy.1999.0957
   Ayala-Pena VB, 2016, BBA-MOL CELL RES, V1863, P1134, DOI 10.1016/j.bbamcr.2016.02.010
   Berka JLW, 2009, CIRC RES, V104, P124, DOI 10.1161/CIRCRESAHA.108.176008
   Bernardo A, 2005, J NEUROCHEM, V92, P895, DOI 10.1111/j.1471-4159.2004.02932.x
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bishop-Bailey D, 2008, PPAR RES, V2008, DOI 10.1155/2008/825970
   Bitsch F, 2003, ANAL BIOCHEM, V323, P139, DOI 10.1016/j.ab.2003.08.029
   Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341
   BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223
   BURDITT AF, 1968, Q J MED, V37, P303
   Capozzi ME, 2013, INVEST OPHTH VIS SCI, V54, P4197, DOI 10.1167/iovs.13-11608
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Choudhary M, 2016, ADV EXP MED BIOL, V854, P45, DOI 10.1007/978-3-319-17121-0_7
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421
   Coppieters F, 2007, AM J HUM GENET, V81, P147, DOI 10.1086/518426
   Costa V, 2012, BRIT J PHARMACOL, V165, P1, DOI 10.1111/j.1476-5381.2011.01443.x
   Cruz NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087942
   Cui GL, 2011, J CLIN INVEST, V121, P658, DOI 10.1172/JCI42974
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Del V. C. M., 2008, PPAR RES, V2008
   Della-Morte D, 2014, PHARMACOGENOMICS, V15, P2063, DOI [10.2217/PGS.14.162, 10.2217/pgs.14.162]
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195
   EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939
   Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012
   Forrest D, 2012, MOL ENDOCRINOL, V26, P905, DOI 10.1210/me.2012-1010
   Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040
   Genuth S, 2001, J PEDIATR-US, V139, P804, DOI 10.1067/mpd.2001.118887
   Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689
   Gomez-Duran A, 2009, BIOCHEM PHARMACOL, V77, P700, DOI 10.1016/j.bcp.2008.08.032
   Graham TL, 2005, ATHEROSCLEROSIS, V181, P29, DOI 10.1016/j.atherosclerosis.2004.12.028
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551
   Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Haider NB, 2009, EXP EYE RES, V89, P365, DOI 10.1016/j.exer.2009.04.006
   Haim Marianne, 2002, Acta Ophthalmol Scand Suppl, P1
   Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hatanaka H, 2012, INVEST OPHTH VIS SCI, V53, P6955, DOI 10.1167/iovs.12-10488
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Hindinger C, 2006, J NEUROSCI RES, V84, P1225, DOI 10.1002/jnr.21038
   HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Ishimura R, 2009, BIOCHEM PHARMACOL, V77, P660, DOI 10.1016/j.bcp.2008.10.030
   Ito A, 2015, ELIFE, V4, DOI 10.7554/eLife.08009
   John SK, 2000, MOL VIS, V6, P204
   Kim EK, 2007, INT J BIOCHEM CELL B, V39, P1260, DOI 10.1016/j.biocel.2007.04.005
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814
   Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Lee SD, 2015, ATHEROSCLEROSIS, V242, P29, DOI 10.1016/j.atherosclerosis.2015.06.042
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2012, J DIGEST DIS, V13, P69, DOI 10.1111/j.1751-2980.2011.00554.x
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Luquet S, 2005, BBA-MOL BASIS DIS, V1740, P313, DOI 10.1016/j.bbadis.2004.11.011
   Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Malek G, 2014, ADV EXP MED BIOL, V801, P317, DOI 10.1007/978-1-4614-3209-8_40
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306
   Qin Q, 2013, J OCUL PHARMACOL TH, V29, P298, DOI 10.1089/jop.2012.0135
   Racke MK, 2006, J NUTR, V136, P700, DOI 10.1093/jn/136.3.700
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rodrigues GA, 2011, INVEST OPHTH VIS SCI, V52, P890, DOI 10.1167/iovs.10-5715
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Ruta LM, 2013, DIABETIC MED, V30, P387, DOI 10.1111/dme.12119
   Schnegg CI, 2011, PPAR RES, V2011, DOI 10.1155/2011/373560
   Scoditti E, 2010, CARDIOVASC RES, V86, P302, DOI 10.1093/cvr/cvp400
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sever R, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016709
   Shearer BG, 2008, MOL ENDOCRINOL, V22, P523, DOI 10.1210/me.2007-0190
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Sohrab MA, 2011, SEMIN OPHTHALMOL, V26, P156, DOI 10.3109/08820538.2011.570848
   Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075
   Song MK, 2012, BRIT J PHARMACOL, V165, P4, DOI 10.1111/j.1476-5381.2011.01411.x
   Sonoda J, 2008, FEBS LETT, V582, P2, DOI 10.1016/j.febslet.2007.11.016
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Suarez S, 2014, INVEST OPHTH VIS SCI, V55, P8232, DOI 10.1167/iovs.14-14217
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Sung BY, 2006, EXP GERONTOL, V41, P590, DOI 10.1016/j.exger.2006.04.005
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Tata JR, 2002, NAT REV MOL CELL BIO, V3, P702, DOI 10.1038/nrm914
   Uchimura K, 2001, HEPATOLOGY, V33, P91, DOI 10.1053/jhep.2001.21145
   Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P69
   Wan TT, 2015, BIOMED PHARMACOTHER, V74, P145, DOI 10.1016/j.biopha.2015.08.002
   Wang YY, 2009, SHOCK, V32, P548, DOI 10.1097/SHK.0b013e3181a47f85
   Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006
   Wenick AS, 2012, MIDDLE EAST AFR J OP, V19, P4, DOI 10.4103/0974-9233.92110
   Wert KJ, 2014, DEV OPHTHALMOL, V53, P33, DOI 10.1159/000357294
   Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Winterfield L, 2003, CLIN DERMATOL, V21, P447, DOI 10.1016/j.clindermatol.2003.08.011
   Witkin AJ, 2011, CURR OPIN OPHTHALMOL, V22, P185, DOI 10.1097/ICU.0b013e3283459724
   Wolkenberg SE, 2006, BIOORG MED CHEM LETT, V16, P5001, DOI 10.1016/j.bmcl.2006.07.056
   Wong A, 2001, EUR J NEUROSCI, V14, P1961, DOI 10.1046/j.0953-816x.2001.01820.x
   Wright Alan F, 2004, Hum Mutat, V24, P439, DOI 10.1002/humu.9285
   Wu DL, 2011, ARTERIOSCL THROM VAS, V31, P1260, DOI 10.1161/ATVBAHA.110.220202
   Wu GF, 2003, AM J PHYSIOL-HEART C, V285, pH2420, DOI 10.1152/ajpheart.00187.2003
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 130
TC 8
Z9 8
U1 0
U2 21
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
EI 1552-454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD DEC
PY 2016
VL 21
IS 10
BP 1007
EP 1018
DI 10.1177/1087057116659856
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA EB9MW
UT WOS:000387720200001
PM 27455994
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Moult, E
   Choi, WJ
   Waheed, NK
   Adhi, M
   Lee, BK
   Lu, CD
   Jayaraman, V
   Potsaid, B
   Rosenfeld, PJ
   Duker, JS
   Fujimoto, JG
AF Moult, Eric
   Choi, WooJhon
   Waheed, Nadia K.
   Adhi, Mehreen
   Lee, ByungKun
   Lu, Chen D.
   Jayaraman, Vijaysekhar
   Potsaid, Benjamin
   Rosenfeld, Philip J.
   Duker, Jay S.
   Fujimoto, James G.
TI Ultrahigh-Speed Swept-Source OCT Angiography in Exudative AMD
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; HUMAN RETINA; BLOOD-FLOW; RANIBIZUMAB;
   CHORIOCAPILLARIS; EYES; THICKNESS; RPE
AB BACKGROUND AND OBJECTIVE: To investigate the potential of ultrahigh-speed swept-source optical coherence tomography angiography (OCTA) to visualize retinal and choroidal vascular changes in patients with exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Observational, prospective cross-sectional study. An ultrahigh-speed swept-source prototype was used to perform OCTA of the retinal and choriocapillaris microvasculature in 63 eyes of 32 healthy controls and 19 eyes of 15 patients with exudative AMD. Main outcome measure: qualitative comparison of the retinal and choriocapillaris microvasculature in the two groups.
   RESULTS: Choroidal neovascularization (CNV) was clearly visualized in 16 of the 19 eyes with exudative AMD, located above regions of severe choriocapillaris alteration. In 14 of these eyes, the CNV lesions were surrounded by regions of choriocapillaris alteration.
   CONCLUSION: OCTA may offer noninvasive monitoring of the retinal and choriocapillaris microvasculature in patients with CNV, which may assist in diagnosis and monitoring.
C1 [Moult, Eric; Choi, WooJhon; Lee, ByungKun; Lu, Chen D.; Potsaid, Benjamin; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Moult, Eric; Choi, WooJhon; Lee, ByungKun; Lu, Chen D.; Potsaid, Benjamin; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Moult, Eric] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
   [Waheed, Nadia K.; Adhi, Mehreen; Duker, Jay S.] Tufts Univ, Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Jayaraman, Vijaysekhar] Praevium Res, Santa Barbara, CA USA.
   [Potsaid, Benjamin] Thorlabs, Adv Imaging Grp, Newton, NJ USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT); Harvard University; Tufts University; Bascom Palmer
   Eye Institute; University of Miami
RP Fujimoto, JG (通讯作者)，MIT, Room 36-361,77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI Jayaraman, Vijaysekhar/GLR-7595-2022; Moult, Eric/G-1099-2017; Adhi,
   Mehreen/AAS-9733-2021
OI Moult, Eric/0000-0003-3859-3094; 
FU Carl Zeiss Meditec; NATIONAL EYE INSTITUTE [R01EY011289] Funding Source:
   NIH RePORTER
FX Dr. Duker is a consultant for Carl Zeiss Meditec and Optovue and has
   stock in Hemera Biosciences, EyeNetra, and Ophthotech. Dr. Fujimoto has
   received royalties from intellectual property owned by Massachusetts
   Institute of Technology and licensed to Carl Zeiss Meditec and Optovue
   and has stock options with Optovue. Dr. Rosenfeld has received research
   support from Carl Zeiss Meditec. The remaining authors have no financial
   or proprietary interest in the materials presented herein.
CR Albert DM, 2008, ALBERT JAKOBIECS PRI, V3rd
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Choi W, 2013, OPT LETT, V38, P338, DOI 10.1364/OL.38.000338
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   Guizar-Sicairos M, 2008, OPT LETT, V33, P156, DOI 10.1364/OL.33.000156
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jonathan E, 2011, P SOC PHOTO-OPT INS, V7898, P1
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lavik EB, 2013, DRUG DELIV, V1, P734
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tao YK, 2008, OPT EXPRESS, V16, P12350, DOI 10.1364/OE.16.012350
   Vakoc BJ, 2009, NAT MED, V15, P1219, DOI 10.1038/nm.1971
   Yu LF, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302806
   Zhu L, 2006, J BIOMECH ENG-T ASME, V128, P203, DOI 10.1115/1.2165692
NR 41
TC 187
Z9 196
U1 0
U2 20
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2014
VL 45
IS 6
BP 496
EP 505
DI 10.3928/23258160-20141118-03
PG 10
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0PQ
UT WOS:000347299300003
PM 25423628
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, J
   Jin, HL
   Jang, DS
   Jeong, KW
   Choung, SY
AF Kim, Jun
   Jin, Hong Lan
   Jang, Dae Sik
   Jeong, Kwang Won
   Choung, Se-Young
TI Hyperoside (quercetin-3-O-beta-D-galactopyranoside) protects A2E-laden
   retinal pigmented epithelium cells against UVA and blue light-induced
   apoptosis in vitro and in vivo
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Hyperoside; A2E; UVA exposure; Blue light exposure; Age-related macular
   degeneration; ARPE-19 cells
ID MACULAR DEGENERATION; OXIDATIVE STRESS; INDUCED DAMAGE; MICE LEADS; A549
   CELLS; EXPRESSION; LIPOFUSCIN; LUTEIN; INVOLVEMENT; RPE
AB Age-related macular degeneration is associated with the degeneration of photoreceptors and retinal pigmented epithelial (RPE) cells in the macular. We, previously, demonstrated the protective effect of hyperoside on RPE cell death. In this study, hyperoside inhibited A2E accumulation and UVA and blue light (BL) induced cell death in RPE cells. Hyperoside exhibited inhibitory effects on AP-1 and NF-kB activities, determined by luciferase assay. BL induced complement C3 activation and poly ADP-ribose polymerase (PARP) cleavage were inhibited by hyperoside treatment in A2E laden RPE cells. Furthermore, expression of AhR target genes (CYP1A1 and CYP1B1) were upregulated by hyperoside treatment. Finally, hyperoside prevented UVA and BL-induced photoreceptor degeneration in the Balb-c mice. The outer nuclear layer thickness, counts and retinal layer folds were ameliorated by hyperoside treatment. The results suggest that hyperoside could be a potential application to prevent the onset and development of AMD.
C1 [Kim, Jun; Jang, Dae Sik; Choung, Se-Young] Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Jin, Hong Lan; Jeong, Kwang Won] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, 191 Hambakmoero, Incheon 21936, South Korea.
C3 Kyung Hee University; Gachon University
RP Choung, SY (通讯作者)，Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Jeong, KW (通讯作者)，Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, 191 Hambakmoero, Incheon 21936, South Korea.
EM kwjeong@gachon.ac.kr; sychoung@khu.ac.kr
RI Jang, Dae Sik/AAI-4526-2020; Choung, Young/AAH-9208-2020
FU Technology Innovation Industrial Program - Ministry of Trade, Industry
   and Energy (MOTE, Korea) [10048028]; Korea Evaluation Institute of
   Industrial Technology (KEIT)
FX This study was supported by the Technology Innovation Industrial Program
   (10048028) funded by the Ministry of Trade, Industry and Energy (MOTE,
   Korea) & Korea Evaluation Institute of Industrial Technology (KEIT).
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Amault E., 2013, PLOS ONE, V8
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Chan CM, 2008, MOL VIS, V14, P2528
   Chang HM, 2015, J CHIN MED ASSOC, V78, P169, DOI 10.1016/j.jcma.2014.08.017
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corbiere V, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-15
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Feng M, 2012, INT J OPHTHALMOL-CHI, V5, P151, DOI 10.3980/j.issn.2222-3959.2012.02.07
   Fontaine V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167793
   Guerrini L, 1996, FEBS LETT, V393, P69, DOI 10.1016/0014-5793(96)00854-X
   GUTIERREZ MA, 2016, SCI REP UK, V6
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Kim SJ, 2011, AM J CHINESE MED, V39, P171, DOI 10.1142/S0192415X11008737
   Ku SK, 2014, ANIM CELLS SYST, V18, P204, DOI 10.1080/19768354.2014.925970
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Liu L, 2009, MOL VIS, V15, P2938
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   McMenamin PG, 2016, INVEST OPHTH VIS SCI, V57, P6513, DOI 10.1167/iovs.16-19928
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Murthy RK, 2014, CUTAN OCUL TOXICOL, V33, P132, DOI 10.3109/15569527.2013.812108
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Patil RH, 2015, MOL CELL BIOCHEM, V403, P95, DOI 10.1007/s11010-015-2340-3
   Pereira C, 2012, QUIM NOVA, V35, P1123, DOI 10.1590/S0100-40422012000600010
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167
   Reeves PG, 1997, J NUTR, V127, pS838
   Sahu A., 2012, UCSD MOL PAGES, V1
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Wang WY, 2016, TRENDS FOOD SCI TECH, V56, P21, DOI 10.1016/j.tifs.2016.07.004
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Yuning G. L. Y, 2001, CHINESE J INFORM TCM, V11
   Zhang JS, 2016, J NAT MED-TOKYO, V70, P740, DOI 10.1007/s11418-016-1007-z
   Zhang J, 2015, J CHROMATOGR B, V995, P1, DOI 10.1016/j.jchromb.2015.04.038
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 53
TC 7
Z9 7
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JAN
PY 2018
VL 40
BP 426
EP 437
DI 10.1016/j.jff.2017.11.021
PG 12
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA GA0LW
UT WOS:000428005500045
DA 2022-11-30
ER

PT J
AU Cullen, AP
AF Cullen, Anthony P.
TI Ozone Depletion and Solar Ultraviolet Radiation: Ocular Effects, a
   United Nations Environment Programme Perspective
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Review
DE Ozone depletion; Climate change; Ultraviolet radiation;
   Ophthalmohelioses; Eye protection
ID UVEAL MELANOMA; INDUCED CATARACT; HOST FACTORS; EXPOSURE; RISK
AB Purpose: To describe he role played by the United Nations Environmental Effects Panel with respect to the ocular effects of stratospheric ozone depletion and present the essence of the Health Chapter of the 2010 Assessment.
   Methods: A consideration of solar ultraviolet radiation (UVR) at the Earth's surface as it is affected by atmospheric changes and how these influence sunlight-related eye diseases. A review of the current Assessment with emphasis on pterygium, cataract, ocular melanoma, and age-related macular degeneration.
   Results: Although the ozone layer is projected to recover slowly in the coming decades, continuing vigilance is required regarding exposure to the sun. Evidence implicating solar UVR, especially UVB, in every tissue of the eye continues to be amassed.
   Conclusion: The need for ocular UV protection existed before the discovery of the depletion of the ozone layer and will continue even when the layer fully recovers in approximately 2100.
C1 Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
C3 University of Waterloo
RP Cullen, AP (通讯作者)，Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
EM acullen@uwaterloo.ca
CR BARKER FM, 1991, 7853450090 US FDA RA
   CULLEN AP, 2005, REV OPTOM, V142, P17
   CULLEN AP, 2004, CLIN CONTACT LENS PR, P881
   Dong XQ, 2003, INVEST OPHTH VIS SCI, V44, P1150, DOI 10.1167/iovs.02-0541
   FARMAN JC, 1985, NATURE, V315, P207, DOI 10.1038/315207a0
   HOLLY EA, 1990, CANCER RES, V50, P5773
   Michael R, 1998, GRAEF ARCH CLIN EXP, V236, P625, DOI 10.1007/s004170050132
   Michael Ralph, 2000, Ophthalmic Research, V32, P1, DOI 10.1159/000055633
   Norval M, 2011, PHOTOCH PHOTOBIO SCI, V10, P199, DOI 10.1039/c0pp90044c
   Oriowo OM, 2001, INVEST OPHTH VIS SCI, V42, P2596
   Schmidt-Pokrzywniak A, 2009, OPHTHALMOLOGY, V116, P340, DOI 10.1016/j.ophtha.2008.09.040
   SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031
   SLINEY DH, 1986, INVEST OPHTH VIS SCI, V27, P781
   *UN ENV PROGR ENV, 2008, ENV EFF OZ DEPL ITS
   *UN ENV PROGR ENV, 2003, ENV EFF OZ DEPL ITS
   *UN ENV PROGR ENV, 2007, ENV EFF OZ DEPL ITS
   United Nation Environmental Programme Environmental Effects Assessment Panel, 2011, ENV EFF OZ DEPL ITS
   United Nation Environmental Programme Environmental Effects Assessment Panel, 2009, ENV EFF OZ DEPL ITS
   Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579
   Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54
NR 20
TC 20
Z9 20
U1 2
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1542-2321
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD JUL
PY 2011
VL 37
IS 4
BP 185
EP 190
DI 10.1097/ICL.0b013e318223392e
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784BJ
UT WOS:000292128300004
PM 21670695
DA 2022-11-30
ER

PT J
AU Gupta, B
   Mohamed, MD
AF Gupta, B.
   Mohamed, M. D.
TI Photodynamic Therapy for Variant Central Serous Chorioretinopathy:
   Efficacy and Side Effects
SO OPHTHALMOLOGICA
LA English
DT Article
DE Central serous chorioretinopathy; Photodynamic therapy; Pigment
   epithelial detachment
AB Background: Retinal pigment epithelial detachment (PED) is a recognised associated finding in central serous chorioretinopathy (CSC). We report our experience in treating patients using photodynamic therapy (PDT) in a variant of chronic CSC that presents with only an isolated PED. We pre sent long-term follow-up data and novel observations on the pattern of retinal pigment epithelium (RPE) changes seen after treatment. Methods: Retrospective case series. Results and Discussion: CSC with subfoveal PED can be associated with a poor visual prognosis especially when the PED becomes chronic. PDT has been used to treat typical CSC with good outcomes. Three eyes in 3 patients were successfully treated with PDT, using the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy protocol. However, marked RPE disturbance was observed after treatment directly overlying the areas of brisk choroidal hyperpermeability. Copyright (C) 2011 S. Karger AG, Basel
C1 [Gupta, B.; Mohamed, M. D.] St Thomas Hosp, London SE1 7EH, England.
C3 Guy's & St Thomas' NHS Foundation Trust
RP Mohamed, MD (通讯作者)，St Thomas Hosp, Lambeth Palace Rd, London SE1 7EH, England.
EM moin.mohamed@gstt.nhs.uk
CR Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
NR 6
TC 12
Z9 13
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 4
BP 207
EP 210
DI 10.1159/000324050
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YO
UT WOS:000289508200004
PM 21325872
DA 2022-11-30
ER

PT J
AU Bishop-Bailey, D
AF Bishop-Bailey, David
TI A Role for PPAR beta/delta in Ocular Angiogenesis
SO PPAR RESEARCH
LA English
DT Review
ID ACTIVATED-RECEPTOR-DELTA; ENDOTHELIAL GROWTH-FACTOR; RETINOIC ACID;
   TUMOR-GROWTH; CANCER; EXPRESSION; INFLAMMATION; LIGANDS;
   NEOVASCULARIZATION; PROLIFERATION
AB The uses of highly selective PPAR beta/delta ligands and PPAR beta/delta knockout mice have shown a direct ability of PPAR beta/delta to regulate angiogenesis in vitro and in vivo in animal models. PPAR beta/delta ligands induce the proangiogenic growth factor VEGF in many cells and tissues, though its actions in the eye are not known. However, virtually, all tissue components of the eye express PPAR beta/delta. Both angiogenesis and in particular VEGF are not only critical for the development of the retina, but they are also a central component in many common pathologies of the eye, including diabetic retinopathy and age-related macular degeneration, the most common causes of blindness in the Western world. This review, therefore, will discuss the recent evidence of PPAR beta/delta-mediated angiogenesis and VEGF release in the context of ocular disorders. Copyright (C) 2008 David Bishop-Bailey.
C1 Barts & London Queen Marys Sch Med & Dent, Ctr Translat Med & Therapeut, William Harvey Res Inst, London EC1M 6BQ, England.
C3 University of London; Queen Mary University London
RP Bishop-Bailey, D (通讯作者)，Barts & London Queen Marys Sch Med & Dent, Ctr Translat Med & Therapeut, William Harvey Res Inst, London EC1M 6BQ, England.
EM d.bishop-bailey@qmul.ac.uk
OI Bishop-Bailey, David/0000-0003-2455-596X
CR Abdollahi A, 2007, P NATL ACAD SCI USA, V104, P12890, DOI 10.1073/pnas.0705505104
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adamkiewicz J, 2007, PROTEOMICS, V7, P1208, DOI 10.1002/pmic.200601003
   Ali FY, 2006, FASEB J, V20, P326, DOI 10.1096/fj.05-4395fje
   Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299
   Bishop-Bailey D, 2003, PROSTAG OTH LIPID M, V71, P1, DOI 10.1016/S0090-6980(03)00003-0
   Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042
   Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Campochiaro PA, 2006, INVEST OPHTH VIS SCI, V47, P462, DOI 10.1167/iovs.05-1494
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Desvergne B, 2007, NAT MED, V13, P671, DOI 10.1038/nm0607-671
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   Fauconnet S, 2002, J BIOL CHEM, V277, P23534, DOI 10.1074/jbc.M200172200
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Ghosh M, 2007, J EXP MED, V204, P2053, DOI 10.1084/jem.20070828
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200
   Higashiyama H, 2007, HISTOCHEM CELL BIOL, V127, P485, DOI 10.1007/s00418-007-0279-5
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hollingshead HE, 2007, CARCINOGENESIS, V28, P2641, DOI 10.1093/carcin/bgm183
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355
   Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131
   Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749
   Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344
   Lee CH, 2006, P NATL ACAD SCI USA, V103, P2434, DOI 10.1073/pnas.0510815103
   Liou JY, 2006, ARTERIOSCL THROM VAS, V26, P1481, DOI 10.1161/01.ATV.0000223875.14120.93
   Luo TL, 2006, J NEUROBIOL, V66, P677, DOI 10.1002/neu.20239
   Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156
   Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Moraes LA, 2006, PHARMACOL THERAPEUT, V110, P371, DOI 10.1016/j.pharmthera.2005.08.007
   Muller-Brusselbach S, 2007, EMBO J, V26, P3686, DOI 10.1038/sj.emboj.7601803
   Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Mwaikambo BR, 2006, INVEST OPHTH VIS SCI, V47, P4356, DOI 10.1167/iovs.05-1656
   Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634
   Piqueras L, 2007, ARTERIOSCL THROM VAS, V27, P63, DOI 10.1161/01.ATV.0000250972.83623.61
   Pola R, 2004, J MOL CELL CARDIOL, V36, P363, DOI 10.1016/j.yjmcc.2003.10.016
   Rak J, 2006, SEMIN THROMB HEMOST, V32, P54, DOI 10.1055/s-2006-933341
   Rival Y, 2002, EUR J PHARMACOL, V435, P143, DOI 10.1016/S0014-2999(01)01589-8
   Saito A, 2007, ENDOCRINOLOGY, V148, P1412, DOI 10.1210/en.2006-0900
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200
   Shojaei F, 2007, LAB INVEST, V87, P227, DOI 10.1038/labinvest.3700526
   STARITA G, 2007, DEV OPHTHALMOL, V39, P122
   Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200
   Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103
   Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587
NR 58
TC 8
Z9 9
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4757
EI 1687-4765
J9 PPAR RES
JI PPAR Res.
PY 2008
VL 2008
AR 825970
DI 10.1155/2008/825970
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V14AF
UT WOS:000207706600001
PM 18382612
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Zayit-Soudry, S
   Moroz, I
   Loewenstein, A
AF Zayit-Soudry, Shiri
   Moroz, Iris
   Loewenstein, Anat
TI Retinal pigment epithelial detachment
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; occult
   CNV; retinal pigment epithelial detachment
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INDOCYANINE-GREEN VIDEOANGIOGRAPHY;
   OPTICAL COHERENCE TOMOGRAPHY; GUIDED LASER PHOTOCOAGULATION; SENILE
   MACULAR DEGENERATION; BRUCHS MEMBRANE CHANGE; PHOTODYNAMIC THERAPY;
   CLINICOPATHOLOGICAL CORRELATION; SEROUS DETACHMENTS; NATURAL-HISTORY
AB Detachment of the retinal pigment epithelium is a prominent feature of many chorioretinal disease processes, the most prevalent of which is age-related macular degeneration (AMD). Detachment of the retinal pigment epithelium may or may not be associated with choroidal neovascularization and may be caused by different types of pathogenesis, each associated with distinct angiographic features, natural course, visual prognosis, and response to treatment. The phrase "detachment of the retinal pigment epithelium" is used quite often, not always in the correct association and with no clear differentiation between its various types. It is important to identify the specific nature of detachment of the retinal-pigment epithelium, and to establish an accurate diagnosis and treatment plan. Therefore, we present a review of the existing types of detachment of the retinal pigment epithelium with what we propose as being appropriate nomenclature and classification, and potential treatment recommendations.
C1 Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   Tel Aviv Univ, Retinal Imaging & OCT Unit, Goldschleger Eye Inst, Chaim Sheba Med Ctr, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim
   Sheba Medical Center; Tel Aviv University
RP Zayit-Soudry, S (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
OI Zayit Soudry, Shiri/0000-0002-8736-1823
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 1999, AM J OPHTHALMOL, V128, P331, DOI 10.1016/S0002-9394(99)00176-2
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Boguszakova J, 2001, Cesk Slov Oftalmol, V57, P367
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Bressler NM, 2001, RETINA, V2001, P1100
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brumm G, 2002, KLIN MONATSBL AUGENH, V219, P791, DOI 10.1055/s-2002-36320
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Costa RA, 2003, GRAEF ARCH CLIN EXP, V241, P245, DOI 10.1007/s00417-003-0627-7
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Jong P T, 1981, Bull Soc Belge Ophtalmol, V197, P55
   De Laey J J, 1983, Bull Soc Belge Ophtalmol, V207, P27
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   FREDERICK AR, 1993, RETINA-J RET VIT DIS, V13, P3, DOI 10.1097/00006982-199313010-00002
   Gass J, 1997, STEREOSCOPIC ATLAS M, P24
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 1998, ACTA OPHTHALMOL SCAN, V76, P384, DOI 10.1034/j.1600-0420.1998.760331.x
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gomez-Ulla F, 2001, ACTA OPHTHALMOL SCAN, V79, P39, DOI 10.1034/j.1600-0420.2001.079001039.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN K, 1990, OPHTHALMIC RES, V22, P287, DOI 10.1159/000267037
   GREEN SN, 1983, RETINA-J RET VIT DIS, V3, P16, DOI 10.1097/00006982-198300310-00004
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   GUYER DR, 1997, INDOCYANINE GREEN AN, P157
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HO PC, 1984, ANN OPHTHALMOL, V16, P213
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KIRCHHOF B, 1993, INT OPHTHALMOL, V17, P19, DOI 10.1007/BF00918862
   KLEIN ML, 1980, BRIT J OPHTHALMOL, V64, P412, DOI 10.1136/bjo.64.6.412
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   MAGUIRE JI, 1990, AM J OPHTHALMOL, V109, P523, DOI 10.1016/S0002-9394(14)70681-6
   Marmor M, 1998, RETINAL PIGMENT EPIT, P3
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MAVROFRIDES EC, OPTICAL COHERENCE TO, P243
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Muller C, 2002, OPHTHALMOLOGE, V99, P85, DOI 10.1007/s003470100511
   Murphy R P, 1985, Trans Am Ophthalmol Soc, V83, P63
   NOROSE K, 1988, BRIT J OPHTHALMOL, V72, P621, DOI 10.1136/bjo.72.8.621
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Parodi MB, 2000, ACTA OPHTHALMOL SCAN, V78, P443, DOI 10.1034/j.1600-0420.2000.078004443.x
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pece A, 1998, OPHTHALMOLOGICA, V212, P295, DOI 10.1159/000027311
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Ryan S., 2001, RETINA-J RET VIT DIS, V3 rd, P1153
   Sallet G, 1996, GRAEF ARCH CLIN EXP, V234, P25, DOI 10.1007/BF00186515
   SARKS SH, 2001, RETINA, P1064
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   SCHATZ H, 1990, OPHTHALMOLOGY, V97, P658
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Schwartz SG, 1998, RETINAL PIGMENT EPIT, P706
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHIRAKASHI A, 1992, Nippon Ganka Gakkai Zasshi, V96, P677
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   SINGERMAN LJ, 1988, RETINA-J RET VIT DIS, V8, P115, DOI 10.1097/00006982-198808020-00006
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Verhoeff FH, 1937, ARCH OPHTHALMOL-CHIC, V18, P561
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
   Weinberger D, 2002, RETINA-J RET VIT DIS, V22, P406, DOI 10.1097/00006982-200208000-00002
   Wolf S, 1994, Ger J Ophthalmol, V3, P224
   Wolfensberger, 1998, RETINAL PIGMENT EPIT, P439
   YANNUZZI LA, 1989, J FR OPHTALMOL, V12, P761
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1989, LASER PHOTOCOAGULATI, P49
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
   Yoshida M, 2002, BRIT J OPHTHALMOL, V86, P737, DOI 10.1136/bjo.86.7.737
   Yoshitani S, 2003, OPHTHALMIC SUR LA IM, V34, P217, DOI 10.3928/1542-8877-20030501-12
   YUZAWA M, 1995, OPHTHALMOLOGY, V102, P622, DOI 10.1016/S0161-6420(95)30990-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 134
TC 94
Z9 105
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2007
VL 52
IS 3
BP 227
EP 243
DI 10.1016/j.survophthal.2007.02.008
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 169QA
UT WOS:000246605500001
PM 17472800
DA 2022-11-30
ER

PT J
AU Michels, S
   Aue, A
   Simader, C
   Geitzenauer, W
   Sacu, S
   Schmidt-Erfurth, U
AF Michels, S
   Aue, A
   Simader, C
   Geitzenauer, W
   Sacu, S
   Schmidt-Erfurth, U
TI Retinal pigment epithelium tears following verteporfin therapy combined
   with intravitreal triamcinolone
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY
AB PURPOSE: To detect patients with neovascular age-related macular degeneration (AMD) who experience retinal pigment epithelium tears after initial verteporfin therapy combined with intravitreal triamcinolone during early follow-up.
   DESIGN: Prospective interventional case series.
   METHODS: Forty-five consecutive patients with choroidal neovascularization (CNV) in AMD were treated with verteporfin therapy combined with 4 mg of intravitreal triamcinolone. Optical coherence tomography (OCT), visual acuity, and fluorescein angiography were performed.
   RESULTS: Two eyes with a predominantly classic CNV developed a retinal pigment epithelium tear. An early onset tear could be differentiated from a delayed onset tear. OCT showed an increased depth signal in areas of missing retinal pigment epithelium and a wavy, contracted, and elevated retinal pigment epithelium band. CONCLUSIONS: Retinal pigment epithelium tears can occur despite adding intravitreal triamcinolone to verteporfin therapy. OCT shows characteristic changes in the evolution of retinal pigment epithelium tears after combination therapy.
C1 Med Univ Wien, Univ Klin Augenheilkunde & Optometrie, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Michels, S (通讯作者)，Med Univ Wien, Univ Klin Augenheilkunde & Optometrie, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM stephan.michels@meduniwien.ac.at
OI Simader, Christian/0000-0002-1784-2883
CR Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5
   GOLDSTEIN M, 2005, IN PRESS EYE
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
NR 7
TC 31
Z9 33
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2006
VL 141
IS 2
BP 396
EP 398
DI 10.1016/j.ajo.2005.08.046
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013LF
UT WOS:000235410100035
PM 16458709
DA 2022-11-30
ER

PT J
AU Peng, JJ
   Song, WT
   Yao, F
   Zhang, X
   Peng, J
   Luo, XJ
   Xia, XB
AF Peng, Jing-Jie
   Song, Wei-Tao
   Yao, Fei
   Zhang, Xuan
   Peng, Jun
   Luo, Xiu-Ju
   Xia, Xiao-Bo
TI Involvement of regulated necrosis in blinding diseases: Focus on
   necroptosis and ferroptosis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Regulated necrosis; Necroptosis; Ferroptosis; Glaucoma; Age-related
   macular degeneration; Retinitis pigmentosa
ID RECEPTOR INTERACTING PROTEIN; CONE CELL-DEATH; MACULAR DEGENERATION;
   OXIDATIVE STRESS; MOUSE MODEL; PHOTORECEPTOR DEGENERATION; RETINAL
   DEGENERATION; IRON; GLAUCOMA; APOPTOSIS
AB Besides apoptosis, necrosis can also occur in a highly regulated and genetically controlled manner, defined as regulated necrosis, which is characterized by a loss of cell membrane integrity and release of cytoplasmic content. Depending on the involvement of its signal pathway, regulated necrosis can be further classified as necroptosis, ferroptosis, pyroptosis and parthanatos. Numerous studies have demonstrated that regulated necrosis is involved in the pathogenesis of many diseases covering almost all organs including the brain, heart, liver, kidney, intestine, blood vessel, eye and skin, particularly myocardial infarction and stroke. Most recently, growing evidence suggests that multiple types of regulated necrosis contribute to the degeneration of retinal ganglion cells, retinal pigment epithelial cells or photoreceptor cells, which are the main pathologic features for glaucoma, age-related macular degeneration or retinitis pigmentosa, respectively. This review focuses on the involvement of necroptosis and ferroptosis in these blinding diseases.
C1 [Peng, Jing-Jie; Song, Wei-Tao; Yao, Fei; Zhang, Xuan; Xia, Xiao-Bo] Cent South Univ, Xiangya Hosp, Dept Ophthalmol, Changsha 410008, Peoples R China.
   [Peng, Jing-Jie; Luo, Xiu-Ju] Cent South Univ, Xiangya Hosp 3, Dept Lab Med, Changsha 410013, Peoples R China.
   [Peng, Jun] Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Xia, XB (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Ophthalmol, Changsha 410008, Peoples R China.; Luo, XJ (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Lab Med, Changsha 410013, Peoples R China.
EM xjluo22@csu.edu.cn; xbxia21@163.com
OI Xia, Xiaobo/0000-0002-2785-3391; Xia, Xiaobo/0000-0003-1720-7860
FU National Natural Science Foundation of China [81670858, 81974134,
   81770927, 81974132, 81573430, 81872873]
FX This work was supported by National Natural Science Foundation of China
   (No.81670858 and 81974134 to Xiao-Bo Xia, No. 81770927 and 81974132 to
   Wei-Tao Song, No. 81573430 to Xiu-Ju Luo, No. 81872873 to Jun Peng).
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Chen Y, 2013, J NEUROSCI, V33, P3582, DOI 10.1523/JNEUROSCI.1497-12.2013
   Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dias Marina Franca, 2018, Prog Retin Eye Res, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Do YJ, 2017, EXP CELL RES, V359, P30, DOI 10.1016/j.yexcr.2017.08.012
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026
   Doonan F, 2003, J NEUROSCI, V23, P5723
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dvoriantchikova G, 2014, EXP EYE RES, V123, P1, DOI 10.1016/j.exer.2014.04.009
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Forcina G.C., 2019, GPX4 CROSSROADS LIPI
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hao SH, 2018, ONCOL LETT, V15, P5405, DOI 10.3892/ol.2018.8066
   Jang KH, 2019, EXP EYE RES, V180, P8, DOI 10.1016/j.exer.2018.11.026
   Kang R, 2019, FREE RADICAL BIO MED, V133, P162, DOI 10.1016/j.freeradbiomed.2018.05.074
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kuehn Markus H, 2005, Ophthalmol Clin North Am, V18, P383, DOI 10.1016/j.ohc.2005.04.002
   Latunde-Dada GO, 2017, BBA-GEN SUBJECTS, V1861, P1893, DOI 10.1016/j.bbagen.2017.05.019
   LaVail MM, 2018, EXP EYE RES, V167, P56, DOI 10.1016/j.exer.2017.10.023
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Levin LA, 2017, EXP EYE RES, V157, P34, DOI 10.1016/j.exer.2016.12.005
   Li WJ, 2019, J CLIN INVEST, V129, P2293, DOI 10.1172/JCI126428
   Li Y, 2019, CELL DEATH DIFFER, V26, P2284, DOI 10.1038/s41418-019-0299-4
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Luo X, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/864871
   Maher P, 2018, CELL CALCIUM, V70, P47, DOI 10.1016/j.ceca.2017.05.007
   Masaldan S, 2019, FREE RADICAL BIO MED, V133, P221, DOI 10.1016/j.freeradbiomed.2018.09.033
   McMonnies C, 2018, J OPTOM, V11, P3, DOI 10.1016/j.optom.2017.06.002
   Muller T, 2017, CELL MOL LIFE SCI, V74, P3631, DOI 10.1007/s00018-017-2547-4
   Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Narayan DS, 2016, ACTA OPHTHALMOL, V94, P748, DOI 10.1111/aos.13141
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191
   Pefanis A., 2019, KIDNEY INT
   Pefanis A, 2019, KIDNEY INT, V96, P291, DOI 10.1016/j.kint.2019.02.009
   Robinson N, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101239
   Sakamoto K, 2018, EXP EYE RES, V171, P30, DOI 10.1016/j.exer.2018.03.008
   Sato K, 2013, J NEUROSCI, V33, P17458, DOI 10.1523/JNEUROSCI.1380-13.2013
   She L, 2019, CARDIOVASC DRUG THER, V33, P13, DOI 10.1007/s10557-018-06848-8
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shosha E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.295
   Singh M, 2017, MED HYPOTHESES, V105, P17, DOI 10.1016/j.mehy.2017.06.012
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomas CN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121517
   Tian J, 2018, TRANSL STROKE RES, V9, P382, DOI 10.1007/s12975-017-0581-z
   Tian Y, 2017, ACTA BIOCH BIOPH SIN, V49, P827, DOI 10.1093/abbs/gmx082
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Usui S, 2011, FREE RADICAL BIO MED, V51, P1347, DOI 10.1016/j.freeradbiomed.2011.06.010
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Viringipurampeer IA, 2019, MOL NEUROBIOL, V56, P1637, DOI 10.1007/s12035-018-1192-8
   Wang K, 2017, INVEST OPHTH VIS SCI, V58, P5287, DOI 10.1167/iovs.17-22096
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055
   Yang H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0202-z
   Ying Y, 2016, CELL MOL LIFE SCI, V73, P2309, DOI 10.1007/s00018-016-2202-5
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yu YX, 2019, J CELL PHYSIOL, V234, P14100, DOI 10.1002/jcp.28100
   Yuan H, 2016, BIOCHEM BIOPH RES CO, V478, P1338, DOI 10.1016/j.bbrc.2016.08.124
   Zanon-Moreno V, 2011, MOL VIS, V17, P2997
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P964, DOI 10.1167/iovs.03-0439
   Zhang Y.Y., 2019, NAUNYN SCHMIEDEBERGS
   Zhang YZ, 2018, ATHEROSCLEROSIS, V274, P128, DOI 10.1016/j.atherosclerosis.2018.04.031
NR 80
TC 27
Z9 27
U1 5
U2 36
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2020
VL 191
AR 107922
DI 10.1016/j.exer.2020.107922
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KM9UV
UT WOS:000514487100002
PM 31923413
DA 2022-11-30
ER

PT J
AU Rosales, MAB
   Shu, DY
   Iacovelli, J
   Saint-Geniez, M
AF Rosales, Mariana Aparecida Brunini
   Shu, Daisy Y.
   Iacovelli, Jared
   Saint-Geniez, Magali
TI Loss of PGC-1 alpha in RPE induces mesenchymal transition and promotes
   retinal degeneration
SO LIFE SCIENCE ALLIANCE
LA English
DT Article
ID PIGMENT EPITHELIUM; REDUCTIVE CARBOXYLATION; CITRATE SYNTHASE;
   AUTOPHAGY; MOUSE; CELLS; EXPRESSION; DIFFERENTIATION; PROLIFERATION;
   METABOLISM
AB The retinal pigment epithelium (RPE) supports visual processing and photoreceptor homeostasis via energetically demanding cellular functions. Here, we describe the consequences of repressing peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), a master regulator of mitochondrial function and biogenesis, on RPE epithelial integrity. The sustained silencing of PGC-1 alpha in differentiating human RPE cells affected mitochondria/autophagy function, redox state, and impaired energy sensor activity ultimately inducing epithelial to mesenchymal transition (EMT). Adult conditional knockout of PGC-1 coactivators in mice resulted in rapid RPE dysfunction and transdifferentiation associated with severe photoreceptor degeneration. RPE anomalies were characteristic of autophagic defect and mesenchymal transition comparable with the ones observed in age-related macular degeneration. These findings demonstrate that PGC-1 alpha is required to maintain the functional and phenotypic status of RPE by supporting the cells' oxidative metabolism and autophagy-mediated repression of EMT.
C1 [Rosales, Mariana Aparecida Brunini; Shu, Daisy Y.; Iacovelli, Jared; Saint-Geniez, Magali] Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Rosales, Mariana Aparecida Brunini; Shu, Daisy Y.; Iacovelli, Jared; Saint-Geniez, Magali] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Schepens Eye
   Research Institute; Harvard University; Harvard Medical School
RP Saint-Geniez, M (通讯作者)，Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.; Saint-Geniez, M (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
EM magali_saintgeniez@meei.harvard.edu
RI Shu, Daisy/D-1187-2018; Rosales, Mariana A B/K-7965-2014
OI Shu, Daisy/0000-0002-5382-6450; Rosales, Mariana A B/0000-0001-8042-0483
FU Alcon Research Institute, Young Investigator Research Grant (M
   Saint-Geniez); Research to Prevent Blindness Dolly Green Special Scholar
   Award; Grimshaw-Gudewicz Charitable Foundation; CNPq, National Council
   of Scientific and Technological Development-Brazil [PDE 210474/2014-9];
   NEI Core Grant [P30EYE003790]; Iraty Award
FX This work was supported by the Alcon Research Institute, Young
   Investigator Research Grant (M Saint-Geniez); the Research to Prevent
   Blindness Dolly Green Special Scholar Award (M Saint-Geniez); the
   Grimshaw-Gudewicz Charitable Foundation (M Saint-Geniez); the Iraty
   Award (M Saint-Geniez); CNPq, National Council of Scientific and
   Technological Development-Brazil (PDE 210474/2014-9) (MAB Rosales); and
   the NEI Core Grant P30EYE003790.
CR Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Ahmad T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.213
   Bertrand M, 2015, CELL CYCLE, V14, P364, DOI 10.4161/15384101.2014.987619
   Campbell SL, 2018, MOL CELL, V71, P398, DOI 10.1016/j.molcel.2018.07.015
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Demers-Lamarche J, 2016, J BIOL CHEM, V291, P10263, DOI 10.1074/jbc.M115.695825
   Diman A, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600031
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   LeMoine CMR, 2010, J MOL EVOL, V70, P492, DOI 10.1007/s00239-010-9347-x
   Li QF, 2009, AM J PHYSIOL-CELL PH, V297, pC299, DOI 10.1152/ajpcell.00037.2009
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   MACHEMER R, 1978, AM J OPHTHALMOL, V85, P181, DOI 10.1016/S0002-9394(14)75946-X
   MacPherson S, 2017, CELL REP, V19, P910, DOI 10.1016/j.celrep.2017.04.012
   Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428
   McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012
   Morandi A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00040
   Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002
   Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037
   Osellame LD, 2013, CELL METAB, V17, P941, DOI 10.1016/j.cmet.2013.04.014
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Rosales MAB, 2014, INVEST OPHTH VIS SCI, V55, P6090, DOI 10.1167/iovs.14-14234
   Rowe GC, 2013, CELL REP, V3, P1449, DOI 10.1016/j.celrep.2013.04.023
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Schlichtholz B, 2005, PANCREAS, V30, P99, DOI 10.1097/01.mpa.0000153326.69816.7d
   Sczelecki S, 2014, AM J PHYSIOL-ENDOC M, V306, pE157, DOI 10.1152/ajpendo.00578.2013
   Seifert P, 2017, J HISTOTECHNOL, V40, P130, DOI 10.1080/01478885.2017.1361117
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   Sripathi Srinivas R, 2012, Adv Biosci Biotechnol, V3, P1167, DOI 10.4236/abb.2012.38143
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Tsunemi T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003799
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Vandenberghe LH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002103
   Vishnyakova PA, 2016, SCI REP-UK, V6, DOI 10.1038/srep32410
   Wu J, 2004, J NEUROPHYSIOL, V91, P1134, DOI 10.1152/jn.00958.2003
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450
NR 66
TC 22
Z9 22
U1 0
U2 6
PU LIFE SCIENCE ALLIANCE LLC
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
EI 2575-1077
J9 LIFE SCI ALLIANCE
JI Life Sci. Alliance
PD JUN
PY 2019
VL 2
IS 3
AR e201800212
DI 10.26508/lsa.201800212
PG 17
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA IF6WT
UT WOS:000473222200001
PM 31142639
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, T
   Zhu, L
   Madigan, MC
   Liu, W
   Shen, WY
   Cherepanoff, S
   Zhou, FF
   Zeng, SX
   Du, JH
   Gillies, MC
AF Zhang, Ting
   Zhu, Ling
   Madigan, Michele C.
   Liu, Wei
   Shen, Weiyong
   Cherepanoff, Svetlana
   Zhou, Fanfan
   Zeng, Shaoxue
   Du, Jianhai
   Gillies, Mark C.
TI Human macular Muller cells rely more on serine biosynthesis to combat
   oxidative stress than those from the periphery
SO ELIFE
LA English
DT Article
ID GLIAL-CELLS; RETINA; PHOTORECEPTORS; MITOCHONDRIA; METABOLISM;
   MECHANISMS; EXPRESSION; PROFILE; CONE
AB The human macula is more susceptible than the peripheral retina to developing blinding conditions such as age-related macular degeneration, diabetic retinopathy. A key difference between them may be the nature of their Muller cells. We found primary cultured Muller cells from macula and peripheral retina display significant morphological and transcriptomic differences. Macular Muller cells expressed more phosphoglycerate dehydrogenase (PHGDH, a rate-limiting enzyme in serine synthesis) than peripheral Muller cells. The serine synthesis, glycolytic and mitochondrial function were more activated in macular than peripheral Muller cells. Serine biosynthesis is critical in defending against oxidative stress. Intracellular reactive oxygen species and glutathione levels were increased in primary cultured macular Muller cells which were more susceptible to oxidative stress after inhibition of PHGDH. Our findings indicate serine biosynthesis is a critical part of the macular defence against oxidative stress and suggest dysregulation of this pathway as a potential cause of macular pathology.
C1 [Zhang, Ting; Zhu, Ling; Madigan, Michele C.; Shen, Weiyong; Zeng, Shaoxue; Gillies, Mark C.] Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Madigan, Michele C.] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Liu, Wei] Clin Genom Lab, Sidra Med, Doha, Qatar.
   [Cherepanoff, Svetlana] St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW, Australia.
   [Zhou, Fanfan] Univ Sydney, Fac Pharm, Sydney, NSW, Australia.
   [Du, Jianhai] West Virginia Univ, Dept Ophthalmol, Morgantown, WV 26506 USA.
   [Du, Jianhai] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.
C3 University of Sydney; University of New South Wales Sydney; Sidra
   Medical & Research Center; St Vincents Hospital Sydney; University of
   Sydney; West Virginia University; West Virginia University
RP Zhu, L (通讯作者)，Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
EM ling.zhu@sydney.edu.au
RI Zhou, Fanfan/J-2327-2019; Zhang, Ting/P-8913-2017
OI Zhou, Fanfan/0000-0002-1982-1541; Madigan, Michele/0000-0003-1053-6979;
   Zhang, Ting/0000-0001-8074-8999
FU Australian National Health and Medical Research Council [APP1145121,
   EY026030]; NATIONAL EYE INSTITUTE [R01EY026030] Funding Source: NIH
   RePORTER
FX Australian National Health and Medical Research Council APP1145121 Ling
   Zhu Weiyong Shen Mark C Gillies; The Ophthalmic Research Institute of
   Australia Ling Zhu Mark C Gillies; National Institutes of Health
   EY026030 Jianhai Du; Lowy Medical Research Institute Ting Zhang Ling Zhu
   Weiyong Shen Mark C Gillies; The funders had no role in study design,
   data collection and interpretation, or the decision to submit the work
   for publication.
CR Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004
   Augustine J, 2018, INVEST OPHTH VIS SCI, V59, P1666, DOI 10.1167/iovs.17-23293
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bringmann A, 2005, ACTA OPHTHALMOL SCAN, V83, P528, DOI 10.1111/j.1600-0420.2005.00565.x
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Klein R, 2010, AM J OPHTHALMOL, V150, P55, DOI 10.1016/j.ajo.2010.02.013
   Kofuji P, 2004, NEUROSCIENCE, V129, P1045, DOI 10.1016/j.neurscience.2004.06.008
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Mori K, 2016, RETINA-J RET VIT DIS, V36, P375, DOI 10.1097/IAE.0000000000000703
   Newman EA, 1996, J NEUROSCI, V16, P159
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1976
   Perkins GA, 2000, MICRON, V31, P97, DOI 10.1016/S0968-4328(99)00065-7
   Perkins GA, 2004, MITOCHONDRION, V4, P695, DOI 10.1016/j.mito.2004.07.020
   Poitry S, 2000, J NEUROSCI, V20, P1809
   POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Song WT, 2013, INT J OPHTHALMOL-CHI, V6, P778, DOI 10.3980/j.issn.2222-3959.2013.06.07
   Too LK, 2017, ACTA HISTOCHEM, V119, P142, DOI 10.1016/j.acthis.2016.12.003
   YAMADA E, 1969, ARCH OPHTHALMOL-CHIC, V82, P151
   Zhang T, 2018, MOL NEUROBIOL, V55, P7025, DOI 10.1007/s12035-017-0840-8
   Zhu L, 2015, J NEUROCHEM, V133, P909, DOI 10.1111/jnc.13075
   Zhu SY, 2018, EXP EYE RES, V174, P113, DOI 10.1016/j.exer.2018.05.032
NR 39
TC 17
Z9 17
U1 0
U2 8
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD APR 30
PY 2019
VL 8
AR e43598
DI 10.7554/eLife.43598
PG 19
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA HZ4ZY
UT WOS:000468861600001
PM 31036157
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Conti, FF
   Young, JM
   Silva, FQ
   Rodrigues, EB
   Singh, RP
AF Conti, Felipe F.
   Young, Jason M.
   Silva, Fabiana Q.
   Rodrigues, Eduardo B.
   Singh, Rishi P.
TI Repeatability of Split-Spectrum Amplitude-Decorrelation Angiography to
   Assess Capillary Perfusion Density Within Optical Coherence Tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID FOVEAL AVASCULAR ZONE; DIABETIC-RETINOPATHY; REPRODUCIBILITY;
   RELIABILITY; EYES
AB BACKGROUND AND OBJECTIVE: To evaluate the repeatability of retinal thickness and vascular density measurements using split-spectrum amplitude-decorrelation angiography (SSADA) with optical coherence tomography (OCT).
   PATIENTS AND METHODS: Forty patients were divided into seven categories according to their diagnosis: no retinopathy (control), retinal vein occlusion, diabetes with no retinopathy, diabetes with retinopathy, non-exudative age-related macular degeneration (AMD), exudative AMD, and epiretinal membrane. Capillary density and retinal thickness measurements were taken and evaluated for reliability by determination of statistically significant differences and coefficient of variability (CoV) between measurements.
   RESULTS: No significant differences (P > .05) were found in any of the within-visit measurements. CoVs ranged from 0.26% to 52.76%, depending on the measure and the disease settings.
   CONCLUSION: The SSADA OCT angiography analysis has a low level of variability between measurements and, thus, is a reliable tool for evaluation of retinal perfusion.
C1 [Conti, Felipe F.; Young, Jason M.; Silva, Fabiana Q.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Conti, Felipe F.; Rodrigues, Eduardo B.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Cleveland Clinic Foundation; Universidade Federal de Sao Paulo (UNIFESP)
RP Singh, RP (通讯作者)，9500 Euclid Ave,Desk i32, Cleveland, OH 44195 USA.
EM singhr@ccf.org
RI Silva, Fabiana/GWU-9143-2022
FU Regeneron; Genentech; Shire; Apellis; Alcon
FX Dr. Singh reports grants and personal fees from Regeneron and Genentech,
   personal fees from Shire, and grants from Apellis and Alcon during the
   conduct of the study. The remaining authors report no relevant financial
   disclosures.
CR Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Al-Sheikh M, 2017, BRIT J OPHTHALMOL, V101, P449, DOI 10.1136/bjophthalmol-2016-308764
   Bartlett JW, 2008, ULTRASOUND OBST GYN, V31, P466, DOI 10.1002/uog.5256
   Carpineto P, 2016, BRIT J OPHTHALMOL, V100, P671, DOI 10.1136/bjophthalmol-2015-307330
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia Y, 1997, INVEST OPHTH VIS SCI, P83
   Kawana K, 2007, ACTA OPHTHALMOL SCAN, V85, P684, DOI 10.1111/j.1600-0420.2006.00836.x
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   La Spina C, 2017, RETINA-J RET VIT DIS, V37, P1636, DOI 10.1097/IAE.0000000000001426
   Lee J, 2016, OPHTHALMOLOGY, V123, P2368, DOI 10.1016/j.ophtha.2016.07.010
   Leveque PM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6956717
   Magrath GN, 2017, RETINA-J RET VIT DIS, V37, P2102, DOI 10.1097/IAE.0000000000001458
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
NR 16
TC 8
Z9 10
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2018
VL 49
IS 9
BP E9
EP E19
DI 10.3928/23258160-20180907-02
PG 11
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GT9AI
UT WOS:000444831000002
PM 30222814
DA 2022-11-30
ER

PT J
AU Xiao, JR
   Do, CW
   To, CH
AF Xiao, Jing-Ru
   Do, Chi-Wai
   To, Chi-Ho
TI Potential Therapeutic Effects of Baicalein, Baicalin, and Wogonin in
   Ocular Disorders
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; PROLIFERATIVE
   DIABETIC-RETINOPATHY; PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY;
   RETINAL GANGLION-CELLS; NF-KAPPA-B; OXIDATIVE-STRESS; SCUTELLARIAE
   RADIX; LIPID-PEROXIDATION
AB Ocular diseases such as cataract, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are the leading causes of blindness. The elderly population is at particular risk of developing one or more of these age-related ocular diseases. By virtue of multiple bioactivities, effort has been made to develop dietary flavonoids as complimentary therapies for ocular disorders. Dietary intake of flavonoids has been reported to reduce the risk of cataract and AMD. This review focuses on the main flavones baicalein, baicalin, and wogonin isolated from the Chinese medicinal herb, Scutellariae radix (SR), which has been widely used in Asian countries for the treatment of many diseases. Interest in SR has grown recently following new findings that suggest multiple routes of therapeutic action. This review will summarize the diverse pharmacological properties, therapeutic roles, and mechanisms of these flavones of SR in cellular and animal models of ocular diseases.
C1 [Xiao, Jing-Ru; Do, Chi-Wai; To, Chi-Ho] Hong Kong Polytech Univ, Lab Expt Optometry, Sch Optometry, Hong Kong 1111, Hong Kong, Peoples R China.
   [To, Chi-Ho] Sun Yat Sen Univ, State Key Lab Ophthalmol, Dept Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
C3 Hong Kong Polytechnic University; Sun Yat Sen University
RP To, CH (通讯作者)，Hong Kong Polytech Univ, Lab Expt Optometry, Sch Optometry, Hong Kong 1111, Hong Kong, Peoples R China.
EM chi-ho.to@polyu.edu.hk
RI Do, Chi Wai/M-4250-2017
OI Do, Chi Wai/0000-0002-7720-7507; To, Chi-ho/0000-0002-1938-8397
FU Henry G. Leong Endowed Professorship in Elderly Vision Health; Research
   Grants Council General Research Fund (RGC GRF) [B-Q34C]; Hong Kong
   Polytechnic University
FX The authors thank Dr. Jeremy Guggenheim for his valuable comments in the
   article. The work is supported by Henry G. Leong Endowed Professorship
   in Elderly Vision Health, Research Grants Council General Research Fund
   (RGC GRF) B-Q34C, and Postgraduate Studentship from The Hong Kong
   Polytechnic University.
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284
   Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Attia SM, 2013, FOOD CHEM TOXICOL, V59, P724, DOI 10.1016/j.fct.2013.07.022
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellot JL, 1997, OPHTHALMIC RES, V29, P227, DOI 10.1159/000268017
   BEYERMEARS A, 1985, DIABETES, V34, P15, DOI 10.2337/diabetes.34.1.15
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Canataroglu H, 2005, OCUL IMMUNOL INFLAMM, V13, P375, DOI 10.1080/09273940490518900
   Chandrasekher G, 2002, INVEST OPHTH VIS SCI, V43, P1422
   Chao HM, 2013, J OCUL PHARMACOL TH, V29, P539, DOI 10.1089/jop.2012.0179
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen YQ, 2012, J OCUL PHARMACOL TH, V28, P110, DOI 10.1089/jop.2011.0099
   Chen YC, 2001, BIOCHEM PHARMACOL, V61, P1417, DOI 10.1016/S0006-2952(01)00594-9
   Chi YS, 2003, BIOCHEM PHARMACOL, V66, P1271, DOI 10.1016/S0006-2952(03)00463-5
   Cotran R.S, 1999, ROBBINS PATHOLOGIC B, P50
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1047
   El-Asrar AM, 2001, AM J OPHTHALMOL, V132, P551, DOI 10.1016/S0002-9394(01)01127-8
   ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Foster Allen, 2008, Community Eye Health, V21, P37
   Gao DY, 1996, BIOCHEM MOL BIOL INT, V39, P215
   Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X
   GRILLI M, 1993, INT REV CYTOL, V143, P1
   Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832
   GUPTA AG, 1993, EXP EYE RES, V56, P701, DOI 10.1006/exer.1993.1087
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hakansson Gisela, 2010, J Ocul Biol Dis Infor, V3, P20, DOI 10.1007/s12177-010-9050-6
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hawkins BS, 1999, MOL VIS, V5
   Head K A, 2001, Altern Med Rev, V6, P141
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   HOEKZEMA R, 1991, INVEST OPHTH VIS SCI, V32, P88
   Hou JC, 2012, INT IMMUNOPHARMACOL, V14, P749, DOI 10.1016/j.intimp.2012.10.013
   Hsieh Chia-Jung, 2007, Clin Mol Allergy, V5, P5, DOI 10.1186/1476-7961-5-5
   Hurst JS, 1997, J OCUL PHARMACOL TH, V13, P415, DOI 10.1089/jop.1997.13.415
   Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jung SH, 2008, NEUROCHEM INT, V53, P325, DOI 10.1016/j.neuint.2008.09.004
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim KC, 2012, CELL BIOL TOXICOL, V28, P421, DOI 10.1007/s10565-012-9233-y
   KIMUYA Y, 1981, CHEM PHARM BULL, V29, P2610
   KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kowluru RA, 2001, ACTA DIABETOL, V38, P179, DOI 10.1007/s592-001-8076-6
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Kramer M, 2005, OCUL IMMUNOL INFLAMM, V13, P305, DOI 10.1080/09273940590950990
   KUBO M, 1984, CHEM PHARM BULL, V32, P2724
   Kyselova Z, 2004, J DIABETES COMPLICAT, V18, P129, DOI 10.1016/S1056-8727(03)00009-6
   LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780
   Lee IS, 2011, PHYTOTHER RES, V25, P1348, DOI 10.1002/ptr.3370
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7
   Li S Z, 1987, Yan Ke Xue Bao, V3, P93
   Li S. Z., 1987, YAN KE XUE BAO, V3, P137
   Lin CM, 2006, PLANTA MED, V72, P1305, DOI 10.1055/s-2006-951692
   Lin CM, 2012, AM J CHINESE MED, V40, P415, DOI 10.1142/S0192415X12500322
   Liu BM, 2012, FREE RADICAL BIO MED, V53, P183, DOI 10.1016/j.freeradbiomed.2012.04.015
   Liu JJ, 2003, INT J CANCER, V106, P559, DOI 10.1002/ijc.11267
   Liu JH, 2010, J OCUL PHARMACOL TH, V26, P421, DOI 10.1089/jop.2010.0063
   Liu PF, 2013, J FOOD SCI TECH MYS, V50, P615, DOI 10.1007/s13197-012-0857-y
   Liu XQ, 2013, J OCUL PHARMACOL TH, V29, P33, DOI 10.1089/jop.2012.0141
   Lombardo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060796
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Mabalirajan U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062916
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Maher P, 2008, EXP EYE RES, V86, P366, DOI 10.1016/j.exer.2007.11.009
   Mandai M, 1996, INVEST OPHTH VIS SCI, V37, P826
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moslehi M, 2012, CELL MOL NEUROBIOL, V32, P549, DOI 10.1007/s10571-011-9795-x
   MURRAY PI, 1990, INVEST OPHTH VIS SCI, V31, P917
   Nagaki Y, 2003, JPN J OPHTHALMOL, V47, P249, DOI 10.1016/S0021-5155(03)00002-9
   Nagaki Y, 2001, JPN J OPHTHALMOL, V45, P216, DOI 10.1016/S0021-5155(01)00330-6
   Nakamura N, 2003, EXP EYE RES, V77, P195, DOI 10.1016/S0014-4835(03)00116-7
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Park CH, 2007, B KOR CHEM SOC, V28, P493
   PARKS DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P544, DOI 10.1001/archopht.1994.01090160124032
   Peng PH, 2011, CURR EYE RES, V36, P238, DOI 10.3109/02713683.2010.539760
   Perez CA, 2009, J INORG BIOCHEM, V103, P326, DOI 10.1016/j.jinorgbio.2008.11.003
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Shieh DE, 2000, ANTICANCER RES, V20, P2861
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   Sun MH, 2010, INVEST OPHTH VIS SCI, V51, P4798, DOI 10.1167/iovs.09-4086
   Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tian H., 2009, FASEB J S, V23, P25
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   VARMA SD, 1979, INVEST OPHTH VIS SCI, V18, P236
   Verma MJ, 1997, CURR EYE RES, V16, P1202, DOI 10.1076/ceyr.16.12.1202.5034
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wakabayashi I, 1999, PHARMACOL TOXICOL, V84, P288, DOI 10.1111/j.1600-0773.1999.tb01496.x
   Wang HZ, 2014, J PHARMACOL EXP THER, V350, P435, DOI 10.1124/jpet.114.215145
   Wang YH, 2013, MOLECULES, V18, P14726, DOI 10.3390/molecules181214726
   Winkler B S, 1999, Mol Vis, V5, P32
   World Health Organization, VIS IMP BLINDN
   Xin HG, 2014, EUR J PHARMACOL, V738, P310, DOI 10.1016/j.ejphar.2014.06.006
   Xu J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.86
   Yang LP, 2009, INVEST OPHTH VIS SCI, V50, P2319, DOI 10.1167/iovs.08-2642
   Yang SJ, 2014, CURR EYE RES, V39, P745, DOI 10.3109/02713683.2013.868908
   Yeh CH, 2015, TOXICOL IND HEALTH, V31, P960, DOI 10.1177/0748233713485886
   Yu CH, 2013, ONCOL REP, V30, P2411, DOI 10.3892/or.2013.2726
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang SH, 2010, J MOL NEUROSCI, V40, P311, DOI 10.1007/s12031-009-9285-5
   Zheng WX, 2014, BRAIN INJURY, V28, P227, DOI 10.3109/02699052.2013.860469
NR 125
TC 48
Z9 51
U1 3
U2 44
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT 1
PY 2014
VL 30
IS 8
BP 605
EP 614
DI 10.1089/jop.2014.0074
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA AQ1SB
UT WOS:000342560200002
PM 25280175
DA 2022-11-30
ER

PT J
AU Zauhar, R
   Biber, J
   Jabri, Y
   Kim, M
   Hu, J
   Kaplan, L
   Pfaller, AM
   Schaefer, N
   Enzmann, V
   Schloetzer-Schrehardt, U
   Straub, T
   Hauck, SM
   Gamlin, PD
   McFerrin, MB
   Messinger, J
   Strang, CE
   Curcio, CA
   Dana, N
   Pauly, D
   Grosche, A
   Li, MY
   Stambolian, D
AF Zauhar, Randy
   Biber, Josef
   Jabri, Yassin
   Kim, Mijin
   Hu, Jian
   Kaplan, Lew
   Pfaller, Anna M.
   Schaefer, Nicole
   Enzmann, Volker
   Schloetzer-Schrehardt, Ursula
   Straub, Tobias
   Hauck, Stefanie M.
   Gamlin, Paul D.
   McFerrin, Michael B.
   Messinger, Jeffrey
   Strang, Christianne E.
   Curcio, Christine A.
   Dana, Nicholas
   Pauly, Diana
   Grosche, Antje
   Li, Mingyao
   Stambolian, Dwight
TI As in Real Estate, Location Matters: Cellular Expression of Complement
   Varies Between Macular and Peripheral Regions of the Retina and
   Supporting Tissues
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE single cell; complement; age-related macular degeneration; retina; RPE;
   choroid
ID PIGMENT EPITHELIUM; STRUCTURAL INSIGHT; DRUSEN FORMATION; KEY
   REGULATORS; MESSENGER-RNA; MOUSE MODEL; DEGENERATION; SYSTEM;
   ACTIVATION; CELLS
AB The cellular events that dictate the initiation of the complement pathway in ocular degeneration, such as age-related macular degeneration (AMD), is poorly understood. Using gene expression analysis (single cell and bulk), mass spectrometry, and immunohistochemistry, we dissected the role of multiple retinal and choroidal cell types in determining the complement homeostasis. Our scRNA-seq data show that the cellular response to early AMD is more robust in the choroid, particularly in fibroblasts, pericytes and endothelial cells. In late AMD, complement changes were more prominent in the retina especially with the expression of the classical pathway initiators. Notably, we found a spatial preference for these differences. Overall, this study provides insights into the heterogeneity of cellular responses for complement expression and the cooperation of neighboring cells to complete the pathway in healthy and AMD eyes. Further, our findings provide new cellular targets for therapies directed at complement.
C1 [Zauhar, Randy] Univ Sci Philadelphia, Dept Chem & Biochem, Philadelphia, PA USA.
   [Biber, Josef; Kaplan, Lew; Pfaller, Anna M.; Grosche, Antje] Ludwig Maximilians Univ Munchen, Dept Physiol Genom, Planegg Martinsried, Germany.
   [Jabri, Yassin; Schaefer, Nicole; Pauly, Diana] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Kim, Mijin; Dana, Nicholas; Stambolian, Dwight] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Hu, Jian; Li, Mingyao] Univ Penn, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA USA.
   [Schaefer, Nicole] Univ Regensburg, Ctr Med Biotechnol ZMB, Dept Orthopaed Surg Expt Orthopaed, Regensburg, Germany.
   [Enzmann, Volker] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Enzmann, Volker] Univ Bern, Dept Biomed Res, Bern, Switzerland.
   [Schloetzer-Schrehardt, Ursula] Friedrich Alexander Univ Erlangen Nurnberg, Dept Ophthalmol, Erlangen, Germany.
   [Straub, Tobias] Ludwig Maximilians Univ Munchen, Biomed Ctr, Bioinformat Unit, Martinsried, Germany.
   [Hauck, Stefanie M.] Helmholtz Zent Munchen, Metabol & Prote Core & Res Unit Prot Sci, Neuherberg, Germany.
   [Gamlin, Paul D.; Messinger, Jeffrey; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [McFerrin, Michael B.; Strang, Christianne E.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL USA.
   [Pauly, Diana] Univ Marburg, Expt Ophthalmol, Marburg, Germany.
C3 University of Munich; University of Regensburg; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; University of Regensburg; University of Bern;
   University Hospital of Bern; University of Bern; University of Erlangen
   Nuremberg; University of Munich; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health; University of
   Alabama System; University of Alabama Birmingham; University of Alabama
   System; University of Alabama Birmingham; Philipps University Marburg
RP Stambolian, D (通讯作者)，Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
EM stamboli@pennmedicine.upenn.edu
RI Grosche, Antje/N-1978-2014
OI Grosche, Antje/0000-0003-0338-7530; Kaplan, Lew/0000-0003-4336-2768
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], CELL ATLAS C1S HUMAN
   [Anonymous], [No title captured]
   Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012
   Atanes P, 2018, CELL MOL LIFE SCI, V75, P715, DOI 10.1007/s00018-017-2655-1
   Bajic G, 2013, P NATL ACAD SCI USA, V110, P16426, DOI 10.1073/pnas.1311261110
   Barnum SR, 2017, PHARMACOL THERAPEUT, V172, P63, DOI 10.1016/j.pharmthera.2016.11.014
   Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Brunner AD, 2022, MOL SYST BIOL, V18, DOI 10.15252/msb.202110798
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   CURCIO CA, 1989, VISION RES, V29, P529, DOI 10.1016/0042-6989(89)90039-4
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Demirs JT, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.7.26
   Desai D, 2022, EYE, V36, P294, DOI 10.1038/s41433-021-01765-x
   Doorduijn DJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008606
   Dos Santos RS, 2017, ENDOCRINOLOGY, V158, P2503, DOI 10.1210/en.2017-00104
   Endo Y, 2011, INT J BIOCHEM CELL B, V43, P705, DOI 10.1016/j.biocel.2011.02.003
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Frik J, 2018, EMBO REP, V19, DOI 10.15252/embr.201745294
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grosche A, 2016, MOL CELL PROTEOMICS, V15, P462, DOI 10.1074/mcp.M115.052183
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jabri Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228468
   Jensen RK, 2021, J IMMUNOL, V206, P3032, DOI 10.4049/jimmunol.2001208
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kjell J, 2020, CELL STEM CELL, V26, P277, DOI 10.1016/j.stem.2020.01.002
   Kolb H., 2005, WEBVISION ORG RETINA
   Kolev M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00001
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Kulkarni HS, 2019, AM J RESP CELL MOL, V60, P144, DOI 10.1165/rcmb.2017-0405OC
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Lepper MF, 2018, J PROTEOME RES, V17, P618, DOI 10.1021/acs.jproteome.7b00712
   Li FY, 2020, GENOM PROTEOM BIOINF, V18, P52, DOI 10.1016/j.gpb.2019.08.002
   Li XJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15851-3
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004
   Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Lyu YF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95122-3
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McKenna A, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.169730
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131
   Park YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136851
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Presumey J, 2017, ADV IMMUNOL, V135, P53, DOI 10.1016/bs.ai.2017.06.004
   Qin SQ, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9945725
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Satyam A, 2017, J IMMUNOL, V198, P788, DOI 10.4049/jimmunol.1502287
   Schafer N, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00197
   Schafer N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00542
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schatz-Jakobsen JA, 2016, IMMUNOL REV, V274, P59, DOI 10.1111/imr.12465
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   Strauss O., 2011, WEBVISION ORGAN RETI, P1, DOI [10.1007/s00347-008-1868-y, DOI 10.1007/S00347-008-1868-Y]
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Sunderhauf A, 2017, MOL IMMUNOL, V90, P227, DOI 10.1016/j.molimm.2017.08.003
   Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010
   THOMPSON RA, 1970, J EXP MED, V131, P629, DOI 10.1084/jem.131.4.629
   VanderMeer J, 2004, ARCH OTOLARYNGOL, V130, P1374, DOI 10.1001/archotol.130.12.1374
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Xu ST, 2017, P NATL ACAD SCI USA, V114, P3403, DOI 10.1073/pnas.1620881114
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhang A, 2002, DIABETES, V51, P3499
   Zheng BQ, 2011, AM J OPHTHALMOL, V152, P1039, DOI 10.1016/j.ajo.2011.05.022
NR 101
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 15
PY 2022
VL 13
AR 895519
DI 10.3389/fimmu.2022.895519
PG 19
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 2M9EM
UT WOS:000817994100001
PM 35784369
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Chen, LW
   Cheng, Y
   Ding, Y
   Li, RS
AF Chen, Ling-Wan
   Cheng, Yu
   Ding, Ying
   Li, Ruosha
TI Quantile association regression on bivariate survival data
SO CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE
LA English
DT Article
DE Conditional association; copula; induced smoothing; odds ratio;
   quantiles regression
ID CROSS-RATIO ESTIMATION; COPULA MODELS; COVARIANCE; DISEASE; EVENT; TAU;
   AGE
AB The association between two event times is of scientific importance in various fields. Due to population heterogeneity, it is desirable to examine the degree to which local association depends on different characteristics of the population. Here we adopt a novel quantile-based local association measure and propose a conditional quantile association regression model to allow covariate effects on local association of two survival times. Estimating equations for the quantile association coefficients are constructed based on the relationship between this quantile association measure and the conditional copula. Asymptotic properties for the resulting estimators are rigorously derived, and induced smoothing is used to obtain the covariance matrix. Through simulations we demonstrate the good practical performance of the proposed inference procedures. An application to age-related macular degeneration (AMD) data reals interesting varying effects of the baseline AMD severity score on the local association between two AMD progression times.
C1 [Chen, Ling-Wan] NIEHS, Biostat & Computat Biol Branch, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Cheng, Yu] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15260 USA.
   [Cheng, Yu; Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Li, Ruosha] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Texas System; University of Texas Health
   Science Center Houston
RP Cheng, Y (通讯作者)，Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15260 USA.; Cheng, Y (通讯作者)，Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
EM yucheng@pitt.edu
FU U.S. National Science Foundation [DMS 1916001]; U.S. National Institute
   of Diabetes and Digestive and Kidney Diseases [R01DK117209]; University
   of Pittsburgh Center for Research Computing
FX The research was partially supported by the U.S. National Science
   Foundation to Cheng (DMS 1916001) and by the U.S. National Institute of
   Diabetes and Digestive and Kidney Diseases to Li (R01DK117209) as well
   as the University of Pittsburgh Center for Research Computing through
   the resources provided. We are grateful to the editor, the review
   editor, and two anonymous reviewers for their constructive comments and
   suggestions that led to an improved article.
CR ANDERSON JE, 1992, J AM STAT ASSOC, V87, P641, DOI 10.2307/2290199
   Bogaerts K, 2008, STAT MED, V27, P6379, DOI 10.1002/sim.3438
   Brown BM, 2007, STAT MED, V26, P828, DOI 10.1002/sim.2576
   Brown BM, 2005, BIOMETRIKA, V92, P149, DOI 10.1093/biomet/92.1.149
   CLAYTON DG, 1978, BIOMETRIKA, V65, P141, DOI 10.2307/2335289
   Geerdens C, 2018, BIOSTATISTICS, V19, P247, DOI 10.1093/biostatistics/kxx034
   Gorfine M, 2006, BIOMETRIKA, V93, P735, DOI 10.1093/biomet/93.3.735
   Hu TL, 2011, BIOMETRIKA, V98, P341, DOI 10.1093/biomet/asr005
   HUS L, 1996, BIOMETRIKA, V83, P491, DOI DOI 10.1093/biomet/83.3.491
   HUSTER WJ, 1989, BIOMETRICS, V45, P145, DOI 10.2307/2532041
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643
   Koenker R, 2008, J STAT SOFTW, V27, P1
   Lakhal L, 2009, INT J BIOSTAT, V5, DOI 10.2202/1557-4679.1121
   Li RS, 2017, BIOMETRICS, V73, P506, DOI 10.1111/biom.12584
   Li RS, 2014, J AM STAT ASSOC, V109, P230, DOI 10.1080/01621459.2013.847375
   Li RS, 2011, BIOMETRICS, V67, P701, DOI 10.1111/j.1541-0420.2010.01521.x
   Nan B, 2006, J AM STAT ASSOC, V101, P65, DOI 10.1198/016214505000000934
   OAKES D, 1989, J AM STAT ASSOC, V84, P487, DOI 10.2307/2289934
   OAKES D, 1982, J ROY STAT SOC B MET, V44, P414
   Oakes D, 2008, BIOMETRIKA, V95, P997, DOI 10.1093/biomet/asn037
   Pang L, 2012, COMPUT STAT DATA AN, V56, P785, DOI 10.1016/j.csda.2010.10.018
   Peng LM, 2008, J AM STAT ASSOC, V103, P637, DOI 10.1198/016214508000000355
   Peng LM, 2009, J AM STAT ASSOC, V104, P1440, DOI 10.1198/jasa.2009.tm08228
   Portnoy S, 2003, J AM STAT ASSOC, V98, P1001, DOI 10.1198/016214503000000954
   PRENTICE RL, 1992, BIOMETRIKA, V79, P495, DOI 10.2307/2336781
   Romeo JS, 2018, LIFETIME DATA ANAL, V24, P355, DOI 10.1007/s10985-017-9396-1
   Shih JH, 1995, BIOMETRICS, V51, P1384, DOI 10.2307/2533269
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Wang WJ, 2000, STAT SINICA, V10, P1199
   Wang YG, 2009, COMPUT STAT DATA AN, V53, P3696, DOI 10.1016/j.csda.2009.03.012
   Yan J, 2005, J AM STAT ASSOC, V100, P184, DOI 10.1198/016214504000001286
   Zeng DL, 2009, BIOMETRIKA, V96, P277, DOI 10.1093/biomet/asp008
NR 33
TC 0
Z9 0
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0319-5724
EI 1708-945X
J9 CAN J STAT
JI Can. J. Stat.-Rev. Can. Stat.
PD SEP
PY 2021
VL 49
IS 3
BP 612
EP 636
DI 10.1002/cjs.11577
EA NOV 2020
PG 25
WC Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA TZ6LB
UT WOS:000583074100001
PM 34720345
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schwikkard, S
   Whitmore, H
   Sishtla, K
   Sulaiman, RS
   Shetty, T
   Basavarajappa, HD
   Waller, C
   Alqahtani, A
   Frankemoelle, L
   Chapman, A
   Crouch, N
   Wetschnig, W
   Knirsch, W
   Andriantiana, J
   Mas-Claret, E
   Langat, MK
   Mulholland, D
   Corson, TW
AF Schwikkard, Sianne
   Whitmore, Hannah
   Sishtla, Kamakshi
   Sulaiman, Rania S.
   Shetty, Trupti
   Basavarajappa, Halesha D.
   Waller, Catherine
   Alqahtani, Alaa
   Frankemoelle, Lennart
   Chapman, Andy
   Crouch, Neil
   Wetschnig, Wolfgang
   Knirsch, Walter
   Andriantiana, Jacky
   Mas-Claret, Eduard
   Langat, Moses K.
   Mulholland, Dulcie
   Corson, Timothy W.
TI The Antiangiogenic Activity of Naturally Occurring and Synthetic
   Homoisoflavonoids from the Hyacinthaceae (sensu APGII)
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OCULAR NEOVASCULARIZATION; THERAPEUTIC
   TARGET; HOMO-ISOFLAVONES; HOMOISOFLAVANONES; INHIBITORS; BULBS;
   3-BENZYL-4-CHROMANONES; CHEMISTRY; PRODUCT
AB Excessive blood vessel formation in the eye is implicated in wet age-related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity, which are major causes of blindness. Small molecule antiangiogenic drugs are strongly needed to supplement existing biologics. Homoisoflavonoids have been previously shown to have potent antiproliferative activities in endothelial cells over other cell types. Moreover, they demonstrated a strong antiangiogenic potential in vitro and in vivo in animal models of ocular neovascularization. Here, we tested the antiangiogenic activity of a group of naturally occurring homoisoflavonoids isolated from the family Hyacinthaceae and related synthetic compounds, chosen for synthesis based on structure-activity relationship observations. Several compounds showed interesting antiproliferative and antiangiogenic activities in vitro on retinal microvascular endothelial cells, a disease-relevant cell type, with the synthetic chromane, 46, showing the best activity (GI(50) of 2.3 x 10(-4) mu M).
C1 [Schwikkard, Sianne; Frankemoelle, Lennart; Chapman, Andy] Univ Kingston, Sch Life Sci Pharm & Chem, Kingston Upon Thames KT1 2EE, Surrey, England.
   [Schwikkard, Sianne; Whitmore, Hannah; Waller, Catherine; Alqahtani, Alaa; Mas-Claret, Eduard; Langat, Moses K.; Mulholland, Dulcie] Univ Surrey, Fac Engn & Phys Sci, Dept Chem, Nat Prod Res Grp, Guildford GU2 7XH, Surrey, England.
   [Sishtla, Kamakshi; Sulaiman, Rania S.; Shetty, Trupti; Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.; Shetty, Trupti; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1160 West Michigan St, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.] Cairo Univ, Dept Biochem, Fac Pharm, Cairo, Egypt.
   [Crouch, Neil] South African Natl Biodivers Inst, Biodivers Econ, POB 52099,4007 Berea Rd, Durban, South Africa.
   [Wetschnig, Wolfgang; Knirsch, Walter] Karl Franzens Univ Graz, NAWI Graz, Inst Biol, A-8010 Graz, Austria.
   [Andriantiana, Jacky] Parc Bot & Zool Tsimbazaza, Rue Fernand Kassanga, Antananarivo 101, Madagascar.
   [Crouch, Neil; Langat, Moses K.; Mulholland, Dulcie] Univ KwaZulu Natal, Sch Chem & Phys, ZA-4041 Durban, South Africa.
C3 Kingston University; University of Surrey; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Egyptian Knowledge Bank (EKB); Cairo University; South
   African National Biodiversity Institute; University of Graz; University
   of Kwazulu Natal
RP Mulholland, D (通讯作者)，Univ Surrey, Fac Engn & Phys Sci, Dept Chem, Nat Prod Res Grp, Guildford GU2 7XH, Surrey, England.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, 1160 West Michigan St, Indianapolis, IN 46202 USA.; Mulholland, D (通讯作者)，Univ KwaZulu Natal, Sch Chem & Phys, ZA-4041 Durban, South Africa.
EM d.mulholland@surrey.ac.uk; tcorson@iu.edu
RI Corson, Timothy W./B-6851-2009; Mulholland, Dulcie/AAN-2512-2020
OI Corson, Timothy W./0000-0002-1402-7875; Schwikkard,
   Sianne/0000-0002-7200-927X; Langat, Moses K./0000-0001-8079-7774;
   Mulholland, Dulcie/0000-0001-7778-5617; Mas-Claret,
   Eduard/0000-0003-4016-6649
FU University of Surrey; Daphne Jackson Trust; Royal Society of Chemistry;
   NIH/NEI [R01EY025641]; International Retinal Research Foundation;
   Research to Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [R01EY025641] Funding Source: NIH RePORTER
FX H.W. acknowledges a Ph.D. scholarship from the University of Surrey.
   S.S. acknowledges support from the Daphne Jackson Trust, the University
   of Surrey, and the Royal Society of Chemistry for funding. T.W.C.
   acknowledges support from NIH/NEI R01EY025641, the International Retinal
   Research Foundation, and an unrestricted grant from Research to Prevent
   Blindness, Inc. S.S. would also like to acknowledge and thank the EPSRC
   UK National Mass Spectrometry Facility, Swansea, for HRMS analysis.
CR ADINOLFI M, 1988, TETRAHEDRON, V44, P4981, DOI 10.1016/S0040-4020(01)86202-5
   ADINOLFI M, 1984, PHYTOCHEMISTRY, V23, P2091, DOI 10.1016/S0031-9422(00)84989-4
   ADINOLFI M, 1987, PHYTOCHEMISTRY, V26, P285, DOI 10.1016/S0031-9422(00)81529-0
   Alali F, 2015, J NAT PROD, V78, P1708, DOI 10.1021/acs.jnatprod.5b00357
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Aziz AN, 2018, PHYTOCHEMISTRY, V156, P193, DOI 10.1016/j.phytochem.2018.10.002
   Basavarajappa H. D., 2014, PLOS ONE, V9
   Basavarajappa HD, 2017, EMBO MOL MED, V9, P786, DOI 10.15252/emmm.201606561
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   BOHLER P, 1967, TETRAHEDRON LETT, P3479
   CORSARO MM, 1992, PHYTOCHEMISTRY, V31, P1395, DOI 10.1016/0031-9422(92)80299-T
   Corson T. W., 2019, [No title captured], Patent No. [US 10,238,627, 10238627]
   Crouch NR, 1999, PHYTOCHEMISTRY, V51, P943, DOI 10.1016/S0031-9422(99)00154-5
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   FARKAS L, 1971, TETRAHEDRON, V27, P5049, DOI 10.1016/S0040-4020(01)98209-2
   FINCKH RE, 1970, EXPERIENTIA, V26, P472, DOI 10.1007/BF01898447
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Hafez-Ghoran S, 2015, BRAZ J PHARM SCI, V51, P949, DOI 10.1590/S1984-82502015000400020
   Kim JH, 2008, MOL VIS, V14, P556
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Koorbanally NA, 2006, BIOCHEM SYST ECOL, V34, P114, DOI 10.1016/j.bse.2005.08.003
   Lee B, 2014, ORG BIOMOL CHEM, V12, P7673, DOI 10.1039/c4ob01604a
   Liao LX, 2017, P NATL ACAD SCI USA, V114, pE5986, DOI 10.1073/pnas.1706778114
   Lin LG, 2014, PLANTA MED, V80, P1053, DOI 10.1055/s-0034-1383026
   Liu SM, 2008, ANGEW CHEM INT EDIT, V47, P8920, DOI 10.1002/anie.200803709
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Moodley N, 2006, S AFR J BOT, V72, P517, DOI 10.1016/j.sajb.2006.01.004
   Mulholland DA, 2013, NAT PROD REP, V30, P1165, DOI 10.1039/c3np70008a
   Nugroho AE, 2014, J NAT MED-TOKYO, V68, P1, DOI 10.1007/s11418-013-0768-x
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pohl TS, 2000, CURR ORG CHEM, V4, P1287, DOI 10.2174/1385272003375806
   Schwikkard S, 2017, J NAT PROD, V80, P30, DOI 10.1021/acs.jnatprod.6b00240
   Schwikkard SL, 2018, PLANTA MED, V84, DOI 10.1055/a-0577-5322
   Shaikh MM, 2012, NAT PROD RES, V26, P1473, DOI 10.1080/14786419.2011.565004
   Sharma P, 2013, MED CHEM RES, V22, P3969, DOI 10.1007/s00044-012-0401-7
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   SIDWELL WTL, 1970, TETRAHEDRON LETT, P475
   Sihra JK, 2017, RSC ADV, V7, P15416, DOI 10.1039/c6ra28584h
   Sparg SG, 2002, J ETHNOPHARMACOL, V80, P95, DOI 10.1016/S0378-8741(02)00007-7
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sulaiman RS, 2018, ACS CHEM BIOL, V13, P45, DOI 10.1021/acschembio.7b00854
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   TAMM C, 1972, ARZNEI-FORSCHUNG, V22, P1776
   Waller CP, 2013, PHYTOCHEMISTRY, V95, P284, DOI 10.1016/j.phytochem.2013.06.024
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 46
TC 12
Z9 13
U1 1
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD MAY
PY 2019
VL 82
IS 5
BP 1227
EP 1239
DI 10.1021/acs.jnatprod.8b00989
PG 13
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Plant Sciences; Pharmacology & Pharmacy
GA IA2RW
UT WOS:000469410200021
PM 30951308
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Mandai, M
   Watanabe, A
   Kurimoto, Y
   Hirami, Y
   Morinaga, C
   Daimon, T
   Fujihara, M
   Akimaru, H
   Sakai, N
   Shibata, Y
   Terada, M
   Nomiya, Y
   Tanishima, S
   Nakamura, M
   Kamao, H
   Sugita, S
   Onishi, A
   Ito, T
   Fujita, K
   Kawamata, S
   Go, MJ
   Shinohara, C
   Hata, K
   Sawada, M
   Yamamoto, M
   Ohta, S
   Ohara, Y
   Yoshida, K
   Kuwahara, J
   Kitano, Y
   Amano, N
   Umekage, M
   Kitaoka, F
   Tanaka, A
   Okada, C
   Takasu, N
   Ogawa, S
   Yamanaka, S
   Takahashi, M
AF Mandai, M.
   Watanabe, A.
   Kurimoto, Y.
   Hirami, Y.
   Morinaga, C.
   Daimon, T.
   Fujihara, M.
   Akimaru, H.
   Sakai, N.
   Shibata, Y.
   Terada, M.
   Nomiya, Y.
   Tanishima, S.
   Nakamura, M.
   Kamao, H.
   Sugita, S.
   Onishi, A.
   Ito, T.
   Fujita, K.
   Kawamata, S.
   Go, M. J.
   Shinohara, C.
   Hata, K.
   Sawada, M.
   Yamamoto, M.
   Ohta, S.
   Ohara, Y.
   Yoshida, K.
   Kuwahara, J.
   Kitano, Y.
   Amano, N.
   Umekage, M.
   Kitaoka, F.
   Tanaka, A.
   Okada, C.
   Takasu, N.
   Ogawa, S.
   Yamanaka, S.
   Takahashi, M.
TI Autologous Induced Stem-Cell-Derived Retinal Cells for Macular
   Degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; PIGMENT EPITHELIUM; TRANSPLANTATION;
   PREVALENCE; TRANSLOCATION; RPE; RANIBIZUMAB; SURGERY; SHEETS
AB We assessed the feasibility of transplanting a sheet of retinal pigment epithelial (RPE) cells differentiated from induced pluripotent stem cells (iPSCs) in a patient with neovascular age-related macular degeneration. The iPSCs were generated from skin fibroblasts obtained from two patients with advanced neovascular agerelated macular degeneration and were differentiated into RPE cells. The RPE cells and the iPSCs from which they were derived were subject to extensive testing. A surgery that included the removal of the neovascular membrane and transplantation of the autologous iPSC-derived RPE cell sheet under the retina was performed in one of the patients. At 1 year after surgery, the transplanted sheet remained intact, best corrected visual acuity had not improved or worsened, and cystoid macular edema was present. (Funded by Highway Program for Realization of Regenerative Medicine and others; University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000011929.)
C1 [Mandai, M.; Kurimoto, Y.; Hirami, Y.; Fujihara, M.; Yamamoto, M.; Ohta, S.; Takahashi, M.] Fdn Biomed Res & Innovat, Div Ophthalmol, Inst Biomed Res & Innovat Hosp, Kobe, Hyogo, Japan.
   [Mandai, M.; Morinaga, C.; Akimaru, H.; Sakai, N.; Shibata, Y.; Terada, M.; Kamao, H.; Sugita, S.; Onishi, A.; Yamamoto, M.; Takahashi, M.] RIKEN, Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Kurimoto, Y.; Hirami, Y.; Fujihara, M.] Gen Hosp, Kobe City Med Ctr, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Ito, T.; Fujita, K.] Fdn Biomed Res & Innovat, Inst Biomed Res & Innovat Hosp, Dept Clin Trial Management, Kobe, Hyogo, Japan.
   [Kawamata, S.; Go, M. J.] Fdn Biomed Res & Innovat, Res & Dev Ctr Cell Therapy, Kobe, Hyogo, Japan.
   [Watanabe, A.; Nomiya, Y.; Nakamura, M.; Kuwahara, J.; Kitano, Y.; Amano, N.; Umekage, M.; Kitaoka, F.; Tanaka, A.; Takasu, N.; Yamanaka, S.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto, Japan.
   [Watanabe, A.] Kyoto Univ, Inst Integrated Cell Mat Sci iCeMS, Kyoto, Japan.
   [Yoshida, K.; Ogawa, S.] Kyoto Univ, Dept Pathol & Tumor Biol, Grad Sch Med, Kyoto, Japan.
   [Daimon, T.] Hyogo Coll Med, Dept Biostat, Nishinomiya, Hyogo, Japan.
   [Akimaru, H.] Natl Inst Biomed Innovat Hlth & Nutr, Platform Therapeut Rare Dis, Ibaraki, Japan.
   [Tanishima, S.; Ohara, Y.; Okada, C.] Mitsubishi Space Software, Tokyo, Japan.
   [Kamao, H.] Kawasaki Med Sch, Dept Ophthalmol, Kurashiki, Okayama, Japan.
   [Shinohara, C.; Hata, K.] Japan Tissue Engn, Gamagori, Japan.
   [Sawada, M.] HEALIOS KK, Tokyo, Japan.
   [Yamanaka, S.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA.
C3 Institute for Biomedical Research & Innovation (IBRI); RIKEN; Kobe City
   Medical Center General Hospital; Institute for Biomedical Research &
   Innovation (IBRI); Institute for Biomedical Research & Innovation
   (IBRI); Kyoto University; Kyoto University; Kyoto University; Hyogo
   College of Medicine; Kawasaki Medical School; University of California
   System; University of California San Francisco; The J David Gladstone
   Institutes
RP Takahashi, M (通讯作者)，RIKEN, Ctr Develop Biol, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Mina Mimachi, Kobe, Hyogo 6500047, Japan.; Yamanaka, S (通讯作者)，Kyoto Univ, Ctr iPS Cell Res & Applicat, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM yamanaka@cira.kyoto-u.ac.jp; retinalab@cdb.riken.jp
OI Nakamura, Masahiro/0000-0002-4363-069X; kawamata,
   shin/0000-0001-5148-1949; Yoshida, Kenichi/0000-0003-4612-2778; Tanaka,
   Azusa/0000-0002-0503-4176; Kamao, Hiroyuki/0000-0002-2194-7063
FU Highway Program for Realization of Regenerative Medicine; University
   Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR]
   [UMIN000011929]; Grants-in-Aid for Scientific Research [15J04853,
   15K06921] Funding Source: KAKEN
FX Funded by Highway Program for Realization of Regenerative Medicine and
   others; University Hospital Medical Information Network Clinical Trials
   Registry [UMIN-CTR] number, UMIN000011929.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 31
TC 773
Z9 797
U1 9
U2 245
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 16
PY 2017
VL 376
IS 11
BP 1038
EP 1046
DI 10.1056/NEJMoa1608368
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EO0QT
UT WOS:000396403700008
PM 28296613
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Terman, A
   Brunk, UT
AF Terman, A
   Brunk, UT
TI Lipofuscin
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE aging; lipofuscin; lysosomes; oxidative stress
ID AGE-RELATED ACCUMULATION; HUMAN FIBROBLASTS; BRAIN; LOCALIZATION
AB Over time, postmitotic cells accumulate a non-degradable intralysosomal substance, lipofuscin, which forms due to iron-catalyzed oxidation/polymerization of protein and lipid residues. Lipofuscin is often considered a hallmark of aging, showing an accumulation rate that inversely correlates with longevity. There is an emerging impression that lipofuscin, although still typically considered a harmless wear-and-tear product, may have multiple negative effects. By interfering with the important autophagic process, by which most worn out cellular components are degraded, it may prevent cellular renewal and advance the accumulation of damaged cellular constituents. Due to binding of transition metals, such as iron and copper, lipofuscin also seems to sensitize lysosomes and cells to oxidative stress. Of importance for the pathogenesis of age-related macular degeneration, lipofuscin deposition interferes with the phagocytic activity of retinal pigment epithelial cells and also sensitizes their lysosomes to blue light. (C) 2003 Published by Elsevier Ltd.
C1 Linkoping Univ, Fac Hlth Sci, Div Pathol 2, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Brunk, UT (通讯作者)，Linkoping Univ, Fac Hlth Sci, Div Pathol 2, SE-58185 Linkoping, Sweden.
EM ulf.brumk@inr.liu.se
CR Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   BRUN A, 1973, HISTOCHEMISTRY, V34, P333, DOI 10.1007/BF00306305
   BRUNK U, 1972, J ULTRA MOL STRUCT R, V38, P1, DOI 10.1016/S0022-5320(72)90080-9
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Dice J. F., 2000, LYSOSOMAL PATHWAYS P
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Jolly RD, 1995, GERONTOLOGY, V41, P283
   KIKUGAWA K, 1989, ADV EXP MED BIOL, V266, P345
   KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q
   Nakano M, 1995, GERONTOLOGY, V41, P69
   NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257
   Terman A, 1998, MECH AGEING DEV, V104, P277, DOI 10.1016/S0047-6374(98)00073-6
   Terman A, 1999, EXP GERONTOL, V34, P943, DOI 10.1016/S0531-5565(99)00070-4
   Terman A, 2001, REDOX REP, V6, P15, DOI 10.1179/135100001101535996
   Terman A, 1999, EXP GERONTOL, V34, P755, DOI 10.1016/S0531-5565(99)00045-5
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
NR 17
TC 335
Z9 346
U1 6
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD AUG
PY 2004
VL 36
IS 8
BP 1400
EP 1404
DI 10.1016/j.biocel.2003.08.009
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 831OP
UT WOS:000222204400006
PM 15147719
DA 2022-11-30
ER

PT J
AU Platania, CBM
   Drago, F
   Bucolo, C
AF Platania, Chaiara Bianca Maria
   Drago, Filippo
   Bucolo, Claudio
TI The P2X7 receptor as a new pharmacological target for retinal diseases
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Diabetic retinopathy; Age-related macular degeneration; Glaucoma;
   Inflammation
ID P2X(7)-INDUCED PORE FORMATION; GANGLION-CELL FUNCTION;
   DIABETIC-RETINOPATHY; PROGRESSIVE LOSS; MULLER CELLS; MICE; EXPRESSION;
   NEURONS; MODEL; ATP
AB Purinergic ionotropic receptors, such as the P2X7 receptor, are activated by extracellular adenosine triphosphate (ATP). The P2X7 receptor is a trimeric ATP-gated cation channel and its activation results in several downstream events, including the release of proinflammatory mediators and cell damage. The P2X7 receptor has been studied as a pharmacological target for inflammatory and neuroinflammatory diseases, and preclinical studies have recently provided evidence that P2X7 receptor activation is implicated in pathophysiology of several retinal agerelated diseases. These diseases are devastating conditions that have an deep impact on the quality of life of patients and on the health systems of all countries. In this review, we discuss the role of the P2X7 receptor in retinal age-related conditions such as glaucoma, age-related macular degeneration, and diabetic retinopathy. Furthermore, we focus on the pharmacological modulation of the P2X7 receptor that could have a relevant clinical impact to prevent retinal diseases.
C1 [Platania, Chaiara Bianca Maria; Drago, Filippo; Bucolo, Claudio] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Drago, Filippo; Bucolo, Claudio] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy.
C3 University of Catania; University of Catania
RP Bucolo, C (通讯作者)，Via St Sofia 97, I-95125 Catania, Italy.
EM claudio.bucolo@unict.it; claudio.bucolo@unict.it
OI Platania, Chiara Bianca Maria/0000-0002-8630-5993
FU University of Catania; MUR grant PRIN [2020FR7TCL];  [2020/2022]
FX University of Catania research grant PIAno inCEntivi RIcerca (PIA-CERI)
   Ateneo 2020/2022 (NanoRET) , and MUR grant PRIN 2020FR7TCL.
CR Abdulqawi R, 2015, LANCET, V385, P1198, DOI 10.1016/S0140-6736(14)61255-1
   Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601
   Amadio M, 2016, PHARMACOL RES, V111, P713, DOI 10.1016/j.phrs.2016.07.042
   Banitt MR, 2013, INVEST OPHTH VIS SCI, V54, P2346, DOI 10.1167/iovs.12-11026
   Barth K, 2016, HISTOCHEM CELL BIOL, V146, P757, DOI 10.1007/s00418-016-1499-3
   Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003
   Benzaquen J, 2020, THERANOSTICS, V10, P10849, DOI 10.7150/thno.48229
   Brandle U, 1998, MOL BRAIN RES, V62, P106, DOI 10.1016/S0169-328X(98)00254-X
   Bucolo C, 2018, J PHARMACOL SCI, V138, P219, DOI 10.1016/j.jphs.2018.11.001
   Bucolo C, 2018, CURR NEUROPHARMACOL, V16, P978, DOI 10.2174/1570159X15666170915142727
   Bucolo C, 2015, CURR PHARM DESIGN, V21, P4673, DOI 10.2174/1381612821666150909095553
   Campagno KE, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02251-7
   Campagno KE, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.645244
   Carvalho K, 2021, PROG NEUROBIOL, V206, DOI 10.1016/j.pneurobio.2021.102139
   Carver KA, 2017, BIOCHEM BIOPH RES CO, V482, P81, DOI 10.1016/j.bbrc.2016.10.140
   Clapp C, 2019, ACTA DIABETOL, V56, P1031, DOI 10.1007/s00592-019-01343-4
   Danquah W, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8463
   Dentchev T., 2003, MOL VISION
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Diabetic Retinopathy Clinical Research Network*, 2013, JAMA Ophthalmol, V131, P283, DOI 10.1001/jamaophthalmol.2013.2015
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Diezmos EF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00865
   Dong LD, 2018, MOL MED REP, V17, P2289, DOI 10.3892/mmr.2017.8137
   Dutot Melody, 2017, Vision (Basel), V1, DOI 10.3390/vision1020014
   Eggers M, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2020.114394
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Fountain SJ, 2009, PURINERG SIGNAL, V5, P269, DOI 10.1007/s11302-008-9127-x
   Franceschini A, 2015, FASEB J, V29, P2450, DOI 10.1096/fj.14-268714
   Fresta CG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239305
   Grygorowicz T, 2018, PURINERG SIGNAL, V14, P385, DOI 10.1007/s11302-018-9620-9
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454
   Ho T, 2016, J OCUL PHARMACOL TH, V32, P509, DOI 10.1089/jop.2015.0158
   Hoyle CHV, 2011, AUTON NEUROSCI-BASIC, V165, P28, DOI 10.1016/j.autneu.2010.05.007
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Illes P, 2021, BRIT J PHARMACOL, V178, P489, DOI 10.1111/bph.15299
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jacobson KA, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2020.114311
   Jacobson KA, 2013, J MED CHEM, V56, P3749, DOI 10.1021/jm400422s
   Jain S, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2020.114393
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karasawa A, 2016, ELIFE, V5, DOI 10.7554/eLife.22153
   Kawamura H, 2003, J PHYSIOL-LONDON, V551, P787, DOI 10.1113/jphsiol.2003.047977
   Kennedy C, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114408
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Lara R, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00793
   Lee JWY, 2019, ASIA-PAC J OPHTHALMO, V8, P457, DOI 10.1097/01.APO.0000605096.48529.9c
   Martinez FJ, 2021, PULM THER, V7, P471, DOI 10.1007/s41030-021-00162-9
   Martinez-Frailes C, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00143
   McCarthy AE, 2019, CELL, V179, P659, DOI 10.1016/j.cell.2019.09.017
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Nagaraju M, 2007, INVEST OPHTH VIS SCI, V48, P4573, DOI 10.1167/iovs.07-0582
   Oliveira-Giacomelli A, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.662935
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Pannuzzo M, 2018, ELIFE, V7, DOI 10.7554/eLife.39441
   Pavlou S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092101
   Pegoraro A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03058-9
   de Lara MJP, 2019, BRAIN RES BULL, V150, P61, DOI 10.1016/j.brainresbull.2019.05.006
   Platania CBM, 2021, METHODS MOL BIOL, V2253, P245, DOI 10.1007/978-1-0716-1154-8_14
   Platania CBM, 2019, BIOCHEM PHARMACOL, V168, P249, DOI 10.1016/j.bcp.2019.07.010
   Platania CBM, 2017, BIOCHEM PHARMACOL, V138, P130, DOI 10.1016/j.bcp.2017.05.001
   Portillo JAC, 2017, DIABETES, V66, P483, DOI 10.2337/db16-0051
   Resta V, 2007, EUR J NEUROSCI, V25, P2741, DOI 10.1111/j.1460-9568.2007.05528.x
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Romano GL, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114199
   Ruan Z, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00396-2
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shibata Maho, 2018, Vision (Basel), V2, DOI 10.3390/vision2030025
   Spadaro A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00708
   Stokes L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00258
   Sugiyama T, 2005, AM J PHYSIOL-CELL PH, V288, pC568, DOI 10.1152/ajpcell.00380.2004
   Sugiyama T, 2004, INVEST OPHTH VIS SCI, V45, P1026, DOI 10.1167/iovs.03-1062
   Tassetto M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137110
   Vallee M, 2014, SCIENCE, V343, P94, DOI 10.1126/science.1243985
   Ventura LM, 2012, INVEST OPHTH VIS SCI, V53, P659, DOI 10.1167/iovs.11-8525
   Verkhratsky A, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2020.114261
   Verkhratsky A, 2014, BIOESSAYS, V36, P697, DOI 10.1002/bies.201400024
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2012, PLOS ONE, V7, P290, DOI 10.1371/journal.pone.0029990
   Wang AYM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83669-0
   Wang MW, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2021-000774
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Wiprich MT, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.657338
   Wu GN, 2014, INFECT GENET EVOL, V24, P82, DOI 10.1016/j.meegid.2014.03.006
   Wu XW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04231-5
   Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983
   Yang MZ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5520644
   Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016
   Zhang YJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107771
NR 91
TC 3
Z9 3
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR
PY 2022
VL 198
AR 114942
DI 10.1016/j.bcp.2022.114942
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZY5LO
UT WOS:000772628100002
PM 35134386
DA 2022-11-30
ER

PT J
AU Dhurandhar, D
   Sahoo, NK
   Mariappan, I
   Narayanan, R
AF Dhurandhar, Deven
   Sahoo, Niroj Kumar
   Mariappan, Indumathi
   Narayanan, Raja
TI Gene therapy in retinal diseases: A review
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Adeno-associated viral vectors (AAVs); age-related macular degeneration
   (AMD); gene delivery systems; gene therapy; inherited retinal diseases;
   Luxturna; non-inherited retinal diseases; visual cycle; voretigene
   neparvovec
ID LEBER CONGENITAL AMAUROSIS; MACULAR DEGENERATION; BINDING PROTEIN;
   OPEN-LABEL; MUTATION; VECTOR; PHENOTYPE; DYSTROPHY; NEOVASCULARIZATION;
   PHASE-1
AB Over 2 million people worldwide are suffering from gene-related retinal diseases, inherited or acquired, and over 270 genes have been identified which are found to be responsible for these conditions. This review article touches upon the mechanisms of gene therapy, various enzymes of the visual cycle responsible for different genetic diseases, Luxturna-the first US Food and Drug Administration (FDA)-approved therapeutic gene product, and several ongoing trials of gene therapy for age-related macular degeneration. Gene therapy has tremendous potential for retinal conditions due to its ease of accessibility, immune-privileged status, and tight blood-retinal barriers, limiting systemic side effects of the drug. In recent years, advances in gene therapy in retinal conditions have increasing significantly, with progress in cell-specific targeting and transduction efficiency of gene products through the use of adeno-associated viral vectors (AAVs), suggesting that even greater success in future clinical trials is possible.
C1 [Dhurandhar, Deven] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
   [Sahoo, Niroj Kumar; Narayanan, Raja] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr VitreoRetinal Dis, Kallam Anji Reddy Campus, Hyderabad, Telangana, India.
   [Mariappan, Indumathi] LV Prasad Eye Inst, Ctr Ocular Regenerat, Hyderabad Eye Res Fdn, Kallam Anji Reddy Campus, Hyderabad, Telangana, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute
RP Narayanan, R (通讯作者)，LV Prasad Eye Inst, Suven Clin Res Ctr, Head Operat & Syst, Banjara Hills, Hyderabad 500034, Telangana, India.
EM narayanan@lvpei.org
RI Sahoo, Niroj/AHD-3438-2022; Sahoo, Niroj/AHD-3511-2022
CR Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Alswailmi FK, 2018, PAK J MED SCI, V34, P751, DOI 10.12669/pjms.343.14510
   Anand V, 2002, MOL THER, V5, P125, DOI 10.1006/mthe.2002.0525
   Arno G, 2015, INVEST OPHTH VIS SCI, V56, P2358, DOI 10.1167/iovs.15-16520
   Bainbridge JWB, 2006, GENE THER, V13, P1191, DOI 10.1038/sj.gt.3302812
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200
   Borman AD, 2012, INVEST OPHTH VIS SCI, V53, P3927, DOI 10.1167/iovs.12-9548
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Chaum E, 2002, SURV OPHTHALMOL, V47, P449, DOI 10.1016/S0039-6257(02)00336-3
   Conley SM, 2008, CURR OPIN MOL THER, V10, P456
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   den Hollander AI, 2009, INVEST OPHTH VIS SCI, V50, P1864, DOI 10.1167/iovs.08-2497
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   GEORGE NDL, 1995, BRIT J OPHTHALMOL, V79, P697, DOI 10.1136/bjo.79.7.697
   Ghosh D, 2007, MOL VIS, V13, P2275
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   HUBBARD R, 1958, P NATL ACAD SCI USA, V44, P130, DOI 10.1073/pnas.44.2.130
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Koenekoop Robert K, 2003, Ophthalmic Genet, V24, P75, DOI 10.1076/opge.24.2.75.13996
   Komor AC, 2017, CELL, V168, P20, DOI 10.1016/j.cell.2016.10.044
   Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3
   Lai LJ, 2007, J BIOMED SCI, V14, P313, DOI 10.1007/s11373-007-9153-7
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Liu YY, 2018, MOL THER, V26, P542, DOI 10.1016/j.ymthe.2017.12.002
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Park Paul Shin-Hyun, 2014, Adv Pharmacol, V70, P1, DOI 10.1016/B978-0-12-417197-8.00001-8
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Perrault Isabelle, 2007, Hum Mutat, V28, P416, DOI 10.1002/humu.9485
   PFEFFER B, 1983, J CELL PHYSIOL, V117, P333, DOI 10.1002/jcp.1041170308
   Pichi F, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/634351
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sahu B, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110746
   Schuster A, 2007, INVEST OPHTH VIS SCI, V48, P1824, DOI 10.1167/iovs.06-0628
   Skorczyk-Werner A, 2015, J APPL GENET, V56, P317, DOI 10.1007/s13353-015-0281-x
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Trapani I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040287
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Willett K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00261
   Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009
NR 56
TC 7
Z9 7
U1 2
U2 6
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2021
VL 69
IS 9
BP 2257
EP 2265
DI 10.4103/ijo.IJO_3117_20
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YN2DP
UT WOS:000747074100006
PM 34427196
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Greco, A
   Garoffolo, G
   Chiesa, E
   Riva, F
   Dorati, R
   Modena, T
   Conti, B
   Pesce, M
   Genta, I
AF Greco, A.
   Garoffolo, G.
   Chiesa, E.
   Riva, Federica
   Dorati, R.
   Modena, T.
   Conti, B.
   Pesce, M.
   Genta, I.
TI Nanotechnology, a booster for the multitarget drug verteporfin
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Review
DE Nanotechnology; Verteporfin; Drug delivery systems; Photodynamic
   therapy; Cancer; Hippo pathway
ID BENZOPORPHYRIN DERIVATIVE BPD; BLOOD-BRAIN-BARRIER; RING-A BPD;
   PHOTODYNAMIC THERAPY; DELIVERY SYSTEMS; FOLIC-ACID; CHOROIDAL
   NEOVASCULARIZATION; YAP; NANOPARTICLES; CANCER
AB In these recent years nanotechnology has gained interest as a powerful tool for drug delivery. It allows to overcome important drawbacks such as drug poor physico-chemical proprieties, toxicity and bioavailability challenges thereby ensuring better therapeutic efficacy with low side-effects and, sometimes, it permits to discover new drug applications. This review aims to analyse the impact of nanotechnology in the pharmaceutical development of VERTEPORFIN (VP), a benzoporphyrin derivative, which was conceived as second generation photosensitizer (PS) in photodynamic therapy (PDT), and later became a milestone in ophthalmology for treating age-related macular degeneration (AMD) disease. VP photoinduced and non-photoinduced biological features will be surveyed and nanotechnology implication in improving VP performances outlined. Currently, VP loaded nanostructured delivery systems (VP-nanoSs), administered alone or in combination with other drugs, are widely studied for the treatment of many widespread diseases including several tumoral forms and severe fibrotic conditions.
C1 [Greco, A.; Dorati, R.; Modena, T.; Conti, B.; Genta, I.] Univ Pavia, Dept Drug Sci, I-27100 Pavia, Italy.
   [Garoffolo, G.; Pesce, M.] IRCCS, Ctr Cardiol Monzino, Unit Cardiovasc Tissue Engn, I-20138 Milan, Italy.
   [Chiesa, E.] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy.
   [Riva, Federica] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Histol & Embryol Unit, Pavia, Italy.
C3 University of Pavia; IRCCS Centro Cardiologico Monzino; University of
   Pavia; University of Pavia
RP Genta, I (通讯作者)，Vle Taramelli 12, I-27100 Pavia, Italy.
EM ida.genta@unipv.it
RI Conti, Bice/AAC-7792-2022; Chiesa, Enrica/AFL-7651-2022; Pesce,
   Maurizio/AAA-4207-2019; Chiesa, Enrica/AAG-7581-2022
OI Conti, Bice/0000-0002-0034-2815; Pesce, Maurizio/0000-0002-3097-8961;
   RIVA, FEDERICA/0000-0001-9000-1696; Dorati,
   Rossella/0000-0001-5774-9547; CHIESA, ENRICA/0000-0002-6248-3795
CR Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24
   Almerie MQ, 2017, PHOTODIAGN PHOTODYN, V20, P276, DOI 10.1016/j.pdpdt.2017.10.021
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Banerjee SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020483
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Bernstein ZP, 2008, CURR HIV RES, V6, P152, DOI 10.2174/157016208783885001
   Biju V, 2014, CHEM SOC REV, V43, P744, DOI 10.1039/c3cs60273g
   Blair HA, 2020, DRUGS, V80, P1235, DOI 10.1007/s40265-020-01357-1
   BOEHNCKE WH, 1994, LANCET, V343, P801, DOI 10.1016/S0140-6736(94)91883-X
   Boehncke WH, 2000, ARCH DERMATOL, V136, P271, DOI 10.1001/archderm.136.2.271
   Brown S B, 2001, Expert Opin Pharmacother, V2, P351
   Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756
   Castillo JJ, 2013, J MATER CHEM B, V1, P1475, DOI 10.1039/c2tb00434h
   Chen WJ, 2018, J MATER CHEM B, V6, P5269, DOI 10.1039/c8tb00994e
   Chiesa E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030260
   Chiesa E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246212
   Chiesa E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082310
   Chiesa E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082304
   Chiesa E, 2017, J PHARM SCI-US, V106, P3631, DOI 10.1016/j.xphs.2017.08.004
   Choi S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165775
   Clement S, 2018, INT J NANOMED, V13, P3553, DOI 10.2147/IJN.S164967
   Cromarty R, 2020, AIDS RES TREAT, V2020, DOI 10.1155/2020/8672850
   Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127
   Deng W, 2020, ACS CENTRAL SCI, V6, P715, DOI 10.1021/acscentsci.9b01121
   Deng W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05118-3
   Diaz U, 2013, CHEM SOC REV, V42, P4083, DOI 10.1039/c2cs35385g
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006
   Dong XW, 2018, THERANOSTICS, V8, P1481, DOI 10.7150/thno.21254
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Driscoll TP, 2015, BIOPHYS J, V108, P2783, DOI 10.1016/j.bpj.2015.05.010
   Elosegui-Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008
   Fang C, 2015, ACS APPL MATER INTER, V7, P6674, DOI 10.1021/am5092165
   Fang ZY, 2016, BIOMATERIALS, V97, P110, DOI 10.1016/j.biomaterials.2016.04.021
   Feng JT, 2016, ONCOTARGETS THER, V9, P5371, DOI 10.2147/OTT.S109979
   Gao KP, 2006, INT J PHARMACEUT, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040
   Garoffolo G, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101419
   Garoffolo G, 2018, VASC PHARMACOL, V111, P7, DOI 10.1016/j.vph.2018.06.013
   Gertz ZM, 2019, JACC-CARDIOONCOL, V1, P221, DOI 10.1016/j.jaccao.2019.11.004
   Ghoncheh Mahshid, 2016, Asian Pac J Cancer Prev, V17, P43
   Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048
   Gisondi P, 2019, CURR OPIN PHARMACOL, V46, P90, DOI 10.1016/j.coph.2019.05.007
   Gomez VE, 2015, SEMIN CANCER BIOL, V35, P11, DOI 10.1016/j.semcancer.2015.09.011
   Gu C., 2020, SCI BULL, V66, P925, DOI [DOI 10.1016/J.SCIB.2020.12.005, 10.1016/j.scib.2020.12.005]
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Hambsch P, 2017, ONCOTARGET, V8, P72411, DOI 10.18632/oncotarget.20403
   Han HS, 2016, ACS NANO, V10, P10858, DOI 10.1021/acsnano.6b05113
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XY, 2014, NANOMATER NANOTECHNO, V4, DOI 10.5772/58290
   Huber G, 2001, Semin Ophthalmol, V16, P213, DOI 10.1076/soph.16.4.213.10294
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Jadia R, 2018, PHOTOCHEM PHOTOBIOL, V94, P765, DOI 10.1111/php.12903
   Jiang D, 2019, ACTA BIOMATER, V88, P406, DOI 10.1016/j.actbio.2019.02.009
   Jori, 1987, LIPOSOMES CARRIERS H, V847
   Juzeniene A, 2007, PHOTODIAGN PHOTODYN, V4, P3, DOI 10.1016/j.pdpdt.2006.11.002
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kaneko K, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0956-7
   Karnkaew A, 2016, ACS NANO, V10, P3918, DOI 10.1021/acsnano.6b01401
   Kessel D, 2017, PHOTOCHEM PHOTOBIOL, V93, P609, DOI 10.1111/php.12692
   Kessel D, 2016, PHOTOCHEM PHOTOBIOL, V92, P620, DOI 10.1111/php.12592
   Kessel D, 2014, PHOTOCHEM PHOTOBIOL, V90, P889, DOI 10.1111/php.12270
   Khan DR, 2008, CHEM BIOL DRUG DES, V71, P3, DOI 10.1111/j.1747-0285.2007.00610.x
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Kydd J, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040226
   Laffleur F, 2020, INT J PHARM-X, V2, DOI 10.1016/j.ijpx.2020.100050
   Lebedeva NS, 2020, MOLECULES, V25, DOI 10.3390/molecules25194368
   Leng ZG, 2017, AUTOPHAGY, V13, P1404, DOI 10.1080/15548627.2017.1328347
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   LOY DA, 1995, CHEM REV, V95, P1431, DOI 10.1021/cr00037a013
   Ma J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073261
   Mamaeva V, 2013, ADV DRUG DELIVER REV, V65, P689, DOI 10.1016/j.addr.2012.07.018
   Mammoto A, 2009, CURR OPIN CELL BIOL, V21, P864, DOI 10.1016/j.ceb.2009.08.001
   Marino M., 2020, PHARMACEUTICS
   [Anonymous], 2016, Nat Rev Dis Primers, V2, P16073, DOI [10.1038/nrdp.2016.72, 10.1038/nrdp.2016.73]
   Martela F, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00363
   Master A, 2013, J CONTROL RELEASE, V168, P88, DOI 10.1016/j.jconrel.2013.02.020
   Mbah CC, 2014, EXPERT OPIN DRUG DEL, V11, P45, DOI 10.1517/17425247.2013.860130
   Meroni D, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8110891
   Michy T, 2019, CANCERS, V11, DOI 10.3390/cancers11111760
   MILLER H, 1993, ARCH OPHTHALMOL-CHIC, V111, P855, DOI 10.1001/archopht.1993.01090060145039
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Molinaro R, 2018, CURR MED CHEM, V25, P4208, DOI 10.2174/0929867324666170920160030
   Morales-Cruz M, 2019, DRUG DES DEV THER, V13, P3753, DOI 10.2147/DDDT.S219489
   Morizur L, 2020, MOL CELL NEUROSCI, V107, DOI 10.1016/j.mcn.2020.103523
   Mosqueira D, 2014, ACS NANO, V8, P2033, DOI 10.1021/nn4058984
   Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006
   Narod S, 2016, NAT REV CLIN ONCOL, V13, P255, DOI 10.1038/nrclinonc.2015.224
   NEYNDORFF HC, 1990, TRANSFUSION, V30, P485, DOI 10.1046/j.1537-2995.1990.30690333476.x
   NORTH J, 1993, J PHOTOCH PHOTOBIO B, V17, P99, DOI 10.1016/1011-1344(93)80002-Q
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Pattni BS, 2015, CHEM REV, V115, P10938, DOI 10.1021/acs.chemrev.5b00046
   Pellosi DS, 2019, MOL PHARMACEUT, V16, P1009, DOI 10.1021/acs.molpharmaceut.8b01001
   Pocaterra A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.230425
   Poh YC, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1873
   Rak J, 2019, ANTICANCER RES, V39, P3323, DOI 10.21873/anticanres.13475
   Ren WX, 2015, CHEM COMMUN, V51, P10403, DOI 10.1039/c5cc03075g
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   RICHTER AM, 1992, BIOCHEM PHARMACOL, V43, P2349, DOI 10.1016/0006-2952(92)90313-8
   Rizvi I, 2019, PHOTOCHEM PHOTOBIOL, V95, P419, DOI 10.1111/php.13066
   Rizzi M, 2017, J PHOTOCH PHOTOBIO B, V167, P1, DOI 10.1016/j.jphotobiol.2016.12.021
   Salleh NM, 2021, DRUG ALCOHOL DEPEN, V218, DOI 10.1016/j.drugalcdep.2020.108342
   Santoro R, 2018, BIOMATERIALS, V181, P268, DOI 10.1016/j.biomaterials.2018.07.033
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Shanti B. Vijaya, 2011, IMPERATIVE NOTE NOVE, V2, P7
   Shi XT, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1560
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Sneider Alexandra, 2017, Oncomedicine, V2, P1, DOI 10.7150/oncm.17406
   Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454
   Sulaiman A, 2019, MOL CANCER THER, V18, P1755, DOI 10.1158/1535-7163.MCT-18-0873
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Tokarska K, 2016, J PHARMACEUT BIOMED, V127, P39, DOI 10.1016/j.jpba.2016.02.052
   Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   Wachowska M, 2015, CENT EUR J IMMUNOL, V40, P481, DOI 10.5114/ceji.2015.56974
   Wang, 2016, AM J CANCER RES
   Weijer R, 2015, J PHOTOCH PHOTOBIO C, V23, P103, DOI 10.1016/j.jphotochemrev.2015.05.002
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007
   Yanovsky RL, 2019, PHOTODERMATOL PHOTO, V35, P295, DOI 10.1111/phpp.12489
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zhang XZ, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119724
   Zhang YM, 2016, INT J NANOMED, V11, P1119, DOI [10.2147/IJN.S101649, 10.2147/UN.S101649]
   Zhou Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0898-7
   Zhou ZJ, 2016, CHEM SOC REV, V45, P6597, DOI 10.1039/c6cs00271d
   Zielonka J, 2017, CHEM REV, V117, P10043, DOI 10.1021/acs.chemrev.7b00042
NR 135
TC 0
Z9 0
U1 3
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773-2247
EI 2588-8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD AUG
PY 2021
VL 64
AR 102562
DI 10.1016/j.jddst.2021.102562
EA MAY 2021
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TL1HZ
UT WOS:000674607000006
DA 2022-11-30
ER

PT J
AU Adam, MK
   Aenchbacher, W
   Kurzweg, T
   Hsu, J
AF Adam, Murtaza K.
   Aenchbacher, Weston
   Kurzweg, Timothy
   Hsu, Jason
TI Plenoptic Ophthalmoscopy: A Novel Imaging Technique
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID SMARTPHONE OPHTHALMOSCOPY; PHOTOGRAPHY; RETINOPATHY
AB This prospective retinal imaging case series was designed to establish feasibility of plenoptic ophthalmoscopy (PO), a novel mydriatic fundus imaging technique. A custom variable intensity LED array light source adapter was created for the Lytro Gen1 light-field camera (Lytro, Mountain View, CA). Initial PO testing was performed on a model eye and rabbit fundi. PO image acquisition was then performed on dilated human subjects with a variety of retinal pathology and images were subjected to computational enhancement. The Lytro Gen1 light-field camera with custom LED array captured fundus images of eyes with diabetic retinopathy, age-related macular degeneration, retinal detachment, and other diagnoses. Post-acquisition computational processing allowed for refocusing and perspective shifting of retinal PO images, resulting in improved image quality. The application of PO to image the ocular fundus is feasible. Additional studies are needed to determine its potential clinical utility.
C1 [Adam, Murtaza K.; Hsu, Jason] Thomas Jefferson Univ, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   [Aenchbacher, Weston; Kurzweg, Timothy] Drexel Univ, Dept Elect & Comp Engn, Philadelphia, PA 19104 USA.
C3 Jefferson University; Drexel University
RP Hsu, J (通讯作者)，Thomas Jefferson Univ, Ophthalmol, Mid Atlantic Retina, Retina Serv,Wills Eye Hosp, Philadelphia, PA 19107 USA.
EM jhsu@midatlan-ticretina.com
OI Adam, Murtaza/0000-0003-2689-7111
FU Heed Ophthalmic Foundation
FX Murtaza K. Adam, MD, was supported by a grant from the Heed Ophthalmic
   Foundation. The Wills Innovation Grant Committee had no role in the
   design or conduct of the study; collection, management, analysis, or
   interpretation of the data; in the preparation, review, or approval of
   the manuscript; or the decision to submit the manuscript for
   publication.
CR Adam MK, 2015, OSLI RETINA, V46, P631, DOI 10.3928/23258160-20150610-06
   Bastawrous A, 2012, OPHTHALMOLOGY, V119, P432, DOI 10.1016/j.ophtha.2011.11.014
   Dansereau D. G, LIGHT FIELD TOOLBOX
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Haddock LJ, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518479
   Lamirel C, 2012, ARCH OPHTHALMOL-CHIC, V130, P939, DOI 10.1001/archophthalmol.2011.2488
   Lord RK, 2010, OPHTHALMOLOGY, V117, P1274, DOI 10.1016/j.ophtha.2010.01.001
   Myung D., 2014, J MOB TECHNOL MED, V3, P9, DOI 10.7309/jmtm.3.1.3
   Ng R., 2005, LIGHT FIELD PHOTOGRA, V2
   Russo A, 2015, AM J OPHTHALMOL, V159, P360, DOI 10.1016/j.ajo.2014.11.008
   Ryan ME, 2015, OPHTHALMOLOGY, V122, P2038, DOI 10.1016/j.ophtha.2015.06.011
NR 11
TC 3
Z9 3
U1 0
U2 16
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV
PY 2016
VL 47
IS 11
BP 1038
EP 1043
DI 10.3928/23258160-20161031-08
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3HY
UT WOS:000393104400008
PM 27842198
DA 2022-11-30
ER

PT J
AU Du, FX
   Gao, L
   Li, L
   Li, Q
   Wang, FH
   Zhou, CQ
   Dai, CX
AF Du, Fengxian
   Gao, Lei
   Li, Lin
   Li, Qian
   Wang, Fenghua
   Zhou, Chuanqing
   Dai, Cuixia
TI In vivo evaluation of laser-induced choroidal neovascularization in rats
   simultaneously using optical coherence tomography and photoacoustic
   microscopy
SO JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES
LA English
DT Article
DE Optical coherence tomography; photoacoustic microscopy; medical and
   biological imaging
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; OCT ANGIOGRAPHY;
   PREVALENCE; DECORRELATION; VASCULATURE; CELLS
AB Determination of the precise location and the degree of the Choroidal neovascularization (CNV) lesion is essential for diagnosation Neovascular age-related macular degeneration (AMD) and evaluation the efficacy of treatment. Noninvasive imaging techniques with specific contrast for CNV evaluation are demanded. In this paper, two noninvasive imaging techniques, namely Optical coherence tomography (OCT) and Photoacoustic microscopy (PAM), are combined to provide specific detection of CNV for their complimentary contrast mechanisms. In vivo time-serial evaluation of Laser-induced CNV in rats is present at days 1, 3, 5, 7, 14, 21 after laser photocoagulation is applied to the rat fundus. Both OCT and PAM show that the CNV increases to its maximum at day 7 and decreases at day 14. Quantification of CNV area and CNV thickness is given. The dual-modal information of CNV is consistent with the histologic evaluation by hematoxylin and eosin (H&E) staining.
C1 [Du, Fengxian; Gao, Lei; Dai, Cuixia] Shanghai Inst Technol, Shanghai, Peoples R China.
   [Li, Lin; Li, Qian; Wang, Fenghua; Zhou, Chuanqing] Shanghai Jiao Tong Univ, Shanghai, Peoples R China.
C3 Shanghai Institute of Technology; Shanghai Jiao Tong University
RP Dai, CX (通讯作者)，Shanghai Inst Technol, Shanghai, Peoples R China.; Zhou, CQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai, Peoples R China.
EM zhoucq@sjtu.edu.cn; sdadai7412@163.com
FU Natural National Science Foundation of China [61675134, 61307015,
   81827807, 68175123]; Science and Technology innovation project of
   Shanghai Science and Technology Commission [19441905800]; Project of
   State Key Laboratory of Ophthalmology, Optometry and Visual Science,
   Wenzhou Medical University [K181002]
FX This work was supported by the Natural National Science Foundation of
   China (Grant Nos. 61675134, 61307015, 81827807 and 68175123), Science
   and Technology innovation project of Shanghai Science and Technology
   Commission (19441905800), Project of State Key Laboratory of
   Ophthalmology, Optometry and Visual Science, Wenzhou Medical University
   (K181002). Fengxian Du and Lei Gao are the co first authors for this
   paper.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Chen RX, 2020, IEEE T MED IMAGING, V39, P4286, DOI 10.1109/TMI.2020.3016334
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P41, DOI 10.1007/s004170000205
   Hou HY, 2011, OPHTHALMIC RES, V45, P1, DOI 10.1159/000313983
   Huang LZ, 2019, IEEE T MED IMAGING, V38, P2695, DOI 10.1109/TMI.2019.2910871
   Jiao J, 2013, GRAEF ARCH CLIN EXP, V251, P301, DOI 10.1007/s00417-012-2204-4
   Li L, 2015, OPT LETT, V40, P4448, DOI 10.1364/OL.40.004448
   Liu T, 2013, GRAEF ARCH CLIN EXP, V251, P1293, DOI 10.1007/s00417-012-2185-3
   Liu XJ, 2015, OPT LETT, V40, P1370, DOI 10.1364/OL.40.001370
   Nguyen V.P., 2018, J IMAGING, V4, P1
   Qiao W, 2017, J INNOV OPT HEAL SCI, V10, DOI 10.1142/S1793545817300063
   Semkova I, 2006, FASEB J, V20, P1689, DOI 10.1096/fj.05-5653fje
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wei Q, 2011, J MOD OPTIC, V58, P1997, DOI 10.1080/09500340.2011.601331
   Xiao MC, 2020, OPHTHALMIC RES, V63, P271, DOI 10.1159/000502800
   Yang ZH, 2020, J INNOV OPT HEAL SCI, V13, DOI 10.1142/S1793545820500108
   Zhao Shi-hong, 2003, Zhonghua Yan Ke Za Zhi, V39, P298
NR 22
TC 3
Z9 3
U1 5
U2 18
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 1793-5458
EI 1793-7205
J9 J INNOV OPT HEAL SCI
JI J. Innov. Opt. Health Sci.
PD MAY
PY 2021
VL 14
IS 03
AR 2140012
DI 10.1142/S1793545821400125
PG 9
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA SK4BM
UT WOS:000656163100002
OA gold
DA 2022-11-30
ER

PT J
AU Kutty, RK
   Samuel, W
   Duncan, T
   Postnikova, O
   Jaworski, C
   Nagineni, CN
   Redmond, TM
AF Kutty, R. Krishnan
   Samuel, William
   Duncan, Todd
   Postnikova, Olga
   Jaworski, Cynthia
   Nagineni, Chandrasekharam N.
   Redmond, T. Michael
TI Proinflammatory cytokine interferon-gamma increases the expression of
   BANCR, a long non-coding RNA, in retinal pigment epithelial cells
SO CYTOKINE
LA English
DT Article
DE BRAF-activated non-coding RNA (BANCR); Long non-coding RNA (lncRNA);
   Interferon-gamma; JAK-STAT1 signaling; Retinal pigment epithelium;
   Age-related macular degeneration
ID MIGRATION; ARPE-19
AB The inflammatory response may contribute to retinal pigment epithelial (RPE) dysfunction associated with the pathogenesis of age-related macular degeneration (AMD). We investigated whether the inflammatory response affects the expression of long coding RNAs (lncRNAs) in human RPE-derived ARPE-19 cells. This class of regulatory RNA molecules recently came to prominence due to their involvement in many pathophysiological processes. A proinflammatory cytokine mixture consisting of IFN-gamma, IL-1 beta and TNF-alpha altered the expression several lncRNAs including BANCR in these cells. The cytokine responsible for increasing BANCR expression in ARPE-19 cells was found to be IFN-gamma. BANCR expression induced by IFN-gamma was suppressed when STAT1 phosphorylation was blocked by JAK inhibitor 1. Thus, proinflammatory cytokines could modulate the expression of lncRNAs in RPE cells and IFN-gamma could upregulate the expression of BANCR by activating JAK-STAT1 signaling pathway.
C1 [Kutty, R. Krishnan; Samuel, William; Duncan, Todd; Postnikova, Olga; Jaworski, Cynthia; Redmond, T. Michael] NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Room 112,6 Ctr Dr,MSC 0608, Bethesda, MD 20892 USA.
   [Nagineni, Chandrasekharam N.] NCI, Radiat Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Kutty, RK (通讯作者)，NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Room 112,6 Ctr Dr,MSC 0608, Bethesda, MD 20892 USA.
EM kuttyk@nei.nih.gov
OI Redmond, T. Michael/0000-0002-1813-5291
FU National Eye Institute, NIH; NATIONAL EYE INSTITUTE [ZIAEY000444]
   Funding Source: NIH RePORTER
FX This study was supported by the Intramural Research Program of the
   National Eye Institute, NIH.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Flockhart RJ, 2012, GENOME RES, V22, P1006, DOI 10.1101/gr.140061.112
   Heward JA, 2014, TRENDS IMMUNOL, V35, P408, DOI 10.1016/j.it.2014.07.005
   Kutty RK, 2016, MOL VIS, V22, P1156
   Kutty RK, 2015, CYTOKINE, V74, P335, DOI 10.1016/j.cyto.2015.03.016
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Quo QH, 2014, ONCOL LETT, V8, P869, DOI 10.3892/ol.2014.2154
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Samuel W, 2017, MOL VIS, V23, P60
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Su SZ, 2015, TUMOR BIOL, V36, P7205, DOI 10.1007/s13277-015-3413-3
   Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68
NR 14
TC 19
Z9 19
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD APR
PY 2018
VL 104
BP 147
EP 150
DI 10.1016/j.cyto.2017.10.009
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA GB9KX
UT WOS:000429393800024
PM 29054724
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Reinhard, J
   Roll, L
   Faissner, A
AF Reinhard, Jacqueline
   Roll, Lars
   Faissner, Andreas
TI Tenascins in Retinal and Optic Nerve Neurodegeneration
SO FRONTIERS IN INTEGRATIVE NEUROSCIENCE
LA English
DT Review
DE extracellular matrix; glaucoma; glycoprotein; neurodegeneration; optic
   nerve; retina; tenascin-C; tenascin-R
ID AUTOIMMUNE GLAUCOMA MODEL; TRABECULAR MESHWORK CELLS; OPEN-ANGLE
   GLAUCOMA; PROLIFERATIVE DIABETIC-RETINOPATHY; EXTRACELLULAR-MATRIX
   COMPARTMENT; CHOROIDAL NEOVASCULAR MEMBRANES; TYROSINE
   PHOSPHATASE-ZETA/BETA; PROMOTES NEURITE OUTGROWTH; SENSORY AXON
   REGENERATION; GROWTH-FACTOR-BETA
AB Tenascins represent key constituents of the extracellular matrix (ECM) with major impact on central nervous system (CNS) development. In this regard, several studies indicate that they play a crucial role in axonal growth and guidance, synaptogenesis and boundary formation. These functions are not only important during development, but also for regeneration under several pathological conditions. Additionally, tenascin-C (Tnc) represents a key modulator of the immune system and inflammatory processes. In the present review article, we focus on the function of Tnc and tenascin-R (Tnr) in the diseased CNS, specifically after retinal and optic nerve damage and degeneration. We summarize the current view on both tenascins in diseases such as glaucoma, retinal ischemia, age-related macular degeneration (AMD) or diabetic retinopathy. In this context, we discuss their expression profile, possible functional relevance, remodeling of the interacting matrisome and tenascin receptors, especially under pathological conditions.
C1 [Reinhard, Jacqueline; Roll, Lars; Faissner, Andreas] Ruhr Univ Bochum, Fac Biol & Biotechnol, Dept Cell Morphol & Mol Neurobiol, Bochum, Germany.
C3 Ruhr University Bochum
RP Faissner, A (通讯作者)，Ruhr Univ Bochum, Fac Biol & Biotechnol, Dept Cell Morphol & Mol Neurobiol, Bochum, Germany.
EM andreas.faissner@rub.de
RI Faissner, Andreas/A-5314-2008
OI Faissner, Andreas/0000-0002-2211-8259; Reinhard,
   Jacqueline/0000-0002-4227-0493
FU Stem Cell Network North Rhine-Westphalia; German Research Foundation
   (Deutsche Forschungsgemeinschaft, DFG) [SFB 509, SFB 642, SPP-1109,
   SPP-1172, Fa 159/11-1, Fa 159/11-2, Fa 159/11-3, Fa 159/16-1, GRK 736,,
   GSC 98/1, SPP-1757, Fa 159/20-1, Fa 159/22-1]; Mercur-Foundation
   (Mercator Research Center Ruhr) [Pr 2011-0010]; German Ministry of
   Education, Research and Technology (Bundesministerium fur Bildung und
   Forschung) [BMBF 01GN0503]; Ruhr-University (International Graduate
   School of Neuroscience and President's special programme call); DFG Open
   Access Publication Funds of the Ruhr-Universitat Bochum
FX We thank Dr. Stephanie C. Joachim for her helpful and critical comments
   on our manuscript. We gratefully acknowledge the Stem Cell Network North
   Rhine-Westphalia, the German Research Foundation (Deutsche
   Forschungsgemeinschaft, DFG: SFB 509, SFB 642, SPP-1109, SPP-1172, Fa
   159/11-1, 2, 3, Fa 159/16-1, GRK 736, GSC 98/1, SPP-1757, Fa 159/20-1,
   Fa 159/22-1), the Mercur-Foundation (Mercator Research Center Ruhr: Pr
   2011-0010), the German Ministry of Education, Research and Technology
   (Bundesministerium fur Bildung und Forschung, BMBF 01GN0503) and the
   Ruhr-University (International Graduate School of Neuroscience and
   President's special programme call 2008) for grant support. We
   acknowledge support by the DFG Open Access Publication Funds of the
   Ruhr-Universitat Bochum.
CR Abu-Hassan DW, 2014, J OCUL BIOL, V2
   Adamsky K, 2001, ONCOGENE, V20, P609, DOI 10.1038/sj.onc.1204119
   Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Agathocleous M, 2009, ANNU REV CELL DEV BI, V25, P45, DOI 10.1146/annurev.cellbio.042308.113259
   Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P64, DOI 10.1016/j.mcn.2004.08.013
   AJEMIAN A, 1994, J COMP NEUROL, V340, P233, DOI 10.1002/cne.903400208
   Andrews MR, 2009, J NEUROSCI, V29, P5546, DOI 10.1523/JNEUROSCI.0759-09.2009
   [Anonymous], 2017, BRIT J OPHTHALMOL, V101, P73, DOI 10.1136/bjophthalmol-2016-EGSguideline.002
   BARNEA G, 1994, J BIOL CHEM, V269, P14349
   BARTSCH S, 1995, EUR J NEUROSCI, V7, P907, DOI 10.1111/j.1460-9568.1995.tb01078.x
   BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108
   BARTSCH U, 1994, J NEUROSCI, V14, P4756
   BATTISTI WP, 1995, J COMP NEUROL, V354, P306, DOI 10.1002/cne.903540211
   Becker CG, 1999, J NEUROSCI, V19, P813
   Becker CG, 2004, MOL CELL NEUROSCI, V26, P376, DOI 10.1016/j.mcn.2004.03.003
   Becker CG, 2002, J NEUROSCI, V22, P842, DOI 10.1523/JNEUROSCI.22-03-00842.2002
   Becker T, 2000, GLIA, V29, P330, DOI 10.1002/(SICI)1098-1136(20000215)29:4<330::AID-GLIA4>3.0.CO;2-L
   Bernhardt RR, 1996, J COMP NEUROL, V376, P253, DOI 10.1002/(SICI)1096-9861(19961209)376:2<253::AID-CNE7>3.0.CO;2-2
   Besser M, 2012, DEV BIOL, V369, P163, DOI 10.1016/j.ydbio.2012.05.020
   Besser M, 2009, EXP BRAIN RES, V198, P37, DOI 10.1007/s00221-009-1932-0
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourne RRA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162229
   Brosicke N, 2015, CELL ADHES MIGR, V9, P131, DOI 10.1080/19336918.2014.1000071
   Brosicke N, 2013, CELL TISSUE RES, V354, P409, DOI 10.1007/s00441-013-1704-9
   Calkins DJ, 2017, EXP EYE RES, V157, P28, DOI 10.1016/j.exer.2017.01.007
   Casola C, 2015, J MOL NEUROSCI, V56, P228, DOI 10.1007/s12031-014-0485-2
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Cheah M, 2016, J NEUROSCI, V36, P7283, DOI 10.1523/JNEUROSCI.0901-16.2016
   Chiquet-Ehrismann R, 2014, MATRIX BIOL, V37, P112, DOI 10.1016/j.matbio.2014.01.007
   Chiquet-Ehrismann R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004960
   CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927
   CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crair MC, 2016, J NEUROSCI, V36, P10707, DOI 10.1523/JNEUROSCI.1711-16.2016
   Czopka T, 2010, J NEUROSCI, V30, P12310, DOI 10.1523/JNEUROSCI.4957-09.2010
   DALESSANDRI L, 1995, CURR EYE RES, V14, P911, DOI 10.3109/02713689508995131
   Dautriche CN, 2014, BIOTECHNOL ADV, V32, P971, DOI 10.1016/j.biotechadv.2014.04.012
   De Laporte L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062076
   Diekmann H, 2013, CELL TISSUE RES, V353, P327, DOI 10.1007/s00441-013-1596-8
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dityatev A, 2010, NAT REV NEUROSCI, V11, P735, DOI 10.1038/nrn2898
   Dobbertin A, 2010, EXP NEUROL, V225, P60, DOI 10.1016/j.expneurol.2010.04.019
   DORRIES U, 1994, J NEUROSCI RES, V37, P336, DOI 10.1002/jnr.490370306
   Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555
   Dzyubenko E, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/5214961
   Erskine L, 2014, ASN NEURO, V6, DOI 10.1177/1759091414562107
   Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938
   FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4
   Faissner A, 2017, MOL CELL NEUROSCI, V81, P22, DOI 10.1016/j.mcn.2016.11.003
   Faissner A, 2015, GLIA, V63, P1330, DOI 10.1002/glia.22839
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   Fawcett JW, 2017, EYE, V31, P206, DOI 10.1038/eye.2016.293
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Ferrer E, 2006, DRUG NEWS PERSPECT, V19, P151, DOI 10.1358/dnp.2006.19.3.985929
   FFRENCHCONSTANT C, 1988, J NEUROCYTOL, V17, P13, DOI 10.1007/BF01735374
   Fischer D, 2012, PROG RETIN EYE RES, V31, P688, DOI 10.1016/j.preteyeres.2012.06.005
   Fischer D, 2012, CELL TISSUE RES, V349, P79, DOI 10.1007/s00441-011-1302-7
   Fuchshofer R, 2012, CELL TISSUE RES, V347, P279, DOI 10.1007/s00441-011-1274-7
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   Garwood J, 2004, EUR J NEUROSCI, V20, P2524, DOI 10.1111/j.1460-9568.2004.03727.x
   Garwood J, 1999, J NEUROSCI, V19, P3888
   Gauthier Angela C., 2016, Yale Journal of Biology and Medicine, V89, P73
   Giuffrida A, 2004, INT J ONCOL, V25, P745
   Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681
   Hagedorn M, 1993, Ger J Ophthalmol, V2, P28
   Harada T, 2007, GENE DEV, V21, P367, DOI 10.1101/gad.1504307
   Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Heikkinen A, 2014, PROG BRAIN RES, V214, P29, DOI 10.1016/B978-0-444-63486-3.00002-5
   Horvat-Broecker A, 2008, NEUROSCIENCE, V152, P618, DOI 10.1016/j.neuroscience.2008.01.016
   Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2
   Ishikawa K, 2015, INVEST OPHTH VIS SCI, V56, P932, DOI 10.1167/iovs.14-15589
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakovcevski I, 2013, AMINO ACIDS, V44, P1115, DOI 10.1007/s00726-012-1446-0
   Joachim SC, 2014, J MOL NEUROSCI, V52, P216, DOI 10.1007/s12031-013-0125-2
   Joachim SC, 2013, MOL VIS, V19, P1804
   Joester A, 2001, MATRIX BIOL, V20, P13, DOI 10.1016/S0945-053X(00)00136-0
   Joester A, 1999, J BIOL CHEM, V274, P17144, DOI 10.1074/jbc.274.24.17144
   Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282
   Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G
   Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2
   Keller KE, 2007, INVEST OPHTH VIS SCI, V48, P1164, DOI 10.1167/iovs.06-0875
   Keller KE, 2013, INVEST OPHTH VIS SCI, V54, P5613, DOI 10.1167/iovs.13-11620
   Kiernan BW, 1999, EUR J NEUROSCI, V11, P3082, DOI 10.1046/j.1460-9568.1999.00729.x
   Kim H, 2013, BRAIN RES, V1502, P11, DOI 10.1016/j.brainres.2013.01.043
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Klausmeyer A, 2007, J COMP NEUROL, V504, P659, DOI 10.1002/cne.21479
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kobayashi Y, 2016, MOL VIS, V22, P436
   Kuriyama N, 2011, HEPATOLOGY, V54, P2125, DOI 10.1002/hep.24639
   Kwok JCF, 2011, DEV NEUROBIOL, V71, P1073, DOI 10.1002/dneu.20974
   Lang DM, 2008, DEV NEUROBIOL, V68, P899, DOI 10.1002/dneu.20624
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loers G, 2007, J NEUROCHEM, V101, P865, DOI 10.1111/j.1471-4159.2006.04409.x
   Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06
   Lundell A, 2004, STRUCTURE, V12, P1495, DOI 10.1016/j.str.2004.05.021
   Marquardt T, 2003, PROG RETIN EYE RES, V22, P567, DOI 10.1016/S1350-9462(03)00036-3
   McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X
   Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987
   Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546
   Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1
   Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501
   Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998
   Mizener JB, 1997, OPHTHALMOLOGY, V104, P859, DOI 10.1016/S0161-6420(97)30221-8
   Momcilovic M, 2017, J NEUROIMMUNOL, V302, P1, DOI 10.1016/j.jneuroim.2016.12.001
   Morrison John C, 2006, Trans Am Ophthalmol Soc, V104, P453
   Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003
   Navarro-Partida J, 2017, OPHTHALMIC GENET, V38, P325, DOI 10.1080/13816810.2016.1227454
   Navarro-Partida J, 2017, GRAEF ARCH CLIN EXP, V255, P995, DOI 10.1007/s00417-017-3610-4
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   NIES DE, 1991, J BIOL CHEM, V266, P2818
   Noristani R, 2016, J MOL NEUROSCI, V58, P470, DOI 10.1007/s12031-015-0707-2
   Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017
   Oster SF, 2004, SEMIN CELL DEV BIOL, V15, P125, DOI 10.1016/j.semcdb.2003.09.006
   Palenski TL, 2013, MICROVASC RES, V89, P57, DOI 10.1016/j.mvr.2013.06.007
   Pattabiraman PP, 2010, AM J PHYSIOL-CELL PH, V298, pC749, DOI 10.1152/ajpcell.00317.2009
   Pena JDO, 1999, EXP EYE RES, V68, P29, DOI 10.1006/exer.1998.0577
   PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K
   Petros TJ, 2008, ANNU REV NEUROSCI, V31, P295, DOI 10.1146/annurev.neuro.31.060407.125609
   Piccinini AM, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3596
   Piccinini AM, 2012, CELL REP, V2, P914, DOI 10.1016/j.celrep.2012.09.005
   Prendes MA, 2013, BRIT J OPHTHALMOL, V97, P680, DOI 10.1136/bjophthalmol-2011-301132
   Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905
   Reinehr S, 2016, J CELL MOL MED, V20, P2122, DOI 10.1111/jcmm.12909
   Reinehr S, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00140
   Reinhard J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43470
   Reinhard J, 2016, INT J BIOCHEM CELL B, V81, P174, DOI 10.1016/j.biocel.2016.05.002
   Reinhard J, 2015, EXP EYE RES, V133, P132, DOI 10.1016/j.exer.2014.07.001
   Ren TC, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0077-15.2015
   Rieck J, 2013, INVEST OPHTH VIS SCI, V54, P2393, DOI 10.1167/iovs.12-9781
   Rigato F, 2002, J NEUROSCI, V22, P6596
   Roll L, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00219
   Roll L, 2012, CELL TISSUE RES, V349, P133, DOI 10.1007/s00441-011-1313-4
   Saika S, 2016, EXP EYE RES, V142, P40, DOI 10.1016/j.exer.2014.12.015
   Sanchez-Lopez A, 2004, GLIA, V46, P261, DOI 10.1002/glia.20007
   SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33
   Schneider M, 2016, EXP EYE RES, V142, P49, DOI 10.1016/j.exer.2015.08.014
   Schumacher S, 2003, J NEUROCHEM, V87, P1213, DOI 10.1046/j.1471-4159.2003.02112.x
   Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200
   Shibuya E, 2008, INVEST OPHTH VIS SCI, V49, P4453, DOI 10.1167/iovs.07-1575
   Siddiqui S, 2008, NEURON GLIA BIOL, V4, P271, DOI 10.1017/S1740925X09990020
   Siddiqui S, 2009, GLIA, V57, P1420, DOI 10.1002/glia.20860
   Silver DJ, 2014, CURR OPIN NEUROBIOL, V27, P171, DOI 10.1016/j.conb.2014.03.016
   SILVER J, 1994, J NEUROL, V242, pS22, DOI 10.1007/BF00939236
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2353, DOI 10.1167/iovs.12-11103
   SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525
   Smith GM, 1997, J NEUROSCI, V17, P9624
   Song I, 2018, BRAIN RES BULL, V136, P101, DOI 10.1016/j.brainresbull.2017.03.003
   SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8
   Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103
   Taki J, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0100-8
   Taki J, 2010, J NUCL MED, V51, P1116, DOI 10.2967/jnumed.109.071340
   Tamm ER, 2017, EXP EYE RES, V157, P5, DOI 10.1016/j.exer.2017.02.006
   Tamm ER, 2015, PROG MOL BIOL TRANSL, V134, P301, DOI 10.1016/bs.pmbts.2015.06.007
   Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003
   Thanos S, 2001, BRAIN RES REV, V35, P205, DOI 10.1016/S0165-0173(01)00049-2
   Theocharidis U, 2014, PROG BRAIN RES, V214, P3, DOI 10.1016/B978-0-444-63486-3.00001-3
   To M, 2013, EXP EYE RES, V116, P298, DOI 10.1016/j.exer.2013.09.011
   Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004
   Tucker RP, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-60
   Tucker RP, 2015, INT J BIOCHEM CELL B, V65, P165, DOI 10.1016/j.biocel.2015.06.003
   Ueda J, 2003, INVEST OPHTH VIS SCI, V44, P4772, DOI 10.1167/iovs.02-1002
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wahlin KJ, 2008, J COMP NEUROL, V506, P822, DOI 10.1002/cne.21582
   Wallace DM, 2015, J OCUL PHARMACOL TH, V31, P386, DOI 10.1089/jop.2014.0163
   Wallace DM, 2014, MATRIX BIOL, V37, P174, DOI 10.1016/j.matbio.2014.03.007
   WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408
   Wang J, 2017, J GLAUCOMA, V26, P390, DOI 10.1097/IJG.0000000000000627
   Weber P, 1999, J NEUROSCI, V19, P4245, DOI 10.1523/jneurosci.19-11-04245.1999
   WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x
   Xiang MQ, 2013, CELL MOL LIFE SCI, V70, P2519, DOI 10.1007/s00018-012-1183-2
   Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092
   Xiao ZC, 1998, J NEUROSCI RES, V52, P390, DOI 10.1002/(SICI)1097-4547(19980515)52:4<390::AID-JNR3>3.3.CO;2-6
   Yang YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep30505
   Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423
   Zhu W, 2017, INVEST OPHTH VIS SCI, V58, P2054, DOI 10.1167/iovs.16-20672
   Zhu W, 2016, P NATL ACAD SCI USA, V113, pE3492, DOI 10.1073/pnas.1604153113
NR 184
TC 23
Z9 23
U1 2
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5145
J9 FRONT INTEGR NEUROSC
JI Front. Integr. Neurosci.
PD OCT 23
PY 2017
VL 11
AR 30
DI 10.3389/fnint.2017.00030
PG 13
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA FK4DT
UT WOS:000413440400001
PM 29109681
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Leszek, J
   Barreto, GE
   Gasiorowski, K
   Koutsouraki, E
   Avila-Rodrigues, M
   Aliev, G
AF Leszek, Jerzy
   Barreto, George E.
   Gasiorowski, Kazimierz
   Koutsouraki, Euphrosyni
   Avila-Rodrigues, Marco
   Aliev, Gjumrakch
TI Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible
   for Progression of Neurodegeneration: Role of Brain Innate Immune System
SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
LA English
DT Article
DE Microglia; neurodegenerative disorders; neuroinflammation; oxidative
   stress; toll-like receptors
ID TOLL-LIKE RECEPTORS; ALZHEIMERS-DISEASE; AMYLOID-BETA; MICROGLIAL
   ACTIVATION; A-BETA; GENE-EXPRESSION; PIVOTAL ROLE; MITOCHONDRIAL;
   NEUROINFLAMMATION; NEURONS
AB Chronic inflammation is characterized by longstanding microglial activation followed by sustained release of inflammatory mediators, which aid in enhanced nitrosative and oxidative stress. The sustained release of inflammatory mediators propels the inflammatory cycle by increased microglial activation, promoting their proliferation and thus stimulating enhanced release of inflammatory factors. Elevated levels of several cytokines and chronic neuroinflammation have been associated with many neurodegenerative disorders of central nervous system like age-related macular degeneration, Alzheimer disease, multiple sclerosis, Parkinson's disease, Huntington' disease, and tauopathies. This review highlights the basic mechanisms of neuroinflammation, the characteristics of neurodegenerative diseases, and the main immunologic responses in CNS neurodegenerative disorders. A comprehensive outline for the crucial role of microglia in neuroinflammation and neurodegeneration and the role of Toll-like receptor signalling in coexistence of inflammatory mechanisms and oxidative stress as major factors responsible for progression of neurodegeneration have also been presented.
C1 [Leszek, Jerzy] Wroclaw Med Univ, Dept Psychiat, Wroclaw, Poland.
   [Barreto, George E.; Avila-Rodrigues, Marco] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, Colombia.
   [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile.
   [Gasiorowski, Kazimierz] Wroclaw Med Univ, Dept Basic Med Sci, Wroclaw, Poland.
   [Koutsouraki, Euphrosyni] Aristotle Univ Thessaloniki, Dept Neurol, Lab Neuroimmunol, GR-54006 Thessaloniki, Greece.
   [Aliev, Gjumrakch] GALLY Int Biomed Res Consulting LLC, San Antonio, TX 78229 USA.
   [Aliev, Gjumrakch] Univ Atlanta, Sch Hlth Sci & Healthcare Adm, Johns Creek, GA 30097 USA.
   [Aliev, Gjumrakch] Russian Acad Sci, Inst Physiologically Act Cpds, Chernogolovka 142432, Russia.
C3 Wroclaw Medical University; Pontificia Universidad Javeriana;
   Universidad Autonoma de Chile; Wroclaw Medical University; Aristotle
   University of Thessaloniki; Russian Academy of Sciences; Institute of
   Physiologically Active Compounds of the Russian Academy of Sciences
RP Aliev, G (通讯作者)，GALLY Int Biomed Res Consulting LLC, San Antonio, TX 78229 USA.
EM aliev03@gmail.com
RI Aliev, Gjumrakch/AAE-7734-2020; Aliev, Gjumrakch/K-7302-2017; Barreto,
   George E./B-5747-2014; Barreto, George E./AAD-7420-2020
OI Aliev, Gjumrakch/0000-0001-7373-3182; Barreto, George
   E./0000-0002-6644-1971; Barreto, George E./0000-0002-6644-1971; Leszek,
   Jerzy/0000-0002-2316-2470; Koutsouraki, Euphrosyni/0000-0001-6057-3749
FU GALLY International Biomedical Research Consulting LLC, San Antonio,
   Texas, USA; Russian Science Foundation (RSCF) [14-23-00160]; Pontificia
   Universidad Javeriana; Universidad Autonoma de Chile
FX This study was supported by the GALLY International Biomedical Research
   Consulting LLC, San Antonio, Texas, USA, and Russian Science Foundation
   (RSCF: No 14-23-00160). GEB work is supported by Pontificia Universidad
   Javeriana and Universidad Autonoma de Chile.
CR Adelson JD, 2012, NEURON, V73, P1100, DOI 10.1016/j.neuron.2012.01.020
   Ahmad A., 2013, MED PLANTS INT J PHY, V5
   Ahmad A, 2012, PHYTOMEDICINE, V19, P639, DOI 10.1016/j.phymed.2012.02.012
   Ahmad A, 2012, CAN J NEUROL SCI, V39, P311, DOI 10.1017/S0317167100013433
   Aliev G, 2014, CURR MED CHEM, V21, P2208, DOI 10.2174/0929867321666131227161303
   Aliev G, 2009, SYSTEMS BIOL FREE RA, P2023
   Aliev G., 2011, SYSTEMS BIOL FREE RA, P2325
   Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231
   [Anonymous], 2009, J MOL NEUROSCI, V39, P1
   Meraz-Rios MA, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/375968
   Arroyo DS, 2011, INT IMMUNOPHARMACOL, V11, P1415, DOI 10.1016/j.intimp.2011.05.006
   Ashraf GM, 2014, CNS NEUROL DISORD-DR, V13, P1280, DOI 10.2174/1871527313666140917095514
   Babot M, 2014, BBA-BIOENERGETICS, V1837, P1083, DOI 10.1016/j.bbabio.2014.02.018
   Bamberger ME, 2003, J NEUROSCI, V23, P2665
   Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132
   Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004
   Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016
   Benakis C, 2010, BRAIN BEHAV IMMUN, V24, P800, DOI 10.1016/j.bbi.2009.11.001
   Beutner C, 2013, GLIA, V61, P1429, DOI 10.1002/glia.22524
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Booy E, 2013, CURRENT MED CHEM ANT, V4, P349
   Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Cabezas R, 2014, NEUROTOX RES
   Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211
   Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008
   Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431
   Castellani RJ, 2006, ACTA NEUROPATHOL, V111, P503, DOI 10.1007/s00401-006-0071-y
   Castellani Rudy J, 2006, Am J Alzheimers Dis Other Demen, V21, P126, DOI 10.1177/153331750602100213
   Chao Y, 2014, BIOMED RES INT, V2014
   Chen Y, 2014, CURR MED CHEM, V21, P2146, DOI 10.2174/0929867321666131228203906
   Chen YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050771
   Chio CC, 2014, CURR MED CHEM
   Christensen LB, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-70
   Crutcher KA, 2006, J NEUROIMMUNE PHARM, V1, P195, DOI 10.1007/s11481-006-9021-7
   Dai XJ, 2014, CELL STRESS CHAPERON
   de la Monte SM, 2014, BIOCHEM PHARMACOL, V88, P548, DOI 10.1016/j.bcp.2013.12.012
   DELBO R, 1995, NEUROSCI LETT, V188, P70, DOI 10.1016/0304-3940(95)11384-9
   Drose S, 2014, BBA-PROTEINS PROTEOM, V1844, P1344, DOI 10.1016/j.bbapap.2014.02.006
   Avila MF, 2014, J THEOR BIOL, V345, P43, DOI 10.1016/j.jtbi.2013.12.010
   Forman MS, 2007, NEUROLOGY, V68, P757, DOI 10.1212/01.wnl.0000256373.39415.b1
   Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47
   GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Harris Robert A, 2014, Front Immunol, V5, P612, DOI 10.3389/fimmu.2014.00612
   Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013
   Sutachan JJ, 2012, NUTR NEUROSCI, V15, P120, DOI 10.1179/1476830511Y.0000000033
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   Kurpius D, 2006, GLIA, V54, P58, DOI 10.1002/glia.20355
   Bitzer-Quintero OK, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/348642
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Lau Francis C, 2007, Subcell Biochem, V42, P299
   Lee EJ, 2014, J IMMUNOL, V193, P2384, DOI 10.4049/jimmunol.1303240
   Lehnardt S, 2008, J NEUROSCI, V28, P2320, DOI 10.1523/JNEUROSCI.4760-07.2008
   Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928
   Letiembre M, 2007, NEUROSCIENCE, V146, P248, DOI 10.1016/j.neuroscience.2007.01.004
   Liazoghli D, 2012, ACS CHEM NEUROSCI, V3, P90, DOI 10.1021/cn2000734
   Liu P, 2014, STROKE
   Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039
   Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014
   Luque-Contreras D, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/497802
   Albarracin SL, 2012, NUTR NEUROSCI, V15, P1, DOI 10.1179/1476830511Y.0000000028
   McGeer EG, 2007, CNS DRUGS, V21, P789, DOI 10.2165/00023210-200721100-00001
   Miklossy J, 2006, EXP NEUROL, V197, P275, DOI 10.1016/j.expneurol.2005.10.034
   Minoretti P, 2006, NEUROSCI LETT, V391, P147, DOI 10.1016/j.neulet.2005.08.047
   Mirza Z, 2014, CNS NEUROL DISORD-DR, V13, P213, DOI 10.2174/18715273113126660144
   Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p
   Moreira PI, 2006, MECH AGEING DEV, V127, P501, DOI 10.1016/j.mad.2006.01.024
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Okamoto Takashi, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P359
   Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001
   Peila R, 2006, ACTA NEUROL SCAND, V114, P102, DOI 10.1111/j.1600-0404.2006.00693.x
   Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398
   Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4
   Qian F, 2014, AGING-US, V6, P131, DOI 10.18632/aging.100642
   Ramesh G, 2013, MEDIATORS INFLAMMATI, V2013
   Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009
   Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565
   Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Scheibye-Knudsen M, 2014, TRENDS CELL BIOL
   Schmid CD, 2009, J NEUROCHEM, V109, P117, DOI 10.1111/j.1471-4159.2009.05984.x
   Schwartz M, 2008, TRENDS IMMUNOL, V29, P211, DOI 10.1016/j.it.2008.01.003
   Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71
   Smith MA, 2002, FREE RADICAL BIO MED, V33, P1194, DOI 10.1016/S0891-5849(02)01021-3
   Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194
   Tang SC, 2008, EXP NEUROL, V213, P114, DOI 10.1016/j.expneurol.2008.05.014
   Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104
   Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004
   Tansey Malu G., 2008, P59
   Trotta T, 2014, J NEUROIMMUNOL, V268, P1, DOI 10.1016/j.jneuroim.2014.01.014
   Vontell R, 2013, DEV NEUROSCI-BASEL, V35, P130, DOI 10.1159/000346158
   Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455
   Wang XL, 2014, BBA-MOL BASIS DIS, V1842, P1240, DOI 10.1016/j.bbadis.2013.10.015
   Wang Y, 2013, CNS NEUROSCI THER, V19, P358, DOI 10.1111/cns.12090
   Xie A, 2014, BIOMED RES INT, V2014
   Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772
   YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693
   Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771
   Zwain IH, 1999, ENDOCRINOLOGY, V140, P3843, DOI 10.1210/en.140.8.3843
NR 102
TC 107
Z9 112
U1 1
U2 51
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871-5273
EI 1996-3181
J9 CNS NEUROL DISORD-DR
JI CNS Neurol. Disord.-Drug Targets
PY 2016
VL 15
IS 3
BP 329
EP 336
DI 10.2174/1871527315666160202125914
PG 8
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DI9DH
UT WOS:000373801100008
PM 26831258
DA 2022-11-30
ER

PT J
AU Batioglu, F
   Oguz, YG
   Demirel, S
   Ozmert, E
AF Batioglu, Figen
   Oguz, Yesim Gedik
   Demirel, Sibel
   Ozmert, Emin
TI Geographic Atrophy Progression in Eyes with Age-Related Macular
   Degeneration: Role of Fundus Autofluorescence Patterns, Fellow Eye and
   Baseline Atrophy Area
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Fundus
   autofluorescence; Progression
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPY; INDOCYANINE
   GREEN ANGIOGRAPHY; FACTOR-H POLYMORPHISM; JUNCTIONAL ZONE; LIPOFUSCIN;
   MACULOPATHY; PREVALENCE; ACCUMULATION; FLUORESCEIN
AB Background/Objective: To evaluate if fundus autofluorescence (FAF) patterns around geographic atrophy (GA) and the status of the fellow eye have an impact on GA progression. Methods: We included 54 eyes of 35 patients with GA. Areas of GA were quantified by RegionFinder software. Results: GA progression rates in eyes with a diffuse trickling pattern (median 1.42 mm(2)/year) were significantly higher than in normal eyes (median 0.22 mm(2)/year) and eyes with other diffuse FAF patterns (median 0.46 mm(2)/year). Eyes with a banded pattern had a significantly higher progression rate (median 0.81 mm(2)/year) than those without any FAF abnormalities (p = 0.038). The group with baseline total atrophy of the eyes <1 disk area (DA; median 0.42 mm(2)) had an inverse relation with GA progression compared to the groups with baseline atrophy >1 DA (p < 0.05). Conclusion: Diffuse trickling and banded patterns may have an impact on GA progression and may serve as prognostic factors. (C) 2014 S. Karger AG, Basel
C1 [Batioglu, Figen; Oguz, Yesim Gedik; Demirel, Sibel; Ozmert, Emin] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Oguz, YG (通讯作者)，Ankara Univ, Fac Med, Dept Ophthalmol, Mamak Cad Dikimevi, TR-06100 Ankara, Turkey.
EM yesimgedik@gmail.com
RI DEMIREL, SIBEL/GQH-3232-2022; Demirel, Sibel/AAQ-4282-2020; Batıoğlu,
   Figen/AAQ-3727-2020
OI DEMIREL, SIBEL/0000-0002-2477-9974; Demirel, Sibel/0000-0002-6430-6565;
   Batıoğlu, Figen/0000-0002-5834-7512
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald A, 2005, OPHTHALMOLOGE, V102, P259, DOI 10.1007/s00347-004-1121-2
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Bindewald A, 2005, ESSENT OPHTHALMOL, P19
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 40
TC 28
Z9 28
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 52
IS 2
BP 53
EP 59
DI 10.1159/000361077
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AP6SC
UT WOS:000342206900001
PM 24993093
DA 2022-11-30
ER

PT J
AU Rencova, E
   Blaha, M
   Studnicka, J
   Blazek, M
   Blaha, V
   Dusova, J
   Maly, J
   Kyprianou, G
   Vasatko, T
   Langrova, H
AF Rencova, Eva
   Blaha, Milan
   Studnicka, Jan
   Blazek, Martin
   Blaha, Vladimir
   Dusova, Jaroslava
   Maly, Jaroslav
   Kyprianou, Georgia
   Vasatko, Tomas
   Langrova, Hana
TI Haemorheopheresis could block the progression of the dry form of
   age-related macular degeneration with soft drusen to the neovascular
   form
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cascade filtration; choroidal
   neovascularization; drusen; haemorheopheresis; microcirculatory
   disorders; retinal pigment epithelium detachment; visual acuity
ID RHEOPHERESIS
AB Purpose: To evaluate the influence of haemorheopheresis on anatomical and functional findings in patients with soft-drusen maculopathy.
   Methods: We investigated 29 eyes (16 patients) and randomized 25 eyes (16 controls) with soft-drusen maculopathy [soft, confluent and reticular drusen, drusenoid retinal pigment epithelium detachment (RPED)]. Each patient received a series of eight haemorheophereses (cascade filtration of 1.5 plasma volume) within 10 weeks. The patients were followed up using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, optical coherence tomography, fluorescein angiography, electroretinography and measurements of pulsed ocular blood flow.
   Results: After the procedures, there was a substantial reduction in rheologically active substances [lipoproteins, alpha 2-macroglobulin, immunoglobulin M (IgM), fibrinogen], plasma and blood viscosity. At the 1.5-year follow-up, we noticed soft drusen absorption; reattachment of drusenoid RPED and stabilization or improvement of visual acuity occurred in 72% of patients in comparison to only 39% of patients in the control group. Full-field electroretinograms showed significantly higher scotopic activity of treated patients in comparison with the control group, and mainly insignificant differences in photopic activity between both groups. Despite the significant increase of activity in the paramacular retina in treated patients, the differences in amplitudes of multifocal electroretinography (mfERG) average responses were insignificant between groups.
   Conclusion: Haemorheopheresis seems to be capable of changing the activity of promoters of the natural course of soft-drusen maculopathy, its development and progression. Visual acuity and electrical activity of the retina can be stabilized or even improved. The therapy has been shown to be effective and safe.
C1 [Rencova, Eva; Studnicka, Jan; Dusova, Jaroslava; Kyprianou, Georgia; Langrova, Hana] Charles Univ Prague, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Blaha, Milan; Blazek, Martin; Maly, Jaroslav; Vasatko, Tomas] Charles Univ Prague, Dept Internal Med 2, Hradec Kralove, Czech Republic.
   [Blaha, Vladimir] Charles Univ Prague, Dept Gerontol & Metab Care, Hradec Kralove, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague
RP Blaha, M (通讯作者)，Fac Hosp, Dept Med 2, Sokolskastr 408, Hradec Kralove 50005, Czech Republic.
EM blaham@email.cz
RI Studnička, Jan/AAC-4127-2022; Maly, Jaroslav/P-6660-2017; Studnicka,
   Jan/K-2875-2017; Blaha, Vladimir/C-1151-2016; Blaha, Milan/H-8955-2016
OI Maly, Jaroslav/0000-0003-4889-5504; Studnicka, Jan/0000-0002-9911-4379;
   Blaha, Vladimir/0000-0001-8088-9919; Blaha, Milan/0000-0003-2330-5838;
   Langrova, Hana/0000-0001-8488-7208
FU Czech Ministry of Health [NR/9118-3, NS/9738-4]
FX This study was supported by a grant from the Czech Ministry of Health
   (no. NR/9118-3 and no. NS/9738-4).
CR Ben Zion I, 2007, BRIT J OPHTHALMOL, V91, P882, DOI 10.1136/bjo.2006.108340
   Blaha M, 2006, VNITR LEK, V52, P1102
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   BOYER DS, 2006, CLIN TRIALS ASSESS R
   BRESSLER S, 2006, AM ACAD OPHTHALMOL, V5, P10
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Ferrannini M, 2007, INT J ARTIF ORGANS, V30, P923, DOI 10.1177/039139880703001010
   Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   Valbonesi M, 2004, INT J ARTIF ORGANS, V27, P806, DOI 10.1177/039139880402700911
NR 23
TC 16
Z9 17
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2011
VL 89
IS 5
BP 463
EP 471
DI 10.1111/j.1755-3768.2009.01710.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 792KH
UT WOS:000292742800033
PM 20102350
OA Bronze
DA 2022-11-30
ER

EF